<SEC-DOCUMENT>0001326110-23-000064.txt : 20230511
<SEC-HEADER>0001326110-23-000064.hdr.sgml : 20230511
<ACCEPTANCE-DATETIME>20230511064706
ACCESSION NUMBER:		0001326110-23-000064
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		87
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230511
DATE AS OF CHANGE:		20230511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ImmunityBio, Inc.
		CENTRAL INDEX KEY:			0001326110
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				431979754
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37507
		FILM NUMBER:		23908718

	BUSINESS ADDRESS:	
		STREET 1:		3530 JOHN HOPKINS COURT
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(844) 696-5235

	MAIL ADDRESS:	
		STREET 1:		3530 JOHN HOPKINS COURT
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NantKwest, Inc.
		DATE OF NAME CHANGE:	20150713

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Conkwest, Inc.
		DATE OF NAME CHANGE:	20140416

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZelleRx Corp
		DATE OF NAME CHANGE:	20050504
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ibrx-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:5993b617-92d4-4bab-a076-33e54147e714,g:68360996-794b-41f6-8c08-63fce426a63c,d:5bbe340c9c8f435088d8011b72b6800d--><html xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ibrx="http://www.immunitybio.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ibrx-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80L2ZyYWc6ZTYyZDE5OTlkN2RiNDQ5NzlkMGEzZDA1ZTIyMGFjZDcvdGFibGU6ODZlYzBmYjIzNWNjNGQ5M2EyMzljYzU4MGQzYWVkMDYvdGFibGVyYW5nZTo4NmVjMGZiMjM1Y2M0ZDkzYTIzOWNjNTgwZDNhZWQwNl8zLTEtMS0xLTI5ODM1Mg_a1adddac-1472-46ea-a210-a22dbc042fdf">false</ix:nonNumeric><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80L2ZyYWc6ZTYyZDE5OTlkN2RiNDQ5NzlkMGEzZDA1ZTIyMGFjZDcvdGFibGU6ODZlYzBmYjIzNWNjNGQ5M2EyMzljYzU4MGQzYWVkMDYvdGFibGVyYW5nZTo4NmVjMGZiMjM1Y2M0ZDkzYTIzOWNjNTgwZDNhZWQwNl80LTEtMS0xLTI5ODM1Mg_05f44fee-ca63-4ac1-b513-29589e8ad7f3">2023</ix:nonNumeric><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80L2ZyYWc6ZTYyZDE5OTlkN2RiNDQ5NzlkMGEzZDA1ZTIyMGFjZDcvdGFibGU6ODZlYzBmYjIzNWNjNGQ5M2EyMzljYzU4MGQzYWVkMDYvdGFibGVyYW5nZTo4NmVjMGZiMjM1Y2M0ZDkzYTIzOWNjNTgwZDNhZWQwNl81LTEtMS0xLTI5ODM1Mg_9bea8791-c4a5-452b-b4a8-f8acb85a0412">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80L2ZyYWc6ZTYyZDE5OTlkN2RiNDQ5NzlkMGEzZDA1ZTIyMGFjZDcvdGFibGU6ODZlYzBmYjIzNWNjNGQ5M2EyMzljYzU4MGQzYWVkMDYvdGFibGVyYW5nZTo4NmVjMGZiMjM1Y2M0ZDkzYTIzOWNjNTgwZDNhZWQwNl82LTEtMS0xLTI5ODM1Mg_f63859a7-36d1-4a27-83dc-0f27906d67e1">0001326110</ix:nonNumeric><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80L2ZyYWc6ZTYyZDE5OTlkN2RiNDQ5NzlkMGEzZDA1ZTIyMGFjZDcvdGFibGU6ODZlYzBmYjIzNWNjNGQ5M2EyMzljYzU4MGQzYWVkMDYvdGFibGVyYW5nZTo4NmVjMGZiMjM1Y2M0ZDkzYTIzOWNjNTgwZDNhZWQwNl83LTEtMS0xLTI5ODM1Mg_a04feee7-2ad9-45c9-91e0-f09c93790c62">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOmUxNmRiNTMwMWViYTRhNmY4NmMxNTNhYjJhNjhiMWIwL3RhYmxlcmFuZ2U6ZTE2ZGI1MzAxZWJhNGE2Zjg2YzE1M2FiMmE2OGIxYjBfNS0wLTEtMS0zMTA3NzY_2350ba70-1f49-4ea5-8303-63ba7471fe59">http://fasb.org/us-gaap/2022#FairValueAdjustmentOfWarrants</ix:nonNumeric><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjQ1NjRiYjg3OWY4MDRmZTc5NzBhNDg1YWUzNmI0YWZiL3RhYmxlcmFuZ2U6NDU2NGJiODc5ZjgwNGZlNzk3MGE0ODVhZTM2YjRhZmJfNS0wLTEtMS0zMzA4Nzg_31727132-f847-41a1-942b-fae5179a937e">http://fasb.org/us-gaap/2022#FairValueAdjustmentOfWarrants</ix:nonNumeric><ix:nonNumeric contextRef="i3e7a5a7bf61f49a4a1941edab3339d2c_I20230331" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfNTkx_1b5ac21f-8317-4cdf-9aa4-b1a83fbec98e">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="i3e7a5a7bf61f49a4a1941edab3339d2c_I20230331" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfNjk5_f0f50d52-6d48-4a58-8a65-ea201cb85f30">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNS0xLTEtMS0yOTgzNTI_716b2b64-20b1-40c3-9b02-a3d14868228b">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNS0xLTEtMS0yOTgzNTI_79bf86fc-1a0b-4632-b3b5-c9756666aba0">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTEtMS0xLTEtMjk4MzUy_1e304c6d-b6fc-4a07-96b6-252e1c6d5e68">http://fasb.org/us-gaap/2022#AccountsPayableAndOtherAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTEtMS0xLTEtMjk4MzUy_7f502521-7e3c-4089-bd21-ee4709a6ff0e">http://fasb.org/us-gaap/2022#AccountsPayableAndOtherAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTQtMS0xLTEtMjk4MzUy_1cbef275-f42e-4514-b41d-8b9c75783db1">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTQtMS0xLTEtMjk4MzUy_cccafda1-bc6a-4e69-9eb2-a02fc2fcc607">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="icb9a543882c24ab288a8fcf5e2373847_D20220101-20220331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84MTYvZnJhZzpmZGU0ZGM3YzEyNmI0YjQyYWU0ZGJiZTM4NTBjNDYzNC90ZXh0cmVnaW9uOmZkZTRkYzdjMTI2YjRiNDJhZTRkYmJlMzg1MGM0NjM0XzM4NDgyOTA2OTk4NjI_3c1f5bf5-32fa-4157-9ea5-7511b9d6ca10">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i4b233a9ab4f44de78485c2c79b62f293_I20230331" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84MTYvZnJhZzpmZGU0ZGM3YzEyNmI0YjQyYWU0ZGJiZTM4NTBjNDYzNC90ZXh0cmVnaW9uOmZkZTRkYzdjMTI2YjRiNDJhZTRkYmJlMzg1MGM0NjM0XzM4NDgyOTA3MDAzNzk_9b2c632e-8e41-4710-811d-b93170dbbc8c">0</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ibrx-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1979cd48647c45d68e7289ac43e0c9c2_I20230505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i8b814f4f02ad4405944defaa7243cdee_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i2021beb688ba4eae880d4d4d8f408525_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c875c85efb244079066f90b6b550c50_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bffc59bc82a4092b0b095eb4b104f99_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0c37984b4ee4c4e8d32a3fcda72fd96_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b6fd5dc04474fc6ad30fdb536534995_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1108b0a3a2da4efeb2c5a0cbce300858_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i384e76ee6b5e47da8ccb8a62c32b63a0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60ef9d75f1cd4d8da9176583a06fab46_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d3142cb095746858e5333f482cb2517_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib92ff44aff9c4c1cb5a8aefa1497878a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie69a285b23fe4b36860e2b1807e68608_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a8153bf4934499497bc454385181d0f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc8a064e60104a7c8b5bbf20eee46ddd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3839414c7384bb580b2b6ee59797d9b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i685f344965a54fa99a8f56307085368a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d76d948cf7740b181d0c99cf8712fc2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9308889d86f04fb9a83d5131a6f7b08a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07a8763cb5b94c5b9da351bedacfbe75_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eba2b75f17a4ca598c012c58e915b51_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f178e191e6a46e2976df6b30834b5d9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d185f091af84493a3bd1346fcb31032_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f9f0c08e99449fe863bdc24f35895c6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1c226aeaa40452fa58e614e48f7b0e9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b3e85a60781496d8fae99c082b6df71_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id72ba77db0da468294e9f5b45ac3b0a5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2aa017e45e2426088230d3c95d08e1b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i421c4794536c433089794d37f3ef6014_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6a407074713405e90702d702e4309b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i256d0f34b668479ba66bd30a77315d12_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f5b67947f77418ea08709523b53563d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bb3408a05c6401c857209bb9b667953_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b766e2f320f442fa3f3102f9c9b0916_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida858a14f0f94f0698e26382d0222a7d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1f4ccbe1a254187a0abcd2fa0ef3671_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e5651caa3fe44d1a48b78dbac979b78_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id819e1b1f878495a86da38176b293b2b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54462f901730493b9ccffd2922a2f380_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i945c8a203dcd4d97bafa5902b5b19503_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic17e90ac99424c33b733b73a4517455d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23f7671e764e4c5ca223c10daf774bf2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i005d4769e3bc4a9eb596324bf4986a4e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i700388aac6ea44b2a5558e75c3835e46_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61c1394ce2204f349c8ec7aa84ca4c0e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29522190e504495593abd361f7b24b19_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81bd9de2db4d40b9879aff68abbefe52_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i168358a7c0ed479b8476f4d8e155cdde_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f8290d605c9473bbd497404748ff594_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib93ec4ea47c24cd1aacb10ddb65cfc49_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idecf558aeafa48f9b21a5ecd3fb24b40_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:February2023ShelfRegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99fc5379a3c146e884bcdad311bb00a7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:RelatedPartyConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icca3815678964e2d94105dd050d212c3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:RelatedPartyConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba6ebd8d72ea4824b03a047a8f09a82d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb98e0036a3b43d497ef0476504101c1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia50e8aab6bce4a40af1190886835cf90_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bc712551fbe42fa830fbfe75a349bb9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4561df868e434e67b57f7aa91baf077a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4868dd8bba544400bbb7baf280da9766_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a1967d8b16b4b2780d09eb32b721ead_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:RelatedPartyWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6785865c42404146b0f6e8d0fc2d2b8c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:RelatedPartyWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d61f38abc9b467da5b3204da34fab5e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalIssued33123Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i684e88f0565f4750ae31d08132ff423b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e62b835f051443d9e55df382ca1fcce_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic374e7c516ef4b06beadcff3736ae51f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee11080abfef48cf9f5c6b933901142a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdb4ac7d53c44d429b5802a108d42fb7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5437c21f4814f59a329a7b0373ddd7c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5ccb25eaaf340a293dbf719e9c93972_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcada495b71b4888ab1fd26a734a81a7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if361174e18104c2d80d8a23d1e42afa0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fdf6d04e3e64c0a85f416eb0b67673a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69a7813607634b75bf6094281fe5a9ef_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OffMarketFavorableLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ac85c2e74bb4d9e983ef489c9b27611_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OffMarketFavorableLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb96fe0125b04e81861415c2d465f7f2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OffMarketFavorableLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d984c547ea04fd4aca46b980c849ad7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OffMarketFavorableLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2302952973d64c9dae6fea63aa9b623d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ibrx:OrganizedWorkforceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b2b8940d45e44b5b593540d8f42fb87_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38d33d35c4f340d094daa523ef91b3a4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93ed60d3f2964554accd7342f72a2587_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d0dcfca4e8b4f1d959f8fc7308c7a47_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib572239e8f7a47589f3771ddf0d4f463_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b9a73d45ec54296b71bec23a3b54530_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad866414f696494880846815781be54d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7db0daa0756249f385a861fd96f3d99c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i178b6f6abcac4b7da1c687641370dde6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>ibrx:Security</xbrli:measure></xbrli:unit><xbrli:context id="iea925c85eab4423786f1fbcb3163e30e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecca882de63d47999c4cdc060161db0b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7abc0bfb0d34a659f0c1f9d70a91b5e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94255247204f487f8a5e6a7b45fd5f53_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia818d8707e4c4c8d99bffda3de67924f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37c25c0026ea4ccdbaa0613624232e13_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03762b77d7b4408594a116ef19d68f4d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf88dacf0a484cb8938868ce11e3fd93_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6edc71b525cb40e5a5d6fb007bb51c16_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia015c55c47d246e6b83da57fa54d9457_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i268f2b405ec94f05a3e088310fef2a41_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d9bd30014c24311a412cab8f1e6736b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e8a0351256343eeb4cc0af08ac1a51d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53ab60edafa6478689087569daf40626_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bd58f7537dc4e4f8fe02f6ad46a9783_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f54811c3bb74c6fbfba10a31850e736_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9102c7f1073b4a35b9194887f3407199_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14d57b1d76d54551b3b3e206ffde3432_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dee1612809b472b83659b4a2b02d81b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i104551fa9a6e4d0db14a884d59a96b54_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice4416a2800b4d009acab3013a489ab7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83982f7c2fc54aa7a359a7a7d975aff2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec99a9e278b242918d95bceb26bbdeec_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf5a9b13f35d422fa1732caa34e706df_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18b9e33de5fb420f85ada2e2f7aecc07_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16979a35fa1d40b997739a4cb809e6f7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i331682550ab14aec904426036c3b2a64_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief94290369fc4061b4a36705889940e8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89f3b040139a4ffeb38a1cd82447d958_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe21c408c60145f1b9446e214b886786_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b47701466154187b9f13a27115955bf_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:RelatedPartyConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia28a5b94bbd2402daf1696b7e83ff97d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:RelatedPartyConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7436b01d201048599ef97748571d8dbe_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:RelatedPartyConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1038882c13304367a352a1ea0d5e9430_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:RelatedPartyConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9b73b9076d14e77bd7f75276c4a8d58_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i946cc463480045ae80cefa68e6b23ca8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6901e0e7cfd4bf4bd21eb35ec6aa8f0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f6382b087284b0ab540c7a4cd9db9da_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d1b12230e8f4233a449b44aa8b89dae_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i075d1102c0894f7aaf61aea36c69248e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a21a545f0c4436c9afb3e11ec80f767_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5143b8cbe5a4e8990bf3e2deb701bef_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa82585cc76945718fa4c122a0abdf22_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34465ea1764e409786a6bf7a192ee52a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6711f0d932ba4e6a92c92baecc798ffe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9024e16e44b4b6a926b58cb4aec8d8f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadecc9749ad74d06bbf65eca3773b162_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7d4c869961845049a837ecf93a7d2d2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba5d6bb2adc04bfeb0876c228f393f9b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia81b7b3cbfab49d8abed2fece23c4eb2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6d9de146cd64ddd838411f8d960bb39_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ef6c543a47549d6ba626e9b621bef9d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i609d1640d799407fa25e8d7bb019d122_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia99b37fb3a1e4839964854bb8c5cd0a6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cfcae1f8c96411fa01b9df7155a5e1b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc22baf6a9234b998bdacc85aa2baa32_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieed74cabe48d445d966192789eaffa46_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e08fabb07e64dc89b54f50eb2cbab9d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89b6ead15154410fbde3c2433bcdd159_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e78df5d936b4e6ea1a77cbeb8c49595_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia279b1b8a68047368e6c50d9ea885c6e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i274686603f6a451f837acc17b08d3411_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic25536a0d63845739ff43e08195cd5c1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icef3562f20dc43dfa08930bb1bd2bc36_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i544de52cd9194dabb073582a30849b58_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76b53cde4e3e4322a061ae53a8f05594_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc84a0efc87f46c8aae6c011790df898_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccfd1df580444d909b6b2d6f8f806e7b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63ac4d5eb374467ab54634d998aec6f5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcf19f6af9824b52a6d8e4395d10134a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c53736371164c6eb06bafd550e0f5fa_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i946b4f2294f644bcafcd5f32b36a4b6a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f8683e6989143198ff853a8fc97d338_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25b2382ccad7475f812c01198c635ee0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibrx:MeasurementInputExpectedMarketYieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i650984f3db47470a9f5389b2e032a01a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibrx:MeasurementInputDiscountPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="y"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit><xbrli:context id="i6f16749c92e842ce81ffb8d9ae2a9c3d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19f26457ccfe499cb0e3bbed35112923_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1191e7cec0f4f78a48f0b7efe88df43_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib93fecbf92174118bdd72fa5e20ea20e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5be77fd9053a42c1821b000e6a63fc53_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9270094ae41a49ccb211054939e04e29_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf8421bdf082438eacb0d8a2bbb510e1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e247e3019ba40cfb87b176aa4e219b6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91d87f21eddb4e8ba52be9c983035646_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05ce9f5c06e84394bfde03b091dcbdf4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9e851daf28c4255b2112c4cd9cefdc6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i092d7c652fa9476b8e128260ffb7cf55_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b1c02b83f5d4e588b5e7f5dfe24a69e_I20230215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18ad3c2a3e4841d3b55094278b55ee00_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba41b7496e6d4908952cd0ecb8a9fcec_I20230215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cc76b0fbcf84e109ae61be53b3d16fa_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib565990d93cd4919b9ad581d54993133_I20230215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b96511d9e744c5099e21750e0d21d2d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3b821833563458f9405084b1ae950db_I20230215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5751565e9bc4821bce01dd4188d7302_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17c9c04b377c4dc0a52cd262037cb9ba_I20230215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8bb04bc74374058a2c1efed036ac8cb_I20230215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c148f91d4ce423f9b310ff8481860bb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cd4532b1fc24c0ca2ef81c7e69794c6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c353c172ccf4147ac57fe34244f439e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:AmyrisIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a9fa31f8b884ef599ea8e3aa1c58f8f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8d44b5214644e5e9b815f99ac56eaec_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5ee1d864d0f40ee97b16088a1116d91_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice37cb09a6664d4da416332415bda35c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4156a8ceac6342d99ce39177a254d1cf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee278c57618e46d09031d4531cc2f979_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i490e76eedd0c4d68a5d119d4f2a8bf67_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia01f754739eb4399a5ec08bb300b5c9c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7c90fc2a58d48e3bec3d91301b599c7_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AccessToAdvancedHealthInstituteAAHIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i717a4e9083794ab9bb82219c0132b1ee_I20220501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AccessToAdvancedHealthInstituteAAHIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c33c2ccc680481ab6ef920d4dfe6fb2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AccessToAdvancedHealthInstituteAAHIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2177094498de4c7ca93c869ccafa1cd8_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AccessToAdvancedHealthInstituteAAHIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if37fa4000f6b4e8d96490b940efbe768_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AccessToAdvancedHealthInstituteAAHIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d13c8c853924031bd029bd4c72b099a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AccessToAdvancedHealthInstituteAAHIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id36600ac1af648c79b04e3c00fadca09_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AccessToAdvancedHealthInstituteAAHIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f73c10bbad4443f9c60a048d6b10f17_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AccessToAdvancedHealthInstituteAAHIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37548de39d884f38a90265fc99953e00_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AccessToAdvancedHealthInstituteAAHIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fbf30bc44d6480e870137c2cd85cdb9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AccessToAdvancedHealthInstituteAAHIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:SponsoredResearchAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbb1145df96744e6a4b78a506fdab0e3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AccessToAdvancedHealthInstituteAAHIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:SponsoredResearchAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bdaaaa534ee490db0798af2622eb12c_I20220214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i425c575827bc4978bf0c2daa8ed81a96_D20220214-20220214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-14</xbrli:startDate><xbrli:endDate>2022-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>ibrx:employee</xbrli:measure></xbrli:unit><xbrli:context id="if6b39365bed8403baef862349455aa3a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:StateOfNewYorkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d26d616708f4d68a522f54d69fb3236_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:StateOfNewYorkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc667aeaffb241769d40ebb768302772_I20150430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34694fa4373945b3a6a665c6a37f4262_D20150401-20150430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-04-01</xbrli:startDate><xbrli:endDate>2015-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d13dc5189894b7d8628892cfb2e7a88_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdeaa2c7746d49a8bd99d6d3afb859aa_D20220901-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4947316a78a241dc928345e7c528266e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida7588e0910c4bb28cb902bc775406de_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsObligationRegulatoryMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40bec98f02134e3b977953843f819e46_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsObligationSalesMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74a7874a4fde4847942459ca136eee6e_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsObligationSalesMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a799dcabd874b6e84ddb0e294bf7f8a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:DrSoonShiongAndRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsObligationSalesMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c8c3835e9294f019b36ddbb7bb615b8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsObligationSalesMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:AltorStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83f402b4c65a4485bfb0dff6c6982341_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3316090351fd4fe4b0dd3da042faabc4_I20220709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bc9adb48922456fa879ef93b8dba645_D20220709-20220709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-09</xbrli:startDate><xbrli:endDate>2022-07-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9143fae2a394bf29dec9fb56f82a9a5_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic746e246685947fd8cfba45a1fed563e_D20221208-20221208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-08</xbrli:startDate><xbrli:endDate>2022-12-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f1bf0ab5b9b480192b280a3bffc0f0f_D20221202-20221202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibrx:SorrentoTherapeuticsIncLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantCellIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-02</xbrli:startDate><xbrli:endDate>2022-12-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i947edf9e6bfb43b892a96c6c6549369d_D20221202-20221202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibrx:SorrentoTherapeuticsIncLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NANTibodyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-02</xbrli:startDate><xbrli:endDate>2022-12-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17ec39591f744eadbe2f276d7fed3a12_D20230207-20230207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibrx:SorrentoTherapeuticsIncLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-07</xbrli:startDate><xbrli:endDate>2023-02-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72f7554fa7494415af05bce0fcffd01e_D20230207-20230207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibrx:SorrentoTherapeuticsIncLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantCellIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-07</xbrli:startDate><xbrli:endDate>2023-02-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e7a5a7bf61f49a4a1941edab3339d2c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97684a88657d4f79b99ef808ef0e0de7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a3e26a21876460b8624019e43e286e0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalIssued33123Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44cc657d262146519329e8d5460c262d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalIssued33123Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if421742d22da4377a2a2d5d3ad4dee90_I20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad7a8cf8ad9546059a44a0c2f4102d99_D20220101-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9adb1d0654114ee5afbed60cfa9e4766_D20220101-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifeeaf31a1b7546b08e11b31f6de4b788_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3be51647022b41c5aac446b43954112a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i700361120e53402ba852dcb639cda333_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia44124c82520433e872adbae39679ee3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c27fb3d47934120827861b39628c2b1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefda7cd80c064a8e958479a947e51afb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if26e41fef20847b6b81445d4a3101377_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id782271befaf426399ce9443216bb892_D20220831-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-31</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id84e4096f5c442528938b4337cf7c8ed_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f716744d3be43e38afdc26a656b33b7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i604c474521cf4dd693f946bc8cff054d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i168a4524f50644799beb0bf0791c2954_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital4Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic72646472e3b48a295ebef3a0ebdf66f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e671951edb7455ea24c2ac0392ea151_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital6Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3d09e78bc0148b7a0f1abb485cdc81a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital6Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if86dd819ffd041e19f08088aa305bbd6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital6Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07cfde51688d493b82c4be4a684839e5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id87c72a123a646d7a99485bf28cfb653_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie84a9931057b4e4aae2bb4ed9870ba8f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1743878cb0574c6cbbbcdd536eda339a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36630a5fb97140119768102b4c075987_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i023872a5c0664193ae14daa63ba5eefc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02d66470d5a1468c83c9015ed4ab3ab0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46483bc0e4034520a181080e17a40498_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20b7ac56635b4a66a2d03236bce015d7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c63ca50dfe64ec5a0637410c6d5397b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa2f8dcc34a64a3f95777076fb02b849_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f7988bcb71d43779a0096791bc726c6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i965c76f591504ffd870c02a47f91e4d1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9880130e66047f2be4005667dcc04df_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3116163dc179457f83c1a522829e482e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic800e90d3fa44e74bfd616fa559ef8f8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76bd041f34bc45308f8baecb04934003_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i273275e6ceed474fa66492ae83f982da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icde6ce22814d4976bf3ce94a8a10aa0a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34b60dc14eca495189c0a9fd77ab929d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa4a4292eb67427d8486a6d30953b1b1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96fd516d0b2c4ab88b68926fb81bb129_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RelatedPartyNotesPrincipalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i860cd6cdf17243bd9cb45083c2bd5bb7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RelatedPartyNotesPrincipalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20deba0784bb4ee28b65cd1d2bd855dc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RelatedPartyNotesInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55ffd3316fb8496aa86fcba67dffd60b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RelatedPartyNotesInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46a185f9ec6445ec8b642258ea67180d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RelatedPartyNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie130450350ca4c9799e1e199a92ec29d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09080f29fd3f433ba1865fa559c0cc3f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i343f173c97cd46298d5be473e16688aa_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:BrinkBiologicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4a76d55cff24142bdf23c290b7ebaac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:BrinkBiologicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7e60a6f6dd54abb86adb37dc98be31f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:VariousMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54c810b34f414a6199d96f563da4e9c9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:VariousMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fb0f449758c4a12bd185f822740269b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0d461d8a57e4f1caf838c6337b4c516_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd31b5f44a3b46e994f04fa346a23f09_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b77d70cfd06469091a1b47d242533d9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f07f511c38b42188903e64e3779976d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfcb45a1b3c349189e4711ea15b357de_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7f7698c742a4d5185ef556099b8f431_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdea96cd4382425faf718c8efb444b64_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d86297744454a6099ce0c427e3111e8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ibrx:ReimbursementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d993de6a09448f3af585a7df1769323_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ibrx:ReimbursementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8890b549aaaa415492f2214c3dc3ac13_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ibrx:ReimbursementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38af9a7ebb684fc3a1ab4a463228f422_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8466a432fa1943f286f3af0a6ccac9e8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34815e4cfa9145e9981cf8ef165dd4fb_I20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i030a8e572dcc4ea2a237d2800d4aa466_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i630c47622bdc4c919e7634771cd094b6_I20220501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00d9386e0ac34e93abf5574655a19034_D20220501-20220501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ab9c997cb0b4744a84d064e48fc1cdf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8601e8ad3ce74646a29a91172dd7b478_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a83e300ee754efcafa7bc50023c4c0c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ConsiderationForFutureServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94b88764cea64ab3a669de4c146f1277_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8ed30fcfd154733b358cf49c7a83340_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a419c5ac53b440da1bf811cf7835f7a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c6db1e3cd124c76b9c449422588a8be_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida6b89dae59349288b67324cfade250c_I20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52d6bbd3e53f4ae6bd3377d2d890068b_D20180801-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75ef1f10c34b47e9a73945153142eec4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b7101f16b5744f081cfce6bb570c9b0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65810f20d431446aa5ab803112a83673_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88ef2e95606a433c97f1f5ade812375d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida89ca2072e7405a83ed27b0d0e50e26_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9e75b2cda544e9dabfb62fd1fae848d_I20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveDougStLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e2a43e076864fbf9c872615bc186b9a_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveDougStLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="term"><xbrli:measure>ibrx:Term</xbrli:measure></xbrli:unit><xbrli:context id="i5f9e4846487241a5b60ad842bb55bb52_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveDougStLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc6ecb543ce2436c9134c23137273055_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveDougStLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76b07b7ed33b45539a4fff62c382480d_I20170228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37723a8685db4f4b9403f2caefc75ecf_D20170201-20170228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-01</xbrli:startDate><xbrli:endDate>2017-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1669c0c201b646b2b7157ca12651f6fe_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:SeptemberTwentyNineteenLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74cbb623279346b9ade405a13aa44d0e_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:JulyTwentyNineteenLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79fafd177360495ea435675f878915de_D20190101-20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>ibrx:lease</xbrli:measure></xbrli:unit><xbrli:context id="iac70357778c94cf1ac486623facee429_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:DueToRelatedPartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a46905c230c4f93bdb4d9448b060e15_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:DueToRelatedPartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaef86b8724ee46feaafd52d401a7f967_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie341383be88d425fa34bddb167224148_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d95ef7c886d4db6963bcdfd488f1553_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialPremisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f92b246bdb84f80a78af70f89f212ce_D20210101-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialPremisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb46af1e101d4c7d85dc1fd805f5e351_I20210401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:ExpansionPremisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ecc9935801543b1b67dcd2ff6f9f08f_D20210401-20210401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:ExpansionPremisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fe81cf5951c403d960758745c545149_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialAndExpansionPremisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifde6772fd7334f07bf86ccb8635eb843_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialAndExpansionPremisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7910abd612b44ff2a9ab87af3766fd8e_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:FourTwoZeroNashLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4b84ae551264070b15b7f777a374c2e_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:FourTwoZeroNashLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8add4a27fd94c3dbba9aebb333c9ce7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:FourTwoZeroNashLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4332025e778479f9e44ae4505eb4896_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:FourTwoZeroNashLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83fb4e02761f48b8ad2de6942bf33580_I20220501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:A23AlaskaLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic48cb211ecb24790be4164033660ec75_D20220501-20220501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:A23AlaskaLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea37f6978bb2478bbedbdc929ab45ee3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:A23AlaskaLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb9a543882c24ab288a8fcf5e2373847_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ibrx:ReimbursementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b233a9ab4f44de78485c2c79b62f293_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf169f3dab5647ae87fdc00595ada62f_D20221212-20221212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-12</xbrli:startDate><xbrli:endDate>2022-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7ac9b711c4447f78c760f85a936a47b_I20221212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02a9bf96e8f246dab50bd1fc37514fa1_D20221212-20221212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-12</xbrli:startDate><xbrli:endDate>2022-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15ed851a2bba4c719f489412c5b04c93_I20221212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id16bb7626e4a4ddf8aef9e47dd2b70f0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79b4caaa6e7c43ee92ac011ad4231f8f_D20230215-20230215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-15</xbrli:startDate><xbrli:endDate>2023-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib182c777505d49e8985cc1dfe3ec4883_I20230215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf589f03986d4c4f8bd91e59ce16854e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenShareRepurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9923376a6fc640ad84dd1c26f06cb886_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenShareRepurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7197e4073a6c44a993ccee88c9827d5b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenShareRepurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee0c8df083bd402b92291e4cdef8b3e2_I20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:February2023ShelfRegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b3c1aa995d649f0b87f547501a451bf_D20230215-20230215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:February2023ShelfRegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-15</xbrli:startDate><xbrli:endDate>2023-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd22fd1d02ef4b8b97689228703adc95_D20210430-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-30</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i537431f5f3b94adb850787c5a596d104_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62cf93746a5f40e7af8acd878f0d0942_I20221212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedf609af3963460b9da2409f804cfa4e_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99b7bacac6fb4b6fa1a147bb0af0b1e3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2e19134c3994d4892eb6d354d8783bc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia07604abb58a44c68163e1cc335f1f6f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2e8096e87554843be3da2502f2fb4f8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9943c4a51f6441e85bc6598893e1fa6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5cf1954f1b04fd3a05943c0f49aea0e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idabb2ea247194a5db776f4872b4ddd96_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d89f301dba24a82a81a3734a866f4df_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ff7cffbd9b44155b9d53cd05a219a87_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6da548dc0629406a8bc5d9e75d8d06d5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8db8d0eea7146a6bf8d54b8044ef8d7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i266ebf8c5da54dd097877b98c122296e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i836c83fbf1c1488cb85f5c607bece830_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d38e9904e994f3c8879c104feedb7da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48b4780d2b7c496aaab05e427e63b362_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if52b579ea3554fc9bfe4ad51961a0c27_D20210304-20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-04</xbrli:startDate><xbrli:endDate>2021-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i908b2f13981e477ca4efac4b387ad72c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3554fcc3e6c04d3d8d76fbad65e1995d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9664eda2c1e467c8dd040b2e7f90f76_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ibrx:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b965bbf47a941848ab9a9b930e7f952_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e5c5c4ae84f441299889d36b9da25d8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c5705f6e6f94780a8e01cc108de9b88_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5bbe340c9c8f435088d8011b72b6800d_1"></div><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.637%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGV4dHJlZ2lvbjo3MmMzZWVjOGQwNzM0YmMyYjk1ZDEzYjViMTdhZTYwY18yMjAw_4ed04efb-c262-4169-9f93-2b05c3dceebd">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.637%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6MTljNDE3OWIwMzRiNGU1M2FiMDU0ZTExMWQ3Y2I3ZTkvdGFibGVyYW5nZToxOWM0MTc5YjAzNGI0ZTUzYWIwNTRlMTExZDdjYjdlOV8wLTAtMS0xLTI5ODM1Mg_aae0f39a-2d48-4b9a-9d04-d49753c21283">&#254;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGV4dHJlZ2lvbjo3MmMzZWVjOGQwNzM0YmMyYjk1ZDEzYjViMTdhZTYwY18yMTkz_89ef8ad9-5cc1-4351-b72e-cbe6bea18411">March&#160;31,&#160;2023</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">or</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:107%"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6NWM4YTVjMGVlZWUzNDU1YmIzZjZhMTBhYzZhMzFjMzcvdGFibGVyYW5nZTo1YzhhNWMwZWVlZTM0NTViYjNmNmExMGFjNmEzMWMzN18wLTAtMS0xLTI5ODM1Mg_226ce189-82a1-4e49-b0d5-aab7767c3129">&#168;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from                                 to                 </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGV4dHJlZ2lvbjo3MmMzZWVjOGQwNzM0YmMyYjk1ZDEzYjViMTdhZTYwY18yMjAx_c301b02f-ae9c-490f-8ff1-31e4e99b4094">001-37507</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#1b4486;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGV4dHJlZ2lvbjo3MmMzZWVjOGQwNzM0YmMyYjk1ZDEzYjViMTdhZTYwY18yMTk0_49d10065-1150-4614-b914-803a6701805c">IMMUNITYBIO,&#160;INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6NTkxODU5MzMzNmQ5NDc0ZDliZGUzZTI2YWIwZjdmYWUvdGFibGVyYW5nZTo1OTE4NTkzMzM2ZDk0NzRkOWJkZTNlMjZhYjBmN2ZhZV8wLTAtMS0xLTI5ODM1Mg_1f97d6b9-a49d-449a-b5e2-f2829c3c01d7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6NTkxODU5MzMzNmQ5NDc0ZDliZGUzZTI2YWIwZjdmYWUvdGFibGVyYW5nZTo1OTE4NTkzMzM2ZDk0NzRkOWJkZTNlMjZhYjBmN2ZhZV8wLTEtMS0xLTI5ODM1Mg_e135c82e-c40d-466d-b544-e2567e991914">43-1979754</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6NTkxODU5MzMzNmQ5NDc0ZDliZGUzZTI2YWIwZjdmYWUvdGFibGVyYW5nZTo1OTE4NTkzMzM2ZDk0NzRkOWJkZTNlMjZhYjBmN2ZhZV8zLTAtMS0xLTI5ODM1Mi90ZXh0cmVnaW9uOjJhNDlkZTgxODlmYTQ5ZmNiMTliOTg1MzllNTk3OGYzXzU_814c3ac3-cd62-4963-9721-f5df637f213f">3530 John Hopkins Court</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6NTkxODU5MzMzNmQ5NDc0ZDliZGUzZTI2YWIwZjdmYWUvdGFibGVyYW5nZTo1OTE4NTkzMzM2ZDk0NzRkOWJkZTNlMjZhYjBmN2ZhZV8zLTAtMS0xLTI5ODM1Mi90ZXh0cmVnaW9uOjJhNDlkZTgxODlmYTQ5ZmNiMTliOTg1MzllNTk3OGYzXzg_e93be681-a706-46cd-8700-6bc587f7389c">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6NTkxODU5MzMzNmQ5NDc0ZDliZGUzZTI2YWIwZjdmYWUvdGFibGVyYW5nZTo1OTE4NTkzMzM2ZDk0NzRkOWJkZTNlMjZhYjBmN2ZhZV8zLTAtMS0xLTI5ODM1Mi90ZXh0cmVnaW9uOjJhNDlkZTgxODlmYTQ5ZmNiMTliOTg1MzllNTk3OGYzXzEy_75987979-c735-45ac-a1c4-9f83c01b3f61">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6NTkxODU5MzMzNmQ5NDc0ZDliZGUzZTI2YWIwZjdmYWUvdGFibGVyYW5nZTo1OTE4NTkzMzM2ZDk0NzRkOWJkZTNlMjZhYjBmN2ZhZV8zLTEtMS0xLTI5ODM1Mg_22daba32-735d-4574-9d52-e05c5abd9981">92121</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Zip Code)</span></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGV4dHJlZ2lvbjo3MmMzZWVjOGQwNzM0YmMyYjk1ZDEzYjViMTdhZTYwY18yMTk1_59799a48-9c6e-4cd8-81af-218aa959a335">844</ix:nonNumeric>) <ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGV4dHJlZ2lvbjo3MmMzZWVjOGQwNzM0YmMyYjk1ZDEzYjViMTdhZTYwY18yMTk2_7c5a068c-233e-430b-b23a-08d6a7038bc0">696-5235</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6ZmQ2NjZmYTZkYjM3NDU5Y2E5NDA4ZTk4N2FhNjFiZjgvdGFibGVyYW5nZTpmZDY2NmZhNmRiMzc0NTljYTk0MDhlOTg3YWE2MWJmOF8xLTAtMS0xLTI5ODM1Mg_238d5835-de32-41e2-843e-630481d47914">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6ZmQ2NjZmYTZkYjM3NDU5Y2E5NDA4ZTk4N2FhNjFiZjgvdGFibGVyYW5nZTpmZDY2NmZhNmRiMzc0NTljYTk0MDhlOTg3YWE2MWJmOF8xLTItMS0xLTI5ODM1Mg_c7a5781c-ba9e-4109-9211-3943a81c5351">IBRX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6ZmQ2NjZmYTZkYjM3NDU5Y2E5NDA4ZTk4N2FhNjFiZjgvdGFibGVyYW5nZTpmZDY2NmZhNmRiMzc0NTljYTk0MDhlOTg3YWE2MWJmOF8xLTQtMS0xLTI5ODM1Mg_f0e858b3-5c2a-49d2-9bf8-dd32981bf06d">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGV4dHJlZ2lvbjo3MmMzZWVjOGQwNzM0YmMyYjk1ZDEzYjViMTdhZTYwY18yMTk3_e8697b1e-eb94-4934-beca-8af9a222d563">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGV4dHJlZ2lvbjo3MmMzZWVjOGQwNzM0YmMyYjk1ZDEzYjViMTdhZTYwY18yMjAz_55004afc-0520-468e-b748-3657dad61a9c">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.676%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:107%">&#168;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:107%">&#168;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6MjhkMTk5ZDAxMjI2NDVkNWFlMjkwMWMxOWJjNGU1NDIvdGFibGVyYW5nZToyOGQxOTlkMDEyMjY0NWQ1YWUyOTAxYzE5YmM0ZTU0Ml8xLTAtMS0xLTI5ODY3MA_27de67b1-908f-4d78-b9fb-aa0fd620db65">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:107%">&#254;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:107%"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6MjhkMTk5ZDAxMjI2NDVkNWFlMjkwMWMxOWJjNGU1NDIvdGFibGVyYW5nZToyOGQxOTlkMDEyMjY0NWQ1YWUyOTAxYzE5YmM0ZTU0Ml8xLTQtMS0xLTI5ODM1Mg_6f7d6293-4a11-4ccf-befc-c3d8f2b01480">&#254;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:107%"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6MjhkMTk5ZDAxMjI2NDVkNWFlMjkwMWMxOWJjNGU1NDIvdGFibGVyYW5nZToyOGQxOTlkMDEyMjY0NWQ1YWUyOTAxYzE5YmM0ZTU0Ml8yLTQtMS0xLTI5ODM1Mg_9d0092cb-dd51-44ee-bdfe-6d4e00d6ab0c">&#168;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGV4dHJlZ2lvbjo3MmMzZWVjOGQwNzM0YmMyYjk1ZDEzYjViMTdhZTYwY18yMTk5_af65add7-e80d-4ff0-950f-23cda480e11d">&#254;</ix:nonNumeric></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares of the Registrant&#8217;s common stock outstanding as of May&#160;5, 2023 was <ix:nonFraction unitRef="shares" contextRef="i1979cd48647c45d68e7289ac43e0c9c2_I20230505" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGV4dHJlZ2lvbjo3MmMzZWVjOGQwNzM0YmMyYjk1ZDEzYjViMTdhZTYwY18yMDYy_857f33e4-8eea-4f64-8790-3a1c61ee73f1">435,984,529</ix:nonFraction> (excluding 163,800&#160;shares held by a majority owned subsidiary of ours which are treated as treasury shares for accounting purposes).</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.137%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_10">PART I&#8212;FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_13">Item 1.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_13">Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_13">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_16">Condensed Consolidated Balance Sheets &#8211; </a></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_16">As of March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_16">&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_16">31,</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_16">&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_16">2023 and December&#160;31,&#160;2022</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_16">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_19">Condensed Consolidated Statements of Operations &#8211; </a></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_19">For the three months ended March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_19">&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_19">31,&#160;2023 and 2022</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_19">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:25.37pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_22">Condensed Consolidated Statements of Comprehensive Loss &#8211; </a></span></div><div style="padding-left:9pt;padding-right:25.37pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_22">For the three months ended March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_22">&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_22">31,</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_22">&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_22">2023 and 2022</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_22">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:25.37pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_25">Condensed Consolidated Statements of Stockholders&#8217; Deficit &#8211; </a></span></div><div style="padding-left:9pt;padding-right:25.37pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_25">&#160;For the three months ended March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_25">&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_25">31,&#160;2023 and 2022</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_25">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:33.35pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_28">Condensed Consolidated Statements of Cash Flows &#8211; </a></span></div><div style="padding-left:9pt;padding-right:33.35pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_28">For the three months ended March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_28">&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_28">31,&#160;2023 and 2022</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_28">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_31">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_31">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_103">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_103">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_103">39</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_166">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_166">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_166">58</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_169">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_169">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_169">58</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_172">PART II&#8212;OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_175">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_175">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_175">59</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_178">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_178">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_178">62</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_181">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_181">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_181">128</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_184">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_184">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_184">128</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_187">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_187">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_187">128</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_190">Item 5.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_190">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_190">128</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_193">Item 6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_193">Exhibits</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_193">129</a></span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_196">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i5bbe340c9c8f435088d8011b72b6800d_196">130</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-i-</span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i5bbe340c9c8f435088d8011b72b6800d_13"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. &#160;&#160;&#160;&#160;FINANCIAL STATEMENTS.</span></div><div id="i5bbe340c9c8f435088d8011b72b6800d_16"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ImmunityBio, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Unaudited) </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfNC0xLTEtMS0yOTgzNTI_0ff5a821-00a4-4ebd-bf48-ac03cf684cb4">88,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfNC0zLTEtMS0yOTgzNTI_f672d450-1618-470c-a998-f84f61645ad4">104,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfNS0xLTEtMS0yOTgzNTI_41c01e09-386d-46f3-9eda-102ae15ebc45">2,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfNS0zLTEtMS0yOTgzNTI_31d60dbd-7a51-42a6-b0b7-a941f06c2d7a">2,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Due from related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:DueFromRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfNi0xLTEtMS0yOTgzNTI_ff33041b-222b-486e-92b0-2a44e56f1f8d">1,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:DueFromRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfNi0zLTEtMS0yOTgzNTI_e49d098c-2611-4c07-8f80-f85b2b9837ad">1,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets (including amounts with related parties)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfNy0xLTEtMS0yOTgzNTI_48e5910e-8261-481d-8368-3bfd1d82090b">20,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfNy0zLTEtMS0yOTgzNTI_3ccc73ba-9423-4c4c-8824-2fe943de1202">31,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfOC0xLTEtMS0yOTgzNTI_ae5d55f4-aca9-4de5-b911-30d13230f742">113,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfOC0zLTEtMS0yOTgzNTI_30b786d7-a834-4f80-aeff-bef64dac0ef3">140,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Marketable securities, noncurrent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfOS0xLTEtMS0yOTgzNTI_d9cb1545-0282-4aaf-8ec5-859ec63b275a">820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfOS0zLTEtMS0yOTgzNTI_1a9e48c0-169b-429b-8952-ca6625fb909a">840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTAtMS0xLTEtMjk4MzUy_ca707a5d-de53-4416-8860-39e783fb0ed7">154,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTAtMy0xLTEtMjk4MzUy_7df1999a-00b1-427b-95e8-8a57292474c6">143,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTItMS0xLTEtMjk4MzUy_3bebf70e-13aa-42ff-b0f7-72ddd3ffb7a0">19,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTItMy0xLTEtMjk4MzUy_6defdf74-8625-4a3a-8b0f-448a16be617a">20,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Convertible note receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:ConvertibleNoteReceivableNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTMtMS0xLTEtMjk4MzUy_5301bdd3-c79e-4930-bc9d-1a95185a2b5b">6,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="ibrx:ConvertibleNoteReceivableNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTMtMy0xLTEtMjk4MzUy_ffe9cc61-23f1-4f6f-9201-6e77412e989f">6,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease right-of-use assets, net (including amounts with related parties)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTQtMS0xLTEtMjk4MzUy_fc331462-e41c-4f0c-91fa-80a64c6b8441">44,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTQtMy0xLTEtMjk4MzUy_0f4a280e-f124-4d92-926b-9c814c89ae0b">45,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other assets (including amounts with related parties)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTUtMS0xLTEtMjk4MzUy_871798b7-e5dd-41e0-a910-3a1a74a5c501">4,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTUtMy0xLTEtMjk4MzUy_10e0d196-4899-4ce8-b4bf-0c1abbd3cde7">4,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total assets</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTYtMS0xLTEtMjk4MzUy_211b2c13-f685-4ce8-94b9-41e08107d5cc">343,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTYtMy0xLTEtMjk4MzUy_d2d5a3fb-41c2-4b4c-8870-68f6db111501">362,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTktMS0xLTEtMjk4MzUy_39a8ff44-6c3b-4273-9775-7d8267c1b5b3">33,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTktMy0xLTEtMjk4MzUy_c8d600e2-b207-4667-9125-145518141b61">21,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjAtMS0xLTEtMjk4MzUy_ff311b4f-c5e0-4674-81fb-80261b67d1aa">54,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjAtMy0xLTEtMjk4MzUy_0418a7c6-18a2-44ec-b3e1-4dccf549c369">41,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.07pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Related-party promissory notes, net of discounts and deferred issuance costs (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_73">Note 9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8c875c85efb244079066f90b6b550c50_I20230331" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjEtMS0xLTEtMjk4MzUy_bed3b18b-cc10-47e0-9ae3-feea1a923fee">441,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bffc59bc82a4092b0b095eb4b104f99_I20221231" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjEtMy0xLTEtMjk4MzUy_502c674d-0129-4d6b-ad7f-79c0c4894f82">431,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.07pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Related-party convertible note at fair value (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_55">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_73">Note 9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c37984b4ee4c4e8d32a3fcda72fd96_I20230331" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjItMS0xLTEtMzIxNjM3_18b28fd9-52c2-45be-890a-c5d0a8917529">29,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6fd5dc04474fc6ad30fdb536534995_I20221231" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjItMy0xLTEtMzIxNjM3_45f0edea-b13d-40fd-bd79-cbb0f73f305f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Due to related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:AccountsPayableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjItMS0xLTEtMjk4MzUy_3645c739-f1a4-45db-8d66-335079274b96">2,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:AccountsPayableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjItMy0xLTEtMjk4MzUy_562da69b-d720-4d24-b114-ebee0ed9ab2c">3,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease liabilities (including amounts with related parties)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjMtMS0xLTEtMjk4MzUy_f639a6e5-0d4e-455c-a8cb-903fc891dce5">2,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjMtMy0xLTEtMjk4MzUy_a793bdcf-4eb0-492a-8d37-75e4d926ef8b">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjQtMS0xLTEtMjk4MzUy_f296dbac-fa1e-418b-9975-810e4a790c4a">564,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjQtMy0xLTEtMjk4MzUy_7abe1a71-de9b-4535-b67b-4e14eb810a90">500,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Related-party convertible notes and accrued interest, net of discount (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_73">Note 9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c37984b4ee4c4e8d32a3fcda72fd96_I20230331" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjYtMS0xLTEtMjk4MzUy_e89948c5-5c0e-4a93-b6c6-a69b28033eca">245,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6fd5dc04474fc6ad30fdb536534995_I20221231" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjYtMy0xLTEtMjk4MzUy_eab6e70d-3578-4ee9-aa62-5eec2f4c71c9">241,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease liabilities, less current portion (including amounts with related parties)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjctMS0xLTEtMjk4MzUy_d392c161-d14a-45d9-bddc-89f9fb3babf9">46,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjctMy0xLTEtMjk4MzUy_ccd45466-c473-43e4-b32a-99fb4a3ff5e4">47,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjgtMS0xLTEtMzA3NTM5_a3c69c05-f454-4030-bdc8-d9add55c879d">17,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjgtMy0xLTEtMzA3NTM5_903d1d2c-12db-4388-a4b0-f4569795ca4a">21,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjktMS0xLTEtMjk4MzUy_9128d65e-4220-4525-b96a-405ee5eedc73">462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjktMy0xLTEtMjk4MzUy_9e694868-c15c-4fac-afa2-e9de4bbdd89b">457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzAtMS0xLTEtMjk4MzUy_f37b2399-c055-4152-8c4b-5610f3ace70c">875,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzAtMy0xLTEtMjk4MzUy_be86849a-d457-4188-9fd1-8c1c75ee1802">812,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Commitments and contingencies (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_67">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzEtMS0xLTEtMjk4MzUy_0636d345-91bb-458d-b1e7-92b2a1a674ee"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzEtMy0xLTEtMjk4MzUy_f336d7fb-c9b3-4977-bd1e-f91675274122"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Stockholders&#8217; deficit:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMC0xLTEtMjk4MzUyL3RleHRyZWdpb246M2NmYmNmZjI1Y2QxNGM4MjlkOTg4NTEyYmUyZjZmN2VfNTQ5NzU1ODE0MTQ5_010b42aa-f45d-49cb-bd26-65c6b4856918"><ix:nonFraction unitRef="usdPerShare" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMC0xLTEtMjk4MzUyL3RleHRyZWdpb246M2NmYmNmZjI1Y2QxNGM4MjlkOTg4NTEyYmUyZjZmN2VfNTQ5NzU1ODE0MTQ5_06bf270c-3df0-4ea1-b6db-b880b25728f1">0.0001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction unitRef="shares" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMC0xLTEtMjk4MzUyL3RleHRyZWdpb246M2NmYmNmZjI1Y2QxNGM4MjlkOTg4NTEyYmUyZjZmN2VfMzI_2683f9a1-f11d-49cf-937b-8cb85b485115"><ix:nonFraction unitRef="shares" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMC0xLTEtMjk4MzUyL3RleHRyZWdpb246M2NmYmNmZjI1Y2QxNGM4MjlkOTg4NTEyYmUyZjZmN2VfMzI_9e399d50-c140-49a5-8581-b4f12ac49ca5">900,000,000</ix:nonFraction></ix:nonFraction>&#160;shares authorized </span></div><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;&#160;&#160;as of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively; <ix:nonFraction unitRef="shares" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMC0xLTEtMjk4MzUyL3RleHRyZWdpb246M2NmYmNmZjI1Y2QxNGM4MjlkOTg4NTEyYmUyZjZmN2VfOTU_6a096be7-a367-41f4-814d-698b789e4b40"><ix:nonFraction unitRef="shares" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMC0xLTEtMjk4MzUyL3RleHRyZWdpb246M2NmYmNmZjI1Y2QxNGM4MjlkOTg4NTEyYmUyZjZmN2VfOTU_afc86ec6-795c-4c9a-bae0-a5d39a72078c">435,923,104</ix:nonFraction></ix:nonFraction> and</span></div><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;&#160;&#160;<ix:nonFraction unitRef="shares" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMC0xLTEtMjk4MzUyL3RleHRyZWdpb246M2NmYmNmZjI1Y2QxNGM4MjlkOTg4NTEyYmUyZjZmN2VfNTQ5NzU1ODE0MTQx_19530e87-6bae-4ece-ac43-c5c5d1d6c9f8"><ix:nonFraction unitRef="shares" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMC0xLTEtMjk4MzUyL3RleHRyZWdpb246M2NmYmNmZjI1Y2QxNGM4MjlkOTg4NTEyYmUyZjZmN2VfNTQ5NzU1ODE0MTQx_f3b12408-f3c9-4bf0-8e59-98b0e4824716">421,569,115</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31,&#160;2023 and</span></div><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;&#160;&#160;December&#160;31,&#160;2022, respectively; excluding treasury stock, <ix:nonFraction unitRef="shares" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMC0xLTEtMjk4MzUyL3RleHRyZWdpb246M2NmYmNmZjI1Y2QxNGM4MjlkOTg4NTEyYmUyZjZmN2VfNTQ5NzU1ODE0MTQ1_3773295d-d22b-431d-9a8a-f7cd2cea39ee"><ix:nonFraction unitRef="shares" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMC0xLTEtMjk4MzUyL3RleHRyZWdpb246M2NmYmNmZjI1Y2QxNGM4MjlkOTg4NTEyYmUyZjZmN2VfNTQ5NzU1ODE0MTQ1_9d79d790-9694-4544-91e8-f037caa811f0">163,800</ix:nonFraction></ix:nonFraction>&#160;shares</span></div><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;&#160;&#160;outstanding as of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMS0xLTEtMjk4MzUy_baa8364c-3bf1-44ef-8ef1-d1c77c6fc261">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMy0xLTEtMjk4MzUy_3e7edfe2-56b8-4bd0-8320-d195963e28a0">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzQtMS0xLTEtMjk4MzUy_a87e2c4d-61e5-438f-bc9a-55772593546f">1,965,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzQtMy0xLTEtMjk4MzUy_5893f6c3-8e16-4132-be01-227f68a86d04">1,930,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzUtMS0xLTEtMjk4MzUy_3d310f6a-ecf7-49c9-b1db-739dffedd720">2,494,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzUtMy0xLTEtMjk4MzUy_08d820e7-9e9f-45c9-80cc-7d406317321b">2,378,488</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzYtMS0xLTEtMjk4MzUy_d7c07581-67d2-49a9-a40c-9c35e3e93819">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzYtMy0xLTEtMjk4MzUy_1df05fcc-1733-4f81-b76a-0c3295f0f095">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total ImmunityBio stockholders&#8217; deficit</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzctMS0xLTEtMjk4MzUy_7635b009-2586-475e-a606-78830c7047ee">528,983</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzctMy0xLTEtMjk4MzUy_0dd9ec38-f1bf-47ba-ab5b-6c1c1679a54d">447,327</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" sign="-" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzgtMS0xLTEtMjk4MzUy_334eaacc-02c0-4b39-9a76-dbb0d590b47c">2,733</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" sign="-" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzgtMy0xLTEtMjk4MzUy_c04abdf2-37ff-4ebb-9d6a-e8fe45c3c98c">2,493</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total stockholders&#8217; deficit</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzktMS0xLTEtMjk4MzUy_405542fe-bfba-4bc8-aed3-8fce769eeed8">531,716</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzktMy0xLTEtMjk4MzUy_7bd484fd-968c-4037-a8ca-582a192adfb3">449,820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total liabilities and stockholders&#8217; deficit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfNDAtMS0xLTEtMjk4MzUy_bf7eb975-1d3d-469e-91b6-315bdac87627">343,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfNDAtMy0xLTEtMjk4MzUy_a6ca2e6d-764a-47fc-b8ca-519f77112dd9">362,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_19"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ImmunityBio, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:71.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.177%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March&#160;31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMi0xLTEtMS0yOTgzNTI_1be49046-ad7c-407d-9705-86bde1d5f18a">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMi0zLTEtMS0yOTgzNTI_33b273b7-7b78-4256-9cee-5038fb3cc850">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:11.07pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development (including amounts </span></div><div style="margin-top:0.75pt;padding-left:11.07pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;with related parties)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfNC0xLTEtMS0yOTgzNTI_baef9bbb-0e18-4a59-87a1-2f5d4539dfb9">79,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfNC0zLTEtMS0yOTgzNTI_a57084f3-a1e0-4ced-ae8c-a7f5cb2dbfea">55,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:11.07pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Selling, general and administrative (including amounts </span></div><div style="margin-top:0.75pt;padding-left:11.07pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;with related parties)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfNS0xLTEtMS0yOTgzNTI_05b1df1c-57e6-4606-9ee9-035f653c2086">32,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfNS0zLTEtMS0yOTgzNTI_81c7a97b-075b-4ab3-9064-f84150ce20de">40,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfNy0xLTEtMS0yOTgzNTI_9cfc2866-84ec-4167-88cd-6bd637729dda">111,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfNy0zLTEtMS0yOTgzNTI_222531f6-9fee-4b1b-a7be-0176cd6c952f">95,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfOC0xLTEtMS0yOTgzNTI_b08795b3-d16b-4fce-84de-4acaa2ea0c24">111,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfOC0zLTEtMS0yOTgzNTI_b5e47856-197e-40b4-ab49-d48596c9ba51">95,972</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest and investment income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTAtMS0xLTEtMjk4MzUy_5582598a-9008-4218-b6bf-0ee260a19ff0">673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTAtMy0xLTEtMjk4MzUy_cdc49f3f-f919-4f7c-a9ab-c05a5b69a287">1,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest expense (including amounts with related parties)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTEtMS0xLTEtMjk4MzUy_377382c3-22dc-411a-9f9a-a6cbf4077073">29,816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTEtMy0xLTEtMjk4MzUy_9882307c-5b20-4e7e-a127-5252496f96c2">8,491</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss on equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTItMS0xLTEtMjk4MzUy_be082988-52df-4858-858f-32b9db208cda">2,337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTItMy0xLTEtMjk4MzUy_4a6f1859-73b4-4346-86b6-bdd882345b62">197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTMtMS0xLTEtMjk4MzUy_92c7ed2e-fa84-489d-a90c-437917760e27">27,554</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTMtMy0xLTEtMjk4MzUy_f2cb7d11-eb26-47a2-9b1c-6e1362bc69bd">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other expense, net (including amounts <br/>&#160;&#160;&#160;with related parties)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTQtMS0xLTEtMjk4MzUy_3ab3a03b-3ee9-4986-8d50-06ea6d583437">1,077</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTQtMy0xLTEtMjk4MzUy_8a3c3dbb-0961-4730-8598-548d4b51afac">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTUtMS0xLTEtMjk4MzUy_fc5e51c5-403f-42a1-bfba-8fcce98b5d2b">5,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTUtMy0xLTEtMjk4MzUy_558a4127-957d-4287-b287-fc0c79495652">7,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Loss before income taxes and noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTYtMS0xLTEtMjk4MzUy_6279d8b6-08e4-46e5-82d6-f5a0d646d736">116,583</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTYtMy0xLTEtMjk4MzUy_29ac70bc-21b5-495b-ac05-9bb8b8b80f82">102,998</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTctMS0xLTEtMjk4MzUy_207610f3-c3bc-45fd-9bea-3595c1f1660a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTctMy0xLTEtMjk4MzUy_06a9bc61-359e-40f2-9186-664eaa60d38d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTgtMS0xLTEtMjk4MzUy_823c9ffe-90b9-4b47-b30f-a97adbb5aee3">116,583</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTgtMy0xLTEtMjk4MzUy_d3815d15-1073-4a9b-a753-de139290dedf">102,998</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss attributable to noncontrolling interests, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTktMS0xLTEtMjk4MzUy_ba3a37ac-acaa-4147-83f1-b3b1bdbf203a">240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTktMy0xLTEtMjk4MzUy_99ceb1fa-c0ec-46a6-9e13-238ec9a51dc3">172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss attributable to ImmunityBio common stockholders</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMjAtMS0xLTEtMjk4MzUy_af484bff-e105-47fa-b990-c698759b67c9">116,343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMjAtMy0xLTEtMjk4MzUy_f20d937c-38a3-443e-b10a-181d21808e69">102,826</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per ImmunityBio common share &#8211; basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMjItMS0xLTEtMjk4MzUy_2c54a149-a1a3-4db8-b613-e55ead07393f"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMjItMS0xLTEtMjk4MzUy_933e4846-3bb7-44a3-91f9-e45d031b23c6">0.27</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMjItMy0xLTEtMjk4MzUy_414bc521-845b-4133-9efb-a4f99c07fa9f"><ix:nonFraction unitRef="usdPerShare" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMjItMy0xLTEtMjk4MzUy_ee738079-e782-4f80-9956-d70a1aecbad4">0.26</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average number of common shares used in computing </span></div><div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;net loss per share &#8211; basic and diluted</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMjQtMS0xLTEtMjk4MzUy_e9f9e18d-53d5-4211-b81f-fceeded34157"><ix:nonFraction unitRef="shares" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMjQtMS0xLTEtMjk4MzUy_ffa40ae9-1291-4d0d-86da-d1c4c40fdb5b">428,381,485</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMjQtMy0xLTEtMjk4MzUy_3685d624-dac7-43d7-9383-a871cd032446"><ix:nonFraction unitRef="shares" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMjQtMy0xLTEtMjk4MzUy_aa2a8355-c0c7-464f-acee-e2cd7fa00647">397,882,441</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_22"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ImmunityBio, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Three Months Ended<br/>March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfMi01LTEtMS0yOTgzNTI_8107529b-1251-447c-8c19-fd66bd1f9c8f">116,583</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfMi03LTEtMS0yOTgzNTI_2ee4f5b7-5239-488f-ba3c-1eef31bf4b71">102,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other comprehensive income (loss), net of income taxes:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net unrealized gains (losses) on available-for-sale securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfNC01LTEtMS0yOTgzNTI_2a25af3a-4b04-413d-9919-ca679be626e9">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfNC03LTEtMS0yOTgzNTI_9df22adb-9e9e-4cf6-b6e3-81895741dec3">310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:11.07pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Reclassification of net realized gains on </span></div><div style="margin-top:0.75pt;padding-left:11.07pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;available-for-sale securities included in net loss</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfNS01LTEtMS0yOTgzNTI_49f16ac3-6798-4d1e-beb4-6e2e97967438">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfNS03LTEtMS0yOTgzNTI_fcf288ae-2a76-49e5-aa08-ef45915a709d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfNi01LTEtMS0yOTgzNTI_c9867188-d2d9-4ecf-aa3c-1311ab6eb42e">226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfNi03LTEtMS0yOTgzNTI_389badaa-c72c-40a4-82f4-aa0f843af09f">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total other comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfNy01LTEtMS0yOTgzNTI_f78c498d-8251-4a21-8af3-3e8f044f7cab">216</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfNy03LTEtMS0yOTgzNTI_d5cc221a-125e-4b24-b64e-de405bd0f8bf">371</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfOC01LTEtMS0yOTgzNTI_b24d2e62-6166-4cad-bbee-18a3c76c8d29">116,799</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfOC03LTEtMS0yOTgzNTI_d95bc94a-9929-4a25-9e4c-622211c0fb10">103,369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Comprehensive loss attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfOS01LTEtMS0yOTgzNTI_2a4f3673-aefb-4344-9b18-492d49d6c1e1">240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfOS03LTEtMS0yOTgzNTI_c915c41b-81c8-4921-8688-a8e2b9bf8f2c">172</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Comprehensive loss attributable to ImmunityBio </span></div><div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;common stockholders</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfMTAtNS0xLTEtMjk4MzUy_90f64319-160a-41ad-96e6-b6b8b934d0da">116,559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfMTAtNy0xLTEtMjk4MzUy_1ba83652-5d9c-436b-aece-e3b4b37fe670">103,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_25"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ImmunityBio, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Deficit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.699%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.699%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.553%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.918%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended March 31, 2023</span></td></tr><tr style="height:30pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Common Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Paid-in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Capital</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Accumulated <br/>Deficit </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Accumulated</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Other</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Comprehensive</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Income (Loss)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">ImmunityBio</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Deficit </span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Noncontrolling <br/>Interests </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Deficit </span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Balance as of December&#160;31,&#160;2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i1108b0a3a2da4efeb2c5a0cbce300858_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMy0yLTEtMS0yOTgzNTI_45f8d403-eb79-4fc6-b629-f551008205ff">421,569,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1108b0a3a2da4efeb2c5a0cbce300858_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMy00LTEtMS0yOTgzNTI_ab35cee3-6d9e-485b-b7cc-5f9ef781bcfc">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i384e76ee6b5e47da8ccb8a62c32b63a0_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMy02LTEtMS0yOTgzNTI_5050f7a8-8041-4fe9-84cf-02a604d77b72">1,930,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i60ef9d75f1cd4d8da9176583a06fab46_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMy04LTEtMS0yOTgzNTI_dee27707-fefd-49ff-9a19-b66337fad1fa">2,378,488</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0d3142cb095746858e5333f482cb2517_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMy0xMC0xLTEtMjk4MzUy_27205cae-adc4-43ee-b492-36dd3c0ef709">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ib92ff44aff9c4c1cb5a8aefa1497878a_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMy0xMi0xLTEtMjk4MzUy_478d86a2-d41b-43f7-afd5-92c20a574b22">447,327</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ie69a285b23fe4b36860e2b1807e68608_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMy0xNC0xLTEtMjk4MzUy_4a0bb01f-ee6d-425a-a54e-c6b71529d9c1">2,493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMy0xNi0xLTEtMjk4MzUy_fa588910-c25a-42f8-8cef-ca608ec155c0">449,820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Issuance of shares in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">registered direct</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> offering,</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;&#160;&#160;net of discount and offering costs of $<ix:nonFraction unitRef="usd" contextRef="i2a8153bf4934499497bc454385181d0f_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNC0wLTEtMS0zMjE2OTAvdGV4dHJlZ2lvbjplZDczNjJlZDMyYTU0NzkzYTE2NjJiYzgyMzZjOGVhYV8xMDk5NTExNjI3OTQ1_55f33eb9-777c-446a-86f8-5da2a2b410f0">2,046</ix:nonFraction> </span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;&#160;&#160;and value ascribed to associated warrants (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_82">Note 11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc8a064e60104a7c8b5bbf20eee46ddd_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNC0yLTEtMS0zMjE2OTg_0dc41def-4595-4d9a-8422-31377b52da8b">14,072,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8a064e60104a7c8b5bbf20eee46ddd_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNC00LTEtMS0zMjE2OTg_59ad9222-cfc8-4673-b0ed-ded524d56133">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3839414c7384bb580b2b6ee59797d9b_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNC02LTEtMS0zMjE2OTg_bac2c017-3b80-4cc2-908f-f6cf10d7e556">24,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i685f344965a54fa99a8f56307085368a_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNC0xMi0xLTEtMzIxNjk4_db90b402-4296-4ed1-9ab2-73778bb8cdab">24,256</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a8153bf4934499497bc454385181d0f_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNC0xNi0xLTEtMzIxNjk4_73bf91c4-8da2-4eb8-840b-c91d04b4d891">24,256</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Stock-based compensation expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8d76d948cf7740b181d0c99cf8712fc2_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNC02LTEtMS0yOTgzNTI_27ab0cfd-ba08-4abb-97d0-791b50203e27">10,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9308889d86f04fb9a83d5131a6f7b08a_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNC0xMi0xLTEtMjk4MzUy_d8eabe6d-55b1-45a5-bb23-e06ddda6a8db">10,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNC0xNi0xLTEtMjk4MzUy_94abb90e-aabf-4560-bd2c-079cad5a9441">10,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i07a8763cb5b94c5b9da351bedacfbe75_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNS0yLTEtMS0yOTgzNTI_75cdb710-293a-47fc-8c27-05a30da4b0b7">81,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8d76d948cf7740b181d0c99cf8712fc2_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNS02LTEtMS0yOTgzNTI_425d6a40-9049-4769-bf6d-f5e6f5755be2">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9308889d86f04fb9a83d5131a6f7b08a_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNS0xMi0xLTEtMjk4MzUy_686ba1db-6553-4583-acda-4167e0a412fb">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNS0xNi0xLTEtMjk4MzUy_dcfa8e04-e5ea-414e-9b9f-ad74401e6900">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Vesting of restricted stock units (RSUs)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i07a8763cb5b94c5b9da351bedacfbe75_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNi0yLTEtMS0yOTgzNTI_2dcf6a4d-68a6-4307-9463-66feed34ad99">313,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net share settlement for RSUs vesting</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="i07a8763cb5b94c5b9da351bedacfbe75_D20230101-20230331" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNy0yLTEtMS0yOTgzNTI_0661158d-668a-4a7e-942f-99641295b384">113,638</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8d76d948cf7740b181d0c99cf8712fc2_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNy02LTEtMS0yOTgzNTI_c7c99c8b-f679-4652-a48f-c562c5c5e353">357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i9308889d86f04fb9a83d5131a6f7b08a_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNy0xMi0xLTEtMjk4MzUy_e7ebc061-3d07-4565-8d3a-f6a5ead8b5a3">357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNy0xNi0xLTEtMjk4MzUy_cc698c32-5aee-41fd-9b92-8a7fc0d59911">357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:0.75pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other comprehensive (loss) income, net of tax</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1eba2b75f17a4ca598c012c58e915b51_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfOC0xMC0xLTEtMjk4MzUy_2c219cc4-c53e-4b1b-88bd-8007c98a70d1">216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i9308889d86f04fb9a83d5131a6f7b08a_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfOC0xMi0xLTEtMjk4MzUy_27512d6b-a55c-4706-86d3-239868655fad">216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfOC0xNi0xLTEtMjk4MzUy_14bb5fcd-0578-4c3a-923b-5343b2c455ed">216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i5f178e191e6a46e2976df6b30834b5d9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfOS04LTEtMS0yOTgzNTI_87944a81-a1b0-4327-b269-db0b8a9fbda0">116,343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i9308889d86f04fb9a83d5131a6f7b08a_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfOS0xMi0xLTEtMjk4MzUy_7a3adcaf-21e5-453c-8a98-c23cc5d7fc33">116,343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i5d185f091af84493a3bd1346fcb31032_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfOS0xNC0xLTEtMjk4MzUy_c9955b87-d002-4680-87e9-8678ccc4711f">240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfOS0xNi0xLTEtMjk4MzUy_c3531e57-82f5-4da0-bcc3-77a5309a237c">116,583</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Balance as of March&#160;31,&#160;2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i7f9f0c08e99449fe863bdc24f35895c6_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMTAtMi0xLTEtMjk4MzUy_b90ec8e7-3d2e-42bf-934b-3a2f3f7f9e40">435,923,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7f9f0c08e99449fe863bdc24f35895c6_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMTAtNC0xLTEtMjk4MzUy_551eb9e6-6727-4e97-92ba-700f04ac753d">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie1c226aeaa40452fa58e614e48f7b0e9_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMTAtNi0xLTEtMjk4MzUy_e55a7436-90f4-413d-9a38-b155b5685fac">1,965,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2b3e85a60781496d8fae99c082b6df71_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMTAtOC0xLTEtMjk4MzUy_ecbbe901-7df4-413d-8a89-882882b019eb">2,494,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="id72ba77db0da468294e9f5b45ac3b0a5_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMTAtMTAtMS0xLTI5ODM1Mg_c622804e-faa9-4710-ac5a-1fb05a51b5be">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="if2aa017e45e2426088230d3c95d08e1b_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMTAtMTItMS0xLTI5ODM1Mg_54ab713b-4570-45ec-8b6f-b0ed38d889cb">528,983</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i421c4794536c433089794d37f3ef6014_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMTAtMTQtMS0xLTI5ODM1Mg_aff5721a-f85e-43a7-9098-18d2a8dbd986">2,733</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMTAtMTYtMS0xLTI5ODM1Mg_dfc4c0ce-41eb-400e-ae32-f01a04eed5eb">531,716</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ImmunityBio, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Deficit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.893%"><tr><td style="width:1.0%"></td><td style="width:34.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.825%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended March 31, 2022</span></td></tr><tr style="height:31pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Common Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Paid-in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Capital </span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Accumulated <br/>Deficit </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Income (Loss)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ImmunityBio</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217;</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deficit</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Noncontrolling <br/>Interests </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217;</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deficit</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 10pt;text-indent:-9pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31,&#160;2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6a407074713405e90702d702e4309b8_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNC0yLTEtMS0yOTgzNTI_90529e81-9276-4410-8519-beb9a33d39ce">397,830,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6a407074713405e90702d702e4309b8_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNC00LTEtMS0yOTgzNTI_8d248e0f-0a3d-4d12-8389-acba0ca5f0ea">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i256d0f34b668479ba66bd30a77315d12_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNC02LTEtMS0yOTgzNTI_5b73853f-e106-4c40-87a5-21cebf0a0320">1,719,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f5b67947f77418ea08709523b53563d_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNC04LTEtMS0yOTgzNTI_bcaeec28-175d-4937-a18b-f6824f3bf2bb">1,961,921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bb3408a05c6401c857209bb9b667953_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNC0xMC0xLTEtMjk4MzUy_06faa357-8ca3-4c55-b4fc-2cb90a8ab7be">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b766e2f320f442fa3f3102f9c9b0916_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNC0xMi0xLTEtMjk4MzUy_c2f77e05-c70f-41c3-917d-15bca8ef9156">242,173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida858a14f0f94f0698e26382d0222a7d_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNC0xNC0xLTEtMjk4MzUy_9509f5b4-01b0-4ee8-bf44-ceba6fc5905d">1,740</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1f4ccbe1a254187a0abcd2fa0ef3671_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNC0xNi0xLTEtMjk4MzUy_0ec5dcec-cd21-4c1c-8949-0fbfc6312350">243,913</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5651caa3fe44d1a48b78dbac979b78_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNS02LTEtMS0yOTgzNTI_3f46c5ae-d1b1-4610-bee1-b80d1316f52a">10,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id819e1b1f878495a86da38176b293b2b_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNS0xMi0xLTEtMjk4MzUy_3b46b5ae-e382-42ba-a5e3-fdb435dc7b73">10,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNS0xNi0xLTEtMjk4MzUy_8f058d7f-816b-43f9-ac92-4115b44d4dc6">10,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54462f901730493b9ccffd2922a2f380_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNi0yLTEtMS0yOTgzNTI_09232d9e-41eb-4a32-8a2d-a3238770bee5">14,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5651caa3fe44d1a48b78dbac979b78_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNi02LTEtMS0yOTgzNTI_cfbb077e-59af-4187-b94d-395b6af3ab7d">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id819e1b1f878495a86da38176b293b2b_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNi0xMi0xLTEtMjk4MzUy_1bfdd252-0488-4f69-89bc-f5a008bf3a26">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNi0xNi0xLTEtMjk4MzUy_6a49fcc6-ca92-4104-abd4-86d4d6f5cf8e">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54462f901730493b9ccffd2922a2f380_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNy0yLTEtMS0yOTgzNTI_947807d7-40ab-4f3f-a6c8-c42a1eb49af8">177,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net share settlement for RSUs vesting</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i54462f901730493b9ccffd2922a2f380_D20220101-20220331" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfOC0yLTEtMS0yOTgzNTI_c78ad01c-f1f2-4297-b371-d7abd31324e1">65,832</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5651caa3fe44d1a48b78dbac979b78_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfOC02LTEtMS0yOTgzNTI_1d7f97cd-6fc3-4b08-815d-14588422f2c2">372</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id819e1b1f878495a86da38176b293b2b_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfOC0xMi0xLTEtMjk4MzUy_7b526be1-048c-450e-99f9-72852cd77a6a">372</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfOC0xNi0xLTEtMjk4MzUy_34ce0932-4bd2-4d8b-83ba-bd17fc36328e">372</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i945c8a203dcd4d97bafa5902b5b19503_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfOS0xMC0xLTEtMjk4MzUy_e5393855-0148-4d5e-84d4-2c113afacc06">371</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id819e1b1f878495a86da38176b293b2b_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfOS0xMi0xLTEtMjk4MzUy_58767c22-d1fa-4b38-9f82-a50d54d64698">371</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfOS0xNi0xLTEtMjk4MzUy_df0334dd-24fc-48ba-acd3-b66423c70392">371</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic17e90ac99424c33b733b73a4517455d_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTAtOC0xLTEtMjk4MzUy_c82d8558-9233-4438-89a6-67a5c3d021fa">102,826</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id819e1b1f878495a86da38176b293b2b_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTAtMTItMS0xLTI5ODM1Mg_1e9737a7-35c9-44ae-8da1-7f4cc020e00a">102,826</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23f7671e764e4c5ca223c10daf774bf2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTAtMTQtMS0xLTI5ODM1Mg_3b20b449-8412-47ab-912f-f94907344916">172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTAtMTYtMS0xLTI5ODM1Mg_60aa97d1-6db3-4797-b481-5eb75cb862e1">102,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March&#160;31,&#160;2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i005d4769e3bc4a9eb596324bf4986a4e_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTEtMi0xLTEtMjk4MzUy_5bda07bd-a3dd-40ce-9fb8-ab3e2d469698">397,956,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i005d4769e3bc4a9eb596324bf4986a4e_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTEtNC0xLTEtMjk4MzUy_3c09d0fd-12bb-47d9-af80-5718803638ee">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i700388aac6ea44b2a5558e75c3835e46_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTEtNi0xLTEtMjk4MzUy_d185d746-0752-471e-9590-a58b735b78c6">1,729,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61c1394ce2204f349c8ec7aa84ca4c0e_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTEtOC0xLTEtMjk4MzUy_1dace43c-0d7c-4ffc-8b7c-df8f05e79112">2,064,747</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29522190e504495593abd361f7b24b19_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTEtMTAtMS0xLTI5ODM1Mg_f0f420f9-dcd7-4143-b063-039121088f19">367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81bd9de2db4d40b9879aff68abbefe52_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTEtMTItMS0xLTI5ODM1Mg_0792628c-2a2a-4675-9364-d6c9174348fb">335,644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i168358a7c0ed479b8476f4d8e155cdde_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTEtMTQtMS0xLTI5ODM1Mg_c95d126a-1969-46f6-833d-c28940b33134">1,912</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f8290d605c9473bbd497404748ff594_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTEtMTYtMS0xLTI5ODM1Mg_4ae0b64d-1a2a-4b65-be4f-5ffd1ba3cb05">337,556</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ImmunityBio, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Three Months Ended<br/>March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMy0xLTEtMS0yOTgzNTI_238baa51-5601-44f0-bbe0-dde894cfcac3">116,583</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMy0zLTEtMS0yOTgzNTI_225a4a32-0cc6-4d86-bf42-6102ac07ea17">102,998</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNS0xLTEtMS0yOTgzNTI_a2540820-2e56-484c-a3df-ceebfb25ef13">10,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNS0zLTEtMS0yOTgzNTI_2699e4e0-5ba1-42f6-a69e-f9aa816da91e">10,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNi0xLTEtMS0zMjE3MTM_eb7ff5ae-f38e-4026-9ebb-8e846ecb6cf5">27,554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNi0zLTEtMS0zMjE3MTM_ae459932-036c-4ce9-8148-9aed62a479ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Transaction costs allocated to warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="ibrx:TransactionCostsWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNy0xLTEtMS0zMjE3MTM_fda8a159-e0ab-4bf7-8563-ab4bd1b444ce">984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="ibrx:TransactionCostsWarrantLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNy0zLTEtMS0zMjE3MTM_4f11c3d6-4fda-4287-afab-3b67a78e7e5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Non-cash interest items, net (including amounts with related parties)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="ibrx:NonCashInterestIncomeExpenseFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNi0xLTEtMS0yOTgzNTI_6672005e-f88c-4dc2-bf34-3f3c683ee0f8">2,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="ibrx:NonCashInterestIncomeExpenseFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNi0zLTEtMS0yOTgzNTI_4fc5c9c0-e95c-4429-b4d7-edbb3aa31e74">3,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Amortization of related-party notes discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNy0xLTEtMS0yOTgzNTI_af2e4009-7e91-4711-85ed-3d2af0f43208">11,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNy0zLTEtMS0yOTgzNTI_70f6b51d-e9ee-4da3-afa3-06492974d563">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfOC0xLTEtMS0yOTgzNTI_0f27b875-3d70-439c-b22d-4d99ec55f4db">4,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfOC0zLTEtMS0yOTgzNTI_18526fbf-4aee-4faf-b0b3-deebe69942df">4,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Non-cash lease expense related to operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMTAtMS0xLTEtMjk4MzUy_b53b962f-98b0-472c-8b63-b448b6ce6e70">1,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMTAtMy0xLTEtMjk4MzUy_646387d5-b9b3-4af6-b6a9-e0475ab8957f">1,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Unrealized (gains) on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMTQtMS0xLTEtMjk4MzUy_1d3fc3cd-5813-4944-8b2a-ea856ba4148e">135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMTQtMy0xLTEtMjk4MzUy_db905bae-f8d3-4097-a71e-e0c73be1dcbc">1,419</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMTctMS0xLTEtMjk4MzUy_bdae6a4a-9923-43aa-b3ae-248b04dfc04f">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMTctMy0xLTEtMjk4MzUy_05da9837-a5d9-4deb-87c0-c522612b8060">1,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMTktMS0xLTEtMjk4MzUy_c22d6b94-d24f-42fe-804b-4dc8c897b43a">9,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMTktMy0xLTEtMjk4MzUy_1536abed-d0e6-4c51-995c-7fcd5b63fea2">218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjAtMS0xLTEtMjk4MzUy_475715b3-ea4b-42f3-9596-da25943b75ef">295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjAtMy0xLTEtMjk4MzUy_76d237f9-3904-4948-9017-a36935403fe2">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjEtMS0xLTEtMjk4MzUy_f3174a14-5e61-439b-9ae1-97944d234b30">668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjEtMy0xLTEtMjk4MzUy_75f3b07a-7729-4430-a9d9-d4c72c651b25">795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjItMS0xLTEtMjk4MzUy_58e6d215-4c04-43ee-ba81-96aba6409d41">18,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjItMy0xLTEtMjk4MzUy_3f65a536-4a3b-43cb-b384-a511a687550d">10,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="ibrx:IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjMtMS0xLTEtMjk4MzUy_0001096d-afcf-472f-9ff3-60cfcbb50003">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="ibrx:IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjMtMy0xLTEtMjk4MzUy_205efe30-09c8-46de-8148-e0ec5677c3ae">1,618</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.72pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjQtMS0xLTEtMjk4MzUy_5b302cbc-3427-40a8-b68a-f58815a81550">1,511</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjQtMy0xLTEtMjk4MzUy_eed7b066-1bf1-4df8-b30e-05d0aa14d02a">339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net cash used in operating activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjUtMS0xLTEtMjk4MzUy_cf4b9fa1-968d-4a70-b2cb-7b3c9ece09eb">84,310</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjUtMy0xLTEtMjk4MzUy_84e1cfa7-0595-4961-8cd2-7f80f00c5c90">74,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjctMS0xLTEtMjk4MzUy_1bb3bf87-8bd9-4b22-bc20-bfc25d3eb02c">8,428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjctMy0xLTEtMjk4MzUy_d56dcea0-a926-4f9f-8893-4f2e4a7acfad">27,347</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Purchase of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjgtMS0xLTEtMjk4MzUy_51e81f06-f3fa-4256-a461-024ec56c5e93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjgtMy0xLTEtMjk4MzUy_594b22a1-ebcd-41cc-b54e-66c31e269d7e">21,229</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Purchases of marketable debt securities, available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzAtMS0xLTEtMjk4MzUy_393b6061-9fc6-4ab7-93f4-09e58bc12bef">158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzAtMy0xLTEtMjk4MzUy_4bc4504f-1131-458c-8dd1-5bf35612834e">34,082</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Maturities of marketable debt securities, available for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzEtMS0xLTEtMjk4MzUy_5f055de0-51e7-46c0-a6c3-0597ad260b90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzEtMy0xLTEtMjk4MzUy_bc9f91ed-8162-4601-8ee8-0329b3a58aa2">14,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from sales of marketable debt and equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzItMS0xLTEtMjk4MzUy_ab781964-5671-46bf-8fa4-2c7083c82e81">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzItMy0xLTEtMjk4MzUy_c6fd5576-07c4-465d-b55e-73245d617dca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Investment in joint venture &#8211; an equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireInterestInJointVenture" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzMtMS0xLTEtMjk4MzUy_ffdfcb19-b2be-47bc-b886-9dee42bd228c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireInterestInJointVenture" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzMtMy0xLTEtMjk4MzUy_8811cc9d-2bd1-4726-b3c1-b0820c9117d3">1,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net cash used in investing activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzQtMS0xLTEtMjk4MzUy_fbb1e9b2-e9d3-4331-9444-3c704cc5990e">8,484</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzQtMy0xLTEtMjk4MzUy_00f1b05c-62e4-4763-8f6f-a9495202cc7f">69,313</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from equity offerings, <br/>&#160;&#160;&#160;net of discounts and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzYtMS0xLTEtMjk4MzUy_ec4a1374-8e0b-4630-bbb4-1812033235f3">47,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzYtMy0xLTEtMjk4MzUy_b52cf522-6baa-4801-ae76-6fca1a0db897">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from issuance of related-party convertible promissory notes, <br/>&#160;&#160;&#160;net of issuance costs paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzgtMS0xLTEtMjk4MzUy_4dc9c984-7375-479b-bceb-125d6aa9758b">29,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzgtMy0xLTEtMjk4MzUy_c9ce6a5a-824a-4f8e-ba75-617c2258c747">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzktMS0xLTEtMjk4MzUy_ddcf2637-d16f-4d9e-95e0-837b234c1881">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzktMy0xLTEtMjk4MzUy_f6afa273-d2bf-4188-93ab-17a111140712">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net share settlement for RSUs vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDEtMS0xLTEtMjk4MzUy_1dfbe327-d670-4fda-b9cd-bad3716ff5c9">357</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDEtMy0xLTEtMjk4MzUy_530deb6a-e03b-433f-897d-917741253605">372</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Principal payments of finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDItMS0xLTEtMjk4MzUy_abe70c6b-2c15-4600-81bb-e2dfe43ddafd">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDItMy0xLTEtMjk4MzUy_55508e7e-14c9-4922-80ea-45e94052047b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:38.42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net cash provided by (used in) financing activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDQtMS0xLTEtMjk4MzUy_c59807ed-14c5-4b70-851e-8bf2512c8a29">76,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDQtMy0xLTEtMjk4MzUy_19847abe-d844-4b45-afeb-6b656993242f">298</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDUtMS0xLTEtMjk4MzUy_f472a1c5-4eea-4ac6-b328-ccc0c8208d35">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDUtMy0xLTEtMjk4MzUy_658441e4-4bd3-4591-99db-cb19ce193e57">175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net change in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDYtMS0xLTEtMjk4MzUy_fd2d90df-dade-4a71-b378-57a26c83f531">16,160</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDYtMy0xLTEtMjk4MzUy_b7fde1c5-7fd2-46fe-aa78-5fe0e9e4e5ff">144,716</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash, cash equivalents, and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDctMS0xLTEtMjk4MzUy_ce234b6a-314c-492d-8fd4-026ddb3117c3">104,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic1f4ccbe1a254187a0abcd2fa0ef3671_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDctMy0xLTEtMjk4MzUy_dd427978-0cb9-4713-8e0f-9a3a302d6ecb">181,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash, cash equivalents, and restricted cash, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDgtMS0xLTEtMjk4MzUy_c04f16af-e73b-4aaa-9fd3-797db9bca291">88,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5f8290d605c9473bbd497404748ff594_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDgtMy0xLTEtMjk4MzUy_c9a48040-c0f0-47d3-bc5e-a08943c4e2eb">36,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ImmunityBio, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Reconciliation of cash, cash equivalents, and restricted cash, end of period:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMy0xLTEtMS0yOTgzNTI_f9f428e8-2330-45e7-9089-aaa6001a728a">88,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5f8290d605c9473bbd497404748ff594_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMy0zLTEtMS0yOTgzNTI_fa40c13e-3ed3-494d-b6df-ecd9872f5451">36,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Restricted cash </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfNC0xLTEtMS0yOTgzNTI_9997784e-c9f1-4656-a91b-9b3f59b58c09">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5f8290d605c9473bbd497404748ff594_I20220331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfNC0zLTEtMS0yOTgzNTI_426a99ae-7806-42e4-aac4-865c44b0e10e">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash, cash equivalents, and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfNS0xLTEtMS0yOTgzNTI_fa124707-e119-47a3-a0fa-cbad3597c1c5">88,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5f8290d605c9473bbd497404748ff594_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfNS0zLTEtMS0yOTgzNTI_195634a7-9694-483d-bf72-0534f5f368cc">36,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash paid during the period for:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfOS0xLTEtMS0yOTgzNTI_bfbe26d3-93c4-4710-adc1-5a1102c3910e">15,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfOS0zLTEtMS0yOTgzNTI_6080ebcc-af18-4a29-9051-aefaf3f006fc">5,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTAtMS0xLTEtMjk4MzUy_dce3521d-d975-46c2-9667-2e7aa3004386">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTAtMy0xLTEtMjk4MzUy_77f5ad1c-4349-4260-9445-b0200ac92f90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Supplemental disclosure of non-cash activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Initial measurement of warrants issued in connection with the </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;registered direct offering accounted for as liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="ibrx:IssuanceOfWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTQtMS0xLTEtMzI0NTY5_17cd0d1a-0e73-4e6c-84fc-031b3f4cb57d">23,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="ibrx:IssuanceOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTQtMy0xLTEtMzI0NTY5_4dad7a9f-6b3f-4bbb-be23-03c875840250">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Property and equipment purchases included in accounts payable, </span></div><div style="margin-top:0.75pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;&#160;&#160;accrued expenses and due to related parties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTUtMS0xLTEtMzI0NTgw_0aea4e1a-d706-4eb4-866d-a38cc884a761">19,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTUtMy0xLTEtMzI0NTgw_a9862b74-5e9b-4a76-86c0-667b3779aff9">1,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Unpaid offering costs included in accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="ibrx:UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTUtMS0xLTEtMjk4MzUy_adcdef24-fb38-40ed-8ef3-80af4bbf1973">318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="ibrx:UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTUtMy0xLTEtMjk4MzUy_ac01ef1f-038f-4417-a926-aea54cd55333">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Unrealized gains (losses) on marketable debt securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTgtMS0xLTEtMjk4MzUy_e4b61e2c-17f2-4c00-9ea1-acd47e4ea723">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTgtMy0xLTEtMjk4MzUy_6bc99776-3bf3-4f83-ad47-b3f56acf33c3">310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTktMS0xLTEtMjk4MzUy_51dbb1fc-b90b-497b-ad8c-f6f6649cddee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTktMy0xLTEtMjk4MzUy_4fad2190-2f40-4322-adbb-def1b366f6cf">911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_31"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ImmunityBio, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div id="i5bbe340c9c8f435088d8011b72b6800d_34"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8zNC9mcmFnOjU5OTM0MDIwNWJjMTQyOGViMGNhM2UxZjc3ZjUyNGJkL3RleHRyZWdpb246NTk5MzQwMjA1YmMxNDI4ZWIwY2EzZTFmNzdmNTI0YmRfMzEyOQ_0e41931a-4a85-4d76-ba65-b17817ac1972" continuedAt="i085664f1d14c449682a29c8c84c8c15f" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="i085664f1d14c449682a29c8c84c8c15f"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In these notes to unaudited condensed consolidated financial statements, the terms &#8220;ImmunityBio,&#8221; &#8220;the company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to ImmunityBio, Inc. and its subsidiaries.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ImmunityBio, Inc. is a clinical-stage biotechnology company developing next-generation therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. We strive to be a vertically-integrated immunotherapy company designing and manufacturing our products so they are more effective, accessible, more conveniently stored, and more easily administered to patients. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our broad immunotherapy and cell therapy platforms are designed to attack cancer and infectious pathogens by activating both the innate immune system&#8212;natural killer (NK) cells, dendritic cells, and macrophages&#8212;and the adaptive immune system&#8212;B&#160;cells and T&#160;cells&#8212;in an orchestrated manner. The goal of this potentially best-in-class approach is to generate immunogenic cell death thereby eliminating rogue cells from the body whether they are cancerous or virally infected. Our ultimate goal is to employ this approach to establish an &#8220;immunological memory&#8221; that confers long-term benefit for the patient. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although such designations may not lead to a faster development process or regulatory review and may not increase the likelihood that a product candidate will receive approval, Anktiva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (N-803), our novel antibody cytokine fusion protein, has received </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designations in combination with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bacillus Calmette-Gu&#233;rin (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BCG) from the United States (U.S.)&#160;Food and Drug Administration (FDA) for</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> BCG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. I</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May&#160;2022, we announced the submission of a Biologics License Application (BLA) to the FDA for our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease. In July&#160;2022, we announced the FDA had accepted our BLA for review and set a target Prescription Drug User Fee Act (PDUFA) action date of May&#160;23,&#160;2023. On May&#160;9,&#160;2023, the FDA delivered a complete response letter to us regarding the BLA. The company plans to request a meeting with the FDA as soon as possible to address the subject matter of the letter and a response timeline, and plans to diligently address and resolve the issues identified and seek approval as expeditiously as possible. It is unclear when the FDA will approve our BLA, if at all.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our platforms include 13&#160;novel therapeutic agents either in clinical trials or for which we are developing protocols. We are currently engaged in 15&#160;active clinical trials involving 10&#160;of these agents. Seven of these trials are being sponsored by ImmunityBio while the remaining eight are investigator-led studies. Twelve&#160;of these trials are in Phase&#160;2 or 3&#160;development across eleven&#160;indications in liquid and solid tumors. These include bladder, pancreatic, and lung cancers, which are among the most frequent and lethal cancer types, and where there are high failure rates for existing standards of care or no available effective treatment. In infectious diseases, our pipeline currently targets such pathogens as the novel strain of the coronavirus (SARS-CoV-2) and human immunodeficiency virus (HIV). </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established Good Manufacturing Practice (GMP) manufacturing capacity at scale with cutting-edge cell manufacturing expertise and ready-to-scale facilities, as well as extensive and seasoned research and development (R&amp;D), clinical trial, and regulatory operations, and development teams.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_40"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMTM2Njc_c7684178-4733-4aad-835b-f09215b13edd" continuedAt="i34a2970a05fc4558b5211440a22d3d01" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i34a2970a05fc4558b5211440a22d3d01" continuedAt="i8c81d4d7786e473ea73d0cd4a481c74c"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMTM2NjI_4b65bc98-64dc-4bdf-96b3-086985004d0f" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.&#160;GAAP) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The unaudited condensed consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of our financial position and results of operations. The unaudited condensed consolidated financial statements do not include all information and notes required by U.S.&#160;GAAP for annual reports and therefore should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December&#160;31,&#160;2022 filed with the SEC on March&#160;1,&#160;2023. These interim financials are not necessarily indicative of results expected for the full fiscal year.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMTM2Njg_f3e1aad2-07be-40ea-bc3d-688210e1799a" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of the company, its wholly-owned subsidiaries, and a variable interest entity (VIE) for which the company is the primary beneficiary. Any material intercompany transactions and balances have been eliminated upon consolidation. For consolidated entities where we have less than 100% of ownership, we record net loss attributable to noncontrolling interest on the unaudited condensed consolidated statements of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether we are the primary beneficiary of a VIE at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.</span></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, the company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-8" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMjExOQ_c8845dad-73f1-4a8d-aadb-203120bdb09d">2.5</ix:nonFraction>&#160;billion. We also had negative cash flows from operations of $<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMjE3NA_4db1c66f-a078-4aba-9995-da9d0f2c0488">84.3</ix:nonFraction>&#160;million for the three months ended March&#160;31,&#160;2023. The company will likely need additional capital to further fund the development of, and to seek regulatory approvals for, our product candidates, and to begin to commercialize any approved products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements have been prepared assuming the company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of the uncertainty of our ability to continue as a going concern. As a result of continuing anticipated operating cash outflows, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash, cash equivalents, and investments in marketable securities, together with capital to be raised through equity offerings (including but not limited to the offering, issuance and sale by us of our common stock that may be issued and sold under an &#8220;at-the-market&#8221; sales agreement (the&#160;Sale Agreement) with our sales agent (the&#160;ATM), of which we had $<ix:nonFraction unitRef="usd" contextRef="ib93ec4ea47c24cd1aacb10ddb65cfc49_I20230331" decimals="-5" name="ibrx:CommonStockValueAvailableForFutureStockIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMzQ2NQ_64ac42b6-7c0b-423b-bc30-6935090e5165">225.4</ix:nonFraction>&#160;million available for future issuance as of March&#160;31,&#160;2023, and a February&#160;2023 shelf registration statement, of which we had $<ix:nonFraction unitRef="usd" contextRef="idecf558aeafa48f9b21a5ecd3fb24b40_I20230331" decimals="-5" name="ibrx:CommonStockValueAvailableForFutureStockIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfNTQ5NzU1ODU3NjY3_6186171d-470f-4ae9-9a1b-82a6b72cba72">640.0</ix:nonFraction>&#160;million available for future offerings as of March&#160;31,&#160;2023), and our potential ability to borrow from affiliated entities, will be sufficient to fund our operations through at least the next 12&#160;months following the issuance date of the condensed consolidated financial statements based primarily upon our Executive Chairman and Global Chief Scientific and Medical Officer&#8217;s intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt. See&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_85">Note</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_85">&#160;12</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders&#8217; Deficit, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for information regarding the ATM and the shelf registration statement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also seek to sell additional equity, through one or more follow-on offerings, or in separate financings, or obtain a credit facility. However, we may not be able to secure such external financing in a timely manner or on favorable terms. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the risk and uncertainties associated with the potential commercialization of our product candidates in development, we may need additional funds to meet our needs sooner than planned.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="i8c81d4d7786e473ea73d0cd4a481c74c" continuedAt="i98f0872416be4f47990fbfc5cb339ce7"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMTM2NjM_441cb3c2-9ea8-47bf-bbf4-2d73c8d0eb7b" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, contingent value right measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value calculation of warrants and convertible promissory notes, fair value measurements, and the assessment of our ability to fund our operations for at least the next 12&#160;months from the date of issuance of these condensed consolidated financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing coronavirus pandemic could have on our significant accounting estimates. Actual results could differ from those estimates.</span></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our significant accounting policies from those described in Note&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Consolidated Financial Statements&#8221; that appears in Part&#160;II, Item&#160;8. &#8220;Financial Statements and Supplementary Data&#8221; of our Annual Report on Form&#160;10-K filed with the SEC on March&#160;1,&#160;2023. </span></div><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="ibrx:WarrantsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMzg0ODI5MDczMjczNw_c271e04a-d76d-47a5-a6ac-1ec5392d12fb" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Accounting Standards Codification (ASC) Topic&#160;480, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC&#160;480), and ASC Topic&#160;815, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC&#160;815). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC&#160;480, meet the definition of a liability pursuant to ASC&#160;480, and whether the warrants meet all of the requirements for equity classification under ASC&#160;815, including whether the warrants are indexed to the&#160;company&#8217;s own stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For warrants that meet all criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and on each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash change in fair value of warrant liabilities in o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ther income (expense), net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations. The fair value of the warrants was estimated using the Black-Scholes option pricing model.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="ibrx:ConvertibleNotesFairValueOptionElectionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMzg0ODI5MDczMjczOA_f7e7a384-77f6-411c-b07e-42bcad0c56b9" continuedAt="i9911db8728054c8e81ceef877ced2828" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Option (FVO) Election</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company accounts for certain convertible notes issued during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the fair value option (FVO) election of ASC&#160;825, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC&#160;825), as discussed below.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The convertible notes accounted for under the FVO election are each debt host financial instruments containing embedded features wherein the entire financial instrument is initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><ix:continuation id="i9911db8728054c8e81ceef877ced2828" continuedAt="i60047bc5e48a41fd946353f4e1faf5b8"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the estimated fair value of the convertible notes are recorded as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other income (expense), net</span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i60047bc5e48a41fd946353f4e1faf5b8"> on the condensed consolidated statements of operations, except that the change in estimated fair value attributable to a change in the instrument-specific credit risks is recognized as a component of other comprehensive income.</ix:continuation> Since the underlying financial instrument was issued on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we did not recognize any change in estimated fair values during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="i98f0872416be4f47990fbfc5cb339ce7"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMTM2NjU_9dbee786-f968-4fb8-98ac-3476b884b1da" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Net Loss per Share of Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed by dividing net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares, including the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. <ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMTM2NjY_6efbc88a-07b2-469b-961a-e07670402975" continuedAt="i01ed45c91f5040a08bbdfc07e59f0643" escape="true">The following table details those securities that have been excluded from the computation of potentially dilutive securities:</ix:nonNumeric></span></div><ix:continuation id="i01ed45c91f5040a08bbdfc07e59f0643"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Related-party convertible notes (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i99fc5379a3c146e884bcdad311bb00a7_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfNC0xLTEtMS0zMjM2ODQ_a8261736-c312-47ff-807d-bdd222232292">46,726,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="icca3815678964e2d94105dd050d212c3_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfNC0zLTEtMS0zMjM2ODQ_bda16b25-627c-4a81-8ebb-bb5cbeaade64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding third-party warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="iba6ebd8d72ea4824b03a047a8f09a82d_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfNS0xLTEtMS0yOTgzNTI_b1e9056b-15f4-451e-9cf8-4ab34fb0387b">23,163,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ifb98e0036a3b43d497ef0476504101c1_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfNS0zLTEtMS0yOTgzNTI_8d689990-7af5-4e9f-93fe-570cdbceb738">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ia50e8aab6bce4a40af1190886835cf90_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfNi0xLTEtMS0yOTgzNTI_84e947d5-d368-4be6-8239-97e8b555e215">9,159,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i4bc712551fbe42fa830fbfe75a349bb9_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfNi0zLTEtMS0yOTgzNTI_1e167d62-87a3-47bf-a58a-d49f21b0f78f">8,819,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i4561df868e434e67b57f7aa91baf077a_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfNy0xLTEtMS0yOTgzNTI_1cea852b-8958-4f1a-8e8a-28a7ba401e7a">6,188,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i4868dd8bba544400bbb7baf280da9766_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfNy0zLTEtMS0yOTgzNTI_3414b4e9-cab4-45d3-84bd-e79f5c4cd2d5">6,149,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding related-party warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i8a1967d8b16b4b2780d09eb32b721ead_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfOC0xLTEtMS0zMjMyMjE_63bef7c1-39c7-454b-adbf-1ca002faccc8">1,638,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i6785865c42404146b0f6e8d0fc2d2b8c_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfOC0zLTEtMS0zMjMyMjE_9fd6a56f-c4ba-4444-923b-2e3e9315fe0a">1,638,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfOC0xLTEtMS0yOTgzNTI_450863ad-8ecb-4e21-9b57-b5a3aa204bcf">86,875,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfOC0zLTEtMS0yOTgzNTI_e15ee030-adfe-4c95-ac03-75fb50897abf">16,606,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount excludes the shares related to the related-party convertible note with a principal amount of $<ix:nonFraction unitRef="usd" contextRef="i4d61f38abc9b467da5b3204da34fab5e_I20230331" decimals="-3" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjcxMWExNzEyMzAzMjRkZTJiYWVjNTM0OGUzYjMyMGY4L3RhYmxlcmFuZ2U6NzExYTE3MTIzMDMyNGRlMmJhZWM1MzQ4ZTNiMzIwZjhfMC0xLTEtMS0zMjM3MjcvdGV4dHJlZ2lvbjoxMDg4ZmQ4NWRmZmM0ZDQ2YjNjOTUwOTA2OTVhZTFiOV81NDk3NTU4MTY1NDA_5977bcfb-4220-4a7a-978a-233ae428b050">30.0</ix:nonFraction>&#160;million issued on March&#160;31,&#160;2023 as the conversion price has not yet been determined. See</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_73"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_73">Note </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_73">9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, for further information.</span></div></td></tr></table></div></ix:continuation></ix:nonNumeric><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMTM2NjE_225c0db2-b239-4d21-b125-cec98814fcba" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Application of New or Revised Accounting Standards &#8211; Not Yet Adopted</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic&#160;820): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the guidance in Topic&#160;820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. In addition, ASU&#160;2022-03 introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. ASU&#160;2022-03 is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years. We are currently evaluating the impact of this standard on our condensed consolidated financial statements. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the FASB issued ASU&#160;2023-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842): Common Control Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that leasehold improvements associated with common control leases be amortized over the useful life of the leasehold improvements to the common control group, regardless of the lease term. ASU&#160;2023-01 is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years. We are currently evaluating the impact of this standard on our condensed consolidated financial statements and related disclosures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC during the three months ended March&#160;31,&#160;2023 did not, or are not expected to, have a material effect on our condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_43"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfOTE3_ae2fc3da-3ff3-4fc5-87d1-c43a7a17ac01" continuedAt="i33089ec2fc4b4c80b0b2f73a36045de2" escape="true">Financial Statement Details</ix:nonNumeric></span></div><ix:continuation id="i33089ec2fc4b4c80b0b2f73a36045de2" continuedAt="idc43f5aa877d43d1a4fd8895e336c412"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets </span></div><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfOTE0_387d5cde-88f6-4ce2-9780-eec0ee5af100" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:PrepaidResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfMy0xLTEtMS0zMjM3Mzc_75d9d173-97de-4773-a35b-685f47c37727">6,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="ibrx:PrepaidResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfMy0zLTEtMS0zMjM3Mzc_728ae1b4-138c-4ac1-b880-750e7fa4b2ed">11,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:PrepaidServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfMy0xLTEtMS0yOTgzNTI_12019245-34fe-41ad-9eb3-32a0f37b8cce">3,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="ibrx:PrepaidServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfMy0zLTEtMS0yOTgzNTI_8419090c-2c07-4b3a-a2c8-63ebbe619f14">8,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:Supplies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfNC0xLTEtMS0zMDMxMDg_50815611-53d6-4f87-8673-0afeb535bd61">2,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:Supplies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfNC0zLTEtMS0zMDMxMTI_9168789f-47a2-4f29-a7c6-bafc84fa0cf8">2,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfNy0xLTEtMS0zMjM3NDk_eb5f5ef2-bfd7-420e-8e94-139857fce9ed">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfNy0zLTEtMS0zMjM3NDk_f8e81ec1-f8a7-464a-9b16-2c888ea69166">2,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid software license fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:PrepaidSoftwareLicenseFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfNS0xLTEtMS0yOTgzNTI_b0d93f08-e8da-48cd-92dc-e3f8b51faea1">1,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="ibrx:PrepaidSoftwareLicenseFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfNS0zLTEtMS0yOTgzNTI_954ee688-1fd3-419e-bd36-2061a56dc3db">2,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Insurance premium financing asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:InsurancePremiumFinancingAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfNi0xLTEtMS0yOTgzNTI_2501696c-b70b-4cf4-9ec0-3324bf31d826">357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="ibrx:InsurancePremiumFinancingAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfNi0zLTEtMS0yOTgzNTI_67ecb0ff-10dc-4577-b2b7-1ee0a17a92bd">1,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfMTctMS0xLTEtMjk4MzUy_b5a6b915-0be9-4d7f-9ec0-ec7b24f874ca">4,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfMTctMy0xLTEtMjk4MzUy_83785217-847a-4c98-b1e4-b17492db571f">3,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfMTgtMS0xLTEtMjk4MzUy_ae81dd50-e20a-4feb-a75d-c918e21e4cf1">20,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfMTgtMy0xLTEtMjk4MzUy_524dd1eb-12fd-4223-b8a8-ef45edb7b22e">31,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment, Net </span></div><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfOTE1_e356903e-a5ea-492c-8397-33e6da671a86" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net, consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i684e88f0565f4750ae31d08132ff423b_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfMy0xLTEtMS0yOTgzNTI_f86c8c2c-f313-4ff2-a857-6fcc54f559a8">73,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6e62b835f051443d9e55df382ca1fcce_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfMy0zLTEtMS0yOTgzNTI_70565aff-1a08-433b-b727-ef0d779de369">68,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic374e7c516ef4b06beadcff3736ae51f_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfNC0xLTEtMS0yOTgzNTI_6540e942-27d6-4269-8065-85ba3ead647d">68,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iee11080abfef48cf9f5c6b933901142a_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfNC0zLTEtMS0yOTgzNTI_248aab7d-5a37-46ee-b43c-9b8f1bb0b843">67,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icdb4ac7d53c44d429b5802a108d42fb7_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfNS0xLTEtMS0yOTgzNTI_3bca24cb-6994-464d-a2b7-d140067d71f1">81,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id5437c21f4814f59a329a7b0373ddd7c_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfNS0zLTEtMS0yOTgzNTI_83247069-8661-493f-8f6c-e0a50e91902d">72,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture &amp; fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id5ccb25eaaf340a293dbf719e9c93972_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfNi0xLTEtMS0yOTgzNTI_1425581e-9913-4019-9ed0-33fa10a56340">1,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ifcada495b71b4888ab1fd26a734a81a7_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfNi0zLTEtMS0yOTgzNTI_dcfb4326-dc84-49f6-ac9e-d396fc97741b">1,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if361174e18104c2d80d8a23d1e42afa0_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfNy0xLTEtMS0yOTgzNTI_5bf6459e-5f0c-4d9e-977d-2dd64d679b57">1,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9fdf6d04e3e64c0a85f416eb0b67673a_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfNy0zLTEtMS0yOTgzNTI_e2ce7fff-377e-40ba-9c3a-50d942ad0dae">1,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Gross property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfOS0xLTEtMS0yOTgzNTI_11c24f7f-5525-4383-9c6c-cc726067dc09">227,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfOS0zLTEtMS0yOTgzNTI_a4656f7d-e4a6-43fe-abdd-f8a19b6079dd">212,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfMTAtMS0xLTEtMjk4MzUy_6ac149d6-e411-4b6c-a9c4-c471ab2fd382">73,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfMTAtMy0xLTEtMjk4MzUy_4b0e3835-ff26-4a5d-8e58-e355cb8be2a1">69,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfMTEtMS0xLTEtMjk4MzUy_8fac998e-31cf-450d-bea2-a74f6d9d4fb3">154,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfMTEtMy0xLTEtMjk4MzUy_927b2b24-71a3-40f7-99a9-9f717a9cfab4">143,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property, plant and equipment totaled $<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfMzQ5_5d7ea2d3-38d0-4452-aebf-cc5c03483ba6">4.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfMzU2_88714a94-fa0e-4190-8ee6-58fb7c026ad7">3.8</ix:nonFraction>&#160;million for the three&#160;months&#160;ended March&#160;31,&#160;2023 and 2022, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="idc43f5aa877d43d1a4fd8895e336c412" continuedAt="i08dfdcc76e714a96b1e06bc820a09633"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net </span></div><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfMzg0ODI5MDcwMDc2Mw_cbf200c2-1cf5-4dec-9288-2aaec355f386" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amounts and accumulated amortization of intangible assets are as follows at the dates indicated (in&#160;thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31,&#160;2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finite-lived: Favorable leasehold rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i69a7813607634b75bf6094281fe5a9ef_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmU1ZmYwM2IyMTEzYzRkZjE4MjZiZGRlNTNjMzI4MmE2L3RhYmxlcmFuZ2U6ZTVmZjAzYjIxMTNjNGRmMTgyNmJkZGU1M2MzMjgyYTZfMy0xLTEtMS0zMjM3NzY_2c6cbc69-09df-46dd-99c4-780efc159d9b">8.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4ac85c2e74bb4d9e983ef489c9b27611_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmU1ZmYwM2IyMTEzYzRkZjE4MjZiZGRlNTNjMzI4MmE2L3RhYmxlcmFuZ2U6ZTVmZjAzYjIxMTNjNGRmMTgyNmJkZGU1M2MzMjgyYTZfMy0zLTEtMS0zMjM3NzY_c17b8964-4659-4252-b0f9-b814bbc19ec8">20,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i4ac85c2e74bb4d9e983ef489c9b27611_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmU1ZmYwM2IyMTEzYzRkZjE4MjZiZGRlNTNjMzI4MmE2L3RhYmxlcmFuZ2U6ZTVmZjAzYjIxMTNjNGRmMTgyNmJkZGU1M2MzMjgyYTZfMy01LTEtMS0zMjM3NzY_e24a1cab-7d9d-42f9-ba95-6ff653a2509c">2,295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4ac85c2e74bb4d9e983ef489c9b27611_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmU1ZmYwM2IyMTEzYzRkZjE4MjZiZGRlNTNjMzI4MmE2L3RhYmxlcmFuZ2U6ZTVmZjAzYjIxMTNjNGRmMTgyNmJkZGU1M2MzMjgyYTZfMy05LTEtMS0zMjM3NzY_07c56706-5868-4169-83bf-5431293d5724">18,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Indefinite-lived: In-process research </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;and development (IPR&amp;D)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmU1ZmYwM2IyMTEzYzRkZjE4MjZiZGRlNTNjMzI4MmE2L3RhYmxlcmFuZ2U6ZTVmZjAzYjIxMTNjNGRmMTgyNmJkZGU1M2MzMjgyYTZfNi0zLTEtMS0zMjM3NzY_98ac95a8-303e-45b7-9426-19f62aa315e6">1,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmU1ZmYwM2IyMTEzYzRkZjE4MjZiZGRlNTNjMzI4MmE2L3RhYmxlcmFuZ2U6ZTVmZjAzYjIxMTNjNGRmMTgyNmJkZGU1M2MzMjgyYTZfNi05LTEtMS0zMjM3NzY_86d8a0e8-2856-4fdf-893d-a7ecff05e920">1,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmU1ZmYwM2IyMTEzYzRkZjE4MjZiZGRlNTNjMzI4MmE2L3RhYmxlcmFuZ2U6ZTVmZjAzYjIxMTNjNGRmMTgyNmJkZGU1M2MzMjgyYTZfNy0zLTEtMS0zMjM3NzY_3cdac5ff-66c9-4dd4-b1c9-7c38216aee39">21,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmU1ZmYwM2IyMTEzYzRkZjE4MjZiZGRlNTNjMzI4MmE2L3RhYmxlcmFuZ2U6ZTVmZjAzYjIxMTNjNGRmMTgyNmJkZGU1M2MzMjgyYTZfNy01LTEtMS0zMjM3NzY_31974813-8a27-4fcd-92d8-3042fd34a6a3">2,295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmU1ZmYwM2IyMTEzYzRkZjE4MjZiZGRlNTNjMzI4MmE2L3RhYmxlcmFuZ2U6ZTVmZjAzYjIxMTNjNGRmMTgyNmJkZGU1M2MzMjgyYTZfNy05LTEtMS0zMjM3NzY_744017aa-06fd-42f8-8579-2074092af1cc">19,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finite-lived: Favorable leasehold rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb96fe0125b04e81861415c2d465f7f2_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfMy0xLTEtMS0zMzIxMzc_81e3d560-085f-479d-a18c-804a65164f12">9.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d984c547ea04fd4aca46b980c849ad7_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfMy0zLTEtMS0zMjM4MTk_818a8e37-08b4-48d6-aa94-fcd7a1c516b6">20,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i4d984c547ea04fd4aca46b980c849ad7_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfMy01LTEtMS0zMjM4Mjc_ad2085e3-dec1-4374-91b1-60d91da62c55">1,785</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4d984c547ea04fd4aca46b980c849ad7_I20221231" decimals="-3" name="ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfMy03LTEtMS0zMjM4MzU_2877440f-db31-452f-89a7-39f946dfb55b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4d984c547ea04fd4aca46b980c849ad7_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfMy05LTEtMS0zMjM4NDM_1e8306f3-2f2d-40f2-b01c-3239abcfdbb1">18,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finite-lived: Organized workforce</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2302952973d64c9dae6fea63aa9b623d_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNC0zLTEtMS0zMjM4MTk_cb636844-c008-43b8-b91b-f01402278388">831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2302952973d64c9dae6fea63aa9b623d_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNC01LTEtMS0zMjM4Mjc_a188c7aa-fdbf-42c0-9e88-79608ef0b818">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2302952973d64c9dae6fea63aa9b623d_I20221231" decimals="-3" name="ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNC03LTEtMS0zMjM4MzU_2cb492f2-37cf-4acb-9375-9f14a56e96b2">681</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2302952973d64c9dae6fea63aa9b623d_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNC05LTEtMS0zMjM4NDM_ecb24917-fa95-4e3a-b12d-316519e35e3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNS0zLTEtMS0zMjM4MTk_c52230c0-c7ea-4a5d-b4f6-9b803b3be5fc">21,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNS01LTEtMS0zMjM4Mjc_c17d7ac2-0de3-4ff9-9718-ff17f10417d4">1,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNS03LTEtMS0zMjM4MzU_55338427-a52f-4c71-b1ff-db695826e9cb">681</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNS05LTEtMS0zMjM4NDM_4588536a-109e-41fb-8fa2-d895bee91f26">18,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Indefinite-lived: IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNi0zLTEtMS0zMjM4MTk_27c4105f-cd8d-48ad-8f69-e6ecfb8fc512">1,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNi05LTEtMS0zMjM4NDM_aa35f196-82e8-484c-a939-a25f1def91d7">1,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNy0zLTEtMS0zMjM4MTk_cfa3e311-b746-48fb-8ace-c6a4b87aeeb7">22,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNy01LTEtMS0zMjM4Mjc_f8f1089e-967a-4b62-817a-29c683ef0f89">1,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNy03LTEtMS0zMjM4MzU_11e3a892-13e8-4a4e-ad1b-bd65e05e0d36">681</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNy05LTEtMS0zMjM4NDM_a61bcdd0-5c06-4590-82ea-9f1a3d1bfde0">20,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of the Dunkirk facility in 2022, we acquired finite-lived intangibles consisting of favorable leasehold rights and an organized workforce. We recorded amortization expense of our finite-lived intangibles totaling $<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfNTQ5NzU1ODE2ODM0_7fe9273b-5200-4f9d-993b-9c70cb1caea9">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfNTQ5NzU1ODE2ODQy_051f1b32-c03e-4a86-9bda-ad8d147709cf">0.3</ix:nonFraction>&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations for the three months ended March&#160;31,&#160;2023 and 2022, respectively. </span></div><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfMzg0ODI5MDcwMDc2NA_8f34ff5a-6b33-49cd-a720-e6ef2186cb0c" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense associated with our finite-lived intangible assets is as follows (in&#160;thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Years ending December 31:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Finite-lived</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Intangible</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Assets</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023 (excluding the three months ended March&#160;31,&#160;2023)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjA1Yjk3NzMzYjQ0NjQzMjk5YTUzNDY0MjJlN2UyZjA5L3RhYmxlcmFuZ2U6MDViOTc3MzNiNDQ2NDMyOTlhNTM0NjQyMmU3ZTJmMDlfMi0xLTEtMS0zMjM5MzQ_94476c07-67fc-4a25-b21c-d2cd1ca6768c">1,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjA1Yjk3NzMzYjQ0NjQzMjk5YTUzNDY0MjJlN2UyZjA5L3RhYmxlcmFuZ2U6MDViOTc3MzNiNDQ2NDMyOTlhNTM0NjQyMmU3ZTJmMDlfMy0xLTEtMS0zMjM5MzQ_104507fa-3073-4c93-b01c-a67bdf9fecdf">2,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjA1Yjk3NzMzYjQ0NjQzMjk5YTUzNDY0MjJlN2UyZjA5L3RhYmxlcmFuZ2U6MDViOTc3MzNiNDQ2NDMyOTlhNTM0NjQyMmU3ZTJmMDlfNC0xLTEtMS0zMjM5MzQ_084a2f79-0cae-4dfd-89f0-d981bf5729d3">2,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjA1Yjk3NzMzYjQ0NjQzMjk5YTUzNDY0MjJlN2UyZjA5L3RhYmxlcmFuZ2U6MDViOTc3MzNiNDQ2NDMyOTlhNTM0NjQyMmU3ZTJmMDlfNS0xLTEtMS0zMjM5MzQ_d62f7140-7ec0-4bc1-a3be-6862c1d1105c">2,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjA1Yjk3NzMzYjQ0NjQzMjk5YTUzNDY0MjJlN2UyZjA5L3RhYmxlcmFuZ2U6MDViOTc3MzNiNDQ2NDMyOTlhNTM0NjQyMmU3ZTJmMDlfNi0xLTEtMS0zMjM5MzQ_b259eb2f-f164-4d6a-a70c-17c1a4d2f125">2,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjA1Yjk3NzMzYjQ0NjQzMjk5YTUzNDY0MjJlN2UyZjA5L3RhYmxlcmFuZ2U6MDViOTc3MzNiNDQ2NDMyOTlhNTM0NjQyMmU3ZTJmMDlfNy0xLTEtMS0zMjM5MzQ_4d293256-d2ba-4243-b79e-16f3c8930c2d">8,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjA1Yjk3NzMzYjQ0NjQzMjk5YTUzNDY0MjJlN2UyZjA5L3RhYmxlcmFuZ2U6MDViOTc3MzNiNDQ2NDMyOTlhNTM0NjQyMmU3ZTJmMDlfOC0xLTEtMS0zMjM5NDU_96c39035-a5e0-414f-8b2f-db29a9bf68e4">18,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="i08dfdcc76e714a96b1e06bc820a09633"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Liabilities</span></div><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfOTE5_68ee42ac-9bef-41d1-af2c-d6a7aad613fa" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities consist of the following (in&#160;thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:AccruedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfMy0xLTEtMS0zMzc3NDc_072cc5d2-c0f8-4c20-9bad-421670a76704">15,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="ibrx:AccruedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfMy0zLTEtMS0zMzc3NDc_d86baf4d-edcc-4eb2-9734-aa35380fa49e">1,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonus</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfMy0xLTEtMS0yOTgzNTI_b0854ad2-27d7-4313-b03c-561b127c2f84">14,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfMy0zLTEtMS0yOTgzNTI_ca56ffe3-d631-428f-842d-6446fe2658d1">12,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional and service fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfNC0xLTEtMS0yOTgzNTI_412c0e93-2702-4098-be44-5d93c6959acb">9,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfNC0zLTEtMS0yOTgzNTI_b282b435-54c7-41a5-80ac-2c7adcd4f3ea">6,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical and clinical trial costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:AccruedPreclinicalAndClinicalTrialCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfNi0xLTEtMS0zMzc3NTg_76d31c52-aef4-4261-b695-e263bdb253bc">5,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="ibrx:AccruedPreclinicalAndClinicalTrialCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfNi0zLTEtMS0zMzc3NTg_6fad973b-dc9d-4da7-96f4-2d1f266bec92">4,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfNi0xLTEtMS0zMjQwMzU_3e2a8499-23bd-4349-a335-80bfbf69f14f">5,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfNi0zLTEtMS0zMjQwMzU_bf392a61-0ad0-45b7-a5b0-97cfc3d7a5a0">6,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:AccruedConstructionCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfOS0xLTEtMS0yOTgzNTI_d745ce2d-cc11-4e51-b18a-75c51dc9cf42">2,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="ibrx:AccruedConstructionCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfOS0zLTEtMS0yOTgzNTI_260f60b7-1295-436e-968c-c0bc89074b73">7,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing obligation &#8211; current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:FinancingObligationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfMTAtMS0xLTEtMjk4MzUy_df10a756-1a87-42f1-aad6-97f6fbbf804a">357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="ibrx:FinancingObligationCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfMTAtMy0xLTEtMjk4MzUy_9c235f67-227e-4080-947a-090826ef85f6">1,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfMTktMS0xLTEtMjk4MzUy_54c0d218-dc3b-4f59-aca6-cf3a6b11acff">988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfMTktMy0xLTEtMjk4MzUy_dd69715d-362d-4cdc-945f-0add25d624e7">1,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfMjAtMS0xLTEtMjk4MzUy_d2a0d2c9-8443-4308-a33c-67799a3d0dc8">54,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfMjAtMy0xLTEtMjk4MzUy_c4c4489c-a733-4478-9416-59da4d6c5dae">41,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest and Investment Income, Net</span></div><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:InterestAndOtherIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfOTE4_5d49d76b-e72b-42f8-a3f1-6683e462585c" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and investment income, net consists of the following (in&#160;thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Three Months Ended<br/>March&#160;31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unrealized gains from equity securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc3NjljYjQ4YWJmNjQzMjc5MGE3ODc3NDM2MDNlY2Q0L3RhYmxlcmFuZ2U6Nzc2OWNiNDhhYmY2NDMyNzkwYTc4Nzc0MzYwM2VjZDRfNC0xLTEtMS0yOTgzNTI_ef18c58a-4fad-4430-8645-14a4958ec88b">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc3NjljYjQ4YWJmNjQzMjc5MGE3ODc3NDM2MDNlY2Q0L3RhYmxlcmFuZ2U6Nzc2OWNiNDhhYmY2NDMyNzkwYTc4Nzc0MzYwM2VjZDRfNC0zLTEtMS0yOTgzNTI_7aa14e13-cabe-4a3e-9a03-01fe6f85aeab">1,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc3NjljYjQ4YWJmNjQzMjc5MGE3ODc3NDM2MDNlY2Q0L3RhYmxlcmFuZ2U6Nzc2OWNiNDhhYmY2NDMyNzkwYTc4Nzc0MzYwM2VjZDRfNS0xLTEtMS0yOTgzNTI_5a8d0469-a906-4c73-8dc4-5c846b213185">284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:InterestAndOtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc3NjljYjQ4YWJmNjQzMjc5MGE3ODc3NDM2MDNlY2Q0L3RhYmxlcmFuZ2U6Nzc2OWNiNDhhYmY2NDMyNzkwYTc4Nzc0MzYwM2VjZDRfNS0zLTEtMS0yOTgzNTI_a6712f90-6680-4161-a64c-003a51d51549">1,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Investment amortization expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc3NjljYjQ4YWJmNjQzMjc5MGE3ODc3NDM2MDNlY2Q0L3RhYmxlcmFuZ2U6Nzc2OWNiNDhhYmY2NDMyNzkwYTc4Nzc0MzYwM2VjZDRfNi0xLTEtMS0yOTgzNTI_95e870b0-95e0-48c6-97f0-380029d16279">260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc3NjljYjQ4YWJmNjQzMjc5MGE3ODc3NDM2MDNlY2Q0L3RhYmxlcmFuZ2U6Nzc2OWNiNDhhYmY2NDMyNzkwYTc4Nzc0MzYwM2VjZDRfNi0zLTEtMS0yOTgzNTI_94a76ff0-3e95-4ff2-b7b7-2fa919bbe829">1,049</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net realized losses on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc3NjljYjQ4YWJmNjQzMjc5MGE3ODc3NDM2MDNlY2Q0L3RhYmxlcmFuZ2U6Nzc2OWNiNDhhYmY2NDMyNzkwYTc4Nzc0MzYwM2VjZDRfNy0xLTEtMS0yOTgzNTI_8d5aa5cb-7384-4cc5-ac75-14daf983050b">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:RealizedInvestmentGainsLosses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc3NjljYjQ4YWJmNjQzMjc5MGE3ODc3NDM2MDNlY2Q0L3RhYmxlcmFuZ2U6Nzc2OWNiNDhhYmY2NDMyNzkwYTc4Nzc0MzYwM2VjZDRfNy0zLTEtMS0yOTgzNTI_4e9ee94f-b49f-4c67-9fb8-2f8546112fa7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest and investment income, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc3NjljYjQ4YWJmNjQzMjc5MGE3ODc3NDM2MDNlY2Q0L3RhYmxlcmFuZ2U6Nzc2OWNiNDhhYmY2NDMyNzkwYTc4Nzc0MzYwM2VjZDRfOC0xLTEtMS0yOTgzNTI_bbfa2a1f-0e2e-4837-bea6-44e5d86fa76b">673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc3NjljYjQ4YWJmNjQzMjc5MGE3ODc3NDM2MDNlY2Q0L3RhYmxlcmFuZ2U6Nzc2OWNiNDhhYmY2NDMyNzkwYTc4Nzc0MzYwM2VjZDRfOC0zLTEtMS0yOTgzNTI_bbda7f9f-8fae-4172-8ab5-02223bd90730">1,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income includes interest from marketable securities, convertible notes receivable, other assets, and on bank deposits.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest expense</span></div><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfOTE2_1afd2dba-1dde-4eae-8a95-1541b66dc21a" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists of the following (in&#160;thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:71.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.302%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Three Months Ended<br/>March&#160;31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest expense on related-party notes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpenseRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc4NGJhYTU2YWExMzQ2MjViY2RjNmZjZjJhMTNkYTMyL3RhYmxlcmFuZ2U6Nzg0YmFhNTZhYTEzNDYyNWJjZGM2ZmNmMmExM2RhMzJfNC0xLTEtMS0yOTgzNTI_203938cb-5007-4a52-8888-b9acde5a5b7d">18,260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpenseRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc4NGJhYTU2YWExMzQ2MjViY2RjNmZjZjJhMTNkYTMyL3RhYmxlcmFuZ2U6Nzg0YmFhNTZhYTEzNDYyNWJjZGM2ZmNmMmExM2RhMzJfNC0zLTEtMS0yOTgzNTI_15773bde-f3e5-436d-9b84-2622f0a5a92c">8,101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization of related-party notes discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="ibrx:AmortizationOfDebtDiscountPremiumRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc4NGJhYTU2YWExMzQ2MjViY2RjNmZjZjJhMTNkYTMyL3RhYmxlcmFuZ2U6Nzg0YmFhNTZhYTEzNDYyNWJjZGM2ZmNmMmExM2RhMzJfNS0xLTEtMS0yOTgzNTI_32114311-badd-4ff0-892b-337e13444182">11,536</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="ibrx:AmortizationOfDebtDiscountPremiumRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc4NGJhYTU2YWExMzQ2MjViY2RjNmZjZjJhMTNkYTMyL3RhYmxlcmFuZ2U6Nzg0YmFhNTZhYTEzNDYyNWJjZGM2ZmNmMmExM2RhMzJfNS0zLTEtMS0yOTgzNTI_9bef5756-69cb-4740-9fb1-e03bb2bad6f1">370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpenseOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc4NGJhYTU2YWExMzQ2MjViY2RjNmZjZjJhMTNkYTMyL3RhYmxlcmFuZ2U6Nzg0YmFhNTZhYTEzNDYyNWJjZGM2ZmNmMmExM2RhMzJfNi0xLTEtMS0yOTgzNTI_bc370ebe-4760-45f5-abfe-9dcc01a0268e">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpenseOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc4NGJhYTU2YWExMzQ2MjViY2RjNmZjZjJhMTNkYTMyL3RhYmxlcmFuZ2U6Nzg0YmFhNTZhYTEzNDYyNWJjZGM2ZmNmMmExM2RhMzJfNi0zLTEtMS0yOTgzNTI_307bafa2-f59c-443d-a567-a26a1ec5c340">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc4NGJhYTU2YWExMzQ2MjViY2RjNmZjZjJhMTNkYTMyL3RhYmxlcmFuZ2U6Nzg0YmFhNTZhYTEzNDYyNWJjZGM2ZmNmMmExM2RhMzJfNy0xLTEtMS0yOTgzNTI_922ea20b-4779-43d4-9d44-604e3321dce8">29,816</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc4NGJhYTU2YWExMzQ2MjViY2RjNmZjZjJhMTNkYTMyL3RhYmxlcmFuZ2U6Nzg0YmFhNTZhYTEzNDYyNWJjZGM2ZmNmMmExM2RhMzJfNy0zLTEtMS0yOTgzNTI_afa8eb6d-7825-49c8-94b4-8172a774fc7b">8,491</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_49"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:InvestmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RleHRyZWdpb246ZThmMjMzMzg3MDVmNDM2NzkzMTYwYTk0NTYwM2RiYmNfOTQw_faaf1fb3-0ac7-4bf8-ab0f-851a54a8e66a" continuedAt="i673c0b608f714d82a178f074898682b8" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i673c0b608f714d82a178f074898682b8" continuedAt="i3939d35e4ec54ac39229a06d254f090c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Debt Securities</span></div><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RleHRyZWdpb246ZThmMjMzMzg3MDVmNDM2NzkzMTYwYTk0NTYwM2RiYmNfOTQx_8e0eb086-619a-4084-9faf-e6a9cf27922a" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, the weighted-average remaining contractual life, amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="27" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31,&#160;2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="27" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual&#160;Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i0b2b8940d45e44b5b593540d8f42fb87_D20230101-20230331" name="ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfNi0xLTEtMS0yOTgzNTI_ff720f91-fbbd-4ea3-90ef-bb47d29d936e">2.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i38d33d35c4f340d094daa523ef91b3a4_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfNi0zLTEtMS0yOTgzNTI_dde3eaed-d00a-4f7e-8424-95449d7fc8d0">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i38d33d35c4f340d094daa523ef91b3a4_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfNi01LTEtMS0yOTgzNTI_93c093b9-e0b8-461b-9b34-c8dcfa82af61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i38d33d35c4f340d094daa523ef91b3a4_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfNi03LTEtMS0yOTgzNTI_471df32f-d27f-4687-9a58-bfda3ed024b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i38d33d35c4f340d094daa523ef91b3a4_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfNi05LTEtMS0yOTgzNTI_657b466d-24a5-45ae-bb72-1657c8a3da4f">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i93ed60d3f2964554accd7342f72a2587_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfNy0zLTEtMS0yOTgzNTI_c4d77eff-9d9a-4427-baa1-dccb4c4553f6">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i93ed60d3f2964554accd7342f72a2587_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfNy01LTEtMS0yOTgzNTI_b61afb71-1643-4b29-8bfa-369c1b76266b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i93ed60d3f2964554accd7342f72a2587_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfNy03LTEtMS0yOTgzNTI_44f5354b-0f5c-4998-a6aa-d4f97202321c">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i93ed60d3f2964554accd7342f72a2587_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfNy05LTEtMS0yOTgzNTI_c773e5dd-bfbd-4faf-8247-d4b6482457bc">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0dcfca4e8b4f1d959f8fc7308c7a47_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfOC0zLTEtMS0yOTgzNTI_ca996de9-6577-4795-a996-3f45053004ad">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0dcfca4e8b4f1d959f8fc7308c7a47_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfOC01LTEtMS0yOTgzNTI_0a3ab497-99b6-423f-96e1-5522fb034bc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d0dcfca4e8b4f1d959f8fc7308c7a47_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfOC03LTEtMS0yOTgzNTI_500e720a-3b80-4ea5-83e2-5e2b29c7484a">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0dcfca4e8b4f1d959f8fc7308c7a47_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfOC05LTEtMS0yOTgzNTI_d1b7ec60-5975-4d99-9617-7a255fe90efe">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="ib572239e8f7a47589f3771ddf0d4f463_D20230101-20230331" name="ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfMTAtMS0xLTEtMjk4MzUy_79d78486-2830-4724-898d-86cb13332bfe">0.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9b9a73d45ec54296b71bec23a3b54530_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfMTAtMy0xLTEtMjk4MzUy_4e36826b-378f-4abe-a4db-001aa6c47a97">902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9b9a73d45ec54296b71bec23a3b54530_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfMTAtNS0xLTEtMjk4MzUy_d90ed13a-61d3-4045-96ac-ea468aebd690">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i9b9a73d45ec54296b71bec23a3b54530_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfMTAtNy0xLTEtMjk4MzUy_25c4fab2-4863-4809-9e1d-6979362e94fe">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9b9a73d45ec54296b71bec23a3b54530_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfMTAtOS0xLTEtMjk4MzUy_6c56ae35-19b8-4ee6-ad20-99c1b4b40b63">820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfMTItMy0xLTEtMjk4MzUy_c26bb9a4-0658-48e1-80e8-edc96b876428">1,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfMTItNS0xLTEtMjk4MzUy_4692a3ec-8ace-40f2-be12-53cb31dddfba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfMTItNy0xLTEtMjk4MzUy_6b8155ef-64bc-43d6-9e77-93f670d22469">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfMTItOS0xLTEtMjk4MzUy_3191dd6c-9856-44b7-80da-ea6998ea1070">964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2022, the weighted-average remaining contractual life, amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual&#160;Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;<br/>Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iad866414f696494880846815781be54d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfNi0zLTEtMS0yOTgzNTI_d79b8f1a-207d-4396-a508-349547b15bb8">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iad866414f696494880846815781be54d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfNi01LTEtMS0yOTgzNTI_3c4eaa9c-ceed-4ee3-b50d-98e2b5c33434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="iad866414f696494880846815781be54d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfNi03LTEtMS0yOTgzNTI_536479be-3555-4da3-9caa-3d61ee86e03b">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iad866414f696494880846815781be54d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfNi05LTEtMS0yOTgzNTI_080c9002-b74a-4dd1-8902-d4713a28e43f">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7db0daa0756249f385a861fd96f3d99c_D20220101-20221231" name="ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfOS0xLTEtMS0yOTgzNTI_a6799d19-1a56-4884-abb0-5f2dc305a1a8">4.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i178b6f6abcac4b7da1c687641370dde6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfOS0zLTEtMS0yOTgzNTI_e77a2cdf-cae6-4cf9-8ade-ee26ea2f5dca">932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i178b6f6abcac4b7da1c687641370dde6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfOS01LTEtMS0yOTgzNTI_0d19d6a6-7b9a-4770-83ea-5b1caec24f7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i178b6f6abcac4b7da1c687641370dde6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfOS03LTEtMS0yOTgzNTI_d48e99a8-e0db-4eda-a4ee-9c98f4586775">92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i178b6f6abcac4b7da1c687641370dde6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfOS05LTEtMS0yOTgzNTI_4cca908b-ccb4-49a9-aca2-4f7b169a3147">840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfMTEtMy0xLTEtMjk4MzUy_09790500-a9de-4e60-a0ad-382612e998ef">970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfMTEtNS0xLTEtMjk4MzUy_287b54a2-d369-46df-9ad8-5e2211034261">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfMTEtNy0xLTEtMjk4MzUy_ba5bde5a-3a52-4c45-a584-d10dfb61fc90">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfMTEtOS0xLTEtMjk4MzUy_7e623741-ee9d-493f-8267-a9dc4bd3df77">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="i3939d35e4ec54ac39229a06d254f090c"><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31,&#160;2023, <ix:nonFraction unitRef="security" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RleHRyZWdpb246ZThmMjMzMzg3MDVmNDM2NzkzMTYwYTk0NTYwM2RiYmNfNTcw_956ceec9-62a4-46d1-bb61-0e0591244dc1">14</ix:nonFraction> of the securities were in an unrealized loss position. <ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RleHRyZWdpb246ZThmMjMzMzg3MDVmNDM2NzkzMTYwYTk0NTYwM2RiYmNfOTQy_d810ff4b-a5c7-4df7-9342-bf089fe3fa53" continuedAt="i8d466e4d6310459e8fa090cb7db23a92" escape="true">Accumulated unrealized losses on marketable debt securities that have been in a continuous loss position for less than 12&#160;months and more than 12&#160;months were as follows (in&#160;thousands): </ix:nonNumeric></span></div><ix:continuation id="i8d466e4d6310459e8fa090cb7db23a92"><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March&#160;31,&#160;2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited) </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea925c85eab4423786f1fbcb3163e30e_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfNi0xLTEtMS0yOTgzNTI_4f1841de-fa55-4acd-8090-002f909e263f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea925c85eab4423786f1fbcb3163e30e_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfNi0zLTEtMS0yOTgzNTI_2462cd57-addb-4e4e-af2e-6a9033d6c78e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea925c85eab4423786f1fbcb3163e30e_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfNi01LTEtMS0yOTgzNTI_790d9671-7d22-4a27-b6e3-50f0195144b9">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea925c85eab4423786f1fbcb3163e30e_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfNi03LTEtMS0yOTgzNTI_d461dd53-6103-4aac-b4c8-d679935eaf9b">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecca882de63d47999c4cdc060161db0b_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfNy0xLTEtMS0yOTgzNTI_d6cad31f-e649-4bac-ae81-6668af4fbfac">581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecca882de63d47999c4cdc060161db0b_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfNy0zLTEtMS0yOTgzNTI_d55874dc-f358-43cc-bd48-13ec747b97b7">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecca882de63d47999c4cdc060161db0b_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfNy01LTEtMS0yOTgzNTI_d7d63929-5589-478a-a13b-ce4cc9dcbd15">346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecca882de63d47999c4cdc060161db0b_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfNy03LTEtMS0yOTgzNTI_8a1b7378-2eaa-40f0-a88a-bb7c79ef1243">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfOC0xLTEtMS0yOTgzNTI_ffce0c11-6a16-43f0-aa2a-30e934de82ea">581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfOC0zLTEtMS0yOTgzNTI_a3334d00-9452-432c-abab-2be0c703efad">58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfOC01LTEtMS0yOTgzNTI_bc480027-e473-4199-85b7-25d94df560b9">383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfOC03LTEtMS0yOTgzNTI_b83852bb-81f0-4495-9def-e4c762c2f830">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7abc0bfb0d34a659f0c1f9d70a91b5e_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNS0xLTEtMS0yOTgzNTI_3a37eac5-9856-46c1-8abc-81766ac40988">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7abc0bfb0d34a659f0c1f9d70a91b5e_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNS0zLTEtMS0yOTgzNTI_36cee297-4112-46c0-b76c-1ad2f434465e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7abc0bfb0d34a659f0c1f9d70a91b5e_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNS01LTEtMS0yOTgzNTI_7c0c12b3-3efe-4d1f-8609-6069a70cf8cc">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7abc0bfb0d34a659f0c1f9d70a91b5e_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNS03LTEtMS0yOTgzNTI_37203de5-805e-4457-87ff-48967506c894">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94255247204f487f8a5e6a7b45fd5f53_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNi0xLTEtMS0yOTgzNTI_58199f17-3423-4c1c-8b95-9ef17700e344">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94255247204f487f8a5e6a7b45fd5f53_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNi0zLTEtMS0yOTgzNTI_97eb5c4b-b9d6-4614-84a5-7ca73d419185">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94255247204f487f8a5e6a7b45fd5f53_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNi01LTEtMS0yOTgzNTI_9e8e4ce3-9298-4a02-ac40-6ab9caec2e87">840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94255247204f487f8a5e6a7b45fd5f53_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNi03LTEtMS0yOTgzNTI_c9b741d5-27bc-4c4e-bfb8-98fecc242e4c">92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNy0xLTEtMS0yOTgzNTI_5b761584-10e2-4e0d-9bed-66f2d1ae0fbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNy0zLTEtMS0yOTgzNTI_7c39eb8d-53d3-4444-99a7-65ecc08b9e47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNy01LTEtMS0yOTgzNTI_6fa41586-8bfc-4bef-93cf-3a828c9605de">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNy03LTEtMS0yOTgzNTI_7a6ca6e8-3d4a-43f9-b960-419eedebb7ec">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Equity Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held investments in marketable equity securities with readily determinable fair values of $<ix:nonFraction unitRef="usd" contextRef="ia818d8707e4c4c8d99bffda3de67924f_I20230331" decimals="-5" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RleHRyZWdpb246ZThmMjMzMzg3MDVmNDM2NzkzMTYwYTk0NTYwM2RiYmNfMTA5OTUxMTYyOTA1MQ_3929104d-7ddf-4f02-b76b-b05775c8f21f">2.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i37c25c0026ea4ccdbaa0613624232e13_I20221231" decimals="-5" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RleHRyZWdpb246ZThmMjMzMzg3MDVmNDM2NzkzMTYwYTk0NTYwM2RiYmNfMTA5OTUxMTYyOTA1OQ_45a2091f-598b-458e-ac35-cfbdf9730a30">2.5</ix:nonFraction>&#160;million as of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively. Unrealized gains recorded on these securities totaled $<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RleHRyZWdpb246ZThmMjMzMzg3MDVmNDM2NzkzMTYwYTk0NTYwM2RiYmNfMTA5OTUxMTYzMDE4NA_f88c31c2-65f0-4997-bd06-b78416babcf7">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RleHRyZWdpb246ZThmMjMzMzg3MDVmNDM2NzkzMTYwYTk0NTYwM2RiYmNfMTA5OTUxMTYzMDIxNg_f409f054-1600-4b14-9388-c24de19ea788">1.4</ix:nonFraction>&#160;million for the three&#160;months&#160;ended March&#160;31,&#160;2023 and 2022, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest and investment income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations.</span></div></ix:continuation><div id="i5bbe340c9c8f435088d8011b72b6800d_55"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RleHRyZWdpb246NDRhMzUzZTlhNjg1NDQyYmExY2ZhNzhiODI4MDM0OTNfMzE5NA_5a05b249-126d-4cb6-97d1-b7863ac2efc0" continuedAt="ic9dc76903d674a75abf876cdf0bcaced" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="ic9dc76903d674a75abf876cdf0bcaced" continuedAt="i3381b52ea50e4c3e93b21068b138ba93"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RleHRyZWdpb246NDRhMzUzZTlhNjg1NDQyYmExY2ZhNzhiODI4MDM0OTNfMzE5NQ_2210acc0-606b-4fe6-9e03-f83420762873" continuedAt="iae40f6360ba541559c1e0f7e9ce6da37" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three tiers are defined as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1&#8212;Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these products does not entail a significant degree of judgment. Our Level&#160;1 assets consist of bank deposits, money market funds, and marketable equity securities.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2&#8212;Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level&#160;2 assets consist of corporate debt securities including commercial paper, government-sponsored securities and corporate bonds, as well as foreign municipal securities.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3&#8212;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="i3381b52ea50e4c3e93b21068b138ba93" continuedAt="i112cf946cb3e42ef9a350e004c9a362a"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iae40f6360ba541559c1e0f7e9ce6da37">We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy. The fair values of financial instruments other than marketable securities and cash and cash equivalents are determined through a combination of management estimates and third-party valuations.</ix:continuation></span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recurring Valuations</span></div><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RleHRyZWdpb246NDRhMzUzZTlhNjg1NDQyYmExY2ZhNzhiODI4MDM0OTNfMzE5Ng_cc4f71fc-5401-4275-a05b-69c623775d60" continuedAt="i8fd1a84eba1e4924895babf4d8ebd950" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below (in&#160;thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Unaudited) </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i03762b77d7b4408594a116ef19d68f4d_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfNi0xLTEtMS0yOTgzNTI_21f4e585-3cc5-47bc-a50b-ba449f34abf1">88,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iaf88dacf0a484cb8938868ce11e3fd93_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfNi00LTEtMS0yOTgzNTI_0ccc80d5-521e-4bd8-8731-226135463a9a">73,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6edc71b525cb40e5a5d6fb007bb51c16_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfNi02LTEtMS0yOTgzNTI_a34751c4-2602-4dca-b81e-ab2025000226">14,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia015c55c47d246e6b83da57fa54d9457_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfNi04LTEtMS0yOTgzNTI_d9d80d01-745b-4fd7-b1db-180bea06b918">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i268f2b405ec94f05a3e088310fef2a41_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfNy0xLTEtMS0yOTgzNTI_86ffc6bd-4b4c-442d-bec3-4ef7b5ff74ae">2,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5d9bd30014c24311a412cab8f1e6736b_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfNy00LTEtMS0yOTgzNTI_26049632-f900-442a-a8d7-39da5be76dea">2,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i3e8a0351256343eeb4cc0af08ac1a51d_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfNy02LTEtMS0yOTgzNTI_ac8e5dd7-ce07-481e-b436-daaa38739213">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i53ab60edafa6478689087569daf40626_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfNy04LTEtMS0yOTgzNTI_4114adee-6aaf-436f-9df9-028a5567e562">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2bd58f7537dc4e4f8fe02f6ad46a9783_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfOS0xLTEtMS0yOTgzNTI_74659b32-9d3d-4dec-97ac-0d19ebe550c8">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7f54811c3bb74c6fbfba10a31850e736_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfOS00LTEtMS0yOTgzNTI_994d9b72-fe76-4fd1-8370-4930a5cf2ec0">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i9102c7f1073b4a35b9194887f3407199_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfOS02LTEtMS0yOTgzNTI_c512dab9-59f9-49d9-a771-168f5c3e487f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i14d57b1d76d54551b3b3e206ffde3432_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfOS04LTEtMS0yOTgzNTI_2f18f773-b826-43f8-8651-6362ba88357c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4dee1612809b472b83659b4a2b02d81b_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTAtMS0xLTEtMjk4MzUy_b352e9d3-0895-4940-85a1-7f6a54eac901">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i104551fa9a6e4d0db14a884d59a96b54_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTAtNC0xLTEtMjk4MzUy_8bace789-32c6-4003-9e9b-f3d3f3af49f2">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ice4416a2800b4d009acab3013a489ab7_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTAtNi0xLTEtMjk4MzUy_72bc4952-930c-4d42-abef-e23f17ca7e68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i83982f7c2fc54aa7a359a7a7d975aff2_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTAtOC0xLTEtMjk4MzUy_5c17e4c2-b74a-41a5-86e1-07951d0534e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec99a9e278b242918d95bceb26bbdeec_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTItMS0xLTEtMjk4MzUy_1a40b5d7-fa4e-4a62-80f3-f968857c4b29">820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf5a9b13f35d422fa1732caa34e706df_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTItNC0xLTEtMjk4MzUy_8c337bbf-7b48-40a3-b38d-c34288f5b86d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18b9e33de5fb420f85ada2e2f7aecc07_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTItNi0xLTEtMjk4MzUy_00d09398-3e28-4e4c-bf31-2fc3b0901d1d">820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16979a35fa1d40b997739a4cb809e6f7_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTItOC0xLTEtMjk4MzUy_67141cb9-b086-4fa2-a30c-cf10b3165224">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i331682550ab14aec904426036c3b2a64_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTMtMS0xLTEtMjk4MzUy_a38f0912-9039-4976-b19b-61673ed6b0c4">92,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief94290369fc4061b4a36705889940e8_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTMtNC0xLTEtMjk4MzUy_b18f7ef6-7089-4c0d-9e2a-bce314ea3ae1">76,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f3b040139a4ffeb38a1cd82447d958_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTMtNi0xLTEtMjk4MzUy_b3028118-23a3-4e04-9210-cf69a0521aad">15,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe21c408c60145f1b9446e214b886786_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTMtOC0xLTEtMjk4MzUy_73471f57-ba8c-4b52-985d-aa5c0fa4959d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Related-party convertible note payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b47701466154187b9f13a27115955bf_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTYtMS0xLTEtMzIxNzMz_8acf8667-bb35-4339-9a20-64915668a2ad">29,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia28a5b94bbd2402daf1696b7e83ff97d_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTYtNC0xLTEtMzIxNzMz_42a75a2d-11a4-474b-90b3-76630c8f2b11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7436b01d201048599ef97748571d8dbe_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTYtNi0xLTEtMzIxNzMz_ecd36d7c-bfc0-4a1e-a8ef-bcbcca40bf95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1038882c13304367a352a1ea0d5e9430_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTYtOC0xLTEtMzIxNzMz_98aa36ca-f2b8-43e2-99b0-5eaea10e4466">29,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9b73b9076d14e77bd7f75276c4a8d58_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTYtMS0xLTEtMjk4MzUy_2c14cb7d-52bf-4a5e-8a2a-59999944d35b">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i946cc463480045ae80cefa68e6b23ca8_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTYtNC0xLTEtMjk4MzUy_70c11131-ab97-4e98-95ca-da84fbc8f104">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6901e0e7cfd4bf4bd21eb35ec6aa8f0_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTYtNi0xLTEtMjk4MzUy_8c3c15b7-9a16-49dc-9698-8c4500062009">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f6382b087284b0ab540c7a4cd9db9da_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTYtOC0xLTEtMjk4MzUy_7e2615e1-6afe-43a7-9989-82d74f53a689">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d1b12230e8f4233a449b44aa8b89dae_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTgtMS0xLTEtMjk4MzUy_0023f7f3-6b5d-4be3-a591-73cb01b0e739">17,780</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i075d1102c0894f7aaf61aea36c69248e_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTgtNC0xLTEtMjk4MzUy_cb303295-b503-4b3b-9310-20b578291f6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a21a545f0c4436c9afb3e11ec80f767_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTgtNi0xLTEtMjk4MzUy_3da7f292-07e9-488c-bbac-76d8f8c8c052">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5143b8cbe5a4e8990bf3e2deb701bef_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTgtOC0xLTEtMjk4MzUy_d1efbb40-b802-4afd-9553-cfd00b6add42">17,780</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total liabilities measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i331682550ab14aec904426036c3b2a64_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTktMS0xLTEtMjk4MzUy_49db4b1a-fba6-4529-8bbc-c6e5ca57b01d">47,650</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief94290369fc4061b4a36705889940e8_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTktNC0xLTEtMjk4MzUy_89c12cb2-6855-4983-ac2d-b309a2ff9efd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f3b040139a4ffeb38a1cd82447d958_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTktNi0xLTEtMjk4MzUy_84fd48b5-902a-4863-8564-566288e81f42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe21c408c60145f1b9446e214b886786_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTktOC0xLTEtMjk4MzUy_c26cf239-2324-463d-b3cd-a6f665523226">47,650</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iaa82585cc76945718fa4c122a0abdf22_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfNS0xLTEtMS0yOTgzNTI_a30b5af5-3d62-4521-aa30-e89fbd883291">104,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i34465ea1764e409786a6bf7a192ee52a_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfNS00LTEtMS0yOTgzNTI_35a021bb-bf8f-46bf-b92e-051bf29ecee0">63,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6711f0d932ba4e6a92c92baecc798ffe_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfNS02LTEtMS0yOTgzNTI_6e418c26-ae31-4de8-8ee7-c8c7fbd0de56">40,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9024e16e44b4b6a926b58cb4aec8d8f_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfNS04LTEtMS0yOTgzNTI_8e8b3fe6-4451-4427-a536-0a73ece62136">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iadecc9749ad74d06bbf65eca3773b162_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfNi0xLTEtMS0yOTgzNTI_f6e582c7-301b-4167-94c6-3f7e91dede5c">2,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie7d4c869961845049a837ecf93a7d2d2_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfNi00LTEtMS0yOTgzNTI_699e4181-60d2-4f8c-845a-da9561112e99">2,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iba5d6bb2adc04bfeb0876c228f393f9b_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfNi02LTEtMS0yOTgzNTI_72da1f46-a0f8-4a51-9a2e-d896409466ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia81b7b3cbfab49d8abed2fece23c4eb2_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfNi04LTEtMS0yOTgzNTI_fde8fd68-dbd5-4e90-8055-e7d803c0e4f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia6d9de146cd64ddd838411f8d960bb39_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfOS0xLTEtMS0yOTgzNTI_1cfda769-dedc-4aaf-9640-761cf7fdfd0a">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5ef6c543a47549d6ba626e9b621bef9d_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfOS00LTEtMS0yOTgzNTI_6b44c6f0-c8ff-4030-b9fa-de8e99c910c2">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i609d1640d799407fa25e8d7bb019d122_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfOS02LTEtMS0yOTgzNTI_6dd02e4d-b8f5-4e5a-b9c6-8a0f5a9614a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia99b37fb3a1e4839964854bb8c5cd0a6_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfOS04LTEtMS0yOTgzNTI_d16e5d30-3669-4465-8aba-a26442b0f905">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cfcae1f8c96411fa01b9df7155a5e1b_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTEtMS0xLTEtMjk4MzUy_4e1124df-5311-40d8-8381-b15d80e095e4">840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc22baf6a9234b998bdacc85aa2baa32_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTEtNC0xLTEtMjk4MzUy_746ed330-7dc6-4647-886e-9f25bdef241a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieed74cabe48d445d966192789eaffa46_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTEtNi0xLTEtMjk4MzUy_77b4a6e5-d25b-4e67-9da7-1e639c1b991d">840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e08fabb07e64dc89b54f50eb2cbab9d_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTEtOC0xLTEtMjk4MzUy_d82c7ac6-40ce-455b-8a93-a854395a8199">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b6ead15154410fbde3c2433bcdd159_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTItMS0xLTEtMjk4MzUy_d9618255-d470-4258-b888-7555865ce5dd">108,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e78df5d936b4e6ea1a77cbeb8c49595_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTItNC0xLTEtMjk4MzUy_0724585c-6ac5-4ecc-b477-67c41ba1d388">66,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia279b1b8a68047368e6c50d9ea885c6e_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTItNi0xLTEtMjk4MzUy_3a1209bb-539f-48d7-8e4f-ad8480efdcb3">41,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274686603f6a451f837acc17b08d3411_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTItOC0xLTEtMjk4MzUy_3f5f82fc-f845-43d8-8103-28c0cb11af9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities at fair value:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25536a0d63845739ff43e08195cd5c1_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTQtMS0xLTEtMjk4MzUy_73bac250-0f03-4a3c-8620-59953538cbf8">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef3562f20dc43dfa08930bb1bd2bc36_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTQtNC0xLTEtMjk4MzUy_6a5246bf-c472-4815-be90-94163be013c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i544de52cd9194dabb073582a30849b58_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTQtNi0xLTEtMjk4MzUy_5f96d716-4520-4905-97f2-c2a9e9c951b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76b53cde4e3e4322a061ae53a8f05594_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTQtOC0xLTEtMjk4MzUy_a05405ac-7a01-4c48-8d0b-3054adce0a9a">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc84a0efc87f46c8aae6c011790df898_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTctMS0xLTEtMzAzMjE4_31e190c1-6ee8-42fd-814c-a10df24f6832">21,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccfd1df580444d909b6b2d6f8f806e7b_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTctNC0xLTEtMzAzMjI2_91bfef8a-f313-4088-8442-45d1c1d8c184">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63ac4d5eb374467ab54634d998aec6f5_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTctNi0xLTEtMzAzMjM0_517b0985-fa14-4da8-975c-98ad50bb9e87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcf19f6af9824b52a6d8e4395d10134a_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTctOC0xLTEtMzAzMjQy_3a1f3c6d-2405-4560-a55e-4541e1b27448">21,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total liabilities measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b6ead15154410fbde3c2433bcdd159_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTgtMS0xLTEtMzAzMjUw_19a90834-0f38-4b7f-a3c0-e115662628f5">21,655</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e78df5d936b4e6ea1a77cbeb8c49595_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTgtNC0xLTEtMzAzMjU4_7e660ea3-36cb-44dc-a1d0-928afb8c642f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia279b1b8a68047368e6c50d9ea885c6e_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTgtNi0xLTEtMzAzMjY2_81d19a3c-2ac8-438a-aa08-167fa820b519">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274686603f6a451f837acc17b08d3411_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTgtOC0xLTEtMzAzMjc0_0cf7d338-50aa-4825-978d-cf5bdc902375">21,655</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="i112cf946cb3e42ef9a350e004c9a362a" continuedAt="iea4246501d204c30b358defab598f4c8"><ix:continuation id="i8fd1a84eba1e4924895babf4d8ebd950" continuedAt="ie6c30af296dc45878faab7148111ccb4"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, the Level&#160;2 measurements include $<ix:nonFraction unitRef="usd" contextRef="i2c53736371164c6eb06bafd550e0f5fa_I20230331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjBjOWNlNWNjMTA0MTQzOTBhYjYwMmIyZWNiZjA3OWNiL3RhYmxlcmFuZ2U6MGM5Y2U1Y2MxMDQxNDM5MGFiNjAyYjJlY2JmMDc5Y2JfMC0xLTEtMS0yOTgzNTIvdGV4dHJlZ2lvbjpmODdiNjk2N2NiZTk0YzYxYmE5ZjVhM2U4ZGQ3YzA1YV8xMDk5NTExNjI4NDc4_955e2ba9-57fa-4d89-818f-edc8e04c9ebf">15.0</ix:nonFraction>&#160;million in U.S. government agency securities with original maturities of less than 90&#160;days. As of December&#160;31,&#160;2022, the Level&#160;2 measurements include $<ix:nonFraction unitRef="usd" contextRef="i946b4f2294f644bcafcd5f32b36a4b6a_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjBjOWNlNWNjMTA0MTQzOTBhYjYwMmIyZWNiZjA3OWNiL3RhYmxlcmFuZ2U6MGM5Y2U1Y2MxMDQxNDM5MGFiNjAyYjJlY2JmMDc5Y2JfMC0xLTEtMS0yOTgzNTIvdGV4dHJlZ2lvbjpmODdiNjk2N2NiZTk0YzYxYmE5ZjVhM2U4ZGQ3YzA1YV8xMDk5NTExNjI4NTky_903a345a-33b1-4ab7-8e6a-8d80251070c9">32.0</ix:nonFraction>&#160;million in U.S. government agency securities and $<ix:nonFraction unitRef="usd" contextRef="i2f8683e6989143198ff853a8fc97d338_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjBjOWNlNWNjMTA0MTQzOTBhYjYwMmIyZWNiZjA3OWNiL3RhYmxlcmFuZ2U6MGM5Y2U1Y2MxMDQxNDM5MGFiNjAyYjJlY2JmMDc5Y2JfMC0xLTEtMS0yOTgzNTIvdGV4dHJlZ2lvbjpmODdiNjk2N2NiZTk0YzYxYmE5ZjVhM2U4ZGQ3YzA1YV8xMDk5NTExNjI4NjI4_de747352-0259-46eb-b70e-d2cdc18529ba">8.8</ix:nonFraction>&#160;million in corporate debt securities with original maturities of less than 90&#160;days.</span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As of March&#160;31,&#160;2023, the company has a related-party convertible note payable with a principal amount of $<ix:nonFraction unitRef="usd" contextRef="i4d61f38abc9b467da5b3204da34fab5e_I20230331" decimals="-5" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOmU1OTNlZDFjYTM0MTRmYmZhMmQ4NmM2YzZkODUwYjEzL3RhYmxlcmFuZ2U6ZTU5M2VkMWNhMzQxNGZiZmEyZDg2YzZjNmQ4NTBiMTNfMC0xLTEtMS0zMjE4MzgvdGV4dHJlZ2lvbjoyZWVkMTNjYTY4ZDg0OWQyYmUxN2U0ZmNlOGMwMjY0Nl81NDk3NTU4MjE3NDU_28189d53-790e-45e7-93a3-df4f7efc30ac">30.0</ix:nonFraction>&#160;million, which is accounted for under the ASC&#160;825-10-15-4 FVO election. Under the FVO election, the financial instrument is initially measured at its issue-date estimated fair value and subsequently re-measured at estimated fair value on a recurring basis at each reporting period date. The company&#8217;s other related-party notes are not accounted for under the fair value election. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_73">Note&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_73">9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, Related-Party Debt, for further information. The estimated fair value of the convertible note was computed using a discounted cash flow method with the following unobservable assumptions:</span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected market yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25b2382ccad7475f812c01198c635ee0_I20230331" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjRkY2EzYjZhZDc0YTQyZDk4ZWUxYzU0NzNlMjQxNjVkL3RhYmxlcmFuZ2U6NGRjYTNiNmFkNzRhNDJkOThlZTFjNTQ3M2UyNDE2NWRfMy0xLTEtMS0zMjQxMzI_cb7ea4d1-d37b-49f8-84ef-6efff2f80f03">17.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount period</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="y" contextRef="i650984f3db47470a9f5389b2e032a01a_I20230331" decimals="0" name="us-gaap:DebtInstrumentMeasurementInput" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjRkY2EzYjZhZDc0YTQyZDk4ZWUxYzU0NzNlMjQxNjVkL3RhYmxlcmFuZ2U6NGRjYTNiNmFkNzRhNDJkOThlZTFjNTQ3M2UyNDE2NWRfNC0xLTEtMS0zMjQxMzI_2b9ae93f-1cf0-4d33-881a-79855a99f8bb">0.1</ix:nonFraction> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount factor</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6f16749c92e842ce81ffb8d9ae2a9c3d_I20230331" decimals="2" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjRkY2EzYjZhZDc0YTQyZDk4ZWUxYzU0NzNlMjQxNjVkL3RhYmxlcmFuZ2U6NGRjYTNiNmFkNzRhNDJkOThlZTFjNTQ3M2UyNDE2NWRfNS0xLTEtMS0zMjQxMzI_352d08dd-05d7-45b6-bd70-30909f4a53b9">0.98</ix:nonFraction></span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Third-Party Warrant Liabilities</span></td></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">December 2022 Warrants</span></div><div style="margin-top:6pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the December&#160;12, 2022 registered direct offering of common stock, the company issued <ix:nonFraction unitRef="shares" contextRef="i19f26457ccfe499cb0e3bbed35112923_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RleHRyZWdpb246NDRhMzUzZTlhNjg1NDQyYmExY2ZhNzhiODI4MDM0OTNfMTA5OTUxMTYzMzgzNg_2fa3b675-943f-4ae4-94d7-cae244a23c06">9,090,909</ix:nonFraction> warrants (December&#160;2022 Warrants). The warrants were classified as a liability at their fair value upon the issuance. As of March&#160;31,&#160;2023, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following date:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ia1191e7cec0f4f78a48f0b7efe88df43_I20230331" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjk4YTQzNTlkZGY2YzRjNjVhZGVlYjhiZDVkNjM0OWJhL3RhYmxlcmFuZ2U6OThhNDM1OWRkZjZjNGM2NWFkZWViOGJkNWQ2MzQ5YmFfNC0xLTEtMS0zMjQxNTY_3e3dc252-f88a-4d74-b591-aca395a8f0d9">6.60</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="y" contextRef="ib93fecbf92174118bdd72fa5e20ea20e_I20230331" decimals="0" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjk4YTQzNTlkZGY2YzRjNjVhZGVlYjhiZDVkNjM0OWJhL3RhYmxlcmFuZ2U6OThhNDM1OWRkZjZjNGM2NWFkZWViOGJkNWQ2MzQ5YmFfMy0xLTEtMS0zMjIxMjQ_caa94ce0-ccce-4fe7-929b-fbabb7a8cd40">1.7</ix:nonFraction> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected average volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5be77fd9053a42c1821b000e6a63fc53_I20230331" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjk4YTQzNTlkZGY2YzRjNjVhZGVlYjhiZDVkNjM0OWJhL3RhYmxlcmFuZ2U6OThhNDM1OWRkZjZjNGM2NWFkZWViOGJkNWQ2MzQ5YmFfNC0xLTEtMS0zMjIxMjQ_3a95fbb5-fa29-4f24-88e2-e46526a70a0b">129.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9270094ae41a49ccb211054939e04e29_I20230331" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjk4YTQzNTlkZGY2YzRjNjVhZGVlYjhiZDVkNjM0OWJhL3RhYmxlcmFuZ2U6OThhNDM1OWRkZjZjNGM2NWFkZWViOGJkNWQ2MzQ5YmFfNS0xLTEtMS0zMjIxMjQ_024e5fa2-07e3-4daf-a76f-6bc21132638c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icf8421bdf082438eacb0d8a2bbb510e1_I20230331" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjk4YTQzNTlkZGY2YzRjNjVhZGVlYjhiZDVkNjM0OWJhL3RhYmxlcmFuZ2U6OThhNDM1OWRkZjZjNGM2NWFkZWViOGJkNWQ2MzQ5YmFfNi0xLTEtMS0zMjIxMjQ_1e057db6-eb97-4370-bce6-2e5664a8d181">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in the carrying amount of the December&#160;2022 Warrants was as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning fair value, at December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e247e3019ba40cfb87b176aa4e219b6_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOmUxNmRiNTMwMWViYTRhNmY4NmMxNTNhYjJhNjhiMWIwL3RhYmxlcmFuZ2U6ZTE2ZGI1MzAxZWJhNGE2Zjg2YzE1M2FiMmE2OGIxYjBfNC0xLTEtMS0zMDg4Njc_ec6813d9-3a17-4950-ad6c-e300702829a8">21,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOmUxNmRiNTMwMWViYTRhNmY4NmMxNTNhYjJhNjhiMWIwL3RhYmxlcmFuZ2U6ZTE2ZGI1MzAxZWJhNGE2Zjg2YzE1M2FiMmE2OGIxYjBfNS0wLTEtMS0zMTA3NzY_2350ba70-1f49-4ea5-8303-63ba7471fe59">Change in fair value</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91d87f21eddb4e8ba52be9c983035646_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOmUxNmRiNTMwMWViYTRhNmY4NmMxNTNhYjJhNjhiMWIwL3RhYmxlcmFuZ2U6ZTE2ZGI1MzAxZWJhNGE2Zjg2YzE1M2FiMmE2OGIxYjBfNS0xLTEtMS0zMDg4Njc_9597c19f-d2e3-4aa7-891f-8004e71b794b">15,818</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending fair value, at March&#160;31,&#160;2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05ce9f5c06e84394bfde03b091dcbdf4_I20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOmUxNmRiNTMwMWViYTRhNmY4NmMxNTNhYjJhNjhiMWIwL3RhYmxlcmFuZ2U6ZTE2ZGI1MzAxZWJhNGE2Zjg2YzE1M2FiMmE2OGIxYjBfNi0xLTEtMS0zMDg4Njc_01d5d1af-7772-4866-bf88-bacc55505c95">5,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="iea4246501d204c30b358defab598f4c8" continuedAt="i1c98ded1b4f541878cb20ddc56d637c1"><ix:continuation id="ie6c30af296dc45878faab7148111ccb4"><div style="margin-top:12pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">February 2023 Warrants</span></div><div style="margin-top:6pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the February&#160;15, 2023 registered direct offering of common stock, the company issued <ix:nonFraction unitRef="shares" contextRef="ie9e851daf28c4255b2112c4cd9cefdc6_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RleHRyZWdpb246NDRhMzUzZTlhNjg1NDQyYmExY2ZhNzhiODI4MDM0OTNfMTA5OTUxMTYzNDUyNQ_790fab1a-1ef6-4319-ac6d-3af6f734447a">14,072,615</ix:nonFraction> warrants (February&#160;2023&#160;Warrants). The warrants were classified as a liability at its fair value upon the issuance. As of March&#160;31,&#160;2023, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following dates:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31,&#160;2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Date<br/>February 15, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i092d7c652fa9476b8e128260ffb7cf55_I20230331" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjc3NGFiMTQ2YzE3MzRjMTBiMWIyNjRiZGI3MjBiMzZjL3RhYmxlcmFuZ2U6Nzc0YWIxNDZjMTczNGMxMGIxYjI2NGJkYjcyMGIzNmNfNC0xLTEtMS0zMjU3MjA_61a82b25-3b7c-4456-bda8-bb8b8fd95e30">4.26</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i4b1c02b83f5d4e588b5e7f5dfe24a69e_I20230215" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjc3NGFiMTQ2YzE3MzRjMTBiMWIyNjRiZGI3MjBiMzZjL3RhYmxlcmFuZ2U6Nzc0YWIxNDZjMTczNGMxMGIxYjI2NGJkYjcyMGIzNmNfMy0zLTEtMS0zMjU3NTk_38eb3e3d-aa9f-41bc-8a75-ec99007043ae">4.26</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="y" contextRef="i18ad3c2a3e4841d3b55094278b55ee00_I20230331" decimals="0" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjc3NGFiMTQ2YzE3MzRjMTBiMWIyNjRiZGI3MjBiMzZjL3RhYmxlcmFuZ2U6Nzc0YWIxNDZjMTczNGMxMGIxYjI2NGJkYjcyMGIzNmNfNS0xLTEtMS0zMjU3MjA_aaee21e5-871c-48dc-8060-d69c83110591">1.9</ix:nonFraction> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="y" contextRef="iba41b7496e6d4908952cd0ecb8a9fcec_I20230215" decimals="0" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjc3NGFiMTQ2YzE3MzRjMTBiMWIyNjRiZGI3MjBiMzZjL3RhYmxlcmFuZ2U6Nzc0YWIxNDZjMTczNGMxMGIxYjI2NGJkYjcyMGIzNmNfNC0zLTEtMS0zMjU3NTk_7d1007b5-a7f9-4caa-b631-b9dc53fc4a9c">2.0</ix:nonFraction> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected average volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8cc76b0fbcf84e109ae61be53b3d16fa_I20230331" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjc3NGFiMTQ2YzE3MzRjMTBiMWIyNjRiZGI3MjBiMzZjL3RhYmxlcmFuZ2U6Nzc0YWIxNDZjMTczNGMxMGIxYjI2NGJkYjcyMGIzNmNfNi0xLTEtMS0zMjU3MjA_19d5bd6d-9649-4c4e-ad1e-339fcd1a6013">127.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib565990d93cd4919b9ad581d54993133_I20230215" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjc3NGFiMTQ2YzE3MzRjMTBiMWIyNjRiZGI3MjBiMzZjL3RhYmxlcmFuZ2U6Nzc0YWIxNDZjMTczNGMxMGIxYjI2NGJkYjcyMGIzNmNfNS0zLTEtMS0zMjU3NTk_43a1e88e-f38c-4ec9-9f0d-a06b8988014d">97.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5b96511d9e744c5099e21750e0d21d2d_I20230331" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjc3NGFiMTQ2YzE3MzRjMTBiMWIyNjRiZGI3MjBiMzZjL3RhYmxlcmFuZ2U6Nzc0YWIxNDZjMTczNGMxMGIxYjI2NGJkYjcyMGIzNmNfNy0xLTEtMS0zMjU3MjA_19674086-df6e-4c46-851a-93e8f695511d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic3b821833563458f9405084b1ae950db_I20230215" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjc3NGFiMTQ2YzE3MzRjMTBiMWIyNjRiZGI3MjBiMzZjL3RhYmxlcmFuZ2U6Nzc0YWIxNDZjMTczNGMxMGIxYjI2NGJkYjcyMGIzNmNfNi0zLTEtMS0zMjU3NTk_cacc9ca9-3d75-479e-abef-2098cfbf5cd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5751565e9bc4821bce01dd4188d7302_I20230331" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjc3NGFiMTQ2YzE3MzRjMTBiMWIyNjRiZGI3MjBiMzZjL3RhYmxlcmFuZ2U6Nzc0YWIxNDZjMTczNGMxMGIxYjI2NGJkYjcyMGIzNmNfOC0xLTEtMS0zMjU3MjA_aba2c5b8-41f5-47e8-838e-62d51228ed3f">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i17c9c04b377c4dc0a52cd262037cb9ba_I20230215" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjc3NGFiMTQ2YzE3MzRjMTBiMWIyNjRiZGI3MjBiMzZjL3RhYmxlcmFuZ2U6Nzc0YWIxNDZjMTczNGMxMGIxYjI2NGJkYjcyMGIzNmNfNy0zLTEtMS0zMjU3NTk_57ff6b21-b2be-41ef-ac90-bdcf28d09a88">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in the carrying amount of the February 2023 Warrants were as follows (in&#160;thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value at the issuance date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8bb04bc74374058a2c1efed036ac8cb_I20230215" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjQ1NjRiYjg3OWY4MDRmZTc5NzBhNDg1YWUzNmI0YWZiL3RhYmxlcmFuZ2U6NDU2NGJiODc5ZjgwNGZlNzk3MGE0ODVhZTM2YjRhZmJfNC0xLTEtMS0zMjU4MjI_f88bf806-c818-4f07-9740-2cd21fbca5d8">23,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjQ1NjRiYjg3OWY4MDRmZTc5NzBhNDg1YWUzNmI0YWZiL3RhYmxlcmFuZ2U6NDU2NGJiODc5ZjgwNGZlNzk3MGE0ODVhZTM2YjRhZmJfNS0wLTEtMS0zMzA4Nzg_31727132-f847-41a1-942b-fae5179a937e">Change in fair value</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c148f91d4ce423f9b310ff8481860bb_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjQ1NjRiYjg3OWY4MDRmZTc5NzBhNDg1YWUzNmI0YWZiL3RhYmxlcmFuZ2U6NDU2NGJiODc5ZjgwNGZlNzk3MGE0ODVhZTM2YjRhZmJfNS0xLTEtMS0zMjU4MjI_5598e54e-c704-4224-b190-3c76a62be24b">11,736</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending fair value, at March&#160;31,&#160;2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cd4532b1fc24c0ca2ef81c7e69794c6_I20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjQ1NjRiYjg3OWY4MDRmZTc5NzBhNDg1YWUzNmI0YWZiL3RhYmxlcmFuZ2U6NDU2NGJiODc5ZjgwNGZlNzk3MGE0ODVhZTM2YjRhZmJfNi0xLTEtMS0zMjU4MjI_75bee9bc-3833-4612-abea-3e7dc81732f2">11,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonrecurring Valuations</span></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><ix:continuation id="i1c98ded1b4f541878cb20ddc56d637c1" continuedAt="i9be2eacdd4a04e54901411c9b2264eb5"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measured the fair value of the fixed-rate promissory notes and variable-rate promissory notes before and after amendments that were entered on August&#160;31,&#160;2022, as they were accounted for under the debt extinguishment accounting model. We used discounted cash flow analyses for promissory notes without a holder conversion option and a binomial lattice convertible note model for the fixed-rate promissory notes with a holder conversion option. Since certain of the factors analyzed are considered to be unobservable inputs, both the discounted cash flow model and the lattice model are considered to be a Level&#160;3 valuation. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_73">Note</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_73">&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_73">9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Related-Party Debt,</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9be2eacdd4a04e54901411c9b2264eb5"> for additional information.</ix:continuation> </span></div><div id="i5bbe340c9c8f435088d8011b72b6800d_58"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfMTIwMTM_180bfdda-e22c-4cad-9084-0c61c2fece5d" continuedAt="i80c4d244056441dd8245af07285cae66" escape="true">Collaboration and License Agreements and Acquisition</ix:nonNumeric></span></div><ix:continuation id="i80c4d244056441dd8245af07285cae66" continuedAt="ie0fb3c3f0c3d44a99ea9410ef310be52"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amyris Joint Venture</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December&#160;2021, ImmunityBio and Amyris, Inc. (Amyris) entered into a 50:50 joint venture arrangement and formed a new limited liability company to conduct the business of the joint venture. The purpose of the joint venture is to accelerate commercialization of a next-generation COVID-19 vaccine utilizing an RNA vaccine-platform. As part of the limited liability agreement, Amyris contributed $<ix:nonFraction unitRef="usd" contextRef="i3c353c172ccf4147ac57fe34244f439e_I20211231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODI2MTU2_93f12651-b79d-4f52-88b6-a648a844c1c1">1.0</ix:nonFraction>&#160;million in cash and rights to its license agreement with the Access to Advanced Health Institute (AAHI) for an RNA platform for the field of COVID-19. ImmunityBio contributed $<ix:nonFraction unitRef="usd" contextRef="i4a9fa31f8b884ef599ea8e3aa1c58f8f_I20211231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODM4MTU3_753b87a5-cef9-469a-b3b4-8b012a3fe7bf">1.0</ix:nonFraction>&#160;million in cash and priority access to its manufacturing capacity for the joint venture product. Both parties agreed to enter into a separate manufacturing and supply agreement and a sublicense agreement following the execution of the joint venture agreement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The joint venture agreement stipulates the initial terms for equal representation in the management of the newly-formed joint venture. The joint venture is managed by a board of directors consisting of four&#160;directors: two appointed by the company and two&#160;appointed by Amyris. Both parties agreed to make additional capital contributions in cash, in proportion to their respective interests, as determined by the board of directors of the joint venture. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="ie0fb3c3f0c3d44a99ea9410ef310be52" continuedAt="i6ed8fc599afe4a23b5142383f98db596"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We considered the joint venture entity as a VIE and determined that we are not the primary beneficiary of the VIE. In February&#160;2022, we made a cash investment totaling $<ix:nonFraction unitRef="usd" contextRef="ic8d44b5214644e5e9b815f99ac56eaec_D20220201-20220228" decimals="-5" name="us-gaap:PaymentsToAcquireInterestInJointVenture" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODM5MDM2_a82e3a91-a78b-4786-acdd-675875d4240a">1.0</ix:nonFraction>&#160;million in the joint venture&#8217;s common stock. We account for our investment in the joint venture using the equity method of accounting, and recorded our <ix:nonFraction unitRef="number" contextRef="ie5ee1d864d0f40ee97b16088a1116d91_I20230331" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODM5MTg0_3852c574-cdad-466e-a094-583704a2f6b4">50</ix:nonFraction>%&#160;share of the net loss from the joint venture totaling $<ix:nonFraction unitRef="usd" contextRef="ice37cb09a6664d4da416332415bda35c_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfMTY0OTI2NzQ3NzI5OA_0f32dc61-daae-4d0d-a28d-a962d23415b0">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4156a8ceac6342d99ce39177a254d1cf_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfMTA5OTUxMTY2MzQ3MA_04b07dd3-6b4c-4e49-8523-d845a7e2069f">0.2</ix:nonFraction> million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other&#160;income (expense), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations for the three months ended March&#160;31,&#160;2023 and 2022. Such losses incurred during the three months ended March&#160;31,&#160;2023 were attributed to expenses incurred by us on behalf of the joint venture. We are not obligated to fund the joint venture&#8217;s potential future losses. As of March&#160;31,&#160;2023, the carrying amount of our equity investment in the joint venture was <ix:nonFraction unitRef="usd" contextRef="ie5ee1d864d0f40ee97b16088a1116d91_I20230331" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODM5Nzc3_84e73026-2ba9-4408-8f0d-0b954afdeedc">zero</ix:nonFraction>.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">3M Innovative Properties Company (3M&#160;IPC) and AAHI License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed rights to 3M-052, a synthetic TLR7/8 agonist, 3M-052 formulations and related technology from 3M&#160;IPC and its affiliates and AAHI. In November 2021 we obtained nonexclusive rights in the field of SARS-CoV-2 and in June&#160;2022 we modified those rights and expanded the scope of the license to include (1)&#160;SARS-CoV-2 and other infectious diseases including malaria, HIV, tuberculosis, hookworm and varicella zoster on an exclusive basis in countries other than low- and middle-income countries (LMIC), and (2)&#160;oncology applications, when used in combination with our proprietary technology and/or IL-15 agonists. In consideration for the license, we agreed to make certain periodic license payments, including $<ix:nonFraction unitRef="usd" contextRef="iee278c57618e46d09031d4531cc2f979_D20230101-20230331" decimals="-4" name="ibrx:CollaborationAgreementsPeriodicLicensePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQwNTg1_dbf0d2f6-3d56-4deb-af77-a0dde47f334c">2.25</ix:nonFraction>&#160;million each year through June 2025, with the June 2022 payment being partially offset by the $<ix:nonFraction unitRef="usd" contextRef="i490e76eedd0c4d68a5d119d4f2a8bf67_D20211101-20211130" decimals="-5" name="ibrx:CollaborationAgreementsPeriodicLicensePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQwNjYz_504cc988-4512-4e41-913d-957adce8bba2">0.5</ix:nonFraction>&#160;million previously paid under the initial November 2021 license agreement. We have also agreed to make payments upon the achievement of certain regulatory milestone events and tiered royalties ranging from the low to high single-digits as a percentage of net sales. Beginning in April&#160;2026, the annual minimum licensing payment is $<ix:nonFraction unitRef="usd" contextRef="iee278c57618e46d09031d4531cc2f979_D20230101-20230331" decimals="-5" name="ibrx:CollaborationAgreementsAnnualMinimumLicensingPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQwOTgw_425cec53-8285-452c-9899-3290d1d27e25">1.0</ix:nonFraction>&#160;million, which can be credited against any royalty payments due under this agreement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we made a payment of $<ix:nonFraction unitRef="usd" contextRef="ia01f754739eb4399a5ec08bb300b5c9c_I20220630" decimals="-4" name="ibrx:CollaborationAgreementsLicenseMaintenanceFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQxMDk5_e1265cff-b43f-4a21-b36d-c11f5623ef89">1.75</ix:nonFraction>&#160;million for the annual license maintenance fee. We expensed $<ix:nonFraction unitRef="usd" contextRef="iee278c57618e46d09031d4531cc2f979_D20230101-20230331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfMTA5OTUxMTY2NDc0NA_9cf2c60f-fd10-4237-9887-c9f3d821915c">0.4</ix:nonFraction>&#160;million for the three&#160;months&#160;ended March&#160;31,&#160;2023, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statement of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AAHI License Agreements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we entered into two&#160;license agreements with AAHI pursuant to which we received a license to certain patents and know-how relating to AAHI&#8217;s (i)&#160;adjuvant formulations for the treatment, prevention and/or diagnosis of SARS-CoV-2 (the AAHI&#160;Adjuvant Formulation License Agreement) and (ii)&#160;RNA vaccine platform as further described below (the AAHI RNA License Agreement). Under both agreements, we were obligated to pay one-time, non-creditable, non-refundable upfront cash payments totaling $<ix:nonFraction unitRef="usd" contextRef="if7c90fc2a58d48e3bec3d91301b599c7_D20210501-20210531" decimals="-5" name="ibrx:CollaborationAgreementsNonrefundableUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQxODM0_73ec91f3-72b2-4477-b3ae-f6eb606160b6">2.0</ix:nonFraction>&#160;million. In addition, under the AAHI Adjuvant Formulation License Agreement we owe milestone payments to a total of up to $<ix:nonFraction unitRef="usd" contextRef="i717a4e9083794ab9bb82219c0132b1ee_I20220501" decimals="-5" name="ibrx:CollaborationAgreementsMilestonePaymentAggregateMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQxOTUy_eed8814c-5358-4382-84a1-1a228890e410">2.5</ix:nonFraction>&#160;million based on the achievement of certain development and regulatory milestones for the first&#160;licensed product and royalties on annual net sales of licensed products on a country-by-country and product-by-product basis of a low-single digit percentage, subject to certain royalty-reduction provisions. <ix:nonFraction unitRef="usd" contextRef="i7c33c2ccc680481ab6ef920d4dfe6fb2_D20230101-20230331" decimals="INF" name="ibrx:CollaborationAgreementsMilestoneFees" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQyMjUy_e2dd7a4c-1a32-40ae-8357-ea6fba61d497">No</ix:nonFraction>&#160;milestone fees were incurred for the three months ended March&#160;31,&#160;2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September&#160;2021, we amended and restated the AAHI RNA License Agreement, pursuant to which AAHI granted us an exclusive, worldwide, sublicensable license to AAHI&#8217;s rights to an RNA&#160;vaccine platform for the development and commercialization of certain therapeutic, diagnostic or prophylactic products for the prevention, treatment or diagnosis of any indication, other than those subject to pre-existing third-party license grants, including, without limitation, SARS-CoV-2. Pursuant to the terms of the amended and restated AAHI RNA License Agreement, we made a one-time, non-creditable, non-refundable, upfront payment to AAHI of $<ix:nonFraction unitRef="usd" contextRef="i2177094498de4c7ca93c869ccafa1cd8_D20210901-20210930" decimals="-5" name="ibrx:CollaborationAgreementsNonrefundableUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQyOTQ3_332c739d-3a1e-42af-bbec-85607c41c87a">1.5</ix:nonFraction>&#160;million and a license maintenance fee of $<ix:nonFraction unitRef="usd" contextRef="if37fa4000f6b4e8d96490b940efbe768_I20220630" decimals="-5" name="ibrx:CollaborationAgreementsLicenseMaintenanceFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODUyOTA2_f1c49a93-e5e7-4843-8d6b-2b3f59d12b84">3.0</ix:nonFraction>&#160;million in June&#160;2022. The company is required to pay license maintenance fees to AAHI of $<ix:nonFraction unitRef="usd" contextRef="i6d13c8c853924031bd029bd4c72b099a_I20230331" decimals="-5" name="ibrx:CollaborationAgreementsLicenseMaintenanceFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQzMDQ4_8262718d-37de-4aff-85c8-b69b82d0b429">5.5</ix:nonFraction>&#160;million annually from 2023 through 2030. The company may terminate the restated agreement without cause by paying AAHI a $<ix:nonFraction unitRef="usd" contextRef="id36600ac1af648c79b04e3c00fadca09_I20230331" decimals="-5" name="ibrx:CollaborationAgreementsTerminationFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQzMTYz_47bfe041-cb58-4bba-baf1-4a8538482d28">10.0</ix:nonFraction>&#160;million one-time early termination fee. In addition, the milestone payments to AAHI based on the achievement of certain development and regulatory milestones for the first&#160;licensed product were amended to a total of up to $<ix:nonFraction unitRef="usd" contextRef="i2f73c10bbad4443f9c60a048d6b10f17_I20210930" decimals="-5" name="ibrx:CollaborationAgreementsMilestonePaymentAggregateMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQzMzgx_34b2bbcc-c021-422c-8116-0af2dd068b93">4.0</ix:nonFraction>&#160;million. We are required to pay royalties on annual net sales of licensed products on a country-by-country and product-by-product basis of a low to mid-single digit percentage. We recorded $<ix:nonFraction unitRef="usd" contextRef="i37548de39d884f38a90265fc99953e00_D20230101-20230331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQzNjQ1_3e5f4805-3841-47df-9f63-4a4e8abf2b4c">0.8</ix:nonFraction>&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated statement of operations during the three months ended March&#160;31,&#160;2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="i6ed8fc599afe4a23b5142383f98db596"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the license agreements, in May&#160;2021 we also entered into a sponsored research agreement with the AAHI pursuant to which we will fund continued research of at least $<ix:nonFraction unitRef="usd" contextRef="i2fbf30bc44d6480e870137c2cd85cdb9_D20230101-20230331" decimals="-5" name="ibrx:CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQzOTc0_1067083f-3375-4c78-9324-47e60bf9de6d">2.0</ix:nonFraction>&#160;million per year, payable in four&#160;equal quarterly installments each year until May&#160;2024, or such year of earlier termination. <ix:nonFraction unitRef="usd" contextRef="ibbb1145df96744e6a4b78a506fdab0e3_D20230101-20230331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfMTA5OTUxMTY2NjY2MQ_40ebd354-275e-4144-bd45-b340c0411c16">No</ix:nonFraction> expenses were incurred for the three months ended March&#160;31,&#160;2023.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dunkirk Facility Leasehold Interest</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;14,&#160;2022, we completed the acquisition of a leasehold interest in approximately <ix:nonFraction unitRef="sqft" contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214" decimals="INF" name="ibrx:NumberOfSquareFootOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQ0MjE3_d644aeae-91ca-4a60-8b1d-d61d6e34bc62">409,000</ix:nonFraction> rentable square feet&#160;of current Good Manufacturing Practice (cGMP) ISO Class&#160;5 pharmaceutical manufacturing space in western New&#160;York (the&#160;Dunkirk Facility) from Athenex,&#160;Inc. (the Seller), which we believe will provide us with a state-of-the-art biotech production center that will substantially expand and diversify our manufacturing capacity in the U.S. and ability to scale production associated with certain of our product candidates. The company accounted for the transaction as an asset acquisition because the Dunkirk Facility&#8217;s integrated set of assets and activities does not meet the definition of a business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total consideration for the acquisition was approximately $<ix:nonFraction unitRef="usd" contextRef="i425c575827bc4978bf0c2daa8ed81a96_D20220214-20220214" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQ0OTUw_d6431715-05a9-480b-8096-87a4fe55743d">40.5</ix:nonFraction>&#160;million, including a cash payment of $<ix:nonFraction unitRef="usd" contextRef="i425c575827bc4978bf0c2daa8ed81a96_D20220214-20220214" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQ0OTgz_f8e3faa6-63b4-4241-9fb6-d3980907f643">40.0</ix:nonFraction>&#160;million, and transaction costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i425c575827bc4978bf0c2daa8ed81a96_D20220214-20220214" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQ1MDI3_91bd7732-7e83-40e9-b5f3-52b831f787ab">0.5</ix:nonFraction>&#160;million. <ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:AssetAcquisitionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfMzg0ODI5MDczNDM2Ng_5eddb2da-ec42-4535-b1bd-9a887ba060f5" continuedAt="i813b06fd6fa44407adb4af19343273ea" escape="true">The following table summarizes the fair value of assets acquired as of the acquisition date (in&#160;thousands):</ix:nonNumeric></span></div><ix:continuation id="i813b06fd6fa44407adb4af19343273ea"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RhYmxlOjdiMzlkYTcyN2JjNzQ3YzViZjJlNmJiNmZkYjk3MjUxL3RhYmxlcmFuZ2U6N2IzOWRhNzI3YmM3NDdjNWJmMmU2YmI2ZmRiOTcyNTFfMC0xLTEtMS0zMDIyMDE_305d4df9-ab56-45de-9415-ba367db8494f">10,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214" decimals="-3" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RhYmxlOjdiMzlkYTcyN2JjNzQ3YzViZjJlNmJiNmZkYjk3MjUxL3RhYmxlcmFuZ2U6N2IzOWRhNzI3YmM3NDdjNWJmMmU2YmI2ZmRiOTcyNTFfMS0xLTEtMS0zMDIyMDE_5a3355e6-e325-41ed-839b-2c9fc15d66f4">6,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RhYmxlOjdiMzlkYTcyN2JjNzQ3YzViZjJlNmJiNmZkYjk3MjUxL3RhYmxlcmFuZ2U6N2IzOWRhNzI3YmM3NDdjNWJmMmU2YmI2ZmRiOTcyNTFfMi0xLTEtMS0zMDIyMDE_e33374b0-a731-4bc4-a4a5-ea22282ae211">21,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other depreciable assets and prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RhYmxlOjdiMzlkYTcyN2JjNzQ3YzViZjJlNmJiNmZkYjk3MjUxL3RhYmxlcmFuZ2U6N2IzOWRhNzI3YmM3NDdjNWJmMmU2YmI2ZmRiOTcyNTFfMy0xLTEtMS0zMDIyMDE_e05e8364-2e8c-4762-a4d0-3039a6f0910b">2,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214" decimals="-3" name="ibrx:AssetAcquisitionFairValueOfAssetsAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RhYmxlOjdiMzlkYTcyN2JjNzQ3YzViZjJlNmJiNmZkYjk3MjUxL3RhYmxlcmFuZ2U6N2IzOWRhNzI3YmM3NDdjNWJmMmU2YmI2ZmRiOTcyNTFfNC0xLTEtMS0zMDIyMDE_2b79886b-9500-4cee-97c9-b32f4b27ff72">40,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_43">Note </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_43">3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Statement Details&#8212;Intangible Assets, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, for further information.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing of the Dunkirk transaction, the company became the tenant of the Dunkirk Facility under the Fort Schuyler Management Corporation Lease, dated October&#160;1,&#160;2021 and as amended as of the February&#160;14,&#160;2022 closing date (as amended, the Dunkirk Lease), with Fort Schuyler Management Corporation, a not-for-profit corporation affiliated with the State of New York (FSMC) as landlord. The Dunkirk Facility, as well as certain equipment, is owned by FSMC and is leased to us under the Dunkirk Lease. Our annual lease payment will be $<ix:nonFraction unitRef="usd" contextRef="i425c575827bc4978bf0c2daa8ed81a96_D20220214-20220214" decimals="INF" name="ibrx:LeaseOperatingLeaseAnnualLeasePayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQ2Mjg4_522cf9f7-b5c1-46df-8768-db0162c35307">2.00</ix:nonFraction> per year&#160;for an initial <ix:nonNumeric contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNDM5ODA0NjU0ODI1NQ_1e11353a-9322-46a3-bf2a-fda04b14b12e">10-year</ix:nonNumeric> term, with an option to renew the lease under substantially the same terms and conditions for an additional <ix:nonNumeric contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNDM5ODA0NjU0ODI1Ng_87c317c2-15a2-4bbb-ac9d-813563030519">10-year</ix:nonNumeric> term. As part of the transaction, we assumed certain of the Seller&#8217;s obligations under various third-party agreements (the Facility Agreements), subject to the terms and conditions of the purchase agreement by and between the company and Seller dated as of January&#160;7,&#160;2022, and committed to spend an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214" decimals="-7" name="ibrx:LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQ2NzM0_8cc788d4-3b17-4033-a6d9-d08d06010567">1.52</ix:nonFraction>&#160;billion on operational expenses during the initial term, and an additional $<ix:nonFraction unitRef="usd" contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214" decimals="-7" name="ibrx:LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQ2ODA1_a65292e7-bc7b-4973-a523-1f57ef443865">1.50</ix:nonFraction>&#160;billion on operational expenses if we elect to renew the lease for the additional <ix:nonNumeric contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNDM5ODA0NjU0ODI1Nw_a39afdb8-ad32-44f4-8e08-294bb7087537">10-year</ix:nonNumeric> term. We also committed to hiring <ix:nonFraction unitRef="employee" contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214" decimals="INF" name="ibrx:LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQ2OTI2_b6b86851-a2d0-4bcd-a23b-6c2134382e4b">450</ix:nonFraction> employees at the Dunkirk Facility within the first five years of operations, with <ix:nonFraction unitRef="employee" contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214" decimals="INF" name="ibrx:LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQ2OTk1_0d5021a6-6968-4adb-b6ae-e67937e41767">300</ix:nonFraction>&#160;such employees to be hired within the first 2.5 years of operation. We are eligible for certain sales-tax exemption savings during the development of the Dunkirk Facility, and certain property tax savings over the next 20 years, subject to certain terms and conditions, including performance of certain of the obligations described above. Failure to satisfy the obligations over the lease term may give rise to certain rights and remedies of governmental authorities including, for example, termination of the Dunkirk Lease and other Facility Agreements and potential recoupment of a percentage of the grant funding received by the Seller for construction of the facility and other benefits received, subject to the terms and conditions of the applicable agreements. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that governmental funding will assist in funding a portion of the further build-out of the Dunkirk Facility, which we estimate to be approximately $<ix:nonFraction unitRef="usd" contextRef="if6b39365bed8403baef862349455aa3a_I20230331" decimals="-5" name="ibrx:LeaseholdInterestGovernmentFundingReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfMTA5OTUxMTY2Mzc4Mw_55337d33-f628-4c38-affa-62c7280e8c43">8.0</ix:nonFraction>&#160;million&#160;to $<ix:nonFraction unitRef="usd" contextRef="i3d26d616708f4d68a522f54d69fb3236_I20230331" decimals="-5" name="ibrx:LeaseholdInterestGovernmentFundingReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfMTA5OTUxMTY2MzgxNQ_ab2614fe-68b8-46ac-b19f-8218f4031b93">10.0</ix:nonFraction>&#160;million of governmental funding remaining available as of March&#160;31,&#160;2023, there can be no assurance as to the final acceptance and timing of the requests for governmental funding that we submit, and we will need to plan and fund most of the additional build-out of, and purchase additional equipment for, the Dunkirk Facility in connection with our planned full operations. In addition, any future governmental funding will be subject to the eligibility of submitted expenses, as well as our compliance with the obligations that we are subject to pursuant to the agreements with parties regarding the Dunkirk Facility as described above.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_67"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfMTA1MjA_bff3e036-f2ac-453a-8d13-ed02123558f1" continuedAt="i1b2e9d1bd8ec47be9f0137371fc388da" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i1b2e9d1bd8ec47be9f0137371fc388da" continuedAt="i1c075db48f1d4687958fe854bd6d9b01"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Related to Business Combinations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VivaBioCell, S.p.A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April&#160;2015, NantWorks,&#160;LLC (NantWorks), a related party, acquired a <ix:nonFraction unitRef="number" contextRef="ibc667aeaffb241769d40ebb768302772_I20150430" decimals="INF" name="ibrx:PercentageOfWhollyOwnedSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfMTg3_adba4861-c22c-4724-bfef-34de1fe0971b">100</ix:nonFraction>% interest in VivaBioCell, S.p.A. (VivaBioCell) through its wholly-owned subsidiary, VBC Holdings,&#160;LLC, (VBC Holdings) for $<ix:nonFraction unitRef="usd" contextRef="i34694fa4373945b3a6a665c6a37f4262_D20150401-20150430" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfMzEx_81373eaa-39f9-4c63-8801-cd8272686d57">0.7</ix:nonFraction>&#160;million, less working capital adjustments. In June&#160;2015, NantWorks contributed its equity interest in VBC Holdings to the company, in exchange for cash consideration equal to its cost basis in the investment. VivaBioCell develops bioreactors and products based on cell culture and tissue engineering in Italy. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of VBC, we are obligated to pay the former owners contingent consideration upon the achievement of certain milestones related to the GMP-in-a-Box technology. A clinical milestone totaling $<ix:nonFraction unitRef="usd" contextRef="i0d13dc5189894b7d8628892cfb2e7a88_D20210101-20211231" decimals="-5" name="ibrx:BusinessCombinationContingentConsiderationArrangementsEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfODQw_68f014fd-8538-437b-bbc6-8f3ff7819c27">0.8</ix:nonFraction>&#160;million was earned by the former owners of VivaBioCell, of which $<ix:nonFraction unitRef="usd" contextRef="i0d13dc5189894b7d8628892cfb2e7a88_D20210101-20211231" decimals="-5" name="ibrx:BusinessCombinationContingentConsiderationArrangementsSettlements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfOTAw_86453043-6aee-4906-8a21-2768d4d8c272"><ix:nonFraction unitRef="usd" contextRef="ibdeaa2c7746d49a8bd99d6d3afb859aa_D20220901-20220930" decimals="-5" name="ibrx:BusinessCombinationContingentConsiderationArrangementsSettlements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfOTAw_8e1e126a-3105-4b36-a5d7-e9c7e6a2e912">0.4</ix:nonFraction></ix:nonFraction>&#160;million was paid during 2021, with the remaining clinical obligation settled in September&#160;2022. If a government agency unconditionally approves the GMP-in-a-Box technology for commercial sale (the regulatory milestone) in the future, we will be obligated to pay an additional approximately $<ix:nonFraction unitRef="usd" contextRef="i4947316a78a241dc928345e7c528266e_D20230101-20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfMTE4NQ_cf0b81c5-8125-45e9-a87c-8f79abfc7c04">2.2</ix:nonFraction>&#160;million to the former owners. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Altor BioScience Corporation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the&#160;2017 acquisition of Altor BioScience Corporation (Altor), we issued contingent value rights (CVRs) under which we agreed to pay the prior stockholders of Altor approximately $<ix:nonFraction unitRef="usd" contextRef="ida7588e0910c4bb28cb902bc775406de_I20171231" decimals="-5" name="ibrx:ContingentValueRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfMTQzNw_73badb9c-c598-4eaf-bf70-981e5a48989e">304.0</ix:nonFraction>&#160;million contingent consideration upon the successful regulatory approval of a BLA by the FDA, or foreign equivalent, for N-803 by December&#160;31,&#160;2022 and approximately $<ix:nonFraction unitRef="usd" contextRef="i40bec98f02134e3b977953843f819e46_I20171231" decimals="-5" name="ibrx:ContingentValueRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfMTU4Mw_7746c9ca-5817-4014-a7fe-a2c15843d001">304.0</ix:nonFraction>&#160;million contingent consideration upon calendar-year worldwide net sales of N-803 exceeding $<ix:nonFraction unitRef="usd" contextRef="i74a7874a4fde4847942459ca136eee6e_D20170101-20171231" decimals="-8" name="ibrx:MinimumNetSalesMilestoneContingentValueRightsObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfMTY2OQ_523ff2d2-9cff-4fb3-963b-0000173d1745">1.0</ix:nonFraction>&#160;billion prior to December&#160;31,&#160;2026, with amounts payable in cash or shares of our common stock or a combination thereof. As the transaction was recorded as an asset acquisition, future CVR payments will be recorded when the corresponding events are probable of achievement or the consideration becomes payable.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the regulatory milestone CVR agreement, in May&#160;2022 we announced the submission of a BLA to the FDA for our product candidate, Anktiva (N-803) in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1 disease</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n July&#160;2022 we announced that the FDA had accepted our BLA for review and set a target PDUFA action date of May&#160;23,&#160;2023. On May&#160;9,&#160;2023, the FDA delivered a complete response letter to us regarding the BLA. The company plans to request a meeting with the FDA as soon as possible to address the subject matter of the letter and a response timeline, and plans to diligently address and resolve the issues identified and seek approval as expeditiously as possible. It is unclear when the FDA will approve our BLA, if at all. The FDA did not approve our BLA on or before December&#160;31,&#160;2022, and therefore the regulatory milestone was not met, and the regulatory milestone CVR agreement terminated in accordance with its terms.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the net sales milestone CVR agreement, as of March&#160;31,&#160;2023, Dr.&#160;Soon-Shiong and his related party hold approximately $<ix:nonFraction unitRef="usd" contextRef="i5a799dcabd874b6e84ddb0e294bf7f8a_I20230331" decimals="-5" name="ibrx:ContingentValueRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfMjcyMg_2a14dffc-2565-47a0-822f-a4135b71980a">139.8</ix:nonFraction>&#160;million of net sales CVRs and they have both irrevocably agreed to receive shares of the company&#8217;s common stock in satisfaction of their CVRs. We may be required to pay the other prior Altor stockholders up to $<ix:nonFraction unitRef="usd" contextRef="i1c8c3835e9294f019b36ddbb7bb615b8_I20230331" decimals="-5" name="ibrx:ContingentValueRightsObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfMjkyNw_487b8522-65ce-4be4-be19-9d054a1bc1cf">164.2</ix:nonFraction>&#160;million for their net sales CVRs should they choose to have their CVRs paid in cash instead of common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. If we are served with any such complaints, we will assess at that time any contingencies for which we may need to reserve. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Altor BioScience, LLC Litigation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, NantCell,&#160;Inc. (NantCell) announced it had entered into a definitive merger agreement to acquire Altor BioScience Corporation. An action captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gray v.&#160;Soon-Shiong, et&#160;al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was filed in Delaware Chancery Court by plaintiffs Clayland Boyden Gray (Gray) and Adam R. Waldman. The plaintiffs, two&#160;minority stockholders, asserted claims against the company and other defendants for (1)&#160;breach of fiduciary duty and (2)&#160;aiding and abetting breach of fiduciary duty and filed a motion to enjoin the merger. The court denied the motion and permitted the merger to close. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="i1c075db48f1d4687958fe854bd6d9b01" continuedAt="i6749cae9ae71404d918f5891f247e7d4"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the close of the merger, in 2017 the plaintiffs (joined by two&#160;additional minority stockholders, Barbara&#160;Sturm Waldman and Douglas E. Henderson (Henderson)) filed a second&#160;amended complaint, including appraisal claims, and which the defendants subsequently moved to dismiss. In a second&#160;action, Dyad Pharmaceutical Corporation (Dyad) filed a petition in Delaware Chancery Court for appraisal in connection with the merger. The defendants moved to dismiss the appraisal petition in 2018. The court issued an oral ruling in 2019 that dismissed certain claims and dismissed Altor BioScience from the action. The following claims remained: (a)&#160;the appraisal claims by all plaintiffs and Dyad (against Altor BioScience,&#160;LLC), and (b)&#160;Henderson&#8217;s claims for breach of fiduciary duty and aiding and abetting breach of fiduciary duty. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the court issued a written order implementing its ruling on the defendants&#8217; motions (the Implementing Order). In the Implementing Order, the court confirmed that all fiduciary duty claims brought by Gray, both individually and as trustee of the Gordon Gray Trust f/b/o&#160;C. Boyden Gray, were dismissed. The plaintiffs then moved for leave to file a third&#160;amended complaint to add two&#160;former Altor stockholders as plaintiffs and a fiduciary duty claim on behalf of a purported class of former Altor stockholders, which the defendants opposed. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the court granted the plaintiffs&#8217; motion, and the plaintiffs filed the third&#160;amended complaint. In 2020, the defendants answered the third&#160;amended complaint and asserted counterclaims against the plaintiffs. The defendants sought damages for attorneys&#8217; fees and costs incurred as a result of the breaches of &#8220;standstill&#8221; agreements and of stockholder releases. The plaintiffs filed an answer denying the counterclaims and asserting defenses. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of the former Altor stockholders seeking appraisal met the definition of dissenting shares under the merger agreement and were not entitled to receive any portion of the merger consideration at the closing date, given that those shares were the subject of the above-described appraisal claims. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late March&#160;2022, the company agreed to the terms of a settlement with the appraisal petitioners, without any admission of liability or fault. The settlement provided that in exchange for complete releases, the appraisal petitioners, who as a group held <ix:nonFraction unitRef="shares" contextRef="i83f402b4c65a4485bfb0dff6c6982341_I20220331" decimals="INF" name="ibrx:NumberOfDissentingShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfNTQ5NzU1ODQyNDU0_ef62d96c-77f0-43e3-877d-6a0003ecaf41">3,167,565</ix:nonFraction>&#160;dissenting Altor shares, collectively would receive an aggregate of <ix:nonFraction unitRef="shares" contextRef="i83f402b4c65a4485bfb0dff6c6982341_I20220331" decimals="INF" name="ibrx:LitigationSettlementNumberOfSharesToBeIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfNTQ5NzU1ODQyNDUw_3c7f28c7-e0f8-471a-9671-268bb068cb2b">2,229,296</ix:nonFraction>&#160;shares of the company&#8217;s common stock issued in a private placement, plus an aggregate of $<ix:nonFraction unitRef="usdPerShare" contextRef="i83f402b4c65a4485bfb0dff6c6982341_I20220331" decimals="INF" name="ibrx:SharesIssuedCashDistributedInLieuOfFractionalShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfNTQ5NzU1ODQyNDU4_1a9e5adb-a868-4fcc-bb6a-6b154724a692">21.13</ix:nonFraction>&#160;in cash in lieu of fractional shares. The company&#8217;s Board of Directors approved the settlement and stock issuance in April&#160;2022, and the court approved the settlement and dismissed the appraisal petitioners&#8217; claims on July&#160;9,&#160;2022. On July&#160;9,&#160;2022, the company issued <ix:nonFraction unitRef="shares" contextRef="i3316090351fd4fe4b0dd3da042faabc4_I20220709" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfNTQ5NzU1ODQyNDYy_a27c227b-b668-4829-979f-4beec31e9eb0">2,229,296</ix:nonFraction>&#160;shares of its common stock with an aggregate market value of $<ix:nonFraction unitRef="usd" contextRef="i1bc9adb48922456fa879ef93b8dba645_D20220709-20220709" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfNTQ5NzU1ODQyNDY2_48e9774e-6963-431b-9835-0d016cd59ef6">10.7</ix:nonFraction>&#160;million, based on the closing price of its common stock on the Nasdaq as of July&#160;8,&#160;2022, to the appraisal petitioners pursuant to the court-approved settlement agreement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late April&#160;2022, the company also agreed to the terms of a settlement with the putative class plaintiffs without any admission of liability or fault. In exchange for class-wide releases, the company committed to make a settlement payment of $<ix:nonFraction unitRef="usd" contextRef="id9143fae2a394bf29dec9fb56f82a9a5_I20220430" decimals="-5" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfNTQ5NzU1ODQyNjAw_cfd5c57d-ab71-4cb4-b4c0-4d1213e87745">5.0</ix:nonFraction>&#160;million in cash by December&#160;31,&#160;2022. On December&#160;8,&#160;2022, the Delaware Court of Chancery entered a final judgment approving the settlement, and the company timely made the $<ix:nonFraction unitRef="usd" contextRef="ic746e246685947fd8cfba45a1fed563e_D20221208-20221208" decimals="-5" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfMjE5OTAyMzI4NDQ0MQ_67f20f3a-e126-4a3b-9c3d-9cf02d775ff9">5.0</ix:nonFraction>&#160;million settlement payment.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sorrento Therapeutics, Inc. Litigation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sorrento Therapeutics,&#160;Inc. (Sorrento), derivatively on behalf of Immunotherapy NANTibody,&#160;LLC (NANTibody) filed an action in the Superior Court of California, Los Angeles County (the Superior Court) against the company&#8217;s subsidiary NantCell, Dr.&#160;Soon-Shiong, and Charles&#160;Kim. The action alleged that the defendants improperly caused NANTibody to acquire IgDraSol,&#160;Inc. (IgDraSol) from NantPharma,&#160;LLC (NantPharma) and sought to have the transaction undone and the purchase amount returned to NANTibody. In 2019, we filed a demurrer to several causes of action alleged in the Superior Court action, and Sorrento filed an amended complaint, eliminating Mr.&#160;Kim as a defendant and dropping the causes of action we had challenged in our demurrer. The company believes the case is without merit and intends to vigorously defend against the claims asserted. Trial has been set to commence in Sorrento&#8217;s Superior Court action on July&#160;17,&#160;2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in 2019, the company and Dr.&#160;Soon-Shiong filed cross-claims in the Superior Court action against Sorrento and its Chief Executive Officer Henry&#160;Ji, asserting claims for fraud, breach of contract, breach of the covenant of good faith and fair dealing, tortious interference with contract, unjust enrichment, and declaratory relief. Our claims alleged that Dr.&#160;Ji and Sorrento breached the terms of an exclusive license agreement between the company and Sorrento related to Sorrento&#8217;s antibody library and that Sorrento did not perform its obligations under the exclusive license agreement. The Superior Court ruled that the company&#8217;s claims should be pursued in arbitration and that Dr.&#160;Soon-Shiong&#8217;s claims could be pursued in Superior Court.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="i6749cae9ae71404d918f5891f247e7d4" continuedAt="i593f057b68494f75998e1ea296cff05f"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the company, along with NANTibody, filed an arbitration against Sorrento and Dr.&#160;Ji asserting our claims relating to the exclusive license agreement. Sorrento filed counterclaims against the company and NANTibody in the arbitration. The hearings in the NANTibody arbitration commenced in April&#160;2021 and concluded in early August&#160;2021. After post-hearing briefing was concluded, the parties were notified on November&#160;30,&#160;2021 that the arbitrator in the NANTibody arbitration had passed away. A substitute arbitrator was appointed on February&#160;25,&#160;2022, and the parties worked with the substitute arbitrator to conclude the proceedings. Additional hearing sessions were held in May and July&#160;2022, and summations took place on August&#160;2,&#160;2022. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;2, 2022, the arbitrator issued a final award finding that Sorrento had breached the two&#160;exclusive license agreements with NantCell and NANTibody. The arbitrator awarded NantCell approximately $<ix:nonFraction unitRef="usd" contextRef="i3f1bf0ab5b9b480192b280a3bffc0f0f_D20221202-20221202" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfNjM4Nw_78150b86-a53d-4193-a63c-0763e30bc8e7">156.8</ix:nonFraction>&#160;million and NANTibody approximately $<ix:nonFraction unitRef="usd" contextRef="i947edf9e6bfb43b892a96c6c6549369d_D20221202-20221202" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfNjQxOA_e499a536-73cc-4dde-bff6-5f92af8cabb1">16.7</ix:nonFraction>&#160;million, plus post-award interest accruing at a daily rate. On December&#160;21,&#160;2022, NantCell and NANTibody filed petitions in the Superior Court to confirm the arbitration award; on January&#160;16,&#160;2023, Sorrento filed a response to the petitions and moved to vacate the award. On February&#160;7, 2023, after a hearing, the Superior Court entered orders confirming the arbitration award and denying Sorrento&#8217;s motion to vacate. The Superior Court entered judgments against Sorrento in the aggregate amount of approximately $<ix:nonFraction unitRef="usd" contextRef="i17ec39591f744eadbe2f276d7fed3a12_D20230207-20230207" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfNjkxMg_340e0087-42ac-42ac-946e-e65c6fc5b366">176.4</ix:nonFraction>&#160;million plus <ix:nonFraction unitRef="number" contextRef="i17ec39591f744eadbe2f276d7fed3a12_D20230207-20230207" decimals="INF" name="ibrx:LitigationSettlementInterestPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfNjkyMA_88832e43-c5b0-41ab-99d4-33e7b3544ea0">10</ix:nonFraction>% post-judgment interest, of which approximately $<ix:nonFraction unitRef="usd" contextRef="i72f7554fa7494415af05bce0fcffd01e_D20230207-20230207" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfNjk3MA_531572cd-ed1b-457c-94c8-6a1c0af6d20d">159.4</ix:nonFraction>&#160;million is payable to NantCell, and the remainder of which is payable to NANTibody. On February&#160;13,&#160;2023, Sorrento informed counsel to the company that it had filed a Chapter&#160;11 proceeding in the U.S. District Court for the Southern District of Texas, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Sorrento Therapeutics,&#160;Inc., et&#160;al.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Case No.&#160;23-bk-90085 (Bankr. S.D. Tex.) (DRJ). The company intends to continue to pursue vigorously, consistent with its rights in light of Sorrento&#8217;s Chapter&#160;11 filing, the collection of the judgments from Sorrento, but we make no assurances that we will receive the full amount or with respect to the timing of our receipt of any funds. As of March&#160;31,&#160;2023, we have not determined the amount we are likely to recover, and thus have not recorded any receivables in relation to the judgments.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Superior Court action remains pending, and it remains to be determined how, if at all, the award in the arbitration will affect the Superior Court action. An estimate of the possible loss or range of loss resulting from the Superior Court litigation cannot be made at this time.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shenzhen Beike Biotechnology Co. Ltd. Arbitration</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we received a Request for Arbitration before the International Chamber of Commerce, International Court of Arbitration. The arbitration relates to a license, development, and commercialization agreement that Altor entered into with Beike in 2014, which agreement was amended and restated in 2017, pursuant to which Altor granted to Beike an exclusive license to use, research, develop and commercialize products based on N-803 in China for human therapeutic uses. In the arbitration, Beike is asserting a claim for breach of contract under the license agreement. Among other things, Beike alleges that we failed to use commercially reasonable efforts to deliver to Beike materials and data related to N-803. Beike is seeking specific performance and declaratory relief for the alleged breaches. On September&#160;25,&#160;2020, the parties entered into a standstill and tolling agreement (standstill agreement) under which, among other things, the parties affirmed they will perform certain of their obligations under the license agreement by specified dates and agreed that all deadlines in the arbitration are indefinitely extended. The standstill agreement could be terminated by any party on ten calendar days&#8217; notice, and upon termination, the parties had the right to pursue claims arising from the license agreement in any appropriate tribunal. On March&#160;20,&#160;2023, we terminated the standstill agreement, and on April&#160;11,&#160;2023, Beike served an amended Request for Arbitration. We have until May&#160;19,&#160;2023 to file a response. Given that this action remains at the pleading stage and no discovery has occurred, it remains too early to evaluate the likely outcome of the case or to estimate any range of potential loss. We believe the claims lack merit and intend to defend the case vigorously and that we may have counterclaims.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stipulation of Settlement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, following approval by our Board of Directors, we entered into a settlement agreement (the Stipulation of Settlement) with three stockholders of the company, each of whom had submitted a stockholder demand for the Board of Directors to take action to remedy purported harm to the company resulting from certain alleged wrongful conduct concerning, among other things, disclosures about Dr. Soon-Shiong&#8217;s compensation and a related-party lease agreement. The Stipulation of Settlement called for us to adopt certain governance changes, and for the three stockholders to file a stockholder derivative action in the Superior Court of the State of California, County of San Diego, followed by an application for court approval of the Stipulation of Settlement. The court entered an order preliminarily approving the Stipulation of Settlement. Pursuant to the Stipulation of Settlement, we provided stockholders with notice of the settlement and the final settlement hearing.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="i593f057b68494f75998e1ea296cff05f" continuedAt="i4c73dcbae0094845b0dc58b755100416"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not enter into any significant contracts during the three months ended March&#160;31,&#160;2023, other than those disclosed in these condensed consolidated financial statements.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><ix:continuation id="i4c73dcbae0094845b0dc58b755100416" continuedAt="i51849485d5234308930de546b27c12d3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are also a party to various contracts with contract research organizations and contract manufacturers that generally provide for termination on notice, with the exact amounts in the event of termination to be based on the timing of the termination and the terms of the agreement. There have been no material changes in unconditional purchase commitments from those disclosed in Note&#160;7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies,</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i51849485d5234308930de546b27c12d3"> of the &#8220;Notes to Consolidated Financial Statements&#8221; that appears in Part&#160;II, Item&#160;8. &#8220;Financial Statements and Supplementary Data&#8221; of our Annual Report on Form&#160;10-K filed with the SEC on March&#160;1,&#160;2023.</ix:continuation> </span></div><div id="i5bbe340c9c8f435088d8011b72b6800d_70"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfMjkxMg_2a62108c-2719-4975-9999-baee47b527ec" continuedAt="id5d32b036ade40ecaf31161ce4a5fc7a" escape="true"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfMjkxMg_ce7b4228-3d82-432c-b983-2c858a2d543d" continuedAt="i9be437b5f7c040f5944ed551f530e427" escape="true">Lease Arrangements</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="id5d32b036ade40ecaf31161ce4a5fc7a" continuedAt="i2609cc78cc464b92b2aa0038f88d95ec"><ix:continuation id="i9be437b5f7c040f5944ed551f530e427" continuedAt="id9be708b2e744bd48c8213f8db8ac14c"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease property in multiple facilities across the U.S. (including the Dunkirk Facility in upstate New York) and Italy, including facilities located in El&#160;Segundo,&#160;CA, which are leased from related parties. Substantially all of our operating lease right-of-use assets and operating lease liabilities relate to facilities leases. All of our finance leases are related to equipment rental at the Dunkirk Facility. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_76">Note&#160;10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information about our related-party leases.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leases generally have initial terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfNTkx_1b5ac21f-8317-4cdf-9aa4-b1a83fbec98e">two</span> to <ix:nonNumeric contextRef="i97684a88657d4f79b99ef808ef0e0de7_I20230331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfNTk3_02f68fc6-b874-4163-b56c-0f213be9f8b0">ten years</ix:nonNumeric> and often include one or more options to renew. These renewal terms can extend the lease term from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfNjk5_f0f50d52-6d48-4a58-8a65-ea201cb85f30">one</span> to <ix:nonNumeric contextRef="i97684a88657d4f79b99ef808ef0e0de7_I20230331" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfNzA1_595d689a-7e22-499e-a109-4105d3dfbf6c">ten years</ix:nonNumeric>, and are included in the lease term when it is reasonably certain that we will exercise the option.</span></div><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="ibrx:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfMjkwOQ_fd3f117e-9ce5-46ea-8b05-55877aaf4cbb" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to our leases is as follows (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:33.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited) </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNC0zLTEtMS0yOTgzNTI_b6661577-184c-4afe-8bd9-cadd20340c3a">44,191</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNC01LTEtMS0yOTgzNTI_765b055e-cc77-44ea-9016-b84021612ba0">45,788</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNS0xLTEtMS0yOTgzNTI_716b2b64-20b1-40c3-9b02-a3d14868228b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNS0xLTEtMS0yOTgzNTI_79bf86fc-1a0b-4632-b3b5-c9756666aba0">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNS0zLTEtMS0yOTgzNTI_7fe32746-65db-4142-9921-5bd89f62d9ec">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNS01LTEtMS0yOTgzNTI_4638ec44-382f-4b0a-8713-6deb9bf93f72">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:LeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNi0zLTEtMS0yOTgzNTI_a4c2ae70-ccf9-4c8b-a109-baa2e42a16f9">44,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="ibrx:LeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNi01LTEtMS0yOTgzNTI_8b728968-d4d5-4dd6-970c-4306b5d85886">45,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTAtMy0xLTEtMjk4MzUy_18eaf4b2-ca44-44a7-9f94-1357df518173">2,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTAtNS0xLTEtMjk4MzUy_29f0cf30-ab75-432c-afe4-8557c662bf9e">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTEtMS0xLTEtMjk4MzUy_1e304c6d-b6fc-4a07-96b6-252e1c6d5e68"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTEtMS0xLTEtMjk4MzUy_7f502521-7e3c-4089-bd21-ee4709a6ff0e">Accrued expenses and other liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTEtMy0xLTEtMjk4MzUy_90416e71-0a01-455a-a3f6-6792d4858f36">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTEtNS0xLTEtMjk4MzUy_36c1e299-7da2-4674-a0a8-6a219f902a8b">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities, less current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTMtMy0xLTEtMjk4MzUy_2b90bf53-927f-4d61-a0ea-f1849b67a84c">46,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTMtNS0xLTEtMjk4MzUy_52f19ea6-ca76-4c15-bca8-dcb6aace0443">47,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTQtMS0xLTEtMjk4MzUy_1cbef275-f42e-4514-b41d-8b9c75783db1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTQtMS0xLTEtMjk4MzUy_cccafda1-bc6a-4e69-9eb2-a02fc2fcc607">Other liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTQtMy0xLTEtMjk4MzUy_2b67648c-fe98-4282-b382-b0fff7cfb979">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTQtNS0xLTEtMjk4MzUy_aa003073-c4dc-4537-811e-70cd3b5e1967">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:LeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTUtMy0xLTEtMjk4MzUy_2c383324-aae3-480e-9759-72328c4eb322">49,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="ibrx:LeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTUtNS0xLTEtMjk4MzUy_fcf5f91c-b9a3-41a8-a2f3-3cb167ebafd5">50,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="i2609cc78cc464b92b2aa0038f88d95ec" continuedAt="i0c9ceea37dbb458e95a2a117ca288cc1"><ix:continuation id="id9be708b2e744bd48c8213f8db8ac14c" continuedAt="i1ececa23f99947cda7e7db30e09ffe74"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfMjkxMA_a919a662-c8ae-4376-bcae-ea76cf6d4ae3" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding our lease terms is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:71.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited) </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average remaining lease term:</span></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjlmMzhmN2I2MTJkNzQ1MmE4MTYzYTg0Y2ZmYjgxOGYwL3RhYmxlcmFuZ2U6OWYzOGY3YjYxMmQ3NDUyYTgxNjNhODRjZmZiODE4ZjBfNC0xLTEtMS0yOTgzNTI_55557dd3-7c2e-4c5d-810a-8b4649021b0b">6.4</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjlmMzhmN2I2MTJkNzQ1MmE4MTYzYTg0Y2ZmYjgxOGYwL3RhYmxlcmFuZ2U6OWYzOGY3YjYxMmQ3NDUyYTgxNjNhODRjZmZiODE4ZjBfNC00LTEtMS0yOTgzNTI_d522ae2e-549f-49af-93d3-cf68ba87bc17">6.6</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance leases</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjlmMzhmN2I2MTJkNzQ1MmE4MTYzYTg0Y2ZmYjgxOGYwL3RhYmxlcmFuZ2U6OWYzOGY3YjYxMmQ3NDUyYTgxNjNhODRjZmZiODE4ZjBfNS0xLTEtMi0yOTgzNTI_368c0496-b16a-459a-a10a-f84395b6faac">1.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjlmMzhmN2I2MTJkNzQ1MmE4MTYzYTg0Y2ZmYjgxOGYwL3RhYmxlcmFuZ2U6OWYzOGY3YjYxMmQ3NDUyYTgxNjNhODRjZmZiODE4ZjBfNS00LTEtMS0yOTgzNTI_739bdd9e-1ff1-4119-a7c4-44b7391ec130">1.8</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average discount rate:</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjlmMzhmN2I2MTJkNzQ1MmE4MTYzYTg0Y2ZmYjgxOGYwL3RhYmxlcmFuZ2U6OWYzOGY3YjYxMmQ3NDUyYTgxNjNhODRjZmZiODE4ZjBfNy0xLTEtMS0yOTgzNTI_f44eed6b-5855-4b52-9921-b712e71904b4">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjlmMzhmN2I2MTJkNzQ1MmE4MTYzYTg0Y2ZmYjgxOGYwL3RhYmxlcmFuZ2U6OWYzOGY3YjYxMmQ3NDUyYTgxNjNhODRjZmZiODE4ZjBfNy00LTEtMS0yOTgzNTI_c9657675-cb22-4683-8810-6c1de5303f59">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance leases</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjlmMzhmN2I2MTJkNzQ1MmE4MTYzYTg0Y2ZmYjgxOGYwL3RhYmxlcmFuZ2U6OWYzOGY3YjYxMmQ3NDUyYTgxNjNhODRjZmZiODE4ZjBfOC0xLTEtMS0yOTgzNTI_18b703aa-b277-4c83-8ffb-19fbe4dc4b72">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjlmMzhmN2I2MTJkNzQ1MmE4MTYzYTg0Y2ZmYjgxOGYwL3RhYmxlcmFuZ2U6OWYzOGY3YjYxMmQ3NDUyYTgxNjNhODRjZmZiODE4ZjBfOC00LTEtMS0yOTgzNTI_50843816-cb33-43c7-971e-d58e76c735f7">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:71.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.302%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March&#160;31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Unaudited)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjgxOTdlNTY4NTI0MDQ5NjliZjJlOGUxMjZjN2E1OTlmL3RhYmxlcmFuZ2U6ODE5N2U1Njg1MjQwNDk2OWJmMmU4ZTEyNmM3YTU5OWZfNC0xLTEtMS0yOTgzNTI_1edbaac1-b9e7-4c5a-be17-cd58821aee5e">2,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjgxOTdlNTY4NTI0MDQ5NjliZjJlOGUxMjZjN2E1OTlmL3RhYmxlcmFuZ2U6ODE5N2U1Njg1MjQwNDk2OWJmMmU4ZTEyNmM3YTU5OWZfNC0zLTEtMS0yOTgzNTI_5f373551-fb55-4e0c-bcfd-ea22c08ebae9">2,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjgxOTdlNTY4NTI0MDQ5NjliZjJlOGUxMjZjN2E1OTlmL3RhYmxlcmFuZ2U6ODE5N2U1Njg1MjQwNDk2OWJmMmU4ZTEyNmM3YTU5OWZfNS0xLTEtMS0yOTgzNTI_b0652179-388a-4f43-81bf-5fd1c0e8e480">1,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjgxOTdlNTY4NTI0MDQ5NjliZjJlOGUxMjZjN2E1OTlmL3RhYmxlcmFuZ2U6ODE5N2U1Njg1MjQwNDk2OWJmMmU4ZTEyNmM3YTU5OWZfNS0zLTEtMS0yOTgzNTI_ae7e2b9d-b22f-4dbb-bb5f-1eb13765434b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease costs (including amortization and <br/>&#160;&#160;&#160;interest costs)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="ibrx:FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjgxOTdlNTY4NTI0MDQ5NjliZjJlOGUxMjZjN2E1OTlmL3RhYmxlcmFuZ2U6ODE5N2U1Njg1MjQwNDk2OWJmMmU4ZTEyNmM3YTU5OWZfNi0xLTEtMS0yOTgzNTI_cd46575b-50ce-4af9-9e8d-ced575a7ef3c">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="ibrx:FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjgxOTdlNTY4NTI0MDQ5NjliZjJlOGUxMjZjN2E1OTlmL3RhYmxlcmFuZ2U6ODE5N2U1Njg1MjQwNDk2OWJmMmU4ZTEyNmM3YTU5OWZfNi0zLTEtMS0yOTgzNTI_d2b904d2-ab6c-4038-9cdb-e6175e12d764">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjgxOTdlNTY4NTI0MDQ5NjliZjJlOGUxMjZjN2E1OTlmL3RhYmxlcmFuZ2U6ODE5N2U1Njg1MjQwNDk2OWJmMmU4ZTEyNmM3YTU5OWZfNy0xLTEtMS0yOTgzNTI_229463bf-6757-4ed8-83df-fb9f612d7372">970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjgxOTdlNTY4NTI0MDQ5NjliZjJlOGUxMjZjN2E1OTlmL3RhYmxlcmFuZ2U6ODE5N2U1Njg1MjQwNDk2OWJmMmU4ZTEyNmM3YTU5OWZfNy0zLTEtMS0yOTgzNTI_cb561d4a-d5e0-497e-8c75-d1766ff9ccd8">1,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjgxOTdlNTY4NTI0MDQ5NjliZjJlOGUxMjZjN2E1OTlmL3RhYmxlcmFuZ2U6ODE5N2U1Njg1MjQwNDk2OWJmMmU4ZTEyNmM3YTU5OWZfOC0xLTEtMS0yOTgzNTI_88e7da97-ea34-4d51-ac04-ea03ebfa4b2d">4,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjgxOTdlNTY4NTI0MDQ5NjliZjJlOGUxMjZjN2E1OTlmL3RhYmxlcmFuZ2U6ODE5N2U1Njg1MjQwNDk2OWJmMmU4ZTEyNmM3YTU5OWZfOC0zLTEtMS0yOTgzNTI_57a542fe-65d7-40c0-be20-57482836f222">3,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities is as follows (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"></td><td style="width:71.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.339%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.341%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash paid for operating leases (excluding variable lease costs)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjQ1NWM3YzZhNTNmMjRjNWFhYjc0NDQwMWU2MWJkY2I0L3RhYmxlcmFuZ2U6NDU1YzdjNmE1M2YyNGM1YWFiNzQ0NDAxZTYxYmRjYjRfNC0xLTEtMS0yOTgzNTI_b4d6bec5-7c0c-4217-b764-d9e2c5ff6be8">3,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjQ1NWM3YzZhNTNmMjRjNWFhYjc0NDQwMWU2MWJkY2I0L3RhYmxlcmFuZ2U6NDU1YzdjNmE1M2YyNGM1YWFiNzQ0NDAxZTYxYmRjYjRfNC0zLTEtMS0yOTgzNTI_ef035119-a96e-4b78-9031-5928f0ca5613">2,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Financing cash flow from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjQ1NWM3YzZhNTNmMjRjNWFhYjc0NDQwMWU2MWJkY2I0L3RhYmxlcmFuZ2U6NDU1YzdjNmE1M2YyNGM1YWFiNzQ0NDAxZTYxYmRjYjRfNS0xLTEtMS0yOTgzNTI_cfd14129-23fb-4bce-b040-3758045e216c">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjQ1NWM3YzZhNTNmMjRjNWFhYjc0NDQwMWU2MWJkY2I0L3RhYmxlcmFuZ2U6NDU1YzdjNmE1M2YyNGM1YWFiNzQ0NDAxZTYxYmRjYjRfNS0zLTEtMS0yOTgzNTI_fe2ccc85-4a17-47c7-8f2d-b1fcb1444ba4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flow from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjQ1NWM3YzZhNTNmMjRjNWFhYjc0NDQwMWU2MWJkY2I0L3RhYmxlcmFuZ2U6NDU1YzdjNmE1M2YyNGM1YWFiNzQ0NDAxZTYxYmRjYjRfNi0xLTEtMS0yOTgzNTI_bd577679-a6f0-4e32-a1e5-294fbf8f22d5">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjQ1NWM3YzZhNTNmMjRjNWFhYjc0NDQwMWU2MWJkY2I0L3RhYmxlcmFuZ2U6NDU1YzdjNmE1M2YyNGM1YWFiNzQ0NDAxZTYxYmRjYjRfNi0zLTEtMS0yOTgzNTI_ce274daf-d491-4197-90c2-70ee6747de21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="i0c9ceea37dbb458e95a2a117ca288cc1"><ix:continuation id="i1ececa23f99947cda7e7db30e09ffe74"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfMjkwNw_6083cf4f-1168-4f27-806b-cb33f486f1f0" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments as of March&#160;31,&#160;2023, including $<ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-5" name="ibrx:OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfMTE4NA_28d0ee6b-dbff-4eed-84da-7f13d38fbcd6">14.8</ix:nonFraction>&#160;million related to options to extend lease terms that are reasonably certain of being exercised, are presented in the following table (in&#160;thousands). Common area maintenance costs and taxes are not included in these payments.</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Years ending December 31:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Operating</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Leases</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Finance <br/>Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023 (excluding the three months ended March&#160;31,&#160;2023)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMi0yLTEtMS0yOTgzNTI_a831e732-3c5b-4997-8a1b-2fbf50edda57">6,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMi00LTEtMS0yOTgzNTI_93f7584c-f29d-420a-9528-e77136bb7c01">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:LeaseLiabilityToBePaidRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMi02LTEtMS0yOTgzNTI_8a448724-b2ed-408a-a1d3-8044c5a85995">6,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMy0yLTEtMS0yOTgzNTI_b6280e47-f4e8-490d-b060-b5e13b776951">12,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMy00LTEtMS0yOTgzNTI_e397216c-39ec-42c8-9037-65a68ca63e46">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:LeaseLiabilityToBePaidYearOne" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMy02LTEtMS0yOTgzNTI_e78b537c-b21b-4c42-9e4e-4edfd0a48ae2">12,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNC0yLTEtMS0yOTgzNTI_476b4715-27f0-498c-88a2-8f6945ca7ae4">12,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNC00LTEtMS0yOTgzNTI_74b87757-dc3b-45ae-841f-77e2a87e1d3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:LeaseLiabilityToBePaidYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNC02LTEtMS0yOTgzNTI_064ee884-43e4-4810-93ad-45a91b181b75">12,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNS0yLTEtMS0yOTgzNTI_38b1addf-00f2-4b58-a649-5d4bf4254f32">10,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNS00LTEtMS0yOTgzNTI_de5e28c8-3f91-4b9e-9533-16b568ef3d9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:LeaseLiabilityToBePaidYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNS02LTEtMS0yOTgzNTI_c37fc7c2-81e4-4183-8f1b-8b1f4fc00d2e">10,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNi0yLTEtMS0yOTgzNTI_443b94ee-451f-4792-9314-0b7c713861f9">8,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNi00LTEtMS0yOTgzNTI_e03affde-8e7f-4098-bac5-01a60ee8d4bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:LeaseLiabilityToBePaidYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNi02LTEtMS0yOTgzNTI_111f2caf-c64d-4a25-89e7-bbb094ab080a">8,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNy0yLTEtMS0yOTgzNTI_ab1cfed6-73c5-4639-833f-57eb0f531f8d">23,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:FinanceLeaseLiabilityToBePaidAfterYearFour" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNy00LTEtMS0yOTgzNTI_900cd633-c29c-499f-b461-261375f886c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:LeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNy02LTEtMS0yOTgzNTI_fdbe60c7-bcfa-476f-9b5e-954465a9f338">23,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfOC0yLTEtMS0yOTgzNTI_a8db0940-612d-4fc0-a28e-2b48c80c30a1">72,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfOC00LTEtMS0yOTgzNTI_7c93bf99-a76d-46c1-9a93-40399294c326">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:LeaseLiabilityToBePaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfOC02LTEtMS0yOTgzNTI_5d8c0de7-3e1e-4b51-9f6c-d5e9efc70114">72,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfOS0yLTEtMS0yOTgzNTI_ee882fa6-c48b-4376-bff1-76791041b6b8">20,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfOS00LTEtMS0yOTgzNTI_423b6336-694a-438c-9bc5-99408a90f03c">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:LeaseLiabilityUndiscountedExcessInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfOS02LTEtMS0yOTgzNTI_85eb0b9a-4279-42ab-a524-acdcd3b2c545">20,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Tenant improvement allowance receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMTAtMi0xLTEtMjk4MzUy_3b3d9b1e-8076-4d88-800b-8e522221679e">2,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:FinanceLeaseLiabilityTenantImprovementAllowanceReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMTAtNC0xLTEtMjk4MzUy_3860de5b-efa7-4e7a-a77e-5c765abaf9e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:LeaseLiabilityTenantImprovementAllowanceReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMTAtNi0xLTEtMjk4MzUy_166cff60-1c15-4d39-86fb-5dcebd389b5d">2,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMTEtMi0xLTEtMjk4MzUy_21fdb8bc-c14d-4c00-929f-90eea47de885">49,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMTEtNC0xLTEtMjk4MzUy_6ccecabb-1cc9-4113-8561-c7805107e43e">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:LeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMTEtNi0xLTEtMjk4MzUy_ebe5b0b9-f9a7-4abf-b059-0d86172d18e5">49,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes related to our existing lease agreements from those disclosed in Note&#160;8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the Notes to Consolidated Financial Statements of our Annual Report on Form&#160;10-K filed with the SEC on March&#160;1,&#160;2023.</span></div></ix:continuation></ix:continuation><div id="i5bbe340c9c8f435088d8011b72b6800d_73"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfODU4MA_0c2e159c-2ea2-4f6f-b7fb-70345b47fc5f" continuedAt="i2e0f85b7ec684019abb7298a401931c7" escape="true">Related-Party Debt</ix:nonNumeric></span></div><ix:continuation id="i2e0f85b7ec684019abb7298a401931c7" continuedAt="i3384d04282614a9c876b7ea17c37e3d7"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Convertible Note at Fair Value</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2023, the company executed a $<ix:nonFraction unitRef="usd" contextRef="i4d61f38abc9b467da5b3204da34fab5e_I20230331" decimals="-5" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ1MzY4NQ_28189d53-790e-45e7-93a3-df4f7efc30ac">30.0</ix:nonFraction>&#160;million promissory note with Nant&#160;Capital, LLC (Nant&#160;Capital), an affiliated entity under common control of our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder. This note bears interest at Term Secured Overnight Financing Rate (SOFR) plus <ix:nonFraction unitRef="number" contextRef="i3a3e26a21876460b8624019e43e286e0_D20230101-20230331" decimals="INF" name="ibrx:RelatedPartyTransactionBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMjc0ODc3OTA4MTQ3Mg_dabfbb08-a781-476f-9987-62083792c977">8.0</ix:nonFraction>%&#160;per annum. The outstanding principal amount and any accrued and unpaid interest are due on December&#160;31,&#160;2023 or upon the occurrence and continuation of an Event of Default (as defined in the note). The interest on this note will be paid on a quarterly basis beginning on June&#160;30,&#160;2023. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. The noteholder may convert the balance of the convertible promissory note and accrued interest in whole at its option following the Conversion Price Date, which is the trading day prior to the opening of the next open trading window, as determined by the company&#8217;s board of directors in accordance with the company&#8217;s Insider Trading Policy. The conversion price is equal to the greater of (i)&#160;the NASDAQ Official Closing Price and (ii)&#160;the consolidated closing bid price of the company&#8217;s common stock on the Conversion Price Date. There is no floor on the conversion price for this convertible note, therefore, as of March&#160;31,&#160;2023 we cannot determine the total number of shares issuable upon conversion that may occur in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i44cc657d262146519329e8d5460c262d_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY1NzEwMA_09b7fe3a-28d5-4a1b-8bec-3d15426d01e0">29.9</ix:nonFraction>&#160;million from this financing, net of a $<ix:nonFraction unitRef="usd" contextRef="i4d61f38abc9b467da5b3204da34fab5e_I20230331" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY1NzExNQ_df0de141-7318-4e8e-8783-8f7e17af5202">0.1</ix:nonFraction>&#160;million origination fee paid to the lender. The note is accounted for under ASC 825-10-15-4 FVO&#160;election. Under the FVO election, the note is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. With each such remeasurement, the note will be adjusted to fair value, with the change in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other income (expense), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statement of operations, except that </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the change in the fair value resulting from a change in the instrument-specific credit risks are recognized as a component of other comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of March&#160;31,&#160;2023, we had a balance of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i4d61f38abc9b467da5b3204da34fab5e_I20230331" decimals="-5" name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY1NzEzMg_11c9fc27-5331-4312-84eb-080a90c74634">29.9</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">related-party convertible note at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated balance sheets related to the convertible promissory note measured at fair value.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="i3384d04282614a9c876b7ea17c37e3d7" continuedAt="i7d86953db9684aa58f1f82ce9b29d507"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Convertible Notes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;31,&#160;2022, the company amended and restated an aggregate of $<ix:nonFraction unitRef="usd" contextRef="if421742d22da4377a2a2d5d3ad4dee90_I20220831" decimals="-5" name="ibrx:NotesPayableRelatedPartiesPrincipalAndAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2MDc1MQ_681ddf6c-510a-4378-aa70-8573816e19b3">315.1</ix:nonFraction>&#160;million (including outstanding principal and accrued and unpaid interest) of fixed-rate promissory notes held by entities affiliated with Dr. Soon-Shiong. Prior to the amendments and restatements, these notes bore and continue to bear interest at a per annum rate ranging from <ix:nonFraction unitRef="number" contextRef="iad7a8cf8ad9546059a44a0c2f4102d99_D20220101-20220731" decimals="INF" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2MDc1OA_b898c81e-45dc-4c38-9221-3f00243a46da">3.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i9adb1d0654114ee5afbed60cfa9e4766_D20220101-20220731" decimals="INF" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2MDc2NQ_16f9d844-f6c1-49ef-9b7a-58e18416f908">6.0</ix:nonFraction>%, provide that the outstanding principal was and continues to be due and payable on September&#160;30,&#160;2025, and accrued and unpaid interest was or continues to be payable either upon maturity or, with respect to one of the notes, on a quarterly basis. Prior to the amendments and restatements, the company could and can continue to prepay the outstanding principal (together with accrued and unpaid interest), either in whole or in part, at any time without premium or penalty and without the prior consent of the lender, now subject to an advance notice period of at least five&#160;business days during which the lender can convert the amount requested to be prepaid by the company into shares of the company&#8217;s common stock, as part of the amendment and restatement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of these fixed-rate promissory notes were amended and restated to include a conversion feature that gives each lender, at its sole option, at any time (other than when the lender is in receipt of a written notice of prepayment from the borrower), the right to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the company&#8217;s common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if421742d22da4377a2a2d5d3ad4dee90_I20220831" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2MDc5NQ_3ebd101b-9ef7-4e80-ab39-edd321b65c08">5.67</ix:nonFraction> per share. Upon receipt of a written notice of prepayment from the borrower, the lender has the right, at its option, to convert the outstanding principal amount to be prepaid and the accrued and unpaid interest thereon (as specified in the notice of prepayment) into shares of the company&#8217;s common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if421742d22da4377a2a2d5d3ad4dee90_I20220831" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfNTQ5NzU1ODU3MTQ0_3ebd101b-9ef7-4e80-ab39-edd321b65c08">5.67</ix:nonFraction>&#160;per share. No other material terms or conditions of these fixed-rate promissory notes were modified as part of the August&#160;31,&#160;2022 amendments and restatements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, the carrying value of the fixed-rated convertible promissory notes of $<ix:nonFraction unitRef="usd" contextRef="ifeeaf31a1b7546b08e11b31f6de4b788_I20230331" decimals="-5" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2MTA5NA_b528d342-cde2-4fba-b378-9948a662a0eb">245.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3be51647022b41c5aac446b43954112a_I20221231" decimals="-5" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2MTEwNQ_959fc23f-6ed7-479b-a64f-858e005e4a10">241.3</ix:nonFraction>&#160;million, respectively, was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">related-party convertible notes and accrued interest, net of discount,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets. During the three months ended March&#160;31,&#160;2023 and 2022, the company made interest payments of $<ix:nonFraction unitRef="usd" contextRef="i700361120e53402ba852dcb639cda333_D20230101-20230331" decimals="-5" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2MTE4Mg_59b0d02b-6036-4628-9cbf-4e64da92e50a">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia44124c82520433e872adbae39679ee3_D20220101-20220331" decimals="-5" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2MTE2Mw_e129a448-064e-4881-8fa1-2dd499a007dd">0.6</ix:nonFraction>&#160;million, respectively, related to our $<ix:nonFraction unitRef="usd" contextRef="i3c27fb3d47934120827861b39628c2b1_I20230331" decimals="-5" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMjE5OTAyMzI5ODE5MA_f95c9537-090e-4d1b-a144-a6529192c3cf">40.0</ix:nonFraction>&#160;million promissory note.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Nonconvertible Notes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, the company had a promissory note outstanding with Nant Capital for $<ix:nonFraction unitRef="usd" contextRef="iefda7cd80c064a8e958479a947e51afb_I20230331" decimals="-5" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2NjU5NA_b490ee2a-588c-4847-94e8-539ac0d23a6e">300.0</ix:nonFraction>&#160;million in principal and a carrying balance of $<ix:nonFraction unitRef="usd" contextRef="iefda7cd80c064a8e958479a947e51afb_I20230331" decimals="-5" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2NjYxNQ_a0f9a645-c554-43b9-a32c-d98b833cdfa9">272.2</ix:nonFraction>&#160;million, net of unamortized discount of $<ix:nonFraction unitRef="usd" contextRef="iefda7cd80c064a8e958479a947e51afb_I20230331" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2NjYzOQ_3f533217-6207-40c9-8ab1-faa78d9b82fc">27.8</ix:nonFraction>&#160;million. The note bears an interest rate of Term&#160;SOFR plus <ix:nonFraction unitRef="number" contextRef="if26e41fef20847b6b81445d4a3101377_D20220101-20221231" decimals="INF" name="ibrx:RelatedPartyTransactionBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2NjcwNw_65fcf6d8-aa15-4ae6-86a4-893ec0c0bb35">8.0</ix:nonFraction>% per annum, payable on a quarterly basis. In the event of a default on the loan (as defined in both the original and amended and restated promissory notes), including if the company does not repay the loan at maturity, the company had and continues to have the right, at its sole option, to convert the outstanding principal amount and accrued and unpaid interest due under this note into fully paid and non-assessable shares of the company&#8217;s common stock at a conversion price per share equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="id782271befaf426399ce9443216bb892_D20220831-20220831" decimals="2" name="ibrx:OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2NjY1MQ_456ec889-ed59-4a8f-bf39-08c6b10e1c09">5.67</ix:nonFraction>. The company made interest payments of $<ix:nonFraction unitRef="usd" contextRef="id84e4096f5c442528938b4337cf7c8ed_D20230101-20230331" decimals="-5" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ4MDg4OQ_1b7c61b9-c2c5-45a8-a525-4b60938723df">9.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7f716744d3be43e38afdc26a656b33b7_D20220101-20220331" decimals="-5" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ4MDkwMA_67b901b8-5a0a-4d1d-bae0-17aab5425098">4.4</ix:nonFraction>&#160;million during the three&#160;months&#160;ended March&#160;31,&#160;2023 and 2022, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, the company had a promissory note outstanding with Nant Capital for $<ix:nonFraction unitRef="usd" contextRef="i604c474521cf4dd693f946bc8cff054d_I20230331" decimals="-5" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ4MDk0Mg_5b666a2d-dc4b-41f6-88fc-2bef10c8c5e7">125.0</ix:nonFraction>&#160;million in principal and a carrying balance of $<ix:nonFraction unitRef="usd" contextRef="i604c474521cf4dd693f946bc8cff054d_I20230331" decimals="-5" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ4MDk2Mw_9ee68348-a8b9-4503-88ee-5c74fd9193bb">119.6</ix:nonFraction>&#160;million, net of unamortized discount of $<ix:nonFraction unitRef="usd" contextRef="i604c474521cf4dd693f946bc8cff054d_I20230331" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ4MDk4Mg_db4ff115-d4c1-4dd1-b657-32209e8e58d8">5.4</ix:nonFraction>&#160;million. The note bears an interest rate of Term&#160;SOFR plus <ix:nonFraction unitRef="number" contextRef="i168a4524f50644799beb0bf0791c2954_D20230101-20230331" decimals="INF" name="ibrx:RelatedPartyTransactionBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMjE5OTAyMzI5ODI2OQ_bbeffc19-6129-4e60-b801-16f0e712d22d">8.0</ix:nonFraction>% per annum, payable on a quarterly basis. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. The company made an interest payment of $<ix:nonFraction unitRef="usd" contextRef="ic72646472e3b48a295ebef3a0ebdf66f_D20230101-20230331" decimals="-5" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ4MDkxMA_105f0a98-71d0-4daf-a3b9-8049a22ed797">3.9</ix:nonFraction>&#160;million during three&#160;months&#160;ended March&#160;31,&#160;2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, the company had a promissory note outstanding with Nant Capital for $<ix:nonFraction unitRef="usd" contextRef="i8e671951edb7455ea24c2ac0392ea151_I20230331" decimals="-5" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ4MTAzMQ_4875bb4e-eaef-4f26-82e4-04ee595b0fb1">50.0</ix:nonFraction>&#160;million in principal and a carrying balance of $<ix:nonFraction unitRef="usd" contextRef="i8e671951edb7455ea24c2ac0392ea151_I20230331" decimals="-5" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ4MTA1MQ_6874fc88-b3ea-4666-aab2-0cb42ec60af0">49.8</ix:nonFraction>&#160;million, net of unamortized discount of $<ix:nonFraction unitRef="usd" contextRef="i8e671951edb7455ea24c2ac0392ea151_I20230331" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ4MTA3MA_5980b03e-b5d1-41a3-a9cb-b24c24967f64">0.2</ix:nonFraction>&#160;million. The note bears an interest rate of Term&#160;SOFR plus <ix:nonFraction unitRef="number" contextRef="if3d09e78bc0148b7a0f1abb485cdc81a_D20230101-20230331" decimals="INF" name="ibrx:RelatedPartyTransactionBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ4MTAxNQ_83b4a703-a8a2-436c-8293-87026fcbf3ab">8.0</ix:nonFraction>% per annum, payable on a quarterly basis. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. In the event of a Specified Transaction (as defined in the loan agreement), the noteholder can request the outstanding principal and interest due on the loan be repaid in full upon consummation of such Specified Transaction. The company made a cash payment of $<ix:nonFraction unitRef="usd" contextRef="if86dd819ffd041e19f08088aa305bbd6_D20230101-20230331" decimals="-5" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ4MDkyMA_70d13231-8aca-4350-819b-10e1756bb686">1.6</ix:nonFraction>&#160;million during three&#160;months&#160;ended March&#160;31,&#160;2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="i7d86953db9684aa58f1f82ce9b29d507" continuedAt="i966f8abd5833480b8d0df51c30ca45ab"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="ibrx:ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfODU3OA_cd16c68c-b637-4e4f-94fd-e83c0865d62a" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our related-party debt is summarized below (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at March&#160;31,&#160;2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Year</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accrued<br/>Interest<br/>Added to<br/>Note</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less:<br/>Unamortized <br/>Discounts</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Nonconvertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term SOFR + <ix:nonFraction unitRef="number" contextRef="if26e41fef20847b6b81445d4a3101377_D20220101-20221231" decimals="INF" name="ibrx:RelatedPartyTransactionBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfNy0zLTEtMS0yOTgzNTIvdGV4dHJlZ2lvbjo3MWZhMjYyOTJlMmI0NmJjOTJiOTA4MGVmOTU0NDUwOF8xMDk5NTExNjI3ODA1_b08d4e75-9568-481e-9d4a-dfd4740af3cc">8.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c875c85efb244079066f90b6b550c50_I20230331" decimals="-3" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfNy01LTEtMS0yOTgzNTI_6035700d-9284-4d63-b99c-c5b302716135">475,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c875c85efb244079066f90b6b550c50_I20230331" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfNy03LTEtMS0yOTgzNTI_e21bdfdb-e9fb-4cf3-a604-92e95719d6fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c875c85efb244079066f90b6b550c50_I20230331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfNy05LTEtMS0yOTgzNTI_833af451-8b05-4e90-9cf3-78d74a8a94e9">33,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c875c85efb244079066f90b6b550c50_I20230331" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfNy0xMS0xLTEtMjk4MzUy_425bf32c-914e-4585-95f6-ae958a2536b4">441,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Convertible Note <br/>&#160;&#160;&#160;at Fair Value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term SOFR + <ix:nonFraction unitRef="number" contextRef="i3a3e26a21876460b8624019e43e286e0_D20230101-20230331" decimals="INF" name="ibrx:RelatedPartyTransactionBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfOS0zLTEtMS0zMjI2OTgvdGV4dHJlZ2lvbjpiOWQwNzYzOGM3MDk0NWYxOTdkNmU2NGQwOWVhYTViOV8xNg_dabfbb08-a781-476f-9987-62083792c977">8.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d61f38abc9b467da5b3204da34fab5e_I20230331" decimals="-3" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfOS01LTEtMS0zMjI2OTg_91491102-1c86-49c9-ad78-e2068b2b5ce6">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d61f38abc9b467da5b3204da34fab5e_I20230331" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfOS03LTEtMS0zMjI2OTg_411ec9c1-478f-4cb6-b514-5d16b79c2c12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d61f38abc9b467da5b3204da34fab5e_I20230331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfOS05LTEtMS0zMjI2OTg_e42b3deb-2142-4eea-9385-aa627365d0a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d61f38abc9b467da5b3204da34fab5e_I20230331" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfOS0xMS0xLTEtMzIyNjk4_e16f98c9-acf6-4fdd-a7de-04b6e0d67b9f">29,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07cfde51688d493b82c4be4a684839e5_D20230101-20230331" decimals="INF" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfOS0zLTEtMS0yOTgzNTI_bb105d64-5ea3-4677-ba68-6330f300f3fa">5.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id87c72a123a646d7a99485bf28cfb653_I20230331" decimals="-3" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfOS01LTEtMS0yOTgzNTI_98eb3388-4247-4545-a9e4-425cf9d4a408">55,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id87c72a123a646d7a99485bf28cfb653_I20230331" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfOS03LTEtMS0yOTgzNTI_ec7d24a5-beb7-45a6-b53e-51a97fa956dc">10,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id87c72a123a646d7a99485bf28cfb653_I20230331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfOS05LTEtMS0yOTgzNTI_de110707-864d-461f-9336-0d7b2ed7e54c">4,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id87c72a123a646d7a99485bf28cfb653_I20230331" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfOS0xMS0xLTEtMjk4MzUy_c3ee1559-0e01-403f-adf5-8588ee82461a">60,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie84a9931057b4e4aae2bb4ed9870ba8f_D20230101-20230331" decimals="INF" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTAtMy0xLTEtMjk4MzUy_f7ebcf97-2b74-4b95-bc9e-be990ed15881">6.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1743878cb0574c6cbbbcdd536eda339a_I20230331" decimals="-3" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTAtNS0xLTEtMjk4MzUy_35433777-20e1-4c85-b8c0-377aa1e93b9d">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1743878cb0574c6cbbbcdd536eda339a_I20230331" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTAtNy0xLTEtMjk4MzUy_d76b971a-33fb-4bcd-988c-ab6994e4aa60">7,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1743878cb0574c6cbbbcdd536eda339a_I20230331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTAtOS0xLTEtMjk4MzUy_53e0aca8-f839-4376-a6a5-38cd8d438db4">3,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1743878cb0574c6cbbbcdd536eda339a_I20230331" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTAtMTEtMS0xLTI5ODM1Mg_2516e0ab-e8ce-4d60-87a3-5cb02327cdba">54,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i36630a5fb97140119768102b4c075987_D20230101-20230331" decimals="INF" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTEtMy0xLTEtMjk4MzUy_6479915e-d626-493a-9131-625a2fe5942e">6.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c27fb3d47934120827861b39628c2b1_I20230331" decimals="-3" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTEtNS0xLTEtMjk4MzUy_14b7b5a9-5b87-431d-af8c-19fe2beca36a">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c27fb3d47934120827861b39628c2b1_I20230331" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTEtNy0xLTEtMjk4MzUy_1534254c-f755-4e09-a7b2-5a704d482601">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c27fb3d47934120827861b39628c2b1_I20230331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTEtOS0xLTEtMjk4MzUy_5e060dd6-2027-4c2a-aa36-0d84e38c562a">2,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c27fb3d47934120827861b39628c2b1_I20230331" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTEtMTEtMS0xLTI5ODM1Mg_2ddb4ff8-c6a7-4e85-a879-f60ca3d765f1">37,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantMobile, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i023872a5c0664193ae14daa63ba5eefc_D20230101-20230331" decimals="INF" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTItMy0xLTEtMjk4MzUy_63ce4d92-c5be-449d-99e8-9d9519982798">3.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02d66470d5a1468c83c9015ed4ab3ab0_I20230331" decimals="-3" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTItNS0xLTEtMjk4MzUy_db2c0a0a-650c-4857-8d8e-b24528c4cc03">55,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02d66470d5a1468c83c9015ed4ab3ab0_I20230331" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTItNy0xLTEtMjk4MzUy_e89aae8e-cb24-4300-8306-f01caf3a93cf">5,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02d66470d5a1468c83c9015ed4ab3ab0_I20230331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTItOS0xLTEtMjk4MzUy_55e20bf8-4869-412a-a5f9-4d8d1664e6db">5,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02d66470d5a1468c83c9015ed4ab3ab0_I20230331" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTItMTEtMS0xLTI5ODM1Mg_b8685d85-9d67-464f-918e-a552da197969">55,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantCancerStemCell, LLC (NCSC)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i46483bc0e4034520a181080e17a40498_D20230101-20230331" decimals="INF" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTMtMy0xLTEtMjk4MzUy_690f036c-9735-40a8-86ae-038c681010f5">5.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b7ac56635b4a66a2d03236bce015d7_I20230331" decimals="-3" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTMtNS0xLTEtMjk4MzUy_1c014a9c-acf2-49fd-889f-1426822dc4a8">33,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b7ac56635b4a66a2d03236bce015d7_I20230331" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTMtNy0xLTEtMjk4MzUy_d338e166-90bf-4ac0-86c1-f88bda135303">8,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b7ac56635b4a66a2d03236bce015d7_I20230331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTMtOS0xLTEtMjk4MzUy_d4576919-3a05-442f-94a5-1ff34e8984ae">3,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b7ac56635b4a66a2d03236bce015d7_I20230331" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTMtMTEtMS0xLTI5ODM1Mg_81e4f438-35e3-491e-8176-a5ac4c7e2292">38,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total related-party convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c37984b4ee4c4e8d32a3fcda72fd96_I20230331" decimals="-3" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTQtNS0xLTEtMjk4MzUy_ad740198-e663-477d-8631-d48b2382750e">233,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c37984b4ee4c4e8d32a3fcda72fd96_I20230331" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTQtNy0xLTEtMjk4MzUy_143ad46e-303e-41df-8c85-753f28b8db34">31,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c37984b4ee4c4e8d32a3fcda72fd96_I20230331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTQtOS0xLTEtMjk4MzUy_b73f3f3a-2d97-48a4-983e-a7104c11a713">19,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c37984b4ee4c4e8d32a3fcda72fd96_I20230331" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTQtMTEtMS0xLTI5ODM1Mg_0a7f01a5-159f-423d-a2bf-f74832ed06c2">245,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total related-party debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTUtNS0xLTEtMjk4MzUy_18fdb1f7-759f-454a-8f64-1a4d331c0474">738,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTUtNy0xLTEtMjk4MzUy_3d4e355e-2918-4512-b176-0ec2041b65fd">31,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTUtOS0xLTEtMjk4MzUy_2bd56d9f-3b34-4cba-98db-874d77e18cc3">52,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTUtMTEtMS0xLTI5ODM1Mg_9134b6cc-4343-43b4-8a91-6442fe98b7e1">717,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"></td><td style="width:3.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.132%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The interest rate on our related-party variable-rate notes as of March&#160;31,&#160;2023 was <ix:nonFraction unitRef="number" contextRef="i6c63ca50dfe64ec5a0637410c6d5397b_D20230101-20230331" decimals="4" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOmI1MWRjOGJiNjc4NjQyMjU4NTk5ZDllNTQyNjg5ZmFmL3RhYmxlcmFuZ2U6YjUxZGM4YmI2Nzg2NDIyNTg1OTlkOWU1NDI2ODlmYWZfMC0xLTEtMS0yOTgzNTIvdGV4dHJlZ2lvbjpjOGQzNWE3NDIxOTA0ZjRjODE3M2Q2NjZmNGNmNTcyN183Ng_c745f04d-e007-4a39-a2a2-3282a31dcd61">12.89</ix:nonFraction>%.</span></div></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December&#160;31,&#160;2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Year</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accrued<br/>Interest<br/>Added to<br/>Note</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less:<br/>Unamortized <br/>Discounts</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Nonconvertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term SOFR + <ix:nonFraction unitRef="number" contextRef="if26e41fef20847b6b81445d4a3101377_D20220101-20221231" decimals="INF" name="ibrx:RelatedPartyTransactionBasisSpreadOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNC0zLTEtMS0yOTgzNTIvdGV4dHJlZ2lvbjo1ZTJhODQwMzk2OTI0MDY3OWIzZDI0MDAyNzNjNWJkMV8xNjQ5MjY3NDQxNjgz_b08d4e75-9568-481e-9d4a-dfd4740af3cc">8.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bffc59bc82a4092b0b095eb4b104f99_I20221231" decimals="-3" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNC01LTEtMS0yOTgzNTI_15567468-30ca-434d-b111-31f4f24e947d">475,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bffc59bc82a4092b0b095eb4b104f99_I20221231" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNC03LTEtMS0yOTgzNTI_0e13cf2d-4bb0-4178-a871-fb4f2f40f443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bffc59bc82a4092b0b095eb4b104f99_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNC05LTEtMS0yOTgzNTI_d9b1b382-2dbd-4bb1-b218-aa34bc4eacde">43,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bffc59bc82a4092b0b095eb4b104f99_I20221231" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNC0xMS0xLTEtMjk4MzUy_ef1a0dc0-89a5-4342-bd8d-95a35ed84268">431,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifa2f8dcc34a64a3f95777076fb02b849_D20220101-20221231" decimals="INF" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNi0zLTEtMS0yOTgzNTI_145d0129-acb6-4224-8a6b-c183f6f94df4">5.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f7988bcb71d43779a0096791bc726c6_I20221231" decimals="-3" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNi01LTEtMS0yOTgzNTI_f788dad5-0d4b-4703-82d6-9a5d9f4e4309">55,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f7988bcb71d43779a0096791bc726c6_I20221231" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNi03LTEtMS0yOTgzNTI_ed3df53b-1341-432f-85eb-afe2e97c9871">9,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f7988bcb71d43779a0096791bc726c6_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNi05LTEtMS0yOTgzNTI_77dfb947-c0a5-430d-b278-a92027b4d5b8">5,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f7988bcb71d43779a0096791bc726c6_I20221231" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNi0xMS0xLTEtMjk4MzUy_c7ea9599-5c7d-4d47-b47d-baaa2948fd9c">59,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i965c76f591504ffd870c02a47f91e4d1_D20220101-20221231" decimals="INF" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNy0zLTEtMS0yOTgzNTI_ff0e2ea4-0cd0-4a1b-903b-4147047b497b">6.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9880130e66047f2be4005667dcc04df_I20221231" decimals="-3" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNy01LTEtMS0yOTgzNTI_a7ea48cf-0fcd-4889-af0a-2f077fec8306">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9880130e66047f2be4005667dcc04df_I20221231" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNy03LTEtMS0yOTgzNTI_cbff73c3-e2c9-4f4d-83ac-c854ea35c93e">7,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9880130e66047f2be4005667dcc04df_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNy05LTEtMS0yOTgzNTI_79d2b085-5470-44fc-82ba-c292725642f6">4,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9880130e66047f2be4005667dcc04df_I20221231" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNy0xMS0xLTEtMjk4MzUy_267c21ba-b292-4f6c-a8f3-1d2eef4e5463">52,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3116163dc179457f83c1a522829e482e_D20220101-20221231" decimals="INF" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfOC0zLTEtMS0yOTgzNTI_b91dcd6b-975a-4fc5-8288-17b864352fab">6.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic800e90d3fa44e74bfd616fa559ef8f8_I20221231" decimals="-3" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfOC01LTEtMS0yOTgzNTI_2f9bbdee-8671-4da6-813d-d83a1523ffb4">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic800e90d3fa44e74bfd616fa559ef8f8_I20221231" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfOC03LTEtMS0yOTgzNTI_df327ad2-d0d4-4a0f-850a-13569bd7dc97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic800e90d3fa44e74bfd616fa559ef8f8_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfOC05LTEtMS0yOTgzNTI_b5813c01-c0b1-4368-b496-d7752cfbbbb6">2,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic800e90d3fa44e74bfd616fa559ef8f8_I20221231" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfOC0xMS0xLTEtMjk4MzUy_5a79351a-978c-418d-9a96-506ed887db88">37,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantMobile</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i76bd041f34bc45308f8baecb04934003_D20220101-20221231" decimals="INF" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfOS0zLTEtMS0yOTgzNTI_94e9bd50-2d3e-441a-b35b-227298a9a023">3.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i273275e6ceed474fa66492ae83f982da_I20221231" decimals="-3" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfOS01LTEtMS0yOTgzNTI_197e95ab-6ab9-4eb9-a88e-63e51b1ad028">55,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i273275e6ceed474fa66492ae83f982da_I20221231" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfOS03LTEtMS0yOTgzNTI_665709b3-727e-4621-8b3d-381d94b34de3">5,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i273275e6ceed474fa66492ae83f982da_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfOS05LTEtMS0yOTgzNTI_b72a8949-e1a2-49a5-abfa-7c59d6262961">5,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i273275e6ceed474fa66492ae83f982da_I20221231" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfOS0xMS0xLTEtMjk4MzUy_a59626ce-90d8-45a6-88d7-1f247983eb46">54,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NCSC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icde6ce22814d4976bf3ce94a8a10aa0a_D20220101-20221231" decimals="INF" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTEtMy0xLTEtMjk4MzUy_c7899529-6ac4-4052-8e2a-78bc2cc371a7">5.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34b60dc14eca495189c0a9fd77ab929d_I20221231" decimals="-3" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTEtNS0xLTEtMjk4MzUy_8e210365-3b70-4ce2-b884-ff4388a8ed52">33,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34b60dc14eca495189c0a9fd77ab929d_I20221231" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTEtNy0xLTEtMjk4MzUy_6fdf96d0-b8ee-4949-8c77-14dbf76bbafc">7,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34b60dc14eca495189c0a9fd77ab929d_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTEtOS0xLTEtMjk4MzUy_c39222d1-0839-4ccd-8a0b-881ce5635939">3,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34b60dc14eca495189c0a9fd77ab929d_I20221231" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTEtMTEtMS0xLTI5ODM1Mg_08b8d9f5-a5ee-49cd-a05d-c3060727943a">37,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total related-party convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6fd5dc04474fc6ad30fdb536534995_I20221231" decimals="-3" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTItNS0xLTEtMjk4MzUy_963c34b9-a899-43e6-9336-ad3761469abf">233,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6fd5dc04474fc6ad30fdb536534995_I20221231" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTItNy0xLTEtMjk4MzUy_211f9faa-2ab8-4237-8bec-2f681cb06243">29,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6fd5dc04474fc6ad30fdb536534995_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTItOS0xLTEtMjk4MzUy_797a4fc9-770d-4b11-bc17-e33c99ef4b8e">21,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6fd5dc04474fc6ad30fdb536534995_I20221231" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTItMTEtMS0xLTI5ODM1Mg_047b17cd-d31f-4b3d-b00f-5a700bea3950">241,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total related-party debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="ibrx:RelatedPartyNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTMtNS0xLTEtMjk4MzUy_b8cd3378-4ee8-4390-9050-98928d4d0316">708,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTMtNy0xLTEtMjk4MzUy_2d8faa43-1a09-4355-9da2-743530f65357">29,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTMtOS0xLTEtMjk4MzUy_def23971-2ca1-4720-bc8f-5767dccfc89e">64,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTMtMTEtMS0xLTI5ODM1Mg_6bffa494-4702-4afc-9763-ee7e0163b1a9">673,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"></td><td style="width:3.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.132%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The interest rate on our related-party variable-rate notes as of December&#160;31,&#160;2022 was <ix:nonFraction unitRef="number" contextRef="ifa4a4292eb67427d8486a6d30953b1b1_D20220101-20221231" decimals="4" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjFhZWY4ODZhMGQ0YzQyN2FiNjNjYzU4OWRjOWNiNDk1L3RhYmxlcmFuZ2U6MWFlZjg4NmEwZDRjNDI3YWI2M2NjNTg5ZGM5Y2I0OTVfMC0xLTEtMS0yOTgzNTIvdGV4dHJlZ2lvbjpjODMwMTlmMTAyMWM0YTc2Yjk4OGExYjliNjMyYmNmYl8xMDk5NTExNjI3ODcw_7fba8940-9be6-4bce-8451-10f9d23b0f27">12.59</ix:nonFraction>%.</span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="i966f8abd5833480b8d0df51c30ca45ab" continuedAt="i722878994cc641a0be27ee02e728a089"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfODU3OQ_1b2f3f12-14f9-42f0-b793-9be37d77b481" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future contractual obligations for our related-party debt as of March&#160;31,&#160;2023 (unaudited; in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.404%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Payments (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible<br/>Notes</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-convertible<br/>Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible<br/>Notes</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-convertible<br/>Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (excluding the three months ended </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;March&#160;31,&#160;2023)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96fd516d0b2c4ab88b68926fb81bb129_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfMy0yLTEtMS0yOTgzNTI_b57c732d-0d2f-4843-8b9a-f80b1e684ac2">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i860cd6cdf17243bd9cb45083c2bd5bb7_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfMy00LTEtMS0yOTgzNTI_5fa7beb4-2698-4f8e-82af-d6be5d8e5502">475,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20deba0784bb4ee28b65cd1d2bd855dc_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfMy02LTEtMS0yOTgzNTI_99a6ec11-53e2-402f-bc09-6847df7cc0b7">4,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55ffd3316fb8496aa86fcba67dffd60b_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfMy04LTEtMS0yOTgzNTI_9d7b7711-1282-4800-b786-7d20a304b4b2">46,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46a185f9ec6445ec8b642258ea67180d_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfMy0xMC0xLTEtMjk4MzUy_b9f25a79-f664-48dc-a371-7b8f8fbfe4eb">555,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96fd516d0b2c4ab88b68926fb81bb129_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNC0yLTEtMS0yOTgzNTI_f4e959af-211a-4588-aa0a-042098497a7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i860cd6cdf17243bd9cb45083c2bd5bb7_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNC00LTEtMS0yOTgzNTI_9a722526-41cd-454e-a9f6-ea89f8a22319">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20deba0784bb4ee28b65cd1d2bd855dc_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNC02LTEtMS0yOTgzNTI_a3eda3c9-c02d-4fb0-b36b-19ad7460e5fc">2,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55ffd3316fb8496aa86fcba67dffd60b_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNC04LTEtMS0yOTgzNTI_50a0d0df-fb2c-4185-a5d4-2b3ade05f452">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46a185f9ec6445ec8b642258ea67180d_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNC0xMC0xLTEtMjk4MzUy_728ac7fd-7d75-48f4-9b51-24868f6588ae">2,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96fd516d0b2c4ab88b68926fb81bb129_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNS0yLTEtMS0yOTgzNTI_e1dc3c81-e420-467a-8c1b-e77e8590c77f">233,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i860cd6cdf17243bd9cb45083c2bd5bb7_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNS00LTEtMS0yOTgzNTI_5e73f197-1f75-411a-9e00-57335903d145">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20deba0784bb4ee28b65cd1d2bd855dc_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNS02LTEtMS0yOTgzNTI_d995d368-c8fb-4efd-ad7d-5e5958c1d33f">61,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55ffd3316fb8496aa86fcba67dffd60b_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNS04LTEtMS0yOTgzNTI_4008234f-b20d-4449-bb4e-017e8e2ff30c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46a185f9ec6445ec8b642258ea67180d_I20230331" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNS0xMC0xLTEtMjk4MzUy_63bdc6bf-98d3-49d0-8b17-55bdb26574ec">294,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal and estimated interest <br/>&#160;&#160;&#160;due on related-party debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96fd516d0b2c4ab88b68926fb81bb129_I20230331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNi0yLTEtMS0yOTgzNTI_2af6c902-9587-45e2-ae3b-0c67799383c7">263,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i860cd6cdf17243bd9cb45083c2bd5bb7_I20230331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNi00LTEtMS0yOTgzNTI_44ed161f-8c1e-41e3-8483-759fcf1200ff">475,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20deba0784bb4ee28b65cd1d2bd855dc_I20230331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNi02LTEtMS0yOTgzNTI_edf3ebcd-eb95-4205-84a3-c210490330c8">68,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55ffd3316fb8496aa86fcba67dffd60b_I20230331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNi04LTEtMS0yOTgzNTI_4b7e4473-f2b6-460b-b174-abaffa701124">46,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46a185f9ec6445ec8b642258ea67180d_I20230331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNi0xMC0xLTEtMjk4MzUy_98016a1c-5637-412d-b2a8-faaeec8bff32">852,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:3.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest payments on our fixed-rate convertible notes are calculated based on contractual interest rates and scheduled maturity dates. Interest payments on our variable-rate notes are calculated based on Term&#160;SOFR plus the contractual spread per the loan agreements. The rate on our variable-rate notes as of March&#160;31,&#160;2023 was <ix:nonFraction unitRef="number" contextRef="i6c63ca50dfe64ec5a0637410c6d5397b_D20230101-20230331" decimals="4" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOmQ1MGZkMzlkYzRjOTQyZjdhZjc2N2E0NDc3YjFhZDU2L3RhYmxlcmFuZ2U6ZDUwZmQzOWRjNGM5NDJmN2FmNzY3YTQ0NzdiMWFkNTZfMC0xLTEtMS0yOTgzNTIvdGV4dHJlZ2lvbjpiNTZmNzcyYTFkYWI0ZDA1YjMwOGVhYTRkYjM0ZTJkNF8zMjA_c745f04d-e007-4a39-a2a2-3282a31dcd61">12.89</ix:nonFraction>%.</span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i5bbe340c9c8f435088d8011b72b6800d_76"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:continuation id="i722878994cc641a0be27ee02e728a089" continuedAt="i926372493e70400ea88a02e9d7e359c4">Related-Party Agreements </ix:continuation></span></div><ix:continuation id="i926372493e70400ea88a02e9d7e359c4" continuedAt="ia1d3101fb1dd46cf97ac09a96c3a9c10"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business with several affiliates under written agreements and informal arrangements. <ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM5NjE_baab2993-4a49-4fab-864c-0bf7de48475d" continuedAt="ie1702e962f084a98989361afeb18cd89" escape="true">Below is a summary of outstanding balances and a description of significant relationships (in&#160;thousands):</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><ix:continuation id="ie1702e962f084a98989361afeb18cd89"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related party&#8211;NantBio, Inc.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie130450350ca4c9799e1e199a92ec29d_I20230331" decimals="-3" name="us-gaap:DueFromRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfNC0xLTEtMS0yOTgzNTI_301c1d80-c4ff-4357-8fb7-e6e1d10c4957">1,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09080f29fd3f433ba1865fa559c0cc3f_I20221231" decimals="-3" name="us-gaap:DueFromRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfNC0zLTEtMS0yOTgzNTI_44978d34-60bb-4662-a9b9-7e90cd4b0783">1,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related party&#8211;Brink Biologics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343f173c97cd46298d5be473e16688aa_I20230331" decimals="-3" name="us-gaap:DueFromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfNS0xLTEtMS0yOTgzNTI_162f9b5e-8d25-43c1-8040-ccfc99afaa05">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4a76d55cff24142bdf23c290b7ebaac_I20221231" decimals="-3" name="us-gaap:DueFromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfNS0zLTEtMS0yOTgzNTI_ddc1757c-6518-4f3d-822a-786a00f3d798">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related parties&#8211;Various</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia7e60a6f6dd54abb86adb37dc98be31f_I20230331" decimals="-3" name="us-gaap:DueFromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfNi0xLTEtMS0yOTgzNTI_bbfc1d40-3702-4459-af57-4befaf2a5889">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i54c810b34f414a6199d96f563da4e9c9_I20221231" decimals="-3" name="us-gaap:DueFromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfNi0zLTEtMS0yOTgzNTI_5a0c64f3-4b2e-4761-b07a-465820932443">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total due from related parties</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:DueFromRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfNy0xLTEtMS0yOTgzNTI_f38edd8b-850a-4417-a6e8-44cc23f83b52">1,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:DueFromRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfNy0zLTEtMS0yOTgzNTI_f16a551c-61ed-4920-bc1c-1d83aa3c948a">1,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;Duley Road, LLC</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0fb0f449758c4a12bd185f822740269b_I20230331" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfOS0xLTEtMS0yOTgzNTI_df0ed7c8-1e18-4176-b0ca-ba5f1709c3a2">1,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic0d461d8a57e4f1caf838c6337b4c516_I20221231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfOS0zLTEtMS0yOTgzNTI_e5bfa536-cf99-4427-95b9-77a95a886d0f">1,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;NantBio, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie130450350ca4c9799e1e199a92ec29d_I20230331" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfMTAtMS0xLTEtMzI4OTA0_bae0e11f-c9c9-439f-a44a-9958de6541de">943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09080f29fd3f433ba1865fa559c0cc3f_I20221231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfMTAtMy0xLTEtMzI4OTA0_ab9b52db-e048-4328-b84a-63e61b8e7e6c">943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;NantWorks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="icd31b5f44a3b46e994f04fa346a23f09_I20230331" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfMTAtMS0xLTEtMjk4MzUy_401c4dbc-b863-49ea-a73a-30fec5830cc5">592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i0b77d70cfd06469091a1b47d242533d9_I20221231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfMTAtMy0xLTEtMjk4MzUy_566eac90-73f4-4641-a95b-dd8fc4d9bc48">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;Immuno-Oncology Clinic, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2f07f511c38b42188903e64e3779976d_I20230331" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfMTMtMS0xLTEtMjk4MzUy_ab522f8f-8d78-4078-940b-9ad20569b39b">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ibfcb45a1b3c349189e4711ea15b357de_I20221231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfMTMtMy0xLTEtMjk4MzUy_2122a911-e261-4eef-8560-b517c71cef0a">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total due to related parties</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfMTUtMS0xLTEtMjk4MzUy_7b0e9dd8-aea3-4203-bfb2-4a5a0258c44f">2,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfMTUtMy0xLTEtMjk4MzUy_cc6f89f7-d462-4a05-b249-3542aad52579">3,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder founded and has a controlling interest in NantWorks, which is a collection of companies in the healthcare and technology space. As described below, we have entered into arrangements with NantWorks, and certain affiliates of NantWorks, to facilitate the development of new immunotherapies for our product pipeline. Affiliates of NantWorks are also affiliates of the company due to the common control by and/or common ownership interest of our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="ia1d3101fb1dd46cf97ac09a96c3a9c10" continuedAt="i61583ab2b2324d71b6d92b0e86f29903"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NantWorks, LLC</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shared Services Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the amended and restated shared services agreement with NantWorks dated as of June&#160;2016, but effective as of August&#160;2015, NantWorks, a related party, provides corporate, general and administrative, certain research and development, and other support services. We are charged for the services at cost plus reasonable allocations of employee benefits, facilities, and other direct or fairly allocated indirect costs that relate to the employees providing the services. For the three months ended March&#160;31,&#160;2023 and 2022, we recorded $<ix:nonFraction unitRef="usd" contextRef="id7f7698c742a4d5185ef556099b8f431_D20230101-20230331" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTI0MA_6a10790a-f597-44d7-827e-99f68be5bf6a">1.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="icdea96cd4382425faf718c8efb444b64_D20220101-20220331" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTI0Nw_dbce4012-9b6d-4efe-889e-2cd5cf8e0a7b">1.3</ix:nonFraction>&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">selling, general and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $<ix:nonFraction unitRef="usd" contextRef="i1d86297744454a6099ce0c427e3111e8_D20230101-20230331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTMxNw_fbbf5e0e-1264-4bbb-9954-74788cba1e05">0.4</ix:nonFraction>&#160;million of expense reimbursements and an immaterial amount, respectively, under this arrangement in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations. These amounts exclude certain general and administrative expenses provided by third-party vendors directly for our benefit, which were reimbursed to NantWorks based on those vendors&#8217; invoiced amounts without markup by NantWorks. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, we owed NantWorks net amounts of $<ix:nonFraction unitRef="usd" contextRef="i4d993de6a09448f3af585a7df1769323_I20230331" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTc2NA_c8695986-168e-45f2-81c2-45e0440ddb21">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8890b549aaaa415492f2214c3dc3ac13_I20221231" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTc3MQ_4c06127f-94ba-46d6-a843-ebfd09f8115a">1.0</ix:nonFraction>&#160;million, respectively, for all agreements between the two&#160;affiliates, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due to related parties,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets. We also recorded $<ix:nonFraction unitRef="usd" contextRef="i38af9a7ebb684fc3a1ab4a463228f422_I20230331" decimals="-5" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTk0NQ_89240956-e87a-4b2c-9d11-f526780cfeee">2.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8466a432fa1943f286f3af0a6ccac9e8_I20221231" decimals="-5" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTk1Mg_121c0769-f123-40fe-b502-e69c05693960">2.0</ix:nonFraction>&#160;million of prepaid expenses for services that have been passed through to the company from NantWorks as of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">prepaid expenses and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated balance sheets.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we entered into a facility license agreement with NantWorks for approximately <ix:nonFraction unitRef="sqft" contextRef="i34815e4cfa9145e9981cf8ef165dd4fb_I20151231" decimals="-2" name="ibrx:NumberOfSquareFootOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMjMwNA_b9fe327b-584d-4ee4-b99e-bb05567f1d3e">9,500</ix:nonFraction> rentable square feet of office space in Culver&#160;City, California, which was converted to a research and development laboratory and a cGMP manufacturing facility. In&#160;2020, we amended this agreement to extend the term of this license agreement through December&#160;31,&#160;2021. Commencing on January&#160;1,&#160;2022, the license fee increased by <ix:nonFraction unitRef="number" contextRef="i030a8e572dcc4ea2a237d2800d4aa466_D20220101-20220101" decimals="2" name="ibrx:AnnualPercentageIncreasesToBaseRent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMjU4Ng_14fc6b74-0198-4d20-ba65-c1d02d12d168">3</ix:nonFraction>% to approximately $<ix:nonFraction unitRef="usd" contextRef="i030a8e572dcc4ea2a237d2800d4aa466_D20220101-20220101" decimals="-1" name="ibrx:BaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMjYwNg_5dca1c53-a833-49bf-9b0a-929a0e642018">56,120</ix:nonFraction> per month.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;6,&#160;2022, we amended our facility license agreement with NantWorks to expand the licensed premises by <ix:nonFraction unitRef="sqft" contextRef="i630c47622bdc4c919e7634771cd094b6_I20220501" decimals="INF" name="ibrx:IncreaseToNumberOfSquareFootOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMjcwOQ_e83ded1a-cddd-4dba-a937-db1f77d36504">36,830</ix:nonFraction>&#160;rentable square feet to an aggregate total of <ix:nonFraction unitRef="sqft" contextRef="i630c47622bdc4c919e7634771cd094b6_I20220501" decimals="INF" name="ibrx:NumberOfSquareFootOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMjc1OA_8cb50236-8129-400e-ad87-5419e4ef9356">46,330</ix:nonFraction> rentable square feet. Effective May&#160;1,&#160;2022, the license fee is approximately $<ix:nonFraction unitRef="usd" contextRef="i00d9386e0ac34e93abf5574655a19034_D20220501-20220501" decimals="-2" name="ibrx:BaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMjgzOQ_035905a1-b844-4c44-9ade-0e98b7b476c9">273,700</ix:nonFraction> per month, which is subject to a <ix:nonFraction unitRef="number" contextRef="i00d9386e0ac34e93abf5574655a19034_D20220501-20220501" decimals="INF" name="ibrx:AnnualPercentageIncreasesToBaseRent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMjg2NQ_e0c3ee85-3994-4835-91fa-3096b52237aa">3</ix:nonFraction>%&#160;increase commencing on January&#160;1 of each year. The space continues to be rented on a month-to-month basis, which can be terminated by either party with at least 30&#160;days&#8217; prior written notice to the other party. We recorded license fee expense for this facility totaling $<ix:nonFraction unitRef="usd" contextRef="i4ab9c997cb0b4744a84d064e48fc1cdf_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMzEzMQ_1c6e2413-6862-4087-83b3-d2f0a61aae5d">0.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8601e8ad3ce74646a29a91172dd7b478_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMzEzOA_7f34126d-e5a3-46f9-a790-a0593c9dc1d5">0.2</ix:nonFraction>&#160;million for the three months ended March&#160;31,&#160;2023 and 2022, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Immuno-Oncology Clinic, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into multiple agreements with Immuno-Oncology Clinic,&#160;Inc.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Clinic)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to conduct clinical trials related to certain of our product candidates. The Clinic is a related party as it is owned by an officer of the company and NantWorks manages the administrative operations of the Clinic. Pursuant to the terms of the Clinic agreement (as amended), we made payments totaling </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i8a83e300ee754efcafa7bc50023c4c0c_D20190101-20191231" decimals="-5" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMzY4Mw_301c7a0a-dc4d-41a4-8e69-152276d83bd0">5.6</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in consideration of future services to be performed by the Clinic. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we completed a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review of alternative structures that could support our more complex clinical trial requirements and made a decision to explore a potential transition of clinical trials at the Clinic to a new structure (including contracting with a new, non-affiliated professional corporation) to be determined and agreed upon by all parties. Based on this decision to explore a potential transition, we determined that it was more likely than not that the previously recorded prepaid asset would not result in the collection of fees for services performed by the Clinic as contemplated in the original agreements. As a result, we wrote down the remaining value of our prepaid asset and recorded approximately $<ix:nonFraction unitRef="usd" contextRef="i94b88764cea64ab3a669de4c146f1277_D20210101-20211231" decimals="-5" name="ibrx:PrepaidExpenseWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNDQ3Mw_ce0d7d00-bda0-4ea2-a958-654d7276889d">4.4</ix:nonFraction>&#160;million in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statement of operations for the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We continue productive negotiations with potential partners around alternative structures, but there can be no assurance that we will be successful.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded $<ix:nonFraction unitRef="usd" contextRef="ie8ed30fcfd154733b358cf49c7a83340_D20230101-20230331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNDYwMw_48ae9ff6-875e-4862-98f6-a0077ecd926d">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7a419c5ac53b440da1bf811cf7835f7a_D20220101-20220331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNDYxMA_70a05f9c-5ce4-4546-b84d-3336976bd763">0.4</ix:nonFraction>&#160;million for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations related to clinical trial and transition services provided by the Clinic. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">owed the&#160;Clinic an immaterial amount and $<ix:nonFraction unitRef="usd" contextRef="i8c6db1e3cd124c76b9c449422588a8be_I20221231" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNDg1OA_f3381ef5-3bdb-424e-a78a-a8b398af8251">0.1</ix:nonFraction>&#160;million, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="i61583ab2b2324d71b6d92b0e86f29903" continuedAt="ib6dd5280b7a6421d89bffbd651e401ab"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NantBio, Inc. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, we entered into a supply agreement with NCSC, a 60%&#160;owned subsidiary of NantBio (with the other&#160;40% owned by Sorrento). Under this agreement, we agreed to supply VivaBioCell&#8217;s proprietary GMP-in-a-Box bioreactors and related consumables, made according to specifications mutually agreed to with both companies. The agreement has an initial term of <ix:nonNumeric contextRef="ida6b89dae59349288b67324cfade250c_I20180831" name="ibrx:SupplyAgreementTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNTI1NQ_44ba4bb7-3399-4c3c-8908-747e6fc7b135">five years</ix:nonNumeric> and renews automatically for successive <ix:nonNumeric contextRef="i52d6bbd3e53f4ae6bd3377d2d890068b_D20180801-20180831" name="ibrx:SupplyAgreementPeriodOfExtendedTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM5NTM_8f8f375b-c3ec-4c4c-8ecc-3c7cbde577f2">one-year</ix:nonNumeric> terms unless terminated by either party in the event of material default upon prior written notice of such default and the failure of the defaulting party to remedy the default within 30&#160;days of the delivery of such notice, or upon 90 days&#8217; prior written notice by NCSC. We recognized <ix:nonFraction unitRef="usd" contextRef="i46483bc0e4034520a181080e17a40498_D20230101-20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNTU5MQ_0bb3cacf-46fe-412e-94b2-f762640ee8bf">no</ix:nonFraction>&#160;revenue for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and <ix:nonFraction unitRef="usd" contextRef="i75ef1f10c34b47e9a73945153142eec4_D20220101-20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNTYyMA_74bd46b4-fcb2-40b7-9637-b5502a9e6761">no</ix:nonFraction> revenue for the three months ended March&#160;31,&#160;2022. We recorded $<ix:nonFraction unitRef="usd" contextRef="i0b7101f16b5744f081cfce6bb570c9b0_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNTY2MQ_dcf76948-ea5d-4951-b5db-8b2ba87d0589">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i65810f20d431446aa5ab803112a83673_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNTY2OA_14ad46e4-824c-4fed-9c1b-10fbb8f12254">0.1</ix:nonFraction>&#160;million of deferred revenue for bioreactors that were delivered but not installed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accrued expenses and other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated balance sheets as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31,&#160;2022, respectively. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31,&#160;2022, we recorded $<ix:nonFraction unitRef="usd" contextRef="i0b7101f16b5744f081cfce6bb570c9b0_I20230331" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNTg5Mw_dddaa25f-1a27-470f-a4d0-2a3c6d668320"><ix:nonFraction unitRef="usd" contextRef="i65810f20d431446aa5ab803112a83673_I20221231" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNTg5Mw_ff5b84ea-aa92-469c-9136-02e6674230a0">0.9</ix:nonFraction></ix:nonFraction>&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due to related parties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated balance sheets related to this agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we entered into a shared service agreement pursuant to which we are charged for services at cost, without mark-up or profit by NantBio, but including reasonable allocations of employee benefits that relate to the employees providing the services. In April&#160;2019, we agreed with NantBio to transfer certain NantBio employees and associated research and development projects to the company. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31,&#160;2022, we recorded a net receivable from NantBio of $<ix:nonFraction unitRef="usd" contextRef="i88ef2e95606a433c97f1f5ade812375d_I20230331" decimals="-5" name="us-gaap:DueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNjUwMg_3d03c8c8-0f3f-4416-af93-1135d15ddf17"><ix:nonFraction unitRef="usd" contextRef="ida89ca2072e7405a83ed27b0d0e50e26_I20221231" decimals="-5" name="us-gaap:DueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNjUwMg_6ab7001c-e3cf-4392-b650-2743c3fc21e8">1.3</ix:nonFraction></ix:nonFraction>&#160;million for amounts we paid on behalf of NantBio during the year ended December&#160;31,&#160;2019.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">605 Doug St, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September&#160;2016, we entered into a lease agreement with 605&#160;Doug&#160;St,&#160;LLC, an entity owned by our Executive Chairman and Global Chief Scientific and Medical Officer, for approximately <ix:nonFraction unitRef="sqft" contextRef="ic9e75b2cda544e9dabfb62fd1fae848d_I20160930" decimals="-1" name="ibrx:NumberOfSquareFootOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNjcyNQ_5ae75359-c129-474f-87bb-a6b6ad937992">24,250</ix:nonFraction> rentable square feet in El&#160;Segundo, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. The lease runs from July&#160;2016 through July&#160;2023. We have the option to extend the lease for <ix:nonFraction unitRef="term" contextRef="i7e2a43e076864fbf9c872615bc186b9a_D20160901-20160930" decimals="INF" name="ibrx:OptionsToExtendNumberOfTerms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNjkzNA_fcc7c2ab-efa3-42e7-aa52-925fe8afed05">one</ix:nonFraction>&#160;additional <ix:nonNumeric contextRef="i7e2a43e076864fbf9c872615bc186b9a_D20160901-20160930" name="ibrx:PeriodOfExtendedLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM5NjA_b0b5476c-ba49-48cf-9705-04a6c6642f0b">three-year</ix:nonNumeric> term through July&#160;2026. The base rent is approximately $<ix:nonFraction unitRef="usd" contextRef="i7e2a43e076864fbf9c872615bc186b9a_D20160901-20160930" decimals="0" name="ibrx:BaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNzAwNA_27bdc60f-f8b4-4dee-ab74-a4db29870856">72,385</ix:nonFraction> per month, with annual increases of <ix:nonFraction unitRef="number" contextRef="i7e2a43e076864fbf9c872615bc186b9a_D20160901-20160930" decimals="2" name="ibrx:AnnualPercentageIncreasesToBaseRent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNzAzMw_3e82d9c5-6894-42b2-9d1a-89e982445402">3</ix:nonFraction>% that began in July&#160;2017. We recorded lease expense for this facility of $<ix:nonFraction unitRef="usd" contextRef="i5f9e4846487241a5b60ad842bb55bb52_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNzEwOA_57b98374-a40c-4324-8d84-c6e86a80886a">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="icc6ecb543ce2436c9134c23137273055_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNzExNQ_30946d9d-21dc-4f33-b101-fe5ae4af6bc9">0.2</ix:nonFraction>&#160;million for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Duley Road, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February&#160;2017, we entered into a lease agreement with Duley&#160;Road, a related party that is indirectly controlled by our Executive Chairman and Global Chief Scientific and Medical Officer, for approximately <ix:nonFraction unitRef="sqft" contextRef="i76b07b7ed33b45539a4fff62c382480d_I20170228" decimals="-1" name="ibrx:NumberOfSquareFootOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNzM5NQ_ae42c7f2-0120-4958-a595-47dfc9b92f3c">11,980</ix:nonFraction> rentable square feet of office and cGMP manufacturing facility space in El&#160;Segundo, California. The lease term is from February&#160;2017 through October&#160;2024. We have the option to extend the initial term for <ix:nonFraction unitRef="term" contextRef="i37723a8685db4f4b9403f2caefc75ecf_D20170201-20170228" decimals="INF" name="ibrx:OptionsToExtendNumberOfTerms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNzU2MQ_3c3e836e-42e7-4129-9cd9-94bd7e728efb">two</ix:nonFraction>&#160;consecutive <ix:nonNumeric contextRef="i37723a8685db4f4b9403f2caefc75ecf_D20170201-20170228" name="ibrx:PeriodOfExtendedLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM5NjI_72e9cccd-78e0-4078-90f5-2c84d3f38c15">five-year</ix:nonNumeric> periods through October&#160;2034. The base rent is approximately $<ix:nonFraction unitRef="usd" contextRef="i37723a8685db4f4b9403f2caefc75ecf_D20170201-20170228" decimals="-2" name="ibrx:BaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNzYzNQ_253a9136-5451-4b8f-9030-f0193d2ff075">40,700</ix:nonFraction> per month, with annual increases of&#160;<ix:nonFraction unitRef="number" contextRef="i37723a8685db4f4b9403f2caefc75ecf_D20170201-20170228" decimals="2" name="ibrx:AnnualPercentageIncreasesToBaseRent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNzY2NA_58d117d8-c02e-4598-93f8-cdbf9a7a10a4">3</ix:nonFraction>%. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective in January&#160;2019, we entered into two&#160;lease agreements with Duley Road for a second&#160;building located in El&#160;Segundo, California. The first&#160;lease is for the first&#160;floor of the building with approximately <ix:nonFraction unitRef="sqft" contextRef="i1669c0c201b646b2b7157ca12651f6fe_I20190101" decimals="-1" name="ibrx:NumberOfSquareFootOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNzg3MA_7eeda44b-efc0-41ad-9d79-ed53acd688af">5,650</ix:nonFraction> rentable square feet. The lease has a <ix:nonNumeric contextRef="i1669c0c201b646b2b7157ca12651f6fe_I20190101" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM5NTU_d3b4ac86-501f-434c-a274-c39f17446c02">seven-year</ix:nonNumeric> term commencing in September&#160;2019. The second&#160;lease is for the second&#160;floor of the building with approximately <ix:nonFraction unitRef="sqft" contextRef="i74cbb623279346b9ade405a13aa44d0e_I20190101" decimals="0" name="ibrx:NumberOfSquareFootOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNzk5Nw_7a017b5b-b25f-4549-a842-d0de90159e91">6,488</ix:nonFraction> rentable square feet. The lease has a <ix:nonNumeric contextRef="i74cbb623279346b9ade405a13aa44d0e_I20190101" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM5NTI_3cac491c-fe62-4959-95af-0bb157ae94f3">seven-year</ix:nonNumeric> term commencing in July&#160;2019. Both floors of the building are used for research and development and office space. We have options to extend the initial terms of both leases for <ix:nonFraction unitRef="term" contextRef="i79fafd177360495ea435675f878915de_D20190101-20190131" decimals="INF" name="ibrx:OptionsToExtendNumberOfTerms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfODE5NQ_09eb6c09-c764-4a72-9c29-ff6e3ba93bba">two</ix:nonFraction>&#160;consecutive <ix:nonNumeric contextRef="i79fafd177360495ea435675f878915de_D20190101-20190131" name="ibrx:PeriodOfExtendedLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM5NTE_36902744-0d5a-4a99-94ed-e1192f6653f6">five-year</ix:nonNumeric> periods through 2036. The base rent for the <ix:nonFraction unitRef="lease" contextRef="i79fafd177360495ea435675f878915de_D20190101-20190131" decimals="INF" name="ibrx:NumberOfLeases" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfODI2Mg_d4794fe2-79bc-433f-8d9f-6e68336ad35b">two</ix:nonFraction>&#160;leases is approximately $<ix:nonFraction unitRef="usd" contextRef="i79fafd177360495ea435675f878915de_D20190101-20190131" decimals="-2" name="ibrx:BaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfODI4OQ_1feddf3b-339c-4f88-b441-faae52ddc4dc">35,800</ix:nonFraction> per month, with annual increases of&#160;<ix:nonFraction unitRef="number" contextRef="i79fafd177360495ea435675f878915de_D20190101-20190131" decimals="2" name="ibrx:AnnualPercentageIncreasesToBaseRent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfODMxOA_ee8fe61f-f75b-4dad-a26e-e531b5360792">3</ix:nonFraction>%.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31,&#160;2022, respectively, we recorded $<ix:nonFraction unitRef="usd" contextRef="iac70357778c94cf1ac486623facee429_I20230331" decimals="-5" name="ibrx:LeaseholdImprovementPayables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfODM1MQ_e13d54d3-51bb-43db-b803-3770db346e07">0.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2a46905c230c4f93bdb4d9448b060e15_I20221231" decimals="-5" name="ibrx:LeaseholdImprovementPayables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTA5OTUxMTY0MjA1Mg_c38258d7-9e3b-49cc-b8e4-6773d37b577b">0.9</ix:nonFraction>&#160;million of leasehold improvement payables, and $<ix:nonFraction unitRef="usd" contextRef="iac70357778c94cf1ac486623facee429_I20230331" decimals="-5" name="ibrx:LeaseRelatedPayables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfODQwNw_344708d8-ea72-40cf-bf50-ebef4aa01531">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2a46905c230c4f93bdb4d9448b060e15_I20221231" decimals="-5" name="ibrx:LeaseRelatedPayables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfODQxNA_93e9ba59-0c2a-4a2e-9432-58a40b7e9c3f">0.6</ix:nonFraction>&#160;million of lease-related payables, to Duley Road, which were included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due to related parties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated balance sheets. We recorded rent expense for these leases totaling $<ix:nonFraction unitRef="usd" contextRef="iaef86b8724ee46feaafd52d401a7f967_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTA5OTUxMTY0MjcwNA_5dbcf5f0-6cc8-471e-b88f-433371b12e90">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie341383be88d425fa34bddb167224148_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTA5OTUxMTY0Mjc0OA_9a957f21-567d-4697-8f8e-cad59561b88b">0.2</ix:nonFraction>&#160;million for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="ib6dd5280b7a6421d89bffbd651e401ab" continuedAt="i042c8e2fa2494342be7cf71b9835c13e"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">605 Nash, LLC </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, but effective on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January&#160;1,&#160;2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we entered into a lease agreement with 605&#160;Nash, a related party, whereby we leased approximately <ix:nonFraction unitRef="sqft" contextRef="i9d95ef7c886d4db6963bcdfd488f1553_I20210101" decimals="0" name="ibrx:NumberOfSquareFootOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfODg4Mw_075fde94-ffb0-4989-9a37-f041fc0ce06a">6,883</ix:nonFraction> rentable square feet (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initial Premises) i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n a two&#160;story mixed use building containing approximately 64,643 rentable square feet on 605-607 Nash Street in El&#160;Segundo, California. This facility is used primarily for pharmaceutical development and manufacturing purposes. The lease term commenced in January&#160;2021 and expires in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;2027</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and includes an option to extend the lease for <ix:nonFraction unitRef="term" contextRef="i9f92b246bdb84f80a78af70f89f212ce_D20210101-20210101" decimals="INF" name="ibrx:OptionsToExtendNumberOfTerms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfOTIxOQ_500c8956-9e72-483b-b6cc-9aa0481cf2c5">one</ix:nonFraction> <ix:nonNumeric contextRef="i9f92b246bdb84f80a78af70f89f212ce_D20210101-20210101" name="ibrx:PeriodOfExtendedLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM5NTg_cfb9a932-d475-4f8b-a903-197d6bfb2dfb">three-year</ix:nonNumeric> term through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;2030</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The base rent is approximately $<ix:nonFraction unitRef="usd" contextRef="i9f92b246bdb84f80a78af70f89f212ce_D20210101-20210101" decimals="-2" name="ibrx:BaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfOTI3OA_ff58af0b-d624-49de-b3da-0baafa153286">20,300</ix:nonFraction> per month with an annual increase of <ix:nonFraction unitRef="number" contextRef="i9f92b246bdb84f80a78af70f89f212ce_D20210101-20210101" decimals="2" name="ibrx:AnnualPercentageIncreasesToBaseRent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfOTMwOA_2595cb55-c40d-4508-a4d9-a17d156bc13d">3</ix:nonFraction>%&#160;on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January&#160;1</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of each year during the initial term and, if applicable, during the option term. In addition, under the agreement, we are required to pay our share of estimated property taxes and operating expenses. We received a rent abatement for the first <ix:nonNumeric contextRef="i9f92b246bdb84f80a78af70f89f212ce_D20210101-20210101" name="ibrx:RentAbatementPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfOTU2MA_839d97a0-edf9-493e-b8d5-3c23b5d885b8">seven months</ix:nonNumeric>. The lease also provides a tenant improvement incentive of $<ix:nonFraction unitRef="usd" contextRef="i9d95ef7c886d4db6963bcdfd488f1553_I20210101" decimals="-5" name="us-gaap:IncentiveFromLessor" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfOTYyMg_9edd883e-7e8b-429b-ab10-9d75f2e79355">0.3</ix:nonFraction>&#160;million for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs and expenses associated with the construction of tenant improvements for the Initial Premises.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May&#160;2021, but effective on April&#160;1,&#160;2021, we entered into an amendment to our Initial Premises lease with 605&#160;Nash. The amendment expanded the leased square feet by approximately <ix:nonFraction unitRef="sqft" contextRef="idb46af1e101d4c7d85dc1fd805f5e351_I20210401" decimals="-1" name="ibrx:NumberOfSquareFootOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfOTg5NQ_4bb78b8a-585d-4726-9c5d-dabfe5154808">57,760</ix:nonFraction> rentable square feet (the Expansion Premises). The lease term of the Expansion Premises commenced in April&#160;2021 and expires in March&#160;2028, whereby the company has the option to extend the initial term for <ix:nonNumeric contextRef="i0ecc9935801543b1b67dcd2ff6f9f08f_D20210401-20210401" name="ibrx:PeriodOfExtendedLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTAwNzQ_4acb5631-a677-4482-a9eb-18b654670849">three years</ix:nonNumeric>. Per the terms of the amendment, the term of the Initial Premises lease was extended for an additional three&#160;months and now expires on March&#160;31,&#160;2028. Base rent for the Expansion Premises is approximately $<ix:nonFraction unitRef="usd" contextRef="i0ecc9935801543b1b67dcd2ff6f9f08f_D20210401-20210401" decimals="INF" name="ibrx:BaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTAyNzA_5f08602d-c314-4f85-b5f1-62fed6834016">170,400</ix:nonFraction>&#160;per month with annual increases of <ix:nonFraction unitRef="number" contextRef="i0ecc9935801543b1b67dcd2ff6f9f08f_D20210401-20210401" decimals="2" name="ibrx:AnnualPercentageIncreasesToBaseRent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTAzMDg_e68bc4e7-ec0e-47dc-b6cf-b0e2a74d39ea">3</ix:nonFraction>% on April&#160;1 of each year. We are responsible for the build out of the facility space and associated costs. We received a rent abatement for the first <ix:nonNumeric contextRef="i0ecc9935801543b1b67dcd2ff6f9f08f_D20210401-20210401" name="ibrx:RentAbatementPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTA0NTU_e06d7126-f87e-49c7-95d5-161d001b7550">seven months</ix:nonNumeric>. The amended lease provides for a tenant improvement allowance of approximately $<ix:nonFraction unitRef="usd" contextRef="idb46af1e101d4c7d85dc1fd805f5e351_I20210401" decimals="-5" name="us-gaap:IncentiveFromLessor" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTA1Mzg_227b731c-931d-44f9-9d87-7fdc06691d77">2.6</ix:nonFraction>&#160;million for costs and expenses related to improvements made by us to the Expansion Premises. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded rent expense for the Initial and Expansion Premises leases totaling $<ix:nonFraction unitRef="usd" contextRef="i6fe81cf5951c403d960758745c545149_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTA3MDc_ca774185-f72a-4dcd-9cf7-42a277ab881d">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ifde6772fd7334f07bf86ccb8635eb843_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTA3MTQ_d4a07808-9b25-41b5-b887-10337d616295">0.5</ix:nonFraction>&#160;million for the three months ended March&#160;31,&#160;2023 and 2022, respectively, i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated statements of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">420 Nash, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;27,&#160;2021, we entered into a lease agreement with 420&#160;Nash,&#160;LLC, a related party, whereby we leased an approximately <ix:nonFraction unitRef="sqft" contextRef="i7910abd612b44ff2a9ab87af3766fd8e_I20211001" decimals="0" name="ibrx:NumberOfSquareFootOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTA5NzI_5745b413-511e-4b7d-99f8-da038a34633e">19,125</ix:nonFraction> rentable square foot property located at 420&#160;Nash Street, El&#160;Segundo, California, to be used primarily for the warehousing and storage of drug manufacturing supplies, products and equipment and ancillary office space. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the lease agreement, the lease term began on October&#160;1,&#160;2021 and expires on September&#160;30,&#160;2026. The base rent is approximately $<ix:nonFraction unitRef="usd" contextRef="ic4b84ae551264070b15b7f777a374c2e_D20211001-20211001" decimals="-1" name="ibrx:BaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTEyOTA_d9c2e740-f799-43fb-bd5e-dfba842b8f26">38,250</ix:nonFraction> per month with an annual increase of <ix:nonFraction unitRef="number" contextRef="ic4b84ae551264070b15b7f777a374c2e_D20211001-20211001" decimals="INF" name="ibrx:AnnualPercentageIncreasesToBaseRent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTEzMjA_bab14ca3-6f17-41eb-a4be-5651d8741d4c">3</ix:nonFraction>% on October&#160;1 of each year beginning in 2022 during the initial term. The company is responsible for the payment of real property taxes, repairs and maintenance, improvements, insurance and operating expenses during the term of the lease. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has options to extend the lease term for <ix:nonFraction unitRef="term" contextRef="ic4b84ae551264070b15b7f777a374c2e_D20211001-20211001" decimals="INF" name="ibrx:OptionsToExtendNumberOfTerms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTE4MjI_f269c592-21ea-4ef2-b90f-66e8d5890edf">two</ix:nonFraction>&#160;additional consecutive periods of <ix:nonNumeric contextRef="ic4b84ae551264070b15b7f777a374c2e_D20211001-20211001" name="ibrx:PeriodOfExtendedLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTE4NTk_e8f4636d-5159-4ff3-b288-60a5a33689ad">five years</ix:nonNumeric> each. At the beginning of each option term, the initial monthly base rent will be adjusted to market rent (as defined in the lease agreement) with an annual increase of <ix:nonFraction unitRef="number" contextRef="ic4b84ae551264070b15b7f777a374c2e_D20211001-20211001" decimals="INF" name="ibrx:AnnualPercentageIncreasesToBaseRent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTIwMzE_3feb3adc-3a5b-4dd9-8bf5-df148fe637fc">3</ix:nonFraction>% during the option term. We have included the first&#160;option to extend the lease term for five&#160;years as part of the initial term of the lease as it is reasonably certain that we will exercise the option, which implies lease expiration in September&#160;2031. We recorded $<ix:nonFraction unitRef="usd" contextRef="if8add4a27fd94c3dbba9aebb333c9ce7_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTIyOTc_b3c24c9f-1d26-46da-b74e-d135d8b3be13">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia4332025e778479f9e44ae4505eb4896_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTA5OTUxMTY0MjEyOQ_5126c50c-fe34-43b8-942c-a8cb2b621c48">0.1</ix:nonFraction>&#160;million of rent expense related to this lease for the three months ended March&#160;31,&#160;2023 and 2022, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">23&#160;Alaska, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;6,&#160;2022, we entered into a lease agreement with 23&#160;Alaska,&#160;LLC, a related party, for a <ix:nonFraction unitRef="sqft" contextRef="i83fb4e02761f48b8ad2de6942bf33580_I20220501" decimals="INF" name="ibrx:NumberOfSquareFootOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTI1NDQ_e09c6593-b2ac-4b55-9259-feec67808a83">47,265</ix:nonFraction> rentable square foot facility located at 2335&#160;Alaska Ave., El&#160;Segundo, California, to be used primarily for pharmaceutical development and manufacturing, research and development, and office space. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the lease term begins on May&#160;1,&#160;2022 and expires on April&#160;30,&#160;2027. The base rent is approximately $<ix:nonFraction unitRef="usd" contextRef="ic48cb211ecb24790be4164033660ec75_D20220501-20220501" decimals="-2" name="ibrx:BaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTI4NTg_688b43e0-714c-44a2-8e49-0f8dbb662773">139,400</ix:nonFraction>&#160;per month with an annual increase of <ix:nonFraction unitRef="number" contextRef="ic48cb211ecb24790be4164033660ec75_D20220501-20220501" decimals="INF" name="ibrx:AnnualPercentageIncreasesToBaseRent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTI4OTg_104e1f4a-b3f6-4a73-aeac-46362280ac86">3</ix:nonFraction>% on May&#160;1 of each year beginning in 2023 during the initial term. We are also required to pay $<ix:nonFraction unitRef="usd" contextRef="ic48cb211ecb24790be4164033660ec75_D20220501-20220501" decimals="-2" name="ibrx:BaseMonthlyRentParking" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTMwNzY_af095b1e-16a2-44c2-8d3a-cc958441d5f8">7,600</ix:nonFraction>&#160;per month for parking during the initial term and extension term, if exercised. The company is responsible for the payment of real property taxes, repairs and maintenance, improvements, insurance, and operating expenses during the term of the lease. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><ix:continuation id="i042c8e2fa2494342be7cf71b9835c13e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has&#160;an option to extend the lease term for <ix:nonFraction unitRef="term" contextRef="ic48cb211ecb24790be4164033660ec75_D20220501-20220501" decimals="INF" name="ibrx:OptionsToExtendNumberOfTerms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM1NzA_8d3ed519-df23-4dd3-8951-b530eb235248">one</ix:nonFraction>&#160;additional consecutive <ix:nonNumeric contextRef="ic48cb211ecb24790be4164033660ec75_D20220501-20220501" name="ibrx:PeriodOfExtendedLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM5NTk_b48e30c5-8afe-43aa-849d-a5b9fa28aa33">five-year</ix:nonNumeric> period. At the beginning of the option term, the initial monthly base rent will be adjusted to market rent (as defined in the lease agreement) with an annual increase of <ix:nonFraction unitRef="number" contextRef="ic48cb211ecb24790be4164033660ec75_D20220501-20220501" decimals="INF" name="ibrx:AnnualPercentageIncreasesToBaseRent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM3NzQ_73825c28-afaf-4fab-a0b2-eae567d98b3f">3</ix:nonFraction>%&#160;during the option term. We recorded $<ix:nonFraction unitRef="usd" contextRef="iea37f6978bb2478bbedbdc929ab45ee3_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM4MTM_4c9f60b0-335a-44df-9a59-5c5f25b1c3a6">0.4</ix:nonFraction>&#160;million of rent expense for this lease for the three months ended March&#160;31,&#160;2023 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statement of operations.</span></ix:continuation></div><div id="i5bbe340c9c8f435088d8011b72b6800d_82"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="ibrx:WarrantLiabilityTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfNDM5ODA0NjUxMzE2OQ_7689c944-1b1a-48ba-908c-49dfe9ece97c" continuedAt="id878e54eab1a49eda7b142cd664c9990" escape="true">Warrant Liabilities</ix:nonNumeric></span></div><ix:continuation id="id878e54eab1a49eda7b142cd664c9990"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">December 2022 Warrants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;12, 2022, in connection with the sale of <ix:nonFraction unitRef="shares" contextRef="icf169f3dab5647ae87fdc00595ada62f_D20221212-20221212" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfNjU_8dcfd561-fcd4-4272-bb5e-f3803b5a404a">9,090,909</ix:nonFraction>&#160;shares of our common stock to an institutional investor, we entered into a warrant agreement that allows such investor to purchase up to <ix:nonFraction unitRef="shares" contextRef="i19f26457ccfe499cb0e3bbed35112923_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMTkx_2fa3b675-943f-4ae4-94d7-cae244a23c06">9,090,909</ix:nonFraction>&#160;shares at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie7ac9b711c4447f78c760f85a936a47b_I20221212" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMjI1_2beaa802-5a5d-49ae-94b7-a59bf59901c0">6.60</ix:nonFraction>&#160;per share. We classified the warrants as a liability at their fair value determined using the Black-Scholes option pricing model. The fair value of the warrants was estimated at </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i02a9bf96e8f246dab50bd1fc37514fa1_D20221212-20221212" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMTA5OTUxMTYzNzc2OA_29c3a612-1afb-4cbe-ae99-a6c965f72021">35.1</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the issuance date. Of the total placement agent fees and other offering costs of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i15ed851a2bba4c719f489412c5b04c93_I20221212" decimals="-5" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMTA5OTUxMTYzODE1Mw_80fe11b3-b9bf-41fe-a491-2361ad7d7fcb">3.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="id16bb7626e4a4ddf8aef9e47dd2b70f0_D20220101-20221231" decimals="-5" name="ibrx:TransactionCostsWarrantLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMzI5ODUzNDg4NzkxOQ_cf2739a5-0a74-464f-9dc9-b82bb059c9ac">1.1</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were allocated to the warrants and recorded to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other income (expense), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the date of the transaction. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, all <ix:nonFraction unitRef="shares" contextRef="i19f26457ccfe499cb0e3bbed35112923_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMzI5ODUzNDg4ODAxNA_2fa3b675-943f-4ae4-94d7-cae244a23c06">9,090,909</ix:nonFraction>&#160;underlying warrants were outstanding, As of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, the estimated fair value of the warrants were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i05ce9f5c06e84394bfde03b091dcbdf4_I20230331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMjE5OTAyMzI2NjM3Nw_14c5e1c1-2e09-4b86-afb5-368d5597f3a4">5.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6e247e3019ba40cfb87b176aa4e219b6_I20221231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMjE5OTAyMzI2NjM5NQ_f6956e81-9ccd-4d21-af9d-8d500e31094f">21.6</ix:nonFraction>&#160;million, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The decrease in fair value of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i91d87f21eddb4e8ba52be9c983035646_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMjE5OTAyMzI2NjQwMQ_0b59d72d-431f-4c4b-b685-46b91f93a4d6">15.8</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other income (expense), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statement of operations for the three months ended March&#160;31,&#160;2023.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">February 2023 Warrants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;15, 2023, in connection with the sale of <ix:nonFraction unitRef="shares" contextRef="i79b4caaa6e7c43ee92ac011ad4231f8f_D20230215-20230215" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMzI5ODUzNDg5MDMyMg_8370fb44-055b-492e-ba45-5b88f2fece37">14,072,615</ix:nonFraction>&#160;shares of our common stock to institutional investors, we entered into a warrant agreement that allows such investors to purchase up to <ix:nonFraction unitRef="shares" contextRef="ie9e851daf28c4255b2112c4cd9cefdc6_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMzI5ODUzNDg5MDMzNQ_790fab1a-1ef6-4319-ac6d-3af6f734447a">14,072,615</ix:nonFraction>&#160;shares at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib8bb04bc74374058a2c1efed036ac8cb_I20230215" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMzI5ODUzNDg5MDM0NQ_5d57e1ce-e316-46a4-b6b3-b326de14d964">4.26</ix:nonFraction>&#160;per share.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classified the warrants as a liability at their fair value determined using the Black-Scholes option pricing model. The fair value of warrants were estimated at </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ib8bb04bc74374058a2c1efed036ac8cb_I20230215" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMzI5ODUzNDg5MjQ5NA_0e340fd3-1da2-440a-a756-75f7779a5f3b">23.7</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the issuance date. Of the total placement agent fees and other offering costs of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ib182c777505d49e8985cc1dfe3ec4883_I20230215" decimals="-5" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMTA5OTUxMTYzODI2MA_2f85a8af-510f-4120-ae8e-76b6ab83b714">3.0</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i9c148f91d4ce423f9b310ff8481860bb_D20230101-20230331" decimals="-5" name="ibrx:TransactionCostsWarrantLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMzI5ODUzNDg5MjUxMw_cb4d96d2-f0a3-425d-850e-2a5f00f84c99">1.0</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were allocated to the warrants </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and recorded to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other income (expense), net, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the date of the transaction</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of March&#160;31,&#160;2023, all <ix:nonFraction unitRef="shares" contextRef="ie9e851daf28c4255b2112c4cd9cefdc6_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMzI5ODUzNDg5Mjc0Ng_790fab1a-1ef6-4319-ac6d-3af6f734447a">14,072,615</ix:nonFraction>&#160;underlying warrants were outstanding, with an estimated fair value of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i2cd4532b1fc24c0ca2ef81c7e69794c6_I20230331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMjE5OTAyMzI2NjQxMA_a6057380-d9ff-4124-ba7c-b33ddb32738f">12.0</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The decrease in fair value of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i9c148f91d4ce423f9b310ff8481860bb_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMjE5OTAyMzI2NjQxOA_9c8fd9da-7255-4d63-9ddf-30257dcfbcac">11.7</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other income (expense), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statement of operations for the three months ended March&#160;31,&#160;2023.</span></div></ix:continuation><div id="i5bbe340c9c8f435088d8011b72b6800d_85"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMzYzMw_78452c3b-ad88-42c4-a80c-3a698202e40b" continuedAt="i612f521eac6f44bb8a39b2cfa7089b05" escape="true">Stockholders&#8217; Deficit </ix:nonNumeric></span></div><ix:continuation id="i612f521eac6f44bb8a39b2cfa7089b05" continuedAt="ib20360702d7f48428e7db2a4db521790"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Repurchases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icf589f03986d4c4f8bd91e59ce16854e_D20220101-20220331" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfNDYw_9e26e316-5cd4-4227-a86c-c0290a598bad"><ix:nonFraction unitRef="shares" contextRef="i9923376a6fc640ad84dd1c26f06cb886_D20230101-20230331" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfNDYw_ce1e68c8-bd21-468d-8fef-24a6fa38867e">No</ix:nonFraction></ix:nonFraction>&#160;shares of our common stock were repurchased during the three months ended March&#160;31,&#160;2023 and 2022 under the company&#8217;s 2015&#160;Share Repurchase Program. As of March&#160;31,&#160;2023, $<ix:nonFraction unitRef="usd" contextRef="i7197e4073a6c44a993ccee88c9827d5b_I20230331" decimals="-5" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfNTky_afd55d20-8ad8-4856-be06-36a492600c9b">18.3</ix:nonFraction>&#160;million remained authorized to use for share repurchases under the program. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration Statement</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During February&#160;2023, we filed a $<ix:nonFraction unitRef="usd" contextRef="iee0c8df083bd402b92291e4cdef8b3e2_I20230228" decimals="-5" name="ibrx:SaleOfStockMaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfNTQ5NzU1ODIzNjAy_b106137c-c419-4296-9532-c9e4d0626a61">750.0</ix:nonFraction>&#160;million shelf registration statement with the SEC on Form&#160;S-3 for the offering and sale of equity and equity-linked securities, including common stock, preferred stock, debt securities, depositary shares, warrants to purchase common stock, preferred stock or debt securities, subscription rights, purchase contracts, and units. In February&#160;2023, we sold shares of our common stock and warrants valued at $<ix:nonFraction unitRef="usd" contextRef="i1b3c1aa995d649f0b87f547501a451bf_D20230215-20230215" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfNTQ5NzU1ODI0MzQ5_0f4a420c-7e4b-4ea8-a1ba-d3887bbffa2d">110.0</ix:nonFraction>&#160;million under the shelf. As of March&#160;31,&#160;2023, we had $<ix:nonFraction unitRef="usd" contextRef="idecf558aeafa48f9b21a5ecd3fb24b40_I20230331" decimals="-5" name="ibrx:CommonStockValueAvailableForFutureStockIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfNTQ5NzU1ODIzOTM4_6186171d-470f-4ae9-9a1b-82a6b72cba72">640.0</ix:nonFraction>&#160;million available for use under the shelf. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Registered Direct Offerings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; below. This available shelf is in addition to the Open Market Sale Agreement described below. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="ib20360702d7f48428e7db2a4db521790"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Open Market Sale Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April&#160;2021, we entered into the Sale Agreement with respect to an&#160;ATM offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock through our sales agent. We pay our sales agent a commission of up to <ix:nonFraction unitRef="number" contextRef="ifd22fd1d02ef4b8b97689228703adc95_D20210430-20210430" decimals="3" name="ibrx:PercentageOfSalesAgentCommission" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMTAyNw_d17c0f24-9f65-4277-ac22-e8fac817bdf4">3.0</ix:nonFraction>%&#160;of the gross sales proceeds of any shares of our common stock sold through them under the Sale Agreement, and also have provided them with customary indemnification and contribution rights. We issued <ix:nonFraction unitRef="shares" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="INF" name="ibrx:IssuanceOfCommonStockUnderAtMarketOfferingShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMTY0OTI2NzQ0NjI0Nw_74882a33-96c6-4842-9cbd-537cdc221cff">no</ix:nonFraction>&#160;shares under the ATM during the three months ended March&#160;31,&#160;2023. As of March&#160;31,&#160;2023, we had $<ix:nonFraction unitRef="usd" contextRef="ib93ec4ea47c24cd1aacb10ddb65cfc49_I20230331" decimals="-5" name="ibrx:CommonStockValueAvailableForFutureStockIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfNTQ5NzU1ODE4NTE2_b2667a3d-fa57-4802-8dd8-6f3b9fa85871">225.4</ix:nonFraction>&#160;million available for future stock issuances under the&#160;ATM.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not obligated to sell any shares and may at any time suspend solicitation and offers under the Sale Agreement. The Sale Agreement may be terminated by us at any time given written notice to the sales agent for any reason or by the sales agent at any time by giving written notice to us for any reason or immediately under certain circumstances, and shall automatically terminate upon the issuance and sale of all of the shares.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registered Direct Offerings</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;12, 2022, we entered into a securities purchase agreement with an institutional investor for the sale of <ix:nonFraction unitRef="shares" contextRef="icf169f3dab5647ae87fdc00595ada62f_D20221212-20221212" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMTA5OTUxMTYzNTgyNw_8dcfd561-fcd4-4272-bb5e-f3803b5a404a">9,090,909</ix:nonFraction> shares of our common stock, as well as warrants that allow such investor to purchase an additional <ix:nonFraction unitRef="shares" contextRef="i19f26457ccfe499cb0e3bbed35112923_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMTA5OTUxMTYzNTgzOQ_2fa3b675-943f-4ae4-94d7-cae244a23c06">9,090,909</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie7ac9b711c4447f78c760f85a936a47b_I20221212" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMTA5OTUxMTYzNTg0Nw_2beaa802-5a5d-49ae-94b7-a59bf59901c0">6.60</ix:nonFraction> per share, for a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i15ed851a2bba4c719f489412c5b04c93_I20221212" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMTA5OTUxMTYzNTg3MQ_61a00fd7-0a82-4053-8bc0-6b0298b54b68">5.50</ix:nonFraction> per share and accompanying warrant, generating net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="icf169f3dab5647ae87fdc00595ada62f_D20221212-20221212" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMTA5OTUxMTYzNTg2Mw_7c98c1fd-5559-455e-839c-2d61e699f94b">47.0</ix:nonFraction>&#160;million, after deducting placement agent fees and other offering costs of $<ix:nonFraction unitRef="usd" contextRef="i15ed851a2bba4c719f489412c5b04c93_I20221212" decimals="-5" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMTA5OTUxMTYzNTg4Ng_80fe11b3-b9bf-41fe-a491-2361ad7d7fcb">3.0</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="i537431f5f3b94adb850787c5a596d104_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMTA5OTUxMTYzNTkwMQ_1832eb38-94b8-4d05-af2a-9456a99ebf87">1.9</ix:nonFraction>&#160;million was allocated to the sale of our common stock and recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional-paid-in capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of stockholders&#8217; deficit, for the year ended December 31, 2022. The warrants became immediately exercisable and expire <ix:nonNumeric contextRef="i62cf93746a5f40e7af8acd878f0d0942_I20221212" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMTA5OTUxMTYzNzM0Mg_8266f012-4a46-4bf9-80fc-a9107b1fe1b1">two years</ix:nonNumeric> after the initial issuance date.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;15, 2023, we entered into a securities purchase agreement with certain institutional investors for the sale of <ix:nonFraction unitRef="shares" contextRef="i79b4caaa6e7c43ee92ac011ad4231f8f_D20230215-20230215" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMjczNg_8370fb44-055b-492e-ba45-5b88f2fece37">14,072,615</ix:nonFraction>&#160;shares of our common stock, as well as warrants that allow such investors to purchase an additional <ix:nonFraction unitRef="shares" contextRef="ie9e851daf28c4255b2112c4cd9cefdc6_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMjgxMw_790fab1a-1ef6-4319-ac6d-3af6f734447a">14,072,615</ix:nonFraction>&#160;shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib8bb04bc74374058a2c1efed036ac8cb_I20230215" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMjg2Mw_5d57e1ce-e316-46a4-b6b3-b326de14d964">4.26</ix:nonFraction>&#160;per share, for an aggregate purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib182c777505d49e8985cc1dfe3ec4883_I20230215" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMjkwMQ_07ad29bd-2096-4961-a2ac-dc42845c51ec">3.55</ix:nonFraction>&#160;per share and accompanying warrant. This transaction generated net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i79b4caaa6e7c43ee92ac011ad4231f8f_D20230215-20230215" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMjk4MQ_337ea193-8f0d-4ccc-ba23-3725e64434cb">47.0</ix:nonFraction>&#160;million, after deducting placement agent fees and other estimated offering costs of $<ix:nonFraction unitRef="usd" contextRef="ib182c777505d49e8985cc1dfe3ec4883_I20230215" decimals="-5" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMTA5OTUxMTYzMjU4MA_2f85a8af-510f-4120-ae8e-76b6ab83b714">3.0</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="i2a8153bf4934499497bc454385181d0f_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMjE5OTAyMzI2NjIwNg_975b0fb7-6a64-403a-b9fb-0f376c36c788">2.0</ix:nonFraction>&#160;million was allocated to the sale of our common stock and recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional-paid-in capital,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated statement of stockholders&#8217; deficit for the three months ended March&#160;31,&#160;2023. The warrants became immediately exercisable and expire <ix:nonNumeric contextRef="iedf609af3963460b9da2409f804cfa4e_I20230217" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMzEzNA_d03ca589-d2ba-4ea6-96d5-4e29a4bbdab8">two years</ix:nonNumeric> after the initial issuance date. The closing of the offering occurred on February&#160;17, 2023. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently intend to use the net proceeds from this offering, together with other available funds, to progress our pre-commercialization efforts and clinical development programs, fund other research and development activities, for capital expenditures, and for other general corporate purposes. We may also use a portion of the net proceeds to license intellectual property or to make acquisitions or investments. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_82">Note&#160;11</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Liabilities, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further information.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_91"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfNDkzOQ_51f1a242-c4a3-4f25-a1ad-37e5b9791e05" continuedAt="ia971d3c64e9748569a662d68167a28fb" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="ia971d3c64e9748569a662d68167a28fb" continuedAt="id1069c384fa54cf9a95063f5e2fe7ff7"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, approximately <ix:nonFraction unitRef="shares" contextRef="i99b7bacac6fb4b6fa1a147bb0af0b1e3_I20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfMTA5OTUxMTYzNTY2OA_3feace27-f2db-443f-a5bf-087c223cb43b">18.6</ix:nonFraction>&#160;million&#160;shares were available for future grants under the 2015&#160;Plan.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfNDk0MA_3f6cb323-9633-4c35-85b7-a7f2b8695d6e" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock-based compensation included on the condensed consolidated statements of operations (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:71.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.302%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Three Months Ended<br/>March&#160;31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Unaudited) </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock-based compensation expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic2e19134c3994d4892eb6d354d8783bc_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfNS0xLTEtMS0yOTgzNTI_c0bcb102-f1ca-45c5-8d37-7b0cb7660cfd">3,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia07604abb58a44c68163e1cc335f1f6f_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfNS0zLTEtMS0yOTgzNTI_95be193e-9738-414d-bb2a-e6760f4951ed">2,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2e8096e87554843be3da2502f2fb4f8_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfNi0xLTEtMS0yOTgzNTI_16f2da67-acf4-4199-a606-e1bb3bfe0e3c">7,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9943c4a51f6441e85bc6598893e1fa6_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfNi0zLTEtMS0yOTgzNTI_6f6fc8eb-0b79-44cb-93ad-74a9be01ad5c">8,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfNy0xLTEtMS0yOTgzNTI_238485b8-1215-4bac-9e54-9a7d21ee55ba">10,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfNy0zLTEtMS0yOTgzNTI_c06bcfbf-59a1-419c-9fe2-0d486fdcf3f8">10,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock-based compensation expense in operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie5cf1954f1b04fd3a05943c0f49aea0e_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfOS0xLTEtMS0yOTgzNTI_fc8cd1cd-4d21-4c4b-bc77-89da7793d997">3,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="idabb2ea247194a5db776f4872b4ddd96_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfOS0zLTEtMS0yOTgzNTI_e55d425c-5b83-4e8e-8d46-cb85e7f19a2d">2,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d89f301dba24a82a81a3734a866f4df_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfMTAtMS0xLTEtMjk4MzUy_5bae0c76-5bde-4a54-a6d3-4ac5845f7140">7,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ff7cffbd9b44155b9d53cd05a219a87_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfMTAtMy0xLTEtMjk4MzUy_2fac9183-8d72-49cd-af7f-16e2e5a12192">7,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfMTEtMS0xLTEtMjk4MzUy_b4d964e5-bf49-4dfb-b156-90e78c59e51d">10,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfMTEtMy0xLTEtMjk4MzUy_1064c350-0d50-4b0f-8431-12ab736e058d">10,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfNDkzNA_1f6437df-65fe-433b-a0cc-d1a3756a6f90" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity and related information for the three months ended March&#160;31,&#160;2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Options</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted-</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exercise</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Aggregate</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Intrinsic</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Value</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted-</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Remaining</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Contractual</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Life</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(in years)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at December&#160;31,&#160;2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfMi0xLTEtMS0yOTgzNTI_f3aaa5d8-7e0f-4102-a32f-9ebad32b45df">9,262,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfMi0zLTEtMS0yOTgzNTI_672ccb89-e8f8-4bf5-bee9-c74df3eb65bb">9.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfMi01LTEtMS0yOTgzNTI_4849b24a-2422-4a7b-955f-d1f97adf30c3">4,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i6da548dc0629406a8bc5d9e75d8d06d5_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfMi03LTEtMS0yOTgzNTI_4a08cc3f-4484-4fd5-90b8-64081eaeb8c1">7.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfMy0xLTEtMS0yOTgzNTI_87612769-bc7a-449a-a04a-97b3bc494ae6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfMy0zLTEtMS0yOTgzNTI_ca16cbf8-e0ae-4315-a8a7-cdd3a2996ed5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNC0xLTEtMS0yOTgzNTI_ceeee07e-3956-4719-9802-04df8727f3a1">81,037</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNC0zLTEtMS0yOTgzNTI_622ab5e7-5226-408d-aed4-5e3512d0f4b7">1.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited/expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNS0xLTEtMS0yOTgzNTI_17f10905-ca2e-455f-b02d-b9cf834c3225">22,224</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNS0zLTEtMS0yOTgzNTI_d564c0f5-a1cd-4ad5-9506-a6abba8f2d31">5.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at March&#160;31,&#160;2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNi0xLTEtMS0yOTgzNTI_d61e5d5a-fa92-4038-90d8-c712795d7e1d">9,159,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNi0zLTEtMS0yOTgzNTI_7205e4b3-1c1a-4b77-8dbd-a3f11cbb85e7">9.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNi01LTEtMS0yOTgzNTI_f2f4b1e7-cf46-429d-ae19-f1b7cdcd916c">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNi03LTEtMS0yOTgzNTI_9f504195-5369-489a-9d03-36382a667dbf">7.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested and exercisable at March&#160;31,&#160;2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNy0xLTEtMS0yOTgzNTI_ee35b653-1138-48d8-90c7-6acb16f6c539">5,053,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNy0zLTEtMS0yOTgzNTI_67f31eaa-e436-4929-9738-bb08a277b4ca">12.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNy01LTEtMS0yOTgzNTI_67571cfa-80a5-452d-932e-95c64bd87bc8">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNy03LTEtMS0yOTgzNTI_65758f70-fe08-4a74-a559-d6807d49a3c0">5.3</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, the unrecognized compensation cost related to outstanding stock options was $<ix:nonFraction unitRef="usd" contextRef="ie8db8d0eea7146a6bf8d54b8044ef8d7_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfMjEzOA_1497ebe6-89c4-4a42-b812-efb62b300a48">16.7</ix:nonFraction>&#160;million, which is expected to be recognized over a remaining weighted-average period of <ix:nonNumeric contextRef="i266ebf8c5da54dd097877b98c122296e_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfMjIyMQ_d3cec649-e18e-4585-bc9a-e47f69f446e0">1.6</ix:nonNumeric> years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised during the three months ended March&#160;31,&#160;2023 was $<ix:nonFraction unitRef="usd" contextRef="i266ebf8c5da54dd097877b98c122296e_D20230101-20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfMjI5OQ_bdd9e14a-94f5-4ed5-ae9c-16e8a8e22f85">0.2</ix:nonFraction>&#160;million. Cash proceeds received from stock option exercises during the three months ended March&#160;31,&#160;2023 and 2022 totaled $<ix:nonFraction unitRef="usd" contextRef="i266ebf8c5da54dd097877b98c122296e_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfMTA5OTUxMTYzNTYwMg_68ced9bf-3df0-4b61-b799-eaca3ed20d1d">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i836c83fbf1c1488cb85f5c607bece830_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfMTA5OTUxMTYzNTU3NA_7bb18520-f4fa-4bc3-be23-0a634c2c09b1">0.1</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2022, a total of <ix:nonFraction unitRef="shares" contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfMjQzMg_0fc10ef6-d90d-41c1-a4ad-70b9cb1d6f28">3,445,499</ix:nonFraction>&#160;vested and exercisable shares were outstanding.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="id1069c384fa54cf9a95063f5e2fe7ff7" continuedAt="i7f093811de8e4a19bebfe446cd242e28"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfNDk0Mw_fab0ea4f-0f89-489e-baac-27f43f298291" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the three months ended March&#160;31,&#160;2023:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Units</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted-</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Grant Date</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested balance at December&#160;31,&#160;2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i0d38e9904e994f3c8879c104feedb7da_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmMwOTg2MDI3MzA5OTRmNTc5NmJmZjRmNTdiMmE5NDI1L3RhYmxlcmFuZ2U6YzA5ODYwMjczMDk5NGY1Nzk2YmZmNGY1N2IyYTk0MjVfMi0xLTEtMS0yOTgzNTI_541aaa23-c871-4401-8f2c-09feff058926">6,551,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0d38e9904e994f3c8879c104feedb7da_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmMwOTg2MDI3MzA5OTRmNTc5NmJmZjRmNTdiMmE5NDI1L3RhYmxlcmFuZ2U6YzA5ODYwMjczMDk5NGY1Nzk2YmZmNGY1N2IyYTk0MjVfMi0zLTEtMS0yOTgzNTI_afe328a9-94b2-4e0d-877c-eaeffa2f124d">18.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ib2e8096e87554843be3da2502f2fb4f8_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmMwOTg2MDI3MzA5OTRmNTc5NmJmZjRmNTdiMmE5NDI1L3RhYmxlcmFuZ2U6YzA5ODYwMjczMDk5NGY1Nzk2YmZmNGY1N2IyYTk0MjVfMy0xLTEtMS0yOTgzNTI_cf9e9032-8599-4458-9073-606678bde5c5">202,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2e8096e87554843be3da2502f2fb4f8_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmMwOTg2MDI3MzA5OTRmNTc5NmJmZjRmNTdiMmE5NDI1L3RhYmxlcmFuZ2U6YzA5ODYwMjczMDk5NGY1Nzk2YmZmNGY1N2IyYTk0MjVfMy0zLTEtMS0yOTgzNTI_391e7fac-9e0d-49da-b2f4-4e7f07ba2b55">1.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="ib2e8096e87554843be3da2502f2fb4f8_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmMwOTg2MDI3MzA5OTRmNTc5NmJmZjRmNTdiMmE5NDI1L3RhYmxlcmFuZ2U6YzA5ODYwMjczMDk5NGY1Nzk2YmZmNGY1N2IyYTk0MjVfNC0xLTEtMS0yOTgzNTI_f5b760a7-0e36-4acf-8160-8e0b7684a978">313,975</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2e8096e87554843be3da2502f2fb4f8_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmMwOTg2MDI3MzA5OTRmNTc5NmJmZjRmNTdiMmE5NDI1L3RhYmxlcmFuZ2U6YzA5ODYwMjczMDk5NGY1Nzk2YmZmNGY1N2IyYTk0MjVfNC0zLTEtMS0yOTgzNTI_c2380b2f-b1d0-4eca-acbf-f791279a3771">15.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited/canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib2e8096e87554843be3da2502f2fb4f8_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmMwOTg2MDI3MzA5OTRmNTc5NmJmZjRmNTdiMmE5NDI1L3RhYmxlcmFuZ2U6YzA5ODYwMjczMDk5NGY1Nzk2YmZmNGY1N2IyYTk0MjVfNS0xLTEtMS0yOTgzNTI_e14da3d2-9f8d-4c8e-97c4-fa8a9d59988b">252,106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2e8096e87554843be3da2502f2fb4f8_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmMwOTg2MDI3MzA5OTRmNTc5NmJmZjRmNTdiMmE5NDI1L3RhYmxlcmFuZ2U6YzA5ODYwMjczMDk5NGY1Nzk2YmZmNGY1N2IyYTk0MjVfNS0zLTEtMS0yOTgzNTI_4e7d9d8e-bcfd-4ef6-aee3-a456ec68daca">4.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested balance at March&#160;31,&#160;2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48b4780d2b7c496aaab05e427e63b362_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmMwOTg2MDI3MzA5OTRmNTc5NmJmZjRmNTdiMmE5NDI1L3RhYmxlcmFuZ2U6YzA5ODYwMjczMDk5NGY1Nzk2YmZmNGY1N2IyYTk0MjVfNi0xLTEtMS0yOTgzNTI_a2c69360-a348-42ef-bd6c-863ef96751d6">6,188,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i48b4780d2b7c496aaab05e427e63b362_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmMwOTg2MDI3MzA5OTRmNTc5NmJmZjRmNTdiMmE5NDI1L3RhYmxlcmFuZ2U6YzA5ODYwMjczMDk5NGY1Nzk2YmZmNGY1N2IyYTk0MjVfNi0zLTEtMS0yOTgzNTI_8db01bc5-2ded-4880-a7c1-718ab2137dd4">18.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, there was $<ix:nonFraction unitRef="usd" contextRef="i48b4780d2b7c496aaab05e427e63b362_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfMzI3Mw_08fb7f47-e1d1-4221-b8f0-6a904aea9723">61.9</ix:nonFraction>&#160;million of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ib2e8096e87554843be3da2502f2fb4f8_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfMzQwOQ_ff0a3f72-4683-4cc4-b701-958b67af9051">2.6</ix:nonNumeric> years. The total intrinsic value of RSUs vested during the three months ended March&#160;31,&#160;2023 was $<ix:nonFraction unitRef="usd" contextRef="ib2e8096e87554843be3da2502f2fb4f8_D20230101-20230331" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfMzQ3NQ_aa788fc6-89b1-4bf1-be35-9e7982a31445">0.9</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs awarded to employees and consultants of affiliated companies are accounted for as stock-based compensation in accordance with ASU 2018-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation (Topic 718)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as the compensation was in exchange for continued support or services expected to be provided to the company over the vesting periods under the NantWorks shared services agreement discussed in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_76">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have evaluated the associated benefit of these awards to the affiliated companies under common control and determined that the benefit is limited to the retention of their employees. We estimated such benefit at the grant date fair value of $<ix:nonFraction unitRef="usd" contextRef="if52b579ea3554fc9bfe4ad51961a0c27_D20210304-20210304" decimals="-5" name="ibrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfNDE0MA_8d400f9d-ccdf-4a90-81db-8c0a93901919">4.0</ix:nonFraction>&#160;million on March&#160;4,&#160;2021 and recorded $<ix:nonFraction unitRef="usd" contextRef="i908b2f13981e477ca4efac4b387ad72c_D20230101-20230331" decimals="-5" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfNDE1Ng_9fe20ee1-0494-4447-ab39-4b12c07fee1c">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3554fcc3e6c04d3d8d76fbad65e1995d_D20220101-20220331" decimals="-5" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfNDE2Mw_2f527411-98e6-49d4-94ec-0d9db99b0cb1">0.1</ix:nonFraction>&#160;million of deemed dividends for the three months ended March&#160;31,&#160;2023 and 2022 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets, with a corresponding credit to stock-based compensation expense.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related-Party Warrants</span></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7f093811de8e4a19bebfe446cd242e28">In connection with the Merger, warrants issued to NantWorks, a related party, in connection with NantCell&#8217;s acquisition of Altor were assumed by the company. After applying the Exchange Ratio at the Effective Time of the Merger, a total of <ix:nonFraction unitRef="shares" contextRef="ia9664eda2c1e467c8dd040b2e7f90f76_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfNDYxMg_7c63ce09-2d66-4b8a-b187-9e5d696fd0cf">1,638,000</ix:nonFraction>&#160;warrants with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia9664eda2c1e467c8dd040b2e7f90f76_I20230331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfNDY1MA_67c4c662-1ee8-4745-ad56-5f8d06dbfc30">3.24</ix:nonFraction>&#160;per share were outstanding as of March&#160;31,&#160;2023. The fair value of $<ix:nonFraction unitRef="usd" contextRef="ia9664eda2c1e467c8dd040b2e7f90f76_I20230331" decimals="-5" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfNDcwOA_2d19c255-0297-47ee-bc51-b9a92d3400db">18.0</ix:nonFraction>&#160;million assigned to the warrants will be recognized in equity upon achievement of a performance-based vesting condition pertaining to building manufacturing capacity to support supply requirements for one of our product candidates.</ix:continuation> </span></div><div id="i5bbe340c9c8f435088d8011b72b6800d_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85Ny9mcmFnOmI2MTM0MWQxMDAxNDRiMDQ5ZWYyOTI3MmUzNTU4MmYzL3RleHRyZWdpb246YjYxMzQxZDEwMDE0NGIwNDllZjI5MjcyZTM1NTgyZjNfMjQ3NQ_95da2ca1-80e7-4cdb-a6b7-7322acd13c4a" continuedAt="i912e8c995a154df0a5381ef4f5379b5a" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i912e8c995a154df0a5381ef4f5379b5a" continuedAt="ice5c0ce618c3485a9751cd4cb4f915d0"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S.&#160;federal income tax, as well as income tax in Italy, South Korea, California and other states. From inception through March&#160;31,&#160;2023, we have not been required to pay U.S.&#160;federal and state income taxes because of current and accumulated net operating losses (NOLs). The company computes its quarterly income tax provision by using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. <ix:nonFraction unitRef="usd" contextRef="i7b965bbf47a941848ab9a9b930e7f952_D20230101-20230331" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85Ny9mcmFnOmI2MTM0MWQxMDAxNDRiMDQ5ZWYyOTI3MmUzNTU4MmYzL3RleHRyZWdpb246YjYxMzQxZDEwMDE0NGIwNDllZjI5MjcyZTM1NTgyZjNfNDY2_4065c0f0-3b59-4bfa-a5b0-d9203fb29a86"><ix:nonFraction unitRef="usd" contextRef="i7e5c5c4ae84f441299889d36b9da25d8_D20230101-20230331" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85Ny9mcmFnOmI2MTM0MWQxMDAxNDRiMDQ5ZWYyOTI3MmUzNTU4MmYzL3RleHRyZWdpb246YjYxMzQxZDEwMDE0NGIwNDllZjI5MjcyZTM1NTgyZjNfNDY2_c3535f2d-5d7d-42ba-ba21-1a3c0bbc61d0"><ix:nonFraction unitRef="usd" contextRef="i2c5705f6e6f94780a8e01cc108de9b88_D20230101-20230331" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85Ny9mcmFnOmI2MTM0MWQxMDAxNDRiMDQ5ZWYyOTI3MmUzNTU4MmYzL3RleHRyZWdpb246YjYxMzQxZDEwMDE0NGIwNDllZjI5MjcyZTM1NTgyZjNfNDY2_d2af63c6-19d2-43e8-b86f-7f8886f49270">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> tax benefit was provided for losses incurred in the U.S., Italy, and South Korea because those losses are offset by a full valuation allowance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our federal returns for tax years 2019 through 2021 remain open to examination, and our state returns remain subject to examination for tax years 2018 through 2021. The Italian and South Korea returns for tax years 2017 through 2021 remain open to examination. Carryforward attributes that were generated in years where the statute of limitations is closed may still be adjusted upon examination by the Internal Revenue Service or other respective tax authorities. No income tax returns are currently under examination by taxing authorities. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><ix:continuation id="ice5c0ce618c3485a9751cd4cb4f915d0"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation Reduction Act of 2022</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Inflation Reduction Act 2022, which incorporates a Corporate Alternative Minimum Tax (CAMT), was signed on August&#160;16,&#160;2022. The changes are effective for the tax years beginning after December&#160;31,&#160;2022. The new tax will require companies to compute two&#160;separate calculations for federal income tax purposes and pay the greater of the new minimum tax or their regular tax liability. The company will be monitoring the impact of the act to determine if it will have an impact on the company for years beginning after December&#160;31,&#160;2022. We currently do not expect this act will have a material effect on our consolidated financial statements. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coronavirus Aid, Relief and Economic Security Act</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;27,&#160;2020, the U.S. enacted the Coronavirus Aid, Relief and Economic Security Act (the CARES Act). The Cares Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the U.S.&#160;economy and fund a nationwide effort to curtail the effect of COVID-19. The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic. Under the CARES Act, some of the more significant provisions are NOL carrybacks for five&#160;years to offset previous years&#8217; income, or can be carried forward indefinitely to offset 100%&#160;of taxable income for the tax year beginning before 2021 and 80%&#160;of taxable income for tax years&#160;2021 and thereafter, increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. During the three&#160;months&#160;ended March&#160;31,&#160;2023 and 2022, we did not record any income tax (expense) benefit resulting from the CARES Act, mainly due to our history of net operating losses generated and the maintenance of a full valuation allowance against our net deferred tax assets. There was no material impact from the provisions of the Cares Act for the three&#160;months&#160;ended March&#160;31,&#160;2023 and 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">State of California Assembly Bill No.&#160;85</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;29,&#160;2020, the state of California enacted Assembly Bill No.&#160;85 (AB&#160;85) suspending California NOL utilization and imposing a cap on the amount of business incentive tax credits companies can utilize, effective for tax years 2020, 2021 and 2022. There was no material impact from the provisions of AB&#160;85 for the three&#160;months&#160;ended March&#160;31,&#160;2022. On February&#160;9,&#160;2022, Senate Bill No.&#160;113 was enacted that removed the limitations on the use of NOLs and the cap on the business incentive tax credits that were suspended in accordance with AB 85 effective for tax year 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_103"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. &#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</span></div><div id="i5bbe340c9c8f435088d8011b72b6800d_106"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis should be read together with our condensed consolidated financial statements and the notes to those statements included elsewhere in this Quarterly Report on Form&#160;10-Q. This Quarterly Report on Form&#160;10-Q contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (Securities Act) and Section&#160;21E of the Exchange Act that are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. The forward-looking statements are contained in this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. Forward-looking statements include, but are not limited to:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop next-generation therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain funding for our operations, including funding necessary to complete further development and any commercialization of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the potential benefits of our strategy and technology;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the operation and effectiveness of our product candidates and related benefits;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to utilize multiple modes to induce cell death;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our beliefs regarding the benefits and perceived limitations of competing approaches, and the future of competing technologies and our industry;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">details regarding our strategic vision and planned product candidate pipeline, including that we eventually plan to advance vaccines and therapies for virally-induced infectious diseases;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our beliefs regarding the success, cost and timing of our product candidate development activities and current and future clinical trials and studies, including study design and the enrollment of patients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of the development and commercialization of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding our ability to utilize the Phase&#160;1/2 aNK and haNK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trials data to support the development of our product candidates, including our haNK, taNK, t&#8209;haNK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MSC, and M-ceNK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the development, application, commercialization, marketing, prospects and use generally of our product candidates, including Anktiva (N-803), </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">self-amplifying RNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (saRNA), hAd5 and yeast constructs, recombinant sub-unit proteins, toll-like receptor-activating adjuvants, and aldoxorubicin;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing or likelihood of regulatory filings or other actions and related regulatory authority responses, including any planned investigational new drug (IND), BLA or New Drug Application (NDA) filings or pursuit of accelerated regulatory approval pathways or orphan drug status and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to implement and support our SARS-CoV-2 (COVID&#8209;19) vaccine and therapeutic programs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to implement an integrated discovery ecosystem and the operation of that planned ecosystem, including being able to regularly add neoepitopes and subsequently formulate new product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability and willingness of strategic collaborators to share our vision and effectively work with us to achieve our goals;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability and willingness of various third parties to engage in research and development activities involving our product candidates, and our ability to leverage those activities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract additional third-party collaborators;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the ease of administration associated with our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding patient compatibility associated with our product candidates;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our beliefs regarding the potential markets for our product candidates and our ability to serve those markets;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the timing of enrollment and submission of our clinical trials, and protocols related to such trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to produce an antibody cytokine fusion protein, a DNA, RNA, or recombinant protein vaccine, a toll-like receptor-activating adjuvant, an NK-cell or T-cell therapy, or a damage-associated molecular patterns (DAMP) inducer therapy;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our beliefs regarding the potential manufacturing and distribution benefits associated with our product candidates, and our ability to scale up the production of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans regarding our manufacturing facilities and our belief that our manufacturing is capable of being conducted in&#8209;house;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief in the potential of our antibody cytokine fusion proteins, DNA, RNA or recombinant protein vaccines, toll-like receptor-activating adjuvants, NK-cell therapies, or DAMP inducer platforms, and the fact that our business is based upon the success individually and collectively of these platforms;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief regarding the magnitude or duration for additional clinical testing of our antibody cytokine fusion proteins, DNA, RNA or recombinant protein vaccines, toll-like receptor-activating adjuvants, NK-cell therapies, or DAMP inducers along with other product candidate families;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">even if we successfully develop and commercialize specific product candidates like our N-803 or PD-L1 t&#8209;haNK, our ability to develop and commercialize our other product candidates either alone or in combination with other therapeutic agents;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to obtain and maintain regulatory approval of any of our product candidates, and any related restrictions, limitations and/or warnings in the label of any approved product candidate;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to commercialize any approved products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance of any approved products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain key personnel;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the accuracy of our estimates regarding our future revenue, as well as our future operating expenses, capital requirements and needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, maintain, protect and enforce intellectual property protection for our product candidates and technology and not infringe upon, misappropriate or otherwise violate the intellectual property of others;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and conditions of licenses granted to us and our ability to license additional intellectual property relating to our product candidates and technology;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact on us, if any, if the contingent value rights (CVRs) held by former Altor BioScience Corporation (Altor) stockholders become due and payable in accordance with their terms; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States (U.S.) and foreign countries; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any impact of the coronavirus pandemic, or responses to the pandemic, on our business, clinical trials or personnel.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements include statements that are not historical facts and can be identified by terms such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or similar expressions and the negatives of those terms. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form&#160;10-Q, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. We discuss these risks in greater detail in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_178">Part&#160;II, Item&#160;1A. &#8220;Risk Factors&#8221;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> of this Quarterly Report on Form&#160;10-Q. Given these uncertainties, you should not place undue reliance on these forward-looking statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame. Also, forward-looking statements represent our management&#8217;s beliefs and assumptions only as of the date of this Quarterly Report on Form&#160;10-Q.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. You should read this Quarterly Report on Form&#160;10-Q completely and with the understanding that our actual future results may be materially different from what we expect.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anktiva, ceNK, Conkwest, GlobeImmune, GlobeImmune (logo), haNK, haNK (Chinese characters), ImmunityBio, NantKwest, NK-92, Outsmart your disease, taNK, Tarmogen, VesAnktiva, and VivaBioCell are trademarks or registered trademarks of ImmunityBio,&#160;Inc., its subsidiaries, or its affiliates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our product candidates, including N-803, are investigational. Safety and efficacy have not been established by any agency, including the U.S.&#160;Food and Drug Administration (FDA).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form&#160;10-Q contains references to our trademarks and trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Quarterly Report on Form&#160;10-Q, including logos, artwork and other visual displays, may appear without the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us, by any other companies.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In this Quarterly Report on Form&#160;10-Q, &#8220;ImmunityBio,&#8221; &#8220;the company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to ImmunityBio,&#160;Inc. and its subsidiaries.</span></div><div id="i5bbe340c9c8f435088d8011b72b6800d_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ImmunityBio, Inc. is a clinical-stage biotechnology company developing next-generation therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. We strive to be a vertically-integrated immunotherapy company designing and manufacturing our products so they are more effective, accessible, more conveniently stored, and more easily administered to patients. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our broad immunotherapy and cell therapy platforms are designed to attack cancer and infectious pathogens by activating both the innate immune system&#8212;natural killer (NK) cells, dendritic cells, and macrophages&#8212;and the adaptive immune system&#8212;B&#160;cells and T&#160;cells&#8212;in an orchestrated manner. The goal of this potentially best-in-class approach is to generate immunogenic cell death thereby eliminating rogue cells from the body whether they are cancerous or virally infected. Our&#160;ultimate goal is to employ this approach to establish an &#8220;immunological memory&#8221; that confers long-term benefit for the patient.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is based on the foundation of multiple platforms that collectively act on the entire immune response with the goal of targeted, durable, coordinated, and safe immunity against disease. These platforms and their associated product candidates are designed to overcome the limitations of the current standards of care in oncology and infectious diseases, such as checkpoint inhibitors and antiretroviral therapies. Our portfolio includes:</span></div><div style="margin-top:12pt;text-align:center"><img src="ibrx-20230331_g1.jpg" alt="Pipeline slide for 10Q April 2023.jpg" style="height:387px;margin-bottom:5pt;vertical-align:text-bottom;width:688px"/></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our platforms include 13&#160;novel therapeutic agents either in clinical trials or for which we are developing protocols. We are currently engaged in 15&#160;active clinical trials involving 10&#160;of these agents. Seven of these trials are being sponsored by ImmunityBio while the remaining eight&#160;are investigator-led studies. Twelve&#160;of these trials are in Phase&#160;2 or 3&#160;development across eleven&#160;indications in liquid and solid tumors. These include bladder, pancreatic, and lung cancers, which are among the most frequent and lethal cancer types, and where there are high failure rates for existing standards of care or no available effective treatment. In infectious diseases, our pipeline currently targets such pathogens as the novel strain of the coronavirus (SARS-CoV-2) and human immunodeficiency virus (HIV). We believe SARS-CoV-2 currently lacks a vaccine that provides long-term protection against the virus, particularly its variants, while HIV affects tens&#160;of millions of people globally and currently has no known cure.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our innovative approach to orchestrate and combine therapies for optimal immune system response will become a therapeutic foundation across multiple indications. Additionally, we believe that data from multiple clinical trials indicates N-803 has broad potential to enhance the activity of therapeutic monoclonal antibodies (mAbs), including checkpoint inhibitors (e.g.,&#160;Keytruda), across a wide range of tumor types. N-803 is currently being studied in 14&#160;clinical trials (both ImmunityBio and investigator-led) across 11&#160;indications. Although such designations may not lead to a faster development process or regulatory review and may not increase the likelihood that a product candidate will receive approval, Anktiva, ImmunityBio&#8217;s novel antibody cytokine fusion protein, has received </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designations from the FDA in combination with bacillus Calmette-</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gu&#233;rin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (BCG) for the treatment of patients with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BCG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without Ta or T1&#160;disease. In May&#160;2022, we announced the submission of a BLA to the FDA for our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In July&#160;2022, we announced that the FDA had accepted our BLA for review and set a target Prescription Drug User Fee Act (PDUFA) action date of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May&#160;23,&#160;2023. On May&#160;9,&#160;2023, the FDA delivered a complete response letter to us regarding the BLA, as described in greater detail in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_163">&#8212;</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_163">Subsequent Events</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below. It is unclear when the FDA will approve our BLA, if at all.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_115"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established GMP manufacturing capacity at scale with cutting-edge cell manufacturing expertise and ready-to-scale facilities, as well as extensive and seasoned R&amp;D, clinical trial, and regulatory operations, and development teams.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to present a substantial public health and economic challenge around the world. Through the date of this Quarterly Report on Form&#160;10-Q, we have not seen a material adverse impact to our business from the pandemic. However, given the unprecedented and continuously evolving nature of the pandemic, we cannot at this time predict the specific extent, duration, or full impact that this pandemic may have on our financial condition and results of operations, including ongoing and planned clinical trials. More specifically, the pandemic may result in prolonged impacts that we cannot predict at this time and we expect that such uncertainties will continue to exist for the foreseeable future. The impact of the pandemic on our financial performance will depend on future developments, including the duration and spread of the outbreak, impact of potential variants and the related governmental advisories and restrictions. These developments and the impact of the ongoing pandemic on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, our results may be adversely affected. In addition, we anticipate that enrollment of patients in certain studies will likely take longer than previously forecasted and that our clinical trials may require additional time to complete which would in turn impact the timeline of BLA submissions of our product candidates and subsequent revenue generation.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors have been accounted for in the company&#8217;s anticipated upcoming milestones. During any such delays in our clinical trials, we will continue to incur fixed costs such as selling, general and administrative expenses and operating expenses related to our laboratory, GMP manufacturing, and office facilities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our office-based employees have been working from home since mid-March&#160;2020. Essential staffing levels for our research and development operations remain in place, including maintaining key personnel in our laboratory and GMP&#160;manufacturing facilities. It is likely that the pandemic and resulting mitigation efforts could have an impact in the future on our third-party suppliers who manufacture laboratory supplies required for our in-house manufacturing process, which in turn could have an impact on having sufficient clinical product supply available for our clinical trials. We have addressed this in part by ensuring that we have sufficient supplies on hand to weather interruptions in our supply chain.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor the impact of the COVID-19 pandemic on our business, including our clinical trials, manufacturing facilities and capabilities, and ability to access necessary resources. For a discussion of the risks presented by the COVID-19 pandemic to our results of operations and financial condition, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_178">Part&#160;II, Item&#160;1A. &#8220;Risk Factors.&#8221;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i5bbe340c9c8f435088d8011b72b6800d_118"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Results</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through the date of this Quarterly Report on Form&#160;10-Q, we have generated minimal revenue from non-exclusive license agreements related to our cell lines, the sale of our bioreactors and related consumables, and grant programs. We have no clinical products approved for commercial sale and have not generated any revenue from therapeutic and vaccine product candidates that are under development. We have incurred net losses in each year since our inception and, as of March&#160;31,&#160;2023, we had an accumulated deficit of $2.5&#160;billion. Our net losses attributable to ImmunityBio common stockholders were $116.3&#160;million and $102.8&#160;million for the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> three months ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> March&#160;31,&#160;2023 and 2022, respectively. Substantially all of our net losses resulted principally from costs incurred in connection with our ongoing clinical trials and operations, our research and development programs, and from selling, general and administrative costs associated with our operations, including stock-based compensation expense.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, we had 703&#160;employees. Personnel of related companies who provide corporate, general and administrative, certain research and development, and other support services under our shared services agreement with NantWorks are not included in this number. For additional information, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_76">Note&#160;10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Related-Party Agreements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Unaudited Condensed Consolidated Financial Statements&#8221; that appears in Item&#160;1.&#160;&#8220;Financial Statements&#8221; of this Quarterly Report on Form&#160;10-Q. In anticipation of the commercialization of select drug candidates, we expect to continue to incur significant expenses and increasing operating losses for the foreseeable future, which may fluctuate significantly from quarter-to-quarter and year-to-year. See &#8220;&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Funding Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; below for a discussion of our anticipated expenditures and sources of capital we expect to access to fund these expenditures.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_121"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that strategic collaborations will continue to be an integral part of our operations, providing opportunities to leverage our partners&#8217; expertise and capabilities to gain access to new technologies and further expand the potential of our technologies and product candidates across relevant platforms. We believe we are well positioned to become a leader in immunotherapy due to our broad and vertically-integrated platforms and through complementary strategic partnerships.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our innovative approach to orchestrate and combine therapies for optimal immune system response will become a therapeutic foundation across multiple indications. Additionally, we believe that data from multiple clinical trials indicates N-803 has broad potential to enhance the activity of therapeutic mAbs, including checkpoint inhibitors (e.g.,&#160;Keytruda), across a wide range of tumor types. N-803 is currently being studied in 14&#160;clinical trials (both ImmunityBio and investigator-led) across 11&#160;indications. We may also enter into supply arrangements for various investigational agents to be used in our clinical trials. See Part&#160;I, Item&#160;1. &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business&#8212;Collaboration and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, of our Annual Report on Form&#160;10-K filed with the SEC on March&#160;1,&#160;2023 for a more detailed discussion regarding our collaboration and license agreements.</span></div><div id="i5bbe340c9c8f435088d8011b72b6800d_124"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agreements with Related Parties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Executive Chairman, Global Chief Scientific and Medical Officer and our principal stockholder, founded and has a controlling interest in NantWorks, which is a collection of companies in the healthcare and technology space. We have entered into arrangements with NantWorks, and certain affiliates of NantWorks. Affiliates of NantWorks are also affiliates of the company due to the common control by and/or common ownership interest of our Executive Chairman and Global Chief Scientific and Medical Officer.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related-Party Debt</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description of the company&#8217;s related-party promissory note does not purport to be complete and is qualified in its entirety by reference to the full text of the note, a copy of which is incorporated by reference in Part&#160;II, Item&#160;6. &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Quarterly Report on Form&#160;10-Q. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Convertible Note at Fair Value </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2023, the company executed a $30.0&#160;million promissory note with Nant&#160;Capital. This note bears interest at Term&#160;SOFR plus 8.0%&#160;per annum. The outstanding principal amount and any accrued and unpaid interest are due on the December&#160;31,&#160;2023 or upon the occurrence and continuation of an Event of Default (as defined in the note). The interest on this note will be paid on a quarterly basis beginning on June&#160;30,&#160;2023. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. The noteholder may convert the balance of the convertible promissory note and accrued interest in whole at their option following the Conversion Price Date, which is the trading day prior to the opening of the next open trading window, as determined by the company&#8217;s board of directors in accordance with the company&#8217;s Insider Trading Policy. The conversion price is equal to the greater of (i)&#160;the Nasdaq Official Closing Price and (ii)&#160;the consolidated closing bid price of the company&#8217;s common stock on the Conversion Price Date. There is no floor on the conversion price for this convertible note, therefore, as of March&#160;31,&#160;2023 we cannot determine the total number of shares issuable upon conversion that may occur in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company received net proceeds of $29.9&#160;million from this financing, net of a $0.1&#160;million origination fee paid to the lender, which we intend to use, together with other available funds, to progress our pre-commercialization efforts and clinical development programs, fund other research and development activities, for capital expenditures, and for other general corporate purposes. We may also use a portion of the net proceeds to license intellectual property or to make acquisitions or investments. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The note is accounted for under ASC 825-10-15-4 FVO election. Under the FVO election, the note is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. With each such remeasurement, the note will be adjusted to fair value, with the change in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other income (expense), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statement of operations. As of March&#160;31,&#160;2023, we had a balance of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$29.9&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">related-party convertible note at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated balance sheet related to this note.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Additional Borrowing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;9,&#160;2023, the company&#8217;s Executive Chairman and Global Chief Scientific and Medical Officer agreed to provide immediate non-convertible debt financing to the company in an amount of $30.0&#160;million, which will be available to the company as soon as the underlying agreements are executed. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_163">&#8212;</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_163">Subsequent Events</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_73">Note 9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_76">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the &#8220;Notes to Unaudited Condensed Consolidated Financial Statements&#8221; that appear in Item 1. &#8220;Financial Statements&#8221; of this Quarterly Report on Form 10-Q for more detailed discussions of our related-party agreements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Immuno-Oncology Clinic, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into multiple agreements with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Clinic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to conduct clinical trials related to certain of our product candidates. The Clinic is a related party as it is owned by an officer of the company and NantWorks manages the administrative operations of the Clinic. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we completed a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review of alternative structures that could support our more complex clinical trial requirements and made a decision to explore a potential transition of clinical trials at the Clinic to a new structure (including contracting with a new, non-affiliated professional corporation) to be determined and agreed upon by all parties. We continue productive negotiations with potential partners around alternative structures, but there can be no assurance that we will be successful. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023 and 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we incurred $0.6&#160;million and $0.4&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statement of operations related to clinical trial and transition services provided by the Clinic.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_73">Note&#160;9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_76">Note&#160;10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the &#8220;Notes to Unaudited Condensed Consolidated Financial Statements&#8221; that appear in Item&#160;1. &#8220;Financial Statements&#8221; of this Quarterly Report on Form&#160;10-Q for more detailed discussions of our related-party agreements.</span></div><div id="i5bbe340c9c8f435088d8011b72b6800d_130"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of our Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through the date of this Quarterly Report on Form&#160;10-Q, we have generated minimal revenue from non-exclusive license agreements related to our cell lines, the sale of our bioreactors and related consumables, and grant programs. We have no clinical products approved for commercial sale and have not generated any revenue from therapeutic and vaccine product candidates that are under development. If we fail to complete the development of our product candidates in a timely manner or fail to obtain regulatory approval for them, we may never be able to generate substantial future revenue.</span></div><div id="i5bbe340c9c8f435088d8011b72b6800d_133"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally classify our operating expenses into research and development, and selling, general and administrative expenses. Personnel costs, including salaries, benefits, bonuses, and stock-based compensation expense comprise a significant component of our research and development, and selling, general and administrative expense categories. We allocate expenses associated with our facilities and information technology costs between these two&#160;categories, primarily based on the nature of each cost.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists of expenses incurred while performing research and development activities to discover and develop our technology and product candidates. This includes conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings for product candidates. We recognize research and development expenses as they are incurred. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses primarily consist of:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial and regulatory-related costs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with investigative sites and consultants that conduct our clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under collaborative agreements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing and testing costs and related supplies and materials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, benefits, travel and stock-based compensation; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility expenses dedicated to research and development.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company classifies its research and development expenses as either external or internal. The&#160;company&#8217;s external research and development expenses support its various preclinical and clinical programs. The&#160;company&#8217;s internal research and development expenses include payroll and benefits expenses, facilities and equipment expense, and other indirect research and development expenses incurred in support of its research and development activities. The&#160;company&#8217;s external and internal resources are not directly tied to any one research or drug discovery program and are typically deployed across multiple programs and are not allocated to specific product candidates or development programs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses to continue to increase significantly for the foreseeable future as we advance our product candidates through clinical development, including the conduct of our ongoing and any future clinical trials. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. The successful development of product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs required to complete the remaining development of any product candidates. This is due to the numerous risks and uncertainties associated with the development of product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs of clinical trials may vary significantly over the life of a project owing to, but not limited to, the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">per patient trial costs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of sites included in the clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the countries in which the clinical trials are conducted;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the length of time required to enroll eligible patients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of patients that participate in the clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of doses that patients receive;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of comparative agents used in clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the drop-out or discontinuation rates of patients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential additional safety monitoring or other studies requested by regulatory agencies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the duration of patient follow-up; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety profile and efficacy of the product candidate.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have only one product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease, for which we submitted a BLA to the FDA in May&#160;2022. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July&#160;2022, we announced the FDA has accepted our BLA for review and set a target PDUFA action date of May&#160;23,&#160;2023. On May&#160;9,&#160;2023, the FDA delivered a complete response letter to us regarding the BLA, as described in greater detail in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_163">&#8212;</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_163">Subsequent Events</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below. There can be no assurance that our product candidate will be approved for commercial sale by the FDA, if ever. We do not expect any of our other product candidates to be commercially available for the foreseeable future, if ever. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_136"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense consists primarily of salaries and personnel-related costs, including employee benefits and any stock-based compensation, for employees performing functions other than research and development. This includes personnel in executive, finance, human resources, information technology, legal, and administrative support functions. Other selling, general and administrative expenses include facility-related costs not otherwise allocated to research and development expense, professional fees for auditing, tax and legal services, advertising costs, expenses associated with strategic business transactions and business development efforts, obtaining and maintaining patents, consulting costs, royalties and licensing costs, and costs of our information systems.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our selling, general and administrative expense will increase for the foreseeable future as we expand operations, build out information systems and increase our headcount to support continued research activities and the development of our clinical programs. We have incurred and expect that we will continue to incur in the future, additional costs associated with operating as a public company, including costs to comply with stock exchange listing and SEC requirements, future funding efforts, corporate governance, internal controls, investor relations, disclosure and similar requirements applicable to public companies. Additionally, if and when we believe that a regulatory approval of a product candidate appears likely, we expect to incur significant increases in our selling, general and administrative expense relating to the sales and marketing of the approved product candidate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income and Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income and expense consists primarily of interest income, interest expense, unrealized gains and losses on investments in equity securities and equity-method investments, realized gains and losses on both debt and equity securities, changes in fair value of warrant liabilities and related-party convertible note payable at fair value, and gains and losses on foreign currency transactions.</span></div><div id="i5bbe340c9c8f435088d8011b72b6800d_139"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S.&#160;federal income tax, as well as income tax in Italy, South Korea, California and other states. From inception through March&#160;31,&#160;2023, we have not been required to pay U.S.&#160;federal and state income taxes because of current and accumulated NOLs. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_142"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discussion of Condensed Consolidated Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March&#160;31,&#160;2023 and 2022</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited, $ in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development (including amounts<br/>&#160;&#160;&#160;with related parties)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative (including amounts<br/>&#160;&#160;&#160;with related parties)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,932)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,940&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,986&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,954&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,580)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,972)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,608)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and investment income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(993)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense (including amounts with related parties)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,816)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,491)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net (including amounts<br/>&#160;&#160;&#160;with related parties)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,077)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,073)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,003)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,026)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes and noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116,583)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,998)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,585)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116,583)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,998)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,585)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased $0.3&#160;million for the three&#160;months&#160;ended March&#160;31,&#160;2023, as compared to the three&#160;months&#160;ended March&#160;31,&#160;2022. The increase was primarily driven by grant revenue received in 2023.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense increased $23.9&#160;million during the three&#160;months&#160;ended March&#160;31,&#160;2023, as compared to the three&#160;months&#160;ended March&#160;31,&#160;2022. The following table summarizes our research and development expenses for the three&#160;months&#160;ended March&#160;31,&#160;2023 and 2022, together with the changes in those items (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.658%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited, $ in thousands)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal research and development expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, depreciation, and facility costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,159)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total internal research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,811&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,414&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(603)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,264&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,886&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense increased $23.9&#160;million primarily attributable to the following:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a $24.5&#160;million increase in external research and development expenses that was primarily due to a rise in contract manufacturing organization (CMO)&#160;fees and drug materials purchased and used in manufacturing, an increase in regulatory and compliance costs resulting from the BLA submission for our product candidate Anktiva, and higher clinical trial costs;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a $1.3&#160;million increase in personnel-related costs that was primarily the result of additional stock awards to our employees and an increase in personnel involved in our quality control, clinical operations, and drug discovery and development activities;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a $1.3&#160;million increase in equipment, depreciation, and facility costs that was primarily due to the expansion of our manufacturing facilities in California and New York, which resulted in increases in lease expense, maintenance costs, and depreciation expense; and</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a $3.2&#160;million decrease in other research and development costs that was primarily attributable to a decrease in lab and material supplies for internal manufacturing, partially offset by lower nonclinical collaboration expenses in the current period allocated to our joint venture and fewer sponsored research reimbursements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses to increase significantly for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates and conduct our ongoing and planned clinical trials</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense decreased $7.9&#160;million during the three&#160;months&#160;ended March&#160;31,&#160;2023, as compared to the three&#160;months&#160;ended March&#160;31,&#160;2022. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reduction in selling, general and administrative expense was primarily driven by a $9.8&#160;million decline in legal expenses related to litigation settlements and defense costs in the prior period, a $0.2&#160;million reduction in IT equipment and software purchases, and a $0.1&#160;million reduction in insurance costs and other professional service fees. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were partially offset by a $2.0&#160;million increase in personnel costs due to higher headcount and increased travel costs, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a $0.2&#160;million increase in stock-based compensation expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Expense, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net decreased $2.0&#160;million during the three&#160;months&#160;ended March&#160;31,&#160;2023, as compared to the three&#160;months&#160;ended March&#160;31,&#160;2022. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in other expense, net was mainly due to a $27.6&#160;million gain from a change in the fair value of warrant liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were partially offset by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a $21.3&#160;million increase in interest expense driven by an increase in related-party borrowings along with an increase in Term&#160;SOFR rates and a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mortization of related-party notes discounts</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a $2.1&#160;million higher loss on our equity method investment, $1.1&#160;million lower net interest and investment income, a $1.0&#160;million increase in issuance costs allocated to the warrant liabilities, and a $0.1&#160;million loss from fixed asset disposals. </span></div><div id="i5bbe340c9c8f435088d8011b72b6800d_148"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Condition, Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal sources of liquidity are our existing cash, cash equivalents, and marketable securities. We have historically invested our cash primarily in investment grade short- to intermediate-term corporate debt securities, commercial paper, government-sponsored securities, U.S.&#160;treasury securities, and foreign government bonds and classify these investments as available-for-sale. Certain of these investments are subject to general credit, liquidity and other market risks. The general condition of the financial markets and the economy may increase those risks and may affect the value and liquidity of investments and restrict our ability to access the capital markets.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Marketable Securities on Hand</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, we had cash and cash equivalents, and marketable securities of $92.1&#160;million compared to $108.0&#160;million as of December&#160;31,&#160;2022. In April&#160;2021, we entered into an open market sale agreement (Sale Agreement) with respect to an&#160;ATM offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, having an aggregate offering price of up to $500.0&#160;million through our sales agent, which was subsequently reduced by $92.0&#160;million during December&#160;2022 in connection with a sale of our common stock. As of March&#160;31,&#160;2023, we had $225.4&#160;million available for future stock issuances under the&#160;ATM. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shelf Registration Statement</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During February&#160;2023, we filed a $750.0&#160;million shelf registration statement with the SEC on Form&#160;S-3 for the offering and sale of equity and equity-linked securities, including common stock, preferred stock, debt securities, depositary shares, warrants to purchase common stock, preferred stock or debt securities, subscription rights, purchase contracts, and units. In February&#160;2023, we sold shares of our common stock and warrants valued at $110.0&#160;million under the shelf. As of March&#160;31,&#160;2023, we had $640.0&#160;million available for use under the shelf. This available shelf is in addition to the Open Market Sale Agreement. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Proceeds from Registered Direct Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; below.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceeds from Registered Direct Offering</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;15, 2023, we entered into a securities purchase agreement with certain institutional investors for the sale of 14,072,615&#160;shares of our common stock, as well as warrants that allow such investors to purchase an additional 14,072,615&#160;shares of common stock at an exercise price of $4.26&#160;per share, for an aggregate purchase price of $3.55&#160;per share and accompanying warrant. This transaction generated net proceeds of approximately $47.0&#160;million, after deducting placement agent fees and other estimated offering costs. The closing of the offering occurred on February&#160;17, 2023. We currently intend to use the net proceeds from this offering, together with other available funds, to progress our pre-commercialization efforts and clinical development programs, fund other research and development activities, for capital expenditures, and for other general corporate purposes. We may also use a portion of the net proceeds to license intellectual property or to make acquisitions or investments.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">$30.0&#160;million Variable-Rate Convertible Promissory Note</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2023, the company executed a $30.0&#160;million promissory note with Nant&#160;Capital, an affiliated entity of the company due to the common control of our Executive Chairman and Global Chief Scientific and Medical Officer. This note bears interest at Term&#160;SOFR plus 8.0% per annum. The outstanding principal amount and any accrued and unpaid interest are due on the December&#160;31,&#160;2023 or upon the occurrence and continuation of an Event of Default (as defined in the note). The interest on this note will be paid on a quarterly basis beginning on June&#160;30,&#160;2023.The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. The noteholder may convert the balance of the convertible promissory note and accrued interest in whole at their option following the Conversion Price Date, which is the trading day prior to the opening of the next open trading window, as determined by the company&#8217;s board of directors in accordance with the company&#8217;s Insider Trading Policy. The conversion price is equal to the greater of (i)&#160;the NASDAQ Official Closing Price and (ii)&#160;the consolidated closing bid price of the company&#8217;s common stock on the Conversion Price Date.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company received net proceeds of $29.9&#160;million&#160;from this financing, net of a $0.1&#160;million origination fee paid to the lender, which we intend to use, together with other available funds, to progress our pre-commercialization efforts and clinical development programs, fund other research and development activities, for capital expenditures, and for other general corporate purposes. We may also use a portion of the net proceeds to license intellectual property or to make acquisitions or investments.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to complete the development of our current product candidates, and implement our business plan, we will require substantial additional funding. Furthermore, changing circumstances may cause us to increase our spending significantly faster than we currently anticipate, and we may need to raise even greater amounts of funds sooner if we choose to expand more rapidly than we presently anticipate. Moreover, our fixed expenses such as rent and other contractual commitments are substantial and are expected to increase in the future.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Additional Borrowing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;9,&#160;2023, the company&#8217;s Executive Chairman and Global Chief Scientific and Medical Officer agreed to provide immediate non-convertible debt financing in an amount of $30.0&#160;million, which will be available to the company as soon as the underlying agreements are executed. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_163">&#8212;</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_163">Subsequent Events</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uses of Liquidity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the cash used to fund our operating activities discussed in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Future Funding Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; below, we will require cash to settle the following obligations:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As of March&#160;31,&#160;2023, our indebtedness payable at maturity totals $769.9&#160;million (excluding unamortized related-party notes discounts and fair value adjustments), held by entities affiliated with Dr.&#160;Soon-Shiong. </span></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of this amount, $505.0&#160;million is due and payable on December&#160;31,&#160;2023. In the event of a default on the $300.0&#160;million loan (as defined in the promissory note), including if we do not repay the loan at maturity, the company has the right, at its sole option, to convert the outstanding principal amount and accrued and unpaid interest due under this note into shares of the company&#8217;s common stock at price of $5.67&#160;per share. </span></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the March&#160;31,&#160;2023 $30.0&#160;million promissory note and accrued interest may be converted in whole at the option of the noteholder following the Conversion Price Date, which is the trading day prior to the opening of the next open trading window, as determined by the company&#8217;s board of directors in accordance with the company&#8217;s Insider Trading Policy. The conversion price is equal to the greater of (i)&#160;the NASDAQ Official Closing Price and (ii)&#160;the consolidated closing bid price of the company&#8217;s common stock on the Conversion Price Date. There is no floor on the conversion price for this convertible note, therefore, as of March&#160;31,&#160;2023 we cannot determine the total number of shares issuable upon conversion that may occur in the future.</span></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, in the event of a Specified Transaction (as defined in the loan agreement), the noteholder can request the outstanding principal and interest due on the $50.0&#160;million promissory note be repaid in full upon consummation of such Specified Transaction. </span></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining $264.9&#160;million is due and payable on September&#160;30,&#160;2025, including any accrued and unpaid interest. The company can prepay the outstanding principal (together with accrued and unpaid interest), in whole or in part, at any time without premium or penalty and without the prior consent of the lender. On August&#160;31,&#160;2022, the terms of these fixed-rate promissory notes were amended and restated to include a conversion feature that gives each lender, at its sole option, at any time (other than when the lender is in receipt of a written notice of prepayment from the borrower), the right to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the company&#8217;s common stock at a price of $5.67 per share. Upon receipt of a written notice of prepayment from the borrower, the lender has the right, at its option, to convert the outstanding principal amount to be prepaid and the accrued and unpaid interest thereon (as specified in the notice of prepayment) into shares of the company&#8217;s common stock at a price of $5.67&#160;per share. </span></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that the company can refinance these promissory notes or what terms will be available in the market at the time of refinancing. Furthermore, if prevailing interest rates or other factors at the time of refinancing result in higher interest rates upon refinancing, then the interest expense relating to the refinanced indebtedness would increase. These risks could materially adversely affect the company&#8217;s financial condition, cash flows and results of operations.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In connection with our 2017 acquisition of Altor, we issued CVRs under which we agreed to pay the prior stockholders of Altor approximately $304.0&#160;million of contingent consideration upon the&#160;successful regulatory approval of a BLA by the FDA, or foreign equivalent, for N-803 by December&#160;31,&#160;2022, and approximately $304.0&#160;million of contingent consideration upon calendar-year worldwide net sales of N-803 exceeding $1.0&#160;billion prior to December&#160;31,&#160;2026, with amounts payable in cash or shares of our common stock or a combination thereof. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the regulatory milestone CVR agreement, in May&#160;2022 we announced the submission of a BLA to the FDA for our product candidate, Anktiva (N-803) in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1 disease</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n July&#160;2022 we announced that the FDA had accepted our BLA for review and set a target PDUFA action date of May&#160;23,&#160;2023. On May&#160;9,&#160;2023, the FDA delivered a complete response letter to us regarding the BLA, as described in greater detail in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_163">&#8212;</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_163">Subsequent Events</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below. It is unclear when the FDA will approve our BLA, if at all. The FDA did not approve our BLA on or before December&#160;31,&#160;2022, and therefore the regulatory milestone was not met, and the regulatory milestone CVR agreement terminated in accordance with its terms.</span></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the net sales milestone CVR agreement, as of March&#160;31,&#160;2023, Dr.&#160;Soon-Shiong and his related party hold approximately $139.8&#160;million of net sales CVRs and they have both irrevocably agreed to receive shares of the company&#8217;s common stock in satisfaction of their CVRs. We may be required to pay the other prior Altor stockholders up to $164.2&#160;million for their net sales CVRs should they choose to have their CVRs paid in cash instead of common stock. We may need to seek additional sources of capital to satisfy the CVR obligations if they are achieved.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In connection with our acquisition of VivaBioCell, we are obligated to pay the former owners approximately $2.2&#160;million of contingent consideration upon the achievement of a regulatory milestone relating to the GMP-in-a-Box technology.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discussion of Condensed Consolidated Cash Flows</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion of ImmunityBio&#8217;s cash flows is based on the condensed consolidated statements of cash flows in Item&#160;1. &#8220;Financial Statements&#8221; and is not meant to be an all&#8209;inclusive discussion of the changes in its cash flows for the periods presented below.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our primary sources and uses of cash for periods indicated (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Three Months Ended<br/>March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(84,310)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(74,930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8,484)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(69,313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">76,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(298)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effect of exchange rate changes on cash, cash equivalents, <br/>&#160;&#160;&#160;and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(254)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net change in cash, cash equivalents, and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(16,160)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(144,716)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31,&#160;2023, net cash used in operating activities of $84.3&#160;million consisted of a net loss of $116.6&#160;million, partially offset by $27.7&#160;million of cash provided by net working capital and $4.6&#160;million in adjustments for non-cash items. The changes in net working capital consisted primarily of an increase of $18.6&#160;million in accrued expenses and other liabilities, a decrease of $9.7&#160;million in prepaid and other current assets, an increase of $0.7&#160;million in accounts payable, and a decrease of $0.3&#160;million in other assets, partially offset by decreases of $1.5&#160;million in operating lease liabilities, and $0.1&#160;million with related parties. Adjustments for non-cash items primarily consisted of $11.5&#160;million in amortization of debt issuance costs and accretion of discounts, $10.9&#160;million in stock-based compensation expense, $4.7&#160;million in depreciation and amortization expense, $2.5&#160;million in non-cash interest and debt discount amortization primarily related to related-party promissory notes, $1.6&#160;million in non-cash lease expense related to operating lease right&#8209;of&#8209;use assets, $1.0&#160;million in transaction costs allocable to warrant liabilities, and $0.1&#160;million of other, reduced by a $27.6&#160;million change in the fair value of warrant liabilities, and $0.1&#160;million in unrealized gains on equity securities driven by an increase in the value of our investments.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31,&#160;2022, net cash used in operating activities of $74.9&#160;million consisted of a net loss of $103.0&#160;million, partially offset by $18.5&#160;million in adjustments for non-cash items and $9.6&#160;million of cash provided by net working capital changes. Adjustments for non-cash items primarily consisted of $10.0&#160;million in stock-based compensation expense, $4.1&#160;million in depreciation and amortization expense, $3.0&#160;million in non-cash interest related primarily to related-party promissory notes, $1.3&#160;million in non-cash lease expense related to operating lease right-of-use assets, $1.1&#160;million in other non-cash items, and a $0.4&#160;million in amortization of debt issuance costs and accretion of discounts, reduced by $1.4&#160;million in unrealized gains on equity securities driven by an increase in the value of our investments. The changes in net working capital consisted primarily of increases of $10.9&#160;million in accrued expenses and other liabilities and $0.8&#160;million in accounts payable and a decrease of $0.1&#160;million in other assets, partially offset by decreases of $1.6&#160;million with related parties and $0.4&#160;million in operating lease liabilities, and an increase of $0.2&#160;million in prepaid and other current assets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically experienced negative cash flows from operating activities, with such negative cash flows likely to continue for the foreseeable future.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31,&#160;2023, net cash used in investing activities was $8.5&#160;million, which included cash outflows of $8.4&#160;million of purchases of property, plant and equipment, and $0.2&#160;million of purchases of marketable debt securities, partially offset by proceeds of $0.1&#160;million from maturities and sales of marketable debt and equity securities. Our investments in property, plant and equipment are primarily related to acquisitions of equipment that will be used for the manufacturing of our product candidates and expenditures related to the build out of our manufacturing facilities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31,&#160;2022, net cash used in in investing activities was $69.3&#160;million, which included $34.1&#160;million of purchases of marketable debt securities, $27.3&#160;million of purchases of property, plant and equipment (including construction in process and depreciable property acquired in the Dunkirk acquisition), $21.2&#160;million for the purchase of intangible assets (related to the Dunkirk acquisition), and a $1.0&#160;million investment in the joint venture, partially offset by cash inflows of $14.3&#160;million from maturities and sales of marketable debt and equity securities. Our investments in property, plant and equipment are primarily related to acquisitions of equipment that will be used for the manufacturing of our product candidates and expenditures related to the build out of our manufacturing facilities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to accelerate our capital spending as we scale our GMP&#160;manufacturing capabilities, which will require significant capital for the foreseeable future.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31,&#160;2023, net cash provided by financing activities was $76.9&#160;million, which consisted of $47.3&#160;million in net proceeds from a registered direct offering, $29.9&#160;million in net proceeds from issuances of related-party promissory notes, and $0.1&#160;million of proceeds from the exercise of stock options, partially offset by $0.4&#160;million related to net share settlement of vested RSUs for payment of payroll tax withholding.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31,&#160;2022, net cash used in financing activities was $0.3&#160;million, which consisted of $0.4&#160;million related to net share settlement of vested RSUs for payment of payroll tax withholding, partially offset by $0.1&#160;million in proceeds from exercises of stock options.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through the date of this Quarterly Report on Form&#160;10-Q, we have generated minimal revenue, we have no clinical products approved for commercial sale and we have not generated any revenue from therapeutic and vaccine product candidates that are under development. We do not expect to generate significant revenue unless and until we obtain regulatory approval of and commercialize any of our product candidates, and we do not know when, or if, this will occur. In addition, we expect our operating expenses to significantly increase in connection with our ongoing development activities, particularly as we continue the research, development and clinical trials of, and seek regulatory approval for, our product candidates. We have also incurred and expect that we will continue to incur in the future additional costs associated with operating as a public company as well as costs related to future fundraising efforts. In addition, subject to obtaining regulatory approval of our product candidates, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing and distribution. We anticipate that we will need substantial additional funding in connection with our continuing operations. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our operating expenses will increase substantially if and as we:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue research and development, including preclinical and clinical development of our existing product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially seek regulatory approval for our product candidates;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to discover and develop additional product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a commercialization infrastructure and scale up our manufacturing and distribution capabilities to commercialize any of our product candidates for which we may obtain regulatory approval;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to comply with regulatory standards and laws;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, leverage and expand our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire clinical, manufacturing, scientific and other personnel to support our product candidates&#8217; development and future commercialization efforts;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add operational, financial and management information systems and personnel; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur additional legal, accounting and other expenses in operating as a public company.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of continuing anticipated operating cash outflows, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash, cash equivalents, and investments in marketable securities, together with capital to be raised through equity offerings (including the&#160;ATM) and our potential ability to borrow from affiliated entities, will be sufficient to fund our operations through at least the next 12&#160;months following the issuance date of the condensed consolidated financial statements based primarily upon our Executive Chairman and Global Chief Scientific and Medical Officer&#8217;s intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt. We may also seek to sell additional equity, through one or more follow-on public offerings, or in separate financings, or obtain a credit facility. However, we may not be able to secure such external financing in a timely manner or on favorable terms. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we may need additional funds to meet our needs sooner than planned.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to obtain additional financing to fund our future operations, including completing the development and commercialization of our product candidates. Changing circumstances may cause us to increase our spending significantly faster than we currently anticipate and we may need to raise additional funds sooner than we presently anticipate. Moreover, research and development and our operating costs and fixed expenses such as rent and other contractual commitments, including those for our research collaborations, are substantial and are expected to increase in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress, timing, number, scope and costs of researching and developing our product candidates and our ongoing, planned and potential clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">time and cost of regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize any product candidates, if approved and the costs of such commercialization activities; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revenue from product candidates that we may commercialize, if any, including the selling prices for such potential products and the availability of adequate third-party coverage and reimbursement for patients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost of building, staffing and validating our own manufacturing facilities in the U.S., including having a product candidate successfully manufactured consistent with FDA and European Medicines Agency (EMA) regulations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">terms, timing and costs of our current and any potential future collaborations, business or product acquisitions, CVRs, milestones, royalties, licensing or other arrangements that we have established or may establish;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">time and cost necessary to respond to technological, regulatory, political and market developments; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of filing, prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property rights.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless and until we can generate a sufficient amount of revenues, we may finance future cash needs through public or private equity offerings, license agreements, debt financings, collaborations, strategic alliances and marketing or distribution arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms, or at all, including but not limited to the offering, issuance and sale by us of our common stock that may be issued and sold under the&#160;ATM. As of March&#160;31,&#160;2023, we had $225.4&#160;million available for future stock issuances under the&#160;ATM. See&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_85">Note&#160;12</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders&#8217; Deficit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the &#8220;Notes to Unaudited Condensed Consolidated Financial Statements&#8221; that appears in Item&#160;1.&#160;&#8220;Financial Statements&#8221; of this Quarterly Report on Form&#160;10-Q. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During February&#160;2023, we filed a $750.0&#160;million shelf registration statement with the SEC on Form&#160;S-3 for the offering and sale of equity and equity-linked securities, including common stock, preferred stock, debt securities, depositary shares, warrants to purchase common stock, preferred stock or debt securities, subscription rights, purchase contracts, and units. As of March&#160;31,&#160;2023, we had $640.0&#160;million available for use under the shelf. See&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_85">Note&#160;12</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders&#8217; Deficit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the &#8220;Notes to Unaudited Condensed Consolidated Financial Statements&#8221; that appears in Item&#160;1.&#160;&#8220;Financial Statements&#8221; of this Quarterly Report on Form&#160;10-Q. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity or equity-linked securities, including convertible debt or through the&#160;ATM or other offerings, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of additional indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third&#160;parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may be required to delay or reduce the scope of or eliminate one or more of our research or development programs or our commercialization efforts. Our current license and collaboration agreements may also be terminated if we are unable to meet the payment obligations under those agreements. As a result, we may seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time.</span></div><div id="i5bbe340c9c8f435088d8011b72b6800d_154"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have material cash requirements to pay related-party affiliates and third parties under various contractual obligations discussed below:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are obligated to make payments to several related-party affiliates under written agreements and other informal arrangements. We are also obligated to pay interest and to repay principal under our related-party notes. For information regarding our financing obligations, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_73">Note&#160;9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Related-Party Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Unaudited Condensed Consolidated Financial Statements&#8221; that appears in Item&#160;1.&#160;&#8220;Financial Statements&#8221; of this Quarterly Report on Form&#160;10-Q. </span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are obligated to make payments under our operating leases, which primarily consist of facility leases. For information regarding our lease obligations, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_70">Note&#160;8</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Lease Arrangements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_76">Note&#160;10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Related-Party Agreements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Unaudited Condensed Consolidated Financial Statements&#8221; that appear in Item&#160;1.&#160;&#8220;Financial Statements&#8221; of this Quarterly Report on Form&#160;10-Q. </span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In connection with the acquisitions of Altor and VivaBioCell, we are obligated to pay contingent consideration upon the achievement of certain milestones. For information regarding our contingent consideration obligations, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_67">Note&#160;7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Commitments and Contingencies&#8212;Contingent Consideration Related to Business Combinations,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Unaudited Condensed Consolidated Financial Statements&#8221; that appears in Item&#160;1.&#160;&#8220;Financial Statements&#8221; of this Quarterly Report on Form&#160;10-Q.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have contractual obligations to make payments to related-party affiliates and third parties under unconditional purchase arrangements. For information on these unconditional purchase obligations, see Note&#160;7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies&#8212;Unconditional Purchase Obligations,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Consolidated Financial Statements&#8221; that appears in Part&#160;II, Item&#160;8. &#8220;Financial Statements and Supplementary Data&#8221; of our Annual Report on Form&#160;10-K filed with the SEC on March&#160;1,&#160;2023. </span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have certain contractual commitments that are expected to be paid within one&#160;year, depending on the progress of build outs, completion of services, and the realization of milestones associated with third-party agreements. This amount totals $132.4&#160;million and is primarily related to capital expenditures, open purchase orders as of March&#160;31,&#160;2023 for the acquisition of goods and services in the ordinary course of business, and near term upfront milestone payments to third parties.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In addition, we have contractual commitments that are expected to be paid in fiscal year 2024 and beyond based on the achievement of various development, regulatory and commercial milestones for agreements with third parties. These payments may not be realized or may be modified and are contingent upon the occurrence of various future events, substantially all of which have a high degree of uncertainty of occurring. As of March&#160;31,&#160;2023, the maximum amount that may be payable related to these commitments is $775.3&#160;million.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In connection with our leasehold interest in the Dunkirk Facility, we committed to spend an aggregate of $1.52&#160;billion on operational expenses during the initial 10-year term, and an additional $1.50&#160;billion on operational expenses if we elect to renew the lease for the additional 10-year term. These amounts are not included in the discussion above. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_58">Note&#160;6</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and License Agreements and Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the &#8220;Notes to Unaudited Condensed Consolidated Financial Statements&#8221; that appears in Item&#160;1. &#8220;Financial Statements&#8221; of this Quarterly Report on Form&#160;10-Q for additional information.</span></div><div id="i5bbe340c9c8f435088d8011b72b6800d_157"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Part&#160;II, Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of our Annual Report on Form&#160;10-K filed with the SEC on March&#160;1,&#160;2023, we disclose those accounting policies that we consider to be significant in determining our results of operations and financial condition. There have been no material changes to those policies that we consider to be significant as of the date of this Quarterly Report on Form&#160;10-Q. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in accordance with U.S.&#160;GAAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The preparation of our condensed consolidated financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses for the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, contingent value right measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value calculation of warrants and convertible promissory notes, fair value measurements, asset acquisition, and the assessment of our ability to fund our operations for at least the next 12&#160;months from the date of issuance of these condensed consolidated financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing coronavirus pandemic could have on our significant accounting estimates. Actual results could differ from those estimates. </span></div><div id="i5bbe340c9c8f435088d8011b72b6800d_160"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_40">Note&#160;2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the &#8220;Notes to Unaudited Condensed Consolidated Financial Statements&#8221; that appears in Item&#160;1. &#8220;Financial Statements&#8221; of this Quarterly Report on Form&#160;10-Q for a discussion of recent accounting pronouncements or changes in accounting pronouncements that are of significance, or potential significance, to us.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_163"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsequent Events </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BLA Update</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ImmunityBio, Inc. announced that it had received a complete response letter from the FDA on May&#160;9,&#160;2023 regarding its BLA for its product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease. The letter indicated that the FDA had determined that it cannot approve the BLA in its present form, and the FDA had made recommendations to address the issues raised. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deficiencies relate to the FDA&#8217;s pre-license inspection of the company&#8217;s third-party contract manufacturing organizations. Satisfactory resolution of the observations noted at the pre-license inspection is required before the BLA may be approved. The FDA further provided recommendations specific to additional Chemistry, Manufacturing and Controls (CMC) issues and assays to be resolved. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No new preclinical studies or Phase&#160;3 clinical trials to evaluate safety or efficacy were requested by the FDA. The FDA requested that the company provide updated duration of response data of the efficacy population as identified by the FDA in the company&#8217;s resubmission, as well as a safety update.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company plans to request a meeting with the FDA as soon as possible to address the subject matter of the letter and a response timeline, and plans to diligently address and resolve the issues identified and seek approval as expeditiously as possible. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Development Updates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;9,&#160;2023, the company&#8217;s Executive Chairman and Global Chief Scientific and Medical Officer agreed to provide immediate non-convertible debt financing to the company in an amount of $30.0&#160;million on substantially similar terms as prior financings, including an interest rate of Term&#160;SOFR plus 8%&#160;per annum and a maturity date of December&#160;31,&#160;2023. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, the company has been exploring partnering with a large biopharmaceutical company for commercialization of N-803 for intravesical administration. The company has confirmed with the potential partner that these negotiations will continue notwithstanding the letter referenced above, with the view of completing such a transaction during 2023, though there can be no assurance that the company will complete a transaction on acceptable terms in accordance with this timeline or at all.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_166"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. &#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial market risks related to interest rates, foreign currency exchange rates, market risk on the price and volatility of our common stock, and inflation are described in Item&#160;7A. &#8220;Quantitative and Qualitative Disclosures About Market Risk&#8221; of our Annual Report on Form&#160;10-K filed with the SEC on March&#160;1,&#160;2023. There have been no material changes to such financial market risks as of the date of this Quarterly Report on Form&#160;10-Q. We do not currently anticipate any other near-term changes in the nature of our financial market risk exposures or in management&#8217;s objectives and strategies with respect to managing such exposures.</span></div><div id="i5bbe340c9c8f435088d8011b72b6800d_169"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. &#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives of ensuring that information we are required to disclose in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our chief executive officer (CEO) and chief financial officer (CFO), as appropriate, to allow timely decisions regarding required disclosures, and is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. There is no assurance that our disclosure controls and procedures will operate effectively under all circumstances.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, with the participation of our CEO and CFO, evaluated the effectiveness of our disclosure controls and procedures as of March&#160;31,&#160;2023. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rule&#160;13a-15(e) of the Exchange Act means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March&#160;31,&#160;2023, our CEO and CFO have concluded that, as of March&#160;31,&#160;2023, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting (as defined in Rules&#160;13a-15(f) and 15d-15(f) of the Exchange Act) during the fiscal quarter ended March&#160;31,&#160;2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management recognizes that a control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or error, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_172"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i5bbe340c9c8f435088d8011b72b6800d_175"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. &#160;&#160;&#160;&#160;LEGAL PROCEEDINGS.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. If we are served with any such complaints, we will assess at that time any contingencies for which we may need to reserve. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Altor BioScience, LLC Litigation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, NantCell,&#160;Inc. (NantCell) announced it had entered into a definitive merger agreement to acquire Altor BioScience Corporation. An action captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gray v.&#160;Soon-Shiong, et&#160;al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was filed in Delaware Chancery Court by plaintiffs Clayland Boyden Gray (Gray) and Adam R. Waldman. The plaintiffs, two&#160;minority stockholders, asserted claims against the company and other defendants for (1)&#160;breach of fiduciary duty and (2)&#160;aiding and abetting breach of fiduciary duty and filed a motion to enjoin the merger. The court denied the motion and permitted the merger to close. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the close of the merger, in 2017 the plaintiffs (joined by two&#160;additional minority stockholders, Barbara&#160;Sturm Waldman and Douglas E. Henderson (Henderson)) filed a second&#160;amended complaint, including appraisal claims, and which the defendants subsequently moved to dismiss. In a second&#160;action, Dyad Pharmaceutical Corporation (Dyad) filed a petition in Delaware Chancery Court for appraisal in connection with the merger. The defendants moved to dismiss the appraisal petition in 2018. The court issued an oral ruling in 2019 that dismissed certain claims and dismissed Altor BioScience from the action. The following claims remained: (a)&#160;the appraisal claims by all plaintiffs and Dyad (against Altor BioScience,&#160;LLC), and (b)&#160;Henderson&#8217;s claims for breach of fiduciary duty and aiding and abetting breach of fiduciary duty. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the court issued a written order implementing its ruling on the defendants&#8217; motions (the Implementing Order). In the Implementing Order, the court confirmed that all fiduciary duty claims brought by Gray, both individually and as trustee of the Gordon Gray Trust f/b/o&#160;C. Boyden Gray, were dismissed. The plaintiffs then moved for leave to file a third&#160;amended complaint to add two&#160;former Altor stockholders as plaintiffs and a fiduciary duty claim on behalf of a purported class of former Altor stockholders, which the defendants opposed. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the court granted the plaintiffs&#8217; motion, and the plaintiffs filed the third&#160;amended complaint. In 2020, the defendants answered the third&#160;amended complaint and asserted counterclaims against the plaintiffs. The defendants sought damages for attorneys&#8217; fees and costs incurred as a result of the breaches of &#8220;standstill&#8221; agreements and of stockholder releases. The plaintiffs filed an answer denying the counterclaims and asserting defenses. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of the former Altor stockholders seeking appraisal met the definition of dissenting shares under the merger agreement and were not entitled to receive any portion of the merger consideration at the closing date, given that those shares were the subject of the above-described appraisal claims. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late March&#160;2022, the company agreed to the terms of a settlement with the appraisal petitioners, without any admission of liability or fault. The settlement provided that in exchange for complete releases, the appraisal petitioners, who as a group held 3,167,565&#160;dissenting Altor shares, collectively would receive an aggregate of 2,229,296&#160;shares of the company&#8217;s common stock issued in a private placement, plus an aggregate of $21.13&#160;in cash in lieu of fractional shares. The company&#8217;s Board of Directors approved the settlement and stock issuance in April&#160;2022, and the court approved the settlement and dismissed the appraisal petitioners&#8217; claims on July&#160;9,&#160;2022. On July&#160;9,&#160;2022, the company issued 2,229,296&#160;shares of its common stock with an aggregate market value of $10.7&#160;million, based on the closing price of its common stock on the Nasdaq as of July&#160;8,&#160;2022, to the appraisal petitioners pursuant to the court-approved settlement agreement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late April&#160;2022, the company also agreed to the terms of a settlement with the putative class plaintiffs without any admission of liability or fault. In exchange for class-wide releases, the company committed to make a settlement payment of $5.0&#160;million in cash by December&#160;31,&#160;2022. On December&#160;8,&#160;2022, the Delaware Court of Chancery entered a final judgment approving the settlement, and the company timely made the $5.0&#160;million settlement payment.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sorrento Therapeutics, Inc. Litigation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sorrento Therapeutics,&#160;Inc. (Sorrento), derivatively on behalf of Immunotherapy NANTibody,&#160;LLC (NANTibody), filed an action in the Superior Court of California, Los Angeles County (the Superior Court) against the company&#8217;s subsidiary NantCell, Dr.&#160;Soon-Shiong, and Charles&#160;Kim. The action alleged that the defendants improperly caused NANTibody to acquire IgDraSol,&#160;Inc. from NantPharma,&#160;LLC (NantPharma) and sought to have the transaction undone and the purchase amount returned to NANTibody. In 2019, we filed a demurrer to several causes of action alleged in the Superior Court action, and Sorrento filed an amended complaint, eliminating Mr.&#160;Kim as a defendant and dropping the causes of action we had challenged in our demurrer. The company believes the case is without merit and intends to vigorously defend against the claims asserted. Trial has been set to commence in Sorrento&#8217;s Superior Court action on July&#160;17,&#160;2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sorrento filed a related arbitration proceeding (the Cynviloq arbitration) against Dr.&#160;Soon-Shiong and NantPharma; the company was not named in the Cynviloq arbitration. In 2020, the Superior Court granted Dr.&#160;Soon-Shiong&#8217;s request for a preliminary injunction barring Sorrento from pursuing claims against him in the Cynviloq arbitration. Sorrento then filed the claims it had previously asserted in arbitration against Dr.&#160;Soon-Shiong in the Superior Court, and at Sorrento&#8217;s request, the arbitrator entered an order dismissing Sorrento&#8217;s claims against Dr.&#160;Soon-Shiong in the Cynviloq arbitration. The hearing in the Cynviloq arbitration commenced in June&#160;2021, and continued with breaks until early October&#160;2021. The parties completed post-hearing briefing in early May&#160;2022, and summations were heard on September&#160;8,&#160;2022. On December&#160;20, 2022, the parties received the arbitrator&#8217;s final award; the award is in favor of Sorrento and against NantPharma in the amount of approximately $125&#160;million. On December&#160;28, 2022, Sorrento submitted an application for modification of the final award to include prejudgment interest in excess of $83&#160;million; on January&#160;20, 2023, Sorrento&#8217;s application was denied. On February&#160;2,&#160;2023, Sorrento filed a petition to confirm the NantPharma award, and on February&#160;13,&#160;2023, NantPharma responded with a motion to vacate; on March&#160;17,&#160;2023, the Superior Court entered an order confirming the NantPharma award and denying the motion to vacate, and on April&#160;7,&#160;2023, the Superior Court entered the judgment on the award. The company was not a party to the Cynviloq arbitration and we believe that neither the company nor any of its subsidiaries has any obligations with respect to the award against NantPharma, and we intend to defend vigorously against attempts by Sorrento to pursue any such theory.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in 2019, the company and Dr.&#160;Soon-Shiong filed cross-claims in the Superior Court action against Sorrento and its Chief Executive Officer Henry&#160;Ji, asserting claims for fraud, breach of contract, breach of the covenant of good faith and fair dealing, tortious interference with contract, unjust enrichment, and declaratory relief. Our claims alleged that Dr.&#160;Ji and Sorrento breached the terms of an exclusive license agreement between the company and Sorrento related to Sorrento&#8217;s antibody library and that Sorrento did not perform its obligations under the exclusive license agreement. The Superior Court ruled that the company&#8217;s claims should be pursued in arbitration and that Dr.&#160;Soon-Shiong&#8217;s claims could be pursued in Superior Court.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the company, along with NANTibody, filed an arbitration against Sorrento and Dr.&#160;Ji asserting our claims relating to the exclusive license agreement. Sorrento filed counterclaims against the company and NANTibody in the arbitration. The hearings in the NANTibody arbitration commenced in April&#160;2021 and concluded in early August&#160;2021. After post-hearing briefing was concluded, the parties were notified on November&#160;30,&#160;2021 that the arbitrator in the NANTibody arbitration had passed away. A substitute arbitrator was appointed on February&#160;25,&#160;2022, and the parties worked with the substitute arbitrator to conclude the proceedings. Additional hearing sessions were held in May and July&#160;2022, and summations took place on August&#160;2,&#160;2022. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;2, 2022, the arbitrator issued a final award finding that Sorrento had breached the two&#160;exclusive license agreements with NantCell and NANTibody. The arbitrator awarded NantCell approximately $156.8&#160;million and NANTibody approximately $16.7&#160;million, plus post-award interest accruing at a daily rate. On December&#160;21,&#160;2022, NantCell and NANTibody filed petitions in the Superior Court to confirm the arbitration award; on January&#160;16,&#160;2023, Sorrento filed a response to the petitions and moved to vacate the award. On February&#160;7, 2023, after a hearing, the Superior Court entered orders confirming the arbitration award and denying Sorrento&#8217;s motion to vacate. The Superior Court entered judgments against Sorrento in the aggregate amount of approximately $176.4&#160;million plus 10% post-judgment interest, of which approximately $159.4&#160;million is payable to NantCell, and the remainder of which is payable to NANTibody. On February&#160;13,&#160;2023, Sorrento informed counsel to the company that it had filed a Chapter&#160;11 proceeding in the U.S. District Court for the Southern District of Texas, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Sorrento Therapeutics,&#160;Inc., et&#160;al.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Case No.&#160;23-bk-90085 (Bankr. S.D. Tex.) (DRJ). The company intends to continue to pursue vigorously, consistent with its rights in light of Sorrento&#8217;s Chapter&#160;11 filing, the collection of the judgments from Sorrento, but we make no assurances that we will receive the full amount or with respect to the timing of our receipt of any funds.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Superior Court action remains pending, and it remains to be determined how, if at all, the award in the arbitration will affect the Superior Court action. An estimate of the possible loss or range of loss resulting from the Superior Court litigation cannot be made at this time.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shenzhen Beike Biotechnology Co. Ltd. Arbitration</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we received a Request for Arbitration before the International Chamber of Commerce, International Court of Arbitration. The arbitration relates to a license, development, and commercialization agreement that Altor entered into with Beike in 2014, which agreement was amended and restated in 2017, pursuant to which Altor granted to Beike an exclusive license to use, research, develop and commercialize products based on N-803 in China for human therapeutic uses. In the arbitration, Beike is asserting a claim for breach of contract under the license agreement. Among other things, Beike alleges that we failed to use commercially reasonable efforts to deliver to Beike materials and data related to N-803. Beike is seeking specific performance and declaratory relief for the alleged breaches. On September&#160;25,&#160;2020, the parties entered into a standstill agreement under which, among other things, the parties affirmed they will perform certain of their obligations under the license agreement by specified dates and agreed that all deadlines in the arbitration are indefinitely extended. The standstill agreement could be terminated by any party on ten&#160;calendar days&#8217; notice, and upon termination, the parties had the right to pursue claims arising from the license agreement in any appropriate tribunal. On March&#160;20,&#160;2023, we terminated the standstill agreement, and on April&#160;11,&#160;2023, Beike served an amended Request for Arbitration. We have until May&#160;19,&#160;2023 to file a response. Given that this action remains at the pleading stage and no discovery has occurred, it remains too early to evaluate the likely outcome of the case or to estimate any range of potential loss. We believe the claims lack merit and intend to defend the case vigorously and that we may have counterclaims.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Altor BioScience, LLC, and NantCell, Inc. Matters Against Dr. Hing Wong and HCW Biologics, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;23,&#160;2022, Altor and NantCell filed an arbitration demand against Dr.&#160;Hing Wong, former CEO of Altor and NantCell. The demand asserts claims for breach of Dr.&#160;Wong&#8217;s contracts with the companies, breach of the covenant of good faith and fair dealing, conversion, fraudulent concealment, unjust enrichment, breach of fiduciary duty, and replevin. The same day, Dr.&#160;Wong filed an arbitration demand seeking a declaratory judgment finding that Dr.&#160;Wong is not liable to Altor or NantCell for any of their claims. The parties have agreed to consolidate the arbitration filings in one proceeding, and on January&#160;23,&#160;2023, Dr.&#160;Wong filed an Answering Statement denying the claims.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also on December&#160;23,&#160;2022, Altor and NantCell filed a complaint in the United States District Court for the Southern District of Florida against HCW&#160;Biologics, Inc. (HCW Biologics), Dr.&#160;Wong&#8217;s new company. Altor&#8217;s and NantCell&#8217;s complaint asserts claims for misappropriation of trade secrets under both Florida and federal law, inducement of breach of contract, tortious interference with contractual relations, inducement of breach of fiduciary duty, conversion, unjust enrichment, replevin, request for assignment of patents and patent applications, and establishment of a constructive trust. On January&#160;31,&#160;2023, HCW Biologics filed motions to compel arbitration of Altor&#8217;s and NantCell&#8217;s claims, or in the alternative to stay or dismiss them. Altor and NantCell filed an opposition to the motions on February&#160;14,&#160;2023, and HCW Biologics filed reply papers on February&#160;21,&#160;2023. At a hearing on April&#160;18,&#160;2023, the court heard argument and requested supplemental briefing. After the hearing, the parties reached an agreement to consolidate all claims in a single arbitration proceeding. On May&#160;1,&#160;2023, we filed our arbitration demand asserting the same claims against HCW that were asserted in the federal court complaint; HCW has yet to respond.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stipulation of Settlement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, following approval by our Board of Directors, we entered into a settlement agreement (the Stipulation of Settlement) with three&#160;stockholders of the company, each of whom had submitted a stockholder demand for the Board of Directors to take action to remedy purported harm to the company resulting from certain alleged wrongful conduct concerning, among other things, disclosures about Dr.&#160;Soon-Shiong&#8217;s compensation and a related-party lease agreement. The Stipulation of Settlement called for us to adopt certain governance changes, and for the three&#160;stockholders to file a stockholder derivative action in the Superior Court of the State of California, County of San Diego, followed by an application for court approval of the Stipulation of Settlement. The court entered an order preliminarily approving the Stipulation of Settlement. Pursuant to the Stipulation of Settlement, we provided stockholders with notice of the settlement and the final settlement hearing. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_178"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. &#160;&#160;&#160;&#160;RISK FACTORS. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, any of which may be relevant to decisions regarding an investment in or ownership of our stock. The occurrence of any of these risks could have a significant adverse effect on our reputation, business, financial condition, results of operations, growth, and ability to accomplish our strategic objectives. We have organized the description of these risks into groupings in an effort to enhance readability, but many of the risks interrelate or could be grouped or ordered in other ways, so no special significance should be attributed to the groupings or order below.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We anticipate needing additional financing to fund our operations and complete the development and commercialization of our various product candidates, and if we are unable to obtain such financing when needed, or on acceptable terms, we may be unable to complete the development and commercialization of our product candidates. </span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our debt could adversely affect our cash flows and limit our flexibility to raise additional capital.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Conversion of certain related-party notes may dilute the ownership interest of existing stockholders or may otherwise depress the price of our common stock.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The accounting method for convertible debt securities could have a material effect on our reported financial results.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The value of our warrants outstanding is subject to potentially material increases and decreases based on fluctuations in the price of our common stock, which may affect our results of operations and financial position and could adversely affect our stock price.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a clinical-stage biotechnology company with a limited operating history and no products approved for commercial sale. We have a history of operating losses, and we expect to continue to incur losses and may never be profitable, which together with our limited operating history, makes it difficult to assess our future viability.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery, Development and Commercialization of our Product Candidates</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will be substantially dependent on the success of our product candidates and cannot guarantee that these product candidates will successfully complete development, receive regulatory approval or be successfully commercialized.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are developing product candidates in combination with other therapies, which exposes us to additional risks.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may choose to expend our limited resources on programs that do not yield successful product candidates as opposed to indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our projections regarding the market opportunities for our product candidates may not be accurate, and the actual market for our products, if approved, may be smaller than we estimate.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates, which would prevent or delay regulatory approval and commercialization. If our trials are not successful, we will be unable to commercialize our product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reliance on Third Parties</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited experience conducting clinical trials and have relied and will rely on third parties and related parties to conduct many of our preclinical studies and clinical trials, to manufacture products and to perform many essential services for any products that we commercialize, including services related to distribution, government price reporting, customer service, accounts receivable management, cash collection and adverse event reporting. Any failure by a third party, related party, or by us to perform as expected, to comply with legal and regulatory requirements or to conduct the clinical trials according to Good Clinical Practice (GCP) regulations, and in a timely manner, may delay or prevent our ability to seek or obtain regulatory approval for or commercialization of our product candidates and our ability to commercialize our current or future product candidates will be significantly impacted and we may be subject to regulatory sanctions.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If third-party manufacturers, wholesalers and distributors fail to perform as expected, or fail to devote sufficient time and resources to our product candidates, our clinical development may be delayed, our costs may be higher than expected or our product candidates may fail to be approved, or we may fail to commercialize any product candidates if approved.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We use the Clinic, a related party, in some of our clinical trials which may expose us to significant regulatory risks. If our data for this site is not sufficiently robust or if there are any data integrity issues, we may be required to repeat such studies or required to contract with other clinical trial sites, and our clinical development plans will be significantly delayed, and we will incur additional costs.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have formed, and may in the future form or seek, strategic alliances or enter into collaborations with third&#160;parties or additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements. If we fail to enter into such strategic alliances, collaborations or licensing arrangements, or such strategic alliances, collaborations or licensing arrangements are not successful, we may not be able to capitalize on the market potential of our product candidates.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Healthcare and Other Government Regulations</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, be unable to commercialize our product candidates. We are, and if we receive regulatory approval of our product candidates, will continue to be subject to ongoing extensive regulation, regulatory obligations and continued regulatory review, which may result in significant additional expense.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we receive regulatory approval for our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease, or any other product candidates, they will be subject to ongoing regulatory requirements, which may result in significant additional expenses. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. </span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to establish sales, marketing and distribution capabilities, we may not be successful commercializing our product candidates if and when they are approved.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Problems related to large scale commercial manufacturing could cause delays in product launches, an increase in costs or shortages of product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain, maintain, protect and enforce patent protection and other proprietary rights for our product candidates and technologies, we may not be able to compete effectively or operate profitably and our ability to prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If any of our owned or in-licensed patent applications do not issue as patents in any jurisdiction, we may not be able to compete effectively. </span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We or our licensors, collaborators, or any future strategic partners may become subject to third-party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to resort to litigation to protect or enforce our patents or other intellectual property or the patents or other intellectual property of our licensors, all of which could be expensive, time-consuming and unsuccessful, may delay or prevent the development and commercialization of our product candidates, or may put our patents and other proprietary rights at risk.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The use of our technology and product candidates could potentially conflict with the rights of others, and third-party claims of intellectual property infringement, misappropriation or other violation against us, our licensors or our collaborators may prevent or delay the development and commercialization of our product candidates and technologies.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock and CVRs</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dr.&#160;Soon-Shiong, our Executive Chairman, Global Chief Scientific and Medical Officer and our principal stockholder, has significant interests in other companies which may conflict with our interests.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dr.&#160;Soon-Shiong, through his voting control of the company, has the ability to control actions that require stockholder approval. </span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market price of our common stock has been and may continue to be volatile, and investors may have difficulty selling their shares.</span></div><div style="margin-top:18pt"><span id="ifa3b7a3cc11d4404ac74f2cf3674ddcf_318922"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need additional financing to fund our operations and complete the development and commercialization of our various product candidates, and if we are unable to obtain such financing when needed, or on acceptable terms, we may be unable to complete the development and commercialization of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception. A significant portion of our funding had been in the form of promissory notes totaling $769.9&#160;million in indebtedness (consisting of related-party promissory notes and accrued and unpaid interest) as of March&#160;31,&#160;2023 held by entities affiliated with Dr.&#160;Soon-Shiong.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, we held cash, cash equivalents and marketable securities totaling $92.1&#160;million. We will need to obtain additional financing to fund our future operations, including completing the development and commercialization of our product candidates. Changing circumstances may cause us to increase our spending significantly faster than we currently anticipate and we may need to raise additional funds sooner than we presently anticipate. Moreover, research and development and our operating costs and fixed expenses such as rent and other contractual commitments, including those for our research collaborations, are substantial and are expected to increase in the future.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless and until we can generate a sufficient amount of revenues, we may finance future cash needs through public or private equity offerings, license agreements, debt financings, collaborations, strategic alliances and marketing or distribution arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms, or at all.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity or equity-linked securities (including warrants) convertible debt, or through the ATM, the shelf registration statement or other offerings, or if any of our current debt is converted into equity, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of additional indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third&#160;parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may be required to delay or reduce the scope of or eliminate one or more of our research or development programs or our commercialization efforts. Our current license and collaboration agreements may also be terminated if we are unable to meet the payment obligations under those agreements. As a result, we may seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our debt could adversely affect our cash flows and limit our flexibility to raise additional capital.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a significant amount of debt and may need to incur additional debt to support our growth. As of March&#160;31,&#160;2023, our indebtedness totals $769.9&#160;million, (consisting of related-party promissory notes and accrued and unpaid interest), held by entities affiliated with Dr.&#160;Soon-Shiong.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our substantial amount of debt could have important consequences and could:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to dedicate a substantial portion of our cash and cash equivalents to make interest and principal payments on our debt, reducing the availability of our cash and cash equivalents and cash flow from operations to fund future capital expenditures, working capital, execution of our strategy and other general corporate requirements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase our cost of borrowing and even limit our ability to access additional debt to fund future growth;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase our vulnerability to general adverse economic and industry conditions and adverse changes in governmental regulations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our flexibility in planning for, or reacting to, changes in our business and industry, which may place us at a disadvantage compared with our competitors; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our ability to borrow additional funds, even when necessary to maintain adequate liquidity, which would also limit our ability to further expand our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of the foregoing factors could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the company&#8217;s ability to make scheduled payments of the principal of, to pay interest on, or to refinance any current or future indebtedness, including the related-party promissory notes, depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not generate sufficient cash flows from operations in the future to service our indebtedness and make necessary capital expenditures. If we are unable to generate such cash flows, we may be required to adopt one or more alternatives, such as selling assets, restructuring indebtedness or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness, at maturity or otherwise, will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we can refinance these promissory notes or what terms will be available in the market at the time of refinancing. Furthermore, if prevailing interest rates or other factors at the time of refinancing result in higher interest rates upon refinancing, then the interest expense relating to the refinanced indebtedness would increase. These risks could materially adversely affect our financial condition, cash flows and results of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion of certain related-party notes may dilute the ownership interest of existing stockholders or may otherwise depress the price of our common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, the company currently has promissory notes totaling an aggregate of $769.9&#160;million, (consisting of related-party promissory notes and accrued and unpaid interest) held by entities affiliated with Dr.&#160;Soon-Shiong (some of which are convertible under certain circumstances), including variable-rate promissory notes in an aggregate amount of $505.0&#160;million that become due and payable on December&#160;31,&#160;2023, and fixed-rate promissory notes in an aggregate amount of $264.9&#160;million (consisting of principal and accrued and unpaid interest) that become due and payable on September&#160;30,&#160;2025. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a default on the $300.0&#160;million loan (as defined in the promissory note), including if the company does not repay the loan at maturity, the company has the right, at its sole option, to convert the outstanding principal amount of accrued and unpaid interest due under this note into shares of the company&#8217;s common stock at a price of $5.67&#160;per share. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the March&#160;31,&#160;2023 $30.0&#160;million promissory note and accrued interest may be converted in whole at the option of the noteholder following the Conversion Price Date, which is the trading day prior to the opening of the next open trading window, as determined by the company&#8217;s board of directors in accordance with the company&#8217;s Insider Trading Policy. The conversion price is equal to the greater of (i)&#160;the NASDAQ Official Closing Price and (ii)&#160;the consolidated closing bid price of the company&#8217;s common stock on the Conversion Price Date. There is no floor on the conversion price for this convertible note, therefore, as of March&#160;31,&#160;2023 we cannot determine the total number of shares issuable upon conversion that may occur in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the fixed-rate promissory notes were amended and restated on August&#160;31,&#160;2022 to include a conversion feature that gives each lender the right at any time, at its sole option (other than when the lender is in receipt of a written notice of prepayment from the borrower), the right to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the company&#8217;s common stock at a price of $5.67 per share. Upon receipt of a written notice of prepayment from the borrower, the lender has the right, at its option, to convert the outstanding principal amount to be prepaid and the accrued and unpaid interest thereon (as specified in the notice of prepayment) into shares of the company&#8217;s common stock at a price of $5.67&#160;per share. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion of some or all of the aforementioned promissory notes, to the extent we deliver shares upon conversion, at a time when the company&#8217;s common stock is valued at greater than $5.67&#160;per share would dilute the ownership interests of existing stockholders. Any sales in the public market of the promissory notes or our common stock issuable upon conversion of the promissory notes could adversely affect prevailing market prices of our common stock </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accounting method for convertible debt securities could have a material effect on our reported financial results.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC&#160;470-50, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt &#8211; Modifications and Extinguishments,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we recorded the amendments to our related-party promissory notes entered into on August&#160;31,&#160;2022 under the extinguishment accounting model, as the amendments to the fixed-rate promissory notes added a substantive conversion option to the debt. Under this model, the company calculated a gain on extinguishment of $82.9&#160;million, representing the difference between the fair value of the new and amended promissory notes and the carrying value of the extinguished debt, net of any unamortized related-party notes discounts plus the cash proceeds from the new promissory note. Since the debt was obtained from entities under common control, such gain was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the condensed consolidated statement of stockholders&#8217; deficit for the three months ended March&#160;31,&#160;2023. Also, the difference between the principal and accrued interest outstanding as of the date of amendment and the fair value of the new and amended promissory notes was recorded as a debt discount to be amortized as interest expense over the remaining term (or until conversion). As a result, we will be required to record a greater amount of non-cash interest expense in current periods presented as a result of the amortization of the discounted carrying value of the promissory notes to their face amount over the term of such notes. We will report lower net income in our consolidated financial results because ASC&#160;470-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt with Conversion and Other Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires interest to include both the current period&#8217;s amortization of the debt discount and the instrument&#8217;s coupon interest, which could adversely affect our reported or future financial results and the trading price of our common stock.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August&#160;2020, the FASB issued ASU&#160;2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt &#8211; Debt with Conversion and Other Options (Subtopic&#160;470-20),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to reduce complexity in applying U.S.&#160;GAAP to certain financial instruments with characteristics of liability and equity. In addition, the new guidance requires diluted earnings per share (diluted EPS) calculations be prepared using the if-converted method instead of the treasury stock method. Under the if-converted method, the denominator of the diluted EPS calculation is adjusted to reflect the full number of common shares issuable upon conversion, assuming the effect is dilutive, while the numerator is adjusted to add back interest expense (after-tax) for the period. Also, the new guidance eliminated the ability to overcome the presumption of share settlement. The company adopted this statement effective January&#160;1,&#160;2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The value of our warrants outstanding is subject to potentially material increases and decreases based on fluctuations in the price of our common stock, which may affect our results of operations and financial position and could adversely affect our stock price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December&#160;2022, we completed a registered direct offering of 9,090,909&#160;shares, raising approximately $47.0&#160;million in net proceeds. In connection with the sale of our common stock, we entered into a warrant agreement that allows the investor to purchase up to 9,090,909&#160;shares at an exercise price of $6.60&#160;per share. The warrants are immediately exercisable and expire two years after the initial issuance date. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February&#160;2023, we completed a registered direct offering of 14,072,615&#160;shares, raising approximately $47.0&#160;million in net proceeds. In connection with the sale of our common stock, we entered into a warrant agreement that allows the investors to purchase up to 14,072,615&#160;shares at an exercise price of $4.26&#160;per share. The warrants are immediately exercisable and expire two years after the initial issuance date. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the warrants as a derivative instrument, and changes in the fair value of the warrants are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other income (expense), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statement of operations for each reporting period. At March&#160;31,&#160;2023, the fair value of warrant liabilities included in the company&#8217;s condensed consolidated balance sheet was $17.8&#160;million. We used the Black-Scholes option pricing model to determine the fair value of the warrants. As a result, the valuation of this derivative instrument is subjective, and the Black-Scholes option pricing model requires the input of highly subjective assumptions, including the expected stock price volatility and probability of a fundamental transaction (a strategic merger or sale). Changes in these assumptions can materially affect the fair value estimate. We could, at any point in time, ultimately incur amounts different than the carrying value, which could have a significant impact on our results of operations and financial position.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#373739;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fluctuations of warrant value and changes in the assumptions and factors used in the model may impact our operating results, making it difficult to forecast our operating results and making period-to-period comparisons less predictive of future performance. In one or more future quarters, our results of operations may fall below the expectations of securities analysts and investors. In that event, the market price of our common stock could decline. In addition, the market price of our common stock may fluctuate or decline regardless of our operating performance.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">clinical-stage biotechnology</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> company with a limited operating history and no products approved for commercial sale. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of operating losses, and we expect to continue to incur losses and may never be profitable, which together with our limited operating history, makes it difficult to assess our future viability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company with a limited operating history upon which you can evaluate our business and prospects, and we have a broad portfolio of product candidates at various stages of development. None of our products have been approved for commercial sale, and we have not generated any revenue from product sales, although we have generated revenues from non-exclusive license agreements related to our cell lines, the sale of our bioreactors and related consumables and grant programs. In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biotechnology industry, including in connection with obtaining marketing approvals, manufacturing a commercial-scale product or arranging for a third&#160;party to do so on our behalf or conducting sales and marketing</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities necessary for successful product commercialization. Because of the numerous risks and uncertainties associated with our product development efforts, we are unable to predict when we may become profitable, if at all.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the commencement of our operations, we have incurred significant losses each year, and, as of March&#160;31,&#160;2023 we had an accumulated deficit of $2.5&#160;billion. We expect to continue to incur significant expenses as we seek to expand our business, including in connection with conducting research and development across multiple therapeutic areas, participating in clinical trial activities, continuing to acquire or in-license technologies, maintaining, protecting and expanding our intellectual property, seeking regulatory approvals, increasing our manufacturing capabilities and, upon successful receipt of FDA approval, commercializing our products. Moreover, we do not expect to have significant product sales or revenue in the near term, if ever.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are required by the FDA or any equivalent foreign regulatory authority to perform clinical trials or studies in addition to those we currently expect to conduct, or if there are any delays in completing the clinical trials of our product candidates, our expenses could increase substantially. We have submitted a BLA for our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease, which was accepted by the FDA for review with a target PDUFA action date of May&#160;23,&#160;2023. On May&#160;9,&#160;2023, the FDA delivered a complete response letter to us regarding the BLA, as described in greater detail in Part&#160;I, Item&#160;2 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_163">&#8212;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_163">Subsequent Events</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_163">.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> It is unclear when the FDA will approve our BLA, if at all, for commercialization and even if approved, the resulting revenue may not enable us to achieve profitability. Even if we obtain regulatory approval to market a product candidate, our future revenues will depend upon the size of any markets in which our product candidates have received approval, and our ability to achieve sufficient market acceptance, reimbursement from third-party payors and adequate market share for our product candidates in those markets. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our expenses and net losses to increase significantly as we prepare to potentially commercialize our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease, if approved by the FDA, continue our development of, and seek regulatory approvals for, our other product candidates, and begin to commercialize other approved products, if any, as well as hire additional personnel, protect our intellectual property and incur additional costs associated with operating as a public company. Our net losses may fluctuate significantly from quarter to quarter and year to year, depending on the timing of our clinical studies and trials, associated manufacturing needs, commercialization activities if our product candidates are approved and our expenditures on other research and development activities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our research and development efforts are successful, we may also face the risks associated with the shift from development to commercialization of new products based on innovative technologies. Our ability to achieve profitability, if ever, is dependent upon, among other things, obtaining regulatory approvals for our product candidates and successfully commercializing our product candidates alone or with third&#160;parties. However, our operations may not be profitable even if one or more of our product candidates under development are successfully developed and produced and thereafter commercialized. Even if we do become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis. As a result, it may be more difficult for you to assess our future viability than it could be if we had a longer operating history.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We invest our cash on hand in various financial instruments which are subject to risks that could adversely affect our business, results of operations, liquidity and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest our cash in a variety of financial instruments, principally commercial paper, corporate debt securities and government bonds. All of these investments are subject to credit, liquidity, market and interest rate risk. Such risks, including the failure or severe financial distress of the financial institutions that hold our cash, cash equivalents and investments, may result in a loss of liquidity, impairment to our investments, realization of substantial future losses, or a complete loss of the investments in the long-term, which may have a material adverse effect on our business, results of operations, liquidity and financial condition. In order to manage the risk to our investments, we maintain an investment policy that, among other things, limits the amount that we may invest in any one issue or any single issuer and requires us to only invest in high credit quality securities to preserve liquidity.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use NOLs and research and development credits to offset future taxable income may be subject to certain limitations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, as amended, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change NOLs or credits, to offset future taxable income or taxes. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at least 5%&#160;of a corporation&#8217;s stock increases its ownership by more than 50&#160;percentage points over its lowest ownership percentage within a specified testing period. We have not conducted a complete study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If we have experienced a change of control, as defined by Section&#160;382, at any time since inception (including as a result of the Merger), utilization of the NOL carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section&#160;382. Any limitation may result in expiration of a portion of the NOL carryforwards or research and development tax credit carryforwards before utilization. In addition, our NOLs or credits may also be impaired under state law. Accordingly, we may not be able to utilize a material portion of our NOLs or credits.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we will need to raise substantial additional funding to finance our operations, we may experience further ownership changes in the future, some of which may be outside of our control. Limits on our ability to use our pre-change NOLs or credits to offset U.S.&#160;federal taxable income could potentially result in increased future tax liability to us if we earn net taxable income in the future. In addition, under the legislation commonly referred to as the Tax Cuts and Jobs Act of 2017 (TCJA), as modified by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), the amount of NOLs generated in taxable periods beginning after December&#160;31,&#160;2017, that we are permitted to deduct in any taxable year beginning after December&#160;31,&#160;2020 is limited to 80%&#160;of our taxable income in such year, where taxable income is determined without regard to the NOL deduction itself. The TCJA allows post-2017 unused NOLs to be carried forward indefinitely. Similar rules may apply under state tax laws.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our transfer pricing policies may be subject to challenge by the Internal Revenue Service or other taxing authorities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intercompany relationships are subject to complex transfer pricing regulations administered by taxing authorities in various jurisdictions. The relevant taxing authorities may disagree with our determinations as to the value of assets sold or acquired or income and expenses attributable to specific jurisdictions. If such a disagreement were to occur, and our position were not sustained, we could be required to pay additional taxes, interest and penalties, which could result in one-time tax charges, higher effective tax rates, reduced cash flows, and lower overall profitability of our operations. We believe that our consolidated financial statements reflect adequate reserves to cover such a contingency, but there can be no assurances in that regard.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span id="ifa3b7a3cc11d4404ac74f2cf3674ddcf_318923"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery, Development and Commercialization of our Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will be substantially dependent on the success of our product candidates and cannot guarantee that these product candidates will successfully complete development, receive regulatory approval or be successfully commercialized.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through the date of this Quarterly Report on Form 10-Q, we have generated minimal revenue from non-exclusive license agreements related to our cell lines, the sale of our bioreactors and related consumables, and grant programs. We have no clinical products approved for commercial sale and have not generated any revenue from therapeutic and vaccine product candidates that are under development. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May&#160;2022, we announced the submission of a BLA to the FDA for our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease. In July&#160;2022, we announced that the FDA had accepted our BLA for review and set a target PDUFA action date of May&#160;23,&#160;2023. On May&#160;9,&#160;2023, the FDA delivered a complete response letter to us regarding the BLA, as described in greater detail in Part&#160;I, Item&#160;2 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_163">&#8212;Subsequent Events</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> It is unclear when the FDA will approve our BLA, if at all. We have invested a significant portion of our efforts and financial resources in the development of our main product candidates, N-803, our novel</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> antibody cytokine fusion protein</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, saRNA and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">second-generation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hAd5 vaccine candidates, and aldoxorubicin, some of which are used in combination with our NK&#160;cell therapy candidates. Our product candidates will require additional clinical and non-clinical development, regulatory approval, commercial manufacturing arrangements, establishment of a commercial organization, significant marketing efforts, and further investment before we can generate any revenues from product sales. We expect to invest heavily in these product candidates as well as in our other existing product candidates and in any future product candidates that we may develop. Our product candidates are susceptible to the risks of failure inherent at any stage of product development, including the appearance of unexpected adverse events or failure to achieve primary endpoints in clinical trials. Furthermore, we cannot assure you that we will meet our timelines for current or future clinical trials, which may be delayed or not completed for a number of reasons. Additionally, our ability to generate revenues from our combination therapy products will also depend on the availability of the other therapies with which our products are intended to be used. We currently generate no meaningful revenues from the sale of any product candidates, and we may never be able to develop or commercialize a product.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are developing product candidates in combination with other therapies, which exposes us to additional risks.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing product candidates in combination with one or more other therapies. We are studying N-803&#160;therapy along with other products and product candidates, such as BCG, PD-L1 t-haNK, hAd5 and yeast tumor-associated antigens (TAAs), and aldoxorubicin. If we choose to develop a product candidate for use in combination with an approved therapy, we are subject to the risk that the FDA, EMA or comparable foreign regulatory authorities in other jurisdictions could revoke approval of, or that safety, efficacy, manufacturing or supply issues could arise with the therapy used in combination with our product candidate. The FDA may require us to use more complex clinical trial designs in order to evaluate the contribution of each product and product candidate to any observed effects. To the extent that we do not have rights to already approved products, this may require us to work with another company to satisfy such a requirement or increase our cost of development. It is possible that the results of these trials could show that any positive results are attributable to the already approved product. Following product approval, the FDA may require that products used in conjunction with each other be cross labeled for combined use. If the therapies we use in combination with our product candidates are replaced as the standard of care for the indications we choose for any of our product candidates, the FDA or comparable foreign regulatory authorities may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, unapproved therapies face the same risks described with respect to our product candidates currently in development and clinical trials, including the potential for serious adverse effects, delays in clinical trials and lack of FDA approval. If the FDA or comparable foreign regulatory authorities do not approve or revoke their approval of these other therapies, or if safety, efficacy, quality, manufacturing or supply issues arise with, the therapies we choose to evaluate in combination with any of our product candidates, we may be unable to obtain approval of or market such combination therapy.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may choose to expend our limited resources on programs that do not yield successful product candidates as opposed to indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have sufficient resources to pursue development of all or even a substantial portion of the potential opportunities that we believe will be afforded to us by our product candidates. Because we have limited resources and access to capital to fund our operations, our management must make strategic decisions as to which product candidates and indications to pursue and how much of our resources to allocate to each. Our management must also evaluate the benefits of developing in&#8209;licensed or jointly owned technologies, which in some circumstances we may be contractually obligated to pursue, relative to developing other product candidates, indications or programs. Our management has broad discretion to suspend, scale down, or discontinue any or all of these development efforts, or to initiate new programs to treat other diseases. If we select and commit resources to opportunities that we are unable to successfully develop, or we forego more promising opportunities, our business, financial condition and results of operations will be adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our projections regarding the market opportunities for our product candidates may not be accurate, and the actual market for our products, if approved, may be smaller than we estimate.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our current product candidates and any future product candidates will represent novel approaches to treating various conditions, it may be difficult, in any event, to accurately estimate the potential revenues from these product candidates. Accordingly, we may spend significant capital trying to obtain approval for product candidates that have an uncertain commercial market. Our projections of addressable patient populations that may benefit from treatment with our product candidates are based on our beliefs and estimates. These estimates, which have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research by third parties, may prove to be incorrect. Further, new studies or approvals of new therapeutics may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates and may also be limited by the cost of our treatments and the reimbursement of those treatment costs by third-party payors. Even if we obtain significant market share for our product candidates, because the potential target populations may be small, we may never achieve profitability without obtaining regulatory approval for additional indications.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates, which would prevent or delay regulatory approval and commercialization. If our trials are not successful, we will be unable to commercialize our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development programs are at various stages of development. The clinical trials of our product candidates as well as the manufacturing and marketing of our product candidates will be subject to extensive and rigorous review and regulation by numerous government authorities in the U.S. and in other countries where we intend to test and market our product candidates. Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are safe, pure, and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. The risk/benefit profile required for product licensure will vary depending on these factors and may include not only the ability to show tumor shrinkage, but also adequate duration of response, a delay in the progression of the disease, and/or an improvement in survival. For example, response rates from the use of our product candidates may not be sufficient to obtain regulatory approval unless we can also show an adequate duration of response. The clinical trials for our product candidates under development may not be completed on schedule and regulatory authorities may ultimately disagree with our chosen endpoints or may find that our studies or study results do not support product approval and we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do or accept the therapeutic effects as valid endpoints in clinical trials necessary for market approval or they may find that our clinical trial design or conduct does not meet the applicable approval requirement and more trials could be required before we submit our product candidates for approval. Success in early clinical trials does not ensure that large-scale clinical trials will be successful, nor does it predict final results. Product candidates in later stages of clinical trials may fail to show the desired safety, tolerability and efficacy traits despite having progressed through preclinical studies and initial clinical trials and after reviewing test results, we or our collaborators may abandon projects that we might previously have believed to be promising. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we do not have data on possible harmful long-term effects of our product candidates and do not expect to have this data in the near future. As a result, our ability to generate clinical safety and effectiveness data sufficient to support submission of a marketing application or commercialization of our product candidates is uncertain and is subject to significant risk.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, initial, &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose preliminary, interim or top-line data from our preclinical studies and clinical trials, which are based on preliminary analyses of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. We also may make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, top-line data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, top-line or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may not be initiated or completed when we expect, or at all, they may take longer and cost more to complete than we project, our clinical trial costs may be higher than for more conventional therapeutic technologies or drug products, and we may be required to conduct additional clinical trials or modify current or future clinical trials based on feedback we receive from the FDA.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that any current or future clinical trials will be conducted as planned or completed on schedule, if at all, or that any of our product candidates will receive regulatory approval. A failure of one or more clinical trials can occur at any stage of the clinical trial process, other events may cause us to temporarily or permanently stop a clinical trial, and our future clinical trials may not be successful. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our product candidates include, and we expect our future product candidates to include, candidates based on advanced therapy technologies, we expect that they will require extensive research and development and have substantial manufacturing costs. In addition, costs to treat patients and to treat potential side effects that may result from our product candidates can be significant. Some clinical trial sites may not bill, or obtain coverage from Medicare, Medicaid, or other third-party payors for some or all of these costs for patients enrolled in our clinical trials, and clinical trial sites outside of the U.S. may not reimburse for costs typically covered by third-party payors in the U.S., and as a result we may be required by those trial sites to pay such costs. Accordingly, our clinical trial costs are likely to be significantly higher per patient than those of more conventional therapeutic technologies or drug products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations with other entities may be subject to additional delays because of the management of the trials, contract negotiations, the need to obtain agreement from multiple parties and the necessity of obtaining additional approvals for therapeutics used in the combination trials. These combination therapies will require additional testing and clinical trials will require additional FDA regulatory approval and will increase our future costs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to successfully complete preclinical and clinical development could result in additional costs to us, slow down our product development and approval process or impair our ability to commence product sales and generate revenues. In addition, if we make manufacturing changes to our product candidates, we may be required to, or we may elect to, conduct additional trials to bridge our modified product candidates to earlier versions. These changes may require FDA approval or notification and may not have their desired effect. The FDA may also not accept data from prior versions of the product to support an application, delaying our clinical trials or programs or necessitating additional clinical trials or preclinical studies. We may find that this change has unintended consequences that necessitates additional development and manufacturing work, additional clinical and preclinical studies, or that results in refusal to file or non-approval of a BLA and/or NDA.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial delays could shorten any periods during which our product candidates have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. In addition, we have in the past experienced clinical holds imposed upon certain of our or investigator-led clinical trials for various reasons, and we may experience further clinical trial holds in the future. If we fail to commence or complete, or experience delays in, any of our planned clinical trials, our stock price and our ability to conduct our business as currently planned could be harmed.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if one of our product candidates is approved and commercialized, we may not become profitable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If approved for marketing by applicable regulatory authorities, our ability to generate revenues from our product candidates will depend on our ability to: </span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">price our product candidates competitively such that third-party and government reimbursement leads to broad product adoption;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prepare a broad network of clinical sites for administration of our product;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">create market demand for our product candidates through our own marketing and sales activities, and any other arrangements to promote these product candidates that we may otherwise establish;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receive regulatory approval for the targeted patient population(s) and claims that are necessary or desirable for successful marketing;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacture product candidates through CMOs or in our own, or our affiliates&#8217;, manufacturing facilities in sufficient quantities and at acceptable quality and manufacturing cost to meet commercial demand at launch and thereafter;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish and maintain agreements with wholesalers, distributors, pharmacies, and group purchasing organizations on commercially reasonable terms;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain, maintain, protect and enforce patent and other intellectual property protection and regulatory exclusivity for our product candidates;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully commercialize any of our product candidates that receive regulatory approval;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain compliance with applicable laws, regulations, and guidance specific to commercialization including interactions with health care professionals, patient advocacy groups, and communication of health care economic information to payors and formularies;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">achieve market acceptance of our product candidates by patients, the medical community, and third-party payors;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">achieve appropriate reimbursement for our product candidates;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain a distribution and logistics network capable of product storage within our specifications and regulatory guidelines, and further capable of timely product delivery to commercial clinical sites;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively compete with other therapies or competitors; and</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">following launch, assure that our product will be used as directed and that additional unexpected safety risks will not arise.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA approves N-803 for certain indications or in combination with other therapeutic products, and even if we obtain significant market share for it, because the potential target population may be small, we may never achieve profitability without obtaining regulatory approval for additional indications. The FDA often approves new therapies initially only for use in patients with r/r&#160;metastatic disease, which may limit our patient population. Additionally, we may not be able to obtain the labeling claims necessary or desirable for the promotion of our product candidates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our 2017 acquisition of Altor, we issued CVRs under which we agreed to pay the prior stockholders of Altor approximately $304.0&#160;million of contingent consideration upon the&#160;successful regulatory approval of a BLA by the FDA, or foreign equivalent, for N-803 by December&#160;31,&#160;2022, and approximately $304.0&#160;million of contingent consideration upon calendar-year worldwide net sales of N-803 exceeding $1.0&#160;billion prior to December&#160;31,&#160;2026 with amounts payable in cash or shares of our common stock or a combination thereof. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the regulatory milestone CVR agreement, in May&#160;2022 we announced the submission of a BLA to the FDA for our product candidate, Anktiva (N-803) in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1 disease. In July&#160;2022 we announced that the FDA had accepted our BLA for review and set a target PDUFA action date of May&#160;23,&#160;2023. On May&#160;9,&#160;2023, the FDA delivered a complete response letter to us regarding the BLA, as described in greater detail in Part&#160;I, Item&#160;2 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_163">&#8212;Subsequent Events</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> It is unclear when the FDA will approve our BLA, if at all. The FDA did not approve our BLA on or before December&#160;31,&#160;2022, and therefore the regulatory milestone was not met, and the regulatory milestone CVR agreement terminated in accordance with its terms. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the net sales milestone CVR agreement, as of December&#160;31,&#160;2022, Dr.&#160;Soon-Shiong and his related party hold approximately $139.8&#160;million of net sales CVRs and they have both irrevocably agreed to receive shares of the company&#8217;s common stock in satisfaction of their CVRs. We may be required to pay the other prior Altor stockholders up to $164.2&#160;million for their net sales CVRs should they choose to have their CVRs paid in cash instead of common stock. If this were to occur, we may need to seek additional sources of capital, and we may not be able to achieve profitability or positive cash flow.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to collaborate with governmental, academic and corporate partners, including affiliates, to improve and develop N-803, hAd5 and other therapies for new indications for use in combination with other therapies and to improve and develop other product candidates, which may expose us to additional risks, or we may not realize the benefits of such collaborations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we encounter delays or difficulties enrolling and/or maintaining patients in our clinical trials, our clinical development activities and receipt of necessary marketing approvals could be delayed or otherwise adversely affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. We may experience difficulties or delays in patient enrollment and retention in our clinical trials for a variety of reasons.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the number of qualified clinical investigators is limited, we may need to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. Moreover, because our product candidates represent a departure from more commonly used methods for cancer and/or viral disease treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy and approved immunotherapies that have established safety and efficacy profiles, rather than enroll patients in any future clinical trial.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays or failures in planned patient enrollment or retention may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates, or could render further development impossible.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results of our trials could reveal a high and unacceptable severity and prevalence of side effects, adverse events or unexpected characteristics. Combination immunotherapy that includes our current product candidates may be associated with more frequent adverse events or additional adverse events. Undesirable side effects or unacceptable toxicities caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials or order our clinical trials to be placed on clinical hold, and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications. The FDA or comparable foreign regulatory authorities may also require additional data, clinical trials, or preclinical studies should unacceptable toxicities arise. We may need to abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk/benefit perspective. Toxicities associated with our clinical trials and product candidates may also negatively impact our ability to conduct clinical trials using tumor-infiltrating lymphocyte therapy in larger patient populations, such as in patients that have not yet been treated with other therapies or have not yet progressed on other therapies. Even if we were to receive product approval, such approval could be contingent on inclusion of unfavorable information in our product labeling, such as limitations on the indicated uses for which the products may be marketed or distributed, a label with significant safety warnings, including boxed warnings, contraindications, and precautions, a label without statements necessary or desirable for successful commercialization, or requirements for costly post marketing testing and surveillance, or other requirements, including a Risk Evaluation and Mitigation Strategy (REMS) to monitor the safety or efficacy of the products, and in turn prevent us from commercializing and generating revenues from the sale of our current or future product candidates. In addition, these serious adverse effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from our product candidates are not normally encountered in the general patient population and by medical personnel. They may have difficulty observing patients and treating toxicities, which may be more challenging due to personnel changes, shift changes, house staff coverage or related issues. This could lead to more severe or prolonged toxicities or even patient deaths, which could result in us or the FDA delaying, suspending or terminating one or more of our clinical trials and which could jeopardize regulatory approval. Any of these occurrences may materially harm our business, financial condition and prospects. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The manufacture of our product candidates is complex, and we may encounter difficulties in production, particularly with respect to process development, quality control, or scaling-up of our manufacturing capabilities. If we or our related parties, or any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of our product candidates involves complex processes, especially for our biologics, vectors and cell therapy product candidates, which are complex, highly regulated and subject to multiple risks. As a result of the complexities, the cost to manufacture biologics, vectors and cell therapies is generally higher than traditional small molecule chemical compounds, and the manufacturing process is less reliable and is more difficult to reproduce. The manufacture of cell therapy products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling up initial production. These problems include difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel and compliance with strictly enforced federal, state, local and foreign regulations. We may also find that the manufacture of our product candidates is more difficult than anticipated, resulting in an inability to produce a sufficient amount of our product candidates for our clinical trials or, if approved, commercial supply. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. Currently, our product candidates are manufactured using processes developed or modified by us, our affiliates or by our third-party collaborators that we may not utilize for more advanced clinical trials or commercialization. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently we manufacture our product candidates or we may use third-party CMOs or some of our related parties to manufacture our product candidates. Our clinical trials will need to be conducted with product candidates and materials that were produced under cGMP and/or Good Tissue Practice regulations, which are enforced by regulatory authorities. Our product candidates may compete with other products and product candidates for access to manufacturing facilities. Moreover, because of the complexity and novelty of our manufacturing process, there are only a limited number of manufacturers that operate under cGMP regulations and that are both capable of manufacturing our product candidates for us and willing to do so. If our CMOs should cease manufacturing for us, we would experience delays in obtaining sufficient quantities of our product candidates for clinical trials and, if approved, commercial supply. Further, our CMOs may breach, terminate, or not renew our agreements with them. If we were to need to find alternative manufacturing facilities it may take us significant time to find a replacement, if we are able to find a replacement at all and it would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. The commercial terms of any new arrangement could be less favorable than our existing arrangements and the expenses relating to the transfer of necessary technology and processes could be significant. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to comply or our CMOs&#8217; failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory review process. We may not be able to demonstrate sufficient comparability between products manufactured at different facilities to allow for inclusion of the clinical results from patients treated with products from these different facilities, in our product registrations. On May&#160;9,&#160;2023, the FDA delivered a complete response letter to us regarding the BLA. The letter indicated that the FDA had determined that it cannot approve the BLA in its present form, and the FDA had made recommendations to address the issues raised. The deficiencies relate to the FDA&#8217;s pre-license inspection of the company&#8217;s third-party contract manufacturing organizations. Satisfactory resolution of the observations noted at the pre-license inspection is required before the BLA may be approved. See Part&#160;I, Item&#160;2 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_163">&#8212;Subsequent Events.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are required to register certain clinical trials and post the results of certain completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so could result in enforcement actions and adverse publicity.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reliance on third-party manufacturers entails exposure to risks to which we would not be subject if we manufactured the product candidate ourselves, including:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to negotiate manufacturing and quality agreements with third&#160;parties under commercially reasonable terms;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced day-to-day control over the manufacturing process for our product candidates as a result of using third-party manufacturers for all aspects of manufacturing activities;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced control over the protection of our trade secrets, know-how and other proprietary information from misappropriation or inadvertent disclosure or from being used in such a way as to expose us to potential litigation;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination or nonrenewal of manufacturing agreements with third&#160;parties in a manner or at a time that may be costly or damaging to us or result in delays in the development or commercialization of our product candidates; and</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions to the operations of our third-party manufacturers or suppliers caused by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, any problems or delays we or our CMOs experience in preparing for commercial scale manufacturing of a product candidate may result in a delay in the FDA approval of the product candidate or may impair our ability to manufacture commercial quantities or such quantities at an acceptable cost, which could result in the delay, prevention, or impairment of clinical development and commercialization of our product candidates and could adversely affect our business. Furthermore, if we or our CMOs fail to deliver the required commercial quantities of our product candidates on a timely basis and at reasonable costs, we would likely be unable to meet demand for our products and we would lose potential revenues. We may ultimately be unable to reduce the cost of goods for our product candidates to levels that will allow for an attractive return on investment if and when those product candidates are commercialized.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the manufacturing process and facilities for any products that we may develop are subject to FDA and foreign regulatory authority approval processes, and we or our CMOs will need to meet all applicable FDA and foreign regulatory authority requirements, including cGMP, on an ongoing basis. The cGMP requirements include quality control, quality assurance and the maintenance of records and documentation. The FDA and other regulatory authorities enforce these requirements through facility inspections. Manufacturing facilities must submit to pre-approval inspections by the FDA that will be conducted after we submit our marketing applications, including BLAs and NDAs, to the FDA. Manufacturers are also subject to continuing FDA and other regulatory authority inspections following marketing approval. Further, we and our third-party CMOs must supply all necessary CMC documentation in support of a BLA or NDA on a timely basis. Our or our CMOs&#8217; manufacturing facilities may be unable to comply with our specifications, cGMP, and with other FDA, state, and foreign regulatory requirements, and there is no guarantee that we or our CMOs will be able to successfully pass all aspects of a pre-approval inspection by the FDA or other foreign regulatory authorities. On May&#160;9,&#160;2023, the FDA delivered a complete response letter to us regarding the BLA. The letter indicated that the FDA had determined that it cannot approve the BLA in its present form, and the FDA had made recommendations to address the issues raised. The deficiencies relate to the FDA&#8217;s pre-license inspection of the company&#8217;s third-party contract manufacturing organizations. Satisfactory resolution of the observations noted at the pre-license inspection is required before the BLA may be approved. See Part&#160;I, Item&#160;2 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_163">&#8212;Subsequent Events.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to resolve the items outlined in the complete response letter in a timely manner, if at all, which could have a material impact on our results of operations, financial condition, and business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of product candidates that may not be detectable in final product testing. If microbial, viral, environmental or other contaminants are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination which could delay clinical trials and adversely harm our business. If we or our CMOs are unable to reliably produce products to specifications acceptable to the FDA or other regulatory authorities, or in accordance with the strict regulatory requirements, we may not obtain or maintain the approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CMOs will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Deviations from manufacturing requirements may further require remedial measures that may be costly and/or time-consuming for us or a third&#160;party to implement and may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third&#160;parties with whom we contract could materially harm our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As product candidates progress through preclinical and clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenues.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we use CMOs, we are ultimately responsible for the manufacture of our products, if approved, and product candidates. A failure to comply with these requirements may result in regulatory enforcement actions against our manufacturers or us, including fines and civil and criminal penalties, which could result in imprisonment, suspension or restrictions of production, injunctions, delay or denial of product approval or supplements to approved products, clinical holds or termination of clinical trials, warning or untitled letters, regulatory authority communications warning the public about safety issues with the biologic, refusal to permit the import or export of the products, product seizure, detention, or recall, operating restrictions, suits under the federal civil False Claims Act (FCA), corporate integrity agreements, consent decrees, or withdrawal of product approval.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidate, impair commercialization efforts, increase our cost of goods, and have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in managing the build-out of our manufacturing facilities and associated costs or satisfying manufacturing related regulatory requirements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into facility leases for our planned manufacturing operations and related activities under which we are responsible for the build-out of the facility space and associated costs. The build-out of these facilities and related equipment purchases are complex and specialized and will involve substantial capital expenditure, and it could take longer, and cost more, than currently expected. Significant delays and/or cost overruns would result in higher expenditures and could be disruptive of operations, any of which could have a negative impact on our financial condition or results of operations. For example, during the first quarter of 2022 we acquired a leasehold interest in the 409,000&#160;square foot Dunkirk Facility as described below. While we believe that governmental funding will assist in funding a small portion of the further build-out of the Dunkirk Facility, we will need to plan and fund most of the additional build-out of, and purchase additional equipment for, the Dunkirk Facility in connection with our planned full operations. In addition, it is possible that, once built, the leased facilities may prove to be less conducive to our operations than is currently anticipated, resulting in operational inefficiencies or similar difficulties that could prove difficult or impossible to remediate and result in an adverse impact on our financial condition or results of operations. We also may not successfully realize the anticipated benefits from the capital expenditure at such facilities based on factors such as delays and uncertainties regarding development, regulatory approval and commercialization of our product candidates, as well as the potential to lose access to the leased facilities. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in the future if we transition from our current CMOs to our own manufacturing facilities for one or more of our product candidates, including our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG&#8209;unresponsive NMIBC with CIS with or without Ta or T1&#160;disease, for which we submitted a BLA in May&#160;2022, we may need to conduct additional preclinical, analytical or clinical trials and obtain FDA approval before such manufacturing changes are implemented. If we are unsuccessful in demonstrating the comparability of supplies before and after a manufacturing change, such manufacturing change can result in a delay or disruption in our clinical development plan or our ability to commercialize any approved product. Any production shortfall that impairs the supply of our product candidates could negatively impact our ability to complete clinical trials, obtain regulatory approval and commercialize our product candidates. If our product candidates receive approval, a product shortfall could have a material adverse effect on our business, financial condition and results of operations and adversely affect our ability to satisfy demand for our product candidates, which could materially and adversely affect our revenue and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our planned operations, including our development, testing and future manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that may have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions. Failure to successfully complete our build-outs and successfully operate our planned manufacturing facilities and satisfy manufacturing-related regulatory requirements could adversely affect the commercial viability of our product candidates and our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cell-based therapies and biologics rely on the availability of reagents, specialized equipment and other specialty materials, which may not be available to us on acceptable terms or at all. For some of these reagents, equipment and materials, we rely or may rely on sole source vendors or a limited number of vendors, which could impair our ability to manufacture and supply our products, if approved.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently depend on a small number of suppliers for some of the materials used in, and processes required to develop, our product candidates. For some of these reagents, equipment and materials used in the manufacture of our product candidates, we rely, and we may in the future rely, on sole source vendors or a limited number of vendors. Some of these suppliers may not have the capacity to support clinical trials and commercial products manufactured under cGMP by biopharmaceutical firms or may otherwise be ill-equipped to support our needs. We also do not have supply contracts with many of these suppliers and may not be able to obtain supply contracts with them on acceptable terms or at all. Accordingly, we may experience delays in receiving key materials and equipment to support clinical or commercial manufacturing. An inability to continue to source product from any of these suppliers could adversely affect our ability to satisfy demand for our product candidates, which could adversely and materially affect our product sales and operating results or our ability to conduct clinical trials, either of which could significantly harm our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we seek to develop and scale our manufacturing process, we expect that we will need to obtain rights to and supplies of certain materials and equipment to be used as part of that process. We may not be able to obtain rights to such materials on commercially reasonable terms, or at all, and if we are unable to alter our process in a commercially viable manner to avoid the use of such materials or find a suitable substitute, it would have a material adverse effect on our business. Even if we are able to alter our process so as to use other materials or equipment, such a change may lead to a delay in our clinical development and/or commercialization plans. If such a change occurs for a product candidate that is already in clinical testing, the change may require us to perform both </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because our current product candidates represent, and our other potential product candidates will represent, novel approaches to the treatment of disease, there are many uncertainties regarding the development, market acceptance, public opinion, third-party reimbursement coverage and the commercial potential of our product candidates, which may impact public perception of us and our product candidates and which may adversely affect our ability to conduct our business and implement our business plans.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human immunotherapy products are a new category of therapeutics. We use relatively novel technologies involving N-803, saRNA, hAd5 and yeast technologies, aldoxorubicin, and cell-based therapies, and our NK&#160;cell platform utilizes a relatively novel technology involving the genetic modification of human cells and utilization of those modified cells in other individuals. Because this is a relatively new and expanding area of novel therapeutic interventions, there are many uncertainties related to development, marketing, reimbursement and the commercial potential for our product candidates. There can be no assurance as to the length of the trial period, the number of patients the FDA will require to be enrolled in the trials in order to establish the safety, efficacy, purity and potency of immunotherapy products, or that the data generated in these trials will be acceptable to the FDA to support marketing approval. Adverse public attitudes may adversely impact our ability to enroll patients in clinical trials. The FDA may take longer than usual to come to a decision on any BLA and/or NDA that we submit and may ultimately determine that there is not enough data, information, or experience with our product candidates to support an approval decision. The FDA may also require that we conduct additional post-marketing studies or implement risk management programs, such as REMS, until more experience with our product candidates is obtained. Finally, after increased usage, we may find that our product candidates do not have the intended effect, do not work with other combination therapies or have unanticipated side effects, potentially jeopardizing initial or continuing regulatory approval and commercial prospects. More restrictive government regulations or negative public opinion could have an adverse effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Adverse events in our clinical trials, even if not ultimately attributable to our product candidates, and the resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our potential product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that the approaches offered by our product candidates will gain broad acceptance among doctors or patients or that governmental agencies or third-party medical insurers will be willing to provide reimbursement coverage for our proposed product candidates. Public perception may be influenced by claims, such as claims that our technologies are unsafe, unethical or immoral and, consequently, our approach may not gain the acceptance of the public or the medical community. Negative public reaction to cell-based immunotherapy in general could result in greater government regulation and stricter labeling requirements of immunotherapy products, including our product candidates, and could cause a decrease in the demand for any products we may develop. Moreover, our success will depend upon physicians specializing in the treatment of those diseases that our product candidates target prescribing, and their patients being willing to receive treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments they are already familiar with and for which greater clinical data may be available. The market for any products that we successfully develop will also depend on the cost of the product. We do not yet have sufficient information to reliably estimate what it will cost to commercially manufacture our current product candidates, and the actual cost to manufacture these products could materially and adversely affect the commercial viability of these products. Our goal is to reduce the cost of manufacturing and providing our therapies. However, unless we can reduce those costs to an acceptable amount, we may never be able to develop a commercially viable product. If we do not successfully develop and commercialize products based upon our approach or find suitable and economical sources for materials used in the production of our potential products, we will not become profitable, which would materially and adversely affect the value of our common stock. Our N-803 therapies and our other therapies may be provided to patients in combination with other agents provided by third&#160;parties or our affiliates. The cost of such combination therapy may increase the overall cost of therapy and may result in issues regarding the allocation of reimbursements between our therapy and the other agents, all of which may affect our ability to obtain reimbursement coverage for the combination therapy from governmental or private third-party medical insurers.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the clinical development, testing and manufacturing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. Large judgements have been awarded in class action lawsuits based on therapeutics that had unanticipated side effects. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a regulatory investigation of the safety and effectiveness of our products, our third-party manufacturer&#8217;s manufacturing processes and facilities or our marketing programs and potentially a recall of our products or more serious enforcement action, including limitations on the approved indications for which our product candidates may be used or suspension or withdrawal of approvals, decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we may develop, alone or with corporate collaborators. Our insurance policies may also have various exclusions, and we may be subject to product liability claims for which we have no coverage. While we have obtained clinical trial insurance for our clinical trials, we may have to pay amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will face significant competition from other biotechnology and pharmaceutical companies and from non-profit institutions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition in the field of cancer and viral infectious disease therapy is intense and is accentuated by the rapid pace of technological development. We compete with a variety of multi-national biopharmaceutical companies and specialized biotechnology companies, as well as technology being developed at universities and other research institutions. These competitors have developed, may develop and are developing product candidates and processes competitive with our product candidates. Research and discoveries by others may result in breakthroughs which may render our product candidates obsolete even before they generate any revenues. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we are developing product candidates. Many of our competitors have several therapeutic products that have already been developed, approved and successfully commercialized, or are in the process of obtaining regulatory approval for their therapeutic products in the U.S. and internationally. Many of our competitors, either alone or with their strategic partners, have substantially greater financial, technical, and human resources than we do, as well as significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of treatments and commercializing those treatments. Accordingly, our competitors may be more successful in obtaining approval of treatments and achieving widespread market acceptance, rendering our treatments obsolete or non-competitive, possibly even before we are able to enter the market. Accelerated merger and acquisition activity in the biotechnology and biopharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third&#160;parties compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval for our product candidates, the availability and price of our competitors&#8217; products could limit the demand and the price we are able to charge for our therapies. The level of generic competition and the availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A large number of companies, government agencies and academic centers around the world are developing COVID</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 vaccines, and many of these entities are in more advanced stages of development than we are, including some that have started Phase&#160;2 and/or 3 clinical trials or have already obtained emergency regulatory approval in the U.S. and internationally. Even if one of our COVID</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 vaccine candidates is ultimately approved for marketing, the value of our opportunity will be adversely impacted by other COVID</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 vaccines that have obtained emergency regulatory approval, obtain full regulatory approval, or demonstrate better efficacy or safety than our COVID</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 vaccine candidate.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from other methods of treatment to our product, or if physicians switch to other new therapies, drugs or biologic products or choose to reserve our product candidates for use in limited circumstances. We may be adversely impacted if any of these competitors gain market share as a result of new technologies, commercialization strategies or otherwise.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek orphan drug status or Fast Track or Breakthrough Therapy designations or other designation for one or more of our product candidates, but even if any such designation or status is granted, it may not lead to a faster development process or regulatory review and may not increase the likelihood that our product candidates will receive marketing approval, and we may be unable to maintain any benefits associated with such designations or status, including market exclusivity.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, the FDA established a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designation, which is intended to expedite, although there is no guarantee, the development and review of products that treat serious or life-threatening conditions. We have been awarded, and may seek in the future, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designation for current or future product candidates. Receipt of a designation to facilitate product candidate development is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for a designation, the FDA may disagree. In any event, the receipt of such a designation for a product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and does not assure ultimate marketing approval by the FDA. In addition, the FDA may later decide that the product candidates no longer meet the designation conditions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition or for which there is no reasonable expectation that the cost of developing and making available the drug or biologic will be recovered from sales in the U.S. If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA to market the same drug or biologic for the same indication for seven&#160;years, except in limited circumstances. We may seek orphan drug status for one or more of our product candidates, but exclusive marketing rights in the U.S. may be lost if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a condition of approval, the FDA may require that we implement various post-marketing requirements and conduct post-marketing studies, any of which would require a substantial investment of time, effort, and money, and which may limit our commercial prospects.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition of biologic licensing, the FDA is authorized to require that sponsors of approved BLAs implement various post-market requirements, including REMS and Phase&#160;4 trials. For example, in connection with FDA approval of another company&#8217;s drug, the FDA required significant post-marketing commitments, including a Phase&#160;4 trial, revalidation of a test method, and a substantial REMS program that included, among other requirements, the certification of hospitals and their associated clinics that dispensed the drug, including the implementation of a training program and limited distribution only to certified hospitals and their associated clinics. If we receive approval of our product candidates, the FDA may determine that similar or additional or more burdensome post-approval requirements are necessary to ensure that our product candidates are safe, pure and potent. To the extent that we are required to establish and implement any post-approval requirements, we will likely need to invest a significant amount of time, effort and money. Such post-approval requirements may also limit the commercial prospects of our product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never commercialized a product candidate before, and we may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators. We may be unable to establish effective marketing and sales capabilities or enter into agreements with third&#160;parties or related parties to market and sell our product candidates, if they are approved, and as a result, we may be unable to generate product revenues.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have little to no prior experience in, and currently have a limited commercial infrastructure for, the marketing, sale and distribution of biopharmaceutical products. To achieve commercial success for the product candidates, which we may license to others, we will rely on the assistance and guidance of those collaborators. For product candidates for which we retain commercialization rights and marketing approval, if approved, in order to commercialize our product candidates, we must continue to build out our marketing, sales and distribution capabilities, including a comprehensive healthcare compliance program, or arrange with third&#160;parties to perform these services, which will take time and require significant financial expenditures and could delay any product launch and we may not be successful in doing so. There are significant risks involved with building and managing a commercial infrastructure. We, or our collaborators, will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train, manage and retain medical affairs, marketing, sales and commercial support personnel. Recruiting, training and retaining a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have incurred these commercialization expenses prematurely or unnecessarily. These efforts may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. In the event we are unable to develop a commercial infrastructure, we may not be able to commercialize our current or future product candidates, which would limit our ability to generate product revenues. Even if we are able to effectively establish a sales force and develop a marketing and sales infrastructure, our sales force and marketing teams may not be successful in commercializing our current or future product candidates. To the extent we rely on third&#160;parties to commercialize any products for which we obtain regulatory approval, we would have less control over their sales efforts and could be held liable if they failed to comply with applicable legal or regulatory requirements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our product candidates do not achieve broad market acceptance, the revenues that we generate from their sales will be limited.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not commercialized a product candidate for any indication. Even if our product candidates are approved by the appropriate regulatory authorities for marketing and sale, they may not gain acceptance among physicians, patients, third-party payors and others in the medical community. If any product candidate for which we obtain regulatory approval does not gain an adequate level of market acceptance, we may not generate significant product revenues or become profitable. Market acceptance of our product candidates by the medical community, patients and third-party payors will depend on a number of factors, some of which are beyond our control. For example, physicians are often reluctant to switch their patients, and patients may be reluctant to switch from, existing therapies even when new and potentially more effective or safer treatments enter the market. Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. Even if the medical community accepts that our product candidates are safe and effective for their approved indications, physicians and patients may not immediately be receptive to such product candidates and may be slow to adopt them as an accepted treatment of the approved indications. If any of our product candidates is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues and we may not become profitable. The degree of market acceptance of any of our product candidates will depend on a number of factors, including:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continued safety and efficacy of our product candidates;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of adverse events associated with such product candidates;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical indications for which the products are approved and the approved claims that we may make for the products;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in the product&#8217;s FDA-approved labeling, including potential limitations or warnings for such products that may be more restrictive than other competitive products or distribution and use restrictions imposed by the FDA with respect to such product candidates or to which we agree as part of a mandatory REMS or voluntary risk management plan;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the standard of care for the targeted indications for such product candidates;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the relative difficulty of administration of such product candidates;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to offer such product candidates for sale at competitive prices, including the cost of treatment versus economic and clinical benefit in relation to alternative treatments or therapies;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of adequate coverage or reimbursement by third&#160;parties, such as insurance companies and other healthcare payors, and by government healthcare programs, including Medicare and Medicaid;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent and strength of our marketing and distribution of such product candidates;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety, efficacy and other potential advantages over, and availability of, alternative treatments already used or that may later be approved for any of our intended indications;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of market introduction of such product candidates, as well as competitive products;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent and strength of our third-party manufacturer and supplier support;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse publicity about the product or favorable publicity about competitive products; and</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential product liability claims.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any product candidate we commercialize fails to achieve market acceptance, it could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may face competition sooner than anticipated.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The enactment of the Biologics Price Competition and Innovation Act of 2009 (BPCIA) created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, the FDA cannot make an approval of an application for a biosimilar product effective until 12&#160;years after the original branded product was approved under a BLA. Certain changes, however, and supplements to an approved BLA, and subsequent applications filed by the same sponsor, manufacturer, licensor, predecessor in interest or other related entity do not qualify for the 12-year exclusivity period.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates may qualify for the BPCIA&#8217;s 12-year period of exclusivity. There is a risk that any product candidates we may develop that are approved as a biological product under a BLA would not qualify for the 12-year period of exclusivity or that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider any product candidates we may develop to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Additionally, this period of regulatory exclusivity does not block companies pursuing regulatory approval via their own traditional BLA, rather than via the abbreviated pathway. Even if we receive a period of BPCIA exclusivity for our first licensed product, if subsequent products do not include a modification to the structure of the product that impacts safety, purity, or potency, we may not receive additional periods of exclusivity for those products. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference product candidates in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. Medicare Part&#160;B encourages use of biosimilars by paying the provider the same percentage of the reference product average sale price as a mark-up, regardless of which product is reimbursed. It is also possible that payors will give reimbursement preference to biosimilars even over reference biologics absent a determination of interchangeability.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our small molecular product candidates, if qualified, the regulatory exclusivity period is less than for our biologic product candidates. The Federal Food, Drug, and Cosmetic Act (FDCA) provides a five-year period of non-patent marketing exclusivity within the U.S. to the first applicant to gain approval of an NDA for a drug where the FDA has not previously approved any other new drug containing the same active molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated NDA or a 505(b)(2)&#160;NDA submitted by another company for a generic version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four&#160;years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three&#160;years of marketing exclusivity for an NDA, 505(b)(2)&#160;NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. As such, we may face competition from generic versions of our small molecule product candidates, which will negatively impact our long-term business prospects and marketing opportunities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to obtain FDA approval of any proposed branded product names, and any failure or delay associated with such approval may adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any name we intend to use for our product candidates in the U.S. will require approval from the FDA regardless of whether we have secured a formal trademark registration from the U.S. Patent and Trademark Office (USPTO). The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. The FDA may also object to a product name if it believes the name inappropriately implies medical claims or contributes to an overstatement of efficacy. If the FDA objects to any of our proposed product names, we may be required to adopt alternative names for our product candidates. If we adopt alternative names, we would lose the benefit of any existing trademark applications for such product candidate and may be required to expend significant additional resources in an effort to identify a suitable product name that would qualify under applicable trademark laws, not infringe or otherwise violate the existing rights of third&#160;parties, and be acceptable to the FDA. We may be unable to build a successful brand identity for a new product name in a timely manner or at all, which would limit our ability to commercialize our product candidates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those used by our CROs, CMOs, clinical sites or other contractors or consultants, may fail or suffer security breaches. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our information technology systems, network-connected control systems and/or our data, interrupt the operation of our business and/or affect our reputation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are and will be dependent upon information technology systems, infrastructure and data. In the ordinary course of our business, we will directly or indirectly collect, store and transmit sensitive data, including intellectual property, confidential information, preclinical and clinical trial data, proprietary business information, personal data and personally identifiable health information of our clinical trial subjects and employees, in our data centers and on our networks, or on those of third&#160;parties. The secure processing, maintenance and transmission of this information is critical to our operations. The multitude and complexity of our computer systems and those of our contract research organizations (CROs), CMOs, clinical sites or other contractors or consultants make them inherently vulnerable to service interruption or destruction, malicious intrusion and random attack. Data privacy or security breaches by third&#160;parties, employees, contractors or others may pose a risk that sensitive data, including our intellectual property, trade secrets or personal information of our employees, patients, or other business partners may be exposed to unauthorized persons or to the public. Further, as many of our employees are working remotely, our reliance on our and third-party information technology systems has increased substantially and is expected to continue to increase.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems and those of our CROs, CMOs, clinical sites and other contractors and consultants are vulnerable to failure or damage from computer viruses and other malware, employee error, unauthorized and authorized access or other cybersecurity attacks, natural disasters, terrorism, war, fire and telecommunication and electrical failures. As the cyberthreat landscape evolves, these cyberattacks are increasing in their frequency, sophistication and intensity and are becoming increasingly difficult to detect. The techniques used by cybercriminals change frequently, may not be recognized until launched and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations or hostile foreign governments or agencies. Cyberattacks could include the deployment of harmful malware, denial-of-service, social engineering and other means to affect service reliability and threaten data confidentiality, integrity and availability. While we and our shared services partner, NantWorks, have invested, and continue to invest, in the protection of our data and information technology infrastructure, there can be no assurance that our efforts, or the efforts of our partners, vendors, CROs, CMOs, clinical sites and other contractors and consultants will prevent service interruptions, or identify breaches in our or their systems, that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business or reputational harm to us. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyberattacks and other related breaches.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any such event were to occur and cause interruptions in our operations, it could result in a disruption of our product development programs. For example, the loss of clinical trial data from completed or ongoing clinical trials for a product candidate could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data, or may limit our ability to effectively execute a product recall, if required. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the further development and commercialization of any product candidates could be delayed. Any such event could also result in legal claims or proceedings, liability under laws that protect the privacy of personal information and significant regulatory penalties, and damage to our reputation and a loss of confidence in us and our ability to conduct clinical trials.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics, pandemics or contagious diseases, including the recent COVID&#8209;19 pandemic and the public and governmental effort to mitigate against the spread of the disease, in regions where we or third&#160;parties on which we rely have significant manufacturing facilities, concentrations of clinical trial sites or other business operations, and may have a material adverse effect, on our clinical trials, operations, supply chains, distribution systems, product development, business and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outbreaks of epidemic, pandemic or contagious diseases, such as the ongoing COVID</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 pandemic, and measures taken in response by governments and businesses worldwide to contain its spread have adversely impacted and may continue to significantly disrupt our operations and adversely affect our business, financial condition and results of operations. Many countries including the U.S. implemented measures such as quarantine, shelter-in-place, curfew, travel and activity restrictions and similar isolation measures, including government orders and other restrictions on the conduct of business operations. The continued spread of this pandemic has caused significant volatility and uncertainty in the U.S. and international markets and has resulted in increased risks to our operations. The COVID&#8209;19 pandemic and any actions we have taken in response, are affecting and could materially affect our operations, including at our headquarters and at our manufacturing facilities, which have been and may in the future be subject to state executive orders and shelter-in-place orders, and at our clinical trial sites, as well as the business or operations of our CROs, CMOs, clinical sites or other third&#160;parties with whom we conduct business. Any such epidemic or pandemic may heighten the risk that a significant portion of our workforce could suffer illness or otherwise not be permitted or be unable to work, and may require that certain of our employees work remotely, which heightens certain risks, including but not limited to, those associated with an increased demand for information technology resources, increased risk of cybersecurity attacks (including social engineering attacks), risks related to internal controls and increased risk of unauthorized dissemination of sensitive personal information or our proprietary or confidential information.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rapid development and fluidity of the pandemic preclude any prediction as to the ultimate effect of COVID-19 on us. While the U.S. and other countries have reopened their economies to varying degrees, the extent to which COVID-19 will impact our future operations will depend on many factors which cannot be predicted with confidence, including the duration of the outbreak. Any resurgence in COVID-19 infections could result in the imposition of new mandates and prolonged restrictive measures implemented in order to control the spread of the disease. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. President Biden has issued an Executive Order requiring federal employees and covered contractors to be vaccinated against COVID-19. Additionally, on November&#160;4,&#160;2021, the U.S. Department of Labor&#8217;s Occupational Safety and Health Administration (OSHA) issued a COVID-19 Vaccination and Testing Emergency Temporary Standard requiring all employers with 100&#160;or more employees to ensure that their employees are fully vaccinated or tested for COVID-19 on at least a weekly basis. On January&#160;20,&#160;2022, The U.S. Supreme Court invalidated this requirement. However additional vaccine and testing mandates may be announced in other jurisdictions in which we operate our business. While it is not currently possible to predict with any certainty the exact impact the new regulations would have on us and our suppliers, the implementation of such government mandated vaccination or testing mandates may impact our ability to retain current employees and attract new employees and result in labor disruptions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are monitoring a number of risks related to this pandemic, including the following:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Financial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We expect to continue spending on research and development during the year ending December&#160;31, 2023 and beyond, and we could also have unexpected expenses related to the pandemic. The short-term continued expenses, as well as the overall uncertainty and disruption caused by the pandemic, will likely cause a delay in our ability to commercialize a product and adversely impact our financial results.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Manufacturing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The pandemic has impacted, and may continue to impact, our manufacturing locations, including through the effects of facility closures, reductions in operating hours and other social distancing efforts. </span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Supply Chain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: As the pandemic continues to progress, it has resulted and could continue to result in significant disruptions in our respective supply chains and distribution channels in the future. In addition, there may be unfavorable changes in the availability or cost of raw materials, intermediates and other materials necessary for production, which may result in disruptions in our supply chain and adversely affect our ability to have manufactured certain product candidates for clinical supply.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Clinical Trials</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: This pandemic may adversely affect certain of our clinical trials, including our ability to initiate and complete our clinical trials within the anticipated timelines. Due to site and participant availability during the pandemic, new subject enrollment has slowed and is expected to continue to slow, at least in the short-term, for most of our clinical trials. For ongoing trials, we have seen, and expect to continue to see an increasing number of clinical trial sites imposing restrictions on patient visits to limit risks of possible COVID</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 exposure, and we may experience issues with participant compliance with clinical trial protocols as a result of quarantines, travel restrictions and interruptions to healthcare services. The current pressures on medical systems and the prioritization of healthcare resources toward the COVID</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 pandemic have also resulted, and may continue to result, in interruptions in data collection and submissions for certain clinical trials and delayed starts for certain planned studies. As a result, our anticipated filing and marketing timelines may be adversely impacted.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Overall Economic and Capital Markets Environment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The continued spread of COVID</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 has led to and could continue to lead to severe disruption and volatility in the U.S. and global capital markets, which could result in a decline in stock price, high inflation, increase our cost of capital and adversely affect our ability to access the capital markets in the future even after local conditions improve. In addition, trading prices on the public stock market have been highly volatile as a result of the COVID</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 pandemic.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Regulatory Reviews</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The operations of the FDA or other regulatory agencies may be adversely affected. The legislative and regulatory environment governing our businesses is dynamic and changing frequently in response to COVID</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19. In response to COVID</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19, federal, state and local governments are issuing new rules, regulations, orders and advisories on a regular basis. These government actions can impact us, our members and our suppliers. There is also the possibility that we may experience delays with obtaining approvals for our IND applications, BLAs, and/or NDAs. The pandemic may also result in greater regulatory uncertainty.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span id="ifa3b7a3cc11d4404ac74f2cf3674ddcf_318924"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reliance on Third Parties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited experience conducting clinical trials and have relied and will rely on third parties and related parties to conduct many of our preclinical studies and clinical trials, to manufacture products and to perform many essential services for any products that we commercialize, including services related to distribution, government price reporting, customer service, accounts receivable management, cash collection and adverse event reporting. Any failure by a third party, related party, or by us to perform as expected, to comply with legal and regulatory requirements or to conduct the clinical trials according to GCP&#160;regulations, and in a timely manner, may delay or prevent our ability to seek or obtain regulatory approval for or commercialization of our product candidates and our ability to commercialize our current or future product candidates will be significantly impacted and we may be subject to regulatory sanctions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large-scale clinical trials require significant financial and management resources. We expect to be heavily reliant on third and related parties, including medical institutions, academic institutions, clinical investigators or CROs to conduct, supervise or monitor some or all aspects of our clinical trials, and in some cases, CMOs to manufacture products, which may force us to encounter delays and challenges that are outside of our control. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable trial protocol and legal, regulatory and scientific standards, and our reliance on CROs, clinical trial sites, and other third parties does not relieve us of these responsibilities. Our CROs and other third parties must communicate and coordinate with one another in order for our trials to be successful. We have a limited history of conducting clinical trials and have no experience as a company in filing and supporting the applications necessary to gain marketing approvals. Our relative lack of experience conducting clinical trials may contribute to our planned clinical trials not beginning or completing on time, if at all. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities and clinical trial sites by, applicable regulatory authorities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial and for ensuring that our preclinical studies are conducted in accordance with Good Laboratory Practice (GLP) regulations, as appropriate. Moreover, the FDA and comparable foreign regulatory authorities require us and the third parties upon which we intend to rely for conducting our clinical trials to comply with GCP for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. Regulatory authorities enforce these requirements through periodic inspections (including pre-approval inspections once a BLA or NDA is filed with the FDA) of trial sponsors, clinical investigators, trial sites and certain third parties including CMOs. If we, our CROs, clinical trial sites, or other third parties fail to comply with applicable GCP or other regulatory requirements, we or they may be subject to enforcement or other legal actions, the clinical data generated in our clinical trials may be deemed unreliable and have to be repeated, and our submission of marketing applications may be delayed or the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third parties to manufacture, package, label and ship some of our product candidates for the clinical trials that we conduct. Any performance failure on the part of these third parties could delay clinical development or marketing approval of our product candidates or commercialization of our product candidates, if approved, producing additional losses and depriving us of potential product revenues. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CROs, clinical trial sites and other third parties may also have relationships with other entities, some of which may be our competitors, for whom they may also be conducting clinical trials or other therapeutic development activities that could harm our competitive position. In addition, these third parties are not our employees, and except for remedies available to us under our agreements with them, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and preclinical programs. If these third parties conducting our clinical trials (i)&#160;do not successfully carry out their contractual duties, (ii)&#160;do not meet expected deadlines, (iii)&#160;experience work stoppages, (iv)&#160;do not conduct our clinical trials in accordance with regulatory requirements or our stated protocols, (v)&#160;need to be replaced, (vi)&#160;experience financial hardships or (vii)&#160;terminate their agreements with us or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical trial protocols, GCP or other regulatory requirements or for other reasons, our trials may need to be repeated, extended, delayed or terminated, we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates, we will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates or we or they may be subject to regulatory enforcement actions. Additionally, we may need to conduct additional clinical trials or enter into new arrangements with alternative CROs, clinical investigators or other third parties, which we may not be able to do on commercially reasonable terms, or at all and which may involve additional cost and time and require management time and focus. As a result, delays could occur, which could compromise our ability to meet our desired development timelines. Furthermore, if any of the third parties conducting our clinical trials experience any financial hardships due to difficulties relating to the operation of their business, it could damage our business, financial condition, results of operations and prospects. In addition, if an agreement with any of our collaborators terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay the continued development of our product candidates using the collaborator&#8217;s technology or intellectual property or require us to stop development of those product candidates completely. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. To the extent we are unable to successfully identify and manage the performance of third-party service providers in the future, our business may be materially and adversely affected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to retain third-party service providers to perform a variety of functions related to the sale of our current or future product candidates, key aspects of which will be out of our direct control. These service providers may provide key services related to distribution, customer service, accounts receivable management, and cash collection. If we retain a service provider, we would substantially rely on it as well as other third-party providers that perform services for us, including entrusting our inventories of products to their care and handling. If these third-party service providers fail to comply with applicable laws and regulations, fail to meet expected deadlines or otherwise do not carry out their contractual duties to us, or encounter physical or natural damage at their facilities, our ability to deliver product to meet commercial demand would be significantly impaired and we may be subject to regulatory enforcement action. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may engage in the future with third parties to perform various other services for us relating to adverse event reporting, safety database management, fulfillment of requests for medical information regarding our product candidates and related services. If the quality or accuracy of the data maintained by these service providers is insufficient, or these third parties otherwise fail to comply with regulatory requirements related to adverse event reporting, we could be subject to regulatory sanctions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we may contract in the future with a third party to calculate and report pricing information mandated by various government programs. If a third party fails to timely report or adjust prices as required or errs in calculating government pricing information from transactional data in our financial records, it could impact our discount and rebate liability, and potentially subject us to regulatory sanctions or FCA lawsuits.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on third and related parties can also present intellectual property-related risks. For example, collaborators may not properly obtain, maintain, enforce or defend intellectual property or proprietary rights relating to our product candidates or technology or may use our proprietary information in such a way as to expose us to potential litigation or other intellectual property-related proceedings, including proceedings challenging the scope, ownership, validity and enforceability of our intellectual property. Collaborators may also own or co-own intellectual property covering our product candidates or technology that results from our collaboration with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property or such product candidates or technology. Collaborators may also gain access to our trade secrets or formulations and impact our ability to commercialize proprietary technology. We may also need the cooperation of our collaborators to enforce or defend any intellectual property we contribute to or that arises out of our collaborations, which may not be provided to us.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also anticipate that part of our strategy for pursuing the wide range of indications potentially addressed by N-803 will involve further investigator-led clinical trials. While these trials generally provide us with valuable clinical data that can inform our future development strategy, we generally have less control over not only the conduct but also the design of these clinical trials. Third-party investigators may design clinical trials involving our product candidates with clinical endpoints that are more difficult to achieve or in other ways that increase the risk of negative clinical trial results compared to clinical trials we may design on our own. Negative results from investigator-led clinical trials, regardless of how the clinical trial was designed or conducted, could have a material adverse effect on our business and the perception of our product candidates. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third-party manufacturers, wholesalers and distributors fail to perform as expected, or fail to devote sufficient time and resources to our product candidates, our clinical development may be delayed, our costs may be higher than expected or our product candidates may fail to be approved, or we may fail to commercialize any product candidates if approved.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on third-party manufacturers, wholesalers and distributors exposes us to the following risks, any of which could delay FDA approval of our product candidates and commercialization of our product candidates if approved, result in higher costs, or deprive us of potential product revenues:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our CMOs, or other third parties we rely on, may encounter difficulties in achieving the volume of production needed to satisfy commercial demand, may experience technical issues that impact quality or compliance with applicable and strictly enforced regulations governing the manufacture of pharmaceutical products, and may experience shortages of qualified personnel to adequately staff production operations;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our wholesalers and distributors could become unable to sell and deliver our product candidates for regulatory, compliance and other reasons;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our CMOs, wholesalers and distributors could breach or default on their agreements with us to meet our requirements for commercialization of our product candidates;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our CMOs, wholesalers and distributors may not perform as agreed or may not remain in business for the time required to successfully produce, store, sell and distribute our product candidates and we may incur additional cost;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our CMOs, wholesalers and distributors may misappropriate our proprietary information; and</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if our CMOs, wholesalers and distributors were to terminate our arrangements or fail to meet their contractual obligations, we may be forced to delay our commercial programs. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on third parties reduces our control over our product candidate development activities but does not relieve us of our responsibility to ensure compliance with all required legal, regulatory and industry standards. For example, the FDA and other regulatory authorities require that our product candidates and any products that we may eventually commercialize be manufactured according to cGMP requirements. Any failure by our third-party manufacturers to comply with cGMP or maintain a compliance status acceptable to the FDA or other regulatory authorities or failure to scale up manufacturing processes, including any failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates. On May&#160;9,&#160;2023, the FDA delivered a complete response letter to us regarding the BLA. The letter indicated that the FDA had determined that it cannot approve the BLA in its present form, and the FDA made recommendations to address the issues raised. The deficiencies relate to the FDA&#8217;s pre-license inspection of the company&#8217;s third-party contract manufacturing organizations. Satisfactory resolution of the observations noted at the pre-license inspection is required before the BLA may be approved. See Part&#160;I, Item&#160;2 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_163">&#8212;Subsequent Events.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our third-party manufacturers will be subject to periodic inspections by the FDA and other regulatory authorities, and failure to comply with cGMP could be the basis for the FDA to issue a warning or untitled letter, withdraw approvals for product candidates previously granted to us, or take other regulatory or legal action, including a request to recall or seize product candidates, total or partial suspension of production, suspension of clinical trials, refusal to approve pending applications or supplemental applications, detention of product, refusal to permit the import or export of product candidates, injunction, imposing civil penalties or pursuing criminal prosecution.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as we scale up manufacturing of our product candidates and conduct required stability testing, we may encounter additional challenges or cGMP issues. These issues may require refinement or resolution in order to proceed with commercial marketing of our product candidates if approved. In addition, quality issues may arise during scale-up and validation of commercial manufacturing processes. Any issues in our manufacturing process could result in increased scrutiny by regulatory authorities, delays in our regulatory review process, increases in our operating expenses, or failure to obtain or maintain approval for our product candidates. If such issues relate to an approved product, we may not be able to commercialize the approved product as we planned or fail to meet commercial demand, any of which can materially and adversely affect our position in the market.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use the Clinic, a related party, in some of our clinical trials which may expose us to significant regulatory risks. If our data for this site is not sufficiently robust or if there are any data integrity issues, we may be required to repeat such studies or required to contract with other clinical trial sites, and our clinical development plans will be significantly delayed, and we will incur additional costs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Clinic has conducted, is currently conducting, and in the future may conduct, clinical trials involving our product candidates. The Clinic is a related party as it is owned by an officer of the company and additionally, NantWorks manages the administrative operations of the Clinic. Prior to June&#160;30,&#160;2019, one of the company&#8217;s officers was an investigator or sub&#8209;investigator for certain of the company&#8217;s trials conducted at the Clinic. NantWorks, which is wholly owned by our Executive Chairman and Global Chief Scientific and Medical Officer, Dr.&#160;Soon&#8209;Shiong, provides certain administrative services (and has loaned money) to the Clinic. Under certain circumstances, we may be required to report some of these relationships to the FDA. Relying on a related party clinical site to develop data that is used as the basis to support regulatory approval can expose us to significant regulatory risks. The FDA may conclude that a financial relationship between us, the Clinic and/or a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. If any data integrity, or regulatory non-compliance issues occur during the study, we may not be able to use the data for our regulatory approval. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of regulatory approval of one or more of our product candidates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have formed, and may in the future form or seek, strategic alliances or enter into collaborations with third&#160;parties or additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to enter into such strategic alliances, collaborations or licensing arrangements, or such strategic alliances, collaborations or licensing arrangements are not successful, we may not be able to capitalize on the market potential of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have formed, and may in the future form or seek, strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third and related parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. We plan to collaborate with governmental, academic and corporate partners, including affiliates, to improve and develop N-803, saRNA, hAd5 and yeast technologies, and other therapies for new indications for use in combination with other therapies and to improve and develop other product candidates, which may expose us to additional risks, or we may not realize the benefits of such collaborations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because some of our collaborations are conducted at outside laboratories, and we do not have complete control over how the studies are conducted or reported or over the manufacturing methods used to manufacture our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease, the results of such studies, which we may use as the basis for our conclusions, projections or decisions with respect to our current or future product candidates, may be incorrect or unreliable, or may have a negative impact on us if the results of such studies are imputed to our product candidates or proposed indications, even if such imputation is improper. Additionally, we may use third&#8209;party data to analyze, reach conclusions or make predictions or decisions with respect to our product candidates that may be incomplete, inaccurate or otherwise unreliable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, collaborations involving our product candidates will be subject to numerous risks, which may include the following:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators, including their related or affiliated companies, may be entitled to receive exclusive rights for or involving our products;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization of our product candidates based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third&#160;parties, products that compete directly or indirectly with our product candidates;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing and distribution;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly maintain, defend or enforce our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if an agreement with any collaborator terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay our continued development of our product candidates using the collaborator&#8217;s technology or intellectual property or require us to stop development of those product candidates completely; and</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may own or co-own intellectual property covering our product candidates or technology that results from our collaborating with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, if we enter into collaboration agreements and strategic partnerships or license our product candidates, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. Additionally, exclusive rights that we may grant in connection with collaboration agreements may limit our ability to enter into new or additional collaboration agreements or strategic partnerships if we experience issues with existing collaborations. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenues or specific net income that justifies such transaction. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third&#160;parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If conflicts arise between our corporate or academic collaborators or strategic partners and us, the other party may act in a manner adverse to us and could limit our ability to implement our strategies. Some of our existing academic collaborators and strategic partners are conducting multiple product development efforts. Such current or future collaborators or strategic partners could become our competitors in the future and could develop competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely or fail to devote sufficient resources to the development and commercialization of our product candidates. Competing product candidates, either developed by the collaborators or strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of our collaborator&#8217;s or partner&#8217;s support for our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in 2019, Sorrento Therapeutics,&#160;Inc. with which we jointly established a new entity called Immunotherapy NANTibody,&#160;LLC as a stand-alone biotechnology company, commenced litigation against us and certain of our officers and directors, alleging that we improperly caused NANTibody to acquire IgDraSol. Additionally, in 2020, we received a Request for Arbitration before the International Chamber of Commerce, International Court of Arbitration, served by Shenzhen Beike Biotechnology Co. Ltd. asserting breach of contract under our subsidiary Altor&#8217;s license agreement with them. For more information regarding these disputes, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_67">Note&#160;7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Commitments and Contingencies&#8212;Litigation,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; that appears in Part&#160;I, Item&#160;1. &#8220;Financial Statements&#8221; of this Quarterly Report on Form&#160;10-Q. Any of these developments could harm our product development efforts.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our use of joint ventures, strategic partnerships and alliances may expose us to risks associated with jointly owned investments.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may operate parts of our business through joint ventures, strategic partnerships and/or alliances with other companies. While such arrangements may, in some cases, give us access to technologies that we may not otherwise have or may give us access to capital, they involve risks not otherwise present in our own investments, including: (i)&#160;we may not control the venture, and it </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may divert management time and resources</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; (ii)&#160;the partner(s) may not agree to distributions that we believe are appropriate; (iii)&#160;we may experience impasses or disputes with such partner(s) on certain decisions, which could require us to expend additional resources to resolve such impasses or disputes, including litigation or arbitration; (iv)&#160;our partner(s) may become insolvent or bankrupt, fail to fund their share of required capital contributions or fail to fulfil their obligations as a venture partner; (v)&#160;the arrangements governing these relationships may contain certain conditions or milestone events that may never be satisfied or achieved; (vi)&#160;our partner(s) may have business or economic interests that are inconsistent with our interests and may take actions contrary to our interests; (vii)&#160;we may suffer losses as a result of actions taken by the partner(s); and (viii)&#160;it may be difficult for us to exit if an impasse arises or if we desire to sell our interest for any reason. For example, we have established a joint venture relationship with Amyris, and there can be no guarantee that it will be successful. In addition, we may, in certain circumstances, be liable for the actions of our partners. Any of the foregoing risks could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are heavily dependent on our senior management, particularly Dr. Soon-Shiong, our Executive Chairman and Global Chief Scientific and Medical Officer, and a loss of a member of our senior management team in the future, even if only temporary, could harm our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations will be dependent upon the services of our executives and our employees who are engaged in research and development. If we lose the services of members of our senior management, particularly Dr.&#160;Soon-Shiong, for a short or an extended time, for any reason, we may not be able to find appropriate replacements on a timely basis, and our business, financial condition and results of operations could be materially adversely affected. Our existing operations and our future development depend to a significant extent upon the performance and active participation of certain key individuals, particularly Dr.&#160;Soon-Shiong, our Executive Chairman and Global Chief Scientific and Medical Officer. Although Dr.&#160;Soon-Shiong focuses heavily on our matters and is highly active in our management, he does devote a significant amount of his time to a number of different endeavors and companies, including NantHealth,&#160;Inc., NantMedia Holdings,&#160;LLC (which operates the Los&#160;Angeles Times and the San&#160;Diego Union-Tribune) and NantWorks, which is a collection of multiple companies in the healthcare and technology space. The risks related to our dependence upon Dr.&#160;Soon-Shiong are particularly acute given his ownership percentage, the commercial and other relationships that we have with entities affiliated with him, his role in our company and his public reputation. We may also be dependent on additional funding from Dr.&#160;Soon-Shiong and his affiliates, which may not be available when needed and which he is under no obligation to provide.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided, and plan to continue providing, equity incentive awards that vest over time. The value to employees of equity incentive awards that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. We do not have employment agreements with our NEOs and do not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of their attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities. In order to develop our business in accordance with our business plan, we will have to hire additional qualified personnel, including in the areas of research, manufacturing, clinical trials management, regulatory affairs, and sales and marketing. We are continuing our efforts to recruit and hire the necessary employees to support our planned operations in the near term. However, competition for qualified personnel in the biotechnology and pharmaceuticals industry is intense due to the limited number of individuals who possess the skills and experience required, and no assurance can be given that we will be able attract, hire, retain and motivate the highly skilled employees that we need, on acceptable terms or at all. Future growth will impose significant added responsibilities on members of management, including:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identifying, recruiting, integrating, maintaining, and motivating additional employees;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">managing our internal development efforts effectively, including the clinical and FDA review process for our product candidates, while complying with our contractual obligations to contractors and other third&#160;parties; and</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">improving our operational, financial and management controls, reporting systems, and procedures.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely, and for the foreseeable future we expect to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements on economically reasonable terms, or at all. In addition, if we are unable to effectively manage our outsourced activities or if the quality, compliance or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development, and commercialization goals on a timely basis, or at all.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assimilation of operations, intellectual property, and products of an acquired company or product, including difficulties associated with integrating new personnel;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the diversion of our managements&#8217; attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant upfront milestone and/or royalty payments from which we may not realize the anticipated benefits;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to generate revenues from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the size and nature of future strategic acquisitions, we may acquire assets or businesses that require us to raise additional capital or to operate or manage businesses in which we have limited experience. Making larger acquisitions that require us to raise additional capital to fund the acquisition will expose us to the risks associated with capital raising activities. Acquiring and thereafter operating larger new businesses will also increase our management, operating and reporting costs and burdens (including increased cash requirements). In addition, if we undertake acquisitions, we may issue dilutive equity securities, assume or incur additional debt obligations or contingent liabilities, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to seek regulatory approval of our product candidates outside of the U.S. and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing regulatory requirements in foreign countries;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign taxes, including withholding of payroll taxes;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties staffing and managing foreign operations;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the U.S.;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing payor reimbursement regimes, governmental payors or patient self-pay systems, and price controls;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential liability under the FCPA or comparable foreign regulations;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the U.S.;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of public health epidemics on the global economy, such as the coronavirus pandemic currently having an impact throughout the world; and</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other risks associated with international operations may materially adversely affect our ability to attain or maintain profitable operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are party to a public-private partnership regarding our manufacturing facility in Dunkirk, New York, and if we or our counterparties fail to meet the obligations of those agreements, it could materially impact our development, operations and prospects.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;14,&#160;2022, we acquired a leasehold interest in the Dunkirk Facility from Athenex. The facility is expected to be a state-of-the-art biotech production center that we believe will substantially expand and diversify our existing manufacturing capacity in the U.S. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid approximately $40.0&#160;million to Athenex, and the leasehold interest in the Dunkirk Facility was transferred to us. Our annual lease payment will be $2.00&#160;per year for an initial 10-year term, with an option to renew the lease under substantially the same terms and conditions for an additional 10-year term. As part of the transaction, we assumed obligations under various third-party agreements, and committed to spend $1.52&#160;billion on operational expenses during the initial term, and an additional $1.50&#160;billion on operational expenses if we elect to renew the lease for the additional 10-year term. We also committed to hiring 450&#160;employees at the Dunkirk Facility within the first five years of operations, with 300&#160;such employees to be hired within the first 2.5 years of operation. We are eligible for certain sales-tax exemption savings during the development of the Dunkirk Facility, and certain property tax savings over the next 20 years, subject to certain terms and conditions, including performance of certain of the obligations described above.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we believe that the Dunkirk Facility has construction needs that may require approximately 12 to 18&#160;months to complete in order for it to be used as intended. Consequently, during the third&#160;quarter of 2022, we determined to conduct a reduction-in-force of a significant portion of the then-current employees at the Dunkirk Facility, which became effective in late December&#160;2022. The construction period and reduction-in-force may adversely affect our ability to satisfy certain operational obligations described above. In addition, while we believe we are in compliance with all applicable laws and agreements implicated by the reduction-in-force, we could become subject to litigation in connection with these measures. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to satisfy the obligations over the lease term, including the milestones we have committed to achieve, may give rise to certain rights and remedies of the lessor and other governmental authorities including, for example, termination of the lease agreement and other related agreements and potential recoupment of a percentage of the grant funding received by the Seller for construction of the Dunkirk Facility and other benefits received, subject to the terms and conditions of the applicable agreements. If we lose access to the Dunkirk Facility and related leased equipment, it could disrupt our operations and manufacturing activities, cause us to divert resources to finding alternative facilities, which would not have any subsidies, and could have a significant impact on our operations and financial performance. We may also be subject to lawsuits or claims for damages against us if we are unable to comply with our obligations under these arrangements or in connection with other aspects of the Dunkirk Facility, which could materially and adversely affect our business, results of operations and financial condition. For example, we were named as a defendant in a lawsuit filed during the fourth&#160;quarter of 2022 by Exyte&#160;U.S., Inc. (Exyte) in New York state court arising from a construction agreement Exyte entered with Athenex pertaining to construction of the Dunkirk Facility. We believe we are entitled to defense costs and indemnification and, accordingly, we have provided notice to Athenex. In April&#160;2023, Athenex announced that it had appointed a Chief Restructuring Officer to support Athenex&#8217;s ongoing review of strategic alternatives. We further believe Exyte&#8217;s claims against us are without merit, and we intend to defend the claims vigorously. Furthermore, there is no guarantee that the counterparties to our public-private partnerships will comply with the terms of the agreements, including that their ability to fund their capital commitments under the agreements may be subject to their ability to raise additional capital and that further construction or operational timetables may not be met. Public-private partnerships are also subject to risks associated with government and government agency counterparties, including risks related to government relations compliance, sovereign immunity, shifts in the political environment, changing economic and legal conditions and social dynamics.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our contractors and subcontractors may place liens on our projects, and if they then successfully foreclose on such projects, we may not be able to use such assets for our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under general property law, any contractor or subcontractor doing work on a project may attach a lien on the property with respect to which it does work to secure the dollar value of all labor and material furnished to the project. A valid lien holder could, after the lien is perfected, institute a collection suit, according to the lien, and if it were successful in obtaining a judgment, the real property and the equipment thereon could be foreclosed upon. If a contractor were to successfully foreclose on such liens, we may not then be able to use such assets to manufacture our products, and our business could be materially harmed. For example, certain contractors have recently recorded liens related to tenant improvements that we have contracted to have installed at one of our leased properties.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span id="ifa3b7a3cc11d4404ac74f2cf3674ddcf_318925"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Healthcare and Other Government Regulations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize our product candidates. We are, and if we receive regulatory approval of our product candidates, will continue to be subject to ongoing extensive regulation, regulatory obligations and continued regulatory review, which may result in significant additional expense.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are subject to extensive governmental regulations relating to, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of drugs and therapeutic biologics. Rigorous preclinical testing and clinical trials and an extensive regulatory review process are required to be successfully completed in the U.S. and in many foreign jurisdictions before a new drug or therapeutic biologic can be marketed. Satisfaction of these and other regulatory requirements is costly, lengthy, time-consuming, uncertain and subject to unanticipated delays and can vary substantially based upon the type, complexity and novelty of the products involved. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May&#160;2022, we announced the submission of a BLA to the FDA for our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease. In July&#160;2022, we announced the FDA has accepted our BLA for review and set a target PDUFA action date of May&#160;23,&#160;2023. On May&#160;9,&#160;2023, the FDA delivered a complete response letter to us regarding the BLA, as described in greater detail in Part&#160;I, Item&#160;2 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_163">&#8212;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_163">Subsequent Events.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> It is unclear when the FDA will approve our BLA, if at all. If the FDA requires additional data, finds that the CMC information in the BLA is deficient, disagrees with our interpretation or analysis of clinical data, identifies any deficiency in our clinical data, or finds deficiencies in our pre-approval inspection, we may fail to obtain approval of the BLA for our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease, or approval may be delayed. The letter referenced above noted deficiencies related to the FDA&#8217;s pre-license inspection of the company&#8217;s third-party contract manufacturing organizations. Satisfactory resolution of the observations noted at the pre-license inspection is required before the BLA may be approved. The FDA further provided recommendations specific to additional CMC&#160;issues and assays to be resolved. We have not submitted any other marketing or drug approval applications to the FDA or comparable foreign authorities, for any other product candidate, and we may never receive such regulatory approval for any of our product candidates or regulatory approval that will allow us to successfully commercialize our product candidates. In addition, regulatory agencies may lack experience with our technologies and products, which may lengthen the regulatory review process, increase our development costs and delay or prevent their commercialization.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical studies, clinical trials or other research. The number and types of preclinical studies and clinical trials that will be required for regulatory approval also vary depending on the product candidate, the disease or condition that the product candidate is designed to address and the regulations applicable to any particular product candidate. Approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay in completing development or obtaining, or failing to obtain, required approvals would have a material and adverse effect on our ability to generate revenue from the particular product candidate for which we are developing and seeking approval. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, be subject to other regulatory enforcement action, and we may not achieve or sustain profitability.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, however a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory review process in others. Approval policies, procedures and requirements may vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the U.S., including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. In many jurisdictions outside the U.S., a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our product candidates is also subject to approval.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries. If we fail to comply with the regulatory requirements in international markets and/or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval for our product candidate, Anktiva in combination with BCG for the treatment of patients with NMIBC with CIS with or without Ta or T1&#160;disease, or any other product candidates, they will be subject to ongoing regulatory requirements, which may result in significant additional expenses. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed, or to conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor safety and efficacy. In addition, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for any approved product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, including reporting of certain adverse events as well as continued compliance with cGMP for the drug products, and GCP for any clinical trials that we conduct post-approval.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Later discovery of previously unknown problems with an approved product, including adverse events of unanticipated severity or frequency, or with manufacturing operations or processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">holds on clinical trials;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of a REMS, which may include distribution or use restrictions;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements to conduct additional post-market clinical trials to assess the safety of the product;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revisions to the labeling, including limitation on approved uses or the addition of additional warnings, contraindications or other safety information, including boxed warnings;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing delays and supply disruptions where regulatory inspections identify observations of noncompliance requiring remediation;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning or untitled letters;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications submitted by us, or withdrawal of product approvals;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of product candidates; and</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or are not able to maintain regulatory compliance, we may lose any marketing approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish sales, marketing and distribution capabilities, we may not be successful commercializing our product candidates if and when they are approved.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in the process of implementing our sales and marketing personnel hiring plan and building out key commercialization infrastructure. To achieve commercial success for any product for which we have obtained marketing approval, we will need to establish a sales and marketing team.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to build a focused sales and marketing infrastructure to market our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease, and potentially other product candidates in the U.S., if and when they are approved. There are risks involved with establishing our own sales, marketing and distribution capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, including failure to receive marketing approval from the FDA, we would have prematurely or unnecessarily incurred these commercialization expenses. We may also inaccurately estimate the number of representatives needed to build our sales force, which may result in unnecessary expense or the inability to scale as quickly as needed. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to commercialize our product candidates, if approved, on our own include:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to recruit, train and retain adequate numbers of effective sales, marketing, reimbursement, customer service, medical affairs, and other support personnel;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of sales personnel to obtain access to physicians or increase market acceptable of our approved product;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of reimbursement professionals to negotiate arrangements for coverage or adequate reimbursement by payors for our approved products;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to price our product candidates at a sufficient price point to ensure an adequate and attractive level of profitability;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restricted or closed distribution channels that make it difficult to distribute our product candidates to segments of the patient population; and</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen costs and expenses associated with creating an independent commercialization organization.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Problems related to large-scale commercial manufacturing could cause delays in product launches, an increase in costs or shortages of product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing finished drug products, especially in large quantities, is complex. If our product candidates receive regulatory approval, they will require several manufacturing steps and may involve complex techniques to assure quality and sufficient quantity, especially as the manufacturing scale increases. Our product candidates will need to be made consistently and in compliance with a clearly defined manufacturing process pursuant to FDA regulations. Accordingly, it will be essential to be able to validate and control the manufacturing process to assure that it is reproducible. Slight deviations anywhere in the manufacturing process, including obtaining materials, filling, labeling, packaging, storage, shipping, quality control and testing, may result in lot failures, delay in the release of lots, product recalls or spoilage. Success rates can vary dramatically at different stages of the manufacturing process, which can lower yields and increase costs. We may experience deviations in the manufacturing process that may take significant time and resources to resolve and, if unresolved, may affect manufacturing output and cause us to fail to satisfy contractual commitments, lead to delays in our clinical trials or result in litigation or regulatory action. Such actions would hinder our ability to meet contractual obligations and could cause material adverse consequences for our business.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business. For example, our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> GMP-in-a-Box will be regulated by the FDA as a medical device, and regulatory compliance for medical devices is expensive, complex and uncertain, and a failure to comply could lead to enforcement actions against us and other negative consequences for our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and similar agencies regulate medical devices. All of our potential medical device products and material modifications will be subject to extensive regulation and clearance or approval from the FDA and non-U.S.&#160;regulatory agencies prior to commercial sale and distribution as well as after clearance or approval. Complying with these regulations is costly, time&#8209;consuming, complex and uncertain. For instance, before a new medical device, or a new intended use for an existing device, can be marketed in the U.S., a company must first submit and receive either 510(k) clearance or pre-marketing approval from the FDA, unless an exemption applies.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA and similar agencies have significant pre- and post-market authority, including requirements related to product design, development, testing, laboratory and clinical trials and preclinical studies approval, manufacturing processes and quality (including suppliers), labeling, packaging, distribution, adverse event and deviation reporting, storage, shipping, pre-market clearance or approval, advertising, marketing, promotion, sale, import, export, product change, recalls, submissions of safety and effectiveness, post-market surveillance and reporting of deaths or serious injuries and certain malfunctions, and other post-marketing information and reports such as deviation reports, registration, product listing, annual user fees, and recordkeeping for our product candidates. The FDA may also require a REMS to approve our product candidates, which may impose further requirements or restrictions on the distribution or use of an approved drug or therapeutic biologic. The FDA may also require post-approval Phase&#160;4 trials. Moreover, the FDA and comparable foreign regulatory authorities will continue to closely monitor the safety profile of any product even after approval. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical devices regulated by the FDA are subject to general controls which include: registration with the FDA; listing commercially distributed products with the FDA; complying with cGMP under Quality Systems Regulations; filing reports with the FDA of and keeping records relative to certain types of adverse events associated with devices under the medical device reporting regulation; assuring that device labeling complies with device labeling requirements; reporting certain device field removals and corrections to the FDA; and obtaining pre-market notification 510(k)&#160;clearance for devices prior to marketing. Some devices known as 510(k)-exempt devices can be marketed without prior marketing-clearance or approval from the FDA. In addition to the general controls, some Class&#160;2 medical devices are also subject to special controls, including adherence to a particular guidance document and compliance with the performance standard. Instead of obtaining 510(k)&#160;clearance, most Class&#160;3 devices are subject to premarket approval (PMA).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA can also refuse to clear or approve pre-market applications for any medical device we develop. We may not be able to obtain the necessary clearances or approvals or may be unduly delayed in doing so, for any medical device products we develop, which could harm our business. Furthermore, even if we are granted regulatory clearances or approvals for any medical device products, they may include significant limitations on the indicated uses for the product, which may limit the market for the product.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we, our contractors, and our collaborators are and will remain responsible for FDA compliance. We and any of our collaborators, including our contract manufacturers, could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with regulatory requirements. Application holders must further notify the FDA, and depending on the nature of the change, obtain FDA pre-approval for product and manufacturing changes. The cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or comparable foreign regulatory authorities become aware of new safety information or previously unknown problems after approval of any of our product candidates, including: (i)&#160;adverse events of unanticipated severity or frequency, (ii)&#160;that the product is less effective than previously thought, (iii)&#160;problems with our third-party manufacturers or manufacturing processes, or (iv)&#160;failure to comply with regulatory requirements, or if we violate regulatory requirements at any stage, whether before or after marketing approval is obtained, we may face a number of regulatory consequences, including fines, warnings or untitled letters, holds on clinical trials, delay of approval or refusal by the FDA to approve pending applications or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, administrative detention of products, refusal to permit the import or export of products, operating restrictions or partial suspension or total shutdown of production, injunctions, consent decrees, civil penalties and criminal prosecution, among other consequences. Additionally, we may face unanticipated expenditures to address or defend such actions and customer notifications for repair, replacement or refunds. Any such restrictions could limit sales of the product. Any of these events could further have other material and adverse effects on our operations and business and could adversely impact our stock price and could significantly harm our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also regulates the advertising and promotion of medical devices to ensure that the claims are consistent with their regulatory clearances or approvals, that there are adequate and reasonable data to substantiate the claims and that the promotional labeling and advertising is neither false nor misleading in any respect. If the FDA determines that any of our advertising or promotional claims are misleading, not substantiated or not permissible, we may be subject to enforcement actions, including warning letters, and we may be required to revise our promotional claims and make other corrections or restitutions. Failure to comply with applicable U.S.&#160;requirements regarding, for example, promoting, manufacturing, or labeling our medical device products, may subject us to a variety of administrative or judicial actions and sanctions, such as Form&#160;483 observations, warning letters, untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution. If any of our medical device products cause or contribute to a death or a serious injury or malfunction in certain ways, we will be required to report under applicable medical device reporting regulations, which can result in voluntary corrective actions or agency enforcement actions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events were to occur, it would have a material and adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results for any patient who receives compassionate use access to our product candidates should not be viewed as representative of how the product candidate will perform in a well-controlled clinical trial, and cannot be used to establish safety or efficacy for regulatory approval. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often receive requests for compassionate use access to our investigational drugs by patients that do not meet the entry criteria for enrollment into our clinical trials. Generally, patients requesting compassionate use have no other treatment alternatives for life threatening conditions. We evaluate each compassionate use request on an individual basis, and in some cases grant access to our investigational product candidates outside of our sponsored clinical trials if a physician certifies that the patient receiving treatment is critically ill and does not meet the entry criteria for one of our open clinical trials. Individual patient results from compassionate use access may not be used to support submission of a regulatory application, may not support approval of a product candidate and should not be considered to be indicative of results from any on-going or future well-controlled clinical trial. Before we can seek regulatory approval for any of our product candidates, we must demonstrate in well-controlled clinical trials statistically significant evidence that the product candidate is both safe and effective for the indication we are seeking approval. The results of our compassionate use program may not be used to establish safety or efficacy or regulatory approval.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are and will be subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal and/or civil liability and other serious consequences for violations, which can harm our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates will be subject to export control and import laws and regulations, including the U.S.&#160;Export Administration Regulations, U.S.&#160;Customs regulations and various economic and trade sanctions regulations administered by the U.S.&#160;Treasury Department&#8217;s Office of Foreign Assets Controls, the FCPA, the U.S.&#160;domestic bribery statute contained in 18&#160;U.S.C.&#160;&#167;201, the U.S.&#160;Travel Act, the USA&#160;PATRIOT Act and possibly other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, third-party intermediaries, joint venture partners and collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. We use CROs abroad for clinical trials. In addition, we may engage third-party intermediaries to sell our product candidates and solutions abroad once we enter a commercialization phase for our product candidates and/or to obtain necessary permits, licenses, and other regulatory approvals. We or our third-party intermediaries may have direct or indirect interactions with officials and employees of government agencies or state-owned or affiliated entities. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors, partners and agents, even if we do not explicitly authorize or have actual knowledge of such activities. if we fail to comply with these laws and regulations, we and certain of our employees could be subject to substantial civil or criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted an anti-corruption policy, which mandates compliance with the FCPA and other anti-corruption laws applicable to our business throughout the world. However, there can be no assurance that our employees and third-party intermediaries will comply with this policy or such anti-corruption laws. Non-compliance with anti-corruption and anti-money laundering laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other investigations, or other enforcement actions. If such actions are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management&#8217;s attention and resources and significant defense and compliance costs and other professional fees. In certain cases, enforcement authorities may even cause us to appoint an independent compliance monitor, which can result in added costs and administrative burdens.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to comply with state, national and/or international data protection laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous laws and legislative and regulatory initiatives at the federal and state levels addressing privacy and security concerns, and some state privacy laws apply more broadly than the Health Insurance Portability and Accountability Act (HIPAA) and associated regulations. For example, California recently enacted legislation&#8212;the California Consumer Privacy Act of 2018 (CCPA)&#8212;which went into effect on January&#160;1,&#160;2020. The CCPA, among other things, creates new data privacy and security obligations for covered companies and provides new privacy rights to California consumers, including the right to opt out of certain disclosures of their information. The CCPA also provides for civil penalties as well as a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. Although the law includes limited exceptions, including for certain information collected as part of clinical trials as specified in the law, it may regulate or impact our processing of personal information depending on the context. Additionally, a new privacy law, the California Privacy Rights Act (CPRA), was approved by California voters in November&#160;2020 and went into effect in most material respects on January&#160;1,&#160;2023. The CPRA significantly modified the CCPA, which may require us to modify our practices and policies and may further increase our compliance costs and potential liability. Certain other state laws impose similar privacy obligations, and all 50&#160;states have laws including obligations to provide notification of security breaches of computer databases that contain personal information to affected individuals, state officers and others. For example, the CCPA has prompted the enactment of several new state laws or amendments of existing state laws, such as in New York, Nevada, Virginia, and Colorado. These laws could mark the beginning of a trend toward more stringent privacy legislation in other U.S. states and have prompted a number of proposals for new federal and state-level privacy legislation. To the extent these state laws as well as other federal and state privacy laws, including new laws and changes in existing laws, apply to our business and operations, our compliance costs and potential liability with respect to personal information we collect could expose us to great liability and increase compliance costs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also various laws and regulations in other jurisdictions relating to privacy and security. For example, European Union (EU) member states and other foreign jurisdictions, including Switzerland, have adopted data protection laws and regulations which impose significant compliance obligations on us. The collection and use of health data in the EU is governed by the EU General Data Protection Regulation (GDPR). The GDPR, which is wide-ranging in scope and applies extraterritorially, imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to such individuals, the security and confidentiality of the personal data, data breach notification, the adoption of appropriate privacy governance, including policies, procedures, training and audits, and the use of third-party processors in connection with the processing of personal data. The GDPR also imposes strict rules on the transfer of personal data out of the EU, including to the U.S., provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to &#8364;20&#160;million or up to 4%&#160;of the total worldwide annual global revenues of the noncompliant entity, whichever is greater. The GDPR requirements apply not only to third-party transactions, but also to transfers of information between us and our subsidiaries, including employee information. In addition, in January 2021, following its exit from the EU, the UK transposed the GDPR into its domestic law with its own version of the GDPR (combining the GDPR and the UK Data Protection Act of 2018) (UK GDPR), which currently imposes the same obligations as the GDPR in most material respects and provides for fines of up &#163;17.5&#160;million or up to 4% of the total worldwide annual global revenues of the noncompliant entity, whichever is greater.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Complying with these numerous, complex and often changing regulations is expensive and difficult, and failure to comply with any privacy laws or data security laws or any security incident or breach involving the misappropriation, loss or other unauthorized processing, use or disclosure of sensitive or confidential patient, consumer or other personal information, whether by us, one of our CROs or business associates or another third&#160;party, could adversely affect our business, financial condition and results of operations, including but not limited to: investigation costs; material fines and penalties; compensatory, special, punitive and statutory damages; litigation; consent orders regarding our privacy and security practices; requirements that we provide notices, credit monitoring services and/or credit restoration services or other relevant services to impacted individuals; adverse actions against our licenses to do business; reputational damage; and injunctive relief. The recent implementation of the CCPA, GDPR and UK GDPR has increased our responsibility and liability in relation to personal data that we process, including in clinical trials, and we may in the future be required to put in place additional mechanisms to ensure compliance with the CCPA, GDPR, UK GDPR and other applicable laws and regulations, which could divert management&#8217;s attention and increase our cost of doing business. In addition, new regulation or legislative actions regarding data privacy and security (together with applicable industry standards) may increase our costs of doing business. In this regard, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection in the U.S., the United Kingdom, the EU and other jurisdictions, and we cannot determine the impact such future laws, regulations and standards may have on our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that our CROs or other third-party service providers with access to our or our customers&#8217;, suppliers&#8217;, trial patients&#8217; and employees&#8217; personally identifiable and other sensitive or confidential information in relation to which we are responsible will not breach contractual obligations imposed by us, or that they will not experience data security breaches, which could have a corresponding effect on our business, including putting us in breach of our obligations under privacy laws and regulations and/or which could in turn adversely affect our business, results of operations and financial condition. We cannot assure you that our contractual measures and our own privacy and security-related safeguards will protect us from the risks associated with the third-party processing, use, storage and transmission of such information. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our third-party contractors must comply with environmental, health and safety laws and regulations. A failure to comply with these laws and regulations could expose us to significant costs or liabilities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and any of our third-party contract manufacturers or suppliers are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, generation, manufacture, storage, treatment and disposal of hazardous materials and wastes. Hazardous chemicals, including flammable and biological materials, are involved in certain aspects of our business, and we cannot eliminate the risk of injury or contamination from the use, generation, manufacture, distribution, storage, handling, treatment or disposal of hazardous materials and wastes. In the event of contamination or injury, or failure to comply with such environmental, health and safety laws and regulations, we could be held liable for any resulting damages, fines and penalties associated with such liability, which could exceed our assets and resources.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we will maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of biological or hazardous materials, or wastes arising out of and in the course of employment, this insurance may not provide adequate coverage against potential liabilities. We do not maintain comprehensive insurance coverage for liabilities arising from medical or hazardous materials, environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Environmental, health and safety laws and regulations are becoming increasingly more stringent. We may incur substantial costs in order to comply with current or future environmental, health, and safety laws and regulations. These current or future laws and regulations may impair our research, development, or production efforts, which could harm our business, prospects, financial condition or results of operations. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both domestic and foreign markets, sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors. Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. Regulatory authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability or that of our collaborators to sell our product candidates profitably. In addition, third&#8209;party payors are requiring higher levels of evidence of the benefits and clinical outcomes of new technologies and are challenging the prices charged. Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Patients are unlikely to use our product candidates unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Such third-party payors include government health programs such as Medicare and Medicaid, managed care providers, private health insurers and other organizations. Obtaining coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. In addition, because our product candidates represent new approaches to the treatment of cancer, we cannot accurately estimate the potential revenues from our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities and third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. These payors may not view our products, if any, as cost-effective, and coverage and reimbursement may not be available to our customers, or those of our collaborators, or may not be sufficient to allow our products, if any, to be marketed on a competitive basis. If reimbursement is not available, or is available only to limited levels, our product candidates may be competitively disadvantaged, and we, or our collaborators, may not be able to successfully commercialize our product candidates. Alternatively, securing favorable reimbursement terms may require us to compromise pricing and prevent us from realizing an adequate margin over cost. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a product is:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a covered benefit under its health plan;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safe, effective and medically necessary;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appropriate for the specific patient;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effective; and</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">neither experimental nor investigational.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. Moreover, the factors noted above have continued to be the focus of policy and regulatory debate that has, thus far, shown the potential for movement towards permanent policy changes; this trend is likely to continue, and may result in more or less favorable impacts on pricing. The recent and ongoing series of congressional hearings relating to drug pricing has presented heightened attention to the biopharmaceutical industry, creating the potential for political and public pressure, while the potential for resulting legislative or policy changes presents uncertainty. Congress is considering legislation that, if passed, could have significant impact on prices of prescription drugs covered by Medicare, including limitations on drug price increases. The impact of these regulations and any future healthcare measures and agency rules implemented by the Biden administration on us and the pharmaceutical industry as a whole is currently unknown. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved. Complying with any new legislation and regulatory changes could be time-intensive and expensive, resulting in a material adverse effect on our business. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prices paid for a drug also vary depending on the class of trade. Prices charged to government customers are subject to price controls, including ceilings, and private institutions obtain discounts through group purchasing organizations. Net prices for drugs may be further reduced by mandatory discounts or rebates required by government healthcare programs and demanded by private payors. It is also not uncommon for market conditions to warrant multiple discounts to different customers on the same unit, such as purchase discounts to institutional care providers and rebates to the health plans that pay them, which reduces the net realization on the original sale.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, federal programs impose penalties on manufacturers of drugs marketed under a BLA or NDA, in the form of mandatory additional rebates and/or discounts if commercial prices increase at a rate greater than the Consumer Price Index-Urban, and these rebates and/or discounts, which can be substantial, may impact our ability to raise commercial prices. For example, under the American Rescue Plan Act of 2021, effective January&#160;1,&#160;2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs will be eliminated. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than it receives on the sale of products, which could have a material impact on our business. In August&#160;2022, Congress passed the Inflation Reduction Act of 2022, which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part&#160;B and Part&#160;D drugs, with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part&#160;D to reduce out-of-pocket prescription drug costs for beneficiaries, among other changes. The impact of these legislative, executive, and administrative actions and any future healthcare measures and agency rules implemented by the Biden administration on us and the pharmaceutical industry as a whole is unclear. Cost control initiatives could cause us, or our collaborators, to decrease, discount, or rebate a portion of the price we, or they, might establish for products, which could result in lower than anticipated product revenues. If the realized prices for our product candidates, if any, decrease or if governmental and other third-party payors do not provide adequate coverage or reimbursement, our prospects for revenues and profitability will suffer.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain coverage for a given product, the resulting approved reimbursement payment rates might not be high enough to allow us to establish or maintain a market share sufficient to realize a sufficient return on our or their investments or achieve or sustain profitability or may require co-payments that patients find unacceptably high. If payors subject our product candidates to maximum payment amounts or impose limitations that make it difficult to obtain reimbursement, providers may choose to use therapies which are less expensive when compared to our product candidates. Additionally, if payors require high co-payments, beneficiaries may decline prescriptions and seek alternative therapies. We may need to conduct post-marketing studies in order to demonstrate the cost-effectiveness of any future products to the satisfaction of hospitals and other target customers and their third-party payors. Such studies might require us to commit a significant amount of management time and financial and other resources. Our future products might not ultimately be considered cost-effective. Adequate third-party coverage and reimbursement might not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment in product development.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, and our collaborators, cannot be sure that coverage will be available for any product candidate that we, or they, commercialize and, if available, that the reimbursement rates will be adequate. Further, the net reimbursement for drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. An inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for any of our product candidates for which we obtain marketing approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products, and our overall financial condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been, and likely will continue to be, legislative and regulatory proposals at the federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the demand for our product candidates, if we obtain regulatory approval;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price that we believe is fair for our product candidates;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenues and achieve or maintain profitability;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of taxes that we are required to pay; and</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability. A particular challenge for our product candidates arises from the fact that they will primarily be used in an inpatient setting. Inpatient reimbursement generally relies on stringent packaging rules that may mean that there is no separate payment for our product candidates. Additionally, data used to set the payment rates for inpatient admissions is usually several years old and would not take into account all of the additional therapy costs associated with the administration of our product candidates. If special rules are not created for reimbursement for immunotherapy treatments such as our product candidates, hospitals might not receive enough reimbursement to cover their costs of treatment, which will have a negative effect on their adoption of our product candidates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face difficulties from changes to current regulations and future legislation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, and affect our ability, or the ability of our collaborators, to profitably sell any products for which we obtain marketing approval. We expect that current laws, as well as other federal and state healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria, increased regulatory burdens and operating costs, decreased revenues from our biopharmaceutical product candidates, decreased potential returns from our development efforts, and additional downward pressure on the price that we, or our collaborators, may receive for any approved products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since enactment of the Affordable Care Act (ACA) in 2010, in both the U.S. and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our product candidates profitably. These changes included aggregate reductions of Medicare payments to providers of up to 2%&#160;per fiscal year, effective April&#160;1,&#160;2013, which, due to subsequent legislative amendments, will stay in effect through 2031, with the exception of a temporary suspension implemented under various COVID&#8209;19 relief legislation from May&#160;1,&#160;2020 through March&#160;31,&#160;2022. Under current legislation, the actual reduction in Medicare payments can vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. In January&#160;2013, the American Taxpayer Relief Act of 2012 (ATRA) was approved which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years. These laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our product candidates, if approved, and accordingly, our financial operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, various portions of the ACA have been subject to judicial and constitutional challenges. In June&#160;2021, the U.S. Supreme Court held that Texas and other challengers had no legal standing to challenge the ACA, dismissing the case without specifically ruling on the constitutionality of the ACA. Accordingly, the ACA remains in effect in its current form. It is unclear how this Supreme Court decision, future litigation, or healthcare measures promulgated by the Biden administration will impact our business, financial condition and results of operations. Complying with any new legislation or reversing changes implemented under the ACA could be time-intensive and expensive, resulting in a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any reduction in reimbursement from Medicare or other government healthcare programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenues, attain profitability or commercialize our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory proposals may also be made to expand post-approval requirements and restrict sales and promotional activities for drugs. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance, or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there have been increasing legislative efforts and enforcement interest in the U.S. with respect to drug pricing practices, including Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. As discussed above, in August 2022, Congress passed the Inflation Reduction Act of 2022, which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part&#160;B and Part&#160;D drugs, with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part&#160;D to reduce out-of-pocket prescription drug costs for beneficiaries, among other changes. The impact of these legislative, executive, and administrative actions and any future healthcare measures and agency rules implemented by the Biden administration on us and the pharmaceutical industry as a whole is unclear. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict the future course of federal or state healthcare legislation in the U.S. directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The ACA and any further changes in the law or regulatory framework that reduce our revenues or increase our costs could also have a material and adverse effect on our business, financial condition and results of operations. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our current product candidates and any future product candidates or additional pricing pressures.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governments outside the U.S. tend to impose strict price controls, which may adversely affect our revenues, if any.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In international markets, reimbursement and health care payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. In some countries, particularly the countries of the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain coverage and reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost&#8209;effectiveness of our product candidate to other available therapies. There can be no assurance that our product candidates will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be available, or that the third-party payors&#8217; reimbursement policies will not adversely affect our ability to sell our product candidates profitably. If reimbursement of our product candidates is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, consultants, commercial partners, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners, principal investigators, CROs, suppliers and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to: comply with the laws of the FDA and other similar foreign regulatory bodies, provide true, complete and accurate information to the FDA and other similar foreign regulatory bodies, comply with manufacturing standards we have established, comply with healthcare fraud and abuse laws in the U.S. and similar foreign fraudulent misconduct laws, or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those product candidates in the U.S., our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws and regulations designed to prevent fraud, kickbacks, self&#8209;dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials, which could result in regulatory sanctions and serious harm to our reputation.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is not always possible to identify and deter misconduct or other improper activities by our employees or third&#160;parties that we engage for our business operations and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material adverse effect on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other sanctions, including exclusion from government healthcare programs, and serious harm to our reputation. In addition, the approval and commercialization of any of our product candidates outside the U.S. will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with health care professionals, institutional providers, principal investigators, consultants, potential customers and third-party payors are, and will continue to be, subject, directly and indirectly, to federal and state health care fraud and abuse, false claims, marketing expenditure tracking and disclosure, government price reporting, and privacy and data security laws. If we are unable to comply, or have not fully complied, with such laws, we could face significant penalties and liabilities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations and activities may be directly or indirectly subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act. If we obtain FDA approval for any of our product candidates and begin commercializing those product candidates in the U.S., our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. Our current and future arrangements with healthcare professionals, clinical investigators, CROs, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. In addition, we may be subject to laws of the federal government and state governments in which we conduct our business relating to privacy and data security with respect to patient information. The laws that may affect our ability to operate include, but are not limited to:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual for a healthcare item or service, or the purchasing or ordering of an item or service, for which payment may be made under a federal healthcare program such as Medicare or Medicaid;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal false claims and civil monetary penalties laws, including the federal civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting or causing to be presented, claims for payment by government funded programs such as Medicare or Medicaid that are false or fraudulent, and which may apply to us by virtue of statements and representations made to customers or third parties; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, which created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud healthcare programs;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by HITECH, which imposes requirements on certain types of people and entities relating to the privacy, security, and transmission of individually identifiable PHI, and requires notification to affected individuals and regulatory authorities of certain breaches of security of PHI; </span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, to report annually to the Centers for Medicare &amp; Medicaid Services (CMS) information related to payments and other transfers of value to covered recipients, including physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare providers (such as physician assistants and nurse practitioners) and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members, which is published in a searchable form on an annual basis; </span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making, or causing to be made, false statements relating to healthcare matters;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Civil Monetary Penalties Law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FCPA, the U.K. Bribery Act of 2010, and other local anti-corruption laws that apply to our international activities; and</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws comparable to each of the above federal laws, such as, for example, anti-kickback and false claims laws that may be broader in scope and also apply to commercial insurers and other non-federal payors, requirements for mandatory corporate regulatory compliance programs, and laws relating to patient data privacy and security. Other state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur increased costs of compliance with such laws and regulations as they continue to evolve. If we or our contractors are unable to comply, or have not fully complied, with such laws, we could face penalties, including, without limitation, civil, criminal, and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal and state health care programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of our operations. Any of these could adversely affect our business, financial condition, and results of operations.</span></div><div style="margin-top:18pt"><span id="ifa3b7a3cc11d4404ac74f2cf3674ddcf_318926"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain, maintain, protect and enforce patent protection and other proprietary rights for our product candidates and technologies, we may not be able to compete effectively or operate profitably and our ability to prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success is dependent in large part on our obtaining, maintaining, protecting and enforcing patents and other proprietary rights in the U.S. and other countries with respect to our product candidates and technology and on our ability to avoid infringing the intellectual property and other proprietary rights of others. Certain of our intellectual property rights are licensed from other entities, and as such the preparation and prosecution of any such patents and patent applications was not performed by us or under our control. Furthermore, patent law relating to the scope of claims in the biotechnology field in which we operate is still evolving and, consequently, patent positions in our industry may not be as strong as in other more well-established fields. The patent positions of biotechnology and pharmaceutical companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved and has been the subject of much litigation in recent years. No consistent policy regarding the breadth of claims allowed in biotechnology patents has emerged to date. As a result, the issuance, scope, validity, enforceability, or commercial value of our patent rights remain highly uncertain.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing therapeutics and technology. There is no guarantee that any of our pending patent applications will result in issued or granted patents, any of our issued or granted patents will not later be found to be invalid or unenforceable, or any issued or granted patents will include claims sufficiently broad to cover our product candidates and technology, or to provide meaningful protection from our competitors. Our owned or in-licensed pending and future patent applications may not result in patents being issued that protect our N-803, saRNA, hAd5 and yeast technologies, cell-based therapies, aldoxorubicin or other product candidates and technologies or that effectively prevent others from commercializing competitive technologies and product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third&#160;parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we own or in-license may be challenged, narrowed, circumvented, or invalidated by third&#160;parties. Consequently, we do not know whether our N-803, saRNA, hAd5 and yeast technologies, cell-based therapies or other product candidates and technologies will be protectable or remain protected by valid and enforceable patents. Our competitors or other third&#160;parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and it is uncertain how much protection, if any, will be provided by our patents, including if they are challenged in the courts or patent offices or in other proceedings, such as re-examinations or oppositions, which may be brought in the U.S. or foreign jurisdictions to challenge the validity of a patent. A third&#160;party may challenge the validity or enforceability of a patent after its issuance. It is possible that a competitor may successfully challenge our patents or that a challenge will result in limiting their coverage. Moreover, it is possible that competitors may infringe our patents or successfully avoid the patented technology through design innovation. To counter infringement or other unauthorized use, we may be required to file infringement claims, which can be expensive and time&#8209;consuming, even if we were successful in stopping the violation of our patent rights.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors may be subject to a third-party preissuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, or interference proceedings or other similar proceedings challenging our owned or licensed patent rights. Should third&#160;parties file patent applications, or be issued patents claiming technology also used or claimed by our licensor(s) or by us in any future patent application, we, or one of our licensors, may be required to participate in interference proceedings in the USPTO to determine priority of invention for those patents or patent applications that are subject to the first-to-invent law in the U.S., or may be required to participate in derivation proceedings in the USPTO for those patents or patent applications that are subject to the first-inventor-to-file law in the U.S. We may be required to participate in such interference or derivation proceedings involving our issued patents and pending applications. We may also be required to participate in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our or our licensor&#8217;s priority of invention or other features of patentability with respect to our owned or in&#8209;licensed patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our N-803, saRNA, hAd5 and yeast technologies, cell-based therapies or other product candidates and technologies. For example, one of our European patents, EP&#160;3601363, has recently been opposed by a third party. We intend to defend our patent and believe we have meritorious defenses against this opposition. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our owned or in&#8209;licensed patent rights, allow third&#160;parties to commercialize our N-803, saRNA, hAd5 and yeast technologies, cell-based therapies or other product candidates or technologies and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaborators are unsuccessful in any such proceeding or other priority or inventorship dispute, we may be required to cease using the technology or to obtain and maintain license rights from prevailing third&#160;parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. A prevailing party in that case may not offer us a license on commercially acceptable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third&#160;parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our owned and in-licensed patents and patent applications are, and may in the future be, co-owned with third&#160;parties. In addition, certain of our licensors co-own the patents and patent applications we in-license with other third&#160;parties with whom we do not have a direct relationship. Our exclusive rights to certain of these patents and patent applications are dependent, in part, on inter-institutional or other operating agreements between the joint owners of such patents and patent applications, who are not parties to our license agreements. If our licensors do not have exclusive control of the grant of licenses under any such third-party co-owners&#8217; interest in such patents or patent applications or we are otherwise unable to secure such exclusive rights, such co-owners may be able to license their rights to other third&#160;parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third&#160;parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and growth prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our owned or in-licensed patent applications do not issue as patents in any jurisdiction, we may not be able to compete effectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or their interpretation in the U.S. and other countries may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and licensed patents. With respect to both in-licensed and owned intellectual property, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third&#160;parties. The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into nondisclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors, and other third&#160;parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in any of our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or our licensors, collaborators, or any future strategic partners may become subject to third-</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to resort to litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">to protect or enforce our patents or other intellectual property or the patents or other intellectual property of our licensors, all of which could be expensive, time-consuming and unsuccessful, may delay or prevent the development and commercialization of our product candidates, or may put our patents and other proprietary rights at risk.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or one of our licensors initiate legal proceedings against a third&#160;party to enforce a patent covering one of our product candidates or other technologies, the defendant could counterclaim that the patent is invalid and/or unenforceable or that we infringe their patents. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third&#160;party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or other applicable body, or made a misleading statement, during prosecution. Third&#160;parties may also raise similar claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g.,&#160;opposition proceedings).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our licensor, our or our licensor&#8217;s patent counsel and the patent examiner were unaware during prosecution. Moreover, even if our patents were to survive such a litigation challenge to their validity, the patents might still be held to be valid but unenforceable if a court were to decide that the patents are being enforced in a manner inconsistent with the antitrust laws, or that the patents were obtained through deceit during patent office examination or other such failure of sufficient candor to the patent office. If a third&#160;party were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business, financial condition, results of operations and prospects. One of our European patents, EP3601363, has recently been opposed by a third party. We intend to defend our patent and believe we have meritorious defenses against this opposition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost to us of any litigation or other proceeding relating to intellectual property rights, even if resolved in our favor, could be substantial. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources, including our scientists and management, from our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An adverse result in any litigation or defense proceeding could put one or more of our owned or licensed patents at risk of being invalidated, held unenforceable, or interpreted narrowly, and could put our patent applications at risk of not issuing. Such proceedings could result in revocation or cancellation of, or amendment to, our patents in such a way that they no longer cover our product candidates or technologies. If the outcome of litigation is adverse to us, third&#160;parties may be able to use our patented invention without payment to us. In addition, in an infringement proceeding, there is a risk that a court may decide that one or more of our patents is not valid or is unenforceable and that we do not have the right to stop the other party from using the inventions. There is also the risk that, even if the validity of our patents were upheld, a court would refuse to stop the other party on the grounds that its activities are not covered by, that is, do not infringe, our patents. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be better able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. The outcome following legal assertions of invalidity and unenforceability is unpredictable. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The use of our technology and product candidates could potentially conflict with the rights of others, and third-party claims of intellectual property infringement, misappropriation or other violation against us, our licensors or our collaborators may prevent or delay the development and commercialization of our product candidates and technologies.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our, our licensors&#8217; and our collaborators&#8217; ability to avoid infringing, misappropriating and otherwise violating the patents and other intellectual property rights of third&#160;parties. There is a substantial amount of complex litigation involving patents and other intellectual property rights in the biopharmaceutical industry. Our potential competitors or other parties may have, develop or acquire patent or other intellectual property rights that they could assert against us. If they do so, then we may be required to alter our product candidates, pay licensing fees or cease our development and commercialization activities with respect to the applicable product candidates or technologies. If our product candidates conflict with patent or other intellectual property rights of others, such parties could bring legal actions against us or our collaborators, licensees, suppliers or customers, claiming damages and seeking to enjoin manufacturing, use and marketing of the affected products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have conducted freedom-to-operate (FTO) analyses of the patent landscape with respect to our lead product candidates and continue to undertake FTO analyses of our manufacturing processes, our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease, and contemplated future processes and products, because patent applications do not publish for 18&#160;months, and because the claims of patent applications can change over time, no FTO analysis can be considered exhaustive. We may not be aware of patents that have already been issued and that a competitor or other third&#160;party might assert are infringed by our current or future product candidates or technologies. It is also possible that we could be found to have infringed patents owned by third&#160;parties of which we are aware, but which we do not believe are relevant to our product candidates or technologies. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates or technologies may infringe. Furthermore, patent and other intellectual property rights in biotechnology remains an evolving area with many risks and uncertainties. As such, we may not be able to ensure that we can market our product candidates without conflict with the rights of others.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If intellectual property-related legal actions asserted against us are successful, in addition to any potential liability for damages (including treble damages and attorneys&#8217; fees for willful infringement), we could be enjoined from, or required to obtain a license to continue, manufacturing, promoting the use of or marketing the affected products. We may not prevail in any legal action and a required license under the applicable patent or other intellectual property may not be available on acceptable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third&#160;parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We also could be required to redesign our infringing products, which may be impossible or require substantial time and monetary expenditure.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defense of infringement claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business, and may impact our reputation. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other immunotherapy and biopharmaceutical companies, our success is dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, the U.S. has recently enacted and is currently implementing wide-ranging patent reform legislation. Assuming that other requirements for patentability are met, prior to March&#160;2013, in the U.S., the first to invent the claimed invention was entitled to the patent, while outside the U.S., the first to file a patent application was entitled to the patent. After March&#160;2013, under the Leahy-Smith America Invents Act (the America Invents Act) enacted in September&#160;2011, the U.S. transitioned to a first-to-file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third&#160;party was the first to invent the claimed invention. A third&#160;party that files a patent application in the USPTO after March&#160;2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third&#160;party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the U.S. and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either file any patent application related to our product candidates or other technologies or invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications. The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO-administered post-grant proceedings, including post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s review, and derivation proceedings. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, U.S.&#160;Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. While we do not believe that any of the patents owned or licensed by us will be found invalid based on the foregoing, we cannot predict how future decisions by Congress, the federal courts or the USPTO may impact the value of our patents.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of a patent. The USPTO and various foreign governmental patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we rely on our licensors to pay these fees and take the necessary actions to comply with these requirements. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market with similar or identical products or technology, which would have a material adverse impact on our business, financial condition, results of operations and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our rights to develop and commercialize our product candidates and technologies are subject, in part, to the terms and conditions of licenses granted to us by others.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will rely on licenses to certain patent rights and proprietary technology from third&#160;parties that are important or necessary to the development of aldoxorubicin as well as products enabled by our adenoviral and yeast, including Tarmogen, vaccine technologies, and saRNA technology.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License agreements may not provide exclusive rights to use certain licensed intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and product candidates in the future. As a result, we may not be able to prevent competitors or other third&#160;parties from developing and commercializing competitive products that also utilizes technology that we have in-licensed.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, subject to the terms of any such license agreements, we do not have the right to control the preparation, filing, prosecution and maintenance, and we may not have the right to control the enforcement, and defense of patents and patent applications covering the technology that we license from third&#160;parties. We cannot be certain that our in-licensed or out-licensed patents and patent applications that are controlled by our licensors or licensees will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our licensors or licensees fail to prosecute, maintain, enforce, and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, our right to develop and commercialize N-803 and any of our product candidates that are subject of such licensed rights could be adversely affected, and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed to and from third&#160;parties, we may still be adversely affected or prejudiced by actions or inactions of our licensees, our licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our owned and in-licensed patents may be subject to a reservation of rights by one or more third&#160;parties. For example, certain of our in-licensed intellectual property was funded in part by the U.S.&#160;government. As a result, the U.S.&#160;government may have certain rights to such intellectual property. When new technologies are developed with U.S.&#160;government funding, the U.S.&#160;government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the U.S.&#160;government to use the invention or to have others use the invention on its behalf. The U.S.&#160;government&#8217;s rights may also permit it to disclose the funded inventions and technology to third&#160;parties and to exercise march-in rights to use or allow third&#160;parties to use the technology we have licensed that was developed using U.S.&#160;government funding. The U.S.&#160;government may exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, or because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S.&#160;industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the U.S. in certain circumstances if this requirement is not waived. Any exercise by the U.S.&#160;government of such rights or by any third&#160;party of its reserved rights could have a material adverse effect on our competitive position, business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third&#160;parties or otherwise experience disruptions to our business relationships with our licensors, we may be required to pay damages and we could lose license rights that are important to our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into license agreements with third&#160;parties and may need to obtain additional licenses from others to advance our research or allow commercialization of our product candidates. We may be unable to obtain certain additional licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates or continue to utilize our existing technology, which could harm our business, financial condition, results of operations and growth prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, manufacturing methods, product candidates, or future methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third&#160;parties, which could be significant.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, each of our license agreements, and we expect our future agreements, will impose various development, diligence, commercialization, and other obligations on us. Certain of our license agreements also require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. In spite of our efforts, our licensors might conclude that we have materially breached our obligations under such license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third&#160;parties would have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of certain of our product candidates or of N-803. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and growth prospects.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights under our collaborative development relationships;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreements under which we currently license intellectual property or technology from third&#160;parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and growth prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights in various jurisdictions throughout the world.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited intellectual property rights outside the U.S. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third&#160;parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with our product candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third&#160;parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third&#160;parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third&#160;parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed trade secrets or other confidential information of third&#160;parties or claims asserting ownership of what we regard as our own intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received confidential and proprietary information from third&#160;parties and their employees and contractors. In addition, we plan to employ and contract with individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed the trade secrets or other confidential information of these third&#160;parties or our employees&#8217; former employers. Litigation may be necessary to defend against or pursue these claims. Even if we are successful in resolving these claims, litigation could result in substantial cost and be a distraction to our management and employees.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees, consultants and independent contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third&#160;parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to license or acquire new or necessary intellectual property rights or technology from third&#160;parties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An element of our intellectual property strategy is to license intellectual property rights and technologies from third&#160;parties and/or our affiliates. Other parties, including our competitors or our affiliates, may have patents relevant to our business, may have already filed patent applications relevant to our business, and are likely filing patent applications potentially relevant to our business. In order to avoid infringing these patents, we may find it necessary or prudent to obtain licenses to such patents from such parties. In addition, with respect to any patents we co-own with other parties, including our affiliates, we may require licenses to such co-owners&#8217; interest to such patents. The licensing or acquisition of intellectual property rights is a competitive area, and other more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No assurance can be given that we will be successful in licensing any additional rights or technologies from third&#160;parties and/or our affiliates. Our inability to license the rights and technologies that we have identified, or that we may in the future identify, could have a material adverse impact on our ability to complete the development of our product candidates or to develop additional product candidates. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third&#160;parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. Failure to obtain any necessary rights or licenses may detrimentally affect our planned development of our current or future additional product candidates and could increase the cost, and extend the timelines associated with our development, of such other products, and we may have to abandon development of the relevant program or product candidate. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our owned or in-licensed U.S.&#160;patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). The Hatch-Waxman Act permits a patent term extension of up to five&#160;years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval. Only one patent may be extended per new drug, and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar extensions as compensation for patent term lost during regulatory review processes are also available in certain foreign countries and territories, such as in Europe under a Supplementary Patent Certificate. However, we may not be granted an extension in the U.S. and/or foreign countries and territories because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is shorter than what we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and growth prospects could be materially harmed.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging rights in our patents and other intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors may be subject to claims that former employees, collaborators or other third&#160;parties have an interest in our owned or in-licensed patents, trade secrets, or other intellectual property, including as an inventor or co-inventor. For example, we or our licensors may have disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship, or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of or right to use valuable intellectual property. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for N-803, saRNA, hAd5 and yeast technologies, cell therapies, and other product candidates and technologies, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information and to maintain our competitive position. Trade secrets and know-how can be difficult to protect. We expect our trade secrets and know-how will over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel from academic to industry scientific positions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to protect these trade secrets and other proprietary technology, in part, by entering into nondisclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors, and other third&#160;parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants as well as train our employees not to bring or use proprietary information or technology from former employers to us or in their work, and remind former employees when they leave their employment of their confidentiality obligations. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite our efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third&#160;party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third&#160;party, our competitive position would be materially and adversely harmed.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third&#160;parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make products that are similar to our product candidates or utilize similar technology but that are not covered by the claims of the patents that we license or may own;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or our current or future licensors or collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or own now or in the future;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or our current or future licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our current or future pending owned or licensed patent applications will not lead to issued patents;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third&#160;parties;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors or other third&#160;parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may harm our business; and</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third&#160;party may subsequently file a patent covering such intellectual property.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:18pt"><span id="ifa3b7a3cc11d4404ac74f2cf3674ddcf_318927"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock and CVRs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dr. Soon-Shiong, our Executive Chairman, Global Chief Scientific and Medical Officer and our principal stockholder, has significant interests in other companies which may conflict with our interests.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Executive Chairman, Global Chief Scientific and Medical Officer and our principal stockholder, Dr.&#160;Soon-Shiong, is the founder of NantWorks. The various NantWorks companies are currently exploring opportunities in the immunotherapy, oncology, infectious disease and inflammatory disease fields. In particular, we have agreements with a number of related parties that provide services, technology and equipment for use in their efforts to develop their product pipelines. Dr.&#160;Soon-Shiong holds a controlling interest, either directly or indirectly, in these entities. Consequently, Dr.&#160;Soon-Shiong&#8217;s interests may not be aligned with our other stockholders and he may from time to time be incentivized to take certain actions that benefit his other interests and that our other stockholders do not view as being in their interest as investors in our company. In addition, other companies affiliated with Dr.&#160;Soon-Shiong may compete with us for business opportunities or, in the future, develop products that are competitive with ours (including products in other therapeutic fields which we may target in the future). Moreover, even if they do not directly relate to us, actions taken by Dr.&#160;Soon-Shiong and the companies with which he is involved could impact us.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also pursuing supply arrangements for various investigational agents controlled by affiliates to be used in their clinical trials. If Dr.&#160;Soon-Shiong were to cease his affiliation with us or NantWorks, these entities may be unwilling to continue these relationships with us on commercially reasonable terms, or at all, and as a result may impede our ability to control the supply chain for our combination therapies. These collaboration agreements do not typically specify how sales will be apportioned between the parties upon successful commercialization of the product. As a result, we cannot guarantee that we will receive a percentage of the revenues that is at least proportional to the costs that we will incur in commercializing the product candidate.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into shared services agreements with NantWorks, pursuant to which NantWorks and its affiliates provide corporate, general and administrative and other support services to us. If Dr.&#160;Soon-Shiong was to cease his affiliation with us or with NantWorks, we may be unable to establish or maintain this relationship with NantWorks on a commercially reasonable basis, if at all. As a result, we could experience a lack of business continuity due to loss of historical and institutional knowledge and a lack of familiarity of new employees and/or new service providers with business processes, operating requirements, policies and procedures, and we may incur additional costs as new employees and/or service providers gain necessary experience. In addition, the loss of the services of NantWorks might significantly delay or prevent the development of our product candidates or achievement of other business objectives by diverting management&#8217;s attention to transition matters and identification of suitable replacements, if any, and could have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dr. Soon-Shiong, through his voting control of the company, has the ability to control actions that require stockholder approval.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr.&#160;Soon-Shiong, through his direct and indirect ownership of the company&#8217;s common stock, has voting control of the company. As of March&#160;31,&#160;2023, Dr.&#160;Soon-Shiong and his affiliates own approximately 74.2% of the company&#8217;s common stock outstanding. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, the company has a $300.0&#160;million promissory note with an entity affiliated with Dr.&#160;Soon-Shiong that is due and payable on December&#160;31,&#160;2023. In the event of a default on the loan (as defined in the promissory note), including if the company does not repay the loan at maturity, the company has the right, at its sole option, to convert the outstanding principal amount and accrued and unpaid interest due under this note into shares of the company&#8217;s common stock at price of $5.67&#160;per share. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the March&#160;31,&#160;2023 $30.0&#160;million promissory note and accrued interest may be converted in whole at the option of the noteholder following the Conversion Price Date, which is the trading day prior to the opening of the next open trading window, as determined by the company&#8217;s board of directors in accordance with the company&#8217;s Insider Trading Policy. The conversion price is equal to the greater of (i)&#160;the NASDAQ Official Closing Price and (ii)&#160;the consolidated closing bid price of the company&#8217;s common stock on the Conversion Price Date. There is no floor on the conversion price for this convertible note, therefore, as of March&#160;31,&#160;2023 we cannot determine the total number of shares issuable upon conversion that may occur in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, entities affiliated with Dr.&#160;Soon-Shiong hold fixed-rate promissory notes representing $264.9&#160;million in indebtedness (including principal and accrued and unpaid interest) as of March&#160;31,&#160;2023. The terms of these fixed-rate promissory notes were amended and restated to include a conversion feature that gives each lender, at its sole option, at any time (other than when the lender is in receipt of a written notice of prepayment from the borrower), the right to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the company&#8217;s common stock at a price of $5.67 per share. Upon receipt of a written notice of prepayment from the borrower, the lender has the right, at its option, to convert the outstanding principal amount to be prepaid and the accrued and unpaid interest thereon (as specified in the notice of prepayment) into shares of the company&#8217;s common stock at a price of $5.67&#160;per share. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An affiliate of Dr.&#160;Soon-Shiong holds a warrant to purchase 1,638,000&#160;shares of the company&#8217;s common stock that will become exercisable if certain performance conditions are satisfied. Dr.&#160;Soon-Shiong and his related party also hold approximately $139.8&#160;million in the aggregate of CVRs issued to the former stockholders of Altor in connection with the 2017&#160;acquisition of Altor. If the underlying conditions for payment are met, the CVRs become payable in cash or shares of the company&#8217;s common stock or any combination as the holder elects. Dr.&#160;Soon-Shiong and his related party have both irrevocably agreed to receive shares of the company&#8217;s common stock in satisfaction of their CVRs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr.&#160;Soon-Shiong also has a total of 1,626,064&#160;stock options outstanding as of March&#160;31,&#160;2023, of which 1,159,398 are exercisable and 466,666&#160;are unvested and unexercisable.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr.&#160;Soon-Shiong is in a position to control the outcome of corporate actions that require, or may be accomplished by, stockholder approval, including amending the bylaws of the company, the election or removal of directors and transactions involving a change of control. Dr.&#160;Soon-Shiong&#8217;s controlling ownership could limit the ability of the remaining stockholders of the company to influence corporate matters, and the interests of Dr.&#160;Soon-Shiong may not coincide with the company&#8217;s interests or the interests of its remaining stockholders. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, pursuant to the Nominating Agreement between us and Cambridge Equities, LP (Cambridge), an entity that Dr.&#160;Soon-Shiong controls, Cambridge has the ability to designate one director to be nominated for election to the Board of Directors for as long as Cambridge continues to hold at least 20%&#160;of the issued and outstanding shares of our common stock. Dr.&#160;Soon-Shiong was selected by Cambridge to hold this board seat. Dr.&#160;Soon-Shiong and his affiliates will therefore have significant influence over management and significant control over matters requiring stockholder approval, including the annual election of directors and significant corporate transactions, such as a merger or other sale of our company or its assets, for the foreseeable future. This control will limit stockholders&#8217; ability to influence corporate matters and, as a result, we may take actions that our stockholders do not view as beneficial. As a result, the market price of our common stock could be adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock has been and may continue to be volatile, and investors may have difficulty selling their shares.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our common stock is listed on the NASDAQ Global Select Market, the market for our shares has demonstrated varying levels of trading activity. You may not be able to sell your shares quickly or at the market price if trading in shares of our common stock is not active. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price of our common stock has been and may continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commencement, enrollment or results of the planned clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse results or delays in clinical trials;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws or regulations applicable to our products, including but not limited to clinical trial requirements for approvals;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to commercialize our product candidates;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key scientific or management personnel;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated serious safety concerns related to the use of our product candidates;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively manage our growth;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our quarterly operating results;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our liquidity position and the amount and nature of any debt we may incur;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements that our revenue or income are below or that costs or losses are greater than analysts&#8217; expectations;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publication of research reports about us or our industry, or immunotherapy in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of large blocks of our common stock;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in stock market prices and volumes;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception of our clinical trial results by retail investors, which investors may be subject to the influence of information provided by third&#160;party investor websites and independent authors distributing information on the internet;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic slowdowns;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government-imposed lockdowns, supply chain disruptions, and adverse economic effects from the ongoing COVID-19 pandemic, in the U.S. and abroad;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">geopolitical tensions and war, including the war in Ukraine;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">coordinated actions by independent third-party actors to affect the price of certain stocks, coordinated via the Internet and otherwise; and</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors described in this &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; section.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plan, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell substantial amounts of our common stock in the public market, including shares obtained from the exercise of our warrants, the market price of our common stock could decline significantly. In addition, our Executive Chairman and Global Chief Scientific and Medical Officer, Dr.&#160;Soon-Shiong, and his affiliates currently own approximately 74.2%&#160;of our outstanding shares of common stock as of March&#160;31,&#160;2023. Sales of stock by Dr.&#160;Soon-Shiong and his affiliates could have an adverse effect on the trading price of our common stock.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain holders of our common stock are entitled to certain rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by our affiliates as defined in Rule&#160;144 under the Securities Act. Any sales of securities by these stockholders could have an adverse effect on the market price of our common stock.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we expect that additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating as a public company. To raise capital, we may sell common stock, convertible securities or other equity securities (including warrants) in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities (including warrants), new investors could gain rights, preferences and privileges senior to the holders of our common stock. The issuance of additional shares of common stock or warrants to purchase common stock, perception that such issuances may occur, or exercise of outstanding warrants or other equity securities will have a material dilutive impact on existing stockholders and could have a material negative effect on the market price of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred and will continue to incur costs as a result of operating as a public company and our management has been and will be required to devote substantial time to compliance initiatives and corporate governance practices, including maintaining an effective system of internal control over financial reporting.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company listed in the U.S., we have incurred and will continue to incur significant additional legal, accounting and other expenses as a result of operating as a public company. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act of 2002 (Sarbanes Oxley) and regulations implemented by the SEC and NASDAQ, may increase legal and financial compliance costs and make some activities more time consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to create a larger finance function with additional personnel to comply with evolving laws, regulations and standards, and this investment will result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If, notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us, and our business may be harmed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company in the U.S., we are required, pursuant to Section&#160;404 of Sarbanes-Oxley (Section&#160;404) to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. The controls and other procedures are designed to ensure that information required to be disclosed by us in the reports that we file with the SEC is disclosed accurately and is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business our controls and procedures may become inadequate because of changes in conditions or the degree of compliance with these policies or procedures may deteriorate and material weaknesses in our internal control over financial reporting may be discovered. We may err in the design or operation of our controls, and all internal control systems, no matter how well designed and operated, can provide only reasonable assurance that the objectives of the control system are met. Because there are inherent limitations in all control systems, there can be no absolute assurance that all control issues have been or will be detected. If we are unable, or are perceived as unable, to produce reliable financial reports due to internal control deficiencies, investors could lose confidence in our reported financial information and operating results, which could result in a negative market reaction.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To fully comply with Section&#160;404, we will need to retain additional employees to supplement our current finance staff, and we may not be able to do so in a timely manner, or at all. In addition, in the process of evaluating our internal control over financial reporting, we expect that certain of our internal control practices will need to be updated to comply with the requirements of Section&#160;404 and the regulations promulgated thereunder, and we may not be able to do so on a timely basis, or at all. In the event that we are not able to demonstrate compliance with Section&#160;404 in a timely manner, or are unable to produce timely or accurate financial statements, we may be subject to sanctions or investigations by regulatory authorities, such as the SEC or NASDAQ, and investors may lose confidence in our operating results and the price of our common stock could decline. Furthermore, if we are unable to certify that our internal control over financial reporting is effective and in compliance with Section&#160;404, we may be subject to sanctions or investigations by regulatory authorities, such as the SEC or stock exchanges, and investors could lose confidence in the accuracy and completeness of our financial reports, which could hurt our business, the price of our common stock and our ability to access the capital markets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating as a public company makes it more expensive for us to obtain directors&#8217; and officers&#8217; liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified persons to serve on the Board of Directors, on committees of the Board of Directors, or as members of senior management.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If a restatement of our consolidated financial statements were to occur, our stockholders&#8217; confidence in the company&#8217;s financial reporting in the future may be affected, which could in turn have a material adverse effect on our business and stock price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any material weaknesses in our internal control over financial reporting are discovered or occur in the future, our consolidated financial statements may contain material misstatements, and we could be required to restate our financial results. In addition, if we are unable to successfully remediate any future material weaknesses in our internal controls or if we are unable to produce accurate and timely financial statements, our stock price may be adversely affected, and we may be unable to maintain compliance with applicable stock exchange listing requirements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not paid cash dividends in the past and do not expect to pay dividends in the future. Any return on investment may be limited to the value of our common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid cash dividends on our common stock and do not anticipate paying cash dividends for the foreseeable future. The payment of dividends on our common stock will depend on earnings, financial condition and other business and economic factors affecting us at such time as the Board of Directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if our stock price appreciates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we are relying on the exemptions from corporate governance requirements as a result of being a &#8220;controlled company&#8221; within the meaning of the NASDAQ listing standards, you do not have the same protections afforded to stockholders of companies that are subject to such requirements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Executive Chairman and Global Chief Scientific and Medical Officer, Dr.&#160;Soon-Shiong, and entities affiliated with him, control a majority of our common stock. As a result, we are a &#8220;controlled company&#8221; within the meaning of the NASDAQ listing standards. Under these rules, a company of which more than 50%&#160;of the voting power is held by an individual, a group or another company is a &#8220;controlled company&#8221; and may elect not to comply with certain NASDAQ corporate governance requirements, including (1)&#160;the requirement that a majority of the Board of Directors consist of independent directors, and (2)&#160;the requirement that we have a Nominating and Corporate Governance Committee that is composed entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities. Accordingly, you do not have the same protections afforded to stockholders of companies that are subject to all of the NASDAQ corporate governance requirements. However, our Board of Directors is currently comprised of a majority of independent directors and we currently have a Nominating and Corporate Governance Committee and the majority of the members of such committee are independent directors.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock and the value of our warrants will depend on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. There can be no assurance that analysts will cover us or provide favorable coverage. If one or more of the analysts who cover us downgrade our stock or change their opinion of our stock, our share price would likely decline. If one or more of these analysts&#8217; cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Holders of our CVRs that are payable contingent upon us achieving certain milestones may not receive any further consideration. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our 2017 acquisition of Altor, we issued CVRs under which we agreed to pay the prior stockholders of Altor approximately $304.0&#160;million of contingent consideration upon the&#160;successful regulatory approval of a BLA by the FDA, or foreign equivalent, for N-803 by December&#160;31,&#160;2022, and approximately $304.0&#160;million of contingent consideration upon calendar-year worldwide sales of N-803 exceeding $1.0&#160;billion prior to December&#160;31,&#160;2026. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the regulatory milestone CVR agreement, in May&#160;2022 we announced the submission of a BLA to the FDA for our product candidate, Anktiva (N-803) in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n July&#160;2022 we announced that the FDA had accepted our BLA for review and set a target PDUFA action date of May&#160;23,&#160;2023. On May&#160;9,&#160;2023, the FDA delivered a complete response letter to us regarding the BLA, as described in greater detail in Part&#160;I, Item&#160;2 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_163">&#8212;Subsequent Events.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> It is unclear when the FDA will approve our BLA, if at all. The FDA did not approve our BLA on or before December&#160;31,&#160;2022, and therefore the regulatory milestone was not met, and the regulatory milestone CVR agreement terminated in accordance with its terms. With respect to the sales milestone CVR agreement, N-803 is not currently approved for commercial sale, and there can be no assurance that such sales milestone will be achieved. Accordingly, holders of our CVRs that are payable contingent upon us achieving the aforementioned milestones may not receive any further consideration.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are not subject to the provisions of Section 203 of the Delaware General Corporation Law (DGCL), which could negatively affect your investment.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected in our amended and restated certificate of incorporation to not be subject to the provisions of Section&#160;203 of the DGCL. In general, Section&#160;203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three&#160;years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221; includes a merger, asset sale or other transaction resulting in a financial benefit to the interested stockholder. An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns (or, in certain cases, within three&#160;years prior, did own) 15%&#160;or more of the corporation&#8217;s voting stock. Our decision not to be subject to Section&#160;203 will allow, for example, our Executive Chairman and Global Chief Scientific and Medical Officer (who, with members of his immediate family and entities affiliated with him, currently own, in the aggregate, approximately 74.2% of our common stock as of March&#160;31,&#160;2023) to transfer shares in excess of 15%&#160;of our voting stock to a third-party free of the restrictions imposed by Section&#160;203. This may make us more vulnerable to takeovers that are completed without the approval of our Board of Directors and/or without giving us the ability to prohibit or delay such takeovers as effectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, as well as provisions of Delaware law, could make it more difficult for a third&#160;party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders. These provisions include:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement that special meetings of stockholders be called only by the board of directors, president or chief executive officer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance notice requirements for stockholder proposals and nominations for election to the board of directors; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These anti-takeover provisions and other provisions in our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our Board of Directors or initiate actions that are opposed by the then-current Board of Directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our Board of Directors could cause the market price of our common stock to decline.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. In addition, as permitted by Section&#160;145 of the DGCL, our Amended and Restated Bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are not obligated pursuant to our Amended and Restated Bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees except with respect to proceedings authorized by our Board of Directors or brought to enforce a right to indemnification.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The rights conferred in our Amended and Restated Bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not retroactively amend our bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a claim for indemnification is brought by any of our directors or officers, it would reduce the amount of funds available for use in our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_181"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. &#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Recent Sales of Unregistered Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i5bbe340c9c8f435088d8011b72b6800d_184"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. &#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i5bbe340c9c8f435088d8011b72b6800d_187"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. &#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i5bbe340c9c8f435088d8011b72b6800d_190"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. &#160;&#160;&#160;&#160;OTHER INFORMATION.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_193"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. &#160;&#160;&#160;&#160;EXHIBITS. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The documents listed below are incorporated by reference or are filed or furnished with this Quarterly Report, in each case as indicated therein (numbered in accordance with Item&#160;601 of Regulation&#160;S&#8209;K).</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.826%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Description of Exhibit</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312515275314/d158803dex31.htm">Amended and Restated Certificate of Incorporation of ImmunityBio,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312515275314/d158803dex31.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312515275314/d158803dex31.htm">Inc. (incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312515275314/d158803dex31.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312515275314/d158803dex31.htm">3.1 to the company&#8217;s Current Report on Form</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312515275314/d158803dex31.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312515275314/d158803dex31.htm">8-K filed with the SEC on August</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312515275314/d158803dex31.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312515275314/d158803dex31.htm">4,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312515275314/d158803dex31.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312515275314/d158803dex31.htm">2015).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;3.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521075243/d307217dex31.htm">Certificate of Amendment of Amended and Restated Certificate of Incorporation of ImmunityBio,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521075243/d307217dex31.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521075243/d307217dex31.htm">Inc. dated March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521075243/d307217dex31.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521075243/d307217dex31.htm">9,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521075243/d307217dex31.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521075243/d307217dex31.htm">2021 (incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521075243/d307217dex31.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521075243/d307217dex31.htm">3.1 to the company&#8217;s Current Report on Form</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521075243/d307217dex31.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521075243/d307217dex31.htm">8-K filed with the SEC on March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521075243/d307217dex31.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521075243/d307217dex31.htm">10,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521075243/d307217dex31.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521075243/d307217dex31.htm">2021).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;3.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522061324/d283375dex33.htm">Certificate of Amendment of Amended and Restated Certificate of Incorporation of ImmunityBio,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522061324/d283375dex33.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522061324/d283375dex33.htm">Inc. dated February</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522061324/d283375dex33.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522061324/d283375dex33.htm">1,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522061324/d283375dex33.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522061324/d283375dex33.htm">2022 (incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522061324/d283375dex33.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522061324/d283375dex33.htm">3.3 to the company&#8217;s POSASR filed with the SEC on March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522061324/d283375dex33.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522061324/d283375dex33.htm">1,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522061324/d283375dex33.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522061324/d283375dex33.htm">2022).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;3.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459021044008/ibrx-ex32_717.htm">Amended and Restated Bylaws of ImmunityBio,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459021044008/ibrx-ex32_717.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459021044008/ibrx-ex32_717.htm">Inc. effective as of March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459021044008/ibrx-ex32_717.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459021044008/ibrx-ex32_717.htm">10,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459021044008/ibrx-ex32_717.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459021044008/ibrx-ex32_717.htm">2021 (incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459021044008/ibrx-ex32_717.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459021044008/ibrx-ex32_717.htm">3.2 to the company&#8217;s Quarterly Report on Form</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459021044008/ibrx-ex32_717.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459021044008/ibrx-ex32_717.htm">10-Q filed with SEC on August</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459021044008/ibrx-ex32_717.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459021044008/ibrx-ex32_717.htm">12,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459021044008/ibrx-ex32_717.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459021044008/ibrx-ex32_717.htm">2021).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312523039833/d644968dex41.htm">Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit&#160;4.1 to </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312523039833/d644968dex41.htm">the company&#8217;s Current Report on Form</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312523039833/d644968dex41.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312523039833/d644968dex41.htm">8-K filed with the SEC on February&#160;15,&#160;2023).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312523039833/d644968dex101.htm">Securities Purchase Agreement dated as of February&#160;15,&#160;2023 (incorporated by reference to Exhibit&#160;10.1 to the company&#8217;s Current Report on Form&#160;8-K filed with the SEC on February&#160;15,&#160;2023).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000028/ibrx-20233318xkexhibit101.htm">Convertible Promissory Note by and between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000028/ibrx-20233318xkexhibit101.htm">ImmunityBio, Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000028/ibrx-20233318xkexhibit101.htm"> and Nant Capital, LLC dated as of March&#160;31,&#160;2023 (incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000028/ibrx-20233318xkexhibit101.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000028/ibrx-20233318xkexhibit101.htm">10.1 to the company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000028/ibrx-20233318xkexhibit101.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000028/ibrx-20233318xkexhibit101.htm">s Current Report on Form</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000028/ibrx-20233318xkexhibit101.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000028/ibrx-20233318xkexhibit101.htm">8-K filed with the SEC on March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000028/ibrx-20233318xkexhibit101.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000028/ibrx-20233318xkexhibit101.htm">31,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000028/ibrx-20233318xkexhibit101.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000028/ibrx-20233318xkexhibit101.htm">2023</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000028/ibrx-20233318xkexhibit101.htm">)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000028/ibrx-20233318xkexhibit101.htm">.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;31.1*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ibrx-20230331x10qexhibit311.htm">Rule 13a-14(a)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ibrx-20230331x10qexhibit311.htm">/</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ibrx-20230331x10qexhibit311.htm">15(d)-14(a) Certification of Principal Executive Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;31.2*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ibrx-20230331x10qexhibit312.htm">Rule 13a-14(a)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ibrx-20230331x10qexhibit312.htm">/</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ibrx-20230331x10qexhibit312.htm">15(d)-14(a) Certification of Principal Financial Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;32.1**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ibrx-20230331x10qexhibit321.htm">Section 1350 Certification of Principal Executive Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;32.2**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ibrx-20230331x10qexhibit322.htm">Section 1350 Certification of Principal Financial Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;101.INS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Instance Document (the instance document does not appear in the <br/>Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;101.SCH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;101.CAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;101.DEF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;101.LAB</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;101.PRE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit&#160;101).</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"></td><td style="width:3.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.132%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.413%"><tr><td style="width:1.0%"></td><td style="width:3.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.033%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The certifications attached as Exhibits&#160;32.1 and 32.2 that accompany this Quarterly Report on Form&#160;10-Q are deemed furnished and not filed with the SEC and are not to be incorporated by reference into any filing of ImmunityBio,&#160;Inc. under the Securities Act or the Exchange Act, whether made before or after the date of this Quarterly Report, irrespective of any general incorporation language contained in such filing. </span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><div id="i5bbe340c9c8f435088d8011b72b6800d_196"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5bbe340c9c8f435088d8011b72b6800d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.999%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">IMMUNITYBIO, INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Registrant</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date: May&#160;11, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Richard Adcock</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Richard Adcock</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date: May&#160;11, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ David C. Sachs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David C. Sachs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Principal Financial Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ibrx-20230331x10qexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i72b9d1c7c4784ed382a642281012eb18_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 31.1</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a)&#47;15d-14(a), </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION&#160;302 OF </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Richard Adcock, certify that&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form 10-Q of ImmunityBio, Inc.&#894;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#894;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#894;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#894;</font></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#894; and</font></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#894; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#894; and</font></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 11, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Richard Adcock</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard Adcock</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ibrx-20230331x10qexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7b10d1d411b645d497d9e32feb9d665d_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a)&#47;15d-14(a), </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION&#160;302 OF </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David C. Sachs, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form 10-Q of ImmunityBio, Inc.&#894;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#894;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#894;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#894;</font></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#894; and</font></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#894; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#894; and</font></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;11, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David C. Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David C. Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ibrx-20230331x10qexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i84b14adc30bd4de0b74b6a5b106db290_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18&#160;U.S.C.&#160;Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, I, Richard Adcock, the Chief Executive Officer of ImmunityBio, Inc. (the &#8220;Company&#8221;), hereby certify, that, to my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">the Quarterly Report of the Company on Form 10-Q for the quarter ended March&#160;31,&#160;2023 (the &#8220;Report&#8221;), fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#894; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 11, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Richard Adcock</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard Adcock</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ibrx-20230331x10qexhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id0c3c05145564b0badacdfac2f4b3318_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18&#160;U.S.C.&#160;Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, I, David&#160;C.&#160;Sachs, the Chief Financial Officer of ImmunityBio, Inc. (the &#8220;Company&#8221;), hereby certify, that, to my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">the Quarterly Report of the Company on Form 10-Q for the quarter ended March&#160;31,&#160;2023 (the &#8220;Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#894; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 11, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David C. Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David C. Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>ibrx-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5993b617-92d4-4bab-a076-33e54147e714,g:68360996-794b-41f6-8c08-63fce426a63c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ibrx="http://www.immunitybio.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.immunitybio.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ibrx-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ibrx-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ibrx-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ibrx-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.immunitybio.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersDeficit" roleURI="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersDeficitParenthetical" roleURI="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficitParenthetical">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000008 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.immunitybio.com/role/DescriptionofBusiness">
        <link:definition>0000009 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialStatementDetails" roleURI="http://www.immunitybio.com/role/FinancialStatementDetails">
        <link:definition>0000011 - Disclosure - Financial Statement Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.immunitybio.com/role/FinancialInstruments">
        <link:definition>0000012 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.immunitybio.com/role/FairValueMeasurements">
        <link:definition>0000013 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsandAcquisition" roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisition">
        <link:definition>0000014 - Disclosure - Collaboration and License Agreements and Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.immunitybio.com/role/CommitmentsandContingencies">
        <link:definition>0000015 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseArrangements" roleURI="http://www.immunitybio.com/role/LeaseArrangements">
        <link:definition>0000016 - Disclosure - Lease Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDebt" roleURI="http://www.immunitybio.com/role/RelatedPartyDebt">
        <link:definition>0000017 - Disclosure - Related-Party Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyAgreements" roleURI="http://www.immunitybio.com/role/RelatedPartyAgreements">
        <link:definition>0000018 - Disclosure - Related-Party Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantLiabilities" roleURI="http://www.immunitybio.com/role/WarrantLiabilities">
        <link:definition>0000019 - Disclosure - Warrant Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficit" roleURI="http://www.immunitybio.com/role/StockholdersDeficit">
        <link:definition>0000020 - Disclosure - Stockholders&#8217; Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.immunitybio.com/role/StockBasedCompensation">
        <link:definition>0000021 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.immunitybio.com/role/IncomeTaxes">
        <link:definition>0000022 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000023 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000024 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialStatementDetailsTables" roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsTables">
        <link:definition>0000025 - Disclosure - Financial Statement Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.immunitybio.com/role/FinancialInstrumentsTables">
        <link:definition>0000026 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.immunitybio.com/role/FairValueMeasurementsTables">
        <link:definition>0000027 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsandAcquisitionTables" roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionTables">
        <link:definition>0000028 - Disclosure - Collaboration and License Agreements and Acquisition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseArrangementsTables" roleURI="http://www.immunitybio.com/role/LeaseArrangementsTables">
        <link:definition>0000029 - Disclosure - Lease Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDebtTables" roleURI="http://www.immunitybio.com/role/RelatedPartyDebtTables">
        <link:definition>0000030 - Disclosure - Related-Party Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyAgreementsTables" roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsTables">
        <link:definition>0000031 - Disclosure - Related-Party Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.immunitybio.com/role/StockBasedCompensationTables">
        <link:definition>0000032 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>0000033 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail" roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail">
        <link:definition>0000034 - Disclosure - Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail" roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail">
        <link:definition>0000035 - Disclosure - Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialStatementDetailsPropertyPlantandEquipmentNetDetail" roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail">
        <link:definition>0000036 - Disclosure - Financial Statement Details - Property, Plant and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialStatementDetailsAdditionalInformationDetail" roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail">
        <link:definition>0000037 - Disclosure - Financial Statement Details - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialStatementDetailsIntangibleAssetsNetDetails" roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails">
        <link:definition>0000038 - Disclosure - Financial Statement Details - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialStatementDetailsIntangibleAssetsNetDetails_1" roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails_1">
        <link:definition>0000038 - Disclosure - Financial Statement Details - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail" roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail">
        <link:definition>0000039 - Disclosure - Financial Statement Details - Accrued Expenses and Other Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialStatementDetailsInterestandInvestmentIncomeNetDetail" roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeNetDetail">
        <link:definition>0000040 - Disclosure - Financial Statement Details - Interest and Investment Income, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialStatementDetailsInterestExpenseDetails" roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails">
        <link:definition>0000041 - Disclosure - Financial Statement Details - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail" roleURI="http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail">
        <link:definition>0000042 - Disclosure - Financial Instruments - Summary of Available-for-Sale Marketable Debt Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsAccumulatedUnrealizedLossesonMarketableDebtSecuritiesinContinuousLossPositionDetail" roleURI="http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonMarketableDebtSecuritiesinContinuousLossPositionDetail">
        <link:definition>0000043 - Disclosure - Financial Instruments - Accumulated Unrealized Losses on Marketable Debt Securities in Continuous Loss Position (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsAdditionalInformationDetail" roleURI="http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail">
        <link:definition>0000044 - Disclosure - Financial Instruments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" roleURI="http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail">
        <link:definition>0000045 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail" roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail">
        <link:definition>0000046 - Disclosure - Collaboration and License Agreements and Acquisition - Collaboration Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail" roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail">
        <link:definition>0000047 - Disclosure - Collaboration and License Agreements and Acquisition - License Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails" roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails">
        <link:definition>0000048 - Disclosure - Collaboration and License Agreements and Acquisition - Acquisition - Consideration Transferred (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails" roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails">
        <link:definition>0000049 - Disclosure - Collaboration and License Agreements and Acquisition - Acquisition - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail" roleURI="http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail">
        <link:definition>0000050 - Disclosure - Commitment and Contingencies - Contingent Consideration Related to Business Combinations - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesLitigationAdditionalInformationDetail" roleURI="http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail">
        <link:definition>0000051 - Disclosure - Commitment and Contingencies - Litigation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseArrangementsSupplementalBalanceSheetInformationDetails" roleURI="http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails">
        <link:definition>0000052 - Disclosure - Lease Arrangements - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseArrangementsSummaryofInformationRegardingLeasesDetail" roleURI="http://www.immunitybio.com/role/LeaseArrangementsSummaryofInformationRegardingLeasesDetail">
        <link:definition>0000053 - Disclosure - Lease Arrangements - Summary of Information Regarding Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseArrangementsComponentsofLeaseExpenseDetail" roleURI="http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail">
        <link:definition>0000054 - Disclosure - Lease Arrangements - Components of Lease Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseArrangementsScheduleofCashPaidforAmountsIncludedinMeasurementofLeaseLiabilitiesDetail" roleURI="http://www.immunitybio.com/role/LeaseArrangementsScheduleofCashPaidforAmountsIncludedinMeasurementofLeaseLiabilitiesDetail">
        <link:definition>0000055 - Disclosure - Lease Arrangements - Schedule of Cash Paid for Amounts Included in Measurement of Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail" roleURI="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail">
        <link:definition>0000056 - Disclosure - Lease Arrangements - Summary of Future Minimum Lease Payments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1" roleURI="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1">
        <link:definition>0000056 - Disclosure - Lease Arrangements - Summary of Future Minimum Lease Payments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_2" roleURI="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_2">
        <link:definition>0000056 - Disclosure - Lease Arrangements - Summary of Future Minimum Lease Payments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseArrangementsAdditionalInformationDetail" roleURI="http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail">
        <link:definition>0000057 - Disclosure - Lease Arrangements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDebtNarrativeDetails" roleURI="http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails">
        <link:definition>0000058 - Disclosure - Related-Party Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail" roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail">
        <link:definition>0000059 - Disclosure - Related-Party Agreements - Summary of Related-Party Promissory Notes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails" roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails">
        <link:definition>0000060 - Disclosure - Related-Party Agreements - Estimated Material Contractual Obligations Related to Related-Party Promissory Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyAgreementsSummaryofOutstandingBalancesofRelatedPartyAgreementsDetail" roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofOutstandingBalancesofRelatedPartyAgreementsDetail">
        <link:definition>0000061 - Disclosure - Related-Party Agreements - Summary of Outstanding Balances of Related-Party Agreements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyAgreementsAdditionalInformationDetail" roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail">
        <link:definition>0000062 - Disclosure - Related-Party Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantLiabilitiesDetails" roleURI="http://www.immunitybio.com/role/WarrantLiabilitiesDetails">
        <link:definition>0000063 - Disclosure - Warrant Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficitAdditionalInformationDetail" roleURI="http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail">
        <link:definition>0000064 - Disclosure - Stockholders' Deficit - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>0000065 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail" roleURI="http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail">
        <link:definition>0000066 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expenses Related to Statement of Operations (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetail" roleURI="http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityDetail">
        <link:definition>0000067 - Disclosure - Stock-Based Compensation - Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRSUsActivityDetail" roleURI="http://www.immunitybio.com/role/StockBasedCompensationRSUsActivityDetail">
        <link:definition>0000068 - Disclosure - Stock-Based Compensation - RSUs Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetail" roleURI="http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail">
        <link:definition>0000069 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ibrx_BrinkBiologicsIncMember" abstract="true" name="BrinkBiologicsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_LeaseLiabilityToBePaid" abstract="false" name="LeaseLiabilityToBePaid" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_LicensingAgreementLineItems" abstract="true" name="LicensingAgreementLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_OptionsToExtendNumberOfTerms" abstract="false" name="OptionsToExtendNumberOfTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ibrx_MeasurementInputExpectedMarketYieldMember" abstract="true" name="MeasurementInputExpectedMarketYieldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_AtTheMarketOfferingProgramMember" abstract="true" name="AtTheMarketOfferingProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_NCSCMember" abstract="true" name="NCSCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_NoncurrentAssetsMember" abstract="true" name="NoncurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_RelatedPartyNotesInterestMember" abstract="true" name="RelatedPartyNotesInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_PrepaidSoftwareLicenseFees" abstract="false" name="PrepaidSoftwareLicenseFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_NumberOfSquareFootOfFacilityLeased" abstract="false" name="NumberOfSquareFootOfFacilityLeased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="ibrx_BaseMonthlyRent" abstract="false" name="BaseMonthlyRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_NantCellIncMember" abstract="true" name="NantCellIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_RelatedPartyWarrantsMember" abstract="true" name="RelatedPartyWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_LeaseLiabilityToBePaidYearThree" abstract="false" name="LeaseLiabilityToBePaidYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_CollaborationAgreementsPeriodicLicensePayments" abstract="false" name="CollaborationAgreementsPeriodicLicensePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_AccruedConstructionCostsCurrent" abstract="false" name="AccruedConstructionCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_NonCashInterestIncomeExpenseFromOperatingActivities" abstract="false" name="NonCashInterestIncomeExpenseFromOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_PrepaidServices" abstract="false" name="PrepaidServices" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_RentAbatementPeriod" abstract="false" name="RentAbatementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember" abstract="true" name="NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_InitialAndExpansionPremisesMember" abstract="true" name="InitialAndExpansionPremisesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_JulyTwentyNineteenLeaseMember" abstract="true" name="JulyTwentyNineteenLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_LitigationTable" abstract="true" name="LitigationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_IssuanceOfCommonStockUnderAtMarketOfferingShares" abstract="false" name="IssuanceOfCommonStockUnderAtMarketOfferingShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ibrx_FinancialStatementDetailsTable" abstract="true" name="FinancialStatementDetailsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_LeaseRelatedPayables" abstract="false" name="LeaseRelatedPayables" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_AccruedPreclinicalAndClinicalTrialCosts" abstract="false" name="AccruedPreclinicalAndClinicalTrialCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_LeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased" abstract="false" name="IncreaseToNumberOfSquareFootOfFacilityLeased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="ibrx_AltorStockholdersMember" abstract="true" name="AltorStockholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable" abstract="false" name="FinanceLeaseLiabilityTenantImprovementAllowanceReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_AmyrisIncMember" abstract="true" name="AmyrisIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_CollaborationAgreementsTerminationFee" abstract="false" name="CollaborationAgreementsTerminationFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_FinancialStatementDetailsLineItems" abstract="true" name="FinancialStatementDetailsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense" abstract="false" name="FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_RelatedPartyNotesPrincipalMember" abstract="true" name="RelatedPartyNotesPrincipalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_February2023WarrantsMember" abstract="true" name="February2023WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_FinancialStatementDetailsAbstract" abstract="true" name="FinancialStatementDetailsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" abstract="false" name="OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ibrx_NANTibodyLLCMember" abstract="true" name="NANTibodyLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_NantCapital6Member" abstract="true" name="NantCapital6Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_SaleOfStockMaximumAggregateOfferingPrice" abstract="false" name="SaleOfStockMaximumAggregateOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_SupplyAgreementPeriodOfExtendedTerm" abstract="false" name="SupplyAgreementPeriodOfExtendedTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" abstract="false" name="AvailableForSaleSecuritiesDebtSecuritiesPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable" abstract="false" name="LeaseLiabilityTenantImprovementAllowanceReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities" abstract="false" name="CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_SupplyAgreementTermOfContract" abstract="false" name="SupplyAgreementTermOfContract" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ibrx_NumberOfLeases" abstract="false" name="NumberOfLeases" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ibrx_VariousMember" abstract="true" name="VariousMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsSettlements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_SixZeroFiveNashLLCMember" abstract="true" name="SixZeroFiveNashLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_DuleyRoadLLCMember" abstract="true" name="DuleyRoadLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_CurrentLiabilitiesMember" abstract="true" name="CurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember" abstract="true" name="CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_PercentageOfWhollyOwnedSubsidiary" abstract="false" name="PercentageOfWhollyOwnedSubsidiary" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ibrx_PrepaidExpenseWriteDown" abstract="false" name="PrepaidExpenseWriteDown" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_TwoThousandFifteenEquityIncentivePlanMember" abstract="true" name="TwoThousandFifteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_FourTwoZeroNashLLCMember" abstract="true" name="FourTwoZeroNashLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_NantCapitalOneMember" abstract="true" name="NantCapitalOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_TwoThousandFifteenShareRepurchasePlanMember" abstract="true" name="TwoThousandFifteenShareRepurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_DueToRelatedPartiesMember" abstract="true" name="DueToRelatedPartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_NantCapitalIssued33123Member" abstract="true" name="NantCapitalIssued33123Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_February2023ShelfRegistrationStatementMember" abstract="true" name="February2023ShelfRegistrationStatementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_LitigationSettlementNumberOfSharesToBeIssued" abstract="false" name="LitigationSettlementNumberOfSharesToBeIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares" abstract="false" name="SharesIssuedCashDistributedInLieuOfFractionalShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable" abstract="false" name="LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_SecuredOvernightFinancingRateSOFRMember" abstract="true" name="SecuredOvernightFinancingRateSOFRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_StateOfNewYorkMember" abstract="true" name="StateOfNewYorkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_IncomeTaxLineItems" abstract="true" name="IncomeTaxLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember" abstract="true" name="NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_ContingentValueRightsObligationRegulatoryMilestoneMember" abstract="true" name="ContingentValueRightsObligationRegulatoryMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_ConsiderationForFutureServicesMember" abstract="true" name="ConsiderationForFutureServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember" abstract="true" name="A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_CollaborationAgreementsLicenseMaintenanceFees" abstract="false" name="CollaborationAgreementsLicenseMaintenanceFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_A23AlaskaLLCMember" abstract="true" name="A23AlaskaLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_LitigationSettlementInterestPercent" abstract="false" name="LitigationSettlementInterestPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment" abstract="false" name="CollaborationAgreementsAnnualMinimumLicensingPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_AccountingPoliciesTable" abstract="true" name="AccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" abstract="false" name="UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_NoncurrentLiabilitiesMember" abstract="true" name="NoncurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm" abstract="false" name="LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_LeaseLiabilityToBePaidYearOne" abstract="false" name="LeaseLiabilityToBePaidYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_SharedServicesAgreementMember" abstract="true" name="SharedServicesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable" abstract="true" name="ResearchAndDevelopmentArrangementsWithFederalGovernmentTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_NumberOfDissentingShares" abstract="false" name="NumberOfDissentingShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ibrx_AssetAcquisitionFairValueOfAssetsAcquired" abstract="false" name="AssetAcquisitionFairValueOfAssetsAcquired" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_SorrentoTherapeuticsIncLitigationMember" abstract="true" name="SorrentoTherapeuticsIncLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_DrSoonShiongAndRelatedPartyMember" abstract="true" name="DrSoonShiongAndRelatedPartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_ExpansionPremisesMember" abstract="true" name="ExpansionPremisesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_ImmunoOncologyClinicMember" abstract="true" name="ImmunoOncologyClinicMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_December2022WarrantsMember" abstract="true" name="December2022WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_VivaBioCellMember" abstract="true" name="VivaBioCellMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_ContingentValueRightsObligations" abstract="false" name="ContingentValueRightsObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum" abstract="false" name="CollaborationAgreementsMilestonePaymentAggregateMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_RelatedPartyConvertibleNotesMember" abstract="true" name="RelatedPartyConvertibleNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain" abstract="true" name="CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation" abstract="false" name="MinimumNetSalesMilestoneContingentValueRightsObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_NantWorksMember" abstract="true" name="NantWorksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_LeaseOperatingLeaseAnnualLeasePayment" abstract="false" name="LeaseOperatingLeaseAnnualLeasePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_MeasurementInputDiscountPeriodMember" abstract="true" name="MeasurementInputDiscountPeriodMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_AltorBioScienceCorporationMember" abstract="true" name="AltorBioScienceCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_DuleyRoadMember" abstract="true" name="DuleyRoadMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_LeaseholdImprovementPayables" abstract="false" name="LeaseholdImprovementPayables" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_CollaborationAgreementsNonrefundableUpfrontPayment" abstract="false" name="CollaborationAgreementsNonrefundableUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_CurrentAssetsMember" abstract="true" name="CurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_CommonStockValueAvailableForFutureStockIssuance" abstract="false" name="CommonStockValueAvailableForFutureStockIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_LeaseLiabilityToBePaidYearFour" abstract="false" name="LeaseLiabilityToBePaidYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_CollaborationAgreementsMilestoneFees" abstract="false" name="CollaborationAgreementsMilestoneFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="FinanceLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_LeaseRightOfUseAsset" abstract="false" name="LeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_LeaseLiabilityToBePaidYearTwo" abstract="false" name="LeaseLiabilityToBePaidYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_RelatedPartyNotesMember" abstract="true" name="RelatedPartyNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_LicensingAgreementTable" abstract="true" name="LicensingAgreementTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_AmyrisJointVentureMember" abstract="true" name="AmyrisJointVentureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_NantBioIncMember" abstract="true" name="NantBioIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_PercentageOfSalesAgentCommission" abstract="false" name="PercentageOfSalesAgentCommission" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ibrx_AccessToAdvancedHealthInstituteAAHIMember" abstract="true" name="AccessToAdvancedHealthInstituteAAHIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_DunkirkFacilityMember" abstract="true" name="DunkirkFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_SixZeroFiveDougStLLCMember" abstract="true" name="SixZeroFiveDougStLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent" abstract="false" name="IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm" abstract="false" name="LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_NantCapitalMember" abstract="true" name="NantCapitalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_OrganizedWorkforceMember" abstract="true" name="OrganizedWorkforceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_FinancingObligationCurrent" abstract="false" name="FinancingObligationCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_SponsoredResearchAgreementMember" abstract="true" name="SponsoredResearchAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_NantMobileMember" abstract="true" name="NantMobileMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_ContingentConsiderationMember" abstract="true" name="ContingentConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock" abstract="false" name="ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ibrx_ReimbursementsMember" abstract="true" name="ReimbursementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear" abstract="false" name="LeaseLiabilityToBePaidRemainderOfFiscalYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_TransactionCostsWarrantLiability" abstract="false" name="TransactionCostsWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_BusinessCombinationContingentConsiderationArrangementsEarned" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsEarned" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_ImmunoOncologyClinicIncMember" abstract="true" name="ImmunoOncologyClinicIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment" abstract="false" name="FiniteLivedIntangibleAssetsAccumulatedImpairment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_InsurancePremiumFinancingAsset" abstract="false" name="InsurancePremiumFinancingAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_ContingentValueRightsObligationSalesMilestoneMember" abstract="true" name="ContingentValueRightsObligationSalesMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_LeaseholdInterestGovernmentFundingReceivable" abstract="false" name="LeaseholdInterestGovernmentFundingReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_NantCapitalTwoMember" abstract="true" name="NantCapitalTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_ConvertibleNoteReceivableNonCurrent" abstract="false" name="ConvertibleNoteReceivableNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_BaseMonthlyRentParking" abstract="false" name="BaseMonthlyRentParking" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_NantCapital3Member" abstract="true" name="NantCapital3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_AltorBioScienceLLCMember" abstract="true" name="AltorBioScienceLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate" abstract="false" name="RelatedPartyTransactionBasisSpreadOnVariableRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ibrx_PrepaidResearchAndDevelopmentCosts" abstract="false" name="PrepaidResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_WarrantsMember" abstract="true" name="WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears" abstract="false" name="LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ibrx_NotesPayableRelatedPartiesPrincipalAndAccruedInterest" abstract="false" name="NotesPayableRelatedPartiesPrincipalAndAccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_LeaseLiabilityToBePaidAbstract" abstract="true" name="LeaseLiabilityToBePaidAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_InitialPremisesMember" abstract="true" name="InitialPremisesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_AnnualPercentageIncreasesToBaseRent" abstract="false" name="AnnualPercentageIncreasesToBaseRent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember" abstract="true" name="CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_WarrantLiabilityTextBlock" abstract="false" name="WarrantLiabilityTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ibrx_SeptemberTwentyNineteenLeaseMember" abstract="true" name="SeptemberTwentyNineteenLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_RelatedPartyNotesPayable" abstract="false" name="RelatedPartyNotesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_AccountingPoliciesLineItems" abstract="true" name="AccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_WarrantsPolicyTextBlock" abstract="false" name="WarrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis" abstract="true" name="CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_AccruedResearchAndDevelopmentCosts" abstract="false" name="AccruedResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems" abstract="true" name="ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare" abstract="false" name="OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears" abstract="false" name="LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ibrx_PeriodOfExtendedLeaseTerm" abstract="false" name="PeriodOfExtendedLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ibrx_LitigationLineItems" abstract="true" name="LitigationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_LeaseLiabilityUndiscountedExcessInterest" abstract="false" name="LeaseLiabilityUndiscountedExcessInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_IssuanceOfWarrants" abstract="false" name="IssuanceOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_AmortizationOfDebtDiscountPremiumRelatedParty" abstract="false" name="AmortizationOfDebtDiscountPremiumRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_IncomeTaxTable" abstract="true" name="IncomeTaxTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_PromissoryNotesPayableMember" abstract="true" name="PromissoryNotesPayableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock" abstract="false" name="ConvertibleNotesFairValueOptionElectionPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ibrx_NantCapital4Member" abstract="true" name="NantCapital4Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>ibrx-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5993b617-92d4-4bab-a076-33e54147e714,g:68360996-794b-41f6-8c08-63fce426a63c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7c763f02-a582-4908-9c82-6f7b26e31e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3defca24-4666-483d-9f4c-cc2432d28fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7c763f02-a582-4908-9c82-6f7b26e31e3f" xlink:to="loc_us-gaap_AccountsPayableCurrent_3defca24-4666-483d-9f4c-cc2432d28fca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4b84e16b-c531-479f-8b84-8ed0266382ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7c763f02-a582-4908-9c82-6f7b26e31e3f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4b84e16b-c531-479f-8b84-8ed0266382ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_23c4f88b-8b6d-4bda-8512-123a2f2774d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7c763f02-a582-4908-9c82-6f7b26e31e3f" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_23c4f88b-8b6d-4bda-8512-123a2f2774d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_e6e31beb-7d50-4bd9-b8df-686437c24680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7c763f02-a582-4908-9c82-6f7b26e31e3f" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_e6e31beb-7d50-4bd9-b8df-686437c24680" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_e2d31c77-421b-4bb4-91a1-2c32ca8614ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7c763f02-a582-4908-9c82-6f7b26e31e3f" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_e2d31c77-421b-4bb4-91a1-2c32ca8614ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c40ff2a1-74ac-4bb5-81e3-4b1a6271d250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bfed2238-cbaa-40e2-a491-a87ae8879023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c40ff2a1-74ac-4bb5-81e3-4b1a6271d250" xlink:to="loc_us-gaap_StockholdersEquity_bfed2238-cbaa-40e2-a491-a87ae8879023" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_152ea7f5-b780-45d9-b05a-36d8f427227b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c40ff2a1-74ac-4bb5-81e3-4b1a6271d250" xlink:to="loc_us-gaap_MinorityInterest_152ea7f5-b780-45d9-b05a-36d8f427227b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_13413222-bdaf-4081-ae23-c458208965df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_22b9aa88-07a1-4338-996e-a469351672dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13413222-bdaf-4081-ae23-c458208965df" xlink:to="loc_us-gaap_AssetsCurrent_22b9aa88-07a1-4338-996e-a469351672dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_876f44fe-2149-4a96-ba82-f42d995bc869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13413222-bdaf-4081-ae23-c458208965df" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_876f44fe-2149-4a96-ba82-f42d995bc869" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d6580aeb-6a30-4743-a371-23df50686f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13413222-bdaf-4081-ae23-c458208965df" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d6580aeb-6a30-4743-a371-23df50686f0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c6b0fc92-9abc-4ab6-8b53-36f559c3cc5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13413222-bdaf-4081-ae23-c458208965df" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c6b0fc92-9abc-4ab6-8b53-36f559c3cc5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ConvertibleNoteReceivableNonCurrent_40840321-9966-4f91-a136-1f5b59642f3d" xlink:href="ibrx-20230331.xsd#ibrx_ConvertibleNoteReceivableNonCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13413222-bdaf-4081-ae23-c458208965df" xlink:to="loc_ibrx_ConvertibleNoteReceivableNonCurrent_40840321-9966-4f91-a136-1f5b59642f3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b0c87465-1059-436b-9da5-b6e26a279a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13413222-bdaf-4081-ae23-c458208965df" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b0c87465-1059-436b-9da5-b6e26a279a9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b1f34b47-25a9-4e92-a01d-59c8f23e869e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_13413222-bdaf-4081-ae23-c458208965df" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b1f34b47-25a9-4e92-a01d-59c8f23e869e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f9b731a7-25f8-4d9f-be2d-1eb44279b986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_690c8896-2587-4797-8858-cf4b602e7f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f9b731a7-25f8-4d9f-be2d-1eb44279b986" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_690c8896-2587-4797-8858-cf4b602e7f2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_28fd760c-4502-43ea-9249-6a80a8a85c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f9b731a7-25f8-4d9f-be2d-1eb44279b986" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_28fd760c-4502-43ea-9249-6a80a8a85c1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_6af16f42-c156-4e2f-bc7f-66f4f30a1d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f9b731a7-25f8-4d9f-be2d-1eb44279b986" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_6af16f42-c156-4e2f-bc7f-66f4f30a1d8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f4c45ec0-fe5e-47eb-8838-510f51f05bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f9b731a7-25f8-4d9f-be2d-1eb44279b986" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f4c45ec0-fe5e-47eb-8838-510f51f05bef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5a870087-f113-4913-a83f-ab4cde7858e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_12c7aa75-fbd6-43fe-9ead-85d0e437b259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5a870087-f113-4913-a83f-ab4cde7858e9" xlink:to="loc_us-gaap_Liabilities_12c7aa75-fbd6-43fe-9ead-85d0e437b259" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_36eff203-a206-42ab-9028-f2ed5427ecba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5a870087-f113-4913-a83f-ab4cde7858e9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_36eff203-a206-42ab-9028-f2ed5427ecba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_326557fa-1e2b-4d1a-88f7-f2983140db03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5a870087-f113-4913-a83f-ab4cde7858e9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_326557fa-1e2b-4d1a-88f7-f2983140db03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c8b0dfda-8d7e-4f70-86d7-087b7cd4bcc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_89385e91-edf4-4816-a8d0-12928dd44664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c8b0dfda-8d7e-4f70-86d7-087b7cd4bcc7" xlink:to="loc_us-gaap_LiabilitiesCurrent_89385e91-edf4-4816-a8d0-12928dd44664" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesNoncurrent_e92b78e3-1e4e-4722-a281-020b3ba54ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c8b0dfda-8d7e-4f70-86d7-087b7cd4bcc7" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesNoncurrent_e92b78e3-1e4e-4722-a281-020b3ba54ec2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d53ff9d2-3367-4a1a-89bd-ca8906837924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c8b0dfda-8d7e-4f70-86d7-087b7cd4bcc7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d53ff9d2-3367-4a1a-89bd-ca8906837924" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_45124379-20e3-4e11-a371-c718e0784324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c8b0dfda-8d7e-4f70-86d7-087b7cd4bcc7" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_45124379-20e3-4e11-a371-c718e0784324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_a36a10cd-0ffd-4b54-9b47-3c95f234b14b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c8b0dfda-8d7e-4f70-86d7-087b7cd4bcc7" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_a36a10cd-0ffd-4b54-9b47-3c95f234b14b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9d984df3-c8af-4cca-b78c-50d8d22ef947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e1533289-aef1-4e46-a57e-2eeb5251a46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9d984df3-c8af-4cca-b78c-50d8d22ef947" xlink:to="loc_us-gaap_CommonStockValue_e1533289-aef1-4e46-a57e-2eeb5251a46d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1df3da51-ac8f-42f9-8ae9-eddd01f38119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9d984df3-c8af-4cca-b78c-50d8d22ef947" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1df3da51-ac8f-42f9-8ae9-eddd01f38119" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_baf27276-d56b-4fa4-9ae5-d2a0d835249d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9d984df3-c8af-4cca-b78c-50d8d22ef947" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_baf27276-d56b-4fa4-9ae5-d2a0d835249d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_df18c4d9-0c0d-4acf-b968-d64be629330d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9d984df3-c8af-4cca-b78c-50d8d22ef947" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_df18c4d9-0c0d-4acf-b968-d64be629330d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2feefde4-9d09-4c39-a1ed-d786a1fe8c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a9ce70dd-f2b7-4e55-b806-c6c8ae0aceb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2feefde4-9d09-4c39-a1ed-d786a1fe8c5b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a9ce70dd-f2b7-4e55-b806-c6c8ae0aceb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_201126b3-b128-4d47-a0fe-6fce417335ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2feefde4-9d09-4c39-a1ed-d786a1fe8c5b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_201126b3-b128-4d47-a0fe-6fce417335ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_389ab4ba-5ec9-4352-a04a-45dfcbf4d24d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3af4cd3a-0ea5-44ae-a492-90ee8d21dd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_389ab4ba-5ec9-4352-a04a-45dfcbf4d24d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3af4cd3a-0ea5-44ae-a492-90ee8d21dd2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_33200fff-3333-4b02-9b3f-ef8a100096e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_389ab4ba-5ec9-4352-a04a-45dfcbf4d24d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_33200fff-3333-4b02-9b3f-ef8a100096e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b606fa10-ba12-42bd-8916-158a34540bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_098d944d-571c-441f-88bd-4a21de2ddf4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b606fa10-ba12-42bd-8916-158a34540bbc" xlink:to="loc_us-gaap_Revenues_098d944d-571c-441f-88bd-4a21de2ddf4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c908150a-61e8-4162-8938-eaf952918740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b606fa10-ba12-42bd-8916-158a34540bbc" xlink:to="loc_us-gaap_OperatingExpenses_c908150a-61e8-4162-8938-eaf952918740" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_58a7e3b2-e74f-47df-ab76-7eed8ed33372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_be2088b3-9415-4e6b-89f4-8b18aed5702c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_58a7e3b2-e74f-47df-ab76-7eed8ed33372" xlink:to="loc_us-gaap_ProfitLoss_be2088b3-9415-4e6b-89f4-8b18aed5702c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_aa76bfdf-fbba-4fe0-a060-f0257d1bf037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_58a7e3b2-e74f-47df-ab76-7eed8ed33372" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_aa76bfdf-fbba-4fe0-a060-f0257d1bf037" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a799754d-ca19-44b1-b8f5-0de0060ac6af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0ba7cd27-99d8-44d6-8fc5-9f5f602495ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a799754d-ca19-44b1-b8f5-0de0060ac6af" xlink:to="loc_us-gaap_OperatingIncomeLoss_0ba7cd27-99d8-44d6-8fc5-9f5f602495ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_708d1662-7448-490d-8e70-ce8cd7e936cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a799754d-ca19-44b1-b8f5-0de0060ac6af" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_708d1662-7448-490d-8e70-ce8cd7e936cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6e03097c-94f9-46ab-a8d0-6c2bc2a7fb37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a6c3f0ec-139b-4235-82f2-79780a56d356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6e03097c-94f9-46ab-a8d0-6c2bc2a7fb37" xlink:to="loc_us-gaap_InterestExpense_a6c3f0ec-139b-4235-82f2-79780a56d356" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_63ded76c-7791-46b8-a595-37a14298176d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6e03097c-94f9-46ab-a8d0-6c2bc2a7fb37" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_63ded76c-7791-46b8-a595-37a14298176d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ee331da0-1d0f-4676-bd61-dc44437da95f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6e03097c-94f9-46ab-a8d0-6c2bc2a7fb37" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ee331da0-1d0f-4676-bd61-dc44437da95f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_b1daba0c-25ad-4538-a5bf-e9ae022c77e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6e03097c-94f9-46ab-a8d0-6c2bc2a7fb37" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_b1daba0c-25ad-4538-a5bf-e9ae022c77e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_488dd87f-c20d-49ac-95d0-357e2235ac4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6e03097c-94f9-46ab-a8d0-6c2bc2a7fb37" xlink:to="loc_us-gaap_GainLossOnInvestments_488dd87f-c20d-49ac-95d0-357e2235ac4f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9d9c1a72-81ee-448f-b46f-db1710cde2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_ddfe9d1f-64ee-46b9-9390-d881b83339c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9d9c1a72-81ee-448f-b46f-db1710cde2b5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_ddfe9d1f-64ee-46b9-9390-d881b83339c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_afe4e26f-8c2a-4ef4-bbd4-825bf0c56d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9d9c1a72-81ee-448f-b46f-db1710cde2b5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_afe4e26f-8c2a-4ef4-bbd4-825bf0c56d1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_dcbebf25-f6a8-45f6-bb46-8cdbeeaa58a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9d9c1a72-81ee-448f-b46f-db1710cde2b5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_dcbebf25-f6a8-45f6-bb46-8cdbeeaa58a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_cc26b8af-212f-4c90-a7ca-57f0f13d8726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5dc2f41c-25b3-4670-beed-740d79fe3c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_cc26b8af-212f-4c90-a7ca-57f0f13d8726" xlink:to="loc_us-gaap_ProfitLoss_5dc2f41c-25b3-4670-beed-740d79fe3c64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9e0d0d1a-8b63-455e-8b10-5b5dcbe52aed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_cc26b8af-212f-4c90-a7ca-57f0f13d8726" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9e0d0d1a-8b63-455e-8b10-5b5dcbe52aed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2ff13dd3-88fd-4958-a064-1affe5caa526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_957145b7-e9b2-4b08-88da-f233e14eb617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2ff13dd3-88fd-4958-a064-1affe5caa526" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_957145b7-e9b2-4b08-88da-f233e14eb617" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_c9ae14bd-f775-48cc-a067-f2fcf12188e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2ff13dd3-88fd-4958-a064-1affe5caa526" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_c9ae14bd-f775-48cc-a067-f2fcf12188e8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1620935b-a683-42e3-901a-95e7ff049817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a302c4ad-6018-491d-877c-3dc40e185299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1620935b-a683-42e3-901a-95e7ff049817" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a302c4ad-6018-491d-877c-3dc40e185299" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b7b1ccde-c3bb-4797-ac8a-ea54511201dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1620935b-a683-42e3-901a-95e7ff049817" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b7b1ccde-c3bb-4797-ac8a-ea54511201dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8f665ae7-ea28-4131-9aa4-293f288e8dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1620935b-a683-42e3-901a-95e7ff049817" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8f665ae7-ea28-4131-9aa4-293f288e8dc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_a936cd3f-9142-4f58-9aa6-d1a2a111a9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1620935b-a683-42e3-901a-95e7ff049817" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_a936cd3f-9142-4f58-9aa6-d1a2a111a9f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e5af7e6b-794e-4990-a181-18c3232f35e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d6e607e8-0b4f-425e-acfc-dcfc01f146c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e5af7e6b-794e-4990-a181-18c3232f35e6" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d6e607e8-0b4f-425e-acfc-dcfc01f146c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_452cb328-badb-47e2-9ba8-12de5aa8cbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e5af7e6b-794e-4990-a181-18c3232f35e6" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_452cb328-badb-47e2-9ba8-12de5aa8cbf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_edaa4297-b7e6-4e53-818a-cea4e6e5ec7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e5af7e6b-794e-4990-a181-18c3232f35e6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_edaa4297-b7e6-4e53-818a-cea4e6e5ec7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_ddcccb86-7a7e-4ae0-8ad6-81a32caadfd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e5af7e6b-794e-4990-a181-18c3232f35e6" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_ddcccb86-7a7e-4ae0-8ad6-81a32caadfd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_cab5273a-e016-4399-887d-9c56f35930e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e5af7e6b-794e-4990-a181-18c3232f35e6" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_cab5273a-e016-4399-887d-9c56f35930e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_dfa4a9e5-ef87-42e2-8429-007dd5710f79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e5af7e6b-794e-4990-a181-18c3232f35e6" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_dfa4a9e5-ef87-42e2-8429-007dd5710f79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80f6d17c-5c69-4d44-9148-6d80d6e85fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f1c52a48-ad84-456c-8a26-9066d404db12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80f6d17c-5c69-4d44-9148-6d80d6e85fdf" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f1c52a48-ad84-456c-8a26-9066d404db12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_23fc5f3f-336e-4ab6-8ec7-a7c8b56b4dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80f6d17c-5c69-4d44-9148-6d80d6e85fdf" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_23fc5f3f-336e-4ab6-8ec7-a7c8b56b4dbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_cdb059de-e0a1-47ce-ab79-dce100fb238a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80f6d17c-5c69-4d44-9148-6d80d6e85fdf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_cdb059de-e0a1-47ce-ab79-dce100fb238a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f75b2752-a70e-4d4d-b73e-5264c574e18b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80f6d17c-5c69-4d44-9148-6d80d6e85fdf" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f75b2752-a70e-4d4d-b73e-5264c574e18b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TransactionCostsWarrantLiability_80214178-bc52-4e30-9945-f5ebf4e5dabf" xlink:href="ibrx-20230331.xsd#ibrx_TransactionCostsWarrantLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80f6d17c-5c69-4d44-9148-6d80d6e85fdf" xlink:to="loc_ibrx_TransactionCostsWarrantLiability_80214178-bc52-4e30-9945-f5ebf4e5dabf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_5f45aa39-441f-4ab7-8659-b93da3701479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80f6d17c-5c69-4d44-9148-6d80d6e85fdf" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_5f45aa39-441f-4ab7-8659-b93da3701479" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_410e467d-66b1-40fa-9d26-f509592c90e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80f6d17c-5c69-4d44-9148-6d80d6e85fdf" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_410e467d-66b1-40fa-9d26-f509592c90e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_1ec9804a-6b9d-420e-85af-6846b88b5c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80f6d17c-5c69-4d44-9148-6d80d6e85fdf" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_1ec9804a-6b9d-420e-85af-6846b88b5c54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NonCashInterestIncomeExpenseFromOperatingActivities_8fcc8044-3136-42fb-9726-b7c154b5dbce" xlink:href="ibrx-20230331.xsd#ibrx_NonCashInterestIncomeExpenseFromOperatingActivities"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80f6d17c-5c69-4d44-9148-6d80d6e85fdf" xlink:to="loc_ibrx_NonCashInterestIncomeExpenseFromOperatingActivities_8fcc8044-3136-42fb-9726-b7c154b5dbce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_2e35cc21-1f29-4385-9e99-927218dfeabc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80f6d17c-5c69-4d44-9148-6d80d6e85fdf" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_2e35cc21-1f29-4385-9e99-927218dfeabc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1902528c-4200-4e81-be43-3afc8085b0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80f6d17c-5c69-4d44-9148-6d80d6e85fdf" xlink:to="loc_us-gaap_ProfitLoss_1902528c-4200-4e81-be43-3afc8085b0a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_9812ed6d-a4d5-4a8a-8399-d8db856c0cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80f6d17c-5c69-4d44-9148-6d80d6e85fdf" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_9812ed6d-a4d5-4a8a-8399-d8db856c0cc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ee3fafce-8f16-4600-b223-a8827bfbf5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80f6d17c-5c69-4d44-9148-6d80d6e85fdf" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ee3fafce-8f16-4600-b223-a8827bfbf5f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7964afdd-9e18-4583-8e23-0b6f89c06bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80f6d17c-5c69-4d44-9148-6d80d6e85fdf" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7964afdd-9e18-4583-8e23-0b6f89c06bfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent_954729e3-24b8-4453-b249-389afab72baf" xlink:href="ibrx-20230331.xsd#ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80f6d17c-5c69-4d44-9148-6d80d6e85fdf" xlink:to="loc_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent_954729e3-24b8-4453-b249-389afab72baf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3dcbd549-e173-44d7-a40a-da90f2191f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80f6d17c-5c69-4d44-9148-6d80d6e85fdf" xlink:to="loc_us-gaap_ShareBasedCompensation_3dcbd549-e173-44d7-a40a-da90f2191f10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c285fb91-d8f8-4708-9c31-fb1c0c268fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3949fe28-6671-4eea-b270-546484e58cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c285fb91-d8f8-4708-9c31-fb1c0c268fa4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3949fe28-6671-4eea-b270-546484e58cf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1a9311e5-32b7-4b37-8531-8582ff340b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c285fb91-d8f8-4708-9c31-fb1c0c268fa4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1a9311e5-32b7-4b37-8531-8582ff340b85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0b1b140b-d741-4493-b93a-4d9aacc575dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_47d82e21-7586-46b5-9462-dba2f6f520cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0b1b140b-d741-4493-b93a-4d9aacc575dc" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_47d82e21-7586-46b5-9462-dba2f6f520cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_c8542df9-d771-45dc-a779-bb38635414d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0b1b140b-d741-4493-b93a-4d9aacc575dc" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_c8542df9-d771-45dc-a779-bb38635414d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_176e9afd-763d-459a-8372-03c43d50563e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0b1b140b-d741-4493-b93a-4d9aacc575dc" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_176e9afd-763d-459a-8372-03c43d50563e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c6653742-f165-4b91-aab2-b2c2469fd062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0b1b140b-d741-4493-b93a-4d9aacc575dc" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c6653742-f165-4b91-aab2-b2c2469fd062" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1abac802-b301-4bcc-9ab5-0223ca8532d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0b1b140b-d741-4493-b93a-4d9aacc575dc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1abac802-b301-4bcc-9ab5-0223ca8532d6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_792e7e45-c3b5-4d5d-b16a-d36726e0ffa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies_6a4a8768-0c81-48f6-adee-a5a29623dbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Supplies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_792e7e45-c3b5-4d5d-b16a-d36726e0ffa0" xlink:to="loc_us-gaap_Supplies_6a4a8768-0c81-48f6-adee-a5a29623dbc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InsurancePremiumFinancingAsset_c571f62c-fdf7-4d08-92d5-eb95755bb622" xlink:href="ibrx-20230331.xsd#ibrx_InsurancePremiumFinancingAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_792e7e45-c3b5-4d5d-b16a-d36726e0ffa0" xlink:to="loc_ibrx_InsurancePremiumFinancingAsset_c571f62c-fdf7-4d08-92d5-eb95755bb622" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidServices_bec713a9-72e0-4b3f-b2df-4b952915ca7b" xlink:href="ibrx-20230331.xsd#ibrx_PrepaidServices"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_792e7e45-c3b5-4d5d-b16a-d36726e0ffa0" xlink:to="loc_ibrx_PrepaidServices_bec713a9-72e0-4b3f-b2df-4b952915ca7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_3c04bfc8-1c33-4d64-b197-3d478ad1a174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_792e7e45-c3b5-4d5d-b16a-d36726e0ffa0" xlink:to="loc_us-gaap_OtherAssetsCurrent_3c04bfc8-1c33-4d64-b197-3d478ad1a174" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidSoftwareLicenseFees_c73f52cb-3a70-4e1d-886f-c1e47288d39f" xlink:href="ibrx-20230331.xsd#ibrx_PrepaidSoftwareLicenseFees"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_792e7e45-c3b5-4d5d-b16a-d36726e0ffa0" xlink:to="loc_ibrx_PrepaidSoftwareLicenseFees_c73f52cb-3a70-4e1d-886f-c1e47288d39f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_b943fd67-762a-41b4-a5ad-14c83dedd478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_792e7e45-c3b5-4d5d-b16a-d36726e0ffa0" xlink:to="loc_us-gaap_PrepaidInsurance_b943fd67-762a-41b4-a5ad-14c83dedd478" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidResearchAndDevelopmentCosts_bc7456df-d0fb-4f98-9733-b6b2580a4f73" xlink:href="ibrx-20230331.xsd#ibrx_PrepaidResearchAndDevelopmentCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_792e7e45-c3b5-4d5d-b16a-d36726e0ffa0" xlink:to="loc_ibrx_PrepaidResearchAndDevelopmentCosts_bc7456df-d0fb-4f98-9733-b6b2580a4f73" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d1f2894d-5e77-4322-a940-56bf37f7e813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_fdb3efa8-2dc7-4eb6-b305-fc82aa737918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_d1f2894d-5e77-4322-a940-56bf37f7e813" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_fdb3efa8-2dc7-4eb6-b305-fc82aa737918" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8d03ea77-e45d-4dc7-bff6-9538b467e851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_d1f2894d-5e77-4322-a940-56bf37f7e813" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8d03ea77-e45d-4dc7-bff6-9538b467e851" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialStatementDetailsIntangibleAssetsNetDetails"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e756a61d-cf09-45a8-aee7-b1ce462dcab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_74a523f4-c122-4135-ab8e-c4eb21847e75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e756a61d-cf09-45a8-aee7-b1ce462dcab4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_74a523f4-c122-4135-ab8e-c4eb21847e75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_64aa4399-010d-4330-9fd9-a3df4d0d346e" xlink:href="ibrx-20230331.xsd#ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e756a61d-cf09-45a8-aee7-b1ce462dcab4" xlink:to="loc_ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_64aa4399-010d-4330-9fd9-a3df4d0d346e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3040f9ab-4cf8-4936-aad5-fbfd894b38ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e756a61d-cf09-45a8-aee7-b1ce462dcab4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3040f9ab-4cf8-4936-aad5-fbfd894b38ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5f9d566e-abb7-4e16-94aa-3df7e9b96e08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e756a61d-cf09-45a8-aee7-b1ce462dcab4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5f9d566e-abb7-4e16-94aa-3df7e9b96e08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fa37c5c2-ea6c-4965-a31f-e11554097ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e756a61d-cf09-45a8-aee7-b1ce462dcab4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fa37c5c2-ea6c-4965-a31f-e11554097ccf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a8a0cc25-92f5-455d-9fdf-923df90ea2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e756a61d-cf09-45a8-aee7-b1ce462dcab4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a8a0cc25-92f5-455d-9fdf-923df90ea2c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d85ff6ef-116e-4b85-9087-9f8c5432043b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_03ff2c68-6f8d-46fe-85cb-3d2244b65dc4" xlink:href="ibrx-20230331.xsd#ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d85ff6ef-116e-4b85-9087-9f8c5432043b" xlink:to="loc_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_03ff2c68-6f8d-46fe-85cb-3d2244b65dc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_fbdf55f9-fe71-4385-8d7a-09645ef9a83f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d85ff6ef-116e-4b85-9087-9f8c5432043b" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_fbdf55f9-fe71-4385-8d7a-09645ef9a83f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_38c56980-7a06-4ca3-b987-24a8b8e02077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d85ff6ef-116e-4b85-9087-9f8c5432043b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_38c56980-7a06-4ca3-b987-24a8b8e02077" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_dbe5e1c9-93d6-4f12-af7a-b65b236c6d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_6ca5053a-3205-44b8-96cb-58b44ac2f8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_dbe5e1c9-93d6-4f12-af7a-b65b236c6d19" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_6ca5053a-3205-44b8-96cb-58b44ac2f8fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_50f1dca3-2cb2-49bd-b2fc-5b2bc20c2301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_dbe5e1c9-93d6-4f12-af7a-b65b236c6d19" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_50f1dca3-2cb2-49bd-b2fc-5b2bc20c2301" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails_1" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialStatementDetailsIntangibleAssetsNetDetails_1"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5bfa84b9-da34-4b3b-a497-df4f99441fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_40ad5c1c-136f-462e-9766-0cb9034ac62b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5bfa84b9-da34-4b3b-a497-df4f99441fb7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_40ad5c1c-136f-462e-9766-0cb9034ac62b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3bac490b-28f6-4752-aa47-5f8bdb322517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5bfa84b9-da34-4b3b-a497-df4f99441fb7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3bac490b-28f6-4752-aa47-5f8bdb322517" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_c3fa85a1-4af3-4758-a751-f25c39df1562" xlink:href="ibrx-20230331.xsd#ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5bfa84b9-da34-4b3b-a497-df4f99441fb7" xlink:to="loc_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_c3fa85a1-4af3-4758-a751-f25c39df1562" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fc841d20-086e-4720-9978-6ac51bf5f959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_cb9cc398-8258-431a-b91b-5e4f1dc81402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fc841d20-086e-4720-9978-6ac51bf5f959" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_cb9cc398-8258-431a-b91b-5e4f1dc81402" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5ada158e-1fdf-4f48-99f5-1e0a2cefa2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fc841d20-086e-4720-9978-6ac51bf5f959" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5ada158e-1fdf-4f48-99f5-1e0a2cefa2c5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_fabbf354-4c2f-4a94-9343-470204df207c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccruedConstructionCostsCurrent_cd02e398-2764-4d25-9fe6-b306abf5ecae" xlink:href="ibrx-20230331.xsd#ibrx_AccruedConstructionCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_fabbf354-4c2f-4a94-9343-470204df207c" xlink:to="loc_ibrx_AccruedConstructionCostsCurrent_cd02e398-2764-4d25-9fe6-b306abf5ecae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancingObligationCurrent_dee26c7e-9a63-464d-a0f1-550c9cb29bee" xlink:href="ibrx-20230331.xsd#ibrx_FinancingObligationCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_fabbf354-4c2f-4a94-9343-470204df207c" xlink:to="loc_ibrx_FinancingObligationCurrent_dee26c7e-9a63-464d-a0f1-550c9cb29bee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_83a17070-a2a1-4f41-9b64-8f4f0e7e92a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_fabbf354-4c2f-4a94-9343-470204df207c" xlink:to="loc_us-gaap_AccruedSalariesCurrent_83a17070-a2a1-4f41-9b64-8f4f0e7e92a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_e2d003a4-2d57-4526-8653-d4b4cbebfac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_fabbf354-4c2f-4a94-9343-470204df207c" xlink:to="loc_us-gaap_AccruedBonusesCurrent_e2d003a4-2d57-4526-8653-d4b4cbebfac5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_79f042ea-32bb-4c61-9629-9385647f0f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_fabbf354-4c2f-4a94-9343-470204df207c" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_79f042ea-32bb-4c61-9629-9385647f0f25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccruedResearchAndDevelopmentCosts_e8a79a17-546e-49dd-912a-ab6fa0650aa8" xlink:href="ibrx-20230331.xsd#ibrx_AccruedResearchAndDevelopmentCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_fabbf354-4c2f-4a94-9343-470204df207c" xlink:to="loc_ibrx_AccruedResearchAndDevelopmentCosts_e8a79a17-546e-49dd-912a-ab6fa0650aa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7bf624d0-15b1-4f7a-96ff-24bdb876391e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_fabbf354-4c2f-4a94-9343-470204df207c" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7bf624d0-15b1-4f7a-96ff-24bdb876391e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccruedPreclinicalAndClinicalTrialCosts_5d4b27f9-22a0-40e6-a841-8b14f8aea2b4" xlink:href="ibrx-20230331.xsd#ibrx_AccruedPreclinicalAndClinicalTrialCosts"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_fabbf354-4c2f-4a94-9343-470204df207c" xlink:to="loc_ibrx_AccruedPreclinicalAndClinicalTrialCosts_5d4b27f9-22a0-40e6-a841-8b14f8aea2b4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeNetDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialStatementDetailsInterestandInvestmentIncomeNetDetail"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_bd0bec9d-e387-44cd-85fa-b569fe2ab6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_84d3213a-32f7-4956-b121-31914d63413d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GainLossOnInvestments_bd0bec9d-e387-44cd-85fa-b569fe2ab6ae" xlink:to="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_84d3213a-32f7-4956-b121-31914d63413d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_020f13b4-0996-4ea3-a8e2-7904dabd6f95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GainLossOnInvestments_bd0bec9d-e387-44cd-85fa-b569fe2ab6ae" xlink:to="loc_us-gaap_InterestAndOtherIncome_020f13b4-0996-4ea3-a8e2-7904dabd6f95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_5facd6f0-05cf-4222-b8a1-a54c714bdd82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GainLossOnInvestments_bd0bec9d-e387-44cd-85fa-b569fe2ab6ae" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_5facd6f0-05cf-4222-b8a1-a54c714bdd82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_8ac9eb74-9f28-48d2-a0bb-725dcf267474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GainLossOnInvestments_bd0bec9d-e387-44cd-85fa-b569fe2ab6ae" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_8ac9eb74-9f28-48d2-a0bb-725dcf267474" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialStatementDetailsInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ae95c62c-1595-4fa0-89b3-c7159d988c04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty_7d617fa1-d53f-4d5e-801f-c1e5d2d31dd2" xlink:href="ibrx-20230331.xsd#ibrx_AmortizationOfDebtDiscountPremiumRelatedParty"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_ae95c62c-1595-4fa0-89b3-c7159d988c04" xlink:to="loc_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty_7d617fa1-d53f-4d5e-801f-c1e5d2d31dd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseOther_87441109-e3b1-4f76-a49a-28332d81a8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_ae95c62c-1595-4fa0-89b3-c7159d988c04" xlink:to="loc_us-gaap_InterestExpenseOther_87441109-e3b1-4f76-a49a-28332d81a8ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseRelatedParty_0fcf6f8e-cde0-4389-a3df-321fb2885829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_ae95c62c-1595-4fa0-89b3-c7159d988c04" xlink:to="loc_us-gaap_InterestExpenseRelatedParty_0fcf6f8e-cde0-4389-a3df-321fb2885829" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6978887c-3549-45c4-bb31-cdd9392886f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_edb6dcd3-e740-4579-9c0c-e3f289b81ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6978887c-3549-45c4-bb31-cdd9392886f1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_edb6dcd3-e740-4579-9c0c-e3f289b81ecc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cf48fe11-2c90-4996-bcea-aa2679cf3f22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6978887c-3549-45c4-bb31-cdd9392886f1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cf48fe11-2c90-4996-bcea-aa2679cf3f22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ba58af84-0a00-4418-a346-0a168ae4d74a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6978887c-3549-45c4-bb31-cdd9392886f1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ba58af84-0a00-4418-a346-0a168ae4d74a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_a3d67b1b-af66-4562-9113-7322f6fde621" xlink:href="ibrx-20230331.xsd#ibrx_AssetAcquisitionFairValueOfAssetsAcquired"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_887bb4e1-2947-45fb-b41b-92522dce8c59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_a3d67b1b-af66-4562-9113-7322f6fde621" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_887bb4e1-2947-45fb-b41b-92522dce8c59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_b0e8c75c-70fd-47a5-92dc-8fbc615c2ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_a3d67b1b-af66-4562-9113-7322f6fde621" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_b0e8c75c-70fd-47a5-92dc-8fbc615c2ea8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_18fee0fe-8ed3-44f7-89b9-5acfbf734702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_a3d67b1b-af66-4562-9113-7322f6fde621" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_18fee0fe-8ed3-44f7-89b9-5acfbf734702" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_b5890e80-b468-4fa8-b488-9b0e539497ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_a3d67b1b-af66-4562-9113-7322f6fde621" xlink:to="loc_us-gaap_ConstructionInProgressGross_b5890e80-b468-4fa8-b488-9b0e539497ce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="ibrx-20230331.xsd#LeaseArrangementsSupplementalBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseRightOfUseAsset_3a4cf326-7b1a-433e-b850-3aeadf1e38d2" xlink:href="ibrx-20230331.xsd#ibrx_LeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_d5147b83-fafd-40e9-b7e2-1d4ec50bfc92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseRightOfUseAsset_3a4cf326-7b1a-433e-b850-3aeadf1e38d2" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_d5147b83-fafd-40e9-b7e2-1d4ec50bfc92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e8e72156-9aba-44e0-841f-8b0c53e6d27e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseRightOfUseAsset_3a4cf326-7b1a-433e-b850-3aeadf1e38d2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e8e72156-9aba-44e0-841f-8b0c53e6d27e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiability_ed2b1b14-d02e-4c58-9dff-559d46819385" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bf3caa9e-79b9-42f1-b10b-9ce17b8214a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiability_ed2b1b14-d02e-4c58-9dff-559d46819385" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bf3caa9e-79b9-42f1-b10b-9ce17b8214a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_58bfc7cf-fba8-486a-9f74-e104cef20f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiability_ed2b1b14-d02e-4c58-9dff-559d46819385" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_58bfc7cf-fba8-486a-9f74-e104cef20f1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_827efd91-21a4-4d6e-ade6-781f8a92017e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiability_ed2b1b14-d02e-4c58-9dff-559d46819385" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_827efd91-21a4-4d6e-ade6-781f8a92017e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8c7e0116-1cd2-439f-a4e5-e14b9bd03ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiability_ed2b1b14-d02e-4c58-9dff-559d46819385" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8c7e0116-1cd2-439f-a4e5-e14b9bd03ef5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#LeaseArrangementsComponentsofLeaseExpenseDetail"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_7d46e5ae-01bc-41ec-870a-aba3b9efe5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_2dcee866-aea3-41c8-b350-9f4e16d4afe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_7d46e5ae-01bc-41ec-870a-aba3b9efe5ec" xlink:to="loc_us-gaap_ShortTermLeaseCost_2dcee866-aea3-41c8-b350-9f4e16d4afe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_bef90a5b-cdec-4dc4-b77e-aa6af04d796b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_7d46e5ae-01bc-41ec-870a-aba3b9efe5ec" xlink:to="loc_us-gaap_OperatingLeaseCost_bef90a5b-cdec-4dc4-b77e-aa6af04d796b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_d53dde5b-d895-445a-98f1-f9754a085b41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_7d46e5ae-01bc-41ec-870a-aba3b9efe5ec" xlink:to="loc_us-gaap_VariableLeaseCost_d53dde5b-d895-445a-98f1-f9754a085b41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense_072d93fe-6a7f-4826-8b6f-6e06378ae3fc" xlink:href="ibrx-20230331.xsd#ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_7d46e5ae-01bc-41ec-870a-aba3b9efe5ec" xlink:to="loc_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense_072d93fe-6a7f-4826-8b6f-6e06378ae3fc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearTwo_6b402d6c-7683-4c98-89e7-15ddc54eb546" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidYearTwo"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_806c8d01-3352-4eb9-aa96-4d07e23a021a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearTwo_6b402d6c-7683-4c98-89e7-15ddc54eb546" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_806c8d01-3352-4eb9-aa96-4d07e23a021a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f77707b1-14d5-4348-8547-6b498cbffa03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearTwo_6b402d6c-7683-4c98-89e7-15ddc54eb546" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f77707b1-14d5-4348-8547-6b498cbffa03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaid_1e71fe25-fc03-41bd-a96e-c4ec4592e313" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaid"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear_d2489f42-1327-4dee-ae30-0a713fb7f695" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaid_1e71fe25-fc03-41bd-a96e-c4ec4592e313" xlink:to="loc_ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear_d2489f42-1327-4dee-ae30-0a713fb7f695" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearTwo_260d6f4a-b297-418f-8363-b1a497ff6ddf" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaid_1e71fe25-fc03-41bd-a96e-c4ec4592e313" xlink:to="loc_ibrx_LeaseLiabilityToBePaidYearTwo_260d6f4a-b297-418f-8363-b1a497ff6ddf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearFour_b9abf77b-a1b9-4cee-95ac-12dc3d3408f3" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaid_1e71fe25-fc03-41bd-a96e-c4ec4592e313" xlink:to="loc_ibrx_LeaseLiabilityToBePaidYearFour_b9abf77b-a1b9-4cee-95ac-12dc3d3408f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidAfterYearFour_de1f54ab-3e94-4033-9a2f-4233be87b808" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaid_1e71fe25-fc03-41bd-a96e-c4ec4592e313" xlink:to="loc_ibrx_LeaseLiabilityToBePaidAfterYearFour_de1f54ab-3e94-4033-9a2f-4233be87b808" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearThree_e56b12af-4f37-4059-aef5-d42db416ea1c" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaid_1e71fe25-fc03-41bd-a96e-c4ec4592e313" xlink:to="loc_ibrx_LeaseLiabilityToBePaidYearThree_e56b12af-4f37-4059-aef5-d42db416ea1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearOne_09cf3ea6-5369-4c9b-acd7-5082af8b0c4f" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidYearOne"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaid_1e71fe25-fc03-41bd-a96e-c4ec4592e313" xlink:to="loc_ibrx_LeaseLiabilityToBePaidYearOne_09cf3ea6-5369-4c9b-acd7-5082af8b0c4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable_550bf85f-50c9-4704-b1df-9b0cb54db746" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable_840ba50c-d923-4b73-bc0b-1eb5956d7caa" xlink:href="ibrx-20230331.xsd#ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable_550bf85f-50c9-4704-b1df-9b0cb54db746" xlink:to="loc_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable_840ba50c-d923-4b73-bc0b-1eb5956d7caa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable_261ab5d3-5a2f-49d8-b065-a14464e11549" xlink:href="ibrx-20230331.xsd#ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable_550bf85f-50c9-4704-b1df-9b0cb54db746" xlink:to="loc_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable_261ab5d3-5a2f-49d8-b065-a14464e11549" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_debed77a-c136-4dd7-9b10-1c9c8267dddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_60cee9f1-c2b1-40a6-bf06-f9770f499f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_debed77a-c136-4dd7-9b10-1c9c8267dddc" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_60cee9f1-c2b1-40a6-bf06-f9770f499f6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_96cc8c5d-1110-41e7-a461-84d018674265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_debed77a-c136-4dd7-9b10-1c9c8267dddc" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_96cc8c5d-1110-41e7-a461-84d018674265" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_0083c898-cf3a-442e-81ba-2e6ef562b376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_debed77a-c136-4dd7-9b10-1c9c8267dddc" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_0083c898-cf3a-442e-81ba-2e6ef562b376" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_989a0549-88d0-4f9d-bbf3-6aae604dc084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_debed77a-c136-4dd7-9b10-1c9c8267dddc" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_989a0549-88d0-4f9d-bbf3-6aae604dc084" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour_a4c0c717-df35-47ad-8768-851b7f4e1e4e" xlink:href="ibrx-20230331.xsd#ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_debed77a-c136-4dd7-9b10-1c9c8267dddc" xlink:to="loc_ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour_a4c0c717-df35-47ad-8768-851b7f4e1e4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_0526a5f0-6272-47f7-a97f-01e9053984b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_debed77a-c136-4dd7-9b10-1c9c8267dddc" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_0526a5f0-6272-47f7-a97f-01e9053984b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityUndiscountedExcessInterest_0d7f597a-ee95-48c9-963a-045b84369353" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityUndiscountedExcessInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2c71103a-f060-40e3-813a-a7a79f2faf57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityUndiscountedExcessInterest_0d7f597a-ee95-48c9-963a-045b84369353" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2c71103a-f060-40e3-813a-a7a79f2faf57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6aa57d4f-e868-4ba8-ae6f-091efacd2f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityUndiscountedExcessInterest_0d7f597a-ee95-48c9-963a-045b84369353" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6aa57d4f-e868-4ba8-ae6f-091efacd2f8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidAfterYearFour_d51a1ce7-68d6-486d-93da-b0956e91af51" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidAfterYearFour"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_464fde69-c374-4762-a025-6ef6ea7e5d22" xlink:href="ibrx-20230331.xsd#ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAfterYearFour_d51a1ce7-68d6-486d-93da-b0956e91af51" xlink:to="loc_ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_464fde69-c374-4762-a025-6ef6ea7e5d22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour_9fd83eed-4713-4e5f-bc6f-2d3f9f862165" xlink:href="ibrx-20230331.xsd#ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAfterYearFour_d51a1ce7-68d6-486d-93da-b0956e91af51" xlink:to="loc_ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour_9fd83eed-4713-4e5f-bc6f-2d3f9f862165" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear_caa524cf-b83a-4d3d-9487-d17982801328" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_c79b147a-a5e1-4ac1-97d8-28a78ac63e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear_caa524cf-b83a-4d3d-9487-d17982801328" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_c79b147a-a5e1-4ac1-97d8-28a78ac63e15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5ee66cad-2077-48de-9394-4d6716bc1a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear_caa524cf-b83a-4d3d-9487-d17982801328" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5ee66cad-2077-48de-9394-4d6716bc1a8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_812c5aef-f629-46f3-b4f1-0f442659be5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_43e46435-07e3-4c8f-8966-9aeb379feeee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_812c5aef-f629-46f3-b4f1-0f442659be5e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_43e46435-07e3-4c8f-8966-9aeb379feeee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_95ec389e-7023-4c5c-a6db-ef891dd766ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_812c5aef-f629-46f3-b4f1-0f442659be5e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_95ec389e-7023-4c5c-a6db-ef891dd766ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_69df7e5f-05ba-4802-8f65-f98f84c14f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_812c5aef-f629-46f3-b4f1-0f442659be5e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_69df7e5f-05ba-4802-8f65-f98f84c14f77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4c53d5a3-1bb9-4b63-be91-c0a74cb8310f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_812c5aef-f629-46f3-b4f1-0f442659be5e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4c53d5a3-1bb9-4b63-be91-c0a74cb8310f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3040d792-8da5-4e07-b6cd-9a9624a35063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_812c5aef-f629-46f3-b4f1-0f442659be5e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3040d792-8da5-4e07-b6cd-9a9624a35063" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_3ddd5dac-e52a-404d-9a48-25da07285e69" xlink:href="ibrx-20230331.xsd#ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_812c5aef-f629-46f3-b4f1-0f442659be5e" xlink:to="loc_ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_3ddd5dac-e52a-404d-9a48-25da07285e69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearOne_df46cfef-a171-47f3-b5e3-4655acf791b9" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidYearOne"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_02f306d9-1379-408b-8636-dcd8945841c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearOne_df46cfef-a171-47f3-b5e3-4655acf791b9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_02f306d9-1379-408b-8636-dcd8945841c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_07e08aba-afa5-4b2b-a81a-65beb3c20cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearOne_df46cfef-a171-47f3-b5e3-4655acf791b9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_07e08aba-afa5-4b2b-a81a-65beb3c20cca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearFour_3e55fbf8-a642-488a-8c13-4920a57773b4" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidYearFour"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4358ce8c-fed1-4b15-a240-20bfc3860e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearFour_3e55fbf8-a642-488a-8c13-4920a57773b4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4358ce8c-fed1-4b15-a240-20bfc3860e2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_af813074-fc3a-4646-a346-9934c3f99e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearFour_3e55fbf8-a642-488a-8c13-4920a57773b4" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_af813074-fc3a-4646-a346-9934c3f99e9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearThree_0c3887f1-84b6-4498-8c79-4eaa4fee413c" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidYearThree"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_ebfd4e38-b1ed-49d5-86ac-64a5e32b65c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearThree_0c3887f1-84b6-4498-8c79-4eaa4fee413c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_ebfd4e38-b1ed-49d5-86ac-64a5e32b65c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0723c2c1-773a-4721-bbd0-7bbd93e53f86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearThree_0c3887f1-84b6-4498-8c79-4eaa4fee413c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0723c2c1-773a-4721-bbd0-7bbd93e53f86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiability_c9f340b1-d1b2-4e4c-a1a8-4a29c17b3330" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8f7820a0-baf1-4496-aef3-489cd2400ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiability_c9f340b1-d1b2-4e4c-a1a8-4a29c17b3330" xlink:to="loc_us-gaap_OperatingLeaseLiability_8f7820a0-baf1-4496-aef3-489cd2400ce6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_366436a2-5841-4900-a2f5-eb4173eaec39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiability_c9f340b1-d1b2-4e4c-a1a8-4a29c17b3330" xlink:to="loc_us-gaap_FinanceLeaseLiability_366436a2-5841-4900-a2f5-eb4173eaec39" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1" xlink:type="simple" xlink:href="ibrx-20230331.xsd#LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaid_f3147525-89e5-4321-b67a-449d060468bd" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaid"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityUndiscountedExcessInterest_1493a1d1-8118-4109-bd20-679bbcb7ebd6" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityUndiscountedExcessInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaid_f3147525-89e5-4321-b67a-449d060468bd" xlink:to="loc_ibrx_LeaseLiabilityUndiscountedExcessInterest_1493a1d1-8118-4109-bd20-679bbcb7ebd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable_b13c7d8d-0d91-45ca-b6db-698773a4a131" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaid_f3147525-89e5-4321-b67a-449d060468bd" xlink:to="loc_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable_b13c7d8d-0d91-45ca-b6db-698773a4a131" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiability_de3ce9c5-125a-4229-a39c-d1ee9c33f680" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaid_f3147525-89e5-4321-b67a-449d060468bd" xlink:to="loc_ibrx_LeaseLiability_de3ce9c5-125a-4229-a39c-d1ee9c33f680" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c3f59d9-bfad-4f89-b387-3f54d2b07c77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e9cd1ed2-6761-41c6-89e3-6990aabb5d76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c3f59d9-bfad-4f89-b387-3f54d2b07c77" xlink:to="loc_us-gaap_OperatingLeaseLiability_e9cd1ed2-6761-41c6-89e3-6990aabb5d76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable_7c79eaba-4436-4008-9ac3-38c9aac1b03a" xlink:href="ibrx-20230331.xsd#ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c3f59d9-bfad-4f89-b387-3f54d2b07c77" xlink:to="loc_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable_7c79eaba-4436-4008-9ac3-38c9aac1b03a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_10e75f33-f9a9-4f23-9952-bd5ca3a45898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c3f59d9-bfad-4f89-b387-3f54d2b07c77" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_10e75f33-f9a9-4f23-9952-bd5ca3a45898" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f19d7321-f94e-49a8-9562-42f9b726ca86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable_06bbc4a0-c76d-4cda-9878-dedd907b94be" xlink:href="ibrx-20230331.xsd#ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f19d7321-f94e-49a8-9562-42f9b726ca86" xlink:to="loc_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable_06bbc4a0-c76d-4cda-9878-dedd907b94be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_44f5c175-a00f-406d-aeb1-bbc620ec0a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f19d7321-f94e-49a8-9562-42f9b726ca86" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_44f5c175-a00f-406d-aeb1-bbc620ec0a1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_fc49cca2-3713-4397-8d44-2eaa5f8a0c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f19d7321-f94e-49a8-9562-42f9b726ca86" xlink:to="loc_us-gaap_FinanceLeaseLiability_fc49cca2-3713-4397-8d44-2eaa5f8a0c8d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_2" xlink:type="simple" xlink:href="ibrx-20230331.xsd#LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_2"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaid_67a9e935-5c34-4e52-b313-2998dec8dea9" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaid"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_31786686-b5ab-4dcc-8a6c-b01e0158c764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaid_67a9e935-5c34-4e52-b313-2998dec8dea9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_31786686-b5ab-4dcc-8a6c-b01e0158c764" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ef716990-9ca8-4c45-8ea6-dc332324bf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaid_67a9e935-5c34-4e52-b313-2998dec8dea9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ef716990-9ca8-4c45-8ea6-dc332324bf2a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_4180c5c3-cc58-4e16-86ca-7d4d4e8153dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesPayable_baf3bff2-32a5-43dd-bfd0-860c0bfbb669" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyNotesPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_4180c5c3-cc58-4e16-86ca-7d4d4e8153dd" xlink:to="loc_ibrx_RelatedPartyNotesPayable_baf3bff2-32a5-43dd-bfd0-860c0bfbb669" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_3108e43b-a22c-4732-99e8-89c992dc4ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_4180c5c3-cc58-4e16-86ca-7d4d4e8153dd" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_3108e43b-a22c-4732-99e8-89c992dc4ace" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_cc3a860b-4569-4e99-8cce-9153a5903615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_4180c5c3-cc58-4e16-86ca-7d4d4e8153dd" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_cc3a860b-4569-4e99-8cce-9153a5903615" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails" xlink:type="simple" xlink:href="ibrx-20230331.xsd#RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_359ef882-8f5b-4d54-ba59-aa0169c5d4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_578f0abd-5e03-4f49-8f32-d4019edc99c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_359ef882-8f5b-4d54-ba59-aa0169c5d4c5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_578f0abd-5e03-4f49-8f32-d4019edc99c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_bb472c7d-8c51-4fb1-9a10-be83de0d40a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_359ef882-8f5b-4d54-ba59-aa0169c5d4c5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_bb472c7d-8c51-4fb1-9a10-be83de0d40a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b5a25db5-b2cd-4636-abaa-126e57c9f4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_359ef882-8f5b-4d54-ba59-aa0169c5d4c5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b5a25db5-b2cd-4636-abaa-126e57c9f4ed" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>ibrx-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5993b617-92d4-4bab-a076-33e54147e714,g:68360996-794b-41f6-8c08-63fce426a63c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i38a3f2ef35cb4fe5b05445001062e69a_CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4b9d49ae-3690-4123-a879-79831eddd1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c48baaea-3cd7-4b6b-948f-8b808d34a3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4b9d49ae-3690-4123-a879-79831eddd1e6" xlink:to="loc_us-gaap_AssetsAbstract_c48baaea-3cd7-4b6b-948f-8b808d34a3e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_317c6e95-c7f4-4f97-91db-cc5a02da9818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_c48baaea-3cd7-4b6b-948f-8b808d34a3e0" xlink:to="loc_us-gaap_AssetsCurrentAbstract_317c6e95-c7f4-4f97-91db-cc5a02da9818" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6e4151b1-3938-4614-ba9c-219c82c589a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_317c6e95-c7f4-4f97-91db-cc5a02da9818" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6e4151b1-3938-4614-ba9c-219c82c589a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_f7fd1029-6a16-49ab-b886-cb34e295254e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_317c6e95-c7f4-4f97-91db-cc5a02da9818" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_f7fd1029-6a16-49ab-b886-cb34e295254e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_2fe10725-871f-43ed-9bf4-9730f4e50e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_317c6e95-c7f4-4f97-91db-cc5a02da9818" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_2fe10725-871f-43ed-9bf4-9730f4e50e00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_724ab9ff-c806-4e78-b2e6-7816bd5cc3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_317c6e95-c7f4-4f97-91db-cc5a02da9818" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_724ab9ff-c806-4e78-b2e6-7816bd5cc3ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_13bdd65a-a13a-4c69-b4f0-4510126f49c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_317c6e95-c7f4-4f97-91db-cc5a02da9818" xlink:to="loc_us-gaap_AssetsCurrent_13bdd65a-a13a-4c69-b4f0-4510126f49c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_63817d24-f2f7-40f0-af77-c880f23f9f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_c48baaea-3cd7-4b6b-948f-8b808d34a3e0" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_63817d24-f2f7-40f0-af77-c880f23f9f6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fd4a8aa9-0565-4a80-969e-a0019cc2b2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_c48baaea-3cd7-4b6b-948f-8b808d34a3e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fd4a8aa9-0565-4a80-969e-a0019cc2b2a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_919ff52d-3979-4d10-a464-952e33593be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_c48baaea-3cd7-4b6b-948f-8b808d34a3e0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_919ff52d-3979-4d10-a464-952e33593be7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ConvertibleNoteReceivableNonCurrent_061e6add-8f63-4d13-bb53-6efe3ddfacb6" xlink:href="ibrx-20230331.xsd#ibrx_ConvertibleNoteReceivableNonCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_c48baaea-3cd7-4b6b-948f-8b808d34a3e0" xlink:to="loc_ibrx_ConvertibleNoteReceivableNonCurrent_061e6add-8f63-4d13-bb53-6efe3ddfacb6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_72b4da84-15ef-4312-995c-96d88044277e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_c48baaea-3cd7-4b6b-948f-8b808d34a3e0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_72b4da84-15ef-4312-995c-96d88044277e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_dc35f7d9-0fc6-4628-8caf-6fa052673d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_c48baaea-3cd7-4b6b-948f-8b808d34a3e0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_dc35f7d9-0fc6-4628-8caf-6fa052673d82" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e5e861cb-f44a-47da-a66c-4a888c5c5474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_c48baaea-3cd7-4b6b-948f-8b808d34a3e0" xlink:to="loc_us-gaap_Assets_e5e861cb-f44a-47da-a66c-4a888c5c5474" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4b9d49ae-3690-4123-a879-79831eddd1e6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_ffcb4936-e3e5-4146-8656-6499d87fab26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_ffcb4936-e3e5-4146-8656-6499d87fab26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0fbe70cf-112b-456f-9aa4-f89e1c1d43c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ffcb4936-e3e5-4146-8656-6499d87fab26" xlink:to="loc_us-gaap_AccountsPayableCurrent_0fbe70cf-112b-456f-9aa4-f89e1c1d43c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_d65d06b6-a522-4e42-bff7-6ec5562a79c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ffcb4936-e3e5-4146-8656-6499d87fab26" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_d65d06b6-a522-4e42-bff7-6ec5562a79c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_30247a23-2983-4116-ab08-dc505f6d7731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ffcb4936-e3e5-4146-8656-6499d87fab26" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_30247a23-2983-4116-ab08-dc505f6d7731" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_9d41a317-5466-4c6c-accf-4fc22e199847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ffcb4936-e3e5-4146-8656-6499d87fab26" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_9d41a317-5466-4c6c-accf-4fc22e199847" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_461cb75a-12da-40cb-9627-990d008af096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ffcb4936-e3e5-4146-8656-6499d87fab26" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_461cb75a-12da-40cb-9627-990d008af096" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_20cb7189-a89b-45b0-8573-67a28e86b24e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ffcb4936-e3e5-4146-8656-6499d87fab26" xlink:to="loc_us-gaap_LiabilitiesCurrent_20cb7189-a89b-45b0-8573-67a28e86b24e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesNoncurrent_21d68379-bd25-439c-8215-ee6af83330f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesNoncurrent_21d68379-bd25-439c-8215-ee6af83330f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_47da2604-564c-4897-809c-6a09d074a240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_47da2604-564c-4897-809c-6a09d074a240" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_276dd604-d818-4870-8760-67f4e7ebc9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_276dd604-d818-4870-8760-67f4e7ebc9c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_777b8903-6e6f-4f8e-8592-f301f48231be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_777b8903-6e6f-4f8e-8592-f301f48231be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_454d5702-7601-4e66-b82c-dc40b423baac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:to="loc_us-gaap_Liabilities_454d5702-7601-4e66-b82c-dc40b423baac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_302d9273-a463-4451-ac7a-97e7b0fbf141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:to="loc_us-gaap_CommitmentsAndContingencies_302d9273-a463-4451-ac7a-97e7b0fbf141" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_50084db4-8a5f-4704-b240-a55c092ed2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:to="loc_us-gaap_StockholdersEquityAbstract_50084db4-8a5f-4704-b240-a55c092ed2b2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_fb9185ee-e45b-4dd9-ae91-13d1ac8c7536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50084db4-8a5f-4704-b240-a55c092ed2b2" xlink:to="loc_us-gaap_CommonStockValue_fb9185ee-e45b-4dd9-ae91-13d1ac8c7536" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d228f9cb-c7f4-4c89-ac24-fe58eafd50d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50084db4-8a5f-4704-b240-a55c092ed2b2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d228f9cb-c7f4-4c89-ac24-fe58eafd50d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b91b7442-61fd-45bf-b2b0-8f3a3df2510d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50084db4-8a5f-4704-b240-a55c092ed2b2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b91b7442-61fd-45bf-b2b0-8f3a3df2510d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a0b311d5-bb1d-404c-90df-c5093a2c28d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50084db4-8a5f-4704-b240-a55c092ed2b2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a0b311d5-bb1d-404c-90df-c5093a2c28d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ca6f3cab-11e2-4923-ae2f-d87210ace750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50084db4-8a5f-4704-b240-a55c092ed2b2" xlink:to="loc_us-gaap_StockholdersEquity_ca6f3cab-11e2-4923-ae2f-d87210ace750" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_56ef81fb-898a-4417-8621-5ee084fe9af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:to="loc_us-gaap_MinorityInterest_56ef81fb-898a-4417-8621-5ee084fe9af0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_36f61f78-0281-44b2-965c-641906116412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_36f61f78-0281-44b2-965c-641906116412" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_dc867876-d8ec-41f8-bf4c-ef34b0a78d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_dc867876-d8ec-41f8-bf4c-ef34b0a78d35" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_982f0c6d-a248-4335-bc86-7e324acc9af5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4b9d49ae-3690-4123-a879-79831eddd1e6" xlink:to="loc_us-gaap_StatementTable_982f0c6d-a248-4335-bc86-7e324acc9af5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6740c8d1-9b08-413e-93b3-7a15b7f37f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_982f0c6d-a248-4335-bc86-7e324acc9af5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6740c8d1-9b08-413e-93b3-7a15b7f37f8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6740c8d1-9b08-413e-93b3-7a15b7f37f8c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6740c8d1-9b08-413e-93b3-7a15b7f37f8c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6740c8d1-9b08-413e-93b3-7a15b7f37f8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_76c837de-1e8d-4a48-9052-0fb49218fa28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6740c8d1-9b08-413e-93b3-7a15b7f37f8c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_76c837de-1e8d-4a48-9052-0fb49218fa28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PromissoryNotesPayableMember_169f5f14-caac-4a62-9f4e-a6878dba9eb0" xlink:href="ibrx-20230331.xsd#ibrx_PromissoryNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_76c837de-1e8d-4a48-9052-0fb49218fa28" xlink:to="loc_ibrx_PromissoryNotesPayableMember_169f5f14-caac-4a62-9f4e-a6878dba9eb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_3ea57560-32cd-464a-b83f-5b6c56000253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_76c837de-1e8d-4a48-9052-0fb49218fa28" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_3ea57560-32cd-464a-b83f-5b6c56000253" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CondensedConsolidatedStatementsofStockholdersDeficit"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit" xlink:type="extended" id="i717b5dd2b03e4694a0c159d59b537f13_CondensedConsolidatedStatementsofStockholdersDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e7c71c41-d7cf-4abd-b299-019cb9b7a7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e7c71c41-d7cf-4abd-b299-019cb9b7a7ca" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bed606af-eb5c-43cf-b654-db3a65dcc272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bed606af-eb5c-43cf-b654-db3a65dcc272" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c0d6e2c0-be6f-4a46-b9ae-0c66c63f5d75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c0d6e2c0-be6f-4a46-b9ae-0c66c63f5d75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a2ef3831-35a4-44ad-b8aa-020ebca630c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a2ef3831-35a4-44ad-b8aa-020ebca630c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5de3e0bb-3489-4030-9fe4-f95142237bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5de3e0bb-3489-4030-9fe4-f95142237bb3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_daaa62fb-9c41-441f-b360-375eb6d01690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_daaa62fb-9c41-441f-b360-375eb6d01690" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_969a4539-0ae9-42cd-9e70-c39ded33706b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_969a4539-0ae9-42cd-9e70-c39ded33706b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_18112d27-b83b-44ae-89a6-a98c1514c6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_18112d27-b83b-44ae-89a6-a98c1514c6e2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_23f43df5-0119-47f9-b28a-c5fdc825f003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_23f43df5-0119-47f9-b28a-c5fdc825f003" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_9f5312f5-1fbd-41e6-a9ae-f7259baa769e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_9f5312f5-1fbd-41e6-a9ae-f7259baa769e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_dc231258-7fe5-4f49-9bfa-87222ca5a1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_dc231258-7fe5-4f49-9bfa-87222ca5a1c7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_186bd76a-2fa4-46b6-b04d-06154314f39b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_186bd76a-2fa4-46b6-b04d-06154314f39b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_cc677fe4-6f8f-4bf6-9c8c-2331eec08fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_ProfitLoss_cc677fe4-6f8f-4bf6-9c8c-2331eec08fa1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_366f6b0a-0a59-4f87-93f9-f72469a04d52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_81b13eaf-6d11-4505-ac9b-cbd01379d956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a3b17a9a-0c14-46a7-af98-8e05df1fe695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e7c71c41-d7cf-4abd-b299-019cb9b7a7ca" xlink:to="loc_us-gaap_StatementTable_a3b17a9a-0c14-46a7-af98-8e05df1fe695" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_707da8dc-2751-47ae-85d0-ab18ab83416c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a3b17a9a-0c14-46a7-af98-8e05df1fe695" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_707da8dc-2751-47ae-85d0-ab18ab83416c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_707da8dc-2751-47ae-85d0-ab18ab83416c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_707da8dc-2751-47ae-85d0-ab18ab83416c" xlink:to="loc_us-gaap_EquityComponentDomain_707da8dc-2751-47ae-85d0-ab18ab83416c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e7548e8f-4c92-4725-95c5-d83d4f2c4049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_707da8dc-2751-47ae-85d0-ab18ab83416c" xlink:to="loc_us-gaap_EquityComponentDomain_e7548e8f-4c92-4725-95c5-d83d4f2c4049" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8d9f819c-c202-4c35-96a0-b0ec3f2cbfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e7548e8f-4c92-4725-95c5-d83d4f2c4049" xlink:to="loc_us-gaap_CommonStockMember_8d9f819c-c202-4c35-96a0-b0ec3f2cbfc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_42eb241d-b928-4b48-956c-adb87893d154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e7548e8f-4c92-4725-95c5-d83d4f2c4049" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_42eb241d-b928-4b48-956c-adb87893d154" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2b41e5cf-257e-427a-8118-84aafe5f8190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e7548e8f-4c92-4725-95c5-d83d4f2c4049" xlink:to="loc_us-gaap_RetainedEarningsMember_2b41e5cf-257e-427a-8118-84aafe5f8190" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0b7386ac-ec9b-4d91-88ae-a8c31c9ffe0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e7548e8f-4c92-4725-95c5-d83d4f2c4049" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0b7386ac-ec9b-4d91-88ae-a8c31c9ffe0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8802fc52-9bfa-403f-a20b-418272e8b974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e7548e8f-4c92-4725-95c5-d83d4f2c4049" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8802fc52-9bfa-403f-a20b-418272e8b974" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_81808be7-cb40-41a1-9ae6-04c649f6c859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e7548e8f-4c92-4725-95c5-d83d4f2c4049" xlink:to="loc_us-gaap_NoncontrollingInterestMember_81808be7-cb40-41a1-9ae6-04c649f6c859" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fb553b19-62d4-498f-8442-8ada2b61ec47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a3b17a9a-0c14-46a7-af98-8e05df1fe695" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fb553b19-62d4-498f-8442-8ada2b61ec47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fb553b19-62d4-498f-8442-8ada2b61ec47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fb553b19-62d4-498f-8442-8ada2b61ec47" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fb553b19-62d4-498f-8442-8ada2b61ec47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf51c72a-a714-4257-b9e9-67a95cc93398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fb553b19-62d4-498f-8442-8ada2b61ec47" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf51c72a-a714-4257-b9e9-67a95cc93398" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_fe52175d-4177-469b-8604-64a43a8b5836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf51c72a-a714-4257-b9e9-67a95cc93398" xlink:to="loc_us-gaap_PrivatePlacementMember_fe52175d-4177-469b-8604-64a43a8b5836" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficitParenthetical" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CondensedConsolidatedStatementsofStockholdersDeficitParenthetical"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficitParenthetical" xlink:type="extended" id="ic30f1cbf5bb84816a54ea999e831130d_CondensedConsolidatedStatementsofStockholdersDeficitParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d6dd8acc-c984-47e5-8427-1c351895c29d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_fe7c8405-1cb9-4171-b0b6-d6ade1645abb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d6dd8acc-c984-47e5-8427-1c351895c29d" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_fe7c8405-1cb9-4171-b0b6-d6ade1645abb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b6cb6e37-5e9e-4c5f-95ec-0e49a2a7a4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d6dd8acc-c984-47e5-8427-1c351895c29d" xlink:to="loc_us-gaap_StatementTable_b6cb6e37-5e9e-4c5f-95ec-0e49a2a7a4c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_46ec7cdc-b5cb-42df-9939-f3b1600b5ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b6cb6e37-5e9e-4c5f-95ec-0e49a2a7a4c3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_46ec7cdc-b5cb-42df-9939-f3b1600b5ab3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_46ec7cdc-b5cb-42df-9939-f3b1600b5ab3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_46ec7cdc-b5cb-42df-9939-f3b1600b5ab3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_46ec7cdc-b5cb-42df-9939-f3b1600b5ab3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2be32467-f690-42e5-97f2-daf17a8b959c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_46ec7cdc-b5cb-42df-9939-f3b1600b5ab3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2be32467-f690-42e5-97f2-daf17a8b959c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_bb7e7622-4cf4-4d34-a83e-45dbfe261a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2be32467-f690-42e5-97f2-daf17a8b959c" xlink:to="loc_us-gaap_PrivatePlacementMember_bb7e7622-4cf4-4d34-a83e-45dbfe261a43" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" id="i8a2b9d803f8d43dc88d092d3ad5f2141_SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccountingPoliciesLineItems_f106c4ad-ae0a-409a-adc2-0366c843b965" xlink:href="ibrx-20230331.xsd#ibrx_AccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3373c6e6-3230-4369-b6ad-85d62011775a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_AccountingPoliciesLineItems_f106c4ad-ae0a-409a-adc2-0366c843b965" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3373c6e6-3230-4369-b6ad-85d62011775a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a497b990-0235-49f8-b4b8-0b60b11ad65e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_AccountingPoliciesLineItems_f106c4ad-ae0a-409a-adc2-0366c843b965" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a497b990-0235-49f8-b4b8-0b60b11ad65e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CommonStockValueAvailableForFutureStockIssuance_bc49e51a-3e2d-4cfa-861e-8ec5d29fc97c" xlink:href="ibrx-20230331.xsd#ibrx_CommonStockValueAvailableForFutureStockIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_AccountingPoliciesLineItems_f106c4ad-ae0a-409a-adc2-0366c843b965" xlink:to="loc_ibrx_CommonStockValueAvailableForFutureStockIssuance_bc49e51a-3e2d-4cfa-861e-8ec5d29fc97c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccountingPoliciesTable_3b77215f-d226-40aa-af97-36eb9133382b" xlink:href="ibrx-20230331.xsd#ibrx_AccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ibrx_AccountingPoliciesLineItems_f106c4ad-ae0a-409a-adc2-0366c843b965" xlink:to="loc_ibrx_AccountingPoliciesTable_3b77215f-d226-40aa-af97-36eb9133382b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f1a237de-d093-4e2f-86e7-a4360d4f51d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_AccountingPoliciesTable_3b77215f-d226-40aa-af97-36eb9133382b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f1a237de-d093-4e2f-86e7-a4360d4f51d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f1a237de-d093-4e2f-86e7-a4360d4f51d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f1a237de-d093-4e2f-86e7-a4360d4f51d3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f1a237de-d093-4e2f-86e7-a4360d4f51d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_21948ed1-9bcc-4101-8154-c4e607db7297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f1a237de-d093-4e2f-86e7-a4360d4f51d3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_21948ed1-9bcc-4101-8154-c4e607db7297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AtTheMarketOfferingProgramMember_7c4c864b-3b24-4d20-80fc-a56fa0c0c6da" xlink:href="ibrx-20230331.xsd#ibrx_AtTheMarketOfferingProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_21948ed1-9bcc-4101-8154-c4e607db7297" xlink:to="loc_ibrx_AtTheMarketOfferingProgramMember_7c4c864b-3b24-4d20-80fc-a56fa0c0c6da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3329ed9d-22df-45a6-80eb-7697a0b925f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_AccountingPoliciesTable_3b77215f-d226-40aa-af97-36eb9133382b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3329ed9d-22df-45a6-80eb-7697a0b925f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3329ed9d-22df-45a6-80eb-7697a0b925f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3329ed9d-22df-45a6-80eb-7697a0b925f1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3329ed9d-22df-45a6-80eb-7697a0b925f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8e49a6c-f7dc-4ebb-a847-8b1694b7a727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3329ed9d-22df-45a6-80eb-7697a0b925f1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8e49a6c-f7dc-4ebb-a847-8b1694b7a727" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023ShelfRegistrationStatementMember_f5c831c6-abd1-44a9-97a4-11030617d8c7" xlink:href="ibrx-20230331.xsd#ibrx_February2023ShelfRegistrationStatementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8e49a6c-f7dc-4ebb-a847-8b1694b7a727" xlink:to="loc_ibrx_February2023ShelfRegistrationStatementMember_f5c831c6-abd1-44a9-97a4-11030617d8c7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail" xlink:type="extended" id="i44f4de82c29a4a5d945f7eaed4408202_SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d6341c5-8f4f-48eb-8e5c-2a3202064331" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6bd30816-5de4-4633-b63e-b8d1c8c15ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d6341c5-8f4f-48eb-8e5c-2a3202064331" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6bd30816-5de4-4633-b63e-b8d1c8c15ea9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesPayable_c656bac2-0627-4144-bfb7-9f56db164728" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d6341c5-8f4f-48eb-8e5c-2a3202064331" xlink:to="loc_ibrx_RelatedPartyNotesPayable_c656bac2-0627-4144-bfb7-9f56db164728" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5c3aa018-5d87-47d4-9f68-7ddeda7cee2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d6341c5-8f4f-48eb-8e5c-2a3202064331" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5c3aa018-5d87-47d4-9f68-7ddeda7cee2e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8cad25dd-ba00-4569-a0f0-5e1a7588f2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5c3aa018-5d87-47d4-9f68-7ddeda7cee2e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8cad25dd-ba00-4569-a0f0-5e1a7588f2f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8cad25dd-ba00-4569-a0f0-5e1a7588f2f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8cad25dd-ba00-4569-a0f0-5e1a7588f2f9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8cad25dd-ba00-4569-a0f0-5e1a7588f2f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea71079d-ad8d-4663-a8b2-26769b7b54c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8cad25dd-ba00-4569-a0f0-5e1a7588f2f9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea71079d-ad8d-4663-a8b2-26769b7b54c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyConvertibleNotesMember_9ef63bb1-60a2-47f0-9a41-4899add96707" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea71079d-ad8d-4663-a8b2-26769b7b54c5" xlink:to="loc_ibrx_RelatedPartyConvertibleNotesMember_9ef63bb1-60a2-47f0-9a41-4899add96707" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b3674ef3-60c6-4d3e-be8e-b143072edecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea71079d-ad8d-4663-a8b2-26769b7b54c5" xlink:to="loc_us-gaap_WarrantMember_b3674ef3-60c6-4d3e-be8e-b143072edecf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b699d4dc-a361-494a-8bcb-7f835735e186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea71079d-ad8d-4663-a8b2-26769b7b54c5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b699d4dc-a361-494a-8bcb-7f835735e186" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_518662d7-0da9-4fd5-9955-1a5d4d3d3981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea71079d-ad8d-4663-a8b2-26769b7b54c5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_518662d7-0da9-4fd5-9955-1a5d4d3d3981" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyWarrantsMember_43d490e8-019b-407c-8ac4-16da8143c4ee" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea71079d-ad8d-4663-a8b2-26769b7b54c5" xlink:to="loc_ibrx_RelatedPartyWarrantsMember_43d490e8-019b-407c-8ac4-16da8143c4ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_04e340e3-3dd6-4513-9dcb-8a67f63d8963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5c3aa018-5d87-47d4-9f68-7ddeda7cee2e" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_04e340e3-3dd6-4513-9dcb-8a67f63d8963" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_04e340e3-3dd6-4513-9dcb-8a67f63d8963_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_04e340e3-3dd6-4513-9dcb-8a67f63d8963" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_04e340e3-3dd6-4513-9dcb-8a67f63d8963_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1f84e4e3-f009-4591-baea-af3519d4560d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_04e340e3-3dd6-4513-9dcb-8a67f63d8963" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1f84e4e3-f009-4591-baea-af3519d4560d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalIssued33123Member_afc862c7-bc71-4165-b399-4458d0318c01" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalIssued33123Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1f84e4e3-f009-4591-baea-af3519d4560d" xlink:to="loc_ibrx_NantCapitalIssued33123Member_afc862c7-bc71-4165-b399-4458d0318c01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_02c6acda-999d-4e52-9c5c-4158afa32fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5c3aa018-5d87-47d4-9f68-7ddeda7cee2e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_02c6acda-999d-4e52-9c5c-4158afa32fcb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_02c6acda-999d-4e52-9c5c-4158afa32fcb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_02c6acda-999d-4e52-9c5c-4158afa32fcb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_02c6acda-999d-4e52-9c5c-4158afa32fcb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ac81ebc2-f0df-4872-82f4-154ed57d2c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_02c6acda-999d-4e52-9c5c-4158afa32fcb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ac81ebc2-f0df-4872-82f4-154ed57d2c79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_ee28abd3-e1e6-4b3e-a424-e0d7072c649e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ac81ebc2-f0df-4872-82f4-154ed57d2c79" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_ee28abd3-e1e6-4b3e-a424-e0d7072c649e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail" xlink:type="extended" id="ibaadb6bf5db34d32bcfc40c7411c6469_FinancialStatementDetailsPropertyPlantandEquipmentNetDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_27d34fb3-d6c2-462c-8e1a-015b69227879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5e2087ff-ab88-464e-838b-572e500f98c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_27d34fb3-d6c2-462c-8e1a-015b69227879" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5e2087ff-ab88-464e-838b-572e500f98c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1aff174b-8e3b-4ecc-8711-32aaf3366eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_27d34fb3-d6c2-462c-8e1a-015b69227879" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1aff174b-8e3b-4ecc-8711-32aaf3366eaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4805e315-7ac5-4914-a58f-776d4a025223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_27d34fb3-d6c2-462c-8e1a-015b69227879" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4805e315-7ac5-4914-a58f-776d4a025223" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf18bf96-5c48-47b9-95db-bb5c25336f84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_27d34fb3-d6c2-462c-8e1a-015b69227879" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf18bf96-5c48-47b9-95db-bb5c25336f84" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_72408717-0eae-4c2f-ad96-929ea51ed727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf18bf96-5c48-47b9-95db-bb5c25336f84" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_72408717-0eae-4c2f-ad96-929ea51ed727" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72408717-0eae-4c2f-ad96-929ea51ed727_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_72408717-0eae-4c2f-ad96-929ea51ed727" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72408717-0eae-4c2f-ad96-929ea51ed727_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_387fd199-3a49-428d-9317-839bbfdd5896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_72408717-0eae-4c2f-ad96-929ea51ed727" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_387fd199-3a49-428d-9317-839bbfdd5896" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_079702b7-3f28-489a-b032-02da9285b5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_387fd199-3a49-428d-9317-839bbfdd5896" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_079702b7-3f28-489a-b032-02da9285b5f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_d318749e-eb35-4c37-8437-cd17cbff39a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_387fd199-3a49-428d-9317-839bbfdd5896" xlink:to="loc_us-gaap_EquipmentMember_d318749e-eb35-4c37-8437-cd17cbff39a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_1f1711e7-920b-4ba7-9036-6bd0d6cef723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_387fd199-3a49-428d-9317-839bbfdd5896" xlink:to="loc_us-gaap_ConstructionInProgressMember_1f1711e7-920b-4ba7-9036-6bd0d6cef723" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3ae1aee4-4dce-4d6d-8e05-4461f3dc648a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_387fd199-3a49-428d-9317-839bbfdd5896" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3ae1aee4-4dce-4d6d-8e05-4461f3dc648a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_8416283e-8170-4df9-93eb-5e1ccbed0636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_387fd199-3a49-428d-9317-839bbfdd5896" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_8416283e-8170-4df9-93eb-5e1ccbed0636" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialStatementDetailsIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails" xlink:type="extended" id="icbda2ab0f221454987d02429a86d49b6_FinancialStatementDetailsIntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsLineItems_f5f97428-2751-45c3-aa5f-45a61450bcd3" xlink:href="ibrx-20230331.xsd#ibrx_FinancialStatementDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f1c4dedf-7675-4010-a920-a16db5fb2abe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_f5f97428-2751-45c3-aa5f-45a61450bcd3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f1c4dedf-7675-4010-a920-a16db5fb2abe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d6b34df1-21e0-49a8-9f43-23c35e7b68d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f1c4dedf-7675-4010-a920-a16db5fb2abe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d6b34df1-21e0-49a8-9f43-23c35e7b68d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_16302205-63c6-43f5-b055-e6aec5bbfe02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f1c4dedf-7675-4010-a920-a16db5fb2abe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_16302205-63c6-43f5-b055-e6aec5bbfe02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_90cb7d8d-7c8b-441a-9588-09187904d3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f1c4dedf-7675-4010-a920-a16db5fb2abe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_90cb7d8d-7c8b-441a-9588-09187904d3a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_24c7f4cb-6906-45cb-a32d-c4db3cc31b46" xlink:href="ibrx-20230331.xsd#ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f1c4dedf-7675-4010-a920-a16db5fb2abe" xlink:to="loc_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_24c7f4cb-6906-45cb-a32d-c4db3cc31b46" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dc4e7930-2e30-4c48-90a7-e9d04c5c66fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f1c4dedf-7675-4010-a920-a16db5fb2abe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dc4e7930-2e30-4c48-90a7-e9d04c5c66fb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_8ae5a70a-f5a4-4986-93fd-3dfa28b8908c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_f5f97428-2751-45c3-aa5f-45a61450bcd3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_8ae5a70a-f5a4-4986-93fd-3dfa28b8908c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4a6172cc-1c8b-46c3-86ac-ba0ebee56396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_8ae5a70a-f5a4-4986-93fd-3dfa28b8908c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4a6172cc-1c8b-46c3-86ac-ba0ebee56396" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_bc1f3cbe-6a1e-4252-8484-d84baf4d900d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_f5f97428-2751-45c3-aa5f-45a61450bcd3" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_bc1f3cbe-6a1e-4252-8484-d84baf4d900d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0179c774-a6f9-40e3-bc3a-6262c3c5db87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_f5f97428-2751-45c3-aa5f-45a61450bcd3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0179c774-a6f9-40e3-bc3a-6262c3c5db87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_a42b7590-7407-4119-b993-108d27691223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_f5f97428-2751-45c3-aa5f-45a61450bcd3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_a42b7590-7407-4119-b993-108d27691223" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_f07abcf7-c8fd-4630-937b-f443ec6bed70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_f5f97428-2751-45c3-aa5f-45a61450bcd3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_f07abcf7-c8fd-4630-937b-f443ec6bed70" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_a4b61391-5cf2-48c5-bc5b-e0cc722af6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_f07abcf7-c8fd-4630-937b-f443ec6bed70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_a4b61391-5cf2-48c5-bc5b-e0cc722af6a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_09656785-dbd9-44ce-acc8-19ae0f1de9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_f07abcf7-c8fd-4630-937b-f443ec6bed70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_09656785-dbd9-44ce-acc8-19ae0f1de9ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b21ef362-9f5a-4437-a1d3-6cdb23b4a95f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_f07abcf7-c8fd-4630-937b-f443ec6bed70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b21ef362-9f5a-4437-a1d3-6cdb23b4a95f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c988c7b1-28aa-4f00-81e9-3b1fe8bc71c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_f07abcf7-c8fd-4630-937b-f443ec6bed70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c988c7b1-28aa-4f00-81e9-3b1fe8bc71c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3e7bdaeb-00a0-493b-b45a-92d1177d310b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_f07abcf7-c8fd-4630-937b-f443ec6bed70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3e7bdaeb-00a0-493b-b45a-92d1177d310b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_431a4116-ae71-4fe0-97e9-a0c054913600" xlink:href="ibrx-20230331.xsd#ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_f07abcf7-c8fd-4630-937b-f443ec6bed70" xlink:to="loc_ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_431a4116-ae71-4fe0-97e9-a0c054913600" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsTable_34d199b7-1293-4d06-aac3-5aefa394dd19" xlink:href="ibrx-20230331.xsd#ibrx_FinancialStatementDetailsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_f5f97428-2751-45c3-aa5f-45a61450bcd3" xlink:to="loc_ibrx_FinancialStatementDetailsTable_34d199b7-1293-4d06-aac3-5aefa394dd19" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2fadcaf3-600d-4a4b-8164-062aeac01040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_FinancialStatementDetailsTable_34d199b7-1293-4d06-aac3-5aefa394dd19" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2fadcaf3-600d-4a4b-8164-062aeac01040" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2fadcaf3-600d-4a4b-8164-062aeac01040_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2fadcaf3-600d-4a4b-8164-062aeac01040" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2fadcaf3-600d-4a4b-8164-062aeac01040_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42013c20-6bfa-4f52-bc6d-f501e7d41f13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2fadcaf3-600d-4a4b-8164-062aeac01040" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42013c20-6bfa-4f52-bc6d-f501e7d41f13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketFavorableLeaseMember_aadee370-1b3d-4696-9475-5d7476b3aa9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffMarketFavorableLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42013c20-6bfa-4f52-bc6d-f501e7d41f13" xlink:to="loc_us-gaap_OffMarketFavorableLeaseMember_aadee370-1b3d-4696-9475-5d7476b3aa9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OrganizedWorkforceMember_0e11d9bb-43d5-460a-aec4-8f4e6743d68b" xlink:href="ibrx-20230331.xsd#ibrx_OrganizedWorkforceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42013c20-6bfa-4f52-bc6d-f501e7d41f13" xlink:to="loc_ibrx_OrganizedWorkforceMember_0e11d9bb-43d5-460a-aec4-8f4e6743d68b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail" xlink:type="extended" id="i1f8541aa017b4f16a60b259a1957f860_FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9b4d9c99-3ba4-4c6c-931f-a51002bbc4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod_a31255fb-cd41-45ab-a005-853073b18855" xlink:href="ibrx-20230331.xsd#ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9b4d9c99-3ba4-4c6c-931f-a51002bbc4e2" xlink:to="loc_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod_a31255fb-cd41-45ab-a005-853073b18855" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f5ef12cd-1286-42bf-9833-7b327e5ac941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9b4d9c99-3ba4-4c6c-931f-a51002bbc4e2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f5ef12cd-1286-42bf-9833-7b327e5ac941" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0cd17f8b-7cef-489e-9a1f-2806a4f62939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9b4d9c99-3ba4-4c6c-931f-a51002bbc4e2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0cd17f8b-7cef-489e-9a1f-2806a4f62939" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1000fe5c-8de4-4368-aba9-5c7f00dcf8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9b4d9c99-3ba4-4c6c-931f-a51002bbc4e2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1000fe5c-8de4-4368-aba9-5c7f00dcf8e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a598a825-f2c1-4590-afa0-b1c791bca311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9b4d9c99-3ba4-4c6c-931f-a51002bbc4e2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a598a825-f2c1-4590-afa0-b1c791bca311" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b6565e8a-cc2d-4624-8494-cb0695c315ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9b4d9c99-3ba4-4c6c-931f-a51002bbc4e2" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b6565e8a-cc2d-4624-8494-cb0695c315ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3c34cf3f-461a-4a85-8f29-d3c5f903a1af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b6565e8a-cc2d-4624-8494-cb0695c315ac" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3c34cf3f-461a-4a85-8f29-d3c5f903a1af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3c34cf3f-461a-4a85-8f29-d3c5f903a1af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3c34cf3f-461a-4a85-8f29-d3c5f903a1af" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3c34cf3f-461a-4a85-8f29-d3c5f903a1af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2521d124-2c67-4a78-b19c-a1efa9ee491e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3c34cf3f-461a-4a85-8f29-d3c5f903a1af" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2521d124-2c67-4a78-b19c-a1efa9ee491e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CurrentAssetsMember_b7e6971b-5b48-42b7-acc8-0366489c142a" xlink:href="ibrx-20230331.xsd#ibrx_CurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2521d124-2c67-4a78-b19c-a1efa9ee491e" xlink:to="loc_ibrx_CurrentAssetsMember_b7e6971b-5b48-42b7-acc8-0366489c142a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NoncurrentAssetsMember_c8c27c95-b555-45aa-a916-995843e6b8c5" xlink:href="ibrx-20230331.xsd#ibrx_NoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2521d124-2c67-4a78-b19c-a1efa9ee491e" xlink:to="loc_ibrx_NoncurrentAssetsMember_c8c27c95-b555-45aa-a916-995843e6b8c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_773748ba-a5c7-4b40-9b1b-58dc353af426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b6565e8a-cc2d-4624-8494-cb0695c315ac" xlink:to="loc_us-gaap_FinancialInstrumentAxis_773748ba-a5c7-4b40-9b1b-58dc353af426" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_773748ba-a5c7-4b40-9b1b-58dc353af426_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_773748ba-a5c7-4b40-9b1b-58dc353af426" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_773748ba-a5c7-4b40-9b1b-58dc353af426_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c1b054f2-6e8a-469c-9891-29478e3d7cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_773748ba-a5c7-4b40-9b1b-58dc353af426" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c1b054f2-6e8a-469c-9891-29478e3d7cd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember_9832e3ec-cdb6-413b-a252-c5ba2f084cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c1b054f2-6e8a-469c-9891-29478e3d7cd0" xlink:to="loc_us-gaap_ForeignGovernmentDebtMember_9832e3ec-cdb6-413b-a252-c5ba2f084cd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_77633fab-880f-42c8-a474-98bd274d384b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MutualFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c1b054f2-6e8a-469c-9891-29478e3d7cd0" xlink:to="loc_us-gaap_MutualFundMember_77633fab-880f-42c8-a474-98bd274d384b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonMarketableDebtSecuritiesinContinuousLossPositionDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialInstrumentsAccumulatedUnrealizedLossesonMarketableDebtSecuritiesinContinuousLossPositionDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonMarketableDebtSecuritiesinContinuousLossPositionDetail" xlink:type="extended" id="i2427cd61f15842b8a8468a1ff67fe58a_FinancialInstrumentsAccumulatedUnrealizedLossesonMarketableDebtSecuritiesinContinuousLossPositionDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d55ea1d4-7bcd-4c14-aba4-857ac294d630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_87e9eb58-f8d1-45c8-ad00-41cd6f126320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d55ea1d4-7bcd-4c14-aba4-857ac294d630" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_87e9eb58-f8d1-45c8-ad00-41cd6f126320" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_147d2c01-193c-420e-b79b-c50883100997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d55ea1d4-7bcd-4c14-aba4-857ac294d630" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_147d2c01-193c-420e-b79b-c50883100997" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_0f93aded-5ff4-4c57-b07b-408d7547ce07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d55ea1d4-7bcd-4c14-aba4-857ac294d630" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_0f93aded-5ff4-4c57-b07b-408d7547ce07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_429c247a-6b5d-46c8-848e-36b994ee1317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d55ea1d4-7bcd-4c14-aba4-857ac294d630" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_429c247a-6b5d-46c8-848e-36b994ee1317" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f4f43c61-3ed3-42ff-8f6c-bf473cb3e190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d55ea1d4-7bcd-4c14-aba4-857ac294d630" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f4f43c61-3ed3-42ff-8f6c-bf473cb3e190" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c84ca971-9e35-42a7-af32-9e9a2e2b430a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f4f43c61-3ed3-42ff-8f6c-bf473cb3e190" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c84ca971-9e35-42a7-af32-9e9a2e2b430a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c84ca971-9e35-42a7-af32-9e9a2e2b430a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c84ca971-9e35-42a7-af32-9e9a2e2b430a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c84ca971-9e35-42a7-af32-9e9a2e2b430a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a56aebc-4362-4b54-a37a-e35dd9a8e16b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c84ca971-9e35-42a7-af32-9e9a2e2b430a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a56aebc-4362-4b54-a37a-e35dd9a8e16b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_6e3807cb-ed19-41f1-852f-d94c53c9e8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MutualFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a56aebc-4362-4b54-a37a-e35dd9a8e16b" xlink:to="loc_us-gaap_MutualFundMember_6e3807cb-ed19-41f1-852f-d94c53c9e8b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember_8515e7ca-21e8-4de2-b97d-5049f5d5b8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a56aebc-4362-4b54-a37a-e35dd9a8e16b" xlink:to="loc_us-gaap_ForeignGovernmentDebtMember_8515e7ca-21e8-4de2-b97d-5049f5d5b8b7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialInstrumentsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail" xlink:type="extended" id="i02c52fe322de4f7196cf6da4e3c59672_FinancialInstrumentsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8fe77ff9-9afc-491f-8a2f-2bdd23b1b963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_e5d8f420-69b6-4728-b1b4-e5db2392a31d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8fe77ff9-9afc-491f-8a2f-2bdd23b1b963" xlink:to="loc_us-gaap_MarketableSecurities_e5d8f420-69b6-4728-b1b4-e5db2392a31d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d4a203dd-74b8-48b4-9d59-e8c72ad1eea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8fe77ff9-9afc-491f-8a2f-2bdd23b1b963" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d4a203dd-74b8-48b4-9d59-e8c72ad1eea0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ca297fc4-37be-4824-a2e4-0238659cc0df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8fe77ff9-9afc-491f-8a2f-2bdd23b1b963" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ca297fc4-37be-4824-a2e4-0238659cc0df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_46ebed09-0b52-40d3-b1a3-7dd72e631c73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ca297fc4-37be-4824-a2e4-0238659cc0df" xlink:to="loc_us-gaap_InvestmentTypeAxis_46ebed09-0b52-40d3-b1a3-7dd72e631c73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_46ebed09-0b52-40d3-b1a3-7dd72e631c73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_46ebed09-0b52-40d3-b1a3-7dd72e631c73" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_46ebed09-0b52-40d3-b1a3-7dd72e631c73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_e4e787f2-1bde-4231-b889-b7569af75219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_46ebed09-0b52-40d3-b1a3-7dd72e631c73" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_e4e787f2-1bde-4231-b889-b7569af75219" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_8b6f0842-19b6-4c77-b5a1-17f4d1fe67d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e4e787f2-1bde-4231-b889-b7569af75219" xlink:to="loc_us-gaap_EquitySecuritiesMember_8b6f0842-19b6-4c77-b5a1-17f4d1fe67d6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended" id="ia125c13712bc41d9abebab2e2c439ca9_FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68404159-677f-42be-8600-63bc7412ad53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6b565c5e-e0b2-4b9e-8e6e-1c16365ff0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68404159-677f-42be-8600-63bc7412ad53" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_6b565c5e-e0b2-4b9e-8e6e-1c16365ff0e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_e40ed8da-6643-4ccb-bb99-7e38f8c7bca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68404159-677f-42be-8600-63bc7412ad53" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_e40ed8da-6643-4ccb-bb99-7e38f8c7bca8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesPayable_14494a99-464a-42bb-bb7a-b73f10252eaa" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68404159-677f-42be-8600-63bc7412ad53" xlink:to="loc_ibrx_RelatedPartyNotesPayable_14494a99-464a-42bb-bb7a-b73f10252eaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_8ac26df0-4972-4b39-b62a-b961bf96a6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68404159-677f-42be-8600-63bc7412ad53" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_8ac26df0-4972-4b39-b62a-b961bf96a6c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_64049c5f-7bd7-4614-baa3-ae32d6f79348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68404159-677f-42be-8600-63bc7412ad53" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_64049c5f-7bd7-4614-baa3-ae32d6f79348" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_83c39e80-b998-41b2-b7f8-2070ed846fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68404159-677f-42be-8600-63bc7412ad53" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_83c39e80-b998-41b2-b7f8-2070ed846fe5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_424f8584-a0ca-4ba2-b843-a88a9fd0f226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68404159-677f-42be-8600-63bc7412ad53" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_424f8584-a0ca-4ba2-b843-a88a9fd0f226" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_af4cafe9-d63b-4339-8b87-8383718c0647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_424f8584-a0ca-4ba2-b843-a88a9fd0f226" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_af4cafe9-d63b-4339-8b87-8383718c0647" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6301c94d-1a85-4e89-a852-d893f182adf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_424f8584-a0ca-4ba2-b843-a88a9fd0f226" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6301c94d-1a85-4e89-a852-d893f182adf3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_dcf8b17a-b9c2-4273-abd9-573f088592d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_8c3b00cc-87b2-485c-8aae-f7257cd603cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68404159-677f-42be-8600-63bc7412ad53" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_8c3b00cc-87b2-485c-8aae-f7257cd603cd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68404159-677f-42be-8600-63bc7412ad53" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c7d69c59-d27b-41b3-a876-f9b9362ce1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c7d69c59-d27b-41b3-a876-f9b9362ce1d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c7d69c59-d27b-41b3-a876-f9b9362ce1d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c7d69c59-d27b-41b3-a876-f9b9362ce1d0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c7d69c59-d27b-41b3-a876-f9b9362ce1d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_914daed4-db79-4796-9066-be5b5d6f8e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c7d69c59-d27b-41b3-a876-f9b9362ce1d0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_914daed4-db79-4796-9066-be5b5d6f8e8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4928322b-98bd-4c9e-8505-9ce88158ec70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_914daed4-db79-4796-9066-be5b5d6f8e8e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4928322b-98bd-4c9e-8505-9ce88158ec70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f6c91f64-de03-40a1-81ad-c39d1e7a612c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f6c91f64-de03-40a1-81ad-c39d1e7a612c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f6c91f64-de03-40a1-81ad-c39d1e7a612c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f6c91f64-de03-40a1-81ad-c39d1e7a612c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f6c91f64-de03-40a1-81ad-c39d1e7a612c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32e73156-dbdd-4782-94d7-8626c1575bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f6c91f64-de03-40a1-81ad-c39d1e7a612c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32e73156-dbdd-4782-94d7-8626c1575bed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b6708e83-a963-4f00-8cf2-82989bea8b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32e73156-dbdd-4782-94d7-8626c1575bed" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b6708e83-a963-4f00-8cf2-82989bea8b6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5bb99b0f-290c-4251-bba2-596b0c3c410f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32e73156-dbdd-4782-94d7-8626c1575bed" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5bb99b0f-290c-4251-bba2-596b0c3c410f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_211f5899-9eaa-4d0a-b396-f27d67665ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32e73156-dbdd-4782-94d7-8626c1575bed" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_211f5899-9eaa-4d0a-b396-f27d67665ff4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1543f89c-c5b0-4a45-b759-a07239d5e9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1543f89c-c5b0-4a45-b759-a07239d5e9ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1543f89c-c5b0-4a45-b759-a07239d5e9ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1543f89c-c5b0-4a45-b759-a07239d5e9ae" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1543f89c-c5b0-4a45-b759-a07239d5e9ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e09a9e13-dbf8-4135-b665-21d0c03aff0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1543f89c-c5b0-4a45-b759-a07239d5e9ae" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e09a9e13-dbf8-4135-b665-21d0c03aff0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CurrentAssetsMember_429f9725-df41-4e43-b654-5c9a04a381e2" xlink:href="ibrx-20230331.xsd#ibrx_CurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e09a9e13-dbf8-4135-b665-21d0c03aff0f" xlink:to="loc_ibrx_CurrentAssetsMember_429f9725-df41-4e43-b654-5c9a04a381e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NoncurrentAssetsMember_5180e9d0-49b5-465e-8fd0-8cc8e2e77693" xlink:href="ibrx-20230331.xsd#ibrx_NoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e09a9e13-dbf8-4135-b665-21d0c03aff0f" xlink:to="loc_ibrx_NoncurrentAssetsMember_5180e9d0-49b5-465e-8fd0-8cc8e2e77693" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CurrentLiabilitiesMember_34edb8bd-32bb-4cbf-83e6-fb4bdf733fcf" xlink:href="ibrx-20230331.xsd#ibrx_CurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e09a9e13-dbf8-4135-b665-21d0c03aff0f" xlink:to="loc_ibrx_CurrentLiabilitiesMember_34edb8bd-32bb-4cbf-83e6-fb4bdf733fcf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NoncurrentLiabilitiesMember_03762c33-64e0-4136-9773-1c72a97b8ea6" xlink:href="ibrx-20230331.xsd#ibrx_NoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e09a9e13-dbf8-4135-b665-21d0c03aff0f" xlink:to="loc_ibrx_NoncurrentLiabilitiesMember_03762c33-64e0-4136-9773-1c72a97b8ea6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_5c68a4c6-8ffd-42af-bdcd-7f53030ea565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_5c68a4c6-8ffd-42af-bdcd-7f53030ea565" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5c68a4c6-8ffd-42af-bdcd-7f53030ea565_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_5c68a4c6-8ffd-42af-bdcd-7f53030ea565" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5c68a4c6-8ffd-42af-bdcd-7f53030ea565_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d4eec82e-60ac-476d-857a-d79b87f501ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_5c68a4c6-8ffd-42af-bdcd-7f53030ea565" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d4eec82e-60ac-476d-857a-d79b87f501ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_338dce48-b04e-4e1c-ba9b-a52c77134306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d4eec82e-60ac-476d-857a-d79b87f501ef" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_338dce48-b04e-4e1c-ba9b-a52c77134306" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_90f98421-977b-4385-957f-1101e1736fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_InvestmentTypeAxis_90f98421-977b-4385-957f-1101e1736fe5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_90f98421-977b-4385-957f-1101e1736fe5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_90f98421-977b-4385-957f-1101e1736fe5" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_90f98421-977b-4385-957f-1101e1736fe5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_19d368e2-b45a-4a8e-b1fa-a49ca4e040db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_90f98421-977b-4385-957f-1101e1736fe5" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_19d368e2-b45a-4a8e-b1fa-a49ca4e040db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_a6551f79-6001-4f2c-a93d-aff266b053b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_19d368e2-b45a-4a8e-b1fa-a49ca4e040db" xlink:to="loc_us-gaap_EquitySecuritiesMember_a6551f79-6001-4f2c-a93d-aff266b053b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_2f5b3b64-6673-4e47-834f-a7efe427040f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MutualFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_19d368e2-b45a-4a8e-b1fa-a49ca4e040db" xlink:to="loc_us-gaap_MutualFundMember_2f5b3b64-6673-4e47-834f-a7efe427040f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember_f275fb1c-588d-4286-a1ea-53898919d788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_19d368e2-b45a-4a8e-b1fa-a49ca4e040db" xlink:to="loc_us-gaap_ForeignGovernmentDebtMember_f275fb1c-588d-4286-a1ea-53898919d788" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_da0de8cb-156d-4206-80dd-56c2156a753c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_da0de8cb-156d-4206-80dd-56c2156a753c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_da0de8cb-156d-4206-80dd-56c2156a753c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_da0de8cb-156d-4206-80dd-56c2156a753c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_da0de8cb-156d-4206-80dd-56c2156a753c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e15b1ca7-2244-42d3-ab81-a59d9f5030e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_da0de8cb-156d-4206-80dd-56c2156a753c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e15b1ca7-2244-42d3-ab81-a59d9f5030e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_b351d96c-fa17-4b88-a888-7479f26db876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e15b1ca7-2244-42d3-ab81-a59d9f5030e7" xlink:to="loc_us-gaap_AgencySecuritiesMember_b351d96c-fa17-4b88-a888-7479f26db876" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_15a4edee-c6bd-4cfb-81c5-74a32fe63938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e15b1ca7-2244-42d3-ab81-a59d9f5030e7" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_15a4edee-c6bd-4cfb-81c5-74a32fe63938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_3dd2984d-59f1-4f9d-9d18-3f809089dee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_3dd2984d-59f1-4f9d-9d18-3f809089dee0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3dd2984d-59f1-4f9d-9d18-3f809089dee0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_3dd2984d-59f1-4f9d-9d18-3f809089dee0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3dd2984d-59f1-4f9d-9d18-3f809089dee0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9ecdd0b2-37e6-4453-a305-f97476a39d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_3dd2984d-59f1-4f9d-9d18-3f809089dee0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9ecdd0b2-37e6-4453-a305-f97476a39d36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyConvertibleNotesMember_3eb5f924-106e-444d-9c9b-78bf5b107d20" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9ecdd0b2-37e6-4453-a305-f97476a39d36" xlink:to="loc_ibrx_RelatedPartyConvertibleNotesMember_3eb5f924-106e-444d-9c9b-78bf5b107d20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ContingentConsiderationMember_477c64f5-b424-4b7a-bd5d-1aa0324c442b" xlink:href="ibrx-20230331.xsd#ibrx_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9ecdd0b2-37e6-4453-a305-f97476a39d36" xlink:to="loc_ibrx_ContingentConsiderationMember_477c64f5-b424-4b7a-bd5d-1aa0324c442b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_eeb2f5fe-87bc-4ae2-8c26-e5797c44950a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9ecdd0b2-37e6-4453-a305-f97476a39d36" xlink:to="loc_us-gaap_WarrantMember_eeb2f5fe-87bc-4ae2-8c26-e5797c44950a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_b47540c9-2a02-42a3-bfd7-9b262b079bff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_b47540c9-2a02-42a3-bfd7-9b262b079bff" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_b47540c9-2a02-42a3-bfd7-9b262b079bff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b47540c9-2a02-42a3-bfd7-9b262b079bff" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_b47540c9-2a02-42a3-bfd7-9b262b079bff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_e1565e93-da2a-43f9-9a30-7f8d5095aff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b47540c9-2a02-42a3-bfd7-9b262b079bff" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_e1565e93-da2a-43f9-9a30-7f8d5095aff7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_f9d8e199-6270-4ca9-ad40-a54ca1999382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_e1565e93-da2a-43f9-9a30-7f8d5095aff7" xlink:to="loc_us-gaap_WarrantMember_f9d8e199-6270-4ca9-ad40-a54ca1999382" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_December2022WarrantsMember_46c7869c-57df-4c42-86d3-74753e58e445" xlink:href="ibrx-20230331.xsd#ibrx_December2022WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_e1565e93-da2a-43f9-9a30-7f8d5095aff7" xlink:to="loc_ibrx_December2022WarrantsMember_46c7869c-57df-4c42-86d3-74753e58e445" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023WarrantsMember_6a0c79b6-3bfe-4d74-bd87-3f187398282a" xlink:href="ibrx-20230331.xsd#ibrx_February2023WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_e1565e93-da2a-43f9-9a30-7f8d5095aff7" xlink:to="loc_ibrx_February2023WarrantsMember_6a0c79b6-3bfe-4d74-bd87-3f187398282a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_3392826d-349f-4e60-9ede-0a1b69838ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_3392826d-349f-4e60-9ede-0a1b69838ff6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_3392826d-349f-4e60-9ede-0a1b69838ff6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3392826d-349f-4e60-9ede-0a1b69838ff6" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_3392826d-349f-4e60-9ede-0a1b69838ff6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d7cb36a1-9e56-4630-aaab-5585fa3160c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3392826d-349f-4e60-9ede-0a1b69838ff6" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d7cb36a1-9e56-4630-aaab-5585fa3160c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MeasurementInputExpectedMarketYieldMember_896e682c-2172-42ab-a465-fff17e5f3e4b" xlink:href="ibrx-20230331.xsd#ibrx_MeasurementInputExpectedMarketYieldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d7cb36a1-9e56-4630-aaab-5585fa3160c0" xlink:to="loc_ibrx_MeasurementInputExpectedMarketYieldMember_896e682c-2172-42ab-a465-fff17e5f3e4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MeasurementInputDiscountPeriodMember_dd329145-2f2a-4e12-88c5-4cc6d5b9c72d" xlink:href="ibrx-20230331.xsd#ibrx_MeasurementInputDiscountPeriodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d7cb36a1-9e56-4630-aaab-5585fa3160c0" xlink:to="loc_ibrx_MeasurementInputDiscountPeriodMember_dd329145-2f2a-4e12-88c5-4cc6d5b9c72d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_1ea7395e-aeb4-467a-b575-9da67c56d66d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d7cb36a1-9e56-4630-aaab-5585fa3160c0" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_1ea7395e-aeb4-467a-b575-9da67c56d66d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember_557bb874-c8ac-4930-a198-e4f8a1f39ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExercisePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d7cb36a1-9e56-4630-aaab-5585fa3160c0" xlink:to="loc_us-gaap_MeasurementInputExercisePriceMember_557bb874-c8ac-4930-a198-e4f8a1f39ecd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_cd84be15-25ca-4973-94ce-e5f84b087b20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d7cb36a1-9e56-4630-aaab-5585fa3160c0" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_cd84be15-25ca-4973-94ce-e5f84b087b20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_12c7d308-7073-492b-a983-752591fd0298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d7cb36a1-9e56-4630-aaab-5585fa3160c0" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_12c7d308-7073-492b-a983-752591fd0298" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_29eff5b9-3550-4350-9003-f7841ed5042c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d7cb36a1-9e56-4630-aaab-5585fa3160c0" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_29eff5b9-3550-4350-9003-f7841ed5042c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_46a99ec4-6823-4408-95b5-9fe59f565d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d7cb36a1-9e56-4630-aaab-5585fa3160c0" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_46a99ec4-6823-4408-95b5-9fe59f565d54" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d18d5520-2c32-4c1e-94b6-15859fb7348c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d18d5520-2c32-4c1e-94b6-15859fb7348c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d18d5520-2c32-4c1e-94b6-15859fb7348c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d18d5520-2c32-4c1e-94b6-15859fb7348c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d18d5520-2c32-4c1e-94b6-15859fb7348c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b8115b4e-8bdc-4f50-85ac-1e6dbac20737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d18d5520-2c32-4c1e-94b6-15859fb7348c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b8115b4e-8bdc-4f50-85ac-1e6dbac20737" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_228bfaf6-59ad-405c-a08a-6b6a189dc35a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b8115b4e-8bdc-4f50-85ac-1e6dbac20737" xlink:to="loc_us-gaap_PrivatePlacementMember_228bfaf6-59ad-405c-a08a-6b6a189dc35a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8609420a-0be9-4b0a-8515-f914d7bae199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8609420a-0be9-4b0a-8515-f914d7bae199" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8609420a-0be9-4b0a-8515-f914d7bae199_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8609420a-0be9-4b0a-8515-f914d7bae199" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8609420a-0be9-4b0a-8515-f914d7bae199_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_76ca0f71-1fea-4d9d-848b-a66f05db3069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8609420a-0be9-4b0a-8515-f914d7bae199" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_76ca0f71-1fea-4d9d-848b-a66f05db3069" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_431a6f6a-e19f-4fea-ad07-e8d420f70b67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_76ca0f71-1fea-4d9d-848b-a66f05db3069" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_431a6f6a-e19f-4fea-ad07-e8d420f70b67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_64741769-8baa-48fb-90da-dad26a4163d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_64741769-8baa-48fb-90da-dad26a4163d4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_64741769-8baa-48fb-90da-dad26a4163d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_64741769-8baa-48fb-90da-dad26a4163d4" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_64741769-8baa-48fb-90da-dad26a4163d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3dd59bd6-2e49-41a9-9930-23c6d1fc1ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_64741769-8baa-48fb-90da-dad26a4163d4" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3dd59bd6-2e49-41a9-9930-23c6d1fc1ff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalIssued33123Member_167432dd-f066-4f4c-b573-5827dba567e5" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalIssued33123Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3dd59bd6-2e49-41a9-9930-23c6d1fc1ff1" xlink:to="loc_ibrx_NantCapitalIssued33123Member_167432dd-f066-4f4c-b573-5827dba567e5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail" xlink:type="extended" id="if6f2d22bbc74450bb32e94e43c462129_CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_435c605d-3cf8-426c-8bf4-b8e027ce1fba" xlink:href="ibrx-20230331.xsd#ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_ed4ef1db-04d1-4574-bdf6-890c670fb563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_435c605d-3cf8-426c-8bf4-b8e027ce1fba" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_ed4ef1db-04d1-4574-bdf6-890c670fb563" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_665b2f6e-a009-48c4-99b4-bf58b0041272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_435c605d-3cf8-426c-8bf4-b8e027ce1fba" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_665b2f6e-a009-48c4-99b4-bf58b0041272" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_538df568-0e95-49f8-953a-eaa5e882db2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_435c605d-3cf8-426c-8bf4-b8e027ce1fba" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_538df568-0e95-49f8-953a-eaa5e882db2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3f5b39ed-56d4-43d5-97c8-f7fa504bfe6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_435c605d-3cf8-426c-8bf4-b8e027ce1fba" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3f5b39ed-56d4-43d5-97c8-f7fa504bfe6f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum_e1d2e868-2d61-48a2-a874-36afe647411b" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_435c605d-3cf8-426c-8bf4-b8e027ce1fba" xlink:to="loc_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum_e1d2e868-2d61-48a2-a874-36afe647411b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_a8c1bc3b-c6a4-4dbf-ba1c-70370bb29575" xlink:href="ibrx-20230331.xsd#ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_435c605d-3cf8-426c-8bf4-b8e027ce1fba" xlink:to="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_a8c1bc3b-c6a4-4dbf-ba1c-70370bb29575" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_576eb7ad-619a-422e-a9b8-dd3a1fda9877" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_a8c1bc3b-c6a4-4dbf-ba1c-70370bb29575" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_576eb7ad-619a-422e-a9b8-dd3a1fda9877" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_576eb7ad-619a-422e-a9b8-dd3a1fda9877_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_576eb7ad-619a-422e-a9b8-dd3a1fda9877" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_576eb7ad-619a-422e-a9b8-dd3a1fda9877_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_4b090e91-65ee-4114-a0ac-71a9f91a7e45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_576eb7ad-619a-422e-a9b8-dd3a1fda9877" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_4b090e91-65ee-4114-a0ac-71a9f91a7e45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AmyrisJointVentureMember_40f356f1-2a58-41ef-9593-b5699d613f78" xlink:href="ibrx-20230331.xsd#ibrx_AmyrisJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_4b090e91-65ee-4114-a0ac-71a9f91a7e45" xlink:to="loc_ibrx_AmyrisJointVentureMember_40f356f1-2a58-41ef-9593-b5699d613f78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a03c1cdd-1a8a-45c4-ba2c-7f32117e1678" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_a8c1bc3b-c6a4-4dbf-ba1c-70370bb29575" xlink:to="loc_dei_LegalEntityAxis_a03c1cdd-1a8a-45c4-ba2c-7f32117e1678" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a03c1cdd-1a8a-45c4-ba2c-7f32117e1678_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_a03c1cdd-1a8a-45c4-ba2c-7f32117e1678" xlink:to="loc_dei_EntityDomain_a03c1cdd-1a8a-45c4-ba2c-7f32117e1678_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b53acee3-106a-4e03-9a08-9ea500398a6d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_a03c1cdd-1a8a-45c4-ba2c-7f32117e1678" xlink:to="loc_dei_EntityDomain_b53acee3-106a-4e03-9a08-9ea500398a6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AmyrisIncMember_6e382764-ab6c-4306-8291-6c843f672c54" xlink:href="ibrx-20230331.xsd#ibrx_AmyrisIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b53acee3-106a-4e03-9a08-9ea500398a6d" xlink:to="loc_ibrx_AmyrisIncMember_6e382764-ab6c-4306-8291-6c843f672c54" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail" xlink:type="extended" id="i449d2a9590ef49afb8ca377604f85cae_CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LicensingAgreementLineItems_a4f6b7b5-2732-4667-8fb7-19a6809e22bf" xlink:href="ibrx-20230331.xsd#ibrx_LicensingAgreementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsPeriodicLicensePayments_be43b876-65ab-4610-9051-9ad27f41e4ae" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsPeriodicLicensePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LicensingAgreementLineItems_a4f6b7b5-2732-4667-8fb7-19a6809e22bf" xlink:to="loc_ibrx_CollaborationAgreementsPeriodicLicensePayments_be43b876-65ab-4610-9051-9ad27f41e4ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment_902ef634-3ad1-4745-a6c1-5bd650323ca8" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LicensingAgreementLineItems_a4f6b7b5-2732-4667-8fb7-19a6809e22bf" xlink:to="loc_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment_902ef634-3ad1-4745-a6c1-5bd650323ca8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsLicenseMaintenanceFees_961feaae-d84f-4749-aee4-05c8143f5af6" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsLicenseMaintenanceFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LicensingAgreementLineItems_a4f6b7b5-2732-4667-8fb7-19a6809e22bf" xlink:to="loc_ibrx_CollaborationAgreementsLicenseMaintenanceFees_961feaae-d84f-4749-aee4-05c8143f5af6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_cce00323-6ec0-4ff1-8e93-cc1933c49bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LicensingAgreementLineItems_a4f6b7b5-2732-4667-8fb7-19a6809e22bf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_cce00323-6ec0-4ff1-8e93-cc1933c49bf9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment_028fc4fc-5076-43f0-a23c-a7a3e8c244e5" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsNonrefundableUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LicensingAgreementLineItems_a4f6b7b5-2732-4667-8fb7-19a6809e22bf" xlink:to="loc_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment_028fc4fc-5076-43f0-a23c-a7a3e8c244e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum_913100ce-20b3-4776-bd7a-46df4cd39b57" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LicensingAgreementLineItems_a4f6b7b5-2732-4667-8fb7-19a6809e22bf" xlink:to="loc_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum_913100ce-20b3-4776-bd7a-46df4cd39b57" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsMilestoneFees_387744ef-2958-47cf-96ed-49332c2a87e9" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsMilestoneFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LicensingAgreementLineItems_a4f6b7b5-2732-4667-8fb7-19a6809e22bf" xlink:to="loc_ibrx_CollaborationAgreementsMilestoneFees_387744ef-2958-47cf-96ed-49332c2a87e9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsTerminationFee_4ebf0da6-da5e-4761-8f6d-aaf648d5d95d" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsTerminationFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LicensingAgreementLineItems_a4f6b7b5-2732-4667-8fb7-19a6809e22bf" xlink:to="loc_ibrx_CollaborationAgreementsTerminationFee_4ebf0da6-da5e-4761-8f6d-aaf648d5d95d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities_ac73a3f4-6830-486a-aa86-e4572d7286d8" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LicensingAgreementLineItems_a4f6b7b5-2732-4667-8fb7-19a6809e22bf" xlink:to="loc_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities_ac73a3f4-6830-486a-aa86-e4572d7286d8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LicensingAgreementTable_61293174-4799-408e-bff9-259486c97108" xlink:href="ibrx-20230331.xsd#ibrx_LicensingAgreementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ibrx_LicensingAgreementLineItems_a4f6b7b5-2732-4667-8fb7-19a6809e22bf" xlink:to="loc_ibrx_LicensingAgreementTable_61293174-4799-408e-bff9-259486c97108" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_40c68ebe-9355-4829-aa6d-b9e307a71752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_LicensingAgreementTable_61293174-4799-408e-bff9-259486c97108" xlink:to="loc_us-gaap_TypeOfArrangementAxis_40c68ebe-9355-4829-aa6d-b9e307a71752" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40c68ebe-9355-4829-aa6d-b9e307a71752_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_40c68ebe-9355-4829-aa6d-b9e307a71752" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40c68ebe-9355-4829-aa6d-b9e307a71752_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8799dbf9-0a10-48fc-9636-305dd452d5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_40c68ebe-9355-4829-aa6d-b9e307a71752" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8799dbf9-0a10-48fc-9636-305dd452d5c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember_6df6f51a-7381-44fa-b763-1f23a6bd615e" xlink:href="ibrx-20230331.xsd#ibrx_A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8799dbf9-0a10-48fc-9636-305dd452d5c7" xlink:to="loc_ibrx_A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember_6df6f51a-7381-44fa-b763-1f23a6bd615e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccessToAdvancedHealthInstituteAAHIMember_2829f80e-518a-4bee-923c-3c3fb9316ccc" xlink:href="ibrx-20230331.xsd#ibrx_AccessToAdvancedHealthInstituteAAHIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8799dbf9-0a10-48fc-9636-305dd452d5c7" xlink:to="loc_ibrx_AccessToAdvancedHealthInstituteAAHIMember_2829f80e-518a-4bee-923c-3c3fb9316ccc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4788c787-b9b1-45c8-b0b3-e8fcc365fbab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_LicensingAgreementTable_61293174-4799-408e-bff9-259486c97108" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4788c787-b9b1-45c8-b0b3-e8fcc365fbab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4788c787-b9b1-45c8-b0b3-e8fcc365fbab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4788c787-b9b1-45c8-b0b3-e8fcc365fbab" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4788c787-b9b1-45c8-b0b3-e8fcc365fbab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_be094496-78f5-4df8-bfde-5847afdef7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4788c787-b9b1-45c8-b0b3-e8fcc365fbab" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_be094496-78f5-4df8-bfde-5847afdef7b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_07476392-38e0-48db-9cd9-af13468b2d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_be094496-78f5-4df8-bfde-5847afdef7b0" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_07476392-38e0-48db-9cd9-af13468b2d49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SponsoredResearchAgreementMember_198137ee-a97b-4fea-bb60-412668c789ca" xlink:href="ibrx-20230331.xsd#ibrx_SponsoredResearchAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_be094496-78f5-4df8-bfde-5847afdef7b0" xlink:to="loc_ibrx_SponsoredResearchAgreementMember_198137ee-a97b-4fea-bb60-412668c789ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4c190fe8-969c-4cb7-ac82-d6a686146270" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_LicensingAgreementTable_61293174-4799-408e-bff9-259486c97108" xlink:to="loc_srt_RangeAxis_4c190fe8-969c-4cb7-ac82-d6a686146270" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4c190fe8-969c-4cb7-ac82-d6a686146270_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4c190fe8-969c-4cb7-ac82-d6a686146270" xlink:to="loc_srt_RangeMember_4c190fe8-969c-4cb7-ac82-d6a686146270_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2f233da1-87f9-4597-a45e-4da20bf56c80" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4c190fe8-969c-4cb7-ac82-d6a686146270" xlink:to="loc_srt_RangeMember_2f233da1-87f9-4597-a45e-4da20bf56c80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_887617ba-143a-4d46-8551-f5ba1aa01d20" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2f233da1-87f9-4597-a45e-4da20bf56c80" xlink:to="loc_srt_MinimumMember_887617ba-143a-4d46-8551-f5ba1aa01d20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis_415de4cd-e206-4829-9dad-9c490d8e4526" xlink:href="ibrx-20230331.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_LicensingAgreementTable_61293174-4799-408e-bff9-259486c97108" xlink:to="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis_415de4cd-e206-4829-9dad-9c490d8e4526" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_415de4cd-e206-4829-9dad-9c490d8e4526_default" xlink:href="ibrx-20230331.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis_415de4cd-e206-4829-9dad-9c490d8e4526" xlink:to="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_415de4cd-e206-4829-9dad-9c490d8e4526_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_c48c189b-40c0-4779-8112-8939761c04e5" xlink:href="ibrx-20230331.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis_415de4cd-e206-4829-9dad-9c490d8e4526" xlink:to="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_c48c189b-40c0-4779-8112-8939761c04e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember_6397b137-8793-469c-a881-730f296f085c" xlink:href="ibrx-20230331.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_c48c189b-40c0-4779-8112-8939761c04e5" xlink:to="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember_6397b137-8793-469c-a881-730f296f085c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember_d824bc6b-34e5-41d9-82a3-8d493e0b9357" xlink:href="ibrx-20230331.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_c48c189b-40c0-4779-8112-8939761c04e5" xlink:to="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember_d824bc6b-34e5-41d9-82a3-8d493e0b9357" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails" xlink:type="extended" id="ia1f5d7326a1f421a827e2e6063dae0d7_CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_d7ecb65e-34f5-4acf-899f-62997f5ff1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_e1167ed7-1549-47b3-ba8f-ed1d79d259de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_d7ecb65e-34f5-4acf-899f-62997f5ff1cc" xlink:to="loc_us-gaap_ConstructionInProgressGross_e1167ed7-1549-47b3-ba8f-ed1d79d259de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_0aba3321-7cd9-4e91-9983-7d855752cf4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_d7ecb65e-34f5-4acf-899f-62997f5ff1cc" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_0aba3321-7cd9-4e91-9983-7d855752cf4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_597823bd-d2b1-485d-9a7d-108023f967f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_d7ecb65e-34f5-4acf-899f-62997f5ff1cc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_597823bd-d2b1-485d-9a7d-108023f967f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_5c6499f4-d802-48cb-b62f-036e6651c029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_d7ecb65e-34f5-4acf-899f-62997f5ff1cc" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_5c6499f4-d802-48cb-b62f-036e6651c029" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_96cd70cd-d9dc-40cd-a40a-fbba293fd3e3" xlink:href="ibrx-20230331.xsd#ibrx_AssetAcquisitionFairValueOfAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_d7ecb65e-34f5-4acf-899f-62997f5ff1cc" xlink:to="loc_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_96cd70cd-d9dc-40cd-a40a-fbba293fd3e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_afa6128a-bd3e-489f-b4f5-09cf25d2451d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_d7ecb65e-34f5-4acf-899f-62997f5ff1cc" xlink:to="loc_us-gaap_AssetAcquisitionTable_afa6128a-bd3e-489f-b4f5-09cf25d2451d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_89b2b414-8a77-4dd2-89bc-b512b326efd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_afa6128a-bd3e-489f-b4f5-09cf25d2451d" xlink:to="loc_us-gaap_AssetAcquisitionAxis_89b2b414-8a77-4dd2-89bc-b512b326efd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_89b2b414-8a77-4dd2-89bc-b512b326efd3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_89b2b414-8a77-4dd2-89bc-b512b326efd3" xlink:to="loc_us-gaap_AssetAcquisitionDomain_89b2b414-8a77-4dd2-89bc-b512b326efd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_4a01c7cf-556b-40bf-8599-6186cc847ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_89b2b414-8a77-4dd2-89bc-b512b326efd3" xlink:to="loc_us-gaap_AssetAcquisitionDomain_4a01c7cf-556b-40bf-8599-6186cc847ea2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DunkirkFacilityMember_d000ba71-ed8b-41a1-ad9e-b1204c87d94f" xlink:href="ibrx-20230331.xsd#ibrx_DunkirkFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4a01c7cf-556b-40bf-8599-6186cc847ea2" xlink:to="loc_ibrx_DunkirkFacilityMember_d000ba71-ed8b-41a1-ad9e-b1204c87d94f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails" xlink:type="extended" id="ibd8e7453a96f45f5938790a887abf6f1_CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfSquareFootOfFacilityLeased_760bcdf1-e40c-4051-ab26-9d34e4f4dffb" xlink:href="ibrx-20230331.xsd#ibrx_NumberOfSquareFootOfFacilityLeased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_ibrx_NumberOfSquareFootOfFacilityLeased_760bcdf1-e40c-4051-ab26-9d34e4f4dffb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_156ee1a6-5718-4feb-9a69-1f5cb5dbe559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_156ee1a6-5718-4feb-9a69-1f5cb5dbe559" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_2120c28f-d527-4276-a51c-23691fd9bbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_2120c28f-d527-4276-a51c-23691fd9bbe4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_7779afd5-75f2-470d-b32d-c4fc30c97515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_7779afd5-75f2-470d-b32d-c4fc30c97515" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseOperatingLeaseAnnualLeasePayment_fb8663ef-4dd5-4b5d-a1df-f81f44363b2b" xlink:href="ibrx-20230331.xsd#ibrx_LeaseOperatingLeaseAnnualLeasePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_ibrx_LeaseOperatingLeaseAnnualLeasePayment_fb8663ef-4dd5-4b5d-a1df-f81f44363b2b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_a566195a-8e53-43f7-a7de-075d7d6c19e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_a566195a-8e53-43f7-a7de-075d7d6c19e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b77ed282-9b65-42c8-aded-6de32388a6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b77ed282-9b65-42c8-aded-6de32388a6e5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm_ab244584-d073-4047-8479-bdd247d5a917" xlink:href="ibrx-20230331.xsd#ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm_ab244584-d073-4047-8479-bdd247d5a917" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm_8ce5a8e9-ffa8-49b8-8acb-2619d741d8b9" xlink:href="ibrx-20230331.xsd#ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm_8ce5a8e9-ffa8-49b8-8acb-2619d741d8b9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears_f8d5959d-4956-49ac-b6ca-f591e392e883" xlink:href="ibrx-20230331.xsd#ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears_f8d5959d-4956-49ac-b6ca-f591e392e883" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears_84648630-ecdb-4edf-8bd4-d6590d05f446" xlink:href="ibrx-20230331.xsd#ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears_84648630-ecdb-4edf-8bd4-d6590d05f446" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestGovernmentFundingReceivable_39251af8-2158-4e5a-b818-f491fcf6d007" xlink:href="ibrx-20230331.xsd#ibrx_LeaseholdInterestGovernmentFundingReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_ibrx_LeaseholdInterestGovernmentFundingReceivable_39251af8-2158-4e5a-b818-f491fcf6d007" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_41c0468b-737b-4e5f-91af-2bf693a72912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_us-gaap_AssetAcquisitionTable_41c0468b-737b-4e5f-91af-2bf693a72912" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_f0db81ef-93ca-43a5-b080-4452a0d7e43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_41c0468b-737b-4e5f-91af-2bf693a72912" xlink:to="loc_us-gaap_AssetAcquisitionAxis_f0db81ef-93ca-43a5-b080-4452a0d7e43d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_f0db81ef-93ca-43a5-b080-4452a0d7e43d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_f0db81ef-93ca-43a5-b080-4452a0d7e43d" xlink:to="loc_us-gaap_AssetAcquisitionDomain_f0db81ef-93ca-43a5-b080-4452a0d7e43d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_aa531de3-d66e-4796-b142-bad0ec95b6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_f0db81ef-93ca-43a5-b080-4452a0d7e43d" xlink:to="loc_us-gaap_AssetAcquisitionDomain_aa531de3-d66e-4796-b142-bad0ec95b6ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DunkirkFacilityMember_35070e62-93fc-42d8-b31c-35e93cc14855" xlink:href="ibrx-20230331.xsd#ibrx_DunkirkFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_aa531de3-d66e-4796-b142-bad0ec95b6ad" xlink:to="loc_ibrx_DunkirkFacilityMember_35070e62-93fc-42d8-b31c-35e93cc14855" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_afd26b0e-6538-4125-abd4-dac645626965" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_41c0468b-737b-4e5f-91af-2bf693a72912" xlink:to="loc_srt_CounterpartyNameAxis_afd26b0e-6538-4125-abd4-dac645626965" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_afd26b0e-6538-4125-abd4-dac645626965_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_afd26b0e-6538-4125-abd4-dac645626965" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_afd26b0e-6538-4125-abd4-dac645626965_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8715796d-c255-4a54-b662-5bc598d73a73" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_afd26b0e-6538-4125-abd4-dac645626965" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8715796d-c255-4a54-b662-5bc598d73a73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StateOfNewYorkMember_489ac745-7965-4e6e-8948-994f7c4d6d00" xlink:href="ibrx-20230331.xsd#ibrx_StateOfNewYorkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8715796d-c255-4a54-b662-5bc598d73a73" xlink:to="loc_ibrx_StateOfNewYorkMember_489ac745-7965-4e6e-8948-994f7c4d6d00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_49955bc6-c525-4699-bec9-0ec323fc0dfb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_41c0468b-737b-4e5f-91af-2bf693a72912" xlink:to="loc_srt_RangeAxis_49955bc6-c525-4699-bec9-0ec323fc0dfb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_49955bc6-c525-4699-bec9-0ec323fc0dfb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_49955bc6-c525-4699-bec9-0ec323fc0dfb" xlink:to="loc_srt_RangeMember_49955bc6-c525-4699-bec9-0ec323fc0dfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_98e9fcef-f0a3-4fe4-ba7c-42edd0d63b26" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_49955bc6-c525-4699-bec9-0ec323fc0dfb" xlink:to="loc_srt_RangeMember_98e9fcef-f0a3-4fe4-ba7c-42edd0d63b26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9c00dff0-fdd9-4b89-85bc-d364cf551ccf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_98e9fcef-f0a3-4fe4-ba7c-42edd0d63b26" xlink:to="loc_srt_MinimumMember_9c00dff0-fdd9-4b89-85bc-d364cf551ccf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9c62aac2-8922-4870-a5ca-811a4c2f5e6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_98e9fcef-f0a3-4fe4-ba7c-42edd0d63b26" xlink:to="loc_srt_MaximumMember_9c62aac2-8922-4870-a5ca-811a4c2f5e6d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail" xlink:type="extended" id="i6e8302cc749840ef949ac70827b6cb90_CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f5a323e1-6b30-4792-835d-e605f7642abb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PercentageOfWhollyOwnedSubsidiary_feed7ec9-fc4b-4b60-8941-6fa8b6435337" xlink:href="ibrx-20230331.xsd#ibrx_PercentageOfWhollyOwnedSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f5a323e1-6b30-4792-835d-e605f7642abb" xlink:to="loc_ibrx_PercentageOfWhollyOwnedSubsidiary_feed7ec9-fc4b-4b60-8941-6fa8b6435337" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_188a919b-1208-4eae-afb8-88afe5ec5655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f5a323e1-6b30-4792-835d-e605f7642abb" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_188a919b-1208-4eae-afb8-88afe5ec5655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned_a8743da5-04fb-4682-a5f1-dc29ea9c3d95" xlink:href="ibrx-20230331.xsd#ibrx_BusinessCombinationContingentConsiderationArrangementsEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f5a323e1-6b30-4792-835d-e605f7642abb" xlink:to="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned_a8743da5-04fb-4682-a5f1-dc29ea9c3d95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements_b5100798-cf27-440c-b9e4-1773765dd020" xlink:href="ibrx-20230331.xsd#ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f5a323e1-6b30-4792-835d-e605f7642abb" xlink:to="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements_b5100798-cf27-440c-b9e4-1773765dd020" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_42025c8e-cd61-4f36-98a1-60a4c32dd0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f5a323e1-6b30-4792-835d-e605f7642abb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_42025c8e-cd61-4f36-98a1-60a4c32dd0f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ContingentValueRightsObligations_bc30abbe-ba18-426a-bab0-632de36176f9" xlink:href="ibrx-20230331.xsd#ibrx_ContingentValueRightsObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f5a323e1-6b30-4792-835d-e605f7642abb" xlink:to="loc_ibrx_ContingentValueRightsObligations_bc30abbe-ba18-426a-bab0-632de36176f9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation_5d203632-50a9-4231-982b-f09dc25d207a" xlink:href="ibrx-20230331.xsd#ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f5a323e1-6b30-4792-835d-e605f7642abb" xlink:to="loc_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation_5d203632-50a9-4231-982b-f09dc25d207a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6beb3f9d-e21b-46f9-a1c1-2cd2f1b8bce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f5a323e1-6b30-4792-835d-e605f7642abb" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6beb3f9d-e21b-46f9-a1c1-2cd2f1b8bce9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6d2bb22c-2f5f-43ab-b2ee-fdc16ed5d53a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6beb3f9d-e21b-46f9-a1c1-2cd2f1b8bce9" xlink:to="loc_dei_LegalEntityAxis_6d2bb22c-2f5f-43ab-b2ee-fdc16ed5d53a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6d2bb22c-2f5f-43ab-b2ee-fdc16ed5d53a_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_6d2bb22c-2f5f-43ab-b2ee-fdc16ed5d53a" xlink:to="loc_dei_EntityDomain_6d2bb22c-2f5f-43ab-b2ee-fdc16ed5d53a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f42a4944-a893-4e73-9c38-7252feb2f034" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_6d2bb22c-2f5f-43ab-b2ee-fdc16ed5d53a" xlink:to="loc_dei_EntityDomain_f42a4944-a893-4e73-9c38-7252feb2f034" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_VivaBioCellMember_e636b312-23f3-43c0-b6b3-5e5c1a3af0af" xlink:href="ibrx-20230331.xsd#ibrx_VivaBioCellMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_f42a4944-a893-4e73-9c38-7252feb2f034" xlink:to="loc_ibrx_VivaBioCellMember_e636b312-23f3-43c0-b6b3-5e5c1a3af0af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bf1916a1-0e30-4c56-8f40-fa457628af4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6beb3f9d-e21b-46f9-a1c1-2cd2f1b8bce9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bf1916a1-0e30-4c56-8f40-fa457628af4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bf1916a1-0e30-4c56-8f40-fa457628af4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bf1916a1-0e30-4c56-8f40-fa457628af4e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bf1916a1-0e30-4c56-8f40-fa457628af4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b4c54e98-2c29-4b48-94a8-de2b180b897f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bf1916a1-0e30-4c56-8f40-fa457628af4e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b4c54e98-2c29-4b48-94a8-de2b180b897f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AltorBioScienceCorporationMember_0072b3fd-4f9c-4a34-b91b-a123259abf46" xlink:href="ibrx-20230331.xsd#ibrx_AltorBioScienceCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b4c54e98-2c29-4b48-94a8-de2b180b897f" xlink:to="loc_ibrx_AltorBioScienceCorporationMember_0072b3fd-4f9c-4a34-b91b-a123259abf46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_8ecdc7c9-2a7f-4186-9e54-0c7fd4c50b14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6beb3f9d-e21b-46f9-a1c1-2cd2f1b8bce9" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_8ecdc7c9-2a7f-4186-9e54-0c7fd4c50b14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_8ecdc7c9-2a7f-4186-9e54-0c7fd4c50b14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_8ecdc7c9-2a7f-4186-9e54-0c7fd4c50b14" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_8ecdc7c9-2a7f-4186-9e54-0c7fd4c50b14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_05fbc5ba-9c21-4d0a-9082-1d448efa6299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_8ecdc7c9-2a7f-4186-9e54-0c7fd4c50b14" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_05fbc5ba-9c21-4d0a-9082-1d448efa6299" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ContingentValueRightsObligationRegulatoryMilestoneMember_47eece05-639c-495a-8b27-898f24945e12" xlink:href="ibrx-20230331.xsd#ibrx_ContingentValueRightsObligationRegulatoryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_05fbc5ba-9c21-4d0a-9082-1d448efa6299" xlink:to="loc_ibrx_ContingentValueRightsObligationRegulatoryMilestoneMember_47eece05-639c-495a-8b27-898f24945e12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ContingentValueRightsObligationSalesMilestoneMember_e9f4dc87-a5eb-43b1-8df1-a7fd746bc72f" xlink:href="ibrx-20230331.xsd#ibrx_ContingentValueRightsObligationSalesMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_05fbc5ba-9c21-4d0a-9082-1d448efa6299" xlink:to="loc_ibrx_ContingentValueRightsObligationSalesMilestoneMember_e9f4dc87-a5eb-43b1-8df1-a7fd746bc72f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a2d26d42-4d6d-40ec-99ef-b858646f62b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6beb3f9d-e21b-46f9-a1c1-2cd2f1b8bce9" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a2d26d42-4d6d-40ec-99ef-b858646f62b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a2d26d42-4d6d-40ec-99ef-b858646f62b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a2d26d42-4d6d-40ec-99ef-b858646f62b3" xlink:to="loc_us-gaap_RelatedPartyDomain_a2d26d42-4d6d-40ec-99ef-b858646f62b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1de7e2a8-50de-4522-8421-684031519851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a2d26d42-4d6d-40ec-99ef-b858646f62b3" xlink:to="loc_us-gaap_RelatedPartyDomain_1de7e2a8-50de-4522-8421-684031519851" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DrSoonShiongAndRelatedPartyMember_a880ec40-c447-43ff-a803-b817ee489b15" xlink:href="ibrx-20230331.xsd#ibrx_DrSoonShiongAndRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1de7e2a8-50de-4522-8421-684031519851" xlink:to="loc_ibrx_DrSoonShiongAndRelatedPartyMember_a880ec40-c447-43ff-a803-b817ee489b15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AltorStockholdersMember_bd3427c9-d267-4f09-8433-93ba29d56255" xlink:href="ibrx-20230331.xsd#ibrx_AltorStockholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1de7e2a8-50de-4522-8421-684031519851" xlink:to="loc_ibrx_AltorStockholdersMember_bd3427c9-d267-4f09-8433-93ba29d56255" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CommitmentandContingenciesLitigationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail" xlink:type="extended" id="i68b68eb5b76d492bac46b44bc08aa295_CommitmentandContingenciesLitigationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationLineItems_4d887acc-26b1-4e51-9de2-f2c7a57632f0" xlink:href="ibrx-20230331.xsd#ibrx_LitigationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfDissentingShares_859c11b7-0803-4b88-8baf-70d9f1473690" xlink:href="ibrx-20230331.xsd#ibrx_NumberOfDissentingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LitigationLineItems_4d887acc-26b1-4e51-9de2-f2c7a57632f0" xlink:to="loc_ibrx_NumberOfDissentingShares_859c11b7-0803-4b88-8baf-70d9f1473690" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationSettlementNumberOfSharesToBeIssued_c3a75250-8388-4b51-bca9-8385d35dc7a1" xlink:href="ibrx-20230331.xsd#ibrx_LitigationSettlementNumberOfSharesToBeIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LitigationLineItems_4d887acc-26b1-4e51-9de2-f2c7a57632f0" xlink:to="loc_ibrx_LitigationSettlementNumberOfSharesToBeIssued_c3a75250-8388-4b51-bca9-8385d35dc7a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares_fefe343b-d4f6-4cbd-b7f0-40b5c8cf9fe5" xlink:href="ibrx-20230331.xsd#ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LitigationLineItems_4d887acc-26b1-4e51-9de2-f2c7a57632f0" xlink:to="loc_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares_fefe343b-d4f6-4cbd-b7f0-40b5c8cf9fe5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_58c5ff92-a616-48e3-88ac-782c1d3b8d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LitigationLineItems_4d887acc-26b1-4e51-9de2-f2c7a57632f0" xlink:to="loc_us-gaap_SharesIssued_58c5ff92-a616-48e3-88ac-782c1d3b8d11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_a40e8f24-dcf8-4229-9567-8a981c183b08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LitigationLineItems_4d887acc-26b1-4e51-9de2-f2c7a57632f0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_a40e8f24-dcf8-4229-9567-8a981c183b08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_68f36e0e-2e1a-4bdf-bc8b-d9cb453f0b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LitigationLineItems_4d887acc-26b1-4e51-9de2-f2c7a57632f0" xlink:to="loc_us-gaap_LitigationReserve_68f36e0e-2e1a-4bdf-bc8b-d9cb453f0b35" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_949c148f-cb8b-4ba4-8b77-18f63f35032a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LitigationLineItems_4d887acc-26b1-4e51-9de2-f2c7a57632f0" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_949c148f-cb8b-4ba4-8b77-18f63f35032a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationSettlementInterestPercent_f798890d-ccd3-4edc-a328-1fad9d3884b2" xlink:href="ibrx-20230331.xsd#ibrx_LitigationSettlementInterestPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LitigationLineItems_4d887acc-26b1-4e51-9de2-f2c7a57632f0" xlink:to="loc_ibrx_LitigationSettlementInterestPercent_f798890d-ccd3-4edc-a328-1fad9d3884b2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_6a804b3a-64a6-49ca-8e2b-09b85108e292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LitigationLineItems_4d887acc-26b1-4e51-9de2-f2c7a57632f0" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_6a804b3a-64a6-49ca-8e2b-09b85108e292" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationTable_3b0f0b33-76d9-4638-83b3-10a85ae2f1ff" xlink:href="ibrx-20230331.xsd#ibrx_LitigationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ibrx_LitigationLineItems_4d887acc-26b1-4e51-9de2-f2c7a57632f0" xlink:to="loc_ibrx_LitigationTable_3b0f0b33-76d9-4638-83b3-10a85ae2f1ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_f974a1ab-22e9-46e5-ba62-1f62b41f0e8b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_LitigationTable_3b0f0b33-76d9-4638-83b3-10a85ae2f1ff" xlink:to="loc_srt_ConsolidatedEntitiesAxis_f974a1ab-22e9-46e5-ba62-1f62b41f0e8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_f974a1ab-22e9-46e5-ba62-1f62b41f0e8b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_f974a1ab-22e9-46e5-ba62-1f62b41f0e8b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_f974a1ab-22e9-46e5-ba62-1f62b41f0e8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_75a8b541-37d5-4074-a4e2-2f9e0081b60c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_f974a1ab-22e9-46e5-ba62-1f62b41f0e8b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_75a8b541-37d5-4074-a4e2-2f9e0081b60c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCellIncMember_aae7c53d-8832-4093-a4af-171ad4cb53f4" xlink:href="ibrx-20230331.xsd#ibrx_NantCellIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_75a8b541-37d5-4074-a4e2-2f9e0081b60c" xlink:to="loc_ibrx_NantCellIncMember_aae7c53d-8832-4093-a4af-171ad4cb53f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NANTibodyLLCMember_d3d99d5f-6ed8-448f-9744-78f6aa89fc58" xlink:href="ibrx-20230331.xsd#ibrx_NANTibodyLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_75a8b541-37d5-4074-a4e2-2f9e0081b60c" xlink:to="loc_ibrx_NANTibodyLLCMember_d3d99d5f-6ed8-448f-9744-78f6aa89fc58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_f8bc24b0-abce-4778-a1ec-0cdc5d50ed75" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_LitigationTable_3b0f0b33-76d9-4638-83b3-10a85ae2f1ff" xlink:to="loc_srt_LitigationCaseAxis_f8bc24b0-abce-4778-a1ec-0cdc5d50ed75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f8bc24b0-abce-4778-a1ec-0cdc5d50ed75_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_f8bc24b0-abce-4778-a1ec-0cdc5d50ed75" xlink:to="loc_srt_LitigationCaseTypeDomain_f8bc24b0-abce-4778-a1ec-0cdc5d50ed75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_8fb65ab4-883d-4b76-a653-9b6e6a9a84e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_f8bc24b0-abce-4778-a1ec-0cdc5d50ed75" xlink:to="loc_srt_LitigationCaseTypeDomain_8fb65ab4-883d-4b76-a653-9b6e6a9a84e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SorrentoTherapeuticsIncLitigationMember_5af9e1a4-13cb-444b-9251-622d2b2845e8" xlink:href="ibrx-20230331.xsd#ibrx_SorrentoTherapeuticsIncLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_8fb65ab4-883d-4b76-a653-9b6e6a9a84e3" xlink:to="loc_ibrx_SorrentoTherapeuticsIncLitigationMember_5af9e1a4-13cb-444b-9251-622d2b2845e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f09667ae-72dc-4f4e-9e03-46439df04440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_LitigationTable_3b0f0b33-76d9-4638-83b3-10a85ae2f1ff" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f09667ae-72dc-4f4e-9e03-46439df04440" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f09667ae-72dc-4f4e-9e03-46439df04440_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f09667ae-72dc-4f4e-9e03-46439df04440" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f09667ae-72dc-4f4e-9e03-46439df04440_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_653f1e10-a3f6-46ca-a0cd-8fe0b2fbaafb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f09667ae-72dc-4f4e-9e03-46439df04440" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_653f1e10-a3f6-46ca-a0cd-8fe0b2fbaafb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AltorBioScienceLLCMember_430a31a9-471f-4e40-8da5-b9950348ecaf" xlink:href="ibrx-20230331.xsd#ibrx_AltorBioScienceLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_653f1e10-a3f6-46ca-a0cd-8fe0b2fbaafb" xlink:to="loc_ibrx_AltorBioScienceLLCMember_430a31a9-471f-4e40-8da5-b9950348ecaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_30ff53c7-2495-4c03-903d-4960d909d1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_LitigationTable_3b0f0b33-76d9-4638-83b3-10a85ae2f1ff" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_30ff53c7-2495-4c03-903d-4960d909d1b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_30ff53c7-2495-4c03-903d-4960d909d1b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_30ff53c7-2495-4c03-903d-4960d909d1b7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_30ff53c7-2495-4c03-903d-4960d909d1b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4baffda0-48ce-481d-b56a-7cb16683e3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_30ff53c7-2495-4c03-903d-4960d909d1b7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4baffda0-48ce-481d-b56a-7cb16683e3bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_9ad982f2-1a71-4c1f-a5c9-02229d10e196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4baffda0-48ce-481d-b56a-7cb16683e3bc" xlink:to="loc_us-gaap_PrivatePlacementMember_9ad982f2-1a71-4c1f-a5c9-02229d10e196" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#LeaseArrangementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail" xlink:type="extended" id="i98fdabebe16b4d3eaf8888030fb76511_LeaseArrangementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_91ea84c1-a6dc-47f2-8aef-d364e9d6986a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_658c32ac-b8e3-4420-99d4-aacda71fc83e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91ea84c1-a6dc-47f2-8aef-d364e9d6986a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_658c32ac-b8e3-4420-99d4-aacda71fc83e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b8ef87de-c938-483f-ac1d-7cf56ba3a9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91ea84c1-a6dc-47f2-8aef-d364e9d6986a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b8ef87de-c938-483f-ac1d-7cf56ba3a9fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms_87372a74-005b-4864-8a71-3053cfd1b741" xlink:href="ibrx-20230331.xsd#ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91ea84c1-a6dc-47f2-8aef-d364e9d6986a" xlink:to="loc_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms_87372a74-005b-4864-8a71-3053cfd1b741" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_94586964-004a-4332-9b26-151266399fea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91ea84c1-a6dc-47f2-8aef-d364e9d6986a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_94586964-004a-4332-9b26-151266399fea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1f72531c-7bd3-408b-990e-9b1558f3924d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_94586964-004a-4332-9b26-151266399fea" xlink:to="loc_srt_RangeAxis_1f72531c-7bd3-408b-990e-9b1558f3924d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1f72531c-7bd3-408b-990e-9b1558f3924d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1f72531c-7bd3-408b-990e-9b1558f3924d" xlink:to="loc_srt_RangeMember_1f72531c-7bd3-408b-990e-9b1558f3924d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_60d1a65b-4b4c-4f74-a14f-c7fb5140e3d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1f72531c-7bd3-408b-990e-9b1558f3924d" xlink:to="loc_srt_RangeMember_60d1a65b-4b4c-4f74-a14f-c7fb5140e3d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cba740a4-9e92-49d4-9a6e-cac11471e7e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_60d1a65b-4b4c-4f74-a14f-c7fb5140e3d7" xlink:to="loc_srt_MinimumMember_cba740a4-9e92-49d4-9a6e-cac11471e7e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e462a74c-1cd1-4603-bd8d-abb8517be92e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_60d1a65b-4b4c-4f74-a14f-c7fb5140e3d7" xlink:to="loc_srt_MaximumMember_e462a74c-1cd1-4603-bd8d-abb8517be92e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails" xlink:type="simple" xlink:href="ibrx-20230331.xsd#RelatedPartyDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails" xlink:type="extended" id="i5edbab8bec794781a42afefadd4f0687_RelatedPartyDebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesPayable_9248bc57-4d68-4a71-9e4a-0fac9b6300d4" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_ibrx_RelatedPartyNotesPayable_9248bc57-4d68-4a71-9e4a-0fac9b6300d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate_5230ade7-7fa0-45c5-82aa-cee0e9eb72f2" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate_5230ade7-7fa0-45c5-82aa-cee0e9eb72f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_8652b398-341b-4487-98b3-dcb6e4facc30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_8652b398-341b-4487-98b3-dcb6e4facc30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_91c251a5-ccad-4a58-8138-17b8c5344bac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_91c251a5-ccad-4a58-8138-17b8c5344bac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_d0a721ab-13ab-4ff5-b577-e710645e2312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_d0a721ab-13ab-4ff5-b577-e710645e2312" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NotesPayableRelatedPartiesPrincipalAndAccruedInterest_db4ce601-6170-4e0f-8e61-bf644adca542" xlink:href="ibrx-20230331.xsd#ibrx_NotesPayableRelatedPartiesPrincipalAndAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_ibrx_NotesPayableRelatedPartiesPrincipalAndAccruedInterest_db4ce601-6170-4e0f-8e61-bf644adca542" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_4a5944f9-7a39-4d6a-a53f-acad0cd34c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_4a5944f9-7a39-4d6a-a53f-acad0cd34c1f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c34f24fe-c61b-40a5-ad29-bc962d74da19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c34f24fe-c61b-40a5-ad29-bc962d74da19" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_6490c887-e685-4eea-aba5-2ace4ea6b7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_6490c887-e685-4eea-aba5-2ace4ea6b7e1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_ebd849b6-9ce1-47f2-ac84-1e30e6ae2893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_us-gaap_InterestPaidNet_ebd849b6-9ce1-47f2-ac84-1e30e6ae2893" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_758a717a-ce1a-4bee-a78d-c0a7eae25474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_758a717a-ce1a-4bee-a78d-c0a7eae25474" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare_76abb171-8d60-4e08-aedf-bc0b99866f9c" xlink:href="ibrx-20230331.xsd#ibrx_OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_ibrx_OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare_76abb171-8d60-4e08-aedf-bc0b99866f9c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d7a9e7e3-fb94-46e1-b8c1-bf69e8f54415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d7a9e7e3-fb94-46e1-b8c1-bf69e8f54415" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d7689694-a1d1-49ad-8428-f1f40bd924b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d7a9e7e3-fb94-46e1-b8c1-bf69e8f54415" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d7689694-a1d1-49ad-8428-f1f40bd924b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d7689694-a1d1-49ad-8428-f1f40bd924b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d7689694-a1d1-49ad-8428-f1f40bd924b5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d7689694-a1d1-49ad-8428-f1f40bd924b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c1369005-34e6-46b0-95bd-df6924f9c047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d7689694-a1d1-49ad-8428-f1f40bd924b5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c1369005-34e6-46b0-95bd-df6924f9c047" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_8b18c396-29f2-4f49-a512-a80a0324f748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c1369005-34e6-46b0-95bd-df6924f9c047" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_8b18c396-29f2-4f49-a512-a80a0324f748" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PromissoryNotesPayableMember_77803e2a-10be-47d8-b538-26853abc485c" xlink:href="ibrx-20230331.xsd#ibrx_PromissoryNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c1369005-34e6-46b0-95bd-df6924f9c047" xlink:to="loc_ibrx_PromissoryNotesPayableMember_77803e2a-10be-47d8-b538-26853abc485c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_c4465903-81ea-4ea0-8c06-d21d05d89d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d7a9e7e3-fb94-46e1-b8c1-bf69e8f54415" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_c4465903-81ea-4ea0-8c06-d21d05d89d9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_c4465903-81ea-4ea0-8c06-d21d05d89d9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c4465903-81ea-4ea0-8c06-d21d05d89d9c" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_c4465903-81ea-4ea0-8c06-d21d05d89d9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2fe50cbb-6793-43a8-a2a2-25ddda01d287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c4465903-81ea-4ea0-8c06-d21d05d89d9c" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2fe50cbb-6793-43a8-a2a2-25ddda01d287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalIssued33123Member_f1258edc-a2b8-48e4-8d05-9873f8e3bab9" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalIssued33123Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2fe50cbb-6793-43a8-a2a2-25ddda01d287" xlink:to="loc_ibrx_NantCapitalIssued33123Member_f1258edc-a2b8-48e4-8d05-9873f8e3bab9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember_5645dcdd-6997-4679-a922-a7bf5822e6ca" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2fe50cbb-6793-43a8-a2a2-25ddda01d287" xlink:to="loc_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember_5645dcdd-6997-4679-a922-a7bf5822e6ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember_810e0214-fab7-4275-afb7-804888e677f5" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2fe50cbb-6793-43a8-a2a2-25ddda01d287" xlink:to="loc_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember_810e0214-fab7-4275-afb7-804888e677f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalTwoMember_8574de97-85a5-4159-81c3-3244629874c1" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2fe50cbb-6793-43a8-a2a2-25ddda01d287" xlink:to="loc_ibrx_NantCapitalTwoMember_8574de97-85a5-4159-81c3-3244629874c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapital3Member_0ab7afdd-cbe7-4220-abea-dd150945193d" xlink:href="ibrx-20230331.xsd#ibrx_NantCapital3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2fe50cbb-6793-43a8-a2a2-25ddda01d287" xlink:to="loc_ibrx_NantCapital3Member_0ab7afdd-cbe7-4220-abea-dd150945193d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapital4Member_3c114244-cee9-44a5-92f6-2d6c43ed2b03" xlink:href="ibrx-20230331.xsd#ibrx_NantCapital4Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2fe50cbb-6793-43a8-a2a2-25ddda01d287" xlink:to="loc_ibrx_NantCapital4Member_3c114244-cee9-44a5-92f6-2d6c43ed2b03" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapital6Member_1a0731be-58c1-4d51-b7fc-896e0870e24d" xlink:href="ibrx-20230331.xsd#ibrx_NantCapital6Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2fe50cbb-6793-43a8-a2a2-25ddda01d287" xlink:to="loc_ibrx_NantCapital6Member_1a0731be-58c1-4d51-b7fc-896e0870e24d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_a675e3a7-fd38-439b-be11-a9cfe6c3fa61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d7a9e7e3-fb94-46e1-b8c1-bf69e8f54415" xlink:to="loc_us-gaap_VariableRateAxis_a675e3a7-fd38-439b-be11-a9cfe6c3fa61" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a675e3a7-fd38-439b-be11-a9cfe6c3fa61_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_a675e3a7-fd38-439b-be11-a9cfe6c3fa61" xlink:to="loc_us-gaap_VariableRateDomain_a675e3a7-fd38-439b-be11-a9cfe6c3fa61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_c2dba134-656d-4543-b605-14eb22f65cac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_a675e3a7-fd38-439b-be11-a9cfe6c3fa61" xlink:to="loc_us-gaap_VariableRateDomain_c2dba134-656d-4543-b605-14eb22f65cac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SecuredOvernightFinancingRateSOFRMember_6917e776-e095-45a5-8e5f-b6dbc024a72e" xlink:href="ibrx-20230331.xsd#ibrx_SecuredOvernightFinancingRateSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_c2dba134-656d-4543-b605-14eb22f65cac" xlink:to="loc_ibrx_SecuredOvernightFinancingRateSOFRMember_6917e776-e095-45a5-8e5f-b6dbc024a72e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_75771e3f-23e9-4e90-9555-0392b9181c1d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d7a9e7e3-fb94-46e1-b8c1-bf69e8f54415" xlink:to="loc_srt_RangeAxis_75771e3f-23e9-4e90-9555-0392b9181c1d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_75771e3f-23e9-4e90-9555-0392b9181c1d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_75771e3f-23e9-4e90-9555-0392b9181c1d" xlink:to="loc_srt_RangeMember_75771e3f-23e9-4e90-9555-0392b9181c1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0834a422-3dc0-4ed0-b0ec-2375fe26cde0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_75771e3f-23e9-4e90-9555-0392b9181c1d" xlink:to="loc_srt_RangeMember_0834a422-3dc0-4ed0-b0ec-2375fe26cde0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ee8cd952-166f-460e-b6b7-dccbade9ae51" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0834a422-3dc0-4ed0-b0ec-2375fe26cde0" xlink:to="loc_srt_MinimumMember_ee8cd952-166f-460e-b6b7-dccbade9ae51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5cbe1608-9004-4b78-b5bf-17b1c156e2ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0834a422-3dc0-4ed0-b0ec-2375fe26cde0" xlink:to="loc_srt_MaximumMember_5cbe1608-9004-4b78-b5bf-17b1c156e2ab" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail" xlink:type="extended" id="i7d8cda0ce0824e77885933b549564312_RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_5c8851e0-9ff6-4a62-aea6-5918acec2bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate_d1085bce-d4f1-498a-b4ff-5655bc4b73a4" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5c8851e0-9ff6-4a62-aea6-5918acec2bbd" xlink:to="loc_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate_d1085bce-d4f1-498a-b4ff-5655bc4b73a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_59515ab9-1cb5-41f4-a27d-77aaadc5fb73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5c8851e0-9ff6-4a62-aea6-5918acec2bbd" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_59515ab9-1cb5-41f4-a27d-77aaadc5fb73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesPayable_da7f5667-6cc3-4cab-9968-baea8a661dfe" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5c8851e0-9ff6-4a62-aea6-5918acec2bbd" xlink:to="loc_ibrx_RelatedPartyNotesPayable_da7f5667-6cc3-4cab-9968-baea8a661dfe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_3154ab90-c429-459d-a56e-628992df775a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5c8851e0-9ff6-4a62-aea6-5918acec2bbd" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_3154ab90-c429-459d-a56e-628992df775a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_0eb8fd2a-e597-41de-bd08-9732ca7959e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5c8851e0-9ff6-4a62-aea6-5918acec2bbd" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_0eb8fd2a-e597-41de-bd08-9732ca7959e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_b1bbc394-beaf-4fc5-8709-15c8a4761253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5c8851e0-9ff6-4a62-aea6-5918acec2bbd" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_b1bbc394-beaf-4fc5-8709-15c8a4761253" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1ba17686-08a3-4772-9eaf-c47313edff48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5c8851e0-9ff6-4a62-aea6-5918acec2bbd" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1ba17686-08a3-4772-9eaf-c47313edff48" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_853a0228-6fa3-42de-89b7-186289e35f67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1ba17686-08a3-4772-9eaf-c47313edff48" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_853a0228-6fa3-42de-89b7-186289e35f67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_853a0228-6fa3-42de-89b7-186289e35f67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_853a0228-6fa3-42de-89b7-186289e35f67" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_853a0228-6fa3-42de-89b7-186289e35f67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_765cd386-4b88-4fec-ab7d-ffad4d37ed2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_853a0228-6fa3-42de-89b7-186289e35f67" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_765cd386-4b88-4fec-ab7d-ffad4d37ed2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapital3Member_9ce0c8e0-6e9c-4c32-974b-b3f54dbacc2d" xlink:href="ibrx-20230331.xsd#ibrx_NantCapital3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_765cd386-4b88-4fec-ab7d-ffad4d37ed2a" xlink:to="loc_ibrx_NantCapital3Member_9ce0c8e0-6e9c-4c32-974b-b3f54dbacc2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalMember_2228dd0f-1590-4f79-8f10-730ad425cdb7" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_765cd386-4b88-4fec-ab7d-ffad4d37ed2a" xlink:to="loc_ibrx_NantCapitalMember_2228dd0f-1590-4f79-8f10-730ad425cdb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalOneMember_e67abdac-0474-408b-983f-aae8cf90e8fd" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_765cd386-4b88-4fec-ab7d-ffad4d37ed2a" xlink:to="loc_ibrx_NantCapitalOneMember_e67abdac-0474-408b-983f-aae8cf90e8fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalTwoMember_f5b3700a-ed1f-4af5-b2d6-a1567e78bccc" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_765cd386-4b88-4fec-ab7d-ffad4d37ed2a" xlink:to="loc_ibrx_NantCapitalTwoMember_f5b3700a-ed1f-4af5-b2d6-a1567e78bccc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalIssued33123Member_d7fb58ac-68d9-42d2-8cb4-6807b6540812" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalIssued33123Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_765cd386-4b88-4fec-ab7d-ffad4d37ed2a" xlink:to="loc_ibrx_NantCapitalIssued33123Member_d7fb58ac-68d9-42d2-8cb4-6807b6540812" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantMobileMember_53c8f4fe-6cfa-4f30-b5da-3553eb883111" xlink:href="ibrx-20230331.xsd#ibrx_NantMobileMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_765cd386-4b88-4fec-ab7d-ffad4d37ed2a" xlink:to="loc_ibrx_NantMobileMember_53c8f4fe-6cfa-4f30-b5da-3553eb883111" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NCSCMember_8c699849-30d8-442c-930f-139de1cff71e" xlink:href="ibrx-20230331.xsd#ibrx_NCSCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_765cd386-4b88-4fec-ab7d-ffad4d37ed2a" xlink:to="loc_ibrx_NCSCMember_8c699849-30d8-442c-930f-139de1cff71e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_a6efa458-d00d-42a5-a3df-7b25186a88ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1ba17686-08a3-4772-9eaf-c47313edff48" xlink:to="loc_us-gaap_VariableRateAxis_a6efa458-d00d-42a5-a3df-7b25186a88ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a6efa458-d00d-42a5-a3df-7b25186a88ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_a6efa458-d00d-42a5-a3df-7b25186a88ac" xlink:to="loc_us-gaap_VariableRateDomain_a6efa458-d00d-42a5-a3df-7b25186a88ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_97cb73ac-a7b3-4f8e-ac72-d144a002bfad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_a6efa458-d00d-42a5-a3df-7b25186a88ac" xlink:to="loc_us-gaap_VariableRateDomain_97cb73ac-a7b3-4f8e-ac72-d144a002bfad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SecuredOvernightFinancingRateSOFRMember_0dd4516a-2099-4933-bbac-215574fafbcb" xlink:href="ibrx-20230331.xsd#ibrx_SecuredOvernightFinancingRateSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_97cb73ac-a7b3-4f8e-ac72-d144a002bfad" xlink:to="loc_ibrx_SecuredOvernightFinancingRateSOFRMember_0dd4516a-2099-4933-bbac-215574fafbcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cbf572ae-1ac1-45f8-ae60-119fec3e2d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1ba17686-08a3-4772-9eaf-c47313edff48" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cbf572ae-1ac1-45f8-ae60-119fec3e2d8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cbf572ae-1ac1-45f8-ae60-119fec3e2d8b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cbf572ae-1ac1-45f8-ae60-119fec3e2d8b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cbf572ae-1ac1-45f8-ae60-119fec3e2d8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e2bb3363-4287-4d65-a9af-33fef4b235ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cbf572ae-1ac1-45f8-ae60-119fec3e2d8b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e2bb3363-4287-4d65-a9af-33fef4b235ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PromissoryNotesPayableMember_a6358df0-3874-4455-a51b-2bdd217280df" xlink:href="ibrx-20230331.xsd#ibrx_PromissoryNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e2bb3363-4287-4d65-a9af-33fef4b235ec" xlink:to="loc_ibrx_PromissoryNotesPayableMember_a6358df0-3874-4455-a51b-2bdd217280df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_468b8ebf-b0eb-40f3-bb0c-aa4e9f6b4b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e2bb3363-4287-4d65-a9af-33fef4b235ec" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_468b8ebf-b0eb-40f3-bb0c-aa4e9f6b4b71" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails" xlink:type="simple" xlink:href="ibrx-20230331.xsd#RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails" xlink:type="extended" id="i07e00e61190b4af6b3dd0c1c48a771cb_RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_b4ad1531-d2b4-4b70-9e33-495f382c151d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_449554a8-5756-4230-8734-25296b9fbe56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b4ad1531-d2b4-4b70-9e33-495f382c151d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_449554a8-5756-4230-8734-25296b9fbe56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_431778fd-ff6e-460f-ba48-872d6d0cd780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b4ad1531-d2b4-4b70-9e33-495f382c151d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_431778fd-ff6e-460f-ba48-872d6d0cd780" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ffaa23a7-98dc-426a-bffb-507d46432f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b4ad1531-d2b4-4b70-9e33-495f382c151d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ffaa23a7-98dc-426a-bffb-507d46432f66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_fe364ba5-d40e-4d2e-85eb-3ed51ebe3569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b4ad1531-d2b4-4b70-9e33-495f382c151d" xlink:to="loc_us-gaap_LongTermDebt_fe364ba5-d40e-4d2e-85eb-3ed51ebe3569" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_a6c1a3be-0532-4ec2-a705-48f656cd1f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b4ad1531-d2b4-4b70-9e33-495f382c151d" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_a6c1a3be-0532-4ec2-a705-48f656cd1f9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6d20e8c8-8ae1-40c5-8b0d-02e2623c0479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b4ad1531-d2b4-4b70-9e33-495f382c151d" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6d20e8c8-8ae1-40c5-8b0d-02e2623c0479" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bdf4217a-1db2-4b23-8299-63c176aac34f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6d20e8c8-8ae1-40c5-8b0d-02e2623c0479" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bdf4217a-1db2-4b23-8299-63c176aac34f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_bdf4217a-1db2-4b23-8299-63c176aac34f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bdf4217a-1db2-4b23-8299-63c176aac34f" xlink:to="loc_us-gaap_RelatedPartyDomain_bdf4217a-1db2-4b23-8299-63c176aac34f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8fde70af-719d-4f88-baac-f784a1f72831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bdf4217a-1db2-4b23-8299-63c176aac34f" xlink:to="loc_us-gaap_RelatedPartyDomain_8fde70af-719d-4f88-baac-f784a1f72831" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_23c3ae0e-da23-45a5-b052-c8673c2952fc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8fde70af-719d-4f88-baac-f784a1f72831" xlink:to="loc_srt_AffiliatedEntityMember_23c3ae0e-da23-45a5-b052-c8673c2952fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2113c886-8c8e-4462-afae-24d9570a6bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6d20e8c8-8ae1-40c5-8b0d-02e2623c0479" xlink:to="loc_us-gaap_DebtInstrumentAxis_2113c886-8c8e-4462-afae-24d9570a6bf1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2113c886-8c8e-4462-afae-24d9570a6bf1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2113c886-8c8e-4462-afae-24d9570a6bf1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2113c886-8c8e-4462-afae-24d9570a6bf1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4e40a424-7054-4b06-99cd-318224c30762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2113c886-8c8e-4462-afae-24d9570a6bf1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4e40a424-7054-4b06-99cd-318224c30762" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesMember_f03ecded-31d5-4976-8580-f7009fe7709a" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4e40a424-7054-4b06-99cd-318224c30762" xlink:to="loc_ibrx_RelatedPartyNotesMember_f03ecded-31d5-4976-8580-f7009fe7709a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesPrincipalMember_a43944ba-1999-4bd8-a241-d23277045d20" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyNotesPrincipalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_RelatedPartyNotesMember_f03ecded-31d5-4976-8580-f7009fe7709a" xlink:to="loc_ibrx_RelatedPartyNotesPrincipalMember_a43944ba-1999-4bd8-a241-d23277045d20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesInterestMember_7fe89de9-d647-4e51-86cd-8de054376589" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyNotesInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_RelatedPartyNotesMember_f03ecded-31d5-4976-8580-f7009fe7709a" xlink:to="loc_ibrx_RelatedPartyNotesInterestMember_7fe89de9-d647-4e51-86cd-8de054376589" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_01527796-cbf6-4a86-a41c-b46e3be3ce0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6d20e8c8-8ae1-40c5-8b0d-02e2623c0479" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_01527796-cbf6-4a86-a41c-b46e3be3ce0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_01527796-cbf6-4a86-a41c-b46e3be3ce0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_01527796-cbf6-4a86-a41c-b46e3be3ce0b" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_01527796-cbf6-4a86-a41c-b46e3be3ce0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_467481fb-c9d3-4335-a0f9-8990543766a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_01527796-cbf6-4a86-a41c-b46e3be3ce0b" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_467481fb-c9d3-4335-a0f9-8990543766a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapital3Member_318b1304-4063-463a-813b-5874cab115c0" xlink:href="ibrx-20230331.xsd#ibrx_NantCapital3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_467481fb-c9d3-4335-a0f9-8990543766a0" xlink:to="loc_ibrx_NantCapital3Member_318b1304-4063-463a-813b-5874cab115c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ff5c6430-f7e3-4c08-97ae-19c8a0fd99d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6d20e8c8-8ae1-40c5-8b0d-02e2623c0479" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ff5c6430-f7e3-4c08-97ae-19c8a0fd99d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ff5c6430-f7e3-4c08-97ae-19c8a0fd99d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ff5c6430-f7e3-4c08-97ae-19c8a0fd99d1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ff5c6430-f7e3-4c08-97ae-19c8a0fd99d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4ac9faf0-94bc-4cfd-9504-dd89bc6853e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ff5c6430-f7e3-4c08-97ae-19c8a0fd99d1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4ac9faf0-94bc-4cfd-9504-dd89bc6853e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_a4ef60db-8d84-4284-a514-39d915650722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4ac9faf0-94bc-4cfd-9504-dd89bc6853e9" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_a4ef60db-8d84-4284-a514-39d915650722" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PromissoryNotesPayableMember_970665de-b51e-46a2-a6b8-3f7f90a2902e" xlink:href="ibrx-20230331.xsd#ibrx_PromissoryNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4ac9faf0-94bc-4cfd-9504-dd89bc6853e9" xlink:to="loc_ibrx_PromissoryNotesPayableMember_970665de-b51e-46a2-a6b8-3f7f90a2902e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofOutstandingBalancesofRelatedPartyAgreementsDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#RelatedPartyAgreementsSummaryofOutstandingBalancesofRelatedPartyAgreementsDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofOutstandingBalancesofRelatedPartyAgreementsDetail" xlink:type="extended" id="ia648dc6a106d4a1497a2d9a368037cd6_RelatedPartyAgreementsSummaryofOutstandingBalancesofRelatedPartyAgreementsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_7c86225f-e385-4e40-a83b-509d6ebe3342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_c185f609-7fd7-48c3-8c53-e4aaee1b6a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7c86225f-e385-4e40-a83b-509d6ebe3342" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_c185f609-7fd7-48c3-8c53-e4aaee1b6a26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_5bb06b72-f6e1-4883-9c28-df775f0ad9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7c86225f-e385-4e40-a83b-509d6ebe3342" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_5bb06b72-f6e1-4883-9c28-df775f0ad9be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b45c27e1-b567-44d1-b958-8a53e6e1f0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7c86225f-e385-4e40-a83b-509d6ebe3342" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b45c27e1-b567-44d1-b958-8a53e6e1f0aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_87d0e673-36b2-49a2-a386-07c0d2bbb0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b45c27e1-b567-44d1-b958-8a53e6e1f0aa" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_87d0e673-36b2-49a2-a386-07c0d2bbb0f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_87d0e673-36b2-49a2-a386-07c0d2bbb0f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_87d0e673-36b2-49a2-a386-07c0d2bbb0f1" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_87d0e673-36b2-49a2-a386-07c0d2bbb0f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_65783059-0110-4317-999d-5ef06a72ade3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_87d0e673-36b2-49a2-a386-07c0d2bbb0f1" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_65783059-0110-4317-999d-5ef06a72ade3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantBioIncMember_049fabe5-3986-446c-8966-0c145068daf8" xlink:href="ibrx-20230331.xsd#ibrx_NantBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_65783059-0110-4317-999d-5ef06a72ade3" xlink:to="loc_ibrx_NantBioIncMember_049fabe5-3986-446c-8966-0c145068daf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BrinkBiologicsIncMember_d0681312-59f2-4998-8c01-bdf21770574a" xlink:href="ibrx-20230331.xsd#ibrx_BrinkBiologicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_65783059-0110-4317-999d-5ef06a72ade3" xlink:to="loc_ibrx_BrinkBiologicsIncMember_d0681312-59f2-4998-8c01-bdf21770574a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DuleyRoadMember_3076799c-2fcd-4c66-bfc8-fbb4851f5a06" xlink:href="ibrx-20230331.xsd#ibrx_DuleyRoadMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_65783059-0110-4317-999d-5ef06a72ade3" xlink:to="loc_ibrx_DuleyRoadMember_3076799c-2fcd-4c66-bfc8-fbb4851f5a06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksMember_0fa26894-449a-45f1-91d8-29ef781678a4" xlink:href="ibrx-20230331.xsd#ibrx_NantWorksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_65783059-0110-4317-999d-5ef06a72ade3" xlink:to="loc_ibrx_NantWorksMember_0fa26894-449a-45f1-91d8-29ef781678a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ImmunoOncologyClinicMember_55e03d51-7852-4b88-aca0-860180c9b407" xlink:href="ibrx-20230331.xsd#ibrx_ImmunoOncologyClinicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_65783059-0110-4317-999d-5ef06a72ade3" xlink:to="loc_ibrx_ImmunoOncologyClinicMember_55e03d51-7852-4b88-aca0-860180c9b407" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_VariousMember_0b7721e1-e53e-4d31-bc95-79a9bae596bc" xlink:href="ibrx-20230331.xsd#ibrx_VariousMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_65783059-0110-4317-999d-5ef06a72ade3" xlink:to="loc_ibrx_VariousMember_0b7721e1-e53e-4d31-bc95-79a9bae596bc" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#RelatedPartyAgreementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail" xlink:type="extended" id="i4436bdfdaf5048cd8a8ed33e1a150e34_RelatedPartyAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f0010f42-cb4d-4b65-8cad-9dc2eb9454ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f0010f42-cb4d-4b65-8cad-9dc2eb9454ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b87f0cf5-6f84-4355-bd80-c709db388315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b87f0cf5-6f84-4355-bd80-c709db388315" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_7a591689-4cba-4e5d-9f18-d56a53bbf027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_7a591689-4cba-4e5d-9f18-d56a53bbf027" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_dbe53e15-c334-48f2-9e21-6b1d29bdc1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_dbe53e15-c334-48f2-9e21-6b1d29bdc1e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfSquareFootOfFacilityLeased_203b0f29-d9d9-4e22-9e41-7f4ff5b7d79e" xlink:href="ibrx-20230331.xsd#ibrx_NumberOfSquareFootOfFacilityLeased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_NumberOfSquareFootOfFacilityLeased_203b0f29-d9d9-4e22-9e41-7f4ff5b7d79e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AnnualPercentageIncreasesToBaseRent_b1da711a-257d-4c46-813f-2befc6cf0d6a" xlink:href="ibrx-20230331.xsd#ibrx_AnnualPercentageIncreasesToBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_AnnualPercentageIncreasesToBaseRent_b1da711a-257d-4c46-813f-2befc6cf0d6a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BaseMonthlyRent_27b12ec8-7df1-48d4-9aaa-e154fa0142ee" xlink:href="ibrx-20230331.xsd#ibrx_BaseMonthlyRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_BaseMonthlyRent_27b12ec8-7df1-48d4-9aaa-e154fa0142ee" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased_d31b0273-7cab-4fec-be28-9c4f4bdbcbae" xlink:href="ibrx-20230331.xsd#ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased_d31b0273-7cab-4fec-be28-9c4f4bdbcbae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_449785f3-6036-454e-9185-e149525eacfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_us-gaap_OperatingLeaseExpense_449785f3-6036-454e-9185-e149525eacfa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_7cf61999-d3e2-4fb1-9e09-fc060c954c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_7cf61999-d3e2-4fb1-9e09-fc060c954c41" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidExpenseWriteDown_90c8d6d1-5e44-45d1-a5f2-8464ef9448b0" xlink:href="ibrx-20230331.xsd#ibrx_PrepaidExpenseWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_PrepaidExpenseWriteDown_90c8d6d1-5e44-45d1-a5f2-8464ef9448b0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SupplyAgreementTermOfContract_484822a4-858f-4446-8860-35f74f6a5cb5" xlink:href="ibrx-20230331.xsd#ibrx_SupplyAgreementTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_SupplyAgreementTermOfContract_484822a4-858f-4446-8860-35f74f6a5cb5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SupplyAgreementPeriodOfExtendedTerm_74db2bcf-787b-4ccb-a563-d24a18e764fc" xlink:href="ibrx-20230331.xsd#ibrx_SupplyAgreementPeriodOfExtendedTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_SupplyAgreementPeriodOfExtendedTerm_74db2bcf-787b-4ccb-a563-d24a18e764fc" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2cff49d6-5f74-4d77-8944-ae9bdc7c2a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2cff49d6-5f74-4d77-8944-ae9bdc7c2a9a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2d3d6c11-b75c-4866-bc24-6c0c06d2ac35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2d3d6c11-b75c-4866-bc24-6c0c06d2ac35" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_859fb1a9-00bc-41f8-ace2-e2cc7208872e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_us-gaap_DueFromRelatedParties_859fb1a9-00bc-41f8-ace2-e2cc7208872e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OptionsToExtendNumberOfTerms_143c94e4-2638-4a3d-b4d7-6bcedffc7a3e" xlink:href="ibrx-20230331.xsd#ibrx_OptionsToExtendNumberOfTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_OptionsToExtendNumberOfTerms_143c94e4-2638-4a3d-b4d7-6bcedffc7a3e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c930b2e3-0519-41cd-bba2-160e9c4b6f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c930b2e3-0519-41cd-bba2-160e9c4b6f04" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PeriodOfExtendedLeaseTerm_693e7e66-494c-4a13-acc8-ce58d34cb68a" xlink:href="ibrx-20230331.xsd#ibrx_PeriodOfExtendedLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_PeriodOfExtendedLeaseTerm_693e7e66-494c-4a13-acc8-ce58d34cb68a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfLeases_79c8cd25-1359-4b23-9ddd-5b16ffaf1771" xlink:href="ibrx-20230331.xsd#ibrx_NumberOfLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_NumberOfLeases_79c8cd25-1359-4b23-9ddd-5b16ffaf1771" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdImprovementPayables_0d5fd741-bed0-4381-8005-67298bb0cd7f" xlink:href="ibrx-20230331.xsd#ibrx_LeaseholdImprovementPayables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_LeaseholdImprovementPayables_0d5fd741-bed0-4381-8005-67298bb0cd7f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseRelatedPayables_d3e9a160-456d-4b8e-bbab-c51cf8fe2829" xlink:href="ibrx-20230331.xsd#ibrx_LeaseRelatedPayables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_LeaseRelatedPayables_d3e9a160-456d-4b8e-bbab-c51cf8fe2829" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RentAbatementPeriod_a09a92d4-13ca-4008-b0c7-5546f2ac0f74" xlink:href="ibrx-20230331.xsd#ibrx_RentAbatementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_RentAbatementPeriod_a09a92d4-13ca-4008-b0c7-5546f2ac0f74" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveFromLessor_17aa5b26-adf2-4060-b56a-15a4f8a78f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncentiveFromLessor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_us-gaap_IncentiveFromLessor_17aa5b26-adf2-4060-b56a-15a4f8a78f27" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BaseMonthlyRentParking_1b6755fb-d0a4-47e0-9c2d-c1a8b41d3c30" xlink:href="ibrx-20230331.xsd#ibrx_BaseMonthlyRentParking"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_BaseMonthlyRentParking_1b6755fb-d0a4-47e0-9c2d-c1a8b41d3c30" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9acfc383-0474-4fef-8906-9307857c33ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9acfc383-0474-4fef-8906-9307857c33ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_d177a4ba-cdb0-4e51-af1d-2ffead5759f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9acfc383-0474-4fef-8906-9307857c33ab" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_d177a4ba-cdb0-4e51-af1d-2ffead5759f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d177a4ba-cdb0-4e51-af1d-2ffead5759f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_d177a4ba-cdb0-4e51-af1d-2ffead5759f8" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d177a4ba-cdb0-4e51-af1d-2ffead5759f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_199b0246-59ea-4401-833d-03b61b7292b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_d177a4ba-cdb0-4e51-af1d-2ffead5759f8" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_199b0246-59ea-4401-833d-03b61b7292b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksMember_69834892-500e-419a-b2d0-c941b146bfec" xlink:href="ibrx-20230331.xsd#ibrx_NantWorksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_199b0246-59ea-4401-833d-03b61b7292b0" xlink:to="loc_ibrx_NantWorksMember_69834892-500e-419a-b2d0-c941b146bfec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ConsiderationForFutureServicesMember_49892b6e-2f8c-4dc9-bdcb-8fee4f3a96e0" xlink:href="ibrx-20230331.xsd#ibrx_ConsiderationForFutureServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_199b0246-59ea-4401-833d-03b61b7292b0" xlink:to="loc_ibrx_ConsiderationForFutureServicesMember_49892b6e-2f8c-4dc9-bdcb-8fee4f3a96e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ImmunoOncologyClinicIncMember_77e6dd2c-9fa3-4918-b014-dd0ab3a748c4" xlink:href="ibrx-20230331.xsd#ibrx_ImmunoOncologyClinicIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_199b0246-59ea-4401-833d-03b61b7292b0" xlink:to="loc_ibrx_ImmunoOncologyClinicIncMember_77e6dd2c-9fa3-4918-b014-dd0ab3a748c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NCSCMember_d16c1825-699d-4866-a2c2-ea1d36d1c72b" xlink:href="ibrx-20230331.xsd#ibrx_NCSCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_199b0246-59ea-4401-833d-03b61b7292b0" xlink:to="loc_ibrx_NCSCMember_d16c1825-699d-4866-a2c2-ea1d36d1c72b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantBioIncMember_44ef746b-741a-48ce-84f7-358a4f65c4f0" xlink:href="ibrx-20230331.xsd#ibrx_NantBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_199b0246-59ea-4401-833d-03b61b7292b0" xlink:to="loc_ibrx_NantBioIncMember_44ef746b-741a-48ce-84f7-358a4f65c4f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SixZeroFiveDougStLLCMember_103404f4-948b-40d7-a156-86b469ef39c2" xlink:href="ibrx-20230331.xsd#ibrx_SixZeroFiveDougStLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_199b0246-59ea-4401-833d-03b61b7292b0" xlink:to="loc_ibrx_SixZeroFiveDougStLLCMember_103404f4-948b-40d7-a156-86b469ef39c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DuleyRoadLLCMember_5507322d-ffa0-4411-9777-ff3d982476de" xlink:href="ibrx-20230331.xsd#ibrx_DuleyRoadLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_199b0246-59ea-4401-833d-03b61b7292b0" xlink:to="loc_ibrx_DuleyRoadLLCMember_5507322d-ffa0-4411-9777-ff3d982476de" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SixZeroFiveNashLLCMember_b3923348-0d2c-4ce5-9f21-ecc4bb93b679" xlink:href="ibrx-20230331.xsd#ibrx_SixZeroFiveNashLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_199b0246-59ea-4401-833d-03b61b7292b0" xlink:to="loc_ibrx_SixZeroFiveNashLLCMember_b3923348-0d2c-4ce5-9f21-ecc4bb93b679" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_efcd961a-da10-4ef9-b748-21506e94cd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9acfc383-0474-4fef-8906-9307857c33ab" xlink:to="loc_us-gaap_TypeOfArrangementAxis_efcd961a-da10-4ef9-b748-21506e94cd7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_efcd961a-da10-4ef9-b748-21506e94cd7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_efcd961a-da10-4ef9-b748-21506e94cd7d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_efcd961a-da10-4ef9-b748-21506e94cd7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9ae6a7e3-30dd-47d3-a498-b0cad4b41b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_efcd961a-da10-4ef9-b748-21506e94cd7d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9ae6a7e3-30dd-47d3-a498-b0cad4b41b52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SharedServicesAgreementMember_0806fa91-9d93-4cf7-84d2-35d550c39c26" xlink:href="ibrx-20230331.xsd#ibrx_SharedServicesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9ae6a7e3-30dd-47d3-a498-b0cad4b41b52" xlink:to="loc_ibrx_SharedServicesAgreementMember_0806fa91-9d93-4cf7-84d2-35d550c39c26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis_49d4d36e-e331-4df0-ba0a-17af68c4d290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9acfc383-0474-4fef-8906-9307857c33ab" xlink:to="loc_us-gaap_TransactionTypeAxis_49d4d36e-e331-4df0-ba0a-17af68c4d290" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_49d4d36e-e331-4df0-ba0a-17af68c4d290_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TransactionTypeAxis_49d4d36e-e331-4df0-ba0a-17af68c4d290" xlink:to="loc_us-gaap_TransactionDomain_49d4d36e-e331-4df0-ba0a-17af68c4d290_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_d460d90a-e179-47d0-b72b-5b3da14e239b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TransactionTypeAxis_49d4d36e-e331-4df0-ba0a-17af68c4d290" xlink:to="loc_us-gaap_TransactionDomain_d460d90a-e179-47d0-b72b-5b3da14e239b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ReimbursementsMember_dd0bad27-d05f-405d-ad26-afd764df7432" xlink:href="ibrx-20230331.xsd#ibrx_ReimbursementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransactionDomain_d460d90a-e179-47d0-b72b-5b3da14e239b" xlink:to="loc_ibrx_ReimbursementsMember_dd0bad27-d05f-405d-ad26-afd764df7432" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_c746485c-3c7b-46bc-89a0-59e64bd8dec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9acfc383-0474-4fef-8906-9307857c33ab" xlink:to="loc_us-gaap_LeaseContractualTermAxis_c746485c-3c7b-46bc-89a0-59e64bd8dec8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_c746485c-3c7b-46bc-89a0-59e64bd8dec8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_c746485c-3c7b-46bc-89a0-59e64bd8dec8" xlink:to="loc_us-gaap_LeaseContractualTermDomain_c746485c-3c7b-46bc-89a0-59e64bd8dec8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_4ccf5145-d54b-4195-81df-22584a748d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_c746485c-3c7b-46bc-89a0-59e64bd8dec8" xlink:to="loc_us-gaap_LeaseContractualTermDomain_4ccf5145-d54b-4195-81df-22584a748d46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SeptemberTwentyNineteenLeaseMember_79a48d23-9265-45db-88b7-ce8345e3d3d6" xlink:href="ibrx-20230331.xsd#ibrx_SeptemberTwentyNineteenLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_4ccf5145-d54b-4195-81df-22584a748d46" xlink:to="loc_ibrx_SeptemberTwentyNineteenLeaseMember_79a48d23-9265-45db-88b7-ce8345e3d3d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_JulyTwentyNineteenLeaseMember_de01775c-e2af-49fd-8325-8390a8b7cbe1" xlink:href="ibrx-20230331.xsd#ibrx_JulyTwentyNineteenLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_4ccf5145-d54b-4195-81df-22584a748d46" xlink:to="loc_ibrx_JulyTwentyNineteenLeaseMember_de01775c-e2af-49fd-8325-8390a8b7cbe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InitialPremisesMember_14230865-d92d-4d74-89b5-85bd74d256d4" xlink:href="ibrx-20230331.xsd#ibrx_InitialPremisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_4ccf5145-d54b-4195-81df-22584a748d46" xlink:to="loc_ibrx_InitialPremisesMember_14230865-d92d-4d74-89b5-85bd74d256d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ExpansionPremisesMember_2b55aa3c-60e4-464c-954a-54e342ed9d10" xlink:href="ibrx-20230331.xsd#ibrx_ExpansionPremisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_4ccf5145-d54b-4195-81df-22584a748d46" xlink:to="loc_ibrx_ExpansionPremisesMember_2b55aa3c-60e4-464c-954a-54e342ed9d10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InitialAndExpansionPremisesMember_c509bf52-e79c-4eda-9584-8391c8403377" xlink:href="ibrx-20230331.xsd#ibrx_InitialAndExpansionPremisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_4ccf5145-d54b-4195-81df-22584a748d46" xlink:to="loc_ibrx_InitialAndExpansionPremisesMember_c509bf52-e79c-4eda-9584-8391c8403377" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b4a5771e-e000-424d-8e09-5b4ce41f9b67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9acfc383-0474-4fef-8906-9307857c33ab" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b4a5771e-e000-424d-8e09-5b4ce41f9b67" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b4a5771e-e000-424d-8e09-5b4ce41f9b67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b4a5771e-e000-424d-8e09-5b4ce41f9b67" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b4a5771e-e000-424d-8e09-5b4ce41f9b67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3e18fb74-60dd-41cd-9dab-e8fc56223336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b4a5771e-e000-424d-8e09-5b4ce41f9b67" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3e18fb74-60dd-41cd-9dab-e8fc56223336" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ac9b9f9b-3cd2-4ac3-893f-b1f0247eaf2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3e18fb74-60dd-41cd-9dab-e8fc56223336" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ac9b9f9b-3cd2-4ac3-893f-b1f0247eaf2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_91dd88c6-65d8-47ac-9a43-31f1da8e3081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9acfc383-0474-4fef-8906-9307857c33ab" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_91dd88c6-65d8-47ac-9a43-31f1da8e3081" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_91dd88c6-65d8-47ac-9a43-31f1da8e3081_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_91dd88c6-65d8-47ac-9a43-31f1da8e3081" xlink:to="loc_us-gaap_RelatedPartyDomain_91dd88c6-65d8-47ac-9a43-31f1da8e3081_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2dcdc57d-ea65-4d7f-ad60-d8d55189e6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_91dd88c6-65d8-47ac-9a43-31f1da8e3081" xlink:to="loc_us-gaap_RelatedPartyDomain_2dcdc57d-ea65-4d7f-ad60-d8d55189e6c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksMember_25e83c5d-4d80-46b2-afea-a8c5560820ec" xlink:href="ibrx-20230331.xsd#ibrx_NantWorksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2dcdc57d-ea65-4d7f-ad60-d8d55189e6c3" xlink:to="loc_ibrx_NantWorksMember_25e83c5d-4d80-46b2-afea-a8c5560820ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ImmunoOncologyClinicIncMember_abea9a94-df03-4479-a269-91ea59460c73" xlink:href="ibrx-20230331.xsd#ibrx_ImmunoOncologyClinicIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2dcdc57d-ea65-4d7f-ad60-d8d55189e6c3" xlink:to="loc_ibrx_ImmunoOncologyClinicIncMember_abea9a94-df03-4479-a269-91ea59460c73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantBioIncMember_9b0fa9b6-2231-4be3-9d0e-71023467ff8b" xlink:href="ibrx-20230331.xsd#ibrx_NantBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2dcdc57d-ea65-4d7f-ad60-d8d55189e6c3" xlink:to="loc_ibrx_NantBioIncMember_9b0fa9b6-2231-4be3-9d0e-71023467ff8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FourTwoZeroNashLLCMember_55117cc1-a3da-4be4-a269-f52c7c306515" xlink:href="ibrx-20230331.xsd#ibrx_FourTwoZeroNashLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2dcdc57d-ea65-4d7f-ad60-d8d55189e6c3" xlink:to="loc_ibrx_FourTwoZeroNashLLCMember_55117cc1-a3da-4be4-a269-f52c7c306515" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A23AlaskaLLCMember_7ff27edd-040c-4bc6-b144-100a79bd229e" xlink:href="ibrx-20230331.xsd#ibrx_A23AlaskaLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2dcdc57d-ea65-4d7f-ad60-d8d55189e6c3" xlink:to="loc_ibrx_A23AlaskaLLCMember_7ff27edd-040c-4bc6-b144-100a79bd229e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_55b5bf94-e7e3-49fa-bfa1-b1f3bc3c43fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9acfc383-0474-4fef-8906-9307857c33ab" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_55b5bf94-e7e3-49fa-bfa1-b1f3bc3c43fd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_55b5bf94-e7e3-49fa-bfa1-b1f3bc3c43fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_55b5bf94-e7e3-49fa-bfa1-b1f3bc3c43fd" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_55b5bf94-e7e3-49fa-bfa1-b1f3bc3c43fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_173a00fc-81cb-483c-a2db-3eea385d9526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_55b5bf94-e7e3-49fa-bfa1-b1f3bc3c43fd" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_173a00fc-81cb-483c-a2db-3eea385d9526" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DueToRelatedPartiesMember_40fa149f-5e66-4da1-9321-2f87153d95f1" xlink:href="ibrx-20230331.xsd#ibrx_DueToRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_173a00fc-81cb-483c-a2db-3eea385d9526" xlink:to="loc_ibrx_DueToRelatedPartiesMember_40fa149f-5e66-4da1-9321-2f87153d95f1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/WarrantLiabilitiesDetails" xlink:type="simple" xlink:href="ibrx-20230331.xsd#WarrantLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/WarrantLiabilitiesDetails" xlink:type="extended" id="i69cbb1892f5c41fd978819d127b13b1d_WarrantLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_c9fb381b-5467-435c-9918-348ce94cdda1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6c7521ca-c268-4f2a-9afc-6780c64f4023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c9fb381b-5467-435c-9918-348ce94cdda1" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6c7521ca-c268-4f2a-9afc-6780c64f4023" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2c174e51-bf53-4ae5-8003-7e42f39baa89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c9fb381b-5467-435c-9918-348ce94cdda1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2c174e51-bf53-4ae5-8003-7e42f39baa89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_73549ca4-7f0c-4bd0-8ad9-3e566ff20b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c9fb381b-5467-435c-9918-348ce94cdda1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_73549ca4-7f0c-4bd0-8ad9-3e566ff20b2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_48c34710-d29c-4c3b-b7d6-25857f7b7252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c9fb381b-5467-435c-9918-348ce94cdda1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_48c34710-d29c-4c3b-b7d6-25857f7b7252" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_61c77dbe-4910-457e-87ea-249ed28a759f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c9fb381b-5467-435c-9918-348ce94cdda1" xlink:to="loc_us-gaap_DeferredOfferingCosts_61c77dbe-4910-457e-87ea-249ed28a759f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TransactionCostsWarrantLiability_02452a2d-7726-4a49-8b7b-bf81a4835289" xlink:href="ibrx-20230331.xsd#ibrx_TransactionCostsWarrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c9fb381b-5467-435c-9918-348ce94cdda1" xlink:to="loc_ibrx_TransactionCostsWarrantLiability_02452a2d-7726-4a49-8b7b-bf81a4835289" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ac4c969f-76ca-43ee-a5a8-b2ab6a42c34d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c9fb381b-5467-435c-9918-348ce94cdda1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ac4c969f-76ca-43ee-a5a8-b2ab6a42c34d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_17e4ddb3-d395-43f6-aab6-fe6b5885777d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c9fb381b-5467-435c-9918-348ce94cdda1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_17e4ddb3-d395-43f6-aab6-fe6b5885777d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_7f3712ff-5f2d-4eb3-857d-e97af74d00b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c9fb381b-5467-435c-9918-348ce94cdda1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_7f3712ff-5f2d-4eb3-857d-e97af74d00b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_86d55279-de84-48c3-87e3-cb0fd65c6fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_7f3712ff-5f2d-4eb3-857d-e97af74d00b8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_86d55279-de84-48c3-87e3-cb0fd65c6fca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86d55279-de84-48c3-87e3-cb0fd65c6fca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_86d55279-de84-48c3-87e3-cb0fd65c6fca" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86d55279-de84-48c3-87e3-cb0fd65c6fca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9a0ba94c-de55-4888-a583-21ac3372a59c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_86d55279-de84-48c3-87e3-cb0fd65c6fca" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9a0ba94c-de55-4888-a583-21ac3372a59c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_880d5047-0f41-44ee-be92-dd6acf82c3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9a0ba94c-de55-4888-a583-21ac3372a59c" xlink:to="loc_us-gaap_PrivatePlacementMember_880d5047-0f41-44ee-be92-dd6acf82c3f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4e439d12-e583-446e-a840-9e47666eafb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_7f3712ff-5f2d-4eb3-857d-e97af74d00b8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4e439d12-e583-446e-a840-9e47666eafb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4e439d12-e583-446e-a840-9e47666eafb8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4e439d12-e583-446e-a840-9e47666eafb8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4e439d12-e583-446e-a840-9e47666eafb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8b232882-595a-4918-988c-eb62758b0434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4e439d12-e583-446e-a840-9e47666eafb8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8b232882-595a-4918-988c-eb62758b0434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_December2022WarrantsMember_d2fb3a2e-ed89-4058-aaf8-554dae256265" xlink:href="ibrx-20230331.xsd#ibrx_December2022WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8b232882-595a-4918-988c-eb62758b0434" xlink:to="loc_ibrx_December2022WarrantsMember_d2fb3a2e-ed89-4058-aaf8-554dae256265" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023WarrantsMember_cee526c4-0de6-45cb-844e-cb138adbc6aa" xlink:href="ibrx-20230331.xsd#ibrx_February2023WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8b232882-595a-4918-988c-eb62758b0434" xlink:to="loc_ibrx_February2023WarrantsMember_cee526c4-0de6-45cb-844e-cb138adbc6aa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#StockholdersDeficitAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail" xlink:type="extended" id="ia4a56cc7f56d4b389ced938a6caf35c5_StockholdersDeficitAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_14b92784-379c-4d63-a793-e333f2723ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_14b92784-379c-4d63-a793-e333f2723ea1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_23f34556-2b35-4d57-9f5c-e193660d4d95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_23f34556-2b35-4d57-9f5c-e193660d4d95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleOfStockMaximumAggregateOfferingPrice_7eaae6a3-05d5-43dc-9fdb-11fe21a6aeb6" xlink:href="ibrx-20230331.xsd#ibrx_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_ibrx_SaleOfStockMaximumAggregateOfferingPrice_7eaae6a3-05d5-43dc-9fdb-11fe21a6aeb6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3aba0d80-fd83-4fc8-9eeb-4c4d5a8ef51c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3aba0d80-fd83-4fc8-9eeb-4c4d5a8ef51c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CommonStockValueAvailableForFutureStockIssuance_6e64cb25-b75a-4508-9e31-a594293bb273" xlink:href="ibrx-20230331.xsd#ibrx_CommonStockValueAvailableForFutureStockIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_ibrx_CommonStockValueAvailableForFutureStockIssuance_6e64cb25-b75a-4508-9e31-a594293bb273" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PercentageOfSalesAgentCommission_bafc39c8-d138-411e-8f9d-d3ba3c80917c" xlink:href="ibrx-20230331.xsd#ibrx_PercentageOfSalesAgentCommission"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_ibrx_PercentageOfSalesAgentCommission_bafc39c8-d138-411e-8f9d-d3ba3c80917c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IssuanceOfCommonStockUnderAtMarketOfferingShares_5b4aa0a3-8179-4028-b9e6-2e081162b8a0" xlink:href="ibrx-20230331.xsd#ibrx_IssuanceOfCommonStockUnderAtMarketOfferingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_ibrx_IssuanceOfCommonStockUnderAtMarketOfferingShares_5b4aa0a3-8179-4028-b9e6-2e081162b8a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_641e4589-ea31-4425-ae34-284df23d2151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_641e4589-ea31-4425-ae34-284df23d2151" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_c5241ca7-e2fe-4b67-84bc-7db9421e28c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_c5241ca7-e2fe-4b67-84bc-7db9421e28c9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5dc4b324-e6da-49ef-b06f-e62d91d3d650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5dc4b324-e6da-49ef-b06f-e62d91d3d650" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_ee9f1fa0-c0eb-42c1-be49-6000e1e74a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_ee9f1fa0-c0eb-42c1-be49-6000e1e74a61" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_3a479a1e-b48b-4ddb-afdd-681e70c327bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_us-gaap_DeferredOfferingCosts_3a479a1e-b48b-4ddb-afdd-681e70c327bb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6cae7d50-b068-4a08-b447-3449d221a11b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_6cae7d50-b068-4a08-b447-3449d221a11b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_549b1faf-e59b-4a67-bd9e-1d4c96aedf5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_549b1faf-e59b-4a67-bd9e-1d4c96aedf5f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_23c0a491-4148-42ed-8d15-aaa1e762e1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_23c0a491-4148-42ed-8d15-aaa1e762e1d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f37f1b61-7571-444b-a96a-1d2e6cf7b66c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_23c0a491-4148-42ed-8d15-aaa1e762e1d7" xlink:to="loc_us-gaap_PlanNameAxis_f37f1b61-7571-444b-a96a-1d2e6cf7b66c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f37f1b61-7571-444b-a96a-1d2e6cf7b66c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_f37f1b61-7571-444b-a96a-1d2e6cf7b66c" xlink:to="loc_us-gaap_PlanNameDomain_f37f1b61-7571-444b-a96a-1d2e6cf7b66c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_05ce1825-5a4b-4307-ae28-e9080ee2af1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_f37f1b61-7571-444b-a96a-1d2e6cf7b66c" xlink:to="loc_us-gaap_PlanNameDomain_05ce1825-5a4b-4307-ae28-e9080ee2af1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TwoThousandFifteenShareRepurchasePlanMember_7bc021cc-ed86-4497-8ebb-95799828160c" xlink:href="ibrx-20230331.xsd#ibrx_TwoThousandFifteenShareRepurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_05ce1825-5a4b-4307-ae28-e9080ee2af1c" xlink:to="loc_ibrx_TwoThousandFifteenShareRepurchasePlanMember_7bc021cc-ed86-4497-8ebb-95799828160c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d521c586-06a8-4349-9d77-5f74fad123e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_23c0a491-4148-42ed-8d15-aaa1e762e1d7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d521c586-06a8-4349-9d77-5f74fad123e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d521c586-06a8-4349-9d77-5f74fad123e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d521c586-06a8-4349-9d77-5f74fad123e5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d521c586-06a8-4349-9d77-5f74fad123e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_035ebc51-eb15-4bdf-9f17-d6881ba21d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d521c586-06a8-4349-9d77-5f74fad123e5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_035ebc51-eb15-4bdf-9f17-d6881ba21d50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AtTheMarketOfferingProgramMember_1cfc2457-b4d0-4d98-ab0c-1bcfc1f18886" xlink:href="ibrx-20230331.xsd#ibrx_AtTheMarketOfferingProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_035ebc51-eb15-4bdf-9f17-d6881ba21d50" xlink:to="loc_ibrx_AtTheMarketOfferingProgramMember_1cfc2457-b4d0-4d98-ab0c-1bcfc1f18886" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_97c765ce-d38b-4c86-a956-63cf3a514984" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_23c0a491-4148-42ed-8d15-aaa1e762e1d7" xlink:to="loc_srt_RangeAxis_97c765ce-d38b-4c86-a956-63cf3a514984" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_97c765ce-d38b-4c86-a956-63cf3a514984_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_97c765ce-d38b-4c86-a956-63cf3a514984" xlink:to="loc_srt_RangeMember_97c765ce-d38b-4c86-a956-63cf3a514984_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_14f0d1d4-09d0-4b94-a3fc-a4c1f46a3bc7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_97c765ce-d38b-4c86-a956-63cf3a514984" xlink:to="loc_srt_RangeMember_14f0d1d4-09d0-4b94-a3fc-a4c1f46a3bc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_49fb69f5-33f2-49ce-9fbd-3c628b0a1a2c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_14f0d1d4-09d0-4b94-a3fc-a4c1f46a3bc7" xlink:to="loc_srt_MaximumMember_49fb69f5-33f2-49ce-9fbd-3c628b0a1a2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_988a345a-9d4e-4eac-b143-a87c64716e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_23c0a491-4148-42ed-8d15-aaa1e762e1d7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_988a345a-9d4e-4eac-b143-a87c64716e50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_988a345a-9d4e-4eac-b143-a87c64716e50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_988a345a-9d4e-4eac-b143-a87c64716e50" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_988a345a-9d4e-4eac-b143-a87c64716e50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94d9c73d-79a1-4785-bcb2-87b65666c488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_988a345a-9d4e-4eac-b143-a87c64716e50" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94d9c73d-79a1-4785-bcb2-87b65666c488" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_ad2b9cb2-58f8-4aee-bb6f-f913d314ad60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94d9c73d-79a1-4785-bcb2-87b65666c488" xlink:to="loc_us-gaap_PrivatePlacementMember_ad2b9cb2-58f8-4aee-bb6f-f913d314ad60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023ShelfRegistrationStatementMember_163745f8-2b5c-40cf-be77-9265c47c55ec" xlink:href="ibrx-20230331.xsd#ibrx_February2023ShelfRegistrationStatementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94d9c73d-79a1-4785-bcb2-87b65666c488" xlink:to="loc_ibrx_February2023ShelfRegistrationStatementMember_163745f8-2b5c-40cf-be77-9265c47c55ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6134f635-2076-448d-9ddf-c3f0e787abe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_23c0a491-4148-42ed-8d15-aaa1e762e1d7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6134f635-2076-448d-9ddf-c3f0e787abe4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6134f635-2076-448d-9ddf-c3f0e787abe4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6134f635-2076-448d-9ddf-c3f0e787abe4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6134f635-2076-448d-9ddf-c3f0e787abe4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_b312af17-a31d-43c9-9923-eaf1ce5a9cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6134f635-2076-448d-9ddf-c3f0e787abe4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_b312af17-a31d-43c9-9923-eaf1ce5a9cc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023WarrantsMember_fb477cc3-6c0a-4dc4-9fda-09e516372d69" xlink:href="ibrx-20230331.xsd#ibrx_February2023WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b312af17-a31d-43c9-9923-eaf1ce5a9cc2" xlink:to="loc_ibrx_February2023WarrantsMember_fb477cc3-6c0a-4dc4-9fda-09e516372d69" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended" id="if4735f3f797f46e29c56a729646279d8_StockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3b2bacd3-5497-4541-8aee-9480db7f741b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3b2bacd3-5497-4541-8aee-9480db7f741b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_60169da0-564f-4407-bc41-e16fe84a48bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_60169da0-564f-4407-bc41-e16fe84a48bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4de890e7-5d65-480a-bc4d-28d61b83c697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4de890e7-5d65-480a-bc4d-28d61b83c697" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6e011aff-365f-4f91-b38c-440a658a4493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6e011aff-365f-4f91-b38c-440a658a4493" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4f5b5411-ad15-4cb4-88b9-052f450e3d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4f5b5411-ad15-4cb4-88b9-052f450e3d6f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_99c76a59-16d4-4d2c-a03a-ffefdcaec1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_99c76a59-16d4-4d2c-a03a-ffefdcaec1a3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_66341896-86ea-4a9b-947b-c157b4e7fd1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_66341896-86ea-4a9b-947b-c157b4e7fd1c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_44c0561d-a54e-40ca-932e-8a2f02b464e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_44c0561d-a54e-40ca-932e-8a2f02b464e9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue_3201fd81-5fb9-42f0-9d5f-845988741631" xlink:href="ibrx-20230331.xsd#ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue_3201fd81-5fb9-42f0-9d5f-845988741631" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_2acae66f-4102-48a2-8579-8718cfe81335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_Dividends_2acae66f-4102-48a2-8579-8718cfe81335" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_98cb5ba0-1695-4378-8ab8-17f0b0f29353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_98cb5ba0-1695-4378-8ab8-17f0b0f29353" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7cdc7591-262e-4a0f-bdd3-23ac0daa9071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7cdc7591-262e-4a0f-bdd3-23ac0daa9071" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_635c2c09-4d67-4bcf-a7c1-e170439b3d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_635c2c09-4d67-4bcf-a7c1-e170439b3d7f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46eb7e49-f4e6-4d9f-ab4e-ca52e9393989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46eb7e49-f4e6-4d9f-ab4e-ca52e9393989" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_39acd91d-fd7d-43f2-9f3b-f0bb03d997f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46eb7e49-f4e6-4d9f-ab4e-ca52e9393989" xlink:to="loc_us-gaap_PlanNameAxis_39acd91d-fd7d-43f2-9f3b-f0bb03d997f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_39acd91d-fd7d-43f2-9f3b-f0bb03d997f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_39acd91d-fd7d-43f2-9f3b-f0bb03d997f0" xlink:to="loc_us-gaap_PlanNameDomain_39acd91d-fd7d-43f2-9f3b-f0bb03d997f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7953bfc1-5d8f-49cb-aa26-7dc31cd2a237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_39acd91d-fd7d-43f2-9f3b-f0bb03d997f0" xlink:to="loc_us-gaap_PlanNameDomain_7953bfc1-5d8f-49cb-aa26-7dc31cd2a237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TwoThousandFifteenEquityIncentivePlanMember_db43f2fa-3638-485f-a94b-56cf9c0e56cb" xlink:href="ibrx-20230331.xsd#ibrx_TwoThousandFifteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7953bfc1-5d8f-49cb-aa26-7dc31cd2a237" xlink:to="loc_ibrx_TwoThousandFifteenEquityIncentivePlanMember_db43f2fa-3638-485f-a94b-56cf9c0e56cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b264f34d-c9e9-443d-a589-50b801ca0f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46eb7e49-f4e6-4d9f-ab4e-ca52e9393989" xlink:to="loc_us-gaap_AwardTypeAxis_b264f34d-c9e9-443d-a589-50b801ca0f66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b264f34d-c9e9-443d-a589-50b801ca0f66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b264f34d-c9e9-443d-a589-50b801ca0f66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b264f34d-c9e9-443d-a589-50b801ca0f66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72e7294e-5084-45a5-ba9a-8685feddc041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b264f34d-c9e9-443d-a589-50b801ca0f66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72e7294e-5084-45a5-ba9a-8685feddc041" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ba9233ce-6fda-4306-ba6f-354fefbd56ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72e7294e-5084-45a5-ba9a-8685feddc041" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ba9233ce-6fda-4306-ba6f-354fefbd56ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f4634881-65ca-4f38-a718-1faddaaefb24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72e7294e-5084-45a5-ba9a-8685feddc041" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f4634881-65ca-4f38-a718-1faddaaefb24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_WarrantsMember_6081100c-1c90-452d-8973-39104d4b7f7f" xlink:href="ibrx-20230331.xsd#ibrx_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72e7294e-5084-45a5-ba9a-8685feddc041" xlink:to="loc_ibrx_WarrantsMember_6081100c-1c90-452d-8973-39104d4b7f7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_59f1191e-eebd-4a23-826f-7653c599f5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46eb7e49-f4e6-4d9f-ab4e-ca52e9393989" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_59f1191e-eebd-4a23-826f-7653c599f5ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_59f1191e-eebd-4a23-826f-7653c599f5ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_59f1191e-eebd-4a23-826f-7653c599f5ea" xlink:to="loc_us-gaap_RelatedPartyDomain_59f1191e-eebd-4a23-826f-7653c599f5ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4466825c-cfef-4a57-b085-4d94ebafe34b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_59f1191e-eebd-4a23-826f-7653c599f5ea" xlink:to="loc_us-gaap_RelatedPartyDomain_4466825c-cfef-4a57-b085-4d94ebafe34b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksMember_a1e0e915-035e-4810-803f-e3371d1b9f2c" xlink:href="ibrx-20230331.xsd#ibrx_NantWorksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4466825c-cfef-4a57-b085-4d94ebafe34b" xlink:to="loc_ibrx_NantWorksMember_a1e0e915-035e-4810-803f-e3371d1b9f2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a900ac50-fe23-416a-b5cd-e835273603dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46eb7e49-f4e6-4d9f-ab4e-ca52e9393989" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a900ac50-fe23-416a-b5cd-e835273603dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a900ac50-fe23-416a-b5cd-e835273603dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a900ac50-fe23-416a-b5cd-e835273603dc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a900ac50-fe23-416a-b5cd-e835273603dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e3047897-90a0-4b53-82a2-1a114dc678bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a900ac50-fe23-416a-b5cd-e835273603dc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e3047897-90a0-4b53-82a2-1a114dc678bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_795b0091-dbb6-4c9d-acf6-84368b1a625a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e3047897-90a0-4b53-82a2-1a114dc678bc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_795b0091-dbb6-4c9d-acf6-84368b1a625a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail" xlink:type="extended" id="i27e458d720204997bc61c531425cb586_StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5afaf065-44c0-4b74-9d51-2421a2b68e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_be9249d9-bf72-4fbf-877b-85e295d8bad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5afaf065-44c0-4b74-9d51-2421a2b68e34" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_be9249d9-bf72-4fbf-877b-85e295d8bad2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4fc58b5d-06b0-4b70-9464-4c6c895b9398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5afaf065-44c0-4b74-9d51-2421a2b68e34" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4fc58b5d-06b0-4b70-9464-4c6c895b9398" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2efcc520-49f8-4ad2-a520-92b7c911f016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4fc58b5d-06b0-4b70-9464-4c6c895b9398" xlink:to="loc_us-gaap_AwardTypeAxis_2efcc520-49f8-4ad2-a520-92b7c911f016" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2efcc520-49f8-4ad2-a520-92b7c911f016_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2efcc520-49f8-4ad2-a520-92b7c911f016" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2efcc520-49f8-4ad2-a520-92b7c911f016_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53c0c2ae-4683-4b05-81fa-bea33d3c8d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2efcc520-49f8-4ad2-a520-92b7c911f016" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53c0c2ae-4683-4b05-81fa-bea33d3c8d13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_b601b4d5-c495-4d2e-abc9-e761e14a3073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53c0c2ae-4683-4b05-81fa-bea33d3c8d13" xlink:to="loc_us-gaap_StockOptionMember_b601b4d5-c495-4d2e-abc9-e761e14a3073" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e7e77ba2-5d80-4cd9-a3e4-d57b6f1556dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53c0c2ae-4683-4b05-81fa-bea33d3c8d13" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e7e77ba2-5d80-4cd9-a3e4-d57b6f1556dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fdc6220d-c252-4dd6-930c-8ec8a7637bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4fc58b5d-06b0-4b70-9464-4c6c895b9398" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fdc6220d-c252-4dd6-930c-8ec8a7637bcf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fdc6220d-c252-4dd6-930c-8ec8a7637bcf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fdc6220d-c252-4dd6-930c-8ec8a7637bcf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fdc6220d-c252-4dd6-930c-8ec8a7637bcf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6d540dad-7d41-4d6e-9300-6ca2f47537db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fdc6220d-c252-4dd6-930c-8ec8a7637bcf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6d540dad-7d41-4d6e-9300-6ca2f47537db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8e1fd962-be10-4927-92bd-8335dda760cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6d540dad-7d41-4d6e-9300-6ca2f47537db" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8e1fd962-be10-4927-92bd-8335dda760cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5cccaa95-9ff8-4950-9a49-79ba7e3ca5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6d540dad-7d41-4d6e-9300-6ca2f47537db" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5cccaa95-9ff8-4950-9a49-79ba7e3ca5a7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockBasedCompensationRSUsActivityDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#StockBasedCompensationRSUsActivityDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/StockBasedCompensationRSUsActivityDetail" xlink:type="extended" id="if09b06c2880b4f2e9a13deeb8977590d_StockBasedCompensationRSUsActivityDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_15c14c09-8ba4-492d-89ce-37ed437127b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa1eb2e-9e9d-4231-8ee1-d1c2d6a474cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_15c14c09-8ba4-492d-89ce-37ed437127b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa1eb2e-9e9d-4231-8ee1-d1c2d6a474cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e09450a8-c29f-4b86-b4e3-26ef232c0d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa1eb2e-9e9d-4231-8ee1-d1c2d6a474cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e09450a8-c29f-4b86-b4e3-26ef232c0d29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a3b984e3-0d29-4141-92b3-3f801783c5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa1eb2e-9e9d-4231-8ee1-d1c2d6a474cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a3b984e3-0d29-4141-92b3-3f801783c5e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_32a5a184-388a-4123-b0be-712e038ca451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa1eb2e-9e9d-4231-8ee1-d1c2d6a474cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_32a5a184-388a-4123-b0be-712e038ca451" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_80f6436a-9313-4a09-855d-eb3e16b3ea13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa1eb2e-9e9d-4231-8ee1-d1c2d6a474cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_80f6436a-9313-4a09-855d-eb3e16b3ea13" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00ca48be-ded5-4e1e-aa4a-529e117eacfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_99592027-8933-4c17-8e15-c2fac914e127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_15c14c09-8ba4-492d-89ce-37ed437127b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_99592027-8933-4c17-8e15-c2fac914e127" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d93a22f7-6a1b-4246-a775-f7329ae2c11a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_99592027-8933-4c17-8e15-c2fac914e127" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d93a22f7-6a1b-4246-a775-f7329ae2c11a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0d316ab6-915e-4a91-b0ff-30755a267207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_99592027-8933-4c17-8e15-c2fac914e127" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0d316ab6-915e-4a91-b0ff-30755a267207" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9c1e547b-d4de-457d-8bf6-ffdf38712344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_99592027-8933-4c17-8e15-c2fac914e127" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9c1e547b-d4de-457d-8bf6-ffdf38712344" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_89c3b6da-6679-40f6-93c5-fa7f78b36fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_99592027-8933-4c17-8e15-c2fac914e127" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_89c3b6da-6679-40f6-93c5-fa7f78b36fdb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e50b4adf-61a8-48ef-a76d-f735f25cb243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82165b7a-5835-4ca8-afa4-d604f6779f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_15c14c09-8ba4-492d-89ce-37ed437127b6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82165b7a-5835-4ca8-afa4-d604f6779f29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2fbd70c2-411c-406a-818c-655e101724ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82165b7a-5835-4ca8-afa4-d604f6779f29" xlink:to="loc_us-gaap_AwardTypeAxis_2fbd70c2-411c-406a-818c-655e101724ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fbd70c2-411c-406a-818c-655e101724ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2fbd70c2-411c-406a-818c-655e101724ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fbd70c2-411c-406a-818c-655e101724ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf0d184b-6176-4533-89a2-1779575f587d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2fbd70c2-411c-406a-818c-655e101724ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf0d184b-6176-4533-89a2-1779575f587d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fff41a9a-ab31-4496-ba41-eece4768c293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf0d184b-6176-4533-89a2-1779575f587d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fff41a9a-ab31-4496-ba41-eece4768c293" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended" id="i6d4715990bd54a1285004c33a3692d09_IncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncomeTaxLineItems_695e477c-b809-4307-8c86-156fcbfeb932" xlink:href="ibrx-20230331.xsd#ibrx_IncomeTaxLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_71262ff4-7186-4104-a637-268d8dce372c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_IncomeTaxLineItems_695e477c-b809-4307-8c86-156fcbfeb932" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_71262ff4-7186-4104-a637-268d8dce372c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncomeTaxTable_c477d6e7-b334-4faa-aa16-23742a827cac" xlink:href="ibrx-20230331.xsd#ibrx_IncomeTaxTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ibrx_IncomeTaxLineItems_695e477c-b809-4307-8c86-156fcbfeb932" xlink:to="loc_ibrx_IncomeTaxTable_c477d6e7-b334-4faa-aa16-23742a827cac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6d71566a-a027-4175-bb83-e9e93bdfdbd3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_IncomeTaxTable_c477d6e7-b334-4faa-aa16-23742a827cac" xlink:to="loc_srt_StatementGeographicalAxis_6d71566a-a027-4175-bb83-e9e93bdfdbd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6d71566a-a027-4175-bb83-e9e93bdfdbd3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6d71566a-a027-4175-bb83-e9e93bdfdbd3" xlink:to="loc_srt_SegmentGeographicalDomain_6d71566a-a027-4175-bb83-e9e93bdfdbd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f63da9fa-2181-46c5-b4f4-1472176afeaf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6d71566a-a027-4175-bb83-e9e93bdfdbd3" xlink:to="loc_srt_SegmentGeographicalDomain_f63da9fa-2181-46c5-b4f4-1472176afeaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3ee15eb9-2ee6-4ddb-b80d-9128522be20c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f63da9fa-2181-46c5-b4f4-1472176afeaf" xlink:to="loc_country_US_3ee15eb9-2ee6-4ddb-b80d-9128522be20c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT_5eacf136-f2e5-49fc-936e-3c2ef823e265" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f63da9fa-2181-46c5-b4f4-1472176afeaf" xlink:to="loc_country_IT_5eacf136-f2e5-49fc-936e-3c2ef823e265" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_KR_a1834be9-d8bf-4d2c-9b57-72d5d9eeda7d" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f63da9fa-2181-46c5-b4f4-1472176afeaf" xlink:to="loc_country_KR_a1834be9-d8bf-4d2c-9b57-72d5d9eeda7d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>ibrx-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5993b617-92d4-4bab-a076-33e54147e714,g:68360996-794b-41f6-8c08-63fce426a63c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm_10a47e76-b537-44b6-8cb1-cab31138e4c5_terseLabel_en-US" xlink:label="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment to spend, operational expenses, initial lease term</link:label>
    <link:label id="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm_label_en-US" xlink:label="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Interest, Operational Expenses, Commitment to Spend, Initial Lease Term</link:label>
    <link:label id="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm_documentation_en-US" xlink:label="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Interest, Operational Expenses, Commitment to Spend, Initial Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm" xlink:href="ibrx-20230331.xsd#ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm" xlink:to="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborationAgreementsTerminationFee_9993bd7d-585f-401b-934b-692bd6f90b82_terseLabel_en-US" xlink:label="lab_ibrx_CollaborationAgreementsTerminationFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination fee</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsTerminationFee_label_en-US" xlink:label="lab_ibrx_CollaborationAgreementsTerminationFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, Termination Fee</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsTerminationFee_documentation_en-US" xlink:label="lab_ibrx_CollaborationAgreementsTerminationFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, Termination Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsTerminationFee" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsTerminationFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborationAgreementsTerminationFee" xlink:to="lab_ibrx_CollaborationAgreementsTerminationFee" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ExpansionPremisesMember_e3b1339c-6417-4439-898b-3ca89dab4415_terseLabel_en-US" xlink:label="lab_ibrx_ExpansionPremisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expansion Premises</link:label>
    <link:label id="lab_ibrx_ExpansionPremisesMember_label_en-US" xlink:label="lab_ibrx_ExpansionPremisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expansion Premises [Member]</link:label>
    <link:label id="lab_ibrx_ExpansionPremisesMember_documentation_en-US" xlink:label="lab_ibrx_ExpansionPremisesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment for expansion of premises, lease term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ExpansionPremisesMember" xlink:href="ibrx-20230331.xsd#ibrx_ExpansionPremisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ExpansionPremisesMember" xlink:to="lab_ibrx_ExpansionPremisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_83cf9bd9-3e5f-4adf-80d4-0623919fb1e2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8a1130ed-df92-40bf-979f-e84edc715674_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Statements of Stockholders&#8217; Deficit [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d7b493d9-94ba-46a0-b76a-687c2d1f9f79_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_479d3ca7-e646-4999-bf1c-e7cc54539de7_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_27055431-307c-4a39-8f8c-8077ca24d1ca_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_ae3d2378-bc95-40d7-a0f9-9bdd7c550f3f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_6b0991c3-c923-4719-b977-a99075194429_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2f762db5-ab9b-4616-ba4a-26f8050286f4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_45f7f66b-ca39-48e3-a454-251193315830_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_1a332494-f9c6-427e-b9ea-5ef423a2907c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum milestone payment due if certain conditions are met</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableRelatedPartiesNoncurrent_e4d9f65f-5d84-43a5-9d67-ed063e642945_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-party convertible notes and accrued interest, net of discount</link:label>
    <link:label id="lab_us-gaap_NotesPayableRelatedPartiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:to="lab_us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9a7c0722-35f9-4dbd-a661-f77ad49dd864_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_17c090ba-8c66-491b-8086-21518f93d851_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and investment income, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_5d066548-2446-4fff-b37e-fae75ddb2836_totalLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and investment income, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_47eefe6c-cbfd-4997-820a-64a514c70069_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AtTheMarketOfferingProgramMember_8e2c7866-c05a-4126-9320-c8dea1957c22_terseLabel_en-US" xlink:label="lab_ibrx_AtTheMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering Program</link:label>
    <link:label id="lab_ibrx_AtTheMarketOfferingProgramMember_label_en-US" xlink:label="lab_ibrx_AtTheMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering Program [Member]</link:label>
    <link:label id="lab_ibrx_AtTheMarketOfferingProgramMember_documentation_en-US" xlink:label="lab_ibrx_AtTheMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market offering program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AtTheMarketOfferingProgramMember" xlink:href="ibrx-20230331.xsd#ibrx_AtTheMarketOfferingProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AtTheMarketOfferingProgramMember" xlink:to="lab_ibrx_AtTheMarketOfferingProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_e8b30419-5f02-4b53-be7f-95e2346d3091_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NANTibodyLLCMember_28157592-d9c6-48c7-b507-aaf6e97bedf8_terseLabel_en-US" xlink:label="lab_ibrx_NANTibodyLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NANTibody, LLC</link:label>
    <link:label id="lab_ibrx_NANTibodyLLCMember_label_en-US" xlink:label="lab_ibrx_NANTibodyLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NANTibody, LLC [Member]</link:label>
    <link:label id="lab_ibrx_NANTibodyLLCMember_documentation_en-US" xlink:label="lab_ibrx_NANTibodyLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NANTibody, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NANTibodyLLCMember" xlink:href="ibrx-20230331.xsd#ibrx_NANTibodyLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NANTibodyLLCMember" xlink:to="lab_ibrx_NANTibodyLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_a723fd23-16ff-4fbc-abf1-f98c5ebc8974_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PrepaidResearchAndDevelopmentCosts_42c9d94a-843b-4301-ab22-82b6e4d3c544_terseLabel_en-US" xlink:label="lab_ibrx_PrepaidResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid research and development costs</link:label>
    <link:label id="lab_ibrx_PrepaidResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_ibrx_PrepaidResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research And Development Costs</link:label>
    <link:label id="lab_ibrx_PrepaidResearchAndDevelopmentCosts_documentation_en-US" xlink:label="lab_ibrx_PrepaidResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research And Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidResearchAndDevelopmentCosts" xlink:href="ibrx-20230331.xsd#ibrx_PrepaidResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PrepaidResearchAndDevelopmentCosts" xlink:to="lab_ibrx_PrepaidResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_6c97d813-8f55-4c8f-abdc-737d00736d07_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration for future services performed by related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_1cedde2e-91a6-4b07-b6ef-a43a7b33519d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SixZeroFiveNashLLCMember_6ac78f4e-80ff-4ff8-8562-03e3343a8a60_terseLabel_en-US" xlink:label="lab_ibrx_SixZeroFiveNashLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">605 Nash, LLC</link:label>
    <link:label id="lab_ibrx_SixZeroFiveNashLLCMember_label_en-US" xlink:label="lab_ibrx_SixZeroFiveNashLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Zero Five Nash, LLC [Member]</link:label>
    <link:label id="lab_ibrx_SixZeroFiveNashLLCMember_documentation_en-US" xlink:label="lab_ibrx_SixZeroFiveNashLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Zero Five Nash, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SixZeroFiveNashLLCMember" xlink:href="ibrx-20230331.xsd#ibrx_SixZeroFiveNashLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SixZeroFiveNashLLCMember" xlink:to="lab_ibrx_SixZeroFiveNashLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_54a91327-9930-4eda-ba66-7d111b3ebad6_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_TwoThousandFifteenEquityIncentivePlanMember_e33de6a1-8669-433d-aec5-8f9c2e0db590_terseLabel_en-US" xlink:label="lab_ibrx_TwoThousandFifteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Equity Incentive Plan</link:label>
    <link:label id="lab_ibrx_TwoThousandFifteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_ibrx_TwoThousandFifteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fifteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_ibrx_TwoThousandFifteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_ibrx_TwoThousandFifteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand fifteen equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TwoThousandFifteenEquityIncentivePlanMember" xlink:href="ibrx-20230331.xsd#ibrx_TwoThousandFifteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_TwoThousandFifteenEquityIncentivePlanMember" xlink:to="lab_ibrx_TwoThousandFifteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTextBlock_6785ef2e-5967-4f85-a534-d8aa0d8beec3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_InvestmentTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTextBlock" xlink:to="lab_us-gaap_InvestmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AccountingPoliciesLineItems_9d823b1b-3a45-442c-ab31-dd9020c895e9_terseLabel_en-US" xlink:label="lab_ibrx_AccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Line Items]</link:label>
    <link:label id="lab_ibrx_AccountingPoliciesLineItems_label_en-US" xlink:label="lab_ibrx_AccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Line Items]</link:label>
    <link:label id="lab_ibrx_AccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_ibrx_AccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccountingPoliciesLineItems" xlink:href="ibrx-20230331.xsd#ibrx_AccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AccountingPoliciesLineItems" xlink:to="lab_ibrx_AccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_99f55b13-1a76-4728-b47d-8306b831d59d_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_OrganizedWorkforceMember_b33a7cff-26eb-43c0-8b79-86387b58d577_terseLabel_en-US" xlink:label="lab_ibrx_OrganizedWorkforceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organized Workforce</link:label>
    <link:label id="lab_ibrx_OrganizedWorkforceMember_label_en-US" xlink:label="lab_ibrx_OrganizedWorkforceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organized Workforce [Member]</link:label>
    <link:label id="lab_ibrx_OrganizedWorkforceMember_documentation_en-US" xlink:label="lab_ibrx_OrganizedWorkforceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organized Workforce</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OrganizedWorkforceMember" xlink:href="ibrx-20230331.xsd#ibrx_OrganizedWorkforceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_OrganizedWorkforceMember" xlink:to="lab_ibrx_OrganizedWorkforceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_IssuanceOfWarrants_32cbf43f-d555-4815-8791-4e7686d3edf0_terseLabel_en-US" xlink:label="lab_ibrx_IssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial measurement of warrants issued in connection with the registered direct offering accounted for as liabilities</link:label>
    <link:label id="lab_ibrx_IssuanceOfWarrants_label_en-US" xlink:label="lab_ibrx_IssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Warrants</link:label>
    <link:label id="lab_ibrx_IssuanceOfWarrants_documentation_en-US" xlink:label="lab_ibrx_IssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IssuanceOfWarrants" xlink:href="ibrx-20230331.xsd#ibrx_IssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_IssuanceOfWarrants" xlink:to="lab_ibrx_IssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_b988f987-1bf0-4890-999d-08719dadadab_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_b71c5687-d9fc-4a6f-934a-0417b198a538_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_aec2fdae-5c8e-4932-a7bb-e0af29af7abc_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_b903ebf4-4a36-443c-9827-3727928258af_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense related to property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c2afa002-5385-4ba6-b1e9-c63313cbc092_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_21bffec3-73bd-4a7e-bcbf-4d687431dd9b_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_TwoThousandFifteenShareRepurchasePlanMember_3e5c0ab6-d0fd-4cce-b1e9-89e13952ef3d_terseLabel_en-US" xlink:label="lab_ibrx_TwoThousandFifteenShareRepurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Share Repurchase Plan</link:label>
    <link:label id="lab_ibrx_TwoThousandFifteenShareRepurchasePlanMember_label_en-US" xlink:label="lab_ibrx_TwoThousandFifteenShareRepurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fifteen Share Repurchase Plan [Member]</link:label>
    <link:label id="lab_ibrx_TwoThousandFifteenShareRepurchasePlanMember_documentation_en-US" xlink:label="lab_ibrx_TwoThousandFifteenShareRepurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 share repurchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TwoThousandFifteenShareRepurchasePlanMember" xlink:href="ibrx-20230331.xsd#ibrx_TwoThousandFifteenShareRepurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_TwoThousandFifteenShareRepurchasePlanMember" xlink:to="lab_ibrx_TwoThousandFifteenShareRepurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable_9db70585-6164-4796-a2b1-8bb3327ec68f_terseLabel_en-US" xlink:label="lab_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Tenant improvement allowance receivable</link:label>
    <link:label id="lab_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable_label_en-US" xlink:label="lab_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Tenant Improvement Allowance Receivable</link:label>
    <link:label id="lab_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable_documentation_en-US" xlink:label="lab_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Tenant Improvement Allowance Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:href="ibrx-20230331.xsd#ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:to="lab_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9ba127e1-0e0c-43c3-8a6c-3ef184b6422b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate, Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_41f7c248-4122-4ed5-a2e6-b5c32a80c787_terseLabel_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government-sponsored securities</link:label>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AgencySecuritiesMember" xlink:to="lab_us-gaap_AgencySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_5e3e7470-bd97-423a-bf31-10d930ca8f3d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of marketable debt and equity securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_97037980-fd12-443b-841f-c89e57f2d6f8_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_9f6907dd-3908-497c-a041-ce008672cdd2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTable" xlink:to="lab_us-gaap_AssetAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_494c830d-04cc-44dc-82a3-a155b714873b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3922a179-7183-4d18-9986-e91527966571_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseRelatedPayables_7310c214-6da7-42ec-a582-5f302cec0710_terseLabel_en-US" xlink:label="lab_ibrx_LeaseRelatedPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease-related payables</link:label>
    <link:label id="lab_ibrx_LeaseRelatedPayables_label_en-US" xlink:label="lab_ibrx_LeaseRelatedPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Related Payables</link:label>
    <link:label id="lab_ibrx_LeaseRelatedPayables_documentation_en-US" xlink:label="lab_ibrx_LeaseRelatedPayables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease-related payables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseRelatedPayables" xlink:href="ibrx-20230331.xsd#ibrx_LeaseRelatedPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseRelatedPayables" xlink:to="lab_ibrx_LeaseRelatedPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_61c289ab-1ffc-4e30-b548-0ee7576eb991_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_WarrantLiabilityTextBlock_dae9a09b-ed71-4c0b-af02-f7a24d9e548a_terseLabel_en-US" xlink:label="lab_ibrx_WarrantLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liabilities</link:label>
    <link:label id="lab_ibrx_WarrantLiabilityTextBlock_label_en-US" xlink:label="lab_ibrx_WarrantLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability [Text Block]</link:label>
    <link:label id="lab_ibrx_WarrantLiabilityTextBlock_documentation_en-US" xlink:label="lab_ibrx_WarrantLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_WarrantLiabilityTextBlock" xlink:href="ibrx-20230331.xsd#ibrx_WarrantLiabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_WarrantLiabilityTextBlock" xlink:to="lab_ibrx_WarrantLiabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_cb64ef03-d709-4a67-a4c4-710d9a20b2f6_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to ImmunityBio common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_7ca9cfd0-898b-4fc9-b78f-7492ad61f3e7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Lease Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_834d85cb-62f0-4e43-9be8-9fa12c5cbe90_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_15f24019-0082-4537-9a94-a16767abc899_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_545c083f-6813-4372-997a-44b86b30df41_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_96ddf20e-64ad-4016-a0ea-88a392df26bc_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_1cca34a2-767b-42ca-9ff7-058258216e93_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_InitialPremisesMember_9f318c89-42c8-4658-a693-c0daa0cd397a_terseLabel_en-US" xlink:label="lab_ibrx_InitialPremisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Premises</link:label>
    <link:label id="lab_ibrx_InitialPremisesMember_label_en-US" xlink:label="lab_ibrx_InitialPremisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Premises [Member]</link:label>
    <link:label id="lab_ibrx_InitialPremisesMember_documentation_en-US" xlink:label="lab_ibrx_InitialPremisesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Premises.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InitialPremisesMember" xlink:href="ibrx-20230331.xsd#ibrx_InitialPremisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_InitialPremisesMember" xlink:to="lab_ibrx_InitialPremisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_5a970e8c-dea2-4a32-b504-b4e170bb138d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 (excluding the three months ended March&#160;31,&#160;2023)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NotesPayableRelatedPartiesPrincipalAndAccruedInterest_185fe79e-658e-4be0-890e-9bd9a4998cfa_terseLabel_en-US" xlink:label="lab_ibrx_NotesPayableRelatedPartiesPrincipalAndAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal and accrued interest</link:label>
    <link:label id="lab_ibrx_NotesPayableRelatedPartiesPrincipalAndAccruedInterest_label_en-US" xlink:label="lab_ibrx_NotesPayableRelatedPartiesPrincipalAndAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties, Principal And Accrued Interest</link:label>
    <link:label id="lab_ibrx_NotesPayableRelatedPartiesPrincipalAndAccruedInterest_documentation_en-US" xlink:label="lab_ibrx_NotesPayableRelatedPartiesPrincipalAndAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties, Principal And Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NotesPayableRelatedPartiesPrincipalAndAccruedInterest" xlink:href="ibrx-20230331.xsd#ibrx_NotesPayableRelatedPartiesPrincipalAndAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NotesPayableRelatedPartiesPrincipalAndAccruedInterest" xlink:to="lab_ibrx_NotesPayableRelatedPartiesPrincipalAndAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_053b2ab2-ccdd-40e7-ba58-aad241894c50_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of net realized gains on available-for-sale securities included in net loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2ea7d30d-d056-453d-861c-0b4e81a7499c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AnnualPercentageIncreasesToBaseRent_689d9a28-25c0-4c32-9185-7fd6425a469d_terseLabel_en-US" xlink:label="lab_ibrx_AnnualPercentageIncreasesToBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of annual increases of base rent</link:label>
    <link:label id="lab_ibrx_AnnualPercentageIncreasesToBaseRent_label_en-US" xlink:label="lab_ibrx_AnnualPercentageIncreasesToBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Percentage Increases To Base Rent</link:label>
    <link:label id="lab_ibrx_AnnualPercentageIncreasesToBaseRent_documentation_en-US" xlink:label="lab_ibrx_AnnualPercentageIncreasesToBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual percentage increases to base rent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AnnualPercentageIncreasesToBaseRent" xlink:href="ibrx-20230331.xsd#ibrx_AnnualPercentageIncreasesToBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AnnualPercentageIncreasesToBaseRent" xlink:to="lab_ibrx_AnnualPercentageIncreasesToBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AccruedResearchAndDevelopmentCosts_17396a3f-87c7-4768-8aa0-5e0fb59b1ef9_terseLabel_en-US" xlink:label="lab_ibrx_AccruedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development costs</link:label>
    <link:label id="lab_ibrx_AccruedResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_ibrx_AccruedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Costs</link:label>
    <link:label id="lab_ibrx_AccruedResearchAndDevelopmentCosts_documentation_en-US" xlink:label="lab_ibrx_AccruedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccruedResearchAndDevelopmentCosts" xlink:href="ibrx-20230331.xsd#ibrx_AccruedResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AccruedResearchAndDevelopmentCosts" xlink:to="lab_ibrx_AccruedResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_25490bcb-29bc-45e2-88ac-5281bb315dfa_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_2e622540-2713-4d9c-ab67-ccb09e415131_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_38977143-8841-49f6-ace1-f325ff3bf35a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount factor</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_899a13e5-a4d9-46c9-8329-db46e8e49e8b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_0ce38cbd-b833-4803-8da9-0076a68e5c62_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionRate_3644cd71-eee8-4bc8-b51c-8ff15f451f9c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionRate_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionRate" xlink:to="lab_us-gaap_RelatedPartyTransactionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_162adc5f-fb94-4b10-a3ea-90a698c71a38_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_5b0e9aed-1c49-4c46-8d26-1a318264e5e1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_69a57c9d-b36b-471e-ab2f-42b6afbaf307_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Lease Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_c2d4e22c-fb16-4c56-a474-7679f4d4c113_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_5ddfacef-1b5f-4b0e-a966-785dcc52bd9e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_4f039bb0-5d9c-4e83-aa6d-d8545f058729_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AltorStockholdersMember_ae3bf4cb-3aa6-4086-a9f6-3f3779ec8969_terseLabel_en-US" xlink:label="lab_ibrx_AltorStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Altor Stockholders</link:label>
    <link:label id="lab_ibrx_AltorStockholdersMember_label_en-US" xlink:label="lab_ibrx_AltorStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Altor Stockholders [Member]</link:label>
    <link:label id="lab_ibrx_AltorStockholdersMember_documentation_en-US" xlink:label="lab_ibrx_AltorStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Altor Stockholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AltorStockholdersMember" xlink:href="ibrx-20230331.xsd#ibrx_AltorStockholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AltorStockholdersMember" xlink:to="lab_ibrx_AltorStockholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_983ca0a1-0355-4b1f-9d6c-a6c8f2c41d03_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_4ce10e90-6aff-41ed-93f2-3c07b958c209_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_db6870be-68d6-4319-ace0-fb1beb241798_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from related parties</link:label>
    <link:label id="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_84953c10-843d-42e1-baa0-bb7321582107_totalLabel_en-US" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_3a964461-139d-451a-9a35-b5a9a50cecb4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total definite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_f6a45ac1-983d-4af2-91d8-6afe6fca639f_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of RSU Activity under Equity Plans</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_36b63591-d866-48f6-9fd8-b5fafab01068_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_12159ddd-5c9a-4847-90cd-75eea42c85c1_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d0b28d8a-201e-4359-b913-9174ad7d0b29_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to non-vested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_f7fb6574-dd9b-4ae5-801d-b210b0def4ec_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4189b550-3978-4a0a-86a4-a1c0a72203e9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 (excluding the three months ended March&#160;31,&#160;2023)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_c70dbfb3-a956-4386-9a3e-6978e76cae0a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d1600db8-7b9e-410c-8ba3-2a363977aa5e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_7431133f-a719-40d6-9d18-4639756c6e32_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_BrinkBiologicsIncMember_8edf0a04-ab3f-4960-b421-a719e1ca1373_terseLabel_en-US" xlink:label="lab_ibrx_BrinkBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brink Biologics, Inc.</link:label>
    <link:label id="lab_ibrx_BrinkBiologicsIncMember_label_en-US" xlink:label="lab_ibrx_BrinkBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brink Biologics, Inc. [Member]</link:label>
    <link:label id="lab_ibrx_BrinkBiologicsIncMember_documentation_en-US" xlink:label="lab_ibrx_BrinkBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brink Biologics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BrinkBiologicsIncMember" xlink:href="ibrx-20230331.xsd#ibrx_BrinkBiologicsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_BrinkBiologicsIncMember" xlink:to="lab_ibrx_BrinkBiologicsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_e6dc7b6a-820b-4b0d-8a3f-f971fc05ab1e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of income taxes:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1c9655da-b945-49c9-9b7e-6e4d76111c0c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_724d824d-6aa1-4f8f-8d06-23605a40797a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_c588d21d-3a86-4508-b08b-fdf270a08c61_totalLabel_en-US" xlink:label="lab_ibrx_AssetAcquisitionFairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_label_en-US" xlink:label="lab_ibrx_AssetAcquisitionFairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Fair Value of Assets Acquired</link:label>
    <link:label id="lab_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_documentation_en-US" xlink:label="lab_ibrx_AssetAcquisitionFairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Fair Value of Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AssetAcquisitionFairValueOfAssetsAcquired" xlink:href="ibrx-20230331.xsd#ibrx_AssetAcquisitionFairValueOfAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AssetAcquisitionFairValueOfAssetsAcquired" xlink:to="lab_ibrx_AssetAcquisitionFairValueOfAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements_3fa1684c-bdbd-4baf-accc-5580a5921f50_terseLabel_en-US" xlink:label="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration arrangements, paid</link:label>
    <link:label id="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements_label_en-US" xlink:label="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Settlements</link:label>
    <link:label id="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements_documentation_en-US" xlink:label="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements" xlink:href="ibrx-20230331.xsd#ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements" xlink:to="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_2f791227-0a4d-49ab-ae92-2cf495915d01_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b5658554-1b18-43f8-9913-8d2b20f4229a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_16f5f769-b929-4a12-b40e-754d6229a08e_negatedLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NoncurrentLiabilitiesMember_2edf2d20-bcf2-45f4-aff5-4f24da799cc9_terseLabel_en-US" xlink:label="lab_ibrx_NoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent Liabilities</link:label>
    <link:label id="lab_ibrx_NoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_ibrx_NoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent Liabilities [Member]</link:label>
    <link:label id="lab_ibrx_NoncurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_ibrx_NoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NoncurrentLiabilitiesMember" xlink:href="ibrx-20230331.xsd#ibrx_NoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NoncurrentLiabilitiesMember" xlink:to="lab_ibrx_NoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_f1fe0632-efb5-4c9d-8397-6131ae93cd87_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities (including amounts with related parties)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_845719ac-f023-4c02-b443-4c69b4a5aed0_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseholdInterestGovernmentFundingReceivable_6a05c5d6-a281-4341-9fa0-2608fcc3f33c_terseLabel_en-US" xlink:label="lab_ibrx_LeaseholdInterestGovernmentFundingReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government funding for leasehold build-out</link:label>
    <link:label id="lab_ibrx_LeaseholdInterestGovernmentFundingReceivable_label_en-US" xlink:label="lab_ibrx_LeaseholdInterestGovernmentFundingReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Interest, Government Funding Receivable</link:label>
    <link:label id="lab_ibrx_LeaseholdInterestGovernmentFundingReceivable_documentation_en-US" xlink:label="lab_ibrx_LeaseholdInterestGovernmentFundingReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Interest, Government Funding Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestGovernmentFundingReceivable" xlink:href="ibrx-20230331.xsd#ibrx_LeaseholdInterestGovernmentFundingReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseholdInterestGovernmentFundingReceivable" xlink:to="lab_ibrx_LeaseholdInterestGovernmentFundingReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d68f6af7-32b7-4aad-b7dc-62056f33668d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_7d374b40-a47e-4986-a83c-c60c1aa23bb4_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Operating Activities Lessee [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncentiveFromLessor_8f7c3250-8207-4e29-9d8a-c0a9ce19dd6d_terseLabel_en-US" xlink:label="lab_us-gaap_IncentiveFromLessor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvements incentive</link:label>
    <link:label id="lab_us-gaap_IncentiveFromLessor_label_en-US" xlink:label="lab_us-gaap_IncentiveFromLessor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive from Lessor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveFromLessor" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncentiveFromLessor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncentiveFromLessor" xlink:to="lab_us-gaap_IncentiveFromLessor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_123df882-05c3-4638-b705-5a04fa1cc9fa_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_53e87213-f407-4ddf-a193-f9dfc0ea1a8e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SorrentoTherapeuticsIncLitigationMember_885f7b21-c710-439d-99b2-0a8f2409db96_terseLabel_en-US" xlink:label="lab_ibrx_SorrentoTherapeuticsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sorrento Therapeutics, Inc. Litigation</link:label>
    <link:label id="lab_ibrx_SorrentoTherapeuticsIncLitigationMember_label_en-US" xlink:label="lab_ibrx_SorrentoTherapeuticsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sorrento Therapeutics, Inc. Litigation [Member]</link:label>
    <link:label id="lab_ibrx_SorrentoTherapeuticsIncLitigationMember_documentation_en-US" xlink:label="lab_ibrx_SorrentoTherapeuticsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sorrento Therapeutics, Inc. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SorrentoTherapeuticsIncLitigationMember" xlink:href="ibrx-20230331.xsd#ibrx_SorrentoTherapeuticsIncLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SorrentoTherapeuticsIncLitigationMember" xlink:to="lab_ibrx_SorrentoTherapeuticsIncLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransactionDomain_250b6739-41b5-4ee2-a12b-a472079a7832_terseLabel_en-US" xlink:label="lab_us-gaap_TransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction</link:label>
    <link:label id="lab_us-gaap_TransactionDomain_label_en-US" xlink:label="lab_us-gaap_TransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionDomain" xlink:to="lab_us-gaap_TransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_d21b3465-00fb-4d3a-a589-21e8bfb829d0_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_36e56796-5d2b-4981-8bdb-726cb0c52b49_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_RelatedPartyConvertibleNotesMember_d27a65b6-ddf3-4a79-9cf6-d700d0440b16_terseLabel_en-US" xlink:label="lab_ibrx_RelatedPartyConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-party convertible notes</link:label>
    <link:label id="lab_ibrx_RelatedPartyConvertibleNotesMember_label_en-US" xlink:label="lab_ibrx_RelatedPartyConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Convertible Notes [Member]</link:label>
    <link:label id="lab_ibrx_RelatedPartyConvertibleNotesMember_documentation_en-US" xlink:label="lab_ibrx_RelatedPartyConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Convertible Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyConvertibleNotesMember" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyConvertibleNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_RelatedPartyConvertibleNotesMember" xlink:to="lab_ibrx_RelatedPartyConvertibleNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SharedServicesAgreementMember_f5f6cc9f-a72a-49b7-ada2-5b9944a3e651_terseLabel_en-US" xlink:label="lab_ibrx_SharedServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shared Services Agreement</link:label>
    <link:label id="lab_ibrx_SharedServicesAgreementMember_label_en-US" xlink:label="lab_ibrx_SharedServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shared Services Agreement [Member]</link:label>
    <link:label id="lab_ibrx_SharedServicesAgreementMember_documentation_en-US" xlink:label="lab_ibrx_SharedServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shared services agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SharedServicesAgreementMember" xlink:href="ibrx-20230331.xsd#ibrx_SharedServicesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SharedServicesAgreementMember" xlink:to="lab_ibrx_SharedServicesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_eb844bd2-5339-4e04-8d29-8784d5ecf7af_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a2dbcae8-f476-4990-9bba-c63d673e8194_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term, Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_bbcdca55-1b4a-4c54-8b6a-bf5158e2dbcc_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_69f15390-267b-4f03-983a-46d9b60334dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities_e439a3f0-f70d-4a24-8008-fadbdc6e51c7_terseLabel_en-US" xlink:label="lab_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual payment for support of research activities</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities_label_en-US" xlink:label="lab_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, Annual Payment For Support Of Research Activities</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities_documentation_en-US" xlink:label="lab_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual payment for support of research activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities" xlink:to="lab_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_b2f8ad04-9ff0-422f-be5c-d29e79dfd98a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment amortization expense, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0b8659a3-0395-4822-b09c-9b3a264534fc_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AltorBioScienceLLCMember_99e3efa7-e776-4b59-910d-a99bd142f8e9_terseLabel_en-US" xlink:label="lab_ibrx_AltorBioScienceLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Altor BioScience, LLC</link:label>
    <link:label id="lab_ibrx_AltorBioScienceLLCMember_label_en-US" xlink:label="lab_ibrx_AltorBioScienceLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Altor BioScience, LLC [Member]</link:label>
    <link:label id="lab_ibrx_AltorBioScienceLLCMember_documentation_en-US" xlink:label="lab_ibrx_AltorBioScienceLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Altor BioScience, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AltorBioScienceLLCMember" xlink:href="ibrx-20230331.xsd#ibrx_AltorBioScienceLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AltorBioScienceLLCMember" xlink:to="lab_ibrx_AltorBioScienceLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_5e553061-a4cc-4ace-8578-23fcb6673d4f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares in a registered direct offering, net of discount and offering costs of $2,046 and value ascribed to associated warrants (Note 11)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_a5e62ea8-62a2-45fe-ab00-4d781a80500e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_32a585fe-98ed-4347-84e7-96df683c4221_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5e8b7ab2-e137-4302-8b47-d28f2219565f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_8853e53b-dc73-4e61-9863-5284cf4056f1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_7fbc74ba-84b6-48c3-bf16-0a92a3166f7c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_0e1e3609-7c15-4552-86a9-601db3937a8a_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4f96c0dc-404f-4d58-bbad-a298e30fd171_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_IncomeTaxTable_7308bd45-1e52-4d57-bfa5-531846da4dfb_terseLabel_en-US" xlink:label="lab_ibrx_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Table]</link:label>
    <link:label id="lab_ibrx_IncomeTaxTable_label_en-US" xlink:label="lab_ibrx_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Table]</link:label>
    <link:label id="lab_ibrx_IncomeTaxTable_documentation_en-US" xlink:label="lab_ibrx_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncomeTaxTable" xlink:href="ibrx-20230331.xsd#ibrx_IncomeTaxTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_IncomeTaxTable" xlink:to="lab_ibrx_IncomeTaxTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ContingentValueRightsObligations_557d9cf9-532a-4b70-91dc-9ada4d7071ff_terseLabel_en-US" xlink:label="lab_ibrx_ContingentValueRightsObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential contingent value rights to be earned</link:label>
    <link:label id="lab_ibrx_ContingentValueRightsObligations_label_en-US" xlink:label="lab_ibrx_ContingentValueRightsObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Value Rights Obligations</link:label>
    <link:label id="lab_ibrx_ContingentValueRightsObligations_documentation_en-US" xlink:label="lab_ibrx_ContingentValueRightsObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value rights obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ContingentValueRightsObligations" xlink:href="ibrx-20230331.xsd#ibrx_ContingentValueRightsObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ContingentValueRightsObligations" xlink:to="lab_ibrx_ContingentValueRightsObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ab862b20-0666-4882-8753-046489287e38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_09ddebef-7b02-4b8a-99d9-444b409041de_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_de3b8bbc-45ea-4789-adc9-4906563f8590_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember_115780eb-5892-4171-b6b7-1a214a63ddd2_terseLabel_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 through 2030</link:label>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember_label_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative, Fee, Tranche Two [Member]</link:label>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember_documentation_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative, Fee, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember" xlink:href="ibrx-20230331.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember" xlink:to="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4f5ab25c-6a58-4dbd-985a-f20839100df1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fe58068b-e9bd-4079-a31b-352fa2c630f7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty_299bf143-e8a3-4fe3-9ba0-2b81bdec41f7_negatedTerseLabel_en-US" xlink:label="lab_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of related-party notes discounts</link:label>
    <link:label id="lab_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty_label_en-US" xlink:label="lab_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Debt Discount (Premium), Related Party</link:label>
    <link:label id="lab_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty_documentation_en-US" xlink:label="lab_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Debt Discount (Premium), Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty" xlink:href="ibrx-20230331.xsd#ibrx_AmortizationOfDebtDiscountPremiumRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty" xlink:to="lab_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_2578998d-3106-44fb-8f42-bb0c8808cf5a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_aa06e188-d5a7-41fd-b65b-ddd3a2aa5e2b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_93abe8fd-a426-440a-a09b-3fe49011b275_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInJointVenture_11940a3d-df18-4202-a2ea-b2ea975c297d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in joint venture &#8211; an equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInJointVenture_c2f5120c-5b55-4cd4-89b8-922b8f7d9847_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to acquire interest in joint venture</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInJointVenture_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PercentageOfWhollyOwnedSubsidiary_71620033-324f-4575-a280-f397bf2a28de_terseLabel_en-US" xlink:label="lab_ibrx_PercentageOfWhollyOwnedSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage acquired</link:label>
    <link:label id="lab_ibrx_PercentageOfWhollyOwnedSubsidiary_label_en-US" xlink:label="lab_ibrx_PercentageOfWhollyOwnedSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Wholly Owned Subsidiary</link:label>
    <link:label id="lab_ibrx_PercentageOfWhollyOwnedSubsidiary_documentation_en-US" xlink:label="lab_ibrx_PercentageOfWhollyOwnedSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of wholly-owned subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PercentageOfWhollyOwnedSubsidiary" xlink:href="ibrx-20230331.xsd#ibrx_PercentageOfWhollyOwnedSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PercentageOfWhollyOwnedSubsidiary" xlink:to="lab_ibrx_PercentageOfWhollyOwnedSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_de979eea-2f5b-479e-8368-b6a8a11654f4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned_619557ec-2808-4f8c-9ae6-22f5296c64c2_terseLabel_en-US" xlink:label="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration arrangements, earned</link:label>
    <link:label id="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned_label_en-US" xlink:label="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Earned</link:label>
    <link:label id="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned_documentation_en-US" xlink:label="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned" xlink:href="ibrx-20230331.xsd#ibrx_BusinessCombinationContingentConsiderationArrangementsEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned" xlink:to="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_1724bfe9-7287-4412-9464-fbab5ed66599_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock_4fa1f621-cac2-48d4-9c23-8bdaf8f0ec12_terseLabel_en-US" xlink:label="lab_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information Related to Leases</link:label>
    <link:label id="lab_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="ibrx-20230331.xsd#ibrx_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_516c31ea-ed9c-4af4-b5ba-dd797e89754d_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares_5365c3d3-51d3-48bf-a802-e8fb06b12a17_terseLabel_en-US" xlink:label="lab_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash to be distributed in lieu of fractional shares (in dollars per share)</link:label>
    <link:label id="lab_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares_label_en-US" xlink:label="lab_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Cash Distributed In Lieu of Fractional Shares</link:label>
    <link:label id="lab_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares_documentation_en-US" xlink:label="lab_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Cash Distributed In Lieu of Fractional Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares" xlink:href="ibrx-20230331.xsd#ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares" xlink:to="lab_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtMember_c30944e6-76b7-4475-8423-4649db23fe9c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign bonds</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Government Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e5c792b2-0159-4a63-b6c8-f19c1aa3f6c1_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_ef59858b-3768-4834-bcf7-d91b6ea15b54_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTableTextBlock_80e49527-20bd-495a-837d-5d3af899bcdc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Value of Assets Acquired</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTableTextBlock" xlink:to="lab_us-gaap_AssetAcquisitionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LitigationLineItems_fe59327f-ddd4-419e-8218-7f4952169790_terseLabel_en-US" xlink:label="lab_ibrx_LitigationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation [Line Items]</link:label>
    <link:label id="lab_ibrx_LitigationLineItems_label_en-US" xlink:label="lab_ibrx_LitigationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation [Line Items]</link:label>
    <link:label id="lab_ibrx_LitigationLineItems_documentation_en-US" xlink:label="lab_ibrx_LitigationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationLineItems" xlink:href="ibrx-20230331.xsd#ibrx_LitigationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LitigationLineItems" xlink:to="lab_ibrx_LitigationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_7f2342b0-5fdc-4fbe-b61e-fc76d9d596cb_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_243e55bd-b66c-4b0e-bf79-ed3d40e529ab_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_5eb8be04-cf84-4bc3-8952-dc34859be698_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount awarded from other party in litigation settlement</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded from Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseRightOfUseAsset_cf098cf1-1a40-4f63-84ab-8ce99fd83081_totalLabel_en-US" xlink:label="lab_ibrx_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease assets</link:label>
    <link:label id="lab_ibrx_LeaseRightOfUseAsset_label_en-US" xlink:label="lab_ibrx_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_ibrx_LeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_ibrx_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseRightOfUseAsset" xlink:href="ibrx-20230331.xsd#ibrx_LeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseRightOfUseAsset" xlink:to="lab_ibrx_LeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_70132643-bca5-4bb3-aefe-3a12cc10ca99_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_4da33188-71b8-4c4b-8605-c52ba142fe2a_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares to be issued in private placement (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_fe06fab8-18a1-4094-8c90-7f38b5fc2760_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_f7ce0946-7579-4b87-8299-580fac1f75c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_BaseMonthlyRent_b6e6c772-fb78-46f4-aac5-5c25f749c79a_terseLabel_en-US" xlink:label="lab_ibrx_BaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base rent - monthly</link:label>
    <link:label id="lab_ibrx_BaseMonthlyRent_label_en-US" xlink:label="lab_ibrx_BaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Monthly Rent</link:label>
    <link:label id="lab_ibrx_BaseMonthlyRent_documentation_en-US" xlink:label="lab_ibrx_BaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base monthly rent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BaseMonthlyRent" xlink:href="ibrx-20230331.xsd#ibrx_BaseMonthlyRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_BaseMonthlyRent" xlink:to="lab_ibrx_BaseMonthlyRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_e6253c55-9d61-43c2-8f37-e4f5dc7af246_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_label_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncome" xlink:to="lab_us-gaap_InterestAndOtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ContingentConsiderationMember_c9e8aea9-f13b-4240-93d4-1b0e34839850_terseLabel_en-US" xlink:label="lab_ibrx_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_ibrx_ContingentConsiderationMember_label_en-US" xlink:label="lab_ibrx_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:label id="lab_ibrx_ContingentConsiderationMember_documentation_en-US" xlink:label="lab_ibrx_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ContingentConsiderationMember" xlink:href="ibrx-20230331.xsd#ibrx_ContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ContingentConsiderationMember" xlink:to="lab_ibrx_ContingentConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f0800c33-6592-4acc-bbc4-784cef514fdc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3412ef7b-5037-4a30-a659-824728250e0b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_VivaBioCellMember_561a5ce1-0548-4bfb-b872-a8f39009bbfc_terseLabel_en-US" xlink:label="lab_ibrx_VivaBioCellMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VivaBioCell</link:label>
    <link:label id="lab_ibrx_VivaBioCellMember_label_en-US" xlink:label="lab_ibrx_VivaBioCellMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VivaBioCell [Member]</link:label>
    <link:label id="lab_ibrx_VivaBioCellMember_documentation_en-US" xlink:label="lab_ibrx_VivaBioCellMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VivaBioCell.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_VivaBioCellMember" xlink:href="ibrx-20230331.xsd#ibrx_VivaBioCellMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_VivaBioCellMember" xlink:to="lab_ibrx_VivaBioCellMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_675d3c87-833b-414a-8c44-1e1b6cb199f3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_DuleyRoadLLCMember_649adc1c-9815-4620-a87e-dc2be28cac2c_terseLabel_en-US" xlink:label="lab_ibrx_DuleyRoadLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duley Road, LLC</link:label>
    <link:label id="lab_ibrx_DuleyRoadLLCMember_label_en-US" xlink:label="lab_ibrx_DuleyRoadLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duley Road, LLC [Member]</link:label>
    <link:label id="lab_ibrx_DuleyRoadLLCMember_documentation_en-US" xlink:label="lab_ibrx_DuleyRoadLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duley Road, LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DuleyRoadLLCMember" xlink:href="ibrx-20230331.xsd#ibrx_DuleyRoadLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_DuleyRoadLLCMember" xlink:to="lab_ibrx_DuleyRoadLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_f6fca75a-f9e7-4392-a36c-d305770430de_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a7298ff7-8c7f-4451-94b0-154b4c6b001e_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes and noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_fbc9462b-e7fd-49a3-80ed-f5b15c4ee2b0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; deficit:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8f1c7863-78dd-4e65-89f3-2680960d6cb8_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets (including amounts with related parties)</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_64bc7ea9-8e97-4f24-9013-1cf221f45350_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_8626ec6e-44ed-4d4e-9813-74d3c7b1b9de_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of related-party notes discounts</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_A23AlaskaLLCMember_8ee8114d-2b4c-43a8-9871-aaa681efe232_terseLabel_en-US" xlink:label="lab_ibrx_A23AlaskaLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">23 Alaska, LLC</link:label>
    <link:label id="lab_ibrx_A23AlaskaLLCMember_label_en-US" xlink:label="lab_ibrx_A23AlaskaLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">23 Alaska, LLC [Member]</link:label>
    <link:label id="lab_ibrx_A23AlaskaLLCMember_documentation_en-US" xlink:label="lab_ibrx_A23AlaskaLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">23 Alaska, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A23AlaskaLLCMember" xlink:href="ibrx-20230331.xsd#ibrx_A23AlaskaLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_A23AlaskaLLCMember" xlink:to="lab_ibrx_A23AlaskaLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_f0aee9a3-8436-4366-9830-a7b63c8bb47e_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantCellIncMember_0a518927-d8a5-4ac2-9f3a-319c2665466b_terseLabel_en-US" xlink:label="lab_ibrx_NantCellIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Cell Inc</link:label>
    <link:label id="lab_ibrx_NantCellIncMember_label_en-US" xlink:label="lab_ibrx_NantCellIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Cell Inc [Member]</link:label>
    <link:label id="lab_ibrx_NantCellIncMember_documentation_en-US" xlink:label="lab_ibrx_NantCellIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NantCell, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCellIncMember" xlink:href="ibrx-20230331.xsd#ibrx_NantCellIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantCellIncMember" xlink:to="lab_ibrx_NantCellIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PrepaidServices_d60093b7-7dc7-4b7a-9aaa-cbb552ab4f7a_terseLabel_en-US" xlink:label="lab_ibrx_PrepaidServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid services</link:label>
    <link:label id="lab_ibrx_PrepaidServices_label_en-US" xlink:label="lab_ibrx_PrepaidServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Services</link:label>
    <link:label id="lab_ibrx_PrepaidServices_documentation_en-US" xlink:label="lab_ibrx_PrepaidServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidServices" xlink:href="ibrx-20230331.xsd#ibrx_PrepaidServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PrepaidServices" xlink:to="lab_ibrx_PrepaidServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_058a3ea9-8009-4429-a706-514d6cff02ff_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3d3bfd06-dd9e-4681-94fa-92d3fd9f1205_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_02d965ba-c6ee-437e-90fc-8f6bdbdf855a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_206965a4-4aa7-4942-8802-8f8fde5322fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b370f499-3568-4d43-88ff-849a30b0097f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_IssuanceOfCommonStockUnderAtMarketOfferingShares_72bf9b86-8113-48a8-923d-b61ecf319067_terseLabel_en-US" xlink:label="lab_ibrx_IssuanceOfCommonStockUnderAtMarketOfferingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under ATM (in shares)</link:label>
    <link:label id="lab_ibrx_IssuanceOfCommonStockUnderAtMarketOfferingShares_label_en-US" xlink:label="lab_ibrx_IssuanceOfCommonStockUnderAtMarketOfferingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Common Stock Under At Market Offering Shares</link:label>
    <link:label id="lab_ibrx_IssuanceOfCommonStockUnderAtMarketOfferingShares_documentation_en-US" xlink:label="lab_ibrx_IssuanceOfCommonStockUnderAtMarketOfferingShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under at-the market offering, shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IssuanceOfCommonStockUnderAtMarketOfferingShares" xlink:href="ibrx-20230331.xsd#ibrx_IssuanceOfCommonStockUnderAtMarketOfferingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_IssuanceOfCommonStockUnderAtMarketOfferingShares" xlink:to="lab_ibrx_IssuanceOfCommonStockUnderAtMarketOfferingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SupplyAgreementPeriodOfExtendedTerm_4ecb5196-c740-45d6-91a0-15352b71c5c0_terseLabel_en-US" xlink:label="lab_ibrx_SupplyAgreementPeriodOfExtendedTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Optional extended term of supply agreement</link:label>
    <link:label id="lab_ibrx_SupplyAgreementPeriodOfExtendedTerm_label_en-US" xlink:label="lab_ibrx_SupplyAgreementPeriodOfExtendedTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Agreement, Period Of Extended Term</link:label>
    <link:label id="lab_ibrx_SupplyAgreementPeriodOfExtendedTerm_documentation_en-US" xlink:label="lab_ibrx_SupplyAgreementPeriodOfExtendedTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Agreement, Period Of Extended Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SupplyAgreementPeriodOfExtendedTerm" xlink:href="ibrx-20230331.xsd#ibrx_SupplyAgreementPeriodOfExtendedTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SupplyAgreementPeriodOfExtendedTerm" xlink:to="lab_ibrx_SupplyAgreementPeriodOfExtendedTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9a412ff1-12f9-4caf-a918-49d6d02e82b0_verboseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e4c886c3-d8c9-43ad-8ff3-26743b842a70_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in a registered direct offering, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidAbstract_aa5935d0-e0e5-4720-bfe2-4e200daf1f20_terseLabel_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidAbstract_label_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, To Be Paid [Abstract]</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidAbstract_documentation_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, To Be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidAbstract" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAbstract" xlink:to="lab_ibrx_LeaseLiabilityToBePaidAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AltorBioScienceCorporationMember_1953f2f6-6e88-4990-904c-4ce3b0117cc7_terseLabel_en-US" xlink:label="lab_ibrx_AltorBioScienceCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Altor BioScience Corporation</link:label>
    <link:label id="lab_ibrx_AltorBioScienceCorporationMember_label_en-US" xlink:label="lab_ibrx_AltorBioScienceCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Altor BioScience Corporation [Member]</link:label>
    <link:label id="lab_ibrx_AltorBioScienceCorporationMember_documentation_en-US" xlink:label="lab_ibrx_AltorBioScienceCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Altor BioScience Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AltorBioScienceCorporationMember" xlink:href="ibrx-20230331.xsd#ibrx_AltorBioScienceCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AltorBioScienceCorporationMember" xlink:to="lab_ibrx_AltorBioScienceCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearTwo_bcd5226a-dfef-42ac-9dd8-e9ce7bbba857_totalLabel_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearTwo" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearTwo_label_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, To Be Paid, Year Two</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearTwo_documentation_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, To Be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearTwo" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearTwo" xlink:to="lab_ibrx_LeaseLiabilityToBePaidYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember_716aa1b5-64c5-41d9-b9d8-ff5fe15e1063_terseLabel_en-US" xlink:label="lab_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC</link:label>
    <link:label id="lab_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember_label_en-US" xlink:label="lab_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC [Member]</link:label>
    <link:label id="lab_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember_documentation_en-US" xlink:label="lab_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember" xlink:to="lab_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_231922e1-fc3f-4138-a282-da26d57d4950_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d874bbad-b302-4b80-9860-e0364629a98c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_6e0b0cf1-8cc2-43ca-a838-87c06377e925_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gains (losses) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseLiability_2d088198-cc38-48df-8084-deeecd12fd36_totalLabel_en-US" xlink:label="lab_ibrx_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_ibrx_LeaseLiability_label_en-US" xlink:label="lab_ibrx_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_ibrx_LeaseLiability_documentation_en-US" xlink:label="lab_ibrx_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiability" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseLiability" xlink:to="lab_ibrx_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_439d81f6-feba-4188-b900-d1f77b4a676d_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_c7ccc4b9-4e45-4618-88b8-e13510c422c7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_995e529c-7fd6-4690-8ac1-daaaa0c70d2e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MutualFundMember_7c7e2a6d-0248-4c1a-86eb-0b7ec1344fd8_terseLabel_en-US" xlink:label="lab_us-gaap_MutualFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_us-gaap_MutualFundMember_label_en-US" xlink:label="lab_us-gaap_MutualFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual Fund [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MutualFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MutualFundMember" xlink:to="lab_us-gaap_MutualFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a19dbe3c-9851-4f1e-8b75-f1a57ee9292a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8a71b6f8-8505-47c6-8877-1da1a1045a6c_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8d2476eb-f65f-4f12-b67b-6e10761005e1_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_deee365b-af35-436f-b42d-b9715bd00645_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantCapital4Member_0ad07280-f5ac-4c39-b101-95e062f1da6d_terseLabel_en-US" xlink:label="lab_ibrx_NantCapital4Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital</link:label>
    <link:label id="lab_ibrx_NantCapital4Member_label_en-US" xlink:label="lab_ibrx_NantCapital4Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital 4 [Member]</link:label>
    <link:label id="lab_ibrx_NantCapital4Member_documentation_en-US" xlink:label="lab_ibrx_NantCapital4Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital 4</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapital4Member" xlink:href="ibrx-20230331.xsd#ibrx_NantCapital4Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantCapital4Member" xlink:to="lab_ibrx_NantCapital4Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_cd1e74b7-eb09-4751-8c76-b3d970800948_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_IncomeTaxLineItems_00171946-da64-4f36-8ac5-293762d1b91c_terseLabel_en-US" xlink:label="lab_ibrx_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Line Items]</link:label>
    <link:label id="lab_ibrx_IncomeTaxLineItems_label_en-US" xlink:label="lab_ibrx_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Line Items]</link:label>
    <link:label id="lab_ibrx_IncomeTaxLineItems_documentation_en-US" xlink:label="lab_ibrx_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncomeTaxLineItems" xlink:href="ibrx-20230331.xsd#ibrx_IncomeTaxLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_IncomeTaxLineItems" xlink:to="lab_ibrx_IncomeTaxLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_3ebc2c82-1ee8-4ec0-b8f5-9e96f4437e2c_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_1c8ee008-f2f3-4da6-9cb9-6f03fd275c97_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_86377ef3-045c-46f2-8b13-915bc57e28e7_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_493fb7d7-0304-4893-9a60-2c4f2c833650_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_983e8c57-e461-4e47-bc0d-f37eae12ebd7_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_00881f0e-8998-4dca-a734-3b5805e27899_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment_b9bcdfb1-347a-4ad1-959f-88169405639b_terseLabel_en-US" xlink:label="lab_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront cash payments</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment_label_en-US" xlink:label="lab_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, Nonrefundable Upfront Payment</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment_documentation_en-US" xlink:label="lab_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable upfront payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsNonrefundableUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment" xlink:to="lab_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_270881bc-1e66-49b3-a148-98ab7b4940bb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender origination fee</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ccbcd8c7-eaa4-482e-b64e-caaf01fea89f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearOne_72dc3a5c-426a-4ddd-81f2-058e2d31b012_totalLabel_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearOne" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearOne_label_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, To Be Paid, Year One</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearOne_documentation_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, To Be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearOne" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearOne" xlink:to="lab_ibrx_LeaseLiabilityToBePaidYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a503dd6c-bb1f-47fa-a991-900ec97d1c85_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock_732a4869-e5b0-4f71-98ad-e46738f03d1e_terseLabel_en-US" xlink:label="lab_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Option (FVO) Election</link:label>
    <link:label id="lab_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock_label_en-US" xlink:label="lab_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes, Fair Value Option Election [Policy Text Block]</link:label>
    <link:label id="lab_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock_documentation_en-US" xlink:label="lab_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes, Fair Value Option Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock" xlink:href="ibrx-20230331.xsd#ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock" xlink:to="lab_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_fcc7e0a3-2cef-41e3-8381-d5a7408827c9_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_1329fd33-abd4-4107-a40a-9fa89942983b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_58f13392-913e-4402-8983-1957466a8c27_terseLabel_en-US" xlink:label="lab_ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_label_en-US" xlink:label="lab_ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Due after Year Four</link:label>
    <link:label id="lab_ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_documentation_en-US" xlink:label="lab_ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee operating lease liability payments due after year four.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:href="ibrx-20230331.xsd#ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:to="lab_ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_156fc49a-2c03-412d-bf09-423471b6b86c_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SeptemberTwentyNineteenLeaseMember_cb02fed4-1411-4213-92bf-4ab25d94f051_terseLabel_en-US" xlink:label="lab_ibrx_SeptemberTwentyNineteenLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September 2019 Lease</link:label>
    <link:label id="lab_ibrx_SeptemberTwentyNineteenLeaseMember_label_en-US" xlink:label="lab_ibrx_SeptemberTwentyNineteenLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September Twenty Nineteen Lease [Member]</link:label>
    <link:label id="lab_ibrx_SeptemberTwentyNineteenLeaseMember_documentation_en-US" xlink:label="lab_ibrx_SeptemberTwentyNineteenLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">September twenty nineteen lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SeptemberTwentyNineteenLeaseMember" xlink:href="ibrx-20230331.xsd#ibrx_SeptemberTwentyNineteenLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SeptemberTwentyNineteenLeaseMember" xlink:to="lab_ibrx_SeptemberTwentyNineteenLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_DuleyRoadMember_527e7a25-208e-41c3-9345-5c9c4d8be811_terseLabel_en-US" xlink:label="lab_ibrx_DuleyRoadMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duley Road, LLC</link:label>
    <link:label id="lab_ibrx_DuleyRoadMember_label_en-US" xlink:label="lab_ibrx_DuleyRoadMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duley Road [Member]</link:label>
    <link:label id="lab_ibrx_DuleyRoadMember_documentation_en-US" xlink:label="lab_ibrx_DuleyRoadMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duley Road.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DuleyRoadMember" xlink:href="ibrx-20230331.xsd#ibrx_DuleyRoadMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_DuleyRoadMember" xlink:to="lab_ibrx_DuleyRoadMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1a4e3429-e367-4dfa-95e8-afea4cc8771a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_7478c26e-e296-45f6-bd5a-a72e6ca4350a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development (including amounts with related parties)</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1a5d686a-33e7-4ed5-acf8-06b470e0532a_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransactionTypeAxis_5b962c90-d643-4296-99e5-31e22d780cc3_terseLabel_en-US" xlink:label="lab_us-gaap_TransactionTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Type</link:label>
    <link:label id="lab_us-gaap_TransactionTypeAxis_label_en-US" xlink:label="lab_us-gaap_TransactionTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionTypeAxis" xlink:to="lab_us-gaap_TransactionTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantCapital3Member_c92f2e54-21e0-4c31-80b9-a46bc0e3309c_terseLabel_en-US" xlink:label="lab_ibrx_NantCapital3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital</link:label>
    <link:label id="lab_ibrx_NantCapital3Member_label_en-US" xlink:label="lab_ibrx_NantCapital3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital 3 [Member]</link:label>
    <link:label id="lab_ibrx_NantCapital3Member_documentation_en-US" xlink:label="lab_ibrx_NantCapital3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapital3Member" xlink:href="ibrx-20230331.xsd#ibrx_NantCapital3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantCapital3Member" xlink:to="lab_ibrx_NantCapital3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_5216bb80-bec1-4d8c-8811-936eef727300_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_9379e265-ae6a-4919-9cee-97ed1e02e5a7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_7279ab50-76a8-4de8-9455-8bb21ef3b429_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_81cb7b1e-4fa5-4238-bfe5-91cb9d029ac5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6bad6be5-a4fd-44f9-a2ee-bfb8c40853de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in units)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_d10403a8-22dc-4745-949f-de72e114dcc2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_89545538-044e-4d57-9cef-4ddf73af0c08_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NumberOfSquareFootOfFacilityLeased_8774f30e-3983-4b62-8067-1d8499fa2ebe_terseLabel_en-US" xlink:label="lab_ibrx_NumberOfSquareFootOfFacilityLeased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of square foot of facility leased</link:label>
    <link:label id="lab_ibrx_NumberOfSquareFootOfFacilityLeased_label_en-US" xlink:label="lab_ibrx_NumberOfSquareFootOfFacilityLeased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Square Foot Of Facility Leased</link:label>
    <link:label id="lab_ibrx_NumberOfSquareFootOfFacilityLeased_documentation_en-US" xlink:label="lab_ibrx_NumberOfSquareFootOfFacilityLeased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of square foot of facility leased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfSquareFootOfFacilityLeased" xlink:href="ibrx-20230331.xsd#ibrx_NumberOfSquareFootOfFacilityLeased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NumberOfSquareFootOfFacilityLeased" xlink:to="lab_ibrx_NumberOfSquareFootOfFacilityLeased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_65de6c1b-aa19-4067-839e-3da56212a0b0_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_1eabde5b-3c6b-4063-9f0b-b2186fe346fe_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from related parties</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_b866dee6-4907-4f18-923c-0501f9efa1a3_verboseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total due from related parties</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NumberOfDissentingShares_d92ce356-1dd3-4304-89b3-b6049497443a_terseLabel_en-US" xlink:label="lab_ibrx_NumberOfDissentingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dissenting shares to be released (in shares)</link:label>
    <link:label id="lab_ibrx_NumberOfDissentingShares_label_en-US" xlink:label="lab_ibrx_NumberOfDissentingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Dissenting Shares</link:label>
    <link:label id="lab_ibrx_NumberOfDissentingShares_documentation_en-US" xlink:label="lab_ibrx_NumberOfDissentingShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Dissenting Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfDissentingShares" xlink:href="ibrx-20230331.xsd#ibrx_NumberOfDissentingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NumberOfDissentingShares" xlink:to="lab_ibrx_NumberOfDissentingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_MeasurementInputExpectedMarketYieldMember_7d58181b-de41-4036-92cc-ee732baeadd1_terseLabel_en-US" xlink:label="lab_ibrx_MeasurementInputExpectedMarketYieldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected market yield</link:label>
    <link:label id="lab_ibrx_MeasurementInputExpectedMarketYieldMember_label_en-US" xlink:label="lab_ibrx_MeasurementInputExpectedMarketYieldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Market Yield [Member]</link:label>
    <link:label id="lab_ibrx_MeasurementInputExpectedMarketYieldMember_documentation_en-US" xlink:label="lab_ibrx_MeasurementInputExpectedMarketYieldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Market Yield</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MeasurementInputExpectedMarketYieldMember" xlink:href="ibrx-20230331.xsd#ibrx_MeasurementInputExpectedMarketYieldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_MeasurementInputExpectedMarketYieldMember" xlink:to="lab_ibrx_MeasurementInputExpectedMarketYieldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_2e2e528c-359f-4239-a2fe-c63e612ff5e0_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NCSCMember_7805eaa6-1322-4da3-aa59-19f63d397acb_verboseLabel_en-US" xlink:label="lab_ibrx_NCSCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NCSC</link:label>
    <link:label id="lab_ibrx_NCSCMember_55ec1cb7-830a-4546-a4b2-8ef651149a8a_terseLabel_en-US" xlink:label="lab_ibrx_NCSCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NCSC</link:label>
    <link:label id="lab_ibrx_NCSCMember_label_en-US" xlink:label="lab_ibrx_NCSCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NCSC [Member]</link:label>
    <link:label id="lab_ibrx_NCSCMember_documentation_en-US" xlink:label="lab_ibrx_NCSCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NCSC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NCSCMember" xlink:href="ibrx-20230331.xsd#ibrx_NCSCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NCSCMember" xlink:to="lab_ibrx_NCSCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_7c4f3133-9e68-446b-bc85-ea1f311120c1_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ae348045-1e0a-47b7-8f22-864fbfa50a78_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, beginning of year</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_73f64dfa-43d7-4516-a365-34c9d064d3f2_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, end of year</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_263462bc-4d38-4b36-85af-292b798de43c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of warrants</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_dc6d55a0-69bf-4e6f-8159-0e5216d3e3de_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PercentageOfSalesAgentCommission_3d4d03da-fd48-4c8b-96cf-9609272830de_terseLabel_en-US" xlink:label="lab_ibrx_PercentageOfSalesAgentCommission" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sales agent commission</link:label>
    <link:label id="lab_ibrx_PercentageOfSalesAgentCommission_label_en-US" xlink:label="lab_ibrx_PercentageOfSalesAgentCommission" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sales Agent Commission</link:label>
    <link:label id="lab_ibrx_PercentageOfSalesAgentCommission_documentation_en-US" xlink:label="lab_ibrx_PercentageOfSalesAgentCommission" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sales Agent Commission</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PercentageOfSalesAgentCommission" xlink:href="ibrx-20230331.xsd#ibrx_PercentageOfSalesAgentCommission"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PercentageOfSalesAgentCommission" xlink:to="lab_ibrx_PercentageOfSalesAgentCommission" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7f0fbe28-50a1-494a-a6be-e2bebb4cf796_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SupplyAgreementTermOfContract_3881baec-f7e0-48ad-ac55-c8506598a70b_terseLabel_en-US" xlink:label="lab_ibrx_SupplyAgreementTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial term of supply agreement</link:label>
    <link:label id="lab_ibrx_SupplyAgreementTermOfContract_label_en-US" xlink:label="lab_ibrx_SupplyAgreementTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Agreement, Term Of Contract</link:label>
    <link:label id="lab_ibrx_SupplyAgreementTermOfContract_documentation_en-US" xlink:label="lab_ibrx_SupplyAgreementTermOfContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Agreement, Term Of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SupplyAgreementTermOfContract" xlink:href="ibrx-20230331.xsd#ibrx_SupplyAgreementTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SupplyAgreementTermOfContract" xlink:to="lab_ibrx_SupplyAgreementTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_9f1587cc-37e8-4be9-a859-d9c5e878dcfd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">More than 12 months, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AccruedPreclinicalAndClinicalTrialCosts_be48e476-bc1f-4dd0-a4a7-264ae1fa605c_terseLabel_en-US" xlink:label="lab_ibrx_AccruedPreclinicalAndClinicalTrialCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued preclinical and clinical trial costs</link:label>
    <link:label id="lab_ibrx_AccruedPreclinicalAndClinicalTrialCosts_label_en-US" xlink:label="lab_ibrx_AccruedPreclinicalAndClinicalTrialCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Preclinical And Clinical Trial Costs</link:label>
    <link:label id="lab_ibrx_AccruedPreclinicalAndClinicalTrialCosts_documentation_en-US" xlink:label="lab_ibrx_AccruedPreclinicalAndClinicalTrialCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued preclinical and clinical trial costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccruedPreclinicalAndClinicalTrialCosts" xlink:href="ibrx-20230331.xsd#ibrx_AccruedPreclinicalAndClinicalTrialCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AccruedPreclinicalAndClinicalTrialCosts" xlink:to="lab_ibrx_AccruedPreclinicalAndClinicalTrialCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_87475de5-f0ae-499d-97f7-032992ffe1af_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3f8a66df-2534-4d59-b7f5-b322ca2ee9bf_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_81edf369-45c4-496e-ae4e-0dea057107bb_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_2a50a0c8-ab07-4668-920e-c7a8c36e41a5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_81cb886f-008a-4d3c-a4b7-5e7269d48648_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid in cash</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_92e04f41-a9a8-4ad8-8775-1bc0a8753f33_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per ImmunityBio common share &#8211; basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5c2b82cb-182e-44ed-8bf9-602cb8976d7c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_e6e6fdc9-35b2-47a1-b91e-dbcae11a4a0a_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborationAgreementsPeriodicLicensePayments_48bd2a92-2959-4cf1-a5cf-7db8e8ba6274_terseLabel_en-US" xlink:label="lab_ibrx_CollaborationAgreementsPeriodicLicensePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Periodic license payments</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsPeriodicLicensePayments_label_en-US" xlink:label="lab_ibrx_CollaborationAgreementsPeriodicLicensePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, Periodic License Payments</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsPeriodicLicensePayments_documentation_en-US" xlink:label="lab_ibrx_CollaborationAgreementsPeriodicLicensePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, Periodic License Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsPeriodicLicensePayments" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsPeriodicLicensePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborationAgreementsPeriodicLicensePayments" xlink:to="lab_ibrx_CollaborationAgreementsPeriodicLicensePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_6598a8b1-d7d6-4bee-8451-b62950b2a6a5_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_3859df2b-bbb9-48f3-83f5-565b1ab02295_terseLabel_en-US" xlink:label="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangements With Federal Government [Table]</link:label>
    <link:label id="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_label_en-US" xlink:label="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangements With Federal Government [Table]</link:label>
    <link:label id="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_documentation_en-US" xlink:label="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangements With Federal Government [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable" xlink:href="ibrx-20230331.xsd#ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable" xlink:to="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_61c3cd90-5a00-4db8-8c66-4a40c92597f8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total ImmunityBio stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c5a375d1-46a5-451c-bc56-f43751f18d14_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6b57175d-9a1c-4220-84bf-30301b40ee40_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1c3b5430-2f60-4fbf-80c0-fc5913e0d92f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d55c49fe-2bd5-49ec-a8b6-ca0db7539aac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_247f2be1-4897-456f-8ca6-669a2f7f43ac_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_df7c3b6c-ff4a-4177-9688-0da7711e2619_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Transaction Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_FinancialStatementDetailsTable_daee08bc-d848-4ee7-ba2b-200e1eef4833_terseLabel_en-US" xlink:label="lab_ibrx_FinancialStatementDetailsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Statement Details [Table]</link:label>
    <link:label id="lab_ibrx_FinancialStatementDetailsTable_label_en-US" xlink:label="lab_ibrx_FinancialStatementDetailsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Statement Details [Table]</link:label>
    <link:label id="lab_ibrx_FinancialStatementDetailsTable_documentation_en-US" xlink:label="lab_ibrx_FinancialStatementDetailsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Statement Details [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsTable" xlink:href="ibrx-20230331.xsd#ibrx_FinancialStatementDetailsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_FinancialStatementDetailsTable" xlink:to="lab_ibrx_FinancialStatementDetailsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_645256cf-62c0-468c-9f48-c7470f2d144d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c71fb31e-9f4d-40fc-b72c-4020eab7e16b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_15fb3da0-9f76-445f-8883-6929c6c2da44_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1631e117-be99-4503-9019-2d4779dc2f90_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_RelatedPartyWarrantsMember_79568b6c-7a42-455f-9ee6-c2a2b41cffd8_terseLabel_en-US" xlink:label="lab_ibrx_RelatedPartyWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding related-party warrants</link:label>
    <link:label id="lab_ibrx_RelatedPartyWarrantsMember_label_en-US" xlink:label="lab_ibrx_RelatedPartyWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Warrants [Member]</link:label>
    <link:label id="lab_ibrx_RelatedPartyWarrantsMember_documentation_en-US" xlink:label="lab_ibrx_RelatedPartyWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyWarrantsMember" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_RelatedPartyWarrantsMember" xlink:to="lab_ibrx_RelatedPartyWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f4bb8a48-2b57-47d0-9204-70c44c9f84bf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8b8c8c6a-e426-4630-814f-3c70ba9cb796_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ReimbursementsMember_11f7f946-6aa1-4906-991d-f5b9aa4a331d_terseLabel_en-US" xlink:label="lab_ibrx_ReimbursementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursements</link:label>
    <link:label id="lab_ibrx_ReimbursementsMember_label_en-US" xlink:label="lab_ibrx_ReimbursementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursements [Member]</link:label>
    <link:label id="lab_ibrx_ReimbursementsMember_documentation_en-US" xlink:label="lab_ibrx_ReimbursementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ReimbursementsMember" xlink:href="ibrx-20230331.xsd#ibrx_ReimbursementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ReimbursementsMember" xlink:to="lab_ibrx_ReimbursementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LitigationTable_a4d167ba-da43-41d4-bda5-c1f5627ff1e3_terseLabel_en-US" xlink:label="lab_ibrx_LitigationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation [Table]</link:label>
    <link:label id="lab_ibrx_LitigationTable_label_en-US" xlink:label="lab_ibrx_LitigationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation [Table]</link:label>
    <link:label id="lab_ibrx_LitigationTable_documentation_en-US" xlink:label="lab_ibrx_LitigationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationTable" xlink:href="ibrx-20230331.xsd#ibrx_LitigationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LitigationTable" xlink:to="lab_ibrx_LitigationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_05f8f39a-c63f-483b-a969-de543d753d3e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_75bdd671-9fe0-4fca-92a5-65601f874e46_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to unvested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_6a3aba49-b636-4130-802f-a70d03fb2078_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_b4533112-b0c7-4ebf-ad6a-7eb138273413_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e0fa7dbe-c8e9-498b-902e-b7a1e74bb6fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expenses Included on Operations Statement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4a0d53f1-0c40-41fe-9754-d16041bb61b2_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to ImmunityBio common stockholders</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_ace8596f-b36b-47c9-af03-f695dbaee636_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Information Regarding Leases (Detail)</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_936332cb-e211-41cc-b3e6-33f26b0143fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for future grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_e6e4b442-953e-45b4-a1d5-a49d25623295_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1a950980-09a4-4602-a256-b31594e0cd14_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AccruedConstructionCostsCurrent_f1134547-8091-4e7f-a371-0acb833eab59_terseLabel_en-US" xlink:label="lab_ibrx_AccruedConstructionCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued construction costs</link:label>
    <link:label id="lab_ibrx_AccruedConstructionCostsCurrent_label_en-US" xlink:label="lab_ibrx_AccruedConstructionCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Construction Costs, Current</link:label>
    <link:label id="lab_ibrx_AccruedConstructionCostsCurrent_documentation_en-US" xlink:label="lab_ibrx_AccruedConstructionCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Construction Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccruedConstructionCostsCurrent" xlink:href="ibrx-20230331.xsd#ibrx_AccruedConstructionCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AccruedConstructionCostsCurrent" xlink:to="lab_ibrx_AccruedConstructionCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PromissoryNotesPayableMember_b7ff9120-6a2b-4f89-a29b-1d1235fd00aa_terseLabel_en-US" xlink:label="lab_ibrx_PromissoryNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes</link:label>
    <link:label id="lab_ibrx_PromissoryNotesPayableMember_90748bd8-0576-4913-b80a-76693e3c81d7_verboseLabel_en-US" xlink:label="lab_ibrx_PromissoryNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-convertible Notes</link:label>
    <link:label id="lab_ibrx_PromissoryNotesPayableMember_label_en-US" xlink:label="lab_ibrx_PromissoryNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes Payable [Member]</link:label>
    <link:label id="lab_ibrx_PromissoryNotesPayableMember_documentation_en-US" xlink:label="lab_ibrx_PromissoryNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PromissoryNotesPayableMember" xlink:href="ibrx-20230331.xsd#ibrx_PromissoryNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PromissoryNotesPayableMember" xlink:to="lab_ibrx_PromissoryNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue_c730cb54-8ca7-44b4-8ca2-b37c364be6ad_terseLabel_en-US" xlink:label="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated benefit at grant date fair value</link:label>
    <link:label id="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue_label_en-US" xlink:label="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Estimated Benefit At Grant Date Fair Value</link:label>
    <link:label id="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue_documentation_en-US" xlink:label="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award estimated benefit at grant date fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" xlink:href="ibrx-20230331.xsd#ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" xlink:to="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_e6a7dbdb-8d9c-43ee-9704-78928906ebe0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Optional extended lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_ff03d265-f2e3-4fa6-9615-0ce6227b0063_terseLabel_en-US" xlink:label="lab_ibrx_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid offering costs included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_ibrx_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_label_en-US" xlink:label="lab_ibrx_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid Offering Costs Included In Accounts Payable And Accrued Expenses</link:label>
    <link:label id="lab_ibrx_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_documentation_en-US" xlink:label="lab_ibrx_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid offering costs included in accounts payable and accrued expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:href="ibrx-20230331.xsd#ibrx_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="lab_ibrx_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_aa7c2178-0f26-4647-8625-50b7b9fb1e47_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, noncurrent</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_71fc0635-4943-4757-97d9-2008f91e838a_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_9504b8d9-c35c-4209-abdf-00c1aa7016eb_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture &amp; fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_ebecebe5-07fb-407c-ad6b-8a044d1fc9e5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c508d4b1-3bdf-40cf-81df-3a06e601e183_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, less current portion (including amounts with related parties)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b4702142-1087-493b-b631-f0f11a73d22e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_00bf97b3-ec04-4c53-bc4c-6584c6a866c1_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_9ea77669-73cc-4177-9503-aee8d228ba66_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_064bb355-3802-4ce2-917c-3bf539dd0b5a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Statement Details</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_431abac5-005c-4cf2-bd4d-ea515ba2bb69_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_19cbda7b-0354-4a48-87f0-1db77585f6b9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_8647a391-5d91-4c0c-8ef1-f287038f5056_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3110b851-2962-4c6b-8112-6bfb2a1aa818_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5ff9458d-6532-498f-b14f-5d2673d8e04f_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_0d2ede35-eb86-4708-8575-6b30a935616d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_d8399d99-2f53-4a59-a53e-9ae550955751_verboseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total ImmunityBio Stockholders&#8217; Deficit</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantMobileMember_22708a56-9008-4988-af27-393c0359e890_terseLabel_en-US" xlink:label="lab_ibrx_NantMobileMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NantMobile</link:label>
    <link:label id="lab_ibrx_NantMobileMember_label_en-US" xlink:label="lab_ibrx_NantMobileMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NantMobile [Member]</link:label>
    <link:label id="lab_ibrx_NantMobileMember_documentation_en-US" xlink:label="lab_ibrx_NantMobileMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NantMobile.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantMobileMember" xlink:href="ibrx-20230331.xsd#ibrx_NantMobileMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantMobileMember" xlink:to="lab_ibrx_NantMobileMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_fbcf1f63-d1b0-4e44-b0c6-c7ce7deed357_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_d3f24327-1bf0-4c1f-a124-3fc8c719cf4e_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total ImmunityBio Stockholders&#8217; (Deficit) Equity</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_b65573a1-28ac-4854-b718-d0d7b0d5843f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_0dc2c941-21f2-41e9-bf4a-66654fdb6f31_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_d10cdd75-8277-46a9-a684-8cdaf29dc5f0_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-Party Debt</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_9745aa7e-6c46-4023-971e-fae802de982b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-Party Agreements</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LitigationSettlementInterestPercent_01188156-882f-47bb-a014-92f173030b91_terseLabel_en-US" xlink:label="lab_ibrx_LitigationSettlementInterestPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest related to litigation settlement, as a percent</link:label>
    <link:label id="lab_ibrx_LitigationSettlementInterestPercent_label_en-US" xlink:label="lab_ibrx_LitigationSettlementInterestPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement Interest, Percent</link:label>
    <link:label id="lab_ibrx_LitigationSettlementInterestPercent_documentation_en-US" xlink:label="lab_ibrx_LitigationSettlementInterestPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement Interest, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationSettlementInterestPercent" xlink:href="ibrx-20230331.xsd#ibrx_LitigationSettlementInterestPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LitigationSettlementInterestPercent" xlink:to="lab_ibrx_LitigationSettlementInterestPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_12784494-4ae2-4c34-b29b-5e979ab78082_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 12 months, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_WarrantsPolicyTextBlock_31b4ae3c-7325-4c51-8b9e-d3aac66f9099_terseLabel_en-US" xlink:label="lab_ibrx_WarrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_ibrx_WarrantsPolicyTextBlock_label_en-US" xlink:label="lab_ibrx_WarrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants [Policy Text Block]</link:label>
    <link:label id="lab_ibrx_WarrantsPolicyTextBlock_documentation_en-US" xlink:label="lab_ibrx_WarrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_WarrantsPolicyTextBlock" xlink:href="ibrx-20230331.xsd#ibrx_WarrantsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_WarrantsPolicyTextBlock" xlink:to="lab_ibrx_WarrantsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_c4fd5aa9-a07e-413e-8cb9-7daa317045ee_verboseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4b19b5ed-8c99-4c8d-b032-4bcfe7a55eea_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_9c235c00-442c-4a01-91c1-f6c4cb3f51e0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_ad0d2245-ff8d-4585-857e-6bf2857f69ae_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of warrants outstanding</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_ee56f1a2-1c68-41ab-b08e-52958cd25eb8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments of finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_10d65870-5a91-400f-8367-d974400a7c2e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flow from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_5bc8df95-378a-421d-b4c3-a9d98e6d3c0d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2a070314-774e-4b7c-b452-6196e5d0f8c4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, beginning balance (in units)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6d12cf99-8d55-46a3-bd14-93bdddc39103_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, ending balance (in units)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_4d716271-9de7-4ec3-8d86-d3039097a729_terseLabel_en-US" xlink:label="lab_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains from equity securities</link:label>
    <link:label id="lab_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Equity Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_abfe9f7a-2f36-495b-9de0-d105db3fdad6_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_a3bb6368-5627-4a67-8198-33a1e19f61eb_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1c82ea93-29dc-4411-90d0-149310ecabbb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_691c3c5b-45b8-415f-a16f-26f74c9e3877_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_0c29b717-503b-4d32-8dee-4fe867f28585_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_789f6748-903f-415b-8b37-dedea251956f_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative (including amounts with related parties)</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_4d420ca8-e471-4cea-a488-e42d141fd66f_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis_252baeb9-9e77-4a28-af30-ad7271e2a911_terseLabel_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Axis]</link:label>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis_label_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Axis]</link:label>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis_documentation_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis" xlink:href="ibrx-20230331.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis" xlink:to="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9978a4c5-0f67-463c-b33e-d23e1df94aa6_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_1bc32dbc-98a5-42a2-9d51-bef08efc9153_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets, net (including amounts with related parties)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_2411af85-4994-46d2-9ca6-058774ace841_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_260416a1-f242-444c-ae0c-f112b306e037_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PrepaidSoftwareLicenseFees_29114bb1-5bbd-4c5e-9156-c35d3ca07a13_terseLabel_en-US" xlink:label="lab_ibrx_PrepaidSoftwareLicenseFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid software license fees</link:label>
    <link:label id="lab_ibrx_PrepaidSoftwareLicenseFees_label_en-US" xlink:label="lab_ibrx_PrepaidSoftwareLicenseFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Software License Fees</link:label>
    <link:label id="lab_ibrx_PrepaidSoftwareLicenseFees_documentation_en-US" xlink:label="lab_ibrx_PrepaidSoftwareLicenseFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid software license fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidSoftwareLicenseFees" xlink:href="ibrx-20230331.xsd#ibrx_PrepaidSoftwareLicenseFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PrepaidSoftwareLicenseFees" xlink:to="lab_ibrx_PrepaidSoftwareLicenseFees" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ContingentValueRightsObligationSalesMilestoneMember_051ccae1-418d-46c0-a71a-648915112669_terseLabel_en-US" xlink:label="lab_ibrx_ContingentValueRightsObligationSalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Value Rights Payable, Sales Milestone</link:label>
    <link:label id="lab_ibrx_ContingentValueRightsObligationSalesMilestoneMember_label_en-US" xlink:label="lab_ibrx_ContingentValueRightsObligationSalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Value Rights Obligation, Sales Milestone [Member]</link:label>
    <link:label id="lab_ibrx_ContingentValueRightsObligationSalesMilestoneMember_documentation_en-US" xlink:label="lab_ibrx_ContingentValueRightsObligationSalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value rights obligation before December 31, 2026.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ContingentValueRightsObligationSalesMilestoneMember" xlink:href="ibrx-20230331.xsd#ibrx_ContingentValueRightsObligationSalesMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ContingentValueRightsObligationSalesMilestoneMember" xlink:to="lab_ibrx_ContingentValueRightsObligationSalesMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantCapital6Member_f0e09c93-6d6a-4f66-943d-43de08d34361_terseLabel_en-US" xlink:label="lab_ibrx_NantCapital6Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital</link:label>
    <link:label id="lab_ibrx_NantCapital6Member_label_en-US" xlink:label="lab_ibrx_NantCapital6Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital 6 [Member]</link:label>
    <link:label id="lab_ibrx_NantCapital6Member_documentation_en-US" xlink:label="lab_ibrx_NantCapital6Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital 6</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapital6Member" xlink:href="ibrx-20230331.xsd#ibrx_NantCapital6Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantCapital6Member" xlink:to="lab_ibrx_NantCapital6Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_February2023ShelfRegistrationStatementMember_fe010a75-07cc-495a-9315-d39d904f5a96_terseLabel_en-US" xlink:label="lab_ibrx_February2023ShelfRegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">February 2023 Shelf Registration Statement</link:label>
    <link:label id="lab_ibrx_February2023ShelfRegistrationStatementMember_label_en-US" xlink:label="lab_ibrx_February2023ShelfRegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">February 2023 Shelf Registration Statement [Member]</link:label>
    <link:label id="lab_ibrx_February2023ShelfRegistrationStatementMember_documentation_en-US" xlink:label="lab_ibrx_February2023ShelfRegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">February 2023 Shelf Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023ShelfRegistrationStatementMember" xlink:href="ibrx-20230331.xsd#ibrx_February2023ShelfRegistrationStatementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_February2023ShelfRegistrationStatementMember" xlink:to="lab_ibrx_February2023ShelfRegistrationStatementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4532421b-4c5a-465c-bafb-f35484e4ab38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_1c4b8688-b684-4bb7-9b31-f713bfb57b4a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_88ff6273-3d1a-478c-8620-2b976009ab01_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_a68caa85-03e9-4075-8a8f-eb968e9d2c91_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment to acquire assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SponsoredResearchAgreementMember_c7fc8244-fc17-44bd-8f27-ea7c566d50d9_terseLabel_en-US" xlink:label="lab_ibrx_SponsoredResearchAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sponsored Research Agreement</link:label>
    <link:label id="lab_ibrx_SponsoredResearchAgreementMember_label_en-US" xlink:label="lab_ibrx_SponsoredResearchAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sponsored Research Agreement [Member]</link:label>
    <link:label id="lab_ibrx_SponsoredResearchAgreementMember_documentation_en-US" xlink:label="lab_ibrx_SponsoredResearchAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sponsored research agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SponsoredResearchAgreementMember" xlink:href="ibrx-20230331.xsd#ibrx_SponsoredResearchAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SponsoredResearchAgreementMember" xlink:to="lab_ibrx_SponsoredResearchAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CurrentAssetsMember_3fe6e389-b331-40bd-8b04-39159dcb343d_terseLabel_en-US" xlink:label="lab_ibrx_CurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_ibrx_CurrentAssetsMember_label_en-US" xlink:label="lab_ibrx_CurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets [Member]</link:label>
    <link:label id="lab_ibrx_CurrentAssetsMember_documentation_en-US" xlink:label="lab_ibrx_CurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CurrentAssetsMember" xlink:href="ibrx-20230331.xsd#ibrx_CurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CurrentAssetsMember" xlink:to="lab_ibrx_CurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_4c37e98f-95b3-47cd-9ae0-29bba263567d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantCapitalIssued33123Member_7bd37e05-5fbc-45df-abfc-3e0975a1c696_terseLabel_en-US" xlink:label="lab_ibrx_NantCapitalIssued33123Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital</link:label>
    <link:label id="lab_ibrx_NantCapitalIssued33123Member_label_en-US" xlink:label="lab_ibrx_NantCapitalIssued33123Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital, Issued 3/31/23 [Member]</link:label>
    <link:label id="lab_ibrx_NantCapitalIssued33123Member_documentation_en-US" xlink:label="lab_ibrx_NantCapitalIssued33123Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital, Issued 3/31/23</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalIssued33123Member" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalIssued33123Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantCapitalIssued33123Member" xlink:to="lab_ibrx_NantCapitalIssued33123Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_94f61b64-dfa2-4842-b808-25cfae1c5c70_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_ab1c8f66-4af2-4112-8171-f2547784a8e3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement agent fees and other offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b0acf921-d71c-4f24-9550-e1df45bd4e44_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity and Related Information under Equity Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_da6b7e48-9525-4a1f-a334-f6f3a638fe48_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2ca3675d-b434-4979-8535-bc059f0d6399_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseOperatingLeaseAnnualLeasePayment_9bed37f2-4f1d-42bc-af14-dc51753d818c_terseLabel_en-US" xlink:label="lab_ibrx_LeaseOperatingLeaseAnnualLeasePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual lease payment</link:label>
    <link:label id="lab_ibrx_LeaseOperatingLeaseAnnualLeasePayment_label_en-US" xlink:label="lab_ibrx_LeaseOperatingLeaseAnnualLeasePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Operating Lease, Annual Lease Payment</link:label>
    <link:label id="lab_ibrx_LeaseOperatingLeaseAnnualLeasePayment_documentation_en-US" xlink:label="lab_ibrx_LeaseOperatingLeaseAnnualLeasePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Operating Lease, Annual Lease Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseOperatingLeaseAnnualLeasePayment" xlink:href="ibrx-20230331.xsd#ibrx_LeaseOperatingLeaseAnnualLeasePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseOperatingLeaseAnnualLeasePayment" xlink:to="lab_ibrx_LeaseOperatingLeaseAnnualLeasePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_444366ec-5fb5-462d-8f07-c03d62b769f7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b296f5e4-9a03-4d24-ba6c-0d037573724b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_892c7ef6-901a-46a8-86b9-59c16581680b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a8e55e5f-c81c-41c8-a188-0abc254f809b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_ee54fc58-d7b9-4b91-bba8-d98373a2861d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances to support operations</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_0cae7270-8b33-46bc-976a-2467c036b46b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities measured at fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d9cc63d4-7cd8-4660-abdc-e7d6d9d79975_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1dc46db3-0270-429e-9e15-7b07ddd407e7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_147c8f37-2319-497d-a535-4c65dd0a2c7e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_b03c2a4e-5a6a-443e-b9dd-af6eed54acca_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_8f0817aa-c535-49a6-ad9e-abf9f3b85ad9_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_daa75833-1512-4639-a99c-26c00c5a1c53_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d6734124-6d07-44a2-9ee8-2b62914cf99b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_eebf3360-4f19-4d52-a92b-6a5aaae6aa5a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0578c2a2-65fe-46af-bd76-a851e1fa9b57_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare_70ec9a70-9b90-4d5c-8f0b-a7b8c8f81af3_terseLabel_en-US" xlink:label="lab_ibrx_OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to convert accrued and unpaid interest to shares of common stock (in dollars per share)</link:label>
    <link:label id="lab_ibrx_OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare_label_en-US" xlink:label="lab_ibrx_OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to Convert Accrued and Unpaid Interest to Shares of Common Stock, Price Per Share</link:label>
    <link:label id="lab_ibrx_OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare_documentation_en-US" xlink:label="lab_ibrx_OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to Convert Accrued and Unpaid Interest to Shares of Common Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare" xlink:href="ibrx-20230331.xsd#ibrx_OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare" xlink:to="lab_ibrx_OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_be67845f-5e97-4953-bd49-d5739cb90e98_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_af9072d1-dcfb-40ee-b7e1-6c909ca88de6_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_79814400-03d3-41fd-9cec-327383a91836_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ba9f50eb-edc3-4d9e-8907-213fdd3447de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of stock option exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_December2022WarrantsMember_cab33be5-1623-423d-a9e9-caa72ccb616a_terseLabel_en-US" xlink:label="lab_ibrx_December2022WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2022 Warrants</link:label>
    <link:label id="lab_ibrx_December2022WarrantsMember_label_en-US" xlink:label="lab_ibrx_December2022WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2022 Warrants [Member]</link:label>
    <link:label id="lab_ibrx_December2022WarrantsMember_documentation_en-US" xlink:label="lab_ibrx_December2022WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2022 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_December2022WarrantsMember" xlink:href="ibrx-20230331.xsd#ibrx_December2022WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_December2022WarrantsMember" xlink:to="lab_ibrx_December2022WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0a43f8ef-2da0-47c9-9f74-d94cbe8335dc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares used in computing net loss per share &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1bf7659c-dc52-4553-8345-954096388fa8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_StateOfNewYorkMember_10d3098a-128f-4000-b72b-1e05941a95ac_terseLabel_en-US" xlink:label="lab_ibrx_StateOfNewYorkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Of New York</link:label>
    <link:label id="lab_ibrx_StateOfNewYorkMember_label_en-US" xlink:label="lab_ibrx_StateOfNewYorkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Of New York [Member]</link:label>
    <link:label id="lab_ibrx_StateOfNewYorkMember_documentation_en-US" xlink:label="lab_ibrx_StateOfNewYorkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Of New York</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StateOfNewYorkMember" xlink:href="ibrx-20230331.xsd#ibrx_StateOfNewYorkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_StateOfNewYorkMember" xlink:to="lab_ibrx_StateOfNewYorkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04f99954-75b9-4372-893e-4e8d4285f3d6_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_FourTwoZeroNashLLCMember_59689f85-363d-4616-a9b8-e35615a4fbc3_terseLabel_en-US" xlink:label="lab_ibrx_FourTwoZeroNashLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">420 Nash, LLC</link:label>
    <link:label id="lab_ibrx_FourTwoZeroNashLLCMember_label_en-US" xlink:label="lab_ibrx_FourTwoZeroNashLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Two Zero Nash, LLC [Member]</link:label>
    <link:label id="lab_ibrx_FourTwoZeroNashLLCMember_documentation_en-US" xlink:label="lab_ibrx_FourTwoZeroNashLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Two Zero Nash, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FourTwoZeroNashLLCMember" xlink:href="ibrx-20230331.xsd#ibrx_FourTwoZeroNashLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_FourTwoZeroNashLLCMember" xlink:to="lab_ibrx_FourTwoZeroNashLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ed1c40f2-b576-4788-ac25-b1f3ee7f65bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_adcda935-eeb0-4b1f-85f7-be7325d3acb7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available-for-Sale Marketable Debt Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_c9bd43ac-d25d-405b-b078-1a28452064c6_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable equity securities with readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_VariousMember_f2582516-b147-4536-b8dd-27424811a247_terseLabel_en-US" xlink:label="lab_ibrx_VariousMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various</link:label>
    <link:label id="lab_ibrx_VariousMember_label_en-US" xlink:label="lab_ibrx_VariousMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various [Member]</link:label>
    <link:label id="lab_ibrx_VariousMember_documentation_en-US" xlink:label="lab_ibrx_VariousMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_VariousMember" xlink:href="ibrx-20230331.xsd#ibrx_VariousMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_VariousMember" xlink:to="lab_ibrx_VariousMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_54317ee6-c188-4ec8-9d87-a755c4eadac0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001&#160;par value; 900,000,000&#160;shares authorized as of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively; 435,923,104 and 421,569,115 shares issued and outstanding as of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively; excluding treasury stock, 163,800&#160;shares outstanding as of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_February2023WarrantsMember_2f53487f-2f73-4295-ab3d-d9c06a50e8ab_terseLabel_en-US" xlink:label="lab_ibrx_February2023WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">February 2023 Warrants</link:label>
    <link:label id="lab_ibrx_February2023WarrantsMember_label_en-US" xlink:label="lab_ibrx_February2023WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">February 2023 Warrants [Member]</link:label>
    <link:label id="lab_ibrx_February2023WarrantsMember_documentation_en-US" xlink:label="lab_ibrx_February2023WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">February 2023 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023WarrantsMember" xlink:href="ibrx-20230331.xsd#ibrx_February2023WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_February2023WarrantsMember" xlink:to="lab_ibrx_February2023WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_7789861b-0ab6-4f9f-9cb5-84504536a05e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_ea5c71f6-a4d6-409c-9ed7-003cf31f138f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0a7039b6-12da-4656-892b-4b1fcbc4ba86_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_d0e69d39-442b-4b95-9967-b5995c952c63_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units (RSUs) (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_RelatedPartyNotesInterestMember_c6a50280-2a9b-4ad4-a4b7-8b66a0abe3ba_terseLabel_en-US" xlink:label="lab_ibrx_RelatedPartyNotesInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payments</link:label>
    <link:label id="lab_ibrx_RelatedPartyNotesInterestMember_label_en-US" xlink:label="lab_ibrx_RelatedPartyNotesInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Notes - Interest [Member]</link:label>
    <link:label id="lab_ibrx_RelatedPartyNotesInterestMember_documentation_en-US" xlink:label="lab_ibrx_RelatedPartyNotesInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Notes - Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesInterestMember" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyNotesInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_RelatedPartyNotesInterestMember" xlink:to="lab_ibrx_RelatedPartyNotesInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_699a9ff0-d36d-4844-9ac8-ecff900476ff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_34609b5c-141a-4c0a-950a-87ece58c5b43_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net realized losses on investments</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5c5d94f2-cf5f-4d0c-9dee-d40924b8de84_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Excluded from the Computation of Potentially Dilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ImmunoOncologyClinicMember_82728ce1-d8e6-4d52-8ee4-e47e5d36c5f0_terseLabel_en-US" xlink:label="lab_ibrx_ImmunoOncologyClinicMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immuno-Oncology Clinic, Inc.</link:label>
    <link:label id="lab_ibrx_ImmunoOncologyClinicMember_label_en-US" xlink:label="lab_ibrx_ImmunoOncologyClinicMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immuno-Oncology Clinic [Member]</link:label>
    <link:label id="lab_ibrx_ImmunoOncologyClinicMember_documentation_en-US" xlink:label="lab_ibrx_ImmunoOncologyClinicMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immuno-Oncology Clinic.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ImmunoOncologyClinicMember" xlink:href="ibrx-20230331.xsd#ibrx_ImmunoOncologyClinicMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ImmunoOncologyClinicMember" xlink:to="lab_ibrx_ImmunoOncologyClinicMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2b20cddc-3461-4f09-957b-c9cce7ade40b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_bbb1312f-6ada-43d7-81a0-39f0a21a22fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease costs</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_916b2e31-5add-4004-b62d-20d04391c27b_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_3cd26274-2878-4dd3-91ae-499e6b9ddbc2_verboseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent_1c9bb33e-6dfc-4981-ad6a-1ca5aef81207_terseLabel_en-US" xlink:label="lab_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related parties</link:label>
    <link:label id="lab_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent_label_en-US" xlink:label="lab_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Due To Related Parties Current And Non Current</link:label>
    <link:label id="lab_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent_documentation_en-US" xlink:label="lab_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in due to related parties current and non current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent" xlink:href="ibrx-20230331.xsd#ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent" xlink:to="lab_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f06b042c-d6df-4cce-9e1c-15019a1ae630_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_e3bb585b-6886-4511-b9cd-a287f92577e9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued bonus</link:label>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Bonuses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0c520ad6-b42a-4d04-bc0c-3bcd8f1c7b8a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_86e8d935-ff7d-4044-bf0d-4f726588084d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantCapitalTwoMember_0820e56c-05fc-4d04-8dd4-2202136fd238_terseLabel_en-US" xlink:label="lab_ibrx_NantCapitalTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital</link:label>
    <link:label id="lab_ibrx_NantCapitalTwoMember_label_en-US" xlink:label="lab_ibrx_NantCapitalTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital Two [Member]</link:label>
    <link:label id="lab_ibrx_NantCapitalTwoMember_documentation_en-US" xlink:label="lab_ibrx_NantCapitalTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant capital two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalTwoMember" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantCapitalTwoMember" xlink:to="lab_ibrx_NantCapitalTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_d32c8f00-bd21-4fa2-8d92-f7103af280e4_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_56c29af4-bebf-42c6-b3e5-5f7691f431be_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_2cfdb946-9117-4a79-8986-a85aa9673378_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercises of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_505fe986-8f3f-47da-a6dc-1f6b0345fa29_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_fe1eb7a0-7e46-41ef-9594-89dfd7ceb5fd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMeasurementInput_f9cd6b44-4547-4a50-94f8-741e640a21b7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable inputs, Level 3 valuations</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMeasurementInput" xlink:to="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_7837687b-a748-4b72-9b8c-d6f57585ca6d_negatedTerseLabel_en-US" xlink:label="lab_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_label_en-US" xlink:label="lab_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Impairment</link:label>
    <link:label id="lab_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_documentation_en-US" xlink:label="lab_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:href="ibrx-20230331.xsd#ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:to="lab_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2fd3495f-7df9-41cb-a0ee-a1a6d9c66542_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment purchases included in accounts payable, accrued expenses and due to related parties</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_aab80b4d-346b-4962-8379-a7209c614458_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liabilities</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_80f3fcd9-29ae-478b-9c13-4e1d674a0c42_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_b4220c04-7458-4b58-ac3d-044f05dbac23_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Terms</link:label>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAgreementTermsMember" xlink:to="lab_us-gaap_LicenseAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_9b3d44b9-15c3-4194-bb62-1deabc00eb89_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseOther_73ebf76a-affa-4737-8d61-c545c06e19ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseOther_label_en-US" xlink:label="lab_us-gaap_InterestExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseOther" xlink:to="lab_us-gaap_InterestExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f0bdf443-d273-4f27-8dfc-23c605e4539f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_273a0292-d77b-4e0f-9086-44fdb38984db_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e1ecfa4b-fe99-4c2a-bad2-058665b2423b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4f0fcce4-4f8f-4644-83d0-32ef37eeae50_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_b478caf4-b874-4aca-8dcc-a6ca2d2f4bce_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaid_7b87de29-6a6e-4edf-b6b3-9ebd688f8f61_totalLabel_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaid" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaid_label_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, To Be Paid</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaid_documentation_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, To Be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaid" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseLiabilityToBePaid" xlink:to="lab_ibrx_LeaseLiabilityToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_d325e298-9ebf-4eaf-b1a1-fce09678aa29_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExercisePriceMember_88887d6c-4f03-4170-af11-bf2eac9f085e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExercisePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExercisePriceMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExercisePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Exercise Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExercisePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExercisePriceMember" xlink:to="lab_us-gaap_MeasurementInputExercisePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_KR_b8618528-7884-41eb-9480-ca951d50f634_terseLabel_en-US" xlink:label="lab_country_KR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South Korea</link:label>
    <link:label id="lab_country_KR_label_en-US" xlink:label="lab_country_KR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KOREA, REPUBLIC OF</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_KR" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_KR" xlink:to="lab_country_KR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_b1f3b392-7750-42dd-be26-9a3405066b75_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2aa7ce80-e13d-4509-a323-d878f0693294_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9ec070ba-7cae-4aca-a79d-fae7bf0e4260_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_56f7ec35-9ac6-495c-a966-056ac910319e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SixZeroFiveDougStLLCMember_f337ba72-8797-4162-8f64-b4cd7b209060_terseLabel_en-US" xlink:label="lab_ibrx_SixZeroFiveDougStLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">605 Doug St, LLC</link:label>
    <link:label id="lab_ibrx_SixZeroFiveDougStLLCMember_label_en-US" xlink:label="lab_ibrx_SixZeroFiveDougStLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Zero Five Doug St, LLC [Member]</link:label>
    <link:label id="lab_ibrx_SixZeroFiveDougStLLCMember_documentation_en-US" xlink:label="lab_ibrx_SixZeroFiveDougStLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Zero Five Doug St, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SixZeroFiveDougStLLCMember" xlink:href="ibrx-20230331.xsd#ibrx_SixZeroFiveDougStLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SixZeroFiveDougStLLCMember" xlink:to="lab_ibrx_SixZeroFiveDougStLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IT_6f30c126-9960-482e-a9b0-a895f29387ba_terseLabel_en-US" xlink:label="lab_country_IT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Italy</link:label>
    <link:label id="lab_country_IT_label_en-US" xlink:label="lab_country_IT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ITALY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IT" xlink:to="lab_country_IT" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_511f0a59-5049-48b6-b1d1-39c6521828dd_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_55271973-f273-4d95-9621-1dd9398e11ff_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_592e735b-5f43-4758-875c-260e2ae18bac_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_db21c724-9b59-47f1-869c-b85849dd4324_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_e2edaeb9-69f5-4e37-b659-7e298490f98d_terseLabel_en-US" xlink:label="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share-based payment award, options, aggregate intrinsic value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="ibrx-20230331.xsd#ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_b0f4a69c-33cf-4b44-b901-d8cbc4d48445_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets (including amounts with related parties)</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AmyrisJointVentureMember_0d0c5de0-4f0f-4b19-a4f4-daa3ffb72247_terseLabel_en-US" xlink:label="lab_ibrx_AmyrisJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amyris Joint Venture</link:label>
    <link:label id="lab_ibrx_AmyrisJointVentureMember_label_en-US" xlink:label="lab_ibrx_AmyrisJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amyris Joint Venture [Member]</link:label>
    <link:label id="lab_ibrx_AmyrisJointVentureMember_documentation_en-US" xlink:label="lab_ibrx_AmyrisJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amyris Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AmyrisJointVentureMember" xlink:href="ibrx-20230331.xsd#ibrx_AmyrisJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AmyrisJointVentureMember" xlink:to="lab_ibrx_AmyrisJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a79adb67-327b-4303-8b43-9a838296eda4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ImmunoOncologyClinicIncMember_cd04f909-6301-4a0f-8b5f-4d895c130e0c_terseLabel_en-US" xlink:label="lab_ibrx_ImmunoOncologyClinicIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immuno-Oncology Clinic, Inc.</link:label>
    <link:label id="lab_ibrx_ImmunoOncologyClinicIncMember_label_en-US" xlink:label="lab_ibrx_ImmunoOncologyClinicIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immuno-Oncology Clinic, Inc [Member]</link:label>
    <link:label id="lab_ibrx_ImmunoOncologyClinicIncMember_documentation_en-US" xlink:label="lab_ibrx_ImmunoOncologyClinicIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immuno Oncology Clinic Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ImmunoOncologyClinicIncMember" xlink:href="ibrx-20230331.xsd#ibrx_ImmunoOncologyClinicIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ImmunoOncologyClinicIncMember" xlink:to="lab_ibrx_ImmunoOncologyClinicIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_aba8fbd5-2957-4b04-9eeb-98a639f5d4eb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_566aad26-441d-469f-9faf-8fce3fb6334e_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AmyrisIncMember_6e567687-ee3a-4805-8b28-e3671718275a_terseLabel_en-US" xlink:label="lab_ibrx_AmyrisIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amyris, Inc.</link:label>
    <link:label id="lab_ibrx_AmyrisIncMember_label_en-US" xlink:label="lab_ibrx_AmyrisIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amyris, Inc. [Member]</link:label>
    <link:label id="lab_ibrx_AmyrisIncMember_documentation_en-US" xlink:label="lab_ibrx_AmyrisIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amyris, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AmyrisIncMember" xlink:href="ibrx-20230331.xsd#ibrx_AmyrisIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AmyrisIncMember" xlink:to="lab_ibrx_AmyrisIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears_eab13b7c-cd1f-457d-a3a0-f3e9fa5a3a72_terseLabel_en-US" xlink:label="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment to hire, number of employees, first five years</link:label>
    <link:label id="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears_label_en-US" xlink:label="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Interest, Commitment to Hire, Number of Employees, First Five Years</link:label>
    <link:label id="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears_documentation_en-US" xlink:label="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Interest, Commitment to Hire, Number of Employees, First Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears" xlink:href="ibrx-20230331.xsd#ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears" xlink:to="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_RelatedPartyNotesPayable_74543ca1-9d5c-4092-a7ba-e617ad2328f0_terseLabel_en-US" xlink:label="lab_ibrx_RelatedPartyNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount</link:label>
    <link:label id="lab_ibrx_RelatedPartyNotesPayable_755e22d3-abfb-4be1-9b47-3ba3922fb109_verboseLabel_en-US" xlink:label="lab_ibrx_RelatedPartyNotesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note payable at fair value</link:label>
    <link:label id="lab_ibrx_RelatedPartyNotesPayable_label_en-US" xlink:label="lab_ibrx_RelatedPartyNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Notes Payable</link:label>
    <link:label id="lab_ibrx_RelatedPartyNotesPayable_documentation_en-US" xlink:label="lab_ibrx_RelatedPartyNotesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-party notes payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesPayable" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_RelatedPartyNotesPayable" xlink:to="lab_ibrx_RelatedPartyNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_16192d68-1b6a-4fde-b27c-6c76838379a1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial term of lease arrangement</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_ecc5a9e5-e027-48e7-956a-c0789e814db1_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_b1a1a37d-321d-43be-9da8-897d4ec9137c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Outstanding Balances of Related-Party Agreements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_38400577-792f-4cfa-9cf1-2a5868115608_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4b7aa1e4-64d8-4a31-9c93-f6081695ff41_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_6f925192-0a4e-4c53-affe-be1b237064ee_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm_2b6e5259-0620-4783-856d-e19f642222f6_terseLabel_en-US" xlink:label="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment to spend, operational expenses, renewal lease term</link:label>
    <link:label id="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm_label_en-US" xlink:label="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Interest, Operational Expenses, Commitment to Spend, Renewal Lease Term</link:label>
    <link:label id="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm_documentation_en-US" xlink:label="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Interest, Operational Expenses, Commitment to Spend, Renewal Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm" xlink:href="ibrx-20230331.xsd#ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm" xlink:to="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_36b84c39-298d-481c-acdf-83994224d59b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_aa8e7ef4-2961-44e3-9beb-a46146a81a6f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Stock By Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PrepaidExpenseWriteDown_a2a754ac-36c8-4dc9-895f-31440b4715fb_terseLabel_en-US" xlink:label="lab_ibrx_PrepaidExpenseWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write down of prepaid expense</link:label>
    <link:label id="lab_ibrx_PrepaidExpenseWriteDown_label_en-US" xlink:label="lab_ibrx_PrepaidExpenseWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Write Down</link:label>
    <link:label id="lab_ibrx_PrepaidExpenseWriteDown_documentation_en-US" xlink:label="lab_ibrx_PrepaidExpenseWriteDown" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Write Down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidExpenseWriteDown" xlink:href="ibrx-20230331.xsd#ibrx_PrepaidExpenseWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PrepaidExpenseWriteDown" xlink:to="lab_ibrx_PrepaidExpenseWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9e8b4c5f-3775-4ccf-a834-5b3ce13b40af_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_4ffbe951-7411-4e0b-9fd6-50459d1b17b3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_58130854-245e-4e16-8281-891544183fda_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0a705847-a541-470e-8389-221bd746a37d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f2ff81fa-d03a-4b43-9899-5d50afc05436_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_FinancialStatementDetailsAbstract_08558c22-be88-4440-8161-07810819487d_terseLabel_en-US" xlink:label="lab_ibrx_FinancialStatementDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Statement Details [Abstract]</link:label>
    <link:label id="lab_ibrx_FinancialStatementDetailsAbstract_label_en-US" xlink:label="lab_ibrx_FinancialStatementDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Statement Details [Abstract]</link:label>
    <link:label id="lab_ibrx_FinancialStatementDetailsAbstract_documentation_en-US" xlink:label="lab_ibrx_FinancialStatementDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial statement details.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsAbstract" xlink:href="ibrx-20230331.xsd#ibrx_FinancialStatementDetailsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract" xlink:to="lab_ibrx_FinancialStatementDetailsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_e8fa59af-ff7a-4574-9708-ad92905704a8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating leases (excluding variable lease costs)</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment_dad824bc-4e28-4b53-85ef-67c3e4cd2aaf_terseLabel_en-US" xlink:label="lab_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual minimum licensing payment</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment_label_en-US" xlink:label="lab_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, Annual Minimum Licensing Payment</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment_documentation_en-US" xlink:label="lab_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, Annual Minimum Licensing Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment" xlink:to="lab_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c203c1f3-7511-4392-87b3-158709e2e237_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Amortization Expense Associated with Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2ba186df-1570-4156-a1d8-3313ff7e10cf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_84fee783-d005-4408-876e-37c1b9f04bd0_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_ad6e4d49-60f4-4b8b-8d2c-66ae1d6aae19_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_77c7c2e5-c847-47ba-8f7c-4747b3015787_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_cb89ab7a-32e2-42e0-8805-0ec6e41730e3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NonCashInterestIncomeExpenseFromOperatingActivities_e52d9c2a-11c6-459c-923f-53ff446c5c81_negatedLabel_en-US" xlink:label="lab_ibrx_NonCashInterestIncomeExpenseFromOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest items, net (including amounts with related parties)</link:label>
    <link:label id="lab_ibrx_NonCashInterestIncomeExpenseFromOperatingActivities_label_en-US" xlink:label="lab_ibrx_NonCashInterestIncomeExpenseFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Income Expense From Operating Activities</link:label>
    <link:label id="lab_ibrx_NonCashInterestIncomeExpenseFromOperatingActivities_documentation_en-US" xlink:label="lab_ibrx_NonCashInterestIncomeExpenseFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cash interest (income) expense from operating activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NonCashInterestIncomeExpenseFromOperatingActivities" xlink:href="ibrx-20230331.xsd#ibrx_NonCashInterestIncomeExpenseFromOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NonCashInterestIncomeExpenseFromOperatingActivities" xlink:to="lab_ibrx_NonCashInterestIncomeExpenseFromOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_3b1f0473-bdef-4224-9c0c-6339c6980e5b_terseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_a900510f-01e3-44f7-8f23-816c5c46ae60_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e69d24b8-f6ab-47ef-aa5c-a4b46d4953f8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_af1aa848-5ae3-487d-be58-b6b31a195500_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/canceled (in units)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_a0a86837-12c6-4049-bf91-b339e1241a8f_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total principal and estimated interest due on related-party debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_0d27b1cb-f5c6-46f2-b59d-183a75119764_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net (including amounts with related parties)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_d6a9f0c6-827e-4f05-97a3-52c6642dd9e3_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_875614df-1b9d-41e4-9802-7344971b8152_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_a4e4626c-36b2-43a0-9e43-7d753911b090_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7b067735-c3fd-4a31-bbfa-dd06f68b8ac0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_665b4e40-7af4-4c58-8ca4-3c48b9731e95_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_9fd686b1-1ab2-40e7-b72b-ac46093adb7d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_5e7406f6-6858-4a6b-9fc7-73faa0fd0e3c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_WarrantsMember_b6cf02ea-5797-4e9a-806d-d9074cbf2095_terseLabel_en-US" xlink:label="lab_ibrx_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_ibrx_WarrantsMember_label_en-US" xlink:label="lab_ibrx_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants [Member]</link:label>
    <link:label id="lab_ibrx_WarrantsMember_documentation_en-US" xlink:label="lab_ibrx_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_WarrantsMember" xlink:href="ibrx-20230331.xsd#ibrx_WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_WarrantsMember" xlink:to="lab_ibrx_WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_11355be1-32fe-427d-afdf-180fd1670109_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LicensingAgreementTable_3c044ea5-7f76-4418-a1b4-4ce8413beb00_terseLabel_en-US" xlink:label="lab_ibrx_LicensingAgreementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreement [Table]</link:label>
    <link:label id="lab_ibrx_LicensingAgreementTable_label_en-US" xlink:label="lab_ibrx_LicensingAgreementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreement [Table]</link:label>
    <link:label id="lab_ibrx_LicensingAgreementTable_documentation_en-US" xlink:label="lab_ibrx_LicensingAgreementTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LicensingAgreementTable" xlink:href="ibrx-20230331.xsd#ibrx_LicensingAgreementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LicensingAgreementTable" xlink:to="lab_ibrx_LicensingAgreementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ce772cf7-fa01-47c8-aedb-4fc09ce2e47a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate_9e1d1d8a-6aef-4c95-b525-0500e2b0efb1_verboseLabel_en-US" xlink:label="lab_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate spread</link:label>
    <link:label id="lab_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate_c1ba1551-992f-45ac-bd8d-67be17e9c83d_terseLabel_en-US" xlink:label="lab_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate</link:label>
    <link:label id="lab_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate_label_en-US" xlink:label="lab_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Basis Spread on Variable Rate</link:label>
    <link:label id="lab_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate_documentation_en-US" xlink:label="lab_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate" xlink:to="lab_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_d5b31ecb-93f9-4030-ad47-fad70d62af41_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_acc92c96-389d-4af5-b7a8-929c7ec37eb6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Business Acquisitions By Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_e7ee28fb-f8ba-4f0f-8bde-ff84ed5a5024_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e0e73152-1c3a-4985-ac42-94a293610896_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_9d239273-50d7-4c91-b755-b160f5ea370a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_MeasurementInputDiscountPeriodMember_fd9dfb1d-a7ec-4367-8da6-2fde90c2f8ea_terseLabel_en-US" xlink:label="lab_ibrx_MeasurementInputDiscountPeriodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount period</link:label>
    <link:label id="lab_ibrx_MeasurementInputDiscountPeriodMember_label_en-US" xlink:label="lab_ibrx_MeasurementInputDiscountPeriodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Period [Member]</link:label>
    <link:label id="lab_ibrx_MeasurementInputDiscountPeriodMember_documentation_en-US" xlink:label="lab_ibrx_MeasurementInputDiscountPeriodMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MeasurementInputDiscountPeriodMember" xlink:href="ibrx-20230331.xsd#ibrx_MeasurementInputDiscountPeriodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_MeasurementInputDiscountPeriodMember" xlink:to="lab_ibrx_MeasurementInputDiscountPeriodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_2a7a32b1-0350-4d69-a5da-a18f472320a2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_743e73bf-65df-49e0-b7b9-6d0f64c90e65_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement payment</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e622795c-1c5a-47a5-b7c1-c2efd90375e4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_86b65088-6cba-42d0-a879-3d428fe4e2cf_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_f03b7a6b-4ddf-4425-99c6-e0429c1ffe90_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_415a2bdf-592f-49ea-b49d-5ba520d91776_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseholdImprovementPayables_9516d635-2051-4c7a-a0fd-eae396f23cd8_terseLabel_en-US" xlink:label="lab_ibrx_LeaseholdImprovementPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvement payables</link:label>
    <link:label id="lab_ibrx_LeaseholdImprovementPayables_label_en-US" xlink:label="lab_ibrx_LeaseholdImprovementPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvement Payables</link:label>
    <link:label id="lab_ibrx_LeaseholdImprovementPayables_documentation_en-US" xlink:label="lab_ibrx_LeaseholdImprovementPayables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvement payables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdImprovementPayables" xlink:href="ibrx-20230331.xsd#ibrx_LeaseholdImprovementPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseholdImprovementPayables" xlink:to="lab_ibrx_LeaseholdImprovementPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_58b63320-6653-4058-a26a-d4ea471dd900_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_204988b8-c0fa-43bc-9490-4e77cc4f7aba_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_a6f9f9ca-a1e5-42be-bd92-9a66d2b3ebef_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense related to operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ContingentValueRightsObligationRegulatoryMilestoneMember_1d84abf7-077c-407d-864e-3e71ee1c72ee_terseLabel_en-US" xlink:label="lab_ibrx_ContingentValueRightsObligationRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Value Rights Payable, Regulatory Milestone</link:label>
    <link:label id="lab_ibrx_ContingentValueRightsObligationRegulatoryMilestoneMember_label_en-US" xlink:label="lab_ibrx_ContingentValueRightsObligationRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Value Rights Obligation, Regulatory Milestone [Member]</link:label>
    <link:label id="lab_ibrx_ContingentValueRightsObligationRegulatoryMilestoneMember_documentation_en-US" xlink:label="lab_ibrx_ContingentValueRightsObligationRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value rights obligation at December 31, 2022.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ContingentValueRightsObligationRegulatoryMilestoneMember" xlink:href="ibrx-20230331.xsd#ibrx_ContingentValueRightsObligationRegulatoryMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ContingentValueRightsObligationRegulatoryMilestoneMember" xlink:to="lab_ibrx_ContingentValueRightsObligationRegulatoryMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_30aca7e2-d098-4859-afca-9d5fa66b701e_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ConvertibleNoteReceivableNonCurrent_1aa07516-b72a-44fa-a720-90e7ca7118da_terseLabel_en-US" xlink:label="lab_ibrx_ConvertibleNoteReceivableNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note receivable</link:label>
    <link:label id="lab_ibrx_ConvertibleNoteReceivableNonCurrent_label_en-US" xlink:label="lab_ibrx_ConvertibleNoteReceivableNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Note Receivable Non Current</link:label>
    <link:label id="lab_ibrx_ConvertibleNoteReceivableNonCurrent_documentation_en-US" xlink:label="lab_ibrx_ConvertibleNoteReceivableNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note receivable, non-current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ConvertibleNoteReceivableNonCurrent" xlink:href="ibrx-20230331.xsd#ibrx_ConvertibleNoteReceivableNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ConvertibleNoteReceivableNonCurrent" xlink:to="lab_ibrx_ConvertibleNoteReceivableNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_cd4c576e-753b-413d-88fd-76b6bf4fc5da_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8f00c151-bb88-4d1c-b7d3-55e3fb3145a4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_ac71e535-8310-435f-a18a-2061a3e46ec6_terseLabel_en-US" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Future Contractual Obligations for Related-Party Promissory Notes</link:label>
    <link:label id="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_label_en-US" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember_33ec56e2-34e5-4d88-af99-fc6da0b24918_terseLabel_en-US" xlink:label="lab_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital, NantCancerStemCell, LLC, and NantMobile, LLC</link:label>
    <link:label id="lab_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember_label_en-US" xlink:label="lab_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital, NantCancerStemCell, LLC, and NantMobile, LLC [Member]</link:label>
    <link:label id="lab_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember_documentation_en-US" xlink:label="lab_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital, NantCancerStemCell, LLC, and NantMobile, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember" xlink:to="lab_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborationAgreementsMilestoneFees_7647b902-d2cb-49a6-a128-fb03b06324a2_terseLabel_en-US" xlink:label="lab_ibrx_CollaborationAgreementsMilestoneFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone fees</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsMilestoneFees_label_en-US" xlink:label="lab_ibrx_CollaborationAgreementsMilestoneFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, Milestone Fees</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsMilestoneFees_documentation_en-US" xlink:label="lab_ibrx_CollaborationAgreementsMilestoneFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, Milestone Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsMilestoneFees" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsMilestoneFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborationAgreementsMilestoneFees" xlink:to="lab_ibrx_CollaborationAgreementsMilestoneFees" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborationAgreementsLicenseMaintenanceFees_90d3f9d9-792c-4e17-80cf-14265fc3c2ec_terseLabel_en-US" xlink:label="lab_ibrx_CollaborationAgreementsLicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License maintenance fees</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsLicenseMaintenanceFees_label_en-US" xlink:label="lab_ibrx_CollaborationAgreementsLicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, License Maintenance Fees</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsLicenseMaintenanceFees_documentation_en-US" xlink:label="lab_ibrx_CollaborationAgreementsLicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, License Maintenance Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsLicenseMaintenanceFees" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsLicenseMaintenanceFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborationAgreementsLicenseMaintenanceFees" xlink:to="lab_ibrx_CollaborationAgreementsLicenseMaintenanceFees" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_FinancialStatementDetailsLineItems_81d61705-9e5b-4cd2-b23a-681205e89dc3_terseLabel_en-US" xlink:label="lab_ibrx_FinancialStatementDetailsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Statement Details [Line Items]</link:label>
    <link:label id="lab_ibrx_FinancialStatementDetailsLineItems_label_en-US" xlink:label="lab_ibrx_FinancialStatementDetailsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Statement Details [Line Items]</link:label>
    <link:label id="lab_ibrx_FinancialStatementDetailsLineItems_documentation_en-US" xlink:label="lab_ibrx_FinancialStatementDetailsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Statement Details [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsLineItems" xlink:href="ibrx-20230331.xsd#ibrx_FinancialStatementDetailsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems" xlink:to="lab_ibrx_FinancialStatementDetailsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3b411a24-5b48-4747-b06e-783856cc707b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_49fa58f1-21c0-407b-9d6d-43990ac9122b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_34552429-7ef2-4f6c-8296-1c87225eeecf_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantBioIncMember_1c146f0c-897d-4b88-862f-335d044d82bf_verboseLabel_en-US" xlink:label="lab_ibrx_NantBioIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NantBio, Inc.</link:label>
    <link:label id="lab_ibrx_NantBioIncMember_label_en-US" xlink:label="lab_ibrx_NantBioIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NantBio Inc [Member]</link:label>
    <link:label id="lab_ibrx_NantBioIncMember_documentation_en-US" xlink:label="lab_ibrx_NantBioIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Bio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantBioIncMember" xlink:href="ibrx-20230331.xsd#ibrx_NantBioIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantBioIncMember" xlink:to="lab_ibrx_NantBioIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_72bf04a6-c018-41f4-9269-d7c6e3f4593c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e936fd8a-ba24-4979-8711-4343dcc41a49_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CommonStockValueAvailableForFutureStockIssuance_ae13bb0f-a12d-4d68-9212-b7e5bb2d6c5d_terseLabel_en-US" xlink:label="lab_ibrx_CommonStockValueAvailableForFutureStockIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for future stock issuance</link:label>
    <link:label id="lab_ibrx_CommonStockValueAvailableForFutureStockIssuance_label_en-US" xlink:label="lab_ibrx_CommonStockValueAvailableForFutureStockIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Value Available For Future Stock Issuance</link:label>
    <link:label id="lab_ibrx_CommonStockValueAvailableForFutureStockIssuance_documentation_en-US" xlink:label="lab_ibrx_CommonStockValueAvailableForFutureStockIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock value available for future stock issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CommonStockValueAvailableForFutureStockIssuance" xlink:href="ibrx-20230331.xsd#ibrx_CommonStockValueAvailableForFutureStockIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CommonStockValueAvailableForFutureStockIssuance" xlink:to="lab_ibrx_CommonStockValueAvailableForFutureStockIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_e464450d-517c-45c4-946b-919e1ff06850_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ConsiderationForFutureServicesMember_f91f9a17-0cb3-4c80-a753-9968aa8b09ee_terseLabel_en-US" xlink:label="lab_ibrx_ConsiderationForFutureServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration for Future Services</link:label>
    <link:label id="lab_ibrx_ConsiderationForFutureServicesMember_label_en-US" xlink:label="lab_ibrx_ConsiderationForFutureServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration for Future Services [Member]</link:label>
    <link:label id="lab_ibrx_ConsiderationForFutureServicesMember_documentation_en-US" xlink:label="lab_ibrx_ConsiderationForFutureServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration for Future Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ConsiderationForFutureServicesMember" xlink:href="ibrx-20230331.xsd#ibrx_ConsiderationForFutureServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ConsiderationForFutureServicesMember" xlink:to="lab_ibrx_ConsiderationForFutureServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_7fc8c1b9-45fe-409e-9d80-46a357a36f47_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Interest Added to Note</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LitigationSettlementNumberOfSharesToBeIssued_1a12a1f9-2863-487a-8273-68e2a6063779_terseLabel_en-US" xlink:label="lab_ibrx_LitigationSettlementNumberOfSharesToBeIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for litigation settlement (in shares)</link:label>
    <link:label id="lab_ibrx_LitigationSettlementNumberOfSharesToBeIssued_label_en-US" xlink:label="lab_ibrx_LitigationSettlementNumberOfSharesToBeIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Number of Shares to be Issued</link:label>
    <link:label id="lab_ibrx_LitigationSettlementNumberOfSharesToBeIssued_documentation_en-US" xlink:label="lab_ibrx_LitigationSettlementNumberOfSharesToBeIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Number of Shares to be Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationSettlementNumberOfSharesToBeIssued" xlink:href="ibrx-20230331.xsd#ibrx_LitigationSettlementNumberOfSharesToBeIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LitigationSettlementNumberOfSharesToBeIssued" xlink:to="lab_ibrx_LitigationSettlementNumberOfSharesToBeIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_0dc326a1-bd34-4c1e-b9de-e08c0f2ce16c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_36ba7e84-ca2c-42d2-ab6e-5ab30c0d184f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_12ac7258-26a9-49c7-88f3-8767a263afe2_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 12 months, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_0ea4f90b-d632-4555-97f0-cad1ff64fc42_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_3e1b43c8-729b-4a20-8174-9af5467076e5_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_efa62d80-4df1-4386-825c-5ff640cb1adb_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearThree_c1e09b4d-d1ab-4d6d-9a07-3f64199b29b5_totalLabel_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearThree" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearThree_label_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, To Be Paid, Year Three</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearThree_documentation_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, To Be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearThree" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearThree" xlink:to="lab_ibrx_LeaseLiabilityToBePaidYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_abee26f0-40fb-42ac-8644-886c103b5656_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_dd0608ad-73ec-440d-8d02-0d759de87e12_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2dead038-e961-4317-bfb5-92b7e5e44f06_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_79143536-1bf9-49a1-ad0b-4847c4ddc04d_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">More than 12 months, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2058a658-a14f-4aec-8c37-65a4e634c05c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e397946-a5a9-4fb2-8770-3159d15ac2a3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_DunkirkFacilityMember_fb7acadc-6a74-40fd-a8cb-929933ef1069_terseLabel_en-US" xlink:label="lab_ibrx_DunkirkFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dunkirk Facility</link:label>
    <link:label id="lab_ibrx_DunkirkFacilityMember_label_en-US" xlink:label="lab_ibrx_DunkirkFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dunkirk Facility [Member]</link:label>
    <link:label id="lab_ibrx_DunkirkFacilityMember_documentation_en-US" xlink:label="lab_ibrx_DunkirkFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dunkirk Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DunkirkFacilityMember" xlink:href="ibrx-20230331.xsd#ibrx_DunkirkFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_DunkirkFacilityMember" xlink:to="lab_ibrx_DunkirkFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4780351f-a6cf-4cb8-8159-c1563da06e18_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_BaseMonthlyRentParking_1cfc7bcc-baec-44a5-9ecc-b8220d6eb281_terseLabel_en-US" xlink:label="lab_ibrx_BaseMonthlyRentParking" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base monthly rent, parking</link:label>
    <link:label id="lab_ibrx_BaseMonthlyRentParking_label_en-US" xlink:label="lab_ibrx_BaseMonthlyRentParking" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Monthly Rent, Parking</link:label>
    <link:label id="lab_ibrx_BaseMonthlyRentParking_documentation_en-US" xlink:label="lab_ibrx_BaseMonthlyRentParking" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Monthly Rent, Parking</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BaseMonthlyRentParking" xlink:href="ibrx-20230331.xsd#ibrx_BaseMonthlyRentParking"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_BaseMonthlyRentParking" xlink:to="lab_ibrx_BaseMonthlyRentParking" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6b0b6ca9-3e88-4a33-8de7-1ffa13db29b6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_542b144e-2f00-4214-bae3-1f73591abca0_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_c9dbba5e-0d2a-4d42-bfdc-8a03c0406edb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_dc3d1f81-3123-4f8e-84f6-ee7a8ce66e3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_83d9f5df-bb81-4171-a0ba-068c9729c1c2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 (excluding the three months ended March&#160;31,&#160;2023)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1a96815e-6540-458e-9053-0d434b370d85_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock issued in transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_7161f59f-c141-4535-af95-593e1a2c3e5e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock_a873be43-61ae-412a-b334-b0a85ed10917_terseLabel_en-US" xlink:label="lab_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Related-Party Promissory Notes</link:label>
    <link:label id="lab_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock_label_en-US" xlink:label="lab_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related-Party Promissory Notes Table [Table Text Block]</link:label>
    <link:label id="lab_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock_documentation_en-US" xlink:label="lab_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of related party notes payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock" xlink:href="ibrx-20230331.xsd#ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock" xlink:to="lab_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_6a5c9556-98d9-4f40-b52f-d1d32126b3e5_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_2e64668f-8229-4ca3-9822-efb207ad936b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unamortized Discounts</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_c3a565c3-3fdb-476e-b279-f6d24fca81df_terseLabel_en-US" xlink:label="lab_ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="ibrx-20230331.xsd#ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidAfterYearFour_2e133c2e-c99a-4ea6-b841-e6a68088356f_totalLabel_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidAfterYearFour" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ibrx_LeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_6ffcd1cc-818a-40eb-a5a6-bf7ba03c8590_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_ce5b066a-e70a-41c1-8998-ce2bd74aacbc_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_e2cf16d2-f087-4ccc-a6e7-f055b940d666_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_eaf43980-2a7e-49ed-b880-59cb88b126ab_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding third-party warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_59649b2d-06a1-4b9b-96e2-12655e8f2af2_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_174f7d67-b030-444a-a41b-e36e4a0e1ed8_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NoncurrentAssetsMember_64725478-ac28-4798-aa1e-13716a3e17a0_terseLabel_en-US" xlink:label="lab_ibrx_NoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent Assets</link:label>
    <link:label id="lab_ibrx_NoncurrentAssetsMember_label_en-US" xlink:label="lab_ibrx_NoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent Assets [Member]</link:label>
    <link:label id="lab_ibrx_NoncurrentAssetsMember_documentation_en-US" xlink:label="lab_ibrx_NoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NoncurrentAssetsMember" xlink:href="ibrx-20230331.xsd#ibrx_NoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NoncurrentAssetsMember" xlink:to="lab_ibrx_NoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1c2f8dd1-128f-4f7c-8afa-8f791f600ca3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from equity offering, net of issuance costs paid</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_74006004-2cca-4a36-b289-ec1b7980fa95_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares used in computing net loss per share &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearFour_806fea27-44e2-4945-b12a-9da66fa89ce3_totalLabel_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearFour" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearFour_label_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, To Be Paid, Year Four</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearFour_documentation_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, To Be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearFour" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearFour" xlink:to="lab_ibrx_LeaseLiabilityToBePaidYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_f6d5b1d0-6bc4-483a-b928-4d8a09df992c_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_3823b763-942b-4211-af47-afed361dd822_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_46b96359-ebb1-4cff-bb85-1fed39bbc84a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of ownership interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_c6cf9be8-da40-4591-9b95-6e06f9ee272c_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_ed3c5942-6719-4d9a-a078-cdd6a8956f0a_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_2638e3ef-fd1f-4b10-902c-510855e5887f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_221478d4-12ea-4cd8-91f9-2dea751cced4_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2324cb87-5745-4bd3-9cff-d1fba198ae84_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5c3a86ea-7a9a-419e-87e6-243e6b1f5b79_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2487ba67-4765-4829-9c48-49c1245bc4e8_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_721683f0-7db1-4b98-b931-d4519681cb3f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseRelatedParty_34482d1c-179f-40fe-b0a0-acd778aa98a6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseRelatedParty" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on related-party notes</link:label>
    <link:label id="lab_us-gaap_InterestExpenseRelatedParty_label_en-US" xlink:label="lab_us-gaap_InterestExpenseRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseRelatedParty" xlink:to="lab_us-gaap_InterestExpenseRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SaleOfStockMaximumAggregateOfferingPrice_f667eae3-b2e1-4931-95a1-424c7aad5136_terseLabel_en-US" xlink:label="lab_ibrx_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum offering</link:label>
    <link:label id="lab_ibrx_SaleOfStockMaximumAggregateOfferingPrice_label_en-US" xlink:label="lab_ibrx_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Offering Price</link:label>
    <link:label id="lab_ibrx_SaleOfStockMaximumAggregateOfferingPrice_documentation_en-US" xlink:label="lab_ibrx_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Offering Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleOfStockMaximumAggregateOfferingPrice" xlink:href="ibrx-20230331.xsd#ibrx_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SaleOfStockMaximumAggregateOfferingPrice" xlink:to="lab_ibrx_SaleOfStockMaximumAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_1664395a-e703-4069-a042-3a161ded196c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant And Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable_8858d655-7c9b-47dd-b378-dba7a77116f1_totalLabel_en-US" xlink:label="lab_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Tenant improvement allowance receivable</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable_label_en-US" xlink:label="lab_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Tenant Improvement Allowance Receivable</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable_documentation_en-US" xlink:label="lab_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Tenant Improvement Allowance Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable" xlink:to="lab_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_RelatedPartyNotesPrincipalMember_58fb3541-0eb5-48b8-b0c1-e0d65c047cac_terseLabel_en-US" xlink:label="lab_ibrx_RelatedPartyNotesPrincipalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Payments</link:label>
    <link:label id="lab_ibrx_RelatedPartyNotesPrincipalMember_label_en-US" xlink:label="lab_ibrx_RelatedPartyNotesPrincipalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Notes - Principal [Member]</link:label>
    <link:label id="lab_ibrx_RelatedPartyNotesPrincipalMember_documentation_en-US" xlink:label="lab_ibrx_RelatedPartyNotesPrincipalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Notes - Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesPrincipalMember" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyNotesPrincipalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_RelatedPartyNotesPrincipalMember" xlink:to="lab_ibrx_RelatedPartyNotesPrincipalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_8c71ff33-46c4-489e-a5fb-f9a8bc7bd597_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other depreciable assets and prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_d0c907e6-f5c4-415a-be2e-ec1bc9cdb5e7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_1b035b47-98e0-4ae3-a567-a4f35e270a87_terseLabel_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Domain]</link:label>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_label_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Domain]</link:label>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_documentation_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain" xlink:href="ibrx-20230331.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain" xlink:to="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_dab3c7f4-2058-4732-8597-5652ec0d16ac_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_ed47c0bf-32a4-4899-8980-81e111f1c798_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour_4c8d95fd-e521-43a7-80c2-53477ec1c6ec_terseLabel_en-US" xlink:label="lab_ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:href="ibrx-20230331.xsd#ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d5831431-d929-41b3-b033-b42b968ef967_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_755e1731-a915-4c8a-90ea-5390bc85ca24_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-party notes</link:label>
    <link:label id="lab_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="lab_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_5a5171d0-3612-48d3-99e7-d5c85aa51334_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate, Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_42f6f682-2962-432c-8d4e-1cdceb038379_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CurrentLiabilitiesMember_b145f761-6de1-401f-81f6-b11f3f62cbcf_terseLabel_en-US" xlink:label="lab_ibrx_CurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_ibrx_CurrentLiabilitiesMember_label_en-US" xlink:label="lab_ibrx_CurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities [Member]</link:label>
    <link:label id="lab_ibrx_CurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_ibrx_CurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CurrentLiabilitiesMember" xlink:href="ibrx-20230331.xsd#ibrx_CurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CurrentLiabilitiesMember" xlink:to="lab_ibrx_CurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_54c9878c-f54c-4a4e-9d7d-bd9d3f4a1b13_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_76e199d4-bc0c-4a24-881e-63aeb9106821_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3e81695d-524b-4bd9-abd4-2fb3eaab635d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net share settlement for RSUs vesting</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_beea865c-2894-4da5-a20e-4851c2ff09b7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_InitialAndExpansionPremisesMember_25427412-4ea3-42cf-8061-285cce62bed8_terseLabel_en-US" xlink:label="lab_ibrx_InitialAndExpansionPremisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial and Expansion Premises</link:label>
    <link:label id="lab_ibrx_InitialAndExpansionPremisesMember_label_en-US" xlink:label="lab_ibrx_InitialAndExpansionPremisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial And Expansion Premises [Member]</link:label>
    <link:label id="lab_ibrx_InitialAndExpansionPremisesMember_documentation_en-US" xlink:label="lab_ibrx_InitialAndExpansionPremisesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial And Expansion Premises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InitialAndExpansionPremisesMember" xlink:href="ibrx-20230331.xsd#ibrx_InitialAndExpansionPremisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_InitialAndExpansionPremisesMember" xlink:to="lab_ibrx_InitialAndExpansionPremisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_abe590c7-cb43-46c9-9f0c-a74baa6350fc_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_FinancingObligationCurrent_4f14aca6-020a-4e1d-a543-c6828f8c9a32_terseLabel_en-US" xlink:label="lab_ibrx_FinancingObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing obligation &#8211; current portion</link:label>
    <link:label id="lab_ibrx_FinancingObligationCurrent_label_en-US" xlink:label="lab_ibrx_FinancingObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Obligation, Current</link:label>
    <link:label id="lab_ibrx_FinancingObligationCurrent_documentation_en-US" xlink:label="lab_ibrx_FinancingObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancingObligationCurrent" xlink:href="ibrx-20230331.xsd#ibrx_FinancingObligationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_FinancingObligationCurrent" xlink:to="lab_ibrx_FinancingObligationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f17c6b7b-146f-44c5-8882-14f01e1845a1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AccountingPoliciesTable_d2d40849-9767-4e78-b893-e8e9c1f1ce1d_terseLabel_en-US" xlink:label="lab_ibrx_AccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Table]</link:label>
    <link:label id="lab_ibrx_AccountingPoliciesTable_label_en-US" xlink:label="lab_ibrx_AccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Table]</link:label>
    <link:label id="lab_ibrx_AccountingPoliciesTable_documentation_en-US" xlink:label="lab_ibrx_AccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccountingPoliciesTable" xlink:href="ibrx-20230331.xsd#ibrx_AccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AccountingPoliciesTable" xlink:to="lab_ibrx_AccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_fc9d83d2-b55a-4b4d-861b-5590a1350ec9_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_f01e7780-20bc-463e-b628-131381c6ad42_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining authorized repurchase amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseLiabilityUndiscountedExcessInterest_272ca4c9-0e3c-4399-bd04-9a9a0038a7fa_totalLabel_en-US" xlink:label="lab_ibrx_LeaseLiabilityUndiscountedExcessInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityUndiscountedExcessInterest_label_en-US" xlink:label="lab_ibrx_LeaseLiabilityUndiscountedExcessInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Undiscounted Excess Interest</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityUndiscountedExcessInterest_documentation_en-US" xlink:label="lab_ibrx_LeaseLiabilityUndiscountedExcessInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Undiscounted Excess Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityUndiscountedExcessInterest" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityUndiscountedExcessInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseLiabilityUndiscountedExcessInterest" xlink:to="lab_ibrx_LeaseLiabilityUndiscountedExcessInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36b8d309-ee66-4391-a705-6369c42ef7c1_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c36f2fee-d51e-448d-a9d1-fb9117357d47_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_fd80b8ef-1ad0-4b03-b8c4-e3a389dcbe9f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_RelatedPartyNotesMember_394c5d8a-1b05-40a7-824d-d7fe4f4a5a03_terseLabel_en-US" xlink:label="lab_ibrx_RelatedPartyNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Notes</link:label>
    <link:label id="lab_ibrx_RelatedPartyNotesMember_label_en-US" xlink:label="lab_ibrx_RelatedPartyNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Notes [Member]</link:label>
    <link:label id="lab_ibrx_RelatedPartyNotesMember_documentation_en-US" xlink:label="lab_ibrx_RelatedPartyNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesMember" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_RelatedPartyNotesMember" xlink:to="lab_ibrx_RelatedPartyNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember_21a7f15d-aa15-4c7a-af75-9e5d6ab35dea_terseLabel_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember_label_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative, Fee One [Member]</link:label>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember_documentation_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative, Fee One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember" xlink:href="ibrx-20230331.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember" xlink:to="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_20c1c9f7-4aa8-47d2-8bd0-1ff7f35ac624_verboseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense_431fa13d-c5bb-4674-a5ab-d0b786676acb_terseLabel_en-US" xlink:label="lab_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease costs (including amortization and interest costs)</link:label>
    <link:label id="lab_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense_label_en-US" xlink:label="lab_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Costs, Right-Of-Use Asset Amortization And Interest Expense</link:label>
    <link:label id="lab_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense_documentation_en-US" xlink:label="lab_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Costs, Right-Of-Use Asset Amortization And Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense" xlink:href="ibrx-20230331.xsd#ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense" xlink:to="lab_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6526a137-475a-4b9b-9d27-a592d1340c6c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_1b0a6176-d8ce-4999-886e-0ca1bbad0f1a_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_7f8b1df4-be8f-473a-997f-69f2af0e6a92_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per ImmunityBio common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_311b90b8-0e9c-488b-947f-375f97c8d1da_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_87740c94-1ee0-4ac1-b173-f98492950604_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_edf54967-b436-4abc-b86b-9a40695b68c0_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms_0067b0f8-3ba2-46dd-a0f7-8bc42da4042c_terseLabel_en-US" xlink:label="lab_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease payments related to options to extend lease terms</link:label>
    <link:label id="lab_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms_label_en-US" xlink:label="lab_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Payments Related To Options To Extend Lease Terms</link:label>
    <link:label id="lab_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms_documentation_en-US" xlink:label="lab_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease payments related to options to extend lease terms.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" xlink:href="ibrx-20230331.xsd#ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" xlink:to="lab_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_31cbc23e-371d-4d68-a06e-b29cb1c0fd7f_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commissions and offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b021db7f-ddd1-4bd8-868d-46ed618e8683_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_f3bd034d-200e-4358-86ed-c140a97cc91a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_1c76c48e-d584-4c55-99f0-e049e79745a1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ca6ebc73-0e96-4478-8b91-50c6ad19e484_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2e8af479-7b8e-4d53-ae14-26e9e2bdc539_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_418656a8-9b1b-49fb-a738-97c5881d50c4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SecuredOvernightFinancingRateSOFRMember_b8093b87-1561-428f-a958-443c95442723_terseLabel_en-US" xlink:label="lab_ibrx_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:label id="lab_ibrx_SecuredOvernightFinancingRateSOFRMember_label_en-US" xlink:label="lab_ibrx_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:label id="lab_ibrx_SecuredOvernightFinancingRateSOFRMember_documentation_en-US" xlink:label="lab_ibrx_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SecuredOvernightFinancingRateSOFRMember" xlink:href="ibrx-20230331.xsd#ibrx_SecuredOvernightFinancingRateSOFRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SecuredOvernightFinancingRateSOFRMember" xlink:to="lab_ibrx_SecuredOvernightFinancingRateSOFRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_35db7c45-3c59-4a30-b02e-e13a16a6432a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_OptionsToExtendNumberOfTerms_267d5867-c2fd-43c1-87aa-60de67c9b872_terseLabel_en-US" xlink:label="lab_ibrx_OptionsToExtendNumberOfTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to extend number of terms</link:label>
    <link:label id="lab_ibrx_OptionsToExtendNumberOfTerms_label_en-US" xlink:label="lab_ibrx_OptionsToExtendNumberOfTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options To Extend Number Of Terms</link:label>
    <link:label id="lab_ibrx_OptionsToExtendNumberOfTerms_documentation_en-US" xlink:label="lab_ibrx_OptionsToExtendNumberOfTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to extend number of terms.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OptionsToExtendNumberOfTerms" xlink:href="ibrx-20230331.xsd#ibrx_OptionsToExtendNumberOfTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_OptionsToExtendNumberOfTerms" xlink:to="lab_ibrx_OptionsToExtendNumberOfTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_08a7684a-5fd0-43fb-a901-a73648f34ab5_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears_dcdd69d1-6410-44d9-b9b4-55aa709a4622_terseLabel_en-US" xlink:label="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment to hire, number of employees, first two and a half years</link:label>
    <link:label id="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears_label_en-US" xlink:label="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Interest, Commitment to Hire, Number of Employees, First Two and a Half Years</link:label>
    <link:label id="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears_documentation_en-US" xlink:label="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Interest, Commitment to Hire, Number of Employees, First Two and a Half Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears" xlink:href="ibrx-20230331.xsd#ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears" xlink:to="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedParties_0197a4f4-3dda-4adb-ac89-fafa2066e252_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from related parties</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties" xlink:to="lab_us-gaap_DueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_66cdc509-e801-4665-98d5-0c13cd5ea61d_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_7dfe42b7-851a-486c-9b0b-9b38a114a52c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_74298d33-cbfb-4a4f-bd4d-63b477caa5c8_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8084366c-3066-4e7d-a9af-6eb2e29d6f1a_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (gains) on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4fd711e8-1c4a-43f3-af8f-0c2bb24a9c30_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) from equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4c572982-8a5b-4408-b6c7-86583cd15d8c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f24a7051-dc89-44a9-b8e0-94f0445c2f15_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_DueToRelatedPartiesMember_e677c70b-f57c-4482-927e-346fe8c73e73_terseLabel_en-US" xlink:label="lab_ibrx_DueToRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:label id="lab_ibrx_DueToRelatedPartiesMember_label_en-US" xlink:label="lab_ibrx_DueToRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due To Related Parties [Member]</link:label>
    <link:label id="lab_ibrx_DueToRelatedPartiesMember_documentation_en-US" xlink:label="lab_ibrx_DueToRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DueToRelatedPartiesMember" xlink:href="ibrx-20230331.xsd#ibrx_DueToRelatedPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_DueToRelatedPartiesMember" xlink:to="lab_ibrx_DueToRelatedPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_84b776f6-b0c0-436f-952e-4d2772ec943a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_e9172527-0be0-4bc7-8cec-b532d13e7da9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on marketable debt securities, net</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased_b49aff94-db8c-4e03-9da0-bb5a65653f93_terseLabel_en-US" xlink:label="lab_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expansion of licensed premises (in square feet)</link:label>
    <link:label id="lab_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased_label_en-US" xlink:label="lab_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase to Number of Square Foot of Facility Leased</link:label>
    <link:label id="lab_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased_documentation_en-US" xlink:label="lab_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase to Number of Square Foot of Facility Leased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased" xlink:href="ibrx-20230331.xsd#ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased" xlink:to="lab_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndOtherIncomeTableTextBlock_c3861a2c-7e03-43db-a72c-0ae83ba4ffd2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Investment Income, Net</link:label>
    <link:label id="lab_us-gaap_InterestAndOtherIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Other Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncomeTableTextBlock" xlink:to="lab_us-gaap_InterestAndOtherIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_InsurancePremiumFinancingAsset_1bde0e4d-f2b9-49c7-a233-be244abb768d_terseLabel_en-US" xlink:label="lab_ibrx_InsurancePremiumFinancingAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance premium financing asset</link:label>
    <link:label id="lab_ibrx_InsurancePremiumFinancingAsset_label_en-US" xlink:label="lab_ibrx_InsurancePremiumFinancingAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Premium Financing Asset</link:label>
    <link:label id="lab_ibrx_InsurancePremiumFinancingAsset_documentation_en-US" xlink:label="lab_ibrx_InsurancePremiumFinancingAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance premium financing asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InsurancePremiumFinancingAsset" xlink:href="ibrx-20230331.xsd#ibrx_InsurancePremiumFinancingAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_InsurancePremiumFinancingAsset" xlink:to="lab_ibrx_InsurancePremiumFinancingAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_4f26c4b2-2f91-4bda-8f96-dddebfb66e61_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term, Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_cd7f6f20-1ccf-41c6-99a9-4742ea075849_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_3a5c2c40-1ac0-41f7-9d0d-53fc5208319d_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense (including amounts with related parties)</link:label>
    <link:label id="lab_us-gaap_InterestExpense_2d43649c-6630-4ee5-87fc-00950c35c2cd_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4993bd52-4854-49e1-a090-a721e77f14db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_27c30c4f-5146-4c11-9845-6a58175b78bc_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents, and restricted cash, end of period:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2b756751-37b7-4023-8d5f-df5d101d96b1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_416ba0e3-7ad4-4cd4-9063-efe8247f9713_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_18fc3593-a696-43fe-9fc8-49674afdf96f_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in units)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_97462be9-03a1-40a1-857a-32788a542a46_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_8df8f726-f2f1-4b53-acfe-222cd4611375_terseLabel_en-US" xlink:label="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangements with Federal Government [Line Items]</link:label>
    <link:label id="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_label_en-US" xlink:label="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangements With Federal Government [Line Items]</link:label>
    <link:label id="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_documentation_en-US" xlink:label="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development arrangements with the federal government.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems" xlink:href="ibrx-20230331.xsd#ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems" xlink:to="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_780f7066-63ec-4371-aedd-a62172ddaeec_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PeriodOfExtendedLeaseTerm_77811ecc-077e-46b4-a175-9731f120e644_terseLabel_en-US" xlink:label="lab_ibrx_PeriodOfExtendedLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Optional extended lease term</link:label>
    <link:label id="lab_ibrx_PeriodOfExtendedLeaseTerm_label_en-US" xlink:label="lab_ibrx_PeriodOfExtendedLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Of Extended Lease Term</link:label>
    <link:label id="lab_ibrx_PeriodOfExtendedLeaseTerm_documentation_en-US" xlink:label="lab_ibrx_PeriodOfExtendedLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of extended lease term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PeriodOfExtendedLeaseTerm" xlink:href="ibrx-20230331.xsd#ibrx_PeriodOfExtendedLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PeriodOfExtendedLeaseTerm" xlink:to="lab_ibrx_PeriodOfExtendedLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_e543fdf6-4912-4ced-834a-168a26626ac0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionLineItems" xlink:to="lab_us-gaap_AssetAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable_96c8267f-783d-4d36-8cf9-00caea8587ee_terseLabel_en-US" xlink:label="lab_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Tenant improvement allowance receivable</link:label>
    <link:label id="lab_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable_label_en-US" xlink:label="lab_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Allowance Receivable</link:label>
    <link:label id="lab_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable_documentation_en-US" xlink:label="lab_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Allowance Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:href="ibrx-20230331.xsd#ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:to="lab_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_93669e60-8064-43d6-bed9-2e9316e93590_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffMarketFavorableLeaseMember_f6424780-0c52-4059-a268-e393619aa8a8_terseLabel_en-US" xlink:label="lab_us-gaap_OffMarketFavorableLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable Leasehold Rights</link:label>
    <link:label id="lab_us-gaap_OffMarketFavorableLeaseMember_label_en-US" xlink:label="lab_us-gaap_OffMarketFavorableLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off-Market Favorable Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketFavorableLeaseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffMarketFavorableLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffMarketFavorableLeaseMember" xlink:to="lab_us-gaap_OffMarketFavorableLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_36308534-df42-42d1-bf57-c48b28d5feef_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 (excluding the three months ended March&#160;31,&#160;2023)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_729f514c-9bf4-401d-8b61-4a9f187c0af8_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_7f4c9602-b74e-4960-8f9a-863cc28fba72_negatedLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net share settlement for RSUs vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember_100e58f0-2266-4fd6-a9fb-25c7d0a746b1_terseLabel_en-US" xlink:label="lab_ibrx_A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3M IPC and Access to Advanced Health Institute License Agreement</link:label>
    <link:label id="lab_ibrx_A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember_label_en-US" xlink:label="lab_ibrx_A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3M IPC and Access to Advanced Health Institute License Agreement [Member]</link:label>
    <link:label id="lab_ibrx_A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember_documentation_en-US" xlink:label="lab_ibrx_A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3M IPC and Access to Advanced Health Institute License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember" xlink:href="ibrx-20230331.xsd#ibrx_A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember" xlink:to="lab_ibrx_A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod_1096cb69-56ec-4fc3-970f-5db2c70ad2b6_terseLabel_en-US" xlink:label="lab_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual&#160;Life (in years)</link:label>
    <link:label id="lab_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod_label_en-US" xlink:label="lab_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Securities Period</link:label>
    <link:label id="lab_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod_documentation_en-US" xlink:label="lab_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale securities debt securities period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" xlink:href="ibrx-20230331.xsd#ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" xlink:to="lab_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_8cdca1b9-b3ba-44f5-9dfc-8ecac6098937_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flow from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3dffad2f-af57-4e28-9b23-fcd38207ccfd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c7eb41c9-5453-4b55-89b7-cd45d20db262_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_TransactionCostsWarrantLiability_d4ea1359-272e-4246-9f9f-653ec17092a6_terseLabel_en-US" xlink:label="lab_ibrx_TransactionCostsWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs allocated to warrant liabilities</link:label>
    <link:label id="lab_ibrx_TransactionCostsWarrantLiability_label_en-US" xlink:label="lab_ibrx_TransactionCostsWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs, Warrant Liability</link:label>
    <link:label id="lab_ibrx_TransactionCostsWarrantLiability_documentation_en-US" xlink:label="lab_ibrx_TransactionCostsWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs, Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TransactionCostsWarrantLiability" xlink:href="ibrx-20230331.xsd#ibrx_TransactionCostsWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_TransactionCostsWarrantLiability" xlink:to="lab_ibrx_TransactionCostsWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation_4e7e6a2a-841a-4597-b13d-e82379d541d9_terseLabel_en-US" xlink:label="lab_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum net sales milestone for contingent value rights payable</link:label>
    <link:label id="lab_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation_label_en-US" xlink:label="lab_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Net Sales Milestone Contingent Value Rights Obligation</link:label>
    <link:label id="lab_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation_documentation_en-US" xlink:label="lab_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum net sales milestone contingent value rights obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation" xlink:href="ibrx-20230331.xsd#ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation" xlink:to="lab_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_DrSoonShiongAndRelatedPartyMember_dd8c8df5-8d89-44ad-be70-728f9792dbd1_terseLabel_en-US" xlink:label="lab_ibrx_DrSoonShiongAndRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Soon-Shiong and Related Party</link:label>
    <link:label id="lab_ibrx_DrSoonShiongAndRelatedPartyMember_label_en-US" xlink:label="lab_ibrx_DrSoonShiongAndRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr Soon Shiong And Related Party [Member]</link:label>
    <link:label id="lab_ibrx_DrSoonShiongAndRelatedPartyMember_documentation_en-US" xlink:label="lab_ibrx_DrSoonShiongAndRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Soon-Shiong and related party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DrSoonShiongAndRelatedPartyMember" xlink:href="ibrx-20230331.xsd#ibrx_DrSoonShiongAndRelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_DrSoonShiongAndRelatedPartyMember" xlink:to="lab_ibrx_DrSoonShiongAndRelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_9962f442-b59c-4b44-a67b-494dccb17611_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Not Settleable in Cash, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4d37627d-09f0-4dc9-b118-714b4036a503_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum_9d1f5195-3d16-46f7-8340-1b56d1098a22_terseLabel_en-US" xlink:label="lab_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment, aggregate maximum</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum_label_en-US" xlink:label="lab_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, Milestone Payment, Aggregate Maximum</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum_documentation_en-US" xlink:label="lab_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, Milestone Payment, Aggregate Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum" xlink:to="lab_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_2e1cc7dc-84f9-43e3-908a-28b4778b34b6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear_7ebe715e-eddf-42fb-8eff-814448d17998_totalLabel_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 (excluding the three months ended March&#160;31,&#160;2023)</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear_label_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, To Be Paid, Remainder of Fiscal Year</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear_documentation_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, To Be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear" xlink:to="lab_ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_3ae85822-6449-48f0-8f71-0040b46be68c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NumberOfLeases_c9b29afc-5f73-40e2-a9a3-1c5956aa34ea_terseLabel_en-US" xlink:label="lab_ibrx_NumberOfLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of leases</link:label>
    <link:label id="lab_ibrx_NumberOfLeases_label_en-US" xlink:label="lab_ibrx_NumberOfLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Leases</link:label>
    <link:label id="lab_ibrx_NumberOfLeases_documentation_en-US" xlink:label="lab_ibrx_NumberOfLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfLeases" xlink:href="ibrx-20230331.xsd#ibrx_NumberOfLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NumberOfLeases" xlink:to="lab_ibrx_NumberOfLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_69ab4214-11a1-44e5-a8f5-eb835bd65d59_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bf38a7ab-8e83-4b18-b880-dbcd0c3fb359_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e7efbf41-7801-4491-9c33-8851545eef92_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_56d609f4-e482-4616-9e29-3dfbbe05668e_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net share settlement for RSUs vesting</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eeae0c2f-a5c6-41a9-9dbc-e34f52171087_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_c5bc7412-a568-4679-8d97-813479ed54eb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_cd9b5dc2-4c87-4921-9631-eaa73113ff6b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_ab2205ca-5ed6-4a18-9c9e-31f58d48636b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_5384e6d7-712c-4324-8147-db0e343cf32d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_3a3d66cf-07bb-4477-b50c-378abba55864_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued litigation expense</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_ac29eb98-edb9-4074-9441-853a0f08078f_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_215d7c44-bb76-4041-8496-a81b45e60247_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_018a44ad-8ca8-4b60-a428-faf8ea02d840_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_7d31e89d-70c7-43ed-82d7-a2a13d7deceb_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional and service fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_7cfb19f8-2ed1-4aa7-814b-c16f78ca3d7f_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_51b3ab19-f576-400a-bc65-63c4222857e9_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_449195d8-91ea-4f4a-832d-b6de69808f8a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_3a428f5c-1c59-4fe8-9ff5-5a692f5cb641_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_RentAbatementPeriod_74c71510-a3f4-456d-b3f0-44adaae622df_terseLabel_en-US" xlink:label="lab_ibrx_RentAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent abatement period</link:label>
    <link:label id="lab_ibrx_RentAbatementPeriod_label_en-US" xlink:label="lab_ibrx_RentAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent Abatement Period</link:label>
    <link:label id="lab_ibrx_RentAbatementPeriod_documentation_en-US" xlink:label="lab_ibrx_RentAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent abatement period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RentAbatementPeriod" xlink:href="ibrx-20230331.xsd#ibrx_RentAbatementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_RentAbatementPeriod" xlink:to="lab_ibrx_RentAbatementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_c29a8756-d1e7-4720-b8a5-ae79bc7009ed_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of marketable debt securities, available for sale</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_c885531b-45f8-4a3c-88f4-a98b51f605c6_verboseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_d090014f-37fb-4727-8aef-32ea32231563_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantWorksMember_29a538b5-1d32-4307-856e-fc6889f92883_terseLabel_en-US" xlink:label="lab_ibrx_NantWorksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NantWorks</link:label>
    <link:label id="lab_ibrx_NantWorksMember_label_en-US" xlink:label="lab_ibrx_NantWorksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NantWorks [Member]</link:label>
    <link:label id="lab_ibrx_NantWorksMember_documentation_en-US" xlink:label="lab_ibrx_NantWorksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NantWorks.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksMember" xlink:href="ibrx-20230331.xsd#ibrx_NantWorksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantWorksMember" xlink:to="lab_ibrx_NantWorksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a1db4f70-7265-47ac-a39a-b60ed8c6a936_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_0f2d300a-7fa2-4fef-9a10-902da4938efc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Comprehensive loss attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_eeb23b58-f23c-4655-b930-87912843b389_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_865ddc85-075a-419a-9a0e-c8651eeada87_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Net Loss per Share of Common Stock</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_bc9cd486-afd9-4326-907d-3892864afd2a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_894a6b42-df7d-4808-a0cf-25fdb0af641e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_ba0f7b82-027e-45cf-9196-1c122d6af874_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares to be issued in private placement</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_JulyTwentyNineteenLeaseMember_2b847e35-55f7-4adf-bc75-7f3d5fb40a2e_terseLabel_en-US" xlink:label="lab_ibrx_JulyTwentyNineteenLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2019 Lease</link:label>
    <link:label id="lab_ibrx_JulyTwentyNineteenLeaseMember_label_en-US" xlink:label="lab_ibrx_JulyTwentyNineteenLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July Twenty Nineteen Lease [Member]</link:label>
    <link:label id="lab_ibrx_JulyTwentyNineteenLeaseMember_documentation_en-US" xlink:label="lab_ibrx_JulyTwentyNineteenLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July twenty nineteen lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_JulyTwentyNineteenLeaseMember" xlink:href="ibrx-20230331.xsd#ibrx_JulyTwentyNineteenLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_JulyTwentyNineteenLeaseMember" xlink:to="lab_ibrx_JulyTwentyNineteenLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_5a1492b0-f91a-4157-875a-124413c17972_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantCapitalMember_7bbdac71-8846-4d56-8442-182e83ebd9be_terseLabel_en-US" xlink:label="lab_ibrx_NantCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital</link:label>
    <link:label id="lab_ibrx_NantCapitalMember_label_en-US" xlink:label="lab_ibrx_NantCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital [Member]</link:label>
    <link:label id="lab_ibrx_NantCapitalMember_documentation_en-US" xlink:label="lab_ibrx_NantCapitalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NantCapital.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalMember" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantCapitalMember" xlink:to="lab_ibrx_NantCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_7da6b0d0-5ef6-4e83-9ff1-357bd2209faf_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_4dac8e6c-b6bf-44d8-84dd-61e78993a80e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants outstanding (in units)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_f7d03d2f-452a-4394-b733-141251359809_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_3927c0b6-40c6-403a-bb3b-2bba353fc28c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_3d06ed06-4e4a-4657-a26a-6f79158593ff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Supplies_fb51d184-fa67-4613-89a5-b5c0b041e700_terseLabel_en-US" xlink:label="lab_us-gaap_Supplies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid supplies</link:label>
    <link:label id="lab_us-gaap_Supplies_label_en-US" xlink:label="lab_us-gaap_Supplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Supplies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Supplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Supplies" xlink:to="lab_us-gaap_Supplies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d15f3cc4-6564-4435-9721-38c38b3bca0f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LicensingAgreementLineItems_632d4b37-3357-4ecd-a9af-3fc9ea3ee1d5_terseLabel_en-US" xlink:label="lab_ibrx_LicensingAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreement [Line Items]</link:label>
    <link:label id="lab_ibrx_LicensingAgreementLineItems_label_en-US" xlink:label="lab_ibrx_LicensingAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreement [Line Items]</link:label>
    <link:label id="lab_ibrx_LicensingAgreementLineItems_documentation_en-US" xlink:label="lab_ibrx_LicensingAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LicensingAgreementLineItems" xlink:href="ibrx-20230331.xsd#ibrx_LicensingAgreementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LicensingAgreementLineItems" xlink:to="lab_ibrx_LicensingAgreementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_239f0815-95fb-4849-9a7a-4f5f5396d411_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_688872f8-4ab0-47d1-8f2b-cf835725675b_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantCapitalOneMember_c774442c-ad09-4917-bd4d-11aef321976b_terseLabel_en-US" xlink:label="lab_ibrx_NantCapitalOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital</link:label>
    <link:label id="lab_ibrx_NantCapitalOneMember_label_en-US" xlink:label="lab_ibrx_NantCapitalOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant Capital One [Member]</link:label>
    <link:label id="lab_ibrx_NantCapitalOneMember_documentation_en-US" xlink:label="lab_ibrx_NantCapitalOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nant capital one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalOneMember" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantCapitalOneMember" xlink:to="lab_ibrx_NantCapitalOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d085148d-eb66-481a-91c9-6138b868cb1e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7f551463-59f6-43f2-b084-56cd40183b6d_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRelatedPartyDebt_f2e39fff-02d3-4e8e-b642-6737ec7a70a8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of related-party convertible promissory notes, net of issuance costs paid</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRelatedPartyDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Related Party Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_6cce03f9-463d-4ef0-a02d-70de16bea7b1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements and Acquisition</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AccessToAdvancedHealthInstituteAAHIMember_02d9b193-c664-4f88-baf4-f68b99d080ca_terseLabel_en-US" xlink:label="lab_ibrx_AccessToAdvancedHealthInstituteAAHIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Access to Advanced Health Institute (formerly IDRI)</link:label>
    <link:label id="lab_ibrx_AccessToAdvancedHealthInstituteAAHIMember_label_en-US" xlink:label="lab_ibrx_AccessToAdvancedHealthInstituteAAHIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Access to Advanced Health Institute (AAHI) [Member]</link:label>
    <link:label id="lab_ibrx_AccessToAdvancedHealthInstituteAAHIMember_documentation_en-US" xlink:label="lab_ibrx_AccessToAdvancedHealthInstituteAAHIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Access to Advanced Health Institute</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccessToAdvancedHealthInstituteAAHIMember" xlink:href="ibrx-20230331.xsd#ibrx_AccessToAdvancedHealthInstituteAAHIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AccessToAdvancedHealthInstituteAAHIMember" xlink:to="lab_ibrx_AccessToAdvancedHealthInstituteAAHIMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>ibrx-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5993b617-92d4-4bab-a076-33e54147e714,g:68360996-794b-41f6-8c08-63fce426a63c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.immunitybio.com/role/CoverPage" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_eb78d9d3-b3ba-48db-b16c-5446939ba969" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_DocumentType_eb78d9d3-b3ba-48db-b16c-5446939ba969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_1670bfa8-16d6-4059-bf02-b650c290a777" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_DocumentQuarterlyReport_1670bfa8-16d6-4059-bf02-b650c290a777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_235a5630-a92a-4ae9-bf41-c2d1fb1664d0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_DocumentPeriodEndDate_235a5630-a92a-4ae9-bf41-c2d1fb1664d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_d0e3a8b3-82d4-48a3-a53e-74bf3bc1be3c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_DocumentTransitionReport_d0e3a8b3-82d4-48a3-a53e-74bf3bc1be3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ce4d13e7-b9a4-490a-a4b0-7f5ef3f65afc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_EntityFileNumber_ce4d13e7-b9a4-490a-a4b0-7f5ef3f65afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1e198050-1e43-4234-8896-1a561d4e8247" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_EntityRegistrantName_1e198050-1e43-4234-8896-1a561d4e8247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_57441386-b9ca-4735-8152-2e9dc34dda95" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_EntityIncorporationStateCountryCode_57441386-b9ca-4735-8152-2e9dc34dda95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_974b2201-e91e-4a1b-a773-cdd3da850db4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_EntityTaxIdentificationNumber_974b2201-e91e-4a1b-a773-cdd3da850db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2b7ddda7-99d0-4af1-a23a-2fa131950182" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_EntityAddressAddressLine1_2b7ddda7-99d0-4af1-a23a-2fa131950182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ede1279d-7e7d-49f5-823e-94ddd101c7a3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_EntityAddressCityOrTown_ede1279d-7e7d-49f5-823e-94ddd101c7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f1f30af7-ac9b-4a2c-a6cc-bdcab3d2b852" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_EntityAddressStateOrProvince_f1f30af7-ac9b-4a2c-a6cc-bdcab3d2b852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e595c502-51bb-4e72-b61f-96d5d8c97daa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_EntityAddressPostalZipCode_e595c502-51bb-4e72-b61f-96d5d8c97daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a900a24e-b9ce-428d-930d-c749acd0f86a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_CityAreaCode_a900a24e-b9ce-428d-930d-c749acd0f86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8cfd305c-3100-41fb-8fca-a7bdb6530edd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_LocalPhoneNumber_8cfd305c-3100-41fb-8fca-a7bdb6530edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5125fa95-e4cb-45e8-9a09-c0dbc67012a8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_Security12bTitle_5125fa95-e4cb-45e8-9a09-c0dbc67012a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2ee0371f-3a30-40d5-9db0-3a0bfb014bd6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_TradingSymbol_2ee0371f-3a30-40d5-9db0-3a0bfb014bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_debe2cf8-5bc9-49ee-847c-8c909e1e34a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_SecurityExchangeName_debe2cf8-5bc9-49ee-847c-8c909e1e34a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_114fe30d-5754-40ed-9148-e9d00dcbcb1a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_EntityCurrentReportingStatus_114fe30d-5754-40ed-9148-e9d00dcbcb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_82a61678-ec1d-469e-8442-757989e8eefe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_EntityInteractiveDataCurrent_82a61678-ec1d-469e-8442-757989e8eefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e5a08f1b-1667-467b-8354-08c93edcd99b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_EntityFilerCategory_e5a08f1b-1667-467b-8354-08c93edcd99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_21b6bdbc-be58-4ac9-97f9-221f716022d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_EntitySmallBusiness_21b6bdbc-be58-4ac9-97f9-221f716022d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_11705c79-91bb-4e69-9a18-6de5faf2e14b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_EntityEmergingGrowthCompany_11705c79-91bb-4e69-9a18-6de5faf2e14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5d582c62-ce87-4c76-b1b4-4f855058e179" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_EntityShellCompany_5d582c62-ce87-4c76-b1b4-4f855058e179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8aa4b480-7cd7-446a-99a9-63f78b4a1b9d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8aa4b480-7cd7-446a-99a9-63f78b4a1b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d98eabc3-7485-4fbb-ac6d-4bfdc45552f0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_AmendmentFlag_d98eabc3-7485-4fbb-ac6d-4bfdc45552f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_50291f7d-765b-4774-91b5-9dcc6fcd3f9e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_DocumentFiscalYearFocus_50291f7d-765b-4774-91b5-9dcc6fcd3f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_678b7ef1-0614-4a5f-a303-e8e3c76b1356" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_DocumentFiscalPeriodFocus_678b7ef1-0614-4a5f-a303-e8e3c76b1356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_14c6d715-6e31-4903-ba8e-5f392bded280" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_EntityCentralIndexKey_14c6d715-6e31-4903-ba8e-5f392bded280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e30ae0a3-e92e-4a00-b10d-f9035f532068" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89effcd6-2cd9-4911-a744-20ed06b72b74" xlink:to="loc_dei_CurrentFiscalYearEndDate_e30ae0a3-e92e-4a00-b10d-f9035f532068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_65ff3019-6e8b-4874-b4f1-a6e2436f9cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_982f0c6d-a248-4335-bc86-7e324acc9af5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_65ff3019-6e8b-4874-b4f1-a6e2436f9cec" xlink:to="loc_us-gaap_StatementTable_982f0c6d-a248-4335-bc86-7e324acc9af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6740c8d1-9b08-413e-93b3-7a15b7f37f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_982f0c6d-a248-4335-bc86-7e324acc9af5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6740c8d1-9b08-413e-93b3-7a15b7f37f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_76c837de-1e8d-4a48-9052-0fb49218fa28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6740c8d1-9b08-413e-93b3-7a15b7f37f8c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_76c837de-1e8d-4a48-9052-0fb49218fa28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PromissoryNotesPayableMember_169f5f14-caac-4a62-9f4e-a6878dba9eb0" xlink:href="ibrx-20230331.xsd#ibrx_PromissoryNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_76c837de-1e8d-4a48-9052-0fb49218fa28" xlink:to="loc_ibrx_PromissoryNotesPayableMember_169f5f14-caac-4a62-9f4e-a6878dba9eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_3ea57560-32cd-464a-b83f-5b6c56000253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_76c837de-1e8d-4a48-9052-0fb49218fa28" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_3ea57560-32cd-464a-b83f-5b6c56000253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4b9d49ae-3690-4123-a879-79831eddd1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_982f0c6d-a248-4335-bc86-7e324acc9af5" xlink:to="loc_us-gaap_StatementLineItems_4b9d49ae-3690-4123-a879-79831eddd1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c48baaea-3cd7-4b6b-948f-8b808d34a3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4b9d49ae-3690-4123-a879-79831eddd1e6" xlink:to="loc_us-gaap_AssetsAbstract_c48baaea-3cd7-4b6b-948f-8b808d34a3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_317c6e95-c7f4-4f97-91db-cc5a02da9818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c48baaea-3cd7-4b6b-948f-8b808d34a3e0" xlink:to="loc_us-gaap_AssetsCurrentAbstract_317c6e95-c7f4-4f97-91db-cc5a02da9818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6e4151b1-3938-4614-ba9c-219c82c589a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_317c6e95-c7f4-4f97-91db-cc5a02da9818" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6e4151b1-3938-4614-ba9c-219c82c589a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_f7fd1029-6a16-49ab-b886-cb34e295254e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_317c6e95-c7f4-4f97-91db-cc5a02da9818" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_f7fd1029-6a16-49ab-b886-cb34e295254e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_2fe10725-871f-43ed-9bf4-9730f4e50e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_317c6e95-c7f4-4f97-91db-cc5a02da9818" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_2fe10725-871f-43ed-9bf4-9730f4e50e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_724ab9ff-c806-4e78-b2e6-7816bd5cc3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_317c6e95-c7f4-4f97-91db-cc5a02da9818" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_724ab9ff-c806-4e78-b2e6-7816bd5cc3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_13bdd65a-a13a-4c69-b4f0-4510126f49c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_317c6e95-c7f4-4f97-91db-cc5a02da9818" xlink:to="loc_us-gaap_AssetsCurrent_13bdd65a-a13a-4c69-b4f0-4510126f49c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_63817d24-f2f7-40f0-af77-c880f23f9f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c48baaea-3cd7-4b6b-948f-8b808d34a3e0" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_63817d24-f2f7-40f0-af77-c880f23f9f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fd4a8aa9-0565-4a80-969e-a0019cc2b2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c48baaea-3cd7-4b6b-948f-8b808d34a3e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fd4a8aa9-0565-4a80-969e-a0019cc2b2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_919ff52d-3979-4d10-a464-952e33593be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c48baaea-3cd7-4b6b-948f-8b808d34a3e0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_919ff52d-3979-4d10-a464-952e33593be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ConvertibleNoteReceivableNonCurrent_061e6add-8f63-4d13-bb53-6efe3ddfacb6" xlink:href="ibrx-20230331.xsd#ibrx_ConvertibleNoteReceivableNonCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c48baaea-3cd7-4b6b-948f-8b808d34a3e0" xlink:to="loc_ibrx_ConvertibleNoteReceivableNonCurrent_061e6add-8f63-4d13-bb53-6efe3ddfacb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_72b4da84-15ef-4312-995c-96d88044277e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c48baaea-3cd7-4b6b-948f-8b808d34a3e0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_72b4da84-15ef-4312-995c-96d88044277e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_dc35f7d9-0fc6-4628-8caf-6fa052673d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c48baaea-3cd7-4b6b-948f-8b808d34a3e0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_dc35f7d9-0fc6-4628-8caf-6fa052673d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e5e861cb-f44a-47da-a66c-4a888c5c5474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c48baaea-3cd7-4b6b-948f-8b808d34a3e0" xlink:to="loc_us-gaap_Assets_e5e861cb-f44a-47da-a66c-4a888c5c5474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4b9d49ae-3690-4123-a879-79831eddd1e6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_ffcb4936-e3e5-4146-8656-6499d87fab26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_ffcb4936-e3e5-4146-8656-6499d87fab26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0fbe70cf-112b-456f-9aa4-f89e1c1d43c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ffcb4936-e3e5-4146-8656-6499d87fab26" xlink:to="loc_us-gaap_AccountsPayableCurrent_0fbe70cf-112b-456f-9aa4-f89e1c1d43c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_d65d06b6-a522-4e42-bff7-6ec5562a79c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ffcb4936-e3e5-4146-8656-6499d87fab26" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_d65d06b6-a522-4e42-bff7-6ec5562a79c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_30247a23-2983-4116-ab08-dc505f6d7731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ffcb4936-e3e5-4146-8656-6499d87fab26" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_30247a23-2983-4116-ab08-dc505f6d7731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_9d41a317-5466-4c6c-accf-4fc22e199847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ffcb4936-e3e5-4146-8656-6499d87fab26" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_9d41a317-5466-4c6c-accf-4fc22e199847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_461cb75a-12da-40cb-9627-990d008af096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ffcb4936-e3e5-4146-8656-6499d87fab26" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_461cb75a-12da-40cb-9627-990d008af096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_20cb7189-a89b-45b0-8573-67a28e86b24e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ffcb4936-e3e5-4146-8656-6499d87fab26" xlink:to="loc_us-gaap_LiabilitiesCurrent_20cb7189-a89b-45b0-8573-67a28e86b24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesNoncurrent_21d68379-bd25-439c-8215-ee6af83330f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesNoncurrent_21d68379-bd25-439c-8215-ee6af83330f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_47da2604-564c-4897-809c-6a09d074a240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_47da2604-564c-4897-809c-6a09d074a240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_276dd604-d818-4870-8760-67f4e7ebc9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_276dd604-d818-4870-8760-67f4e7ebc9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_777b8903-6e6f-4f8e-8592-f301f48231be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_777b8903-6e6f-4f8e-8592-f301f48231be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_454d5702-7601-4e66-b82c-dc40b423baac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:to="loc_us-gaap_Liabilities_454d5702-7601-4e66-b82c-dc40b423baac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_302d9273-a463-4451-ac7a-97e7b0fbf141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:to="loc_us-gaap_CommitmentsAndContingencies_302d9273-a463-4451-ac7a-97e7b0fbf141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_50084db4-8a5f-4704-b240-a55c092ed2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:to="loc_us-gaap_StockholdersEquityAbstract_50084db4-8a5f-4704-b240-a55c092ed2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_fb9185ee-e45b-4dd9-ae91-13d1ac8c7536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50084db4-8a5f-4704-b240-a55c092ed2b2" xlink:to="loc_us-gaap_CommonStockValue_fb9185ee-e45b-4dd9-ae91-13d1ac8c7536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d228f9cb-c7f4-4c89-ac24-fe58eafd50d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50084db4-8a5f-4704-b240-a55c092ed2b2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d228f9cb-c7f4-4c89-ac24-fe58eafd50d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b91b7442-61fd-45bf-b2b0-8f3a3df2510d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50084db4-8a5f-4704-b240-a55c092ed2b2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b91b7442-61fd-45bf-b2b0-8f3a3df2510d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a0b311d5-bb1d-404c-90df-c5093a2c28d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50084db4-8a5f-4704-b240-a55c092ed2b2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a0b311d5-bb1d-404c-90df-c5093a2c28d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ca6f3cab-11e2-4923-ae2f-d87210ace750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50084db4-8a5f-4704-b240-a55c092ed2b2" xlink:to="loc_us-gaap_StockholdersEquity_ca6f3cab-11e2-4923-ae2f-d87210ace750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_56ef81fb-898a-4417-8621-5ee084fe9af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:to="loc_us-gaap_MinorityInterest_56ef81fb-898a-4417-8621-5ee084fe9af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_36f61f78-0281-44b2-965c-641906116412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_36f61f78-0281-44b2-965c-641906116412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_dc867876-d8ec-41f8-bf4c-ef34b0a78d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_21f96eef-4003-42b6-bd0b-38b1d102e819" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_dc867876-d8ec-41f8-bf4c-ef34b0a78d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_153416e9-4fb9-4f2f-8a12-98283bf0e4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_dcf1cf3b-b024-4344-9e11-bc437d724ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_153416e9-4fb9-4f2f-8a12-98283bf0e4ed" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_dcf1cf3b-b024-4344-9e11-bc437d724ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2cfbe0e4-e798-41f5-a742-179a4ec2320b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_153416e9-4fb9-4f2f-8a12-98283bf0e4ed" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2cfbe0e4-e798-41f5-a742-179a4ec2320b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4b104a5c-f24d-4b81-91ab-91963d95b811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_153416e9-4fb9-4f2f-8a12-98283bf0e4ed" xlink:to="loc_us-gaap_CommonStockSharesIssued_4b104a5c-f24d-4b81-91ab-91963d95b811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0c87b11b-dd2d-40f7-bd67-025adb6e47f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_153416e9-4fb9-4f2f-8a12-98283bf0e4ed" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0c87b11b-dd2d-40f7-bd67-025adb6e47f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_f283ebb9-3639-40a2-b547-ecbf0f01c0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_153416e9-4fb9-4f2f-8a12-98283bf0e4ed" xlink:to="loc_us-gaap_TreasuryStockCommonShares_f283ebb9-3639-40a2-b547-ecbf0f01c0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_5c637f22-f58c-41ab-85a6-67d7d1e80883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_42cf4849-b06d-47a7-b741-9678e95f449a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5c637f22-f58c-41ab-85a6-67d7d1e80883" xlink:to="loc_us-gaap_Revenues_42cf4849-b06d-47a7-b741-9678e95f449a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_0f8ad189-0572-4883-998d-1cb76144a63c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5c637f22-f58c-41ab-85a6-67d7d1e80883" xlink:to="loc_us-gaap_OperatingExpensesAbstract_0f8ad189-0572-4883-998d-1cb76144a63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_63cd798e-a28b-44ad-8709-f283da458061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0f8ad189-0572-4883-998d-1cb76144a63c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_63cd798e-a28b-44ad-8709-f283da458061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_13ac7e00-bd6b-4c8e-89f3-6e3096b9462b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0f8ad189-0572-4883-998d-1cb76144a63c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_13ac7e00-bd6b-4c8e-89f3-6e3096b9462b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_bb013659-e9e2-494b-a987-886bc30063a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0f8ad189-0572-4883-998d-1cb76144a63c" xlink:to="loc_us-gaap_OperatingExpenses_bb013659-e9e2-494b-a987-886bc30063a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_04e3864f-02e2-4d08-8eff-ef1cc33ddf5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5c637f22-f58c-41ab-85a6-67d7d1e80883" xlink:to="loc_us-gaap_OperatingIncomeLoss_04e3864f-02e2-4d08-8eff-ef1cc33ddf5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1b3b2300-01b6-4abf-9552-9c48e9566ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5c637f22-f58c-41ab-85a6-67d7d1e80883" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1b3b2300-01b6-4abf-9552-9c48e9566ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_faf2a904-d952-418a-832e-dff8a663f155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1b3b2300-01b6-4abf-9552-9c48e9566ae9" xlink:to="loc_us-gaap_GainLossOnInvestments_faf2a904-d952-418a-832e-dff8a663f155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_dd7d332d-39da-4c9c-8e91-a84a53d20c81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1b3b2300-01b6-4abf-9552-9c48e9566ae9" xlink:to="loc_us-gaap_InterestExpense_dd7d332d-39da-4c9c-8e91-a84a53d20c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4bc10a65-0730-4283-a624-d2888cd06513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1b3b2300-01b6-4abf-9552-9c48e9566ae9" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4bc10a65-0730-4283-a624-d2888cd06513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_a310ed5e-a5d9-42ed-99fd-cfe6d04539ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1b3b2300-01b6-4abf-9552-9c48e9566ae9" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_a310ed5e-a5d9-42ed-99fd-cfe6d04539ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b1cb1ad0-15fd-436f-a891-068f36ad1790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1b3b2300-01b6-4abf-9552-9c48e9566ae9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b1cb1ad0-15fd-436f-a891-068f36ad1790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_73b5008a-4a2d-456f-af88-e203f64a971f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1b3b2300-01b6-4abf-9552-9c48e9566ae9" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_73b5008a-4a2d-456f-af88-e203f64a971f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7d4591e5-96d7-4928-b010-09de98dcc81a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5c637f22-f58c-41ab-85a6-67d7d1e80883" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7d4591e5-96d7-4928-b010-09de98dcc81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_957ec3d5-b8ce-47c1-894c-7a725ad29419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5c637f22-f58c-41ab-85a6-67d7d1e80883" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_957ec3d5-b8ce-47c1-894c-7a725ad29419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c537e3fc-1c60-4b8e-9658-9ae080d04058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5c637f22-f58c-41ab-85a6-67d7d1e80883" xlink:to="loc_us-gaap_ProfitLoss_c537e3fc-1c60-4b8e-9658-9ae080d04058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_45c833b6-0454-43eb-8916-9fe6dd41120b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5c637f22-f58c-41ab-85a6-67d7d1e80883" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_45c833b6-0454-43eb-8916-9fe6dd41120b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9ff17457-e129-4dbd-8f70-2b7aa26fcbc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5c637f22-f58c-41ab-85a6-67d7d1e80883" xlink:to="loc_us-gaap_NetIncomeLoss_9ff17457-e129-4dbd-8f70-2b7aa26fcbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_32f235ab-4096-4c92-b9f6-e629d67a4134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5c637f22-f58c-41ab-85a6-67d7d1e80883" xlink:to="loc_us-gaap_EarningsPerShareBasic_32f235ab-4096-4c92-b9f6-e629d67a4134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b9b9e8a3-7baa-4b11-8c87-9a384c8d0f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5c637f22-f58c-41ab-85a6-67d7d1e80883" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b9b9e8a3-7baa-4b11-8c87-9a384c8d0f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a2f50e0c-e896-420a-80df-9180ec5751c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5c637f22-f58c-41ab-85a6-67d7d1e80883" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a2f50e0c-e896-420a-80df-9180ec5751c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c63d9455-8af1-4284-bf86-211fec2a7e94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5c637f22-f58c-41ab-85a6-67d7d1e80883" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c63d9455-8af1-4284-bf86-211fec2a7e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_653a9c8a-6f47-4447-8cae-f065b6628faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_418322bc-173f-4b5c-90d7-77ff7050a966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_653a9c8a-6f47-4447-8cae-f065b6628faa" xlink:to="loc_us-gaap_ProfitLoss_418322bc-173f-4b5c-90d7-77ff7050a966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_968df661-f70d-490b-b3b7-7f56235d7349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_653a9c8a-6f47-4447-8cae-f065b6628faa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_968df661-f70d-490b-b3b7-7f56235d7349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_c27ac273-eb4d-4767-a85d-4d0dc1659135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_968df661-f70d-490b-b3b7-7f56235d7349" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_c27ac273-eb4d-4767-a85d-4d0dc1659135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_60d39a04-8087-4b6f-b033-86539c81225c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_968df661-f70d-490b-b3b7-7f56235d7349" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_60d39a04-8087-4b6f-b033-86539c81225c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1ae3f3c7-fb6a-4d10-a258-b2aa056923bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_968df661-f70d-490b-b3b7-7f56235d7349" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1ae3f3c7-fb6a-4d10-a258-b2aa056923bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9a60a6c5-38c2-473f-9289-138fb8c44df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_968df661-f70d-490b-b3b7-7f56235d7349" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9a60a6c5-38c2-473f-9289-138fb8c44df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b208dc25-b7eb-4ba9-aa67-0750b419f5ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_653a9c8a-6f47-4447-8cae-f065b6628faa" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b208dc25-b7eb-4ba9-aa67-0750b419f5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_4d5d0c33-26e7-458a-8e42-75ec145076fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_653a9c8a-6f47-4447-8cae-f065b6628faa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_4d5d0c33-26e7-458a-8e42-75ec145076fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4152830d-ea3e-49c4-9798-e3496fd0f08e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_653a9c8a-6f47-4447-8cae-f065b6628faa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4152830d-ea3e-49c4-9798-e3496fd0f08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CondensedConsolidatedStatementsofStockholdersDeficit"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9978befd-7958-4f89-b088-368104395cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a3b17a9a-0c14-46a7-af98-8e05df1fe695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9978befd-7958-4f89-b088-368104395cd0" xlink:to="loc_us-gaap_StatementTable_a3b17a9a-0c14-46a7-af98-8e05df1fe695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_707da8dc-2751-47ae-85d0-ab18ab83416c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a3b17a9a-0c14-46a7-af98-8e05df1fe695" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_707da8dc-2751-47ae-85d0-ab18ab83416c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e7548e8f-4c92-4725-95c5-d83d4f2c4049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_707da8dc-2751-47ae-85d0-ab18ab83416c" xlink:to="loc_us-gaap_EquityComponentDomain_e7548e8f-4c92-4725-95c5-d83d4f2c4049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8d9f819c-c202-4c35-96a0-b0ec3f2cbfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e7548e8f-4c92-4725-95c5-d83d4f2c4049" xlink:to="loc_us-gaap_CommonStockMember_8d9f819c-c202-4c35-96a0-b0ec3f2cbfc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_42eb241d-b928-4b48-956c-adb87893d154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e7548e8f-4c92-4725-95c5-d83d4f2c4049" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_42eb241d-b928-4b48-956c-adb87893d154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2b41e5cf-257e-427a-8118-84aafe5f8190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e7548e8f-4c92-4725-95c5-d83d4f2c4049" xlink:to="loc_us-gaap_RetainedEarningsMember_2b41e5cf-257e-427a-8118-84aafe5f8190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0b7386ac-ec9b-4d91-88ae-a8c31c9ffe0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e7548e8f-4c92-4725-95c5-d83d4f2c4049" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0b7386ac-ec9b-4d91-88ae-a8c31c9ffe0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8802fc52-9bfa-403f-a20b-418272e8b974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e7548e8f-4c92-4725-95c5-d83d4f2c4049" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8802fc52-9bfa-403f-a20b-418272e8b974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_81808be7-cb40-41a1-9ae6-04c649f6c859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e7548e8f-4c92-4725-95c5-d83d4f2c4049" xlink:to="loc_us-gaap_NoncontrollingInterestMember_81808be7-cb40-41a1-9ae6-04c649f6c859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fb553b19-62d4-498f-8442-8ada2b61ec47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a3b17a9a-0c14-46a7-af98-8e05df1fe695" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fb553b19-62d4-498f-8442-8ada2b61ec47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf51c72a-a714-4257-b9e9-67a95cc93398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fb553b19-62d4-498f-8442-8ada2b61ec47" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf51c72a-a714-4257-b9e9-67a95cc93398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_fe52175d-4177-469b-8604-64a43a8b5836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bf51c72a-a714-4257-b9e9-67a95cc93398" xlink:to="loc_us-gaap_PrivatePlacementMember_fe52175d-4177-469b-8604-64a43a8b5836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e7c71c41-d7cf-4abd-b299-019cb9b7a7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a3b17a9a-0c14-46a7-af98-8e05df1fe695" xlink:to="loc_us-gaap_StatementLineItems_e7c71c41-d7cf-4abd-b299-019cb9b7a7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e7c71c41-d7cf-4abd-b299-019cb9b7a7ca" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bed606af-eb5c-43cf-b654-db3a65dcc272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bed606af-eb5c-43cf-b654-db3a65dcc272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c0d6e2c0-be6f-4a46-b9ae-0c66c63f5d75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c0d6e2c0-be6f-4a46-b9ae-0c66c63f5d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a2ef3831-35a4-44ad-b8aa-020ebca630c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a2ef3831-35a4-44ad-b8aa-020ebca630c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5de3e0bb-3489-4030-9fe4-f95142237bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5de3e0bb-3489-4030-9fe4-f95142237bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_daaa62fb-9c41-441f-b360-375eb6d01690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_daaa62fb-9c41-441f-b360-375eb6d01690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_969a4539-0ae9-42cd-9e70-c39ded33706b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_969a4539-0ae9-42cd-9e70-c39ded33706b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_18112d27-b83b-44ae-89a6-a98c1514c6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_18112d27-b83b-44ae-89a6-a98c1514c6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_23f43df5-0119-47f9-b28a-c5fdc825f003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_23f43df5-0119-47f9-b28a-c5fdc825f003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_9f5312f5-1fbd-41e6-a9ae-f7259baa769e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_9f5312f5-1fbd-41e6-a9ae-f7259baa769e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_dc231258-7fe5-4f49-9bfa-87222ca5a1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_dc231258-7fe5-4f49-9bfa-87222ca5a1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_186bd76a-2fa4-46b6-b04d-06154314f39b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_186bd76a-2fa4-46b6-b04d-06154314f39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_cc677fe4-6f8f-4bf6-9c8c-2331eec08fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_ProfitLoss_cc677fe4-6f8f-4bf6-9c8c-2331eec08fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_366f6b0a-0a59-4f87-93f9-f72469a04d52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_366f6b0a-0a59-4f87-93f9-f72469a04d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_81b13eaf-6d11-4505-ac9b-cbd01379d956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2e2ed09e-feea-40ce-aa38-fb8a29877e7e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_81b13eaf-6d11-4505-ac9b-cbd01379d956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficitParenthetical" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CondensedConsolidatedStatementsofStockholdersDeficitParenthetical"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ea32d6ea-8577-402c-bca4-5a9fb0f13cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b6cb6e37-5e9e-4c5f-95ec-0e49a2a7a4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ea32d6ea-8577-402c-bca4-5a9fb0f13cb3" xlink:to="loc_us-gaap_StatementTable_b6cb6e37-5e9e-4c5f-95ec-0e49a2a7a4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_46ec7cdc-b5cb-42df-9939-f3b1600b5ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b6cb6e37-5e9e-4c5f-95ec-0e49a2a7a4c3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_46ec7cdc-b5cb-42df-9939-f3b1600b5ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2be32467-f690-42e5-97f2-daf17a8b959c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_46ec7cdc-b5cb-42df-9939-f3b1600b5ab3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2be32467-f690-42e5-97f2-daf17a8b959c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_bb7e7622-4cf4-4d34-a83e-45dbfe261a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2be32467-f690-42e5-97f2-daf17a8b959c" xlink:to="loc_us-gaap_PrivatePlacementMember_bb7e7622-4cf4-4d34-a83e-45dbfe261a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d6dd8acc-c984-47e5-8427-1c351895c29d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b6cb6e37-5e9e-4c5f-95ec-0e49a2a7a4c3" xlink:to="loc_us-gaap_StatementLineItems_d6dd8acc-c984-47e5-8427-1c351895c29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_fe7c8405-1cb9-4171-b0b6-d6ade1645abb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d6dd8acc-c984-47e5-8427-1c351895c29d" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_fe7c8405-1cb9-4171-b0b6-d6ade1645abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d2a32fa6-1132-4044-9aa3-cbbab95909c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7ab8d774-039f-4da9-a4f9-6c5a13866818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d2a32fa6-1132-4044-9aa3-cbbab95909c4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7ab8d774-039f-4da9-a4f9-6c5a13866818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_dd8d0fca-f6d5-44b5-9c38-fa001c8e4702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7ab8d774-039f-4da9-a4f9-6c5a13866818" xlink:to="loc_us-gaap_ProfitLoss_dd8d0fca-f6d5-44b5-9c38-fa001c8e4702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe59319d-b7f4-40b9-be5d-fa0405294ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7ab8d774-039f-4da9-a4f9-6c5a13866818" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe59319d-b7f4-40b9-be5d-fa0405294ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bb535830-2136-4807-9dc8-0c2a5b872c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe59319d-b7f4-40b9-be5d-fa0405294ae1" xlink:to="loc_us-gaap_ShareBasedCompensation_bb535830-2136-4807-9dc8-0c2a5b872c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_11a3d990-e721-4e3c-808e-04a920b20e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe59319d-b7f4-40b9-be5d-fa0405294ae1" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_11a3d990-e721-4e3c-808e-04a920b20e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TransactionCostsWarrantLiability_48bfce69-9bcd-471a-b252-79653bcf8cf7" xlink:href="ibrx-20230331.xsd#ibrx_TransactionCostsWarrantLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe59319d-b7f4-40b9-be5d-fa0405294ae1" xlink:to="loc_ibrx_TransactionCostsWarrantLiability_48bfce69-9bcd-471a-b252-79653bcf8cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NonCashInterestIncomeExpenseFromOperatingActivities_1b69cd48-2e31-411e-92c8-49f6ce8d95bf" xlink:href="ibrx-20230331.xsd#ibrx_NonCashInterestIncomeExpenseFromOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe59319d-b7f4-40b9-be5d-fa0405294ae1" xlink:to="loc_ibrx_NonCashInterestIncomeExpenseFromOperatingActivities_1b69cd48-2e31-411e-92c8-49f6ce8d95bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2372ebe1-c1ff-430d-80a7-b11067dc68c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe59319d-b7f4-40b9-be5d-fa0405294ae1" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2372ebe1-c1ff-430d-80a7-b11067dc68c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7f9717b1-b637-43b4-a18f-287fe53c86b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe59319d-b7f4-40b9-be5d-fa0405294ae1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7f9717b1-b637-43b4-a18f-287fe53c86b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_6790632f-7fda-4ebc-8be7-72bdf084f164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe59319d-b7f4-40b9-be5d-fa0405294ae1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_6790632f-7fda-4ebc-8be7-72bdf084f164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5190825b-6313-410a-b0be-5a142529b7da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe59319d-b7f4-40b9-be5d-fa0405294ae1" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5190825b-6313-410a-b0be-5a142529b7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_87aced98-90bf-4dea-a709-d034c9fa5a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe59319d-b7f4-40b9-be5d-fa0405294ae1" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_87aced98-90bf-4dea-a709-d034c9fa5a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9bdf6ab9-f79c-4b1c-bd5c-92d225b71fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe59319d-b7f4-40b9-be5d-fa0405294ae1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9bdf6ab9-f79c-4b1c-bd5c-92d225b71fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_68898a43-a870-470b-8afb-d67c4b68bac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9bdf6ab9-f79c-4b1c-bd5c-92d225b71fe0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_68898a43-a870-470b-8afb-d67c4b68bac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7e620f89-1a2f-4d4b-a922-5a66ffa46b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9bdf6ab9-f79c-4b1c-bd5c-92d225b71fe0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7e620f89-1a2f-4d4b-a922-5a66ffa46b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1062943f-4395-4aad-b7ac-db287fa7fed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9bdf6ab9-f79c-4b1c-bd5c-92d225b71fe0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1062943f-4395-4aad-b7ac-db287fa7fed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_3f22ecf5-b7f9-4ca1-9048-44a98b15d459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9bdf6ab9-f79c-4b1c-bd5c-92d225b71fe0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_3f22ecf5-b7f9-4ca1-9048-44a98b15d459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent_5b6f7f61-dc5e-4a03-b7ff-070b967ab200" xlink:href="ibrx-20230331.xsd#ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9bdf6ab9-f79c-4b1c-bd5c-92d225b71fe0" xlink:to="loc_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent_5b6f7f61-dc5e-4a03-b7ff-070b967ab200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4e446f90-13a9-4ede-9c08-827c2386ed12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9bdf6ab9-f79c-4b1c-bd5c-92d225b71fe0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4e446f90-13a9-4ede-9c08-827c2386ed12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9852099c-1aa8-40d5-ad3d-55580638e84b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7ab8d774-039f-4da9-a4f9-6c5a13866818" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9852099c-1aa8-40d5-ad3d-55580638e84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9bb56366-9e94-4278-a596-735c7e39b087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d2a32fa6-1132-4044-9aa3-cbbab95909c4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9bb56366-9e94-4278-a596-735c7e39b087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f34d1b4d-4431-49f6-b7d0-2fb1630ea579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9bb56366-9e94-4278-a596-735c7e39b087" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f34d1b4d-4431-49f6-b7d0-2fb1630ea579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a22fd592-eaa0-40f5-b5ba-2e9100fd9022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9bb56366-9e94-4278-a596-735c7e39b087" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a22fd592-eaa0-40f5-b5ba-2e9100fd9022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_04396b0c-385e-4ffa-9025-b6a8264415c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9bb56366-9e94-4278-a596-735c7e39b087" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_04396b0c-385e-4ffa-9025-b6a8264415c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_21203937-5cba-4cf8-8349-21b16705c607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9bb56366-9e94-4278-a596-735c7e39b087" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_21203937-5cba-4cf8-8349-21b16705c607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_19603676-9baf-4099-a174-877e5726e82c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9bb56366-9e94-4278-a596-735c7e39b087" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_19603676-9baf-4099-a174-877e5726e82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_624fc5b0-dc3e-4770-bdc4-dab3f1bb3237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9bb56366-9e94-4278-a596-735c7e39b087" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_624fc5b0-dc3e-4770-bdc4-dab3f1bb3237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5f723fe6-5f54-4518-82ae-1c79ca2742df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9bb56366-9e94-4278-a596-735c7e39b087" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5f723fe6-5f54-4518-82ae-1c79ca2742df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c16f3335-b7fb-45d2-b21f-19cb93060443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d2a32fa6-1132-4044-9aa3-cbbab95909c4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c16f3335-b7fb-45d2-b21f-19cb93060443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_53e81f9a-d568-4f57-addb-8019dc12e482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c16f3335-b7fb-45d2-b21f-19cb93060443" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_53e81f9a-d568-4f57-addb-8019dc12e482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_1226854b-ccdb-4113-b266-ecc00c918ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c16f3335-b7fb-45d2-b21f-19cb93060443" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_1226854b-ccdb-4113-b266-ecc00c918ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_8a2ed876-6f40-419e-9607-e7949b2335dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c16f3335-b7fb-45d2-b21f-19cb93060443" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_8a2ed876-6f40-419e-9607-e7949b2335dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3a72ace4-7175-49d5-b4d4-0c61f0071c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c16f3335-b7fb-45d2-b21f-19cb93060443" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3a72ace4-7175-49d5-b4d4-0c61f0071c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_30adb33a-8365-4547-9551-677e1ff7bdc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c16f3335-b7fb-45d2-b21f-19cb93060443" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_30adb33a-8365-4547-9551-677e1ff7bdc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5e1205a-4139-4a7a-809b-87b4fc42dd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c16f3335-b7fb-45d2-b21f-19cb93060443" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5e1205a-4139-4a7a-809b-87b4fc42dd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_60f52a8c-8b30-4d22-bb2f-f29f40bafc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d2a32fa6-1132-4044-9aa3-cbbab95909c4" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_60f52a8c-8b30-4d22-bb2f-f29f40bafc2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_db715f4b-251b-4a84-b49d-723f2b1a1b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d2a32fa6-1132-4044-9aa3-cbbab95909c4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_db715f4b-251b-4a84-b49d-723f2b1a1b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_62fee6cf-e4fb-4868-aa18-6f9e90376d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d2a32fa6-1132-4044-9aa3-cbbab95909c4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_62fee6cf-e4fb-4868-aa18-6f9e90376d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c1afdda3-8570-4362-b45e-778ce64e56cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d2a32fa6-1132-4044-9aa3-cbbab95909c4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c1afdda3-8570-4362-b45e-778ce64e56cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0ace0109-a8d4-444a-b072-3a16bd60d13d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d2a32fa6-1132-4044-9aa3-cbbab95909c4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0ace0109-a8d4-444a-b072-3a16bd60d13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_385c1715-66ca-42bd-8aee-c53affa172a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0ace0109-a8d4-444a-b072-3a16bd60d13d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_385c1715-66ca-42bd-8aee-c53affa172a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_99d2df8b-31f4-45b1-800a-531c7ebbbffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0ace0109-a8d4-444a-b072-3a16bd60d13d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_99d2df8b-31f4-45b1-800a-531c7ebbbffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_65385f68-6bf2-4220-811e-1e3a5215918e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0ace0109-a8d4-444a-b072-3a16bd60d13d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_65385f68-6bf2-4220-811e-1e3a5215918e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_b674cd4c-23b5-4869-baaa-4ba07a95817a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d2a32fa6-1132-4044-9aa3-cbbab95909c4" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_b674cd4c-23b5-4869-baaa-4ba07a95817a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_b50b41b1-d94f-463b-b4c4-7ec6e00141cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b674cd4c-23b5-4869-baaa-4ba07a95817a" xlink:to="loc_us-gaap_InterestPaidNet_b50b41b1-d94f-463b-b4c4-7ec6e00141cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_e204409b-6ade-4696-9c49-ced32fb35e37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b674cd4c-23b5-4869-baaa-4ba07a95817a" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_e204409b-6ade-4696-9c49-ced32fb35e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_51cae897-3bec-49a8-abf8-34bba4525499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d2a32fa6-1132-4044-9aa3-cbbab95909c4" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_51cae897-3bec-49a8-abf8-34bba4525499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IssuanceOfWarrants_41f5dcb7-ed37-481d-bcda-8f55cdbdfe5f" xlink:href="ibrx-20230331.xsd#ibrx_IssuanceOfWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_51cae897-3bec-49a8-abf8-34bba4525499" xlink:to="loc_ibrx_IssuanceOfWarrants_41f5dcb7-ed37-481d-bcda-8f55cdbdfe5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1dce8050-ba7a-4d05-9610-61c212b85ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_51cae897-3bec-49a8-abf8-34bba4525499" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1dce8050-ba7a-4d05-9610-61c212b85ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_a4827298-40c8-4f69-af74-b67b908f936d" xlink:href="ibrx-20230331.xsd#ibrx_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_51cae897-3bec-49a8-abf8-34bba4525499" xlink:to="loc_ibrx_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_a4827298-40c8-4f69-af74-b67b908f936d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_5aaef297-7250-4f76-9d50-24092676939c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_51cae897-3bec-49a8-abf8-34bba4525499" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_5aaef297-7250-4f76-9d50-24092676939c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a0916714-e4d7-41c3-9963-e4745b56c848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_51cae897-3bec-49a8-abf8-34bba4525499" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a0916714-e4d7-41c3-9963-e4745b56c848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="ibrx-20230331.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_84f2f2b2-e53a-4931-a5df-6c257c755255" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_4260dca0-5cc9-41a3-8884-975d02b9d718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_84f2f2b2-e53a-4931-a5df-6c257c755255" xlink:to="loc_us-gaap_NatureOfOperations_4260dca0-5cc9-41a3-8884-975d02b9d718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ibrx-20230331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9278ed1a-2ca2-429e-8867-b86a56458627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_cdc72e19-2f7e-4cbf-bfe5-c3d7fc6c55ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9278ed1a-2ca2-429e-8867-b86a56458627" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_cdc72e19-2f7e-4cbf-bfe5-c3d7fc6c55ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetails" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialStatementDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsAbstract_ded328da-37be-42eb-a362-467123640b06" xlink:href="ibrx-20230331.xsd#ibrx_FinancialStatementDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_38599901-74aa-4df6-b231-0d8b1fab2f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_ded328da-37be-42eb-a362-467123640b06" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_38599901-74aa-4df6-b231-0d8b1fab2f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialInstruments" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f297464c-cc89-4b63-8c3a-48d56d2c371a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTextBlock_12524fa4-dad6-4190-af21-d40554cdd0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f297464c-cc89-4b63-8c3a-48d56d2c371a" xlink:to="loc_us-gaap_InvestmentTextBlock_12524fa4-dad6-4190-af21-d40554cdd0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_15935d0f-f2c3-4bba-8b89-3eb46681a14d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_b525041f-9e2e-4140-9be4-3b7934c53de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_15935d0f-f2c3-4bba-8b89-3eb46681a14d" xlink:to="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_b525041f-9e2e-4140-9be4-3b7934c53de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisition" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CollaborationandLicenseAgreementsandAcquisition"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_4a877e7c-07fb-44be-a50a-8e2e1f21d9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_906674dd-44e9-4818-888a-609330b472c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_4a877e7c-07fb-44be-a50a-8e2e1f21d9a7" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_906674dd-44e9-4818-888a-609330b472c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_63f432fe-3351-4c0c-a6d7-97e54538cbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5a537c7f-6e44-4e9f-81b0-f5181443addb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_63f432fe-3351-4c0c-a6d7-97e54538cbeb" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5a537c7f-6e44-4e9f-81b0-f5181443addb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangements" xlink:type="simple" xlink:href="ibrx-20230331.xsd#LeaseArrangements"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_eed2801d-9495-4519-a30b-3fb3544867c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_d06fc09c-2aba-4b79-a820-e96d39a2be11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_eed2801d-9495-4519-a30b-3fb3544867c3" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_d06fc09c-2aba-4b79-a820-e96d39a2be11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_9abef1bf-87c0-48ee-93e9-b00fd61b5506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_eed2801d-9495-4519-a30b-3fb3544867c3" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_9abef1bf-87c0-48ee-93e9-b00fd61b5506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyDebt" xlink:type="simple" xlink:href="ibrx-20230331.xsd#RelatedPartyDebt"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1c651dff-b5a5-407f-ad69-e0747f2508e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_23602953-2bb7-4fab-b773-e9cdd896a54d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1c651dff-b5a5-407f-ad69-e0747f2508e5" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_23602953-2bb7-4fab-b773-e9cdd896a54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyAgreements" xlink:type="simple" xlink:href="ibrx-20230331.xsd#RelatedPartyAgreements"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_f222e995-d8d7-44f7-86f7-1cf759b61358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_3254dcaf-0b82-49d0-9449-739e63195ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_f222e995-d8d7-44f7-86f7-1cf759b61358" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_3254dcaf-0b82-49d0-9449-739e63195ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/WarrantLiabilities" xlink:type="simple" xlink:href="ibrx-20230331.xsd#WarrantLiabilities"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/WarrantLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b7765046-d112-4f3b-9ee5-d501c2949fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_WarrantLiabilityTextBlock_a46d8685-208b-4b56-9249-2ac3f8cb7f7f" xlink:href="ibrx-20230331.xsd#ibrx_WarrantLiabilityTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b7765046-d112-4f3b-9ee5-d501c2949fa8" xlink:to="loc_ibrx_WarrantLiabilityTextBlock_a46d8685-208b-4b56-9249-2ac3f8cb7f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockholdersDeficit" xlink:type="simple" xlink:href="ibrx-20230331.xsd#StockholdersDeficit"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/StockholdersDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1e0948e3-c967-49ff-b791-e36bab16e524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a58ce8e8-93cd-4cd4-bf06-7f0f21db8914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1e0948e3-c967-49ff-b791-e36bab16e524" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a58ce8e8-93cd-4cd4-bf06-7f0f21db8914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="ibrx-20230331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_379fa6f4-4fac-4f42-844d-623644eeaaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0ba7a959-f3a7-4365-afed-2e6eb9d7f43a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_379fa6f4-4fac-4f42-844d-623644eeaaa0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0ba7a959-f3a7-4365-afed-2e6eb9d7f43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ibrx-20230331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d6e7104b-0634-4150-bac2-3a2eefbe795f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_fad11f29-e81f-4990-9b4f-006d067fefe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d6e7104b-0634-4150-bac2-3a2eefbe795f" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_fad11f29-e81f-4990-9b4f-006d067fefe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ibrx-20230331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4b15d51d-2bb9-42df-bf56-2f9ff041ba5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_42215d4b-46de-45bf-b786-5d3aabcc63b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4b15d51d-2bb9-42df-bf56-2f9ff041ba5a" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_42215d4b-46de-45bf-b786-5d3aabcc63b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_abcc5473-71aa-41e1-9c32-54d9d636fd58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4b15d51d-2bb9-42df-bf56-2f9ff041ba5a" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_abcc5473-71aa-41e1-9c32-54d9d636fd58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_6ff5106a-abe1-4af5-af3d-9c3bc1f08480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4b15d51d-2bb9-42df-bf56-2f9ff041ba5a" xlink:to="loc_us-gaap_UseOfEstimates_6ff5106a-abe1-4af5-af3d-9c3bc1f08480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_WarrantsPolicyTextBlock_8741fc8a-79a7-48a7-b31d-56c158a6f824" xlink:href="ibrx-20230331.xsd#ibrx_WarrantsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4b15d51d-2bb9-42df-bf56-2f9ff041ba5a" xlink:to="loc_ibrx_WarrantsPolicyTextBlock_8741fc8a-79a7-48a7-b31d-56c158a6f824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock_3bd2fe9f-8304-48f9-8761-af57977bd6a9" xlink:href="ibrx-20230331.xsd#ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4b15d51d-2bb9-42df-bf56-2f9ff041ba5a" xlink:to="loc_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock_3bd2fe9f-8304-48f9-8761-af57977bd6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_9eb3d82f-8b1e-4054-b505-90c8a5eb88f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4b15d51d-2bb9-42df-bf56-2f9ff041ba5a" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_9eb3d82f-8b1e-4054-b505-90c8a5eb88f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3155f1c6-6307-4395-a161-ecc8943874d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4b15d51d-2bb9-42df-bf56-2f9ff041ba5a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3155f1c6-6307-4395-a161-ecc8943874d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6806f53f-330c-4fb5-aa04-7dbb8f11d6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4b15d51d-2bb9-42df-bf56-2f9ff041ba5a" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6806f53f-330c-4fb5-aa04-7dbb8f11d6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ibrx-20230331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b75b31c1-5792-4673-a500-96651c484a64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5fd8f906-89e7-4859-a53a-73f7cc8379cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b75b31c1-5792-4673-a500-96651c484a64" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5fd8f906-89e7-4859-a53a-73f7cc8379cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsTables" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialStatementDetailsTables"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsAbstract_ee526876-c3fe-4d8d-9a57-b848cd6ae077" xlink:href="ibrx-20230331.xsd#ibrx_FinancialStatementDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_2d3dfd6b-2db4-47e6-90c2-d9684b9f217c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_ee526876-c3fe-4d8d-9a57-b848cd6ae077" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_2d3dfd6b-2db4-47e6-90c2-d9684b9f217c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f8f28146-a10d-4476-bdd0-03ed7537d513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_ee526876-c3fe-4d8d-9a57-b848cd6ae077" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f8f28146-a10d-4476-bdd0-03ed7537d513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_3481354f-e189-4062-bb3a-7ffa3699b3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_ee526876-c3fe-4d8d-9a57-b848cd6ae077" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_3481354f-e189-4062-bb3a-7ffa3699b3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f796e88c-64c4-4efd-8403-3ed837271a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_ee526876-c3fe-4d8d-9a57-b848cd6ae077" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f796e88c-64c4-4efd-8403-3ed837271a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_856f6a3b-3808-464f-8a79-6d877e5cd3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_ee526876-c3fe-4d8d-9a57-b848cd6ae077" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_856f6a3b-3808-464f-8a79-6d877e5cd3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncomeTableTextBlock_dcf184b2-bfbd-4504-b381-b1ccb652bef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncomeTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_ee526876-c3fe-4d8d-9a57-b848cd6ae077" xlink:to="loc_us-gaap_InterestAndOtherIncomeTableTextBlock_dcf184b2-bfbd-4504-b381-b1ccb652bef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_9cd95289-f4d4-42bd-8f17-fbed471111c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_ee526876-c3fe-4d8d-9a57-b848cd6ae077" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_9cd95289-f4d4-42bd-8f17-fbed471111c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8bcdd675-49dc-4e88-a4ca-bb512f93a072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_164452aa-795d-4db1-a56a-323038dd91fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8bcdd675-49dc-4e88-a4ca-bb512f93a072" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_164452aa-795d-4db1-a56a-323038dd91fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_97a04e1e-2232-4578-913e-1e5275a5b15e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8bcdd675-49dc-4e88-a4ca-bb512f93a072" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_97a04e1e-2232-4578-913e-1e5275a5b15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c21282e5-93d2-4969-97e9-a309bd727e41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_6d1b5c45-7f82-4152-adfe-0e36e75c6952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c21282e5-93d2-4969-97e9-a309bd727e41" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_6d1b5c45-7f82-4152-adfe-0e36e75c6952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionTables" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CollaborationandLicenseAgreementsandAcquisitionTables"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_ca13137a-6b4b-4ebe-95e9-12469d63d34c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTableTextBlock_7c3484b1-71c0-4207-875f-8c454ae51860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_ca13137a-6b4b-4ebe-95e9-12469d63d34c" xlink:to="loc_us-gaap_AssetAcquisitionTableTextBlock_7c3484b1-71c0-4207-875f-8c454ae51860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsTables" xlink:type="simple" xlink:href="ibrx-20230331.xsd#LeaseArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2462be51-534e-48b3-afbb-2722a4641f41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock_64d14458-33dd-4c73-8264-3bafbc198a8e" xlink:href="ibrx-20230331.xsd#ibrx_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2462be51-534e-48b3-afbb-2722a4641f41" xlink:to="loc_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock_64d14458-33dd-4c73-8264-3bafbc198a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_d7c49a20-b8ed-4035-bb6a-9794ca891a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2462be51-534e-48b3-afbb-2722a4641f41" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_d7c49a20-b8ed-4035-bb6a-9794ca891a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_953d2161-de28-41a8-8eb9-9a952452ec9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2462be51-534e-48b3-afbb-2722a4641f41" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_953d2161-de28-41a8-8eb9-9a952452ec9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyDebtTables" xlink:type="simple" xlink:href="ibrx-20230331.xsd#RelatedPartyDebtTables"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_5fb6693d-e6e0-444d-9721-51dc5dc6fa58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock_66ca5a74-e43e-4380-aee7-4b37f6578650" xlink:href="ibrx-20230331.xsd#ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_5fb6693d-e6e0-444d-9721-51dc5dc6fa58" xlink:to="loc_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock_66ca5a74-e43e-4380-aee7-4b37f6578650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_353d585a-711d-4ad8-9588-909000730f39" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_5fb6693d-e6e0-444d-9721-51dc5dc6fa58" xlink:to="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_353d585a-711d-4ad8-9588-909000730f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsTables" xlink:type="simple" xlink:href="ibrx-20230331.xsd#RelatedPartyAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_ce0bb85a-0c36-4812-b7a1-caa6a660b5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_7f7a8df3-9a76-48fe-a747-def0c2508248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_ce0bb85a-0c36-4812-b7a1-caa6a660b5d0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_7f7a8df3-9a76-48fe-a747-def0c2508248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="ibrx-20230331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_45b9591f-05e0-4810-a42c-4f2805aa679a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3f0a4ce7-3e4d-46d6-b0b9-f5a2e784707f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_45b9591f-05e0-4810-a42c-4f2805aa679a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3f0a4ce7-3e4d-46d6-b0b9-f5a2e784707f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4b467c5e-fa80-47e6-9a68-d208dc4ca92f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_45b9591f-05e0-4810-a42c-4f2805aa679a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4b467c5e-fa80-47e6-9a68-d208dc4ca92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_0100c6bc-a272-4288-b176-82009186baa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_45b9591f-05e0-4810-a42c-4f2805aa679a" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_0100c6bc-a272-4288-b176-82009186baa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_174b4e32-f9cf-46c8-8787-2b0815cab4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccountingPoliciesTable_3b77215f-d226-40aa-af97-36eb9133382b" xlink:href="ibrx-20230331.xsd#ibrx_AccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_174b4e32-f9cf-46c8-8787-2b0815cab4aa" xlink:to="loc_ibrx_AccountingPoliciesTable_3b77215f-d226-40aa-af97-36eb9133382b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f1a237de-d093-4e2f-86e7-a4360d4f51d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesTable_3b77215f-d226-40aa-af97-36eb9133382b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f1a237de-d093-4e2f-86e7-a4360d4f51d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_21948ed1-9bcc-4101-8154-c4e607db7297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f1a237de-d093-4e2f-86e7-a4360d4f51d3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_21948ed1-9bcc-4101-8154-c4e607db7297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AtTheMarketOfferingProgramMember_7c4c864b-3b24-4d20-80fc-a56fa0c0c6da" xlink:href="ibrx-20230331.xsd#ibrx_AtTheMarketOfferingProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_21948ed1-9bcc-4101-8154-c4e607db7297" xlink:to="loc_ibrx_AtTheMarketOfferingProgramMember_7c4c864b-3b24-4d20-80fc-a56fa0c0c6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3329ed9d-22df-45a6-80eb-7697a0b925f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesTable_3b77215f-d226-40aa-af97-36eb9133382b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3329ed9d-22df-45a6-80eb-7697a0b925f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8e49a6c-f7dc-4ebb-a847-8b1694b7a727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3329ed9d-22df-45a6-80eb-7697a0b925f1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8e49a6c-f7dc-4ebb-a847-8b1694b7a727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023ShelfRegistrationStatementMember_f5c831c6-abd1-44a9-97a4-11030617d8c7" xlink:href="ibrx-20230331.xsd#ibrx_February2023ShelfRegistrationStatementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8e49a6c-f7dc-4ebb-a847-8b1694b7a727" xlink:to="loc_ibrx_February2023ShelfRegistrationStatementMember_f5c831c6-abd1-44a9-97a4-11030617d8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccountingPoliciesLineItems_f106c4ad-ae0a-409a-adc2-0366c843b965" xlink:href="ibrx-20230331.xsd#ibrx_AccountingPoliciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesTable_3b77215f-d226-40aa-af97-36eb9133382b" xlink:to="loc_ibrx_AccountingPoliciesLineItems_f106c4ad-ae0a-409a-adc2-0366c843b965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3373c6e6-3230-4369-b6ad-85d62011775a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesLineItems_f106c4ad-ae0a-409a-adc2-0366c843b965" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3373c6e6-3230-4369-b6ad-85d62011775a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a497b990-0235-49f8-b4b8-0b60b11ad65e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesLineItems_f106c4ad-ae0a-409a-adc2-0366c843b965" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a497b990-0235-49f8-b4b8-0b60b11ad65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CommonStockValueAvailableForFutureStockIssuance_bc49e51a-3e2d-4cfa-861e-8ec5d29fc97c" xlink:href="ibrx-20230331.xsd#ibrx_CommonStockValueAvailableForFutureStockIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesLineItems_f106c4ad-ae0a-409a-adc2-0366c843b965" xlink:to="loc_ibrx_CommonStockValueAvailableForFutureStockIssuance_bc49e51a-3e2d-4cfa-861e-8ec5d29fc97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bca5304d-8a75-4e67-a2c5-be8b0bbc9814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5c3aa018-5d87-47d4-9f68-7ddeda7cee2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bca5304d-8a75-4e67-a2c5-be8b0bbc9814" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5c3aa018-5d87-47d4-9f68-7ddeda7cee2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8cad25dd-ba00-4569-a0f0-5e1a7588f2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5c3aa018-5d87-47d4-9f68-7ddeda7cee2e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8cad25dd-ba00-4569-a0f0-5e1a7588f2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea71079d-ad8d-4663-a8b2-26769b7b54c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8cad25dd-ba00-4569-a0f0-5e1a7588f2f9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea71079d-ad8d-4663-a8b2-26769b7b54c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyConvertibleNotesMember_9ef63bb1-60a2-47f0-9a41-4899add96707" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyConvertibleNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea71079d-ad8d-4663-a8b2-26769b7b54c5" xlink:to="loc_ibrx_RelatedPartyConvertibleNotesMember_9ef63bb1-60a2-47f0-9a41-4899add96707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b3674ef3-60c6-4d3e-be8e-b143072edecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea71079d-ad8d-4663-a8b2-26769b7b54c5" xlink:to="loc_us-gaap_WarrantMember_b3674ef3-60c6-4d3e-be8e-b143072edecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b699d4dc-a361-494a-8bcb-7f835735e186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea71079d-ad8d-4663-a8b2-26769b7b54c5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b699d4dc-a361-494a-8bcb-7f835735e186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_518662d7-0da9-4fd5-9955-1a5d4d3d3981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea71079d-ad8d-4663-a8b2-26769b7b54c5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_518662d7-0da9-4fd5-9955-1a5d4d3d3981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyWarrantsMember_43d490e8-019b-407c-8ac4-16da8143c4ee" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyWarrantsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ea71079d-ad8d-4663-a8b2-26769b7b54c5" xlink:to="loc_ibrx_RelatedPartyWarrantsMember_43d490e8-019b-407c-8ac4-16da8143c4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_04e340e3-3dd6-4513-9dcb-8a67f63d8963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5c3aa018-5d87-47d4-9f68-7ddeda7cee2e" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_04e340e3-3dd6-4513-9dcb-8a67f63d8963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1f84e4e3-f009-4591-baea-af3519d4560d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_04e340e3-3dd6-4513-9dcb-8a67f63d8963" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1f84e4e3-f009-4591-baea-af3519d4560d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalIssued33123Member_afc862c7-bc71-4165-b399-4458d0318c01" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalIssued33123Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1f84e4e3-f009-4591-baea-af3519d4560d" xlink:to="loc_ibrx_NantCapitalIssued33123Member_afc862c7-bc71-4165-b399-4458d0318c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_02c6acda-999d-4e52-9c5c-4158afa32fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5c3aa018-5d87-47d4-9f68-7ddeda7cee2e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_02c6acda-999d-4e52-9c5c-4158afa32fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ac81ebc2-f0df-4872-82f4-154ed57d2c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_02c6acda-999d-4e52-9c5c-4158afa32fcb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ac81ebc2-f0df-4872-82f4-154ed57d2c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_ee28abd3-e1e6-4b3e-a424-e0d7072c649e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ac81ebc2-f0df-4872-82f4-154ed57d2c79" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_ee28abd3-e1e6-4b3e-a424-e0d7072c649e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d6341c5-8f4f-48eb-8e5c-2a3202064331" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5c3aa018-5d87-47d4-9f68-7ddeda7cee2e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d6341c5-8f4f-48eb-8e5c-2a3202064331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6bd30816-5de4-4633-b63e-b8d1c8c15ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d6341c5-8f4f-48eb-8e5c-2a3202064331" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6bd30816-5de4-4633-b63e-b8d1c8c15ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesPayable_c656bac2-0627-4144-bfb7-9f56db164728" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d6341c5-8f4f-48eb-8e5c-2a3202064331" xlink:to="loc_ibrx_RelatedPartyNotesPayable_c656bac2-0627-4144-bfb7-9f56db164728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsAbstract_36cc388a-22d9-47d6-9715-a259ec0f27f0" xlink:href="ibrx-20230331.xsd#ibrx_FinancialStatementDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidResearchAndDevelopmentCosts_5a0ae89c-9b11-4002-b03b-f7397ca5fa29" xlink:href="ibrx-20230331.xsd#ibrx_PrepaidResearchAndDevelopmentCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_36cc388a-22d9-47d6-9715-a259ec0f27f0" xlink:to="loc_ibrx_PrepaidResearchAndDevelopmentCosts_5a0ae89c-9b11-4002-b03b-f7397ca5fa29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidServices_097e617d-f940-4e8e-b35c-e06a5d566127" xlink:href="ibrx-20230331.xsd#ibrx_PrepaidServices"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_36cc388a-22d9-47d6-9715-a259ec0f27f0" xlink:to="loc_ibrx_PrepaidServices_097e617d-f940-4e8e-b35c-e06a5d566127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies_e771d189-5a61-4586-a0e1-600f6ae1eb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Supplies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_36cc388a-22d9-47d6-9715-a259ec0f27f0" xlink:to="loc_us-gaap_Supplies_e771d189-5a61-4586-a0e1-600f6ae1eb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_cadb5c22-b56a-47a5-b423-1a5e2897ce09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_36cc388a-22d9-47d6-9715-a259ec0f27f0" xlink:to="loc_us-gaap_PrepaidInsurance_cadb5c22-b56a-47a5-b423-1a5e2897ce09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidSoftwareLicenseFees_f1a5a821-9cf8-40fe-a264-a3d819fe7d7e" xlink:href="ibrx-20230331.xsd#ibrx_PrepaidSoftwareLicenseFees"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_36cc388a-22d9-47d6-9715-a259ec0f27f0" xlink:to="loc_ibrx_PrepaidSoftwareLicenseFees_f1a5a821-9cf8-40fe-a264-a3d819fe7d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InsurancePremiumFinancingAsset_a4a2350c-0d3d-4bd3-b564-9b904621dfcf" xlink:href="ibrx-20230331.xsd#ibrx_InsurancePremiumFinancingAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_36cc388a-22d9-47d6-9715-a259ec0f27f0" xlink:to="loc_ibrx_InsurancePremiumFinancingAsset_a4a2350c-0d3d-4bd3-b564-9b904621dfcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_0d8cd2dc-8b30-40c4-b278-b60cd2f5cccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_36cc388a-22d9-47d6-9715-a259ec0f27f0" xlink:to="loc_us-gaap_OtherAssetsCurrent_0d8cd2dc-8b30-40c4-b278-b60cd2f5cccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e85445c9-d3f6-40f9-a9ed-6fd92f824e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_36cc388a-22d9-47d6-9715-a259ec0f27f0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e85445c9-d3f6-40f9-a9ed-6fd92f824e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsAbstract_cf2a2a1b-2a0a-4b6c-8638-c771d6fc6198" xlink:href="ibrx-20230331.xsd#ibrx_FinancialStatementDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf18bf96-5c48-47b9-95db-bb5c25336f84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_cf2a2a1b-2a0a-4b6c-8638-c771d6fc6198" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf18bf96-5c48-47b9-95db-bb5c25336f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_72408717-0eae-4c2f-ad96-929ea51ed727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf18bf96-5c48-47b9-95db-bb5c25336f84" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_72408717-0eae-4c2f-ad96-929ea51ed727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_387fd199-3a49-428d-9317-839bbfdd5896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_72408717-0eae-4c2f-ad96-929ea51ed727" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_387fd199-3a49-428d-9317-839bbfdd5896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_079702b7-3f28-489a-b032-02da9285b5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_387fd199-3a49-428d-9317-839bbfdd5896" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_079702b7-3f28-489a-b032-02da9285b5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_d318749e-eb35-4c37-8437-cd17cbff39a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_387fd199-3a49-428d-9317-839bbfdd5896" xlink:to="loc_us-gaap_EquipmentMember_d318749e-eb35-4c37-8437-cd17cbff39a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_1f1711e7-920b-4ba7-9036-6bd0d6cef723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_387fd199-3a49-428d-9317-839bbfdd5896" xlink:to="loc_us-gaap_ConstructionInProgressMember_1f1711e7-920b-4ba7-9036-6bd0d6cef723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3ae1aee4-4dce-4d6d-8e05-4461f3dc648a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_387fd199-3a49-428d-9317-839bbfdd5896" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3ae1aee4-4dce-4d6d-8e05-4461f3dc648a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_8416283e-8170-4df9-93eb-5e1ccbed0636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_387fd199-3a49-428d-9317-839bbfdd5896" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_8416283e-8170-4df9-93eb-5e1ccbed0636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_27d34fb3-d6c2-462c-8e1a-015b69227879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf18bf96-5c48-47b9-95db-bb5c25336f84" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_27d34fb3-d6c2-462c-8e1a-015b69227879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5e2087ff-ab88-464e-838b-572e500f98c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_27d34fb3-d6c2-462c-8e1a-015b69227879" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5e2087ff-ab88-464e-838b-572e500f98c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1aff174b-8e3b-4ecc-8711-32aaf3366eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_27d34fb3-d6c2-462c-8e1a-015b69227879" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1aff174b-8e3b-4ecc-8711-32aaf3366eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4805e315-7ac5-4914-a58f-776d4a025223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_27d34fb3-d6c2-462c-8e1a-015b69227879" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4805e315-7ac5-4914-a58f-776d4a025223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialStatementDetailsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsAbstract_b9d83b8c-f8b4-4320-aef3-262de784b9be" xlink:href="ibrx-20230331.xsd#ibrx_FinancialStatementDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_d4b77fe4-b064-4348-b53b-ae59dfe8d823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_b9d83b8c-f8b4-4320-aef3-262de784b9be" xlink:to="loc_us-gaap_Depreciation_d4b77fe4-b064-4348-b53b-ae59dfe8d823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialStatementDetailsIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsAbstract_3f411602-6991-4a7e-9a77-772b88ba90fd" xlink:href="ibrx-20230331.xsd#ibrx_FinancialStatementDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsTable_34d199b7-1293-4d06-aac3-5aefa394dd19" xlink:href="ibrx-20230331.xsd#ibrx_FinancialStatementDetailsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_3f411602-6991-4a7e-9a77-772b88ba90fd" xlink:to="loc_ibrx_FinancialStatementDetailsTable_34d199b7-1293-4d06-aac3-5aefa394dd19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2fadcaf3-600d-4a4b-8164-062aeac01040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsTable_34d199b7-1293-4d06-aac3-5aefa394dd19" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2fadcaf3-600d-4a4b-8164-062aeac01040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42013c20-6bfa-4f52-bc6d-f501e7d41f13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2fadcaf3-600d-4a4b-8164-062aeac01040" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42013c20-6bfa-4f52-bc6d-f501e7d41f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketFavorableLeaseMember_aadee370-1b3d-4696-9475-5d7476b3aa9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffMarketFavorableLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42013c20-6bfa-4f52-bc6d-f501e7d41f13" xlink:to="loc_us-gaap_OffMarketFavorableLeaseMember_aadee370-1b3d-4696-9475-5d7476b3aa9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OrganizedWorkforceMember_0e11d9bb-43d5-460a-aec4-8f4e6743d68b" xlink:href="ibrx-20230331.xsd#ibrx_OrganizedWorkforceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42013c20-6bfa-4f52-bc6d-f501e7d41f13" xlink:to="loc_ibrx_OrganizedWorkforceMember_0e11d9bb-43d5-460a-aec4-8f4e6743d68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsLineItems_f5f97428-2751-45c3-aa5f-45a61450bcd3" xlink:href="ibrx-20230331.xsd#ibrx_FinancialStatementDetailsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsTable_34d199b7-1293-4d06-aac3-5aefa394dd19" xlink:to="loc_ibrx_FinancialStatementDetailsLineItems_f5f97428-2751-45c3-aa5f-45a61450bcd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f1c4dedf-7675-4010-a920-a16db5fb2abe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_f5f97428-2751-45c3-aa5f-45a61450bcd3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f1c4dedf-7675-4010-a920-a16db5fb2abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d6b34df1-21e0-49a8-9f43-23c35e7b68d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f1c4dedf-7675-4010-a920-a16db5fb2abe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d6b34df1-21e0-49a8-9f43-23c35e7b68d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_16302205-63c6-43f5-b055-e6aec5bbfe02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f1c4dedf-7675-4010-a920-a16db5fb2abe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_16302205-63c6-43f5-b055-e6aec5bbfe02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_90cb7d8d-7c8b-441a-9588-09187904d3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f1c4dedf-7675-4010-a920-a16db5fb2abe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_90cb7d8d-7c8b-441a-9588-09187904d3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_24c7f4cb-6906-45cb-a32d-c4db3cc31b46" xlink:href="ibrx-20230331.xsd#ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f1c4dedf-7675-4010-a920-a16db5fb2abe" xlink:to="loc_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_24c7f4cb-6906-45cb-a32d-c4db3cc31b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dc4e7930-2e30-4c48-90a7-e9d04c5c66fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_f1c4dedf-7675-4010-a920-a16db5fb2abe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_dc4e7930-2e30-4c48-90a7-e9d04c5c66fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_8ae5a70a-f5a4-4986-93fd-3dfa28b8908c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_f5f97428-2751-45c3-aa5f-45a61450bcd3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_8ae5a70a-f5a4-4986-93fd-3dfa28b8908c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4a6172cc-1c8b-46c3-86ac-ba0ebee56396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_8ae5a70a-f5a4-4986-93fd-3dfa28b8908c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4a6172cc-1c8b-46c3-86ac-ba0ebee56396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_bc1f3cbe-6a1e-4252-8484-d84baf4d900d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_f5f97428-2751-45c3-aa5f-45a61450bcd3" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_bc1f3cbe-6a1e-4252-8484-d84baf4d900d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0179c774-a6f9-40e3-bc3a-6262c3c5db87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_f5f97428-2751-45c3-aa5f-45a61450bcd3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0179c774-a6f9-40e3-bc3a-6262c3c5db87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_a42b7590-7407-4119-b993-108d27691223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_f5f97428-2751-45c3-aa5f-45a61450bcd3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_a42b7590-7407-4119-b993-108d27691223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_f07abcf7-c8fd-4630-937b-f443ec6bed70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_f5f97428-2751-45c3-aa5f-45a61450bcd3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_f07abcf7-c8fd-4630-937b-f443ec6bed70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_a4b61391-5cf2-48c5-bc5b-e0cc722af6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_f07abcf7-c8fd-4630-937b-f443ec6bed70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_a4b61391-5cf2-48c5-bc5b-e0cc722af6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_09656785-dbd9-44ce-acc8-19ae0f1de9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_f07abcf7-c8fd-4630-937b-f443ec6bed70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_09656785-dbd9-44ce-acc8-19ae0f1de9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b21ef362-9f5a-4437-a1d3-6cdb23b4a95f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_f07abcf7-c8fd-4630-937b-f443ec6bed70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b21ef362-9f5a-4437-a1d3-6cdb23b4a95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c988c7b1-28aa-4f00-81e9-3b1fe8bc71c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_f07abcf7-c8fd-4630-937b-f443ec6bed70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c988c7b1-28aa-4f00-81e9-3b1fe8bc71c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3e7bdaeb-00a0-493b-b45a-92d1177d310b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_f07abcf7-c8fd-4630-937b-f443ec6bed70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3e7bdaeb-00a0-493b-b45a-92d1177d310b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_431a4116-ae71-4fe0-97e9-a0c054913600" xlink:href="ibrx-20230331.xsd#ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_f07abcf7-c8fd-4630-937b-f443ec6bed70" xlink:to="loc_ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_431a4116-ae71-4fe0-97e9-a0c054913600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails_1" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialStatementDetailsIntangibleAssetsNetDetails_1"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsAbstract_9bf05642-ed2f-48ce-a157-8382c1934a00" xlink:href="ibrx-20230331.xsd#ibrx_FinancialStatementDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccruedResearchAndDevelopmentCosts_3269adcf-6a92-4be5-a9ab-97b28a5e2dfe" xlink:href="ibrx-20230331.xsd#ibrx_AccruedResearchAndDevelopmentCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_9bf05642-ed2f-48ce-a157-8382c1934a00" xlink:to="loc_ibrx_AccruedResearchAndDevelopmentCosts_3269adcf-6a92-4be5-a9ab-97b28a5e2dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_7fd504c5-b380-403d-9b1a-816b927b9946" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_9bf05642-ed2f-48ce-a157-8382c1934a00" xlink:to="loc_us-gaap_AccruedBonusesCurrent_7fd504c5-b380-403d-9b1a-816b927b9946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_9e83ebc7-5598-45a9-8ed4-7c683f0d3ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_9bf05642-ed2f-48ce-a157-8382c1934a00" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_9e83ebc7-5598-45a9-8ed4-7c683f0d3ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccruedPreclinicalAndClinicalTrialCosts_b2776b2a-d200-48bd-9c3c-524f880aff62" xlink:href="ibrx-20230331.xsd#ibrx_AccruedPreclinicalAndClinicalTrialCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_9bf05642-ed2f-48ce-a157-8382c1934a00" xlink:to="loc_ibrx_AccruedPreclinicalAndClinicalTrialCosts_b2776b2a-d200-48bd-9c3c-524f880aff62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_cc6f8a25-4899-4a18-8a1f-1cd29cc2859c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_9bf05642-ed2f-48ce-a157-8382c1934a00" xlink:to="loc_us-gaap_AccruedSalariesCurrent_cc6f8a25-4899-4a18-8a1f-1cd29cc2859c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccruedConstructionCostsCurrent_5efa1416-90c9-4f30-8c3f-7db65b45c354" xlink:href="ibrx-20230331.xsd#ibrx_AccruedConstructionCostsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_9bf05642-ed2f-48ce-a157-8382c1934a00" xlink:to="loc_ibrx_AccruedConstructionCostsCurrent_5efa1416-90c9-4f30-8c3f-7db65b45c354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancingObligationCurrent_be06c452-affc-4cbd-ad66-3e0bb537b81e" xlink:href="ibrx-20230331.xsd#ibrx_FinancingObligationCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_9bf05642-ed2f-48ce-a157-8382c1934a00" xlink:to="loc_ibrx_FinancingObligationCurrent_be06c452-affc-4cbd-ad66-3e0bb537b81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d3020b7c-d3e6-4eb7-946b-25d729b951a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_9bf05642-ed2f-48ce-a157-8382c1934a00" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d3020b7c-d3e6-4eb7-946b-25d729b951a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5e495703-4b36-47eb-9c41-e7d1e0a97de2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_9bf05642-ed2f-48ce-a157-8382c1934a00" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5e495703-4b36-47eb-9c41-e7d1e0a97de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeNetDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialStatementDetailsInterestandInvestmentIncomeNetDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsAbstract_56f8cdd3-0d65-4265-a5db-0504c8eb01b1" xlink:href="ibrx-20230331.xsd#ibrx_FinancialStatementDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_e2641899-3c59-4e76-8868-f6d41940730e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_56f8cdd3-0d65-4265-a5db-0504c8eb01b1" xlink:to="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_e2641899-3c59-4e76-8868-f6d41940730e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_d7f85e12-9f79-4167-b7a7-6bd8e53dd44a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_56f8cdd3-0d65-4265-a5db-0504c8eb01b1" xlink:to="loc_us-gaap_InterestAndOtherIncome_d7f85e12-9f79-4167-b7a7-6bd8e53dd44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_f7553498-f3b4-4ca2-91da-0e4f3200cf80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_56f8cdd3-0d65-4265-a5db-0504c8eb01b1" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_f7553498-f3b4-4ca2-91da-0e4f3200cf80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_7053b209-794f-476d-a218-469a29a502bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_56f8cdd3-0d65-4265-a5db-0504c8eb01b1" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_7053b209-794f-476d-a218-469a29a502bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_15565e77-eb95-43d2-98e2-77ccb56f93f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_56f8cdd3-0d65-4265-a5db-0504c8eb01b1" xlink:to="loc_us-gaap_GainLossOnInvestments_15565e77-eb95-43d2-98e2-77ccb56f93f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialStatementDetailsInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsAbstract_e7341431-8582-4b59-9f52-1f88afdec018" xlink:href="ibrx-20230331.xsd#ibrx_FinancialStatementDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseRelatedParty_505812aa-8953-4ba5-939b-337feedfa4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_e7341431-8582-4b59-9f52-1f88afdec018" xlink:to="loc_us-gaap_InterestExpenseRelatedParty_505812aa-8953-4ba5-939b-337feedfa4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty_ea39277b-ca90-4180-bf9c-4de0ee964765" xlink:href="ibrx-20230331.xsd#ibrx_AmortizationOfDebtDiscountPremiumRelatedParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_e7341431-8582-4b59-9f52-1f88afdec018" xlink:to="loc_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty_ea39277b-ca90-4180-bf9c-4de0ee964765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseOther_411e7e42-aec3-41af-9d58-8318ca524aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_e7341431-8582-4b59-9f52-1f88afdec018" xlink:to="loc_us-gaap_InterestExpenseOther_411e7e42-aec3-41af-9d58-8318ca524aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_d174caf7-36f2-464a-8223-edb0bb99ab53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_e7341431-8582-4b59-9f52-1f88afdec018" xlink:to="loc_us-gaap_InterestExpense_d174caf7-36f2-464a-8223-edb0bb99ab53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_38bbaa4e-4d3b-48b8-9c68-af375b451d51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b6565e8a-cc2d-4624-8494-cb0695c315ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_38bbaa4e-4d3b-48b8-9c68-af375b451d51" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b6565e8a-cc2d-4624-8494-cb0695c315ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3c34cf3f-461a-4a85-8f29-d3c5f903a1af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b6565e8a-cc2d-4624-8494-cb0695c315ac" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3c34cf3f-461a-4a85-8f29-d3c5f903a1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2521d124-2c67-4a78-b19c-a1efa9ee491e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3c34cf3f-461a-4a85-8f29-d3c5f903a1af" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2521d124-2c67-4a78-b19c-a1efa9ee491e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CurrentAssetsMember_b7e6971b-5b48-42b7-acc8-0366489c142a" xlink:href="ibrx-20230331.xsd#ibrx_CurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2521d124-2c67-4a78-b19c-a1efa9ee491e" xlink:to="loc_ibrx_CurrentAssetsMember_b7e6971b-5b48-42b7-acc8-0366489c142a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NoncurrentAssetsMember_c8c27c95-b555-45aa-a916-995843e6b8c5" xlink:href="ibrx-20230331.xsd#ibrx_NoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2521d124-2c67-4a78-b19c-a1efa9ee491e" xlink:to="loc_ibrx_NoncurrentAssetsMember_c8c27c95-b555-45aa-a916-995843e6b8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_773748ba-a5c7-4b40-9b1b-58dc353af426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b6565e8a-cc2d-4624-8494-cb0695c315ac" xlink:to="loc_us-gaap_FinancialInstrumentAxis_773748ba-a5c7-4b40-9b1b-58dc353af426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c1b054f2-6e8a-469c-9891-29478e3d7cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_773748ba-a5c7-4b40-9b1b-58dc353af426" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c1b054f2-6e8a-469c-9891-29478e3d7cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember_9832e3ec-cdb6-413b-a252-c5ba2f084cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c1b054f2-6e8a-469c-9891-29478e3d7cd0" xlink:to="loc_us-gaap_ForeignGovernmentDebtMember_9832e3ec-cdb6-413b-a252-c5ba2f084cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_77633fab-880f-42c8-a474-98bd274d384b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MutualFundMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c1b054f2-6e8a-469c-9891-29478e3d7cd0" xlink:to="loc_us-gaap_MutualFundMember_77633fab-880f-42c8-a474-98bd274d384b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9b4d9c99-3ba4-4c6c-931f-a51002bbc4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_b6565e8a-cc2d-4624-8494-cb0695c315ac" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9b4d9c99-3ba4-4c6c-931f-a51002bbc4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod_a31255fb-cd41-45ab-a005-853073b18855" xlink:href="ibrx-20230331.xsd#ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9b4d9c99-3ba4-4c6c-931f-a51002bbc4e2" xlink:to="loc_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod_a31255fb-cd41-45ab-a005-853073b18855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f5ef12cd-1286-42bf-9833-7b327e5ac941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9b4d9c99-3ba4-4c6c-931f-a51002bbc4e2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f5ef12cd-1286-42bf-9833-7b327e5ac941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0cd17f8b-7cef-489e-9a1f-2806a4f62939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9b4d9c99-3ba4-4c6c-931f-a51002bbc4e2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0cd17f8b-7cef-489e-9a1f-2806a4f62939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1000fe5c-8de4-4368-aba9-5c7f00dcf8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9b4d9c99-3ba4-4c6c-931f-a51002bbc4e2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1000fe5c-8de4-4368-aba9-5c7f00dcf8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a598a825-f2c1-4590-afa0-b1c791bca311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9b4d9c99-3ba4-4c6c-931f-a51002bbc4e2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a598a825-f2c1-4590-afa0-b1c791bca311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonMarketableDebtSecuritiesinContinuousLossPositionDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialInstrumentsAccumulatedUnrealizedLossesonMarketableDebtSecuritiesinContinuousLossPositionDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonMarketableDebtSecuritiesinContinuousLossPositionDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8062d4f9-5937-416e-afe8-dc7df289eace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_53ba844f-0fe2-46e1-9d7f-95157266e5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8062d4f9-5937-416e-afe8-dc7df289eace" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_53ba844f-0fe2-46e1-9d7f-95157266e5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f4f43c61-3ed3-42ff-8f6c-bf473cb3e190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8062d4f9-5937-416e-afe8-dc7df289eace" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f4f43c61-3ed3-42ff-8f6c-bf473cb3e190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c84ca971-9e35-42a7-af32-9e9a2e2b430a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f4f43c61-3ed3-42ff-8f6c-bf473cb3e190" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c84ca971-9e35-42a7-af32-9e9a2e2b430a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a56aebc-4362-4b54-a37a-e35dd9a8e16b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c84ca971-9e35-42a7-af32-9e9a2e2b430a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a56aebc-4362-4b54-a37a-e35dd9a8e16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_6e3807cb-ed19-41f1-852f-d94c53c9e8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MutualFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a56aebc-4362-4b54-a37a-e35dd9a8e16b" xlink:to="loc_us-gaap_MutualFundMember_6e3807cb-ed19-41f1-852f-d94c53c9e8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember_8515e7ca-21e8-4de2-b97d-5049f5d5b8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a56aebc-4362-4b54-a37a-e35dd9a8e16b" xlink:to="loc_us-gaap_ForeignGovernmentDebtMember_8515e7ca-21e8-4de2-b97d-5049f5d5b8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d55ea1d4-7bcd-4c14-aba4-857ac294d630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f4f43c61-3ed3-42ff-8f6c-bf473cb3e190" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d55ea1d4-7bcd-4c14-aba4-857ac294d630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_87e9eb58-f8d1-45c8-ad00-41cd6f126320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d55ea1d4-7bcd-4c14-aba4-857ac294d630" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_87e9eb58-f8d1-45c8-ad00-41cd6f126320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_147d2c01-193c-420e-b79b-c50883100997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d55ea1d4-7bcd-4c14-aba4-857ac294d630" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_147d2c01-193c-420e-b79b-c50883100997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_0f93aded-5ff4-4c57-b07b-408d7547ce07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d55ea1d4-7bcd-4c14-aba4-857ac294d630" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_0f93aded-5ff4-4c57-b07b-408d7547ce07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_429c247a-6b5d-46c8-848e-36b994ee1317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d55ea1d4-7bcd-4c14-aba4-857ac294d630" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_429c247a-6b5d-46c8-848e-36b994ee1317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FinancialInstrumentsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b9f185de-8f11-4e82-afb2-9cf5e2c8eab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ca297fc4-37be-4824-a2e4-0238659cc0df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b9f185de-8f11-4e82-afb2-9cf5e2c8eab5" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ca297fc4-37be-4824-a2e4-0238659cc0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_46ebed09-0b52-40d3-b1a3-7dd72e631c73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ca297fc4-37be-4824-a2e4-0238659cc0df" xlink:to="loc_us-gaap_InvestmentTypeAxis_46ebed09-0b52-40d3-b1a3-7dd72e631c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_e4e787f2-1bde-4231-b889-b7569af75219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_46ebed09-0b52-40d3-b1a3-7dd72e631c73" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_e4e787f2-1bde-4231-b889-b7569af75219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_8b6f0842-19b6-4c77-b5a1-17f4d1fe67d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e4e787f2-1bde-4231-b889-b7569af75219" xlink:to="loc_us-gaap_EquitySecuritiesMember_8b6f0842-19b6-4c77-b5a1-17f4d1fe67d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8fe77ff9-9afc-491f-8a2f-2bdd23b1b963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ca297fc4-37be-4824-a2e4-0238659cc0df" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8fe77ff9-9afc-491f-8a2f-2bdd23b1b963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_e5d8f420-69b6-4728-b1b4-e5db2392a31d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8fe77ff9-9afc-491f-8a2f-2bdd23b1b963" xlink:to="loc_us-gaap_MarketableSecurities_e5d8f420-69b6-4728-b1b4-e5db2392a31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d4a203dd-74b8-48b4-9d59-e8c72ad1eea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8fe77ff9-9afc-491f-8a2f-2bdd23b1b963" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d4a203dd-74b8-48b4-9d59-e8c72ad1eea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5606e83e-3a9a-453e-a732-6a0e4603a9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5606e83e-3a9a-453e-a732-6a0e4603a9e3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c7d69c59-d27b-41b3-a876-f9b9362ce1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c7d69c59-d27b-41b3-a876-f9b9362ce1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_914daed4-db79-4796-9066-be5b5d6f8e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c7d69c59-d27b-41b3-a876-f9b9362ce1d0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_914daed4-db79-4796-9066-be5b5d6f8e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4928322b-98bd-4c9e-8505-9ce88158ec70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_914daed4-db79-4796-9066-be5b5d6f8e8e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4928322b-98bd-4c9e-8505-9ce88158ec70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f6c91f64-de03-40a1-81ad-c39d1e7a612c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f6c91f64-de03-40a1-81ad-c39d1e7a612c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32e73156-dbdd-4782-94d7-8626c1575bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f6c91f64-de03-40a1-81ad-c39d1e7a612c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32e73156-dbdd-4782-94d7-8626c1575bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b6708e83-a963-4f00-8cf2-82989bea8b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32e73156-dbdd-4782-94d7-8626c1575bed" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b6708e83-a963-4f00-8cf2-82989bea8b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5bb99b0f-290c-4251-bba2-596b0c3c410f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32e73156-dbdd-4782-94d7-8626c1575bed" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5bb99b0f-290c-4251-bba2-596b0c3c410f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_211f5899-9eaa-4d0a-b396-f27d67665ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32e73156-dbdd-4782-94d7-8626c1575bed" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_211f5899-9eaa-4d0a-b396-f27d67665ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1543f89c-c5b0-4a45-b759-a07239d5e9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1543f89c-c5b0-4a45-b759-a07239d5e9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e09a9e13-dbf8-4135-b665-21d0c03aff0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1543f89c-c5b0-4a45-b759-a07239d5e9ae" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e09a9e13-dbf8-4135-b665-21d0c03aff0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CurrentAssetsMember_429f9725-df41-4e43-b654-5c9a04a381e2" xlink:href="ibrx-20230331.xsd#ibrx_CurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e09a9e13-dbf8-4135-b665-21d0c03aff0f" xlink:to="loc_ibrx_CurrentAssetsMember_429f9725-df41-4e43-b654-5c9a04a381e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NoncurrentAssetsMember_5180e9d0-49b5-465e-8fd0-8cc8e2e77693" xlink:href="ibrx-20230331.xsd#ibrx_NoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e09a9e13-dbf8-4135-b665-21d0c03aff0f" xlink:to="loc_ibrx_NoncurrentAssetsMember_5180e9d0-49b5-465e-8fd0-8cc8e2e77693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CurrentLiabilitiesMember_34edb8bd-32bb-4cbf-83e6-fb4bdf733fcf" xlink:href="ibrx-20230331.xsd#ibrx_CurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e09a9e13-dbf8-4135-b665-21d0c03aff0f" xlink:to="loc_ibrx_CurrentLiabilitiesMember_34edb8bd-32bb-4cbf-83e6-fb4bdf733fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NoncurrentLiabilitiesMember_03762c33-64e0-4136-9773-1c72a97b8ea6" xlink:href="ibrx-20230331.xsd#ibrx_NoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e09a9e13-dbf8-4135-b665-21d0c03aff0f" xlink:to="loc_ibrx_NoncurrentLiabilitiesMember_03762c33-64e0-4136-9773-1c72a97b8ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_5c68a4c6-8ffd-42af-bdcd-7f53030ea565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_5c68a4c6-8ffd-42af-bdcd-7f53030ea565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d4eec82e-60ac-476d-857a-d79b87f501ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_5c68a4c6-8ffd-42af-bdcd-7f53030ea565" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d4eec82e-60ac-476d-857a-d79b87f501ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_338dce48-b04e-4e1c-ba9b-a52c77134306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d4eec82e-60ac-476d-857a-d79b87f501ef" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_338dce48-b04e-4e1c-ba9b-a52c77134306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_90f98421-977b-4385-957f-1101e1736fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_InvestmentTypeAxis_90f98421-977b-4385-957f-1101e1736fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_19d368e2-b45a-4a8e-b1fa-a49ca4e040db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_90f98421-977b-4385-957f-1101e1736fe5" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_19d368e2-b45a-4a8e-b1fa-a49ca4e040db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_a6551f79-6001-4f2c-a93d-aff266b053b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_19d368e2-b45a-4a8e-b1fa-a49ca4e040db" xlink:to="loc_us-gaap_EquitySecuritiesMember_a6551f79-6001-4f2c-a93d-aff266b053b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_2f5b3b64-6673-4e47-834f-a7efe427040f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MutualFundMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_19d368e2-b45a-4a8e-b1fa-a49ca4e040db" xlink:to="loc_us-gaap_MutualFundMember_2f5b3b64-6673-4e47-834f-a7efe427040f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember_f275fb1c-588d-4286-a1ea-53898919d788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_19d368e2-b45a-4a8e-b1fa-a49ca4e040db" xlink:to="loc_us-gaap_ForeignGovernmentDebtMember_f275fb1c-588d-4286-a1ea-53898919d788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_da0de8cb-156d-4206-80dd-56c2156a753c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_da0de8cb-156d-4206-80dd-56c2156a753c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e15b1ca7-2244-42d3-ab81-a59d9f5030e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_da0de8cb-156d-4206-80dd-56c2156a753c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e15b1ca7-2244-42d3-ab81-a59d9f5030e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_b351d96c-fa17-4b88-a888-7479f26db876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e15b1ca7-2244-42d3-ab81-a59d9f5030e7" xlink:to="loc_us-gaap_AgencySecuritiesMember_b351d96c-fa17-4b88-a888-7479f26db876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_15a4edee-c6bd-4cfb-81c5-74a32fe63938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e15b1ca7-2244-42d3-ab81-a59d9f5030e7" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_15a4edee-c6bd-4cfb-81c5-74a32fe63938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_3dd2984d-59f1-4f9d-9d18-3f809089dee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_3dd2984d-59f1-4f9d-9d18-3f809089dee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9ecdd0b2-37e6-4453-a305-f97476a39d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_3dd2984d-59f1-4f9d-9d18-3f809089dee0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9ecdd0b2-37e6-4453-a305-f97476a39d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyConvertibleNotesMember_3eb5f924-106e-444d-9c9b-78bf5b107d20" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyConvertibleNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9ecdd0b2-37e6-4453-a305-f97476a39d36" xlink:to="loc_ibrx_RelatedPartyConvertibleNotesMember_3eb5f924-106e-444d-9c9b-78bf5b107d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ContingentConsiderationMember_477c64f5-b424-4b7a-bd5d-1aa0324c442b" xlink:href="ibrx-20230331.xsd#ibrx_ContingentConsiderationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9ecdd0b2-37e6-4453-a305-f97476a39d36" xlink:to="loc_ibrx_ContingentConsiderationMember_477c64f5-b424-4b7a-bd5d-1aa0324c442b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_eeb2f5fe-87bc-4ae2-8c26-e5797c44950a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9ecdd0b2-37e6-4453-a305-f97476a39d36" xlink:to="loc_us-gaap_WarrantMember_eeb2f5fe-87bc-4ae2-8c26-e5797c44950a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_b47540c9-2a02-42a3-bfd7-9b262b079bff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_b47540c9-2a02-42a3-bfd7-9b262b079bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_e1565e93-da2a-43f9-9a30-7f8d5095aff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b47540c9-2a02-42a3-bfd7-9b262b079bff" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_e1565e93-da2a-43f9-9a30-7f8d5095aff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_f9d8e199-6270-4ca9-ad40-a54ca1999382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_e1565e93-da2a-43f9-9a30-7f8d5095aff7" xlink:to="loc_us-gaap_WarrantMember_f9d8e199-6270-4ca9-ad40-a54ca1999382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_December2022WarrantsMember_46c7869c-57df-4c42-86d3-74753e58e445" xlink:href="ibrx-20230331.xsd#ibrx_December2022WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_e1565e93-da2a-43f9-9a30-7f8d5095aff7" xlink:to="loc_ibrx_December2022WarrantsMember_46c7869c-57df-4c42-86d3-74753e58e445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023WarrantsMember_6a0c79b6-3bfe-4d74-bd87-3f187398282a" xlink:href="ibrx-20230331.xsd#ibrx_February2023WarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_e1565e93-da2a-43f9-9a30-7f8d5095aff7" xlink:to="loc_ibrx_February2023WarrantsMember_6a0c79b6-3bfe-4d74-bd87-3f187398282a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_3392826d-349f-4e60-9ede-0a1b69838ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_3392826d-349f-4e60-9ede-0a1b69838ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d7cb36a1-9e56-4630-aaab-5585fa3160c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3392826d-349f-4e60-9ede-0a1b69838ff6" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d7cb36a1-9e56-4630-aaab-5585fa3160c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MeasurementInputExpectedMarketYieldMember_896e682c-2172-42ab-a465-fff17e5f3e4b" xlink:href="ibrx-20230331.xsd#ibrx_MeasurementInputExpectedMarketYieldMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d7cb36a1-9e56-4630-aaab-5585fa3160c0" xlink:to="loc_ibrx_MeasurementInputExpectedMarketYieldMember_896e682c-2172-42ab-a465-fff17e5f3e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MeasurementInputDiscountPeriodMember_dd329145-2f2a-4e12-88c5-4cc6d5b9c72d" xlink:href="ibrx-20230331.xsd#ibrx_MeasurementInputDiscountPeriodMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d7cb36a1-9e56-4630-aaab-5585fa3160c0" xlink:to="loc_ibrx_MeasurementInputDiscountPeriodMember_dd329145-2f2a-4e12-88c5-4cc6d5b9c72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_1ea7395e-aeb4-467a-b575-9da67c56d66d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d7cb36a1-9e56-4630-aaab-5585fa3160c0" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_1ea7395e-aeb4-467a-b575-9da67c56d66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember_557bb874-c8ac-4930-a198-e4f8a1f39ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExercisePriceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d7cb36a1-9e56-4630-aaab-5585fa3160c0" xlink:to="loc_us-gaap_MeasurementInputExercisePriceMember_557bb874-c8ac-4930-a198-e4f8a1f39ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_cd84be15-25ca-4973-94ce-e5f84b087b20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d7cb36a1-9e56-4630-aaab-5585fa3160c0" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_cd84be15-25ca-4973-94ce-e5f84b087b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_12c7d308-7073-492b-a983-752591fd0298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d7cb36a1-9e56-4630-aaab-5585fa3160c0" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_12c7d308-7073-492b-a983-752591fd0298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_29eff5b9-3550-4350-9003-f7841ed5042c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d7cb36a1-9e56-4630-aaab-5585fa3160c0" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_29eff5b9-3550-4350-9003-f7841ed5042c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_46a99ec4-6823-4408-95b5-9fe59f565d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d7cb36a1-9e56-4630-aaab-5585fa3160c0" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_46a99ec4-6823-4408-95b5-9fe59f565d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d18d5520-2c32-4c1e-94b6-15859fb7348c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d18d5520-2c32-4c1e-94b6-15859fb7348c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b8115b4e-8bdc-4f50-85ac-1e6dbac20737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d18d5520-2c32-4c1e-94b6-15859fb7348c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b8115b4e-8bdc-4f50-85ac-1e6dbac20737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_228bfaf6-59ad-405c-a08a-6b6a189dc35a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b8115b4e-8bdc-4f50-85ac-1e6dbac20737" xlink:to="loc_us-gaap_PrivatePlacementMember_228bfaf6-59ad-405c-a08a-6b6a189dc35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8609420a-0be9-4b0a-8515-f914d7bae199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8609420a-0be9-4b0a-8515-f914d7bae199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_76ca0f71-1fea-4d9d-848b-a66f05db3069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8609420a-0be9-4b0a-8515-f914d7bae199" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_76ca0f71-1fea-4d9d-848b-a66f05db3069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_431a6f6a-e19f-4fea-ad07-e8d420f70b67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_76ca0f71-1fea-4d9d-848b-a66f05db3069" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_431a6f6a-e19f-4fea-ad07-e8d420f70b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_64741769-8baa-48fb-90da-dad26a4163d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_64741769-8baa-48fb-90da-dad26a4163d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3dd59bd6-2e49-41a9-9930-23c6d1fc1ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_64741769-8baa-48fb-90da-dad26a4163d4" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3dd59bd6-2e49-41a9-9930-23c6d1fc1ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalIssued33123Member_167432dd-f066-4f4c-b573-5827dba567e5" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalIssued33123Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3dd59bd6-2e49-41a9-9930-23c6d1fc1ff1" xlink:to="loc_ibrx_NantCapitalIssued33123Member_167432dd-f066-4f4c-b573-5827dba567e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68404159-677f-42be-8600-63bc7412ad53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e7970f1-447b-465a-a532-5f7f5b8e929b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68404159-677f-42be-8600-63bc7412ad53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6b565c5e-e0b2-4b9e-8e6e-1c16365ff0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68404159-677f-42be-8600-63bc7412ad53" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_6b565c5e-e0b2-4b9e-8e6e-1c16365ff0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_e40ed8da-6643-4ccb-bb99-7e38f8c7bca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68404159-677f-42be-8600-63bc7412ad53" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_e40ed8da-6643-4ccb-bb99-7e38f8c7bca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesPayable_14494a99-464a-42bb-bb7a-b73f10252eaa" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68404159-677f-42be-8600-63bc7412ad53" xlink:to="loc_ibrx_RelatedPartyNotesPayable_14494a99-464a-42bb-bb7a-b73f10252eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_8ac26df0-4972-4b39-b62a-b961bf96a6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68404159-677f-42be-8600-63bc7412ad53" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_8ac26df0-4972-4b39-b62a-b961bf96a6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_64049c5f-7bd7-4614-baa3-ae32d6f79348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68404159-677f-42be-8600-63bc7412ad53" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_64049c5f-7bd7-4614-baa3-ae32d6f79348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_83c39e80-b998-41b2-b7f8-2070ed846fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68404159-677f-42be-8600-63bc7412ad53" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_83c39e80-b998-41b2-b7f8-2070ed846fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_424f8584-a0ca-4ba2-b843-a88a9fd0f226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68404159-677f-42be-8600-63bc7412ad53" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_424f8584-a0ca-4ba2-b843-a88a9fd0f226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_af4cafe9-d63b-4339-8b87-8383718c0647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_424f8584-a0ca-4ba2-b843-a88a9fd0f226" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_af4cafe9-d63b-4339-8b87-8383718c0647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6301c94d-1a85-4e89-a852-d893f182adf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_424f8584-a0ca-4ba2-b843-a88a9fd0f226" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6301c94d-1a85-4e89-a852-d893f182adf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_dcf8b17a-b9c2-4273-abd9-573f088592d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_424f8584-a0ca-4ba2-b843-a88a9fd0f226" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_dcf8b17a-b9c2-4273-abd9-573f088592d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_8c3b00cc-87b2-485c-8aae-f7257cd603cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68404159-677f-42be-8600-63bc7412ad53" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_8c3b00cc-87b2-485c-8aae-f7257cd603cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_208c78c9-8f18-48f4-95f0-7a91a38fa0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_a8c1bc3b-c6a4-4dbf-ba1c-70370bb29575" xlink:href="ibrx-20230331.xsd#ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_208c78c9-8f18-48f4-95f0-7a91a38fa0f9" xlink:to="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_a8c1bc3b-c6a4-4dbf-ba1c-70370bb29575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_576eb7ad-619a-422e-a9b8-dd3a1fda9877" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_a8c1bc3b-c6a4-4dbf-ba1c-70370bb29575" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_576eb7ad-619a-422e-a9b8-dd3a1fda9877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_4b090e91-65ee-4114-a0ac-71a9f91a7e45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_576eb7ad-619a-422e-a9b8-dd3a1fda9877" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_4b090e91-65ee-4114-a0ac-71a9f91a7e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AmyrisJointVentureMember_40f356f1-2a58-41ef-9593-b5699d613f78" xlink:href="ibrx-20230331.xsd#ibrx_AmyrisJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_4b090e91-65ee-4114-a0ac-71a9f91a7e45" xlink:to="loc_ibrx_AmyrisJointVentureMember_40f356f1-2a58-41ef-9593-b5699d613f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a03c1cdd-1a8a-45c4-ba2c-7f32117e1678" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_a8c1bc3b-c6a4-4dbf-ba1c-70370bb29575" xlink:to="loc_dei_LegalEntityAxis_a03c1cdd-1a8a-45c4-ba2c-7f32117e1678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b53acee3-106a-4e03-9a08-9ea500398a6d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_a03c1cdd-1a8a-45c4-ba2c-7f32117e1678" xlink:to="loc_dei_EntityDomain_b53acee3-106a-4e03-9a08-9ea500398a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AmyrisIncMember_6e382764-ab6c-4306-8291-6c843f672c54" xlink:href="ibrx-20230331.xsd#ibrx_AmyrisIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b53acee3-106a-4e03-9a08-9ea500398a6d" xlink:to="loc_ibrx_AmyrisIncMember_6e382764-ab6c-4306-8291-6c843f672c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_435c605d-3cf8-426c-8bf4-b8e027ce1fba" xlink:href="ibrx-20230331.xsd#ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_a8c1bc3b-c6a4-4dbf-ba1c-70370bb29575" xlink:to="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_435c605d-3cf8-426c-8bf4-b8e027ce1fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_ed4ef1db-04d1-4574-bdf6-890c670fb563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_435c605d-3cf8-426c-8bf4-b8e027ce1fba" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_ed4ef1db-04d1-4574-bdf6-890c670fb563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_665b2f6e-a009-48c4-99b4-bf58b0041272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_435c605d-3cf8-426c-8bf4-b8e027ce1fba" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_665b2f6e-a009-48c4-99b4-bf58b0041272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_538df568-0e95-49f8-953a-eaa5e882db2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_435c605d-3cf8-426c-8bf4-b8e027ce1fba" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_538df568-0e95-49f8-953a-eaa5e882db2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3f5b39ed-56d4-43d5-97c8-f7fa504bfe6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_435c605d-3cf8-426c-8bf4-b8e027ce1fba" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3f5b39ed-56d4-43d5-97c8-f7fa504bfe6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum_e1d2e868-2d61-48a2-a874-36afe647411b" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_435c605d-3cf8-426c-8bf4-b8e027ce1fba" xlink:to="loc_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum_e1d2e868-2d61-48a2-a874-36afe647411b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_a2ef80e8-ba84-4b15-92bd-e702e2a7fcd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LicensingAgreementTable_61293174-4799-408e-bff9-259486c97108" xlink:href="ibrx-20230331.xsd#ibrx_LicensingAgreementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_a2ef80e8-ba84-4b15-92bd-e702e2a7fcd1" xlink:to="loc_ibrx_LicensingAgreementTable_61293174-4799-408e-bff9-259486c97108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_40c68ebe-9355-4829-aa6d-b9e307a71752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementTable_61293174-4799-408e-bff9-259486c97108" xlink:to="loc_us-gaap_TypeOfArrangementAxis_40c68ebe-9355-4829-aa6d-b9e307a71752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8799dbf9-0a10-48fc-9636-305dd452d5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_40c68ebe-9355-4829-aa6d-b9e307a71752" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8799dbf9-0a10-48fc-9636-305dd452d5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember_6df6f51a-7381-44fa-b763-1f23a6bd615e" xlink:href="ibrx-20230331.xsd#ibrx_A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8799dbf9-0a10-48fc-9636-305dd452d5c7" xlink:to="loc_ibrx_A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember_6df6f51a-7381-44fa-b763-1f23a6bd615e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccessToAdvancedHealthInstituteAAHIMember_2829f80e-518a-4bee-923c-3c3fb9316ccc" xlink:href="ibrx-20230331.xsd#ibrx_AccessToAdvancedHealthInstituteAAHIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8799dbf9-0a10-48fc-9636-305dd452d5c7" xlink:to="loc_ibrx_AccessToAdvancedHealthInstituteAAHIMember_2829f80e-518a-4bee-923c-3c3fb9316ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4788c787-b9b1-45c8-b0b3-e8fcc365fbab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementTable_61293174-4799-408e-bff9-259486c97108" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4788c787-b9b1-45c8-b0b3-e8fcc365fbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_be094496-78f5-4df8-bfde-5847afdef7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4788c787-b9b1-45c8-b0b3-e8fcc365fbab" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_be094496-78f5-4df8-bfde-5847afdef7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_07476392-38e0-48db-9cd9-af13468b2d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_be094496-78f5-4df8-bfde-5847afdef7b0" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_07476392-38e0-48db-9cd9-af13468b2d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SponsoredResearchAgreementMember_198137ee-a97b-4fea-bb60-412668c789ca" xlink:href="ibrx-20230331.xsd#ibrx_SponsoredResearchAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_be094496-78f5-4df8-bfde-5847afdef7b0" xlink:to="loc_ibrx_SponsoredResearchAgreementMember_198137ee-a97b-4fea-bb60-412668c789ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4c190fe8-969c-4cb7-ac82-d6a686146270" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementTable_61293174-4799-408e-bff9-259486c97108" xlink:to="loc_srt_RangeAxis_4c190fe8-969c-4cb7-ac82-d6a686146270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2f233da1-87f9-4597-a45e-4da20bf56c80" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4c190fe8-969c-4cb7-ac82-d6a686146270" xlink:to="loc_srt_RangeMember_2f233da1-87f9-4597-a45e-4da20bf56c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_887617ba-143a-4d46-8551-f5ba1aa01d20" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2f233da1-87f9-4597-a45e-4da20bf56c80" xlink:to="loc_srt_MinimumMember_887617ba-143a-4d46-8551-f5ba1aa01d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis_415de4cd-e206-4829-9dad-9c490d8e4526" xlink:href="ibrx-20230331.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementTable_61293174-4799-408e-bff9-259486c97108" xlink:to="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis_415de4cd-e206-4829-9dad-9c490d8e4526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_c48c189b-40c0-4779-8112-8939761c04e5" xlink:href="ibrx-20230331.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis_415de4cd-e206-4829-9dad-9c490d8e4526" xlink:to="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_c48c189b-40c0-4779-8112-8939761c04e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember_6397b137-8793-469c-a881-730f296f085c" xlink:href="ibrx-20230331.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_c48c189b-40c0-4779-8112-8939761c04e5" xlink:to="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember_6397b137-8793-469c-a881-730f296f085c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember_d824bc6b-34e5-41d9-82a3-8d493e0b9357" xlink:href="ibrx-20230331.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_c48c189b-40c0-4779-8112-8939761c04e5" xlink:to="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember_d824bc6b-34e5-41d9-82a3-8d493e0b9357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LicensingAgreementLineItems_a4f6b7b5-2732-4667-8fb7-19a6809e22bf" xlink:href="ibrx-20230331.xsd#ibrx_LicensingAgreementLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementTable_61293174-4799-408e-bff9-259486c97108" xlink:to="loc_ibrx_LicensingAgreementLineItems_a4f6b7b5-2732-4667-8fb7-19a6809e22bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsPeriodicLicensePayments_be43b876-65ab-4610-9051-9ad27f41e4ae" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsPeriodicLicensePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementLineItems_a4f6b7b5-2732-4667-8fb7-19a6809e22bf" xlink:to="loc_ibrx_CollaborationAgreementsPeriodicLicensePayments_be43b876-65ab-4610-9051-9ad27f41e4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment_902ef634-3ad1-4745-a6c1-5bd650323ca8" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementLineItems_a4f6b7b5-2732-4667-8fb7-19a6809e22bf" xlink:to="loc_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment_902ef634-3ad1-4745-a6c1-5bd650323ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsLicenseMaintenanceFees_961feaae-d84f-4749-aee4-05c8143f5af6" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsLicenseMaintenanceFees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementLineItems_a4f6b7b5-2732-4667-8fb7-19a6809e22bf" xlink:to="loc_ibrx_CollaborationAgreementsLicenseMaintenanceFees_961feaae-d84f-4749-aee4-05c8143f5af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_cce00323-6ec0-4ff1-8e93-cc1933c49bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementLineItems_a4f6b7b5-2732-4667-8fb7-19a6809e22bf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_cce00323-6ec0-4ff1-8e93-cc1933c49bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment_028fc4fc-5076-43f0-a23c-a7a3e8c244e5" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsNonrefundableUpfrontPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementLineItems_a4f6b7b5-2732-4667-8fb7-19a6809e22bf" xlink:to="loc_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment_028fc4fc-5076-43f0-a23c-a7a3e8c244e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum_913100ce-20b3-4776-bd7a-46df4cd39b57" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementLineItems_a4f6b7b5-2732-4667-8fb7-19a6809e22bf" xlink:to="loc_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum_913100ce-20b3-4776-bd7a-46df4cd39b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsMilestoneFees_387744ef-2958-47cf-96ed-49332c2a87e9" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsMilestoneFees"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementLineItems_a4f6b7b5-2732-4667-8fb7-19a6809e22bf" xlink:to="loc_ibrx_CollaborationAgreementsMilestoneFees_387744ef-2958-47cf-96ed-49332c2a87e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsTerminationFee_4ebf0da6-da5e-4761-8f6d-aaf648d5d95d" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsTerminationFee"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementLineItems_a4f6b7b5-2732-4667-8fb7-19a6809e22bf" xlink:to="loc_ibrx_CollaborationAgreementsTerminationFee_4ebf0da6-da5e-4761-8f6d-aaf648d5d95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities_ac73a3f4-6830-486a-aa86-e4572d7286d8" xlink:href="ibrx-20230331.xsd#ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementLineItems_a4f6b7b5-2732-4667-8fb7-19a6809e22bf" xlink:to="loc_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities_ac73a3f4-6830-486a-aa86-e4572d7286d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_b2aa1696-f3ac-4b5f-96f8-455306030f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_afa6128a-bd3e-489f-b4f5-09cf25d2451d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_b2aa1696-f3ac-4b5f-96f8-455306030f6b" xlink:to="loc_us-gaap_AssetAcquisitionTable_afa6128a-bd3e-489f-b4f5-09cf25d2451d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_89b2b414-8a77-4dd2-89bc-b512b326efd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_afa6128a-bd3e-489f-b4f5-09cf25d2451d" xlink:to="loc_us-gaap_AssetAcquisitionAxis_89b2b414-8a77-4dd2-89bc-b512b326efd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_4a01c7cf-556b-40bf-8599-6186cc847ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_89b2b414-8a77-4dd2-89bc-b512b326efd3" xlink:to="loc_us-gaap_AssetAcquisitionDomain_4a01c7cf-556b-40bf-8599-6186cc847ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DunkirkFacilityMember_d000ba71-ed8b-41a1-ad9e-b1204c87d94f" xlink:href="ibrx-20230331.xsd#ibrx_DunkirkFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4a01c7cf-556b-40bf-8599-6186cc847ea2" xlink:to="loc_ibrx_DunkirkFacilityMember_d000ba71-ed8b-41a1-ad9e-b1204c87d94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_d7ecb65e-34f5-4acf-899f-62997f5ff1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_afa6128a-bd3e-489f-b4f5-09cf25d2451d" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_d7ecb65e-34f5-4acf-899f-62997f5ff1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_e1167ed7-1549-47b3-ba8f-ed1d79d259de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_d7ecb65e-34f5-4acf-899f-62997f5ff1cc" xlink:to="loc_us-gaap_ConstructionInProgressGross_e1167ed7-1549-47b3-ba8f-ed1d79d259de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_0aba3321-7cd9-4e91-9983-7d855752cf4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_d7ecb65e-34f5-4acf-899f-62997f5ff1cc" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_0aba3321-7cd9-4e91-9983-7d855752cf4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_597823bd-d2b1-485d-9a7d-108023f967f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_d7ecb65e-34f5-4acf-899f-62997f5ff1cc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_597823bd-d2b1-485d-9a7d-108023f967f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_5c6499f4-d802-48cb-b62f-036e6651c029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_d7ecb65e-34f5-4acf-899f-62997f5ff1cc" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_5c6499f4-d802-48cb-b62f-036e6651c029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_96cd70cd-d9dc-40cd-a40a-fbba293fd3e3" xlink:href="ibrx-20230331.xsd#ibrx_AssetAcquisitionFairValueOfAssetsAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_d7ecb65e-34f5-4acf-899f-62997f5ff1cc" xlink:to="loc_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_96cd70cd-d9dc-40cd-a40a-fbba293fd3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_ca1b4b09-b1d8-4ab5-a00b-c66ecab36f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_41c0468b-737b-4e5f-91af-2bf693a72912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_ca1b4b09-b1d8-4ab5-a00b-c66ecab36f7e" xlink:to="loc_us-gaap_AssetAcquisitionTable_41c0468b-737b-4e5f-91af-2bf693a72912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_f0db81ef-93ca-43a5-b080-4452a0d7e43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_41c0468b-737b-4e5f-91af-2bf693a72912" xlink:to="loc_us-gaap_AssetAcquisitionAxis_f0db81ef-93ca-43a5-b080-4452a0d7e43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_aa531de3-d66e-4796-b142-bad0ec95b6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_f0db81ef-93ca-43a5-b080-4452a0d7e43d" xlink:to="loc_us-gaap_AssetAcquisitionDomain_aa531de3-d66e-4796-b142-bad0ec95b6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DunkirkFacilityMember_35070e62-93fc-42d8-b31c-35e93cc14855" xlink:href="ibrx-20230331.xsd#ibrx_DunkirkFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_aa531de3-d66e-4796-b142-bad0ec95b6ad" xlink:to="loc_ibrx_DunkirkFacilityMember_35070e62-93fc-42d8-b31c-35e93cc14855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_afd26b0e-6538-4125-abd4-dac645626965" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_41c0468b-737b-4e5f-91af-2bf693a72912" xlink:to="loc_srt_CounterpartyNameAxis_afd26b0e-6538-4125-abd4-dac645626965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8715796d-c255-4a54-b662-5bc598d73a73" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_afd26b0e-6538-4125-abd4-dac645626965" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8715796d-c255-4a54-b662-5bc598d73a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StateOfNewYorkMember_489ac745-7965-4e6e-8948-994f7c4d6d00" xlink:href="ibrx-20230331.xsd#ibrx_StateOfNewYorkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8715796d-c255-4a54-b662-5bc598d73a73" xlink:to="loc_ibrx_StateOfNewYorkMember_489ac745-7965-4e6e-8948-994f7c4d6d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_49955bc6-c525-4699-bec9-0ec323fc0dfb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_41c0468b-737b-4e5f-91af-2bf693a72912" xlink:to="loc_srt_RangeAxis_49955bc6-c525-4699-bec9-0ec323fc0dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_98e9fcef-f0a3-4fe4-ba7c-42edd0d63b26" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_49955bc6-c525-4699-bec9-0ec323fc0dfb" xlink:to="loc_srt_RangeMember_98e9fcef-f0a3-4fe4-ba7c-42edd0d63b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9c00dff0-fdd9-4b89-85bc-d364cf551ccf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_98e9fcef-f0a3-4fe4-ba7c-42edd0d63b26" xlink:to="loc_srt_MinimumMember_9c00dff0-fdd9-4b89-85bc-d364cf551ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9c62aac2-8922-4870-a5ca-811a4c2f5e6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_98e9fcef-f0a3-4fe4-ba7c-42edd0d63b26" xlink:to="loc_srt_MaximumMember_9c62aac2-8922-4870-a5ca-811a4c2f5e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_41c0468b-737b-4e5f-91af-2bf693a72912" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfSquareFootOfFacilityLeased_760bcdf1-e40c-4051-ab26-9d34e4f4dffb" xlink:href="ibrx-20230331.xsd#ibrx_NumberOfSquareFootOfFacilityLeased"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_ibrx_NumberOfSquareFootOfFacilityLeased_760bcdf1-e40c-4051-ab26-9d34e4f4dffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_156ee1a6-5718-4feb-9a69-1f5cb5dbe559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_156ee1a6-5718-4feb-9a69-1f5cb5dbe559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_2120c28f-d527-4276-a51c-23691fd9bbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_2120c28f-d527-4276-a51c-23691fd9bbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_7779afd5-75f2-470d-b32d-c4fc30c97515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_7779afd5-75f2-470d-b32d-c4fc30c97515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseOperatingLeaseAnnualLeasePayment_fb8663ef-4dd5-4b5d-a1df-f81f44363b2b" xlink:href="ibrx-20230331.xsd#ibrx_LeaseOperatingLeaseAnnualLeasePayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_ibrx_LeaseOperatingLeaseAnnualLeasePayment_fb8663ef-4dd5-4b5d-a1df-f81f44363b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_a566195a-8e53-43f7-a7de-075d7d6c19e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_a566195a-8e53-43f7-a7de-075d7d6c19e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b77ed282-9b65-42c8-aded-6de32388a6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b77ed282-9b65-42c8-aded-6de32388a6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm_ab244584-d073-4047-8479-bdd247d5a917" xlink:href="ibrx-20230331.xsd#ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm_ab244584-d073-4047-8479-bdd247d5a917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm_8ce5a8e9-ffa8-49b8-8acb-2619d741d8b9" xlink:href="ibrx-20230331.xsd#ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm_8ce5a8e9-ffa8-49b8-8acb-2619d741d8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears_f8d5959d-4956-49ac-b6ca-f591e392e883" xlink:href="ibrx-20230331.xsd#ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears_f8d5959d-4956-49ac-b6ca-f591e392e883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears_84648630-ecdb-4edf-8bd4-d6590d05f446" xlink:href="ibrx-20230331.xsd#ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears_84648630-ecdb-4edf-8bd4-d6590d05f446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestGovernmentFundingReceivable_39251af8-2158-4e5a-b818-f491fcf6d007" xlink:href="ibrx-20230331.xsd#ibrx_LeaseholdInterestGovernmentFundingReceivable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_ad89177b-24cf-48da-accf-c03f57b62a34" xlink:to="loc_ibrx_LeaseholdInterestGovernmentFundingReceivable_39251af8-2158-4e5a-b818-f491fcf6d007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_04380e51-79b5-4a34-8550-d849b18b3d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6beb3f9d-e21b-46f9-a1c1-2cd2f1b8bce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_04380e51-79b5-4a34-8550-d849b18b3d1a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6beb3f9d-e21b-46f9-a1c1-2cd2f1b8bce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6d2bb22c-2f5f-43ab-b2ee-fdc16ed5d53a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6beb3f9d-e21b-46f9-a1c1-2cd2f1b8bce9" xlink:to="loc_dei_LegalEntityAxis_6d2bb22c-2f5f-43ab-b2ee-fdc16ed5d53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f42a4944-a893-4e73-9c38-7252feb2f034" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_6d2bb22c-2f5f-43ab-b2ee-fdc16ed5d53a" xlink:to="loc_dei_EntityDomain_f42a4944-a893-4e73-9c38-7252feb2f034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_VivaBioCellMember_e636b312-23f3-43c0-b6b3-5e5c1a3af0af" xlink:href="ibrx-20230331.xsd#ibrx_VivaBioCellMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_f42a4944-a893-4e73-9c38-7252feb2f034" xlink:to="loc_ibrx_VivaBioCellMember_e636b312-23f3-43c0-b6b3-5e5c1a3af0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bf1916a1-0e30-4c56-8f40-fa457628af4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6beb3f9d-e21b-46f9-a1c1-2cd2f1b8bce9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bf1916a1-0e30-4c56-8f40-fa457628af4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b4c54e98-2c29-4b48-94a8-de2b180b897f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bf1916a1-0e30-4c56-8f40-fa457628af4e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b4c54e98-2c29-4b48-94a8-de2b180b897f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AltorBioScienceCorporationMember_0072b3fd-4f9c-4a34-b91b-a123259abf46" xlink:href="ibrx-20230331.xsd#ibrx_AltorBioScienceCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b4c54e98-2c29-4b48-94a8-de2b180b897f" xlink:to="loc_ibrx_AltorBioScienceCorporationMember_0072b3fd-4f9c-4a34-b91b-a123259abf46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_8ecdc7c9-2a7f-4186-9e54-0c7fd4c50b14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6beb3f9d-e21b-46f9-a1c1-2cd2f1b8bce9" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_8ecdc7c9-2a7f-4186-9e54-0c7fd4c50b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_05fbc5ba-9c21-4d0a-9082-1d448efa6299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_8ecdc7c9-2a7f-4186-9e54-0c7fd4c50b14" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_05fbc5ba-9c21-4d0a-9082-1d448efa6299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ContingentValueRightsObligationRegulatoryMilestoneMember_47eece05-639c-495a-8b27-898f24945e12" xlink:href="ibrx-20230331.xsd#ibrx_ContingentValueRightsObligationRegulatoryMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_05fbc5ba-9c21-4d0a-9082-1d448efa6299" xlink:to="loc_ibrx_ContingentValueRightsObligationRegulatoryMilestoneMember_47eece05-639c-495a-8b27-898f24945e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ContingentValueRightsObligationSalesMilestoneMember_e9f4dc87-a5eb-43b1-8df1-a7fd746bc72f" xlink:href="ibrx-20230331.xsd#ibrx_ContingentValueRightsObligationSalesMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_05fbc5ba-9c21-4d0a-9082-1d448efa6299" xlink:to="loc_ibrx_ContingentValueRightsObligationSalesMilestoneMember_e9f4dc87-a5eb-43b1-8df1-a7fd746bc72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a2d26d42-4d6d-40ec-99ef-b858646f62b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6beb3f9d-e21b-46f9-a1c1-2cd2f1b8bce9" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a2d26d42-4d6d-40ec-99ef-b858646f62b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1de7e2a8-50de-4522-8421-684031519851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a2d26d42-4d6d-40ec-99ef-b858646f62b3" xlink:to="loc_us-gaap_RelatedPartyDomain_1de7e2a8-50de-4522-8421-684031519851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DrSoonShiongAndRelatedPartyMember_a880ec40-c447-43ff-a803-b817ee489b15" xlink:href="ibrx-20230331.xsd#ibrx_DrSoonShiongAndRelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1de7e2a8-50de-4522-8421-684031519851" xlink:to="loc_ibrx_DrSoonShiongAndRelatedPartyMember_a880ec40-c447-43ff-a803-b817ee489b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AltorStockholdersMember_bd3427c9-d267-4f09-8433-93ba29d56255" xlink:href="ibrx-20230331.xsd#ibrx_AltorStockholdersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1de7e2a8-50de-4522-8421-684031519851" xlink:to="loc_ibrx_AltorStockholdersMember_bd3427c9-d267-4f09-8433-93ba29d56255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f5a323e1-6b30-4792-835d-e605f7642abb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6beb3f9d-e21b-46f9-a1c1-2cd2f1b8bce9" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_f5a323e1-6b30-4792-835d-e605f7642abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PercentageOfWhollyOwnedSubsidiary_feed7ec9-fc4b-4b60-8941-6fa8b6435337" xlink:href="ibrx-20230331.xsd#ibrx_PercentageOfWhollyOwnedSubsidiary"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f5a323e1-6b30-4792-835d-e605f7642abb" xlink:to="loc_ibrx_PercentageOfWhollyOwnedSubsidiary_feed7ec9-fc4b-4b60-8941-6fa8b6435337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_188a919b-1208-4eae-afb8-88afe5ec5655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f5a323e1-6b30-4792-835d-e605f7642abb" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_188a919b-1208-4eae-afb8-88afe5ec5655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned_a8743da5-04fb-4682-a5f1-dc29ea9c3d95" xlink:href="ibrx-20230331.xsd#ibrx_BusinessCombinationContingentConsiderationArrangementsEarned"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f5a323e1-6b30-4792-835d-e605f7642abb" xlink:to="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned_a8743da5-04fb-4682-a5f1-dc29ea9c3d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements_b5100798-cf27-440c-b9e4-1773765dd020" xlink:href="ibrx-20230331.xsd#ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f5a323e1-6b30-4792-835d-e605f7642abb" xlink:to="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements_b5100798-cf27-440c-b9e4-1773765dd020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_42025c8e-cd61-4f36-98a1-60a4c32dd0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f5a323e1-6b30-4792-835d-e605f7642abb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_42025c8e-cd61-4f36-98a1-60a4c32dd0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ContingentValueRightsObligations_bc30abbe-ba18-426a-bab0-632de36176f9" xlink:href="ibrx-20230331.xsd#ibrx_ContingentValueRightsObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f5a323e1-6b30-4792-835d-e605f7642abb" xlink:to="loc_ibrx_ContingentValueRightsObligations_bc30abbe-ba18-426a-bab0-632de36176f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation_5d203632-50a9-4231-982b-f09dc25d207a" xlink:href="ibrx-20230331.xsd#ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f5a323e1-6b30-4792-835d-e605f7642abb" xlink:to="loc_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation_5d203632-50a9-4231-982b-f09dc25d207a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#CommitmentandContingenciesLitigationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_16e07a23-989d-4234-a531-673e0d0413d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationTable_3b0f0b33-76d9-4638-83b3-10a85ae2f1ff" xlink:href="ibrx-20230331.xsd#ibrx_LitigationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_16e07a23-989d-4234-a531-673e0d0413d3" xlink:to="loc_ibrx_LitigationTable_3b0f0b33-76d9-4638-83b3-10a85ae2f1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_f974a1ab-22e9-46e5-ba62-1f62b41f0e8b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationTable_3b0f0b33-76d9-4638-83b3-10a85ae2f1ff" xlink:to="loc_srt_ConsolidatedEntitiesAxis_f974a1ab-22e9-46e5-ba62-1f62b41f0e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_75a8b541-37d5-4074-a4e2-2f9e0081b60c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_f974a1ab-22e9-46e5-ba62-1f62b41f0e8b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_75a8b541-37d5-4074-a4e2-2f9e0081b60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCellIncMember_aae7c53d-8832-4093-a4af-171ad4cb53f4" xlink:href="ibrx-20230331.xsd#ibrx_NantCellIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_75a8b541-37d5-4074-a4e2-2f9e0081b60c" xlink:to="loc_ibrx_NantCellIncMember_aae7c53d-8832-4093-a4af-171ad4cb53f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NANTibodyLLCMember_d3d99d5f-6ed8-448f-9744-78f6aa89fc58" xlink:href="ibrx-20230331.xsd#ibrx_NANTibodyLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_75a8b541-37d5-4074-a4e2-2f9e0081b60c" xlink:to="loc_ibrx_NANTibodyLLCMember_d3d99d5f-6ed8-448f-9744-78f6aa89fc58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_f8bc24b0-abce-4778-a1ec-0cdc5d50ed75" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationTable_3b0f0b33-76d9-4638-83b3-10a85ae2f1ff" xlink:to="loc_srt_LitigationCaseAxis_f8bc24b0-abce-4778-a1ec-0cdc5d50ed75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_8fb65ab4-883d-4b76-a653-9b6e6a9a84e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_f8bc24b0-abce-4778-a1ec-0cdc5d50ed75" xlink:to="loc_srt_LitigationCaseTypeDomain_8fb65ab4-883d-4b76-a653-9b6e6a9a84e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SorrentoTherapeuticsIncLitigationMember_5af9e1a4-13cb-444b-9251-622d2b2845e8" xlink:href="ibrx-20230331.xsd#ibrx_SorrentoTherapeuticsIncLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_8fb65ab4-883d-4b76-a653-9b6e6a9a84e3" xlink:to="loc_ibrx_SorrentoTherapeuticsIncLitigationMember_5af9e1a4-13cb-444b-9251-622d2b2845e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f09667ae-72dc-4f4e-9e03-46439df04440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationTable_3b0f0b33-76d9-4638-83b3-10a85ae2f1ff" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f09667ae-72dc-4f4e-9e03-46439df04440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_653f1e10-a3f6-46ca-a0cd-8fe0b2fbaafb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f09667ae-72dc-4f4e-9e03-46439df04440" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_653f1e10-a3f6-46ca-a0cd-8fe0b2fbaafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AltorBioScienceLLCMember_430a31a9-471f-4e40-8da5-b9950348ecaf" xlink:href="ibrx-20230331.xsd#ibrx_AltorBioScienceLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_653f1e10-a3f6-46ca-a0cd-8fe0b2fbaafb" xlink:to="loc_ibrx_AltorBioScienceLLCMember_430a31a9-471f-4e40-8da5-b9950348ecaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_30ff53c7-2495-4c03-903d-4960d909d1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationTable_3b0f0b33-76d9-4638-83b3-10a85ae2f1ff" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_30ff53c7-2495-4c03-903d-4960d909d1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4baffda0-48ce-481d-b56a-7cb16683e3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_30ff53c7-2495-4c03-903d-4960d909d1b7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4baffda0-48ce-481d-b56a-7cb16683e3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_9ad982f2-1a71-4c1f-a5c9-02229d10e196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4baffda0-48ce-481d-b56a-7cb16683e3bc" xlink:to="loc_us-gaap_PrivatePlacementMember_9ad982f2-1a71-4c1f-a5c9-02229d10e196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationLineItems_4d887acc-26b1-4e51-9de2-f2c7a57632f0" xlink:href="ibrx-20230331.xsd#ibrx_LitigationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationTable_3b0f0b33-76d9-4638-83b3-10a85ae2f1ff" xlink:to="loc_ibrx_LitigationLineItems_4d887acc-26b1-4e51-9de2-f2c7a57632f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfDissentingShares_859c11b7-0803-4b88-8baf-70d9f1473690" xlink:href="ibrx-20230331.xsd#ibrx_NumberOfDissentingShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationLineItems_4d887acc-26b1-4e51-9de2-f2c7a57632f0" xlink:to="loc_ibrx_NumberOfDissentingShares_859c11b7-0803-4b88-8baf-70d9f1473690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationSettlementNumberOfSharesToBeIssued_c3a75250-8388-4b51-bca9-8385d35dc7a1" xlink:href="ibrx-20230331.xsd#ibrx_LitigationSettlementNumberOfSharesToBeIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationLineItems_4d887acc-26b1-4e51-9de2-f2c7a57632f0" xlink:to="loc_ibrx_LitigationSettlementNumberOfSharesToBeIssued_c3a75250-8388-4b51-bca9-8385d35dc7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares_fefe343b-d4f6-4cbd-b7f0-40b5c8cf9fe5" xlink:href="ibrx-20230331.xsd#ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationLineItems_4d887acc-26b1-4e51-9de2-f2c7a57632f0" xlink:to="loc_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares_fefe343b-d4f6-4cbd-b7f0-40b5c8cf9fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_58c5ff92-a616-48e3-88ac-782c1d3b8d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationLineItems_4d887acc-26b1-4e51-9de2-f2c7a57632f0" xlink:to="loc_us-gaap_SharesIssued_58c5ff92-a616-48e3-88ac-782c1d3b8d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_a40e8f24-dcf8-4229-9567-8a981c183b08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationLineItems_4d887acc-26b1-4e51-9de2-f2c7a57632f0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_a40e8f24-dcf8-4229-9567-8a981c183b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_68f36e0e-2e1a-4bdf-bc8b-d9cb453f0b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationLineItems_4d887acc-26b1-4e51-9de2-f2c7a57632f0" xlink:to="loc_us-gaap_LitigationReserve_68f36e0e-2e1a-4bdf-bc8b-d9cb453f0b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_949c148f-cb8b-4ba4-8b77-18f63f35032a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationLineItems_4d887acc-26b1-4e51-9de2-f2c7a57632f0" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_949c148f-cb8b-4ba4-8b77-18f63f35032a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationSettlementInterestPercent_f798890d-ccd3-4edc-a328-1fad9d3884b2" xlink:href="ibrx-20230331.xsd#ibrx_LitigationSettlementInterestPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationLineItems_4d887acc-26b1-4e51-9de2-f2c7a57632f0" xlink:to="loc_ibrx_LitigationSettlementInterestPercent_f798890d-ccd3-4edc-a328-1fad9d3884b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_6a804b3a-64a6-49ca-8e2b-09b85108e292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationLineItems_4d887acc-26b1-4e51-9de2-f2c7a57632f0" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_6a804b3a-64a6-49ca-8e2b-09b85108e292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="ibrx-20230331.xsd#LeaseArrangementsSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a4d0bcad-2222-4b9d-9ca5-4c34487dbe49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a13d476c-282f-4f88-bde6-2885cec4fc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a4d0bcad-2222-4b9d-9ca5-4c34487dbe49" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a13d476c-282f-4f88-bde6-2885cec4fc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_0ad8dcde-b5dc-4db1-a874-93d34cd5e7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a4d0bcad-2222-4b9d-9ca5-4c34487dbe49" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_0ad8dcde-b5dc-4db1-a874-93d34cd5e7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseRightOfUseAsset_f119755f-0d79-45ee-a8f9-98a1f5a850c5" xlink:href="ibrx-20230331.xsd#ibrx_LeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a4d0bcad-2222-4b9d-9ca5-4c34487dbe49" xlink:to="loc_ibrx_LeaseRightOfUseAsset_f119755f-0d79-45ee-a8f9-98a1f5a850c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b81d5400-9eb8-46f9-9252-803120ebc79a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a4d0bcad-2222-4b9d-9ca5-4c34487dbe49" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b81d5400-9eb8-46f9-9252-803120ebc79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_8e31527f-29b3-4cee-98bc-7309c018a1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a4d0bcad-2222-4b9d-9ca5-4c34487dbe49" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_8e31527f-29b3-4cee-98bc-7309c018a1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_17de4b51-1944-4d1d-b057-6347d354503c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a4d0bcad-2222-4b9d-9ca5-4c34487dbe49" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_17de4b51-1944-4d1d-b057-6347d354503c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_acdc5377-1223-4e48-9b81-9c911e292496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a4d0bcad-2222-4b9d-9ca5-4c34487dbe49" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_acdc5377-1223-4e48-9b81-9c911e292496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiability_82d671c0-5778-4b1b-b3c5-d4717e1baa56" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a4d0bcad-2222-4b9d-9ca5-4c34487dbe49" xlink:to="loc_ibrx_LeaseLiability_82d671c0-5778-4b1b-b3c5-d4717e1baa56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_b0a9be8f-216e-4b5d-956f-fcab5ba7273e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a4d0bcad-2222-4b9d-9ca5-4c34487dbe49" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_b0a9be8f-216e-4b5d-956f-fcab5ba7273e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_6af37939-a212-4050-9ffd-20deeb5949b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a4d0bcad-2222-4b9d-9ca5-4c34487dbe49" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_6af37939-a212-4050-9ffd-20deeb5949b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_86a03e83-0372-4a96-bd1b-b15f8a7aebd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a4d0bcad-2222-4b9d-9ca5-4c34487dbe49" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_86a03e83-0372-4a96-bd1b-b15f8a7aebd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsSummaryofInformationRegardingLeasesDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#LeaseArrangementsSummaryofInformationRegardingLeasesDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsSummaryofInformationRegardingLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4de5fcf1-909e-43cc-bb6b-44523a1fa67a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2e3e1760-b51b-487c-b4a7-39b11bf7b5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4de5fcf1-909e-43cc-bb6b-44523a1fa67a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2e3e1760-b51b-487c-b4a7-39b11bf7b5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_05fcbebd-54d1-4073-b55a-6cf1c110ece3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4de5fcf1-909e-43cc-bb6b-44523a1fa67a" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_05fcbebd-54d1-4073-b55a-6cf1c110ece3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_87a600a7-eb8a-4513-a3f0-138b371ac77d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4de5fcf1-909e-43cc-bb6b-44523a1fa67a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_87a600a7-eb8a-4513-a3f0-138b371ac77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_a2c4be26-ea28-44d4-9b9c-4443d77fbc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4de5fcf1-909e-43cc-bb6b-44523a1fa67a" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_a2c4be26-ea28-44d4-9b9c-4443d77fbc2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#LeaseArrangementsComponentsofLeaseExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3e02e87c-dfb1-4793-9bd9-e05e4c46b19f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_a4d397dc-0950-434d-b4fc-0e41059d4263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e02e87c-dfb1-4793-9bd9-e05e4c46b19f" xlink:to="loc_us-gaap_OperatingLeaseCost_a4d397dc-0950-434d-b4fc-0e41059d4263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_574ebfc0-093d-40f3-9d8d-1f1fbff69a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e02e87c-dfb1-4793-9bd9-e05e4c46b19f" xlink:to="loc_us-gaap_ShortTermLeaseCost_574ebfc0-093d-40f3-9d8d-1f1fbff69a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense_2f457e63-e1b5-4552-967a-186e40ba9f98" xlink:href="ibrx-20230331.xsd#ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e02e87c-dfb1-4793-9bd9-e05e4c46b19f" xlink:to="loc_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense_2f457e63-e1b5-4552-967a-186e40ba9f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_f1bbdc5a-0cfa-4384-be70-37933aac8b08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e02e87c-dfb1-4793-9bd9-e05e4c46b19f" xlink:to="loc_us-gaap_VariableLeaseCost_f1bbdc5a-0cfa-4384-be70-37933aac8b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_ee8392e6-404a-431d-bafa-57cb1f93ba75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e02e87c-dfb1-4793-9bd9-e05e4c46b19f" xlink:to="loc_us-gaap_LeaseCost_ee8392e6-404a-431d-bafa-57cb1f93ba75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsScheduleofCashPaidforAmountsIncludedinMeasurementofLeaseLiabilitiesDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#LeaseArrangementsScheduleofCashPaidforAmountsIncludedinMeasurementofLeaseLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsScheduleofCashPaidforAmountsIncludedinMeasurementofLeaseLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4718ec67-7db6-4f53-8d60-edfd42d6c7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_7fc13bf9-d9b8-4ce3-be3f-976646e8ae7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4718ec67-7db6-4f53-8d60-edfd42d6c7d5" xlink:to="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_7fc13bf9-d9b8-4ce3-be3f-976646e8ae7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_763323e5-0a03-4256-97c7-753ef94561dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_7fc13bf9-d9b8-4ce3-be3f-976646e8ae7f" xlink:to="loc_us-gaap_OperatingLeasePayments_763323e5-0a03-4256-97c7-753ef94561dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_a48136a5-7fc2-4e52-b9d0-6ef341acea0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_7fc13bf9-d9b8-4ce3-be3f-976646e8ae7f" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_a48136a5-7fc2-4e52-b9d0-6ef341acea0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_8ec0c0ae-65f3-4bf8-9a1c-9fdde5f5908f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_7fc13bf9-d9b8-4ce3-be3f-976646e8ae7f" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_8ec0c0ae-65f3-4bf8-9a1c-9fdde5f5908f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b723afd5-1238-451f-93d7-6b26cb56cfb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c1eb5034-2cf3-423a-8d2b-72c4f4ed655a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b723afd5-1238-451f-93d7-6b26cb56cfb8" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c1eb5034-2cf3-423a-8d2b-72c4f4ed655a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b5960e5b-1497-416b-8476-905fcc13207c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c1eb5034-2cf3-423a-8d2b-72c4f4ed655a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b5960e5b-1497-416b-8476-905fcc13207c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1ae72cb8-0f7b-4ebc-ae22-e283ac93f80d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c1eb5034-2cf3-423a-8d2b-72c4f4ed655a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1ae72cb8-0f7b-4ebc-ae22-e283ac93f80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3248e1d2-ca1b-4fef-b28c-6a62b098e129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c1eb5034-2cf3-423a-8d2b-72c4f4ed655a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3248e1d2-ca1b-4fef-b28c-6a62b098e129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a1788416-f5f9-44f6-b28b-65837b05dc82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c1eb5034-2cf3-423a-8d2b-72c4f4ed655a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a1788416-f5f9-44f6-b28b-65837b05dc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4399ef0d-ecc3-4875-bdcd-6654add9db97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c1eb5034-2cf3-423a-8d2b-72c4f4ed655a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4399ef0d-ecc3-4875-bdcd-6654add9db97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_babe3aa1-70cd-460e-8c49-0561060e45bc" xlink:href="ibrx-20230331.xsd#ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c1eb5034-2cf3-423a-8d2b-72c4f4ed655a" xlink:to="loc_ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_babe3aa1-70cd-460e-8c49-0561060e45bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_783eb61c-b7b8-434b-b13b-d88de3100f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c1eb5034-2cf3-423a-8d2b-72c4f4ed655a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_783eb61c-b7b8-434b-b13b-d88de3100f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fd65a82b-b7c2-4223-9d0a-825509ce6181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c1eb5034-2cf3-423a-8d2b-72c4f4ed655a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fd65a82b-b7c2-4223-9d0a-825509ce6181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable_1536d3d2-9ad4-4677-b4b8-6bbb09599263" xlink:href="ibrx-20230331.xsd#ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c1eb5034-2cf3-423a-8d2b-72c4f4ed655a" xlink:to="loc_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable_1536d3d2-9ad4-4677-b4b8-6bbb09599263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b06f1633-9eb4-4f56-af98-97085a73bcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c1eb5034-2cf3-423a-8d2b-72c4f4ed655a" xlink:to="loc_us-gaap_OperatingLeaseLiability_b06f1633-9eb4-4f56-af98-97085a73bcd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1196d8c5-0ea0-4a64-9bbb-bd7fbde72c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b723afd5-1238-451f-93d7-6b26cb56cfb8" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1196d8c5-0ea0-4a64-9bbb-bd7fbde72c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_b1772678-0577-4b6a-a17b-639af7f3cb29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1196d8c5-0ea0-4a64-9bbb-bd7fbde72c57" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_b1772678-0577-4b6a-a17b-639af7f3cb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a367b672-82d4-4a63-b072-0141bd54b662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1196d8c5-0ea0-4a64-9bbb-bd7fbde72c57" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a367b672-82d4-4a63-b072-0141bd54b662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_407b469f-be14-4980-b854-68499c9641ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1196d8c5-0ea0-4a64-9bbb-bd7fbde72c57" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_407b469f-be14-4980-b854-68499c9641ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_97c2b30f-3fb4-4696-ac91-0807a316c7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1196d8c5-0ea0-4a64-9bbb-bd7fbde72c57" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_97c2b30f-3fb4-4696-ac91-0807a316c7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_fd2414c5-6705-42e7-a056-760623b2e0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1196d8c5-0ea0-4a64-9bbb-bd7fbde72c57" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_fd2414c5-6705-42e7-a056-760623b2e0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour_5858cfa6-2520-4005-b884-85ab9c3116ff" xlink:href="ibrx-20230331.xsd#ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1196d8c5-0ea0-4a64-9bbb-bd7fbde72c57" xlink:to="loc_ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour_5858cfa6-2520-4005-b884-85ab9c3116ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f6cbc9dc-3ca8-4fa9-a02d-37131adff422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1196d8c5-0ea0-4a64-9bbb-bd7fbde72c57" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f6cbc9dc-3ca8-4fa9-a02d-37131adff422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_79379176-c798-40ea-bc5c-be89b83f5e55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1196d8c5-0ea0-4a64-9bbb-bd7fbde72c57" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_79379176-c798-40ea-bc5c-be89b83f5e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable_c113a164-5d05-478d-82e0-2a26ec6a7cef" xlink:href="ibrx-20230331.xsd#ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1196d8c5-0ea0-4a64-9bbb-bd7fbde72c57" xlink:to="loc_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable_c113a164-5d05-478d-82e0-2a26ec6a7cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_32d23a4c-aa9d-4f04-a010-2ba91b0e2ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1196d8c5-0ea0-4a64-9bbb-bd7fbde72c57" xlink:to="loc_us-gaap_FinanceLeaseLiability_32d23a4c-aa9d-4f04-a010-2ba91b0e2ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidAbstract_7f509333-6f9a-4ac8-8ed1-e9bbd5f6d635" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b723afd5-1238-451f-93d7-6b26cb56cfb8" xlink:to="loc_ibrx_LeaseLiabilityToBePaidAbstract_7f509333-6f9a-4ac8-8ed1-e9bbd5f6d635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear_4b460fcd-3898-42fb-befb-b0baa80f3ab8" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAbstract_7f509333-6f9a-4ac8-8ed1-e9bbd5f6d635" xlink:to="loc_ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear_4b460fcd-3898-42fb-befb-b0baa80f3ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearOne_b611cd85-24ce-4891-b89f-ff4ff400e0e3" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidYearOne"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAbstract_7f509333-6f9a-4ac8-8ed1-e9bbd5f6d635" xlink:to="loc_ibrx_LeaseLiabilityToBePaidYearOne_b611cd85-24ce-4891-b89f-ff4ff400e0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearTwo_6cb96410-bbde-462b-ac37-31d21f06e115" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAbstract_7f509333-6f9a-4ac8-8ed1-e9bbd5f6d635" xlink:to="loc_ibrx_LeaseLiabilityToBePaidYearTwo_6cb96410-bbde-462b-ac37-31d21f06e115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearThree_95c7e3ba-7a15-42aa-aafe-8857d25b7303" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAbstract_7f509333-6f9a-4ac8-8ed1-e9bbd5f6d635" xlink:to="loc_ibrx_LeaseLiabilityToBePaidYearThree_95c7e3ba-7a15-42aa-aafe-8857d25b7303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearFour_6adf24a7-ff4c-4b43-b02c-4a481103127e" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAbstract_7f509333-6f9a-4ac8-8ed1-e9bbd5f6d635" xlink:to="loc_ibrx_LeaseLiabilityToBePaidYearFour_6adf24a7-ff4c-4b43-b02c-4a481103127e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidAfterYearFour_11b4304a-20e2-4e22-9779-e7713f1707bc" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAbstract_7f509333-6f9a-4ac8-8ed1-e9bbd5f6d635" xlink:to="loc_ibrx_LeaseLiabilityToBePaidAfterYearFour_11b4304a-20e2-4e22-9779-e7713f1707bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaid_a4a9f779-f01d-4da3-aba1-4d2f2ab22e50" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityToBePaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAbstract_7f509333-6f9a-4ac8-8ed1-e9bbd5f6d635" xlink:to="loc_ibrx_LeaseLiabilityToBePaid_a4a9f779-f01d-4da3-aba1-4d2f2ab22e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityUndiscountedExcessInterest_aa8b6961-1be6-41cf-a17b-59ef852de70e" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityUndiscountedExcessInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAbstract_7f509333-6f9a-4ac8-8ed1-e9bbd5f6d635" xlink:to="loc_ibrx_LeaseLiabilityUndiscountedExcessInterest_aa8b6961-1be6-41cf-a17b-59ef852de70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable_75cbc54f-52c3-4c80-a80f-4234482a3e46" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAbstract_7f509333-6f9a-4ac8-8ed1-e9bbd5f6d635" xlink:to="loc_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable_75cbc54f-52c3-4c80-a80f-4234482a3e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiability_f4b3133a-de52-475b-b570-aa9153e69faa" xlink:href="ibrx-20230331.xsd#ibrx_LeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAbstract_7f509333-6f9a-4ac8-8ed1-e9bbd5f6d635" xlink:to="loc_ibrx_LeaseLiability_f4b3133a-de52-475b-b570-aa9153e69faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1" xlink:type="simple" xlink:href="ibrx-20230331.xsd#LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_2" xlink:type="simple" xlink:href="ibrx-20230331.xsd#LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_2"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#LeaseArrangementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0268a86d-35e0-4575-a934-10d049c3b28e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_94586964-004a-4332-9b26-151266399fea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0268a86d-35e0-4575-a934-10d049c3b28e" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_94586964-004a-4332-9b26-151266399fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1f72531c-7bd3-408b-990e-9b1558f3924d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_94586964-004a-4332-9b26-151266399fea" xlink:to="loc_srt_RangeAxis_1f72531c-7bd3-408b-990e-9b1558f3924d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_60d1a65b-4b4c-4f74-a14f-c7fb5140e3d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1f72531c-7bd3-408b-990e-9b1558f3924d" xlink:to="loc_srt_RangeMember_60d1a65b-4b4c-4f74-a14f-c7fb5140e3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cba740a4-9e92-49d4-9a6e-cac11471e7e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_60d1a65b-4b4c-4f74-a14f-c7fb5140e3d7" xlink:to="loc_srt_MinimumMember_cba740a4-9e92-49d4-9a6e-cac11471e7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e462a74c-1cd1-4603-bd8d-abb8517be92e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_60d1a65b-4b4c-4f74-a14f-c7fb5140e3d7" xlink:to="loc_srt_MaximumMember_e462a74c-1cd1-4603-bd8d-abb8517be92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_91ea84c1-a6dc-47f2-8aef-d364e9d6986a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_94586964-004a-4332-9b26-151266399fea" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_91ea84c1-a6dc-47f2-8aef-d364e9d6986a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_658c32ac-b8e3-4420-99d4-aacda71fc83e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91ea84c1-a6dc-47f2-8aef-d364e9d6986a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_658c32ac-b8e3-4420-99d4-aacda71fc83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b8ef87de-c938-483f-ac1d-7cf56ba3a9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91ea84c1-a6dc-47f2-8aef-d364e9d6986a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b8ef87de-c938-483f-ac1d-7cf56ba3a9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms_87372a74-005b-4864-8a71-3053cfd1b741" xlink:href="ibrx-20230331.xsd#ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91ea84c1-a6dc-47f2-8aef-d364e9d6986a" xlink:to="loc_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms_87372a74-005b-4864-8a71-3053cfd1b741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails" xlink:type="simple" xlink:href="ibrx-20230331.xsd#RelatedPartyDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_b6a0b83d-3c10-46d0-96bd-f3ee7c993733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d7a9e7e3-fb94-46e1-b8c1-bf69e8f54415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_b6a0b83d-3c10-46d0-96bd-f3ee7c993733" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d7a9e7e3-fb94-46e1-b8c1-bf69e8f54415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d7689694-a1d1-49ad-8428-f1f40bd924b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d7a9e7e3-fb94-46e1-b8c1-bf69e8f54415" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d7689694-a1d1-49ad-8428-f1f40bd924b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c1369005-34e6-46b0-95bd-df6924f9c047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d7689694-a1d1-49ad-8428-f1f40bd924b5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c1369005-34e6-46b0-95bd-df6924f9c047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_8b18c396-29f2-4f49-a512-a80a0324f748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c1369005-34e6-46b0-95bd-df6924f9c047" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_8b18c396-29f2-4f49-a512-a80a0324f748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PromissoryNotesPayableMember_77803e2a-10be-47d8-b538-26853abc485c" xlink:href="ibrx-20230331.xsd#ibrx_PromissoryNotesPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c1369005-34e6-46b0-95bd-df6924f9c047" xlink:to="loc_ibrx_PromissoryNotesPayableMember_77803e2a-10be-47d8-b538-26853abc485c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_c4465903-81ea-4ea0-8c06-d21d05d89d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d7a9e7e3-fb94-46e1-b8c1-bf69e8f54415" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_c4465903-81ea-4ea0-8c06-d21d05d89d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2fe50cbb-6793-43a8-a2a2-25ddda01d287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c4465903-81ea-4ea0-8c06-d21d05d89d9c" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2fe50cbb-6793-43a8-a2a2-25ddda01d287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalIssued33123Member_f1258edc-a2b8-48e4-8d05-9873f8e3bab9" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalIssued33123Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2fe50cbb-6793-43a8-a2a2-25ddda01d287" xlink:to="loc_ibrx_NantCapitalIssued33123Member_f1258edc-a2b8-48e4-8d05-9873f8e3bab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember_5645dcdd-6997-4679-a922-a7bf5822e6ca" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2fe50cbb-6793-43a8-a2a2-25ddda01d287" xlink:to="loc_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember_5645dcdd-6997-4679-a922-a7bf5822e6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember_810e0214-fab7-4275-afb7-804888e677f5" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2fe50cbb-6793-43a8-a2a2-25ddda01d287" xlink:to="loc_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember_810e0214-fab7-4275-afb7-804888e677f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalTwoMember_8574de97-85a5-4159-81c3-3244629874c1" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalTwoMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2fe50cbb-6793-43a8-a2a2-25ddda01d287" xlink:to="loc_ibrx_NantCapitalTwoMember_8574de97-85a5-4159-81c3-3244629874c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapital3Member_0ab7afdd-cbe7-4220-abea-dd150945193d" xlink:href="ibrx-20230331.xsd#ibrx_NantCapital3Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2fe50cbb-6793-43a8-a2a2-25ddda01d287" xlink:to="loc_ibrx_NantCapital3Member_0ab7afdd-cbe7-4220-abea-dd150945193d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapital4Member_3c114244-cee9-44a5-92f6-2d6c43ed2b03" xlink:href="ibrx-20230331.xsd#ibrx_NantCapital4Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2fe50cbb-6793-43a8-a2a2-25ddda01d287" xlink:to="loc_ibrx_NantCapital4Member_3c114244-cee9-44a5-92f6-2d6c43ed2b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapital6Member_1a0731be-58c1-4d51-b7fc-896e0870e24d" xlink:href="ibrx-20230331.xsd#ibrx_NantCapital6Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2fe50cbb-6793-43a8-a2a2-25ddda01d287" xlink:to="loc_ibrx_NantCapital6Member_1a0731be-58c1-4d51-b7fc-896e0870e24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_a675e3a7-fd38-439b-be11-a9cfe6c3fa61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d7a9e7e3-fb94-46e1-b8c1-bf69e8f54415" xlink:to="loc_us-gaap_VariableRateAxis_a675e3a7-fd38-439b-be11-a9cfe6c3fa61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_c2dba134-656d-4543-b605-14eb22f65cac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_a675e3a7-fd38-439b-be11-a9cfe6c3fa61" xlink:to="loc_us-gaap_VariableRateDomain_c2dba134-656d-4543-b605-14eb22f65cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SecuredOvernightFinancingRateSOFRMember_6917e776-e095-45a5-8e5f-b6dbc024a72e" xlink:href="ibrx-20230331.xsd#ibrx_SecuredOvernightFinancingRateSOFRMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_c2dba134-656d-4543-b605-14eb22f65cac" xlink:to="loc_ibrx_SecuredOvernightFinancingRateSOFRMember_6917e776-e095-45a5-8e5f-b6dbc024a72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_75771e3f-23e9-4e90-9555-0392b9181c1d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d7a9e7e3-fb94-46e1-b8c1-bf69e8f54415" xlink:to="loc_srt_RangeAxis_75771e3f-23e9-4e90-9555-0392b9181c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0834a422-3dc0-4ed0-b0ec-2375fe26cde0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_75771e3f-23e9-4e90-9555-0392b9181c1d" xlink:to="loc_srt_RangeMember_0834a422-3dc0-4ed0-b0ec-2375fe26cde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ee8cd952-166f-460e-b6b7-dccbade9ae51" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0834a422-3dc0-4ed0-b0ec-2375fe26cde0" xlink:to="loc_srt_MinimumMember_ee8cd952-166f-460e-b6b7-dccbade9ae51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5cbe1608-9004-4b78-b5bf-17b1c156e2ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0834a422-3dc0-4ed0-b0ec-2375fe26cde0" xlink:to="loc_srt_MaximumMember_5cbe1608-9004-4b78-b5bf-17b1c156e2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d7a9e7e3-fb94-46e1-b8c1-bf69e8f54415" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesPayable_9248bc57-4d68-4a71-9e4a-0fac9b6300d4" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyNotesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_ibrx_RelatedPartyNotesPayable_9248bc57-4d68-4a71-9e4a-0fac9b6300d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate_5230ade7-7fa0-45c5-82aa-cee0e9eb72f2" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate_5230ade7-7fa0-45c5-82aa-cee0e9eb72f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_8652b398-341b-4487-98b3-dcb6e4facc30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_8652b398-341b-4487-98b3-dcb6e4facc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_91c251a5-ccad-4a58-8138-17b8c5344bac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_91c251a5-ccad-4a58-8138-17b8c5344bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_d0a721ab-13ab-4ff5-b577-e710645e2312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_d0a721ab-13ab-4ff5-b577-e710645e2312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NotesPayableRelatedPartiesPrincipalAndAccruedInterest_db4ce601-6170-4e0f-8e61-bf644adca542" xlink:href="ibrx-20230331.xsd#ibrx_NotesPayableRelatedPartiesPrincipalAndAccruedInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_ibrx_NotesPayableRelatedPartiesPrincipalAndAccruedInterest_db4ce601-6170-4e0f-8e61-bf644adca542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_4a5944f9-7a39-4d6a-a53f-acad0cd34c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_4a5944f9-7a39-4d6a-a53f-acad0cd34c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c34f24fe-c61b-40a5-ad29-bc962d74da19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c34f24fe-c61b-40a5-ad29-bc962d74da19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_6490c887-e685-4eea-aba5-2ace4ea6b7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_6490c887-e685-4eea-aba5-2ace4ea6b7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_ebd849b6-9ce1-47f2-ac84-1e30e6ae2893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_us-gaap_InterestPaidNet_ebd849b6-9ce1-47f2-ac84-1e30e6ae2893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_758a717a-ce1a-4bee-a78d-c0a7eae25474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_758a717a-ce1a-4bee-a78d-c0a7eae25474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare_76abb171-8d60-4e08-aedf-bc0b99866f9c" xlink:href="ibrx-20230331.xsd#ibrx_OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2a0ddefc-87fe-4dcc-a929-f6fbf5d39269" xlink:to="loc_ibrx_OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare_76abb171-8d60-4e08-aedf-bc0b99866f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_340c80d0-bd9d-47ed-8f38-824f858645cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1ba17686-08a3-4772-9eaf-c47313edff48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_340c80d0-bd9d-47ed-8f38-824f858645cf" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1ba17686-08a3-4772-9eaf-c47313edff48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_853a0228-6fa3-42de-89b7-186289e35f67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1ba17686-08a3-4772-9eaf-c47313edff48" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_853a0228-6fa3-42de-89b7-186289e35f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_765cd386-4b88-4fec-ab7d-ffad4d37ed2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_853a0228-6fa3-42de-89b7-186289e35f67" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_765cd386-4b88-4fec-ab7d-ffad4d37ed2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapital3Member_9ce0c8e0-6e9c-4c32-974b-b3f54dbacc2d" xlink:href="ibrx-20230331.xsd#ibrx_NantCapital3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_765cd386-4b88-4fec-ab7d-ffad4d37ed2a" xlink:to="loc_ibrx_NantCapital3Member_9ce0c8e0-6e9c-4c32-974b-b3f54dbacc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalMember_2228dd0f-1590-4f79-8f10-730ad425cdb7" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_765cd386-4b88-4fec-ab7d-ffad4d37ed2a" xlink:to="loc_ibrx_NantCapitalMember_2228dd0f-1590-4f79-8f10-730ad425cdb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalOneMember_e67abdac-0474-408b-983f-aae8cf90e8fd" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalOneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_765cd386-4b88-4fec-ab7d-ffad4d37ed2a" xlink:to="loc_ibrx_NantCapitalOneMember_e67abdac-0474-408b-983f-aae8cf90e8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalTwoMember_f5b3700a-ed1f-4af5-b2d6-a1567e78bccc" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalTwoMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_765cd386-4b88-4fec-ab7d-ffad4d37ed2a" xlink:to="loc_ibrx_NantCapitalTwoMember_f5b3700a-ed1f-4af5-b2d6-a1567e78bccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalIssued33123Member_d7fb58ac-68d9-42d2-8cb4-6807b6540812" xlink:href="ibrx-20230331.xsd#ibrx_NantCapitalIssued33123Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_765cd386-4b88-4fec-ab7d-ffad4d37ed2a" xlink:to="loc_ibrx_NantCapitalIssued33123Member_d7fb58ac-68d9-42d2-8cb4-6807b6540812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantMobileMember_53c8f4fe-6cfa-4f30-b5da-3553eb883111" xlink:href="ibrx-20230331.xsd#ibrx_NantMobileMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_765cd386-4b88-4fec-ab7d-ffad4d37ed2a" xlink:to="loc_ibrx_NantMobileMember_53c8f4fe-6cfa-4f30-b5da-3553eb883111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NCSCMember_8c699849-30d8-442c-930f-139de1cff71e" xlink:href="ibrx-20230331.xsd#ibrx_NCSCMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_765cd386-4b88-4fec-ab7d-ffad4d37ed2a" xlink:to="loc_ibrx_NCSCMember_8c699849-30d8-442c-930f-139de1cff71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_a6efa458-d00d-42a5-a3df-7b25186a88ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1ba17686-08a3-4772-9eaf-c47313edff48" xlink:to="loc_us-gaap_VariableRateAxis_a6efa458-d00d-42a5-a3df-7b25186a88ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_97cb73ac-a7b3-4f8e-ac72-d144a002bfad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_a6efa458-d00d-42a5-a3df-7b25186a88ac" xlink:to="loc_us-gaap_VariableRateDomain_97cb73ac-a7b3-4f8e-ac72-d144a002bfad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SecuredOvernightFinancingRateSOFRMember_0dd4516a-2099-4933-bbac-215574fafbcb" xlink:href="ibrx-20230331.xsd#ibrx_SecuredOvernightFinancingRateSOFRMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_97cb73ac-a7b3-4f8e-ac72-d144a002bfad" xlink:to="loc_ibrx_SecuredOvernightFinancingRateSOFRMember_0dd4516a-2099-4933-bbac-215574fafbcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cbf572ae-1ac1-45f8-ae60-119fec3e2d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1ba17686-08a3-4772-9eaf-c47313edff48" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cbf572ae-1ac1-45f8-ae60-119fec3e2d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e2bb3363-4287-4d65-a9af-33fef4b235ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cbf572ae-1ac1-45f8-ae60-119fec3e2d8b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e2bb3363-4287-4d65-a9af-33fef4b235ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PromissoryNotesPayableMember_a6358df0-3874-4455-a51b-2bdd217280df" xlink:href="ibrx-20230331.xsd#ibrx_PromissoryNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e2bb3363-4287-4d65-a9af-33fef4b235ec" xlink:to="loc_ibrx_PromissoryNotesPayableMember_a6358df0-3874-4455-a51b-2bdd217280df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_468b8ebf-b0eb-40f3-bb0c-aa4e9f6b4b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e2bb3363-4287-4d65-a9af-33fef4b235ec" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_468b8ebf-b0eb-40f3-bb0c-aa4e9f6b4b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_5c8851e0-9ff6-4a62-aea6-5918acec2bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1ba17686-08a3-4772-9eaf-c47313edff48" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_5c8851e0-9ff6-4a62-aea6-5918acec2bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate_d1085bce-d4f1-498a-b4ff-5655bc4b73a4" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5c8851e0-9ff6-4a62-aea6-5918acec2bbd" xlink:to="loc_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate_d1085bce-d4f1-498a-b4ff-5655bc4b73a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_59515ab9-1cb5-41f4-a27d-77aaadc5fb73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5c8851e0-9ff6-4a62-aea6-5918acec2bbd" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_59515ab9-1cb5-41f4-a27d-77aaadc5fb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesPayable_da7f5667-6cc3-4cab-9968-baea8a661dfe" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5c8851e0-9ff6-4a62-aea6-5918acec2bbd" xlink:to="loc_ibrx_RelatedPartyNotesPayable_da7f5667-6cc3-4cab-9968-baea8a661dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_3154ab90-c429-459d-a56e-628992df775a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5c8851e0-9ff6-4a62-aea6-5918acec2bbd" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_3154ab90-c429-459d-a56e-628992df775a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_0eb8fd2a-e597-41de-bd08-9732ca7959e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5c8851e0-9ff6-4a62-aea6-5918acec2bbd" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_0eb8fd2a-e597-41de-bd08-9732ca7959e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_b1bbc394-beaf-4fc5-8709-15c8a4761253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5c8851e0-9ff6-4a62-aea6-5918acec2bbd" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_b1bbc394-beaf-4fc5-8709-15c8a4761253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails" xlink:type="simple" xlink:href="ibrx-20230331.xsd#RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_8eaba9e4-8db8-4a9f-8e01-30b731b4109e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6d20e8c8-8ae1-40c5-8b0d-02e2623c0479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_8eaba9e4-8db8-4a9f-8e01-30b731b4109e" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6d20e8c8-8ae1-40c5-8b0d-02e2623c0479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bdf4217a-1db2-4b23-8299-63c176aac34f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6d20e8c8-8ae1-40c5-8b0d-02e2623c0479" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bdf4217a-1db2-4b23-8299-63c176aac34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8fde70af-719d-4f88-baac-f784a1f72831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bdf4217a-1db2-4b23-8299-63c176aac34f" xlink:to="loc_us-gaap_RelatedPartyDomain_8fde70af-719d-4f88-baac-f784a1f72831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_23c3ae0e-da23-45a5-b052-c8673c2952fc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8fde70af-719d-4f88-baac-f784a1f72831" xlink:to="loc_srt_AffiliatedEntityMember_23c3ae0e-da23-45a5-b052-c8673c2952fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2113c886-8c8e-4462-afae-24d9570a6bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6d20e8c8-8ae1-40c5-8b0d-02e2623c0479" xlink:to="loc_us-gaap_DebtInstrumentAxis_2113c886-8c8e-4462-afae-24d9570a6bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4e40a424-7054-4b06-99cd-318224c30762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2113c886-8c8e-4462-afae-24d9570a6bf1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4e40a424-7054-4b06-99cd-318224c30762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesMember_f03ecded-31d5-4976-8580-f7009fe7709a" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4e40a424-7054-4b06-99cd-318224c30762" xlink:to="loc_ibrx_RelatedPartyNotesMember_f03ecded-31d5-4976-8580-f7009fe7709a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesPrincipalMember_a43944ba-1999-4bd8-a241-d23277045d20" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyNotesPrincipalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_RelatedPartyNotesMember_f03ecded-31d5-4976-8580-f7009fe7709a" xlink:to="loc_ibrx_RelatedPartyNotesPrincipalMember_a43944ba-1999-4bd8-a241-d23277045d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesInterestMember_7fe89de9-d647-4e51-86cd-8de054376589" xlink:href="ibrx-20230331.xsd#ibrx_RelatedPartyNotesInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_RelatedPartyNotesMember_f03ecded-31d5-4976-8580-f7009fe7709a" xlink:to="loc_ibrx_RelatedPartyNotesInterestMember_7fe89de9-d647-4e51-86cd-8de054376589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_01527796-cbf6-4a86-a41c-b46e3be3ce0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6d20e8c8-8ae1-40c5-8b0d-02e2623c0479" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_01527796-cbf6-4a86-a41c-b46e3be3ce0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_467481fb-c9d3-4335-a0f9-8990543766a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_01527796-cbf6-4a86-a41c-b46e3be3ce0b" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_467481fb-c9d3-4335-a0f9-8990543766a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapital3Member_318b1304-4063-463a-813b-5874cab115c0" xlink:href="ibrx-20230331.xsd#ibrx_NantCapital3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_467481fb-c9d3-4335-a0f9-8990543766a0" xlink:to="loc_ibrx_NantCapital3Member_318b1304-4063-463a-813b-5874cab115c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ff5c6430-f7e3-4c08-97ae-19c8a0fd99d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6d20e8c8-8ae1-40c5-8b0d-02e2623c0479" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ff5c6430-f7e3-4c08-97ae-19c8a0fd99d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4ac9faf0-94bc-4cfd-9504-dd89bc6853e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ff5c6430-f7e3-4c08-97ae-19c8a0fd99d1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4ac9faf0-94bc-4cfd-9504-dd89bc6853e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_a4ef60db-8d84-4284-a514-39d915650722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4ac9faf0-94bc-4cfd-9504-dd89bc6853e9" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_a4ef60db-8d84-4284-a514-39d915650722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PromissoryNotesPayableMember_970665de-b51e-46a2-a6b8-3f7f90a2902e" xlink:href="ibrx-20230331.xsd#ibrx_PromissoryNotesPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4ac9faf0-94bc-4cfd-9504-dd89bc6853e9" xlink:to="loc_ibrx_PromissoryNotesPayableMember_970665de-b51e-46a2-a6b8-3f7f90a2902e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_b4ad1531-d2b4-4b70-9e33-495f382c151d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6d20e8c8-8ae1-40c5-8b0d-02e2623c0479" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_b4ad1531-d2b4-4b70-9e33-495f382c151d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_449554a8-5756-4230-8734-25296b9fbe56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b4ad1531-d2b4-4b70-9e33-495f382c151d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_449554a8-5756-4230-8734-25296b9fbe56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_431778fd-ff6e-460f-ba48-872d6d0cd780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b4ad1531-d2b4-4b70-9e33-495f382c151d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_431778fd-ff6e-460f-ba48-872d6d0cd780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ffaa23a7-98dc-426a-bffb-507d46432f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b4ad1531-d2b4-4b70-9e33-495f382c151d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ffaa23a7-98dc-426a-bffb-507d46432f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_fe364ba5-d40e-4d2e-85eb-3ed51ebe3569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b4ad1531-d2b4-4b70-9e33-495f382c151d" xlink:to="loc_us-gaap_LongTermDebt_fe364ba5-d40e-4d2e-85eb-3ed51ebe3569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_a6c1a3be-0532-4ec2-a705-48f656cd1f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b4ad1531-d2b4-4b70-9e33-495f382c151d" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_a6c1a3be-0532-4ec2-a705-48f656cd1f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofOutstandingBalancesofRelatedPartyAgreementsDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#RelatedPartyAgreementsSummaryofOutstandingBalancesofRelatedPartyAgreementsDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofOutstandingBalancesofRelatedPartyAgreementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6872218e-9a31-46a0-96ad-b808857c09e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b45c27e1-b567-44d1-b958-8a53e6e1f0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6872218e-9a31-46a0-96ad-b808857c09e7" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b45c27e1-b567-44d1-b958-8a53e6e1f0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_87d0e673-36b2-49a2-a386-07c0d2bbb0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b45c27e1-b567-44d1-b958-8a53e6e1f0aa" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_87d0e673-36b2-49a2-a386-07c0d2bbb0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_65783059-0110-4317-999d-5ef06a72ade3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_87d0e673-36b2-49a2-a386-07c0d2bbb0f1" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_65783059-0110-4317-999d-5ef06a72ade3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantBioIncMember_049fabe5-3986-446c-8966-0c145068daf8" xlink:href="ibrx-20230331.xsd#ibrx_NantBioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_65783059-0110-4317-999d-5ef06a72ade3" xlink:to="loc_ibrx_NantBioIncMember_049fabe5-3986-446c-8966-0c145068daf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BrinkBiologicsIncMember_d0681312-59f2-4998-8c01-bdf21770574a" xlink:href="ibrx-20230331.xsd#ibrx_BrinkBiologicsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_65783059-0110-4317-999d-5ef06a72ade3" xlink:to="loc_ibrx_BrinkBiologicsIncMember_d0681312-59f2-4998-8c01-bdf21770574a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DuleyRoadMember_3076799c-2fcd-4c66-bfc8-fbb4851f5a06" xlink:href="ibrx-20230331.xsd#ibrx_DuleyRoadMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_65783059-0110-4317-999d-5ef06a72ade3" xlink:to="loc_ibrx_DuleyRoadMember_3076799c-2fcd-4c66-bfc8-fbb4851f5a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksMember_0fa26894-449a-45f1-91d8-29ef781678a4" xlink:href="ibrx-20230331.xsd#ibrx_NantWorksMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_65783059-0110-4317-999d-5ef06a72ade3" xlink:to="loc_ibrx_NantWorksMember_0fa26894-449a-45f1-91d8-29ef781678a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ImmunoOncologyClinicMember_55e03d51-7852-4b88-aca0-860180c9b407" xlink:href="ibrx-20230331.xsd#ibrx_ImmunoOncologyClinicMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_65783059-0110-4317-999d-5ef06a72ade3" xlink:to="loc_ibrx_ImmunoOncologyClinicMember_55e03d51-7852-4b88-aca0-860180c9b407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_VariousMember_0b7721e1-e53e-4d31-bc95-79a9bae596bc" xlink:href="ibrx-20230331.xsd#ibrx_VariousMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_65783059-0110-4317-999d-5ef06a72ade3" xlink:to="loc_ibrx_VariousMember_0b7721e1-e53e-4d31-bc95-79a9bae596bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_7c86225f-e385-4e40-a83b-509d6ebe3342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b45c27e1-b567-44d1-b958-8a53e6e1f0aa" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_7c86225f-e385-4e40-a83b-509d6ebe3342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_c185f609-7fd7-48c3-8c53-e4aaee1b6a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7c86225f-e385-4e40-a83b-509d6ebe3342" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_c185f609-7fd7-48c3-8c53-e4aaee1b6a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_5bb06b72-f6e1-4883-9c28-df775f0ad9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7c86225f-e385-4e40-a83b-509d6ebe3342" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_5bb06b72-f6e1-4883-9c28-df775f0ad9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#RelatedPartyAgreementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6b8542ad-9328-4b2e-961d-c3ca842717b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9acfc383-0474-4fef-8906-9307857c33ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6b8542ad-9328-4b2e-961d-c3ca842717b8" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9acfc383-0474-4fef-8906-9307857c33ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_d177a4ba-cdb0-4e51-af1d-2ffead5759f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9acfc383-0474-4fef-8906-9307857c33ab" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_d177a4ba-cdb0-4e51-af1d-2ffead5759f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_199b0246-59ea-4401-833d-03b61b7292b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_d177a4ba-cdb0-4e51-af1d-2ffead5759f8" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_199b0246-59ea-4401-833d-03b61b7292b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksMember_69834892-500e-419a-b2d0-c941b146bfec" xlink:href="ibrx-20230331.xsd#ibrx_NantWorksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_199b0246-59ea-4401-833d-03b61b7292b0" xlink:to="loc_ibrx_NantWorksMember_69834892-500e-419a-b2d0-c941b146bfec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ConsiderationForFutureServicesMember_49892b6e-2f8c-4dc9-bdcb-8fee4f3a96e0" xlink:href="ibrx-20230331.xsd#ibrx_ConsiderationForFutureServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_199b0246-59ea-4401-833d-03b61b7292b0" xlink:to="loc_ibrx_ConsiderationForFutureServicesMember_49892b6e-2f8c-4dc9-bdcb-8fee4f3a96e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ImmunoOncologyClinicIncMember_77e6dd2c-9fa3-4918-b014-dd0ab3a748c4" xlink:href="ibrx-20230331.xsd#ibrx_ImmunoOncologyClinicIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_199b0246-59ea-4401-833d-03b61b7292b0" xlink:to="loc_ibrx_ImmunoOncologyClinicIncMember_77e6dd2c-9fa3-4918-b014-dd0ab3a748c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NCSCMember_d16c1825-699d-4866-a2c2-ea1d36d1c72b" xlink:href="ibrx-20230331.xsd#ibrx_NCSCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_199b0246-59ea-4401-833d-03b61b7292b0" xlink:to="loc_ibrx_NCSCMember_d16c1825-699d-4866-a2c2-ea1d36d1c72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantBioIncMember_44ef746b-741a-48ce-84f7-358a4f65c4f0" xlink:href="ibrx-20230331.xsd#ibrx_NantBioIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_199b0246-59ea-4401-833d-03b61b7292b0" xlink:to="loc_ibrx_NantBioIncMember_44ef746b-741a-48ce-84f7-358a4f65c4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SixZeroFiveDougStLLCMember_103404f4-948b-40d7-a156-86b469ef39c2" xlink:href="ibrx-20230331.xsd#ibrx_SixZeroFiveDougStLLCMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_199b0246-59ea-4401-833d-03b61b7292b0" xlink:to="loc_ibrx_SixZeroFiveDougStLLCMember_103404f4-948b-40d7-a156-86b469ef39c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DuleyRoadLLCMember_5507322d-ffa0-4411-9777-ff3d982476de" xlink:href="ibrx-20230331.xsd#ibrx_DuleyRoadLLCMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_199b0246-59ea-4401-833d-03b61b7292b0" xlink:to="loc_ibrx_DuleyRoadLLCMember_5507322d-ffa0-4411-9777-ff3d982476de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SixZeroFiveNashLLCMember_b3923348-0d2c-4ce5-9f21-ecc4bb93b679" xlink:href="ibrx-20230331.xsd#ibrx_SixZeroFiveNashLLCMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_199b0246-59ea-4401-833d-03b61b7292b0" xlink:to="loc_ibrx_SixZeroFiveNashLLCMember_b3923348-0d2c-4ce5-9f21-ecc4bb93b679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_efcd961a-da10-4ef9-b748-21506e94cd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9acfc383-0474-4fef-8906-9307857c33ab" xlink:to="loc_us-gaap_TypeOfArrangementAxis_efcd961a-da10-4ef9-b748-21506e94cd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9ae6a7e3-30dd-47d3-a498-b0cad4b41b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_efcd961a-da10-4ef9-b748-21506e94cd7d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9ae6a7e3-30dd-47d3-a498-b0cad4b41b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SharedServicesAgreementMember_0806fa91-9d93-4cf7-84d2-35d550c39c26" xlink:href="ibrx-20230331.xsd#ibrx_SharedServicesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9ae6a7e3-30dd-47d3-a498-b0cad4b41b52" xlink:to="loc_ibrx_SharedServicesAgreementMember_0806fa91-9d93-4cf7-84d2-35d550c39c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis_49d4d36e-e331-4df0-ba0a-17af68c4d290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9acfc383-0474-4fef-8906-9307857c33ab" xlink:to="loc_us-gaap_TransactionTypeAxis_49d4d36e-e331-4df0-ba0a-17af68c4d290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_d460d90a-e179-47d0-b72b-5b3da14e239b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionTypeAxis_49d4d36e-e331-4df0-ba0a-17af68c4d290" xlink:to="loc_us-gaap_TransactionDomain_d460d90a-e179-47d0-b72b-5b3da14e239b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ReimbursementsMember_dd0bad27-d05f-405d-ad26-afd764df7432" xlink:href="ibrx-20230331.xsd#ibrx_ReimbursementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionDomain_d460d90a-e179-47d0-b72b-5b3da14e239b" xlink:to="loc_ibrx_ReimbursementsMember_dd0bad27-d05f-405d-ad26-afd764df7432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_c746485c-3c7b-46bc-89a0-59e64bd8dec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9acfc383-0474-4fef-8906-9307857c33ab" xlink:to="loc_us-gaap_LeaseContractualTermAxis_c746485c-3c7b-46bc-89a0-59e64bd8dec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_4ccf5145-d54b-4195-81df-22584a748d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_c746485c-3c7b-46bc-89a0-59e64bd8dec8" xlink:to="loc_us-gaap_LeaseContractualTermDomain_4ccf5145-d54b-4195-81df-22584a748d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SeptemberTwentyNineteenLeaseMember_79a48d23-9265-45db-88b7-ce8345e3d3d6" xlink:href="ibrx-20230331.xsd#ibrx_SeptemberTwentyNineteenLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_4ccf5145-d54b-4195-81df-22584a748d46" xlink:to="loc_ibrx_SeptemberTwentyNineteenLeaseMember_79a48d23-9265-45db-88b7-ce8345e3d3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_JulyTwentyNineteenLeaseMember_de01775c-e2af-49fd-8325-8390a8b7cbe1" xlink:href="ibrx-20230331.xsd#ibrx_JulyTwentyNineteenLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_4ccf5145-d54b-4195-81df-22584a748d46" xlink:to="loc_ibrx_JulyTwentyNineteenLeaseMember_de01775c-e2af-49fd-8325-8390a8b7cbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InitialPremisesMember_14230865-d92d-4d74-89b5-85bd74d256d4" xlink:href="ibrx-20230331.xsd#ibrx_InitialPremisesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_4ccf5145-d54b-4195-81df-22584a748d46" xlink:to="loc_ibrx_InitialPremisesMember_14230865-d92d-4d74-89b5-85bd74d256d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ExpansionPremisesMember_2b55aa3c-60e4-464c-954a-54e342ed9d10" xlink:href="ibrx-20230331.xsd#ibrx_ExpansionPremisesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_4ccf5145-d54b-4195-81df-22584a748d46" xlink:to="loc_ibrx_ExpansionPremisesMember_2b55aa3c-60e4-464c-954a-54e342ed9d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InitialAndExpansionPremisesMember_c509bf52-e79c-4eda-9584-8391c8403377" xlink:href="ibrx-20230331.xsd#ibrx_InitialAndExpansionPremisesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_4ccf5145-d54b-4195-81df-22584a748d46" xlink:to="loc_ibrx_InitialAndExpansionPremisesMember_c509bf52-e79c-4eda-9584-8391c8403377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b4a5771e-e000-424d-8e09-5b4ce41f9b67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9acfc383-0474-4fef-8906-9307857c33ab" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b4a5771e-e000-424d-8e09-5b4ce41f9b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3e18fb74-60dd-41cd-9dab-e8fc56223336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b4a5771e-e000-424d-8e09-5b4ce41f9b67" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3e18fb74-60dd-41cd-9dab-e8fc56223336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ac9b9f9b-3cd2-4ac3-893f-b1f0247eaf2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3e18fb74-60dd-41cd-9dab-e8fc56223336" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ac9b9f9b-3cd2-4ac3-893f-b1f0247eaf2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_91dd88c6-65d8-47ac-9a43-31f1da8e3081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9acfc383-0474-4fef-8906-9307857c33ab" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_91dd88c6-65d8-47ac-9a43-31f1da8e3081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2dcdc57d-ea65-4d7f-ad60-d8d55189e6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_91dd88c6-65d8-47ac-9a43-31f1da8e3081" xlink:to="loc_us-gaap_RelatedPartyDomain_2dcdc57d-ea65-4d7f-ad60-d8d55189e6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksMember_25e83c5d-4d80-46b2-afea-a8c5560820ec" xlink:href="ibrx-20230331.xsd#ibrx_NantWorksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2dcdc57d-ea65-4d7f-ad60-d8d55189e6c3" xlink:to="loc_ibrx_NantWorksMember_25e83c5d-4d80-46b2-afea-a8c5560820ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ImmunoOncologyClinicIncMember_abea9a94-df03-4479-a269-91ea59460c73" xlink:href="ibrx-20230331.xsd#ibrx_ImmunoOncologyClinicIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2dcdc57d-ea65-4d7f-ad60-d8d55189e6c3" xlink:to="loc_ibrx_ImmunoOncologyClinicIncMember_abea9a94-df03-4479-a269-91ea59460c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantBioIncMember_9b0fa9b6-2231-4be3-9d0e-71023467ff8b" xlink:href="ibrx-20230331.xsd#ibrx_NantBioIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2dcdc57d-ea65-4d7f-ad60-d8d55189e6c3" xlink:to="loc_ibrx_NantBioIncMember_9b0fa9b6-2231-4be3-9d0e-71023467ff8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FourTwoZeroNashLLCMember_55117cc1-a3da-4be4-a269-f52c7c306515" xlink:href="ibrx-20230331.xsd#ibrx_FourTwoZeroNashLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2dcdc57d-ea65-4d7f-ad60-d8d55189e6c3" xlink:to="loc_ibrx_FourTwoZeroNashLLCMember_55117cc1-a3da-4be4-a269-f52c7c306515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A23AlaskaLLCMember_7ff27edd-040c-4bc6-b144-100a79bd229e" xlink:href="ibrx-20230331.xsd#ibrx_A23AlaskaLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2dcdc57d-ea65-4d7f-ad60-d8d55189e6c3" xlink:to="loc_ibrx_A23AlaskaLLCMember_7ff27edd-040c-4bc6-b144-100a79bd229e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_55b5bf94-e7e3-49fa-bfa1-b1f3bc3c43fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9acfc383-0474-4fef-8906-9307857c33ab" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_55b5bf94-e7e3-49fa-bfa1-b1f3bc3c43fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_173a00fc-81cb-483c-a2db-3eea385d9526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_55b5bf94-e7e3-49fa-bfa1-b1f3bc3c43fd" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_173a00fc-81cb-483c-a2db-3eea385d9526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DueToRelatedPartiesMember_40fa149f-5e66-4da1-9321-2f87153d95f1" xlink:href="ibrx-20230331.xsd#ibrx_DueToRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_173a00fc-81cb-483c-a2db-3eea385d9526" xlink:to="loc_ibrx_DueToRelatedPartiesMember_40fa149f-5e66-4da1-9321-2f87153d95f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9acfc383-0474-4fef-8906-9307857c33ab" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f0010f42-cb4d-4b65-8cad-9dc2eb9454ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f0010f42-cb4d-4b65-8cad-9dc2eb9454ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b87f0cf5-6f84-4355-bd80-c709db388315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b87f0cf5-6f84-4355-bd80-c709db388315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_7a591689-4cba-4e5d-9f18-d56a53bbf027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_7a591689-4cba-4e5d-9f18-d56a53bbf027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_dbe53e15-c334-48f2-9e21-6b1d29bdc1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_dbe53e15-c334-48f2-9e21-6b1d29bdc1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfSquareFootOfFacilityLeased_203b0f29-d9d9-4e22-9e41-7f4ff5b7d79e" xlink:href="ibrx-20230331.xsd#ibrx_NumberOfSquareFootOfFacilityLeased"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_NumberOfSquareFootOfFacilityLeased_203b0f29-d9d9-4e22-9e41-7f4ff5b7d79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AnnualPercentageIncreasesToBaseRent_b1da711a-257d-4c46-813f-2befc6cf0d6a" xlink:href="ibrx-20230331.xsd#ibrx_AnnualPercentageIncreasesToBaseRent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_AnnualPercentageIncreasesToBaseRent_b1da711a-257d-4c46-813f-2befc6cf0d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BaseMonthlyRent_27b12ec8-7df1-48d4-9aaa-e154fa0142ee" xlink:href="ibrx-20230331.xsd#ibrx_BaseMonthlyRent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_BaseMonthlyRent_27b12ec8-7df1-48d4-9aaa-e154fa0142ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased_d31b0273-7cab-4fec-be28-9c4f4bdbcbae" xlink:href="ibrx-20230331.xsd#ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased_d31b0273-7cab-4fec-be28-9c4f4bdbcbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_449785f3-6036-454e-9185-e149525eacfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_us-gaap_OperatingLeaseExpense_449785f3-6036-454e-9185-e149525eacfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_7cf61999-d3e2-4fb1-9e09-fc060c954c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_7cf61999-d3e2-4fb1-9e09-fc060c954c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidExpenseWriteDown_90c8d6d1-5e44-45d1-a5f2-8464ef9448b0" xlink:href="ibrx-20230331.xsd#ibrx_PrepaidExpenseWriteDown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_PrepaidExpenseWriteDown_90c8d6d1-5e44-45d1-a5f2-8464ef9448b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SupplyAgreementTermOfContract_484822a4-858f-4446-8860-35f74f6a5cb5" xlink:href="ibrx-20230331.xsd#ibrx_SupplyAgreementTermOfContract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_SupplyAgreementTermOfContract_484822a4-858f-4446-8860-35f74f6a5cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SupplyAgreementPeriodOfExtendedTerm_74db2bcf-787b-4ccb-a563-d24a18e764fc" xlink:href="ibrx-20230331.xsd#ibrx_SupplyAgreementPeriodOfExtendedTerm"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_SupplyAgreementPeriodOfExtendedTerm_74db2bcf-787b-4ccb-a563-d24a18e764fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2cff49d6-5f74-4d77-8944-ae9bdc7c2a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2cff49d6-5f74-4d77-8944-ae9bdc7c2a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2d3d6c11-b75c-4866-bc24-6c0c06d2ac35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2d3d6c11-b75c-4866-bc24-6c0c06d2ac35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_859fb1a9-00bc-41f8-ace2-e2cc7208872e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_us-gaap_DueFromRelatedParties_859fb1a9-00bc-41f8-ace2-e2cc7208872e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OptionsToExtendNumberOfTerms_143c94e4-2638-4a3d-b4d7-6bcedffc7a3e" xlink:href="ibrx-20230331.xsd#ibrx_OptionsToExtendNumberOfTerms"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_OptionsToExtendNumberOfTerms_143c94e4-2638-4a3d-b4d7-6bcedffc7a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c930b2e3-0519-41cd-bba2-160e9c4b6f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c930b2e3-0519-41cd-bba2-160e9c4b6f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PeriodOfExtendedLeaseTerm_693e7e66-494c-4a13-acc8-ce58d34cb68a" xlink:href="ibrx-20230331.xsd#ibrx_PeriodOfExtendedLeaseTerm"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_PeriodOfExtendedLeaseTerm_693e7e66-494c-4a13-acc8-ce58d34cb68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfLeases_79c8cd25-1359-4b23-9ddd-5b16ffaf1771" xlink:href="ibrx-20230331.xsd#ibrx_NumberOfLeases"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_NumberOfLeases_79c8cd25-1359-4b23-9ddd-5b16ffaf1771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdImprovementPayables_0d5fd741-bed0-4381-8005-67298bb0cd7f" xlink:href="ibrx-20230331.xsd#ibrx_LeaseholdImprovementPayables"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_LeaseholdImprovementPayables_0d5fd741-bed0-4381-8005-67298bb0cd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseRelatedPayables_d3e9a160-456d-4b8e-bbab-c51cf8fe2829" xlink:href="ibrx-20230331.xsd#ibrx_LeaseRelatedPayables"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_LeaseRelatedPayables_d3e9a160-456d-4b8e-bbab-c51cf8fe2829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RentAbatementPeriod_a09a92d4-13ca-4008-b0c7-5546f2ac0f74" xlink:href="ibrx-20230331.xsd#ibrx_RentAbatementPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_RentAbatementPeriod_a09a92d4-13ca-4008-b0c7-5546f2ac0f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveFromLessor_17aa5b26-adf2-4060-b56a-15a4f8a78f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncentiveFromLessor"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_us-gaap_IncentiveFromLessor_17aa5b26-adf2-4060-b56a-15a4f8a78f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BaseMonthlyRentParking_1b6755fb-d0a4-47e0-9c2d-c1a8b41d3c30" xlink:href="ibrx-20230331.xsd#ibrx_BaseMonthlyRentParking"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e9fb96a7-19fa-4b19-965f-a1d08100eab8" xlink:to="loc_ibrx_BaseMonthlyRentParking_1b6755fb-d0a4-47e0-9c2d-c1a8b41d3c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/WarrantLiabilitiesDetails" xlink:type="simple" xlink:href="ibrx-20230331.xsd#WarrantLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/WarrantLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_addf656c-8054-46b1-b007-50bd83e8e3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_7f3712ff-5f2d-4eb3-857d-e97af74d00b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_addf656c-8054-46b1-b007-50bd83e8e3c2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_7f3712ff-5f2d-4eb3-857d-e97af74d00b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_86d55279-de84-48c3-87e3-cb0fd65c6fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_7f3712ff-5f2d-4eb3-857d-e97af74d00b8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_86d55279-de84-48c3-87e3-cb0fd65c6fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9a0ba94c-de55-4888-a583-21ac3372a59c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_86d55279-de84-48c3-87e3-cb0fd65c6fca" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9a0ba94c-de55-4888-a583-21ac3372a59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_880d5047-0f41-44ee-be92-dd6acf82c3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9a0ba94c-de55-4888-a583-21ac3372a59c" xlink:to="loc_us-gaap_PrivatePlacementMember_880d5047-0f41-44ee-be92-dd6acf82c3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4e439d12-e583-446e-a840-9e47666eafb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_7f3712ff-5f2d-4eb3-857d-e97af74d00b8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4e439d12-e583-446e-a840-9e47666eafb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8b232882-595a-4918-988c-eb62758b0434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4e439d12-e583-446e-a840-9e47666eafb8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8b232882-595a-4918-988c-eb62758b0434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_December2022WarrantsMember_d2fb3a2e-ed89-4058-aaf8-554dae256265" xlink:href="ibrx-20230331.xsd#ibrx_December2022WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8b232882-595a-4918-988c-eb62758b0434" xlink:to="loc_ibrx_December2022WarrantsMember_d2fb3a2e-ed89-4058-aaf8-554dae256265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023WarrantsMember_cee526c4-0de6-45cb-844e-cb138adbc6aa" xlink:href="ibrx-20230331.xsd#ibrx_February2023WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8b232882-595a-4918-988c-eb62758b0434" xlink:to="loc_ibrx_February2023WarrantsMember_cee526c4-0de6-45cb-844e-cb138adbc6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_c9fb381b-5467-435c-9918-348ce94cdda1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_7f3712ff-5f2d-4eb3-857d-e97af74d00b8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_c9fb381b-5467-435c-9918-348ce94cdda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6c7521ca-c268-4f2a-9afc-6780c64f4023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c9fb381b-5467-435c-9918-348ce94cdda1" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6c7521ca-c268-4f2a-9afc-6780c64f4023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2c174e51-bf53-4ae5-8003-7e42f39baa89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c9fb381b-5467-435c-9918-348ce94cdda1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2c174e51-bf53-4ae5-8003-7e42f39baa89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_73549ca4-7f0c-4bd0-8ad9-3e566ff20b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c9fb381b-5467-435c-9918-348ce94cdda1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_73549ca4-7f0c-4bd0-8ad9-3e566ff20b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_48c34710-d29c-4c3b-b7d6-25857f7b7252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c9fb381b-5467-435c-9918-348ce94cdda1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_48c34710-d29c-4c3b-b7d6-25857f7b7252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_61c77dbe-4910-457e-87ea-249ed28a759f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c9fb381b-5467-435c-9918-348ce94cdda1" xlink:to="loc_us-gaap_DeferredOfferingCosts_61c77dbe-4910-457e-87ea-249ed28a759f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TransactionCostsWarrantLiability_02452a2d-7726-4a49-8b7b-bf81a4835289" xlink:href="ibrx-20230331.xsd#ibrx_TransactionCostsWarrantLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c9fb381b-5467-435c-9918-348ce94cdda1" xlink:to="loc_ibrx_TransactionCostsWarrantLiability_02452a2d-7726-4a49-8b7b-bf81a4835289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ac4c969f-76ca-43ee-a5a8-b2ab6a42c34d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c9fb381b-5467-435c-9918-348ce94cdda1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ac4c969f-76ca-43ee-a5a8-b2ab6a42c34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_17e4ddb3-d395-43f6-aab6-fe6b5885777d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c9fb381b-5467-435c-9918-348ce94cdda1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_17e4ddb3-d395-43f6-aab6-fe6b5885777d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#StockholdersDeficitAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_417d362a-65b8-4d8d-a623-e9178132f1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_23c0a491-4148-42ed-8d15-aaa1e762e1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_417d362a-65b8-4d8d-a623-e9178132f1d2" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_23c0a491-4148-42ed-8d15-aaa1e762e1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f37f1b61-7571-444b-a96a-1d2e6cf7b66c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_23c0a491-4148-42ed-8d15-aaa1e762e1d7" xlink:to="loc_us-gaap_PlanNameAxis_f37f1b61-7571-444b-a96a-1d2e6cf7b66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_05ce1825-5a4b-4307-ae28-e9080ee2af1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_f37f1b61-7571-444b-a96a-1d2e6cf7b66c" xlink:to="loc_us-gaap_PlanNameDomain_05ce1825-5a4b-4307-ae28-e9080ee2af1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TwoThousandFifteenShareRepurchasePlanMember_7bc021cc-ed86-4497-8ebb-95799828160c" xlink:href="ibrx-20230331.xsd#ibrx_TwoThousandFifteenShareRepurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_05ce1825-5a4b-4307-ae28-e9080ee2af1c" xlink:to="loc_ibrx_TwoThousandFifteenShareRepurchasePlanMember_7bc021cc-ed86-4497-8ebb-95799828160c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d521c586-06a8-4349-9d77-5f74fad123e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_23c0a491-4148-42ed-8d15-aaa1e762e1d7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d521c586-06a8-4349-9d77-5f74fad123e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_035ebc51-eb15-4bdf-9f17-d6881ba21d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d521c586-06a8-4349-9d77-5f74fad123e5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_035ebc51-eb15-4bdf-9f17-d6881ba21d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AtTheMarketOfferingProgramMember_1cfc2457-b4d0-4d98-ab0c-1bcfc1f18886" xlink:href="ibrx-20230331.xsd#ibrx_AtTheMarketOfferingProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_035ebc51-eb15-4bdf-9f17-d6881ba21d50" xlink:to="loc_ibrx_AtTheMarketOfferingProgramMember_1cfc2457-b4d0-4d98-ab0c-1bcfc1f18886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_97c765ce-d38b-4c86-a956-63cf3a514984" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_23c0a491-4148-42ed-8d15-aaa1e762e1d7" xlink:to="loc_srt_RangeAxis_97c765ce-d38b-4c86-a956-63cf3a514984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_14f0d1d4-09d0-4b94-a3fc-a4c1f46a3bc7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_97c765ce-d38b-4c86-a956-63cf3a514984" xlink:to="loc_srt_RangeMember_14f0d1d4-09d0-4b94-a3fc-a4c1f46a3bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_49fb69f5-33f2-49ce-9fbd-3c628b0a1a2c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_14f0d1d4-09d0-4b94-a3fc-a4c1f46a3bc7" xlink:to="loc_srt_MaximumMember_49fb69f5-33f2-49ce-9fbd-3c628b0a1a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_988a345a-9d4e-4eac-b143-a87c64716e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_23c0a491-4148-42ed-8d15-aaa1e762e1d7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_988a345a-9d4e-4eac-b143-a87c64716e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94d9c73d-79a1-4785-bcb2-87b65666c488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_988a345a-9d4e-4eac-b143-a87c64716e50" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94d9c73d-79a1-4785-bcb2-87b65666c488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_ad2b9cb2-58f8-4aee-bb6f-f913d314ad60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94d9c73d-79a1-4785-bcb2-87b65666c488" xlink:to="loc_us-gaap_PrivatePlacementMember_ad2b9cb2-58f8-4aee-bb6f-f913d314ad60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023ShelfRegistrationStatementMember_163745f8-2b5c-40cf-be77-9265c47c55ec" xlink:href="ibrx-20230331.xsd#ibrx_February2023ShelfRegistrationStatementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94d9c73d-79a1-4785-bcb2-87b65666c488" xlink:to="loc_ibrx_February2023ShelfRegistrationStatementMember_163745f8-2b5c-40cf-be77-9265c47c55ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6134f635-2076-448d-9ddf-c3f0e787abe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_23c0a491-4148-42ed-8d15-aaa1e762e1d7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6134f635-2076-448d-9ddf-c3f0e787abe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_b312af17-a31d-43c9-9923-eaf1ce5a9cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6134f635-2076-448d-9ddf-c3f0e787abe4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_b312af17-a31d-43c9-9923-eaf1ce5a9cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023WarrantsMember_fb477cc3-6c0a-4dc4-9fda-09e516372d69" xlink:href="ibrx-20230331.xsd#ibrx_February2023WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b312af17-a31d-43c9-9923-eaf1ce5a9cc2" xlink:to="loc_ibrx_February2023WarrantsMember_fb477cc3-6c0a-4dc4-9fda-09e516372d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_23c0a491-4148-42ed-8d15-aaa1e762e1d7" xlink:to="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_14b92784-379c-4d63-a793-e333f2723ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_14b92784-379c-4d63-a793-e333f2723ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_23f34556-2b35-4d57-9f5c-e193660d4d95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_23f34556-2b35-4d57-9f5c-e193660d4d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleOfStockMaximumAggregateOfferingPrice_7eaae6a3-05d5-43dc-9fdb-11fe21a6aeb6" xlink:href="ibrx-20230331.xsd#ibrx_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_ibrx_SaleOfStockMaximumAggregateOfferingPrice_7eaae6a3-05d5-43dc-9fdb-11fe21a6aeb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3aba0d80-fd83-4fc8-9eeb-4c4d5a8ef51c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3aba0d80-fd83-4fc8-9eeb-4c4d5a8ef51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CommonStockValueAvailableForFutureStockIssuance_6e64cb25-b75a-4508-9e31-a594293bb273" xlink:href="ibrx-20230331.xsd#ibrx_CommonStockValueAvailableForFutureStockIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_ibrx_CommonStockValueAvailableForFutureStockIssuance_6e64cb25-b75a-4508-9e31-a594293bb273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PercentageOfSalesAgentCommission_bafc39c8-d138-411e-8f9d-d3ba3c80917c" xlink:href="ibrx-20230331.xsd#ibrx_PercentageOfSalesAgentCommission"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_ibrx_PercentageOfSalesAgentCommission_bafc39c8-d138-411e-8f9d-d3ba3c80917c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IssuanceOfCommonStockUnderAtMarketOfferingShares_5b4aa0a3-8179-4028-b9e6-2e081162b8a0" xlink:href="ibrx-20230331.xsd#ibrx_IssuanceOfCommonStockUnderAtMarketOfferingShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_ibrx_IssuanceOfCommonStockUnderAtMarketOfferingShares_5b4aa0a3-8179-4028-b9e6-2e081162b8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_641e4589-ea31-4425-ae34-284df23d2151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_641e4589-ea31-4425-ae34-284df23d2151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_c5241ca7-e2fe-4b67-84bc-7db9421e28c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_c5241ca7-e2fe-4b67-84bc-7db9421e28c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5dc4b324-e6da-49ef-b06f-e62d91d3d650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5dc4b324-e6da-49ef-b06f-e62d91d3d650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_ee9f1fa0-c0eb-42c1-be49-6000e1e74a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_ee9f1fa0-c0eb-42c1-be49-6000e1e74a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_3a479a1e-b48b-4ddb-afdd-681e70c327bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_us-gaap_DeferredOfferingCosts_3a479a1e-b48b-4ddb-afdd-681e70c327bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6cae7d50-b068-4a08-b447-3449d221a11b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_6cae7d50-b068-4a08-b447-3449d221a11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_549b1faf-e59b-4a67-bd9e-1d4c96aedf5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_44a08e52-38cc-4b7c-93e3-3ef2939b8fcb" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_549b1faf-e59b-4a67-bd9e-1d4c96aedf5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_923c3867-4f67-4196-99bd-806cdd6dcfd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46eb7e49-f4e6-4d9f-ab4e-ca52e9393989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_923c3867-4f67-4196-99bd-806cdd6dcfd4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46eb7e49-f4e6-4d9f-ab4e-ca52e9393989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_39acd91d-fd7d-43f2-9f3b-f0bb03d997f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46eb7e49-f4e6-4d9f-ab4e-ca52e9393989" xlink:to="loc_us-gaap_PlanNameAxis_39acd91d-fd7d-43f2-9f3b-f0bb03d997f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7953bfc1-5d8f-49cb-aa26-7dc31cd2a237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_39acd91d-fd7d-43f2-9f3b-f0bb03d997f0" xlink:to="loc_us-gaap_PlanNameDomain_7953bfc1-5d8f-49cb-aa26-7dc31cd2a237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TwoThousandFifteenEquityIncentivePlanMember_db43f2fa-3638-485f-a94b-56cf9c0e56cb" xlink:href="ibrx-20230331.xsd#ibrx_TwoThousandFifteenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7953bfc1-5d8f-49cb-aa26-7dc31cd2a237" xlink:to="loc_ibrx_TwoThousandFifteenEquityIncentivePlanMember_db43f2fa-3638-485f-a94b-56cf9c0e56cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b264f34d-c9e9-443d-a589-50b801ca0f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46eb7e49-f4e6-4d9f-ab4e-ca52e9393989" xlink:to="loc_us-gaap_AwardTypeAxis_b264f34d-c9e9-443d-a589-50b801ca0f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72e7294e-5084-45a5-ba9a-8685feddc041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b264f34d-c9e9-443d-a589-50b801ca0f66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72e7294e-5084-45a5-ba9a-8685feddc041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ba9233ce-6fda-4306-ba6f-354fefbd56ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72e7294e-5084-45a5-ba9a-8685feddc041" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ba9233ce-6fda-4306-ba6f-354fefbd56ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f4634881-65ca-4f38-a718-1faddaaefb24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72e7294e-5084-45a5-ba9a-8685feddc041" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f4634881-65ca-4f38-a718-1faddaaefb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_WarrantsMember_6081100c-1c90-452d-8973-39104d4b7f7f" xlink:href="ibrx-20230331.xsd#ibrx_WarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72e7294e-5084-45a5-ba9a-8685feddc041" xlink:to="loc_ibrx_WarrantsMember_6081100c-1c90-452d-8973-39104d4b7f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_59f1191e-eebd-4a23-826f-7653c599f5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46eb7e49-f4e6-4d9f-ab4e-ca52e9393989" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_59f1191e-eebd-4a23-826f-7653c599f5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4466825c-cfef-4a57-b085-4d94ebafe34b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_59f1191e-eebd-4a23-826f-7653c599f5ea" xlink:to="loc_us-gaap_RelatedPartyDomain_4466825c-cfef-4a57-b085-4d94ebafe34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksMember_a1e0e915-035e-4810-803f-e3371d1b9f2c" xlink:href="ibrx-20230331.xsd#ibrx_NantWorksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4466825c-cfef-4a57-b085-4d94ebafe34b" xlink:to="loc_ibrx_NantWorksMember_a1e0e915-035e-4810-803f-e3371d1b9f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a900ac50-fe23-416a-b5cd-e835273603dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46eb7e49-f4e6-4d9f-ab4e-ca52e9393989" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a900ac50-fe23-416a-b5cd-e835273603dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e3047897-90a0-4b53-82a2-1a114dc678bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a900ac50-fe23-416a-b5cd-e835273603dc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e3047897-90a0-4b53-82a2-1a114dc678bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_795b0091-dbb6-4c9d-acf6-84368b1a625a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e3047897-90a0-4b53-82a2-1a114dc678bc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_795b0091-dbb6-4c9d-acf6-84368b1a625a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46eb7e49-f4e6-4d9f-ab4e-ca52e9393989" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3b2bacd3-5497-4541-8aee-9480db7f741b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3b2bacd3-5497-4541-8aee-9480db7f741b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_60169da0-564f-4407-bc41-e16fe84a48bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_60169da0-564f-4407-bc41-e16fe84a48bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4de890e7-5d65-480a-bc4d-28d61b83c697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4de890e7-5d65-480a-bc4d-28d61b83c697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6e011aff-365f-4f91-b38c-440a658a4493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6e011aff-365f-4f91-b38c-440a658a4493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4f5b5411-ad15-4cb4-88b9-052f450e3d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4f5b5411-ad15-4cb4-88b9-052f450e3d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_99c76a59-16d4-4d2c-a03a-ffefdcaec1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_99c76a59-16d4-4d2c-a03a-ffefdcaec1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_66341896-86ea-4a9b-947b-c157b4e7fd1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_66341896-86ea-4a9b-947b-c157b4e7fd1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_44c0561d-a54e-40ca-932e-8a2f02b464e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_44c0561d-a54e-40ca-932e-8a2f02b464e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue_3201fd81-5fb9-42f0-9d5f-845988741631" xlink:href="ibrx-20230331.xsd#ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue_3201fd81-5fb9-42f0-9d5f-845988741631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_2acae66f-4102-48a2-8579-8718cfe81335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_Dividends_2acae66f-4102-48a2-8579-8718cfe81335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_98cb5ba0-1695-4378-8ab8-17f0b0f29353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_98cb5ba0-1695-4378-8ab8-17f0b0f29353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7cdc7591-262e-4a0f-bdd3-23ac0daa9071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7cdc7591-262e-4a0f-bdd3-23ac0daa9071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_635c2c09-4d67-4bcf-a7c1-e170439b3d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d39d13c3-d29c-4b5e-b3c3-0715c407a70f" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_635c2c09-4d67-4bcf-a7c1-e170439b3d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0e52421-d12e-4597-b64c-b5e2aef864ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4fc58b5d-06b0-4b70-9464-4c6c895b9398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0e52421-d12e-4597-b64c-b5e2aef864ed" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4fc58b5d-06b0-4b70-9464-4c6c895b9398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2efcc520-49f8-4ad2-a520-92b7c911f016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4fc58b5d-06b0-4b70-9464-4c6c895b9398" xlink:to="loc_us-gaap_AwardTypeAxis_2efcc520-49f8-4ad2-a520-92b7c911f016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53c0c2ae-4683-4b05-81fa-bea33d3c8d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2efcc520-49f8-4ad2-a520-92b7c911f016" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53c0c2ae-4683-4b05-81fa-bea33d3c8d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_b601b4d5-c495-4d2e-abc9-e761e14a3073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53c0c2ae-4683-4b05-81fa-bea33d3c8d13" xlink:to="loc_us-gaap_StockOptionMember_b601b4d5-c495-4d2e-abc9-e761e14a3073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e7e77ba2-5d80-4cd9-a3e4-d57b6f1556dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53c0c2ae-4683-4b05-81fa-bea33d3c8d13" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e7e77ba2-5d80-4cd9-a3e4-d57b6f1556dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fdc6220d-c252-4dd6-930c-8ec8a7637bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4fc58b5d-06b0-4b70-9464-4c6c895b9398" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fdc6220d-c252-4dd6-930c-8ec8a7637bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6d540dad-7d41-4d6e-9300-6ca2f47537db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fdc6220d-c252-4dd6-930c-8ec8a7637bcf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6d540dad-7d41-4d6e-9300-6ca2f47537db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8e1fd962-be10-4927-92bd-8335dda760cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6d540dad-7d41-4d6e-9300-6ca2f47537db" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8e1fd962-be10-4927-92bd-8335dda760cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5cccaa95-9ff8-4950-9a49-79ba7e3ca5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6d540dad-7d41-4d6e-9300-6ca2f47537db" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5cccaa95-9ff8-4950-9a49-79ba7e3ca5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5afaf065-44c0-4b74-9d51-2421a2b68e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4fc58b5d-06b0-4b70-9464-4c6c895b9398" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5afaf065-44c0-4b74-9d51-2421a2b68e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_be9249d9-bf72-4fbf-877b-85e295d8bad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5afaf065-44c0-4b74-9d51-2421a2b68e34" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_be9249d9-bf72-4fbf-877b-85e295d8bad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#StockBasedCompensationStockOptionActivityDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d3d37c2e-3e9a-4383-a1ce-221631da1cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ca270089-c4f5-486f-9f32-004ee2999c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d3d37c2e-3e9a-4383-a1ce-221631da1cb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ca270089-c4f5-486f-9f32-004ee2999c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_abf7316d-ec15-48ad-86cb-9927c9f674b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ca270089-c4f5-486f-9f32-004ee2999c33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_abf7316d-ec15-48ad-86cb-9927c9f674b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0d4a7e15-ef53-437d-b138-1fcf0714cd49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ca270089-c4f5-486f-9f32-004ee2999c33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0d4a7e15-ef53-437d-b138-1fcf0714cd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1cff87e8-7ce4-48e6-820c-506eb096f6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ca270089-c4f5-486f-9f32-004ee2999c33" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1cff87e8-7ce4-48e6-820c-506eb096f6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_d2f3b2c5-d259-429b-b7ab-1b50d7ac7862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ca270089-c4f5-486f-9f32-004ee2999c33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_d2f3b2c5-d259-429b-b7ab-1b50d7ac7862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_26e4a36f-92ee-429a-aa2d-8819767b9031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ca270089-c4f5-486f-9f32-004ee2999c33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_26e4a36f-92ee-429a-aa2d-8819767b9031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_48c5317c-d87f-4ae1-8a8e-cfdd1a7ba04c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ca270089-c4f5-486f-9f32-004ee2999c33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_48c5317c-d87f-4ae1-8a8e-cfdd1a7ba04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_18595ba3-edc1-4d21-b3c6-cc5dd19b9fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d3d37c2e-3e9a-4383-a1ce-221631da1cb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_18595ba3-edc1-4d21-b3c6-cc5dd19b9fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cd3a6480-3928-4f74-87ad-20a99f23d789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_18595ba3-edc1-4d21-b3c6-cc5dd19b9fca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cd3a6480-3928-4f74-87ad-20a99f23d789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6ee91b54-0509-41b7-aabc-d102556ac085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_18595ba3-edc1-4d21-b3c6-cc5dd19b9fca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6ee91b54-0509-41b7-aabc-d102556ac085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_01d0ef9b-194f-4bbd-b48d-4d607ffb750e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_18595ba3-edc1-4d21-b3c6-cc5dd19b9fca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_01d0ef9b-194f-4bbd-b48d-4d607ffb750e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_cb22ad1d-b672-4d24-8ea9-85254ce34d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_18595ba3-edc1-4d21-b3c6-cc5dd19b9fca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_cb22ad1d-b672-4d24-8ea9-85254ce34d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2e444b88-2bc0-46d7-9528-51afb8326fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_18595ba3-edc1-4d21-b3c6-cc5dd19b9fca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2e444b88-2bc0-46d7-9528-51afb8326fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_9d332680-bced-4870-b8ef-c2e72cf6ac42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_18595ba3-edc1-4d21-b3c6-cc5dd19b9fca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_9d332680-bced-4870-b8ef-c2e72cf6ac42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_8b2688ef-6f8c-4ee7-a982-5486a84cf4af" xlink:href="ibrx-20230331.xsd#ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d3d37c2e-3e9a-4383-a1ce-221631da1cb5" xlink:to="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_8b2688ef-6f8c-4ee7-a982-5486a84cf4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a4cd1960-19e9-4139-9cc4-c3c0ae4a0058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_8b2688ef-6f8c-4ee7-a982-5486a84cf4af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a4cd1960-19e9-4139-9cc4-c3c0ae4a0058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5ae154c8-cb98-4058-bc43-d47d3444e184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_8b2688ef-6f8c-4ee7-a982-5486a84cf4af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5ae154c8-cb98-4058-bc43-d47d3444e184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_e8cf82ad-da5c-4e73-8fbd-3447b94fca58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_8b2688ef-6f8c-4ee7-a982-5486a84cf4af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_e8cf82ad-da5c-4e73-8fbd-3447b94fca58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e03977cf-48a0-48da-b9e7-216ccbabf773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d3d37c2e-3e9a-4383-a1ce-221631da1cb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e03977cf-48a0-48da-b9e7-216ccbabf773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bbb08013-c82f-4bf6-b210-8424776bd13c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e03977cf-48a0-48da-b9e7-216ccbabf773" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bbb08013-c82f-4bf6-b210-8424776bd13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_712d9d0c-cbb9-46d8-8bc7-580f883c6407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e03977cf-48a0-48da-b9e7-216ccbabf773" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_712d9d0c-cbb9-46d8-8bc7-580f883c6407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockBasedCompensationRSUsActivityDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#StockBasedCompensationRSUsActivityDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/StockBasedCompensationRSUsActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c48e21ee-0ffc-46f7-9949-2eecfd1eff72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82165b7a-5835-4ca8-afa4-d604f6779f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c48e21ee-0ffc-46f7-9949-2eecfd1eff72" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82165b7a-5835-4ca8-afa4-d604f6779f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2fbd70c2-411c-406a-818c-655e101724ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82165b7a-5835-4ca8-afa4-d604f6779f29" xlink:to="loc_us-gaap_AwardTypeAxis_2fbd70c2-411c-406a-818c-655e101724ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf0d184b-6176-4533-89a2-1779575f587d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2fbd70c2-411c-406a-818c-655e101724ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf0d184b-6176-4533-89a2-1779575f587d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fff41a9a-ab31-4496-ba41-eece4768c293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf0d184b-6176-4533-89a2-1779575f587d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fff41a9a-ab31-4496-ba41-eece4768c293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_15c14c09-8ba4-492d-89ce-37ed437127b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82165b7a-5835-4ca8-afa4-d604f6779f29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_15c14c09-8ba4-492d-89ce-37ed437127b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa1eb2e-9e9d-4231-8ee1-d1c2d6a474cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_15c14c09-8ba4-492d-89ce-37ed437127b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa1eb2e-9e9d-4231-8ee1-d1c2d6a474cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e09450a8-c29f-4b86-b4e3-26ef232c0d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa1eb2e-9e9d-4231-8ee1-d1c2d6a474cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e09450a8-c29f-4b86-b4e3-26ef232c0d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a3b984e3-0d29-4141-92b3-3f801783c5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa1eb2e-9e9d-4231-8ee1-d1c2d6a474cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a3b984e3-0d29-4141-92b3-3f801783c5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_32a5a184-388a-4123-b0be-712e038ca451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa1eb2e-9e9d-4231-8ee1-d1c2d6a474cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_32a5a184-388a-4123-b0be-712e038ca451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_80f6436a-9313-4a09-855d-eb3e16b3ea13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa1eb2e-9e9d-4231-8ee1-d1c2d6a474cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_80f6436a-9313-4a09-855d-eb3e16b3ea13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00ca48be-ded5-4e1e-aa4a-529e117eacfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9fa1eb2e-9e9d-4231-8ee1-d1c2d6a474cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00ca48be-ded5-4e1e-aa4a-529e117eacfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_99592027-8933-4c17-8e15-c2fac914e127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_15c14c09-8ba4-492d-89ce-37ed437127b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_99592027-8933-4c17-8e15-c2fac914e127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d93a22f7-6a1b-4246-a775-f7329ae2c11a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_99592027-8933-4c17-8e15-c2fac914e127" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d93a22f7-6a1b-4246-a775-f7329ae2c11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0d316ab6-915e-4a91-b0ff-30755a267207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_99592027-8933-4c17-8e15-c2fac914e127" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0d316ab6-915e-4a91-b0ff-30755a267207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9c1e547b-d4de-457d-8bf6-ffdf38712344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_99592027-8933-4c17-8e15-c2fac914e127" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9c1e547b-d4de-457d-8bf6-ffdf38712344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_89c3b6da-6679-40f6-93c5-fa7f78b36fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_99592027-8933-4c17-8e15-c2fac914e127" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_89c3b6da-6679-40f6-93c5-fa7f78b36fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e50b4adf-61a8-48ef-a76d-f735f25cb243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_99592027-8933-4c17-8e15-c2fac914e127" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e50b4adf-61a8-48ef-a76d-f735f25cb243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20230331.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7a446ab4-b480-4797-92ac-6cadfd6f57db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncomeTaxTable_c477d6e7-b334-4faa-aa16-23742a827cac" xlink:href="ibrx-20230331.xsd#ibrx_IncomeTaxTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7a446ab4-b480-4797-92ac-6cadfd6f57db" xlink:to="loc_ibrx_IncomeTaxTable_c477d6e7-b334-4faa-aa16-23742a827cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6d71566a-a027-4175-bb83-e9e93bdfdbd3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_IncomeTaxTable_c477d6e7-b334-4faa-aa16-23742a827cac" xlink:to="loc_srt_StatementGeographicalAxis_6d71566a-a027-4175-bb83-e9e93bdfdbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f63da9fa-2181-46c5-b4f4-1472176afeaf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6d71566a-a027-4175-bb83-e9e93bdfdbd3" xlink:to="loc_srt_SegmentGeographicalDomain_f63da9fa-2181-46c5-b4f4-1472176afeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3ee15eb9-2ee6-4ddb-b80d-9128522be20c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f63da9fa-2181-46c5-b4f4-1472176afeaf" xlink:to="loc_country_US_3ee15eb9-2ee6-4ddb-b80d-9128522be20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT_5eacf136-f2e5-49fc-936e-3c2ef823e265" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f63da9fa-2181-46c5-b4f4-1472176afeaf" xlink:to="loc_country_IT_5eacf136-f2e5-49fc-936e-3c2ef823e265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_KR_a1834be9-d8bf-4d2c-9b57-72d5d9eeda7d" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f63da9fa-2181-46c5-b4f4-1472176afeaf" xlink:to="loc_country_KR_a1834be9-d8bf-4d2c-9b57-72d5d9eeda7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncomeTaxLineItems_695e477c-b809-4307-8c86-156fcbfeb932" xlink:href="ibrx-20230331.xsd#ibrx_IncomeTaxLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_IncomeTaxTable_c477d6e7-b334-4faa-aa16-23742a827cac" xlink:to="loc_ibrx_IncomeTaxLineItems_695e477c-b809-4307-8c86-156fcbfeb932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_71262ff4-7186-4104-a637-268d8dce372c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_IncomeTaxLineItems_695e477c-b809-4307-8c86-156fcbfeb932" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_71262ff4-7186-4104-a637-268d8dce372c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ibrx-20230331_g1.jpg
<TEXT>
begin 644 ibrx-20230331_g1.jpg
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M ?_$ 00  0 " P$! 0$!           ("08'"@4$ P(! 0$  @,! 0$
M        !08#! <" 0@0  $# P,! P(-" X6!0@ %P ! @,$!081!P@2(1,)
M,11!42+4%;75EA=7&#A883(6=J9WIQEQ@4(CI+1UE:56AK8W.9&AL5)BLM(S
M<[/3XW245<7E-F:'2&AR4R0T-?""DJ)#8Y.$)4G!T<2%@Z/#)L)49$9G*"=X
M1+?A1=81 0 ! @,"!@T("@(#  $"!P ! @,1! 4A,4%1H=$2!F%Q@9&QX5*B
M$U,4%1;!(C)RDK+2-/!"8H+B,V-D-1?"<_$C!T,D@T235#8ELR;_V@ , P$
M A$#$0 _ +_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MZE5=$5VB:J<^S5J+5VNB-U-4QWIP66U5TZ(JGAB&1&![
M
M
M
M
M
M
M
M
M
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M+HJ%;N4315-,[XG#O)6FJ*HB8X7W'A]
M
M
M
M
M
M
M
M
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M24E2Z-55BR00LC<K55$54U;V=AS3,5Q<N551NF9GORM=NGHTQ$\$/<,+V
M
M
M
M
M
M
M
M
M
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M?M:M/Z3B.!:A^9N?7J\,NC9?^53VH\#.#49@
M
M
M
M                                                   \EE\M;[@M
MJ;5(M<CE:L/2[35J:JG5IT^3ZH'K    #STNE"ZX/M23:US&];H>EWUNB+KU
M::>1?3 45TH;B^JCHYN]?1OZ*A.ES>EVJIIJY$U\B^0#T /"K,ELE!,Z"IKV
MI,Q='QL:Z3I7TEZ$5$7Z@'HT5PHKC%WU%4,J(T71RM\J+Z2HNBI^6!\5?D%H
MMDO<UE:V.;L58FM<]R:^FC473\L#[J*OH[C#W]%4,J(M>E7-]!?25%[4_+ ^
M*OO]HMDG=5E:V.;358FHY[D_)1J+I^6!^]ONUNNC7.H*IE1T?7L35KD^JK7(
MB_R@/SN%\M=J<UE=5MAD<FK8D1SW:>GTM153\L#]J"Z6^YL<^AJFU",TZT35
M'-U\FK7(BI_( ^\
M
M
M
M
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M5(R-NLE;;OKZFET3M<YJ)WD:=O:CFIVO,W5+6?8LQZ*N?_7<V3V*N"?DGO\
M \:SD?:+72I^E3RQPPHP.Q*.Z;-LOX-MO?M:M/Z3B/SYJ'YFY]>KPRZ5E_Y5
M/:CP*/-T^0N^%MW.W%MMOW3R.AM]NR>[TM#105LD<4,,-9+''&QC51$:UK41
M$0Z_INAY&O*VJJK-,S-%,S.'#,0I6:U#,4WJXBN<(JGPKU\-J:BMQ#%:RKF?
M45579Z&:IJ)%ZGODDIV.<YRKY555U4XYFJ8IO5Q&Z*I\*[VIQHB9XH9(8&0
M
M
M
M
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M17::?D*!LP
M
M
M
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M&QB=+6,:W1$1$31$0T)F:IQG>V(C!^I\?0
M
M
M
M                                             & YQ5R21T%EIO53
MU\J.<Q/11%Z6(OY+E_E ?*^UY?);?8ET5%YFD21(W5-=&Z:+KZ>J:Z@?KA]<
M];=<K14>IGMZ2*QB^5&NU1R?^:[7^2!]& =U[%573IWWG2][Z>G0WIU^IY=
M/Q@<U<^J/-].GN%2J5ODU2-NOD^KH P!C4I[I+IZMT[6JOU&HJI_- _N+_7^
MJ_P9/[6P#_<+_P"]Y'_A3?Z:0#/0->76]5U]JGV3'T7NOK:RO\B=/D71?0;]
M7RKZ'U0R2VV&GM-LGHZ;U<U1&Y)ZA>Q7O5JHGY")KV(!XF RM6UU5.O9+#5.
M5[%\J(YK=.S\E% _%ZI4Y_#W?JDHJ=4E5/07NW?_ %7H!^]]R&JDJEL=A8LU
M>]59/4-_]GZ:-7R:IZ*KY/R?('K8]CT5EA<][^_KZA/^TU'\OI;KZ&O\D#]8
MZVT9#Y[;5:LZ4CVI4PR(K=51RZ*G:BKHK0,/K:2*P91:6VESH65[F-J:-'*J
M=+G]*^5?(J=J:^14 V<
M
M
M
M
M
M
M
M
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MKV*FFOE7R@?I:L7;1UJW.OK7W.O_ #$KTT1O9IKHJJJKZ7\P#+
M
M
M
M
M
M
M
M
M
M                              _ES4>US')JUR*CD^HH'R4%NHK7"ZGH
M8>XA<]9',ZG.]4J(BKJY57R(@'V@
M
M
M
M                                          %;GBH;DY_M9Q?BR3;?
M,+KA&03YC::&2]V:I?257FTL-6]\231JCD:YT;==%[=-/(!7!X6'(K?C=#E"
M_&=QMW\MS?'DP^[UB62]7:JK*;SB*6E2.7NI7N;U-1RZ+IZ('2$
M   'X5-1#1TU15U#^[IZ6-\T\FBKTL8BN<NB(JKHB>@!0INQXO=TS#<S#=O>
M../I9\6N.3VN@NVX>04[9*ZNIY:V..9E%0/ZHZ>.1BJG7-U2*UW8R)R:@7Y
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MX=;.9?G.1W#+<IO$=\6ZY!=:A]565"P7ZXP1=[-(JN=T11M8FJ]B(B 32
M
M
M
M
M
M
M
M
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MD:Q_J55]0^&)-?1>!<X
M
M
M
M
M
M
M
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MJWJQR>G GY87:@
M
M
M
M
M
M
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M*-M.:K\CRO'LHM%ZQO$KC0Q6BJN%9;JR*JAI605[:>9SI'1(W1C5=Z2 =&8
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MY\$CVHLU+.C57HE@?K'(U>UKD5 *!?&KW:QC)L_VCVHL5QAN-YVXHKM<LP;
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M'8]L?M?;-E=H=NMJK1T/I,&L5);):EB=*5%3&Q'552J:)VSSN?*O9Y7*!M0
M
M
M
M
M
M
M
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MA/[*?"GRGM&67&C\XQK9JADRBM>]J+$ZY*OF]KB5?0>DSUJ&_P!A4#K%
M
M
M
M
M
M
M
M
M                                   YHO&T_A[VG^T!/;2M G#X*WS5
M\[^^G=?:6R 6^
M                         *X^?_-K,.&Z[45&.X!:\VM^X/LW'<);A53T
MRTTML2A6)K%A:Y/SQ*IRKJGYGLT YJ^3O)O<3E;N.NX>X#:.ADI*-EKQW'+8
MV1M%;Z&.1\C8HTD>]SGN?(YSWN75RKZ#4:UH=(?A;<;+ML%Q]??,QM$EFW!W
M<K67V]VZIC6*JH[="Q8K91SL<B.:]K'23*UW:U9E8Y$<U4 LM
M
M
M
M
M
M
M
M
M                            U%N'L%LGNU<Z*];G;5XQGMVMM+YE;[C?
M+;!6S0T_6Z3NF/E:Y6MZWN=HGHJ!D>WVV.W>T]EJ<<VSPJS8)8:RM?<:JT62
MDBHJ>2KDCCB?.Z.)K45[F0L:J^71J)Z &=
M                                              -/;P; [/;^VRUV
M?=_!:+-[?9)99[1%5R3PNII)VM9(Z*2FEB>U7(U$71WH :UV[X/<3MJKM17[
M"=CL>H;U;7I+;;K7I47:HIY475LD,ESFJG,>U4['-5')Z"@2K
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MT::Z9GBB8EGYI,X
M
M
M
M
M       %+'B-_P -V+?:/0^V5S.L=1/R-?\ V3]VE3>L/YBGZL>&4 B[($
M
M
M
M
M                                                         "5/
M";YSFV?_ -N?:6N*WUM_Q=W]W[]*4T7\W1W?NRO[.*KX
M
M
M
M
M                                    !2QXC?\ #=BWVCT/ME<SK'43
M\C7_ -D_=I4WK#^8I^K'AE (NR!
M
M
M
M
M                           E3PF^<YMG_P#;GVEKBM];?\7=_=^_2E-%
M_-T=W[LK^SBJ^
M
M
M
M
M      4L>(W_  W8M]H]#[97,ZQU$_(U_P#9/W:5-ZP_F*?JQX90"+L@0
M           #WJ7%<GKH'55%CETK*9K>IU1!1SR,1OIJYK%30P59FU3.$U1$
M]N&2+5<QC$3WGB2120R/BFC=%*Q='QO16N1?25%[4,T3$[8>,,'\'U\
M                                      />I,5R>X4_G=!CETK:56]7
MG-/1S21]*^CU-8J:&"K,VJ9PJJB)[<,D6JYC&(GO/%FAFIY9()XGP31.5LL,
MC5:YKD\J*U=%13-$Q,8P\3&#\SZ^
M                                 #]Z6DJJV9M/1TTM74/^L@A8Z1Z_
MD-:BJIYJJBF,9G"'V(F=D/KN-FO%G>V*[VJLM<C^UL=9!) Y?R$D:U3S;NT7
M/HS$]J<7VJBJG?&#S3(\@
M    #Z:2BK+A.REH*2:MJI->[IJ>-TDCM/+HUJ*JGFJNFB,:IPA]BF9G"'VW
M*PWVS='LQ9:^U=XNC//*:6#J7RZ)WC6ZGBW>MW/HU1/:G%ZJMU4[XF'DF5X
M/Z8Q\CVQQM5\CU1K&-3555>Q$1$\JJ?)G >]-B654],M;/C-U@HT17+5R44[
M8M$[57K5B)HGY)AC,VIG"*Z<>W#)-JN(QPGO,?,[&
M                       ]]N*90^D2X,QNZNH'-ZFUJ4<ZPJW377O.CITT
M^J8/:;6/1Z=./%C#)Z*O#'"<.T\ SL8
M                                       $J>$WSG-L_P#[<^TM<5OK
M;_B[O[OWZ4IHOYNCN_=E?V<57P
M
M
M
M
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M[F:YRU^>E.&--4[]F^)X^.)W[^PKNM:;1:B+MN,(QPF.#MJTB_JV
M9UM=66^W;F;=7"[3PTMJH<GM%1<ZFH5$ACIXJV)\KY%=V(UK455U] TM1HJK
MRMVFF,9FBJ(PX\)P9\K,1=HF=W2CPKA>36]VS63;$[C6+'-QL=O%[N-!%';[
M91UL,D\STJH7*C&-755Z453EW5_2,[9S]JNY:JBF)VS,3ANE;M2SMBO+UTTU
MQ,S''V5(!UY2@      %_.8[];%5.V&56F@W.Q>6NJ,7KJ2BH(:Z#K=*^B?&
MR)C47RJY41$0XKE=%S\9JBJJU7ATXF9PGC7R]GLO-FJ(KIQZ,\/84#':E#
M       'N8O8JC*<FQW&:21L55D=SI+732O^M;)63,A8J_417F',7HLVJKD[
MJ8F>]&+):HFY7%,<,Q'?="]IQO:SC#M?<[C;[2VU8_C-"R>_W6GITEN->^/1
MB23O:B.ED>]VB:JC6ZZ)TM3LX?<OYK6<U%-56-54[(Q^;3VN*([_ &Y7^FW9
MR-F9B,(B-O'+'=JM[=J.4EDRNRT=@J*NBM2Q1WW&\CHX'))!4=?<RHUDD\;D
M58W?FNIJI^0JY]2TC-Z+717-41,[JJ9G?&^.">=CRN=LY^FJF(V1OB8_\J<^
M46U%NV<WAOV*V-9$QZKBANU@BE57.BIJM%7N>I557)%(U[&JO:J(FO;J=3ZN
MZE5G\G3<K^E&,3VXX>[&$JAJ>5C+7YHIW;X[J/1.(\ N2\."&)=J<WD6)BR.
MRQ[7/5J:JC:&E5$U])-5.5=?)GVNW]3_ )2N'5V/_35];Y(2XS/>S:';V\-Q
M_-<UMF.WE].RJ;;ZKK1ZPR*YK'^I8Y-%5J^CZ!6<II.<S5'3LVYJIQPQCC2M
M[.V+-71KJB)?5C>8[0[M4U;!C=YQO.H8&?\ T1H(UIZM\;']B+- ]%<UKO(B
MN;HIYOY7.9&8FY371Q3MCO2]6[UC,1/1F*E:7-WC%C.!6VDW5VZMC++9JBL9
M0Y5CE,B-I:>29%[BJIV?^S:YR=#V)ZE%5JM1/5%_ZH]8;N:JG+7YZ56&--4[
MYPWQ/'QQ/;5O6M-HM1Z6W&$<,?*K8+\K@                 70[2<,]L,)
MP*;+LHIVY_E=QL$E;%+<8F^84:STJR(V"D57-<YO5IUR*Y=4U:C#D^I]:\UF
M,QZ*W/HZ(JPV?2G">&?DCNXKCE-'LVK?3J^=5,<.Z-G$I>.L*<OYS'?K8JIV
MPRJTT&YV+RUU1B]=245!#70=;I7T3XV1,:B^57*B(B'%<KHN?C-4556J\.G$
MS.$\:^7L]EYLU1%=./1GA["@8[4H8             #H.XH;:XU@.RV"5MJM
M=/#>\NLE%>\@O'=IYS4RU\+:EK))%3JZ8FR(QK==$TUTU557B'674+N:SMR*
MIGHT533$<$=&<.7>OVE9:BU8IF(VS$3,]O:C!R+YE;49?MCN3M[B;[K59%<&
M):Z*JJ*-K*.9J54;:B2.3O'.1.Z1ZM5S$55T+%H757-V,U:OW>C%,;9V[8V;
M.7!&:AK%FY9KMT8XSLW;-ZI Z:JC9^SNU60;S9[9\%Q]4@DK56>Z7-[>J.BH
M8E3OZEZ:IKTHJ(UNJ=3E:W5-2.U34K>GY>J]7P;HXYX(_3@VMK*96K,W(HI_
M\1QKW]NME]H./^,OJK7;K?;%M=-WM^SJ[+%YW(C&_GDLU7)HD3/*O2SI8GH(
M<;S^K9S5+N%4S.,[*(W=J(X?"O&7R=C*48Q$1AOF=_??Q8N3VP>27Z+&K/N=
M::B[U$B14T,O?4\4LCNQK(ZB>..%[G+V(C7JJKV)VB]U>U"S;])7:JZ/<GDB
M<>0HU/+5U=&*XQ_3N,!Y$\4,(W@L-SN=AM%'CFY-/$^:TWVE8VG963-35(*]
MK$1)&R:=*2*G6SL5%5J*UV[H766_D+D4UU35:X8G;AV:>+#BW3RM?4-*MYBF
M9IB(KX)X^VH:K*2IM]754%; ^EK**9]/5TTB:/CEC<K7L<GH*U45%.S4U15$
M51MB5&F)B<)?.>GP                             Z67001[1*QD+&,9
MB&C&M:B(B)0=B(B>30X!TIG-_O\ _)T?#_T?N_(YICO[G !?OPGAA3C+MLY(
MF=4BWATCNE-7+[,5J:JOH]B(AQ7K;,^\[O[OW*5\T6/_ -)1W?#*H?E.B)R%
MW71$T1+V_1$_L<9T_JY_CK/U52U3\S7VV@";:   L0\//;7&LOS'-LOR*UT]
MWEP:FM[+'3U<:2Q155P?4+YPC'(K5?&VF5&JJ=G5JG;HJ47KQG[MBS;M6YF.
MG,XX<5.&SM3BL'5_+47*ZJZHQZ.&'=QYEB6\7)?;+8Z[66QYI)<Y+E?*9U9!
M3VVE2H[JG:]8TDE5TD:(CG-<B(W5>Q>PHVE=7\UJ5%5=K#"F<-LX;>PL.<U*
MUE:HIKQQGB43[QYE2;@[IY[F=O:YMMR"]553:D>SNW^:(]64ZO9Z#EB:U53T
MSL>E96<KE;=JK?33$3V^'E4?.7HO7JJXW3/(UJ2#6    !ZEBM;[Y>[/9(YF
MT\EXKJ>ACG<BJUCJB1L:.5$\J)U:F*]<]'157Q1,]Y[HIZ544\<K><LXC[6[
M-<?MT+FVB3+\TAQNJD=EETC:YT,K6HJ.HJ?U3*?14['(KI/3>J=AS#+=9\UJ
M&H6:<>A;Z<?-CA^M/#X.PMEW2;.6RU<X=*K#?/R<7A56;75EOMVYFW5PNT\-
M+:J')[147.IJ%1(8Z>*MB?*^17=B-:U%5=?0.CZC157E;M-,8S-%41AQX3@J
M^5F(NT3.[I1X5PO)K>[9K)MB=QK%CFXV.WB]W&@BCM]LHZV&2>9Z54+E1C&K
MJJ]**IR[J_I&=LY^U7<M513$[9F)PW2MVI9VQ7EZZ::XF9CC[*D Z\I0
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MJZJO2BJ<NZOZ1G;.?M5W+544Q.V9B<-TK=J6=L5Y>NFFN)F8X^RI .O*4
M                                 2IX3?.<VS_^W/M+7%;ZV_XN[^[]
M^E*:+^;H[OW97]G%5\
M
M
M
M
M           I8\1O^&[%OM'H?;*YG6.HGY&O_LG[M*F]8?S%/U8\,H!%V0(
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MPF^<YMG_ /;GVEKBM];?\7=_=^_2E-%_-T=W[LK^SBJ^
M
M
M
M
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M-K7L5?\ I%@ZBW8JR5=/#%<\L1XT;UAHF+\3QT_+* !=D"W'2<?=YKAAEJW
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M8]L_R+S[<UQQ3K;_ )2[^[]RE?-%_*4=W[TJSL_^?2W[YUD_3E(= R7^"_\
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M5_9Q5?
M
M
M
M                                                           *
M6/$;_ANQ;[1Z'VRN9UCJ)^1K_P"R?NTJ;UA_,4_5CPR@$79 @
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MDB7H75$>UKM6Z=2HO8:V5UG2<]9CVZFF+O#/1GYW9B:(Q[G'N9;V1SN7N?\
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M633I7T>AWI$OU!LU].[<_5PB.W._DCPM+K'73T:*>';/<_3P*FSI:J@
M       2IX3?.<VS_P#MS[2UQ6^MO^+N_N_?I2FB_FZ.[]V5_9Q5?
M
M
M
M
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MV_XN[^[]^E*:+^;H[OW97]G%5\
M
M
M
M
M                   I8\1O^&[%OM'H?;*YG6.HGY&O_LG[M*F]8?S%/U8\
M,H!%V0(
M                     ,PV\R:#"L^PC,:FE?74^*7ZW7B>BB<C7S,H:F.=
MT;7.[$5R,T15-3/9><QE[EJ)PFJF:<>W&#-E[GHKE-<\$Q/>E/'?'G'C&[.U
M>6;>T&"72T5>1QTK(;C454,D<7F]7#4JKFL:BKJD2IV>F4W1^J%W(YJB_5<B
M8IQV83PQ,?*G,[K=&8LU6XIF,>?%6\7U70
M
M
M
M               2IX3?.<VS_P#MS[2UQ6^MO^+N_N_?I2FB_FZ.[]V5_9Q5
M?
M
M
M
M                                                      *6/$;_
M (;L6^T>A]LKF=8ZB?D:_P#LG[M*F]8?S%/U8\,H!%V0(
M
M
M
M
M                                            $J>$WSG-L_\ [<^T
MM<5OK;_B[O[OWZ4IHOYNCN_=E?V<57P
M
M
M
M
M                       "ECQ&_P"&[%OM'H?;*YG6.HGY&O\ [)^[2IO6
M'\Q3]6/#* 1=D"
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M1(
M                                             $J>$WSG-L__ +<^
MTM<5OK;_ (N[^[]^E*:+^;H[OW97]G%5\
M
M
M
M
M                          I8\1O^&[%OM'H?;*YG6.HGY&O_ +)^[2IO
M6'\Q3]6/#* 1=D"
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MRJ=GMT113%,;HC".XHM54U3,SOE\1[>0#I/V;C=+L?M7$S3KEP:QL;KZ;K9
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MHJ'3]%U.-1RM-[#"=TQQ3'Z8JEG\I.5NS1CC'!VFFB6:8
M
M                         E3PF^<YMG_]N?:6N*WUM_Q=W]W[]*4T7\W1
MW?NRO[.*KX
M
M
M
M
M  !2QXC?\-V+?:/0^V5S.L=1/R-?_9/W:5-ZP_F*?JQX90"+L@0
M
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MS3;]'TXF,,-LQVG.*=X<\ .B6W_-9H?O51>T:'#*_P#*S_W?\W0:?R<?]?\
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M4H[OWI1.X=[[_8_NCFNS&2UG39LFR"Y5.&3RN]33W):B19:5%7R-J&IJU/\
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M/&TJ2[2
M                                               $J>$WSG-L_P#[
M<^TM<5OK;_B[O[OWZ4IHOYNCN_=E?V<57P
M
M
M
M
M                          "ECQ&_X;L6^T>A]LKF=8ZB?D:_^R?NTJ;U
MA_,4_5CPR@$79 @
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M=.?R==JGZ6^GMQMCO[NZIFG9GV>_37.[=/:E='OELIA_)[ K&VER-E++2O\
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M@0RG[>*[VMMAR;KW^>H_ZX^]4N75W\O5]:?!"OWFI\YK<W_IVCVGHB[=4_\
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MD3$USC$=B(V3W?!@KVNYFB[>B*=O1C#'LH,EQ0@
M
M                   E3PF^<YMG_P#;GVEKBM];?\7=_=^_2E-%_-T=W[LK
M^SBJ^
M
M
M
M                                                          4L
M>(W_  W8M]H]#[97,ZQU$_(U_P#9/W:5-ZP_F*?JQX90"+L@0
M
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M>OW(PJKF8[;5!)M4
M                                                         )4\
M)OG.;9__ &Y]I:XK?6W_ !=W]W[]*4T7\W1W?NRO[.*KX
M
M
M
M
M                                     !2QXC?\-V+?:/0^V5S.L=1/
MR-?_ &3]VE3>L/YBGZL>&4 B[($
M
M                                                   &VMK=\MSM
MF77?X/,A;98K\L#KQ3R4E+5LG6F[SNE7SF*16]/>N^L5-=>W71",U'1\KJ'1
M]/3CT<<-LQACOW3'%PMO*YV]EL?1SACOV1/A>AN+R(WEW6H/8C.,XJKG9NML
MCK-!%!14KW-7J9WD5)'$DO2J:IWG5HO:ACR.A9+(U=*S;B*N/;,]^9G#N/68
MU"_F(PKJQCBW>!I4EVD
M
M                                                  "5/";YSFV?
M_P!N?:6N*WUM_P 7=_=^_2E-%_-T=W[LK^SBJ^
M
M
M
M
M                               4L>(W_#=BWVCT/ME<SK'43\C7_P!D
M_=I4WK#^8I^K'AE (NR!
M
M
M
M
M                    E3PF^<YMG_\ ;GVEKBM];?\ %W?W?OTI31?S='=^
M[*_LXJO@
M
M
M
M
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M^<]Z^Y]NKG/8<OZNG[,<Q\!6R/Q.8/[WK;ZW'OG/>ON?;JYSV'+^KI^S',?
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M^<]Z^Y]NKG/8<OZNG[,<Q\!6R/Q.8/[WK;ZW'OG/>ON?;JYSV'+^KI^S',?
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M^<]Z^Y]NKG/8<OZNG[,<Q\!6R/Q.8/[WK;ZW'OG/>ON?;JYSV'+^KI^S',?
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M^<]Z^Y]NKG/8<OZNG[,<Q\!6R/Q.8/[WK;ZW'OG/>ON?;JYSV'+^KI^S',?
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M^<]Z^Y]NKG/8<OZNG[,<Q\!6R/Q.8/[WK;ZW'OG/>ON?;JYSV'+^KI^S',?
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M^<]Z^Y]NKG/8<OZNG[,<Q\!6R/Q.8/[WK;ZW'OG/>ON?;JYSV'+^KI^S',?
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M$,_-)G
M
M
M
M
M                                                _A\D<35?(]L;
M$\KG*B)_)4^Q&(\R:_V*G72>]4$"^E)4Q-_FN0R18N3NIGO2\3<IC?,/P^RC
M&?VQ6S_&X?ZL^^S7?(GO2^>FH\J.^?91C/[8K9_C</\ 5CV:[Y$]Z3TU'E1W
MS[*,9_;%;/\ &X?ZL>S7?(GO2>FH\J.^?91C/[8K9_C</]6/9KOD3WI/34>5
M'?/LHQG]L5L_QN'^K'LUWR)[TGIJ/*COGV48S^V*V?XW#_5CV:[Y$]Z3TU'E
M1WS[*,9_;%;/\;A_JQ[-=\B>])Z:CRH[Y]E&,_MBMG^-P_U8]FN^1/>D]-1Y
M4=\^RC&?VQ6S_&X?ZL>S7?(GO2>FH\J.^?91C/[8K9_C</\ 5CV:[Y$]Z3TU
M'E1WS[*,9_;%;/\ &X?ZL>S7?(GO2>FH\J.^?91C/[8K9_C</]6/9KOD3WI/
M34>5'?/LHQG]L5L_QN'^K'LUWR)[TGIJ/*COGV48S^V*V?XW#_5CV:[Y$]Z3
MTU'E1WS[*,9_;%;/\;A_JQ[-=\B>])Z:CRH[Y]E&,_MBMG^-P_U8]FN^1/>D
M]-1Y4=\^RC&?VQ6S_&X?ZL>S7?(GO2>FH\J.^?91C/[8K9_C</\ 5CV:[Y$]
MZ3TU'E1WS[*,9_;%;/\ &X?ZL>S7?(GO2>FH\J.^?91C/[8K9_C</]6/9KOD
M3WI/34>5'?/LHQG]L5L_QN'^K'LUWR)[TGIJ/*COGV48S^V*V?XW#_5CV:[Y
M$]Z3TU'E1WS[*,9_;%;/\;A_JQ[-=\B>])Z:CRH[Y]E&,_MBMG^-P_U8]FN^
M1/>D]-1Y4=\^RC&?VQ6S_&X?ZL>S7?(GO2>FH\J.^?91C/[8K9_C</\ 5CV:
M[Y$]Z3TU'E1WS[*,9_;%;/\ &X?ZL>S7?(GO2>FH\J.^?91C/[8K9_C</]6/
M9KOD3WI/34>5'?/LHQG]L5L_QN'^K'LUWR)[TGIJ/*COGV48S^V*V?XW#_5C
MV:[Y$]Z3TU'E1WS[*,9_;%;/\;A_JQ[-=\B>])Z:CRH[Y]E&,_MBMG^-P_U8
M]FN^1/>D]-1Y4=\^RC&?VQ6S_&X?ZL>S7?(GO2>FH\J.^?91C/[8K9_C</\
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MZL>S7?(GO2>FH\J.^?91C/[8K9_C</\ 5CV:[Y$]Z3TU'E1WS[*,9_;%;/\
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M]FN^1/>D]-1Y4=\^RC&?VQ6S_&X?ZL>S7?(GO2>FH\J.^?91C/[8K9_C</\
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M*COO1@N%!4JB4U;3U"KY$BD:_7^0JF.:*J=\2]15$[I?6>7H
M
M
M
M
M
M
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M>)M5QOB7ER12Q+TRQNB=_.O16K_+,D3$[GB8P?F?0
M
M
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MI\?0
M
M
M
M
M
M                                                 '^.:UR*US4<
MU>Q6JFJ*!YLUDLU3KYQ:**?7R]Y3QN_FM4R1>KC=5/?>)MTSOB'DS83B=1KU
MV"C;KY>[9W?])TF6,Y>C]:7B;%N>"'E3;98;+];;'P*OYJ.>;^8Y[D_E&6-1
MOQP\D/$Y2W/ \F;:'&)-5CJ;A OH(V6-4_\ 6C5?Y9DC5;L<$?IW7B<E1V7E
M3;,T+M?-[[/%Z7>0MD_F.898U>KAICOO$Y&."7E3[,US=?-K[!*GH=Y"Z/\
MF.>98U>GAIGOO$Y&>"7DS;0Y-'JL53;ZA/01LLC5_P#6C1/Y9EC5;4[XG].Z
M\3DJ^P\F;;',HM>FV,G1/1CJ(?YCGM4R1J-B>'DEXG*7(X'E383ED&O78*MV
MG_5L[S^DZC+&<LS^M#S.7N1P2\J:R7JFU\XM%;3Z>7O*>1G\UJ&6+U$[JH[[
M'-NJ-\2\US7,56O:K')Y6JFBF2)Q>7\@
M
M
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M#^QL:W^8B&*:IG?+W$1&Y]!Y?0
M
M
M
M
M
M
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M4\J'MY
M
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M:>;T%/3Z>3NXF,T_D(ACFY5.^9>XIB-T/M/#T
M
M
M
M
M
M
M
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M*^FU\XHIX-/+WD;F_P U$,L7*9W3#Q-,QOA\AZ?
M
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M!IY.[@C;_,:ACF[7.^9[[W%%,;HAZ"(B(B(FB)Y$0QO3_0
M
M
M
M
M
M
M
M                                                ?+-0T53KYQ1P
M3Z^7O(VNU_DHIZBNJ-TR^33$[X>3-BF,U&O>V"WJJ^5S:>-J_P EJ(IEC,W8
MW53WWB;-$\$/*FV[PV?5761C%7T8Y9F?RFO1#+&?OQ^MX'B<K;G@>3-M/B4N
MO0RKIM?^KFU_IVN,D:G>CBGN/$Y.W/&\J;9NRN_[O=:V+TN\2.3^8UAEC5KG
M#3#Q.1IX)EY,VR[NU:?(47TFR4VG\M)5_F&6-7XZ>7Q/$Y'BJY'E3;.7YO\
M6+E02_\ 365B_P ICC+&K6^&)Y'B<C5P3#R9MJLNBUZ*>FJ=/^KG:G]/TF2-
M3LSPS'<>)R=R'E3;?9C!KUV.5VG_ %;XI/Z1ZF6,]8G];PO$Y:Y' \F;&,CI
M]5FL-P8B>5WFTBM_DHW0RQF;4[JH[[Q-JN."7E34M33]E13RP+Z4C'-_FHAE
MBJ)W2\3$QO?@?7P
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MCF<7M_1\
M
M
M
M
M
M
M
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M^2K3+&8MSNJCOP\3:KC?$O+DAFA7IFB?$[^=>U6K_+,D3$[GB8P?F?0
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M,'ZGQ]
M
M
M
M
M
M
M
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M1#'-4SOE[B(C<^@\OH
M
M
M
M
M
M
M
M
M                                   /XDBCE3IEC;(W^=<B*G\L^Q,P
M8/+FQ^Q5&OG%EH)M?1?3Q.7^6TR1?N1NJGOR\3;IG?$/*FP7$9]>NPTS=?\
MJT='_2*TRQG;T?K2\3E[<\#R9MK\.EUZ*"6GU_ZN>5?Z=SC)&I7XX>2'B<I;
MXGE3;/XV_58:VX0+Z"=<;F_R%CU_EF6-5NQOB/T[KQ.2HXY>3-LQ2NU\WO\
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M$;H?8>'H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MC3L+MJ9FW,X;=],\T\'*M.E:I[5C17LJCEA-\J*:
M
M
M
M
M
M
M
M
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M$('*:Y7?NTVYIB,9XUG!SY9
M
M
M
M
M
M
M
M
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M+Q+_ /OVSG]@OW]-0'2?_G_T;_;I_P"2K=9-]ON_(^SPS?K=ZOR<<_SH>/\
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M5[5..YG,5YB[5=N3C55.,KM:M4VJ(HIW0YH<M_UQR;]6:W],/._97^11]6/
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MFY%<558QVN9-DJ29
M
M
M
M
M
M
M
M
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M[!?OZ:@+[_\ /_HW^W3_ ,E<ZR;[?=^1]GAF_6[U?DXY_G0\?_0/_P '[_\
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MGK:J=WUGG=9%)2TL?_27KDD3_H$MUTSL6<EZ+'YUR8CN1MGY([K2T'+S<O\
M3X*8Y9V0V9XE'^N>V7ZBUOZ8::'4'^3=^M'@;/6/Z=':ELGPUO\ 5+=']5[?
M_:)2/Z_?SK/U9\+9ZN?RZ^W'@?USDXU4-TLM7O)@EHBI;W9FNESNW4D:,2LI
M/*ZOZ&)HLL*]LBZ>J9JY5]1VNI^OU45QE;U6-,_0F>"?)[4\'%/;-;TV*J?3
M41MC?V8X^W" ''O?&^[%YY19!1RS5.-U[V4V86%KO45=&KNU[6JJ-[Z+571N
M]/5NO2YVMUUS1[>I9>:)V5QMIGBGFGA\2!T_/596YTH^C.^.QSNAFR7JUY'9
M[7?[)6QW&SWFEBK;97PKJR6"9J/8]OY**</O6JK5<T5QA5$X3'9A?Z*XKIBJ
MG;$N93+?]<<F_5FM_3#S] Y7^11]6/ YM>_F5=N?"LK\2?#_ %6VN?P1>5*O
M'[G/IZ6E52-U_+G4H/4'-?S;$]BJ/!/_ !6/K'9^A<[<?+'RJM)*B>9E/'--
M)+'21K%2L>Y7)'&KW2*QB*OJ45[W.T3T55?*IT6*8C'#A5B9F5J6^&'?8)P,
MVXQY\/<53:JSU]QC5/5-J;BD];,UWU6OF5OY1SC2,U[3KUVYP851':IPICP+
M3G;/HM.II[7+M:K\.+^&;+OM+JO;&WDEU\_)4?\ 9'W:FIU=_GU?5^6'F[Z\
MG>2>%[IY]A#=P7VR@L-XJ8+93TMNM\:I1/=WM([O%IED55@>Q>UZF31NKVFY
MC*6[WH\9JIC'&:M^Z>'#?B\Y[4\U:O54=+"(GBC=P<'$LQXV;SVC>3;/'[HE
MVBJLOM=%#1YI;G.:VICKH6(R2=T2+JD<ZIWC'(FG;T^5JHG/]?TJO3\U53T<
M*)F9IG@PXL>.-TK)IV<IS-J)Q^=$;>WXWA<N*7;!^R^95>XD%N6LBM=2S#:F
M=D:US;JL:^:-HW*G>=2RJWK1O9T=77ZG4S=6:LU&=MQ8QPQCI<71X>EP;N7=
MM>-5BUZ"J;F&[9QX\&"C[:"*MFW8VQBMR*M>_++,E'IJNDGGT/2O9Z2]IU[5
M)IC*7NENZ%7@E2LG$S?HPW]*/"Z6:JJIJ*FJ*RMJ(J2CI(W3555,]L<<4;$Z
MG/>]RHC6M1-555[#@--,U3$1&,RZ-,Q$8RQ6@W$V_NE93V^V9UCUQKZM_=TM
M#2W.DFFE>OYED;)%<Y?J(ALUY',41-55NJ(CAFF>9CIOVZIPBJ)GMPS$U64
M
M
M
M
M
M
M
M
M
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M\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M2M\GHM _;!>2_'K<RX16? MZL,RF\SZ>;V2AO-(^NDU[$Z*59$E=V^DT#>
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M135,$K4='+#-&KF/8YJHJ.:JHJ>0#[P
M
M
M
M
M
M
M
M
M        1-YV?,]Y$?:97_S&@<8=KN=QLESMUYM%;-;+M:*J&MM=QIGK'-3U
M%.])(I8WMT5KF/:CD5/(J =EO"#D];N5&Q=AS2:6&+.[%TV7<NTQ(C.YNL#&
MJM0R/T(JIBI-'IV)JZ/558X"*'C0?-1Q7[Y=H]J[N!![P2/X;-X?M(B]LJ<#
M47C"_/!D^TJR?T]2!:WX.WS07?;Q>_[52 8'XE7B#Q[.6ZY[#[,7EK]V;O3]
MUF.4TCT5<:I)V:]S"]J]E=*QVJ>C"Q>OL>YBM"AGC;QNW(Y4;FT> X+3.]6Y
M*O+<MJFO?1VBA5^DE75/3M<Y5U2-B+U2/[$_-.0.P'CQQYVZXS[;6K;;;FW=
MQ1TVE1?+Y.C5KKM7N:C9:VLD:B=3W:(B(GJ6-1&,1&HB ;T   .:SG-P+Y9;
MO<JMV]QMNMI9,CPS):JV262]-O-DI4G;3VFCII%[FJKX96],L3F^J8GDU3LT
M4"NW>CA[R-X\XY;<NWBVX?AV/7>Y,M%NN+KI:JY)*V2&6H;%W=!65$B:QP/=
MJK4;V::ZJ@&"[,;$;K\A<HK\+V>Q-V8Y-;+5+>JZV-K**A6.AAG@II)N\KYZ
M>-=)*F-O2CE=ZK731%5 DU^+"YS_ !%2^^''/=0#L%             !P3XE
M_K=C/ZL47Z88!WL  *2/&[_@CV4^V^M_2#@**-D..>\G(Z\7JP;,X?\ 9C=L
M>HV7"\4GLA;[=W-.^1(FOZ[C4TS':O5$T:JK]0"1=1X7_.BFADGDV+D>R)JN
M<D618W*]41-?4LCNCG.7ZB(!&_%LSWMXM[G3SV*XW[:[<3$*^..]V:19:5ZR
M4[D?YM7TKE1D\+T7M9(CF/:NO:BZ@=AW%;?:GY);#8#N_';V6>NR2EFBOUHC
M5SHZ:XT,\E)5LC5W:L:R1*^/557H<W7MU D*  YH/$9\17,<XS+)-CMD,FJL
M9VWQ>JEM>593:I9*:MOU= Y8ZJ)E3&K7LHXWHL:(Q4[[17.5T;FM @+L=PPY
M)<BK8^_[5[:U5WQ>.H=2R9575-+;;>LC-4>D4U;+#W_0J:.[E'JU>Q= ,;WO
MXP[\<;+A;H-W,!KL3CN3U2RWZ.6&LM]3(SU73#74<DL/>(B=7=JY'HG:K4 N
M&\*_G=F&3Y51\:=Y,@JLGDN=-*_:K++A)WM9')1POFFM=5.]>N5KH6.? ]ZJ
MYJM6/5R.C1@7[@   #B_Y\?/'Y"_;;4?VN,#IKV5_B]]O?O%4G[WT Y1>-'S
MCN/_ -\G%/;BE [CP      :;Y";N6W8C93<G=FYK&YF%V6>KMU-*O2VIN$F
MD%!3*O\ [^IDCC_\X#AXN]VN5_NUTOMYK)+C=[U5SU]UN$RZR3U-3(Z6:5Z^
MBY[W*J@=#/@L;Z^RV);A\>KS6]=;B<_V685#([5RVZM>V"XPQM]!D-2L<G_2
MG<!>D     '*;SI\0+?O<[/=R-G[3>/@YVTQ2_W7'*BQ6"5\=3=H[?524CI+
MC7>IE>V3NU586=$>B]+VO5.H#IWVM>^3;+;J21RO>_&+0Y[W+JJJM%$JJJKY
M54#FGYB<'N5NX?)[>K-L+V8O%_Q7),DGK+'>8)Z)L=1 YC$1[4DJ&.1%5%\J
M(!T/\8L8OV$\<]C,/RFVR6;)<8P6Q6N_6F96NDIJNEH8HIHG*Q7-56/:J+HJ
MH!O0       #E-YT^(%OWN=GNY&S]IO'P<[:8I?[KCE18K!*^.INT=OJI*1T
MEQKO4RO;)W:JL+.B/1>E[7JG4!T[[6O?)MEMU)(Y7O?C%H<][EU556BB5555
M\JJ!G8
M
M
M
M
M
M
M
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M_=W&J=;=!D4,D=VL<DB2RVZXTKUAJZ1[T1O5T2-56.5J=;%:_1.H#>@
M
M
M
M
M
M
M
M
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MK)&N8U[7-Z7(BIH!M@
M
M
M
M
M
M
M
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M0MW\$NJR&79'=RFK$E=B]+FL7L%*]RJQ*Q]OA6NC8BKHFC.X<NG\\!=.
M
M
M
M
M
M
M
M
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M/&\/IZ3;>P8#DU+1WJEI<;I;!D%&]G?4=6R.C;2U$:LE:G7'(B.31S>UJ]J
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MM:DDTSO5.71$\C6HUC6M0-K
M
M
M
M
M
M
M
M                                                 ,1S^PWK*,&S
M#&\;R.IP_(;[9JVAL65T>G?VZLG@>R"JCU1>V*14=Y/0 K6X4>'%+L3FSM^-
M[<T^$G?"K;5RTSHI)JFCMM37M<RJJG5=4B3UE5(Q[VK*]K41'O\ 4N71X%JX
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MK-^7R4\Q\(>Z_P =^ZOO_P I]TQ\):7ZKSJ_Q'OK-^7R4\Q\(>Z_QW[J^_\
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MJO.K_$>^LWY?)3S'PA[K_'?NK[_\I]TQ\):7ZKSJ_P 1[ZS?E\E/,?"'NO\
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MLWY?)3S'PA[K_'?NK[_\I]TQ\):7ZKSJ_P 1[ZS?E\E/,?"'NO\ '?NK[_\
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MJO.K_$>^LWY?)3S'PA[K_'?NK[_\I]TQ\):7ZKSJ_P 1[ZS?E\E/,?"'NO\
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MJO.K_$>^LWY?)3S'PA[K_'?NK[_\I]TQ\):7ZKSJ_P 1[ZS?E\E/,?"'NO\
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MLWY?)3S'PA[K_'?NK[_\I]TQ\):7ZKSJ_P 1[ZS?E\E/,?"'NO\ '?NK[_\
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MJO.K_$>^LWY?)3S'PA[K_'?NK[_\I]TQ\):7ZKSJ_P 1[ZS?E\E/,?"'NO\
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M(]]9OR^2GF/A#W7^._=7W_Y3[ICX2TOU7G5_B/?6;\ODIYCX0]U_COW5]_\
ME/NF/A+2_5>=7^(]]9OR^2GF/A#W7^._=7W_ .4^Z8^$M+]5YU?XCWUF_+Y*
M>8^$/=?X[]U??_E/NF/A+2_5>=7^(]]9OR^2GF/A#W7^._=7W_Y3[ICX2TOU
M7G5_B/?6;\ODIYCX0]U_COW5]_\ E/NF/A+2_5>=7^(]]9OR^2GF/A#W7^._
M=7W_ .4^Z8^$M+]5YU?XCWUF_+Y*>8^$/=?X[]U??_E/NF/A+2_5>=7^(]]9
MOR^2GF/A#W7^._=7W_Y3[ICX2TOU7G5_B/?6;\ODIYCX0]U_COW5]_\ E/NF
M/A+2_5>=7^(]]9OR^2GF/A#W7^._=7W_ .4^Z8^$M+]5YU?XCWUF_+Y*>8^$
M/=?X[]U??_E/NF/A+2_5>=7^(]]9OR^2GF/A#W7^._=7W_Y3[ICX2TOU7G5_
MB/?6;\ODIYCX0]U_COW5]_\ E/NF/A+2_5>=7^(]]9OR^2GF/A#W7^._=7W_
M .4^Z8^$M+]5YU?XCWUF_+Y*>8^$/=?X[]U??_E/NF/A+2_5>=7^(]]9OR^2
MGF/A#W7^._=7W_Y3[ICX2TOU7G5_B/?6;\ODIYCX0]U_COW5]_\ E/NF/A+2
M_5>=7^(]]9OR^2GF/A#W7^._=7W_ .4^Z8^$M+]5YU?XCWUF_+Y*>8^$/=?X
M[]U??_E/NF/A+2_5>=7^(]]9OR^2GF/A#W7^._=7W_Y3[ICX2TOU7G5_B/?6
M;\ODIYCX0]U_COW5]_\ E/NF/A+2_5>=7^(]]9OR^2GF/A#W7^._=7W_ .4^
MZ8^$M+]5YU?XCWUF_+Y*>8^$/=?X[]U??_E/NF/A+2_5>=7^(]]9OR^2GF/A
M#W7^._=7W_Y3[ICX2TOU7G5_B/?6;\ODIYCX0]U_COW5]_\ E/NF/A+2_5>=
M7^(]]9OR^2GF/A#W7^._=7W_ .4^Z8^$M+]5YU?XCWUF_+Y*>8^$/=?X[]U?
M?_E/NF/A+2_5>=7^(]]9OR^2GF/A#W7^._=7W_Y3[ICX2TOU7G5_B/?6;\OD
MIYCX0]U_COW5]_\ E/NF/A+2_5>=7^(]]9OR^2GF/A#W7^._=7W_ .4^Z8^$
MM+]5YU?XCWUF_+Y*>8^$/=?X[]U??_E/NF/A+2_5>=7^(]]9OR^2GF/A#W7^
M._=7W_Y3[ICX2TOU7G5_B/?6;\ODIYCX0]U_COW5]_\ E/NF/A+2_5>=7^(]
M]9OR^2GF/A#W7^._=7W_ .4^Z8^$M+]5YU?XCWUF_+Y*>8^$/=?X[]U??_E/
MNF/A+2_5>=7^(]]9OR^2GF/A#W7^._=7W_Y3[ICX2TOU7G5_B/?6;\ODIYCX
M0]U_COW5]_\ E/NF/A+2_5>=7^(]]9OR^2GF/A#W7^._=7W_ .4^Z8^$M+]5
MYU?XCWUF_+Y*>8^$/=?X[]U??_E/NF/A+2_5>=7^(]]9OR^2GF/A#W7^._=7
MW_Y3[ICX2TOU7G5_B/?6;\ODIYCX0]U_COW5]_\ E/NF/A+2_5>=7^(]]9OR
M^2GF/A#W7^._=7W_ .4^Z8^$M+]5YU?XCWUF_+Y*>8^$/=?X[]U??_E/NF/A
M+2_5>=7^(]]9OR^2GF/A#W7^._=7W_Y3[ICX2TOU7G5_B/?6;\ODIYCX0]U_
MCOW5]_\ E/NF/A+2_5>=7^(]]9OR^2GF/A#W7^._=7W_ .4^Z8^$M+]5YU?X
MCWUF_+Y*>8^$/=?X[]U??_E/NF/A+2_5>=7^(]]9OR^2GF/A#W7^._=7W_Y3
M[ICX2TOU7G5_B/?6;\ODIYCX0]U_COW5]_\ E/NF/A+2_5>=7^(]]9OR^2GF
M/A#W7^._=7W_ .4^Z8^$M+]5YU?XCWUF_+Y*>8^$/=?X[]U??_E/NF/A+2_5
M>=7^(]]9OR^2GF/A#W7^._=7W_Y3[ICX2TOU7G5_B/?6;\ODIYCX0]U_COW5
M]_\ E/NF/A+2_5>=7^(]]9OR^2GF66>$3N%GVY7&W-K[N-G&09_>Z3<JY4%+
M>,DN=5=:J*ECL]FE9 R>LDE>V-KY7N1B+HBN<NFJJ<57Q:>  YHN9>].]-J\
M0K<?;VQ[S[@8W@U/[#^:XG9,IO%KH(>O$Z&K?W,%%5PMCZIU61W0B=3E55UU
M4F^KN4M9O/V[5V,:)Z6,8S&ZF9X,)WPT-3O5V<O571.$QAX8>#\(>Z_QW[J^
M_P#RGW3.G_"6E^J\ZO\ $J7OK-^7R4\Q\(>Z_P =^ZOO_P I]TQ\):7ZKSJ_
MQ'OK-^7R4\Q\(>Z_QW[J^_\ RGW3'PEI?JO.K_$>^LWY?)3S'PA[K_'?NK[_
M /*?=,?"6E^J\ZO\1[ZS?E\E/,?"'NO\=^ZOO_RGW3'PEI?JO.K_ !'OK-^7
MR4\Q\(>Z_P =^ZOO_P I]TQ\):7ZKSJ_Q'OK-^7R4\Q\(>Z_QW[J^_\ RGW3
M'PEI?JO.K_$>^LWY?)3S'PA[K_'?NK[_ /*?=,?"6E^J\ZO\1[ZS?E\E/,?"
M'NO\=^ZOO_RGW3'PEI?JO.K_ !'OK-^7R4\Q\(>Z_P =^ZOO_P I]TQ\):7Z
MKSJ_Q'OK-^7R4\Q\(>Z_QW[J^_\ RGW3'PEI?JO.K_$>^LWY?)3S'PA[K_'?
MNK[_ /*?=,?"6E^J\ZO\1[ZS?E\E/,?"'NO\=^ZOO_RGW3'PEI?JO.K_ !'O
MK-^7R4\Q\(>Z_P =^ZOO_P I]TQ\):7ZKSJ_Q'OK-^7R4\Q\(>Z_QW[J^_\
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MK-^7R4\Q\(>Z_P =^ZOO_P I]TQ\):7ZKSJ_Q'OK-^7R4\Q\(>Z_QW[J^_\
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M1E<AZ'T%'1Z72QVS..'1P^E,\<I[1,[>S/3])..&&&R(WX\4.API2>
MY \A^>_RK^WC.?WRN+KU$_/5_P#7/WJ4#UA_+T_6CP2VP=94T
M
M                     _G'OX;N*GW\L&]LFE)Z]_D:/^R/NU)[J]^8J^K/
MAAU3')UR - <L?FL<EOO59E[1U@',)LC_!AC'_SOZ=G.U=4O\7:_>^_4H>M?
MFZ^Y]V&UBR(L
M                                            WYX87S]MY?O55'Z>
MQLXIUM_REW]W[E*^:+^4H[OWI=%!7$H 0 \4?YB>^?[F?WSVD"@39'^##&/_
M )W].SG:NJ7^+M?O??J4/6OS=?<^[#:Q9$6
M
M       31\&S_7CFK^KN-?IG(S@>L_GK_P#V5_>ET;(_E[?U:?!"],C6T 4
M^.=_PN_NV_S !%D_1SEX
M                                                     LF\%3YK
M&???5NOM'8S\XNH+?@ '*QS9_C.]S/\ [3?O+H2Q]4O\I:_>^Y4B]:_*5]S[
MT/[.UJ&
M                                       :IWN_@PR?_P"2_3L!6^MO
M^+N_N_?I2FB_FZ.[]V77T<57P  <5_&/_P#7?_[6_P#V4='_ /G_ /\ Q'[G
M_-5^LG_X_P![Y$K#HZK@
M                                                   &T^*GS[.*
MW[N?WL59SC_Z!_\ P_[_ /P6CJW_ /D_=^5THG.%H      Y \A^>_RK^WC.
M?WRN+KU$_/5_]<_>I0/6'\O3]:/!+;!UE30
M
M      #^<>_ANXJ??RP;VR:4GKW^1H_[(^[4GNKWYBKZL^&'5,<G7( T!RQ^
M:QR6^]5F7M'6 <PFR/\ !AC'_P [^G9SM75+_%VOWOOU*'K7YNON?=AM8LB+
M
M                                -^>&%\_;>7[U51^GL;.*=;?\I=_=
M^Y2OFB_E*.[]Z7105Q* $ /%'^8GOG^YG]\]I H$V1_@PQC_ .=_3LYVKJE_
MB[7[WWZE#UK\W7W/NPVL61%@
M                                                       $T?!L
M_P!>.:OZNXU^F<C.!ZS^>O\ _97]Z71LC^7M_5I\$+TR-;0!0#XYW_"[^[;_
M # !%D_1SEX
M                                            LF\%3YK&???5NOM'
M8S\XNH+?@ '*QS9_C.]S/_M-^\NA+'U2_P I:_>^Y4B]:_*5]S[T/[.UJ&
M
M                              :IWN_@PR?_ .2_3L!6^MO^+N_N_?I2
MFB_FZ.[]V77T<57P  <5_&/_ /7?_P"UO_V4='_^?_\ \1^Y_P U7ZR?_C_>
M^1*PZ.JX
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M<WFLU;LUT41%4X3A%6/WI67.:)9LV:JXFK&([',JG.DJL
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M^E];L]G<U19BBW\Z=NRK=OF?I<6*?SFBY>Q:JN=*K9''&_@X.-5.=)58
M      +=LDX ;1V3!+]DT.4Y?-<;18:JYQ1OJ:#N'ST]*Z9$<U*'JZ%<WM3J
MUT]'T3F%CKKG+E^FW-%&$U1&ZK'"9P\I;+F@V*;<U=*K&(QX.+M*B3IZI@
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M'KY'(4+1^M^:SF;MV:Z:(IJG;A$X[IGRI6+/:+9L6:KE,U8QQX<RK0Z,K
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M9]#ZVVL_<BS<IZ%<[MN--78[$]CE1.H:-7EJ>G3/2IX>.$'RX(0
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M-4TTCHJBGE:K'QR,56N:YJZ*BHJ:*BG0::HJC&-TJU,3$X2_(]/@
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MU6=CETU_G4,>C:K&I6)O13T8Z4QACCNX7O/9.<K<Z$SCLB6EB6:0
M        U3O=_!AD_P#\E^G8"M];?\7=_=^_2E-%_-T=W[LNOHXJO@  XK^,
M?_Z[_P#VM_\ LHZ/_P#/_P#^(_<_YJOUD_\ Q_O?(E8='5<
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M.L%_5*KE-VFF.C$8=''AQXYE@U;3;>4BF:)F<<=^'-"#Y;T(
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MLD<GU&K,Q%_).'Q1,TS5P1L[^/-*_P",8X*K?$P_[[LW_8+]_36\Z/\ _/\
MZ-_]S_DJ_63?;[OR)[\=OX"-H/M2M/Z584O7/S]_Z]7A3NG_ )>W]6/ IOW#
MY+;\V?<3.K=;=T+U2T%MR*Z4U#2-D8L<4,-7*R-C6N8J:-:B(AU3(Z!D+F6M
MU56:9F::9GNQ"H9C4LS3=JB*YPB9\*PKA#OSGV\=ES*TY](V[UV'/H74F3-A
MCA?/'6I.G<SMB:QBOC[C5'(U%5%]5VIJM'ZW:-E]/KHJL[(KQ^;OPPPVQCMV
MXI_1<]<S--47-LTX;>VT%XE=CH:>^;49'%%&RXW2BNUOK)41$D?%0R4LL**O
MHHU:I_\ ))KJ!>JFB];X(FF8[N./W8:'6.B(JHJX9B8[V'.K#.AJTG]X<G\-
MN5?:/6^V5M*3U[_(T?\ 9'W:D]U>_,5?5GPPW_XDW^HVVOZNU?Z6(7J#_/N_
M5CPM_K'_ "Z.W\B+.SG";+-XMOK-N%;LUM%FH;W)5,IK?4P3R2M2EJ)*9RO5
MB(WM=$JIIZ&A8M5ZVV<AF*K%5NJ9IPVQ,<,1/RHS)Z+7F;47(JB(G_PR+ O#
M\W,RFKN[\DOM'A-DH+A54-OK:BGDJ:NM933.B2ICHT?%T12=.K5DD:Y4T5&]
M*HJX,[UVRMF*?1TS75,1,QCA$8QCATMNV.'"&2QH%VY,]*>C&/=GLX/4W!\.
M[<'&K37W;#,MH,[=01.F6SNI7VZMF:U-7-@8LM1&]_I-61NOH=NB&/)=><O>
MKBF[1-&/#CTHCM[(GD>LQU?NT4S-%45=C#"?E5YN:K55KD5KFKHYJ]BHJ>@I
M>%?3IVBX&;C;BV*BR;)[W3;=VFZ1-GME-4TSZRX21/35DCZ5)(&QM<BZHCI.
MKTVIV:T[5.N>6RER;=NF;E4;\)PI[^W'O8=E.930KMZF*JIZ,3W9[S8MPX Y
MW@60XID^*971YY16:]V^KNE M*MMK&P15,;Y'Q1NFGCDZ&HJJG>(Y?S**O8:
M-'76QFK==NY1-$S3,1./2C'#AV1,=YL5:#<M54U45=*(F.Q._NI^<H/F^[L_
M:_4?S6E*ZO?Y"S]:$]J?Y:YVE,O'KC;?^0K\M2RY';\>9B*4*U;JV.6195K_
M #CNT8D:?F?-G:ZKZ*'5M<U^WI70Z=,U=/'=A^KASJ=I^G59SI=&8C##EQYG
MA[^[%7?8+)[1C%XOM'?ZB[VMMTCJJ..2-C&.GE@Z%23MUUB5?RS-HNLT:I:J
MN44S3$3AM[43\KQG\C5E*XIF<<8Q>UQ[XWW[D++ED=ER.@QYF),HG5;ZV.61
M95KEG1B,2-/S/F[M=5]%#%KFO6]*BCITS5T\=V'!ASO>GZ=5G.ET9B,,.7_P
M\??[8B[[ Y+9L:O%^H[_ #WFV)<XJFCCDC8QBS20]"I)VZZQJIET76:-4M57
M**9IPG#;VHGY7C/Y&K*5Q3,XXQBR_8_B/N;O;0LR"C\VQ7#WO<R'([HC_P#M
M*L7I?YI Q.J5&KV*Y5:S5%3JU14-75^L^5TZKH3C57Y,<';G@Y9[#-DM)NYJ
M.E&RGCGY$GZOPT;BRF1U#O!35%9HNL,]C?#%KZ"=XVNE7_U"O4]?Z<=MB</K
M8_\ &$G/5N<-ESD\:#.\.QV?['WRGLV;6^)L-P:^2SWRB>LU#6,8NC^ZD5K5
M1S=4ZF/:UR:HJIHJ*MPTO6,OJ5N:[,[M\3OCM\^Y!YO)7<K5A7&_=/!+RMK-
MI,YWDR1N,8-:O/JMC$EN%?,[NJ.BA5=.]J9M%1J:^1$17.\C6JIDU'4[&GVO
M27IPC@CAF>*(_3LO.5RES,U]&B.:.VGQ0^&C=9*)C[GN]2TER5J+)2TUE?40
M([T429];"Y4^KW:?D%+KZ_T15\VQ,QV:L)[W1GPIVGJW.&VYM[7C1;WRXG[E
M['4R7RYI39+A[Y&Q+DUKZU9 ]ZZ,;5PO1'PJY>Q%]4S71.OJ5$+%H_67+:E/
M0IQIK\F>'M3P^'L(S.Z5=RL=*=M/''RL2V#V,O._F5W3%;->Z.PS6JU276>L
MK622-<QD\,'0UL::ZJLR+V^@AM:UK%&EVHN5TS5C5AL[4S\C%D,E5FZYHIF(
MPC%)A_AV[E)E-!9&99:9+++1NJ[GD_<3I%3N21&,@9$NCI9'IJ[1%1$1/5.3
M5NM?CKSEO137T*NECA%.,;>SCP0D?A^[TXIZ48<;#]^>%UZV8QZUY#09Q39F
MR[76FLU%9FV^6CKZBLJT=W4=-"R6J255Z'=G4U=$[-?(;6C=;*-0N315;FC"
MF:IG&)IB(WXSA3@Q9[1JLM3%45=+&<,,,)QGBWLYPGPZ-Q;Y;::OS/,+9A%3
M4:.6T10.NE1"U4\DJQRPQ([ZC9')_1&GF^O66MU33:HFN./'HQW-DSR0SV>K
MUVJ,:ZHI[&]D5_\ #6R6EHYI<9W3MUYKF-58:.XVR6WL>J)V(LL515JFO_0,
M%GK]:F<+EF8CL515R84LESJY7$?-KB9[,8?+*O3-,+R;;W);IB.76J6SWVT2
M=W5TDO:BHO:R2-Z:M>QZ=K7-545.U"\93-VLU:B[:G&F?T[ZOWK-=FN:*XPF
M&+&RQ                    ?SCW\-W%3[^6#>V32D]>_R-'_9'W:D]U>_,
M5?5GPPZICDZY &@.6/S6.2WWJLR]HZP#F$V1_@PQC_YW].SG:NJ7^+M?O??J
M4/6OS=?<^[#:Q9$6                       )-<-_G*;7_P"%5_M;5E>Z
MU?XR]VH^]"2TC\U1W?!*VOF%EV38/L5D618C>JFP7REKK;'3W.D=TRL;+51L
M>B+HOUS55%.9]5\K:S.?IMW:8JIF*MD]I:]7NUVLO-5$X3C'A5&V7EYR)LE=
M3UL>Y5=<FP/1SZ*XQP54$K4\K'M?'KHOD56JB^DJ*=.N]6-.N4S'HHCLQC$^
M%5*-6S5,X].9[:Y/C;O;'OOMM399/10VR_6^KDMF36VG5W<QU<362(^'K57=
MW)'(UR(JKHJJW5>G5>5:_I$Z9F9M1.-,QC3/#AV>S$\ZWZ=G?:[73PPF-DJA
M>9FVM#MKOE?(+13-H[)EE-%D5LI(VHV.%:M\C*B-B)V(U)XI%1$1.EJHAU#J
MIGZLYD:9JG&JB>C/<W<DPJ>L9:+&8G#=.WO^-?%8/_ K+_@%-_:FG&KW\RKM
MSX5XM_1CM(0<ZMB?A PANY./4?>9=@-.]UQCB;K)66=%5\S>SM5U,JK*W^A[
MQ.U50MW4[6?9;_L]R?F7)V=BO@^UN[R%US(^FM^DI^E3RQXM_?1'\.G^'+(/
MM+K_ -/V\L_7K\C3_P!D?=J1/5[\Q/U9\,-R>)A_W/9O^S7[^EMY%?\ S_Z5
M_P#<_P"3<ZR;K?=^15(=)59T.<6MMF[5;(XC9:R%*6\72!;[DO6G2YM77M;(
MK)/26&)&1+_T#AO6+/\ MN>KKC;3$]&GM4\\XSW70-,RWL^7IB=\[9[<_I@V
M9BV3XCN_@D=[M#FWC$LKIJNC>R5$1)H4?)25$;VHJZ:JUS5[?(1^9R][(7^A
M5LKIF)\$PV;5VC,6^E&VF<>9SK[JX'6[8[BY?@E=UNDQRXRT]-.]-%FI7:24
MTVG_ +V%S'_EG=--SM.<RU%Z/UHQ[4\,=R<8<^S5B;%VJW/!/_CD:_-YK@'0
MOQ0W%^$O8S"[M43]_=[)![ 7Y575WG-N1(FN>O\ /20]W*O_ $CA_67(^QYZ
MY3$?-JGI1VJN:<8[B_Z5F/3Y>F>&-D]SQ*A>8&WOP>;\YA34\'<6G*)&Y'9T
M1-&K'<%<Z=&IY$1M2V5J(GH(AT_JOGO:\A1,_2I^;/[N[S<%3U?+^AS-4<$[
M8[OCQ28\.';_ ,\R'.-S*N#6&RTL=ALTCDU1:BK5)ZES5]!T<<<;?R)"O]?,
M[T;=O+QPSTI[4;([\X]Y)=7<OC55<G@V1W=_Z=EFGB.[B^:V?"=K:*?2:ZS/
MR"_1M714IZ?J@HVN]-KY%E=^3&AJ=0\CTJ[F9F-WS8[<[9Y,.^S=8LQA33:C
MAVS\GR]Y$;8[A_N3O9:X\F@J*3$L/ED?'2WRY-D=)5+&NCEI:=B(LC4=V*YS
MFMU14155%0L^L=:,MIU?HYB:Z^*.#MSP<J)R6D7<U'2W4\<_(DT_PSZM($='
MO)"ZJT]5$ZPN;'K]1Z7!5_\ 5*]'_P! C'^1L^O_  I+X;G#^9R>-#C?/C7N
M'L+44,V2LI;MCMUE6&UY/;7/=3/F1%=W,K7M:^*3I17(CDT5$7I<[I=I:M'U
M_+ZG$Q;QBJ-],[^W'''Z2B,]IMW*8=+;$\,-<;<[:9GNODM-BF#V>2[W69JR
MS+JC(*:!JHCIJB5WJ8V-U1-5\JZ-35RHB[^?U"SD;4W;U6$<LSQ1'#+6R^6N
M9BOH41C*?]G\-.^ST+)+_NS0VRXJW62DH+3+6PM=IY$FEJJ5RI]7NT*5=Z_V
MXJ^99F8[-6$]["KPIZCJY5,?.N1$]B,?EAI?>+@]N;M98ZW*K7<*/.\<M<2S
MW::@CD@K::)OU\KZ5ZOZHVIVN5CW*B:JJ(U%4E=*ZWY7.W(MU1-%4[L=L3V,
M>/MPT\YHEZQ3-43THC?AO[R%S&.D<UC&J][U1K&-3555>Q$1$+9,X(9/7;+P
M_=S<SM-+>LPO='MU2UT;9::VU%.^MN2,<FK5FIFOA9%JB_6NDZT\CFM4IFH=
M=LKEZYHM4S<F.&)PI[D[<>]@G<MH-VY'2KGH\L]YF^2^&SE=%0U$^*;F6V_U
ML3.J&@N%ODMJ2*GE:DK)ZM$5?0U33TU3RFGE^OUJJJ(N6IICCB>E\E+/<ZN5
MQ'S:XF>S&'RRKTR[$<BP3(KIBF66N:S7ZS3+#7T$VFK5TU:YKFJK7L<BHYKF
MJJ.145%5"\97-6\S;B[:G&F=TJ_=M56JIHKC"86S9-M%RVIL!R"ONW(JAK+/
M!C]747*T,MT?Y[3-I7NE@1_F[5]4Q%:B]AS3+ZII$YBFFG*S%72C"<>''9.]
M:[N4SL6YF;L883LP[':5O[$;*W??C,ZK#;->:.Q5%':I[M-6UK)'L6."6&%6
M-;&BJKE=,GE[--2^ZSJU&F68NUTS5$U1&$=F)GY%=R.2JS=SH4SALQ2&O_A_
M[LV[)L<QVRW:V7^GO4-347/(NB:FH;;'3NB:G?O<USG/D[SU#&-5RZ*NFB*J
M05GKME*[55RNF:9C#"G9,U8X[NUAMF6_<T&]37%,3$X\/!#9U1X:5[;;VR4F
M[=#-==/54<UHDBI]=/(D[:J1_E]'NB/IZ_T=+;9G#ZVWO8?*VIZN58;+D8]K
MQ_(@7NMM1F&S>6U&'9I21P7".)M315=,]9*:KII%<UD\#U1JJU5:Y.U$5%14
M5$4N>FZE9U"S%VU.S=..^)XI06:RM>6KZ%>_PLDV6X_[A[Z76HHL/H8J>UVY
MS4O.2U[G14-+U=J,5[6N<^14[48Q%7T5T;VF#5M;R^FT1-V=L[J8WSXNS+)D
M\A=S4X41LC?,[DV4\-"X>9H]=X:=+ATZK3>P;^YZM/)WOGW5IKZ/1^45'X_I
MZ7\B</K;>]T?E37PW.'\S;VO&AAO9QUW&V)K:9F64<-=8[C(L=JRFW.=+13/
M1.KNG*YK712=/;TO:FNB]*N1%4M>D:[EM3IGT4X51OIG?'9[,=F.[@AL[I]W
M*S\_=.Z8W-$$TT0                        WYX87S]MY?O55'Z>QLXIU
MM_REW]W[E*^:+^4H[OWI=%!7$H 0 \4?YB>^?[F?WSVD"@39'^##&/\ YW].
MSG:NJ7^+M?O??J4/6OS=?<^[#:Q9$6                       )U^'E_#
MQ</M3N'Z9HRF]>/R$?7CP2G.K_YF?JSX838YV[A9KMUMWB%TP?)*W&;A79&E
M+5U=$]&/DA\TG?T.547LZFHOY14NIN1L9O,5TWJ(JB*,=O'C"9US,7+-JF:)
MF)Q^257U+RKY#T=1#4Q[K7J1\#VO:R=T4T:JU=='1R1N:Y/314T.AU=6].JC
M#T-/+"M1JF:B<>G*[_C]G60[E[/8/F^5445#?K[23/KHH&JR-_<U,L$<S&*J
M]*3,C;)IZ'5V=AR+6\G;R><N6;<XTTSL[T3AW)V+ID+]5^Q377&V>?Y50>[5
M!;;;S:JZ:U-8VE?G]DJ7MC3I;YQ4RTD]3V)Z/?2/U^J=/TRNJO1(FK?Z*J.Y
M&,1R8*EFZ8IS^$>7'R8\J]\XVO*K7Q MB>^BI]\,:H_SV!(:#/H(F]KF=D=)
M7+I_.]D+U]+N_2<IT7J3K.$SD[D]FCY:?ECNJQKV1Q_]]/:J^2?D[SX/#._[
MSO-_8\?_ )MQ/?\ ] W6/W_^+SU;WW/W?E:[\1[^&+#OM-I_;"N-[J'^3K_[
M)^[2U^L7\^GZORR@);K?6W>X4%JMU.^KN%SJ(J2@I6=KI9IGI'&QJ>FYRHB%
MUN5TVZ9JJG"(C&>U""IIFJ8B-\ND##K%8=BMG+5::J9L-EV[Q]]1>JV-.R1U
M/$ZHK9T1=.V23K?IZ:G!LU>N:EG)JCZ5RK9';G"F.Y&$.B6:*<K8B)W4QM\,
MOLR:S8]O;M/<;5',V?'MQ<?22VUJHB]#:R%LU+4(G;ZJ-ZL>B>FAYR]VYIV;
MBK]:W5MCM3A,=W;#[=HIS5F8X*H\.YS=7JSW#'KS=K!=J=:6Z62LGH+E2N\L
M<]-(Z*1B_D.:J'>K-VF[1373.,51$QVI<ZKHFBJ:9WQL>89'E]%'5U-OJZ6O
MHIWTU913,J*2IC71T<L;D<Q[5]!45$5#S53%433.V)?8F8G&'2OM=FE#NGMG
MB.9L9%+!E5IBEN%+HCHVU"M6*K@5%U149*U[%_(. ZCE*LEFJ[7#35L[6^)[
MV$NCY6]%^U37QQ_Y<]F\N!2[8[HYO@SV.;!8;I-';5?KU/HI=)J-ZJOHN@>Q
M5.X:5G8SF5MWO*C;V]U7+BH&<L>@O54<4\G!R+/?#HV_]B<"RS<6K@Z:K+[B
MVW6N1R=OF5M1>M[%])\\CVK]6-#GG7K.]/,46(W41C/;J\4<JS=7LOT;=5R>
M&<.Y'C\#17B)[B^S6X.-[<44_51X50>>W:-J]GLA<D:]K7IZ*LIVQN3^R*3/
M47(^CR]=^8VUSA'U:>><>\T>L&8Z5V+<?JQM[<^+PL#V?X,[F;GV&ARJ[W2B
MP.P76))[2M=%)45U1$[ZR5*5JQHUCD[6J^1%5-%1O2J*;FJ=<,KD[DVZ8FNJ
M-^&R([&/'VH8,IHEV_3%<S%,3NX^\W=6>&A<&4ZNH-X:>HJD8ND-18WPQJ[T
M$ZV5TJHGU>DB*>O]./SK$X?6Q_XPW9ZMSALN<GC08WDV/SO8W((+#FE'"L=P
MC?-9;W1/66BK8V*B/6)[FL<CF*J(YCVHY-4731S56XZ5J]C4K<UVIW;XG?';
MYT)G,E<RM71KX=T\$OXVAV1W WNODMEPBV,EBHD8^\7RK<L-#1,>JHU9I4:Y
M=7:+TL8USET54;HBJC5-7R^G6^G>G?NB/I3VH^7<^93)7<U5T:([<\$)STGA
MHW-]$CZ[=^EI[@K=74T%D?-"CO11)G5L3E3ZO=_E%/JZ_P!/2V6)P^MM[W1G
MPIN.K<X;;FWM>-&??'B)N7LE;GY)524F5X='(R.?(+:CVNIG2+TM\ZIWIU1H
MYW8CD5S=51%<BJB%@T?K/EM1J]'&--?%/#VIX>24;G=)NY6.E.VGCCY48;;;
M;A>+A16FTT4]RN=RF934%OIF.EFFFD<C61QL:BJYSE71$0L-RY3;IFJJ<(C;
M,SP(VFF:IB(C&96$X/X<V?WRVT]?FV:6["*BH8CTM%/2NNM3$B_F9E;-3Q([
MZC'O3ZI1\YU[R]NJ:;-N:XXYGHQW-DSWXA/V.KUVJ,:ZHI[&_F?WF?AR9]9[
M=45N%YO;,RJH$5S;34TSK5-,U$\D3G35$75Z2/>U/Z(93KWE[E41=MS1''$]
M*/!$]Z)+W5ZY3&-%45=C=SH08G8LHI=R\7QND<_&<RAR6AM]'+61JQ]!<DJV
M11NEC<URIW4NBJBM7R>12W9F]:JRU=R?G4="9G#]:G#@[<(6U17%VFF-E72B
M.U.*R+?C:SD_8MH\WNV;[]TF5XK14<;[SCT=OCB=51K41-:Q'I"U4T<J+Y?0
M*'HVHZ7<SENFSEIIKF=DX[MD]E8L]E<W18JFN[C3PQ@AAQ[XX7[D)/E<-ER*
M@QYN*1T;ZI];'+(LJUJS(Q&)&GH=P[75?2+7KFO6]*BB:Z9JZ6.[#@PYT/I^
MG59SI=&8C##E;C=X?VZ[\Z7%*:[6V2PT]!!77#-Y630T;73OE9YM#&J+)-*U
M(^I4;HU$5.IS=4UBOC;*>@])-,]+&8BG9CLPVSP1&WFAN>X;WI.A$QAAOX.T
MV/>/#5R."A[RP;JVZYW%&*OFE?:Y:*%7:=B)-'453M%]/NS0M=?K<U?/LS$=
MBJ)Y,*?"V*^KE41\VN)GLQA\LJ\<VPO(]O,IO&&Y9;W6R_V.9(:ZE5R/;ZIJ
M/8]CVZHYCV.1S53RHJ%YRF;MYNU3=M3C35N5^]9JLUS17&$PW5L9Q:W(WU;+
M<[*RGL&)4TJPU&57/K2%\C?KHZ:-B*^9S?1TT:GD5R+V$3K'6/+:;\VO&JN?
MU8^7B\/8;N2TR[FMM.RGCGY.-+"M\-&YLHW/MV[]+57!&JK*:ILCX(5=Z"+*
MRMF<B?5[M?R"M4=?Z9J^=8F([%6,][HQX4I5U;G#9<V]KQH(;M;,Y[LKD+<?
MSBUMIG5372VF[TSEEHJZ)BZ.?3S:-UZ55.IKD:]NJ=34U36Y:9JN7U&WT[,[
MM\3OCMQ^D(/-Y.YEJNC7':G@EJLDFJ                        $T?!L_
MUXYJ_J[C7Z9R,X'K/YZ__P!E?WI=&R/Y>W]6GP0O3(UM % /CG?\+O[MO\P
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MW;QZUV.SQ+)43OI:E7/<O8R*)OE?)([1K6IVJI7LGURIS=VFU:LU35/9CO\
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MEUU] O&,88H#!/W;KP]MRLLL])><OR.@P!M?&R:FM,M/)75[&/3J_P"T0M?
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MZ,=S9,SWH>LOU?N5TXUU='L88SW=S =[>$FXFTECJ\LM5TIL]Q:V,66[U='
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M9*-4NU446YIZ,8S,S'>[OR-G/Z75E*(JJJB<9PP10+*B@
M   ;3XJ?/LXK?NY_>Q5G./\ Z!__  _[_P#P6CJW_P#D_=^5THG.%H
MY \A^>_RK^WC.?WRN+KU$_/5_P#7/WJ4#UA_+T_6CP2VP=94T
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M]T=&U:FCRQE+#*J>J2.IH:I[T1?258&Z_D(9NH=<QF[E/!-&/>F.=XZQ4_\
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MOUD__'^]\B5AT=5P                  6=^&G_ ..[M?X!:/[;5'/.O_\
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M/W95J]_D/_W(\*U[EQ\W+=3]38?TY <VZL?Y*SVY\$K3JWY6OM?+#GI.X*
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MB+V(W2R]0\Y<JFY8F<:8B*H[&W">^BNL5BF.C<C?.R>RJO.CJN
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MM/BP;]S-YZB,9M1AV_&H]54555$T15[$](Z\I3_#Z
M    #?GAA?/VWE^]54?I[&SBG6W_ "EW]W[E*^:+^4H[OWI=%!7$H 0 \4?Y
MB>^?[F?WSVD"@39'^##&/_G?T[.=JZI?XNU^]]^I0]:_-U]S[L-K%D18
M                   G7X>7\/%P^U.X?IFC*;UX_(1]>/!*<ZO_ )F?JSX8
M2F\2'^"S!?MJ3](U)7>H?YJY]3Y82G6+^33];Y)1SX4<E:["LFHMK<VN\L^$
M9'(VFQRIJY%<RTU[UTC8USE7H@G5>E6_6M>K7>I17JL[UMT"G,6IS-FG_P!E
M.VK#]:GGCEC9Q([1M2FU7%JN?FSN[$\TK&N1^P]DWTP2MM3Z>"FS&U1OJ,.O
MSFHU\-2U%5())-->YF^M>GD3L?IU-0HF@ZS7IM^*L9Z$[*H[''VXX.]PK#J.
M1IS5O#]:-T_IP2HLV]MEPLF\F#6>[4DEONEJS*UTEQH9DZ9(9X;A$R2-Z>@K
M7(J*=ASURFYDKE=,XQ-NJ8GCB:94C+TS3?IB=\51X5Y'+OYN.Z?ZG4_Z=ISD
M'5C_ "5GMSX)7;5ORM?:^6%9'"/??X,,_P#L*R"L[G"<_GCIY'R.TCHKHNC*
M:I[>QK9.R*1?^@Y5T8=!ZW:-[9E_341_[+?+3PQW-\=WC5K1<]Z"YT*OHU<D
M\$_(O$[J-)%F2-J3.:C'2Z)U*U%54:J^71%5>PY#C.&"[8*9?$>_ABP[[3:?
MVPKCJO4/\G7_ -D_=I4[K%_/I^K\LIJ\&]M/L"V1MMZK*?NKWN'-[.U;G)H]
M*1S>BA9KZ+5B3O4_LBE3ZX:A[5GIHB?FV_F]W];EV=Q,Z)EO19>*IWU;>YP<
M_=;%OW*G8#&;U=<=OFX])17FR54M%=*/S6NE[FH@<K)(U?%3O8JM<BHNBKVF
MA9ZN:A>HBY1:F::HQB<8W3W6Q<U3+453357MCL3S/YLG*WC[D5XM=@L^Y-'5
MW:]5<-#;*1:2NB[VHG>D<4?7+3L8BN<Y$3540^WNK>H6J)KKM3%,1C.V-T=T
MHU3+5U13%>V>Q/,QSF/ME\)6Q^1I1T_?WW#?_P 8K+TIJ]WF;7><Q)IVKUT[
MI-&IY7(TS]5=0]CSU.,_-K^;/=W<N'<Q8]8RWI\O.&^G;'<W\B@,[6H8!(CB
MKN+\&>^6%7FHG[BT7>I]@K\Y5T9YK<52+K>O\[%+W<J_] @NLF1]LR-RB/I1
M'2CMT[>6,8[J0TO,>@S%-7!.R>[^F*^_+\)Q_.*>QTV04OG4>.WN@R"UIV>H
MK;=+WD+EU145%[6N3T454.+Y7-W,M-4T3ATJ9IGM5;U[O6:;L1%7!,3W81<Y
MV;B_85LA76&DG[J[[AU3++ C5T>E&GY]6OT]%JQM2)W]D+'U.R/M&>BN8^;;
MCI=W=3R[>XB]<S'HLO-,;ZMG<X>;NJ=-G<*IMQ=T<$PFNF=!09%>*>FN,L:Z
M/2FZNN=&*OD<L;7(U?3.I:KFYRF5N7HWTTS,=O@Y51R=F+UZFB=TROMW%RG&
M>-^SMUR&P8>QUCQ&&"&W8S;&MIHW/J)HZ>-7R(UW2G6]%?(J.<O:OJG+V\8R
M.6NZOG(HKK^=7CC5.W=&/_B%ZS%VC)6)JIIV1P0B1QVY8;N;[[RV['9K!:+-
MA%%1UM=?H;?3S22LB9"YE/WU5-(]$UG?&B=+6Z_R2S:[U:R>F9*;D553<F8B
M,9CCVX1$<6/&B=/U6_F[\4X1%.W'#G[;(/$=U^!O$.SU/V9TVJ_5]CJ_0P]0
M_P [7_US]ZEDZQ?R*?K?)*5VQ-[I,AV8VLNU%(V2*?%[7%(K=-&S4],R"=G9
M_.2,<U?R"M:S9FUG;U,^75WIG&.1*Y&N*[%$QY,>!S[[J8)?-O-Q<IPZ\T$U
M-66^Y3LHD<QR)4TSY7>;SPZHBO9*S16JG\T[;IN<MYK+47:)QB8C'L3AMB>T
MH.:L56;M5$QNE-.R>';F%\PS'<A3.Z2RY!>+?#6W#%[G;Y8O,Y)F]:0OJ(Y9
M'*YJ*B.UB31=4*G>Z\V;=ZJCT<S3$X15$QMPX<,(\*9HZOUU6XJZ6$S&Z8W?
MIVFQ?#FKJ*V77>C#%N%-75E-46^IHZJE<KHJJ&F?54\LT*N1KE9JZ-456IV.
M3L0T.O=%5=%B[A,1,3$X\$SA,1/9W]YL=7JHIFY1CQ?*\+Q(,&O3[W@NXM-1
M2U-B9;9+'<ZV-KG,I9HZA\\'?*B:-27OW(U5\JM5/2US=0\Y1T+EB9^=CTHC
MCC#"<.UARO'6*Q5TJ;D1LPP1LXX<6+WR"I,HN:7YV(6>P]S!17:6A6KBK*N3
MJ<^!OY]!IW;$17*BKIU-[.TG]>ZQT:7-%/1Z=56^,<,(X]T[^!':=I=6;BJ<
M>C$<.&.,O5O6PMVV!W_V3QZ\Y-:\AJ;UDEEKZ=M DS)8H$ND,373QRM1&];F
MN1O2YWUJ^3T<=K6J-4T_,5T433$451MPW]&9V=IZKR-64S-NF9B<9B=G;6J<
MN/FY;J?J;#^G(#G'5C_)6>W/@E:-6_*U]KY80R\,_P#[WO+_ &&P?TUP+7_]
M W6/W_\ BA^K>^YW/E89XD3E7<[ F:^I;BZJB?56MGU_F&UU"_*W/K_)##UB
M_G4_5^665^&C_P"+;O)Z'FEE_ME::W7_ .A8[=7_ !9>K?TKG<^5_7/"[QV#
M?79&^RZ=U9:6EKY->U.FFN?>KK^4T=3;7I<AF*(_6F8[].!KE?0S%NKBV\JS
MS*+G>*/$;]>,2H8;_?*6UU%9CUL<_P#.JVH9"Z2")'M7R2N1&HJ+Z)SW+VZ*
MKU-%V>C3,Q$SQ1CMGN+-=JJBB9HC&<-G95@V'G_NUDV26O$;-M/9:K(;Q71V
MZBMO?U;7K42/[M&OZE3HZ5^N5VB-1%5=$0Z%>ZE92S:F[7>JBF(QF<(W*S;U
MZ]77%$41C,X<+9.]>Z?*NV[=YW;\NV,L='BETL5?;KSDEONK*IM-3UD#Z>29
M&-G5Z=*2:IU,\IH:3IVE5YBW5:S%4UQ5$Q3-.&,Q..&[#E;.=S6<IM517:CH
MS$Q,Q/'W5.IU-4                         FCX-G^O'-7]7<:_3.1G ]
M9_/7_P#LK^]+HV1_+V_JT^"%Z9&MH H!\<[_ (7?W;?Y@ BR?HYR\    'J6
M.[U5@O5GOU"J-KK)6T]?1N7R)+32-E8O_I-0Q7K47:*J*MU43$]W8]T5S15%
M4;XG%TKVRXXWNWMU!7TC_/,7W L3FN1%3J6FN$"LEC=IKH]J/5KD]!R*AP*Y
M;N9',]&=E=NKEIET:FJC,6L8^C5'A<^V[FQFX.SF25UDR6R54EOCE=[$Y+!"
MY]#6P*Y4CDCE;U-:YR::L<O4U>Q4\FO;=,UC+ZA;BNW5&/#3PQ/:^7=*A9O(
MW<M7--4;.">"4N.$W&BX9%D<VX^Y.(L=A=OHYH+#:;Y1H^.YU52U8UE2GJ&J
MU\4+%=ZIS=%>K>G56KI6.MO6"FU;]!EZ_P#V3.V:9^C$<&,<,SR8X[TKHVFS
M75Z2Y3\V-T3&_N<3U.<NSVQVU^/X[<L/QQ<<S;*+D]L%#0U,B4:T=.SJJ974
MTBO:S1SXVM2/H3U6OH&/J?JF>SMRJF[5TK=,;YC;C.Z,>_OQ>];RF7L4Q-$8
M53/<PX=CR?#LW)]A<[R3;.NJ.FBS.C]D+-&Y>Q+A;VN=(QB>G)3JYR_V-#+U
MZR'I+%.8B-M$X3]6KFGPO'5_,]&Y-N=U48QVX\7@655VS]GK=\;#O2_N_9&S
M8S56+S?IT<L\DS5AJ$7315;#)/&NO;HYOH(4&C5*Z<C5E.":XJ[F&V._%,K'
M5E*9S$7N&*9CQ][%7UXCNX_G5VPK:NAGUAM<3LAO\;5U3OY^J"C8[TG,C25V
MGI/:7;J'D,*+F9F-_P V.U&VKEP[R!ZQ9C&JFU'!MGY/E[[S?#75/LSW-3T5
MLM$J?E5#C)U^_DVOK3X'CJY_,K[4>%]_B50RKD6T\J1N5DMOND<;D1=%<V:G
M56I]7U2'CJ#,>CO=NGP2]=8X^=1VI^1N?PZ+_1UVT&3X\V5OLE8,FFGJ:9/K
MFT];30+#(O\ TGQ2HG_1(GKU9JISE%?!51RQ,X^&.^W.KUR)L54\,5>&(\:*
M'/[;G(+'O!4;@OH9IL9S6CHDANK&N=#%64=.RE?32.TT:]60M>U/S2*NFNCM
M++U*S]NYDXL8_/HF=G#A,XX\N"+U[+U4W_28?-JPV]F-F#*?#NVZR"KS^][E
MST,U-B]GM,]LH[A(US&55;521ZQPN5$1Z1QQN5^B^I56:^4UNO.?MTY>G+Q.
M-<U1.'%$8[^W.[NLO5_+U3<FYA\V(P[K;_B2Y'0PX5MWB/>M=<KC>YKND"*B
MN;!1TSZ?J<GE1'.JM$]/1?2(OJ%8JF_=N\$4Q3W9G'_BV^L5R(MT4<,SCWH\
M:;FR?\#6TGVEV'VN@*CJWYV]_P!E?WI362_D6_JQX(:IV,Y2XGOCF.=XI:J*
M2U28Y(D^./J7:2W*W-5(I:CN]/4.9+HJMU^M>ST4=I):QU=NZ;9MW:IQZ7TL
M/U:M\1WN6):N1U2C-5U41&&&[LP@)SVV0^PW-(-U+!1]WC>>3*R^LC;HRFO*
M-5SW+IY$JF(LG_3;(OHH77J7J_M%CV:N?G4;NS1_#N[6"!UW)>BN>EIW5;^W
MX^=)7PX/X(<S^W";VOHB Z^?G+?U(^]4DNKO\BKZWR0A3SN^<;DWZFVG])QE
MLZF_XVCMU>%"ZY^:J[4>!<YN.Y6;39X]JZ.;B5T5J_52@E.4Y#\W;^O3]Z%Q
MS/\ )J^K/@<SY^@'-W2_F/;M)E2KY5Q&NU_Q!Y^?\K^;H^O'WG2+W\FKZL^!
M!3PV+Y3RXGN7C?>,2KH;M1W)(=4ZUCJH%AZD3RJB+3Z?4U^J7+K]9F+UJYP3
M3,=Z<?E0?5RN.A73V8G].\VERCY-[@<?\DL-);,%MU\Q;(*#O:2_5<D[/^VQ
MR/;/3+W:]**UG=O37RH[ZBZ1O5WJ_E]4MU35<FFNF=T8;N"?#WFUJ>I7<I7$
M13$TS&_L\3%-N.2/)[=G&*S+<%V2QVZVBDJW4372W-U(^:6-K7O[E*F6-KT;
MU(BKKIKV>5%TV<_H.EY&[%J]F*HJF,?HXX=O")8LOJ.;S%'3HMQ,=O#PJ_\
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M*WUM_P 7=_=^_2E-%_-T=W[LNOHXJO@  XK^,?\ ^N__ -K?_LHZ/_\ /_\
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M&&,?_._IV<[5U2_Q=K][[]2AZU^;K[GW8;6+(BP
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MIGI]*G'CPV^#% CECS!H]W+5\'FW=/54F%.F9/?KS6,[F>Y/@?UQ11Q(Y59
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MHZ,31AOIG;C$\$SQ)+6<_8S%JFFW5C,3CNF.">.&GN$V[.W^T6=9=>=P[_\
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MA5B='5<     #5.]W\&&3_\ R7Z=@*WUM_Q=W]W[]*4T7\W1W?NRZ^CBJ^
M#BOXQ_\ Z[__ &M_^RCH_P#\_P#_ .(_<_YJOUD__'^]\B5AT=5P
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MW^5?V\9S^^5Q=>HGYZO_ *Y^]2@>L/Y>GZT>"6V#K*F@
M
M               '\X]_#=Q4^_E@WMDTI/7O\C1_V1]VI/=7OS%7U9\,.J8Y
M.N0!H#EC\UCDM]ZK,O:.L YA-D?X,,8_^=_3LYVKJE_B[7[WWZE#UK\W7W/N
MPVL61%@
M                                      &_/#"^?MO+]ZJH_3V-G%.M
MO^4N_N_<I7S1?RE'=^]+HH*XE " 'BC_ #$]\_W,_OGM(% FR/\ !AC'_P [
M^G9SM75+_%VOWOOU*'K7YNON?=AM8LB+
M
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M#I3P8=B)VS/<8M8U&BW:FW1.-56S9P1PJ43K:F
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MN71%5$U*9U*RUVWGJIKIF(Z$[XF.&E.Z]=HJR\1$Q/SHX>Q*FHZJIX
M                                              :IWN_@PR?_ .2_
M3L!6^MO^+N_N_?I2FB_FZ.[]V77T<57P  <5_&/_ /7?_P"UO_V4='_^?_\
M\1^Y_P U7ZR?_C_>^1*PZ.JX
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M>AU(WT#L'5_2O=V4IMS]*=M7;GFC"%)U+.>U7IKC=NCM- $VT
M         -I\5/GV<5OW<_O8JSG'_P! _P#X?]__ (+1U;__ "?N_*Z43G"T
M      <@>0_/?Y5_;QG/[Y7%UZB?GJ_^N?O4H'K#^7I^M'@EM@ZRIH
M
M                         !_./?PW<5/OY8-[9-*3U[_(T?\ 9'W:D]U>
M_,5?5GPPZICDZY &@.6/S6.2WWJLR]HZP#F$V1_@PQC_ .=_3LYVKJE_B[7[
MWWZE#UK\W7W/NPVL61%@
M                                                   &_/#"^?MO
M+]ZJH_3V-G%.MO\ E+O[OW*5\T7\I1W?O2Z*"N)0 @!XH_S$]\_W,_OGM(%
MFR/\&&,?_._IV<[5U2_Q=K][[]2AZU^;K[GW8;6+(BP
M
M              ":/@V?Z\<U?U=QK],Y&<#UG\]?_P"RO[TNC9'\O;^K3X(7
MID:V@"@'QSO^%W]VW^8 (LGZ.<O          #_4<Y$<U'*B.^N1%[%T],^#
M_#Z
M                       !9-X*GS6,^^^K=?:.QGYQ=06_  .5CFS_ !G>
MYG_VF_>70ECZI?Y2U^]]RI%ZU^4K[GWH?V=K4,
M
M          U3O=_!AD__ ,E^G8"M];?\7=_=^_2E-%_-T=W[LNOHXJO@  XK
M^,?_ .N__P!K?_LHZ/\ _/\ _P#B/W/^:K]9/_Q_O?(E8='5<
M                                                         #_7
M.<Y>ISE<OIJNJ]A\'^'T                     ;3XJ?/LXK?NY_>Q5G./
M_H'_ /#_ +__  6CJW_^3]WY72B<X6@     #E#QG:[.]V^?7+7'-OK%]D%Z
MHLJSVY55'YU2TG32QY2V%\G75RPL71\S$T1VO;Y-$4M'5/4;&1S55R_5T:9H
MF,<)G;C3/!$\4HG6<K<S%F*;<8STL>".">-,'Y$W)SXL_P!F;+Z^.A?%NE^M
M\VO\*L^Y<WY'+3SGR)N3GQ9_LS9?7P^+=+];YM?X3W+F_(Y:><^1-R<^+/\
M9FR^OA\6Z7ZWS:_PGN7-^1RT\Y\B;DY\6?[,V7U\/BW2_6^;7^$]RYOR.6GG
M/D3<G/BS_9FR^OA\6Z7ZWS:_PGN7-^1RT\Y\B;DY\6?[,V7U\/BW2_6^;7^$
M]RYOR.6GG/D3<G/BS_9FR^OA\6Z7ZWS:_P )[ES?D<M/.?(FY.?%G^S-E]?#
MXMTOUOFU_A/<N;\CEIYSY$W)SXL_V9LOKX?%NE^M\VO\)[ES?D<M/.?(FY.?
M%G^S-E]?#XMTOUOFU_A/<N;\CEIYSY$W)SXL_P!F;+Z^'Q;I?K?-K_">Y<WY
M'+3SGR)N3GQ9_LS9?7P^+=+];YM?X3W+F_(Y:><^1-R<^+/]F;+Z^'Q;I?K?
M-K_">Y<WY'+3SGR)N3GQ9_LS9?7P^+=+];YM?X3W+F_(Y:><^1-R<^+/]F;+
MZ^'Q;I?K?-K_  GN7-^1RT\Y\B;DY\6?[,V7U\/BW2_6^;7^$]RYOR.6GG/D
M3<G/BS_9FR^OA\6Z7ZWS:_PGN7-^1RT\Y\B;DY\6?[,V7U\/BW2_6^;7^$]R
MYOR.6GG/D3<G/BS_ &9LOKX?%NE^M\VO\)[ES?D<M/.?(FY.?%G^S-E]?#XM
MTOUOFU_A/<N;\CEIYSY$W)SXL_V9LOKX?%NE^M\VO\)[ES?D<M/.?(FY.?%G
M^S-E]?#XMTOUOFU_A/<N;\CEIYSY$W)SXL_V9LOKX?%NE^M\VO\ ">Y<WY'+
M3SGR)N3GQ9_LS9?7P^+=+];YM?X3W+F_(Y:><^1-R<^+/]F;+Z^'Q;I?K?-K
M_">Y<WY'+3SGR)N3GQ9_LS9?7P^+=+];YM?X3W+F_(Y:><^1-R<^+/\ 9FR^
MOA\6Z7ZWS:_PGN7-^1RT\Y\B;DY\6?[,V7U\/BW2_6^;7^$]RYOR.6GG/D3<
MG/BS_9FR^OA\6Z7ZWS:_PGN7-^1RT\Y\B;DY\6?[,V7U\/BW2_6^;7^$]RYO
MR.6GG/D3<G/BS_9FR^OA\6Z7ZWS:_P )[ES?D<M/.?(FY.?%G^S-E]?#XMTO
MUOFU_A/<N;\CEIYSY$W)SXL_V9LOKX?%NE^M\VO\)[ES?D<M/.?(FY.?%G^S
M-E]?#XMTOUOFU_A/<N;\CEIYSY$W)SXL_P!F;+Z^'Q;I?K?-K_">Y<WY'+3S
MGR)N3GQ9_LS9?7P^+=+];YM?X3W+F_(Y:><^1-R<^+/]F;+Z^'Q;I?K?-K_"
M>Y<WY'+3SGR)N3GQ9_LS9?7P^+=+];YM?X3W+F_(Y:><^1-R<^+/]F;+Z^'Q
M;I?K?-K_  GN7-^1RT\Y\B;DY\6?[,V7U\/BW2_6^;7^$]RYOR.6GG/D3<G/
MBS_9FR^OA\6Z7ZWS:_PGN7-^1RT\Y\B;DY\6?[,V7U\/BW2_6^;7^$]RYOR.
M6GG/D3<G/BS_ &9LOKX?%NE^M\VO\)[ES?D<M/.?(FY.?%G^S-E]?#XMTOUO
MFU_A/<N;\CEIYSY$W)SXL_V9LOKX?%NE^M\VO\)[ES?D<M/.?(FY.?%G^S-E
M]?#XMTOUOFU_A/<N;\CEIYSY$W)SXL_V9LOKX?%NE^M\VO\ ">Y<WY'+3SGR
M)N3GQ9_LS9?7P^+=+];YM?X3W+F_(Y:><^1-R<^+/]F;+Z^'Q;I?K?-K_">Y
M<WY'+3SGR)N3GQ9_LS9?7P^+=+];YM?X3W+F_(Y:><^1-R<^+/\ 9FR^OA\6
MZ7ZWS:_PGN7-^1RT\Y\B;DY\6?[,V7U\/BW2_6^;7^$]RYOR.6GG/D3<G/BS
M_9FR^OA\6Z7ZWS:_PGN7-^1RT\Y\B;DY\6?[,V7U\/BW2_6^;7^$]RYOR.6G
MG/D3<G/BS_9FR^OA\6Z7ZWS:_P )[ES?D<M/.?(FY.?%G^S-E]?#XMTOUOFU
M_A/<N;\CEIYSY$W)SXL_V9LOKX?%NE^M\VO\)[ES?D<M/.?(FY.?%G^S-E]?
M#XMTOUOFU_A/<N;\CEIYSY$W)SXL_P!F;+Z^'Q;I?K?-K_">Y<WY'+3SGR)N
M3GQ9_LS9?7P^+=+];YM?X3W+F_(Y:><^1-R<^+/]F;+Z^'Q;I?K?-K_">Y<W
MY'+3SGR)N3GQ9_LS9?7P^+=+];YM?X3W+F_(Y:><^1-R<^+/]F;+Z^'Q;I?K
M?-K_  GN7-^1RT\Y\B;DY\6?[,V7U\/BW2_6^;7^$]RYOR.6GG/D3<G/BS_9
MFR^OA\6Z7ZWS:_PGN7-^1RT\Y\B;DY\6?[,V7U\/BW2_6^;7^$]RYOR.6GG/
MD3<G/BS_ &9LOKX?%NE^M\VO\)[ES?D<M/.?(FY.?%G^S-E]?#XMTOUOFU_A
M/<N;\CEIYSY$W)SXL_V9LOKX?%NE^M\VO\)[ES?D<M/.?(FY.?%G^S-E]?#X
MMTOUOFU_A/<N;\CEIYSY$W)SXL_V9LOKX?%NE^M\VO\ ">Y<WY'+3SGR)N3G
MQ9_LS9?7P^+=+];YM?X3W+F_(Y:><^1-R<^+/]F;+Z^'Q;I?K?-K_">Y<WY'
M+3SGR)N3GQ9_LS9?7P^+=+];YM?X3W+F_(Y:><^1-R<^+/\ 9FR^OA\6Z7ZW
MS:_PGN7-^1RT\Y\B;DY\6?[,V7U\/BW2_6^;7^$]RYOR.6GG/D3<G/BS_9FR
M^OA\6Z7ZWS:_PGN7-^1RT\Y\B;DY\6?[,V7U\/BW2_6^;7^$]RYOR.6GG/D3
M<G/BS_9FR^OA\6Z7ZWS:_P )[ES?D<M/.?(FY.?%G^S-E]?#XMTOUOFU_A/<
MN;\CEIYT?LFPG)]I.4W$K;C<&V?8_F=;NK@624MF[Z&KZK7)?'4;*COZ22:%
M-9H7MZ%?U]FO3HJ*5?K9KF3SV5IMV*^E5%<3AA5&S"J.&(XX2^C:??R]Z:KE
M.$='#?$\,<4NGPYZLH!H#EC\UCDM]ZK,O:.L YX^(6PN[&\VS5%?-ML4^R2U
MX_=:^R7>J\^H*/N:]CVUJP]%940.=I!5Q/ZFHK?5::]2.1.H=7>L60RF0MVK
MMS"N.EC'1JG?5,\$3&Z52U/3,Q>S%5=%.,3APQQ1V4H/D3<G/BS_ &9LOKXF
MOBW2_6^;7^%H>Y<WY'+3SGR)N3GQ9_LS9?7P^+=+];YM?X3W+F_(Y:><^1-R
M<^+/]F;+Z^'Q;I?K?-K_  GN7-^1RT\Y\B;DY\6?[,V7U\/BW2_6^;7^$]RY
MOR.6GG/D3<G/BS_9FR^OA\6Z7ZWS:_PGN7-^1RT\Y\B;DY\6?[,V7U\/BW2_
M6^;7^$]RYOR.6GG/D3<G/BS_ &9LOKX?%NE^M\VO\)[ES?D<M/.?(FY.?%G^
MS-E]?#XMTOUOFU_A/<N;\CEIYSY$W)SXL_V9LOKX?%NE^M\VO\)[ES?D<M/.
M?(FY.?%G^S-E]?#XMTOUOFU_A/<N;\CEIYSY$W)SXL_V9LOKX?%NE^M\VO\
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MK?-K_">Y<WY'+3SGR)N3GQ9_LS9?7P^+=+];YM?X3W+F_(Y:><^1-R<^+/\
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MK?-K_">Y<WY'+3SGR)N3GQ9_LS9?7P^+=+];YM?X3W+F_(Y:><^1-R<^+/\
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M?(FY.?%G^S-E]?#XMTOUOFU_A/<N;\CEIYSY$W)SXL_V9LOKX?%NE^M\VO\
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MK?-K_">Y<WY'+3SGR)N3GQ9_LS9?7P^+=+];YM?X3W+F_(Y:><^1-R<^+/\
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M"_X
M                                   !0#SZ_C3>%?\ NX_?O<0+_@ &
M@.6/S6.2WWJLR]HZP" '@J?-8S[[ZMU]H[&!;\
M
M           H!X"_QIO-3_>/^_>W 7_  ( >*/\ ,3WS_<S^^>T@/"X^8GL9
M^Z;]\]V G^
M                                           H!\#'_BB_<3_G\"_X
M !0#XYW_  N_NV_S !?\
M                                                     T!RQ^:Q
MR6^]5F7M'6 0 \%3YK&???5NOM'8P+?@ % /_P!/7_\ +XL0+_@
M
M                       % /CG?\+O[MO\P 7_    !0#X&/\ Q1?N)_S^
M!?\
M                                     * ?_IZ__E\6(%_P      *
M> O\:;S4_P!X_P"_>W 7_
M                                                      * >?7\
M:;PK_P!W'[][B!?\  T!RQ^:QR6^]5F7M'6 0 \%3YK&???5NOM'8P+?@
M
M                             % / 7^--YJ?[Q_W[VX"_P"  0 \4?YB
M>^?[F?WSVD!X7'S$]C/W3?OGNP$_P
M
M % /@8_\47[B?\_@7_  * ?'._X7?W;?Y@ O^
M
M          : Y8_-8Y+?>JS+VCK ( >"I\UC/OOJW7VCL8%OP "@'_Z>O_Y?
M%B!?\
M                                      H!\<[_ (7?W;?Y@ O^   *
M ? Q_P"*+]Q/^?P+_@
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MW_V<HMVJ'8FISV@BW<N47?46#],RU3V>:OK=>I(UC3\XC=)HK_(GY &X0
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MF34V6XG733T]+>J1LC8GRTSUCE:B2L8[5KDT7L SX
M                   H!Y]?QIO"O_=Q^_>X@7_  - <L?FL<EOO59E[1U@$
M /!4^:QGWWU;K[1V,"WX
M                                                    !0#P%_C3
M>:G^\?\ ?O;@+_@ $ /%'^8GOG^YG]\]I >%Q\Q/8S]TW[Y[L!/\
M
M                        !0#X&/\ Q1?N)_S^!?\   * ?'._X7?W;?Y@
M O\ @
M                                     &@.6/S6.2WWJLR]HZP" '@J
M?-8S[[ZMU]H[&!;\  H!_P#IZ_\ Y?%B!?\
M
M         * ?'._X7?W;?Y@ O^   * ? Q_XHOW$_P"?P+_@
M
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MO[AY]M7M_E<M[S;;*6I@S*UNMU=2LI7T=6M#,C9ZF".*7IG16ZQN=KY4U3M
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ML>U51S7(J*BHNBH!^X                   4 \^OXTWA7_ +N/W[W$"_X
M!H#EC\UCDM]ZK,O:.L @!X*GS6,^^^K=?:.Q@6_
M
M            * > O\:;S4_WC_OWMP%_P " 'BC_ #$]\_W,_OGM(#PN/F)[
M&?NF_?/=@)_@
M                                            * ? Q_XHOW$_Y_ O
M^  4 ^.=_P +O[MO\P 7_
M                                                      - <L?F
ML<EOO59E[1U@$ /!4^:QGWWU;K[1V,"WX !0#_\ 3U__ "^+$"_X
M
M                        !0#XYW_"[^[;_, %_P    4 ^!C_ ,47[B?\
M_@7_
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MY/@-_N"W!=IL@;18\Z1562&TW*'SF&!SE555K)VS]&OD;HQ.QJ 6[@
M            !0#SZ_C3>%?^[C]^]Q O^  : Y8_-8Y+?>JS+VCK ( >"I\U
MC/OOJW7VCL8%OP
M                                              "@'@+_ !IO-3_>
M/^_>W 7_   " 'BC_,3WS_<S^^>T@/"X^8GL9^Z;]\]V G^
M
M                    H!\#'_BB_<3_ )_ O^  4 ^.=_PN_NV_S !?\
M
M                              T!RQ^:QR6^]5F7M'6 0 \%3YK&???5
MNOM'8P+?@ % /_T]?_R^+$"_X
M                                                         !0#
MXYW_  N_NV_S !?\   4 ^!C_P 47[B?\_@7_
M
M          * ?_IZ_P#Y?%B!?\      "@'@+_&F\U/]X_[][<!?\    ,$W
M!VPVZW7LK<<W+PBR9W9(Y4G@MM[HH:R.*9$5J2Q=ZURQO1%5.IBHNB^4#[<(
MP#!]M+!!BNWN(VC"<<IGOEALEEHX:*F223Z^18X6M17NT]4Y>U?14#+@
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M #0'+'YK');[U69>T=8! #P5/FL9]]]6Z^T=C M^
M
M             4 \!?XTWFI_O'_?O;@+_@ $ /%'^8GOG^YG]\]I >%Q\Q/8
MS]TW[Y[L!/\
M                                             4 ^!C_Q1?N)_P _
M@7_  * ?'._X7?W;?Y@ O^
M                                                       : Y8_
M-8Y+?>JS+VCK ( >"I\UC/OOJW7VCL8%OP "@'_Z>O\ ^7Q8@7_
M
M                        * ?'._X7?W;?Y@ O^   * ? Q_XHOW$_Y_ O
M^
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MTVBU4\=);+711,@IJ:GA:C(XH8HT:QC&-1$:UJ(B)V(!]P
M     4 \^OXTWA7_ +N/W[W$"_X !H#EC\UCDM]ZK,O:.L @!X*GS6,^^^K=
M?:.Q@6_
M                                        * > O\:;S4_WC_OWMP%_
MP " 'BC_ #$]\_W,_OGM(#PN/F)[&?NF_?/=@)_@
M
M            * ? Q_XHOW$_Y_ O^  4 ^.=_P +O[MO\P 7_
M
M                      - <L?FL<EOO59E[1U@$ /!4^:QGWWU;K[1V,"W
MX !0#_\ 3U__ "^+$"_X
M                                                    !0#XYW_"
M[^[;_, %_P    4 ^!C_ ,47[B?\_@7_
M
M      "@'_Z>O_Y?%B!?\      "@'@+_&F\U/\ >/\ OWMP%_P
M
M                       "@'GU_&F\*_\ =Q^_>X@7_  - <L?FL<EOO59
ME[1U@$ /!4^:QGWWU;K[1V,"WX
M                                                          !0
M#P%_C3>:G^\?]^]N O\ @ $ /%'^8GOG^YG]\]I >%Q\Q/8S]TW[Y[L!/\
M
M                              !0#X&/_%%^XG_/X%_P "@'QSO^%W]V
MW^8 +_@
M                                       &@.6/S6.2WWJLR]HZP" '
M@J?-8S[[ZMU]H[&!;\  H!_^GK_^7Q8@7_
M
M       * ?'._P"%W]VW^8 +_@  "@'P,?\ BB_<3_G\"_X
M
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MM2@Q''*&!U3<+C,DD4<JPQ(K6M9%WS%>^1[6IJB:]2M10W^
M                                               * >?7\:;PK_W<
M?OWN(%_P #0'+'YK');[U69>T=8! #P5/FL9]]]6Z^T=C M^
M
M                     4 \!?XTWFI_O'_?O;@+_@ $ /%'^8GOG^YG]\]I
M >%Q\Q/8S]TW[Y[L!/\
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MC\UCDM]ZK,O:.L @!X*GS6,^^^K=?:.Q@6_  * ?_IZ__E\6(%_P
M
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M6B%U+;<]QZVW^CHWN1[X&7"FCJ.Y>Y$1%='U]#NSRHH&=@
M                                      "@'_Z>O_Y?%B!?\      "
M@'@+_&F\U/\ >/\ OWMP%_P            5F^+?\R_+/MBL'Z<:!4?PBKZ[
MBURNXV7FOJ9(<(Y,X30TLD\B^H7V<D=1LC5WUNL=WH8W=OUL;D]/50Z>\URV
MSX#AV5YSD,_FUAPZT5M[O,_9JVEH('U$JIKZ/2Q= .*W=ZSY5EN-T?)K+Y)&
MW#?G/<P=#3N[6.2W+;ZF>:)537H[ZY/A:GH=TJ: =F&[F[.#['[>Y'N=N)=D
MM&+8Q3]]62M3KFFD>Y&0TU/'JG>2S/5&,;KVJO:J)JJ!4=1>*1R&W*?=,CV'
MX59%F^V]FJI(I[]I<:Z:9D>BJU7V^C?!#-TN1SHVNF5J+Y53M F-PYY];<\M
MG77&([%5[=[JX_3OK+Q@5?,E4V2ECD;$^HHJM(X>]:QSVI(U\;'L5?K7-]4!
MY7,SQ \+XIW*S8':,7J=SMWLB@CJ:##*2=:>&D@J'K%3R5<[8YG]<ST7NX8V
M*]R)JJL16*X(';U^(EO!4;.[F;:<DN*>1[.1[LX9?[-A.7.AKJ>G=6U5!+'3
MP2TUPIHNKU3VI(YDW4S5%6+1>P)6^#W\SV#[=+Y_,I@-J<)>;%3R^NF\UOGV
MYBP%FU%5::>"6.ZNN2UR71]Q9JY%I*;NEC\P3R=6O5Z&G:&5<W^6E1P]VTQC
M/Z;!8\_ER/)HL?\ 8N6XK;&PMDHZJK6;O6TU4KE3S9&]/2GUVNO9HH1!\5S)
M'9EP4VVR]]&EO?E63XM>'4"/[U(%KK375"Q))TMZNCKTUT37TD F_L9G>+[8
M\)-C]P<UNC+-BN(;-8G<[Y<7HKN[@AL5(JHUC=7/>Y=&L8U-7.5&HBJJ 0&A
M\4+?3=F>^57&+AIDFX&)6:J=3IEM8ZKJ4DZ41_3+3V^F6*&56JB]VE5([147
MT0-I<5O$M7>3=YFP&\>TE9LSNC5.J(+7%-/*L$M931.J'T5335<-//23+&U5
M8CNM'KV>I56HX*[O%6W<W#RC?K;3'[YLQ=\2LNU%]NL&WV1U:U"Q9BR6:V22
M2T7721-T8^!C?SITO]<3M\FH7;;#<C,KSC9W-=VM_MIKAQGBPFY5T=PL^2/J
M4<MIHJ*FJUN6M51T;^ASII(T1L:ZNC5$57>I0( U'BI[K;H9%?:#BKQ+R/=3
M&L=D:E9D=0RMGE<Q=519:2W4\K*99$:O=H^=SG?SNNK4"0G%'Q(,1W_SRIV9
MW"P&X[);S0RU$%%BMSE?/!6RTC'/J*=LDL%++!4QM8]RPRQ)V)ZE[G:M0/NY
M>^(-;.)&[FWVWU_V\DR/'<KLJ7R]Y/3W!8JFCA\YGIUC@HO-GMF>O<=G5,Q-
M7(BJU$5P&G.+WB6[E\A-\\9VVN/'=,4P[-J>OK[1E/LC4JZCH*"G?.^JEEFI
M(X:IBN8D>L?=^J>WM7T0\B_^*)N/N%G.48EQ%XS7;>VRXG-W59FRK6/AG;UN
M8V9*6EI_SB*56.6)99D<].WH:J*T#9W&_P 2;X4-YJ?CUO5LM=MBMTJ]7P6F
MFK9Y)8)ZN.%U1YO/#4TU)-2NEC:JQ:I(U_8B.17-Z@M(
M                                    * >?7\:;PK_W<?OWN(%_P #0
M'+'YK');[U69>T=8! #P5/FL9]]]6Z^T=C M^
M
M          4 \!?XTWFI_O'_ '[VX"_X ! #Q1_F)[Y_N9_?/:0'A<?,3V,_
M=-^^>[ 3_
M                                          4 ^!C_ ,47[B?\_@7_
M   "@'QSO^%W]VW^8 +_ (           4<<]_$YW,V*WHNFRNS5BLD,V&04
M3\NR>^4TE8^>KK::*M93TL3)HF,C9#,Q'N=U.<Y7(G1TZN";7 +E]6\O-JKQ
MD&2V*DQ_.\)N;+3E=-;NOS&H[Z))J>KIF2OD?&V1.IJL<YVCFKHY45- G:
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MO:.L @!X*GS6,^^^K=?:.Q@6_  * ?\ Z>O_ .7Q8@7_
M
M                  "@'QSO^%W]VW^8 +_@  "@'P,?^*+]Q/\ G\"_X
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M+ L=ME@IZOHZ%G2WTL=.LRMU719%8KU[5[5 ST
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MZFTU7H[W7I:H7@@
M      % //K^--X5_P"[C]^]Q O^  : Y8_-8Y+?>JS+VCK ( >"I\UC/OOJ
MW7VCL8%OP
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M!/W,EPIZN@CCJ%II:FE1(ZF":E<Z9DK_ ,\1=$5SD<B,"ZL
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M*JJJ(Z1SG(BH$Q@
M         H!_^GK_ /E\6(%_P      * > O\:;S4_WC_OWMP%_P
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M\.Q_!JBCDS[=*MI:>CJEB96QU#ZRODI7R1(^!C%2F8LSY9%5=-$[&ATQ
M                                                % //K^--X5_[
MN/W[W$"_X !H#EC\UCDM]ZK,O:.L @!X*GS6,^^^K=?:.Q@6_
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MML,ZN2R[O[3TL5-6RU+OS^[V5BI#35Z]7JGRPKI#4+VKU=$CEUET0-.^-O\
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MB\N-N<$Q#;>]8Y9+EB^2.O%?/DM35TT#X'4<U/TQ.HZ.L<K^J1%T5J)IZ/H
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MSIGRS4%"RM>Q]3(R:ICCFGGEZ$:LBL8UC%6-K-%ZE"S
M T!RQ^:QR6^]5F7M'6 0 \%3YK&???5NOM'8P+?@ % /_P!/7_\ +XL0+_@
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MDKG4[>GOW1.FJ%8KO261VGI@;.
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M;[52QT5KH:>VT46O=4E+$R&)NOET8Q$1/Y 'V
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M>FKFO9JKE17*%@H                      "@'@+_&F\U/]X_[][<!?\
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MY_ O^  4 ^.=_P +O[MO\P 7_
M                                                          -
M<L?FL<EOO59E[1U@$ /!4^:QGWWU;K[1V,"WX !0#_\ 3U__ "^+$"_X
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M]VW^8 +_ (   H!\#'_BB_<3_G\"_P"
M
M    4 __ $]?_P OBQ O^      !0#P%_C3>:G^\?]^]N O^
M
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M25F0)#%!5U$4-4^BK:>N93(V!9::9&-:^-$ZT<O5JK5>X+:
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M-C4B[QRHWJ5_3ZE'A*3;"KAK?!NN<L$C9&Q[4Y= ]6KKH^"JN,3VK]5'-5%
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MZM9U>I5P=$E'1TUOHZ2@HH6TU'0PQT])3L31L<4348QC4])$1$0#Z0
M                    H!\<[_A=_=M_F "_X   H!\#'_BB_<3_ )_ O^
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M[:[?_9S>JORNU[69[09G78/+##E4%"V9/,WU#YF1(]98V([J=3R(BM5?K?R
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MN/W[W$"_X !H#EC\UCDM]ZK,O:.L @!X*GS6,^^^K=?:.Q@6_
M               !6ERIX:[G[X\K.-^^>)WW%[=B6SU98JC)K==ZJMAN,[;9
M??9.9*.."BJ(GJZ+U+>N5FKNQ=$]4!9:!2[Q[X <E]BN.7*':V@S+ /L^WQI
M;5;,9O5+<;KYA1T;4J::YNJ976IDS)'4M2]L/=QN]5VJK= )=\ N)ESXC[.W
M/$LLK[1><^RF^U%WRF[V22>:C6-K6T]%3PRU,%-*YL<3.M>J-NCY'HFJ:*H3
MG J-W,X$;Q0\Y[%RRV+R7#K'9%NENO.5X_>JRX4E7-.L:T=ZAA92V^JC5E;2
MZJKG2(O>2/U1$1%4,WYL>']<=^\RL6^NR6:Q[8;]8VRG;[*ROFIJ6X^9=M),
MZII&NFIZF%-&-E:U_4Q&L<U$:BH$:\KX2>(ER4L$N+\EN0F.MQ*QT=9/C^-V
MUS(TN%XBIY$MLE>ENM=/&Z'O^A7R2=[(QG4L<76NH$_^!O'3-N+NPT>UVX%T
ML=XO[,@N-V6LQ^>IJ*/N:Q(DC;UU=-22=2=VNJ=WI]50(0YYX<6_.SV\=ZWH
MX)[KVO;],A=4/N&"7=700TT=0])9*.#JIJVEJJ99$ZF1U$;.ZT;TN<J(Y \6
MW>'CRNY);AXWF/.G>FAOF*8LY%IL,L$K5EGCZFNDIXXZ2DHJ*C;-HB231H^5
MR-T[%Z7M"[V@H**U4-%;+;214%NMT$=+04,#$CBA@A:C(XXV-T1K6M1$1$\B
M :5Y,83N1N5L3N5M[M-=+18\XS:TOLE!=[Y/44U'3TU:]L->YTM)3U,K7K2N
ME;&K8^QZM75/*!HW@%Q,N?$?9VYXEEE?:+SGV4WVHN^4W>R23S4:QM:VGHJ>
M&6I@II7-CB9UKU1MT?(]$U315"<X%1NYG C>*'G/8N66Q>2X=8[(MTMUYRO'
M[U67"DJYIUC6CO4,+*6WU4:LK:755<Z1%[R1^J(B(JA_G)_P\MQ+OO4O)SB-
MN+3;7;L5E0M;D5IK))*6DJ:QS49-54\\,,[46H;KW\,T3HY7*YSE3J<BAHK<
MCP^^>G)ZPUMSY&;^8Q<,CQ^DC3;3#H9'4]JCK)*F%M3-<$MMKBAC_P"S)+TO
MBAED<_H:KF,10+7.-&S-SVFXV[>[);@+:,AK\<L4]FR9E"LE3;*ME1+,Z1C?
M.88'OC?'+TN1\::]J:: 5E57AU\I^-^X.1YEP9WQH+!B^1)UU>%Y+(J2HU'N
M<RF?'-15M%5I$CE2.:5L<C$<K477J>X/MQ+PY>0N^6[EBW8YW;N6S.*#&W1.
MHL#LCG2,J8HG+(E&_NZ:BI:.!S]%D2"-[I4U17-<O6!(KQ&>&^YG+NP;56G;
M.]XO89<%KKI4W1<DJ:VEC?'6Q4T<20>9458JJBPKKU(WT--0+)8&+%!#&[17
M1L:URIY-430"M?BSPUW/V0Y8\D=]LKON+W#$=X:R_P!1C-NM-56RW*!MUOJ7
M2%*R*>B@B8K8DZ7=$K]'=B:IZH# ^3GAV9SD6]'RE^)^YT&TN[M;5)6W^@KG
MS4U!452QHR6J@GI8*AS75"-TGAEA?',KG.<J:N1P:3R3@WX@O**X6&Q<K^0-
MBH]MK'5-J)[78TA=+,YFC5ECH:"@H*6256]71)4/58^I>EFBJT"YC:[;3$=G
M=OL4VRP2W>Q>*8=0LH+32N7JD<B*KY)IGHB=<LTCG22.T3J>YR^B!7=XBW ;
M+.7%TVYR_;&\XUCV98K2U=HR&HR2>KIH:NV2/2>E:R2CI*QW5!,Z5416HBI(
MO;V:*$Z>/6T5NV&V4VVVDMSHI6X598*2XUD"*D=3<)-9Z^I:BHU=)JJ221-4
MU]4!#>]\-=S[EXBV.<NH+[B[-MK/1I3U-DDJJU+XYR8]46G5D"42TRIWTJ.[
M:A/4:KY?4@.4O#7<_>[EIQNWXQ2^XO;\0V>K,?J,FMUVJJV*Y3MM5^6Z3I1Q
M044\+U="O2SKE9J[L71/5 607*W4-XMU?:;G2QUUMNE-+27"BE3JCF@G8L<D
M;T]%'-<J*!1!1>';S5XS9UE5VX;[WV>BP[*I6,=1W65L-;YNSK6%E=255#64
M4SJ?O7-9,U>M=5<C&:Z >3DGA2<E\SR##-U\UWOQ[.MWZJ_17+<BJO577LHX
MJ&C6F\SI[?-';YI)Y&I'(CNID$;4Z&,;HBN M*YE\3,;Y=[6,PBYW9<8R>P5
MB77",K;%W[:2KZ%CDCGA1S%DAGC7I>B.145&O356=*A7?8N/7B\X/C-+M5C&
M_F'RX=;Z5MMM-_DJ8)ZBEHVM[MD<=95V9UP;T,T1JIU.8B(C')H@$T^#G"&V
M<2;'DEXOF3.SK=O<%(79KE"(]*6-D3WRI34?>IWKFK)(KI)9%ZI7(U5:S1&@
M3U                       4 \!?XTWFI_O'_?O;@+_@ $ /%'^8GOG^YG
M]\]I >%Q\Q/8S]TW[Y[L!/\             #5FZ^R6TV^=ACQK=K [5G%H@
M>Z2BCN$2]_2R.31SZ6IB5D\#E3L5T3VJJ=@$+?Q37"CS]*S[ KUYOKK[%?9#
M<_-_+Y.KO^^_^^ 3=VNV?VQV5QMF);583:\(L"/[V:CMT72^>733O:B=ZNEG
M?IV=<KW.T[-= /9SK <+W.Q>YX7N#C%OR[%KQ'W=PLERA;-"_3ZU[=>UCV+V
MM>U4<U>UJHO:!!MOA5<(VWA+JFUM:M.CD<EC7(+PM'JBZ^1:OO51?2633Z@$
M\,1P_%<!QVUXCA./6_%<8LD7<VJPVNGCI:6!BN5SNB*-$1%<Y5<Y?*YRJY=5
M55 U3LKQDV/X[U.85>SN$_8?49]+239;)[)7*X>=OH5J'4ZZ7"JJ4CZ%JY?Z
MVC=>KMUT;H'^MXR[(-WR?R2;A.F],D7<OS/V2N7:SV/2UZ>8^=>9_P#=42/^
ML_T7UWJ@-\ 8_EF+6/.,7R+#,GI'W#&\LMM5:+_01SSTKIZ*MB=!41)/3213
M1]<;U;U,>UR:]BH!K39'CMLUQRLEXQW9G"X\,M.05R7&\0)6UUPDGJ&QMA:Y
MT]PJ*F5$:QNB,1R-3M5$U<Y5#=8$=M\>)W'[DA6X]<=Z-O8\RK\5@J*:Q5:7
M&YVV2&&J<Q\L;G6VKI5D171HJ))U=/;TZ=3M0_6'BOL/!O#9=_F80]^[N/4<
M=!:<QEN]VE?'!#;W6IC74TE8ZFD7S5ZQJY\3G+KUJJO]4!L3=+:W!-Z<$ONV
MFYEB^R7"<E\U]FK+YU54??>9U459!^?T4L$S>F:!CO4O3731=6JJ*'T;;;;X
M7M#A%@VYV[LWV/89C$4L-CLWG%35]PR::2H>G?U<LTS]9)7+ZMZ^73R:(!K^
MR<9=D,<WFOG(.S83YGN]DD4L%ZR[V2N4G?1S1QQ2)YG)5.I&ZLA8GJ84\G9V
MJH%.>Z>(XQGOC-V3#LSL5%DV+Y!9%I+S8KA$V:GJ(G815KTO8[T45$<U4[6N
M1'-5%1% L%L7A@<*<?R>/)Z;:/S]]/*D])8KG=KE7VR-Z>G2U%2]LK?Z"97M
M^H!/FGIZ>CIX*2D@CI:6EC;#34T+49''&Q$:UC&M1$:UJ)HB)Y -&;*\9-C^
M.]3F%7L[A/V'U&?2TDV6R>R5RN'G;Z%:AU.NEPJJE(^A:N7^MHW7J[==&Z!_
MNS7&79#C[<,RNNT.$_8C7[@2T\V73^R5RK_.WTCYWPKTW"JJ6Q]+JF5?SM&Z
M]7;KHF@&\9=D&[Y/Y)-PG3>F2+N7YG[)7+M9['I:]/,?.O,_^ZHD?]9_HOKO
M5 8+R#YL<>^--7<+#N5F$M+F\-C;?;3A-+05T]7<(9G3Q4[8)HX'4S5EEIWL
MUDE:C=-7]*:*!7MX/^SU75Q[O\J<BL<-HJ]R[G4V;!Z>&+NH8Z!*I:RYOIFZ
M?UE]3W<+-/(L#T NEO\ 8K5E%BO6-7VE\^LF14%3;+Q1=;XN^I:N)T,T?7$Y
MCV]3'JFK7(J>@J*!IS;/C)L?L]MWEFU&W.$?8[@&<R5LN4V#V2N=7YT^X4D=
M#4KYQ654T\?7!$UGYW(W335NCM5 ]?938+:7CMC%QPW9S$_L/QN[722]7"V^
M?U]P[RNEAAIWR][<*BID36.GC;THY&]FNFJJJAY.]'&79#D+6X=<-X,)^R^L
MP"6JFQ&;V2N5O\T?6.IWSKTV^JIDDZEI8E_/$=IT]FFKM0U1SHY#;@\8MGK?
MNC@V!V_/Z*'(*6V9M;[BE1W5+;*R"H1*E7P*G0GG#8HE<]%;K(B:=H$%<:O'
M@];BXY:=W\HL&"8;DDU$VNR+"YYKG0RT=:]B/J:?V&I9(XJGHDU:U8H'M=^8
M\H&J>"4=+R#\0_=7D3M_B3L8V=PJTS4.-MCI&4E-!$E!36*TT;88D1D3Y*.!
M\W=M[&(U6KZ&H=!X&N-U]I-O=\,(N6W.Z./_ &3X9>):::XV;SNKHN\?23,J
M(5[^BF@F;TR,:OJ7IKY%U3L ^W;7;7"MH,'L.W&W5E^QW#,8CEBL=F\YJ:ON
M&3SR5$B=_5RS3/UDE<[U;U\NB=FB 9T!%G >%7&7:[<Y^\6WVV:8IN#)/7SO
MN]#>+RVG5;DDC:IGL>ZN=1=V[O%Z8^YZ&+TJQK5:W0,JM'&#8RP[TW;D-:L'
M\UWAOC9673+_ &3N;^];/ RFD3S*2K=2-UB8UOJ84\FJ=O:!OP",VY_#KC;O
M+N!:]TMQMLH+]GMG921T6117&Z6^32AD66F66.@JZ>*9T;ET1TC'+THC57I1
M$0/NK.)O'ZX;VQ<BZ_ $KMY(*B&J@R^HNEUE1DU/2)0PN;0NK%HD[N!J-;I!
MV*B/3U?J@)%@8KG&$XMN1B&1X%FUHCOV)99036V_V>5\D39Z:=O2]J20NCD8
MOHM>QS7-71S51410-?;(\=]GN.5DO&-[-8F_#['?ZY+E=;<MSN5Q9)5I$V'O
M6^R-55*Q58QK5Z%371-==$ W6!2UXG.WN1[4[F;'<Z]O:&6IK]K[K;[7N+30
M(NCZ**I62CEE5$]3',DLU'*Y?0DB:!;CC60X=NW@%GR6T.I,HP7<&RQU=*RH
MB9-3UEON$.JQ3PO1S51S'JR2-R>FUR>5 (1Y)X6'"K([Q+>$VRJ[ ^IE=-4V
MZSWFXTU&]SUU7I@6=[8F^DV+H:GH(@$M]GMC-I]@L87#]HL*H<,L<LOG%;'3
M+)-454VG2DM555#Y9YWHG8BR/=HG8FB=@&D=ZN _%K?S):G,\^VW8W,*Y&I<
MLDLU956NHJU:B(CZEM-(R*9^B(G6]BOTT3JT1 /WP_@/Q(P;%LIQ&P;,VQMM
MS6W/M63UM755U7<:FDDT5\3+A/4/J:='*U'*E/)'VHB^5$ V3BW&?9/"]G[[
ML)C6&OM^TN20U]/>,2==+I4))%<V]-6QM745<E5&DG:OYW*W1556Z*JJ![VS
M.QFUG'S$I\%VAQ?[$<5J;C-=IK7Y[75_565$<44DO>W"HJ94ZFPL3I1_2FG8
MG:H&V0(LUO"KC+7;P-W[DVS2EW9;>(;_ /9707B\T.MQ@Z=)W4E+714KE?T_
MGK5BZ9=7=XC^MVH95DW&#8S,=X,<W\R/!_9'=G$FTK,?ROV3N</F[:-9%@3S
M.&K92/Z5E=]?$NNO;KV ;\ COOAQ0X_<D*NP5^\^W4&8U^,0S4]DKTK[C;9X
MH:AS7R1.EMM52ND9U-U:V17(U5<K=.IVH?-NUQ%X][YVG!K%NG@+\IM&VU')
M0850^S%XHF44$L<$3V_]AK:=955E-&G5*KG>I\O:NH2&M]!16J@HK7;J:.BM
M]M@CI:"CB3ICBAA:C(XV-3R(UJ(B(!]8$:]O.(/'7:?<R];P[>;>)C&X60K7
M^S%[I[M=GQ3-N<R5%4SS&:LDI&L?(B.1K84:S1.A&Z(!6/M[;UYP^)1D&[\*
MON6R'%E*:WXK<VHJTM;=+=)(ZC2%Z>I=UU[IZQ')_P"RCC1WUS0+S
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M\UC/OOJW7VCL8%OP "@'_P"GK_\ E\6(%_P
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MTKYJRY53$=U(R:NJWRSJQ'=J1]:,1>U&H!OL
M   % /CG?\+O[MO\P 7_    !0#X&/\ Q1?N)_S^!?\                >
M6R^662YR62.[T3[S"Q)9;0VHC6J:Q?(YT*.ZT3ZN@'J       XC\VMV66W=
MK>?=3%)'03[6;DR7"6MCU[RDFGO-4M'5>ETLJ(&-_P"D]H'9;M)N):]V]K\
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MDVZ>1U7LYC&'WS\^EHYY521ERNK'IHM3Y%A@5.F!-%<G>(UL(76@
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M_&F\*_\ =Q^_>X@7_  - <L?FL<EOO59E[1U@$ /!4^:QGWWU;K[1V,"WX
M
M                              !0#P%_C3>:G^\?]^]N O\ @ $ /%'^
M8GOG^YG]\]I >%Q\Q/8S]TW[Y[L!/\
M  :AGV$V>JMUZ7?*HP&VR[M44?=4N<JDGGK&>:.H=$]7T?\ =WNC^M\B@;>
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M6/S6.2WWJLR]HZP" '@J?-8S[[ZMU]H[&!;\  H!_P#IZ_\ Y?%B!?\
M
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MN(%_P #0'+'YK');[U69>T=8! #P5/FL9]]]6Z^T=C M^
M
M                  4 \!?XTWFI_O'_ '[VX"_X ! #Q1_F)[Y_N9_?/:0'
MA<?,3V,_=-^^>[ 3_
M                                                  4 ^!C_ ,47
M[B?\_@7_   "@'QSO^%W]VW^8 +_ (           1=W[X:\=^2MQM=\W9P-
MMWR*SP)2461T-74VZN6E1ZO2GEEI9(^]C1SG*U)$=T]3NCIZEU#;VUFT^WFR
MF&6W;_:_%Z7$<3M2N?36RE5[U?+)IWDT\TKGRS2OT3J?(YSET3MT1 -B
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MNF:Q,8WKT5ZN]3JC7:!A5=_$JL^T>G_?$P"4?A9?,8V7_LN2_OCN8$).9_\
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M2JBKVN[F=)XNSL:SND]% -)^#+_KUS&_5/'/TU?@-O\ C6?-?V]^^E;?:2]
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MFL9]]]6Z^T=C M^  4 __3U__+XL0+_@
M
M    % /CG?\ "[^[;_, %_P  !0#X&/_ !1?N)_S^!?\              !I
M:BXX; VW.5W,H-F<-H\_6H=6)EL-FHV5K:IRJKJELB1ZMF<JJJR)ZM=>UP&Z
M0      4&^%;\[GF3_A%=[?U $:.5N095P?Y;<GZ3#J9]-8.2>#W%UHZ'=VV
M!F4.1\]7$B=C7TM;%5,CT^M:O9IJ!9WLGLU\"?A:YU8ZNE\UR'+=ILOS#*FJ
MWI?YY>K)4SQLD;Z#X:5((7)Z; -3^$7C4&9\)=[</J5:VFRS.\DLU0YR:M1E
M?C=FIW*J>EH\"&W >[\<]F=Q-VN.G-#;? J+*J*]Z6',,ZLMNKJ:EK*1%@JJ
M&2OKZ>1((96L9- ]SVQ.]4NJ*]O4$K.8/(#@AL=9K%:]D]A-@MZ]R[Y7Q-DL
M]NQNQW&W45!HJR/J*FW0*G?2.5K(HD?U=JN<FB(C@D;RCI:VD\,/-FW+;RR[
M37&JPRTUM?MMC].VDM]EFK+G1U,E'% R.)L;F.D7O$1O]<ZO+Y5#+_"R^8QL
MO_9<E_?'<P(2VC^/'RC]3(_W@4@$M_%I^97F_P"KN/\ MC$!&S<S:*_[O^$+
MM11XO0+=;Y@F.V?,::W,15EEAMJ5#*SN6HBJY[:6>5Z-3M=ITIJJH@&X/#\Y
MR;%7[CI@&!Y_N5CNW.=[5V6GQRYVO);E!:XZFBML?<45523UCXHYFNIHV=;6
MN5S'([5.GI<X(-<Q=R[+SXYC["[*;(3+F&)X/5OI+GEU(Q[Z1ZUM5!->JR-7
M(B.IJ6FHV:2)V2.1R,ZD5BN#<'B$?QC_  6_5/#/WX. OB HA\3:PU_'SDQQ
MQYIXQ0R/@@NE):LVBIM&+45%J<LK(WO73U5=;GS4_E^MB ROPD,$NV;7C?[E
M_FE/UY)NED%9:;)4OU54CEJ$N5V?&KO+&^>2"-JIY.Y<@%V8&I=^-JK=OALY
MN/M-<YF4L&<V.IMU-7O9WC:6K5O71U*L_-=Q4,CDT]'I HHX%<N(>%=^SKBG
MRFHJ[![=;K]-5V7()::::.UULS6LGBG9$QTCZ2J1C)H9HVN;ZI7+ZA_4P+5]
MQ?$0XA[>8K69*N\MBS.IBA62W8SB]0RZ7&KET560MC@56Q*Y?*Z9S&IZ*@5R
M>')0;Q\DN5&Z7,/+:B\8YM[/4U_F5JIZZHCMU?<ZB)M'26_N^IC:J*W42]KG
M-T1Z1+IU?6A,'Q7MD?A6XM7C*[;2=_DVS%6W*:%[&ZR.MO3W%UBU]!B0.2H=
M_84 K7X?77)N<_,_:#.<WI9:G'^-N 6-U>^H7K;45]AA9'33.7M:DE1=9W56
MGE5C%3T.P+5_%+IYJC@UO.L+%D6"3')I&M155&-R&W(Y=$]!-=5^H!JO@;N)
MM+O+PLQSCA:<ZM53N)+@.0V7)L,?(K:VD@JIZFEDFDA5NJQZ5<:]3=4T<GHZ
M@1"\,;D3B?%Z^[P<6>0MUI-KKS3Y5+<;9=KW,E-;VW.&%E#7TM152=,,*.92
M0R0R/<C)$U]5JK$<&SO%-YB[3Y;LZG'K:3,+9N=EFX%VMKK^[&JEESI:.BH:
MIM5'%YQ2K)%)4354,36Q-<KD1'*Y&KT=08QS&VNO&S'A3;(;<9# M)D-AOEB
MFO\ 0KIU4U=<6W*X5-.[15170RU+HU5%T56ZH!Z&Y?!+%=UO#OV'RW:+$*6T
M[N87@EJS&/V.BZ:K('7.WP5EWIYWIK)--([\]@U55:YJ1,Z6/[ EEX:/,!.2
M.TR8;F=R[[>':VGAH\C=,[\^NUM3\[I+HFO:YZZ=U4+V_GB(]=.]:@$2O!I_
MA YC_JGCWZ;OH#AM_&R\O_U,R_\ ?!: )O>*7\Q;>S_IXS^^2U@0LK]H;_O%
MX-^WMJQ:WK=<AP^B?EMNMK$599F6N[U_G;86HBJZ1*6296M3M<J=*=JH!_/
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M-<US4<U4<UR:M<G:BHOD5% _T               !0#_ /3U_P#R^+$"_P"
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MTUNVWVTP]R>8[?VZ6%)):97QR3TE#34]35/@2J=&B33U$ZRZ(B-14:SI"?\
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M_P   T!RQ^:QR6^]5F7M'6 0 \%3YK&???5NOM'8P+?@
M
M                % / 7^--YJ?[Q_W[VX"_X ! #Q1_F)[Y_N9_?/:0'A<?
M,3V,_=-^^>[ 3_
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M_!D5)58W44M-5.JH*6JI&L>^LI*QBQJRK>JHC$75&^JTU10S2^;(8#E&RB;
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M[U69>T=8! #P5/FL9]]]6Z^T=C M^  4 _\ T]?_ ,OBQ O^
M
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MQB@@MEDI*BJJ:V2*EIF)'#&ZHJY)IY.AC41%>]RZ)Y0,@
M 4 __3U__+XL0+_@      4 \!?XTWFI_O'_ '[VX"_X
M                                                    /XDCCFCD
MAE8V2*5JLEC<FK7-<FBHJ+Y45 *(;+P\YW\+\]S:NX<72P[B[89E4><,Q*]5
M-''.V.%S_-65D5PDI&=]"V16)+3U"=XG:]K>QJ!]7R*.:7,+<W$,LYO9%9\1
MVYPN7K@V_LM132S21/=&^>GI(K<^:&+SGNT;+42U#Y6HB(UKD1O2%Z<,,5/%
M%!!&V&"!C8X86(C6L8U-&M:B=B(B)HB ?H                   % //K^-
M-X5_[N/W[W$"_P"  : Y8_-8Y+?>JS+VCK ( >"I\UC/OOJW7VCL8%OP
M
M                            "@'@+_&F\U/]X_[][<!?\  @!XH_S$]\
M_P!S/[Y[2 \+CYB>QG[IOWSW8"?X
M
M"@'P,?\ BB_<3_G\"_X !0#XYW_"[^[;_, %_P
M                                                "OK?'PRN+.^V
M573-[Q8[UA.57V62IO\ =L2KHZ)*VIE7J?42T]5!5TZ2.757.9&U7*JN?U.[
M0/6V#\.'B_QZR6BS7&<<N66YE:G]Y9,ERRL;<):&1-/SVF@AAIZ9DB*FK9.Y
M5[5^M<T"=X                    - <L?FL<EOO59E[1U@$ /!4^:QGWWU
M;K[1V,"WX !0#_\ 3U__ "^+$"_X
M
M!0#XYW_"[^[;_, %_P    4 ^!C_ ,47[B?\_@7_
M                      1=VSX6<6]GLL3.=N]F[-8,LCD?-1WM\E772TCW
MM5CG4:5T\[:95:JI^<HSL5?34"40      (Q9QPRXP[E[D5.[>>[06G*\^KD
MITK[O<)JR6&I\UACIX>_H>_2DE5D4+&(KX5[$T DQ!!#30PT]/"RGIZ=C8X(
M(VHQC&,31K6M31$1$31$0#]0
M     4 __3U__+XL0+_@      4 \!?XTWFI_O'_ '[VX"_X
M
M                    !0#SZ_C3>%?^[C]^]Q O^  : Y8_-8Y+?>JS+VCK
M ( >"I\UC/OOJW7VCL8%OP
M                                                      "@'@+_
M !IO-3_>/^_>W 7_   " 'BC_,3WS_<S^^>T@/"X^8GL9^Z;]\]V G^
M
M                            H!\#'_BB_<3_ )_ O^  4 ^.=_PN_NV_
MS !?\
M                                      T!RQ^:QR6^]5F7M'6 0 \%
M3YK&???5NOM'8P+?@ % /_T]?_R^+$"_X
M
M     !0#XYW_  N_NV_S !?\   4 ^!C_P 47[B?\_@7_
M
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M.U%10,?MN;89>;A-:;1EUENMUI^RHME'7T\]0S_I11R.<GY: 9.
M                                            * >?7\:;PK_W<?OW
MN(%_P #0'+'YK');[U69>T=8! #P5/FL9]]]6Z^T=C M^
M
M                  4 \!?XTWFI_O'_ '[VX"_X ! #Q1_F)[Y_N9_?/:0'
MA<?,3V,_=-^^>[ 3_
M                                                  4 ^!C_ ,47
M[B?\_@7_   "@'QSO^%W]VW^8 +_ (
M
M  !H#EC\UCDM]ZK,O:.L @!X*GS6,^^^K=?:.Q@6_  * ?\ Z>O_ .7Q8@7_
M
M                                  "@'QSO^%W]VW^8 +_@  "@'P,?
M^*+]Q/\ G\"_X
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M
M                                "@'@+_&F\U/]X_[][<!?\  @!XH_
MS$]\_P!S/[Y[2 \+CYB>QG[IOWSW8"?X
M
M    "@'P,?\ BB_<3_G\"_X !0#XYW_"[^[;_, %_P
M
M                T!RQ^:QR6^]5F7M'6 0 \%3YK&???5NOM'8P+?@ % /_
M -/7_P#+XL0+_@
M                                              % /CG?\+O[MO\
M, %_P  !0#X&/_%%^XG_ #^!?\
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M5V^LIN\ACJIO+/-"^)_5([U3FN9U*YVKE"U
M                            H!Y]?QIO"O\ W<?OWN(%_P   T!RQ^:Q
MR6^]5F7M'6 0 \%3YK&???5NOM'8P+?@
M
M    % / 7^--YJ?[Q_W[VX"_X ! #Q1_F)[Y_N9_?/:0'A<?,3V,_=-^^>[
M3_
M                                   4 ^!C_P 47[B?\_@7_  * ?'.
M_P"%W]VW^8 +_@
M                                              &@.6/S6.2WWJLR
M]HZP" '@J?-8S[[ZMU]H[&!;\  H!_\ IZ__ )?%B!?\
M
M                 H!\<[_A=_=M_F "_P"   * ? Q_XHOW$_Y_ O\ @
M
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MUK^]K;G<)(V1R5=2]$:WJ<V-K4:QK6-:B(UJ ;W
M                               * >?7\:;PK_W<?OWN(%_P #0'+'YK
M');[U69>T=8! #P5/FL9]]]6Z^T=C M^
M
M     4 \!?XTWFI_O'_?O;@+_@ $ /%'^8GOG^YG]\]I >%Q\Q/8S]TW[Y[L
M!/\
M                                     4 ^!C_Q1?N)_P _@7_  * ?
M'._X7?W;?Y@ O^
M                                               : Y8_-8Y+?>JS
M+VCK ( >"I\UC/OOJW7VCL8%OP "@'_Z>O\ ^7Q8@7_
M
M                * ?'._X7?W;?Y@ O^   * ? Q_XHOW$_Y_ O^
M
M                          4 _P#T]?\ \OBQ O\ @      4 \!?XTWF
MI_O'_?O;@+_@                   Q'/<%Q3<W#<CP#.+/#?\ $\KHI+?>
M[5/KTRPR>BUR:.8]CD1S'M5'-<B.:J.1% J-J/" 7'KA=(]G^6&<[98K=IUD
MJ\=;2NJ7OC5-.B2>BN%M9(J)V(Y\*]G8NOE EQQ+X![/\3:NOR>QU=QSG<B[
MTSJ2NSJ]]VV2&"16NEAH::).B!LCFHKE<Y\B^3O.GU($Z
M                                                       4 \^O
MXTWA7_NX_?O<0+_@ &@.6/S6.2WWJLR]HZP" '@J?-8S[[ZMU]H[&!;\
M
M                             H!X"_QIO-3_ 'C_ +][<!?\  @!XH_S
M$]\_W,_OGM(#PN/F)[&?NF_?/=@)_@
M
M  * ? Q_XHOW$_Y_ O\ @ % /CG?\+O[MO\ , %_P
M
M             #0'+'YK');[U69>T=8! #P5/FL9]]]6Z^T=C M^  4 _P#T
M]?\ \OBQ O\ @
M                                             % /CG?\+O[MO\P
M7_   % /@8_\47[B?\_@7_
M                                                       * ?\
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M6K"\CMUJIK5;LC]D)*NKDN'G71T>=2+)(LC6(QJ*J)HJJ'3\  T?R;M-UO\
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M?H5_@XS?W1 ?+Z\4WZ%?X.,W]T0'R^O%-^A7^#C-_=$!\OKQ3?H5_@XS?W1
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M/E]>*;]"O\'&;^Z(#Y?7BF_0K_!QF_NB ^7UXIOT*_P<9O[H@/E]>*;]"O\
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M/E]>*;]"O\'&;^Z(#Y?7BF_0K_!QF_NB ^7UXIOT*_P<9O[H@/E]>*;]"O\
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M7JD=HWZY&@='P
M
M
M
M
M
M
M
M
M
M
M
M
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M>XN1/'WIYGJQ2MF;U,1Z)_1L<Q?Y#T13',8/43B_0^/H
M
M
M
M
M
M
M                  \^:TVJHU\XME)/KY>\A8[^:BGN+M<;IGOO,T4SOB'E
M3X=BM1_7,?H6_P!CA;'_ $B-,L9N]'ZT]]XFQ1/!#RIMM<,F1?\ Z$=TY?S4
M<\R:?E=:I_*,L:A?C];DAXG*VYX'DS;1XK+]9)7T_P!2.9B_T\;C+&J7HXN\
M\3DK?9>3-LU;':^;WJJB]+O(V2?S.@R1JU?#3#Q.1IX)>5-LQ4M_[O?XI/J2
M4ZL_F2/,L:O'#3RO$Y&>"7E3;/Y&S58:VWS(GD3KE:Y?Y,>G\LRQJMKAB>3G
M>)R5?'#R9MKLQB^LH(JC^QU$2?T[FF6-2LSPX=QXG*7.)Y4^"9=3Z]Y8:EVG
ME[M&R_TBN,D9VS/ZT/$Y>Y' \F;'[]3=M19*^%/3?32M3^2K3+%^W.ZJ._#Q
M-JN.">\\N2*2)W3+&Z-W\Z]%1?Y"F2)B=SQ,8/X/H
M
M
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M[.^J>^]Q9HC@AZL%#14VGFU'!3Z>3NXVL_F(ABFNJK?+W%,1NA]1Y?0
M
M
M
M
M
M
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M56N:K7)Y6JFBF1Y?X
M
M                                           #](X99EZ88GRN_G6-
M5R_RCY,Q&\B,7J0X[D%1VP6.OF3^>932JG\E&Z&.<Q;C?5'?A[BU7.Z)>M#@
M>7U&G18JANO_ %G1'_3N:8ISMF/UH>XR]R>!ZL.UN8RZ==%#3?V2>-?Z17&*
M=2LQPX]Q[C*7)X'K0[/9$_19J^WPHOE1'RO<GY7=HG\LQSJMO@B>3G>XR5?'
M#U8=F)U_[QD$<?U(Z=7_ ,M9&F*=7C@IY?$]QD9X9>M#LU:FZ><7BKE3T>[8
MR/\ F]9BG5J^"F'N,C3PS+U8=I,5B^O?75']DF:G](QIBG5+T\4=Q[C)6^R]
M:';;#(=%]ATE<GYJ2:9VOY77I_*,<ZA?G];DA[C*VXX'JPX?BU/_ %O'Z%?J
MR0LD_IT<8IS=V?UI[[W%BB."'JPVNV4^GF]NI8-/)W<+&_S$0Q3<JG?,O<41
M&Z'WGAZ
M
M
M
M
M
M
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MNYTVOG%NJH-/+WD+V_S40RQ=HG=,=]XFBJ-\/@\G8O8J'MY
M
M                                                ']-8]ZHUC5>Y
M?(UJ:K_*$S@/2AL=ZJ=/-[/6SZ^3NZ>1W\QJF.;UN-]4=][BW5.Z)>K#A&6S
MZ=%@JVZ_]8SN_P"G5IBG.68_6A[C+W)X)>M#MCF4NG5;60(OHR5$/\QKW*8I
MU&Q'#R2]QE+D\#UH=H,FDT66JM\">BBR2.=_ZL:I_+,4ZK:C=$_IW7N,E7V'
MJP[,UKM/.+[!%Z?=P.D_FN88YU>G@IY7N,C/#+U8=F:!NGG%\J)?3[N%L?\
M-<\Q3JU7!3#W&1CAEZT.T.+QZ+)47"=?11TL:)_ZL:+_ "S%.JW9X(_3NO<9
M*CLO5AVRPR+3JM;IU3\U)/-_,:]$_E&*=1OS^MR0]QE+<<#UH<*Q.#3HL%&[
M3_K(TD_I^HQSG+T_K2]18MQP0]6&RV>FT\WM-'!IY.[@C;_,:ABF]7.^J>^]
MQ;IC=$/21J-1&M1&M3R(G8B&-[?Z
M
M
M
M
M
M
M
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M4\&GE[R-S?YJ(98KIG=,/$TS&^'RGI\
M
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M-T0]2...)O3%&V-O\ZU$1/Y"&.9F7O!_9\
M
M
M
M
M
M
M
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M!]?
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MQ:HC@AZL5/3P)I!!'"GI1M1O\Q#%-4SO>XB(?L?'T
M
M
M
M
M
M
M
M
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M5'?AXFU7&^)>7)%+"O3+$^)W\Z]JM7^69(F)W/$Q@_,^@
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MJ>^]Q9HC@AZL-%14VGF])#!IY.[C:W^8B&*:ZIWR]Q3$;H?4>7T
M
M
M
M
M
M
M
M
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M8YS5V?UI[[W%BB."'JPVRVTVGF]OIH-/)W<3&_S$0Q3<JG?,O<41&Z'W'AZ
M
M
M
M
M
M
M
M
M
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M9BL=_P!XOT,7I]W Y_\ ->PQSJ]/!3RO<9&>&7JP[,V]NGG%[J)?3[N)D?\
M-5YBG5JN"F'N,C'#+UH=HL7CT62>OJ%]%'RL1/\ U8T_FF*=4NSQ?IW7N,E1
MV7JP[9X;#HJVMTZIZ,D\R_RD>B?RC%.HWY_6Y(>XREN.!ZT.%XG!IT6"C=I_
MUD:2?T_48YSEZ?UI>XL6XX(>K#9K13:>;VJC@T\G=P1M_F-0Q3=KG?5/?>XH
MIC=$/11K6HC6HC43R(G8AC>G^@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M>C&BJ)AFIJ,P
M
M
M
M
M
M
M
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MIP=$LW8NT4UQPQ$]]DQKLH
M
M
M
M
M
M
M
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M,]MM["\#P[;JT+8<(QVBQJT/F6IEHZ)G0DDSFM8LLCE57/>K6-17.55T1$]
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M)'NDDDL5N=)(Y55SG+31JJJJ]JJJG$,Y&%^Y]:?"O]C^73VH\#*S690
M
M
M
M
M
M
M
M
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MVH5/08R1BU$3G?5<K$_(+'E.OEBO"+UN:>S$]*/DGPHR]U=N4[;=43V]G/\
M(@%>;-E6W65U5HNU/5XSEV+5C4FB1_144M3$J/8]DD;E3TG->UVBIHYJZ:*7
M6U=M9NU%5,Q515'<F/TWP@:Z*[->$[*HET&\<-R*[=?9G"LSNRHZ]U=-)1WR
M1$:U)*NAF?322]+=$3O>[[S1$T3JT.(Z]D*<CG;EJGZ,3C':F,<.YN7[3LQ.
M8L4USOX>W&QN-UMMSW.>^@IG.<JJYRQ,555?*JKH1?I*N.6WT8XGV(B-1&M1
M&M:FB(G8B(AX>G^@
M
M
M
M
M
M
M
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M>3]%72IBKCAZIC>@
M
M
M
M
M
M
M
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MJ6+5^N'O#*UV/0]'I8;>ECNF)W=&.+C1F2T3V:[%SIXX8[,,-\8<:?I2D\
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MEONK<-KZ/:*JP66@QVKR!;S->F7!KFTE12P+#W+:*G5%=YSKU=79IY.T"SL
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M;_-#4ZRN1K$8DU%*U[M53L]3KZ: =!S%<YC%>WH>J(KV:ZZ+Z*:^CH!_0
M
M
M
M
M
M
M
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M%:Y-=45%1=%0#)
M
M
M
M
M
M
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M5OK*.B>^)J_6K-#6>KT\O=LU\B ='@
M
M
M
M
M
M
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MI2U",7J;UQR]#M%]%-4 ZG/& ^9W7?;A8_YLX%6?@R_.RR'[W%X]L;6!U)@
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M,^HOL?<V_P Q0*Y?!9HH*GE/FM5-&U[[=ME=):553562/N]GB5R>EZASD_+
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MW7^0JH!5QX,GSL<B^]O=_;&U@=20
M
M
M
M
M
M
M                                                       -0[];
M-8WR VCS?:/*G.@M>84"T\5QC8CY:*KB>V:DJXVNT1703L8_35.K3I7L50.-
M?>#9S=[BINJ_%\PI:[$LNQJL9<,6RB@DDBCJHX)>JFN5LK&=*JU7-1S7-5'L
M=ZEZ->U6H%@6$^,SR4QK&:*QY'B6&9U=+?3M@BRJOIZRFK*CH:J))6,I:F.&
M1ZKHJK&R-%]+5=0*\=[M]-U>3.XDN=[E79^0Y-7MCM]HMM'#W=-24Z/58:*A
MIF:]+$<]=$]4YSE5SG.>JJH=+'AB<0[YQJVLO64[A4,=#N?NL^DJ[E:E36:T
MVNF8Y:2AF5?),KI7R3(WR*K&+JZ/4"G7Q=&JWF;DBK^;QFPN3_%E3_Z@%V/A
M4)IP>VH7TZW)%3]?:Y .4_<]JLW+W#8OE9DUV:NGU*R4#MBW/8KM@-PXTTZE
MV^NS47T-?8J5 .-;C"FO)7CRGI[F8DG[,TH'<4!PV\E$TY%[^HOE3<?*D_9>
MJ ZA^4<3OQ;&8QZIU,VKLNJ^AZB&B5?Y@'/SX:":\X=AT_\ TV\+_(L5P4"_
M'Q/.-%^Y$<?V5F$6]]US_:NO?D-CM$+5?/7T;H717"C@:B*KI7,1DK&IVO=&
MC$[7(!S=\6^3>?\ $C=)<^Q&B@N7?TLEGR[$;EWD<%?1.E9(^%ZM]5%*Q\:.
M9(B*K')VM<U7-<$I>8_B:YGRKV_I=KK5M]3[88=45=/795"VYNNU5<Y:5W>0
M0K,M+1MCA9+I)THQSG.:Q>M$16J&]/",XNY-E-]S7?R^4M19<4IL?NN*[?7=
M^L:U5UN4:TM75T[?S<=+"LD:N^M61^B*KHWHT*AKE:,HVCW$GM&2V-+=EVWE
M]2.ZV"Y1=<;:RW3HYT4S-41\;G,[=%T<U=471=0+TL_\;&RUVVDU+MSM+=K1
MNK<Z!:=U;=ZFFDL]KJI(U:ZH@=$JS5?=N[6-?'"B]G4O9TJ% 39ZFEN+:F='
MK64U0DLS9=4?WK']3D?U=NNJ=NH'4IXL-XMV3<'J?)+-5,K+1?,AQJYVRLC7
M5DU-5MDDAD:J>5'->BH!61X,B:\L<B7TMM[PJ_KC:T ZD@ ')_XNS5;S+OZK
M^;Q>PN3_ . Y/_J 8CQI\27>/B[ME%M9A&&8;?+'#<ZNZMKKY3W"2K[VLZ.M
MJNIJZG9TIT)IZC7ZH&0[N>+!ROW6QJMQ2FK<<VRMMSC?!<JO#Z*IIJ^>"1JM
M?%YW6U=8^)%1?KH>[=_1::@:7X9<0,WY8;E6VT45!5VS;2S54<NX><K$Y*:E
MI6*U[Z2"54Z754[5Z8V(JJFO>.3H:H'5-R.X_P!GWIXVYQL-:88+'2W&P046
M&1Q_G<%%5VET51:F]G:V)DU-$UR)^8U0#D,VVSS=+B+OO;,JIK5+CVXNV-TF
MI;SC%VC>QKT5KH*NAJXVJU5CFB>YNK5\BH]BZ]+@+1-_/&.N^XVT=XPG:_;J
MY[99KE%,E'<LT6\I*^VP/1._6W/IX8)>]>FK&R*K%8B]2)U:=(?IX8VXO-/>
MW>&@]D=Y,QN^RF#]55N#7WV5MVAJG(Q?-K5'57&.>1)9WJU7=#T<V)'.U:O1
MJ'0]DV.6?,,;R#$LAHVW"P91;:JTWN@?];-25L+H)XU^HYCU0#ARWOVLO.R.
M[FX.U%^ZG7#![U4VYM2Y.GSFF:[KI*I$]!M1 Z.5OU'(!<9X*VQ2U^0;C<A[
MQ1HZEL$7V'X5(]NJ+6U+8ZFY3LU3L=% L,:*GE25Z>@!?9N'A-HW*P+-=N[_
M -XECSJQW"P79T2Z2-I[C3OII'1KZ#FMD56KZ"@<5>9XANIQ(WW?:;BR?&MP
M]J[]#<+#=.[5(JCS2=):.NI^KLE@G:Q')Y4<U5:[MZD MMR7QL+G==J[E:;)
ML\ZP;LW&V.HHLC;<TEM%'5RL5CZZ"!T7?+T*O7'$YW8NB.D<B>J"-G!;=GG-
MO3O9BF!X?OKG57BU)605^X5\NU6Z^4ULLT<G54.>MU;5L:^5K5CA;^:>J=FB
M.5 G-XWS57;38I_H-R:ZM7\NCC_^L!K+P-D_^C7))?02BQ5/Y,EU ]+QA>*.
M372\VOD_@]GDNUKI[7#9MTZ2CB=)/2^9K(M+=I&M156+NG)!*[R1]$:KV.<K
M0@'PS\0;<;B#2WG%Z?'*7<3;B]U2W&;$*RK?034M>YC(WST=8V*H[OO&1M1[
M'1/:NB*G2NJN#_.9GB"[B\OJ:RXQ4XY2[>;<6*J2XP8A1U;Z^6IKVL?&RHK*
MQT5/WG=LD<D;6Q,:G4Y5ZET5H6(>$#Q(R7'JRX\G\_M$UFANEKDM.U-LJV.C
MGGIZM6K5798W(BMC>QJ10*OU[72/TZ.[<X('>*^U4YM[D*OYJUXZJ?K12I_]
M0#S>%G/W/N'--=\<GQ!F?[9Y;.MV3&JBJ?;IX*WLIGUE#5]S4-Z7MAZ)&+&J
M.5B:.8J.U#%>:O.+,^8U_P =6OQV#!<%PU)W8UA]/5.K7^<52,;/55=4L<"3
M2*D:-9I$U&-U1-5<YS@MQ\'3C=D&W^"Y?OQF%MEM5;NG!2V_!J*I8L<_L)3/
M=-)6*QR(J,JYE8L>OUS(T>FK7M50J?\ $Y33G+OM_A%A_>]; .COP\FJWA=Q
M_1?1QZ1?Y-;4K_\ 5 YZ_%<14YN[G+_/6W'%3]9J1/\ Z@%]7A@_,7V*_L60
M_OCN@%&7BYM5O,W)57\WC5@<G^*Z?_4 LTXG;*0\AO"@HMHWSMI*W*X,C=8:
MQR]+(;I0Y%5UEO?(J=J,\Y@8C]/*Q7)Z(%!VVV>;I<1=][9E5-:I<>W%VQND
MU+><8NT;V->BM=!5T-7&U6JL<T3W-U:OD5'L77I<!:)OYXQUWW&VCO&$[7[=
M7/;+-<HIDH[EFBWE)7VV!Z)WZVY]/#!+WKTU8V158K$7J1.K3I#]/#&W%YI[
MV[PT'LCO)F-WV4P?JJMP:^^RMNT-4Y&+YM:HZJXQSR)+.]6J[H>CFQ(YVK5Z
M-0\[QN6JF\NS+_0=AE2U/RKC+_\ 7 E_X*"?_NU;DKZ>YE:G[#6D#Y_&Q3_]
MW3;!?03<>G3^3:+F!%#P1&JN[>]C_0;B-$U?RZ]/_K ;(\<7&[F^/COE\5*^
M2S4SLCL]=6HGJ(JJ=*"HIXW+Z<C(9E;_ -!0( \+^?-_X<X[N-C]KVYH<\9G
M-11UU#45=QDH/,:JE9)$YTC8X)N_8]KT]2BQJBIKU+KH@=9N!9,W-<%PO,F1
MLB9EMBMUZ9%&JN8U*^ECJ$1JKVJB=YV 98!SD>-\U4W+V*?Z#L9NC4_*K(__
M *X&Z/ ^:J8%O\_T'7^R-3\JEJ?_ *X%YX #D3\51/\ ]^/=SZM)C?M#0 7_
M /AFIIP=V'3_ /0[TO\ )OUQ4#97,KC]\IGCWG&UM')3TN2U3(;IA5?5=D4%
MVH)$E@ZW(B]#9F]<#W:+TMD<NBZ <B>$YANYQ0WJHLCMM'583NAMM<)8:VS7
M:G<G2YS'13TM7 Y6J^*:)ZM71>UKD<QR>I<!:%N%XU6Y^38%6X[A6TEJP#-+
MC2K339U[+RW)E,LB=+YJ.A?20=W(B:JQ9)I$:NBJCM *]>)_&/.N6&[EJP^R
M4U6W'(*J*MW(S5S7.AMEN<_JFD?,Y%1:B9$<V%B]KW]J^H:]S0N[\9:T6^P\
M4MH[':*9E%:;+N%:Z"V4;/K8J>GL5UBBC;KZ#6-1$ B=X([57>?>1_H-PNG1
M?R[C#_\ 6 G3XRR*O$JS+_.[AV=5_P 1N2?_ %0*[?!2^<[N)]Z^X>W5F LP
M\7]JNX=7!4_,9A8W+_Z4R?\ U0*M/!C37ECDB^EMO=U7]<K4@'4B  XPN?C5
M9S)Y"(OHY7,[L_HH8E_^J!(#9?Q6=]=CMKL-VGQG \$NEAPFB6AMM?<Z:YOJ
MY8UE?+K,Z&XQ1JNLBIZEB ;/_'7\DOBTVU_Q2\>ZH&_^+/BK[Z[Z<@-L=ILE
MP3 [78LVN<E%<Z^V4US95Q1LIII]8737&9B.UC1/5,4"/OC/[?Y+:.0N'[BS
MT=1+B.88C26ZVW94U@CK[945/G-&CD^M<D<L4J(OEZUTUZ7:!\G _P 2K#.+
M>TEUVHSW;F[7VG@NU5>,>OF..I4EF?6-C22&NCJ9(4U:Z/U,K7.7I5&]'J$5
MP0DY>\G<GY:;LS;HWVQQXS::6@CL6(8[#(Z=M'04KY)^[?4*V-)9725#GO<C
M6_7(B(C4:!=IX.<V/9GQ3W@VTNJLJT=F=RAR"U]2=:VV]V>AIV*Y/0258)VI
M_P!%0*)>1.P^><7MX+[MYD\-51U-EK%J\1R:-'Q1W*W]YU4=?2RIHBZHB=72
MNL<B.8NCFJ!9O8?&PW0MVW,=AO&T%FOVY-/0I2PY^MSEIZ*6=K5:VJJ+2RE<
MKG=B*YK*EC7.U5.A/4@5B;0;6[E\KM\*'$K(E1?<PSV[SW7+,BD;ZBEAGG[Z
MXW2K<U$:QC%D5R^3J<K6-17N:U0N>\9K';=B>RO&C&++&Z&S8O<JRT6J%[E>
MYM-26VGAA:KE\JHR-$50,3\#9/\ Z+<E5]!*3$T_DR7<"??BKIKP?W67TJ['
M%7]?*) *4/"+:KN9F.JGYC&+\Y?\61/_ *H'6&  Y0O%Y:K>9-[5?S>*V%R?
M_!>G_P!0"W3P?FJWAY1JOYO,KXY/_O"?_4 M)  4=>-\U5VTV*?Z#<FNK5_+
MHX__ *P&LO V3_Z-<DE]!*+%4_DR74"$'BB;?Y+A7,?<RZWJCJ&VC/\ S"_X
MI=I4_.ZNE?1002I&Y.S\XGBDA5/*G2B^1R*H2WXL>+%A.QG'K&-J<LVGN]XR
M? *.:@QZJL<]+!;[C$LLDT3JMTSDDIY-9.F1S(Y>I=7Z(KNE J@W^WDRKD%N
MWF&\.8TL5#=\UJ63Q6^F1WF]-24T3:2EIX5?VN;%% UBN_-.17+VJH'3[X8M
MUH,NX'[<V6BJHY*NS_9)8;NQ%U[BH?=:V=C'HGD58*J)^GI.0#E&8E\V^S-J
M5E%YCDN$7I$JK=4IKW-=;:CU<4J-5/K9(U:Y$7\L#J:X,^(3<^8FX.;8?7[;
MT.W\.+8Y3WBD2"YR7*>ID\Y935"JYU/3-:Q%D:K41JJFNBN4#GAYMM5O+KD8
MB^CGMY7^34N7_P"J!UL\3OFL<:?O58;[248',!XAG%')N..^&3W>FL\B[4;B
MW2JO.!WVGB=YG!YY(^>6TR/TZ62TRJY&M5=71(UZ?FD:$@..WB\[E;,;:6;;
M?-=MJ+=>'%*..VXID+KM):*R&B@8D=/!5KYI6-J.Z:B-:Y$C<K41'*Y?5*$$
MN0F_^Z?+_=UF9911+6WVY)!9,+PNR0RRQTE,LKEIJ&CA3KEED?)*JJO:Y[W>
M1$Z6H'3AX<_%NY\7]AH;=E\#(-R=P:Q,@S:E:Y'^8JL38Z2W*]O8Y:>)-7Z:
MIWKY$:YS4:JAS'\Q$TY8<D?OE9/[9S@=?W&=.GCAQ^;Z6VV*)^P]*!7'XUR?
M_NT;<+_^TVA]IKN!#SP1VJN\^\C_ $&X73HOY=QA_P#K 3I\99%7B59E_G=P
M[.J_XC<D_P#J@5V^"E\YW<3[U]P]NK,!9AXO[5=PZN"I^8S"QN7_ -*9/_J@
M5:>#&FO+')%]+;>[JOZY6I .I$
M
M
M
M
M
M
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MHK:B[11/:NJ.2CF?YJYR*B*BNA547ZU4 G>QC8VM8QJ,8Q$:QC4T1$3L1$1
M.27Q8?GM;B_J3COM33 6N\,N+6Q7)+@-Q_I-WL"I,CJ[7'DS+/D$,DM%<Z1K
MLGNRJR*LIGQR]&JZK&Y71JO:K=0-][>^&!PXV\OU+D=/MQ/EEQH)4FH(LGN%
M1<J2)Z+JBK1N<RGET]!)8WI^7V@6 QQLB8R*)C8XXVHV.-J(C6M1-$1$3L1$
M0"(&Y_ ?B9O+G5]W*W)VH^R/-<F=3NO=Z]G;[1]^M+3Q4D*]Q1W""%O3#"QO
MJ6)KIJNJJJJ$C]O=OL0VJPO']O<"M'L#A^+4RTEAM'G%15=Q"KW2=/?54DTS
M_5/5=7O50(];K\$^*N^&;W/<;=':S[)\SO$5-#<;S[.7RB[QE)"RGA3N**X0
M0MZ8V-3U+$U\JZKV@;ZVOVPP;9G!;%MKMK8_L;PG&DJ$LEE\YJ:SN$JZF6KF
M_/ZR6>9_5-,]WJGKIKHFB(B(&C=W>#O%S?C,ZC<'=;;#[*LOJJ6GHI[O[-WN
MAZH*5O1"SN:&OIX4Z47RHS5?150-V;5;48!LE@UHVWVPL'V,X78GU,EJLWG5
M56]TZLGDJIU[^MFGF=U2RN=ZIZZ:Z)HFB :TWOXD<>>13HJK=G;6WW^]4\20
M4N3T[YK?=(XV_6,6MHY(97L;^99(KF)V^I[5 C+:O"8X66VN\\J<)OE[B1Z/
M;;JZ_P!>D":+KT_]FD@>J?DO4"?F$8%A6VN.T6([?XK:\-QFW:K26.T4L=)3
MM<[Z]ZLB:U'/>J:N>[5SE[7*J@::WNXB<>.1UXLM_P!YMO?LRNV/4;[?9ZOV
M6NUN[FGDD65S.BW5E,QVKU5=7(J_5T R_9/8#:3CKC-RP_9S$_L/QR[W-]YN
M-N\_K[AWE;)##3NE[VX5%3(W6.!C>EKD;V:Z:JJJ'^;V<?MHN1>.6S$MY,2^
MS''K-<FW>VV_S^OM_=UC(98&R]Y;JFFD=I',].ESE;VZZ:H@&*;(<1^/7'&Z
MWR];,;??8;<\DI8Z&]57LK=KCWT$3^\8SIN-94M9H[MU8B*OH@;+W2VFVYWK
MP^NP+=+$Z+,<4N#FRS6NLZVJR5B*C)H)HG,EAE:CE1LD3VO1%71>U0(-0>$O
MPKANBW!^#WRJI5>CTLDN07!*5$3\RCF2LGT7ZLNOU0+$,<QZS8ECUAQ3'*!E
MJQ[&+=2VFPVR-7.9345%$V"GA:KU<Y49&QK4U55[.U0/9 CEOAQ*X^\C[E8;
MOO/@'V97#&:::CL=1[*W:W=Q#.]))&]-NK*5K]7-1=7HJ^D![6Q_&S97C?;[
M_:ME\+^PV@R>HAJ[Y![(W*X]_-3L<R)W5<:JJ<SI:Y4T8J(OH@;S  1$W5X(
M<4M[<YN^Y&Y^U?V39I?64T=UO/LY?:+O6T<$=+ G<45P@A;TQ1-;ZEB:Z:KJ
MNJ@2!VTVUPG9_![#MOMS9$QW"\8CFBL=F2HJ:ON&SSR5,B=_5RS3/ZI97.U>
M]?+IY-$ SH#0.]7%S8/D+!&W=S;2U937T\*04>0:24=U@B:JN;''<*1\-0C$
M<JKT=?1KKJWM4"*%%X2G"VDN*5LV&W^Y4Z/1WL14Y!7)3Z)^9UA?%-HO]DU^
MJ!//;O;+;[:7&J7$-M,/M>%8W2+U1VJU4[8&/D5$1TLKD3JED=HG4]ZN<OHJ
MH&+[U[ [2<BL8MV';QXG]F&.6FZ1WFWV[SZOM_=UT4,U.R7O;?44TBZ1U$C>
ME7*WMUTU1%0,/V1XA\>..5YO60;,[>_8;=\AHFV^\5?LM=KCWU,R1)6LZ+C6
M5+&Z/1%U:B+]70#.MY=CMK>0.(Q8+N[B_P!EN*P7"&ZQ6KSVNH-*NG9)'%)W
MM!44TOJ6RO33KZ5U[4[$ USLIPUXV\=LGN.9;.;<?8?DEVM<EEN%R]F+Q<.\
MH99X:A\7=7"MJ8TUDIXW=2-1W9IKHJHH;-W?V8VTWZPV7;_=C&_LKQ&>K@KY
M;3YY64.M13*JQ/[Z@GIY?4JY>SKT7T4 U9LQPMXT<>\LJ<XV@VU^Q'*:RVS6
MBINGLS>;AU44\L4TD7=7"NJ8DU? Q>I&]79V+HJZA*0 !#'<#P]^(&Z69Y#N
M#G>T7L[E^552UM^N_L_D%+W\ZM1JO[FEN44+.QJ=C&(GU ,._%<<$_B,^Z;)
M_=8!^*XX)_$9]TV3^ZP&:[=^'WQ$VGS7']Q, VD]@,QQ:H=56*\>SU_JNXE=
M&Z)7=S57&:%_J'N31[%0"1VY&U^WV[^*UV$;F8E;LSQ>X]L]JN,76ULB(J-F
MAD322&5J*O3)&YKV_F7(!!%/"7X5I=6W#[![XM(CD5;%]D%Q\U5$7717=[YQ
MHOD_KH$A,LX3<6<VP+%]L;]LY:4P;#*R6X8Y8[9/6VE(*J>-(IIWSVZHIIIG
MRM1.M97N5ZHBNU5$5 ]_8WBGL)QMJ<CJ]EL%=A<^6Q4T.0JEVNUQ;4LHW2.@
MU9<:RJ:U6+,_16(B]JZ@9ENUL?M+OMC[<7W;P.UYQ9X7.?1LKHW-J*5[T1'/
MI*N%T<].YR)HKHI&JJ=BKH!"5OA)<+FW!:U</R!]-JJ^Q#L@KO-^U==.I'I-
MV>3^N 3/V?V"V<V#L;\?VBV_M>%4,^GGT]*QTM;5JWM:M575#I:F=4U[.\D=
MIZ&@'G;X<;MEN1]LL5GWGPS[,K=C-5+662G]D;C;NXGG8D<C^JW55,Y^K41-
M'*J>D!YNQO%?8;C9+DTVRN"?87+F#*1F1N]E+I<?.&T*S+3II<JNJ1G0M1)]
M9TZZ]NNB:!GVZVT^ ;W8/=MM]S[!]DV%WQ]-)=+-YU5T7>NI)XZF!>_HIH)F
M],L37>I>FNFBZIJ@&E-H>#W%W8?,X-P=J-L/L5R^FI9Z*"[^S5[KNF"J:C9F
M=S75]1"O4B>56:IZ"H!+  !%'=_@_P 7M^LREW W8VP^RO+IZ2"AENWLU>Z'
M6GID5(F=S05]/%ZE%7MZ-5]%0-N[/[+[:;"8='@&T^-?8IB,59/7QVGSRLKM
M*BIZ5E?WU?/42^JZ4[.O1/00#:( #1^]_&_9?D?:[%9MY\,^S*VXU52UMEIO
M9&XV[N9YF)&]_5;JJF<[5J::.54^H!Y>QO%;87C;-DM1LK@GV&39>RDCR)_L
MI=+CYPVA69:=-+C5U2,Z%G?]9TZZ]NNB:!DV\FPNT7(#'&8KN[@UOS*U4[UD
MM[ZA'PU='([3J?25E.Z.H@5W2B.[M[>I.QVJ=@$.[1X3W"RU7AEVEP.\7B&*
M1)8K+7WVO?1HK>U$5L4D<CVZ^@]ZHOD75.P#>VY7"#BMNW2XA0YQL[;*N@P&
MWR6K$*"U5=PL=/0T4DG>N@9%:*JC8YO7JY.I%T57*GUSM0V+LEQ\VAXZ8_=<
M5V;Q-V'V"]W%;K<[<MQN-Q;)6.BC@65'7&IJ7L58XF-5&JB=B=@&BMY/#OXH
M[XY-<\VR[;R2VYA>Y.^O.0V"OJ;;)5RZZNEF@B>M,^1ZJJOD6+K=^:<H&9<?
MN%O'KC)=KGD6TV'U%LR:\T#K7<LBKKE65U1)1/EBG= C9I5A8U9(6.7HC155
M$U70#%,X\.[AUN/E^1YYF>S_ +,Y7EM?-<\@NOV09#3^<54[NJ23N::Y11,U
M7T&,1/20"6N)XM8<&Q7&L*Q:A]B\8P^U4=DQRV=[+/YO06^!E-30][.^25_1
M%&UO4]SG+IJY57M _G*\0Q7.[!<,5S7'+;EF-79B1W*PW:EBK*2=J*CF]<,S
M7-56JB*BZ:HO:G:! +(_"BX6Y!<9KC3X%=L:6HE6:6BM%[KHZ?5RZJUL<\DZ
M,:J_F6:(GD31 -^;(<,.-?'FL]F-L-LJ&W9+TJS[++C+/<[FU')HY(:FMDE=
M CD[')#T(OHHH$HP(29CX<_#7/\ +,DSC+MG?9;*<NN53=\BNGV0Y#!YQ6UD
MKIIY>ZI[G'$SJ>Y5Z6-:U/01$ F#C>.V;$,=L&)X[1I;L?Q>W4MIL5O1\DJ0
M4=%"V"GB[R5SWNZ(V-35SE<OE554#6^]>P.TG(K&+=AV\>)_9ACEIND=YM]N
M\^K[?W==%#-3LE[VWU%-(ND=1(WI5RM[==-414##]D>(?'CCE>;UD&S.WOV&
MW?(:)MOO%7[+7:X]]3,D25K.BXUE2QNCT1=6HB_5T SK>78[:WD#B,6"[NXO
M]EN*P7"&ZQ6KSVNH-*NG9)'%)WM!44TOJ6RO33KZ5U[4[$ USLIPUXV\=LGN
M.9;.;<?8?DEVM<EEN%R]F+Q<.\H99X:A\7=7"MJ8TUDIXW=2-1W9IKHJHH;-
MW?V8VTWZPV7;_=C&_LKQ&>K@KY;3YY64.M13*JQ/[Z@GIY?4JY>SKT7T4 U9
MLQPMXT<>\LJ<XV@VU^Q'*:RVS6BINGLS>;AU44\L4TD7=7"NJ8DU? Q>I&]7
M9V+HJZA*0
M
M
M
M
M
M
M
M                              4^<NO"YO?)W?/)=X:+>2AP^GO]';:5
MEAGLDE:^):"CBI5<LS:V%%ZUCZM.GLUT G]Q4V/J>-^P>!;+UF1Q994X8ES2
M3((:9U&RH]D+I5W%-('23*WH2I1GUZZZ:]FN@$A0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M\2?T_.\1\JOG9]*G[AL8]:#_ %__ ''F?QGQ)_3\[Q'RJ^=GTJ?N&QCUH/\
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M_.\1\JOG9]*G[AL8]:#_ %__ ''F?QGQ)_3\[Q'RJ^=GTJ?N&QCUH/\ 7_\
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M\2?T_.\1\JOG9]*G[AL8]:#_ %__ ''F?QGQ)_3\[Q'RJ^=GTJ?N&QCUH/\
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M_.\1\JOG9]*G[AL8]:#_ %__ ''F?QGQ)_3\[Q'RJ^=GTJ?N&QCUH/\ 7_\
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M
M                                VCX2'SW]\?M'R;]\MG.!ZS^>O_\
M97]Z71LC^7M_5I\$.E,C6T 0 \4?YB>^?[F?WSVD"@39'^##&/\ YW].SG:N
MJ7^+M?O??J4/6OS=?<^[#:Q9$6
M                                                          ;\
M\,+Y^V\OWJJC]/8V<4ZV_P"4N_N_<I7S1?RE'=^]+HH*XE "H'QJ_FL8#]]6
MU>T=\ JNP/\ U'PS]0K=^EHSOFC?D;'_ %T?=ASG/?F+GUJO#+*R2:H
M
M                          !:AX2'\".^/W\LF]K;.<#UG\]?_P"RO[TN
MC9'\O;^K3X(6J$:V@"@'QSO^%W]VW^8 (LGZ.<O
M
M            %DW@J?-8S[[ZMU]H[&?G%U!;\  J!\:OYK& _?5M7M'? *KL
M#_U'PS]0K=^EHSOFC?D;'_71]V'.<]^8N?6J\,LK))J@
M
M               $T?!L_P!>.:OZNXU^F<C.!ZS^>O\ _97]Z71LC^7M_5I\
M$+TR-;0! #Q1_F)[Y_N9_?/:0*!-D?X,,8_^=_3LYVKJE_B[7[WWZE#UK\W7
MW/NPVL61%@
M                                         &_/#"^?MO+]ZJH_3V-G
M%.MO^4N_N_<I7S1?RE'=^]+HH*XE    T!RQ^:QR6^]5F7M'6 <U^!_ZCX9^
MH5N_2T9WS1OR-C_KH^[#G.>_,7/K5>&65DDU0
M
M        #:/A(?/?WQ^T?)OWRV<X'K/YZ_\ ]E?WI=&R/Y>W]6GP0Z4R-;0!
M #Q1_F)[Y_N9_?/:0*!-D?X,,8_^=_3LYVKJE_B[7[WWZE#UK\W7W/NPVL61
M%@
M                                 &_/#"^?MO+]ZJH_3V-G%.MO^4N_
MN_<I7S1?RE'=^]+HH*XE "H'QJ_FL8#]]6U>T=\ JNP/_4?#/U"MWZ6C.^:-
M^1L?]='W8<YSWYBY]:KPRRLDFJ
M                                                          6H
M>$A_ COC]_+)O:VSG ]9_/7_ /LK^]+HV1_+V_JT^"%JA&MH H!\<[_A=_=M
M_F "+)^CG+P
M                                           !9-X*GS6,^^^K=?:.
MQGYQ=06_  *@?&K^:Q@/WU;5[1WP"J[ _P#4?#/U"MWZ6C.^:-^1L?\ 71]V
M'.<]^8N?6J\,LK))J@
M                                                 $T?!L_UXYJ_
MJ[C7Z9R,X'K/YZ__ -E?WI=&R/Y>W]6GP0O3(UM $ /%'^8GOG^YG]\]I H$
MV1_@PQC_ .=_3LYVKJE_B[7[WWZE#UK\W7W/NPVL61%@
M
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MVX8[.U,L&;RE>6KZ%6&/8:O)%J@
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MK:"IC=%-#*Q>ES)(WHCFN:J:*BH6^BNFNF*J9QB=TQN0M5,TSA.R7R'MY
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M4[=5=J*HB)P^=$1P8\$RQ9W(UY2J*:YC;&.S](:9)9I@
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M7KY&)4P.DAZE]!.K4D,EJV4SFRS<BJ>+A[TX2U[^3O6/ITS'@[[6!(M4
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MX)X9$\K9(Y$:YJIZ2H3MNY3<IBJB8F)W3&V$?53-,X3&$OA,CR
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M<X'K/YZ__P!E?WI=&R/Y>W]6GP0M4(UM % /CG?\+O[MO\P 19/T<Y>
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M%N>U'T?EY$'H6<FY7715OF>ES_(\7Q&]LO\ 4[=NWT_^SN2O8G_3GH97:?\
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ML;',^G1ZI$Z5C5<C7*S17(BJB+Z)UNW-4TQTM^&W#=CPJ95AC.&Y\1[>0
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MCO@%5V!_ZCX9^H5N_2T9WS1OR-C_ *Z/NPYSGOS%SZU7AEE9)-4
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MC9'\O;^K3X(7ID:V@" 'BC_,3WS_ ',_OGM(% FR/\&&,?\ SOZ=G.U=4O\
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M-3M&GY2,IEZ+,;>C$1V^.>[*BYF]-ZY57/#+!S<8
M-H^$A\]_?'[1\F_?+9S@>L_GK_\ V5_>ET;(_E[?U:?!#I3(UM $ /%'^8GO
MG^YG]\]I H$V1_@PQC_YW].SG:NJ7^+M?O??J4/6OS=?<^[#:Q9$6
M                )-<.%1.2FU^JZ?\ :J_VMJRO=:O\9>[4?>A):1^:H[O@
ME?'F&&8OGUBJ,9S"SPWZQ5;XY*BVU"O1CWPO1\:KT.:OJ7(B^4XUE<W=RMR+
MEJKHU1PKS>LT7J>C7&,-54G&KCS89Z>XQ[7X[!)1JCX9:N+OF(K5ZD5S:A[V
M.5%]-%)*K7]1NQ-/IJMO%L\#5C3<K1MZ$,4WCY9;2[0VBLI**]T659;#3N;:
M,4L\C9VME1ND:54T6L=.Q%TU15Z^GZUBFSI75K-Y^N)FF::,=M56SO1.V9Y.
M.6+.:K9R].$3$U<$1\O$HCRS*+UFV2WS+<BJO/+WD-9+77&HTZ6K)*[71C?S
M+6IZEK4\B(B'9,MEJ,M:IM6XPIIC"%'NW:KM<UU;Y=&.9_P*97]I-=[6O.$Y
M3\[1_P!D?>="O?EZOJSX'-<USFN1S55KFKJUR=BHJ>144[XYROQX@[ZMWFVV
MAI;S5I+G6%MBM^3(]?SRICZ52FKM/1[YK51Z_P#6-=Y$5IQ?K1HWN_,XT1_Z
MZ]M/8XZ>YP=C!>])SWM-K"?I4[)^2?TX6AO$'QVX9?>>/>*VEJ/N>27BZVR@
M1WUO?53[;$Q7+Z"(KM57TB9ZD7Z;%&9N5;J::9GN=*6CK]N;E5JF-\S,>!.^
MEI\<V@VUB@1?-<7VZQ_U<G8CO-;;3ZO>OIO<C%5?3<I3JJKF?S..^NY5RU2G
M(BG+VOV:8\#G'RS.<BR_*,ARJXW*I979%<:FXU,;)G]#'5,CI.AB:IHUO5TM
M3T$0[MELG;L6J;=,1A3$1NXG/+M^JY7-4SMF<7XXYFF1XOD%CR6V76I;<;!7
MT]PHE?*]6K+32-D:CDZNUJJW14]%#U?REN];JMU1&%43$]U\MWJK=451.V)Q
M=(=GN..[K[=T-Q2)M;C&X%B:^:E>J+U4MPI])(7^DY$>K')Z"ZG!KMNYD<Q-
M.ZNW5RTSO=$HJIS%J)_5JCPN<7<7#*[;O.\LPBXN[RIQFYU%#W_D[V.-R]U,
MB>@DD:M>GY)W?(YNG-V*+U.ZJ(GGCN3L<\S%F;-RJB>"<&&&VPOLM]?66JOH
M;I;YW4M?;:B*JH:IG8Z.:%Z/C>WZK7(BH>*Z(KIFFJ,8F,)[KU35-,Q,;X=+
M^V>:T>XVW^(9Q0]+8<FM=/62PL75(IW-TGAU].*5',7ZJ' -0RDY3,5V9_5F
M8[G!/=C:Z/EKT7K5-<<,*L_$7W%]ELWQ7;2BGZJ3$J);G>8VKV+77!$[ICT]
M..!B.3ZDJG1>HN1Z%BO,3&VN<([5._OSX%8ZPYCI7*;<<$8SVY\7A5X6BY3V
M:[6N\4R(M3:JN"LIT7R=<$C9&Z_EM+S=MQ<HFF=TQ,=]7Z*NC5$QP.CC%,PV
MZY"[;U,MLJX+WCN4VUU#D5E[U$J:3SJ)6S4M2UCNJ*1J*J:_^<U5313A&9RN
M9TK,Q%43353.-,\$X3LF../_ !+H=J]:SEK9MB8VQQ=B4>\9X[<<.+=S^%#(
MLGJ8ZFB>]MBK<DJX7MI7R(K%\TIZ>&-TTO2Y4UZ7JB=J(GE)S,:[J6M4^SVZ
M(PG?%,3M[<S,X1WD?;T_*Y&?2U5=K&? VSRLQFJS'CSN=:K=I)4Q6N.[0Z+K
MU-M=1%<'HWTU=' Y$_)(SJWF(R^HVJJMV.'VHFGPRV]4MS<RM<1Q8][;\B O
M!WDMCV!T]9M3N!<X[/9+A6.KL5R&J<C*:FJ)D1)J:HD7LC8]6H]KUT:CNKJ7
MU2%UZWZ!<S,QF;$8U1&%41OF."8XYC=,=I!:)J5-J/17)PB=T_(L$W)XY[,;
MU7"@R?+,?;<KFVG;'#?+=5R4SZFGT_.TD?3O1LJ-_,JNJHG8BZ=A2,AKN=TZ
MF;=JK",=TQCA/=W)[,Z?8S,Q57&,\<2_W.]RMI>,NW]/0R245GI+)0+'B>"T
MDK?/*M6Z]#(HW*Z14<]?5ROU1%57.55\K)Y#-ZQF)G;,U3\ZN=T=O@[4=R"_
MF;.1M8;(PC9'#/Z<:H_8GDU7X#OI?]R,M[VJLNXM34-S:"#5[H6U4_?1SPL\
MJ^;.[$;_ -7U-3MT.FZSU?IS60IR]K95;B.CW(PPGZWA53(ZE-G,3<KW5;_T
M['@7#9+B6SO)+"Z)MQ]C\YQF1Z5-JNU!4JDM/+IHJQ3PN1\3].Q[%T])[>S0
MY;E\SG-(OST<:*]TQ,;^Y.R>Q/>6ZY:L9VW&.%4<</GQ7"MF>-&(W26VK0X/
MCT\WG-XO-SJU62HE1%2-KYIWJYZM35&1M^KTMZE77UF<WG=8O1TL:ZMT1$;N
MY'++Y:LV,E1.&%,<,S*E;E%O9'OEN?59#;(Y8,7LM,VTXO#-JU[Z:)[WNJ'L
M[.ETSWJ[3RHWI:OUIUGJ[I$Z;E8HJ^G,XU=OB[G.INIYWVJ]TH^C&R/T[*]'
M/OX),T^U"Y?I"0X]DOS=OZ\?>A=\Q_)J^K/@5U>&?_WO>7^PV#^FN!>O_H&Z
MQ^__ ,5>ZM[[G<^5A?B1?PH8']JW_P!FU!M]0ORMSZ_R0P]8OYU/U?EEEGAH
M_P#B^[W^!V7^V5AJ]?\ Z%CMU?\ %EZM_2N=SY6.>)$Y6[C[>*UW2]N.2.14
M714_[9)HIL=0ORUWZWR,?6+^;1VOE3.XS<D,1WFPFTV"_P!WI8=Q:"B909'8
M:]S&27%8V)&ZJ@:]=)FS)VO:WM:Y514Z>E75/K!H-[3[]5=%,^BF<:9C]7L3
MQ8<'&F--U&C,VXIJGY^&V)X>R_?'>%NQF+9_2;@VNU7%*NVU:5]JQZ:K22UT
MM2QW7'+'$L?>KW;M'-1TKFHJ)V=A\O\ 6S/7LO-BJ8PF,)G#YTQV]VWM/MO1
MLO;N^DB)V;<,=GZ=UHSG!R(P>##:_:K%JRWY-EM\5L-YK:?N:J*TTK7HLK%E
M3J1M1)T]'2GJFM5SEZ5Z-9CJAH=^;T9FY$TT4[HVQTIX-GDQO[/9VM+6M0MQ
M;FU3A-4[^QXU/YU%40                        WYX87S]MY?O55'Z>QL
MXIUM_P I=_=^Y2OFB_E*.[]Z7105Q* %0/C5_-8P'[ZMJ]H[X!5=@?\ J/AG
MZA6[]+1G?-&_(V/^NC[L.<Y[\Q<^M5X996235
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MAN?PEY]]K+?TY"3G7W\M;^O\DH_J[_-J^K\K.?$@_P#'MD/R+S_;;>:?4/\
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M%-V[:G?5$3'[LS$_>1W6.U,T45\4S'?_ /":6P'\!FSWVF63](PE3UO\]?\
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MGJ%\C5.DZ[ILZUD[6:L1\^*<<..)WT]N)W=U5M/S7L%^NU<^CCOXN*>ZLJW
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M\LK?U=_DU?6^2$,>=OSCLI_4ZT_I*,M?4W_&T=NKPRA]<_-5=J/ S3@KOO\
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M\Q,;*8PCMU;^]'WFAUAS'1MTVHX=L]J/'X%/QU%40
M-^>&%\_;>7[U51^GL;.*=;?\I=_=^Y2OFB_E*.[]Z7105Q*   !H#EC\UCDM
M]ZK,O:.L YK\#_U'PS]0K=^EHSOFC?D;'_71]V'.<]^8N?6J\,LK))J@
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M*!-D?X,,8_\ G?T[.=JZI?XNU^]]^I0]:_-U]S[L-K%D18
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M9.^+_P!!7JW^488RUJ)QBB,>/"&2;M<QA,SAVW@F=C
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MI;ED%RN%,Q-&4]35S2QHGI(U[U0Q49>U1.--,1/8B'JJY55&$S,O$,SP
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M]6U>T=\ JNP/_4?#/U"MWZ6C.^:-^1L?]='W8<YSWYBY]:KPRRLDFJ
M    'U4=?76Z=*FWUD]!4M31M13R.B>B?4<Q44\5T4UQA5$3'9?8JF-L/JN=
M]O=Z<Q]YO%==G1Z]VZMJ))U;KY=%D<[0\V[-%OZ%,1VHP>JJZJM\S+RS*\
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M=_3LYVKJE_B[7[WWZE#UK\W7W/NPVL61%@
M    !_<4LL$C)H9'0S1.1T<K%5KFN3M145.U%0^3$3&$OL3@]NLRG)[C3-H[
MAD=TKZ1J:-I:BLFEC1/J,>]4_E&&C+6J)QIIB)[$0]U7:ZHPF9[[P3.Q@'T4
MM75T,[*JBJIJ.IC_ *W40/=&]NOI.:J*AYJIBJ,)C&'V)F-L/ON607Z\HUMW
MO=PNK6:=#:RIEG1-/)IWCG:'BW8MV_HTQ':B(>JKE56^9EY!E>
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MH^&?J%;OTM&=\T;\C8_ZZ/NPYSGOS%SZU7AEE9)-4
M
M             VCX2'SW]\?M'R;]\MG.!ZS^>O\ _97]Z71LC^7M_5I\$.E,
MC6T 0 \4?YB>^?[F?WSVD"@39'^##&/_ )W].SG:NJ7^+M?O??J4/6OS=?<^
M[#:Q9$6
M                                       ;\\,+Y^V\OWJJC]/8V<4Z
MV_Y2[^[]RE?-%_*4=W[TNB@KB4 *@?&K^:Q@/WU;5[1WP"J[ _\ 4?#/U"MW
MZ6C.^:-^1L?]='W8<YSWYBY]:KPRRLDFJ
M
M     6H>$A_ COC]_+)O:VSG ]9_/7_^RO[TNC9'\O;^K3X(6J$:V@"@'QSO
M^%W]VW^8 (LGZ.<O          "1F.<M.0>)X_;<7L.X4E'9+/20T-JI'VZV
MSN@IX&)''&R2:E>_1K41$U<I W^K.GW[DW*[6-4SC.VJ,9GM3@D;>JYFW3%-
M->R-FZ.9J3-MPLVW'NB7G.<GK\FN+&JR":ME5S86*NJLAB31D357MZ6-1-23
MRF1L92CH6:(ICL?+PSW6I>S%R].-=4S+#C;80
M                                                       !9-X*
MGS6,^^^K=?:.QGYQ=06_  *@?&K^:Q@/WU;5[1WP"J[ _P#4?#/U"MWZ6C.^
M:-^1L?\ 71]V'.<]^8N?6J\,LK))J@
M     &[+5R0WTLELMMEM.YU[H+5:*6&BME#%*U(X:>G8D<4;$Z>Q&M:B(1%S
M0<A<JFNJU3,S.,SQS.]NTZCF*8BF*YPAI5[W2/=(]RN>]5<]R^BJ]JJ2T1@T
MG\GT                                                    ":/@
MV?Z\<U?U=QK],Y&<#UG\]?\ ^RO[TNC9'\O;^K3X(7ID:V@" 'BC_,3WS_<S
M^^>T@4";(_P88Q_\[^G9SM75+_%VOWOOU*'K7YNON?=AM8LB+
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MJA@R>@9'*5=.U:B*HX9QJF.UTIG#N,E_4<Q>C"NN<.]X&CR8:0
M          #?GAA?/VWE^]54?I[&SBG6W_*7?W?N4KYHOY2CN_>ET4%<2@
M : Y8_-8Y+?>JS+VCK .:_ _]1\,_4*W?I:,[YHWY&Q_UT?=ASG/?F+GUJO#
M+*R2:H
M                                     !M'PD/GO[X_:/DW[Y;.<#UG
M\]?_ .RO[TNC9'\O;^K3X(=*9&MH @!XH_S$]\_W,_OGM(% FR/\&&,?_._I
MV<[5U2_Q=K][[]2AZU^;K[GW8;6+(BP
M
M  #?GAA?/VWE^]54?I[&SBG6W_*7?W?N4KYHOY2CN_>ET4%<2@!4#XU?S6,!
M^^K:O:.^ 578'_J/AGZA6[]+1G?-&_(V/^NC[L.<Y[\Q<^M5X996235
M
M                           +4/"0_@1WQ^_EDWM;9S@>L_GK_P#V5_>E
MT;(_E[?U:?!"U0C6T 4 ^.=_PN_NV_S !%D_1SEX
M
M             LF\%3YK&???5NOM'8S\XNH+?@ %0/C5_-8P'[ZMJ]H[X!5=
M@?\ J/AGZA6[]+1G?-&_(V/^NC[L.<Y[\Q<^M5X996235
M
M                 )H^#9_KQS5_5W&OTSD9P/6?SU__ +*_O2Z-D?R]OZM/
M@A>F1K: ( >*/\Q/?/\ <S^^>T@4";(_P88Q_P#._IV<[5U2_P 7:_>^_4H>
MM?FZ^Y]V&UBR(L
M                                              WYX87S]MY?O55'
MZ>QLXIUM_P I=_=^Y2OFB_E*.[]Z7105Q*   !H#EC\UCDM]ZK,O:.L @!X*
MGS6,^^^K=?:.Q@6_
M                                                 * > O\ &F\U
M/]X_[][<!?\   ( >*/\Q/?/]S/[Y[2 \+CYB>QG[IOWSW8"?X
M
M                      "@'@+_ !IO-3_>/^_>W 7_   "H'QJ_FL8#]]6
MU>T=\ G_ ,3OFL<:?O58;[1T8&_P
M                                                           -
M <L?FL<EOO59E[1U@$ /!4^:QGWWU;K[1V,"WX !0#XYW_"[^[;_ # !?\
M
M                               T!RQ^:QR6^]5F7M'6 0 \%3YK&???
M5NOM'8P+?@ %0/C5_-8P'[ZMJ]H[X!/_ (G?-8XT_>JPWVCHP-_@
M
M                        * ? Q_XHOW$_Y_ O^  0 \4?YB>^?[F?WSVD
M!X7'S$]C/W3?OGNP$_P
M                                                   % / 7^--Y
MJ?[Q_P!^]N O^    &@.6/S6.2WWJLR]HZP" '@J?-8S[[ZMU]H[&!;\
M
M                             H!X"_QIO-3_ 'C_ +][<!?\  @!XH_S
M$]\_W,_OGM(#PN/F)[&?NF_?/=@)_@
M
M  * > O\:;S4_P!X_P"_>W 7_  *@?&K^:Q@/WU;5[1WP"?_ !.^:QQI^]5A
MOM'1@;_
M                                       T!RQ^:QR6^]5F7M'6 0 \
M%3YK&???5NOM'8P+?@ % /CG?\+O[MO\P 7_
M
M          #0'+'YK');[U69>T=8! #P5/FL9]]]6Z^T=C M^  5 ^-7\UC
M?OJVKVCO@$_^)WS6.-/WJL-]HZ,#?X
M
M  "@'P,?^*+]Q/\ G\"_X ! #Q1_F)[Y_N9_?/:0'A<?,3V,_=-^^>[ 3_
M
M                               4 \!?XTWFI_O'_?O;@+_@   !H#EC
M\UCDM]ZK,O:.L @!X*GS6,^^^K=?:.Q@6_
M
M       * > O\:;S4_WC_OWMP%_P " 'BC_,3WS_ ',_OGM(#PN/F)[&?NF_
M?/=@)_@
M                                       * > O\:;S4_WC_OWMP%_P
M "H'QJ_FL8#]]6U>T=\ G_Q.^:QQI^]5AOM'1@;_
M
M             - <L?FL<EOO59E[1U@$ /!4^:QGWWU;K[1V,"WX !0#XYW_
M  N_NV_S !?\
M                                             T!RQ^:QR6^]5F7M
M'6 0 \%3YK&???5NOM'8P+?@ %0/C5_-8P'[ZMJ]H[X!/_B=\UCC3]ZK#?:.
MC W^
M                                     H!\#'_BB_<3_G\"_P"  0 \
M4?YB>^?[F?WSVD!X7'S$]C/W3?OGNP$_P
M
M     % / 7^--YJ?[Q_W[VX"_P"    &@.6/S6.2WWJLR]HZP" '@J?-8S[[
MZMU]H[&!;\
M                                           H!X"_QIO-3_>/^_>W
M 7_  ( >*/\ ,3WS_<S^^>T@/"X^8GL9^Z;]\]V G^
M
M               H!X"_QIO-3_>/^_>W 7_  *@?&K^:Q@/WU;5[1WP"?_$[
MYK'&G[U6&^T=&!O\
M                                               #0'+'YK');[U6
M9>T=8! #P5/FL9]]]6Z^T=C M^  4 ^.=_PN_NV_S !?\
M
M                  T!RQ^:QR6^]5F7M'6 0 \%3YK&???5NOM'8P+?@ %0
M/C5_-8P'[ZMJ]H[X!/\ XG?-8XT_>JPWVCHP-_@
M
M           * ? Q_P"*+]Q/^?P+_@ $ /%'^8GOG^YG]\]I >%Q\Q/8S]TW
M[Y[L!/\
M                                         4 \!?XTWFI_O'_?O;@+
M_@   !H#EC\UCDM]ZK,O:.L @!X*GS6,^^^K=?:.Q@6_
M
M                 * > O\ &F\U/]X_[][<!?\   ( >*/\Q/?/]S/[Y[2
M\+CYB>QG[IOWSW8"?X
M                                                  "@'@+_ !IO
M-3_>/^_>W 7_   "H'QJ_FL8#]]6U>T=\ G_ ,3OFL<:?O58;[1T8&_P
M
M                           - <L?FL<EOO59E[1U@$ /!4^:QGWWU;K[
M1V,"WX !0#XYW_"[^[;_ # !?\
M                                                           T
M!RQ^:QR6^]5F7M'6 0 \%3YK&???5NOM'8P+?@ %0/C5_-8P'[ZMJ]H[X!/_
M (G?-8XT_>JPWVCHP-_@
M                                                    * ? Q_XH
MOW$_Y_ O^  0 \4?YB>^?[F?WSVD!X7'S$]C/W3?OGNP$_P
M
M                   % / 7^--YJ?[Q_P!^]N O^    &@.6/S6.2WWJLR]
MHZP" '@J?-8S[[ZMU]H[&!;\
M                                                         H!X
M"_QIO-3_ 'C_ +][<!?\  @!XH_S$]\_W,_OGM(#PN/F)[&?NF_?/=@)_@
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M5Z-<]='/5SM/*J@67
M      H!X"_QIO-3_>/^_>W 7_  *@?&K^:Q@/WU;5[1WP"?_$[YK'&G[U6&
M^T=&!O\
M                                        T!RQ^:QR6^]5F7M'6 0
M\%3YK&???5NOM'8P+?@ % /CG?\ "[^[;_, %_P
M
M           #0'+'YK');[U69>T=8! #P5/FL9]]]6Z^T=C M^  5 ^-7\UC
M ?OJVKVCO@$_^)WS6.-/WJL-]HZ,#?X
M
M   "@'P,?^*+]Q/^?P+_ ( ! #Q1_F)[Y_N9_?/:0'A<?,3V,_=-^^>[ 3_
M
M                                4 \!?XTWFI_O'_?O;@+_ (    :
MY8_-8Y+?>JS+VCK ( >"I\UC/OOJW7VCL8%OP
M
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M$>"/_ OO)]NL'M="!=>
M       "@'@+_&F\U/\ >/\ OWMP%_P "H'QJ_FL8#]]6U>T=\ G_P 3OFL<
M:?O58;[1T8&_P
M                                            - <L?FL<EOO59E[1
MU@$ /!4^:QGWWU;K[1V,"WX !0#XYW_"[^[;_, %_P
M
M                T!RQ^:QR6^]5F7M'6 0 \%3YK&???5NOM'8P+?@ %0/C
M5_-8P'[ZMJ]H[X!/_B=\UCC3]ZK#?:.C W^
M
M        H!\#'_BB_<3_ )_ O^  0 \4?YB>^?[F?WSVD!X7'S$]C/W3?OGN
MP$_P
M                                    % / 7^--YJ?[Q_W[VX"_X
M : Y8_-8Y+?>JS+VCK ( >"I\UC/OOJW7VCL8%OP
M
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M/?M=NGZ4E J#\$?^!?>3[=8/:Z$"Z\
M                  % / 7^--YJ?[Q_W[VX"_X !4#XU?S6,!^^K:O:.^ 3
M_P")WS6.-/WJL-]HZ,#?X
M                                                    &@.6/S6.
M2WWJLR]HZP" '@J?-8S[[ZMU]H[&!;\  H!\<[_A=_=M_F "_P"
M
M                        : Y8_-8Y+?>JS+VCK ( >"I\UC/OOJW7VCL8
M%OP "H'QJ_FL8#]]6U>T=\ G_P 3OFL<:?O58;[1T8&_P
M
M                 % /@8_\47[B?\_@7_  ( >*/\Q/?/\ <S^^>T@/"X^8
MGL9^Z;]\]V G^
M                                              H!X"_QIO-3_>/^
M_>W 7_    #0'+'YK');[U69>T=8! #P5/FL9]]]6Z^T=C M^
M
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MRLBM#)*)(HU5%9(^CM=!/4225/0YR(^LD;THJHUVFK5"]3;#;7$-GL Q;;/
M[;[$XGA]$VAM%&KE>_IZE?)+*]>U\DLCW22._-.<J^B!ZN;6^LN^&Y;:;?#Y
MQ<+G9:^DH:?J:SKFFIY(XV]3U:U-7.1-55$],"N/PM>.N\?'+;'<O'MYL/\
ML.O&091%<;11^R%ON/>TS***)9.NW5-2QOJVJFCG(OU- +0P
M                                    4 \!?XTWFI_O'_?O;@+_ ( !
M4#XU?S6,!^^K:O:.^ 3_ .)WS6.-/WJL-]HZ,#?X
M
M           &@.6/S6.2WWJLR]HZP" '@J?-8S[[ZMU]H[&!;\  H!\<[_A=
M_=M_F "_X
M                                         !H#EC\UCDM]ZK,O:.L
M@!X*GS6,^^^K=?:.Q@6_  *@?&K^:Q@/WU;5[1WP"?\ Q.^:QQI^]5AOM'1@
M;_
M                                   4 ^!C_P 47[B?\_@7_  ( >*/
M\Q/?/]S/[Y[2 \+CYB>QG[IOWSW8"?X
M
M   "@'@+_&F\U/\ >/\ OWMP%_P    T!RQ^:QR6^]5F7M'6 0 \%3YK&???
M5NOM'8P+?@
M                                          % / 7^--YJ?[Q_W[VX
M"_X ! #Q1_F)[Y_N9_?/:0'A<?,3V,_=-^^>[ 3_
M
M              % / 7^--YJ?[Q_W[VX"_X !4#XU?S6,!^^K:O:.^ 3_P")
MWS6.-/WJL-]HZ,#?X
M                                                &@.6/S6.2WWJ
MLR]HZP" '@J?-8S[[ZMU]H[&!;\  H!\<[_A=_=M_F "_P"
M
M                    : Y8_-8Y+?>JS+VCK ( >"I\UC/OOJW7VCL8%OP
M"H'QJ_FL8#]]6U>T=\ G_P 3OFL<:?O58;[1T8&_P
M
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M
M                                 H!X"_QIO-3_ 'C_ +][<!?\  @!
MXH_S$]\_W,_OGM(#PN/F)[&?NF_?/=@)_@
M
M      * > O\:;S4_P!X_P"_>W 7_  *@?&K^:Q@/WU;5[1WP"?_ !.^:QQI
M^]5AOM'1@;_
M                                           T!RQ^:QR6^]5F7M'6
M 0 \%3YK&???5NOM'8P+?@ % /CG?\+O[MO\P 7_
M
M              #0'+'YK');[U69>T=8! #P5/FL9]]]6Z^T=C M^  5 ^-7
M\UC ?OJVKVCO@$_^)WS6.-/WJL-]HZ,#?X
M
M      "@'P,?^*+]Q/\ G\"_X ! #Q1_F)[Y_N9_?/:0'A<?,3V,_=-^^>[
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MG*-VLCJO9S&L1O?Y]+03RJDC+E=&/[%J_(L,*ITTZ:*J=ZC6PA=*
M                                       % / 7^--YJ?[Q_P!^]N O
M^    &@.6/S6.2WWJLR]HZP" '@J?-8S[[ZMU]H[&!;\
M
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M.IC1>E9(GH]NJ=NFK57M[0/W
M  * > O\:;S4_P!X_P"_>W 7_  *@?&K^:Q@/WU;5[1WP"?_ !.^:QQI^]5A
MOM'1@;_
M                                       T!RQ^:QR6^]5F7M'6 0 \
M%3YK&???5NOM'8P+?@ % /CG?\+O[MO\P 7_
M
M          #0'+'YK');[U69>T=8! #P5/FL9]]]6Z^T=C M^  5 ^-7\UC
M?OJVKVCO@$_^)WS6.-/WJL-]HZ,#?X
M
M  "@'P,?^*+]Q/\ G\"_X ! #Q1_F)[Y_N9_?/:0'A<?,3V,_=-^^>[ 3_
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M6U-ZLU+I'TR=?JG55%HC)47U3F=+UZG)*Y MW
M                        "@'@+_&F\U/]X_[][<!?\    - <L?FL<EOO
M59E[1U@$ /!4^:QGWWU;K[1V,"WX
M
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MA$J9(I4_GJ>-8Z?_ .YH!+\
M H!X"_QIO-3_ 'C_ +][<!?\  J!\:OYK& _?5M7M'? )_\ $[YK'&G[U6&^
MT=&!O\
M                                     #0'+'YK');[U69>T=8! #P5
M/FL9]]]6Z^T=C M^  4 ^.=_PN_NV_S !?\
M #P\GN%1:<;R&ZTG3YU;+95U=-UIU-[R&%[V]2=FJ:IV@4-\&?%(W&SW>>@V
MTY'7FU5%DSU([=A^1TU#!;TH+PKU2GAG[E&HZ.K5W=(KM5;)W?D:YZH'0 !5
M'MYRRWFR3Q)MP>-ESN]O=M3CU/7NMEICH(&5+74UMIZABNJT3O7?GDCE75?J
M>0"UP !2]O'STY%[G<A,AXV<(\%ME\NF%U%7291G%VC;,BS4#T@K96)4/AIJ
M:GIYU6+O)>M97:=VGJFH\,4IN=W+[BGNEB.$<Y,&L]9@V9N:RES^QQ11R0Q-
MD9'/60R4+GT]0VG[Q%F@6)DJ(J.;Y6H\+<=Z]Y\-V)VGRO>#,*ATF-XO0MJF
MPTJM=-6S3N;%2TU-U*C5?/+(QC55=$UZE5&HJ@4Y8CR8\5#DI8[ENWL9MUC>
M,;9LJ)VX[:I8;?UW!E.O0^.":[2MEJE:J*UTK$BC<]'-;HYJL0)F\#^<==R:
M^RO;3<_%VX-OQMPR23)['%#+34U730SI32S14]0]\U/+!*YL<\3U7I<YKFKZ
MI6,#TN>/.*+B=9L9QO#\<BS7>/<'K^Q7'ZA)74M+3-=W7G=3'!I+-US*D<4+
M'-5Z]7JTZ='!"W*M]/%PV>Q!^]NX.!XG=<"ML++ADN(^:4,DUNHE35\E3%0U
M#:R-K6KJ]4D>L?ED1&HX"TSBIR2Q?E3L]9]U,:HGV:>2HEM>4XU+*DTELNM,
MUCIJ994:U)&JR1DD;NE.ICVJK6NU:@2/
M                       : Y8_-8Y+?>JS+VCK ( >"I\UC/OOJW7VCL8%
MOP "H'QJ_FL8#]]6U>T=\ G_ ,3OFL<:?O58;[1T8&_P
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MWN<K3Y@Z-9:?$;[326ROJ&M:KG^:I+^=U#F-:KG-B>YS417*G3V@3"
M                                 % /@8_\47[B?\_@7_  ( >*/\Q/
M?/\ <S^^>T@/"X^8GL9^Z;]\]V G^
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M7>%C731)KVNB>CDDB=Z+')KH]'-0).
M                "@'@+_&F\U/]X_[][<!?\    - <L?FL<EOO59E[1U@$
M /!4^:QGWWU;K[1V,"WX
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MA:W6ECKFPPW2_P 2I_.2U"4] NGHHGD] .D0
M               4 \!?XTWFI_O'_?O;@+_@ %0/C5_-8P'[ZMJ]H[X!/_B=
M\UCC3]ZK#?:.C W^
M                                               !H#EC\UCDM]ZK
M,O:.L @!X*GS6,^^^K=?:.Q@6_  * ?'._X7?W;?Y@ O^
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M2,=HYKD0++P
M &@.6/S6.2WWJLR]HZP" '@J?-8S[[ZMU]H[&!;\  J!\:OYK& _?5M7M'?
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M1W=2.:BO9U)V+TKJFH'U                                      %
M/@8_\47[B?\ /X%_P " 'BC_ #$]\_W,_OGM(#PN/F)[&?NF_?/=@)_@
M                              _&HIZ>KADIJJ".IIYDZ98)6H]CD])S
M7(J*GY('R6RSVBR4ZTEFM5':*17*]:6B@CIX^I?*O1&UJ:K^0!Z(
M                                               * > O\:;S4_WC
M_OWMP%_P    T!RQ^:QR6^]5F7M'6 0 \%3YK&???5NOM'8P+?@
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MRHIXJUCJYE9-<(Y%D=5KTN5C:1BZL1/KNWT +
M         "@'@+_&F\U/]X_[][<!?\  @!XH_P Q/?/]S/[Y[2 \+CYB>QG[
MIOWSW8"?X             ('<B.$OP]\BMC-_?A-^Q3X%JFT5'V)^POGWLE[
M%7?V5Z?///Z?N.\_K>O<OZ?KNWZT">(%4NTGAH7G:'87D%LK8^0:RU6_<5KH
MZO,&XMW+K=143I6UD"4GLN_O_.X)WPJO>LZ455T<!*WAUQ8LO$7:5^VMNR/[
M,KE<+S5WO(,L6A2W.K*BH1D434IN_JE8V*"&-B)WKM51SNSJT0)6@5K;L>'E
M]G'+/'N6&"[OKMID-JK;/<[KCC;![)1U]9:^F&5ZU#;E1]#*JEC9#(SNG?FG
M*J]>B!FW,C@-MURW]B<DEO=3MYNGCM.E)9\\H($J4EIF.=)'35M,LD7>LC>]
MSF.;(Q[%5?5*GJ0(EQ^%%N)G\+X>1/+O*=TZ.SVZX4N$6>I;7UE/;ZVHIGPT
ME<Y:ZY2*J0R*R1T,:,63H1BRHT"?7$;C!3\7-EI-G*S+8]R*2>[7"Y55UFM:
M6Z.6.X-C8^G?2.J:Q%:B,5%57^JU\@$&LS\*"Y8UG=YS[BCR)R'8&2]I(E1C
M=-YVC(6S/5[X*>X4%72S-IT[.F*1DBII]>O9H&>\=?#"L6W&Y]+OAOING=-_
MMT+=51W"SU5SCE;2P5T.B0UE1)55%545DT72U8G/>UK%1%Z'*UKFA:J  HXO
M_@V7FYYGE^8V;E;6XS-EEVKKG-2T6*2-=&VLJ7U'<NECOT2R(Q7Z:JU-=-=$
M ^)W@NW:YK'3Y5R[OF06I'M=+;UQR1JNT])T][J6(OI*K% LZXQ\3-I.)^*W
M#&]LZ&KGKK]+%/E&67:1D]RN,D+5;&DLD;(V,CCZG=$;&M:U7.7M<YRJ&J-E
MN$OP0<L-X^4'PF_9#\+5->:?[!_87S3V/]EKE1W'J\_\_F[[N_-.C3N&=75U
M=FFBA(_?K8[">16UV1[49_%4+8L@9&^.OHW-CJZ*KIWI)3U5,][7M1\;TU]4
MU4<FK7(K7*@%6^)>&%R1P"@J<%P7G=DN'[73R3/99[515],^-)W*Z1L=-%=H
MXHU?JO6YDC>I>U6@9'2>$-A^(9CL_GNUN\]VQ;*]M;I37W(+Q>K4E[DOMRI*
MV.LBE5K:ZACI6)T+'T-8_5JIU*YR*K@F_P K>(VV7+?"Z/&<Z\ZM-\Q]\\^&
M9I;M/.[9/4-:DJ=#_430R]VSO(W:=72G2YCD1R!79+X4N^5\ME%MUF/.#)[[
MLU;G0)!B#J:XR1.@@5.B%E#47:6EA1C6HD:^K:Q>U&>@H69XAQIP#;7CY>>/
M&VT;L:QR[8_=;.^]3L;5U<M5=J:2GFN-8K5@\XF57HY4U8FB(QO0Q&HT,$X4
M<3OD>[8Y%MQ]GWPB>S^45&2>S/L5[$=UW]%1T?F_<>>5O5IYIU=?6GUVG3V:
MJ&(\T^$ORO[GL[<?A-^#SX)JFZU'<^POLM[(>R;[<_IZO/Z+N>[\PTUT?U=?
MH=/:$[I)(X8WRRO;%%$U7R2/5&M:UJ:JJJO8B(@'.%Q#V>P7>CQ,-WMQL#IV
M5NS^T>2W;*[;5LZ9*.>YU-3)#;TIW,]2D;JI9JJGT[.B%H'1[+%%/%)#-&V:
M&9JLEB>B.:YKDT5KD7L5%3RH!2KEGA'7K&\[O&8\8^2-]V6H;U(Y%L$3*R.>
MC@E762"*Y4%;32RQ(JJC(Y(]4;V.D<O:!_3O!MQ]S,)OC]_+O6[CVF^K>\YS
M.ZVAUP2\=+X'PTT,#KE$M.D:Q/59)))GO5^JJB-1H$_.9/&#Y6VT=-M9]G'P
M?^;Y!17WV=]C/977S2&HB[GS?SNCTZN_UZN\[-/(NO8&[MI<$^"W:O;7;/V5
M]G?@\Q:SXU[-]QYKYY[$T45'YQW'>2]UWG==71UNZ==.I?*!KSEA<]O[5QMW
MLGW0GBAPN?$+K2W-DCV1R323TSXZ>&F5_9YQ),YC8=.WO.G0"L7P6MCW6';W
M<#?R[T?179[6)C>(S2-T<EKM;^NLEC=Z+9ZM4C7^BIP+O@
M                        !0#P%_C3>:G^\?\ ?O;@+_@ %0/C5_-8P'[Z
MMJ]H[X!/_B=\UCC3]ZK#?:.C W^
M                                                          !H
M#EC\UCDM]ZK,O:.L @!X*GS6,^^^K=?:.Q@6_  * ?'._P"%W]VW^8 +_@
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M3M,^@VZM=7#5[<X?*QS(+BRBE66AI:."3M;;J9Z];WN_[P_J^OZY'('0(
M                                    * ? Q_XHOW$_Y_ O^  0 \4?
MYB>^?[F?WSVD!X7'S$]C/W3?OGNP$_P
M
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M;T3\TU0,_                           !0#P%_C3>:G^\?\ ?O;@+_@
M$ /%'^8GOG^YG]\]I >%Q\Q/8S]TW[Y[L!/\
M                  "!_-C@_2<QF[=N?N;6;;5.!I=(99*:W)<65]-='4;I
M(I&+54O2K/-/4KJY/5+JU=$ VMQ7XK;=<3-OI\&P.2KNM5=ZQ;CE.5W+N_/;
MC4]/0SK[MK6LCB9ZF.-O8WM7M<YSG!)H     *I>0_A98QR(WYR3>&_;RWK'
M[%EDE#/=\%M]MBD<V:CH::@5]/735#F1K(VGZEZJ9W:[TD LJV_P/%MK\*QC
M;W";6RS8KB%OAMMDMS%5>B&%--7N7M>]ZZN>]>USE5R]JJ!F
M                            H!X"_P :;S4_WC_OWMP%_P   J!\:OYK
M& _?5M7M'? )_P#$[YK'&G[U6&^T=&!O\
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MN>Y[E5$1&M:$ZP
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MW$_Y_ O^  0 \4?YB>^?[F?WSVD!X7'S$]C/W3?OGNP$_P
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M-ZM^^1?(7;O<6\6^NQ;;Y*YV+T5';X*5\/<W=:1B/EC3K?I%V>J5?3\H%M0
M"J?GWXC.,<?[%<=NMG,@M^1[[54K8*J2!L==1XU&QZ+*^M14=$^I<B*QD"ZJ
MU5ZY$1$:V0)M<5\\R;=#CKL[N%F59'<,IR_&:.Y7VMBACIV2U,S55[FQ1-:Q
MB+Z341 -_ :$Y.;[4'&O9'-=Y;CC]1E,.)LHVPV&FF;3.J9Z^LAH8&NF>UZ1
ML22=JO<C7*C471JKV ?YQ=W;O&^VPFV^[=_ME'9KOF]!/6U=KM_>+30=%7/
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M5J9%E$5'%;XJNJ<JND=%2P^HBC:J]+&]J]*)U*YVJJ&6@
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M(K)(W-5%1%145 ,P
M         % / 7^--YJ?[Q_W[VX"_P"  5 ^-7\UC ?OJVKVCO@$_P#B=\UC
MC3]ZK#?:.C W^                          $,.6G.7:'B'%8*'-::Z9-
ME^40R55FPZR-A=4)21N6-:NIDGDC9#$KT5C5[7.<CNEJHUZM#WN*?,;:CEUC
MU[NNWZ7"S7O%Y(H\GQ"\LBCKJ5M1U]Q.U89)8Y8I.[<C7-=JBHJ.:U=-0EB
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M!4^:QGWWU;K[1V,"WX !0#XYW_"[^[;_ # !?\
M
M           T!RQ^:QR6^]5F7M'6 0 \%3YK&???5NOM'8P+?@ %0/C5_-8P
M'[ZMJ]H[X!/_ (G?-8XT_>JPWVCHP-_@
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MV*FIHFHR..-B(UK&-:B(B(B:(B ?L
M       4 ^!C_P 47[B?\_@7_  ( >*/\Q/?/]S/[Y[2 \+CYB>QG[IOWSW8
M"?X                      "$W-KFEC7#C#,<NM9C<N:9EG%34TV(XLRH\
MSB>RB;&ZKJJFI[N561P]]&FC6*YSGM1-$ZG-#3/!WQ([-RQRR[;:Y-@S=O\
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M(X:G,\_F8U*N\U*-U:[5JN[N!G4O<Q-<K6(NJJY[GO<$I@
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M+5:ZV.Z8_>*2:AKJ9[[G5R-;-35#&2,56.1R(YJ=BHOH@3"
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MQL'W7Q&T9YMSDU%EV)7R-9+;>J!ZNC?TJK7L>UR-?'(QR*U['M:]JIHY$7L
MAKXF&]_P*<4<X]CZSS7*=S-,*QOH=I(WV38_SZ5NGJD[NB9-HY/K7JSM[4 H
MZVVQ[)N >[/##?J]SU,>*;R8Q%=,T21%:V.BN<[XJ^E[M$15\VM]51U*-<NO
M>^EH!U@12Q3Q1SP2-FAF:CX9F*CFO:Y-6N:Y.Q45.U%0#2^]_(K9SCGCU-DN
M[^:TN*T=P>^*ST*LDJ:ZNDC1%>REI*=LDTG3U)U.1O2W5.IS=4 K_P!WO$+X
MK[\<=^0N#89GTMOS"Z;=Y/%9;!?J"HMLE<YMMGT;332-6![W?F8^\[QWH,7M
M ][P?7(WAY"YRHUK<SOBN<O8B(C:;M4"NWAQL!M)S8WFY:[Q;X,J)\,I\C=<
MK-4-N4ELB2HOU?7U2*LS',]3%!"UO2JZ(CD LWQCPNN%$%79LIQK';K7+;ZJ
M"OM5PI\CJZF!TM/(V2-R.;*YKD1S4 LI  <W.439MXI/-*^[:Q956V'CIM+4
M5<C$H).J'V-M]1YHM?$QWYT^LN4KM(GO:O=Q+]:Y(W(\+7;9X:W"NVXZW'%V
M2H;C%W"0SWBMK[C)<97::+*M4E2U['*JZ_G?2B>@B)H@%<&/\:-_N#/-W&:C
MCOBV8;C;#YWYH_*8*2F?44T5FGJ70U=#<:E4;3^<4*ZST\CW,<YJM37U4NH?
MYXV$$55G/%^FG;UP5$&013,U5-6/J;6UR:IHJ:HOH 6$_BM^"GQ'+[YLF]U0
M/TB\+S@O#+'-'L>K9(G(^-WV39,NCFKJBZ+=?3 GX!S^\[I*GF#SQV=XAV2Z
M34V,X/$Y,LK:71W<5E;3>R=SE3RL58:&"%C%=KTR*]OE544,^\(/="\8M7[T
M\1,[>M'D^W-XK+Q8K?*[58UAJ$M]ZI6=6GJ8JEL4C41.U9)'>@!>(
M                                              * > O\:;S4_P!X
M_P"_>W 7_  *@?&K^:Q@/WU;5[1WP"?_ !.^:QQI^]5AOM'1@;_
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M8V6GHKC;:VL\PG?-0/?*R"NI%3K:^-RZIT)U]+WQH'36
M                 &@.6/S6.2WWJLR]HZP" '@J?-8S[[ZMU]H[&!;\  H!
M\<[_ (7?W;?Y@ O^
M                                                 : Y8_-8Y+?>
MJS+VCK ( >"I\UC/OOJW7VCL8%OP "H'QJ_FL8#]]6U>T=\ G_Q.^:QQI^]5
MAOM'1@;_
M                                          % /@8_\47[B?\ /X%_
MP " 'BC_ #$]\_W,_OGM(#PN/F)[&?NF_?/=@)_@
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MGH-Q< 9/2;?SW/JCJ:NAM_4VHM$[9-')4T",7H:O:L+5;HG<JK@NK
M                   "@'@+_&F\U/\ >/\ OWMP%_P    T!RQ^:QR6^]5F
M7M'6 0 \%3YK&???5NOM'8P+?@
M                                                          %
M/ 7^--YJ?[Q_W[VX"_X ! #Q1_F)[Y_N9_?/:0'A<?,3V,_=-^^>[ 3_
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M&WU,=907"".IHJR%R/CEAE:CXY&.3L5KFJBHJ ?4
M                                4 \!?XTWFI_O'_?O;@+_ ( !4#XU
M?S6,!^^K:O:.^ 3_ .)WS6.-/WJL-]HZ,#?X
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M=[JF.%9WK)--4+U/158W75.["_D
M- <L?FL<EOO59E[1U@$ /!4^:QGWWU;K[1V,"WX !0#XYW_"[^[;_, %_P
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M5M,])(TC615>K9::6*1-?1<K>WI EH
M                 % /@8_\47[B?\_@7_  ( >*/\Q/?/\ <S^^>T@/"X^8
MGL9^Z;]\]V G^                               0D\0O:+</?+B[F&W
M6UN/?91F5UN5FJ*"S^=TE%WD=)7PS3.[ZNFIX4Z6-5=%>FOH:J!F?";;?--H
MN+>T6W.X=F^Q[,L7M]9!?;-YQ35?<22W&JG8G?TDLT+]8Y&KZAZ^73RZ@2H
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MD2',,;CJZ.N@2KA58W5%/-0U%3%W4^B2-;UJYG5T.U5NJAM0
M             4 \!?XTWFI_O'_?O;@+_@   !H#EC\UCDM]ZK,O:.L @!X*
MGS6,^^^K=?:.Q@6_
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MENS,Z8G=6O=K(^W,9WEIF5.W1OF_YPFOE6%R@65@
M                               % / 7^--YJ?[Q_P!^]N O^  5 ^-7
M\UC ?OJVKVCO@$_^)WS6.-/WJL-]HZ,#?X
M
M     &@.6/S6.2WWJLR]HZP" '@J?-8S[[ZMU]H[&!;\  H!\<[_ (7?W;?Y
M@ O^                 (S<Q-[KOQUXX;F;NX_;H;ID&-4E)!8J:J1SJ=M9
M<ZVGM\$TS6JBN9"^H216ZIU=/3JFNH'/+Q]\3CE5;=ZL/ESW/I=Q,/R>^4=N
MR;$ZRAHHV+3UL[(7OHEI:>)\,L2.ZF(Q>E531S7(H'5F      "D;Q6.+-W;
M[$<R-GXYK7GFW<M'-N#+;DZ:AU-0O8M#>H^E->]HG-:R1VB_G72Y=&PKJ$5L
M;OFYWBV<@=M[1E5MEQ79W9^QT-3N+'0R.[CSB9K%N,D+M$1D]SGC6*!NJK%"
MQ7^J5C^H.D^RV:TXY9[5C]AM\%ILECI(:"SVJE8D<%-2TS$BAAB8WL:UC&HU
M$3T .>;,:W,_$PYA9WM-=-Q:S;_C;LY55*2VR":)GG#;;4>8K41QO5(I:JMG
MZW1OE1R01:Z-545L@>WR?\/W$N+N!3\B^*6\61V#--K.ZN%SM]9=:2>>>DZV
M12RTD]+%3.:]B/5TL4B/9*SJ;HGUKPGUA/(C>SD#P$3=;93&4O'(&\6B2Q1V
MZ&:BI60WFGJDH*^XPK62PP-Z8D?5Q1N5>U6,Z7>B$0MA_"CM&X.$2[F\Q<LS
M:7=W+9ZJLO=K;=J='V^-LCXXW5E9-'6.J)WM:DJN[Q&-1R,Z55JJH1YVCLD7
M"[Q(<"VEV=W5?GNU^X=316^\T3:Z"I:Z"ZI-3)2W)M$Y('55'.Q)6.Z&.Z>G
MU*->Y%"3?C'[EY?9HMB-J&9-785M;N-5W&HW#O5$Q\BU,5%-11=$D<2M?+'3
M1U#YG0H[21RLU35K0,2N'A@<5=S=H+K?N*>]%PS7<BT6Q:_&[BR_VROI:VNB
M9UQTM;#!! ZD=,].A'*YBQ.5%>B]*M4)@X%Q<W)WAX96W87F;<KK%D6-W5U1
M3WNR7BFK+E5T-!K/;UJJR2&JC<Z/O70N14<Y6QL<K]550*O?"AXH;;;XW>^[
MM9?<L@H\FV/S'&[MB%-:ZFFAHYIZ>1]>Q*R.6EF?(U9*9B*C'L7IU377M0.F
MT"ESQM?X"-I/M]7VKJP/JVG\6GBMA>UFVN'7BES=UWQ/%+-9KHM/:*=\2U-!
M0PT\O=O6M:KF];%T5435 (B<U?$"IN9^+V+CIQYVSRBM9E%ZHZBXU%RIXO9*
MOEI7.=3T='0T4U4B,616R.D?)KZG3H1-7 3UWYVCK=AO"@R7:>XS0S7C$</M
ML5]DIEUA]D*N]TU96MC=^::D\[T1WYI.W1-= *WN(/AW7[F1L]%N;GV\-QQ2
MT6A9L6VNM<-$VXM@I;>]7RO<R2>!K(>_ED1(XU:KG];W.15[0D%S,RC<I<\X
M^^&?Q_R6KL=LIL>L=FS'(H:B2"IKUE@6+HK71NZTIX:.):N=C7+WG7HJ*C&H
MX-HY%X*^T,>WLE-A>YV6T^ZU%2)+;\FN+Z1;545[&H[IDHH:=LL,+WIHWHG<
M^/7572].BA[?AI<MLXO>';T;3\@+G77'*>.M+47.?(KC(E17>Q%#WL-;25<B
MJKI9*.6!=)'.<KFO1JKZA%4(A<==DLM\4S=7<S>[?_-;Y:=L\5N*6_'L7L\\
M;5B?4(Z:*V4+IHY8H(:6'NUF?W*OE5Z+KUJYZ!J/Q#N&-?Q$M&+Q[?9OD&0;
M#Y[>5G7&[S.R1ULR*BII&Q.D6%D,4BRT\LW=O2)KD:US'J[1KE"WKEVJIX7M
M_P!%T_\ X<X:G\FHM(&9>%Q\Q/8S]TW[Y[L!!WEFJKXN/%+5==+9BR)^NEV
M][Q+-Y-UMP=\=J^#^S=^GQQ^>LH)<XN-),Z!]3)=:A\<%+42LZ7I3TT$3JB9
MK5TD1Z(J+T:*'TYKX,FV%JVIN$FW.?Y;4[T62WNKK+>JV:E9;Z^Y4\?>-@\T
MB@:^GCE>W2-R3N=&JHKG2::*&9X+R&Y,<:N .<YAR+Q*ZT>Z>#5+,?VON-_E
M@GJKG'<DBAMU17(DTDCW4<DDBR=ZB.DCC:BJYRN<!&WB[P&QSE9A+>1_++>'
M(;[EFYSIJNS6RCNE+!4Q4;)'PQSU<]3%4+J_H58H8VL9''T^77H8'QXN_+/#
M/YA[>;88_N/6Y_QMWLJZ=BV>JGBD=3>?U/F'?2LCTB954<JQR/EB8Q)HO4JU
M%[&!)GQ7^0VXF)T>U_&_:&Y55IS#>F=RWVMM\JT]:^@DG90T=!#,BHK$K*B1
MZ/<US5Z8^C7I>Y ,9IO!@V\MVW-+);-V\JH-]Z&F96T>9P2P16>.[QHCV(RD
M9 E2R%'IHCTJ.\1?5Z_^S T=X/T>40\FN2L.<25$N:Q6:=F82U;^\J'71MZ1
M*UTS]5ZGK-U=2^BH'1&                          &@.6/S6.2WWJLR]
MHZP" '@J?-8S[[ZMU]H[&!;\  J!\:OYK& _?5M7M'? )_\ $[YK'&G[U6&^
MT=&!O\                          *G\X\8/C5AVX]?@]+8LJRRR6>O?;
MKKGMIAI'4"R1O[N26DCEJ&2U$3%1?5HC>I$UC1[5:JA:!BF4X_G&,V#,<4ND
M-ZQK**"GN=BNU.JK'44M5&DD4C=414U:Y.Q414\BHB@9      '._P [/93E
M5XBNT_%22XU5%AN)K;*&ZTT$B)TNN%*V^7>LB1=6I+[']W&U51=%9]50+_L2
MQ'&,#QNS8?AMCH\;QC'Z9E)9[)01-A@@A8G8UK6^BOE55[57555555 U5R2V
M%Q;DCL_E^U>30TT<EZHY'8U?IH$GDM-UC:KJ2NA35KD6.33K1KFJ]BNC5>ER
M@8QQ$XZ57%G9JW[1U&?5&XD-MN59<**ZS43;>RF96JV22E@@2:H5(TF[R357
MJNKW 5->%5\\/EU_T+G^^!P'0&  Y^+%*WFMXK=PNDD3+UM7QYBGAA9*WO*9
M\&/.=3QJU5]0[SB\5*S-_GHD]'IU _+@E=JKB+SQWHXD9!4R4^*9W6318:ZH
M<NCJBC8^X66;J=V(M3;IGL=HOJI.[;JJH@'08
M                        % /@8_\ %%^XG_/X%_P " 'BC_,3WS_<S^^>
MT@/"X^8GL9^Z;]\]V G^
M                                                     H!X"_QI
MO-3_ 'C_ +][<!?\    - <L?FL<EOO59E[1U@$ /!4^:QGWWU;K[1V,"WX
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M'%K/<[M5(QL:25-710S3/1C$:UO4]ZKHU$1/0 SX
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MOZ_))U)V 2< ^6NHJ2Y459;KA31UE!<()*:MI)FHZ.6&5JLDC>U>Q4<U514
MC]L?Q.V!XWUV07+9?!'X75Y3!!37]R7B[W!E3'3.>^'JBN-;4L16+([1S6H[
MM5-=% D6
M4 \!?XTWFI_O'_?O;@+_ ( !4#XU?S6,!^^K:O:.^ 3_ .)WS6.-/WJL-]HZ
M,#?X
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MGF^.TVS6U&V[ZN%^67G,DR2FH$76:.W6VWUM)+*Y$^M:^6N8UNOUVCM->E=
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MC/OOJW7VCL8%OP "H'QJ_FL8#]]6U>T=\ G_ ,3OFL<:?O58;[1T8&_P
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MLYLM+=88$=UK3RS,3OZ9ZI^;@E1\3OZ)J@;)
M                      % /@8_\47[B?\ /X%_P " 'BC_ #$]\_W,_OGM
M(#PN/F)[&?NF_?/=@)_@                                !_+7L>BJ
MQZ/1%5JJU==%3L5.ST@/Z
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MJ?[Q_P!^]N O^  0 \4?YB>^?[F?WSVD!X7'S$]C/W3?OGNP$_P
M
M                       % / 7^--YJ?[Q_P!^]N O^  5 ^-7\UC ?OJV
MKVCO@$_^)WS6.-/WJL-]HZ,#?X
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MW*IDK;C<L9M%57UDJ]4DL\U'$^21Z^BKG*JJ!G0
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M\Q3[ \ P?!O/_97[#,?MEB]E.Z[CSGV.I8Z;ONZZY.CK[OJZ>MVFNFJ^4#,
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MQ(951&]3GO<Y5 F7RMXC;9<M\+H\9SKSJTWS'WSSX9FENT\[MD]0UJ2IT/\
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M/^?P+_@ $ /%'^8GOG^YG]\]I >%Q\Q/8S]TW[Y[L!/\
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M;@OSOU^LV+6.\9+D5SI[+C^/T4]QO=XJWI%3TM)2QNEFFE>[L:UC&JY57T$
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M&VU%RJK?W%-"Z:;22MK*:"-J(U>WS5?R /.\#Q4^POD&W7M2]6!53\FFK/\
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MWS*+VFNP%F^Q7;LCLXJ=J+@^/>UM.!M0
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M]+51MEAE8OHM>QR*@'I@
M            "@'@+_&F\U/]X_[][<!?\  J!\:OYK& _?5M7M'? )_\3OFL
M<:?O58;[1T8&_P                           *C?$<\0C-.+63XKM9M3
M8K759G?;,W(;YD=[BDJ:>CHIZB:FIH:>GCDB1\SWT\CG.>JM:U&^I<K]6!F'
MAR\[\EY:4V:XCN/8K;:MP,'IZ>XLNEF9)#1W&WU$CH5<L$LDKHI87HU':.5K
MD>BHC=%0"T(     *VO%"Y&[@<=]@;54[95C[)E.X.01X\F51M19;;2>:SU,
M\E,Y=49._NFL8Y47I:KW-T>C50(AX;X=>]>=;867=W$>>&47K<K)++%=[5<Z
M"X7&6V2U$T:2I2I=H[FM0K4>O0LW1JB]JQ?F0)L>'GF/)^Z;3Y+8N5&*9+;<
MGPROC;C.3Y#2+%776US1.7NWHFLL\U/)$Y%D<WJ>U\?:YVKE""6*X;SBY][K
M[D5N<[B9[Q1V@Q*H[FRXBE#<;1-)#522+2TOF?>6]:N5D4?5//.]W2YR(QO2
MY&M#3W)3:/DMX;=QV_W7V\Y*Y%G6'7R\I;JNV7.2IAA6KCC=4MI*Z@DJJJGJ
M8IXHY/5^I<U471&KTN N5Y09)#F7!C>++Z>G=24^5[2U]X@I7.ZG1,KK6M0U
MBN1$U5J/TUT J!\.[G]L'QCV'N>W6YJY&F15>77"]1>Q-M;5P>:U-+10QZR+
M/'ZKJ@=JFGI 2[SSQG>.EIQVY3[?XGF&7Y7W+DLMNKJ.GMM LZIZE:JI6IDD
M8Q%\O=Q/5?)V>5 UWX26Q&Y])EV['*/<NRU..)N523V[&J:M@?2S7#V0KV7*
MOKF0/Z7,@[R&-L3E3U>KNGL;JX-<\P\6Q_-_%<V2P_*[7#>\:R>SV"V7VTU"
M=4512U*W".6-VFBIJU5[475/*G:!@FU.1Y+X6W,N\[59Q7U-5QZW3EA=3WV?
M58DMTTCF6^\)HB(DU$]705:-1-6];D:OYR!)OQL9H:C8S9FHIY63P3YJ^2">
M-R.8]CK94*US7)JBHJ+JBH!;+M)-%3[/[95%1*R""##K+)--(Y&L8QMOA5SG
M.71$1$3554"D/AGYSS!\1;=[D_7,?4X1M>L[L.<]%[M._CDM%BC5B]C56CBF
MJ':>25-?*NH'D;?52\'?%-R/!9W>Q>UF_E2D-N8OJ*>.FR27SFV/8U=$1M+<
MFNI$<J^I9WBZ@=#H #GPYAXMC^;^*YLEA^5VN&]XUD]GL%LOMIJ$ZHJBEJ5N
M$<L;M-%35JKVHNJ>5.T#!-J<CR7PMN9=YVJSBOJ:KCUNG+"ZGOL^JQ);II',
MM]X31$1)J)ZN@JT:B:MZW(U?SD"3?C8S0U&QFS-13RLG@GS5\D$\;D<Q['6R
MH5KFN35%1475%0"VK9_^"3:W[4;)^D(0-B@
M      #0'+'YK');[U69>T=8! #P5/FL9]]]6Z^T=C M^  4 ^.=_P +O[MO
M\P 7_
M                                      - <L?FL<EOO59E[1U@$ /!
M4^:QGWWU;K[1V,"WX !4#XU?S6,!^^K:O:.^ 3_XG?-8XT_>JPWVCHP-_@
M
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M58,_+VNC8S)F/=).VMIJAC7>=K'TK1]6C&JU4:WO%@Z0ZA
M               * > O\:;S4_WC_OWMP%_P    T!RQ^:QR6^]5F7M'6 0
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M)0=XQS$=-04J]VZ)S&IU2.7U#41$0"PH
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MU4CYK5*OI(QK9:=J>@V%/3 M.
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MC_5,FH)D[I$=I^=JQNFL;E4.N;9_^"3:W[4;)^D(0-B@
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MFV6>6+.[5"YK*JKLE=!6) ]VO2R=L3G.B<NB^I>B+]0#/P
M      : Y8_-8Y+?>JS+VCK ( >"I\UC/OOJW7VCL8%OP "H'QJ_FL8#]]6U
M>T=\ G_Q.^:QQI^]5AOM'1@;_
M                                                          4
M^!C_ ,47[B?\_@7_   " 'BC_,3WS_<S^^>T@/"X^8GL9^Z;]\]V G^
M                  C7R=XJ[5\L,+H</W+IZVFELE4ZNQG)[3*R"XVZ>1J,
ME[E\L<K',E:B))&]CFNT:O8YK'-#67%#@+LQQ)N-YR7$*J[Y9FU\I5H)\LOT
MD#I:>B<YKWTU)%3Q1,B;(YC7/5>IZZ(G5T]@$X0     KI\4K9RZ[O\ $K)G
MX_1RW&^[97.DS:BH($UDF@H8YZ:N1$]'NZ2JEET3M7HT3MT \7PO^2N)[O\
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MR6^]5F7M'6 0 \%3YK&???5NOM'8P+?@
M
M    % / 7^--YJ?[Q_W[VX"_X ! #Q1_F)[Y_N9_?/:0'A<?,3V,_=-^^>[
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MVP7BK6:T(J]$;52GJTCA1^B=,;G]OEU#JN
M                           % / 7^--YJ?[Q_P!^]N O^  5 ^-7\UC
M?OJVKVCO@$_^)WS6.-/WJL-]HZ,#?X
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M>JS+VCK ( >"I\UC/OOJW7VCL8%OP "@'QSO^%W]VW^8 +_@
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MQ@6_  *@?&K^:Q@/WU;5[1WP"?\ Q.^:QQI^]5AOM'1@;_
M                    !4=XAG,S=S;;/<"XR<;:-';O;C0TLU5?FPQ5-12L
MN-0^EHJ2BCJ$6%LTSXW.?+(BI&SI5-%=UL#1T7!'Q,KC0ID=?S5KK?E<S._]
M@&Y=DJ4T;W)U=RZ2"-(6Z+HBHR)6>EJ@&4\-N9?(7$>14_#GE^WV1RN>62BQ
M?+JAD3:R.M9 M5!#/-3M;%5T]7"FL,VG7U*U'.<COSL+N0        %.'B\[
MW[M[,6#8N;:G<&\X%-D-PO[+W+9ZA:=U2VEBH5A;(J)JJ,65^B?5 N/
M                                       4 ^!C_P 47[B?\_@7_  (
M >*/\Q/?/]S/[Y[2 \+CYB>QG[IOWSW8"?X
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MW5C6ZOJEVO?CGG]*MLJU:ZNM#JIMUINJGD7J[K6'6+\[5.I\:.4+5P
M                     4 \!?XTWFI_O'_?O;@+_@   !H#EC\UCDM]ZK,O
M:.L @!X*GS6,^^^K=?:.Q@6_
M                                                         * >
M O\ &F\U/]X_[][<!?\   ( >*/\Q/?/]S/[Y[2 \+CYB>QG[IOWSW8"?X
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MO\
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MH]TLB]@$H.!4%?3\.>/,=R32H=B%+)'Y?^[RO>^G\O\ [ES )<@
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M'X\6>JRJ_8/34$=_L-OI_/:ZEJ;3/)+35C*)J*^J@ECD[J5C$5S4;KITN<K
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M_BB_<3_G\"_X ! #Q1_F)[Y_N9_?/:0'A<?,3V,_=-^^>[ 3_
M
M                      4 \!?XTWFI_O'_ '[VX"_X    : Y8_-8Y+?>J
MS+VCK ( >"I\UC/OOJW7VCL8%OP
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M]8      ,9^PK#?/TNOV)67V41>I+EYA3^<:ZZZ][W?5Y?J@9,
M                                                H!X"_P :;S4_
MWC_OWMP%_P   J!\:OYK& _?5M7M'? )_P#$[YK'&G[U6&^T=&!O\
M
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MZ^T=C M^  5 ^-7\UC ?OJVKVCO@$_\ B=\UCC3]ZK#?:.C W^
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M1?N)_P _@7_  ( >*/\ ,3WS_<S^^>T@/"X^8GL9^Z;]\]V G^
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M\
M                                  H!X"_QIO-3_>/^_>W 7_  ( >*
M/\Q/?/\ <S^^>T@/"X^8GL9^Z;]\]V G^
M
M      H!X"_QIO-3_>/^_>W 7_  *@?&K^:Q@/WU;5[1WP"?_$[YK'&G[U6&
M^T=&!O\
M                                        T!RQ^:QR6^]5F7M'6 0
M\%3YK&???5NOM'8P+?@ % /CG?\ "[^[;_, %_P
M    _"JIH*VEJ:.I9WM-5Q/AJ(]5;U,D:K7)JU45-47T% T;L;QCV/XVT^24
MNRV$?89!ETE++D,?LE<[CYP^B25L"ZW&JJE9T),_ZSIUU[==$ WR!%K=7A7Q
MFWJSN'<[<?;-MYSV"&E@CR:CO%XM%1I1*JTSW>Q==2M=)%V(V145Z(C6]6C6
MH@;USG ,*W,Q:Y85N!C-OR_%;O'W=PLMSA2>)^GUKTZO5->U>UKVJCFKVM5%
M[0(.-\*KA&V\)=4VMK5IT<CDL:Y!>%H]477R+5]ZJ+Z2R:?4 GAB.'XK@..V
MO$<)QZWXKC%DB[FU6&UT\=+2P,5RN=T11HB(KG*KG+Y7.57+JJJH&B]\N'_'
M7D;54MSW9VWI+]?Z&!:>CR:EGJ;;<6Q?F6/J:*6%TS6?F6R];6ZKHB:J!X.Q
M_!OC'QZO+<HVWVV@@RUD:QP97=JFINE= UR*URTSJN21E.YS7*USH6,5R+HJ
MJG8!)V_X_8LKLMRQS)[-19#C]Y@=2W:R7&".II:F%_UT<L,J.8]J^DJ 0&N'
MA6<)*^\-NJ;65E#$KE?-9J6_W>.CD<JZKJU:MSVI]1CVIZ2 3<V_VYP3:G%Z
M#"MN,4MV&XM;>I:2RVR%L,2/?VOD?IZI\CU[7/>JN<OE50->8;QEV0V^W9S#
M?+$,)]B-TL]BK(<LRCV2N51YVROJ(:JI3S2HJI*6/KE@C=^=Q-TTT31%5%#V
M-Z]A-I^1.+6_"MX\4^S#&;7=8KW0VSSZOM_=U\$$]-'-WMOJ*:5=(JF1O2KE
M;ZK54U1%0-CX[C]HQ/'[%BV/TGF%AQJWTMJLE#WDDO<4E'$V""/O)7/D=TQL
M1-7.5R^5550-0;6<9=D-E<MS?.ML\)^QK*MQI7SYG=/9*Y5GGDCYWU3E[JMJ
MIXHM99'._.F-\NGDT0#![OP<XJW_ "#<C*;YM%17B_;M]Z[/:ZMN%TG\[?-4
MLJWRQ1R5:QTLG?1M<CZ9L;F]J-5&JJ*&'[:>'-Q VIRNDS7&MJ8ZW(;75>=V
M2IO=PKKK#12)VL6&FJYY(55B]K'R,<]JHCFN14U F5?[%:LHL5ZQJ^TOGUDR
M*@J;9>*+K?%WU+5Q.AFCZXG,>WJ8]4U:Y%3T%10-.;9\9-C]GMN\LVHVYPC[
M'< SF2MERFP>R5SJ_.GW"DCH:E?.*RJFGCZX(FL_.Y&Z::MT=JH'K[*;!;2\
M=L8N.&[.8G]A^-W:Z27JX6WS^ON'>5TL,-.^7O;A45,B:QT\;>E'(WLUTU55
M4/)WHXR[(<A:W#KAO!A/V7UF 2U4V(S>R5RM_FCZQU.^=>FWU5,DG4M+$OYX
MCM.GLTU=J&P]PMN<&W7Q.Z8-N-B]!F&)WEK6W"RW&/O(W*Q>IDC%14='(Q>U
MCV*CFKVM5% A/9_"PX2V>[^RWP555T1CVR4UJN%]NT]'$YJZI^=^=-61/3;*
MYZ+Z0&^'</N-R;EXCN_2;745GS_!*>DI,2NUHK*^V4]%!0L?'3QLM]%4PT3F
MM8]6:.A75OJ7:IH@'NU/&79"LWPHN1]3A/>;SVZ+N:/,O9*Y)T,\Q?;=/,DJ
MDHU_[-(YG;#Z/5]=V@;7R[%;!G>*Y+A.54'LKC&86NLLN16SO98/.*&OA?3U
M,/>P/CE9UQO<WJ8YKDUU147M PG9O8_:[C_B,F";18Q]B6*2W":Z26KSVMK]
M:NH9&R63OJ^>IE]4V)J:=>B:=B>4#0EX\/7B->]Q_A6J=J64>9.N\=^DJK;=
M;I04SKC%*D[:A*2EJXX6.65$>J,8U%7M5%U74)I :XW7VDV]WPPBY;<[HX_]
MD^&7B6FFN-F\[JZ+O'TDS*B%>_HIH)F],C&KZEZ:^1=4[ /MVUVUPK:#![#M
MQMU9?L=PS&(Y8K'9O.:FK[AD\\E1(G?U<LTS]9)7.]6]?+HG9H@&= 19P'A5
MQEVNW.?O%M]MFF*;@R3U\[[O0WB\MIU6Y)(VJ9['NKG47=N[Q>F/N>AB]*L:
MU6MT#7%Y\,_A)D%XNM^N^RGG=VO=9/7W2K^R3)(^]J*F1TLK^B.Z-8WJ>Y5T
M:B(GH(!^5!X8_!JVU,=53[$TTDL2HYK:J^Y!5QJJ?ST51<I&._(5H$SL2P[$
M\"L5%B^$8U:\1QRW-Z:&QV>EBHZ6+7RJV*%K6ZKZ*Z:KZ($>]Y.$_&/D!E[,
M\W<VS^RW*XZ"&V,NOLS>J#2DIW/?%'W-!74\7J5D<NO1JNO:OD UA2^&#P8I
M)F5$6Q43Y(^UK9LAR.=GY<<MT>U?RT E-MALEM'LM;9K5M5MW8L$I*K3SY]J
MI(XIZGI75JU-1HLTRIKV=X]VGH ;1                    !H#EC\UCDM]
MZK,O:.L @!X*GS6,^^^K=?:.Q@6_  *@?&K^:Q@/WU;5[1WP"?\ Q.^:QQI^
M]5AOM'1@;_                                  !7?S>\/O#^7"6S+K
M3?DP#=O'Z3S*@R?N%GI*^D8]9(Z:OB:YC_SMSG=W*Q>IG4NK9$Z6M"#U%Q7\
M7/#[='AF.\C*"OQR!O<4EQ^R*:=\4+/4L1E17V]:R-J-1$1K5[$[$ D#Q1\-
M2][?;IT_(3DQN3\+V[M%.E=9Z:.>JK:2FKT:C65M375R,GJY8D[(D6-C(U1'
M)U*C.D)F<M^*N%\MML'8%D];+8+Q:JKV3PW+Z:)DLUNKDC='JZ-RM[V&5KNF
M6/J;U)HJ.:YK7(%:UHXA>*11XFS8=>3>,T&S[:5+:Z^PU,L]?':U]0M+!4.M
M3+BFD:]*1^<-8C?SM)$9V :Y\)C#X=O>6O*C :>N?<Z?!Z&X8_!<I&)&^H9;
M+\E*V5S$5R-5Z1]2HBKIJ!(CE/X=^[M^W_EY0<4=R;?@>X=PD2MO-IN,LU"L
M=<VF2EEJ*&IA@J6.\ZCU[Z*9B-55>JO5']+0TYG'AT<WN2EBNM]Y)[_V.\9G
M8Z3HVPQ1)G,M4-7/-"E3+6NH;='#3M6!CO\ N]/(^1R,ZGL:BZA-]_!Z;,^"
MF(\3MQ<AH:#*L8H(WT6767O:RCI+M35<]13SQMJ(Z626-63+&]KFL56N=HJ+
MHX")FV?&?Q6]G\7I]G\!WQV_H-O[4V6''[U6O;6NH:>1[EZ*=U39YZIB>J56
ML5KFL\C5:@'@4/A3[XX1N[L]O9BF\E@S[.K!DE-ENZMRR^>OH_/;C!<(ZMS*
M+S>CKI)6R1H]CWSR-<YWJD1J.Z6A+/Q'.&NY_+ZT[3T&VM]Q>QS8)5WBHN[L
MFJJVF;(VX1TC8D@6CHJU7*BT[NKJ1OH::^@$A^6_%'">7&VC<%RFMFQ^\6>J
M6Y8;F%+$R:>W5G0L;NJ-ZM[V&5JZ2Q]3>K1JHYKFM5 K:L'&#Q9=L\7AVGP/
MD7B53@-/3K0V:Z2U225-!1IZED4556V>6N@1K-$8V*1R1HB)&K=$ EYP9X&6
MWB@W(\VRW)V[@;SYM M-?LFB;*VEHZ221D\U+2NF7O9EEG8DDLTB-<_I9ZAF
MB]0>%>.&NY]P\1C'N7<-]Q=NVUIH_-ZFR/JJU+XYWV.U%HU9 E$M,J=]*CNV
MH3U&J_7>I FUOEA%VW,V5W=VXL-124E\S[#+[CMGJJ]\D=)%572WSTL+YWQ1
MRO;&U\B*Y6L<J)KHU5[ (V<%>+N5\;N/EXV<W5JL<RFKO5_NM?71V:2HK+=-
M07&FIZ=8)?/:6E<Y7)$]'M6/IT7RKV@0DJO#KY3\;]P<CS+@SOC06#%\B3KJ
M\+R614E1J/<YE,^.:BK:*K2)'*D<TK8Y&(Y6HNO4]P?;B7AR\A=\MW+%NQSN
MW<MF<4&-NB=18'9'.D94Q1.61*-_=TU%2T<#GZ+(D$;W2IJBN:Y>L"[-K6L:
MUK6HUK41&M1-$1$\B(@'^@                                !0#X&/
M_%%^XG_/X%_P " 'BC_,3WS_ ',_OGM(#PN/F)[&?NF_?/=@)_@
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M*P!F,XI"V[Y9=V12YUGM1$UE9=*EB+HU$U<L5/$JJD4**J-3M<KGN<]P2M
M                                      "@'@+_ !IO-3_>/^_>W 7_
M      T!RQ^:QR6^]5F7M'6 0 \%3YK&???5NOM'8P+?@
M
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ME5'WE5;9'(Z:@KH7+%5T<JHB:NAF:YNNFCDT>GJ7(!N,
M            "@'@+_&F\U/]X_[][<!?\  J!\:OYK& _?5M7M'? )_\3OFL
M<:?O58;[1T8&_P
M                                              #0'+'YK');[U69
M>T=8! #P5/FL9]]]6Z^T=C M^  4 ^.=_P +O[MO\P 7_
M
M                  - <L?FL<EOO59E[1U@$ /!4^:QGWWU;K[1V,"WX !4
M#XU?S6,!^^K:O:.^ 3_XG?-8XT_>JPWVCHP-_@
M                 !7;Q:X797L#R,Y [UWK,[3?K3O%5W2HM5EHH9XZBC2O
MN[KDQ)G2(C'*UCNE>GT?J 6)
M               * ? Q_P"*+]Q/^?P+_@ $ /%'^8GOG^YG]\]I >%Q\Q/8
MS]TW[Y[L!/\                        4=>-KD>X5LP'96PV:JKJ/;C(K
MK=_LU\V5[*>IN%+'2/ME/5.;HBIT.J9&1N71RL5VFL;50(B^#3D>X=-R.O\
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MNEI*R-6OI':]*/?ZE%[]5:'18
M      "@'@+_ !IO-3_>/^_>W 7_      T!RQ^:QR6^]5F7M'6 0 \%3YK&
M???5NOM'8P+?@
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M-ZN%TQYLGJ?S^S7#V%N4C$_]^U:5VB?SJKZ*@7I@
M        4 \!?XTWFI_O'_?O;@+_ ( !4#XU?S6,!^^K:O:.^ 3_ .)WS6.-
M/WJL-]HZ,#?X
M                                           &@.6/S6.2WWJLR]HZ
MP" '@J?-8S[[ZMU]H[&!;\  H!\<[_A=_=M_F "_X
M
M             !H#EC\UCDM]ZK,O:.L @!X*GS6,^^^K=?:.Q@6_  *@?&K^
M:Q@/WU;5[1WP"?\ Q.^:QQI^]5AOM'1@;_
M
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MV]'%'>WRN1)+W;&JD4%U8B]KI$54CJ=/(_I?V)*C4"S4
M                        * > O\:;S4_WC_OWMP%_P    T!RQ^:QR6^]
M5F7M'6 0 \%3YK&???5NOM'8P+?@
M
M% / 7^--YJ?[Q_W[VX"_X ! #Q1_F)[Y_N9_?/:0'A<?,3V,_=-^^>[ 3_
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MTWFI_O'_ '[VX"_X !4#XU?S6,!^^K:O:.^ 3_XG?-8XT_>JPWVCHP-_@
M
M                            : Y8_-8Y+?>JS+VCK ( >"I\UC/OOJW7
MVCL8%OP "@'QSO\ A=_=M_F "_X
M                                                           !
MH#EC\UCDM]ZK,O:.L @!X*GS6,^^^K=?:.Q@6_  *@?&K^:Q@/WU;5[1WP"?
M_$[YK'&G[U6&^T=&!O\
M                                                     4 ^!C_Q
M1?N)_P _@7_  ( >*/\ ,3WS_<S^^>T@/"X^8GL9^Z;]\]V G^
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M@2M                                        "@'@+_&F\U/\ >/\
MOWMP%_P    T!RQ^:QR6^]5F7M'6 0 \%3YK&???5NOM'8P+?@
M
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M]130?9S>JRT8[/-Y'/NE<MXN<;>W32'2D8FG9VJU/(!>8
M             !0#P%_C3>:G^\?]^]N O^  5 ^-7\UC ?OJVKVCO@$_^)WS
M6.-/WJL-]HZ,#?X
M                                              &@.6/S6.2WWJLR
M]HZP" '@J?-8S[[ZMU]H[&!;\  H!\<[_A=_=M_F "_X
M
M                !H#EC\UCDM]ZK,O:.L @!X*GS6,^^^K=?:.Q@6_  *@?
M&K^:Q@/WU;5[1WP"?_$[YK'&G[U6&^T=&!O\
M
M        !0#X&/\ Q1?N)_S^!?\   ( >*/\Q/?/]S/[Y[2 \+CYB>QG[IOW
MSW8"?X
M                                      "@'@+_ !IO-3_>/^_>W 7_
M      T!RQ^:QR6^]5F7M'6 0 \%3YK&???5NOM'8P+?@
M
M                 % / 7^--YJ?[Q_W[VX"_P"  0 \4?YB>^?[F?WSVD!X
M7'S$]C/W3?OGNP$_P
M     5S>(!Q4S3>FV;?[O[&M;3\A]D[I3W#"])J>E6XTK:F.=:5T]2^*)KX)
M6I-$LCT9_7&+_7-4"=V"W/)[UAF+7;-<:7#LPN%KI9\HQ7SB"K2@N#HVK4T[
M*BFDFBD:R35&N:]=6Z+Y>P#*P         "#G/G#^06Z6SM/L[L%C++C/N=<
MH[7N'EL]QHJ&"SV%KF.J.MM3/'-+YPJHUR01R.[ILK>GJ<S4)";";,XQQ]VD
MPK:3$M9;7B-"D,UQD:C):ZLE<LU762HFNCIYGN?IKZE%1J=B(!M\
M                    "@'@+_&F\U/]X_[][<!?\  J!\:OYK& _?5M7M'?
M )_\3OFL<:?O58;[1T8&_P
M                                                      #0'+'Y
MK');[U69>T=8! #P5/FL9]]]6Z^T=C M^  4 ^.=_P +O[MO\P 7_
M
M                          - <L?FL<EOO59E[1U@$ /!4^:QGWWU;K[1
MV,"WX !4#XU?S6,!^^K:O:.^ 3_XG?-8XT_>JPWVCHP-_@
M
M                  * ? Q_XHOW$_Y_ O\ @ $ /%'^8GOG^YG]\]I >%Q\
MQ/8S]TW[Y[L!/\
M                                              !0#P%_C3>:G^\?
M]^]N O\ @   !H#EC\UCDM]ZK,O:.L @!X*GS6,^^^K=?:.Q@6_
M
M                        * > O\:;S4_WC_OWMP%_P " 'BC_ #$]\_W,
M_OGM(#PN/F)[&?NF_?/=@)_@                             /X;)&]7
MHQ[7K&O2]$5%Z5])?2 _L
M                      * > O\:;S4_P!X_P"_>W 7_  *@?&K^:Q@/WU;
M5[1WP"?_ !.^:QQI^]5AOM'1@;_
M                                                           T
M!RQ^:QR6^]5F7M'6 0 \%3YK&???5NOM'8P+?@ % /CG?\+O[MO\P 7_
M
M                              #0'+'YK');[U69>T=8! #P5/FL9]]]
M6Z^T=C M^  5 ^-7\UC ?OJVKVCO@$_^)WS6.-/WJL-]HZ,#?X
M
M                      "@'P,?^*+]Q/\ G\"_X ! #Q1_F)[Y_N9_?/:0
M'A<?,3V,_=-^^>[ 3_
M                                                   4 \!?XTWF
MI_O'_?O;@+_@   !H#EC\UCDM]ZK,O:.L @!X*GS6,^^^K=?:.Q@6_
M
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MOJVKVCO@$_\ B=\UCC3]ZK#?:.C W^
M
M !H#EC\UCDM]ZK,O:.L @!X*GS6,^^^K=?:.Q@6_  * ?'._X7?W;?Y@ O\
M@
M                                 &@.6/S6.2WWJLR]HZP" '@J?-8S
M[[ZMU]H[&!;\  J!\:OYK& _?5M7M'? )_\ $[YK'&G[U6&^T=&!O\
M
M                          !0#X&/_%%^XG_/X%_P " 'BC_,3WS_ ',_
MOGM(#PN/F)[&?NF_?/=@)_@
M                                                       * > O
M\:;S4_WC_OWMP%_P    T!RQ^:QR6^]5F7M'6 0 \%3YK&???5NOM'8P+?@
M
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M7="]U.2YIA]MOMFN&0U<KYI*VFH;6R"@J$?(YSU9)2,A<SJ7J1G2B]H'3&
M        4 \!?XTWFI_O'_?O;@+_ ( !4#XU?S6,!^^K:O:.^ 3_ .)WS6.-
M/WJL-]HZ,#?X
M                                           &@.6/S6.2WWJLR]HZ
MP" '@J?-8S[[ZMU]H[&!;\  H!\<[_A=_=M_F "_X
M
M             !H#EC\UCDM]ZK,O:.L @!X*GS6,^^^K=?:.Q@6_  *@?&K^
M:Q@/WU;5[1WP"?\ Q.^:QQI^]5AOM'1@;_
M
M       4 ^!C_P 47[B?\_@7_  ( >*/\Q/?/]S/[Y[2 \+CYB>QG[IOWSW8
M"?X
M                                   "@'@+_&F\U/\ >/\ OWMP%_P
M   T!RQ^:QR6^]5F7M'6 0 \%3YK&???5NOM'8P+?@
M
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M$>:6O/;[:F2:HJTOL<^@:Y&KVHCGT;G)Z:+U)V*!K#PS?XO+E?\ JGF7[TJ
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M%1/4IU4G2BKV:NT\JH!:UL=G./[E[/;:9UB]7#663),<M]52O@5.F-W<,;+
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MG[U6&^T=&!O\
M                                           #0'+'YK');[U69>T=
M8! #P5/FL9]]]6Z^T=C M^  4 ^.=_PN_NV_S !?\
M
M              T!RQ^:QR6^]5F7M'6 0 \%3YK&???5NOM'8P+?@ %0/C5_
M-8P'[ZMJ]H[X!/\ XG?-8XT_>JPWVCHP-_@
M
M       * ? Q_P"*+]Q/^?P+_@ $ /%'^8GOG^YG]\]I >%Q\Q/8S]TW[Y[L
M!/\
M                                     4 \!?XTWFI_O'_?O;@+_@
M !H#EC\UCDM]ZK,O:.L @!X*GS6,^^^K=?:.Q@6_
M
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MJBPBOM2+425%1;XZ6JJY+FE;T_GLZ/G1C:9$:CN[1=&]2A:$          4
M\!?XTWFI_O'_ '[VX"_X !4#XU?S6,!^^K:O:.^ 3_XG?-8XT_>JPWVCHP-_
M@
M                                : Y8_-8Y+?>JS+VCK ( >"I\UC/O
MOJW7VCL8%OP "@'QSO\ A=_=M_F "_X
M
M   !H#EC\UCDM]ZK,O:.L @!X*GS6,^^^K=?:.Q@6_  *@?&K^:Q@/WU;5[1
MWP"?_$[YK'&G[U6&^T=&!O\
M                                                         4 ^
M!C_Q1?N)_P _@7_  ( >*/\ ,3WS_<S^^>T@/"X^8GL9^Z;]\]V G^
M
M                           H!X"_QIO-3_>/^_>W 7_    #0'+'YK')
M;[U69>T=8! #P5/FL9]]]6Z^T=C M^
M
M   4 \!?XTWFI_O'_?O;@+_@ $ /%'^8GOG^YG]\]I >%Q\Q/8S]TW[Y[L!/
M\                                0IVFX68YM/R?W5Y.4&<7*[WK=2G
MNM/78M44L,=+2)=:ZEKGK',URO=T.I4:FJ=J*H$U@
M                  "%O,GAACG,:U8):LAS>Y86S!*NOJZ66W4L-2M0M<R%
MCFO25S>GI[E--/3 F=%&D44<2+JD;4:B^GHF@'Z                  "@'
M@+_&F\U/]X_[][<!?\  J!\:OYK& _?5M7M'? )_\3OFL<:?O58;[1T8&_P
M
M                              - <L?FL<EOO59E[1U@$ /!4^:QGWWU
M;K[1V,"WX !0#XYW_"[^[;_, %_P
M
M#0'+'YK');[U69>T=8! #P5/FL9]]]6Z^T=C M^  5 ^-7\UC ?OJVKVCO@$
M_P#B=\UCC3]ZK#?:.C W^
M                                                      H!\#'_
M (HOW$_Y_ O^  0 \4?YB>^?[F?WSVD!X7'S$]C/W3?OGNP$_P
M
M                       !0#P%_C3>:G^\?]^]N O^    &@.6/S6.2WWJ
MLR]HZP" '@J?-8S[[ZMU]H[&!;\
M
MH!X"_P :;S4_WC_OWMP%_P   @!XH_S$]\_W,_OGM(#PN/F)[&?NF_?/=@)_
M@
M                                 * > O\ &F\U/]X_[][<!?\   *@
M?&K^:Q@/WU;5[1WP"?\ Q.^:QQI^]5AOM'1@;_
M
M          T!RQ^:QR6^]5F7M'6 0 \%3YK&???5NOM'8P+?@ % /CG?\+O[
MMO\ , %_P
M                                         #0'+'YK');[U69>T=8!
M #P5/FL9]]]6Z^T=C M^  5 ^-7\UC ?OJVKVCO@$_\ B=\UCC3]ZK#?:.C
MW^
M                                   H!\#'_BB_<3_G\"_X ! #Q1_F
M)[Y_N9_?/:0'A<?,3V,_=-^^>[ 3_
M
M  4 \!?XTWFI_O'_ '[VX"_X    : Y8_-8Y+?>JS+VCK ( >"I\UC/OOJW7
MVCL8%OP
M                                       "@'@+_&F\U/\ >/\ OWMP
M%_P " 'BC_,3WS_<S^^>T@/"X^8GL9^Z;]\]V G^
M
M             H!X"_QIO-3_ 'C_ +][<!?\  J!\:OYK& _?5M7M'? )_\
M$[YK'&G[U6&^T=&!O\
M                                                 #0'+'YK');[
MU69>T=8! #P5/FL9]]]6Z^T=C M^  4 ^.=_PN_NV_S !?\
M
M                     - <L?FL<EOO59E[1U@$ /!4^:QGWWU;K[1V,"WX
M !4#XU?S6,!^^K:O:.^ 3_XG?-8XT_>JPWVCHP-_@
M
M             * ? Q_XHOW$_P"?P+_@ $ /%'^8GOG^YG]\]I >%Q\Q/8S]
MTW[Y[L!/\
M                                         !0#P%_C3>:G^\?]^]N
MO^    &@.6/S6.2WWJLR]HZP" '@J?-8S[[ZMU]H[&!;\
M
M                  H!X"_QIO-3_>/^_>W 7_  ( >*/\Q/?/\ <S^^>T@/
M"X^8GL9^Z;]\]V G^
M                                                  H!X"_QIO-3
M_>/^_>W 7_  *@?&K^:Q@/WU;5[1WP"?_$[YK'&G[U6&^T=&!O\
M
M                        T!RQ^:QR6^]5F7M'6 0 \%3YK&???5NOM'8P
M+?@ % /CG?\ "[^[;_, %_P
M                                                       #0'+'
MYK');[U69>T=8! #P5/FL9]]]6Z^T=C M^  5 ^-7\UC ?OJVKVCO@$_^)WS
M6.-/WJL-]HZ,#?X
M                                               "@'P,?^*+]Q/^
M?P+_ ( ! #Q1_F)[Y_N9_?/:0'A<?,3V,_=-^^>[ 3_
M
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MOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G
M/D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(
M^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF
M_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N<
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M3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y
MOBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_
MN< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU
M/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"
M^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^
MYP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34
M_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+
MXIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[
MG /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3
M\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y O
MBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N
M< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/
MPCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^
M*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^Y
MP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_
M"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+X
MIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G
M /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\
M(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OB
MF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N<
M ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N<!Y]V\._Q.+_
M &JYV*^\P:2]62]4DU!>+/7[@YI4TM72U+%BG@G@EMKF21R,<K7L<BHY%5%3
M0"Q_P].+^?<3-E\GVYW&N^/WJ]WK-:W)*6JQNHJJFE;2U-NMM&QCWUE)1O21
M'T;U5$8J:*WU6NJ($[P %8'B0\*MT^8/P-?!I?\ %+'\'?V1>S7V3U5=3=[[
M+^QG<>;^94-;U=/F3^OJZ=-6Z=7;H$0/D"^*;]-3\(^;^YP#Y OBF_34_"/F
M_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOT
MU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D
M"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;
M^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_3
M4_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0
M+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO
M[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-
M3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y
MOBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_
MN< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU
M/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"
M^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^
MYP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34
M_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+
MXIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[
MG /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3
M\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y O
MBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N
M< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/
MPCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^
M*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^Y
MP#Y OBF_34_"/F_N<!Y]V\._Q.+_ &JYV*^\P:2]62]4DU!>+/7[@YI4TM72
MU+%BG@G@EMKF21R,<K7L<BHY%5%30"Q_P].+^?<3-E\GVYW&N^/WJ]WK-:W)
M*6JQNHJJFE;2U-NMM&QCWUE)1O21'T;U5$8J:*WU6NJ($[P $$/$+XOY]RSV
M7QC;G;F[X_9;W9<UHLDJJK)*BJIJ5U+36ZY4;V,?1TE8]9%?6,5$5B)HCO5:
MZ(H5P6GP[_$XL%JMEBL7,&DLMDLM)#06>ST&X.:4U+24M,Q(H((((K:UD<<;
M&HUC&HB-1$1$T ]#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^
M;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_
M34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^
M0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCY
MO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]
M-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y
M OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F
M_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOT
MU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D
M"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;
M^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_3
M4_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0
M+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO
M[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-
M3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y
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MOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G
M/D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(
M^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF
M_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N<
M^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PC
MYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;
M]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#
MY OBF_34_"/F_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/
MF_N< ^0+XIOTU/PCYO[G /D"^*;]-3\(^;^YP#Y OBF_34_"/F_N< ^0+XIO
MTU/PCYO[G /D"^*;]-3\(^;^YP$@.!7 K?WC7O[G6\>\>=8IFGV:8I<[575U
MJN=UN-UJ;K<;K;[A)5U<EPM]+U]?FLBR2+(YZO<BJBZJJ!;\
M
M
M
M
M
M
M
M
M
M
M
M
M
M    'YRK,C?SEC)'>D]ZL3^2C7?S#[&'"^2\J:?(&Z]Q:[?*B?SU=*Q5_0CD
M_EF2*;?#,]Z.=YF:^*._XGDS7;,(M>C#X*C^QW1B?T\+3+%JS/Z\Q^[XWB:[
MGD\OB>5/E>84^O>;>SNT_P"KKHY?Z2)QEC+69_\ R\GC>)O7(_4Y7DS;BY%3
MHJS[>W")J?FW/EZ?Y/FVAEC(6YW78Y.=XG,UQ^I/Z=QY4N\4\"Z3XI)"OI/J
ME;_-@,D:5$[J^3QO$YZ8_5Y?$_+X:?\ 9K]&?W@]>Z/V^3QOGM_[/+XCX:?]
MFOT9_>![H_;Y/&>W_L\OB/AI_P!FOT9_>![H_;Y/&>W_ +/+XCX:?]FOT9_>
M![H_;Y/&>W_L\OB/AI_V:_1G]X'NC]OD\9[?^SR^(^&G_9K]&?W@>Z/V^3QG
MM_[/+XCX:?\ 9K]&?W@>Z/V^3QGM_P"SR^(^&G_9K]&?W@>Z/V^3QGM_[/+X
MCX:?]FOT9_>![H_;Y/&>W_L\OB/AI_V:_1G]X'NC]OD\9[?^SR^(^&G_ &:_
M1G]X'NC]OD\9[?\ L\OB/AI_V:_1G]X'NC]OD\9[?^SR^(^&G_9K]&?W@>Z/
MV^3QGM_[/+XCX:?]FOT9_>![H_;Y/&>W_L\OB/AI_P!FOT9_>![H_;Y/&>W_
M +/+XCX:?]FOT9_>![H_;Y/&>W_L\OB/AI_V:_1G]X'NC]OD\9[?^SR^(^&G
M_9K]&?W@>Z/V^3QGM_[/+XCX:?\ 9K]&?W@>Z/V^3QGM_P"SR^(^&G_9K]&?
MW@>Z/V^3QGM_[/+XCX:?]FOT9_>![H_;Y/&>W_L\OB/AI_V:_1G]X'NC]OD\
M9[?^SR^(^&G_ &:_1G]X'NC]OD\9[?\ L\OB/AI_V:_1G]X'NC]OD\9[?^SR
M^(^&G_9K]&?W@>Z/V^3QGM_[/+XCX:?]FOT9_>![H_;Y/&>W_L\OB/AI_P!F
MOT9_>![H_;Y/&>W_ +/+XCX:?]FOT9_>![H_;Y/&>W_L\OB/AI_V:_1G]X'N
MC]OD\9[?^SR^(^&G_9K]&?W@>Z/V^3QGM_[/+XCX:?\ 9K]&?W@>Z/V^3QGM
M_P"SR^(^&G_9K]&?W@>Z/V^3QGM_[/+XCX:?]FOT9_>![H_;Y/&>W_L\OB/A
MI_V:_1G]X'NC]OD\9[?^SR^(^&G_ &:_1G]X'NC]OD\9[?\ L\OB/AI_V:_1
MG]X'NC]OD\9[?^SR^(^&G_9K]&?W@>Z/V^3QGM_[/+XCX:?]FOT9_>![H_;Y
M/&>W_L\OB/AI_P!FOT9_>![H_;Y/&>W_ +/+XCX:?]FOT9_>![H_;Y/&>W_L
M\OB/AI_V:_1G]X'NC]OD\9[?^SR^(^&G_9K]&?W@>Z/V^3QGM_[/+XCX:?\
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MYIM1NJGO?Q/<37Q1W_$]6!U6[_O,$,7]CE=)_-C88IB.#].5[C'A?2>7T
M
M
M
M
M
M
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M\UIDB_;G=5'?AXFW5&^)>8^.2)W3(QT;OYUR*B_R%,L3$[GC!_
M
M
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M,XO;^SX
M
M
M
M
M
M
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M3^2U#+%ZB=U4=]XFBJ-\2\Y6JU5:Y%:J>5%[%,CR_P
M
M
M    ^R&W7"HT\WH*B?7R=W$]W\Q%/$W*8WS#[%,SNAZT.(Y1/IW>/U^B^17P
M/8G\ER(8YS5J/UH[[W%FN>"7K0[<9G-HJ69T;5]&2:%G\I7Z_P HQ3J%B/UN
M262,K<G@>K!M-E<NG>+14VO_ %DRKI_Z#'F*=4LQQSW'J,G<GB>K#LW=W:><
M7>CB]/NVR2?S488IU:C@IE[C(U<,P]:'9>)-%J,@>_TVQTR-_EK([^88YU>>
M"GE\3)&1CAEZL.SN/MT[^X7"94_G71,3^1W;E_EF*=6N<$1R\[W&1HXY>M#M
M9A\6G723U.GE[R=Z:_\ H*PQ3J5Z>&([CU&3MQP/5AP'#X-.BQ0.T_ZQTDG]
M.YQBG/7I_6E[C+6XX'K0XWCU/IW-BM\2IY'-IHD7^3TZF.<Q<G?5/?E[BU1'
M!#U8H(($Z8(8X6^DQJ-3^48IJF=[W$1#]3X^@
M
M
M
M
M
M
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M+%RF=TP\315&^'PGMY
M
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M '>EA@T\G=L:W^8B&*:YG?+W%,1N?2>7T
M
M
M
M
M
M
M
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MS4593:^<4DT&GE[R-S?YJ(98KIG=,/$TS&^'S'I\
M
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MZ>;T%-!IY.[B8W^8B&*;E4[YE[BB(W0^T\/0
M
M
M
M
M
M
M
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M\S$P_$^O@
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M3R=W!&W^8U#'-VN=\SWWN**8W1#T$1&HB-1$1/(B&-Z?Z
M
M
M
M
M
M
M
M
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M_+:98OVYW51WX>)MUQP2\N2*2)W3+&Z-W\ZY%1?Y9DB8G<\3&#^#Z
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M7M_9\
M
M
M
M
M
M
M
M
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M@D;_ #6H98O43NJCOO$VZHWQ+S7-<Q5:YJM<GE:J:*9'E_@
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M-(860IZ3&HW^88IF9WO41@_4^/H
M
M
M
M
M
M
M
M
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MY?0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,,BL8R.-CD:B(B>@A-:+HV2N9*U57:HFJ:8F9F(F9:.?S]^F_7%-<Q$3/"N
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M;CNGG6S'-%J
M
M
M
M
M
M
M
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MV+=NJKTM6R)G='!"K6^L-RJJ(Z$;9[*VLYFM8
M
M
M
M
M
M
M
M
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M5M56M/HHKC"J)JB8[,5U,^KUQ7F:JJ=L3$>"%NW$7YN.UGZG3_IRH.8]9_\
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MW+[ZLPW::@J-64;5R+(XVKV=[(CX**-VGD5K>]>J+_/,4Z3U$T_"FO,U1O\
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MB+HJM[=%+C<Z\YNY1-,T4;8F/UN'NH.CJ_9IF)Z56SM<R?I2D\
M
M
M
M
M
M
M
M
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MQ4%;;?PBX#]L=J_3<1VC/_EKGU*O!*B9;^;3VX\*Y+GQ@-7E^R?L];:=9ZW
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MK/,R^TVO+I[\,Z--G
M
M
M
M
M
M
M
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MB_;QZ,_KT\7;<_LY*_%=,S;JWQP3S.BXX4Z$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MZP1U5LNU#,RHIJF"5J.CEAFC5S'L<U45'-545/(!]X
M
M
M
M
M
M
M
M
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MDB149ZOK1.IJ]0=2     Y.?%R^>=DWVM6#]*@79>%1\Q_:G_#LC]O*T"Q0
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MQ<\\OGB<A_MPK/YC .K+AK\TWC?][C&_:Z$"2@
M
M
M
M
M
M
M
M
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MQ4J7JB@<QE1%/3Q-9&VIAZT?K&U$?'U+T-6-SGA<$
M
M
M
M
M
M
M
M
M                         #!-RL*V_P!Q,+O>&[H6>VW[";Y#W-XMEU5K
M:=Z(J.8Y'JYJQO8Y$<Q['(YKD1S514U I1W6\%S$\B2?(N/&\26V@KNJ6VXY
MDT:7"A755[(KM1+WB1M5-$ZH)7>FY53M"LW>OPZN5VQ=LN619'MZF3XE:6/E
MN&5XI4LNM-#%&BJ^:6!J,JXHVM3J<^2!K6IVJJ 8AP^Y5YOQ8W6L636B[54F
M!W.NIX-R,/ZWOI+A;G/1DTB0(O3YQ"Q5?#(B=2.3I75CGM<%D_C<YI55N2;
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MTJYLRJG4G>-9U(BA90
M
M
M
M
M
M
M
M
M  #E,\7/;"\X3RLN&8R0U;L9W4L]#>++62=;J9M720LH*ZFB>[5$<UT#)7M1
M>Q)6KY%0"3?AJ^(CMCM?MI2;![[7B3$Z/&JJIEP'-9(9JBB=25DLE5+15BPM
MDDB='/(]8W]/0K7=*JSH3K"P7>GQ-.)NWF%7FX6#/[?NMDLU'*RQX78F2U+:
MR=\:]#*FH6/N((E54217.ZD;KTL>OJ0.37'<>O.:9/9,6QRW.N&095<Z>V6.
MU4Z=LU76S-A@A8B^3J>]$0"]?QFMHKO;,/XZ9]14[Z^SXA1U>%9'=NU7,E?%
M3S6]7]FNDG<5.JKY%T3RN0")_AJ/X@9'D&9;<<G\7QR>[WQU+6;=95DD\E-2
M=<;7LJK>Z?O8HXGOU8^/K71RHYNO5TM<$RN7>0>&_P 9G8E;,5XYX-O7E-_F
M=+=[!9K]+ RVVYK-6U$]3!YZU))7JB1Q*B*YO4[5$1.H)!>'/G_%;=K*,UR/
M8CC#6[,Y/BMGBH\CRE9&5-"Z"XS->VA94><=;GR.I>\T6!$TCU5R=B*%4?BY
M?/.R;[6K!^E0+/N(FWMPW6\)BY;>6>G;67S*L>SBDQ^D<J-;+<?92X243%<O
M8G5.QB:^@!SL;2W?#\/W8P>Z[HXM]D^#V6_4WV=8K.U[7ST#9>[JX^A%8[K8
MQ7*C=4]4B(JH!TFY+MWX46.[5W+=UF,[:7G&*2V.N-!!0W-[ZVM>K%=#20TG
MG7?]_(Y.A(W,1S7:]2-Z7:!7AM#R-X&;C9;C&$77P^/,;_EETI;19Z;';M[,
M.EJ:R5L,2(RI6VZ:N<FOJNSTP,X\;+;.XV_<39W=BFI'KC]VQF3#YZAB:QP5
M5KJIZV%CU]!TL=:_IU\J1N](#\?"2Y?;8;06K/-E-V,HH,%M^1WEF38AD]UE
M2GM[JN2ECI*VFJJIZI% O=TL+HW/5&N]6U7([H1P2;\0'Q+;=MM08?B7%C<^
MQ9)G,UR6X9?D=H;0WZV4ULBA>QM$Z9S9Z=TL\LC7+W2J]B1JCE;UIJ&Q?#5Y
M@<A>5U7N(_="SXNS#\$HZ.&GR*TT-31UM3=:V1SF1.5U5+ YC(87N>C(FJBN
M9VZ*!2/XE$3XN;N_3'HK56XVMZ(O9V/LU YJ_EHH%\_A^\D-BUXU\==LW[IX
M['N/4V]]ABP1:V-;LE=!/.JQOHT596(YJ=37N:C7)ITJH%F '\O8R1CXY&-D
MCD:K9(W(BM<U4T5%1?*B@<3_ "]X^7KC3OQFVW-?13Q8_P">2W+ ;E(U>BML
M=5(YU'(Q_D<Z-NL4FGDD8Y +I^$WBH;3OVUQK;7D7>Y<&R_"[?36BW9K-3U-
M9;[U34S4A@?,ZEBE?3U#8VM219$Z'JG6CT5W0T/=YG^*7LW;-K,DP?CWE#L]
MW!S2W36R/(Z.FJ(+?9::K8L4]0LU0R%TE0D;E[EL:.1KO5/5.GH>%&7$;;/-
M-WN0VV>"8/=;OCU?=+K%)>LELD\U+56VTTZI+<*IM1 K71JR%KD8JN1%>K&Z
MZN0#HA\7QB1\-ZN-JN5K,OL36JYRN=HBS)VN<JJJ_550*MO!E^=ED/WN+Q[8
MVL"9GC?_ ,&^Q'VRW;])Q :S\#?_ ,;Y)?X#BO\ ;;J!$7Q;?GHY?]K^/_I%
M@%W_ (5OS&]H?\*R3V_N %?/CD?^.\;O\ RG^VVH#9W@@?P;;[?;+:OTG*!7
M_P"+E\\[)OM:L'Z5 MKX$X5)N3X8D6WD+VQ39W8,^QZ"5RHB,DN==<Z5CE5?
M)TK(BZ@<SN(7Z_;/[I8OE#[8Z#*-K<JHKH^S5:+&YE?9*YDZT\R)VM5)8>EW
MHH!UZV'G]Q&OFW,>Y+M[L:M%"E"E76XO<*Z&&_P2(U5?3+:5=YU)*CD5J)%&
MY'::L5S?5 4:M\7?EA)N'?YL49C^08S?;_4_83A=[LK))::BJ:ER4-$LMNEI
M)I7MC<QBN61SG.]%0/Q\7C+]Q;MOCMGBF=K%1NQW;BT5[[10*]+<EUN4DZW2
MHI6R/>[I=- D35<Y5Z8FZJOE4-^^%KQUX?[E[8W[.MSZ*QYUNE9;S40W7&LC
MJT2EM-NC9&ZFE2W/D9%-',BN<LTK7MU16-Z5:[4(=>)QN#LEF.^]BQ_82CQV
M'"]N<8AL5968M2TU-:IKBM74U,[:7S1C(961LEC9ULU17=2(JHFJA;=X+TL<
MG%++&,<BO@W,NS)4U[45;7:')K^4J 45\\OGB<A_MPK/YC .K+AK\TWC?][C
M&_:Z$"2@ "-W,7YI_)'[VV3>ULX'(IQ-^=/QI^^IAWMW2 =O@'(EXJ?SX]W?
M\$QOV@H +_?#*8V/@WL0UJ:(M+?'?ENO]R<O\M0,H\0;YF/(+[6O_LJ #FU\
M-'Y\&PW^'7CVCN $E/&>RS);CR4Q+$+A/-'C&,X51UF/6]57N737&JJO.ZIK
M?)U/6!D2KZ42 ;C\+7CKP_W+VQOV=;GT5CSK=*RWFHANN-9'5HE+:;=&R-U-
M*EN?(R*:.9%<Y9I6O;JBL;TJUVH0Z\3C<'9+,=][%C^PE'CL.%[<XQ#8JRLQ
M:EIJ:U37%:NIJ9VTOFC&0RLC9+&SK9JBNZD151-5"V[P7I8Y.*66,8Y%?!N9
M=F2IKVHJVNT.37\I4 HKYY?/$Y#_ &X5G\Q@'0_8>15/Q;\//CSNU78/<\\M
MM!A>(6ZXT%LFBIUI65MOC9'4SRRHY&Q=\C(M4:Y>J1O9Y0((XKS,XA\W=WX<
M*Y+\<L3V[M5]M\L-AW/K[RY+BMQB='YO35=VI::VOABDC1_0KY58CT:SMZP/
M#YE>'?Q,VCVJRO=';[?"?%;O;*1U7CN$WBYT%UI[O/JG=T- C&Q5?7(FNCNJ
M73ZYVC4<J! ;P[ZG(Z;F?L(N,-EDKI[])#7Q1*J=5N?1U"7!7:>5K:;O'*B^
MD!V5
M
M
M
M
M
M
M
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M6:"VP*KWM63L;)*]W4YK=&MC:Y[7!8L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUJL?NX _'5\6/V@[J_K58_=P!^.KXL?M!W5_6JQ^[@#\=7Q8_:#NK^M5C]W
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MK58_=P!^.KXL?M!W5_6JQ^[@#\=7Q8_:#NK^M5C]W 'XZOBQ^T'=7]:K'[N
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M6JQ^[@#\=7Q8_:#NK^M5C]W 'XZOBQ^T'=7]:K'[N /QU?%C]H.ZOZU6/W<
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MM5C]W 'XZOBQ^T'=7]:K'[N /QU?%C]H.ZOZU6/W< ?CJ^+'[0=U?UJL?NX
M_'5\6/V@[J_K58_=P!^.KXL?M!W5_6JQ^[@#\=7Q8_:#NK^M5C]W 'XZOBQ^
MT'=7]:K'[N /QU?%C]H.ZOZU6/W< ?CJ^+'[0=U?UJL?NX _'5\6/V@[J_K5
M8_=P!^.KXL?M!W5_6JQ^[@#\=7Q8_:#NK^M5C]W )?\ %+FKM9S!^SWX-+!E
M=C^#OV+]FOLGI:&F[WV7\\[CS?S*NK>KI\R?U]73IJW3J[= E^
M
M
M
M
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M5>\VQ^LP'R3N+'T:=JO>;8_68#Y)W%CZ-.U7O-L?K,!\D[BQ]&G:KWFV/UF
M^2=Q8^C3M5[S;'ZS ?).XL?1IVJ]YMC]9@/DG<6/HT[5>\VQ^LP'R3N+'T:=
MJO>;8_68#Y)W%CZ-.U7O-L?K,!\D[BQ]&G:KWFV/UF ^2=Q8^C3M5[S;'ZS
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M_68#Y)W%CZ-.U7O-L?K,!\D[BQ]&G:KWFV/UF!4!X&/_ !1?N)_S^!?\
M
M
M
M
M           5 ^-7\UC ?OJVKVCO@$_^)WS6.-/WJL-]HZ,#?X
M
M
M
M
M
M                           "@'P,?^*+]Q/^?P+_ (
M
M
M
M
M J!\:OYK& _?5M7M'? )_P#$[YK'&G[U6&^T=&!O\
M
M
M
M
M
M                  !0#X&/_%%^XG_/X%_P
M
M
M
M                                                  !4#XU?S6,!
M^^K:O:.^ 3_XG?-8XT_>JPWVCHP-_@
M
M
M
M
M
M       * ? Q_P"*+]Q/^?P+_@
M
M
M
M                                        "H'QJ_FL8#]]6U>T=\ G
M_P 3OFL<:?O58;[1T8&_P
M
M
M
M
M                                                          %
M/@8_\47[B?\ /X%_P
M
M
M
M                               !4#XU?S6,!^^K:O:.^ 3_ .)WS6.-
M/WJL-]HZ,#?X
M
M
M
M
M                                                 "@'P,?^*+]Q
M/^?P+_@
M
M
M
M                     "H'QJ_FL8#]]6U>T=\ G_Q.^:QQI^]5AOM'1@;_
M
M
M
M
M
M                                       % /@8_P#%%^XG_/X%_P
M
M
M
M
M              5 ^-7\UC ?OJVKVCO@$_\ B=\UCC3]ZK#?:.C W^
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MR),J+Z:- \C!^4''/<JX4=FP7>_"LDO=P=T4%@I;U2>R$[O+I%1OD;.]?R&
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MW&SO'\#M<S^[@N&07*FML4C_ .<C?4R1H]WU&ZJ!INU<S^)EYK76^AY%[?\
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MG6\>#X7>$35;5?<AMMNJ41>W58:FHC?_ "@,YQ[)<<RVUT]\Q3(+;DUEJO\
MNMXM-7#6TLFG\Y- Y['>7T% ]L#%,NSS!L H&W7/,SL6$VM[E:RY7ZXTUMIU
M<G:J)+521M5?RP/)PW=K:O<7^#_<O%<Y5.I53'[S0W-4Z?KM4I9I/)Z(&P0
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M0     #^7O9&QTDCD8QB*Y[U[$1$[555/DSAM&D%Y*;&(JI\(UM[/294+_\
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M7T        H!\#'_ (HOW$_Y_ O^
M
M
M
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M:?58IT;J7J7M>0BB9^=;^;/:_5Y-G[JX]6\[[1E(IGZ5'S9[7!R;.XE*6Y8
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M$7         H!\#'_BB_<3_G\"_X
M
M
M
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M^T%/;2M L*QGQ9.'-KQO'[;5Y)DC:JW6VDIJEK;%4N1)(86L<B+Y%[4 C#S
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M;][%[?WJ7&\\WHP3"<B@CCFGL-_R.V6VM9'*G5&]U/55$<B->G:U5;HJ>0"
MMVVB\)S(-P,GW-R/.=H;_E.6W*:[W9:S<&C6B6KJ7=<\C:&.Z,I_SQZJ]W5&
MOJE5?1 LAV]EP*7",83:ZJLE9MY34$5+B$V.305%J2BID[F-E'+3.?$L;.CH
M3H71--/0 S(    ?#=/_  RX_P""S?TBF.]]"KM2\U_1GM*6]B-P]T-OZ[(J
MC;+#VY=4W."GCNT+K=6W#N(XW/6-W31R1JSJ5RIJ[R^@<+ZO:EG<E77.4M].
M9B,?FU58<7T9ARO1\[FLM-4Y>CIS.&.R:L/LMXY+R2Y3+:*UM3MZ[$H71.22
M]0X_<8GP-T[7M?5R31M5$]%6]A/YOK1K?HYQL]"/*]'5&'VIF$O?UW5.A.-K
MH]GH5;._,P]?A+-@4F1Y!7W&]5%1NE=8964]%6L1L;J17I-.^FEZW+-*]6HZ
M3J1KD1%T14ZG&;J'5E?35U553.8JB<(GR=\X3CMGCW3Q;,99>JDV)N55553-
MZ>/BWSAQSQOTY\_^)[8_X+=?Z>E/7_T7Z=CM5?\ $ZY?2M=JKY%A]@_\!LG^
M 4W]J:=*RW\JCZL>!=K/T*>U#US.R(X<J<]^P;:"^LIINZNV6*EBMG2NCD2I
M:[SAZ:=J=,#7HB^@Y6E7ZWZC['I]<1/SJ_F1W?I>;CW<$)UASGLV4JPWU?-C
MN[^3%B'#W;N"P[1S7>Z4;7U6XDTE3512-^NM\:.@IXW)Z+7(KY$^H\TNI.F1
M9R$UUQMNSC/U=T1X9_>:O5G)1:RG2JC;<V]S='/W4;]E*Z?8CDO?-N;E,Z*R
M7ZK?9&ND71')*J3VJ=?3<]'M9]3O%*OH-R=&UFO*US\VJ>AW]MN>[LC]Z4'I
M54Z;J55BKZ-4]'Y:)^3NK3CKKH(!K/>'.8]N-MLKRWK:VLH*)T=H:O;U5M0J
M0TR:>BB2/15^HBD5K>H>P9.Y>X8C9]:=E/+R-'4\W&5R]=WAB-G;G9'*BAP9
MP>2"T97N5<6.?5WRH]B;542=KU@@5):J1'+VJDDJM1?JQJ4[_P"?Z?A;N9JK
M?5/1CM1MJGNSA]E7.J64F**[]6^J<([4;^_/@:GO\B\=^6"79O\ V3%<@JTK
M)D3U,?L7>'*VH33^=IYT<YJ?^[:0V9GW%KO3W6ZIQ_<KW_9JQP^K".O3[KU7
MI;J*IQ_=JW]Z? LESS*8\,PG*<N5C9TL%KJ:Z"%>ULLD<:NB8NGH/?HGY9U+
M4<W&4RUR]OZ-,SVYPV=^5YS>8BQ9KN>3$RK?XZ;-P;^7?+-R]TJVKO=!'<%I
MW4R3OB=6UKV)+*DLC%1[(XF/CZ6L5OE1$5&MT7E_5G0XUJY<S6;F:HZ6&_#I
M588SC,;8B(F,(C#O1@H^B:9&IUUYC,3-48X;]\[^]&S#!LC>SB5YBZP9)L+:
M*BAO=+6L;666*OZ$CZ462.L@GK)D=&Z-[$14Z_116HFBZRFO=3>AT+NG4S%4
M3MIZ7=BJ*JIV83V>+##!O:KU<Z/1N9.G"J)W8\L3,[,.V_'E7N3F]BVOV\P>
M[O6TY5EM!WN>+2R-7J2D9'')$V2)>GHGE<KG(U?(WI\BKKYZWZIF;.2LY>OY
MMRN/_9AV,(F-G!5.W9Q8;GSK%G[UK*V[56RNN/G8=C#&.[+8>W/#K;*WXC;V
MYW:)LARJOI62W6H=65$$=+-(Q%=#3MIY(VJD:]G4[J55U7L1>E)/3.I&2HR]
M/M%,U7)C&=LQT9XHZ,QNXYQQY&[D>K&6HM1Z:GI5S&W;.SL1AAN8EM-LANCL
MYOG<),<I9:[::N<Z"NN,]73-6:EDB62!70=XDCI::5W3U)&FJ([31'FEHV@9
M[2M3GT43.7G9,S,;:<,8V8XXTSPX<?&U]-TG,Y#/3Z.,;,\.,;L-FSCB>QX6
MN>1&173=K?FU;.I?&8_BECJ8:6JJ)IN[IUF="E355<J*K6N=''JR-'>BBZ*G
M6I&=9LS7J>J4Y+I]&W3,1MG9CATJJI[,1LCY,6CK5ZK/9^G*]+HT1.WBW8S/
M<C9'C;KJN-G&*;'G6BFO%)275(>B+*$OJ/JN]TT[UT3IO-UU5-5:D:)Z6A.U
M]5]$FUT(KB*L/I=/;CQX8]'S4K5H.FS;Z,3$3Y72V^'#D:SXAYC>,7W#R_92
MXW1EYL]*^M?9ZJ*;O8(ZF@F6.5:;M5.[G8JOT1?*U%\JN(KJ7GKF7S=S(55=
M*F.EAMV8TSMZ/8JC;W.VT.K69KLYBO*53C3&.';IG"<.Q.]IK-,$K=R^5658
M31U+J-E[OLB7*K;_ .RI(8FSSOT7L<J,C56HOE=H0F>T^K/ZY<L4SATJYQGB
MIB,9Y(V=E%YO)U9O5:[43AC5M[41C/Z<:9.6<.=J*_#ZFU8O:IK+D]-3.6U9
M ZKGE?+4M;JWSEDCW1JV1R)U=+&Z?F>GR%WSG4C(UY>:+-,TW(C95C,XS^UC
MLPGAPB.PL^9ZL92JS--NGHU8;)QG?V>#]-C6?"_,J^^6G-MHLGDDJZ2T4ZS6
MVGE>[KBI9G.IZRF1R+JUC7N:K41>Q7.^H1747/57K=W)7=L4QC$<43LJCM;L
M.W+1ZK9JJY1<RUS;T=W:W3'Z<;3%^VHP2BY7V[;&FLKH\*J*BB9+:/.JE55L
MUN;.]._619NV1=?K_J>0@\QI&5HUV,I%/_JQC9C/#1$[\<=_915[3;%.JQEX
MI_\ 7.&S&?)QWXX\K<O*>]TFS6W&*;/[=0RX_:<@?6SUJQ5,SY8Z-DJ220)+
M(]TBI/+,JNU=]:U6_6NT)SK=?ITK)V\EEHZ--6,SMG'HXXX8SM^=,[=NZ,-T
MI3K#>C(9:C+6/FQ5CPSNQQPQW[9GY'L[=<;N/]NQ2@;G5XMF29174[);K4NO
M:T\5-*]J*Z&G93SQ)HQ>SJ>BJJZKV(O2F;3.K&DT6(]HJIKN3&,_/PB)XHPF
M-W9QQY&;):#D*+4>EF*JYC;\[##M83#2-++3\;.0MDHL,R=F08-DZTB5E-'5
M,F;YE6S/IW1U"Q*K5DIWM5[':(NFG\\X@:*HT'5J:;%SI6J\,=N/S:IF,*L-
MF-,[8\<HFG#2=0IIM5=*W5ALQX)G#;V8WQ_Y;GYO[@W6UVK&-NK-424Z9/WM
M;?NZ56OEIXG-C@I]4\K)'JY7)_0M]#4G>OVI5VZ+>6HG#IXS5V8C9$=J9QQ[
M4)/K9G:Z**+%'ZVV>UP1W?D9EAW#3:VBQ"CH<OMU5>,KJJ9KKI>8ZV>'S>H>
MU%>RFCB>V+IC=V-5[':^5?2-[(]1\C3EXIOTS5<F-LXS&$_LQ&S9V8EM9;JO
ME:;41<B9KPVSC,;>QAL0]Q? *K;#E3BF%U-0ZMBM60TKK;6NT19J29O>P/5$
M[$7H<B.1/S2*4C*:;.GZY;L3./1KC">.)VQR;^RK66R4Y/5:+4SC$5;)[&&Q
M<*=M=+83N1EJ8)@66Y?T,DEL-LGJJ2&77HDJ$;TP,=IHNCI%:U=/3-#5,[['
ME;E_AIIF8[?!'=G!JY[,^SV*[ODQ,]W@Y5=O'792GWXK\GW0W3K*N]4+[D^G
M;2),Z)U=6*Q))G2R1JU[(XVR,1C6*WTD5$;HO,^K.@QK-=S-YN9JCI888X=*
MK?..&V(C&,,,.]&"DZ)I4:E57F,S,S&/'OGA[D<&#+^1W&7%L)Q.7<;;"*IQ
MZHQJ6&:Z6ME5-*SN72(U*B"29[Y621O<U5T?ITZJFBIV[O6?JI8RECVK*8TS
M1,8QC,[,?I1,XS$Q.'#N[39US0+67M>GR^-,T[9C&>_&.V)A(#:#<.OW+X]U
MU[O#^^O5OM=RM5WJ==5FFI:==)G>DZ2-S7._HE7T"QZ+J=>H:35<KVU1353,
M\<Q&_MS&$SV4UIF=JS>0Z=7THB8GMQ&_NH'<8-E[=O'?KRF35=2F)XC'#455
MMIY5C=/55JN;&SJT7I:K:=W6K='+HU$7T4Y[U3T*C5;M7I9GT=&$S$3OFK=W
M/FSCP[E/ZOZ53GZZO23/0HX..9_\;>'<VIRDXYX-MWB%#FV"4\]G;3U\5%=;
M5)42U,3V3M=T2L?.][VN:]NBIKHJ.]#3ME^MW5C+9'+Q?R\33MB)C&9C;P[<
M9_\ *1ZP:'8RMF+MF,,)PF,9G?VTV]A\AN&4[/X!>[K,M1<*FULBJZERZNE=
M3/=3]XY5\KG=WJJ^F7SJ[F:\SI]FY7.,S3A/9PGHX\BUZ1>JO92W75OFGP;&
MVR:2(!%#F?\ P(UOZL6_^G<4[KS_ (V?K4J[UH_)3VX\+Y]@_FE4GZBY+^FZ
M\\]7O\#'U+GAJ?-%_P 5'U:_#4UOP)_U?W&_5"@_M4Q%_P#SO^5?[=/@EH]3
MOY5SMQX&R.:O\"K_ -7:#^9*2G7O_'?OT_*WNM/Y*?K0]W:7YJ]I^U*Y?TM2
M9]&_P=/_ %U?\F?3?\93]2?E:9X%-1V/;CM<B.:ZOH$<U>U%189NQ2$_^=_R
MK_;I\$HKJ?\ RKG;CP-=[>-=L)RPN&(2JM+C>45+[91HO8SS6Y*V>W*FO8JL
MEZ(E7T/5$9ID>YM=FS.RBN>C'U:]M'>G"G'MM')?_P"-U6;6ZBO9':JVT\NS
MOI1<NLZ^P_:&YVZFF[NZ9K*VRTJ(OJD@D17U;M/26)JQK]5Z%MZZ:A[+I]5$
M3\ZY/1[GZW)L[JP=9,WZ#*3$;Z_F\_)X7W<4,$^PG9^R3U,/=77+W+?;@JIZ
MI&5#6I2M[>W1(&L=IZ"N<9.IVG^R:?3,Q\ZY\^>[]'S<)[<R]=7<G[/E*<=]
M7SI[N[DP24+2G0".'(+?ZS;06*:@H)H;AGMTA5++:$5'>;->BHE74HGUK&_F
M6KVO7L3LZG-J_63K';TNU--,Q-ZJ/FQQ?M5=CBCA[6,Q":SK-&1MX1MN3NCB
M[,]CPM-\,]K+[;$O>[64LFAK<KIG4MBCJ=>^FIII6SSU<G5VZ3/8WH5>U417
M>1S56#ZC:1=M]+.W<<:XPIQWS$SC-4]N8C#CVSNF$7U7T^Y1TLS<WU[L=^&.
M,SW6HN6=7B5/NY;+EM[<;C\*U+/2-O<-NB1T+:F)K4I7,D:[O/.41&-5C6N1
M4TU5KD5'0O7&O+TZA37EJJO:(F.EA&S&/HX3OZ>Z,(B8W;IWQO62JU&;IJL3
M/IHPQPX^#][=LXF/[M9MRGN&#)0;B6:X6?$JE(V72MBM[*;O^U%8VK?$BK&B
MN1/4JC$5>Q4] U]9S^N5Y;HYJFJFW.&,]'#'ZV&[M;&'4LUJE5C"]3,43OF(
MPQ[>&[D33XGLVXAVOC@V^KZFOD2K=+E3[A&R&M;7O:U%26)CGM:SH:B1]+G)
MTI]<KNHO74Z,G&2PRTS.WY^.RKI=F-N$8;L)GMXXK3U=C+QE<+$S.WYV._I=
MGY$G2V)X   *].5._<-YBGV9V[>Z]W&[3LH\FKZ'675W>(B6^GZ-5D>]Z(DG
M3V)]9VJKNGFG6_K%%V)R.6^=,SA5,;>'Z%.&^9G?]GCPI?6'6(KCV6QMF=E4
MQ]V.SQ]YOG9G;6MV@V/N-JN*M;D-;2U]ZO;&+JD-3+3HC84<W77NXXF-54U3
MJ153L+%H>EU:7IE5%7TYBJJKL3,;NY$1W<4SI60G(Y.::OI3$U3V\/DC!'O@
M)!'T[IU*MUE1;-$UWI-_[:JHGY*Z%;_^=1^8GZG_ "0?4VG9=GZORIM;IT\=
M5MEN+32HBQSXS=F/U]):.5-2^:Q3%62OQ/JZ_NRMF?IBK+7(GR:O!*(W N:1
MV)9]3KKW45WI9&)Z'4^!4=I^4Q"F?_/*I]!>C]J/!XE:ZGS_ .FY'[7R)Y22
M1Q1OEE>V.*-JNDD<J(UK435555[$1$.AS,1&,KA,X*QN1F\-9O9D5JV=VKAD
MOML2O9YS6TVJMN58S5&I&O8GF\.JN5Z^I54Z_K6HY>4=9];JU:]3DLG'2IZ6
M^/UZNQ^S3OQW<.Z,9H6N:G.H7(RN7^=&.V8_6G\,<?,GUM3@L>VNWN+X4R=M
M3+9:54K:IB:-DJ9WNGJ'-UT7I621W3KVZ:'1='T^,AE+=C''HQMGLS.,\L[.
MPN&GY2,IEZ+7%'+OGE9_))'%&^65[8XHVJZ21RHC6M1-5557L1$0DIF(C&6[
M,X*QN1F\-9O9D5JV=VKADOML2O9YS6TVJMN58S5&I&O8GF\.JN5Z^I54Z_K6
MHY>4=9];JU:]3DLG'2IZ6^/UZNQ^S3OQW<.Z,9H6N:G.H7(RN7^=&.V8_6G\
M,<?,GUM3@L>VNWN+X4R=M3+9:54K:IB:-DJ9WNGJ'-UT7I621W3KVZ:'1='T
M^,AE+=C''HQMGLS.,\L[.PN&GY2,IEZ+7%'+OGE;")-N@&M=YOX(MT?M3O/Z
M2E(O7/R%_P#ZZ_NRT=4_*7?J5>"5:7'+D1CNRUDR.UWJPW&[RWJNBJH)*)T*
M-8V./H5'=XYJZZ^D<KZL=9;6DVZZ+E%572F)V8<79430];MY"W5373,XSCLP
MXF^;MSTQYE)+[!8#<:BN5BI!Y_510Q(_T%=W22N5$\NB::^FGE+%>_\ H=J*
M?_79JF>S,1')BF+G7"UA\RW,SV9B.=A'&/"<SW(W=K-\LMI)*6W4TU570U<D
M*Q15M;5QOA9'3([RQPL>J]2*NBM:W5>W2/ZJ9#,Y_/SJ%Z,*8F9QPV553&&%
M/8IQY(AJ:#E+V;S<YR[&$;9[<S&&SL1'R/GY:_.,VY_4NR^VM6>>N?\ E[/U
M:/OU//6/_(VNU3]Z5GIUA?F,YK0T]SP[++=5M:^EKK/74]0UZ:M5DE.]KM4_
M(4U,_;BYE[E-6Z::HY)8,S1%=JNF=TQ/@0!X#3SI<=S:5.I:9]-:I7_SJ2-?
M5-;V>FJ.7^0<Y_\ G54]._'!A3_R4WJ;,]*['!\WY7BY;\^VD_5JR>U%*8,[
M_P#W/'UZ/N4L68_SL?6I^Y"SXZPOR+W,3^ K(?\ #K;^FHRI]=O\97VZ?#"
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M0#X&/_%%^XG_ #^!?\
M
M
M
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M2,2:IA=)*]7STTCU5SE]%P$$*/Q&^:\E72QOW[N[F23,:]OF-J[45R(J?]R
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M+:MXP[*Y%O%-O;!FD=@J[?2KC[,>=;UE\_JXZ7J\X6Y5'3T=YU:="ZZ:=GE
MT)PBX45',RY[AVVGW'CV\7 :6VU+II+2MU\Z]D'U#$:B)5TG=]'<:ZZNUU]#
M0"[OACX:-9Q+W?J-TY]Y(<\9/C];8_82.PNMJHM7+3R]]WZW"J^M[C3IZ.W7
MR]@%K $(O$?^9-OY^I%![:T0',OPAV$Q#DMR&QG:7.;E>+3CEZM]UJZJML4U
M/!6M?0T<E1&C'U5/51HBN8B.UC7L\FGE N^G\%+C&Z-R4VXNY\,JIZA\MPLL
MC47ZK6V=BK_) IHYN\0;OPSW-L%FH<JDR;%\KI)+OA&1]VM+6Q+2S(R6"H1B
M]*30.5B]<:Z.1S7:-75J!<]POWFSKEGP*WPP?,ZV;)-P,=Q_),%;>IW]=7<Z
M:X663V/EJ':(KI4[]T*N75S^[1[E5[G*!SY\9LQH-O\ D1L?FMVJ&4EGQO.;
M%6WFKD7I9%1,KH?.9%7T$;$KE [C$5%1%1=47R*!HWD3R!P7C+MC<=U=PH[A
M5V*@K:*WQ6RT1PRU]545LR1MCIXZB:GC<K&]4KM9$]0QRIJNB*&&[#<SN.G)
M*I]B=K<_BN&3QTSZNIPZX4T]ON<44?3WCDAJ&-;*UG4G4Z%SVIKY0.67GSB%
M7A7,3D!;*JD?2^R>5U5_ID<FB217Q&W-LC5\BH[SGT/1U3RHH'41P3W#L^Y?
M$K8J\VFX-N$MDQ2W8U?.U>\BN-C@9;ZF.5J]J.5T/6FOUS7-<G8Y% K+YT>'
M%R)Y#\D\RW5V^?BS<6OM%:(*%+I<Y*:IZZ*WP4TO5$VFD1$ZXUT]5VH!23OE
MLKF?'O<N^[4;@+0+E6.QT<MP6V3K4TO374L57%T2N9&J_G<K=?4]B@=9?AU?
M,JV!_4.I]L:L":H    ^&Z?^&7'_  6;^D4QWOH5=J7FOZ,]I6_P(_\ 'MQ_
M\ M_]MF.7_\ SO\ FWOJT^&5&ZG?3N]J/E67*B*FB]J+Y4.J+VJ3NZV6+F1:
M&[;QPQ6^/++7'*VWZ)3]>D+;GW:1]B-_KJ/1.SZ[T#C5[T<=8:?9<.CZ2GZ.
M[@Z>&'!]+'NN<W>A&L4^@W=.-V[@Z?RX]UL;GS_XGMC_ (+=?Z>E)3_Z+].Q
MVJO^+<ZY?2M=JKY%A]@_\!LG^ 4W]J:=*RW\JCZL>!=K/T*>U#US.R*ON4EW
MKMUM\\3VEL4_5%9I(+:KD17,977%S)*F5R(J:I%%T:^ETN.3=;KU6I:G;R=N
M?HX4_O5835/<C#O2H'6"Y5G<]1EJ.#".[5OGN1ARLU3@1 B:)NM.B)Y$2SIZ
M]-W_ %S'_P#4>9_&V_@^/73]GQM#;Z\<KEL9;\<RFW95+D5-5UZTTU:E)YG)
M1U+&I+3JBI--KUHQZZZIHK4\NO97NL'5BO1Z*+M-SIQ,X8X='HSOCAG?M[6"
M'U?0ZM.IINTUS5MWX883OCAE9_M+G4.Y&W>+9A&YOG%SHVMND3?)'6PJL52S
M3T$21KM/Z'13K6C:A&?REN_&^8V_6C95R\B_Z=FXS>7HNQPQM[?#RMC$FW5<
MW.'-*BX7'#=J[0KJB=[VW:YTL7:Y\\RNIZ*+1/1[9%T7^>:IS'K]GIKKM9.C
M;/TICLSLICP]^%(ZV9J:JJ,M3OWSX*8\/(_6DX%:TM.ZIW0DIJE\;'5,$5I1
M[&2*B=;6N\\;U(B]B+HFHH_^=8Q&-_"?J?Q/5/4_9MNSWO&U;O5Q,J]K,(J,
MUH,PDRF*W54$5SI'T'FJQ4\[EC29'I43:Z2.8W31/KM=>PB=<ZFU:;EIOTW.
MG$3&,='HX1.S'?/#A'=1VJ]7)R=B;L5]+"8QV8;./?/"D+C.73[L<0,KIUE?
M49!C5AJK7=6-U=+(^V1MGA=IY7++ UFJ^B[J0LN4SDZEU?N1CC711-,_N1C'
M?IP[N*;R^9G.Z37PU4TS$_NQL[\8'!2^T%3MWE..ME8ETM5^?6STZ=CO-ZRF
MA9%(OIZO@>GY2#_Y]F**LI<M8_.BO'N51$1]V7SJC>IJRU5'#%6/<F(YI2*W
M@W;L6SF,T^1WNEFN/GE;'0T=LIGL;-*][7/<YO6J)HQK555_(3T2SZWK-K2K
M,7;D3.,X1$;_ -(3>I:E;R%KTE<8XSAA&] +EM?DS*BV9W.HK766^V9':ZSS
M6AKVMZV)!.R1G7W;GM_/6R=3>WM;^6<XZY9CVNG+9NFF8IKIG")[$]CCQQ[2
MG=9+WIZ;&8B)B*HG?VXGE6@62\4&0V>UWZU3MJK;>:2&MH:AOD?%.Q'L7^0I
MUG+WZ+]NFY1.--41,=J5^M7*;M$5TSC$QC#2%RY$8U0;P4FSM/9;A=;S4ST]
M+)<Z-T+H(99HTE>DB.>UVD3%ZGJFJIVIIJA 7>LUFC4(R,45553,1C&&$3,8
M\D;T5<UJU3FXRL4S-4X;8PPCAY(WH#Y[AF/7;EC?L4SNXUMIL&27M5DN=,]D
M4K%KZ9):3I?-'*SI65[&*JMT1->U-#G>HY&U<UVNSF*IIHKKWQO^=&-.^)C?
M,0IV=RMNYJM5N],Q355OCLQLWQ/#L2F^0IM1^V7+/\9H?6);O]?9#R[G?I_"
ML'PAE?*K[\?A8GL7AW'FS;PQP;?9AE5YS#'/9&)M-6,B?;YF,B?3SO[V&DC1
M6)U^I=UHBKTZ:ZIKI]7\CI%K4(C+7+E5RCI;\.C.R8G;%,;-NS;&W!KZ1E=/
MMYO"Q77-=.._Z/%.V(CPL,Q:^6^Q<WL@=<IF4\5UN==;:>9_8B5%33(D+=?3
M>]$8GU7&AE,Q19ZRU]+9%555/=F-G?G9W6ME[U-O6ZNEPS,=V8V+)KG<J&S6
MVON]SJ64=NM=/+5U]5(NC8X86J][W+Z2-15.I7;M-JB:ZYPIIB9F>*(WKS77
M%%,U53A$1C*MWA33SWK=+<S,8H71T"V^2)_H-;)<JYM1&W3R:]-.XY=U#IF[
MGK]^(V=&?/JB8^[*C=58FYFKUV-V'WIQ^1].5=G.VSJO8BU=MT5?JVEB'K-_
M_P!ST]NG[D/68_SE/<^Z^7GG;)X\DV]O+VR/HJJW5='V=C4?3S-D<B+HJ(KD
MF3^1]0\__0[4Q>LW.":9CO3C\KQUPMS%RU7P83'+XVQ[%POV7R2S6N_V?+LJ
MK+7>*6*KH:EE50Z.CE:CF_\ ]#V+VZ*B^1>PE,OU&T[,6Z;E%RY--41,;:=T
M_NMZUU5R5VB*Z:ZYB8QC;'X6L\KV3XQ[?YI;<-O6<YJS):GS:6"GI/-JE&/G
MDZ8&/6&@<J/<J(J-1-=%1?10BL[H.BY+,18N7;O3G#=A._=NHWM',:3IF5O1
M:JN7.G.&["=^[=2_?G#25-LW VWRE\+I*%;>Z"/^=62AJ^_>WZBJV=I]Z_T5
M6\W9O<'1P[M,X_\ *'KK93-%^U<X,/!./RK'K1=:"^VJVWJU5+:RV7:FBK*"
MJ9];)#,Q'L<GY**AU"S>HO44W*)QIJB)B>Q*[V[E-RF*J9QB8QA6[F]\M][Y
MLXLENE9.RSW.V6RJFC[46H@C596Z^FQSNA?JMT.7:AF*+W62WT=O1JIIGMQO
M[V[N*/FKU-S6J.CP3$=W!9F=67MI3D9:IKSLCN-14[7/E9:UJT:U.I52CECJ
M7=G;Z$2D#UGLS=TR]3'DX_9F*OD1>MVYN9*[$>3CWMOR-+<',@MU;ME>L=CF
M8EUL=ZEGJZ77U?<5D<:PRZ>DYT;V_P#FD%U S-%>3KM1/SJ:YF8[%41A/),=
MQ%=4[]-65FCAIJGO3NGPMI\H<BMV/;)9HE=,QDU[IVVJV0.^NEJ*EZ)TM3TV
ML1S_ ,AJDOUMS5%C3;O2WU1T8[,SXL9[B0U^_3:R5S'AC".W/Z8M-\4K94T/
M&_-:N=CF17JKO=71*OD=$RABIE<W_P"Z0O3\H@^J%JJC1[M4_K37,=KHQ3X8
ME&=7+<TZ=7,_K35/)$?(Q[@.B>Q&Y:Z)JM9;$5?R(ZDUO_G7T+_;I_Y,'4[^
M7=[<>"6V.9W\"-?^J]O_ *=Q,]>?\;/UJ4EUH_(U=N/"S3C#_ 1MW_@=3^G)
MS=ZI?XNSVI^]+:T'\C:[7RRWT6-+HK89R+K,EWTR':*Y8_26:EM4]TH[;<?.
M'23U4U!(O1HU6M:B21,<_1-5^J5#(]9ZLQJ=>2KHBF*9JB)QVS-,_+$3*OY7
M6YNYZK+54Q&&,1.._#GC:\OFQ<:2EV<9133L9572]T;*.!53K?W222/5K?*J
M-1O:OH:IZ9AZ^7::=/BF9VU5QAW,98^M5<4Y/"=\U1AX7H;$T<\'$^W0/8J2
MSV'()&,T754FJ:U[/Y+7(IDZOT3&@Q''1<Y9J>]'HF-+IC]FKEF6HN!%;3+;
M=R+;WS$K&U-NJ4IU5.M8E9.Q7(GE5$5-%7T-4],AO_G=R.C?IQVXTSX49U.K
MCH7:>'&)\+/N<-XHZ/:FU6B29J5]YOU.M+3:IUNCIHI7RR(GET:JL15]-R$C
MU^OTTY&FB9VU5QA'8B)QGP=]N=;+L4Y2*>&:HY,69;2_-7M/VI7+^EJ3=T;_
M  =/_75_R;FF_P",I^I/RM-<"?\ 5_<;]4*#^U3$)_\ ._Y5_MT^"45U._E7
M.W'@?SSBPN=E-AVZ5J1T-;9ITM-SJHNQ[6.<L]'+JGD[N1'IKZ;VGSK_ )"8
MBWFZ-],]&9Y:9[DX]^'SK9E9Z-&8IWTSA/ACO3X6I,[RM_)S=G9[%*&3KMC;
M70NOD<6O3!45,;:N[JU4[-8XXT8G]$W0AM0SD]8,_EK-/T>C3TNQ,QTKG>B,
M.W".SF8][YNQ;I^CA&/8F=M?>C9VUJ\,,5/#%3P1MA@@8V.&%B:-:QJ:-:B)
MY$1$T.P4TQ3$1&Z'0HB(C"'ZGU]18Y(\B*?:.WQX_CJ15V>WB#O*9DB(^*WP
M.U:E1,W\TY51>[8O8NG4[L31U0ZT=9HTRCT5K";U4=RF..>SQ1W9XIK^N:W&
M1IZ%&VY/)''/R0TUL7QENN37)NZF^'?W.ON<J5]#C5P57RSO=HK9[@CO0TTZ
M8?2T1^B>H(/J_P!5*\Q7[9G\9F=L4SOGLU_A[_$B](T&N[5[3F]LSMBF?#5^
M'O\ $L+:UK&M8QJ-:U$1K431$1/(B(=+B,%T5:\=O8]G*K,VY:L+KXVHO[;2
MZ=4U2ZI6(C^[ZNU7=SWR)Z.AR/JST(UR[Z;#IXW,,?+Z6WNX=)S_ $3H^];G
MI/I8UX?6QYL5F]\CM$MENT60-IW6*2CG;>6U>G<>:K&[ON]ZNSIZ-==?0.K9
MB+<VZHNX=#">ECNZ.&W'L8+Y=BB:)Z>'1PVX[L.%7%P6\X3-MQVV]TCK!['0
M=2O5459/.7>:JY/)KW?>',/_ )]TO:;W1^AT8[^/S>3I*1U1_G7>C]'"/#.'
M)BLQ.JKV  *].0'(+),HR.39?9EL]7<*N=UNO-YH.VHJ)^U)*6D>BIT,9HO>
M2ZIY%T5K45SN:=9.LE[,7O8<CC,S/1F8WS/#33Q1'ZU7@B,9I>LZU<NW/9<K
MMF=DS&_'BCY9;AX^\:+-M13P9'D20WO/YX^VK1.JGMS7IHZ*EU3M<J+HZ14U
M7R-T;KU3G5OJK;TV(NW<*KW'P4]BGL\=7<C9CC)Z+H5&2CIU[;G'P4]B.=)^
MOI(Z^AK*"552*M@D@D5/+TR-5J_RE+9<HBNF:9X8P3]5/2B8XU;O"6YIB^?;
MD[?WAR4EXJXHNFE>NBK46B::*>-NOE<B3JNGI-5?0.7=0KOL^:OY:O95,1L[
M-$S$QR\BC=5*_0W[MBK95\M,S$^%,GD%DM'BVS>X%=5SMA?7VBIM5 BKHY]1
M<(UIHVL3T519.K\A%7R(7CK)FJ<OIUZJJ=],TQVZOFQX<5HUF_%G)W*IG?3,
M1VYV0T;P@LTEIVKO]_K=*>GO=[FDIY9/4L6GHX8XUDZET31).\1?^B0'4&Q-
MO(UW*MD55SWJ8B,>_CWD1U3M31E:JY_6JGO1$1X<6GMV=Y,UY!98[:+9Z&9V
M,S2.BKJZ)5C6X1QJB2SU$O\ [*D;Z"?F^S757-8D'K.N9G6[_L62B?1\,^5Q
MS,\%'AX=LQ"-U+5+VIW?9<K]'AGCXYGBI\/(EYL?L'C.S5JZX>B\9?7Q(V]9
M(]FCM%T58*9J]L<2*GY+E[7>@C;KH'5RSI5&,?.N3OJ^2GBCP\/!A9-)T>UD
M*-FVN=]7R1Q0WQ))'#')++(V**)JOEE>J-:UK4U555>Q$1"PS,1&,IB9P5E[
ML[R9KR"RQVT6ST,SL9FD=%75T2K&MPCC5$EGJ)?_ &5(WT$_-]FNJN:Q.4ZS
MKF9UN_[%DHGT?#/E<<S/!1X>';,0H>I:I>U.[[+E?H\,\?',\5/AY$O-C]@\
M9V:M77#T7C+Z^)&WK)'LT=HNBK!3-7MCB14_)<O:[T$;== ZN6=*HQCYUR=]
M7R4\4>'AX,+)I.CVLA1LVUSOJ^2.*&^RQ)@  :UWF_@BW1^U.\_I*4B]<_(7
M_P#KK^[+1U3\I=^I5X)0XX1XMC&08KF\U^QRUWN:GNU.R"6OHX:ES&K!JK6K
M*QRHBKZ"%'ZAY.Q?L79N44U3%4;XB>#LJQU3L6[EFN:Z8GYW#$3P)R4V X+1
MR-FI,*L-+,Q45DL-MI6.14\BHK8T4O\ 1IN5HG&FU1$]BF.9;:<I9IVQ13'<
MAEB(C41K41K6IHUJ=B(B&ZV%8?+7YQFW/ZEV7VUJSD_7/_+V?JT??J4'K'_D
M;7:I^]*STZPOR/')/=2R[>;;Y#1.N,*93DM#-;;!:FO3SA5JFNB?4]"+JC(F
MJYW4J:=2(WRJ5GK3J]O(Y.NGI1Z2N)IICAV[.EVHWX\>Q"ZYJ-&5R]48_/JB
M8B.';LQ[C47!C$JRTX/E.65<"PQY9<(8;<KDT62GMS9&K(G]"LLSV_DM4A?_
M )_DZK>6N7ICZ=41':HQV]^9CN(WJCEIHL57)CZ4[.U3XYEIG?BL9@'+C'\R
MN:+#:YZBQ7>>9$5?^R1-91SO1$355:E._L3TB#ZPUQDM>HOU_1F:*OW8PIG[
MLHO5ZXRNK47:MWS9[GT9\"T.EJJ:MIH*RCJ(ZNDJHVRTU5"Y'QR1O3J:]CFJ
MJ*BHNJ*AUJBNFNF*J9QB=TPO]-451C&Y#7FYEEMMNV5#BBU,;KQDETIY(Z%'
M)WB4M)U223*WRHWK1C4]-5^HI1^ON<HMY*+./SJZHV=B-N/?PA6.M>9IHRL6
M\?G53&SL1MQ;0XMVBHLVQ.!053.[GK(*JOT]..LJYIX5_+B>U26ZHV9M:79B
M=\Q,_:JF8Y,&_P!7[4V\C;B>&)GOS,QR(A[5?/7RW]6<F_F3E*T?_P#N.Y]>
M[_R5O3_\U7VZUGIUE?0"N;G#FE1<+CANU=H5U1.][;M<Z6+M<^>974]%%HGH
M]LBZ+_/-4YCU^STUUVLG1MGZ4QV9V4QX>_"D=;,U-55&6IW[Y\%,>'D?K2<"
MM:6G=4[H24U2^-CJF"*TH]C)%1.MK7>>-ZD1>Q%T344?_.L8C&_A/U/XGJGJ
M?LVW9[WC:MWJXF5>UF$5&:T&8293%;JJ"*YTCZ#S58J>=RQI,CTJ)M=)',;I
MHGUVNO81.N=3:M-RTWZ;G3B)C&.CT<(G9COGAPCNH[5>KDY.Q-V*^EA,8[,-
MG'OGA3@XP;@_"!M)89:J?OKSC*>PEYZEU>KJ5K>YD77M7KA5BJOHNZO2+_U3
MU+VW(48S\ZCYD]S=/=IP[N*V:!G?:LI3,_2I^;/<W=^,$ABRII7)S\_KNU/_
M $+W_-H#F/\ ]&WY?]__ (*/UR__  _O?\4^<0_U2Q?]2*+^T,.B9'\O;^K3
MX(7++_RZ>U'@8UNGN7C^UF)7/([U6P1U,4$GL+:WO1)JVJTTCAB9KU.U<J=2
MHGJ6ZN7L0U=7U6UIV7JNW)C'#YL<-4\$1\O%&U@U#/V\G:FY7/:CCGBA"/@Q
MC5SKLASS<6N8YT#Z9+3%6O3^OU-3,RJJ>E?38D;%=_TD*%_\_P K77>NYFK=
MAT<>.9F*I[V$=]4^J5BJJY<OU=K'CF9QGY'E[OY?N%O1OQ+LGC&128YC])62
M6U(8Y)(8I74D#IZRHJN[5'2JWH>C&?6]C?(JJXPZUG<WJVJ>P6J^A1$]'AB)
MZ,8U35AOW3A&[9';>-3S.8S^>]DMU=&F)P[T8S,\?8ALJW<(=M;#2377,LUN
M]RI;;"^IN,T?<6^F2.)JOD?)U-G>C41%5='I^22MOJ%D[-,UW[M4Q$8SNIC"
M-^/TIP[K>HZIY:W'2NUU3AMG=$?+X6K.#3J9=R<\2C1S:5UD<M*UZZN2+SR+
MIZOJZ*FI#_\ S^8]LNX;NA_RA']4L/:+O1W8;.^]G*NSG;9U7L1:NVZ*OU;2
MQ#/F_P#^YZ>W3]R&7,?YRGN?=9WSPME1/A&$W:-'NI[=>I:>H1J*K46JIU<Q
MSO2_K*HGY)(__0K4SEK5?!%4QWX\3;ZWVYFQ15P15X8\3%]K>)FT&X^ 8OF$
M.49*L]VH8W76"GJ:+NX*UB=%5"U'42N1&2HY$U7731>W74U=(ZG:?G\I;OQ<
MN8U1MPFG95^M'T>"6OI_5O*9JQ1=BNO;&W"8V3PQ]'C>'N3L'QFVGJ[10YCG
M&94M7>F22TL%,ZDJ',BC5&K)(V.A56M55T;V=NBZ>137U3J[HVFU4TW[MV)J
MW8=&=G'/S6'/:-IN2FF+MRN)GM3_ ,5A^)45#;L4QFWVN:IJ+906FBI[=/6(
MK:E\$4#&1NF:K6*CU:B*Y.E.WT$\ATK)6Z+=BW31,S3%,1&._"(C#'=MX]D+
MMEZ8HM4TTXX1$88[]W#V60FTS*S..?SL-T/^GDGMG&<JZL?YV_\ _N??A0]#
M_P K>_?^]#^]Q7,V.Y;V7-%=YEC68RQUMRE\D38:]'4E>KU]'HE19U3ZJ#4Y
M]T:]3?W47)QGBPJ^;7WI^=WGW/3[NU:F[NHKVSW=E7>GYS).,=/-NAO=N=O7
M<(G.I:662GL2R)VL=6*L<2(OIPTD2,7_ *:&UU4IG4=2OY^K=&,4_O;(^S1&
M'=9]!B<YG;N;G=NCN\U,8=UC%N^?G)^J=5[1R&K:_P#[H_>G_P#URUZ/\[W9
M^XV7S)W@RG"X\<PC$;E-9*G(*>6MO%UI7.CJ4@:_NHHH96JBL1SD>KE;ZKL1
M-415UE.O&MW\I%%BS5-,U1,U3&_#=$1/!PX\.YO]9]3NY>*;5J<)JVS,;\.*
M'B8WP9HZRGI[AN#GMQK+O5,;)<:6V,8G1(J(KF)55/?+)IY.I6)^08,K_P#/
MZ:HBK,WJIJG?%/XJL<>WA#%8ZI4U1TK]R9JG?ASSCBT53XSB.$\LL3Q7"YYJ
MFRV+(+72/GGF2=ZU2-C6H17M1J:MD<K51$3145"O4Y7+Y37;=FQ,S3373&V<
M=NS'EV=M$TY>SE]6HMVOHTU1''MX5GFY^%P;A8!E6'3HWKO5!)'12/\ )'5,
MTDII%_Z$K6J=8U;(QGLI<L3^M&SZV^F>Y."^Y_*QFK%=J>&.7@Y556'[OUF&
M[$;J;7U<SZ2]UMQAI+/32:]XR*NZHKG'T^5$8RG5%_HI#D&2UJK*Z7F,I5LJ
MFJ(CM5;*X[U/?J<\RNISE\C>R\[*L<(_>V5=[#E3\XH8)]A.S]DGJ8>ZNN7N
M6^UZJGJD94-:E*WM[=$@:QVGH*YQT;J=I_LFGTS,?.N?/GN_1\W">W,KCU=R
M?L^4IQWU?.GN[N3!)4M2=8KFV9V';_&;KEF257FMJM,77+TZ+)*]R],<4355
M.I[W*C6IK^3HFJFGG\]:R5FJ]=G"FGEXHCLRU\UFK>6MS<N3A$*TJ>GW1YE9
MJZHJ)'8WMQ8:C1--74M$U?S#$]3YQ5/8O:J^1%_,M5$7EE-.>ZU9G&?F6:9_
M=I_%7,?I$80HD1F=>O8S\VU3/<CGJ\"R3 L Q?;;':7&<3MS:&WT_JYI5T=/
M4S*B(Z:>31%>]VG:OD1.Q$1J(B=0T[3;&GV8M6:<(COS/',\,_\ B-B\Y/)V
MLI;BW;C"(Y>S+5&_._[-CWXZR7$)\D3(FU#H)VU;:2*-U,L:/8JK%,JKI*B^
M0A^L763W1-'_ *^GT\>'H[L.Q/&CM8UF-.Z.-$U=+'APW8=OC;YM%VH+[:K;
M>K74,J[;=J:*KH:EBHK7Q3-1['(J:^5%+%8O47K=-RB<::HB8GL2F+=RFY3%
M5,XQ,8PJ_P"3;;?/R:Q*'$NZ^R)_L''=5@T1?95:M4A[Q6]O7W*PZ_4Z3DW6
MN*:M:MQ8PZ?S,</+QV8]G#HJ#KW1G4[<6_I?-Q^MCL[N&"U$Z\Z"  -$[\[W
MVG9C&F52Q,N64WA'QXY97+HUSF:=4\^BHJ11ZIKIVN71J:=JMKW6+7[>E6<=
M]RKZ-/RSV(Y=W9B(U?5J,A;QWUS]&/EGL0B#M'L5EV_%^3=O>BMJI+%<'-GH
M+?(JQ37&-JZQMC:FG<4J?F>G17)];HB]92M&ZO9C6;OMF>F>A.V(W37'8\FC
MM;^#C5K3=(NZE<]IS<ST9W1Y7-3X>5950T-%;**EMUNI(:&@H8F04=% Q(XH
MHF)TM8QC41&HB)HB(=3MVZ;=,4T1$1$81$;HA>J*(HB*:8PB%;'*YLF&<@=L
MMP9F.2VI';*QTJ)KU2VFO5\[$T\ND;HU_+.6]<,<IJMC,S'S?FSW:*L9Y,%&
MZQ?_ *?/V;\[MD_9JV\F"RJFJ:>MIJ>LI)V5-)5QLFIJF-R.9)&]$<U[7)V*
MBHNJ*=3HKBNF*J9QB=L+U35%48QN5GV"HCW(YN5=XM,B5=JL=;++)51^J8D5
MIH$H^MJIV*U\[6HB^3U78<KRU49_K+-=&VFF9V]BBGHX]J:HCOJ)9J]JUN:J
M=L4S]VGH^%)#DCR(I]H[?'C^.I%79[>(.\IF2(CXK? [5J5$S?S3E5%[MB]B
MZ=3NQ-'6?K1UFC3*/16L)O51W*8XY[/%'=GBF<US6XR-/0HVW)Y(XY^2&FMB
M^,MUR:Y-W4WP[^YU]SE2OH<:N"J^6=[M%;/<$=Z&FG3#Z6B/T3U!!]7^JE>8
MK]LS^,S.V*9WSV:_P]_B1>D:#7=J]IS>V9VQ3/AJ_#W^)86UK6-:QC4:UJ(C
M6HFB(B>1$0Z7$8+HC)<>2MMM&]L&SMTQB2W-EK(Z)V45%8QL?74TZ34RM@[I
M=4E<]C$UD337\HJ=WK51:U*,C7;PVQ'2FKCC&G9APXQ&_A0->NTT9V,K53AM
MPZ6/'&,;.SNWI,R+&D;UE5J1(U>\5^G3TZ=NNO9IH6N<,-J>E5IQK912\I<K
MDPWH3%(UO[Z9(.R+V,6HZ:;HT[.CJ=%T_4T.1]5HIG6[DV/Y?_LW;NAC\WN?
M1<^T+HSJE?HOH?.^SCL^1:<===!        * ? Q_P"*+]Q/^?P+_@
M
M
M
M
M        "H'QJ_FL8#]]6U>T=\ G_P 3OFL<:?O58;[1T8&_P
M         <F]ZW1Q;97Q2\WW1S9]5'BV(;H9%57A]%#YQ4)'(RK@;W<6K>I>
MN1/1\@%P"^,!P[1/^_9BOU/8-?[N!7KSQ\4'%-_-K[KLILQC%XH,=R>HIES#
M+K^R*FGFI:.>.J9345-!-*K4DFB9UOD<B]**SN_5]2!8AX4/'W*-DN/5PO\
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M+1QK63QR/=75[)HZ>.=T<:M;"Q>M6.<LB::L0"!_"7^-=W:^V7<K].U0'2R
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MHDD16R+ Q7/<Y[FJK>MRIV:HC4U4L?5_JE:TROTU=73N8;-F$4X[\.SP8\7
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M$U7HU^H773]-N9?38RM4QTXHFG&,<,9Q[&/#Q+-E,G79R<6)F.E%,QV/T[C
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M6]/HF(G&J=\_)'8;U+"EP       "@'P,?\ BB_<3_G\"_X
M
M
M
M
M  J!\:OYK& _?5M7M'? )_\ $[YK'&G[U6&^T=&!O\
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MMBK*ZW4C$K:AC/K6U%;)UU$R)Y4[R1P&W@
M       AUC6QN;VGDQ=]V:I;=]BM=/7R0(RH<M5TU%*L+-8NA$3U2]OJBD97
MJ_F;>LU9R>CZ.9JX=NV,-V"M6-)O4:E5F9PZ$X\.W;&"8I=UE
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MXH[,1QMF$JW@
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M
M
M
M
M               J!\:OYK& _?5M7M'? )_\3OFL<:?O58;[1T8&_P
M
M     "O[EEP2HN1.X6V^\>#[ANV;W<V\J(7QYC3VQ+EYY%1RI447>P^<TOYY
M32HJL?U+JURL<UR(SI"?5,VH934[*N6.>K;&Q*J>)BQQOD1$ZW,8KGJU%754
M17+IZ:@?N                    "+O+S8#*^3.T55M)CFYK=KK=?+A3399
M<TM;KI)74-,JRI1(QM91]VUTR1O<O4NJ,Z=-'*!GNP&R&'\=MJ,3VGPJ+6V8
MY3?]NNDC$9/<:^7U=575&BKZN:35=-51K>EC?4M:@&Y0
M
M
M
M                                            "@'P,?\ BB_<3_G\
M"_X
M
M
M
M                  J!\:OYK& _?5M7M'? )_\ $[YK'&G[U6&^T=&!O\
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M+35U#4Q5E%61,GHZR![9(I8I&HYDD;VJK7-<U45%1=%0#Z
M -07WD)L'B]WK\?R;?# ,=OUJE6"Z62YY+:J2LII41%5DT$U2R1CM%\CD10-
MIVZXV^[V^ANUIKJ>Z6JYT\57;;E22LGIZBGF:CXIH98U<U['M5'-<U51475
M/BR#(L?Q*S5V195?;?C./VMB27.^W6JBHJ.G8YR,1TU1.YD;$5SD35SD[51
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M>;3<8DFM]TH9F5%-/&[R/BEB5S'M7T%1= /0
M
M
M                                    "@'P,?\ BB_<3_G\"_X
M
M
M
M
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MFD\COO>W_P#24@%<7@B?P3;V?;=0_I! +N0 '-5P,_C2=X?U5W$]LI .E4
M     "JGQ+^<]TXSX]9]L]KJR&'>+.J1U<^[R1MF2Q6=7/A2K:R35CIYY6.9
M"CFN:U&/<Y/K.H(!\:/"QW#Y%V>FWJY'[B7K%J;.&>R=#;=%KLEN4,[4=%6U
ME56K(V!)6JCFM>R1[FZ*Y&=@&_MU/!-P5<8KJC97=;(:?+J6%TM#;<P2CJZ&
MMD:Q=(%GH::C?3];M-']$G3Z+5\J!I;PXN76Z&S6]4'$/?:JKGV*YW>;&K)!
M?*ATE5C5_@ZH8J&*1[GZTU3*Q(6QM56MD<Q\>C7/Z@Z/0
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MCV.14 ]0
M
M
M       4 ^!C_P 47[B?\_@7_
M
M
M
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MWF'V1N=5+5S]VR.EZ6=Y,Y[M$U71-0*WN#/\:GNW^KNX_P"GZ@#8?CD?^/\
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M%3)W,;*.6F<^)8V='0G0NB::>@!F0
M
M
M                            H!\#'_BB_<3_ )_ O^
M
M
M
M
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M_JV=/GL]^L<-0B)ZKNHJ6J=%JOI:R/T_+ L(\0CYF'(+[6T_3=.!"CP2_P"
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M?U#J?;&K FJ
M
M
M          * ? Q_XHOW$_Y_ O\ @
M
M
M
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MFODMJS6S7"X;=5[*JU5SJ=G5)=,8K94GM]RHG2=$<DL+HXU>B+]<V:'J1>U
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M;&*[1RN1 Z&L_N]'?O#:RJ]4$[*FCNG'FHJ8)F+JBI)C"KZ'HHO8J>@H$&_
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MTL]5-4)$Z2)SF*YK941W2Y4UU350)/
M
M
M                             "@'P,?^*+]Q/^?P+_@
M
M
M
M
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M@2!M5KH;':[;9;7!YK;+12PT5NINIS^[@IV)'$SJ>KG.Z6M1-7*JKZ*@?>
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MN<+'M75JNHI)4I).E?)WD+M/+Y0)ZL8R-C8XVHQC$1K&-31$1.Q$1$\F@']
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M5E=;J1B5M0QGUK:BMDZZB9$\J=Y(X#;P
M
M
M                                4 ^!C_Q1?N)_S^!?\
M
M
M
M
M    5 ^-7\UC ?OJVKVCO@$_^)WS6.-/WJL-]HZ,#?X
M                                      (Q<M.+^(\L=IJ[;C(ZM+%=
MJ>HCN.'9C'3I4S6JOB[.\2)7Q]Y')&KHY(^MO4U=45'-:YH9EQWVQRG9C9W"
M=KLNSQ-RKCA-&MLHLL6@6W/EH(7N2CA? M15=M/#TQ([K[6M35-=54-U@
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MH[;;Z9C8X8*>!B1Q11L:B(UK&M1J(B:(@'V@
M
M
M
M                       "@'P,?^*+]Q/^?P+_ (
M
M
M
M                                                         J!\
M:OYK& _?5M7M'? )_P#$[YK'&G[U6&^T=&!O\
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MMNV^[V(9M=EB=/["VB\4=37)$WZY[J1DBS-:GHJK -O@
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M/ND^YQ[9[FXKN%)9&PNO,>-WBBNJTC:A7I"LZ4DLO=I)W;NGJTUZ5T\B@;%
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MT SFQ7^Q91:*#(,9O5!D5ANL23VN]VRIBJZ.IB551'PSPN?&]NJ+VM54 ]8
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M(<<O-#='TS)5<D;IFTDTJL1ZM5&J[371=/(!GP
M
M                  !0#X&/_%%^XG_/X%_P
M
M
M
M                                                  !4#XU?S6,!
M^^K:O:.^ 3_XG?-8XT_>JPWVCHP-_@
M                      "KSQ?/F<73[;;%_3R@5A\,_#)QCE-LC0;LW7=B
MZ8A5UMWN%M6S4EKAJHVMHGM8C^]DGC55=KKIH!)VY^!UC;Z29+-R'N5/7]*K
M3NK<=AFA5WH(Y(Z^)VB^FB]GI+Y (*;6[@[W>&?RI3;G-+U,_"8KG21Y[C]/
M-++9KO9*_I1MVHXGM[)8XU[QCVM:]',="]=.MH'68BHJ(J+JB]J*@'^@
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M/NA<4N>YNVM#3U5NR*:3JJKY97/[A9JA%[7STLBQLED_-I)&YVK^MRA;2
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M/^I&._IBO Z(0 ')WXNGSS,C^UFP_I90.@3@%\S7CW]JL7]NE F
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M
M                                         H!\#'_BB_<3_G\"_P"
M
M
M
M
M              *@?&K^:Q@/WU;5[1WP"?\ Q.^:QQI^]5AOM'1@;_
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M6V_TM%*J.D@;<*:.H[EZIV*Z-7]*Z>B@&>@
M
M          !0#X&/_%%^XG_/X%_P
M
M
M
M                                          !4#XU?S6,!^^K:O:.^
M 3_XG?-8XT_>JPWVCHP-_@
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MZUW'78'&L=N-W<MOI<GOM(ZYY!<(GO18V]S;W4S6.<Y$7NEDG37T5 A[RJW
MYV;I8/8LOY-VK)K/MJZ^QPXK176R0X_0I<Y::H?$L%+W%//*O<,FTD>C_4ZI
MU]J 6,>!JCO8WDNJN7H6IQ%&M]!%1EXU7\OL J;YP_.]Y%_;U=O[<H%U_B><
M3/A4V+Q3?W"[9WV?;48[2MRFG@8G>7'&VQ-EE<OHN?0.<Z9O_NW2^548@%%6
MW7('(\%V7WSV+D[RX85O)16R1*+J[*"\6NYT=9'61HJZ(DL%.^&1$35WYTNO
MYWHH3Q\%WYUN7_>QNWMM9P,W\;?^&W9[[1Y?;*H BIP2X-91RVS!;K=_.<=V
M7Q6K8S,LK8G3+5S-1LGL9;U<BHZ=[7(KWZ*V)BHYVKG,8\-4<P..=[XJ[\9)
MMZY]2_'^\;>=N;^]='U5GJ'N=3/ZVZ?GL#FNAD5$3\\C<Y$1JM Z2/#EY<1\
MGMF8;?D]P;+NYMI'!:LZ9(J)+<(5:J4=V:U/+YPUBMET\DK7]B-<S4+#  %$
MFXG@OW#.]P,YSAO(FGM;<RR"YWQML7%7S+3I<:N2I[E9?99G7T=YT]72FNFN
MB>0"DKD9LW)Q]WJSS9V7(6Y7)@]73TKL@92K1)4]_20U74E.LL_1IWW3IUKY
M-?J 6[6KP0KC<[9;KDG).FA2X4L-2D/V)/=T=ZQ'].OLPFNFNFN@%X^R&V[]
MGMH-M]K)+PF0/P#'Z&QNO;8/-4JEHXDB[Y(%DE[OJTUZ>MVGIJ!M,#G_ /&L
MWQU=MEQXM%8OJ=<US6*-R^CWM':H7JG9_P#G$CF+_P"Z=IY% K;X4<OZ+AWE
M&;9BS:J#<>_Y5:Z>SV^MFNRVM;?2-F6>J8W2CJ^\\X>R%5^MZ>[]'7L!S7Y?
MT/,3)\)S!^U-/MQ?\4ME39[A70W9;HZX4CYDGI8W:T=)W?F[WS*GUW5WGH:=
MH3Z\%C?3V)RW</CU>*OHH\L@^RW#(GJB-2XT3&07&%B:ZJ^:F2.333L; X"8
MGC,?-+L7WQ;/^D+F!$3P._\ 6[D/^I&._IBO J?Y4W&ONW)OD+7W1KHZZ7<C
M*&S0O[5B[NZU,;8O_N;6HU/R .UW#;'9\9Q#%L<QZGBI+!8+116ZR4L#$CBC
MI*:!D4#6,3L1$8U$1$ Y,_%,L5GL7-C=-+/'% V[TUDNESIH4Z6LK*FUTRS.
M5$_-2JG>N7T5>J^B!*CE9=+E2>%#P[MU+))%;[M>[<ET5CE:V1(**[R11/T7
MM:KO5Z+Z+47T /8\$'%L?K\]WXR^LIH9LEQNRV2W6*=Z:R14UUGK'UJQZ]B:
MK1PHJ^71=/(JZA>!R7Q;'LTX][U8WE5/#46.NPR\R52SMZF0OIJ22HAJ$])T
M$L;96KZ#FHH')#P8NURLO,#CM66ISVU4V;6VAE6-=%\VKW^:52+]18)GHOU
M.NGD)M]MKN?LSN%A^[LE/1X!66>HJ+]>ZAS(_8ME(Q9VW&.5Z*D;Z5S$E:Y>
MSU/:BM544.':Z04-+<KC36RO6ZVVGJ9HK?<UB= M3 QZMCF6%RJL?6U$=TJJ
MJFN@'3MX.N&;16WCW=<UQ"M9=]S\BNTU'NC-.QK*JW+2O=YC01M155*=87).
MUVOYX][M>UG0P(X>./=+DE9QPLO>2,M#H<GK5A1RI'+4HZV1HYS==%=&Q51%
M7R=:^FH&UO!)Q;'X-FMW<UBIH5RJZ9HVR5U9IK,EOH+=2U--'JOD:LM9,O9Y
M53M\B:!,+Q+<6Q[)^%^\C[_3PODQJDHKW8*R5NKJ:X4U;"R)\2_F72-D?#K_
M #LCD]$"A_PE+M<K=S3PRCH7/;2WZP9!0WE&KHBTS*"2K:C_ $T[^FB7\G0#
M!/$X^?+OM_A%A_>_;0.EK@MB]MQ'B#QYMMLI64L-?A5MO=0UB:==3>8DN51(
M[TU?)4.55 AEXU7S6,"^^I:O:2^ 1J\#=R>S?))NOJEH<55$^HDEUU_F@29\
M::5K.*V$QJOJIMT+4UJ?D6>\N7^8!&'P./\ 6'D?^IV+_P!MN8%1O*#YRW(?
M[YN6^W-6!VR899;/C>'XICV.T\5+8+%9Z&WV2F@8D<4=)30,B@:QC>QK48U$
M1$ Y-O%.L-GL/-?=%+/'%3MO%+9+I<J:%.EK*RIME.LSE1/S4JM[UR^BKE7T
M0+3LVK[A<O!:HJBYQK%4QX#C]+&URZJM/2WVCIZ9W_G0QL5 *_O!P^=U7?:#
M>OTS0 :9\3BXUUQYO[W^>O>Y*&>RTE'$]=4C@BLE!T(Q/01=5?\ DN5?1 Z7
M>#EHM%EXA<=J2R014]'/@UJKYV0L1C5K*^%*NL>J)Y7.J)9'.7T555 S;(.,
M_'G+LXN>XV6;-8AEF<W9*;V3R"]6NFN,TBTL+(('*VJ9(Q',CB:U'(U%T:GI
M 0!\8FWT%JX?8Q;+714]MMU!N!98*&WTL;88(8F6^Y(V..-B(UK6IV(B)H@$
M4/ [_P!;N0_ZD8[^F*\"&?BJ?/CW<_P3&_:&@ Z->!ECH<?X=\>J*WT[*:&I
MP^CN<K&(B(Z>Y*ZMG>NGHODF<Y5^J!SF^*K0P4?-_=:6%B,6X46.U,Z)V:O]
MA**)5_+2- .D+@^JNXA\=%5=5^P6TI^4D*(@$J
M
M               H!\#'_BB_<3_G\"_X
M
M
M
M                                               J!\:OYK& _?5M
M7M'? )_\3OFL<:?O58;[1T8&_P
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MVW7%U*]7)#307*H;34<3))$:KHXXW,C:]4[434"?7CE_^(<9_P#!\O\ Z>S
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MM33 =&G!WYH7'7[1K5_:4 E2
M
M% /@8_\ %%^XG_/X%_P
M
M
M
M                                 !4#XU?S6,!^^K:O:.^ 3_XG?-8X
MT_>JPWVCHP-_@
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MOJRT9ACTL\M@KY;Y=JEE(M3!)32HR&:K<QZ.BE>W25'^7T^T#/<-X?<=-O\
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M48[F>,[+QT&1XI<::[6&NEOV05;(*RCE;-!*L%5<I89.A[4<B/8YO9VH!-X
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M[5WTU1YO2P-Z8X^^J'RROT3T7O55]%0,J
M
M         "@'P,?^*+]Q/^?P+_@
M
M
M
M                                         "H'QJ_FL8#]]6U>T=\
MG_Q.^:QQI^]5AOM'1@;_
M
M
M
M
M                                                           %
M /@8_P#%%^XG_/X%_P
M
M
M
M                                  5 ^-7\UC ?OJVKVCO@$_\ B=\U
MCC3]ZK#?:.C W^
M
M
M
M
M                                                    H!\#'_BB
M_<3_ )_ O^
M
M
M
M                         *@?&K^:Q@/WU;5[1WP"?_$[YK'&G[U6&^T=
M&!O\
M              #G6YE;];W8OXCV.8!C.[F7X[@SK]@E-)A]LO-926U\5;YD
MZI8^EAE9$Y)ED=U]35ZM=%[ .BD               !4YX@7B/P<:JV3:7:B
MCH\AWCJ*2*HO%UK-)K?CT-0G5$DL+519JJ2/1[8W*C6-<Q[^I%1C@@'B_&_Q
M3^5%O9GF4;J7S";1D#(ZBWT^4Y'6V"GG@D;U-EALMHAD2!BHJ:=5-'KY414[
M0,9SVU>)GP&DMV>WS<B]93@=--%35%R2]5.4XRCI7]+:>KHKCI)3=XJ(U).Y
MC[7(UDO6N@%V?"/F)C?+W;6>^1T<5@W$Q%:>CW&Q2)7+#!/.UZPU=(YZN<M/
M4]T]6(Y5<Q6N8Y7=*/<$T@                      ')#S&Y0\D<9Y2[[X
M]C>_6?X]8+)F%QHK/8[9D5QHZ.EIX9.B.*&"&=C&-1$\B(!=OX9_+>7DELW]
MC.9W9U=N[M8R&WY145#U=472WOU;0W15<JJ][FM6*=VJKWC>MVG>M0#;'B%9
MCE> \.]Y\LPC(KAB>46JFM"6S(;5424E93><7J@IY5AGB5KV*Z*1S=6JBZ*H
M%3OA*[\;W;G<E<IQ_<?=W,L\L5-MY<ZZGLV07NNN5*RJCN=JC9.V&IFD8CVL
MD>U'(FJ(Y4]%0.C$ !2-XD_B+9OLMF51L'L94T]FRZ@H8*C/LYF@945% ^NB
M944U'0,EZHFR+ ]LDDCV.T1[49TO17(%44>]7B)U>.2;TPYYO=-@L".?+FT4
MUZ^QYK&N5KGJK4\QZ$<G2KNGI1>Q5U[ +1?#=\1W/-U\[MVP&_%;#?[]?*6=
M=O\ /64[8*NIJ:2)]1+17%(4;$Y701N='*C&KJSI?UN>BH%BG-?E5:N)6S=7
MG*T4%[S*^5*6?;['9W.2*IN$C'/66HZ/5=Q3QM61^BIU>IC1S5>CD#F8N/+3
MG9OAD%XN]AW3W-N5511OK:^T8%-<:"CH*;55ZG4ME[MC(V)V(^1%7L]4Y5[0
M):<)O%!W9Q#<+&\!Y!Y?-GFV.2U<5MERN\JUUTL4T[DCBJWUFB/G@1RIWS9E
M<Y&^K8Y.E6/#I)S7,+!M]A^3YUE-:ENQO#[75WB^5JIKW=+1Q.FE5K?*YW2U
M>EJ=JKHB=H'*KO=XDG*[D!G,UIVQR.^[<8U<JSS3#<#PGO(KM,CGJV%)JRD;
MYY/42(J=38WM9K]9&GE4,0QOFMSLXW9C04.9YOFZU]N<RKK\ W0BKJI:JFEU
MT;-'=42L9&_1>ET<C%[/4N[ .G/BIR,QSE+LSCVZV/TBVFJJ9)+;E>.ND[UU
MLN]*C%J*;O>EO6WID9)&[1-8WL54:[5J!(T !AF?[B81M7BU?FVXF34.(XI:
MWPQU]\N$G=P1OJ)6PQ-541557O>C41$ P[:OD)LKO?47JEVFW&M&=U&.QP2W
MN*UR.>M,RI5[872=36Z=:QNT_( W(  _.66*"*2::1L,,+5?+*]4:UK6IJKG
M*O8B(G:JJ!SB\SO%CSF]9->MO.,-VCQ7#+1/)15FYT<4<URN\D3U:^2WND1\
M=/3+IZAZ-65Z:/1T:+T@5RT=_P":NX-%+FMNN^]>9VQBNJ)<JHYLBKZ9G:O4
M_P ZB5[&HBHOYH#;W'WQ)^3FQM]MZW?-KCNSA,<C6W?"\NJY*Y[X4714I;C/
MWM53/:FO1HYT:?FHW(B(!U8;/[KX=OAMMB>Z>!URUV,Y?1I542R(C9H)&N=%
M/33M151LL$K'1O1%5.IJZ*J:*!R>[3<J^35TY#;9V>Y<@MPZ^T7'<2S4=?:*
MC)+E)2S4TUVACD@D@=.L;HW,56JQ6]*IV:: =A@         !Q\<D^57)JR<
MBM^K)9>0.X=FLUEW$R>WV>T4&27*FI:6DI;K4PP00PQ3M8QD<;$:UK41$1 .
MP"E574U.YRJYSHF*YR^555J ?N         K9\4_,]T,&XTVN[;2Y'D>+Y-4
MYO:Z2HN6+U%32URT;Z2NDDC[VD5LB,5\;%=HNBZ)J!&+PB=R=]\\R;>^'>/-
M\WRVEMMLL;[#%EU?<*QD$DDU8DRTZ5SW(U7(UO5T^71-0+PP  #R[W=Z/'[+
M=[]<5>VWV2BJ*^N=&WJ>D--&Z616M]%>EJZ(!1GBWBHYQOWRKV9VQVNQV/ M
MIK[EE+07FHN<<-7>[O2R=2.;-_7(:1B^7HB5S]4_KVBJT"^
M
M
M                          4 ^!C_ ,47[B?\_@7_
M
M
M
M
M!4#XU?S6,!^^K:O:.^ 3_P")WS6.-/WJL-]HZ,#?X
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M;!6T^*TN/5E_O59E.)KCER@C8]D%(E&L%/01N62>5J*DD3]6->J:*FH%U0
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M4>Q9)-7==0_MU\F@%A@
M
M                                                       !0#X&
M/_%%^XG_ #^!?\
M
M
M
M                             5 ^-7\UC ?OJVKVCO@$_P#B=\UCC3]Z
MK#?:.C W^
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M>J(G4K8T:BKHB)J!Z
M
M                                                      !0#X&/
M_%%^XG_/X%_P
M
M
M
M                          !4#XU?S6,!^^K:O:.^ 3_XG?-8XT_>JPWV
MCHP-_@
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ML)K,*QO<?:1,#S"VQW?%\NQB*UWRW2=B24]12M8[I<G:UR:ZM<G:UR(Y.U$
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MUBN71$ MN\;C:ZX>RFS.\])1NFMCJ.KPV_5K6+I!+%*ZOM['N_\ >I+5:?\
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M;P
M
M                                      !0#X&/_%%^XG_/X%_P
M
M
M
M
M          !4#XU?S6,!^^K:O:.^ 3_XG?-8XT_>JPWVCHP-_@
M
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M+OD:8_GUB^$GX1_LXN%%7^=>PWL/YKYG%)%T='GU=WG5WFNNK=-/(H$H=W\
M^%?:C<G;'V6]@?A"QBZXY[.=QYUYG[)TDE+W_<=Y#WG=]YU=/6W733J3R@1>
MX/<+?D:6#/K'\)7PC_9S<**N\Z]AO8?S7S.*2+HZ//J[O.KO-==6Z:>10(J[
MCX)P1\3#/+K9\2S>[8OO[B=OG?<[I16NJH*N>AM\S*14KH:ZF935;89)6-3H
MD;,B:)U=VW1 P?#O!+VVL-[9=MQM];OEF+T+_.*FRV^T0V)7Q1KUJR>LDK:[
M1BHBH]6,8NGD<U>T"(OAKVC';UXBN57/;RE9#@6/1YI=,9AA5[HX;++.ZBH$
M:Z15?THRKB:BN77T^T#J#  :%Y!\:]I>3F&MPS=:P+<:>DD6>QWVC>E/=+9.
MY$1TM'4]+^CJ1$1S7-<Q^B=;7:)H%.&7^!]7I7UD^ [_ ,"VU\BNMUNO]C<D
M\3/0;+54M4K9%3^>; S_ *(&9[6^"5BEJO5!=-W]Y*K+[13JCZK$\>MGL6D[
MFJBHQ]PFJ:B3NU\CD9"QVGUKVJ!=3@N"8AMEB-BP3 [!2XQB6-4R4EELE&BI
M%#&BJY>URN<]SG*KGO>JN>Y5<Y5<JJ!61RU\*C N0F=73=/ \WDVKS;(YDJ<
MLHWT#;A:KA4HWI=4MA9+324\\BHCI7HY[7KZKH1[G.<&AK)X/.?Y/76^#>[E
M1=LEQ2W3)*ECML-74SO1J='YS/<JJ2*G=T=B.[B31.S30#;N4>$;A=)NQ@.Y
MFQVZ<FS5-M_["U=!C\EEDOTD]TL]1W_G\E9+=:5W5/TLZV]WIJBJG8[I0-]\
MY>"7RT*C;.?X4_@V^#J.[Q]'L'[,>>>RJT:ZZ^R%#W7=^:?T75U>AIVA-[",
M;^PW"\1Q#SWV1^Q6RV^S^R'=]SW_ )C31T_>]WU/Z.OHZNGJ73R:KY0(0\Y>
M"?RT*C;.?X4_@V^#J.\1]/L'[,>>>RJT2ZZ^R%#W7=^:?T75U>AIVA-W",;^
MPW"\0Q#SWV2^Q2R6^S^R/=]SW_F--'3][W?4_HZ^CJZ>I=-=-5\H%3/(WP@=
MN]S<NN6>[.9S)M#=[Q5/KKIC,M%Y_:%JI'=;Y*/NYH):3J<JN5J+(Q%[&-8W
ML0-6X/X+E179);[UOEO]5Y=:J1__ &RQV6BE94U4;7*YL?LE6U$JQ-557J1L
M"KVKTN:OJ@+J\<VZPC$L"MVU]@QJAH<!M=I]@Z7%^[22E6@=&L3X9&OZN\21
MKG=XK]5>JN5RJJJH%.F\'@P8G>,GJ,GV)W7JMM::>=U3#B=VI)+C!1R.=U(E
M%713PSQL9^9;(V1W_O ,?PCP6I*[(J&];X;_ -;EENIVM;66>R44D=5.R/3H
MB2Y5T\ZQL1.Q42!5T^M5OE NKQ+;[$]O\%M6W.#6:FQC$[%;EMEEM5*S\[@B
MZ53J75>I[W.<KWN<JN>Y5<Y5<JJ!!'A%X>_R-\PS3*_A=^$;[,+/#:?,/8#V
M(\W[JH;/WO>>R5;UZZ:=/2WT]0+(P      4J[X^#[\,V[VXNZWRA_L;^S^^
MU=Z]@?L2\\\T\Z?U]SYQ[-0=YT^3J[MNOI(!<U:*#V+M5LMG>]_['4D-+W_3
MT]?<QHSJZ=5TUTUTU A1S9X-XGS)L>),J<G^#[-<-J9/8O-(K<ES<^WU#?S^
MAFIO.:3K:Y[6/8[O/4*CM$]6[4-1<+O#9^2#NM=]SOAG^$/V5QBKQSV$^QWV
M)[OSJKHZKO\ O_92MUZ?-.GIZ$UZM>I--%"T0 !"CEGP2V;Y;4U-<\H;58GN
M)::1U'9-PK0C/.6PZJ]D%; _U%5"QRJJ-<K7MU=T2,ZG:A5A)X'F:)=&10\@
M[*^RK]?<'V"I95)^13)6.8O_ ,9 +,.'_A];2\27RY+05U5G^Z5;2R4=;GUQ
MB2F;#3RJU9(;?0LDE93M?T)U.<^21>U.\Z%Z0);;I;78/O-@F0;;[C6*'(<3
MR6#N;A02ZM<US51T4T,C='1RQ/1'L>U=6N1% HSS;P0;DM[J9=N=]J5N.32J
MZCH<CM3UK:>)5^L?44DO=SN1/S211:_SJ 3$X@>%YMSQKRFBW+R_*)-U-Q[4
MCG8[4/HTH;7:I'MZ5F@IEDG?+.B*J-E>]$;KJV-KM'(%H[FM>US'M1S7(J.:
MJ:HJ+Y45 *:.0/@X[8;BY+79;LYG$NT$UUEFJKIB4]![*6A9Y7*]5HD2HIY:
M1BJJ^HUD8G8D;6-1&@:AV[\$."GO%!6[J;Y)<;)3SH^X8]C5I=!-51(OUC;A
M55#DBU]'_L[OJ*GE N[VTVSP;9[";%MWMQCU/B^(8Y$Z*UVFG5[D;UN62222
M21SI)))'N5SWO<KG.5550,[        @CRL\/C8_E54KDUYBJL%W*9$R%N?6
M-L?>U+(TZ8V7"E>G=U2-3L1VK9$1$:DG2G2!6'4^![G+;@D=)R L4]JZU1:R
M:QU,50C?07N&U4C=?J=[^6!,CC;X26RVR^06W--Q,BJMZ,LLM5'66."KHVVR
MRTLT3D?%(Z@;-4NG>QR:IWLRQK_U6H%L0%'>%^#+]B&Y>)[B?*0]D?L7R:@R
M/V'^P_N>_P#,JQE7W'?>S;^CKZ.GJZ%T\O2OD O$ H\QKP9OL=W-Q_<;Y1_G
MGL%D])DGL-]A_=][YK6MK/-^_P#9MW3U=/3U]"Z>7I7R 7&[C;<X7NUA60;>
M;A6&GR7$<GIEI;O::E%T<W5',?&]JH^.2-Z(^.1BHYCD1S51410*/]Q/!$IZ
MB\5=9M5OA['6.=[G4EBR:UK43TZ*NJ,6NI)HTE1$[-5@:OY(&8;,^"MA6.9#
M0WW>C=*?<"V4$D4Z8;9*!;72U#XW=2QU=7)//,^)WD5L;8G?T: 7;VNUVVQV
MRWV6S6^GM-HM--%1VNUT<38:>FIX&)'%#%$Q$:QC&HC6M1-$3L J:Y.>$?M9
MO/E-US_;#+9=G\GOL[ZN^V9M"VX62JJ9%5TDT5.V6GDI7R.55?T/<S7ZV-JJ
MJJ$7,;\#W('W"%V7\@+?36N.9JU$-GL4LU1+"BIU-;)45<38G.3L15:]$7MT
M=Y +HN/7'3;#C)@$&WNU]JEI;<LRU=XO-<]L]QN=6Y$:M163M9&CG=*(UJ-:
MUC431K4 JRW3\&?X2]SMQ]Q_E'^POP@91>,D]AOL/\Y\T]E:V:L\W[_V;B[S
MN^]Z>OH;U::]*>0"Z._XQ9,KQB\8?DMOAO./9#;9[3?+94-UBJ:2IB6&:)[?
M2>QRHH%)5C\%VXX;FELS;!.5=7C5SQN[QW?$ZA</;45-%)33)-2]<R7J)LKF
M=+4<O=M1W;ZA$7I B;XT+9V<H-O654K)ZINT]H2IGC8L;'R)>;WU.:Q7/5J*
MO:B*Y=/34#.>/?AE83RDXD;3;HXWF=1MSN;7OOL%^JYJ=URMET927JNIX%E@
M66)\$C(HV,ZXW=*M:FL:NU<!N;:?P3;5;,DHKIO-N\F38Y12MDGQ/&Z&2B=6
MHUVJ1RU\\SGQQNTT<D<76J*O3(Q=' 7H6"P67%;'9\9QRV4]EQ_'Z*"W62ST
MC$C@I:2FC2*&&)B=C6L8U$1 (&<L/#@V3Y272HS1]15[;;H5$;65F:6:*.:*
MX=W&D<2W*AD5C9UC:U$1['QR*B(USU:UJ(%<+? ]S=;@D3^0-C;:M4ZJU+%4
MK4(FO:J4_G:,UT_]Z!:+Q*X#[-\2VU%[L"U.:[D7&G6FN.X-X9&V:.%WU\%!
M3LU92QO_ #6CG/=Y'2.;HB!F',SB[\KG:6AVN^SGX/O,LCH[_P"SOL9[+=7F
ME/4P=QYOYW1Z=7G.O5WG9IITKKV!J+@[P(^1E=]P[K\*_P )'V>T=NI.X]@O
M8?S3S"2=_5U>R%=WG7W^FFC=-/1U[ TSRJ\*SY36^.7;S_#O]A/V50VV+[&_
ML7]DNX]CZ"GH=?.O9>EZ^ON.O^M)IKIVZ:J%E&RNW'P/[2;<;6>S/V1?!_CU
M!8?9WS?S3SOS*%L/?>;][-W?7TZ]/>.T]-0*W^6'A9_*?WMR/>/X=?L'^R"D
MMU+]CGV,>R?<^84D5+U><^RU)U=?=]6G=IIKIV^4"QG9';%NS>S^W>T[KRF3
M,P*PTED=?'4WFB5GFT?0LJT_>S]WU?SO>.T]-0*;MW/!2H[WF%XONT6[]/B^
M-7>L?4TV(7RUOG6W-E<KW0P5E-,WO(V*ND;70M5K=$<]R^J4+ N"_#NLX=81
ME^+UVX3<^JLQNL-UJ'PVY;?!1OAA[A61HZHG=)UHB*KEZ?)IT^B!.0
M
M
M                               H!\#'_BB_<3_G\"_X
M
M
M
M
M   J!\:OYK& _?5M7M'? )_\3OFL<:?O58;[1T8&_P
M
M     *'N1GAG;XXOO9=-_P#AKF<5FNEWN<]Y^QI;B^U7*W5M:KGU:4=7)^<3
M4\SWOUCE>S1KN[T>P#6N3[*^,GOC:*G;G<B_2V?#;JU:*\S5%WQ>VTD].]%:
M]E4_'^JKGB<U='L5CT<G8K5\@%F?!7@UCW#[%[O55UWAR_=3,HX699E$,;HZ
M6GIX55[*"@;)ZM(FO7J>]R(Z5R-<YK4:UK0GP
M                                                     "DWQ(.!
MV_?*#?+%\_VMI[!+C]IP:AQ^K==+EYG-YY3W*YU3T;'W;]6]W51Z+KY=?2 G
MYP:V:S38#C)M]M3N"RBCRS&YKR^Y,M\_G-.B5UVJZR'HEZ6]7YW,W7L[%[ )
M;
M
M                                                     "@'P,?^
M*+]Q/^?P+_@
M
M
M
M                         "H'QJ_FL8#]]6U>T=\ G_Q.^:QQI^]5AOM'
M1@;_
M
M
M
M
M                                           % /@8_P#%%^XG_/X%
M_P
M
M
M
M                  5 ^-7\UC ?OJVKVCO@$_\ B=\UCC3]ZK#?:.C W^
M
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M&#87(\EN]7?[_>L'LU7>+U<)GU%555$E*Q7S3S2*Y\CW+VN<Y555[5 D2
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M(C6H@&<
M
M                                     % /@8_\47[B?\_@7_
M
M
M
M
M         %0/C5_-8P'[ZMJ]H[X!/_B=\UCC3]ZK#?:.C W^
M                                                         "K_
M ,6W=JOVWXI5V-V>:6FN6[E[I<7FJ87=#H[>C)*VN[4\K964Z0.3T6R. UQX
M/7'VR89L?4[\W"@27--V*JKI+77RM3KI;%;:EU,V&+7M;W]3!)(]?S;6Q?SJ
M*H7#@::Y!;-6'D!LYGNTN0=U%3Y=;):>VW*6+O?,+@Q.\H:UK=6JJP3M8_1%
M3J1%;KHJ@:"X0<,W<-\6R_'UW.K-PG9I5T=PK('T#+=0T=331R1O?31)-42*
MZ5CV->YTG:D;-&M[0*B.#/\ &I[M_J[N/^GZ@"?GB;<Q]XN*,VR\&U#K)&F=
MLR"2^R7>A6M=_P#0Q;<D"1?GL:-3_M3^KL77L\FG:%BV#YHRNVBP_<3+[A26
MQE;B%OR+)[I*K:>DITEH(ZNJF<KEZ8XV:N<NJZ(@%'FX_BE\A=ZMSI-LN%6V
MZ55,V2ICMEWJ+<ZZWBYPPKIY\E-)TT]% B=NDS7JB*BO<Q5Z$#!\CYG^*'Q;
MK+1?^0V'Q7O$[G4MA1M\LMKCHI%7U:T[+CCR0LAF<S7H21SE[%7H=TN0"[#B
MSR>P/E;MA2;B86V6V5=-,M!EN)U3VOJK5<&-1SH7N;HDD;VJCXI$1$>U>U&O
M1S&AS*T/(:LXO\Z>0&[5LQR'*;O;LPS^W6>U5,SH:;SFON57#'+.YB*]61Z]
M2M;HKM.GJ;KU($Q+KR,\82DQR3>>IQ&NMFW;:?V4EL[,8LRPQ472DJR/HWQR
M79L2,757N=V-]4KNS4"Q3@/X@%IY;T5QPS*[+!B>\6+6]MPNM#1N7V-NM&DC
M8GUE V1[Y8UC>]B21/5W3U-5KW(JHP*RO%%_C MFOU"P_P!O*T#H+WEW:Q'8
MO;',-ULYJ7T^-X=0K5U<<*-6>HE<YL5/2P->YK5EGF>R-B*J)U.354350*)J
M/GMXAO*[(K_'Q1VR@QS%[/*C$DHJ"BN$E,UZ>H9776]]-"LST]4C&QL73\RJ
M(KE#$LHYO^)UQ8O-HFY#8W!=+1=)T;3QY#8[;%0U2-U62"GN6/)3PI+THJZ*
M]RM['*Q6^4+VMD>0>&[U;#X[OW0/2R8Y<K147*_TL\G>NM<MO[QMQ@E>UK5=
MW#X7HCNE.IJ(Y$T<@%,-U\1'FOR?W&R;%.%^W<=%C%D5RT5<EMI:VY)2N<YD
M-5<JNYO=;Z9TW0JLC5J:=K>J3IU QR_\XO$MXG7JPS\F<(I,AQZ\3=$3+Q;;
M;30U2,U62&ENN.]-/'/T]J(])%1/5+&J 6L9UR#W/W1XC6+?'A[C+<JS;,?,
M);+CMPABGDIFI5K3W2"5CIX8UDIGQ21JO7IJFK=>P#G$XW9;RJQ_E!F60;+8
MC!D>_E2N0)E-@J*:"5D;IJM'71>Z=-#&WHF[/4O[/0U Z$\[YDWGC)Q4P'<S
MDGCS5WSRBGDI&;8T3HJ.6LNC)9%>U%8M0V""&'H=+(G6C>IJ(BO>UJA6ECG+
MSQ5>2]+<,PV'PJ*S87#5S-IJFRV2UK2*D2KK3LK,A69*A[$T1_=+KU>@WZT#
M--E/%3WHVSW.;M-S5PIMMCBJXZ"\91';76J[VB25=&U-91-TAJ*=45KE="QB
M]&KV=[ZEJA=!OIN#<,#V"W8W1P^>BKKGB>#WG),8J94\XHY9J.WRU5,]R,<W
MO(W*UJ]CNU/1 H?P?Q9N3>;87\'V);?T>=\A\JO\D.-U-LM#Y*.EL[:6)4[F
M@@F?)/4]ZDKE<_2*.-$<[K35&AXN7\W?$\XS7ZPWG?RRLDQ^]SJM%9K_ &"U
M0VZJ:Q$=)3Q5UFCA>R1&KJB.F5R>56JFJ ;YSOQ.M^=_+K8MO^#NTM=69#/9
MJ6XYA?:R@2YU-!5S1-?/30,DZ:2*&GD58EJ*E.F5WUC&ITJ\-(6CQ(N<?&S<
MZU8MRMQE;];)5CGO5ANMFHK1<GV^616+56VJML5/3R="L<C55KV.5KF*J+ZI
MH7X[C[Z[?;8[+7??J^W-9\!MUC@OM'54R)WM=%6MC6AAIF2*Q%DJGS1LC1RH
MG4Y.I4354"CNCY[>(;RNR*_Q\4=LH,<Q>SRHQ)**@HKA)3->GJ&5UUO?30K,
M]/5(QL;%T_,JB*Y0Q+*.;_B=<6+S:)N0V-P72T72=&T\>0V.VQ4-4C=5D@I[
MECR4\*2]**NBO<K>QRL5OE"^OCSO;CO(G9W"=WL9@=0T.64;GUEH?(DLE!74
M\CH*ND>]&LZEBFC<U'=*=3='HB(Y -T@    !Q5\X?G>\B_MZNW]N4#QN-.^
MF7\4=]\>W$HZ*K@GQVLDM6=XI,UT$U7;))$CN%!-')TJR1.CJ8CT]1*QCE3U
M.@'2KX@N88[N!X=VZ><8E<H[QC.5V;&;I8[G%];-35-]M<D;M%[6KHNCFKVM
M75%[4 J.\%WYUN7_ 'L;M[;6<#J)  <BWBD;;95@W,#<2_7NBJ$L6Y'F=^Q&
M\O:Y8:JG2C@IYXV2*G3U4\T;HW-1=6MZ%\CF@6Z8OXDW#ZV<4[11U-XC9?;3
M@T./5&ROL;4+/)5PV]*1;>S2!*5:=ZITI+UHSH7MT=JP"FWPT]N<KS[E_M36
MX[1U#K;@=>[),LN\2*D-'0TD4FB2O1%1/.)%;"U/S2O])%5 EQXVN9U5?O1M
M%M_WKUM^,X;+?6Q:^H\XO-?-3O73T^BVL_*4">O@\8/:\=XGORR"E8V[[A95
M=*RY5W2G>/AM[FT%/"KO+T1K#(YJ>@KW>F!17XA>#VG;WF7OMCMCI&4-KFO-
M->H*6-.F-C[Y;Z6ZS(QJ=B-26J?HB=B>1/(!TT[;8[9N5O"3;3'=Q*VY/MVY
MNWU@BS"NMU3YK6RU$$-.^I>R;I?IWD\"]2*BHK55J^4#3>R7 ?CKPGS3).04
M&;WF>U6#':VG?59A)0S06:&9\;ZBMCJ*:EIU:](F.BUZ=>A[T[>H"H_Q6>4>
MSG(O-=L+3M#6MR>FVYHKJR^9Q'3R00U<ESDI5CI(%F9')(RG\V<[J5O0JR+T
M+]<JA:'X06U^7[>\8+A>\LHI[7%N;E$^28O;9T<QZVM:.DI8:M8W(BM\X= Y
MS?YZ-&/3L<@%JP'B7W)<<Q:DCK\FO]MQVAFE2"*MNE5#21.E<BN2-KYG,:KE
M1JKIKKHB@5C>*5N3MU?^&N?6BPY]CE[NM7=K!YK;*"ZTE342]W<X)']$44KG
MNZ6-5RZ)V(BJ!!7P6<NQ3$\EY R93D]IQIE;;,=;1/NM;!1I,L<U>KTC6=[.
MKIZDUT\FH'0A8]P,"R:M6VXWF]@R"XI&Z9:"VW*EJYDC:J(Y_=PR/=THJIJN
MGH@9<!!_Q(OF2;]_J5;O;>A H,\)?YZN#?J'D/M=*!U?7U]CCLEWDR9]#'CD
M=',Z^ON:Q)1)1HQ5G6I6;\[[OHUZ^OU.FNO8!PV[Z/P1^]&[#MKXXX=N5RZ\
M?81' J+ EK\\E\U[C_W2QZ+&B]O1IKV@7K<_771WA=\:'7Q'-O+HMO5NK7IH
M]*A<;J.]ZD7R.ZM=?J@: \$C^&S>'[2(?;* #HUR/&L=S"RW#&\LL-OR;'KM
M$L%TL=TIHJNDJ(U\K)8)FN8]/J*@'')STV(L_';DYGN!8O ZEPVL2EO^'TCG
M*[N*&YQ)*M.BNU56P3)+$Q5555K455UU Z9O#VW+N.ZO$#9C)+S4R5EZMUKF
MQZZ5,R]<DC[)52V^*1[U[7.?#!&]RKVJJKKV@30 UQO%_!%NG]J%\_2$X'&O
MP^^==QM^^9B_MI3@=MX "H_Q=K]NM2[6;4X?M1<<ECN>X.455JNN/XLM4M9=
MH&T+Y$I'14>LLS%7M6-$5%]%% I%W>X-[M["<?;%OANU'%B5PR?+J+&K-MW(
MB2W"."IH:^L=65LD;U9 O_8VM;%ZI^CE5_=JWI4+&? V_P#&>2?^!8I_;+L!
MT(@ .+[F;R1W*Y$[L7*7<.6VK'MY777'\9IK92>;,CHV5\JIWBJ][GO7I:BJ
MKO0\GEU#>'!;FUO=M+DVTG'_ !2:QNV]S#<2U4]WAK;?WU9W=[KZ6EJTCJ&R
M,5NK-5:NBZ+_ " .M$ !R+>*M\^'=?\ P+&_:*A S^'Q1][L4VDVKV;V&LM'
MB%/MWB-NM-YRVLHH[M<ZNIH:9C:B:""5)*:"!JM=IUQR.5J=:JS7H0/=V3\8
M'D=B.3VSX99K=NQA4]0QE]8EMH[7=H*=SD1\M%+;XZ:!7L3M1DL:H_3IZF:]
M:!TL7+<3#;5MY5[JUE\@9@-%8'91-D;55T*VIM-YYYRS1-7(Z'U341-5]#M
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M3Y-.QJ5UXN"M1)*JI<G\AC$7IC;ZE/150D"
M
M
M      * ? Q_XHOW$_Y_ O\ @
M
M
M
M                                       "H'QJ_FL8#]]6U>T=\ G_
M ,3OFL<:?O58;[1T8&_P
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MMA>1M9G&[6V,V(8M+A]SMD=UDN=JJT6KJ*BC?%'W=%63R>J;$Y=>G3L[5 Z
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MZ-A[JDN-2SS',\?C?UNM=YIVM\ZI5U[>GU221*O:Z)['+HJZ 2,
M
M
M                      % /@8_\47[B?\ /X%_P
M
M
M
M                                                       !4#XU
M?S6,!^^K:O:.^ 3_ .)WS6.-/WJL-]HZ,#?X
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MS'L<FK7-<FJ*BHNJ*@'Z
M
M                                                  % /@8_\47[
MB?\ /X%_P
M
M
M
M                       !4#XU?S6,!^^K:O:.^ 3_ .)WS6.-/WJL-]HZ
M,#?X
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MR7-ZK'O!\.?V<^PM#<*+['?L9]C.\\_IGT_7YS[+5?3T=75IW:Z^35/*!;2
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MC#HW4-FRJ2V>Q<J6UB_]DI)(?.ZSJ\W9^=M?UIZA&IIJW50WJ
M
M
M                   4 ^!C_P 47[B?\_@7_
M
M
M
M                                                    %0/C5_-8
MP'[ZMJ]H[X!/_B=\UCC3]ZK#?:.C W^
M
M
M
M
M
M         H!\#'_BB_<3_G\"_P"
M
M
M
M                                          *@?&K^:Q@/WU;5[1WP
M"?\ Q.^:QQI^]5AOM'1@;_
M
M
M
M
M
M4 ^!C_Q1?N)_S^!?\
M
M
M
M                                5 ^-7\UC ?OJVKVCO@$_^)WS6.-/
MWJL-]HZ,#?X
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MXMT<DSNQ[H6N6AQQ^376KN7F5YHD=54_<OJY9.Z2>)LT2HW3K>L7I(!TG
M',AXG'(G?S;_ );Y=BV![T9MA>-4%FL;Z.PV*^UUOHXWS4,<LKTAIIHV=3WN
M557350)L^%'S/O>\-BOFQN[.45>1;E8JDMWQ/([M4/J*V[VB1Z+/#-/,YSY9
MJ25^J*Y=5B>U$32)R@6;<AKS=<<V!WQR&Q7">TWRQ;?Y-<;-=:9ZQSTU72VJ
MIE@FB>G:U\;VHYJIY%0#G \/#DAR#SKF/LSBF:[X9WEN,7::]I=,>O&0W&MH
MJA(;%<)HTEIYYWQOZ)&->FJ=CD1?*@'4^
M
M
M            % /@8_\ %%^XG_/X%_P
M
M
M
M                                             !4#XU?S6,!^^K:O
M:.^ 3_XG?-8XT_>JPWVCHP-_@
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ML/M/3[%[1X1M+1Y%6Y518/124%%?;@R.*HE@6>26)KV1>I1(F2)&W3\RU/1
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M_P#[WKF!V$
M
M                                                 !0#X&/_ !1?
MN)_S^!?\
M
M
M
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M&_4K9<8NU=)0+'076F>DM)4ZQS*]J->WI=T]JL<YO:CE0#?'@CYI4W/:K>C
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MC)K)F\LBZR5T#X;1['W-5[=5J(XG-D7RK+'([1&N:!;SX*/S9]Q_OG5WM-:
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M/FV)_L]__>]<P.P@
M
M                                                       * ? Q
M_P"*+]Q/^?P+_@
M
M
M
M                            "H'QJ_FL8#]]6U>T=\ G_P 3OFL<:?O5
M8;[1T8&_P
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MVG[Q&*U%1':.1%U0#H=W]J(JOPCJ2I@<CH9]G,$?&J>DK+1V?E 4]>$U\]?
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MN[7@>QX8OSYMB?[/?_WO7,#L(
M
M
M    "@'P,?\ BB_<3_G\"_X
M
M
M
M                                      J!\:OYK& _?5M7M'? )_\
M$[YK'&G[U6&^T=&!O\
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M_K3M=-.S75 N$
M
M                                                    "@'P,?\
MBB_<3_G\"_X
M
M
M
M                          J!\:OYK& _?5M7M'? )_\ $[YK'&G[U6&^
MT=&!O\
M
M                              ?-6T=-<:.KM];"E11UT,E/5P.U1'Q2
MM5CVKIHO:BJG8!";BYP V*XKW>X9;BE-793GE<M3#39A?)&R34-%4._[K111
MM;'$G0B-?)HLC_5>K1CN@"<0
M
M
M                                  "@'P,?^*+]Q/\ G\"_X
M
M
M
M
M        J!\:OYK& _?5M7M'? )_\3OFL<:?O58;[1T8&_P
M
M
M
M
M
M                        % /@8_\ %%^XG_/X%_P
M
M
M
M                                                         !4#
MXU?S6,!^^K:O:.^ 3_XG?-8XT_>JPWVCHP-_@
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MWKK9=Z5&+44W>]+>MO3(R2-VB:QO8JHUVK4"1H
M
M
M
M* ? Q_XHOW$_Y_ O^
M
M
M
M                                *@?&K^:Q@/WU;5[1WP"?_$[YK'&G
M[U6&^T=&!O\
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MX= YS?YZ-&/3L<@%JP
M
M
M                                        * ? Q_XHOW$_Y_ O^
M
M
M
M
M            *@?&K^:Q@/WU;5[1WP"?_$[YK'&G[U6&^T=&!O\
M
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M RG;=[54.=$V:6&%&QLF@D:C']#6M<CF*C=>L"U,
M
M
M
M  % /@8_\47[B?\ /X%_P
M
M
M
M                                   !4#XU?S6,!^^K:O:.^ 3_ .)W
MS6.-/WJL-]HZ,#?X
M                           #E_\ #^_C-\J_53/OZ>J Z@ (^\M/FK\E
M?O69A[2U8%/?@9_]ZY.?V+#?Z:]@:D\;/YP.U?WO8_;6O Z/\0_U3Q?]2*+^
MT, AQXC6QWPY\5-P+;04?G658)&F98DC6]<BU%I8]]3"Q$[7.GHW3QM:GE>Y
MOET YY*_EQ557A^6?BWY](M^@SV9:EB]3D=BD/3=88G.\B*MSEU:FOUL>B)Z
M0='? ?8WX >+NV^)5M%YEE-_I?LIS=CFHV5+I=VMF=%*B?FZ:!(J=?[&!,D
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M^/4UGI<1M=<Y%;3U574U$==5,8OD<ZG93PJ[TDE3TP.AX
M
M
M
M       % /@8_P#%%^XG_/X%_P
M
M
M
M                                          5 ^-7\UC ?OJVKVCO@
M$_\ B=\UCC3]ZK#?:.C W^
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MGX+.R"V+;W<'?N[4?179Y6IC>(S2-3J2UVMW762QN_G9ZM4C5/YZG N_
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M;=[<8]3XOB&.1.BM=IIU>Y&];EDDDDDD<Z2221[E<][W*YSE554#.P
M
M
M
M                4 ^!C_Q1?N)_S^!?\
M
M
M
M                                                5 ^-7\UC ?OJ
MVKVCO@$_^)WS6.-/WJL-]HZ,#?X
M
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MDKU=)([3M<Y5]$#/
M
M
M
M    !0#X&/\ Q1?N)_S^!?\
M
M
M
M                                       %0/C5_-8P'[ZMJ]H[X!/_
M (G?-8XT_>JPWVCHP-_@
M
M
M
M
M                                                         * ?
M Q_XHOW$_P"?P+_@
M
M
M
M                              "H'QJ_FL8#]]6U>T=\ G_Q.^:QQI^]
M5AOM'1@;_
M
M
M
M
M                                               4 ^!C_P 47[B?
M\_@7_
M
M
M
M                    %0/C5_-8P'[ZMJ]H[X!/_B=\UCC3]ZK#?:.C W^
M
M
M
M
M
M                                     H!\#'_BB_<3_G\"_P"
M
M
M
M
M          *@?&K^:Q@/WU;5[1WP"?\ Q.^:QQI^]5AOM'1@;_
M
M
M
M
M
M                            4 ^!C_Q1?N)_S^!?\
M
M
M
M
M5 ^-7\UC ?OJVKVCO@$_^)WS6.-/WJL-]HZ,#?X
M
M
M
M
M
M                "@'P,?\ BB_<3_G\"_X
M
M
M
M                                                  J!\:OYK& _
M?5M7M'? (?[3^,I\%^UFVFVGR<?9SX.\4LV,>S7V7^;>>>Q%##1><=Q["2]U
MWO==71UNZ==.IWE V!^/._Y7?NV_T  _'G?\KOW;?Z  ?CSO^5W[MO\ 0 #\
M>=_RN_=M_H !^/._Y7?NV_T  _'G?\KOW;?Z  ?CSO\ E=^[;_0 #\>=_P K
MOW;?Z  ?CSO^5W[MO]  /QYW_*[]VW^@ 'X\[_E=^[;_ $  _'G?\KOW;?Z
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MNV_T  _'G?\ *[]VW^@ 'X\[_E=^[;_0 #\>=_RN_=M_H !^/._Y7?NV_P!
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MM_H !^/._P"5W[MO]  /QYW_ "N_=M_H !^/._Y7?NV_T  _'G?\KOW;?Z
M?CSO^5W[MO\ 0 #\>=_RN_=M_H !^/._Y7?NV_T  _'G?\KOW;?Z  ?CSO\
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M_=M_H !^/._Y7?NV_P!  /QYW_*[]VW^@ 'X\[_E=^[;_0 #\>=_RN_=M_H
M!^/._P"5W[MO]  /QYW_ "N_=M_H !^/._Y7?NV_T  _'G?\KOW;?Z  ?CSO
M^5W[MO\ 0 #\>=_RN_=M_H !^/._Y7?NV_T  _'G?\KOW;?Z  ?CSO\ E=^[
M;_0 #\>=_P KOW;?Z  ?CSO^5W[MO]  /QYW_*[]VW^@ 'X\[_E=^[;_ $
M_'G?\KOW;?Z  ?CSO^5W[MO]  /QYW_*[]VW^@ 'X\[_ )7?NV_T  _'G?\
M*[]VW^@ 'X\[_E=^[;_0 #\>=_RN_=M_H !^/._Y7?NV_P!  /QYW_*[]VW^
M@ 'X\[_E=^[;_0 #\>=_RN_=M_H !^/._P"5W[MO]  /QYW_ "N_=M_H !^/
M._Y7?NV_T  _'G?\KOW;?Z  ?CSO^5W[MO\ 0 #\>=_RN_=M_H !^/._Y7?N
MV_T  _'G?\KOW;?Z  ?CSO\ E=^[;_0 #\>=_P KOW;?Z  ?CSO^5W[MO]
M/QYW_*[]VW^@ 'X\[_E=^[;_ $  _'G?\KOW;?Z  ?CSO^5W[MO]  /QYW_*
M[]VW^@ 'X\[_ )7?NV_T  _'G?\ *[]VW^@ 'X\[_E=^[;_0 #\>=_RN_=M_
MH !^/._Y7?NV_P!  /QYW_*[]VW^@ 'X\[_E=^[;_0 #\>=_RN_=M_H !^/.
M_P"5W[MO]  /QYW_ "N_=M_H !^/._Y7?NV_T  _'G?\KOW;?Z  ?CSO^5W[
MMO\ 0 #\>=_RN_=M_H !^/._Y7?NV_T  _'G?\KOW;?Z  ?CSO\ E=^[;_0
M#\>=_P KOW;?Z  ?CSO^5W[MO]  /QYW_*[]VW^@ 'X\[_E=^[;_ $  _'G?
M\KOW;?Z  ?CSO^5W[MO]  /QYW_*[]VW^@ 'X\[_ )7?NV_T  _'G?\ *[]V
MW^@ 'X\[_E=^[;_0 #\>=_RN_=M_H !^/._Y7?NV_P!  /QYW_*[]VW^@ 'X
M\[_E=^[;_0 #\>=_RN_=M_H !^/._P"5W[MO]  /QYW_ "N_=M_H !^/._Y7
M?NV_T  _'G?\KOW;?Z  >!C_ ,47[B?\_@7_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
1                    _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820109962000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 05, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IMMUNITYBIO,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">43-1979754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3530 John Hopkins Court<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-5235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IBRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,984,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001326110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820110372848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 88,481<span></span>
</td>
<td class="nump">$ 104,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">2,787<span></span>
</td>
<td class="nump">2,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Due from related parties</a></td>
<td class="nump">1,464<span></span>
</td>
<td class="nump">1,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets (including amounts with related parties)</a></td>
<td class="nump">20,754<span></span>
</td>
<td class="nump">31,503<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">113,486<span></span>
</td>
<td class="nump">140,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, noncurrent</a></td>
<td class="nump">820<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">154,165<span></span>
</td>
<td class="nump">143,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">19,502<span></span>
</td>
<td class="nump">20,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ConvertibleNoteReceivableNonCurrent', window );">Convertible note receivable</a></td>
<td class="nump">6,691<span></span>
</td>
<td class="nump">6,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net (including amounts with related parties)</a></td>
<td class="nump">44,191<span></span>
</td>
<td class="nump">45,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets (including amounts with related parties)</a></td>
<td class="nump">4,545<span></span>
</td>
<td class="nump">4,860<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">343,400<span></span>
</td>
<td class="nump">362,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">33,573<span></span>
</td>
<td class="nump">21,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">54,118<span></span>
</td>
<td class="nump">41,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">2,932<span></span>
</td>
<td class="nump">3,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities (including amounts with related parties)</a></td>
<td class="nump">2,844<span></span>
</td>
<td class="nump">2,650<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">564,945<span></span>
</td>
<td class="nump">500,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion (including amounts with related parties)</a></td>
<td class="nump">46,289<span></span>
</td>
<td class="nump">47,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities</a></td>
<td class="nump">17,780<span></span>
</td>
<td class="nump">21,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">462<span></span>
</td>
<td class="nump">457<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">875,116<span></span>
</td>
<td class="nump">812,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001&#160;par value; 900,000,000&#160;shares authorized as of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively; 435,923,104 and 421,569,115 shares issued and outstanding as of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively; excluding treasury stock, 163,800&#160;shares outstanding as of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,965,838<span></span>
</td>
<td class="nump">1,930,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,494,831)<span></span>
</td>
<td class="num">(2,378,488)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(33)<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total ImmunityBio stockholders&#8217; deficit</a></td>
<td class="num">(528,983)<span></span>
</td>
<td class="num">(447,327)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(2,733)<span></span>
</td>
<td class="num">(2,493)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(531,716)<span></span>
</td>
<td class="num">(449,820)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">343,400<span></span>
</td>
<td class="nump">362,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Related-party notes</a></td>
<td class="nump">441,628<span></span>
</td>
<td class="nump">431,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Related-party notes</a></td>
<td class="nump">29,850<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesNoncurrent', window );">Related-party convertible notes and accrued interest, net of discount</a></td>
<td class="nump">$ 245,640<span></span>
</td>
<td class="nump">$ 241,271<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ConvertibleNoteReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible note receivable, non-current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ConvertibleNoteReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820109952992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">900,000,000<span></span>
</td>
<td class="nump">900,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">435,923,104<span></span>
</td>
<td class="nump">435,923,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">421,569,115<span></span>
</td>
<td class="nump">421,569,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, common shares (in shares)</a></td>
<td class="nump">163,800<span></span>
</td>
<td class="nump">163,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820109685600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 360<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (including amounts with related parties)</a></td>
<td class="nump">79,264<span></span>
</td>
<td class="nump">55,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative (including amounts with related parties)</a></td>
<td class="nump">32,676<span></span>
</td>
<td class="nump">40,608<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">111,940<span></span>
</td>
<td class="nump">95,986<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(111,580)<span></span>
</td>
<td class="num">(95,972)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Interest and investment income, net</a></td>
<td class="nump">673<span></span>
</td>
<td class="nump">1,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense (including amounts with related parties)</a></td>
<td class="num">(29,816)<span></span>
</td>
<td class="num">(8,491)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="num">(2,337)<span></span>
</td>
<td class="num">(197)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">27,554<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net (including amounts with related parties)</a></td>
<td class="num">(1,077)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(5,003)<span></span>
</td>
<td class="num">(7,026)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes and noncontrolling interests</a></td>
<td class="num">(116,583)<span></span>
</td>
<td class="num">(102,998)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(116,583)<span></span>
</td>
<td class="num">(102,998)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests, net of tax</a></td>
<td class="num">(240)<span></span>
</td>
<td class="num">(172)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to ImmunityBio common stockholders</a></td>
<td class="num">$ (116,343)<span></span>
</td>
<td class="num">$ (102,826)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per ImmunityBio common share &#8211; basic (in dollars per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per ImmunityBio common share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares used in computing net loss per share &#8211; basic (in shares)</a></td>
<td class="nump">428,381,485<span></span>
</td>
<td class="nump">397,882,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of common shares used in computing net loss per share &#8211; diluted (in shares)</a></td>
<td class="nump">428,381,485<span></span>
</td>
<td class="nump">397,882,441<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820106012800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (116,583)<span></span>
</td>
<td class="num">$ (102,998)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Net unrealized gains (losses) on available-for-sale securities</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(310)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of net realized gains on available-for-sale securities included in net loss</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(226)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive loss</a></td>
<td class="num">(216)<span></span>
</td>
<td class="num">(371)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(116,799)<span></span>
</td>
<td class="num">(103,369)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Less: Comprehensive loss attributable to noncontrolling interests</a></td>
<td class="num">(240)<span></span>
</td>
<td class="num">(172)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Comprehensive loss attributable to ImmunityBio common stockholders</a></td>
<td class="num">$ (116,559)<span></span>
</td>
<td class="num">$ (103,197)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820111507792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Deficit - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Registered Direct Offering</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Registered Direct Offering</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Registered Direct Offering</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Total ImmunityBio Stockholders&#8217; Deficit</div></th>
<th class="th">
<div>Total ImmunityBio Stockholders&#8217; Deficit </div>
<div>Registered Direct Offering</div>
</th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397,830,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="num">$ (243,913)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,719,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,961,921)<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">$ (242,173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Statements of Stockholders&#8217; Deficit [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">10,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (RSUs) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Net share settlement for RSUs vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,832)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Net share settlement for RSUs vesting</a></td>
<td class="num">(372)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(372)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(372)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income, net of tax</a></td>
<td class="num">(371)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(371)<span></span>
</td>
<td class="num">(371)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(102,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102,826)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102,826)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(172)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397,956,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="num">$ (337,556)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,729,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,064,747)<span></span>
</td>
<td class="num">(367)<span></span>
</td>
<td class="num">(335,644)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,912)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">421,569,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421,569,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="num">$ (449,820)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,930,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,378,488)<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="num">(447,327)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,493)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Statements of Stockholders&#8217; Deficit [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in a registered direct offering, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,072,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares in a registered direct offering, net of discount and offering costs of $2,046 and value ascribed to associated warrants (Note 11)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 10,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">81,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (RSUs) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Net share settlement for RSUs vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Net share settlement for RSUs vesting</a></td>
<td class="num">(357)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(357)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(357)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income, net of tax</a></td>
<td class="num">(216)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(216)<span></span>
</td>
<td class="num">(216)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (116,583)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(116,343)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(116,343)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(240)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">421,569,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,923,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="num">$ (531,716)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,965,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,494,831)<span></span>
</td>
<td class="num">$ (33)<span></span>
</td>
<td class="num">$ (528,983)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,733)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820115745280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Deficit (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Commissions and offering costs</a></td>
<td class="nump">$ 2,046<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820110719040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (116,583)<span></span>
</td>
<td class="num">$ (102,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">10,878<span></span>
</td>
<td class="nump">10,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(27,554)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_TransactionCostsWarrantLiability', window );">Transaction costs allocated to warrant liabilities</a></td>
<td class="nump">984<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NonCashInterestIncomeExpenseFromOperatingActivities', window );">Non-cash interest items, net (including amounts with related parties)</a></td>
<td class="nump">2,505<span></span>
</td>
<td class="nump">3,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of related-party notes discounts</a></td>
<td class="nump">11,536<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,681<span></span>
</td>
<td class="nump">4,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense related to operating lease right-of-use assets</a></td>
<td class="nump">1,597<span></span>
</td>
<td class="nump">1,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized (gains) on equity securities</a></td>
<td class="num">(135)<span></span>
</td>
<td class="num">(1,419)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">1,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">9,689<span></span>
</td>
<td class="num">(218)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">668<span></span>
</td>
<td class="nump">795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">18,590<span></span>
</td>
<td class="nump">10,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent', window );">Related parties</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(1,618)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(1,511)<span></span>
</td>
<td class="num">(339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(84,310)<span></span>
</td>
<td class="num">(74,930)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(8,428)<span></span>
</td>
<td class="num">(27,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(21,229)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable debt securities, available-for-sale</a></td>
<td class="num">(158)<span></span>
</td>
<td class="num">(34,082)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of marketable debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales of marketable debt and equity securities</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Investment in joint venture &#8211; an equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(8,484)<span></span>
</td>
<td class="num">(69,313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from equity offering, net of issuance costs paid</a></td>
<td class="nump">47,288<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from issuance of related-party convertible promissory notes, net of issuance costs paid</a></td>
<td class="nump">29,850<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of stock options</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Net share settlement for RSUs vesting</a></td>
<td class="num">(357)<span></span>
</td>
<td class="num">(372)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments of finance leases</a></td>
<td class="num">(19)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">76,888<span></span>
</td>
<td class="num">(298)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="num">(254)<span></span>
</td>
<td class="num">(175)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(16,160)<span></span>
</td>
<td class="num">(144,716)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="nump">104,965<span></span>
</td>
<td class="nump">181,280<span></span>
</td>
<td class="nump">$ 181,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">88,805<span></span>
</td>
<td class="nump">36,564<span></span>
</td>
<td class="nump">104,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents, and restricted cash, end of period:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">88,481<span></span>
</td>
<td class="nump">36,385<span></span>
</td>
<td class="nump">104,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">324<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">88,805<span></span>
</td>
<td class="nump">36,564<span></span>
</td>
<td class="nump">$ 104,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">15,515<span></span>
</td>
<td class="nump">5,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_IssuanceOfWarrants', window );">Initial measurement of warrants issued in connection with the registered direct offering accounted for as liabilities</a></td>
<td class="nump">23,698<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable, accrued expenses and due to related parties</a></td>
<td class="nump">19,033<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses', window );">Unpaid offering costs included in accounts payable and accrued expenses</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gains (losses) on marketable debt securities, net</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in due to related parties current and non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_IssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_IssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_NonCashInterestIncomeExpenseFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash interest (income) expense from operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_NonCashInterestIncomeExpenseFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_TransactionCostsWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs, Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_TransactionCostsWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unpaid offering costs included in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820116907072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In these notes to unaudited condensed consolidated financial statements, the terms &#8220;ImmunityBio,&#8221; &#8220;the company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to ImmunityBio, Inc. and its subsidiaries.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ImmunityBio, Inc. is a clinical-stage biotechnology company developing next-generation therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. We strive to be a vertically-integrated immunotherapy company designing and manufacturing our products so they are more effective, accessible, more conveniently stored, and more easily administered to patients. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our broad immunotherapy and cell therapy platforms are designed to attack cancer and infectious pathogens by activating both the innate immune system&#8212;natural killer (NK) cells, dendritic cells, and macrophages&#8212;and the adaptive immune system&#8212;B&#160;cells and T&#160;cells&#8212;in an orchestrated manner. The goal of this potentially best-in-class approach is to generate immunogenic cell death thereby eliminating rogue cells from the body whether they are cancerous or virally infected. Our ultimate goal is to employ this approach to establish an &#8220;immunological memory&#8221; that confers long-term benefit for the patient. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although such designations may not lead to a faster development process or regulatory review and may not increase the likelihood that a product candidate will receive approval, Anktiva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (N-803), our novel antibody cytokine fusion protein, has received </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designations in combination with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bacillus Calmette-Gu&#233;rin (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BCG) from the United States (U.S.)&#160;Food and Drug Administration (FDA) for</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> BCG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. I</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May&#160;2022, we announced the submission of a Biologics License Application (BLA) to the FDA for our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease. In July&#160;2022, we announced the FDA had accepted our BLA for review and set a target Prescription Drug User Fee Act (PDUFA) action date of May&#160;23,&#160;2023. On May&#160;9,&#160;2023, the FDA delivered a complete response letter to us regarding the BLA. The company plans to request a meeting with the FDA as soon as possible to address the subject matter of the letter and a response timeline, and plans to diligently address and resolve the issues identified and seek approval as expeditiously as possible. It is unclear when the FDA will approve our BLA, if at all.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our platforms include 13&#160;novel therapeutic agents either in clinical trials or for which we are developing protocols. We are currently engaged in 15&#160;active clinical trials involving 10&#160;of these agents. Seven of these trials are being sponsored by ImmunityBio while the remaining eight are investigator-led studies. Twelve&#160;of these trials are in Phase&#160;2 or 3&#160;development across eleven&#160;indications in liquid and solid tumors. These include bladder, pancreatic, and lung cancers, which are among the most frequent and lethal cancer types, and where there are high failure rates for existing standards of care or no available effective treatment. In infectious diseases, our pipeline currently targets such pathogens as the novel strain of the coronavirus (SARS-CoV-2) and human immunodeficiency virus (HIV). </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established Good Manufacturing Practice (GMP) manufacturing capacity at scale with cutting-edge cell manufacturing expertise and ready-to-scale facilities, as well as extensive and seasoned research and development (R&amp;D), clinical trial, and regulatory operations, and development teams.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820116787936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.&#160;GAAP) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The unaudited condensed consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of our financial position and results of operations. The unaudited condensed consolidated financial statements do not include all information and notes required by U.S.&#160;GAAP for annual reports and therefore should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December&#160;31,&#160;2022 filed with the SEC on March&#160;1,&#160;2023. These interim financials are not necessarily indicative of results expected for the full fiscal year.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of the company, its wholly-owned subsidiaries, and a variable interest entity (VIE) for which the company is the primary beneficiary. Any material intercompany transactions and balances have been eliminated upon consolidation. For consolidated entities where we have less than 100% of ownership, we record net loss attributable to noncontrolling interest on the unaudited condensed consolidated statements of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether we are the primary beneficiary of a VIE at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, the company had an accumulated deficit of $2.5&#160;billion. We also had negative cash flows from operations of $84.3&#160;million for the three months ended March&#160;31,&#160;2023. The company will likely need additional capital to further fund the development of, and to seek regulatory approvals for, our product candidates, and to begin to commercialize any approved products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements have been prepared assuming the company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of the uncertainty of our ability to continue as a going concern. As a result of continuing anticipated operating cash outflows, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash, cash equivalents, and investments in marketable securities, together with capital to be raised through equity offerings (including but not limited to the offering, issuance and sale by us of our common stock that may be issued and sold under an &#8220;at-the-market&#8221; sales agreement (the&#160;Sale Agreement) with our sales agent (the&#160;ATM), of which we had $225.4&#160;million available for future issuance as of March&#160;31,&#160;2023, and a February&#160;2023 shelf registration statement, of which we had $640.0&#160;million available for future offerings as of March&#160;31,&#160;2023), and our potential ability to borrow from affiliated entities, will be sufficient to fund our operations through at least the next 12&#160;months following the issuance date of the condensed consolidated financial statements based primarily upon our Executive Chairman and Global Chief Scientific and Medical Officer&#8217;s intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt. See&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i5bbe340c9c8f435088d8011b72b6800d_85" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note</a><a href="#i5bbe340c9c8f435088d8011b72b6800d_85" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;12</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders&#8217; Deficit, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for information regarding the ATM and the shelf registration statement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also seek to sell additional equity, through one or more follow-on offerings, or in separate financings, or obtain a credit facility. However, we may not be able to secure such external financing in a timely manner or on favorable terms. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the risk and uncertainties associated with the potential commercialization of our product candidates in development, we may need additional funds to meet our needs sooner than planned.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, contingent value right measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value calculation of warrants and convertible promissory notes, fair value measurements, and the assessment of our ability to fund our operations for at least the next 12&#160;months from the date of issuance of these condensed consolidated financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing coronavirus pandemic could have on our significant accounting estimates. Actual results could differ from those estimates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our significant accounting policies from those described in Note&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Consolidated Financial Statements&#8221; that appears in Part&#160;II, Item&#160;8. &#8220;Financial Statements and Supplementary Data&#8221; of our Annual Report on Form&#160;10-K filed with the SEC on March&#160;1,&#160;2023. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Accounting Standards Codification (ASC) Topic&#160;480, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC&#160;480), and ASC Topic&#160;815, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC&#160;815). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC&#160;480, meet the definition of a liability pursuant to ASC&#160;480, and whether the warrants meet all of the requirements for equity classification under ASC&#160;815, including whether the warrants are indexed to the&#160;company&#8217;s own stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For warrants that meet all criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and on each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash change in fair value of warrant liabilities in o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ther income (expense), net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations. The fair value of the warrants was estimated using the Black-Scholes option pricing model.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Option (FVO) Election</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company accounts for certain convertible notes issued during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the fair value option (FVO) election of ASC&#160;825, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC&#160;825), as discussed below.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The convertible notes accounted for under the FVO election are each debt host financial instruments containing embedded features wherein the entire financial instrument is initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the estimated fair value of the convertible notes are recorded as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other income (expense), net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated statements of operations, except that the change in estimated fair value attributable to a change in the instrument-specific credit risks is recognized as a component of other comprehensive income. Since the underlying financial instrument was issued on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we did not recognize any change in estimated fair values during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Net Loss per Share of Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed by dividing net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares, including the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. The following table details those securities that have been excluded from the computation of potentially dilutive securities:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Related-party convertible notes (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,726,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding third-party warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,163,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,159,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,819,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,188,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,149,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding related-party warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,638,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,638,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">86,875,888&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,606,877&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.641%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount excludes the shares related to the related-party convertible note with a principal amount of $30.0&#160;million issued on March&#160;31,&#160;2023 as the conversion price has not yet been determined. See</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> </a><a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Note </a><a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, for further information.</span></div></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Application of New or Revised Accounting Standards &#8211; Not Yet Adopted</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic&#160;820): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the guidance in Topic&#160;820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. In addition, ASU&#160;2022-03 introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. ASU&#160;2022-03 is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years. We are currently evaluating the impact of this standard on our condensed consolidated financial statements. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the FASB issued ASU&#160;2023-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842): Common Control Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that leasehold improvements associated with common control leases be amortized over the useful life of the leasehold improvements to the common control group, regardless of the lease term. ASU&#160;2023-01 is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years. We are currently evaluating the impact of this standard on our condensed consolidated financial statements and related disclosures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC during the three months ended March&#160;31,&#160;2023 did not, or are not expected to, have a material effect on our condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820113535328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statement Details<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinancialStatementDetailsAbstract', window );"><strong>Financial Statement Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Financial Statement Details</a></td>
<td class="text">Financial Statement Details<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid software license fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Insurance premium financing asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,754&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31,503&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment, Net </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net, consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">68,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">68,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">67,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">81,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture &amp; fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Gross property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">227,580&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">212,911&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">154,165&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">143,659&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property, plant and equipment totaled $4.2&#160;million and $3.8&#160;million for the three&#160;months&#160;ended March&#160;31,&#160;2023 and 2022, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amounts and accumulated amortization of intangible assets are as follows at the dates indicated (in&#160;thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.101%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31,&#160;2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finite-lived: Favorable leasehold rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,295)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Indefinite-lived: In-process research </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;and development (IPR&amp;D)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,797&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,295)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,502&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.101%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finite-lived: Favorable leasehold rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finite-lived: Organized workforce</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,229&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,935)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(681)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,613&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Indefinite-lived: IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22,619&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,935)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(681)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,003&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of the Dunkirk facility in 2022, we acquired finite-lived intangibles consisting of favorable leasehold rights and an organized workforce. We recorded amortization expense of our finite-lived intangibles totaling $0.5&#160;million and $0.3&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations for the three months ended March&#160;31,&#160;2023 and 2022, respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense associated with our finite-lived intangible assets is as follows (in&#160;thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.825%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Years ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Finite-lived</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Intangible</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Assets</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023 (excluding the three months ended March&#160;31,&#160;2023)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,103&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Liabilities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities consist of the following (in&#160;thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonus</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional and service fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical and clinical trial costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing obligation &#8211; current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,118&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,825&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest and Investment Income, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and investment income, net consists of the following (in&#160;thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Three Months Ended<br/>March&#160;31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unrealized gains from equity securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Investment amortization expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,049)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net realized losses on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest and investment income, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">673&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,666&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income includes interest from marketable securities, convertible notes receivable, other assets, and on bank deposits.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists of the following (in&#160;thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:71.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.302%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Three Months Ended<br/>March&#160;31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest expense on related-party notes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization of related-party notes discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,536)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(370)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(29,816)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8,491)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinancialStatementDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinancialStatementDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820113379536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Debt Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, the weighted-average remaining contractual life, amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.101%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="27" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31,&#160;2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="27" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual&#160;Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,048&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(84)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">964&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2022, the weighted-average remaining contractual life, amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.101%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual&#160;Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;<br/>Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">970&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(94)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">876&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31,&#160;2023, 14 of the securities were in an unrealized loss position. Accumulated unrealized losses on marketable debt securities that have been in a continuous loss position for less than 12&#160;months and more than 12&#160;months were as follows (in&#160;thousands): </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March&#160;31,&#160;2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited) </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">876&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(94)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Equity Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held investments in marketable equity securities with readily determinable fair values of $2.6&#160;million and $2.5&#160;million as of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively. Unrealized gains recorded on these securities totaled $0.1&#160;million and $1.4&#160;million for the three&#160;months&#160;ended March&#160;31,&#160;2023 and 2022, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest and investment income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI https://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI https://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820116762752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three tiers are defined as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1&#8212;Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these products does not entail a significant degree of judgment. Our Level&#160;1 assets consist of bank deposits, money market funds, and marketable equity securities.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2&#8212;Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level&#160;2 assets consist of corporate debt securities including commercial paper, government-sponsored securities and corporate bonds, as well as foreign municipal securities.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3&#8212;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy. The fair values of financial instruments other than marketable securities and cash and cash equivalents are determined through a combination of management estimates and third-party valuations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recurring Valuations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below (in&#160;thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.641%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="24" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="24" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Unaudited) </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">88,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,088&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,274&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,814&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Related-party convertible note payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,850)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,850)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,780)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,780)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total liabilities measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,650)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,650)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.641%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">63,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,024&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,403&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,621&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities at fair value:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total liabilities measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,655)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,655)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.641%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, the Level&#160;2 measurements include $15.0&#160;million in U.S. government agency securities with original maturities of less than 90&#160;days. As of December&#160;31,&#160;2022, the Level&#160;2 measurements include $32.0&#160;million in U.S. government agency securities and $8.8&#160;million in corporate debt securities with original maturities of less than 90&#160;days.</span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.641%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As of March&#160;31,&#160;2023, the company has a related-party convertible note payable with a principal amount of $30.0&#160;million, which is accounted for under the ASC&#160;825-10-15-4 FVO election. Under the FVO election, the financial instrument is initially measured at its issue-date estimated fair value and subsequently re-measured at estimated fair value on a recurring basis at each reporting period date. The company&#8217;s other related-party notes are not accounted for under the fair value election. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Note&#160;</a><a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, Related-Party Debt, for further information. The estimated fair value of the convertible note was computed using a discounted cash flow method with the following unobservable assumptions:</span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected market yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount period</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount factor</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.98</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.641%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Third-Party Warrant Liabilities</span></td></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">December 2022 Warrants</span></div><div style="margin-top:6pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the December&#160;12, 2022 registered direct offering of common stock, the company issued 9,090,909 warrants (December&#160;2022 Warrants). The warrants were classified as a liability at their fair value upon the issuance. As of March&#160;31,&#160;2023, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following date:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$6.60</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected average volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in the carrying amount of the December&#160;2022 Warrants was as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning fair value, at December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOmUxNmRiNTMwMWViYTRhNmY4NmMxNTNhYjJhNjhiMWIwL3RhYmxlcmFuZ2U6ZTE2ZGI1MzAxZWJhNGE2Zjg2YzE1M2FiMmE2OGIxYjBfNS0wLTEtMS0zMTA3NzY_2350ba70-1f49-4ea5-8303-63ba7471fe59">Change in fair value</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,818)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending fair value, at March&#160;31,&#160;2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">February 2023 Warrants</span></div><div style="margin-top:6pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the February&#160;15, 2023 registered direct offering of common stock, the company issued 14,072,615 warrants (February&#160;2023&#160;Warrants). The warrants were classified as a liability at its fair value upon the issuance. As of March&#160;31,&#160;2023, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following dates:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31,&#160;2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Date<br/>February 15, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$4.26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$4.26</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected average volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in the carrying amount of the February 2023 Warrants were as follows (in&#160;thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value at the issuance date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjQ1NjRiYjg3OWY4MDRmZTc5NzBhNDg1YWUzNmI0YWZiL3RhYmxlcmFuZ2U6NDU2NGJiODc5ZjgwNGZlNzk3MGE0ODVhZTM2YjRhZmJfNS0wLTEtMS0zMzA4Nzg_31727132-f847-41a1-942b-fae5179a937e">Change in fair value</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,736)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending fair value, at March&#160;31,&#160;2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,962&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonrecurring Valuations</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measured the fair value of the fixed-rate promissory notes and variable-rate promissory notes before and after amendments that were entered on August&#160;31,&#160;2022, as they were accounted for under the debt extinguishment accounting model. We used discounted cash flow analyses for promissory notes without a holder conversion option and a binomial lattice convertible note model for the fixed-rate promissory notes with a holder conversion option. Since certain of the factors analyzed are considered to be unobservable inputs, both the discounted cash flow model and the lattice model are considered to be a Level&#160;3 valuation. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note</a><a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;</a><a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Related-Party Debt,</span> for additional information.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI https://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820113315264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements and Acquisition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Collaboration and License Agreements and Acquisition</a></td>
<td class="text">Collaboration and License Agreements and Acquisition<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amyris Joint Venture</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December&#160;2021, ImmunityBio and Amyris, Inc. (Amyris) entered into a 50:50 joint venture arrangement and formed a new limited liability company to conduct the business of the joint venture. The purpose of the joint venture is to accelerate commercialization of a next-generation COVID-19 vaccine utilizing an RNA vaccine-platform. As part of the limited liability agreement, Amyris contributed $1.0&#160;million in cash and rights to its license agreement with the Access to Advanced Health Institute (AAHI) for an RNA platform for the field of COVID-19. ImmunityBio contributed $1.0&#160;million in cash and priority access to its manufacturing capacity for the joint venture product. Both parties agreed to enter into a separate manufacturing and supply agreement and a sublicense agreement following the execution of the joint venture agreement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The joint venture agreement stipulates the initial terms for equal representation in the management of the newly-formed joint venture. The joint venture is managed by a board of directors consisting of four&#160;directors: two appointed by the company and two&#160;appointed by Amyris. Both parties agreed to make additional capital contributions in cash, in proportion to their respective interests, as determined by the board of directors of the joint venture. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We considered the joint venture entity as a VIE and determined that we are not the primary beneficiary of the VIE. In February&#160;2022, we made a cash investment totaling $1.0&#160;million in the joint venture&#8217;s common stock. We account for our investment in the joint venture using the equity method of accounting, and recorded our 50%&#160;share of the net loss from the joint venture totaling $2.3 million and $0.2 million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other&#160;income (expense), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations for the three months ended March&#160;31,&#160;2023 and 2022. Such losses incurred during the three months ended March&#160;31,&#160;2023 were attributed to expenses incurred by us on behalf of the joint venture. We are not obligated to fund the joint venture&#8217;s potential future losses. As of March&#160;31,&#160;2023, the carrying amount of our equity investment in the joint venture was zero.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">3M Innovative Properties Company (3M&#160;IPC) and AAHI License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed rights to 3M-052, a synthetic TLR7/8 agonist, 3M-052 formulations and related technology from 3M&#160;IPC and its affiliates and AAHI. In November 2021 we obtained nonexclusive rights in the field of SARS-CoV-2 and in June&#160;2022 we modified those rights and expanded the scope of the license to include (1)&#160;SARS-CoV-2 and other infectious diseases including malaria, HIV, tuberculosis, hookworm and varicella zoster on an exclusive basis in countries other than low- and middle-income countries (LMIC), and (2)&#160;oncology applications, when used in combination with our proprietary technology and/or IL-15 agonists. In consideration for the license, we agreed to make certain periodic license payments, including $2.25&#160;million each year through June 2025, with the June 2022 payment being partially offset by the $0.5&#160;million previously paid under the initial November 2021 license agreement. We have also agreed to make payments upon the achievement of certain regulatory milestone events and tiered royalties ranging from the low to high single-digits as a percentage of net sales. Beginning in April&#160;2026, the annual minimum licensing payment is $1.0&#160;million, which can be credited against any royalty payments due under this agreement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we made a payment of $1.75&#160;million for the annual license maintenance fee. We expensed $0.4&#160;million for the three&#160;months&#160;ended March&#160;31,&#160;2023, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statement of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AAHI License Agreements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we entered into two&#160;license agreements with AAHI pursuant to which we received a license to certain patents and know-how relating to AAHI&#8217;s (i)&#160;adjuvant formulations for the treatment, prevention and/or diagnosis of SARS-CoV-2 (the AAHI&#160;Adjuvant Formulation License Agreement) and (ii)&#160;RNA vaccine platform as further described below (the AAHI RNA License Agreement). Under both agreements, we were obligated to pay one-time, non-creditable, non-refundable upfront cash payments totaling $2.0&#160;million. In addition, under the AAHI Adjuvant Formulation License Agreement we owe milestone payments to a total of up to $2.5&#160;million based on the achievement of certain development and regulatory milestones for the first&#160;licensed product and royalties on annual net sales of licensed products on a country-by-country and product-by-product basis of a low-single digit percentage, subject to certain royalty-reduction provisions. No&#160;milestone fees were incurred for the three months ended March&#160;31,&#160;2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September&#160;2021, we amended and restated the AAHI RNA License Agreement, pursuant to which AAHI granted us an exclusive, worldwide, sublicensable license to AAHI&#8217;s rights to an RNA&#160;vaccine platform for the development and commercialization of certain therapeutic, diagnostic or prophylactic products for the prevention, treatment or diagnosis of any indication, other than those subject to pre-existing third-party license grants, including, without limitation, SARS-CoV-2. Pursuant to the terms of the amended and restated AAHI RNA License Agreement, we made a one-time, non-creditable, non-refundable, upfront payment to AAHI of $1.5&#160;million and a license maintenance fee of $3.0&#160;million in June&#160;2022. The company is required to pay license maintenance fees to AAHI of $5.5&#160;million annually from 2023 through 2030. The company may terminate the restated agreement without cause by paying AAHI a $10.0&#160;million one-time early termination fee. In addition, the milestone payments to AAHI based on the achievement of certain development and regulatory milestones for the first&#160;licensed product were amended to a total of up to $4.0&#160;million. We are required to pay royalties on annual net sales of licensed products on a country-by-country and product-by-product basis of a low to mid-single digit percentage. We recorded $0.8&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated statement of operations during the three months ended March&#160;31,&#160;2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the license agreements, in May&#160;2021 we also entered into a sponsored research agreement with the AAHI pursuant to which we will fund continued research of at least $2.0&#160;million per year, payable in four&#160;equal quarterly installments each year until May&#160;2024, or such year of earlier termination. No expenses were incurred for the three months ended March&#160;31,&#160;2023.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dunkirk Facility Leasehold Interest</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;14,&#160;2022, we completed the acquisition of a leasehold interest in approximately 409,000 rentable square feet&#160;of current Good Manufacturing Practice (cGMP) ISO Class&#160;5 pharmaceutical manufacturing space in western New&#160;York (the&#160;Dunkirk Facility) from Athenex,&#160;Inc. (the Seller), which we believe will provide us with a state-of-the-art biotech production center that will substantially expand and diversify our manufacturing capacity in the U.S. and ability to scale production associated with certain of our product candidates. The company accounted for the transaction as an asset acquisition because the Dunkirk Facility&#8217;s integrated set of assets and activities does not meet the definition of a business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total consideration for the acquisition was approximately $40.5&#160;million, including a cash payment of $40.0&#160;million, and transaction costs of approximately $0.5&#160;million. The following table summarizes the fair value of assets acquired as of the acquisition date (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other depreciable assets and prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,508&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i5bbe340c9c8f435088d8011b72b6800d_43" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Note </a><a href="#i5bbe340c9c8f435088d8011b72b6800d_43" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Statement Details&#8212;Intangible Assets, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, for further information.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing of the Dunkirk transaction, the company became the tenant of the Dunkirk Facility under the Fort Schuyler Management Corporation Lease, dated October&#160;1,&#160;2021 and as amended as of the February&#160;14,&#160;2022 closing date (as amended, the Dunkirk Lease), with Fort Schuyler Management Corporation, a not-for-profit corporation affiliated with the State of New York (FSMC) as landlord. The Dunkirk Facility, as well as certain equipment, is owned by FSMC and is leased to us under the Dunkirk Lease. Our annual lease payment will be $2.00 per year&#160;for an initial 10-year term, with an option to renew the lease under substantially the same terms and conditions for an additional 10-year term. As part of the transaction, we assumed certain of the Seller&#8217;s obligations under various third-party agreements (the Facility Agreements), subject to the terms and conditions of the purchase agreement by and between the company and Seller dated as of January&#160;7,&#160;2022, and committed to spend an aggregate of $1.52&#160;billion on operational expenses during the initial term, and an additional $1.50&#160;billion on operational expenses if we elect to renew the lease for the additional 10-year term. We also committed to hiring 450 employees at the Dunkirk Facility within the first five years of operations, with 300&#160;such employees to be hired within the first 2.5 years of operation. We are eligible for certain sales-tax exemption savings during the development of the Dunkirk Facility, and certain property tax savings over the next 20 years, subject to certain terms and conditions, including performance of certain of the obligations described above. Failure to satisfy the obligations over the lease term may give rise to certain rights and remedies of governmental authorities including, for example, termination of the Dunkirk Lease and other Facility Agreements and potential recoupment of a percentage of the grant funding received by the Seller for construction of the facility and other benefits received, subject to the terms and conditions of the applicable agreements. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that governmental funding will assist in funding a portion of the further build-out of the Dunkirk Facility, which we estimate to be approximately $8.0&#160;million&#160;to $10.0&#160;million of governmental funding remaining available as of March&#160;31,&#160;2023, there can be no assurance as to the final acceptance and timing of the requests for governmental funding that we submit, and we will need to plan and fund most of the additional build-out of, and purchase additional equipment for, the Dunkirk Facility in connection with our planned full operations. In addition, any future governmental funding will be subject to the eligibility of submitted expenses, as well as our compliance with the obligations that we are subject to pursuant to the agreements with parties regarding the Dunkirk Facility as described above.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI https://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820113261584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Related to Business Combinations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VivaBioCell, S.p.A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April&#160;2015, NantWorks,&#160;LLC (NantWorks), a related party, acquired a 100% interest in VivaBioCell, S.p.A. (VivaBioCell) through its wholly-owned subsidiary, VBC Holdings,&#160;LLC, (VBC Holdings) for $0.7&#160;million, less working capital adjustments. In June&#160;2015, NantWorks contributed its equity interest in VBC Holdings to the company, in exchange for cash consideration equal to its cost basis in the investment. VivaBioCell develops bioreactors and products based on cell culture and tissue engineering in Italy. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of VBC, we are obligated to pay the former owners contingent consideration upon the achievement of certain milestones related to the GMP-in-a-Box technology. A clinical milestone totaling $0.8&#160;million was earned by the former owners of VivaBioCell, of which $0.4&#160;million was paid during 2021, with the remaining clinical obligation settled in September&#160;2022. If a government agency unconditionally approves the GMP-in-a-Box technology for commercial sale (the regulatory milestone) in the future, we will be obligated to pay an additional approximately $2.2&#160;million to the former owners. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Altor BioScience Corporation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the&#160;2017 acquisition of Altor BioScience Corporation (Altor), we issued contingent value rights (CVRs) under which we agreed to pay the prior stockholders of Altor approximately $304.0&#160;million contingent consideration upon the successful regulatory approval of a BLA by the FDA, or foreign equivalent, for N-803 by December&#160;31,&#160;2022 and approximately $304.0&#160;million contingent consideration upon calendar-year worldwide net sales of N-803 exceeding $1.0&#160;billion prior to December&#160;31,&#160;2026, with amounts payable in cash or shares of our common stock or a combination thereof. As the transaction was recorded as an asset acquisition, future CVR payments will be recorded when the corresponding events are probable of achievement or the consideration becomes payable.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the regulatory milestone CVR agreement, in May&#160;2022 we announced the submission of a BLA to the FDA for our product candidate, Anktiva (N-803) in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1 disease</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n July&#160;2022 we announced that the FDA had accepted our BLA for review and set a target PDUFA action date of May&#160;23,&#160;2023. On May&#160;9,&#160;2023, the FDA delivered a complete response letter to us regarding the BLA. The company plans to request a meeting with the FDA as soon as possible to address the subject matter of the letter and a response timeline, and plans to diligently address and resolve the issues identified and seek approval as expeditiously as possible. It is unclear when the FDA will approve our BLA, if at all. The FDA did not approve our BLA on or before December&#160;31,&#160;2022, and therefore the regulatory milestone was not met, and the regulatory milestone CVR agreement terminated in accordance with its terms.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the net sales milestone CVR agreement, as of March&#160;31,&#160;2023, Dr.&#160;Soon-Shiong and his related party hold approximately $139.8&#160;million of net sales CVRs and they have both irrevocably agreed to receive shares of the company&#8217;s common stock in satisfaction of their CVRs. We may be required to pay the other prior Altor stockholders up to $164.2&#160;million for their net sales CVRs should they choose to have their CVRs paid in cash instead of common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. If we are served with any such complaints, we will assess at that time any contingencies for which we may need to reserve. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Altor BioScience, LLC Litigation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, NantCell,&#160;Inc. (NantCell) announced it had entered into a definitive merger agreement to acquire Altor BioScience Corporation. An action captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gray v.&#160;Soon-Shiong, et&#160;al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was filed in Delaware Chancery Court by plaintiffs Clayland Boyden Gray (Gray) and Adam R. Waldman. The plaintiffs, two&#160;minority stockholders, asserted claims against the company and other defendants for (1)&#160;breach of fiduciary duty and (2)&#160;aiding and abetting breach of fiduciary duty and filed a motion to enjoin the merger. The court denied the motion and permitted the merger to close. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the close of the merger, in 2017 the plaintiffs (joined by two&#160;additional minority stockholders, Barbara&#160;Sturm Waldman and Douglas E. Henderson (Henderson)) filed a second&#160;amended complaint, including appraisal claims, and which the defendants subsequently moved to dismiss. In a second&#160;action, Dyad Pharmaceutical Corporation (Dyad) filed a petition in Delaware Chancery Court for appraisal in connection with the merger. The defendants moved to dismiss the appraisal petition in 2018. The court issued an oral ruling in 2019 that dismissed certain claims and dismissed Altor BioScience from the action. The following claims remained: (a)&#160;the appraisal claims by all plaintiffs and Dyad (against Altor BioScience,&#160;LLC), and (b)&#160;Henderson&#8217;s claims for breach of fiduciary duty and aiding and abetting breach of fiduciary duty. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the court issued a written order implementing its ruling on the defendants&#8217; motions (the Implementing Order). In the Implementing Order, the court confirmed that all fiduciary duty claims brought by Gray, both individually and as trustee of the Gordon Gray Trust f/b/o&#160;C. Boyden Gray, were dismissed. The plaintiffs then moved for leave to file a third&#160;amended complaint to add two&#160;former Altor stockholders as plaintiffs and a fiduciary duty claim on behalf of a purported class of former Altor stockholders, which the defendants opposed. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the court granted the plaintiffs&#8217; motion, and the plaintiffs filed the third&#160;amended complaint. In 2020, the defendants answered the third&#160;amended complaint and asserted counterclaims against the plaintiffs. The defendants sought damages for attorneys&#8217; fees and costs incurred as a result of the breaches of &#8220;standstill&#8221; agreements and of stockholder releases. The plaintiffs filed an answer denying the counterclaims and asserting defenses. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of the former Altor stockholders seeking appraisal met the definition of dissenting shares under the merger agreement and were not entitled to receive any portion of the merger consideration at the closing date, given that those shares were the subject of the above-described appraisal claims. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late March&#160;2022, the company agreed to the terms of a settlement with the appraisal petitioners, without any admission of liability or fault. The settlement provided that in exchange for complete releases, the appraisal petitioners, who as a group held 3,167,565&#160;dissenting Altor shares, collectively would receive an aggregate of 2,229,296&#160;shares of the company&#8217;s common stock issued in a private placement, plus an aggregate of $21.13&#160;in cash in lieu of fractional shares. The company&#8217;s Board of Directors approved the settlement and stock issuance in April&#160;2022, and the court approved the settlement and dismissed the appraisal petitioners&#8217; claims on July&#160;9,&#160;2022. On July&#160;9,&#160;2022, the company issued 2,229,296&#160;shares of its common stock with an aggregate market value of $10.7&#160;million, based on the closing price of its common stock on the Nasdaq as of July&#160;8,&#160;2022, to the appraisal petitioners pursuant to the court-approved settlement agreement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late April&#160;2022, the company also agreed to the terms of a settlement with the putative class plaintiffs without any admission of liability or fault. In exchange for class-wide releases, the company committed to make a settlement payment of $5.0&#160;million in cash by December&#160;31,&#160;2022. On December&#160;8,&#160;2022, the Delaware Court of Chancery entered a final judgment approving the settlement, and the company timely made the $5.0&#160;million settlement payment.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sorrento Therapeutics, Inc. Litigation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sorrento Therapeutics,&#160;Inc. (Sorrento), derivatively on behalf of Immunotherapy NANTibody,&#160;LLC (NANTibody) filed an action in the Superior Court of California, Los Angeles County (the Superior Court) against the company&#8217;s subsidiary NantCell, Dr.&#160;Soon-Shiong, and Charles&#160;Kim. The action alleged that the defendants improperly caused NANTibody to acquire IgDraSol,&#160;Inc. (IgDraSol) from NantPharma,&#160;LLC (NantPharma) and sought to have the transaction undone and the purchase amount returned to NANTibody. In 2019, we filed a demurrer to several causes of action alleged in the Superior Court action, and Sorrento filed an amended complaint, eliminating Mr.&#160;Kim as a defendant and dropping the causes of action we had challenged in our demurrer. The company believes the case is without merit and intends to vigorously defend against the claims asserted. Trial has been set to commence in Sorrento&#8217;s Superior Court action on July&#160;17,&#160;2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in 2019, the company and Dr.&#160;Soon-Shiong filed cross-claims in the Superior Court action against Sorrento and its Chief Executive Officer Henry&#160;Ji, asserting claims for fraud, breach of contract, breach of the covenant of good faith and fair dealing, tortious interference with contract, unjust enrichment, and declaratory relief. Our claims alleged that Dr.&#160;Ji and Sorrento breached the terms of an exclusive license agreement between the company and Sorrento related to Sorrento&#8217;s antibody library and that Sorrento did not perform its obligations under the exclusive license agreement. The Superior Court ruled that the company&#8217;s claims should be pursued in arbitration and that Dr.&#160;Soon-Shiong&#8217;s claims could be pursued in Superior Court.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the company, along with NANTibody, filed an arbitration against Sorrento and Dr.&#160;Ji asserting our claims relating to the exclusive license agreement. Sorrento filed counterclaims against the company and NANTibody in the arbitration. The hearings in the NANTibody arbitration commenced in April&#160;2021 and concluded in early August&#160;2021. After post-hearing briefing was concluded, the parties were notified on November&#160;30,&#160;2021 that the arbitrator in the NANTibody arbitration had passed away. A substitute arbitrator was appointed on February&#160;25,&#160;2022, and the parties worked with the substitute arbitrator to conclude the proceedings. Additional hearing sessions were held in May and July&#160;2022, and summations took place on August&#160;2,&#160;2022. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;2, 2022, the arbitrator issued a final award finding that Sorrento had breached the two&#160;exclusive license agreements with NantCell and NANTibody. The arbitrator awarded NantCell approximately $156.8&#160;million and NANTibody approximately $16.7&#160;million, plus post-award interest accruing at a daily rate. On December&#160;21,&#160;2022, NantCell and NANTibody filed petitions in the Superior Court to confirm the arbitration award; on January&#160;16,&#160;2023, Sorrento filed a response to the petitions and moved to vacate the award. On February&#160;7, 2023, after a hearing, the Superior Court entered orders confirming the arbitration award and denying Sorrento&#8217;s motion to vacate. The Superior Court entered judgments against Sorrento in the aggregate amount of approximately $176.4&#160;million plus 10% post-judgment interest, of which approximately $159.4&#160;million is payable to NantCell, and the remainder of which is payable to NANTibody. On February&#160;13,&#160;2023, Sorrento informed counsel to the company that it had filed a Chapter&#160;11 proceeding in the U.S. District Court for the Southern District of Texas, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Sorrento Therapeutics,&#160;Inc., et&#160;al.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Case No.&#160;23-bk-90085 (Bankr. S.D. Tex.) (DRJ). The company intends to continue to pursue vigorously, consistent with its rights in light of Sorrento&#8217;s Chapter&#160;11 filing, the collection of the judgments from Sorrento, but we make no assurances that we will receive the full amount or with respect to the timing of our receipt of any funds. As of March&#160;31,&#160;2023, we have not determined the amount we are likely to recover, and thus have not recorded any receivables in relation to the judgments.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Superior Court action remains pending, and it remains to be determined how, if at all, the award in the arbitration will affect the Superior Court action. An estimate of the possible loss or range of loss resulting from the Superior Court litigation cannot be made at this time.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shenzhen Beike Biotechnology Co. Ltd. Arbitration</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we received a Request for Arbitration before the International Chamber of Commerce, International Court of Arbitration. The arbitration relates to a license, development, and commercialization agreement that Altor entered into with Beike in 2014, which agreement was amended and restated in 2017, pursuant to which Altor granted to Beike an exclusive license to use, research, develop and commercialize products based on N-803 in China for human therapeutic uses. In the arbitration, Beike is asserting a claim for breach of contract under the license agreement. Among other things, Beike alleges that we failed to use commercially reasonable efforts to deliver to Beike materials and data related to N-803. Beike is seeking specific performance and declaratory relief for the alleged breaches. On September&#160;25,&#160;2020, the parties entered into a standstill and tolling agreement (standstill agreement) under which, among other things, the parties affirmed they will perform certain of their obligations under the license agreement by specified dates and agreed that all deadlines in the arbitration are indefinitely extended. The standstill agreement could be terminated by any party on ten calendar days&#8217; notice, and upon termination, the parties had the right to pursue claims arising from the license agreement in any appropriate tribunal. On March&#160;20,&#160;2023, we terminated the standstill agreement, and on April&#160;11,&#160;2023, Beike served an amended Request for Arbitration. We have until May&#160;19,&#160;2023 to file a response. Given that this action remains at the pleading stage and no discovery has occurred, it remains too early to evaluate the likely outcome of the case or to estimate any range of potential loss. We believe the claims lack merit and intend to defend the case vigorously and that we may have counterclaims.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stipulation of Settlement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, following approval by our Board of Directors, we entered into a settlement agreement (the Stipulation of Settlement) with three stockholders of the company, each of whom had submitted a stockholder demand for the Board of Directors to take action to remedy purported harm to the company resulting from certain alleged wrongful conduct concerning, among other things, disclosures about Dr. Soon-Shiong&#8217;s compensation and a related-party lease agreement. The Stipulation of Settlement called for us to adopt certain governance changes, and for the three stockholders to file a stockholder derivative action in the Superior Court of the State of California, County of San Diego, followed by an application for court approval of the Stipulation of Settlement. The court entered an order preliminarily approving the Stipulation of Settlement. Pursuant to the Stipulation of Settlement, we provided stockholders with notice of the settlement and the final settlement hearing.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not enter into any significant contracts during the three months ended March&#160;31,&#160;2023, other than those disclosed in these condensed consolidated financial statements.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are also a party to various contracts with contract research organizations and contract manufacturers that generally provide for termination on notice, with the exact amounts in the event of termination to be based on the timing of the termination and the terms of the agreement. There have been no material changes in unconditional purchase commitments from those disclosed in Note&#160;7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies,</span> of the &#8220;Notes to Consolidated Financial Statements&#8221; that appears in Part&#160;II, Item&#160;8. &#8220;Financial Statements and Supplementary Data&#8221; of our Annual Report on Form&#160;10-K filed with the SEC on March&#160;1,&#160;2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820113218416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lease Arrangements</a></td>
<td class="text">Lease Arrangements<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease property in multiple facilities across the U.S. (including the Dunkirk Facility in upstate New York) and Italy, including facilities located in El&#160;Segundo,&#160;CA, which are leased from related parties. Substantially all of our operating lease right-of-use assets and operating lease liabilities relate to facilities leases. All of our finance leases are related to equipment rental at the Dunkirk Facility. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i5bbe340c9c8f435088d8011b72b6800d_76" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information about our related-party leases.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leases generally have initial terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfNTkx_1b5ac21f-8317-4cdf-9aa4-b1a83fbec98e">two</span> to ten years and often include one or more options to renew. These renewal terms can extend the lease term from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfNjk5_f0f50d52-6d48-4a58-8a65-ea201cb85f30">one</span> to ten years, and are included in the lease term when it is reasonably certain that we will exercise the option.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to our leases is as follows (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:33.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.453%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.284%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,191&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,788&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNS0xLTEtMS0yOTgzNTI_716b2b64-20b1-40c3-9b02-a3d14868228b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNS0xLTEtMS0yOTgzNTI_79bf86fc-1a0b-4632-b3b5-c9756666aba0">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,306&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,923&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTEtMS0xLTEtMjk4MzUy_1e304c6d-b6fc-4a07-96b6-252e1c6d5e68"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTEtMS0xLTEtMjk4MzUy_7f502521-7e3c-4089-bd21-ee4709a6ff0e">Accrued expenses and other liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities, less current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTQtMS0xLTEtMjk4MzUy_1cbef275-f42e-4514-b41d-8b9c75783db1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTQtMS0xLTEtMjk4MzUy_cccafda1-bc6a-4e69-9eb2-a02fc2fcc607">Other liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,255&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,742&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding our lease terms is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:71.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average remaining lease term:</span></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance leases</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average discount rate:</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance leases</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:71.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.302%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March&#160;31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease costs (including amortization and <br/>&#160;&#160;&#160;interest costs)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,964&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities is as follows (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:71.298%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.339%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.341%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash paid for operating leases (excluding variable lease costs)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Financing cash flow from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flow from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments as of March&#160;31,&#160;2023, including $14.8&#160;million related to options to extend lease terms that are reasonably certain of being exercised, are presented in the following table (in&#160;thousands). Common area maintenance costs and taxes are not included in these payments.</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.331%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Years ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Operating</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Finance <br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023 (excluding the three months ended March&#160;31,&#160;2023)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72,758&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">132&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72,890&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Tenant improvement allowance receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49,133&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">122&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49,255&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes related to our existing lease agreements from those disclosed in Note&#160;8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the Notes to Consolidated Financial Statements of our Annual Report on Form&#160;10-K filed with the SEC on March&#160;1,&#160;2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Lease Arrangements</a></td>
<td class="text">Lease Arrangements<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease property in multiple facilities across the U.S. (including the Dunkirk Facility in upstate New York) and Italy, including facilities located in El&#160;Segundo,&#160;CA, which are leased from related parties. Substantially all of our operating lease right-of-use assets and operating lease liabilities relate to facilities leases. All of our finance leases are related to equipment rental at the Dunkirk Facility. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i5bbe340c9c8f435088d8011b72b6800d_76" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information about our related-party leases.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leases generally have initial terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfNTkx_1b5ac21f-8317-4cdf-9aa4-b1a83fbec98e">two</span> to ten years and often include one or more options to renew. These renewal terms can extend the lease term from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfNjk5_f0f50d52-6d48-4a58-8a65-ea201cb85f30">one</span> to ten years, and are included in the lease term when it is reasonably certain that we will exercise the option.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to our leases is as follows (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:33.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.453%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.284%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,191&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,788&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNS0xLTEtMS0yOTgzNTI_716b2b64-20b1-40c3-9b02-a3d14868228b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNS0xLTEtMS0yOTgzNTI_79bf86fc-1a0b-4632-b3b5-c9756666aba0">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,306&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,923&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTEtMS0xLTEtMjk4MzUy_1e304c6d-b6fc-4a07-96b6-252e1c6d5e68"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTEtMS0xLTEtMjk4MzUy_7f502521-7e3c-4089-bd21-ee4709a6ff0e">Accrued expenses and other liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities, less current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTQtMS0xLTEtMjk4MzUy_1cbef275-f42e-4514-b41d-8b9c75783db1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTQtMS0xLTEtMjk4MzUy_cccafda1-bc6a-4e69-9eb2-a02fc2fcc607">Other liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,255&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,742&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding our lease terms is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:71.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average remaining lease term:</span></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance leases</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average discount rate:</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance leases</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:71.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.302%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March&#160;31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease costs (including amortization and <br/>&#160;&#160;&#160;interest costs)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,964&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities is as follows (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:71.298%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.339%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.341%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash paid for operating leases (excluding variable lease costs)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Financing cash flow from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flow from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments as of March&#160;31,&#160;2023, including $14.8&#160;million related to options to extend lease terms that are reasonably certain of being exercised, are presented in the following table (in&#160;thousands). Common area maintenance costs and taxes are not included in these payments.</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.331%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Years ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Operating</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Finance <br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023 (excluding the three months ended March&#160;31,&#160;2023)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72,758&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">132&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72,890&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Tenant improvement allowance receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49,133&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">122&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49,255&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes related to our existing lease agreements from those disclosed in Note&#160;8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the Notes to Consolidated Financial Statements of our Annual Report on Form&#160;10-K filed with the SEC on March&#160;1,&#160;2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820113205184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Debt</a></td>
<td class="text">Related-Party Debt<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Convertible Note at Fair Value</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2023, the company executed a $30.0&#160;million promissory note with Nant&#160;Capital, LLC (Nant&#160;Capital), an affiliated entity under common control of our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder. This note bears interest at Term Secured Overnight Financing Rate (SOFR) plus 8.0%&#160;per annum. The outstanding principal amount and any accrued and unpaid interest are due on December&#160;31,&#160;2023 or upon the occurrence and continuation of an Event of Default (as defined in the note). The interest on this note will be paid on a quarterly basis beginning on June&#160;30,&#160;2023. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. The noteholder may convert the balance of the convertible promissory note and accrued interest in whole at its option following the Conversion Price Date, which is the trading day prior to the opening of the next open trading window, as determined by the company&#8217;s board of directors in accordance with the company&#8217;s Insider Trading Policy. The conversion price is equal to the greater of (i)&#160;the NASDAQ Official Closing Price and (ii)&#160;the consolidated closing bid price of the company&#8217;s common stock on the Conversion Price Date. There is no floor on the conversion price for this convertible note, therefore, as of March&#160;31,&#160;2023 we cannot determine the total number of shares issuable upon conversion that may occur in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company received net proceeds of $29.9&#160;million from this financing, net of a $0.1&#160;million origination fee paid to the lender. The note is accounted for under ASC 825-10-15-4 FVO&#160;election. Under the FVO election, the note is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. With each such remeasurement, the note will be adjusted to fair value, with the change in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other income (expense), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statement of operations, except that </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the change in the fair value resulting from a change in the instrument-specific credit risks are recognized as a component of other comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of March&#160;31,&#160;2023, we had a balance of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$29.9&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">related-party convertible note at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated balance sheets related to the convertible promissory note measured at fair value.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Convertible Notes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;31,&#160;2022, the company amended and restated an aggregate of $315.1&#160;million (including outstanding principal and accrued and unpaid interest) of fixed-rate promissory notes held by entities affiliated with Dr. Soon-Shiong. Prior to the amendments and restatements, these notes bore and continue to bear interest at a per annum rate ranging from 3.0% to 6.0%, provide that the outstanding principal was and continues to be due and payable on September&#160;30,&#160;2025, and accrued and unpaid interest was or continues to be payable either upon maturity or, with respect to one of the notes, on a quarterly basis. Prior to the amendments and restatements, the company could and can continue to prepay the outstanding principal (together with accrued and unpaid interest), either in whole or in part, at any time without premium or penalty and without the prior consent of the lender, now subject to an advance notice period of at least five&#160;business days during which the lender can convert the amount requested to be prepaid by the company into shares of the company&#8217;s common stock, as part of the amendment and restatement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of these fixed-rate promissory notes were amended and restated to include a conversion feature that gives each lender, at its sole option, at any time (other than when the lender is in receipt of a written notice of prepayment from the borrower), the right to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the company&#8217;s common stock at a price of $5.67 per share. Upon receipt of a written notice of prepayment from the borrower, the lender has the right, at its option, to convert the outstanding principal amount to be prepaid and the accrued and unpaid interest thereon (as specified in the notice of prepayment) into shares of the company&#8217;s common stock at a price of $5.67&#160;per share. No other material terms or conditions of these fixed-rate promissory notes were modified as part of the August&#160;31,&#160;2022 amendments and restatements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, the carrying value of the fixed-rated convertible promissory notes of $245.6&#160;million and $241.3&#160;million, respectively, was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">related-party convertible notes and accrued interest, net of discount,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets. During the three months ended March&#160;31,&#160;2023 and 2022, the company made interest payments of $0.6&#160;million and $0.6&#160;million, respectively, related to our $40.0&#160;million promissory note.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Nonconvertible Notes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, the company had a promissory note outstanding with Nant Capital for $300.0&#160;million in principal and a carrying balance of $272.2&#160;million, net of unamortized discount of $27.8&#160;million. The note bears an interest rate of Term&#160;SOFR plus 8.0% per annum, payable on a quarterly basis. In the event of a default on the loan (as defined in both the original and amended and restated promissory notes), including if the company does not repay the loan at maturity, the company had and continues to have the right, at its sole option, to convert the outstanding principal amount and accrued and unpaid interest due under this note into fully paid and non-assessable shares of the company&#8217;s common stock at a conversion price per share equal to $5.67. The company made interest payments of $9.4&#160;million and $4.4&#160;million during the three&#160;months&#160;ended March&#160;31,&#160;2023 and 2022, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, the company had a promissory note outstanding with Nant Capital for $125.0&#160;million in principal and a carrying balance of $119.6&#160;million, net of unamortized discount of $5.4&#160;million. The note bears an interest rate of Term&#160;SOFR plus 8.0% per annum, payable on a quarterly basis. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. The company made an interest payment of $3.9&#160;million during three&#160;months&#160;ended March&#160;31,&#160;2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, the company had a promissory note outstanding with Nant Capital for $50.0&#160;million in principal and a carrying balance of $49.8&#160;million, net of unamortized discount of $0.2&#160;million. The note bears an interest rate of Term&#160;SOFR plus 8.0% per annum, payable on a quarterly basis. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. In the event of a Specified Transaction (as defined in the loan agreement), the noteholder can request the outstanding principal and interest due on the loan be repaid in full upon consummation of such Specified Transaction. The company made a cash payment of $1.6&#160;million during three&#160;months&#160;ended March&#160;31,&#160;2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our related-party debt is summarized below (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.406%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at March&#160;31,&#160;2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Year</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accrued<br/>Interest<br/>Added to<br/>Note</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less:<br/>Unamortized <br/>Discounts</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Nonconvertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term SOFR + 8.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Convertible Note <br/>&#160;&#160;&#160;at Fair Value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term SOFR + 8.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantMobile, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantCancerStemCell, LLC (NCSC)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total related-party convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,226&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,713&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,299&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,640&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total related-party debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738,226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,713&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,671&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,118&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:3.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.132%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The interest rate on our related-party variable-rate notes as of March&#160;31,&#160;2023 was 12.89%.</span></div></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.406%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December&#160;31,&#160;2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Year</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accrued<br/>Interest<br/>Added to<br/>Note</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less:<br/>Unamortized <br/>Discounts</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Nonconvertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term SOFR + 8.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantMobile</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NCSC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total related-party convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,226&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,153&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,108&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241,271&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total related-party debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,153&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,207&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673,172&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:3.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.132%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The interest rate on our related-party variable-rate notes as of December&#160;31,&#160;2022 was 12.59%.</span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future contractual obligations for our related-party debt as of March&#160;31,&#160;2023 (unaudited; in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.404%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Payments (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible<br/>Notes</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-convertible<br/>Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible<br/>Notes</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-convertible<br/>Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (excluding the three months ended </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;March&#160;31,&#160;2023)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal and estimated interest <br/>&#160;&#160;&#160;due on related-party debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,181&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,131&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:3.661%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest payments on our fixed-rate convertible notes are calculated based on contractual interest rates and scheduled maturity dates. Interest payments on our variable-rate notes are calculated based on Term&#160;SOFR plus the contractual spread per the loan agreements. The rate on our variable-rate notes as of March&#160;31,&#160;2023 was 12.89%.</span></div></td></tr></table></div>Related-Party Agreements <div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business with several affiliates under written agreements and informal arrangements. Below is a summary of outstanding balances and a description of significant relationships (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related party&#8211;NantBio, Inc.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related party&#8211;Brink Biologics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related parties&#8211;Various</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total due from related parties</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,464&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,890&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;Duley Road, LLC</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;NantBio, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;NantWorks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;Immuno-Oncology Clinic, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total due to related parties</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,932&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,469&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder founded and has a controlling interest in NantWorks, which is a collection of companies in the healthcare and technology space. As described below, we have entered into arrangements with NantWorks, and certain affiliates of NantWorks, to facilitate the development of new immunotherapies for our product pipeline. Affiliates of NantWorks are also affiliates of the company due to the common control by and/or common ownership interest of our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NantWorks, LLC</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shared Services Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the amended and restated shared services agreement with NantWorks dated as of June&#160;2016, but effective as of August&#160;2015, NantWorks, a related party, provides corporate, general and administrative, certain research and development, and other support services. We are charged for the services at cost plus reasonable allocations of employee benefits, facilities, and other direct or fairly allocated indirect costs that relate to the employees providing the services. For the three months ended March&#160;31,&#160;2023 and 2022, we recorded $1.0&#160;million and $1.3&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">selling, general and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $0.4&#160;million of expense reimbursements and an immaterial amount, respectively, under this arrangement in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations. These amounts exclude certain general and administrative expenses provided by third-party vendors directly for our benefit, which were reimbursed to NantWorks based on those vendors&#8217; invoiced amounts without markup by NantWorks. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, we owed NantWorks net amounts of $0.6&#160;million and $1.0&#160;million, respectively, for all agreements between the two&#160;affiliates, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due to related parties,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets. We also recorded $2.1&#160;million and $2.0&#160;million of prepaid expenses for services that have been passed through to the company from NantWorks as of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">prepaid expenses and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated balance sheets.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we entered into a facility license agreement with NantWorks for approximately 9,500 rentable square feet of office space in Culver&#160;City, California, which was converted to a research and development laboratory and a cGMP manufacturing facility. In&#160;2020, we amended this agreement to extend the term of this license agreement through December&#160;31,&#160;2021. Commencing on January&#160;1,&#160;2022, the license fee increased by 3% to approximately $56,120 per month.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;6,&#160;2022, we amended our facility license agreement with NantWorks to expand the licensed premises by 36,830&#160;rentable square feet to an aggregate total of 46,330 rentable square feet. Effective May&#160;1,&#160;2022, the license fee is approximately $273,700 per month, which is subject to a 3%&#160;increase commencing on January&#160;1 of each year. The space continues to be rented on a month-to-month basis, which can be terminated by either party with at least 30&#160;days&#8217; prior written notice to the other party. We recorded license fee expense for this facility totaling $0.8&#160;million and $0.2&#160;million for the three months ended March&#160;31,&#160;2023 and 2022, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Immuno-Oncology Clinic, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into multiple agreements with Immuno-Oncology Clinic,&#160;Inc.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Clinic)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to conduct clinical trials related to certain of our product candidates. The Clinic is a related party as it is owned by an officer of the company and NantWorks manages the administrative operations of the Clinic. Pursuant to the terms of the Clinic agreement (as amended), we made payments totaling </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.6&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in consideration of future services to be performed by the Clinic. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we completed a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review of alternative structures that could support our more complex clinical trial requirements and made a decision to explore a potential transition of clinical trials at the Clinic to a new structure (including contracting with a new, non-affiliated professional corporation) to be determined and agreed upon by all parties. Based on this decision to explore a potential transition, we determined that it was more likely than not that the previously recorded prepaid asset would not result in the collection of fees for services performed by the Clinic as contemplated in the original agreements. As a result, we wrote down the remaining value of our prepaid asset and recorded approximately $4.4&#160;million in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statement of operations for the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We continue productive negotiations with potential partners around alternative structures, but there can be no assurance that we will be successful.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded $0.6&#160;million and $0.4&#160;million for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations related to clinical trial and transition services provided by the Clinic. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">owed the&#160;Clinic an immaterial amount and $0.1&#160;million, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NantBio, Inc. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, we entered into a supply agreement with NCSC, a 60%&#160;owned subsidiary of NantBio (with the other&#160;40% owned by Sorrento). Under this agreement, we agreed to supply VivaBioCell&#8217;s proprietary GMP-in-a-Box bioreactors and related consumables, made according to specifications mutually agreed to with both companies. The agreement has an initial term of five years and renews automatically for successive one-year terms unless terminated by either party in the event of material default upon prior written notice of such default and the failure of the defaulting party to remedy the default within 30&#160;days of the delivery of such notice, or upon 90 days&#8217; prior written notice by NCSC. We recognized no&#160;revenue for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and no revenue for the three months ended March&#160;31,&#160;2022. We recorded $0.1&#160;million and $0.1&#160;million of deferred revenue for bioreactors that were delivered but not installed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accrued expenses and other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated balance sheets as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31,&#160;2022, respectively. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31,&#160;2022, we recorded $0.9&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due to related parties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated balance sheets related to this agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we entered into a shared service agreement pursuant to which we are charged for services at cost, without mark-up or profit by NantBio, but including reasonable allocations of employee benefits that relate to the employees providing the services. In April&#160;2019, we agreed with NantBio to transfer certain NantBio employees and associated research and development projects to the company. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31,&#160;2022, we recorded a net receivable from NantBio of $1.3&#160;million for amounts we paid on behalf of NantBio during the year ended December&#160;31,&#160;2019.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">605 Doug St, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September&#160;2016, we entered into a lease agreement with 605&#160;Doug&#160;St,&#160;LLC, an entity owned by our Executive Chairman and Global Chief Scientific and Medical Officer, for approximately 24,250 rentable square feet in El&#160;Segundo, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. The lease runs from July&#160;2016 through July&#160;2023. We have the option to extend the lease for one&#160;additional three-year term through July&#160;2026. The base rent is approximately $72,385 per month, with annual increases of 3% that began in July&#160;2017. We recorded lease expense for this facility of $0.2&#160;million and $0.2&#160;million for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Duley Road, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February&#160;2017, we entered into a lease agreement with Duley&#160;Road, a related party that is indirectly controlled by our Executive Chairman and Global Chief Scientific and Medical Officer, for approximately 11,980 rentable square feet of office and cGMP manufacturing facility space in El&#160;Segundo, California. The lease term is from February&#160;2017 through October&#160;2024. We have the option to extend the initial term for two&#160;consecutive five-year periods through October&#160;2034. The base rent is approximately $40,700 per month, with annual increases of&#160;3%. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective in January&#160;2019, we entered into two&#160;lease agreements with Duley Road for a second&#160;building located in El&#160;Segundo, California. The first&#160;lease is for the first&#160;floor of the building with approximately 5,650 rentable square feet. The lease has a seven-year term commencing in September&#160;2019. The second&#160;lease is for the second&#160;floor of the building with approximately 6,488 rentable square feet. The lease has a seven-year term commencing in July&#160;2019. Both floors of the building are used for research and development and office space. We have options to extend the initial terms of both leases for two&#160;consecutive five-year periods through 2036. The base rent for the two&#160;leases is approximately $35,800 per month, with annual increases of&#160;3%.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31,&#160;2022, respectively, we recorded $0.9&#160;million and $0.9&#160;million of leasehold improvement payables, and $0.5&#160;million and $0.6&#160;million of lease-related payables, to Duley Road, which were included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due to related parties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated balance sheets. We recorded rent expense for these leases totaling $0.2&#160;million and $0.2&#160;million for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">605 Nash, LLC </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, but effective on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January&#160;1,&#160;2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we entered into a lease agreement with 605&#160;Nash, a related party, whereby we leased approximately 6,883 rentable square feet (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initial Premises) i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n a two&#160;story mixed use building containing approximately 64,643 rentable square feet on 605-607 Nash Street in El&#160;Segundo, California. This facility is used primarily for pharmaceutical development and manufacturing purposes. The lease term commenced in January&#160;2021 and expires in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;2027</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and includes an option to extend the lease for one three-year term through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;2030</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The base rent is approximately $20,300 per month with an annual increase of 3%&#160;on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January&#160;1</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of each year during the initial term and, if applicable, during the option term. In addition, under the agreement, we are required to pay our share of estimated property taxes and operating expenses. We received a rent abatement for the first seven months. The lease also provides a tenant improvement incentive of $0.3&#160;million for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs and expenses associated with the construction of tenant improvements for the Initial Premises.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May&#160;2021, but effective on April&#160;1,&#160;2021, we entered into an amendment to our Initial Premises lease with 605&#160;Nash. The amendment expanded the leased square feet by approximately 57,760 rentable square feet (the Expansion Premises). The lease term of the Expansion Premises commenced in April&#160;2021 and expires in March&#160;2028, whereby the company has the option to extend the initial term for three years. Per the terms of the amendment, the term of the Initial Premises lease was extended for an additional three&#160;months and now expires on March&#160;31,&#160;2028. Base rent for the Expansion Premises is approximately $170,400&#160;per month with annual increases of 3% on April&#160;1 of each year. We are responsible for the build out of the facility space and associated costs. We received a rent abatement for the first seven months. The amended lease provides for a tenant improvement allowance of approximately $2.6&#160;million for costs and expenses related to improvements made by us to the Expansion Premises. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded rent expense for the Initial and Expansion Premises leases totaling $0.5&#160;million and $0.5&#160;million for the three months ended March&#160;31,&#160;2023 and 2022, respectively, i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated statements of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">420 Nash, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;27,&#160;2021, we entered into a lease agreement with 420&#160;Nash,&#160;LLC, a related party, whereby we leased an approximately 19,125 rentable square foot property located at 420&#160;Nash Street, El&#160;Segundo, California, to be used primarily for the warehousing and storage of drug manufacturing supplies, products and equipment and ancillary office space. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the lease agreement, the lease term began on October&#160;1,&#160;2021 and expires on September&#160;30,&#160;2026. The base rent is approximately $38,250 per month with an annual increase of 3% on October&#160;1 of each year beginning in 2022 during the initial term. The company is responsible for the payment of real property taxes, repairs and maintenance, improvements, insurance and operating expenses during the term of the lease. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has options to extend the lease term for two&#160;additional consecutive periods of five years each. At the beginning of each option term, the initial monthly base rent will be adjusted to market rent (as defined in the lease agreement) with an annual increase of 3% during the option term. We have included the first&#160;option to extend the lease term for five&#160;years as part of the initial term of the lease as it is reasonably certain that we will exercise the option, which implies lease expiration in September&#160;2031. We recorded $0.1&#160;million and $0.1&#160;million of rent expense related to this lease for the three months ended March&#160;31,&#160;2023 and 2022, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">23&#160;Alaska, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;6,&#160;2022, we entered into a lease agreement with 23&#160;Alaska,&#160;LLC, a related party, for a 47,265 rentable square foot facility located at 2335&#160;Alaska Ave., El&#160;Segundo, California, to be used primarily for pharmaceutical development and manufacturing, research and development, and office space. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the lease term begins on May&#160;1,&#160;2022 and expires on April&#160;30,&#160;2027. The base rent is approximately $139,400&#160;per month with an annual increase of 3% on May&#160;1 of each year beginning in 2023 during the initial term. We are also required to pay $7,600&#160;per month for parking during the initial term and extension term, if exercised. The company is responsible for the payment of real property taxes, repairs and maintenance, improvements, insurance, and operating expenses during the term of the lease. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has&#160;an option to extend the lease term for one&#160;additional consecutive five-year period. At the beginning of the option term, the initial monthly base rent will be adjusted to market rent (as defined in the lease agreement) with an annual increase of 3%&#160;during the option term. We recorded $0.4&#160;million of rent expense for this lease for the three months ended March&#160;31,&#160;2023 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statement of operations.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820113261584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Agreements</a></td>
<td class="text">Related-Party Debt<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Convertible Note at Fair Value</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2023, the company executed a $30.0&#160;million promissory note with Nant&#160;Capital, LLC (Nant&#160;Capital), an affiliated entity under common control of our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder. This note bears interest at Term Secured Overnight Financing Rate (SOFR) plus 8.0%&#160;per annum. The outstanding principal amount and any accrued and unpaid interest are due on December&#160;31,&#160;2023 or upon the occurrence and continuation of an Event of Default (as defined in the note). The interest on this note will be paid on a quarterly basis beginning on June&#160;30,&#160;2023. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. The noteholder may convert the balance of the convertible promissory note and accrued interest in whole at its option following the Conversion Price Date, which is the trading day prior to the opening of the next open trading window, as determined by the company&#8217;s board of directors in accordance with the company&#8217;s Insider Trading Policy. The conversion price is equal to the greater of (i)&#160;the NASDAQ Official Closing Price and (ii)&#160;the consolidated closing bid price of the company&#8217;s common stock on the Conversion Price Date. There is no floor on the conversion price for this convertible note, therefore, as of March&#160;31,&#160;2023 we cannot determine the total number of shares issuable upon conversion that may occur in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company received net proceeds of $29.9&#160;million from this financing, net of a $0.1&#160;million origination fee paid to the lender. The note is accounted for under ASC 825-10-15-4 FVO&#160;election. Under the FVO election, the note is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. With each such remeasurement, the note will be adjusted to fair value, with the change in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other income (expense), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statement of operations, except that </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the change in the fair value resulting from a change in the instrument-specific credit risks are recognized as a component of other comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of March&#160;31,&#160;2023, we had a balance of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$29.9&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">related-party convertible note at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated balance sheets related to the convertible promissory note measured at fair value.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Convertible Notes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;31,&#160;2022, the company amended and restated an aggregate of $315.1&#160;million (including outstanding principal and accrued and unpaid interest) of fixed-rate promissory notes held by entities affiliated with Dr. Soon-Shiong. Prior to the amendments and restatements, these notes bore and continue to bear interest at a per annum rate ranging from 3.0% to 6.0%, provide that the outstanding principal was and continues to be due and payable on September&#160;30,&#160;2025, and accrued and unpaid interest was or continues to be payable either upon maturity or, with respect to one of the notes, on a quarterly basis. Prior to the amendments and restatements, the company could and can continue to prepay the outstanding principal (together with accrued and unpaid interest), either in whole or in part, at any time without premium or penalty and without the prior consent of the lender, now subject to an advance notice period of at least five&#160;business days during which the lender can convert the amount requested to be prepaid by the company into shares of the company&#8217;s common stock, as part of the amendment and restatement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of these fixed-rate promissory notes were amended and restated to include a conversion feature that gives each lender, at its sole option, at any time (other than when the lender is in receipt of a written notice of prepayment from the borrower), the right to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the company&#8217;s common stock at a price of $5.67 per share. Upon receipt of a written notice of prepayment from the borrower, the lender has the right, at its option, to convert the outstanding principal amount to be prepaid and the accrued and unpaid interest thereon (as specified in the notice of prepayment) into shares of the company&#8217;s common stock at a price of $5.67&#160;per share. No other material terms or conditions of these fixed-rate promissory notes were modified as part of the August&#160;31,&#160;2022 amendments and restatements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, the carrying value of the fixed-rated convertible promissory notes of $245.6&#160;million and $241.3&#160;million, respectively, was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">related-party convertible notes and accrued interest, net of discount,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets. During the three months ended March&#160;31,&#160;2023 and 2022, the company made interest payments of $0.6&#160;million and $0.6&#160;million, respectively, related to our $40.0&#160;million promissory note.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Nonconvertible Notes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, the company had a promissory note outstanding with Nant Capital for $300.0&#160;million in principal and a carrying balance of $272.2&#160;million, net of unamortized discount of $27.8&#160;million. The note bears an interest rate of Term&#160;SOFR plus 8.0% per annum, payable on a quarterly basis. In the event of a default on the loan (as defined in both the original and amended and restated promissory notes), including if the company does not repay the loan at maturity, the company had and continues to have the right, at its sole option, to convert the outstanding principal amount and accrued and unpaid interest due under this note into fully paid and non-assessable shares of the company&#8217;s common stock at a conversion price per share equal to $5.67. The company made interest payments of $9.4&#160;million and $4.4&#160;million during the three&#160;months&#160;ended March&#160;31,&#160;2023 and 2022, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, the company had a promissory note outstanding with Nant Capital for $125.0&#160;million in principal and a carrying balance of $119.6&#160;million, net of unamortized discount of $5.4&#160;million. The note bears an interest rate of Term&#160;SOFR plus 8.0% per annum, payable on a quarterly basis. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. The company made an interest payment of $3.9&#160;million during three&#160;months&#160;ended March&#160;31,&#160;2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, the company had a promissory note outstanding with Nant Capital for $50.0&#160;million in principal and a carrying balance of $49.8&#160;million, net of unamortized discount of $0.2&#160;million. The note bears an interest rate of Term&#160;SOFR plus 8.0% per annum, payable on a quarterly basis. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. In the event of a Specified Transaction (as defined in the loan agreement), the noteholder can request the outstanding principal and interest due on the loan be repaid in full upon consummation of such Specified Transaction. The company made a cash payment of $1.6&#160;million during three&#160;months&#160;ended March&#160;31,&#160;2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our related-party debt is summarized below (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.406%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at March&#160;31,&#160;2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Year</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accrued<br/>Interest<br/>Added to<br/>Note</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less:<br/>Unamortized <br/>Discounts</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Nonconvertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term SOFR + 8.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Convertible Note <br/>&#160;&#160;&#160;at Fair Value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term SOFR + 8.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantMobile, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantCancerStemCell, LLC (NCSC)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total related-party convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,226&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,713&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,299&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,640&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total related-party debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738,226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,713&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,671&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,118&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:3.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.132%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The interest rate on our related-party variable-rate notes as of March&#160;31,&#160;2023 was 12.89%.</span></div></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.406%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December&#160;31,&#160;2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Year</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accrued<br/>Interest<br/>Added to<br/>Note</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less:<br/>Unamortized <br/>Discounts</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Nonconvertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term SOFR + 8.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantMobile</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NCSC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total related-party convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,226&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,153&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,108&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241,271&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total related-party debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,153&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,207&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673,172&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:3.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.132%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The interest rate on our related-party variable-rate notes as of December&#160;31,&#160;2022 was 12.59%.</span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future contractual obligations for our related-party debt as of March&#160;31,&#160;2023 (unaudited; in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.404%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Payments (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible<br/>Notes</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-convertible<br/>Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible<br/>Notes</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-convertible<br/>Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (excluding the three months ended </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;March&#160;31,&#160;2023)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal and estimated interest <br/>&#160;&#160;&#160;due on related-party debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,181&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,131&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:3.661%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest payments on our fixed-rate convertible notes are calculated based on contractual interest rates and scheduled maturity dates. Interest payments on our variable-rate notes are calculated based on Term&#160;SOFR plus the contractual spread per the loan agreements. The rate on our variable-rate notes as of March&#160;31,&#160;2023 was 12.89%.</span></div></td></tr></table></div>Related-Party Agreements <div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business with several affiliates under written agreements and informal arrangements. Below is a summary of outstanding balances and a description of significant relationships (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related party&#8211;NantBio, Inc.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related party&#8211;Brink Biologics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related parties&#8211;Various</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total due from related parties</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,464&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,890&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;Duley Road, LLC</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;NantBio, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;NantWorks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;Immuno-Oncology Clinic, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total due to related parties</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,932&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,469&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder founded and has a controlling interest in NantWorks, which is a collection of companies in the healthcare and technology space. As described below, we have entered into arrangements with NantWorks, and certain affiliates of NantWorks, to facilitate the development of new immunotherapies for our product pipeline. Affiliates of NantWorks are also affiliates of the company due to the common control by and/or common ownership interest of our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NantWorks, LLC</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shared Services Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the amended and restated shared services agreement with NantWorks dated as of June&#160;2016, but effective as of August&#160;2015, NantWorks, a related party, provides corporate, general and administrative, certain research and development, and other support services. We are charged for the services at cost plus reasonable allocations of employee benefits, facilities, and other direct or fairly allocated indirect costs that relate to the employees providing the services. For the three months ended March&#160;31,&#160;2023 and 2022, we recorded $1.0&#160;million and $1.3&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">selling, general and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $0.4&#160;million of expense reimbursements and an immaterial amount, respectively, under this arrangement in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations. These amounts exclude certain general and administrative expenses provided by third-party vendors directly for our benefit, which were reimbursed to NantWorks based on those vendors&#8217; invoiced amounts without markup by NantWorks. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, we owed NantWorks net amounts of $0.6&#160;million and $1.0&#160;million, respectively, for all agreements between the two&#160;affiliates, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due to related parties,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets. We also recorded $2.1&#160;million and $2.0&#160;million of prepaid expenses for services that have been passed through to the company from NantWorks as of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">prepaid expenses and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated balance sheets.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we entered into a facility license agreement with NantWorks for approximately 9,500 rentable square feet of office space in Culver&#160;City, California, which was converted to a research and development laboratory and a cGMP manufacturing facility. In&#160;2020, we amended this agreement to extend the term of this license agreement through December&#160;31,&#160;2021. Commencing on January&#160;1,&#160;2022, the license fee increased by 3% to approximately $56,120 per month.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;6,&#160;2022, we amended our facility license agreement with NantWorks to expand the licensed premises by 36,830&#160;rentable square feet to an aggregate total of 46,330 rentable square feet. Effective May&#160;1,&#160;2022, the license fee is approximately $273,700 per month, which is subject to a 3%&#160;increase commencing on January&#160;1 of each year. The space continues to be rented on a month-to-month basis, which can be terminated by either party with at least 30&#160;days&#8217; prior written notice to the other party. We recorded license fee expense for this facility totaling $0.8&#160;million and $0.2&#160;million for the three months ended March&#160;31,&#160;2023 and 2022, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Immuno-Oncology Clinic, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into multiple agreements with Immuno-Oncology Clinic,&#160;Inc.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Clinic)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to conduct clinical trials related to certain of our product candidates. The Clinic is a related party as it is owned by an officer of the company and NantWorks manages the administrative operations of the Clinic. Pursuant to the terms of the Clinic agreement (as amended), we made payments totaling </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.6&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in consideration of future services to be performed by the Clinic. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we completed a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review of alternative structures that could support our more complex clinical trial requirements and made a decision to explore a potential transition of clinical trials at the Clinic to a new structure (including contracting with a new, non-affiliated professional corporation) to be determined and agreed upon by all parties. Based on this decision to explore a potential transition, we determined that it was more likely than not that the previously recorded prepaid asset would not result in the collection of fees for services performed by the Clinic as contemplated in the original agreements. As a result, we wrote down the remaining value of our prepaid asset and recorded approximately $4.4&#160;million in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statement of operations for the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We continue productive negotiations with potential partners around alternative structures, but there can be no assurance that we will be successful.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded $0.6&#160;million and $0.4&#160;million for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations related to clinical trial and transition services provided by the Clinic. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">owed the&#160;Clinic an immaterial amount and $0.1&#160;million, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NantBio, Inc. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, we entered into a supply agreement with NCSC, a 60%&#160;owned subsidiary of NantBio (with the other&#160;40% owned by Sorrento). Under this agreement, we agreed to supply VivaBioCell&#8217;s proprietary GMP-in-a-Box bioreactors and related consumables, made according to specifications mutually agreed to with both companies. The agreement has an initial term of five years and renews automatically for successive one-year terms unless terminated by either party in the event of material default upon prior written notice of such default and the failure of the defaulting party to remedy the default within 30&#160;days of the delivery of such notice, or upon 90 days&#8217; prior written notice by NCSC. We recognized no&#160;revenue for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and no revenue for the three months ended March&#160;31,&#160;2022. We recorded $0.1&#160;million and $0.1&#160;million of deferred revenue for bioreactors that were delivered but not installed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accrued expenses and other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated balance sheets as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31,&#160;2022, respectively. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31,&#160;2022, we recorded $0.9&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due to related parties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated balance sheets related to this agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we entered into a shared service agreement pursuant to which we are charged for services at cost, without mark-up or profit by NantBio, but including reasonable allocations of employee benefits that relate to the employees providing the services. In April&#160;2019, we agreed with NantBio to transfer certain NantBio employees and associated research and development projects to the company. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31,&#160;2022, we recorded a net receivable from NantBio of $1.3&#160;million for amounts we paid on behalf of NantBio during the year ended December&#160;31,&#160;2019.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">605 Doug St, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September&#160;2016, we entered into a lease agreement with 605&#160;Doug&#160;St,&#160;LLC, an entity owned by our Executive Chairman and Global Chief Scientific and Medical Officer, for approximately 24,250 rentable square feet in El&#160;Segundo, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. The lease runs from July&#160;2016 through July&#160;2023. We have the option to extend the lease for one&#160;additional three-year term through July&#160;2026. The base rent is approximately $72,385 per month, with annual increases of 3% that began in July&#160;2017. We recorded lease expense for this facility of $0.2&#160;million and $0.2&#160;million for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Duley Road, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February&#160;2017, we entered into a lease agreement with Duley&#160;Road, a related party that is indirectly controlled by our Executive Chairman and Global Chief Scientific and Medical Officer, for approximately 11,980 rentable square feet of office and cGMP manufacturing facility space in El&#160;Segundo, California. The lease term is from February&#160;2017 through October&#160;2024. We have the option to extend the initial term for two&#160;consecutive five-year periods through October&#160;2034. The base rent is approximately $40,700 per month, with annual increases of&#160;3%. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective in January&#160;2019, we entered into two&#160;lease agreements with Duley Road for a second&#160;building located in El&#160;Segundo, California. The first&#160;lease is for the first&#160;floor of the building with approximately 5,650 rentable square feet. The lease has a seven-year term commencing in September&#160;2019. The second&#160;lease is for the second&#160;floor of the building with approximately 6,488 rentable square feet. The lease has a seven-year term commencing in July&#160;2019. Both floors of the building are used for research and development and office space. We have options to extend the initial terms of both leases for two&#160;consecutive five-year periods through 2036. The base rent for the two&#160;leases is approximately $35,800 per month, with annual increases of&#160;3%.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31,&#160;2022, respectively, we recorded $0.9&#160;million and $0.9&#160;million of leasehold improvement payables, and $0.5&#160;million and $0.6&#160;million of lease-related payables, to Duley Road, which were included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due to related parties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated balance sheets. We recorded rent expense for these leases totaling $0.2&#160;million and $0.2&#160;million for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">605 Nash, LLC </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, but effective on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January&#160;1,&#160;2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we entered into a lease agreement with 605&#160;Nash, a related party, whereby we leased approximately 6,883 rentable square feet (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initial Premises) i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n a two&#160;story mixed use building containing approximately 64,643 rentable square feet on 605-607 Nash Street in El&#160;Segundo, California. This facility is used primarily for pharmaceutical development and manufacturing purposes. The lease term commenced in January&#160;2021 and expires in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;2027</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and includes an option to extend the lease for one three-year term through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;2030</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The base rent is approximately $20,300 per month with an annual increase of 3%&#160;on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January&#160;1</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of each year during the initial term and, if applicable, during the option term. In addition, under the agreement, we are required to pay our share of estimated property taxes and operating expenses. We received a rent abatement for the first seven months. The lease also provides a tenant improvement incentive of $0.3&#160;million for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs and expenses associated with the construction of tenant improvements for the Initial Premises.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May&#160;2021, but effective on April&#160;1,&#160;2021, we entered into an amendment to our Initial Premises lease with 605&#160;Nash. The amendment expanded the leased square feet by approximately 57,760 rentable square feet (the Expansion Premises). The lease term of the Expansion Premises commenced in April&#160;2021 and expires in March&#160;2028, whereby the company has the option to extend the initial term for three years. Per the terms of the amendment, the term of the Initial Premises lease was extended for an additional three&#160;months and now expires on March&#160;31,&#160;2028. Base rent for the Expansion Premises is approximately $170,400&#160;per month with annual increases of 3% on April&#160;1 of each year. We are responsible for the build out of the facility space and associated costs. We received a rent abatement for the first seven months. The amended lease provides for a tenant improvement allowance of approximately $2.6&#160;million for costs and expenses related to improvements made by us to the Expansion Premises. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded rent expense for the Initial and Expansion Premises leases totaling $0.5&#160;million and $0.5&#160;million for the three months ended March&#160;31,&#160;2023 and 2022, respectively, i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated statements of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">420 Nash, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;27,&#160;2021, we entered into a lease agreement with 420&#160;Nash,&#160;LLC, a related party, whereby we leased an approximately 19,125 rentable square foot property located at 420&#160;Nash Street, El&#160;Segundo, California, to be used primarily for the warehousing and storage of drug manufacturing supplies, products and equipment and ancillary office space. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the lease agreement, the lease term began on October&#160;1,&#160;2021 and expires on September&#160;30,&#160;2026. The base rent is approximately $38,250 per month with an annual increase of 3% on October&#160;1 of each year beginning in 2022 during the initial term. The company is responsible for the payment of real property taxes, repairs and maintenance, improvements, insurance and operating expenses during the term of the lease. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has options to extend the lease term for two&#160;additional consecutive periods of five years each. At the beginning of each option term, the initial monthly base rent will be adjusted to market rent (as defined in the lease agreement) with an annual increase of 3% during the option term. We have included the first&#160;option to extend the lease term for five&#160;years as part of the initial term of the lease as it is reasonably certain that we will exercise the option, which implies lease expiration in September&#160;2031. We recorded $0.1&#160;million and $0.1&#160;million of rent expense related to this lease for the three months ended March&#160;31,&#160;2023 and 2022, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">23&#160;Alaska, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;6,&#160;2022, we entered into a lease agreement with 23&#160;Alaska,&#160;LLC, a related party, for a 47,265 rentable square foot facility located at 2335&#160;Alaska Ave., El&#160;Segundo, California, to be used primarily for pharmaceutical development and manufacturing, research and development, and office space. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the lease term begins on May&#160;1,&#160;2022 and expires on April&#160;30,&#160;2027. The base rent is approximately $139,400&#160;per month with an annual increase of 3% on May&#160;1 of each year beginning in 2023 during the initial term. We are also required to pay $7,600&#160;per month for parking during the initial term and extension term, if exercised. The company is responsible for the payment of real property taxes, repairs and maintenance, improvements, insurance, and operating expenses during the term of the lease. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has&#160;an option to extend the lease term for one&#160;additional consecutive five-year period. At the beginning of the option term, the initial monthly base rent will be adjusted to market rent (as defined in the lease agreement) with an annual increase of 3%&#160;during the option term. We recorded $0.4&#160;million of rent expense for this lease for the three months ended March&#160;31,&#160;2023 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statement of operations.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820113382016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_WarrantLiabilityTextBlock', window );">Warrant Liabilities</a></td>
<td class="text">Warrant Liabilities<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">December 2022 Warrants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;12, 2022, in connection with the sale of 9,090,909&#160;shares of our common stock to an institutional investor, we entered into a warrant agreement that allows such investor to purchase up to 9,090,909&#160;shares at an exercise price of $6.60&#160;per share. We classified the warrants as a liability at their fair value determined using the Black-Scholes option pricing model. The fair value of the warrants was estimated at </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$35.1&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the issuance date. Of the total placement agent fees and other offering costs of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.0&#160;million, $1.1&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were allocated to the warrants and recorded to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other income (expense), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the date of the transaction. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, all 9,090,909&#160;underlying warrants were outstanding, As of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, the estimated fair value of the warrants were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.8&#160;million and $21.6&#160;million, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The decrease in fair value of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15.8&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other income (expense), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statement of operations for the three months ended March&#160;31,&#160;2023.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">February 2023 Warrants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;15, 2023, in connection with the sale of 14,072,615&#160;shares of our common stock to institutional investors, we entered into a warrant agreement that allows such investors to purchase up to 14,072,615&#160;shares at an exercise price of $4.26&#160;per share.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classified the warrants as a liability at their fair value determined using the Black-Scholes option pricing model. The fair value of warrants were estimated at </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$23.7&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the issuance date. Of the total placement agent fees and other offering costs of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.0&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.0&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were allocated to the warrants </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and recorded to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other income (expense), net, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the date of the transaction</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of March&#160;31,&#160;2023, all 14,072,615&#160;underlying warrants were outstanding, with an estimated fair value of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$12.0&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The decrease in fair value of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$11.7&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other income (expense), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statement of operations for the three months ended March&#160;31,&#160;2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_WarrantLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_WarrantLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820113260352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Deficit<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Deficit</a></td>
<td class="text">Stockholders&#8217; Deficit <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Repurchases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;shares of our common stock were repurchased during the three months ended March&#160;31,&#160;2023 and 2022 under the company&#8217;s 2015&#160;Share Repurchase Program. As of March&#160;31,&#160;2023, $18.3&#160;million remained authorized to use for share repurchases under the program. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration Statement</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During February&#160;2023, we filed a $750.0&#160;million shelf registration statement with the SEC on Form&#160;S-3 for the offering and sale of equity and equity-linked securities, including common stock, preferred stock, debt securities, depositary shares, warrants to purchase common stock, preferred stock or debt securities, subscription rights, purchase contracts, and units. In February&#160;2023, we sold shares of our common stock and warrants valued at $110.0&#160;million under the shelf. As of March&#160;31,&#160;2023, we had $640.0&#160;million available for use under the shelf. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Registered Direct Offerings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; below. This available shelf is in addition to the Open Market Sale Agreement described below. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Open Market Sale Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April&#160;2021, we entered into the Sale Agreement with respect to an&#160;ATM offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock through our sales agent. We pay our sales agent a commission of up to 3.0%&#160;of the gross sales proceeds of any shares of our common stock sold through them under the Sale Agreement, and also have provided them with customary indemnification and contribution rights. We issued no&#160;shares under the ATM during the three months ended March&#160;31,&#160;2023. As of March&#160;31,&#160;2023, we had $225.4&#160;million available for future stock issuances under the&#160;ATM.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not obligated to sell any shares and may at any time suspend solicitation and offers under the Sale Agreement. The Sale Agreement may be terminated by us at any time given written notice to the sales agent for any reason or by the sales agent at any time by giving written notice to us for any reason or immediately under certain circumstances, and shall automatically terminate upon the issuance and sale of all of the shares.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registered Direct Offerings</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;12, 2022, we entered into a securities purchase agreement with an institutional investor for the sale of 9,090,909 shares of our common stock, as well as warrants that allow such investor to purchase an additional 9,090,909 shares of common stock at an exercise price of $6.60 per share, for a purchase price of $5.50 per share and accompanying warrant, generating net proceeds of approximately $47.0&#160;million, after deducting placement agent fees and other offering costs of $3.0&#160;million, of which $1.9&#160;million was allocated to the sale of our common stock and recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional-paid-in capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of stockholders&#8217; deficit, for the year ended December 31, 2022. The warrants became immediately exercisable and expire two years after the initial issuance date.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;15, 2023, we entered into a securities purchase agreement with certain institutional investors for the sale of 14,072,615&#160;shares of our common stock, as well as warrants that allow such investors to purchase an additional 14,072,615&#160;shares of common stock at an exercise price of $4.26&#160;per share, for an aggregate purchase price of $3.55&#160;per share and accompanying warrant. This transaction generated net proceeds of approximately $47.0&#160;million, after deducting placement agent fees and other estimated offering costs of $3.0&#160;million, of which $2.0&#160;million was allocated to the sale of our common stock and recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional-paid-in capital,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated statement of stockholders&#8217; deficit for the three months ended March&#160;31,&#160;2023. The warrants became immediately exercisable and expire two years after the initial issuance date. The closing of the offering occurred on February&#160;17, 2023. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently intend to use the net proceeds from this offering, together with other available funds, to progress our pre-commercialization efforts and clinical development programs, fund other research and development activities, for capital expenditures, and for other general corporate purposes. We may also use a portion of the net proceeds to license intellectual property or to make acquisitions or investments. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i5bbe340c9c8f435088d8011b72b6800d_82" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;11</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Liabilities, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820113390112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, approximately 18.6&#160;million&#160;shares were available for future grants under the 2015&#160;Plan.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock-based compensation included on the condensed consolidated statements of operations (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:71.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.302%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Three Months Ended<br/>March&#160;31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Unaudited) </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock-based compensation expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,878&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,024&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock-based compensation expense in operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,878&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,024&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity and related information for the three months ended March&#160;31,&#160;2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Options</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted-</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exercise</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Aggregate</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Intrinsic</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Value</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted-</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Remaining</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Contractual</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Life</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(in years)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at December&#160;31,&#160;2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,262,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(81,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited/expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,224)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at March&#160;31,&#160;2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,159,665&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested and exercisable at March&#160;31,&#160;2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,053,597&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.3</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, the unrecognized compensation cost related to outstanding stock options was $16.7&#160;million, which is expected to be recognized over a remaining weighted-average period of 1.6 years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised during the three months ended March&#160;31,&#160;2023 was $0.2&#160;million. Cash proceeds received from stock option exercises during the three months ended March&#160;31,&#160;2023 and 2022 totaled $0.1&#160;million and $0.1 million, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2022, a total of 3,445,499&#160;vested and exercisable shares were outstanding.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the three months ended March&#160;31,&#160;2023:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Units</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted-</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Grant Date</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested balance at December&#160;31,&#160;2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,551,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">202,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(313,975)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited/canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252,106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested balance at March&#160;31,&#160;2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,188,292&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, there was $61.9&#160;million of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted-average period of 2.6 years. The total intrinsic value of RSUs vested during the three months ended March&#160;31,&#160;2023 was $0.9&#160;million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs awarded to employees and consultants of affiliated companies are accounted for as stock-based compensation in accordance with ASU 2018-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation (Topic 718)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as the compensation was in exchange for continued support or services expected to be provided to the company over the vesting periods under the NantWorks shared services agreement discussed in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i5bbe340c9c8f435088d8011b72b6800d_76" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have evaluated the associated benefit of these awards to the affiliated companies under common control and determined that the benefit is limited to the retention of their employees. We estimated such benefit at the grant date fair value of $4.0&#160;million on March&#160;4,&#160;2021 and recorded $0.1&#160;million and $0.1&#160;million of deemed dividends for the three months ended March&#160;31,&#160;2023 and 2022 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets, with a corresponding credit to stock-based compensation expense.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related-Party Warrants</span></div>In connection with the Merger, warrants issued to NantWorks, a related party, in connection with NantCell&#8217;s acquisition of Altor were assumed by the company. After applying the Exchange Ratio at the Effective Time of the Merger, a total of 1,638,000&#160;warrants with an exercise price of $3.24&#160;per share were outstanding as of March&#160;31,&#160;2023. The fair value of $18.0&#160;million assigned to the warrants will be recognized in equity upon achievement of a performance-based vesting condition pertaining to building manufacturing capacity to support supply requirements for one of our product candidates.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820109633248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S.&#160;federal income tax, as well as income tax in Italy, South Korea, California and other states. From inception through March&#160;31,&#160;2023, we have not been required to pay U.S.&#160;federal and state income taxes because of current and accumulated net operating losses (NOLs). The company computes its quarterly income tax provision by using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. No tax benefit was provided for losses incurred in the U.S., Italy, and South Korea because those losses are offset by a full valuation allowance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our federal returns for tax years 2019 through 2021 remain open to examination, and our state returns remain subject to examination for tax years 2018 through 2021. The Italian and South Korea returns for tax years 2017 through 2021 remain open to examination. Carryforward attributes that were generated in years where the statute of limitations is closed may still be adjusted upon examination by the Internal Revenue Service or other respective tax authorities. No income tax returns are currently under examination by taxing authorities. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation Reduction Act of 2022</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Inflation Reduction Act 2022, which incorporates a Corporate Alternative Minimum Tax (CAMT), was signed on August&#160;16,&#160;2022. The changes are effective for the tax years beginning after December&#160;31,&#160;2022. The new tax will require companies to compute two&#160;separate calculations for federal income tax purposes and pay the greater of the new minimum tax or their regular tax liability. The company will be monitoring the impact of the act to determine if it will have an impact on the company for years beginning after December&#160;31,&#160;2022. We currently do not expect this act will have a material effect on our consolidated financial statements. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coronavirus Aid, Relief and Economic Security Act</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;27,&#160;2020, the U.S. enacted the Coronavirus Aid, Relief and Economic Security Act (the CARES Act). The Cares Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the U.S.&#160;economy and fund a nationwide effort to curtail the effect of COVID-19. The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic. Under the CARES Act, some of the more significant provisions are NOL carrybacks for five&#160;years to offset previous years&#8217; income, or can be carried forward indefinitely to offset 100%&#160;of taxable income for the tax year beginning before 2021 and 80%&#160;of taxable income for tax years&#160;2021 and thereafter, increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. During the three&#160;months&#160;ended March&#160;31,&#160;2023 and 2022, we did not record any income tax (expense) benefit resulting from the CARES Act, mainly due to our history of net operating losses generated and the maintenance of a full valuation allowance against our net deferred tax assets. There was no material impact from the provisions of the Cares Act for the three&#160;months&#160;ended March&#160;31,&#160;2023 and 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">State of California Assembly Bill No.&#160;85</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;29,&#160;2020, the state of California enacted Assembly Bill No.&#160;85 (AB&#160;85) suspending California NOL utilization and imposing a cap on the amount of business incentive tax credits companies can utilize, effective for tax years 2020, 2021 and 2022. There was no material impact from the provisions of AB&#160;85 for the three&#160;months&#160;ended March&#160;31,&#160;2022. On February&#160;9,&#160;2022, Senate Bill No.&#160;113 was enacted that removed the limitations on the use of NOLs and the cap on the business incentive tax credits that were suspended in accordance with AB 85 effective for tax year 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820105057808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.&#160;GAAP) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The unaudited condensed consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of our financial position and results of operations. The unaudited condensed consolidated financial statements do not include all information and notes required by U.S.&#160;GAAP for annual reports and therefore should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December&#160;31,&#160;2022 filed with the SEC on March&#160;1,&#160;2023. These interim financials are not necessarily indicative of results expected for the full fiscal year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of the company, its wholly-owned subsidiaries, and a variable interest entity (VIE) for which the company is the primary beneficiary. Any material intercompany transactions and balances have been eliminated upon consolidation. For consolidated entities where we have less than 100% of ownership, we record net loss attributable to noncontrolling interest on the unaudited condensed consolidated statements of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether we are the primary beneficiary of a VIE at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, contingent value right measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value calculation of warrants and convertible promissory notes, fair value measurements, and the assessment of our ability to fund our operations for at least the next 12&#160;months from the date of issuance of these condensed consolidated financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing coronavirus pandemic could have on our significant accounting estimates. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Accounting Standards Codification (ASC) Topic&#160;480, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC&#160;480), and ASC Topic&#160;815, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC&#160;815). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC&#160;480, meet the definition of a liability pursuant to ASC&#160;480, and whether the warrants meet all of the requirements for equity classification under ASC&#160;815, including whether the warrants are indexed to the&#160;company&#8217;s own stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For warrants that meet all criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and on each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash change in fair value of warrant liabilities in o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ther income (expense), net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the condensed consolidated statements of operations. The fair value of the warrants was estimated using the Black-Scholes option pricing model.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock', window );">Fair Value Option (FVO) Election</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Option (FVO) Election</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company accounts for certain convertible notes issued during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the fair value option (FVO) election of ASC&#160;825, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC&#160;825), as discussed below.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The convertible notes accounted for under the FVO election are each debt host financial instruments containing embedded features wherein the entire financial instrument is initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date.</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the estimated fair value of the convertible notes are recorded as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other income (expense), net</span> on the condensed consolidated statements of operations, except that the change in estimated fair value attributable to a change in the instrument-specific credit risks is recognized as a component of other comprehensive income.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss per Share of Common Stock</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Net Loss per Share of Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed by dividing net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares, including the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. The following table details those securities that have been excluded from the computation of potentially dilutive securities:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Related-party convertible notes (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,726,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding third-party warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,163,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,159,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,819,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,188,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,149,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding related-party warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,638,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,638,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">86,875,888&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,606,877&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.641%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount excludes the shares related to the related-party convertible note with a principal amount of $30.0&#160;million issued on March&#160;31,&#160;2023 as the conversion price has not yet been determined. See</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> </a><a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Note </a><a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, for further information.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Application of New or Revised Accounting Standards &#8211; Not Yet Adopted</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic&#160;820): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which amends the guidance in Topic&#160;820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. In addition, ASU&#160;2022-03 introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. ASU&#160;2022-03 is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years. We are currently evaluating the impact of this standard on our condensed consolidated financial statements. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the FASB issued ASU&#160;2023-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842): Common Control Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that leasehold improvements associated with common control leases be amortized over the useful life of the leasehold improvements to the common control group, regardless of the lease term. ASU&#160;2023-01 is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years. We are currently evaluating the impact of this standard on our condensed consolidated financial statements and related disclosures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC during the three months ended March&#160;31,&#160;2023 did not, or are not expected to, have a material effect on our condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three tiers are defined as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1&#8212;Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these products does not entail a significant degree of judgment. Our Level&#160;1 assets consist of bank deposits, money market funds, and marketable equity securities.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2&#8212;Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level&#160;2 assets consist of corporate debt securities including commercial paper, government-sponsored securities and corporate bonds, as well as foreign municipal securities.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3&#8212;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></div>We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy. The fair values of financial instruments other than marketable securities and cash and cash equivalents are determined through a combination of management estimates and third-party valuations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Notes, Fair Value Option Election</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820113325856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Securities Excluded from the Computation of Potentially Dilutive Securities</a></td>
<td class="text">The following table details those securities that have been excluded from the computation of potentially dilutive securities:<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Related-party convertible notes (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46,726,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding third-party warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,163,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,159,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,819,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,188,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,149,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding related-party warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,638,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,638,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">86,875,888&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,606,877&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.641%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount excludes the shares related to the related-party convertible note with a principal amount of $30.0&#160;million issued on March&#160;31,&#160;2023 as the conversion price has not yet been determined. See</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> </a><a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Note </a><a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, for further information.</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820109813744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statement Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinancialStatementDetailsAbstract', window );"><strong>Financial Statement Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid software license fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Insurance premium financing asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,754&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31,503&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment, Net</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net, consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">68,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">68,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">67,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">81,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture &amp; fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Gross property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">227,580&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">212,911&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">154,165&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">143,659&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Intangible Assets, Net</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amounts and accumulated amortization of intangible assets are as follows at the dates indicated (in&#160;thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.101%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31,&#160;2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finite-lived: Favorable leasehold rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,295)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Indefinite-lived: In-process research </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;and development (IPR&amp;D)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,797&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,295)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,502&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.101%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finite-lived: Favorable leasehold rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finite-lived: Organized workforce</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,229&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,935)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(681)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,613&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Indefinite-lived: IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22,619&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,935)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(681)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,003&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Future Amortization Expense Associated with Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense associated with our finite-lived intangible assets is as follows (in&#160;thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.825%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Years ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Finite-lived</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Intangible</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Assets</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023 (excluding the three months ended March&#160;31,&#160;2023)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,103&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses and Other Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities consist of the following (in&#160;thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonus</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional and service fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical and clinical trial costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing obligation &#8211; current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,118&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,825&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncomeTableTextBlock', window );">Interest and Investment Income, Net</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and investment income, net consists of the following (in&#160;thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Three Months Ended<br/>March&#160;31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unrealized gains from equity securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Investment amortization expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,049)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net realized losses on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest and investment income, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">673&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,666&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Interest expense</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists of the following (in&#160;thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:71.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.302%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Three Months Ended<br/>March&#160;31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest expense on related-party notes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization of related-party notes discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,536)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(370)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(29,816)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(8,491)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinancialStatementDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinancialStatementDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820109939008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Available-for-Sale Marketable Debt Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, the weighted-average remaining contractual life, amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.101%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="27" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31,&#160;2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="27" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual&#160;Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,048&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(84)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">964&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2022, the weighted-average remaining contractual life, amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.101%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual&#160;Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;<br/>Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">970&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(94)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">876&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position</a></td>
<td class="text">Accumulated unrealized losses on marketable debt securities that have been in a continuous loss position for less than 12&#160;months and more than 12&#160;months were as follows (in&#160;thousands): <div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March&#160;31,&#160;2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited) </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">876&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(94)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820113325856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below (in&#160;thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.641%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="24" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="24" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Unaudited) </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">88,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,088&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,274&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,814&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Related-party convertible note payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,850)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,850)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,780)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,780)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total liabilities measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,650)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,650)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.641%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">63,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,024&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,403&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,621&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities at fair value:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total liabilities measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,655)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,655)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.641%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31,&#160;2023, the Level&#160;2 measurements include $15.0&#160;million in U.S. government agency securities with original maturities of less than 90&#160;days. As of December&#160;31,&#160;2022, the Level&#160;2 measurements include $32.0&#160;million in U.S. government agency securities and $8.8&#160;million in corporate debt securities with original maturities of less than 90&#160;days.</span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.641%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As of March&#160;31,&#160;2023, the company has a related-party convertible note payable with a principal amount of $30.0&#160;million, which is accounted for under the ASC&#160;825-10-15-4 FVO election. Under the FVO election, the financial instrument is initially measured at its issue-date estimated fair value and subsequently re-measured at estimated fair value on a recurring basis at each reporting period date. The company&#8217;s other related-party notes are not accounted for under the fair value election. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Note&#160;</a><a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, Related-Party Debt, for further information. The estimated fair value of the convertible note was computed using a discounted cash flow method with the following unobservable assumptions:</span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected market yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount period</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount factor</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.98</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.641%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Third-Party Warrant Liabilities</span></td></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">December 2022 Warrants</span></div><div style="margin-top:6pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the December&#160;12, 2022 registered direct offering of common stock, the company issued 9,090,909 warrants (December&#160;2022 Warrants). The warrants were classified as a liability at their fair value upon the issuance. As of March&#160;31,&#160;2023, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following date:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$6.60</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected average volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in the carrying amount of the December&#160;2022 Warrants was as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning fair value, at December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOmUxNmRiNTMwMWViYTRhNmY4NmMxNTNhYjJhNjhiMWIwL3RhYmxlcmFuZ2U6ZTE2ZGI1MzAxZWJhNGE2Zjg2YzE1M2FiMmE2OGIxYjBfNS0wLTEtMS0zMTA3NzY_2350ba70-1f49-4ea5-8303-63ba7471fe59">Change in fair value</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,818)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending fair value, at March&#160;31,&#160;2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">February 2023 Warrants</span></div><div style="margin-top:6pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the February&#160;15, 2023 registered direct offering of common stock, the company issued 14,072,615 warrants (February&#160;2023&#160;Warrants). The warrants were classified as a liability at its fair value upon the issuance. As of March&#160;31,&#160;2023, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following dates:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March&#160;31,&#160;2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Date<br/>February 15, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$4.26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$4.26</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected average volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in the carrying amount of the February 2023 Warrants were as follows (in&#160;thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value at the issuance date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjQ1NjRiYjg3OWY4MDRmZTc5NzBhNDg1YWUzNmI0YWZiL3RhYmxlcmFuZ2U6NDU2NGJiODc5ZjgwNGZlNzk3MGE0ODVhZTM2YjRhZmJfNS0wLTEtMS0zMzA4Nzg_31727132-f847-41a1-942b-fae5179a937e">Change in fair value</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,736)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending fair value, at March&#160;31,&#160;2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,962&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820113261584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements and Acquisition (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">Summary of Fair Value of Assets Acquired</a></td>
<td class="text">The following table summarizes the fair value of assets acquired as of the acquisition date (in&#160;thousands):<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other depreciable assets and prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,508&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i5bbe340c9c8f435088d8011b72b6800d_43" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Note </a><a href="#i5bbe340c9c8f435088d8011b72b6800d_43" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Statement Details&#8212;Intangible Assets, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, for further information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820115031104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Supplemental Balance Sheet Information Related to Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to our leases is as follows (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:33.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.453%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.284%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,191&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,788&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNS0xLTEtMS0yOTgzNTI_716b2b64-20b1-40c3-9b02-a3d14868228b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNS0xLTEtMS0yOTgzNTI_79bf86fc-1a0b-4632-b3b5-c9756666aba0">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,306&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,923&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTEtMS0xLTEtMjk4MzUy_1e304c6d-b6fc-4a07-96b6-252e1c6d5e68"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTEtMS0xLTEtMjk4MzUy_7f502521-7e3c-4089-bd21-ee4709a6ff0e">Accrued expenses and other liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities, less current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTQtMS0xLTEtMjk4MzUy_1cbef275-f42e-4514-b41d-8b9c75783db1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTQtMS0xLTEtMjk4MzUy_cccafda1-bc6a-4e69-9eb2-a02fc2fcc607">Other liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,255&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,742&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Information Regarding Leases (Detail)</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding our lease terms is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:71.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average remaining lease term:</span></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance leases</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average discount rate:</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance leases</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:71.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.302%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March&#160;31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease costs (including amortization and <br/>&#160;&#160;&#160;interest costs)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,964&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities is as follows (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:71.298%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.339%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.341%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash paid for operating leases (excluding variable lease costs)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Financing cash flow from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flow from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Lease Payments</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments as of March&#160;31,&#160;2023, including $14.8&#160;million related to options to extend lease terms that are reasonably certain of being exercised, are presented in the following table (in&#160;thousands). Common area maintenance costs and taxes are not included in these payments.</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.331%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Years ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Operating</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Finance <br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023 (excluding the three months ended March&#160;31,&#160;2023)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72,758&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">132&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72,890&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Tenant improvement allowance receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49,133&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">122&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49,255&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820105957936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock', window );">Summary of Related-Party Promissory Notes</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our related-party debt is summarized below (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.406%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at March&#160;31,&#160;2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Year</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accrued<br/>Interest<br/>Added to<br/>Note</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less:<br/>Unamortized <br/>Discounts</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Nonconvertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term SOFR + 8.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Convertible Note <br/>&#160;&#160;&#160;at Fair Value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term SOFR + 8.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantMobile, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantCancerStemCell, LLC (NCSC)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total related-party convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,226&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,713&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,299&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,640&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total related-party debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738,226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,713&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,671&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,118&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:3.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.132%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The interest rate on our related-party variable-rate notes as of March&#160;31,&#160;2023 was 12.89%.</span></div></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.406%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December&#160;31,&#160;2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Year</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accrued<br/>Interest<br/>Added to<br/>Note</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less:<br/>Unamortized <br/>Discounts</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Nonconvertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term SOFR + 8.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantMobile</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NCSC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total related-party convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,226&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,153&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,108&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241,271&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total related-party debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,153&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,207&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673,172&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:3.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.132%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The interest rate on our related-party variable-rate notes as of December&#160;31,&#160;2022 was 12.59%.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Estimated Future Contractual Obligations for Related-Party Promissory Notes</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future contractual obligations for our related-party debt as of March&#160;31,&#160;2023 (unaudited; in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.404%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Payments (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible<br/>Notes</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-convertible<br/>Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible<br/>Notes</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-convertible<br/>Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (excluding the three months ended </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;March&#160;31,&#160;2023)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal and estimated interest <br/>&#160;&#160;&#160;due on related-party debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,181&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,131&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:3.661%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest payments on our fixed-rate convertible notes are calculated based on contractual interest rates and scheduled maturity dates. Interest payments on our variable-rate notes are calculated based on Term&#160;SOFR plus the contractual spread per the loan agreements. The rate on our variable-rate notes as of March&#160;31,&#160;2023 was 12.89%.</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of related party notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 303<br> -Paragraph (a)<br> -Subparagraph (5)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820113380352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Summary of Outstanding Balances of Related-Party Agreements</a></td>
<td class="text">Below is a summary of outstanding balances and a description of significant relationships (in&#160;thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related party&#8211;NantBio, Inc.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related party&#8211;Brink Biologics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related parties&#8211;Various</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total due from related parties</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,464&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,890&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;Duley Road, LLC</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;NantBio, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;NantWorks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;Immuno-Oncology Clinic, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total due to related parties</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,932&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,469&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820110302416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expenses Included on Operations Statement</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock-based compensation included on the condensed consolidated statements of operations (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:71.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.302%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Three Months Ended<br/>March&#160;31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Unaudited) </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock-based compensation expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,878&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,024&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock-based compensation expense in operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,878&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,024&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity and Related Information under Equity Plans</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity and related information for the three months ended March&#160;31,&#160;2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Options</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted-</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exercise</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Aggregate</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Intrinsic</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Value</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted-</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Remaining</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Contractual</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Life</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(in years)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at December&#160;31,&#160;2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,262,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(81,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited/expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,224)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding at March&#160;31,&#160;2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,159,665&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested and exercisable at March&#160;31,&#160;2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,053,597&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.3</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of RSU Activity under Equity Plans</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the three months ended March&#160;31,&#160;2023:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Units</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted-</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Grant Date</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested balance at December&#160;31,&#160;2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,551,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">202,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(313,975)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited/canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252,106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested balance at March&#160;31,&#160;2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,188,292&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820114925408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 2,494,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,378,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="nump">84,310<span></span>
</td>
<td class="nump">$ 74,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_February2023ShelfRegistrationStatementMember', window );">February 2023 Shelf Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CommonStockValueAvailableForFutureStockIssuance', window );">Available for future stock issuance</a></td>
<td class="nump">640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_AtTheMarketOfferingProgramMember', window );">ATM Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CommonStockValueAvailableForFutureStockIssuance', window );">Available for future stock issuance</a></td>
<td class="nump">$ 225,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CommonStockValueAvailableForFutureStockIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock value available for future stock issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CommonStockValueAvailableForFutureStockIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_February2023ShelfRegistrationStatementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ibrx_February2023ShelfRegistrationStatementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibrx_AtTheMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibrx_AtTheMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820105679104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">86,875,888<span></span>
</td>
<td class="nump">16,606,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Principal Amount</a></td>
<td class="nump">$ 738,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 708,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Principal Amount</a></td>
<td class="nump">233,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalIssued33123Member', window );">Nant Capital | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Principal Amount</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ibrx_RelatedPartyConvertibleNotesMember', window );">Related-party convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">46,726,407<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Outstanding third-party warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">23,163,524<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">9,159,665<span></span>
</td>
<td class="nump">8,819,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Outstanding RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">6,188,292<span></span>
</td>
<td class="nump">6,149,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ibrx_RelatedPartyWarrantsMember', window );">Outstanding related-party warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">1,638,000<span></span>
</td>
<td class="nump">1,638,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_RelatedPartyNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related-party notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_RelatedPartyNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalIssued33123Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalIssued33123Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ibrx_RelatedPartyConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ibrx_RelatedPartyConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ibrx_RelatedPartyWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ibrx_RelatedPartyWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820109846176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinancialStatementDetailsAbstract', window );"><strong>Financial Statement Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PrepaidResearchAndDevelopmentCosts', window );">Prepaid research and development costs</a></td>
<td class="nump">$ 6,741<span></span>
</td>
<td class="nump">$ 11,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PrepaidServices', window );">Prepaid services</a></td>
<td class="nump">3,246<span></span>
</td>
<td class="nump">8,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Supplies', window );">Prepaid supplies</a></td>
<td class="nump">2,160<span></span>
</td>
<td class="nump">2,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">2,150<span></span>
</td>
<td class="nump">2,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PrepaidSoftwareLicenseFees', window );">Prepaid software license fees</a></td>
<td class="nump">1,672<span></span>
</td>
<td class="nump">2,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_InsurancePremiumFinancingAsset', window );">Insurance premium financing asset</a></td>
<td class="nump">357<span></span>
</td>
<td class="nump">1,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">4,428<span></span>
</td>
<td class="nump">3,732<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 20,754<span></span>
</td>
<td class="nump">$ 31,503<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinancialStatementDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinancialStatementDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_InsurancePremiumFinancingAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance premium financing asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_InsurancePremiumFinancingAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PrepaidResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research And Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PrepaidResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PrepaidServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PrepaidServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PrepaidSoftwareLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid software license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PrepaidSoftwareLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820105085584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statement Details - Property, Plant and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property, plant and equipment</a></td>
<td class="nump">$ 227,580<span></span>
</td>
<td class="nump">$ 212,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="nump">73,415<span></span>
</td>
<td class="nump">69,252<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">154,165<span></span>
</td>
<td class="nump">143,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property, plant and equipment</a></td>
<td class="nump">73,078<span></span>
</td>
<td class="nump">68,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property, plant and equipment</a></td>
<td class="nump">68,973<span></span>
</td>
<td class="nump">67,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property, plant and equipment</a></td>
<td class="nump">81,941<span></span>
</td>
<td class="nump">72,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture &amp; fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property, plant and equipment</a></td>
<td class="nump">1,931<span></span>
</td>
<td class="nump">1,906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property, plant and equipment</a></td>
<td class="nump">$ 1,657<span></span>
</td>
<td class="nump">$ 1,657<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820113282048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statement Details - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinancialStatementDetailsAbstract', window );"><strong>Financial Statement Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense related to property, plant and equipment</a></td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinancialStatementDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinancialStatementDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820111576560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statement Details - Intangible Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Total definite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (2,295)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,935)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(681)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">18,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">1,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,390<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">21,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,619<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">19,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2023 (excluding the three months ended March&#160;31,&#160;2023)</a></td>
<td class="nump">1,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">2,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">2,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">2,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">2,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">$ 8,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OffMarketFavorableLeaseMember', window );">Favorable Leasehold Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Total definite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted- Average Life (in years)</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 20,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,295)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,785)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 18,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ibrx_OrganizedWorkforceMember', window );">Organized Workforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Total definite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(681)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Accumulated Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OffMarketFavorableLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OffMarketFavorableLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ibrx_OrganizedWorkforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ibrx_OrganizedWorkforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820109588480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statement Details - Accrued Expenses and Other Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinancialStatementDetailsAbstract', window );"><strong>Financial Statement Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AccruedResearchAndDevelopmentCosts', window );">Accrued research and development costs</a></td>
<td class="nump">$ 15,916<span></span>
</td>
<td class="nump">$ 1,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonus</a></td>
<td class="nump">14,642<span></span>
</td>
<td class="nump">12,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional and service fees</a></td>
<td class="nump">9,229<span></span>
</td>
<td class="nump">6,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AccruedPreclinicalAndClinicalTrialCosts', window );">Accrued preclinical and clinical trial costs</a></td>
<td class="nump">5,523<span></span>
</td>
<td class="nump">4,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued compensation</a></td>
<td class="nump">5,327<span></span>
</td>
<td class="nump">6,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AccruedConstructionCostsCurrent', window );">Accrued construction costs</a></td>
<td class="nump">2,136<span></span>
</td>
<td class="nump">7,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinancingObligationCurrent', window );">Financing obligation &#8211; current portion</a></td>
<td class="nump">357<span></span>
</td>
<td class="nump">1,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">988<span></span>
</td>
<td class="nump">1,628<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">$ 54,118<span></span>
</td>
<td class="nump">$ 41,825<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AccruedConstructionCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Construction Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AccruedConstructionCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AccruedPreclinicalAndClinicalTrialCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued preclinical and clinical trial costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AccruedPreclinicalAndClinicalTrialCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AccruedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AccruedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinancialStatementDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinancialStatementDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinancingObligationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Obligation, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinancingObligationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820110640896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statement Details - Interest and Investment Income, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinancialStatementDetailsAbstract', window );"><strong>Financial Statement Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss', window );">Unrealized gains from equity securities</a></td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">$ 1,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest income</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">1,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Investment amortization expense, net</a></td>
<td class="nump">260<span></span>
</td>
<td class="num">(1,049)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Net realized losses on investments</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Interest and investment income, net</a></td>
<td class="nump">$ 673<span></span>
</td>
<td class="nump">$ 1,666<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinancialStatementDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinancialStatementDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820109474464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statement Details - Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinancialStatementDetailsAbstract', window );"><strong>Financial Statement Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Interest expense on related-party notes</a></td>
<td class="num">$ (18,260)<span></span>
</td>
<td class="num">$ (8,101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty', window );">Amortization of related-party notes discounts</a></td>
<td class="num">(11,536)<span></span>
</td>
<td class="num">(370)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Other interest expense</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">$ (29,816)<span></span>
</td>
<td class="num">$ (8,491)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Debt Discount (Premium), Related Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AmortizationOfDebtDiscountPremiumRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinancialStatementDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinancialStatementDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on a debt or other obligation to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820109985728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Summary of Available-for-Sale Marketable Debt Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,048<span></span>
</td>
<td class="nump">$ 970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">964<span></span>
</td>
<td class="nump">876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ibrx_CurrentAssetsMember', window );">Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ibrx_CurrentAssetsMember', window );">Current Assets | Foreign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod', window );">Weighted- Average Remaining Contractual&#160;Life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ibrx_CurrentAssetsMember', window );">Current Assets | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ibrx_NoncurrentAssetsMember', window );">Noncurrent Assets | Foreign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod', window );">Weighted- Average Remaining Contractual&#160;Life (in years)</a></td>
<td class="text">3 months 18 days<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 902<span></span>
</td>
<td class="nump">$ 932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(82)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 820<span></span>
</td>
<td class="nump">$ 840<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities debt securities period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ibrx_CurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ibrx_CurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ibrx_NoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ibrx_NoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820105829968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Accumulated Unrealized Losses on Marketable Debt Securities in Continuous Loss Position (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities in an unrealized loss position | Security</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Estimated Fair Value</a></td>
<td class="nump">$ 581<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Gross Unrealized Losses</a></td>
<td class="num">(58)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">More than 12 months, Estimated Fair Value</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">More than 12 months, Gross Unrealized Losses</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">More than 12 months, Estimated Fair Value</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">More than 12 months, Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtMember', window );">Foreign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Estimated Fair Value</a></td>
<td class="nump">581<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Gross Unrealized Losses</a></td>
<td class="num">(58)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">More than 12 months, Estimated Fair Value</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">More than 12 months, Gross Unrealized Losses</a></td>
<td class="num">$ (24)<span></span>
</td>
<td class="num">$ (92)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820109462992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains (losses) from equity securities</a></td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">$ 1,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Investments in marketable equity securities with readily determinable fair values</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820102318000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>yr </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 15, 2023 </div>
<div>$ / shares </div>
<div>yr</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Principal Amount</a></td>
<td class="nump">$ 738,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 708,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Change in fair value of warrant liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Principal Amount</a></td>
<td class="nump">$ 233,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | Nant Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Principal Amount</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=ibrx_MeasurementInputExpectedMarketYieldMember', window );">Expected market yield | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Significant unobservable inputs, Level 3 valuations</a></td>
<td class="nump">0.175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=ibrx_MeasurementInputDiscountPeriodMember', window );">Discount period | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Significant unobservable inputs, Level 3 valuations | yr</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount factor | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Significant unobservable inputs, Level 3 valuations</a></td>
<td class="nump">0.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember', window );">December 2022 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, beginning of year</a></td>
<td class="num">$ (21,636)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">(15,818)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, end of year</a></td>
<td class="num">$ (5,818)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember', window );">December 2022 Warrants | Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in units) | shares</a></td>
<td class="nump">9,090,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember', window );">December 2022 Warrants | Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input | $ / shares</a></td>
<td class="nump">6.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember', window );">December 2022 Warrants | Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input | yr</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember', window );">December 2022 Warrants | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">1.293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember', window );">December 2022 Warrants | Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember', window );">December 2022 Warrants | Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember', window );">February 2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">$ (11,736)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, end of year</a></td>
<td class="num">$ (11,962)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember', window );">February 2023 Warrants | Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in units) | shares</a></td>
<td class="nump">14,072,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember', window );">February 2023 Warrants | Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input | $ / shares</a></td>
<td class="nump">4.26<span></span>
</td>
<td class="nump">4.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember', window );">February 2023 Warrants | Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input | yr</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember', window );">February 2023 Warrants | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">1.278<span></span>
</td>
<td class="nump">0.970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember', window );">February 2023 Warrants | Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember', window );">February 2023 Warrants | Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.041<span></span>
</td>
<td class="nump">0.046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 92,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="num">(47,650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,655)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Current Assets | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">2,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Current Assets | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Current Assets | Foreign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Current Assets | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">88,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Current Assets | Cash and cash equivalents | Government-sponsored securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Current Assets | Cash and cash equivalents | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Noncurrent Assets | Foreign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Current Liabilities | Related-party convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="num">(29,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Current Liabilities | Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Noncurrent Liabilities | Outstanding third-party warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="num">(17,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,636)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">76,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Current Assets | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">2,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Current Assets | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Current Assets | Foreign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Current Assets | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">73,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Noncurrent Assets | Foreign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Current Liabilities | Related-party convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Current Liabilities | Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Noncurrent Liabilities | Outstanding third-party warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">15,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Current Assets | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Current Assets | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Current Assets | Foreign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Current Assets | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">14,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Noncurrent Assets | Foreign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Current Liabilities | Related-party convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Current Liabilities | Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Noncurrent Liabilities | Outstanding third-party warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="num">(47,650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,655)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Current Assets | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Current Assets | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Current Assets | Foreign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Current Assets | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Noncurrent Assets | Foreign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Current Liabilities | Related-party convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="num">(29,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Current Liabilities | Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Noncurrent Liabilities | Outstanding third-party warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="num">$ (17,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,636)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_RelatedPartyNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related-party notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_RelatedPartyNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalIssued33123Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalIssued33123Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ibrx_MeasurementInputExpectedMarketYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ibrx_MeasurementInputExpectedMarketYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ibrx_MeasurementInputDiscountPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ibrx_MeasurementInputDiscountPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ibrx_CurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ibrx_CurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ForeignGovernmentDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ForeignGovernmentDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ibrx_NoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ibrx_NoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ibrx_CurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ibrx_CurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=ibrx_RelatedPartyConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=ibrx_RelatedPartyConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=ibrx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=ibrx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ibrx_NoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ibrx_NoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820105693696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements and Acquisition - Collaboration Agreements - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems', window );"><strong>Research and Development Arrangements with Federal Government [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Payment to acquire interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,337<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ibrx_AmyrisJointVentureMember', window );">Amyris Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems', window );"><strong>Research and Development Arrangements with Federal Government [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Advances to support operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Payment to acquire interest in joint venture</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ibrx_AmyrisJointVentureMember', window );">Amyris Joint Venture | Amyris, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems', window );"><strong>Research and Development Arrangements with Federal Government [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Advances to support operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development arrangements with the federal government.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ibrx_AmyrisJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ibrx_AmyrisJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ibrx_AmyrisIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ibrx_AmyrisIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820106091520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements and Acquisition - License Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>May 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,264,000<span></span>
</td>
<td class="nump">$ 55,378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember', window );">3M IPC and Access to Advanced Health Institute License Agreement | License Agreement Terms | 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsPeriodicLicensePayments', window );">Periodic license payments</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment', window );">Annual minimum licensing payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsLicenseMaintenanceFees', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_AccessToAdvancedHealthInstituteAAHIMember', window );">Access to Advanced Health Institute (formerly IDRI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment', window );">Non-refundable upfront cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum', window );">Milestone payment, aggregate maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsMilestoneFees', window );">Milestone fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_AccessToAdvancedHealthInstituteAAHIMember', window );">Access to Advanced Health Institute (formerly IDRI) | License Agreement Terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment', window );">Non-refundable upfront cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum', window );">Milestone payment, aggregate maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsTerminationFee', window );">Termination fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_AccessToAdvancedHealthInstituteAAHIMember', window );">Access to Advanced Health Institute (formerly IDRI) | License Agreement Terms | 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsLicenseMaintenanceFees', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_AccessToAdvancedHealthInstituteAAHIMember', window );">Access to Advanced Health Institute (formerly IDRI) | License Agreement Terms | 2023 through 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsLicenseMaintenanceFees', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_AccessToAdvancedHealthInstituteAAHIMember', window );">Access to Advanced Health Institute (formerly IDRI) | Sponsored Research Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_AccessToAdvancedHealthInstituteAAHIMember', window );">Access to Advanced Health Institute (formerly IDRI) | Sponsored Research Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities', window );">Annual payment for support of research activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Annual Minimum Licensing Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual payment for support of research activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsLicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, License Maintenance Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsLicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsMilestoneFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Milestone Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsMilestoneFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Milestone Payment, Aggregate Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsNonrefundableUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsPeriodicLicensePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Periodic License Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsPeriodicLicensePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Termination Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LicensingAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LicensingAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibrx_A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibrx_A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis=ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis=ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibrx_AccessToAdvancedHealthInstituteAAHIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibrx_AccessToAdvancedHealthInstituteAAHIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis=ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis=ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ibrx_SponsoredResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ibrx_SponsoredResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820114764304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and License Agreements and Acquisition - Acquisition - Consideration Transferred (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 14, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets</a></td>
<td class="nump">$ 21,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibrx_DunkirkFacilityMember', window );">Dunkirk Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Other depreciable assets and prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,983<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AssetAcquisitionFairValueOfAssetsAcquired', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,508<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AssetAcquisitionFairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Fair Value of Assets Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AssetAcquisitionFairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibrx_DunkirkFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibrx_DunkirkFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820110682864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and License Agreements and Acquisition - Acquisition - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Feb. 14, 2022 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>employee</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibrx_DunkirkFacilityMember', window );">Dunkirk Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="nump">409,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total consideration</a></td>
<td class="nump">$ 40,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Cash payment to acquire assets</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Transaction costs</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseOperatingLeaseAnnualLeasePayment', window );">Annual lease payment</a></td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease arrangement</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Optional extended lease term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm', window );">Commitment to spend, operational expenses, initial lease term</a></td>
<td class="nump">$ 1,520,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm', window );">Commitment to spend, operational expenses, renewal lease term</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears', window );">Commitment to hire, number of employees, first five years | employee</a></td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears', window );">Commitment to hire, number of employees, first two and a half years | employee</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibrx_DunkirkFacilityMember', window );">Dunkirk Facility | State Of New York | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseholdInterestGovernmentFundingReceivable', window );">Government funding for leasehold build-out</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibrx_DunkirkFacilityMember', window );">Dunkirk Facility | State Of New York | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseholdInterestGovernmentFundingReceivable', window );">Government funding for leasehold build-out</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseOperatingLeaseAnnualLeasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Operating Lease, Annual Lease Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseOperatingLeaseAnnualLeasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leasehold Interest, Commitment to Hire, Number of Employees, First Five Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leasehold Interest, Commitment to Hire, Number of Employees, First Two and a Half Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseholdInterestGovernmentFundingReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leasehold Interest, Government Funding Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseholdInterestGovernmentFundingReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leasehold Interest, Operational Expenses, Commitment to Spend, Initial Lease Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leasehold Interest, Operational Expenses, Commitment to Spend, Renewal Lease Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_NumberOfSquareFootOfFacilityLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of square foot of facility leased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_NumberOfSquareFootOfFacilityLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibrx_DunkirkFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibrx_DunkirkFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibrx_StateOfNewYorkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibrx_StateOfNewYorkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820102205520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Contingent Consideration Related to Business Combinations - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Apr. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceCorporationMember', window );">Altor BioScience Corporation | Contingent Value Rights Payable, Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ContingentValueRightsObligations', window );">Potential contingent value rights to be earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 304.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceCorporationMember', window );">Altor BioScience Corporation | Contingent Value Rights Payable, Sales Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ContingentValueRightsObligations', window );">Potential contingent value rights to be earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation', window );">Minimum net sales milestone for contingent value rights payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceCorporationMember', window );">Altor BioScience Corporation | Contingent Value Rights Payable, Sales Milestone | Dr. Soon-Shiong and Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ContingentValueRightsObligations', window );">Potential contingent value rights to be earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceCorporationMember', window );">Altor BioScience Corporation | Contingent Value Rights Payable, Sales Milestone | Altor Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ContingentValueRightsObligations', window );">Potential contingent value rights to be earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ibrx_VivaBioCellMember', window );">VivaBioCell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PercentageOfWhollyOwnedSubsidiary', window );">Ownership percentage acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business combination, consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned', window );">Contingent consideration arrangements, earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements', window );">Contingent consideration arrangements, paid</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh', window );">Maximum milestone payment due if certain conditions are met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Earned</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_BusinessCombinationContingentConsiderationArrangementsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Settlements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ContingentValueRightsObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent value rights obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ContingentValueRightsObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum net sales milestone contingent value rights obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PercentageOfWhollyOwnedSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of wholly-owned subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PercentageOfWhollyOwnedSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ibrx_ContingentValueRightsObligationRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ibrx_ContingentValueRightsObligationRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ibrx_ContingentValueRightsObligationSalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ibrx_ContingentValueRightsObligationSalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_DrSoonShiongAndRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_DrSoonShiongAndRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_AltorStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_AltorStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ibrx_VivaBioCellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ibrx_VivaBioCellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820110616144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Litigation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Feb. 07, 2023</div></th>
<th class="th"><div>Dec. 08, 2022</div></th>
<th class="th"><div>Dec. 02, 2022</div></th>
<th class="th"><div>Jul. 09, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LitigationLineItems', window );"><strong>Litigation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares to be issued in private placement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,229,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Value of shares to be issued in private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceLLCMember', window );">Altor BioScience, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LitigationLineItems', window );"><strong>Litigation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfDissentingShares', window );">Dissenting shares to be released (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,167,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LitigationSettlementNumberOfSharesToBeIssued', window );">Shares issued for litigation settlement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,229,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares', window );">Cash to be distributed in lieu of fractional shares (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Accrued litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibrx_SorrentoTherapeuticsIncLitigationMember', window );">Sorrento Therapeutics, Inc. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LitigationLineItems', window );"><strong>Litigation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Amount awarded from other party in litigation settlement</a></td>
<td class="nump">$ 176.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LitigationSettlementInterestPercent', window );">Interest related to litigation settlement, as a percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ibrx_NantCellIncMember', window );">Nant Cell Inc | Sorrento Therapeutics, Inc. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LitigationLineItems', window );"><strong>Litigation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Amount awarded from other party in litigation settlement</a></td>
<td class="nump">$ 159.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ibrx_NANTibodyLLCMember', window );">NANTibody, LLC | Sorrento Therapeutics, Inc. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LitigationLineItems', window );"><strong>Litigation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Amount awarded from other party in litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LitigationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LitigationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LitigationSettlementInterestPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement Interest, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LitigationSettlementInterestPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LitigationSettlementNumberOfSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Number of Shares to be Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LitigationSettlementNumberOfSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_NumberOfDissentingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Dissenting Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_NumberOfDissentingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Cash Distributed In Lieu of Fractional Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ibrx_SorrentoTherapeuticsIncLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ibrx_SorrentoTherapeuticsIncLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ibrx_NantCellIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ibrx_NantCellIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ibrx_NANTibodyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ibrx_NANTibodyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820114763360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Arrangements - Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 44,191<span></span>
</td>
<td class="nump">$ 45,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease assets</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseRightOfUseAsset', window );">Total lease assets</a></td>
<td class="nump">44,306<span></span>
</td>
<td class="nump">45,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">2,844<span></span>
</td>
<td class="nump">2,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">46,289<span></span>
</td>
<td class="nump">47,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 49,255<span></span>
</td>
<td class="nump">$ 50,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other assets (including amounts with related parties)<span></span>
</td>
<td class="text">Other assets (including amounts with related parties)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued expenses and other liabilities<span></span>
</td>
<td class="text">Accrued expenses and other liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other liabilities<span></span>
</td>
<td class="text">Other liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820109637312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Arrangements - Summary of Information Regarding Leases (Detail)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term, Operating leases</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term, Finance leases</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate, Operating leases</a></td>
<td class="nump">10.60%<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate, Finance leases</a></td>
<td class="nump">11.70%<span></span>
</td>
<td class="nump">11.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820109846768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Arrangements - Components of Lease Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 2,921<span></span>
</td>
<td class="nump">$ 2,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease costs</a></td>
<td class="nump">1,050<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense', window );">Finance lease costs (including amortization and interest costs)</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">970<span></span>
</td>
<td class="nump">1,182<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 4,964<span></span>
</td>
<td class="nump">$ 3,490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease Costs, Right-Of-Use Asset Amortization And Interest Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820110276032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Arrangements - Schedule of Cash Paid for Amounts Included in Measurement of Lease Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash Flow Operating Activities Lessee [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating leases (excluding variable lease costs)</a></td>
<td class="nump">$ 3,179<span></span>
</td>
<td class="nump">$ 2,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flow from finance leases</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flow from finance leases</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820102185536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Arrangements - Summary of Future Minimum Lease Payments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023 (excluding the three months ended March&#160;31,&#160;2023)</a></td>
<td class="nump">$ 6,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">12,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">12,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">10,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">8,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">23,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">72,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="nump">20,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable', window );">Less: Tenant improvement allowance receivable</a></td>
<td class="nump">2,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">49,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023 (excluding the three months ended March&#160;31,&#160;2023)</a></td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable', window );">Less: Tenant improvement allowance receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiabilityToBePaidAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear', window );">2023 (excluding the three months ended March&#160;31,&#160;2023)</a></td>
<td class="nump">6,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiabilityToBePaidYearOne', window );">2024</a></td>
<td class="nump">12,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiabilityToBePaidYearTwo', window );">2025</a></td>
<td class="nump">12,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiabilityToBePaidYearThree', window );">2026</a></td>
<td class="nump">10,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiabilityToBePaidYearFour', window );">2027</a></td>
<td class="nump">8,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">23,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiabilityToBePaid', window );">Total future minimum lease payments</a></td>
<td class="nump">72,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiabilityUndiscountedExcessInterest', window );">Less: Interest</a></td>
<td class="nump">20,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable', window );">Less: Tenant improvement allowance receivable</a></td>
<td class="nump">2,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 49,255<span></span>
</td>
<td class="nump">$ 50,742<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, Tenant Improvement Allowance Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, Tenant Improvement Allowance Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiabilityToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, To Be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiabilityToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiabilityToBePaidAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, To Be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiabilityToBePaidAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, To Be Paid, Remainder of Fiscal Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiabilityToBePaidYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, To Be Paid, Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiabilityToBePaidYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiabilityToBePaidYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, To Be Paid, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiabilityToBePaidYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiabilityToBePaidYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, To Be Paid, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiabilityToBePaidYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiabilityToBePaidYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, To Be Paid, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiabilityToBePaidYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiabilityUndiscountedExcessInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, Undiscounted Excess Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiabilityUndiscountedExcessInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Tenant Improvement Allowance Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820110352112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Arrangements - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms', window );">Operating lease payments related to options to extend lease terms</a></td>
<td class="nump">$ 14.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease arrangement</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Optional extended lease term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease arrangement</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Optional extended lease term</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease payments related to options to extend lease terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820105248768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Debt - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Convertible note payable at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 738,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 708,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from issuance of related-party convertible promissory notes, net of issuance costs paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,850<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Net proceeds from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">717,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">673,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,515<span></span>
</td>
<td class="nump">5,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalIssued33123Member', window );">Nant Capital | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalTwoMember', window );">Nant Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapital3Member', window );">Nant Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.59%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare', window );">Option to convert accrued and unpaid interest to shares of common stock (in dollars per share)</a></td>
<td class="nump">$ 5.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapital3Member', window );">Nant Capital | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapital4Member', window );">Nant Capital | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapital6Member', window );">Nant Capital | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Convertible note payable at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Related-party notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Net proceeds from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | Nant Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Convertible note payable at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from issuance of related-party convertible promissory notes, net of issuance costs paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Lender origination fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Related-party notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Net proceeds from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NotesPayableRelatedPartiesPrincipalAndAccruedInterest', window );">Aggregate principal and accrued interest</a></td>
<td class="nump">$ 315,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">$ 5.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | Nant Capital, NantCancerStemCell, LLC, and NantMobile, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Net proceeds from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | Nant Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Convertible note payable at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Net proceeds from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Convertible note payable at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Related-party notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Net proceeds from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | Nant Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Convertible note payable at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Net proceeds from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,400<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | Nant Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Convertible note payable at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Net proceeds from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | Nant Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Convertible note payable at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Net proceeds from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_NotesPayableRelatedPartiesPrincipalAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Related Parties, Principal And Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_NotesPayableRelatedPartiesPrincipalAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option to Convert Accrued and Unpaid Interest to Shares of Common Stock, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_RelatedPartyNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related-party notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_RelatedPartyNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Basis Spread on Variable Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalIssued33123Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalIssued33123Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=ibrx_SecuredOvernightFinancingRateSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=ibrx_SecuredOvernightFinancingRateSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapital3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapital3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapital4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapital4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapital6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapital6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820104864112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Agreements - Summary of Related-Party Promissory Notes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Principal Amount</a></td>
<td class="nump">$ 738,226<span></span>
</td>
<td class="nump">$ 708,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued Interest Added to Note</a></td>
<td class="nump">31,713<span></span>
</td>
<td class="nump">29,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="nump">52,671<span></span>
</td>
<td class="nump">64,207<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">717,118<span></span>
</td>
<td class="nump">673,172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Non-convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Principal Amount</a></td>
<td class="nump">475,000<span></span>
</td>
<td class="nump">475,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued Interest Added to Note</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="nump">33,372<span></span>
</td>
<td class="nump">43,099<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">441,628<span></span>
</td>
<td class="nump">431,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Principal Amount</a></td>
<td class="nump">233,226<span></span>
</td>
<td class="nump">233,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued Interest Added to Note</a></td>
<td class="nump">31,713<span></span>
</td>
<td class="nump">29,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="nump">19,299<span></span>
</td>
<td class="nump">21,108<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">$ 245,640<span></span>
</td>
<td class="nump">$ 241,271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapital3Member', window );">Nant Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest Rate</a></td>
<td class="nump">12.89%<span></span>
</td>
<td class="nump">12.59%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapital3Member', window );">Nant Capital | Non-convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Principal Amount</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="nump">27,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">$ 272,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapital3Member', window );">Nant Capital | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalMember', window );">Nant Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest Rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalMember', window );">Nant Capital | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Principal Amount</a></td>
<td class="nump">$ 55,226<span></span>
</td>
<td class="nump">$ 55,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued Interest Added to Note</a></td>
<td class="nump">10,113<span></span>
</td>
<td class="nump">9,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="nump">4,742<span></span>
</td>
<td class="nump">5,188<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">$ 60,597<span></span>
</td>
<td class="nump">$ 59,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalOneMember', window );">Nant Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest Rate</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalOneMember', window );">Nant Capital | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Principal Amount</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued Interest Added to Note</a></td>
<td class="nump">7,870<span></span>
</td>
<td class="nump">7,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="nump">3,696<span></span>
</td>
<td class="nump">4,068<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">$ 54,174<span></span>
</td>
<td class="nump">$ 52,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalTwoMember', window );">Nant Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest Rate</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalTwoMember', window );">Nant Capital | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Principal Amount</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued Interest Added to Note</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="nump">2,373<span></span>
</td>
<td class="nump">2,580<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">37,627<span></span>
</td>
<td class="nump">$ 37,420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalIssued33123Member', window );">Nant Capital | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Principal Amount</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued Interest Added to Note</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">$ 29,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalIssued33123Member', window );">Nant Capital | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate', window );">Interest Rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantMobileMember', window );">NantMobile</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest Rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantMobileMember', window );">NantMobile | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Principal Amount</a></td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued Interest Added to Note</a></td>
<td class="nump">5,554<span></span>
</td>
<td class="nump">5,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="nump">5,482<span></span>
</td>
<td class="nump">5,978<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">$ 55,072<span></span>
</td>
<td class="nump">$ 54,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NCSCMember', window );">NCSC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest Rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NCSCMember', window );">NCSC | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyNotesPayable', window );">Principal Amount</a></td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued Interest Added to Note</a></td>
<td class="nump">8,176<span></span>
</td>
<td class="nump">7,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="nump">3,006<span></span>
</td>
<td class="nump">3,294<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">$ 38,170<span></span>
</td>
<td class="nump">$ 37,390<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_RelatedPartyNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related-party notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_RelatedPartyNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Basis Spread on Variable Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapital3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapital3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=ibrx_SecuredOvernightFinancingRateSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=ibrx_SecuredOvernightFinancingRateSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalIssued33123Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalIssued33123Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantMobileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantMobileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NCSCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NCSCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820106562096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Agreements - Estimated Material Contractual Obligations Related to Related-Party Promissory Notes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapital3Member', window );">Nant Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest Rate</a></td>
<td class="nump">12.89%<span></span>
</td>
<td class="nump">12.59%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Related Party Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2023 (excluding the three months ended March&#160;31,&#160;2023)</a></td>
<td class="nump">$ 555,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">2,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">294,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total principal and estimated interest due on related-party debt</a></td>
<td class="nump">852,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Principal Payments | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2023 (excluding the three months ended March&#160;31,&#160;2023)</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">233,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total principal and estimated interest due on related-party debt</a></td>
<td class="nump">263,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Principal Payments | Non-convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2023 (excluding the three months ended March&#160;31,&#160;2023)</a></td>
<td class="nump">475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total principal and estimated interest due on related-party debt</a></td>
<td class="nump">475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Interest Payments | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2023 (excluding the three months ended March&#160;31,&#160;2023)</a></td>
<td class="nump">4,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">2,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">61,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total principal and estimated interest due on related-party debt</a></td>
<td class="nump">68,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Interest Payments | Non-convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2023 (excluding the three months ended March&#160;31,&#160;2023)</a></td>
<td class="nump">46,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total principal and estimated interest due on related-party debt</a></td>
<td class="nump">$ 46,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapital3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapital3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibrx_RelatedPartyNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibrx_RelatedPartyNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibrx_RelatedPartyNotesPrincipalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibrx_RelatedPartyNotesPrincipalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibrx_RelatedPartyNotesInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibrx_RelatedPartyNotesInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820104782672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related-Party Agreements - Summary of Outstanding Balances of Related-Party Agreements (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Total due from related parties</a></td>
<td class="nump">$ 1,464<span></span>
</td>
<td class="nump">$ 1,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Total due to related parties</a></td>
<td class="nump">2,932<span></span>
</td>
<td class="nump">3,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantBioIncMember', window );">NantBio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Total due from related parties</a></td>
<td class="nump">1,294<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Total due to related parties</a></td>
<td class="nump">943<span></span>
</td>
<td class="nump">943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_BrinkBiologicsIncMember', window );">Brink Biologics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Total due from related parties</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_DuleyRoadMember', window );">Duley Road, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Total due to related parties</a></td>
<td class="nump">1,356<span></span>
</td>
<td class="nump">1,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksMember', window );">NantWorks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Total due to related parties</a></td>
<td class="nump">592<span></span>
</td>
<td class="nump">986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_ImmunoOncologyClinicMember', window );">Immuno-Oncology Clinic, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Total due to related parties</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_VariousMember', window );">Various</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Total due from related parties</a></td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_BrinkBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_BrinkBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_DuleyRoadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_DuleyRoadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_ImmunoOncologyClinicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_ImmunoOncologyClinicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_VariousMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_VariousMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820097949264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Agreements - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 01, 2022 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Term</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Term</div>
</th>
<th class="th">
<div>Apr. 01, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Term</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($) </div>
<div>lease </div>
<div>Term</div>
</th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Term</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Term</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,676,000<span></span>
</td>
<td class="nump">$ 40,608,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,264,000<span></span>
</td>
<td class="nump">55,378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,932,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,469,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_NantWorksMember', window );">NantWorks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="nump">46,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AnnualPercentageIncreasesToBaseRent', window );">Percentage of annual increases of base rent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_BaseMonthlyRent', window );">Base rent - monthly</a></td>
<td class="nump">$ 273,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased', window );">Expansion of licensed premises (in square feet) | ft&#178;</a></td>
<td class="nump">36,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_NantBioIncMember', window );">NantBio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_FourTwoZeroNashLLCMember', window );">420 Nash, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AnnualPercentageIncreasesToBaseRent', window );">Percentage of annual increases of base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_BaseMonthlyRent', window );">Base rent - monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_OptionsToExtendNumberOfTerms', window );">Options to extend number of terms | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PeriodOfExtendedLeaseTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_A23AlaskaLLCMember', window );">23 Alaska, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="nump">47,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AnnualPercentageIncreasesToBaseRent', window );">Percentage of annual increases of base rent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_BaseMonthlyRent', window );">Base rent - monthly</a></td>
<td class="nump">$ 139,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_OptionsToExtendNumberOfTerms', window );">Options to extend number of terms | Term</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PeriodOfExtendedLeaseTerm', window );">Optional extended lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_BaseMonthlyRentParking', window );">Base monthly rent, parking</a></td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense | 420 Nash, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense | 23 Alaska, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksMember', window );">NantWorks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">592,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">986,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AnnualPercentageIncreasesToBaseRent', window );">Percentage of annual increases of base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_BaseMonthlyRent', window );">Base rent - monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksMember', window );">NantWorks | Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksMember', window );">NantWorks | Shared Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksMember', window );">NantWorks | Shared Services Agreement | Reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_ConsiderationForFutureServicesMember', window );">Consideration for Future Services | Immuno-Oncology Clinic, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Consideration for future services performed by related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_ImmunoOncologyClinicIncMember', window );">Immuno-Oncology Clinic, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_ImmunoOncologyClinicIncMember', window );">Immuno-Oncology Clinic, Inc. | Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PrepaidExpenseWriteDown', window );">Write down of prepaid expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NCSCMember', window );">NCSC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_SupplyAgreementTermOfContract', window );">Initial term of supply agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_SupplyAgreementPeriodOfExtendedTerm', window );">Optional extended term of supply agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantBioIncMember', window );">NantBio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">943,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">943,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_SixZeroFiveDougStLLCMember', window );">605 Doug St, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AnnualPercentageIncreasesToBaseRent', window );">Percentage of annual increases of base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_BaseMonthlyRent', window );">Base rent - monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_OptionsToExtendNumberOfTerms', window );">Options to extend number of terms | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PeriodOfExtendedLeaseTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_SixZeroFiveDougStLLCMember', window );">605 Doug St, LLC | Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_DuleyRoadLLCMember', window );">Duley Road, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AnnualPercentageIncreasesToBaseRent', window );">Percentage of annual increases of base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_BaseMonthlyRent', window );">Base rent - monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_OptionsToExtendNumberOfTerms', window );">Options to extend number of terms | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PeriodOfExtendedLeaseTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfLeases', window );">Number of leases | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_DuleyRoadLLCMember', window );">Duley Road, LLC | Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseholdImprovementPayables', window );">Leasehold improvement payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseRelatedPayables', window );">Lease-related payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_DuleyRoadLLCMember', window );">Duley Road, LLC | September 2019 Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_DuleyRoadLLCMember', window );">Duley Road, LLC | July 2019 Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_SixZeroFiveNashLLCMember', window );">605 Nash, LLC | Initial Premises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AnnualPercentageIncreasesToBaseRent', window );">Percentage of annual increases of base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_BaseMonthlyRent', window );">Base rent - monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_OptionsToExtendNumberOfTerms', window );">Options to extend number of terms | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PeriodOfExtendedLeaseTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RentAbatementPeriod', window );">Rent abatement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncentiveFromLessor', window );">Tenant improvements incentive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_SixZeroFiveNashLLCMember', window );">605 Nash, LLC | Expansion Premises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AnnualPercentageIncreasesToBaseRent', window );">Percentage of annual increases of base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_BaseMonthlyRent', window );">Base rent - monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PeriodOfExtendedLeaseTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RentAbatementPeriod', window );">Rent abatement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncentiveFromLessor', window );">Tenant improvements incentive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_SixZeroFiveNashLLCMember', window );">605 Nash, LLC | Initial and Expansion Premises | Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AnnualPercentageIncreasesToBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual percentage increases to base rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AnnualPercentageIncreasesToBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_BaseMonthlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Base monthly rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_BaseMonthlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_BaseMonthlyRentParking">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Base Monthly Rent, Parking</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_BaseMonthlyRentParking</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase to Number of Square Foot of Facility Leased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseRelatedPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease-related payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseRelatedPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseholdImprovementPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leasehold improvement payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseholdImprovementPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_NumberOfLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_NumberOfLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_NumberOfSquareFootOfFacilityLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of square foot of facility leased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_NumberOfSquareFootOfFacilityLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_OptionsToExtendNumberOfTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options to extend number of terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_OptionsToExtendNumberOfTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PeriodOfExtendedLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of extended lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PeriodOfExtendedLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PrepaidExpenseWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expense, Write Down</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PrepaidExpenseWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_RentAbatementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rent abatement period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_RentAbatementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_SupplyAgreementPeriodOfExtendedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply Agreement, Period Of Extended Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_SupplyAgreementPeriodOfExtendedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_SupplyAgreementTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply Agreement, Term Of Contract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_SupplyAgreementTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncentiveFromLessor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of incentive received by lessee from lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39896-112707<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 30<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123388062&amp;loc=SL77916639-209961<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 55<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123386226&amp;loc=d3e41620-112719<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e40010-112707<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncentiveFromLessor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_NantWorksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_NantWorksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_NantBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_NantBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_FourTwoZeroNashLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_FourTwoZeroNashLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_A23AlaskaLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_A23AlaskaLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibrx_SharedServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibrx_SharedServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=ibrx_ReimbursementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=ibrx_ReimbursementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_ConsiderationForFutureServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_ConsiderationForFutureServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_ImmunoOncologyClinicIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_ImmunoOncologyClinicIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_ImmunoOncologyClinicIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_ImmunoOncologyClinicIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NCSCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NCSCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_SixZeroFiveDougStLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_SixZeroFiveDougStLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_DuleyRoadLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_DuleyRoadLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=ibrx_DueToRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=ibrx_DueToRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibrx_SeptemberTwentyNineteenLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibrx_SeptemberTwentyNineteenLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibrx_JulyTwentyNineteenLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibrx_JulyTwentyNineteenLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_SixZeroFiveNashLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_SixZeroFiveNashLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibrx_InitialPremisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibrx_InitialPremisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibrx_ExpansionPremisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibrx_ExpansionPremisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibrx_InitialAndExpansionPremisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibrx_InitialAndExpansionPremisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820110025136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liabilities (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 15, 2023</div></th>
<th class="th"><div>Dec. 12, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_TransactionCostsWarrantLiability', window );">Transaction costs allocated to warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 984<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember', window );">December 2022 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_TransactionCostsWarrantLiability', window );">Transaction costs allocated to warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Estimated fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Decrease in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember', window );">February 2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 4.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_TransactionCostsWarrantLiability', window );">Transaction costs allocated to warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Estimated fair value of warrants</a></td>
<td class="nump">$ 23,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Decrease in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock issued in transaction (in shares)</a></td>
<td class="nump">14,072,615<span></span>
</td>
<td class="nump">9,090,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Placement agent fees and other offering costs</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering | December 2022 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in units)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,090,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering | February 2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in units)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,072,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_TransactionCostsWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs, Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_TransactionCostsWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820102275552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 15, 2023</div></th>
<th class="th"><div>Dec. 12, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Feb. 17, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_IssuanceOfCommonStockUnderAtMarketOfferingShares', window );">Shares issued under ATM (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember', window );">February 2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 4.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock issued in transaction</a></td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock issued in transaction (in shares)</a></td>
<td class="nump">14,072,615<span></span>
</td>
<td class="nump">9,090,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock (in dollars per share)</a></td>
<td class="nump">$ 3.55<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Placement agent fees and other offering costs</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Commissions and offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering | February 2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in units)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,072,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_February2023ShelfRegistrationStatementMember', window );">February 2023 Shelf Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_SaleOfStockMaximumAggregateOfferingPrice', window );">Maximum offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock issued in transaction</a></td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CommonStockValueAvailableForFutureStockIssuance', window );">Available for future stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_AtTheMarketOfferingProgramMember', window );">ATM Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CommonStockValueAvailableForFutureStockIssuance', window );">Available for future stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_AtTheMarketOfferingProgramMember', window );">ATM Offering Program | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PercentageOfSalesAgentCommission', window );">Percentage of sales agent commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibrx_TwoThousandFifteenShareRepurchasePlanMember', window );">2015 Share Repurchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of common stock, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CommonStockValueAvailableForFutureStockIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock value available for future stock issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CommonStockValueAvailableForFutureStockIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_IssuanceOfCommonStockUnderAtMarketOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock under at-the market offering, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_IssuanceOfCommonStockUnderAtMarketOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PercentageOfSalesAgentCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Sales Agent Commission</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PercentageOfSalesAgentCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_SaleOfStockMaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Aggregate Offering Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_SaleOfStockMaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_February2023ShelfRegistrationStatementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ibrx_February2023ShelfRegistrationStatementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibrx_AtTheMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibrx_AtTheMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ibrx_TwoThousandFifteenShareRepurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ibrx_TwoThousandFifteenShareRepurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820106095808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 04, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,053,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,445,499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock option exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to non-vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate intrinsic value, vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | NantWorks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue', window );">Estimated benefit at grant date fair value</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ibrx_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in units)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,638,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibrx_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock reserved for future grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award estimated benefit at grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_NantWorksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_NantWorksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ibrx_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ibrx_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ibrx_TwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ibrx_TwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820105614304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Based Compensation Expenses Related to Statement of Operations (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 10,878<span></span>
</td>
<td class="nump">$ 10,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">3,634<span></span>
</td>
<td class="nump">2,985<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">7,244<span></span>
</td>
<td class="nump">7,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">3,643<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 7,235<span></span>
</td>
<td class="nump">$ 8,002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820111563152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">9,262,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(81,037)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited/expired (in shares)</a></td>
<td class="num">(22,224)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">9,159,665<span></span>
</td>
<td class="nump">9,262,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable (in shares)</a></td>
<td class="nump">5,053,597<span></span>
</td>
<td class="nump">3,445,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 9.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">1.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited/expired (in dollars per share)</a></td>
<td class="nump">5.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">9.96<span></span>
</td>
<td class="nump">$ 9.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and exercisable (in dollars per share)</a></td>
<td class="nump">$ 12.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, beginning balance</a></td>
<td class="nump">$ 4,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, ending balance</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">$ 4,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and exercisable</a></td>
<td class="nump">$ 234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- Average Remaining Contractual Life (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share-based payment award, options, aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820114569280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - RSUs Activity (Detail) - Outstanding RSUs<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, beginning balance (in units) | shares</a></td>
<td class="nump">6,551,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in units) | shares</a></td>
<td class="nump">202,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in units) | shares</a></td>
<td class="num">(313,975)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited/canceled (in units) | shares</a></td>
<td class="num">(252,106)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, ending balance (in units) | shares</a></td>
<td class="nump">6,188,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 18.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">1.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">15.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited/canceled (in dollars per share) | $ / shares</a></td>
<td class="nump">4.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 18.45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139820110016672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IT', window );">Italy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KR', window );">South Korea</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>ibrx-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:ibrx="http://www.immunitybio.com/20230331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ibrx-20230331.xsd" xlink:type="simple"/>
    <context id="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1979cd48647c45d68e7289ac43e0c9c2_I20230505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2023-05-05</instant>
        </period>
    </context>
    <context id="i8b814f4f02ad4405944defaa7243cdee_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2021beb688ba4eae880d4d4d8f408525_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8c875c85efb244079066f90b6b550c50_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6bffc59bc82a4092b0b095eb4b104f99_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia0c37984b4ee4c4e8d32a3fcda72fd96_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5b6fd5dc04474fc6ad30fdb536534995_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1108b0a3a2da4efeb2c5a0cbce300858_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i384e76ee6b5e47da8ccb8a62c32b63a0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i60ef9d75f1cd4d8da9176583a06fab46_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d3142cb095746858e5333f482cb2517_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib92ff44aff9c4c1cb5a8aefa1497878a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie69a285b23fe4b36860e2b1807e68608_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2a8153bf4934499497bc454385181d0f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifc8a064e60104a7c8b5bbf20eee46ddd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia3839414c7384bb580b2b6ee59797d9b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i685f344965a54fa99a8f56307085368a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8d76d948cf7740b181d0c99cf8712fc2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9308889d86f04fb9a83d5131a6f7b08a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i07a8763cb5b94c5b9da351bedacfbe75_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1eba2b75f17a4ca598c012c58e915b51_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5f178e191e6a46e2976df6b30834b5d9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5d185f091af84493a3bd1346fcb31032_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7f9f0c08e99449fe863bdc24f35895c6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie1c226aeaa40452fa58e614e48f7b0e9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2b3e85a60781496d8fae99c082b6df71_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id72ba77db0da468294e9f5b45ac3b0a5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if2aa017e45e2426088230d3c95d08e1b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i421c4794536c433089794d37f3ef6014_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie6a407074713405e90702d702e4309b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i256d0f34b668479ba66bd30a77315d12_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f5b67947f77418ea08709523b53563d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3bb3408a05c6401c857209bb9b667953_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b766e2f320f442fa3f3102f9c9b0916_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida858a14f0f94f0698e26382d0222a7d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic1f4ccbe1a254187a0abcd2fa0ef3671_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0e5651caa3fe44d1a48b78dbac979b78_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id819e1b1f878495a86da38176b293b2b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i54462f901730493b9ccffd2922a2f380_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i945c8a203dcd4d97bafa5902b5b19503_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic17e90ac99424c33b733b73a4517455d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i23f7671e764e4c5ca223c10daf774bf2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i005d4769e3bc4a9eb596324bf4986a4e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i700388aac6ea44b2a5558e75c3835e46_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i61c1394ce2204f349c8ec7aa84ca4c0e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i29522190e504495593abd361f7b24b19_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i81bd9de2db4d40b9879aff68abbefe52_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i168358a7c0ed479b8476f4d8e155cdde_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5f8290d605c9473bbd497404748ff594_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib93ec4ea47c24cd1aacb10ddb65cfc49_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idecf558aeafa48f9b21a5ecd3fb24b40_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:February2023ShelfRegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i99fc5379a3c146e884bcdad311bb00a7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:RelatedPartyConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icca3815678964e2d94105dd050d212c3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:RelatedPartyConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iba6ebd8d72ea4824b03a047a8f09a82d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifb98e0036a3b43d497ef0476504101c1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia50e8aab6bce4a40af1190886835cf90_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4bc712551fbe42fa830fbfe75a349bb9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4561df868e434e67b57f7aa91baf077a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4868dd8bba544400bbb7baf280da9766_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8a1967d8b16b4b2780d09eb32b721ead_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:RelatedPartyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6785865c42404146b0f6e8d0fc2d2b8c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:RelatedPartyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4d61f38abc9b467da5b3204da34fab5e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalIssued33123Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i684e88f0565f4750ae31d08132ff423b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6e62b835f051443d9e55df382ca1fcce_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic374e7c516ef4b06beadcff3736ae51f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iee11080abfef48cf9f5c6b933901142a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icdb4ac7d53c44d429b5802a108d42fb7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id5437c21f4814f59a329a7b0373ddd7c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id5ccb25eaaf340a293dbf719e9c93972_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifcada495b71b4888ab1fd26a734a81a7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if361174e18104c2d80d8a23d1e42afa0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9fdf6d04e3e64c0a85f416eb0b67673a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i69a7813607634b75bf6094281fe5a9ef_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OffMarketFavorableLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4ac85c2e74bb4d9e983ef489c9b27611_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OffMarketFavorableLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idb96fe0125b04e81861415c2d465f7f2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OffMarketFavorableLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4d984c547ea04fd4aca46b980c849ad7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OffMarketFavorableLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2302952973d64c9dae6fea63aa9b623d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ibrx:OrganizedWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0b2b8940d45e44b5b593540d8f42fb87_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i38d33d35c4f340d094daa523ef91b3a4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i93ed60d3f2964554accd7342f72a2587_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1d0dcfca4e8b4f1d959f8fc7308c7a47_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib572239e8f7a47589f3771ddf0d4f463_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9b9a73d45ec54296b71bec23a3b54530_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iad866414f696494880846815781be54d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7db0daa0756249f385a861fd96f3d99c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i178b6f6abcac4b7da1c687641370dde6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iea925c85eab4423786f1fbcb3163e30e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iecca882de63d47999c4cdc060161db0b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia7abc0bfb0d34a659f0c1f9d70a91b5e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i94255247204f487f8a5e6a7b45fd5f53_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia818d8707e4c4c8d99bffda3de67924f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i37c25c0026ea4ccdbaa0613624232e13_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i03762b77d7b4408594a116ef19d68f4d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iaf88dacf0a484cb8938868ce11e3fd93_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6edc71b525cb40e5a5d6fb007bb51c16_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia015c55c47d246e6b83da57fa54d9457_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i268f2b405ec94f05a3e088310fef2a41_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5d9bd30014c24311a412cab8f1e6736b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3e8a0351256343eeb4cc0af08ac1a51d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i53ab60edafa6478689087569daf40626_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2bd58f7537dc4e4f8fe02f6ad46a9783_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7f54811c3bb74c6fbfba10a31850e736_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9102c7f1073b4a35b9194887f3407199_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i14d57b1d76d54551b3b3e206ffde3432_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4dee1612809b472b83659b4a2b02d81b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i104551fa9a6e4d0db14a884d59a96b54_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ice4416a2800b4d009acab3013a489ab7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i83982f7c2fc54aa7a359a7a7d975aff2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iec99a9e278b242918d95bceb26bbdeec_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icf5a9b13f35d422fa1732caa34e706df_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i18b9e33de5fb420f85ada2e2f7aecc07_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i16979a35fa1d40b997739a4cb809e6f7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i331682550ab14aec904426036c3b2a64_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ief94290369fc4061b4a36705889940e8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i89f3b040139a4ffeb38a1cd82447d958_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibe21c408c60145f1b9446e214b886786_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6b47701466154187b9f13a27115955bf_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:RelatedPartyConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia28a5b94bbd2402daf1696b7e83ff97d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:RelatedPartyConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7436b01d201048599ef97748571d8dbe_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:RelatedPartyConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1038882c13304367a352a1ea0d5e9430_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:RelatedPartyConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if9b73b9076d14e77bd7f75276c4a8d58_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i946cc463480045ae80cefa68e6b23ca8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib6901e0e7cfd4bf4bd21eb35ec6aa8f0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3f6382b087284b0ab540c7a4cd9db9da_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2d1b12230e8f4233a449b44aa8b89dae_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i075d1102c0894f7aaf61aea36c69248e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3a21a545f0c4436c9afb3e11ec80f767_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia5143b8cbe5a4e8990bf3e2deb701bef_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iaa82585cc76945718fa4c122a0abdf22_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i34465ea1764e409786a6bf7a192ee52a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6711f0d932ba4e6a92c92baecc798ffe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia9024e16e44b4b6a926b58cb4aec8d8f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iadecc9749ad74d06bbf65eca3773b162_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie7d4c869961845049a837ecf93a7d2d2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iba5d6bb2adc04bfeb0876c228f393f9b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia81b7b3cbfab49d8abed2fece23c4eb2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia6d9de146cd64ddd838411f8d960bb39_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5ef6c543a47549d6ba626e9b621bef9d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i609d1640d799407fa25e8d7bb019d122_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia99b37fb3a1e4839964854bb8c5cd0a6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6cfcae1f8c96411fa01b9df7155a5e1b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icc22baf6a9234b998bdacc85aa2baa32_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieed74cabe48d445d966192789eaffa46_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e08fabb07e64dc89b54f50eb2cbab9d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i89b6ead15154410fbde3c2433bcdd159_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7e78df5d936b4e6ea1a77cbeb8c49595_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia279b1b8a68047368e6c50d9ea885c6e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i274686603f6a451f837acc17b08d3411_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic25536a0d63845739ff43e08195cd5c1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icef3562f20dc43dfa08930bb1bd2bc36_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i544de52cd9194dabb073582a30849b58_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i76b53cde4e3e4322a061ae53a8f05594_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifc84a0efc87f46c8aae6c011790df898_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iccfd1df580444d909b6b2d6f8f806e7b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i63ac4d5eb374467ab54634d998aec6f5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idcf19f6af9824b52a6d8e4395d10134a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2c53736371164c6eb06bafd550e0f5fa_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i946b4f2294f644bcafcd5f32b36a4b6a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2f8683e6989143198ff853a8fc97d338_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i25b2382ccad7475f812c01198c635ee0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibrx:MeasurementInputExpectedMarketYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i650984f3db47470a9f5389b2e032a01a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibrx:MeasurementInputDiscountPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6f16749c92e842ce81ffb8d9ae2a9c3d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i19f26457ccfe499cb0e3bbed35112923_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia1191e7cec0f4f78a48f0b7efe88df43_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib93fecbf92174118bdd72fa5e20ea20e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5be77fd9053a42c1821b000e6a63fc53_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9270094ae41a49ccb211054939e04e29_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icf8421bdf082438eacb0d8a2bbb510e1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6e247e3019ba40cfb87b176aa4e219b6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i91d87f21eddb4e8ba52be9c983035646_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i05ce9f5c06e84394bfde03b091dcbdf4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie9e851daf28c4255b2112c4cd9cefdc6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i092d7c652fa9476b8e128260ffb7cf55_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4b1c02b83f5d4e588b5e7f5dfe24a69e_I20230215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-15</instant>
        </period>
    </context>
    <context id="i18ad3c2a3e4841d3b55094278b55ee00_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iba41b7496e6d4908952cd0ecb8a9fcec_I20230215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-15</instant>
        </period>
    </context>
    <context id="i8cc76b0fbcf84e109ae61be53b3d16fa_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib565990d93cd4919b9ad581d54993133_I20230215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-15</instant>
        </period>
    </context>
    <context id="i5b96511d9e744c5099e21750e0d21d2d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic3b821833563458f9405084b1ae950db_I20230215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-15</instant>
        </period>
    </context>
    <context id="if5751565e9bc4821bce01dd4188d7302_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i17c9c04b377c4dc0a52cd262037cb9ba_I20230215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-15</instant>
        </period>
    </context>
    <context id="ib8bb04bc74374058a2c1efed036ac8cb_I20230215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-15</instant>
        </period>
    </context>
    <context id="i9c148f91d4ce423f9b310ff8481860bb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2cd4532b1fc24c0ca2ef81c7e69794c6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3c353c172ccf4147ac57fe34244f439e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:AmyrisIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a9fa31f8b884ef599ea8e3aa1c58f8f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic8d44b5214644e5e9b815f99ac56eaec_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="ie5ee1d864d0f40ee97b16088a1116d91_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ice37cb09a6664d4da416332415bda35c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4156a8ceac6342d99ce39177a254d1cf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iee278c57618e46d09031d4531cc2f979_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i490e76eedd0c4d68a5d119d4f2a8bf67_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="ia01f754739eb4399a5ec08bb300b5c9c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if7c90fc2a58d48e3bec3d91301b599c7_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AccessToAdvancedHealthInstituteAAHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i717a4e9083794ab9bb82219c0132b1ee_I20220501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AccessToAdvancedHealthInstituteAAHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-01</instant>
        </period>
    </context>
    <context id="i7c33c2ccc680481ab6ef920d4dfe6fb2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AccessToAdvancedHealthInstituteAAHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2177094498de4c7ca93c869ccafa1cd8_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AccessToAdvancedHealthInstituteAAHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if37fa4000f6b4e8d96490b940efbe768_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AccessToAdvancedHealthInstituteAAHIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6d13c8c853924031bd029bd4c72b099a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AccessToAdvancedHealthInstituteAAHIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id36600ac1af648c79b04e3c00fadca09_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AccessToAdvancedHealthInstituteAAHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2f73c10bbad4443f9c60a048d6b10f17_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AccessToAdvancedHealthInstituteAAHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i37548de39d884f38a90265fc99953e00_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AccessToAdvancedHealthInstituteAAHIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2fbf30bc44d6480e870137c2cd85cdb9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:SponsoredResearchAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AccessToAdvancedHealthInstituteAAHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibbb1145df96744e6a4b78a506fdab0e3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:SponsoredResearchAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AccessToAdvancedHealthInstituteAAHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9bdaaaa534ee490db0798af2622eb12c_I20220214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-14</instant>
        </period>
    </context>
    <context id="i425c575827bc4978bf0c2daa8ed81a96_D20220214-20220214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-14</startDate>
            <endDate>2022-02-14</endDate>
        </period>
    </context>
    <context id="if6b39365bed8403baef862349455aa3a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:StateOfNewYorkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3d26d616708f4d68a522f54d69fb3236_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:StateOfNewYorkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibc667aeaffb241769d40ebb768302772_I20150430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-04-30</instant>
        </period>
    </context>
    <context id="i34694fa4373945b3a6a665c6a37f4262_D20150401-20150430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-04-01</startDate>
            <endDate>2015-04-30</endDate>
        </period>
    </context>
    <context id="i0d13dc5189894b7d8628892cfb2e7a88_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibdeaa2c7746d49a8bd99d6d3afb859aa_D20220901-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4947316a78a241dc928345e7c528266e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ida7588e0910c4bb28cb902bc775406de_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsObligationRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i40bec98f02134e3b977953843f819e46_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsObligationSalesMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i74a7874a4fde4847942459ca136eee6e_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsObligationSalesMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i5a799dcabd874b6e84ddb0e294bf7f8a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsObligationSalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:DrSoonShiongAndRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1c8c3835e9294f019b36ddbb7bb615b8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsObligationSalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:AltorStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i83f402b4c65a4485bfb0dff6c6982341_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3316090351fd4fe4b0dd3da042faabc4_I20220709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-09</instant>
        </period>
    </context>
    <context id="i1bc9adb48922456fa879ef93b8dba645_D20220709-20220709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-09</startDate>
            <endDate>2022-07-09</endDate>
        </period>
    </context>
    <context id="id9143fae2a394bf29dec9fb56f82a9a5_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="ic746e246685947fd8cfba45a1fed563e_D20221208-20221208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-08</startDate>
            <endDate>2022-12-08</endDate>
        </period>
    </context>
    <context id="i3f1bf0ab5b9b480192b280a3bffc0f0f_D20221202-20221202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibrx:SorrentoTherapeuticsIncLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-02</startDate>
            <endDate>2022-12-02</endDate>
        </period>
    </context>
    <context id="i947edf9e6bfb43b892a96c6c6549369d_D20221202-20221202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NANTibodyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibrx:SorrentoTherapeuticsIncLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-02</startDate>
            <endDate>2022-12-02</endDate>
        </period>
    </context>
    <context id="i17ec39591f744eadbe2f276d7fed3a12_D20230207-20230207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibrx:SorrentoTherapeuticsIncLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-07</startDate>
            <endDate>2023-02-07</endDate>
        </period>
    </context>
    <context id="i72f7554fa7494415af05bce0fcffd01e_D20230207-20230207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibrx:SorrentoTherapeuticsIncLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-07</startDate>
            <endDate>2023-02-07</endDate>
        </period>
    </context>
    <context id="i3e7a5a7bf61f49a4a1941edab3339d2c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i97684a88657d4f79b99ef808ef0e0de7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3a3e26a21876460b8624019e43e286e0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalIssued33123Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i44cc657d262146519329e8d5460c262d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalIssued33123Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if421742d22da4377a2a2d5d3ad4dee90_I20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="iad7a8cf8ad9546059a44a0c2f4102d99_D20220101-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i9adb1d0654114ee5afbed60cfa9e4766_D20220101-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="ifeeaf31a1b7546b08e11b31f6de4b788_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3be51647022b41c5aac446b43954112a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i700361120e53402ba852dcb639cda333_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia44124c82520433e872adbae39679ee3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3c27fb3d47934120827861b39628c2b1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iefda7cd80c064a8e958479a947e51afb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if26e41fef20847b6b81445d4a3101377_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id782271befaf426399ce9443216bb892_D20220831-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-31</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="id84e4096f5c442528938b4337cf7c8ed_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7f716744d3be43e38afdc26a656b33b7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i604c474521cf4dd693f946bc8cff054d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i168a4524f50644799beb0bf0791c2954_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic72646472e3b48a295ebef3a0ebdf66f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8e671951edb7455ea24c2ac0392ea151_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if3d09e78bc0148b7a0f1abb485cdc81a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital6Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if86dd819ffd041e19f08088aa305bbd6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i07cfde51688d493b82c4be4a684839e5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id87c72a123a646d7a99485bf28cfb653_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie84a9931057b4e4aae2bb4ed9870ba8f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1743878cb0574c6cbbbcdd536eda339a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i36630a5fb97140119768102b4c075987_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i023872a5c0664193ae14daa63ba5eefc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i02d66470d5a1468c83c9015ed4ab3ab0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i46483bc0e4034520a181080e17a40498_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i20b7ac56635b4a66a2d03236bce015d7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6c63ca50dfe64ec5a0637410c6d5397b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifa2f8dcc34a64a3f95777076fb02b849_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3f7988bcb71d43779a0096791bc726c6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i965c76f591504ffd870c02a47f91e4d1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib9880130e66047f2be4005667dcc04df_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3116163dc179457f83c1a522829e482e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic800e90d3fa44e74bfd616fa559ef8f8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i76bd041f34bc45308f8baecb04934003_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i273275e6ceed474fa66492ae83f982da_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icde6ce22814d4976bf3ce94a8a10aa0a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i34b60dc14eca495189c0a9fd77ab929d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifa4a4292eb67427d8486a6d30953b1b1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapital3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i96fd516d0b2c4ab88b68926fb81bb129_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RelatedPartyNotesPrincipalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i860cd6cdf17243bd9cb45083c2bd5bb7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RelatedPartyNotesPrincipalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i20deba0784bb4ee28b65cd1d2bd855dc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RelatedPartyNotesInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i55ffd3316fb8496aa86fcba67dffd60b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RelatedPartyNotesInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i46a185f9ec6445ec8b642258ea67180d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RelatedPartyNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie130450350ca4c9799e1e199a92ec29d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i09080f29fd3f433ba1865fa559c0cc3f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i343f173c97cd46298d5be473e16688aa_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:BrinkBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id4a76d55cff24142bdf23c290b7ebaac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:BrinkBiologicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia7e60a6f6dd54abb86adb37dc98be31f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:VariousMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i54c810b34f414a6199d96f563da4e9c9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:VariousMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0fb0f449758c4a12bd185f822740269b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic0d461d8a57e4f1caf838c6337b4c516_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icd31b5f44a3b46e994f04fa346a23f09_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0b77d70cfd06469091a1b47d242533d9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2f07f511c38b42188903e64e3779976d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibfcb45a1b3c349189e4711ea15b357de_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id7f7698c742a4d5185ef556099b8f431_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icdea96cd4382425faf718c8efb444b64_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1d86297744454a6099ce0c427e3111e8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ibrx:ReimbursementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4d993de6a09448f3af585a7df1769323_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ibrx:ReimbursementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8890b549aaaa415492f2214c3dc3ac13_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ibrx:ReimbursementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i38af9a7ebb684fc3a1ab4a463228f422_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8466a432fa1943f286f3af0a6ccac9e8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i34815e4cfa9145e9981cf8ef165dd4fb_I20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="i030a8e572dcc4ea2a237d2800d4aa466_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="i630c47622bdc4c919e7634771cd094b6_I20220501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-01</instant>
        </period>
    </context>
    <context id="i00d9386e0ac34e93abf5574655a19034_D20220501-20220501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-01</endDate>
        </period>
    </context>
    <context id="i4ab9c997cb0b4744a84d064e48fc1cdf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8601e8ad3ce74646a29a91172dd7b478_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8a83e300ee754efcafa7bc50023c4c0c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ConsiderationForFutureServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i94b88764cea64ab3a669de4c146f1277_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie8ed30fcfd154733b358cf49c7a83340_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7a419c5ac53b440da1bf811cf7835f7a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8c6db1e3cd124c76b9c449422588a8be_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ida6b89dae59349288b67324cfade250c_I20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="i52d6bbd3e53f4ae6bd3377d2d890068b_D20180801-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="i75ef1f10c34b47e9a73945153142eec4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0b7101f16b5744f081cfce6bb570c9b0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i65810f20d431446aa5ab803112a83673_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i88ef2e95606a433c97f1f5ade812375d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ida89ca2072e7405a83ed27b0d0e50e26_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic9e75b2cda544e9dabfb62fd1fae848d_I20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveDougStLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="i7e2a43e076864fbf9c872615bc186b9a_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveDougStLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i5f9e4846487241a5b60ad842bb55bb52_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveDougStLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icc6ecb543ce2436c9134c23137273055_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveDougStLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i76b07b7ed33b45539a4fff62c382480d_I20170228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-28</instant>
        </period>
    </context>
    <context id="i37723a8685db4f4b9403f2caefc75ecf_D20170201-20170228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-02-28</endDate>
        </period>
    </context>
    <context id="i1669c0c201b646b2b7157ca12651f6fe_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:SeptemberTwentyNineteenLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i74cbb623279346b9ade405a13aa44d0e_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:JulyTwentyNineteenLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i79fafd177360495ea435675f878915de_D20190101-20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="iac70357778c94cf1ac486623facee429_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:DueToRelatedPartiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2a46905c230c4f93bdb4d9448b060e15_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:DueToRelatedPartiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaef86b8724ee46feaafd52d401a7f967_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie341383be88d425fa34bddb167224148_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9d95ef7c886d4db6963bcdfd488f1553_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialPremisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i9f92b246bdb84f80a78af70f89f212ce_D20210101-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialPremisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="idb46af1e101d4c7d85dc1fd805f5e351_I20210401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:ExpansionPremisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-01</instant>
        </period>
    </context>
    <context id="i0ecc9935801543b1b67dcd2ff6f9f08f_D20210401-20210401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:ExpansionPremisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-01</endDate>
        </period>
    </context>
    <context id="i6fe81cf5951c403d960758745c545149_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialAndExpansionPremisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifde6772fd7334f07bf86ccb8635eb843_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialAndExpansionPremisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7910abd612b44ff2a9ab87af3766fd8e_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:FourTwoZeroNashLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="ic4b84ae551264070b15b7f777a374c2e_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:FourTwoZeroNashLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="if8add4a27fd94c3dbba9aebb333c9ce7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:FourTwoZeroNashLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia4332025e778479f9e44ae4505eb4896_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:FourTwoZeroNashLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i83fb4e02761f48b8ad2de6942bf33580_I20220501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:A23AlaskaLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-01</instant>
        </period>
    </context>
    <context id="ic48cb211ecb24790be4164033660ec75_D20220501-20220501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:A23AlaskaLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-01</endDate>
        </period>
    </context>
    <context id="iea37f6978bb2478bbedbdc929ab45ee3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:A23AlaskaLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icb9a543882c24ab288a8fcf5e2373847_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ibrx:ReimbursementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4b233a9ab4f44de78485c2c79b62f293_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icf169f3dab5647ae87fdc00595ada62f_D20221212-20221212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-12</startDate>
            <endDate>2022-12-12</endDate>
        </period>
    </context>
    <context id="ie7ac9b711c4447f78c760f85a936a47b_I20221212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-12</instant>
        </period>
    </context>
    <context id="i02a9bf96e8f246dab50bd1fc37514fa1_D20221212-20221212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-12</startDate>
            <endDate>2022-12-12</endDate>
        </period>
    </context>
    <context id="i15ed851a2bba4c719f489412c5b04c93_I20221212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-12</instant>
        </period>
    </context>
    <context id="id16bb7626e4a4ddf8aef9e47dd2b70f0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i79b4caaa6e7c43ee92ac011ad4231f8f_D20230215-20230215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-15</startDate>
            <endDate>2023-02-15</endDate>
        </period>
    </context>
    <context id="ib182c777505d49e8985cc1dfe3ec4883_I20230215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-15</instant>
        </period>
    </context>
    <context id="icf589f03986d4c4f8bd91e59ce16854e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenShareRepurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9923376a6fc640ad84dd1c26f06cb886_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenShareRepurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7197e4073a6c44a993ccee88c9827d5b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenShareRepurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iee0c8df083bd402b92291e4cdef8b3e2_I20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:February2023ShelfRegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="i1b3c1aa995d649f0b87f547501a451bf_D20230215-20230215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:February2023ShelfRegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-15</startDate>
            <endDate>2023-02-15</endDate>
        </period>
    </context>
    <context id="ifd22fd1d02ef4b8b97689228703adc95_D20210430-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i537431f5f3b94adb850787c5a596d104_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i62cf93746a5f40e7af8acd878f0d0942_I20221212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2022-12-12</instant>
        </period>
    </context>
    <context id="iedf609af3963460b9da2409f804cfa4e_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="i99b7bacac6fb4b6fa1a147bb0af0b1e3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic2e19134c3994d4892eb6d354d8783bc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia07604abb58a44c68163e1cc335f1f6f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib2e8096e87554843be3da2502f2fb4f8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia9943c4a51f6441e85bc6598893e1fa6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie5cf1954f1b04fd3a05943c0f49aea0e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idabb2ea247194a5db776f4872b4ddd96_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7d89f301dba24a82a81a3734a866f4df_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5ff7cffbd9b44155b9d53cd05a219a87_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6da548dc0629406a8bc5d9e75d8d06d5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie8db8d0eea7146a6bf8d54b8044ef8d7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i266ebf8c5da54dd097877b98c122296e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i836c83fbf1c1488cb85f5c607bece830_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0d38e9904e994f3c8879c104feedb7da_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i48b4780d2b7c496aaab05e427e63b362_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if52b579ea3554fc9bfe4ad51961a0c27_D20210304-20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-04</startDate>
            <endDate>2021-03-04</endDate>
        </period>
    </context>
    <context id="i908b2f13981e477ca4efac4b387ad72c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3554fcc3e6c04d3d8d76fbad65e1995d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia9664eda2c1e467c8dd040b2e7f90f76_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ibrx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7b965bbf47a941848ab9a9b930e7f952_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7e5c5c4ae84f441299889d36b9da25d8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2c5705f6e6f94780a8e01cc108de9b88_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="security">
        <measure>ibrx:Security</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="y">
        <measure>utr:Y</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="employee">
        <measure>ibrx:employee</measure>
    </unit>
    <unit id="term">
        <measure>ibrx:Term</measure>
    </unit>
    <unit id="lease">
        <measure>ibrx:lease</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80L2ZyYWc6ZTYyZDE5OTlkN2RiNDQ5NzlkMGEzZDA1ZTIyMGFjZDcvdGFibGU6ODZlYzBmYjIzNWNjNGQ5M2EyMzljYzU4MGQzYWVkMDYvdGFibGVyYW5nZTo4NmVjMGZiMjM1Y2M0ZDkzYTIzOWNjNTgwZDNhZWQwNl8zLTEtMS0xLTI5ODM1Mg_a1adddac-1472-46ea-a210-a22dbc042fdf">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80L2ZyYWc6ZTYyZDE5OTlkN2RiNDQ5NzlkMGEzZDA1ZTIyMGFjZDcvdGFibGU6ODZlYzBmYjIzNWNjNGQ5M2EyMzljYzU4MGQzYWVkMDYvdGFibGVyYW5nZTo4NmVjMGZiMjM1Y2M0ZDkzYTIzOWNjNTgwZDNhZWQwNl80LTEtMS0xLTI5ODM1Mg_05f44fee-ca63-4ac1-b513-29589e8ad7f3">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80L2ZyYWc6ZTYyZDE5OTlkN2RiNDQ5NzlkMGEzZDA1ZTIyMGFjZDcvdGFibGU6ODZlYzBmYjIzNWNjNGQ5M2EyMzljYzU4MGQzYWVkMDYvdGFibGVyYW5nZTo4NmVjMGZiMjM1Y2M0ZDkzYTIzOWNjNTgwZDNhZWQwNl81LTEtMS0xLTI5ODM1Mg_9bea8791-c4a5-452b-b4a8-f8acb85a0412">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80L2ZyYWc6ZTYyZDE5OTlkN2RiNDQ5NzlkMGEzZDA1ZTIyMGFjZDcvdGFibGU6ODZlYzBmYjIzNWNjNGQ5M2EyMzljYzU4MGQzYWVkMDYvdGFibGVyYW5nZTo4NmVjMGZiMjM1Y2M0ZDkzYTIzOWNjNTgwZDNhZWQwNl82LTEtMS0xLTI5ODM1Mg_f63859a7-36d1-4a27-83dc-0f27906d67e1">0001326110</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80L2ZyYWc6ZTYyZDE5OTlkN2RiNDQ5NzlkMGEzZDA1ZTIyMGFjZDcvdGFibGU6ODZlYzBmYjIzNWNjNGQ5M2EyMzljYzU4MGQzYWVkMDYvdGFibGVyYW5nZTo4NmVjMGZiMjM1Y2M0ZDkzYTIzOWNjNTgwZDNhZWQwNl83LTEtMS0xLTI5ODM1Mg_a04feee7-2ad9-45c9-91e0-f09c93790c62">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOmUxNmRiNTMwMWViYTRhNmY4NmMxNTNhYjJhNjhiMWIwL3RhYmxlcmFuZ2U6ZTE2ZGI1MzAxZWJhNGE2Zjg2YzE1M2FiMmE2OGIxYjBfNS0wLTEtMS0zMTA3NzY_2350ba70-1f49-4ea5-8303-63ba7471fe59">http://fasb.org/us-gaap/2022#FairValueAdjustmentOfWarrants</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjQ1NjRiYjg3OWY4MDRmZTc5NzBhNDg1YWUzNmI0YWZiL3RhYmxlcmFuZ2U6NDU2NGJiODc5ZjgwNGZlNzk3MGE0ODVhZTM2YjRhZmJfNS0wLTEtMS0zMzA4Nzg_31727132-f847-41a1-942b-fae5179a937e">http://fasb.org/us-gaap/2022#FairValueAdjustmentOfWarrants</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i3e7a5a7bf61f49a4a1941edab3339d2c_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfNTkx_1b5ac21f-8317-4cdf-9aa4-b1a83fbec98e">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i3e7a5a7bf61f49a4a1941edab3339d2c_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfNjk5_f0f50d52-6d48-4a58-8a65-ea201cb85f30">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNS0xLTEtMS0yOTgzNTI_716b2b64-20b1-40c3-9b02-a3d14868228b">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNS0xLTEtMS0yOTgzNTI_79bf86fc-1a0b-4632-b3b5-c9756666aba0">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTEtMS0xLTEtMjk4MzUy_1e304c6d-b6fc-4a07-96b6-252e1c6d5e68">http://fasb.org/us-gaap/2022#AccountsPayableAndOtherAccruedLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTEtMS0xLTEtMjk4MzUy_7f502521-7e3c-4089-bd21-ee4709a6ff0e">http://fasb.org/us-gaap/2022#AccountsPayableAndOtherAccruedLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTQtMS0xLTEtMjk4MzUy_1cbef275-f42e-4514-b41d-8b9c75783db1">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTQtMS0xLTEtMjk4MzUy_cccafda1-bc6a-4e69-9eb2-a02fc2fcc607">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icb9a543882c24ab288a8fcf5e2373847_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84MTYvZnJhZzpmZGU0ZGM3YzEyNmI0YjQyYWU0ZGJiZTM4NTBjNDYzNC90ZXh0cmVnaW9uOmZkZTRkYzdjMTI2YjRiNDJhZTRkYmJlMzg1MGM0NjM0XzM4NDgyOTA2OTk4NjI_3c1f5bf5-32fa-4157-9ea5-7511b9d6ca10"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i4b233a9ab4f44de78485c2c79b62f293_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84MTYvZnJhZzpmZGU0ZGM3YzEyNmI0YjQyYWU0ZGJiZTM4NTBjNDYzNC90ZXh0cmVnaW9uOmZkZTRkYzdjMTI2YjRiNDJhZTRkYmJlMzg1MGM0NjM0XzM4NDgyOTA3MDAzNzk_9b2c632e-8e41-4710-811d-b93170dbbc8c"
      unitRef="usd">0</us-gaap:DueToRelatedPartiesCurrent>
    <dei:DocumentType
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGV4dHJlZ2lvbjo3MmMzZWVjOGQwNzM0YmMyYjk1ZDEzYjViMTdhZTYwY18yMjAw_4ed04efb-c262-4169-9f93-2b05c3dceebd">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6MTljNDE3OWIwMzRiNGU1M2FiMDU0ZTExMWQ3Y2I3ZTkvdGFibGVyYW5nZToxOWM0MTc5YjAzNGI0ZTUzYWIwNTRlMTExZDdjYjdlOV8wLTAtMS0xLTI5ODM1Mg_aae0f39a-2d48-4b9a-9d04-d49753c21283">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGV4dHJlZ2lvbjo3MmMzZWVjOGQwNzM0YmMyYjk1ZDEzYjViMTdhZTYwY18yMTkz_89ef8ad9-5cc1-4351-b72e-cbe6bea18411">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6NWM4YTVjMGVlZWUzNDU1YmIzZjZhMTBhYzZhMzFjMzcvdGFibGVyYW5nZTo1YzhhNWMwZWVlZTM0NTViYjNmNmExMGFjNmEzMWMzN18wLTAtMS0xLTI5ODM1Mg_226ce189-82a1-4e49-b0d5-aab7767c3129">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGV4dHJlZ2lvbjo3MmMzZWVjOGQwNzM0YmMyYjk1ZDEzYjViMTdhZTYwY18yMjAx_c301b02f-ae9c-490f-8ff1-31e4e99b4094">001-37507</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGV4dHJlZ2lvbjo3MmMzZWVjOGQwNzM0YmMyYjk1ZDEzYjViMTdhZTYwY18yMTk0_49d10065-1150-4614-b914-803a6701805c">IMMUNITYBIO,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6NTkxODU5MzMzNmQ5NDc0ZDliZGUzZTI2YWIwZjdmYWUvdGFibGVyYW5nZTo1OTE4NTkzMzM2ZDk0NzRkOWJkZTNlMjZhYjBmN2ZhZV8wLTAtMS0xLTI5ODM1Mg_1f97d6b9-a49d-449a-b5e2-f2829c3c01d7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6NTkxODU5MzMzNmQ5NDc0ZDliZGUzZTI2YWIwZjdmYWUvdGFibGVyYW5nZTo1OTE4NTkzMzM2ZDk0NzRkOWJkZTNlMjZhYjBmN2ZhZV8wLTEtMS0xLTI5ODM1Mg_e135c82e-c40d-466d-b544-e2567e991914">43-1979754</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6NTkxODU5MzMzNmQ5NDc0ZDliZGUzZTI2YWIwZjdmYWUvdGFibGVyYW5nZTo1OTE4NTkzMzM2ZDk0NzRkOWJkZTNlMjZhYjBmN2ZhZV8zLTAtMS0xLTI5ODM1Mi90ZXh0cmVnaW9uOjJhNDlkZTgxODlmYTQ5ZmNiMTliOTg1MzllNTk3OGYzXzU_814c3ac3-cd62-4963-9721-f5df637f213f">3530 John Hopkins Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6NTkxODU5MzMzNmQ5NDc0ZDliZGUzZTI2YWIwZjdmYWUvdGFibGVyYW5nZTo1OTE4NTkzMzM2ZDk0NzRkOWJkZTNlMjZhYjBmN2ZhZV8zLTAtMS0xLTI5ODM1Mi90ZXh0cmVnaW9uOjJhNDlkZTgxODlmYTQ5ZmNiMTliOTg1MzllNTk3OGYzXzg_e93be681-a706-46cd-8700-6bc587f7389c">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6NTkxODU5MzMzNmQ5NDc0ZDliZGUzZTI2YWIwZjdmYWUvdGFibGVyYW5nZTo1OTE4NTkzMzM2ZDk0NzRkOWJkZTNlMjZhYjBmN2ZhZV8zLTAtMS0xLTI5ODM1Mi90ZXh0cmVnaW9uOjJhNDlkZTgxODlmYTQ5ZmNiMTliOTg1MzllNTk3OGYzXzEy_75987979-c735-45ac-a1c4-9f83c01b3f61">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6NTkxODU5MzMzNmQ5NDc0ZDliZGUzZTI2YWIwZjdmYWUvdGFibGVyYW5nZTo1OTE4NTkzMzM2ZDk0NzRkOWJkZTNlMjZhYjBmN2ZhZV8zLTEtMS0xLTI5ODM1Mg_22daba32-735d-4574-9d52-e05c5abd9981">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGV4dHJlZ2lvbjo3MmMzZWVjOGQwNzM0YmMyYjk1ZDEzYjViMTdhZTYwY18yMTk1_59799a48-9c6e-4cd8-81af-218aa959a335">844</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGV4dHJlZ2lvbjo3MmMzZWVjOGQwNzM0YmMyYjk1ZDEzYjViMTdhZTYwY18yMTk2_7c5a068c-233e-430b-b23a-08d6a7038bc0">696-5235</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6ZmQ2NjZmYTZkYjM3NDU5Y2E5NDA4ZTk4N2FhNjFiZjgvdGFibGVyYW5nZTpmZDY2NmZhNmRiMzc0NTljYTk0MDhlOTg3YWE2MWJmOF8xLTAtMS0xLTI5ODM1Mg_238d5835-de32-41e2-843e-630481d47914">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6ZmQ2NjZmYTZkYjM3NDU5Y2E5NDA4ZTk4N2FhNjFiZjgvdGFibGVyYW5nZTpmZDY2NmZhNmRiMzc0NTljYTk0MDhlOTg3YWE2MWJmOF8xLTItMS0xLTI5ODM1Mg_c7a5781c-ba9e-4109-9211-3943a81c5351">IBRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6ZmQ2NjZmYTZkYjM3NDU5Y2E5NDA4ZTk4N2FhNjFiZjgvdGFibGVyYW5nZTpmZDY2NmZhNmRiMzc0NTljYTk0MDhlOTg3YWE2MWJmOF8xLTQtMS0xLTI5ODM1Mg_f0e858b3-5c2a-49d2-9bf8-dd32981bf06d">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGV4dHJlZ2lvbjo3MmMzZWVjOGQwNzM0YmMyYjk1ZDEzYjViMTdhZTYwY18yMTk3_e8697b1e-eb94-4934-beca-8af9a222d563">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGV4dHJlZ2lvbjo3MmMzZWVjOGQwNzM0YmMyYjk1ZDEzYjViMTdhZTYwY18yMjAz_55004afc-0520-468e-b748-3657dad61a9c">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6MjhkMTk5ZDAxMjI2NDVkNWFlMjkwMWMxOWJjNGU1NDIvdGFibGVyYW5nZToyOGQxOTlkMDEyMjY0NWQ1YWUyOTAxYzE5YmM0ZTU0Ml8xLTAtMS0xLTI5ODY3MA_27de67b1-908f-4d78-b9fb-aa0fd620db65">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6MjhkMTk5ZDAxMjI2NDVkNWFlMjkwMWMxOWJjNGU1NDIvdGFibGVyYW5nZToyOGQxOTlkMDEyMjY0NWQ1YWUyOTAxYzE5YmM0ZTU0Ml8xLTQtMS0xLTI5ODM1Mg_6f7d6293-4a11-4ccf-befc-c3d8f2b01480">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGFibGU6MjhkMTk5ZDAxMjI2NDVkNWFlMjkwMWMxOWJjNGU1NDIvdGFibGVyYW5nZToyOGQxOTlkMDEyMjY0NWQ1YWUyOTAxYzE5YmM0ZTU0Ml8yLTQtMS0xLTI5ODM1Mg_9d0092cb-dd51-44ee-bdfe-6d4e00d6ab0c">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGV4dHJlZ2lvbjo3MmMzZWVjOGQwNzM0YmMyYjk1ZDEzYjViMTdhZTYwY18yMTk5_af65add7-e80d-4ff0-950f-23cda480e11d">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i1979cd48647c45d68e7289ac43e0c9c2_I20230505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xL2ZyYWc6NzJjM2VlYzhkMDczNGJjMmI5NWQxM2I1YjE3YWU2MGMvdGV4dHJlZ2lvbjo3MmMzZWVjOGQwNzM0YmMyYjk1ZDEzYjViMTdhZTYwY18yMDYy_857f33e4-8eea-4f64-8790-3a1c61ee73f1"
      unitRef="shares">435984529</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfNC0xLTEtMS0yOTgzNTI_0ff5a821-00a4-4ebd-bf48-ac03cf684cb4"
      unitRef="usd">88481000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfNC0zLTEtMS0yOTgzNTI_f672d450-1618-470c-a998-f84f61645ad4"
      unitRef="usd">104641000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfNS0xLTEtMS0yOTgzNTI_41c01e09-386d-46f3-9eda-102ae15ebc45"
      unitRef="usd">2787000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfNS0zLTEtMS0yOTgzNTI_31d60dbd-7a51-42a6-b0b7-a941f06c2d7a"
      unitRef="usd">2543000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfNi0xLTEtMS0yOTgzNTI_ff33041b-222b-486e-92b0-2a44e56f1f8d"
      unitRef="usd">1464000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfNi0zLTEtMS0yOTgzNTI_e49d098c-2611-4c07-8f80-f85b2b9837ad"
      unitRef="usd">1890000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfNy0xLTEtMS0yOTgzNTI_48e5910e-8261-481d-8368-3bfd1d82090b"
      unitRef="usd">20754000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfNy0zLTEtMS0yOTgzNTI_3ccc73ba-9423-4c4c-8824-2fe943de1202"
      unitRef="usd">31503000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfOC0xLTEtMS0yOTgzNTI_ae5d55f4-aca9-4de5-b911-30d13230f742"
      unitRef="usd">113486000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfOC0zLTEtMS0yOTgzNTI_30b786d7-a834-4f80-aeff-bef64dac0ef3"
      unitRef="usd">140577000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfOS0xLTEtMS0yOTgzNTI_d9cb1545-0282-4aaf-8ec5-859ec63b275a"
      unitRef="usd">820000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfOS0zLTEtMS0yOTgzNTI_1a9e48c0-169b-429b-8952-ca6625fb909a"
      unitRef="usd">840000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTAtMS0xLTEtMjk4MzUy_ca707a5d-de53-4416-8860-39e783fb0ed7"
      unitRef="usd">154165000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTAtMy0xLTEtMjk4MzUy_7df1999a-00b1-427b-95e8-8a57292474c6"
      unitRef="usd">143659000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTItMS0xLTEtMjk4MzUy_3bebf70e-13aa-42ff-b0f7-72ddd3ffb7a0"
      unitRef="usd">19502000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTItMy0xLTEtMjk4MzUy_6defdf74-8625-4a3a-8b0f-448a16be617a"
      unitRef="usd">20003000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <ibrx:ConvertibleNoteReceivableNonCurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTMtMS0xLTEtMjk4MzUy_5301bdd3-c79e-4930-bc9d-1a95185a2b5b"
      unitRef="usd">6691000</ibrx:ConvertibleNoteReceivableNonCurrent>
    <ibrx:ConvertibleNoteReceivableNonCurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTMtMy0xLTEtMjk4MzUy_ffe9cc61-23f1-4f6f-9201-6e77412e989f"
      unitRef="usd">6629000</ibrx:ConvertibleNoteReceivableNonCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTQtMS0xLTEtMjk4MzUy_fc331462-e41c-4f0c-91fa-80a64c6b8441"
      unitRef="usd">44191000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTQtMy0xLTEtMjk4MzUy_0f4a280e-f124-4d92-926b-9c814c89ae0b"
      unitRef="usd">45788000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTUtMS0xLTEtMjk4MzUy_871798b7-e5dd-41e0-a910-3a1a74a5c501"
      unitRef="usd">4545000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTUtMy0xLTEtMjk4MzUy_10e0d196-4899-4ce8-b4bf-0c1abbd3cde7"
      unitRef="usd">4860000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTYtMS0xLTEtMjk4MzUy_211b2c13-f685-4ce8-94b9-41e08107d5cc"
      unitRef="usd">343400000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTYtMy0xLTEtMjk4MzUy_d2d5a3fb-41c2-4b4c-8870-68f6db111501"
      unitRef="usd">362356000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTktMS0xLTEtMjk4MzUy_39a8ff44-6c3b-4273-9775-7d8267c1b5b3"
      unitRef="usd">33573000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMTktMy0xLTEtMjk4MzUy_c8d600e2-b207-4667-9125-145518141b61"
      unitRef="usd">21016000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjAtMS0xLTEtMjk4MzUy_ff311b4f-c5e0-4674-81fb-80261b67d1aa"
      unitRef="usd">54118000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjAtMy0xLTEtMjk4MzUy_0418a7c6-18a2-44ec-b3e1-4dccf549c369"
      unitRef="usd">41825000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent
      contextRef="i8c875c85efb244079066f90b6b550c50_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjEtMS0xLTEtMjk4MzUy_bed3b18b-cc10-47e0-9ae3-feea1a923fee"
      unitRef="usd">441628000</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent
      contextRef="i6bffc59bc82a4092b0b095eb4b104f99_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjEtMy0xLTEtMjk4MzUy_502c674d-0129-4d6b-ad7f-79c0c4894f82"
      unitRef="usd">431901000</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent
      contextRef="ia0c37984b4ee4c4e8d32a3fcda72fd96_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjItMS0xLTEtMzIxNjM3_18b28fd9-52c2-45be-890a-c5d0a8917529"
      unitRef="usd">29850000</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent
      contextRef="i5b6fd5dc04474fc6ad30fdb536534995_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjItMy0xLTEtMzIxNjM3_45f0edea-b13d-40fd-bd79-cbb0f73f305f"
      unitRef="usd">0</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjItMS0xLTEtMjk4MzUy_3645c739-f1a4-45db-8d66-335079274b96"
      unitRef="usd">2932000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjItMy0xLTEtMjk4MzUy_562da69b-d720-4d24-b114-ebee0ed9ab2c"
      unitRef="usd">3469000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjMtMS0xLTEtMjk4MzUy_f639a6e5-0d4e-455c-a8cb-903fc891dce5"
      unitRef="usd">2844000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjMtMy0xLTEtMjk4MzUy_a793bdcf-4eb0-492a-8d37-75e4d926ef8b"
      unitRef="usd">2650000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjQtMS0xLTEtMjk4MzUy_f296dbac-fa1e-418b-9975-810e4a790c4a"
      unitRef="usd">564945000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjQtMy0xLTEtMjk4MzUy_7abe1a71-de9b-4535-b67b-4e14eb810a90"
      unitRef="usd">500861000</us-gaap:LiabilitiesCurrent>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent
      contextRef="ia0c37984b4ee4c4e8d32a3fcda72fd96_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjYtMS0xLTEtMjk4MzUy_e89948c5-5c0e-4a93-b6c6-a69b28033eca"
      unitRef="usd">245640000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent
      contextRef="i5b6fd5dc04474fc6ad30fdb536534995_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjYtMy0xLTEtMjk4MzUy_eab6e70d-3578-4ee9-aa62-5eec2f4c71c9"
      unitRef="usd">241271000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjctMS0xLTEtMjk4MzUy_d392c161-d14a-45d9-bddc-89f9fb3babf9"
      unitRef="usd">46289000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjctMy0xLTEtMjk4MzUy_ccd45466-c473-43e4-b32a-99fb4a3ff5e4"
      unitRef="usd">47951000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjgtMS0xLTEtMzA3NTM5_a3c69c05-f454-4030-bdc8-d9add55c879d"
      unitRef="usd">17780000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjgtMy0xLTEtMzA3NTM5_903d1d2c-12db-4388-a4b0-f4569795ca4a"
      unitRef="usd">21636000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjktMS0xLTEtMjk4MzUy_9128d65e-4220-4525-b96a-405ee5eedc73"
      unitRef="usd">462000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMjktMy0xLTEtMjk4MzUy_9e694868-c15c-4fac-afa2-e9de4bbdd89b"
      unitRef="usd">457000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzAtMS0xLTEtMjk4MzUy_f37b2399-c055-4152-8c4b-5610f3ace70c"
      unitRef="usd">875116000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzAtMy0xLTEtMjk4MzUy_be86849a-d457-4188-9fd1-8c1c75ee1802"
      unitRef="usd">812176000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzEtMS0xLTEtMjk4MzUy_0636d345-91bb-458d-b1e7-92b2a1a674ee"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzEtMy0xLTEtMjk4MzUy_f336d7fb-c9b3-4977-bd1e-f91675274122"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMC0xLTEtMjk4MzUyL3RleHRyZWdpb246M2NmYmNmZjI1Y2QxNGM4MjlkOTg4NTEyYmUyZjZmN2VfNTQ5NzU1ODE0MTQ5_010b42aa-f45d-49cb-bd26-65c6b4856918"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMC0xLTEtMjk4MzUyL3RleHRyZWdpb246M2NmYmNmZjI1Y2QxNGM4MjlkOTg4NTEyYmUyZjZmN2VfNTQ5NzU1ODE0MTQ5_06bf270c-3df0-4ea1-b6db-b880b25728f1"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMC0xLTEtMjk4MzUyL3RleHRyZWdpb246M2NmYmNmZjI1Y2QxNGM4MjlkOTg4NTEyYmUyZjZmN2VfMzI_2683f9a1-f11d-49cf-937b-8cb85b485115"
      unitRef="shares">900000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMC0xLTEtMjk4MzUyL3RleHRyZWdpb246M2NmYmNmZjI1Y2QxNGM4MjlkOTg4NTEyYmUyZjZmN2VfMzI_9e399d50-c140-49a5-8581-b4f12ac49ca5"
      unitRef="shares">900000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMC0xLTEtMjk4MzUyL3RleHRyZWdpb246M2NmYmNmZjI1Y2QxNGM4MjlkOTg4NTEyYmUyZjZmN2VfOTU_6a096be7-a367-41f4-814d-698b789e4b40"
      unitRef="shares">435923104</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMC0xLTEtMjk4MzUyL3RleHRyZWdpb246M2NmYmNmZjI1Y2QxNGM4MjlkOTg4NTEyYmUyZjZmN2VfOTU_afc86ec6-795c-4c9a-bae0-a5d39a72078c"
      unitRef="shares">435923104</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMC0xLTEtMjk4MzUyL3RleHRyZWdpb246M2NmYmNmZjI1Y2QxNGM4MjlkOTg4NTEyYmUyZjZmN2VfNTQ5NzU1ODE0MTQx_19530e87-6bae-4ece-ac43-c5c5d1d6c9f8"
      unitRef="shares">421569115</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMC0xLTEtMjk4MzUyL3RleHRyZWdpb246M2NmYmNmZjI1Y2QxNGM4MjlkOTg4NTEyYmUyZjZmN2VfNTQ5NzU1ODE0MTQx_f3b12408-f3c9-4bf0-8e59-98b0e4824716"
      unitRef="shares">421569115</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMC0xLTEtMjk4MzUyL3RleHRyZWdpb246M2NmYmNmZjI1Y2QxNGM4MjlkOTg4NTEyYmUyZjZmN2VfNTQ5NzU1ODE0MTQ1_3773295d-d22b-431d-9a8a-f7cd2cea39ee"
      unitRef="shares">163800</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMC0xLTEtMjk4MzUyL3RleHRyZWdpb246M2NmYmNmZjI1Y2QxNGM4MjlkOTg4NTEyYmUyZjZmN2VfNTQ5NzU1ODE0MTQ1_9d79d790-9694-4544-91e8-f037caa811f0"
      unitRef="shares">163800</us-gaap:TreasuryStockCommonShares>
    <us-gaap:CommonStockValue
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMS0xLTEtMjk4MzUy_baa8364c-3bf1-44ef-8ef1-d1c77c6fc261"
      unitRef="usd">43000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzMtMy0xLTEtMjk4MzUy_3e7edfe2-56b8-4bd0-8320-d195963e28a0"
      unitRef="usd">42000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzQtMS0xLTEtMjk4MzUy_a87e2c4d-61e5-438f-bc9a-55772593546f"
      unitRef="usd">1965838000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzQtMy0xLTEtMjk4MzUy_5893f6c3-8e16-4132-be01-227f68a86d04"
      unitRef="usd">1930936000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzUtMS0xLTEtMjk4MzUy_3d310f6a-ecf7-49c9-b1db-739dffedd720"
      unitRef="usd">-2494831000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzUtMy0xLTEtMjk4MzUy_08d820e7-9e9f-45c9-80cc-7d406317321b"
      unitRef="usd">-2378488000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzYtMS0xLTEtMjk4MzUy_d7c07581-67d2-49a9-a40c-9c35e3e93819"
      unitRef="usd">-33000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzYtMy0xLTEtMjk4MzUy_1df05fcc-1733-4f81-b76a-0c3295f0f095"
      unitRef="usd">183000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzctMS0xLTEtMjk4MzUy_7635b009-2586-475e-a606-78830c7047ee"
      unitRef="usd">-528983000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzctMy0xLTEtMjk4MzUy_0dd9ec38-f1bf-47ba-ab5b-6c1c1679a54d"
      unitRef="usd">-447327000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzgtMS0xLTEtMjk4MzUy_334eaacc-02c0-4b39-9a76-dbb0d590b47c"
      unitRef="usd">-2733000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzgtMy0xLTEtMjk4MzUy_c04abdf2-37ff-4ebb-9d6a-e8fe45c3c98c"
      unitRef="usd">-2493000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzktMS0xLTEtMjk4MzUy_405542fe-bfba-4bc8-aed3-8fce769eeed8"
      unitRef="usd">-531716000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfMzktMy0xLTEtMjk4MzUy_7bd484fd-968c-4037-a8ca-582a192adfb3"
      unitRef="usd">-449820000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfNDAtMS0xLTEtMjk4MzUy_bf7eb975-1d3d-469e-91b6-315bdac87627"
      unitRef="usd">343400000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xNi9mcmFnOjc0ODU0MTYzNTA3YjQwMmZiODQ2NWRlNzI1ZTFmOWZlL3RhYmxlOjY4OWRjZDgxYWY3OTQ5MTU5YTljMjcwNWUzYmU3NDZjL3RhYmxlcmFuZ2U6Njg5ZGNkODFhZjc5NDkxNTlhOWMyNzA1ZTNiZTc0NmNfNDAtMy0xLTEtMjk4MzUy_a6ca2e6d-764a-47fc-b8ca-519f77112dd9"
      unitRef="usd">362356000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMi0xLTEtMS0yOTgzNTI_1be49046-ad7c-407d-9705-86bde1d5f18a"
      unitRef="usd">360000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMi0zLTEtMS0yOTgzNTI_33b273b7-7b78-4256-9cee-5038fb3cc850"
      unitRef="usd">14000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfNC0xLTEtMS0yOTgzNTI_baef9bbb-0e18-4a59-87a1-2f5d4539dfb9"
      unitRef="usd">79264000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfNC0zLTEtMS0yOTgzNTI_a57084f3-a1e0-4ced-ae8c-a7f5cb2dbfea"
      unitRef="usd">55378000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfNS0xLTEtMS0yOTgzNTI_05b1df1c-57e6-4606-9ee9-035f653c2086"
      unitRef="usd">32676000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfNS0zLTEtMS0yOTgzNTI_81c7a97b-075b-4ab3-9064-f84150ce20de"
      unitRef="usd">40608000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfNy0xLTEtMS0yOTgzNTI_9cfc2866-84ec-4167-88cd-6bd637729dda"
      unitRef="usd">111940000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfNy0zLTEtMS0yOTgzNTI_222531f6-9fee-4b1b-a7be-0176cd6c952f"
      unitRef="usd">95986000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfOC0xLTEtMS0yOTgzNTI_b08795b3-d16b-4fce-84de-4acaa2ea0c24"
      unitRef="usd">-111580000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfOC0zLTEtMS0yOTgzNTI_b5e47856-197e-40b4-ab49-d48596c9ba51"
      unitRef="usd">-95972000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnInvestments
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTAtMS0xLTEtMjk4MzUy_5582598a-9008-4218-b6bf-0ee260a19ff0"
      unitRef="usd">673000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTAtMy0xLTEtMjk4MzUy_cdc49f3f-f919-4f7c-a9ab-c05a5b69a287"
      unitRef="usd">1666000</us-gaap:GainLossOnInvestments>
    <us-gaap:InterestExpense
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTEtMS0xLTEtMjk4MzUy_377382c3-22dc-411a-9f9a-a6cbf4077073"
      unitRef="usd">29816000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTEtMy0xLTEtMjk4MzUy_9882307c-5b20-4e7e-a127-5252496f96c2"
      unitRef="usd">8491000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTItMS0xLTEtMjk4MzUy_be082988-52df-4858-858f-32b9db208cda"
      unitRef="usd">-2337000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTItMy0xLTEtMjk4MzUy_4a6f1859-73b4-4346-86b6-bdd882345b62"
      unitRef="usd">-197000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTMtMS0xLTEtMjk4MzUy_92c7ed2e-fa84-489d-a90c-437917760e27"
      unitRef="usd">-27554000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTMtMy0xLTEtMjk4MzUy_f2cb7d11-eb26-47a2-9b1c-6e1362bc69bd"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTQtMS0xLTEtMjk4MzUy_3ab3a03b-3ee9-4986-8d50-06ea6d583437"
      unitRef="usd">-1077000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTQtMy0xLTEtMjk4MzUy_8a3c3dbb-0961-4730-8598-548d4b51afac"
      unitRef="usd">-4000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTUtMS0xLTEtMjk4MzUy_fc5e51c5-403f-42a1-bfba-8fcce98b5d2b"
      unitRef="usd">-5003000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTUtMy0xLTEtMjk4MzUy_558a4127-957d-4287-b287-fc0c79495652"
      unitRef="usd">-7026000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTYtMS0xLTEtMjk4MzUy_6279d8b6-08e4-46e5-82d6-f5a0d646d736"
      unitRef="usd">-116583000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTYtMy0xLTEtMjk4MzUy_29ac70bc-21b5-495b-ac05-9bb8b8b80f82"
      unitRef="usd">-102998000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTctMS0xLTEtMjk4MzUy_207610f3-c3bc-45fd-9bea-3595c1f1660a"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTctMy0xLTEtMjk4MzUy_06a9bc61-359e-40f2-9186-664eaa60d38d"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTgtMS0xLTEtMjk4MzUy_823c9ffe-90b9-4b47-b30f-a97adbb5aee3"
      unitRef="usd">-116583000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTgtMy0xLTEtMjk4MzUy_d3815d15-1073-4a9b-a753-de139290dedf"
      unitRef="usd">-102998000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTktMS0xLTEtMjk4MzUy_ba3a37ac-acaa-4147-83f1-b3b1bdbf203a"
      unitRef="usd">-240000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMTktMy0xLTEtMjk4MzUy_99ceb1fa-c0ec-46a6-9e13-238ec9a51dc3"
      unitRef="usd">-172000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMjAtMS0xLTEtMjk4MzUy_af484bff-e105-47fa-b990-c698759b67c9"
      unitRef="usd">-116343000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMjAtMy0xLTEtMjk4MzUy_f20d937c-38a3-443e-b10a-181d21808e69"
      unitRef="usd">-102826000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMjItMS0xLTEtMjk4MzUy_2c54a149-a1a3-4db8-b613-e55ead07393f"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMjItMS0xLTEtMjk4MzUy_933e4846-3bb7-44a3-91f9-e45d031b23c6"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMjItMy0xLTEtMjk4MzUy_414bc521-845b-4133-9efb-a4f99c07fa9f"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMjItMy0xLTEtMjk4MzUy_ee738079-e782-4f80-9956-d70a1aecbad4"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMjQtMS0xLTEtMjk4MzUy_e9f9e18d-53d5-4211-b81f-fceeded34157"
      unitRef="shares">428381485</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMjQtMS0xLTEtMjk4MzUy_ffa40ae9-1291-4d0d-86da-d1c4c40fdb5b"
      unitRef="shares">428381485</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMjQtMy0xLTEtMjk4MzUy_3685d624-dac7-43d7-9383-a871cd032446"
      unitRef="shares">397882441</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8xOS9mcmFnOjRiM2FmMDQzNjgzNTQ2YWI4ZDYxZDYyMWNmZDdiMTM1L3RhYmxlOmJjM2I4ZTgyYmI3NzRhMmJiNzk1ZjVkOGFiNWNjMmQ0L3RhYmxlcmFuZ2U6YmMzYjhlODJiYjc3NGEyYmI3OTVmNWQ4YWI1Y2MyZDRfMjQtMy0xLTEtMjk4MzUy_aa2a8355-c0c7-464f-acee-e2cd7fa00647"
      unitRef="shares">397882441</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfMi01LTEtMS0yOTgzNTI_8107529b-1251-447c-8c19-fd66bd1f9c8f"
      unitRef="usd">-116583000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfMi03LTEtMS0yOTgzNTI_2ee4f5b7-5239-488f-ba3c-1eef31bf4b71"
      unitRef="usd">-102998000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfNC01LTEtMS0yOTgzNTI_2a25af3a-4b04-413d-9919-ca679be626e9"
      unitRef="usd">4000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfNC03LTEtMS0yOTgzNTI_9df22adb-9e9e-4cf6-b6e3-81895741dec3"
      unitRef="usd">-310000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfNS01LTEtMS0yOTgzNTI_49f16ac3-6798-4d1e-beb4-6e2e97967438"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfNS03LTEtMS0yOTgzNTI_fcf288ae-2a76-49e5-aa08-ef45915a709d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfNi01LTEtMS0yOTgzNTI_c9867188-d2d9-4ecf-aa3c-1311ab6eb42e"
      unitRef="usd">-226000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfNi03LTEtMS0yOTgzNTI_389badaa-c72c-40a4-82f4-aa0f843af09f"
      unitRef="usd">-61000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfNy01LTEtMS0yOTgzNTI_f78c498d-8251-4a21-8af3-3e8f044f7cab"
      unitRef="usd">-216000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfNy03LTEtMS0yOTgzNTI_d5cc221a-125e-4b24-b64e-de405bd0f8bf"
      unitRef="usd">-371000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfOC01LTEtMS0yOTgzNTI_b24d2e62-6166-4cad-bbee-18a3c76c8d29"
      unitRef="usd">-116799000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfOC03LTEtMS0yOTgzNTI_d95bc94a-9929-4a25-9e4c-622211c0fb10"
      unitRef="usd">-103369000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfOS01LTEtMS0yOTgzNTI_2a4f3673-aefb-4344-9b18-492d49d6c1e1"
      unitRef="usd">-240000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfOS03LTEtMS0yOTgzNTI_c915c41b-81c8-4921-8688-a8e2b9bf8f2c"
      unitRef="usd">-172000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfMTAtNS0xLTEtMjk4MzUy_90f64319-160a-41ad-96e6-b6b8b934d0da"
      unitRef="usd">-116559000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yMi9mcmFnOmM1YjAyMzQ5ZDU1MzQ2NjVhNzE2MDlmZjdjODFjNjNjL3RhYmxlOmVhNmEwZmZlMzRiNTQ5NDY5M2JhYzI0NDdiYWI2MzM2L3RhYmxlcmFuZ2U6ZWE2YTBmZmUzNGI1NDk0NjkzYmFjMjQ0N2JhYjYzMzZfMTAtNy0xLTEtMjk4MzUy_1ba83652-5d9c-436b-aece-e3b4b37fe670"
      unitRef="usd">-103197000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1108b0a3a2da4efeb2c5a0cbce300858_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMy0yLTEtMS0yOTgzNTI_45f8d403-eb79-4fc6-b629-f551008205ff"
      unitRef="shares">421569115</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1108b0a3a2da4efeb2c5a0cbce300858_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMy00LTEtMS0yOTgzNTI_ab35cee3-6d9e-485b-b7cc-5f9ef781bcfc"
      unitRef="usd">42000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i384e76ee6b5e47da8ccb8a62c32b63a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMy02LTEtMS0yOTgzNTI_5050f7a8-8041-4fe9-84cf-02a604d77b72"
      unitRef="usd">1930936000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i60ef9d75f1cd4d8da9176583a06fab46_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMy04LTEtMS0yOTgzNTI_dee27707-fefd-49ff-9a19-b66337fad1fa"
      unitRef="usd">-2378488000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0d3142cb095746858e5333f482cb2517_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMy0xMC0xLTEtMjk4MzUy_27205cae-adc4-43ee-b492-36dd3c0ef709"
      unitRef="usd">183000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib92ff44aff9c4c1cb5a8aefa1497878a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMy0xMi0xLTEtMjk4MzUy_478d86a2-d41b-43f7-afd5-92c20a574b22"
      unitRef="usd">-447327000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie69a285b23fe4b36860e2b1807e68608_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMy0xNC0xLTEtMjk4MzUy_4a0bb01f-ee6d-425a-a54e-c6b71529d9c1"
      unitRef="usd">-2493000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMy0xNi0xLTEtMjk4MzUy_fa588910-c25a-42f8-8cef-ca608ec155c0"
      unitRef="usd">-449820000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i2a8153bf4934499497bc454385181d0f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNC0wLTEtMS0zMjE2OTAvdGV4dHJlZ2lvbjplZDczNjJlZDMyYTU0NzkzYTE2NjJiYzgyMzZjOGVhYV8xMDk5NTExNjI3OTQ1_55f33eb9-777c-446a-86f8-5da2a2b410f0"
      unitRef="usd">2046000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ifc8a064e60104a7c8b5bbf20eee46ddd_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNC0yLTEtMS0zMjE2OTg_0dc41def-4595-4d9a-8422-31377b52da8b"
      unitRef="shares">14072615</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ifc8a064e60104a7c8b5bbf20eee46ddd_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNC00LTEtMS0zMjE2OTg_59ad9222-cfc8-4673-b0ed-ded524d56133"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia3839414c7384bb580b2b6ee59797d9b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNC02LTEtMS0zMjE2OTg_bac2c017-3b80-4cc2-908f-f6cf10d7e556"
      unitRef="usd">24255000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i685f344965a54fa99a8f56307085368a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNC0xMi0xLTEtMzIxNjk4_db90b402-4296-4ed1-9ab2-73778bb8cdab"
      unitRef="usd">24256000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2a8153bf4934499497bc454385181d0f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNC0xNi0xLTEtMzIxNjk4_73bf91c4-8da2-4eb8-840b-c91d04b4d891"
      unitRef="usd">24256000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8d76d948cf7740b181d0c99cf8712fc2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNC02LTEtMS0yOTgzNTI_27ab0cfd-ba08-4abb-97d0-791b50203e27"
      unitRef="usd">10878000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9308889d86f04fb9a83d5131a6f7b08a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNC0xMi0xLTEtMjk4MzUy_d8eabe6d-55b1-45a5-bb23-e06ddda6a8db"
      unitRef="usd">10878000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNC0xNi0xLTEtMjk4MzUy_94abb90e-aabf-4560-bd2c-079cad5a9441"
      unitRef="usd">10878000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i07a8763cb5b94c5b9da351bedacfbe75_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNS0yLTEtMS0yOTgzNTI_75cdb710-293a-47fc-8c27-05a30da4b0b7"
      unitRef="shares">81037</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8d76d948cf7740b181d0c99cf8712fc2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNS02LTEtMS0yOTgzNTI_425d6a40-9049-4769-bf6d-f5e6f5755be2"
      unitRef="usd">126000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9308889d86f04fb9a83d5131a6f7b08a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNS0xMi0xLTEtMjk4MzUy_686ba1db-6553-4583-acda-4167e0a412fb"
      unitRef="usd">126000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNS0xNi0xLTEtMjk4MzUy_dcfa8e04-e5ea-414e-9b9f-ad74401e6900"
      unitRef="usd">126000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i07a8763cb5b94c5b9da351bedacfbe75_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNi0yLTEtMS0yOTgzNTI_2dcf6a4d-68a6-4307-9463-66feed34ad99"
      unitRef="shares">313975</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i07a8763cb5b94c5b9da351bedacfbe75_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNy0yLTEtMS0yOTgzNTI_0661158d-668a-4a7e-942f-99641295b384"
      unitRef="shares">113638</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i8d76d948cf7740b181d0c99cf8712fc2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNy02LTEtMS0yOTgzNTI_c7c99c8b-f679-4652-a48f-c562c5c5e353"
      unitRef="usd">357000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9308889d86f04fb9a83d5131a6f7b08a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNy0xMi0xLTEtMjk4MzUy_e7ebc061-3d07-4565-8d3a-f6a5ead8b5a3"
      unitRef="usd">357000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfNy0xNi0xLTEtMjk4MzUy_cc698c32-5aee-41fd-9b92-8a7fc0d59911"
      unitRef="usd">357000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1eba2b75f17a4ca598c012c58e915b51_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfOC0xMC0xLTEtMjk4MzUy_2c219cc4-c53e-4b1b-88bd-8007c98a70d1"
      unitRef="usd">-216000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9308889d86f04fb9a83d5131a6f7b08a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfOC0xMi0xLTEtMjk4MzUy_27512d6b-a55c-4706-86d3-239868655fad"
      unitRef="usd">-216000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfOC0xNi0xLTEtMjk4MzUy_14bb5fcd-0578-4c3a-923b-5343b2c455ed"
      unitRef="usd">-216000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i5f178e191e6a46e2976df6b30834b5d9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfOS04LTEtMS0yOTgzNTI_87944a81-a1b0-4327-b269-db0b8a9fbda0"
      unitRef="usd">-116343000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9308889d86f04fb9a83d5131a6f7b08a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfOS0xMi0xLTEtMjk4MzUy_7a3adcaf-21e5-453c-8a98-c23cc5d7fc33"
      unitRef="usd">-116343000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5d185f091af84493a3bd1346fcb31032_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfOS0xNC0xLTEtMjk4MzUy_c9955b87-d002-4680-87e9-8678ccc4711f"
      unitRef="usd">-240000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfOS0xNi0xLTEtMjk4MzUy_c3531e57-82f5-4da0-bcc3-77a5309a237c"
      unitRef="usd">-116583000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7f9f0c08e99449fe863bdc24f35895c6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMTAtMi0xLTEtMjk4MzUy_b90ec8e7-3d2e-42bf-934b-3a2f3f7f9e40"
      unitRef="shares">435923104</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7f9f0c08e99449fe863bdc24f35895c6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMTAtNC0xLTEtMjk4MzUy_551eb9e6-6727-4e97-92ba-700f04ac753d"
      unitRef="usd">43000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie1c226aeaa40452fa58e614e48f7b0e9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMTAtNi0xLTEtMjk4MzUy_e55a7436-90f4-413d-9a38-b155b5685fac"
      unitRef="usd">1965838000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2b3e85a60781496d8fae99c082b6df71_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMTAtOC0xLTEtMjk4MzUy_ecbbe901-7df4-413d-8a89-882882b019eb"
      unitRef="usd">-2494831000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id72ba77db0da468294e9f5b45ac3b0a5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMTAtMTAtMS0xLTI5ODM1Mg_c622804e-faa9-4710-ac5a-1fb05a51b5be"
      unitRef="usd">-33000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2aa017e45e2426088230d3c95d08e1b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMTAtMTItMS0xLTI5ODM1Mg_54ab713b-4570-45ec-8b6f-b0ed38d889cb"
      unitRef="usd">-528983000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i421c4794536c433089794d37f3ef6014_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMTAtMTQtMS0xLTI5ODM1Mg_aff5721a-f85e-43a7-9098-18d2a8dbd986"
      unitRef="usd">-2733000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOjU1YWM2ODQ0YjFkMDQzOTliYjg1YThkOGEwZDZkN2NhL3RhYmxlcmFuZ2U6NTVhYzY4NDRiMWQwNDM5OWJiODVhOGQ4YTBkNmQ3Y2FfMTAtMTYtMS0xLTI5ODM1Mg_dfc4c0ce-41eb-400e-ae32-f01a04eed5eb"
      unitRef="usd">-531716000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie6a407074713405e90702d702e4309b8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNC0yLTEtMS0yOTgzNTI_90529e81-9276-4410-8519-beb9a33d39ce"
      unitRef="shares">397830044</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie6a407074713405e90702d702e4309b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNC00LTEtMS0yOTgzNTI_8d248e0f-0a3d-4d12-8389-acba0ca5f0ea"
      unitRef="usd">40000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i256d0f34b668479ba66bd30a77315d12_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNC02LTEtMS0yOTgzNTI_5b73853f-e106-4c40-87a5-21cebf0a0320"
      unitRef="usd">1719704000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0f5b67947f77418ea08709523b53563d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNC04LTEtMS0yOTgzNTI_bcaeec28-175d-4937-a18b-f6824f3bf2bb"
      unitRef="usd">-1961921000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3bb3408a05c6401c857209bb9b667953_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNC0xMC0xLTEtMjk4MzUy_06faa357-8ca3-4c55-b4fc-2cb90a8ab7be"
      unitRef="usd">4000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2b766e2f320f442fa3f3102f9c9b0916_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNC0xMi0xLTEtMjk4MzUy_c2f77e05-c70f-41c3-917d-15bca8ef9156"
      unitRef="usd">-242173000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ida858a14f0f94f0698e26382d0222a7d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNC0xNC0xLTEtMjk4MzUy_9509f5b4-01b0-4ee8-bf44-ceba6fc5905d"
      unitRef="usd">-1740000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic1f4ccbe1a254187a0abcd2fa0ef3671_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNC0xNi0xLTEtMjk4MzUy_0ec5dcec-cd21-4c1c-8949-0fbfc6312350"
      unitRef="usd">-243913000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0e5651caa3fe44d1a48b78dbac979b78_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNS02LTEtMS0yOTgzNTI_3f46c5ae-d1b1-4610-bee1-b80d1316f52a"
      unitRef="usd">10024000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id819e1b1f878495a86da38176b293b2b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNS0xMi0xLTEtMjk4MzUy_3b46b5ae-e382-42ba-a5e3-fdb435dc7b73"
      unitRef="usd">10024000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNS0xNi0xLTEtMjk4MzUy_8f058d7f-816b-43f9-ac92-4115b44d4dc6"
      unitRef="usd">10024000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i54462f901730493b9ccffd2922a2f380_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNi0yLTEtMS0yOTgzNTI_09232d9e-41eb-4a32-8a2d-a3238770bee5"
      unitRef="shares">14767</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0e5651caa3fe44d1a48b78dbac979b78_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNi02LTEtMS0yOTgzNTI_cfbb077e-59af-4187-b94d-395b6af3ab7d"
      unitRef="usd">74000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id819e1b1f878495a86da38176b293b2b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNi0xMi0xLTEtMjk4MzUy_1bfdd252-0488-4f69-89bc-f5a008bf3a26"
      unitRef="usd">74000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNi0xNi0xLTEtMjk4MzUy_6a49fcc6-ca92-4104-abd4-86d4d6f5cf8e"
      unitRef="usd">74000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i54462f901730493b9ccffd2922a2f380_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfNy0yLTEtMS0yOTgzNTI_947807d7-40ab-4f3f-a6c8-c42a1eb49af8"
      unitRef="shares">177783</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i54462f901730493b9ccffd2922a2f380_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfOC0yLTEtMS0yOTgzNTI_c78ad01c-f1f2-4297-b371-d7abd31324e1"
      unitRef="shares">65832</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0e5651caa3fe44d1a48b78dbac979b78_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfOC02LTEtMS0yOTgzNTI_1d7f97cd-6fc3-4b08-815d-14588422f2c2"
      unitRef="usd">372000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id819e1b1f878495a86da38176b293b2b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfOC0xMi0xLTEtMjk4MzUy_7b526be1-048c-450e-99f9-72852cd77a6a"
      unitRef="usd">372000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfOC0xNi0xLTEtMjk4MzUy_34ce0932-4bd2-4d8b-83ba-bd17fc36328e"
      unitRef="usd">372000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i945c8a203dcd4d97bafa5902b5b19503_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfOS0xMC0xLTEtMjk4MzUy_e5393855-0148-4d5e-84d4-2c113afacc06"
      unitRef="usd">-371000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id819e1b1f878495a86da38176b293b2b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfOS0xMi0xLTEtMjk4MzUy_58767c22-d1fa-4b38-9f82-a50d54d64698"
      unitRef="usd">-371000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfOS0xNi0xLTEtMjk4MzUy_df0334dd-24fc-48ba-acd3-b66423c70392"
      unitRef="usd">-371000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="ic17e90ac99424c33b733b73a4517455d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTAtOC0xLTEtMjk4MzUy_c82d8558-9233-4438-89a6-67a5c3d021fa"
      unitRef="usd">-102826000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id819e1b1f878495a86da38176b293b2b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTAtMTItMS0xLTI5ODM1Mg_1e9737a7-35c9-44ae-8da1-7f4cc020e00a"
      unitRef="usd">-102826000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i23f7671e764e4c5ca223c10daf774bf2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTAtMTQtMS0xLTI5ODM1Mg_3b20b449-8412-47ab-912f-f94907344916"
      unitRef="usd">-172000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTAtMTYtMS0xLTI5ODM1Mg_60aa97d1-6db3-4797-b481-5eb75cb862e1"
      unitRef="usd">-102998000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i005d4769e3bc4a9eb596324bf4986a4e_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTEtMi0xLTEtMjk4MzUy_5bda07bd-a3dd-40ce-9fb8-ab3e2d469698"
      unitRef="shares">397956762</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i005d4769e3bc4a9eb596324bf4986a4e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTEtNC0xLTEtMjk4MzUy_3c09d0fd-12bb-47d9-af80-5718803638ee"
      unitRef="usd">40000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i700388aac6ea44b2a5558e75c3835e46_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTEtNi0xLTEtMjk4MzUy_d185d746-0752-471e-9590-a58b735b78c6"
      unitRef="usd">1729430000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i61c1394ce2204f349c8ec7aa84ca4c0e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTEtOC0xLTEtMjk4MzUy_1dace43c-0d7c-4ffc-8b7c-df8f05e79112"
      unitRef="usd">-2064747000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i29522190e504495593abd361f7b24b19_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTEtMTAtMS0xLTI5ODM1Mg_f0f420f9-dcd7-4143-b063-039121088f19"
      unitRef="usd">-367000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i81bd9de2db4d40b9879aff68abbefe52_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTEtMTItMS0xLTI5ODM1Mg_0792628c-2a2a-4675-9364-d6c9174348fb"
      unitRef="usd">-335644000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i168358a7c0ed479b8476f4d8e155cdde_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTEtMTQtMS0xLTI5ODM1Mg_c95d126a-1969-46f6-833d-c28940b33134"
      unitRef="usd">-1912000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f8290d605c9473bbd497404748ff594_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yNS9mcmFnOjRiMmY1NzU1MjEzMTRlNmNiNmYwZWQzMWZiOGIzM2Q1L3RhYmxlOmQ2ZDRkMzhiNDkwOTRiNDY4NTU5ZTY5OWRhNzBkZjVmL3RhYmxlcmFuZ2U6ZDZkNGQzOGI0OTA5NGI0Njg1NTllNjk5ZGE3MGRmNWZfMTEtMTYtMS0xLTI5ODM1Mg_4ae0b64d-1a2a-4b65-be4f-5ffd1ba3cb05"
      unitRef="usd">-337556000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMy0xLTEtMS0yOTgzNTI_238baa51-5601-44f0-bbe0-dde894cfcac3"
      unitRef="usd">-116583000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMy0zLTEtMS0yOTgzNTI_225a4a32-0cc6-4d86-bf42-6102ac07ea17"
      unitRef="usd">-102998000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNS0xLTEtMS0yOTgzNTI_a2540820-2e56-484c-a3df-ceebfb25ef13"
      unitRef="usd">10878000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNS0zLTEtMS0yOTgzNTI_2699e4e0-5ba1-42f6-a69e-f9aa816da91e"
      unitRef="usd">10024000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNi0xLTEtMS0zMjE3MTM_eb7ff5ae-f38e-4026-9ebb-8e846ecb6cf5"
      unitRef="usd">-27554000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNi0zLTEtMS0zMjE3MTM_ae459932-036c-4ce9-8148-9aed62a479ea"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <ibrx:TransactionCostsWarrantLiability
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNy0xLTEtMS0zMjE3MTM_fda8a159-e0ab-4bf7-8563-ab4bd1b444ce"
      unitRef="usd">984000</ibrx:TransactionCostsWarrantLiability>
    <ibrx:TransactionCostsWarrantLiability
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNy0zLTEtMS0zMjE3MTM_4f11c3d6-4fda-4287-afab-3b67a78e7e5c"
      unitRef="usd">0</ibrx:TransactionCostsWarrantLiability>
    <ibrx:NonCashInterestIncomeExpenseFromOperatingActivities
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNi0xLTEtMS0yOTgzNTI_6672005e-f88c-4dc2-bf34-3f3c683ee0f8"
      unitRef="usd">-2505000</ibrx:NonCashInterestIncomeExpenseFromOperatingActivities>
    <ibrx:NonCashInterestIncomeExpenseFromOperatingActivities
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNi0zLTEtMS0yOTgzNTI_4fc5c9c0-e95c-4429-b4d7-edbb3aa31e74"
      unitRef="usd">-3028000</ibrx:NonCashInterestIncomeExpenseFromOperatingActivities>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNy0xLTEtMS0yOTgzNTI_af2e4009-7e91-4711-85ed-3d2af0f43208"
      unitRef="usd">11536000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNy0zLTEtMS0yOTgzNTI_70f6b51d-e9ee-4da3-afa3-06492974d563"
      unitRef="usd">370000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfOC0xLTEtMS0yOTgzNTI_0f27b875-3d70-439c-b22d-4d99ec55f4db"
      unitRef="usd">4681000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfOC0zLTEtMS0yOTgzNTI_18526fbf-4aee-4faf-b0b3-deebe69942df"
      unitRef="usd">4090000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMTAtMS0xLTEtMjk4MzUy_b53b962f-98b0-472c-8b63-b448b6ce6e70"
      unitRef="usd">1597000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMTAtMy0xLTEtMjk4MzUy_646387d5-b9b3-4af6-b6a9-e0475ab8957f"
      unitRef="usd">1318000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMTQtMS0xLTEtMjk4MzUy_1d3fc3cd-5813-4944-8b2a-ea856ba4148e"
      unitRef="usd">135000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMTQtMy0xLTEtMjk4MzUy_db905bae-f8d3-4097-a71e-e0c73be1dcbc"
      unitRef="usd">1419000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMTctMS0xLTEtMjk4MzUy_bdae6a4a-9923-43aa-b3ae-248b04dfc04f"
      unitRef="usd">111000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMTctMy0xLTEtMjk4MzUy_05da9837-a5d9-4deb-87c0-c522612b8060"
      unitRef="usd">1045000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMTktMS0xLTEtMjk4MzUy_c22d6b94-d24f-42fe-804b-4dc8c897b43a"
      unitRef="usd">-9689000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMTktMy0xLTEtMjk4MzUy_1536abed-d0e6-4c51-995c-7fcd5b63fea2"
      unitRef="usd">218000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjAtMS0xLTEtMjk4MzUy_475715b3-ea4b-42f3-9596-da25943b75ef"
      unitRef="usd">-295000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjAtMy0xLTEtMjk4MzUy_76d237f9-3904-4948-9017-a36935403fe2"
      unitRef="usd">-101000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjEtMS0xLTEtMjk4MzUy_f3174a14-5e61-439b-9ae1-97944d234b30"
      unitRef="usd">668000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjEtMy0xLTEtMjk4MzUy_75f3b07a-7729-4430-a9d9-d4c72c651b25"
      unitRef="usd">795000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjItMS0xLTEtMjk4MzUy_58e6d215-4c04-43ee-ba81-96aba6409d41"
      unitRef="usd">18590000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjItMy0xLTEtMjk4MzUy_3f65a536-4a3b-43cb-b384-a511a687550d"
      unitRef="usd">10891000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <ibrx:IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjMtMS0xLTEtMjk4MzUy_0001096d-afcf-472f-9ff3-60cfcbb50003"
      unitRef="usd">-61000</ibrx:IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent>
    <ibrx:IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjMtMy0xLTEtMjk4MzUy_205efe30-09c8-46de-8148-e0ec5677c3ae"
      unitRef="usd">-1618000</ibrx:IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjQtMS0xLTEtMjk4MzUy_5b302cbc-3427-40a8-b68a-f58815a81550"
      unitRef="usd">-1511000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjQtMy0xLTEtMjk4MzUy_eed7b066-1bf1-4df8-b30e-05d0aa14d02a"
      unitRef="usd">-339000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjUtMS0xLTEtMjk4MzUy_cf4b9fa1-968d-4a70-b2cb-7b3c9ece09eb"
      unitRef="usd">-84310000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjUtMy0xLTEtMjk4MzUy_84e1cfa7-0595-4961-8cd2-7f80f00c5c90"
      unitRef="usd">-74930000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjctMS0xLTEtMjk4MzUy_1bb3bf87-8bd9-4b22-bc20-bfc25d3eb02c"
      unitRef="usd">8428000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjctMy0xLTEtMjk4MzUy_d56dcea0-a926-4f9f-8893-4f2e4a7acfad"
      unitRef="usd">27347000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjgtMS0xLTEtMjk4MzUy_51e81f06-f3fa-4256-a461-024ec56c5e93"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMjgtMy0xLTEtMjk4MzUy_594b22a1-ebcd-41cc-b54e-66c31e269d7e"
      unitRef="usd">21229000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzAtMS0xLTEtMjk4MzUy_393b6061-9fc6-4ab7-93f4-09e58bc12bef"
      unitRef="usd">158000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzAtMy0xLTEtMjk4MzUy_4bc4504f-1131-458c-8dd1-5bf35612834e"
      unitRef="usd">34082000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzEtMS0xLTEtMjk4MzUy_5f055de0-51e7-46c0-a6c3-0597ad260b90"
      unitRef="usd">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzEtMy0xLTEtMjk4MzUy_bc9f91ed-8162-4601-8ee8-0329b3a58aa2"
      unitRef="usd">14345000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzItMS0xLTEtMjk4MzUy_ab781964-5671-46bf-8fa4-2c7083c82e81"
      unitRef="usd">102000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzItMy0xLTEtMjk4MzUy_c6fd5576-07c4-465d-b55e-73245d617dca"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireInterestInJointVenture
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzMtMS0xLTEtMjk4MzUy_ffdfcb19-b2be-47bc-b886-9dee42bd228c"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:PaymentsToAcquireInterestInJointVenture
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzMtMy0xLTEtMjk4MzUy_8811cc9d-2bd1-4726-b3c1-b0820c9117d3"
      unitRef="usd">1000000</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzQtMS0xLTEtMjk4MzUy_fbb1e9b2-e9d3-4331-9444-3c704cc5990e"
      unitRef="usd">-8484000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzQtMy0xLTEtMjk4MzUy_00f1b05c-62e4-4763-8f6f-a9495202cc7f"
      unitRef="usd">-69313000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzYtMS0xLTEtMjk4MzUy_ec4a1374-8e0b-4630-bbb4-1812033235f3"
      unitRef="usd">47288000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzYtMy0xLTEtMjk4MzUy_b52cf522-6baa-4801-ae76-6fca1a0db897"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzgtMS0xLTEtMjk4MzUy_4dc9c984-7375-479b-bceb-125d6aa9758b"
      unitRef="usd">29850000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzgtMy0xLTEtMjk4MzUy_c9ce6a5a-824a-4f8e-ba75-617c2258c747"
      unitRef="usd">0</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzktMS0xLTEtMjk4MzUy_ddcf2637-d16f-4d9e-95e0-837b234c1881"
      unitRef="usd">126000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfMzktMy0xLTEtMjk4MzUy_f6afa273-d2bf-4188-93ab-17a111140712"
      unitRef="usd">74000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDEtMS0xLTEtMjk4MzUy_1dfbe327-d670-4fda-b9cd-bad3716ff5c9"
      unitRef="usd">357000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDEtMy0xLTEtMjk4MzUy_530deb6a-e03b-433f-897d-917741253605"
      unitRef="usd">372000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDItMS0xLTEtMjk4MzUy_abe70c6b-2c15-4600-81bb-e2dfe43ddafd"
      unitRef="usd">19000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDItMy0xLTEtMjk4MzUy_55508e7e-14c9-4922-80ea-45e94052047b"
      unitRef="usd">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDQtMS0xLTEtMjk4MzUy_c59807ed-14c5-4b70-851e-8bf2512c8a29"
      unitRef="usd">76888000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDQtMy0xLTEtMjk4MzUy_19847abe-d844-4b45-afeb-6b656993242f"
      unitRef="usd">-298000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDUtMS0xLTEtMjk4MzUy_f472a1c5-4eea-4ac6-b328-ccc0c8208d35"
      unitRef="usd">-254000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDUtMy0xLTEtMjk4MzUy_658441e4-4bd3-4591-99db-cb19ce193e57"
      unitRef="usd">-175000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDYtMS0xLTEtMjk4MzUy_fd2d90df-dade-4a71-b378-57a26c83f531"
      unitRef="usd">-16160000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDYtMy0xLTEtMjk4MzUy_b7fde1c5-7fd2-46fe-aa78-5fe0e9e4e5ff"
      unitRef="usd">-144716000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDctMS0xLTEtMjk4MzUy_ce234b6a-314c-492d-8fd4-026ddb3117c3"
      unitRef="usd">104965000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ic1f4ccbe1a254187a0abcd2fa0ef3671_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDctMy0xLTEtMjk4MzUy_dd427978-0cb9-4713-8e0f-9a3a302d6ecb"
      unitRef="usd">181280000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDgtMS0xLTEtMjk4MzUy_c04f16af-e73b-4aaa-9fd3-797db9bca291"
      unitRef="usd">88805000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i5f8290d605c9473bbd497404748ff594_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1MDEwMzM3MjM3NTQ4Mjg5MGRmNjMyNWQ2YjFlMzlkL3RhYmxlcmFuZ2U6YjUwMTAzMzcyMzc1NDgyODkwZGY2MzI1ZDZiMWUzOWRfNDgtMy0xLTEtMjk4MzUy_c9a48040-c0f0-47d3-bc5e-a08943c4e2eb"
      unitRef="usd">36564000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMy0xLTEtMS0yOTgzNTI_f9f428e8-2330-45e7-9089-aaa6001a728a"
      unitRef="usd">88481000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5f8290d605c9473bbd497404748ff594_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMy0zLTEtMS0yOTgzNTI_fa40c13e-3ed3-494d-b6df-ecd9872f5451"
      unitRef="usd">36385000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfNC0xLTEtMS0yOTgzNTI_9997784e-c9f1-4656-a91b-9b3f59b58c09"
      unitRef="usd">324000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i5f8290d605c9473bbd497404748ff594_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfNC0zLTEtMS0yOTgzNTI_426a99ae-7806-42e4-aac4-865c44b0e10e"
      unitRef="usd">179000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfNS0xLTEtMS0yOTgzNTI_fa124707-e119-47a3-a0fa-cbad3597c1c5"
      unitRef="usd">88805000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i5f8290d605c9473bbd497404748ff594_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfNS0zLTEtMS0yOTgzNTI_195634a7-9694-483d-bf72-0534f5f368cc"
      unitRef="usd">36564000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfOS0xLTEtMS0yOTgzNTI_bfbe26d3-93c4-4710-adc1-5a1102c3910e"
      unitRef="usd">15515000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfOS0zLTEtMS0yOTgzNTI_6080ebcc-af18-4a29-9051-aefaf3f006fc"
      unitRef="usd">5036000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTAtMS0xLTEtMjk4MzUy_dce3521d-d975-46c2-9667-2e7aa3004386"
      unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTAtMy0xLTEtMjk4MzUy_77f5ad1c-4349-4260-9445-b0200ac92f90"
      unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <ibrx:IssuanceOfWarrants
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTQtMS0xLTEtMzI0NTY5_17cd0d1a-0e73-4e6c-84fc-031b3f4cb57d"
      unitRef="usd">23698000</ibrx:IssuanceOfWarrants>
    <ibrx:IssuanceOfWarrants
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTQtMy0xLTEtMzI0NTY5_4dad7a9f-6b3f-4bbb-be23-03c875840250"
      unitRef="usd">0</ibrx:IssuanceOfWarrants>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTUtMS0xLTEtMzI0NTgw_0aea4e1a-d706-4eb4-866d-a38cc884a761"
      unitRef="usd">19033000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTUtMy0xLTEtMzI0NTgw_a9862b74-5e9b-4a76-86c0-667b3779aff9"
      unitRef="usd">1061000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <ibrx:UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTUtMS0xLTEtMjk4MzUy_adcdef24-fb38-40ed-8ef3-80af4bbf1973"
      unitRef="usd">318000</ibrx:UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <ibrx:UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTUtMy0xLTEtMjk4MzUy_ac01ef1f-038f-4417-a926-aea54cd55333"
      unitRef="usd">0</ibrx:UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTgtMS0xLTEtMjk4MzUy_e4b61e2c-17f2-4c00-9ea1-acd47e4ea723"
      unitRef="usd">10000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTgtMy0xLTEtMjk4MzUy_6bc99776-3bf3-4f83-ad47-b3f56acf33c3"
      unitRef="usd">-310000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTktMS0xLTEtMjk4MzUy_51dbb1fc-b90b-497b-ad8c-f6f6649cddee"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8yOC9mcmFnOjg4ZjczMjQwNjE1ODRmZTBhNTc1MWExMGRkNzA3ZjI5L3RhYmxlOmI1ZGE5MzRkOTk4ODRlZmE5ZjAwNDIwMTg0ODdlM2E1L3RhYmxlcmFuZ2U6YjVkYTkzNGQ5OTg4NGVmYTlmMDA0MjAxODQ4N2UzYTVfMTktMy0xLTEtMjk4MzUy_4fad2190-2f40-4322-adbb-def1b366f6cf"
      unitRef="usd">911000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF8zNC9mcmFnOjU5OTM0MDIwNWJjMTQyOGViMGNhM2UxZjc3ZjUyNGJkL3RleHRyZWdpb246NTk5MzQwMjA1YmMxNDI4ZWIwY2EzZTFmNzdmNTI0YmRfMzEyOQ_0e41931a-4a85-4d76-ba65-b17817ac1972">Description of Business&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In these notes to unaudited condensed consolidated financial statements, the terms &#x201c;ImmunityBio,&#x201d; &#x201c;the company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d; refer to ImmunityBio, Inc. and its subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Our Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ImmunityBio, Inc. is a clinical-stage biotechnology company developing next-generation therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. We strive to be a vertically-integrated immunotherapy company designing and manufacturing our products so they are more effective, accessible, more conveniently stored, and more easily administered to patients. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our broad immunotherapy and cell therapy platforms are designed to attack cancer and infectious pathogens by activating both the innate immune system&#x2014;natural killer (NK) cells, dendritic cells, and macrophages&#x2014;and the adaptive immune system&#x2014;B&#160;cells and T&#160;cells&#x2014;in an orchestrated manner. The goal of this potentially best-in-class approach is to generate immunogenic cell death thereby eliminating rogue cells from the body whether they are cancerous or virally infected. Our ultimate goal is to employ this approach to establish an &#x201c;immunological memory&#x201d; that confers long-term benefit for the patient. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although such designations may not lead to a faster development process or regulatory review and may not increase the likelihood that a product candidate will receive approval, Anktiva&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (N-803), our novel antibody cytokine fusion protein, has received &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Breakthrough Therapy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fast Track&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; designations in combination with &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;bacillus Calmette-Gu&#xe9;rin (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BCG) from the United States (U.S.)&#160;Food and Drug Administration (FDA) for&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; BCG&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. I&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;May&#160;2022, we announced the submission of a Biologics License Application (BLA) to the FDA for our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease. In July&#160;2022, we announced the FDA had accepted our BLA for review and set a target Prescription Drug User Fee Act (PDUFA) action date of May&#160;23,&#160;2023. On May&#160;9,&#160;2023, the FDA delivered a complete response letter to us regarding the BLA. The company plans to request a meeting with the FDA as soon as possible to address the subject matter of the letter and a response timeline, and plans to diligently address and resolve the issues identified and seek approval as expeditiously as possible. It is unclear when the FDA will approve our BLA, if at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our platforms include 13&#160;novel therapeutic agents either in clinical trials or for which we are developing protocols. We are currently engaged in 15&#160;active clinical trials involving 10&#160;of these agents. Seven of these trials are being sponsored by ImmunityBio while the remaining eight are investigator-led studies. Twelve&#160;of these trials are in Phase&#160;2 or 3&#160;development across eleven&#160;indications in liquid and solid tumors. These include bladder, pancreatic, and lung cancers, which are among the most frequent and lethal cancer types, and where there are high failure rates for existing standards of care or no available effective treatment. In infectious diseases, our pipeline currently targets such pathogens as the novel strain of the coronavirus (SARS-CoV-2) and human immunodeficiency virus (HIV). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have established Good Manufacturing Practice (GMP) manufacturing capacity at scale with cutting-edge cell manufacturing expertise and ready-to-scale facilities, as well as extensive and seasoned research and development (R&amp;amp;D), clinical trial, and regulatory operations, and development teams.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMTM2Njc_c7684178-4733-4aad-835b-f09215b13edd">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.&#160;GAAP) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The unaudited condensed consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of our financial position and results of operations. The unaudited condensed consolidated financial statements do not include all information and notes required by U.S.&#160;GAAP for annual reports and therefore should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December&#160;31,&#160;2022 filed with the SEC on March&#160;1,&#160;2023. These interim financials are not necessarily indicative of results expected for the full fiscal year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of the company, its wholly-owned subsidiaries, and a variable interest entity (VIE) for which the company is the primary beneficiary. Any material intercompany transactions and balances have been eliminated upon consolidation. For consolidated entities where we have less than 100% of ownership, we record net loss attributable to noncontrolling interest on the unaudited condensed consolidated statements of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess whether we are the primary beneficiary of a VIE at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31,&#160;2023, the company had an accumulated deficit of $2.5&#160;billion. We also had negative cash flows from operations of $84.3&#160;million for the three months ended March&#160;31,&#160;2023. The company will likely need additional capital to further fund the development of, and to seek regulatory approvals for, our product candidates, and to begin to commercialize any approved products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements have been prepared assuming the company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of the uncertainty of our ability to continue as a going concern. As a result of continuing anticipated operating cash outflows, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash, cash equivalents, and investments in marketable securities, together with capital to be raised through equity offerings (including but not limited to the offering, issuance and sale by us of our common stock that may be issued and sold under an &#x201c;at-the-market&#x201d; sales agreement (the&#160;Sale Agreement) with our sales agent (the&#160;ATM), of which we had $225.4&#160;million available for future issuance as of March&#160;31,&#160;2023, and a February&#160;2023 shelf registration statement, of which we had $640.0&#160;million available for future offerings as of March&#160;31,&#160;2023), and our potential ability to borrow from affiliated entities, will be sufficient to fund our operations through at least the next 12&#160;months following the issuance date of the condensed consolidated financial statements based primarily upon our Executive Chairman and Global Chief Scientific and Medical Officer&#x2019;s intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt. See&#160;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_85" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&lt;/a&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_85" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&#160;12&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; Deficit, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for information regarding the ATM and the shelf registration statement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may also seek to sell additional equity, through one or more follow-on offerings, or in separate financings, or obtain a credit facility. However, we may not be able to secure such external financing in a timely manner or on favorable terms. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the risk and uncertainties associated with the potential commercialization of our product candidates in development, we may need additional funds to meet our needs sooner than planned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, contingent value right measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value calculation of warrants and convertible promissory notes, fair value measurements, and the assessment of our ability to fund our operations for at least the next 12&#160;months from the date of issuance of these condensed consolidated financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing coronavirus pandemic could have on our significant accounting estimates. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to our significant accounting policies from those described in Note&#160;2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; that appears in Part&#160;II, Item&#160;8. &#x201c;Financial Statements and Supplementary Data&#x201d; of our Annual Report on Form&#160;10-K filed with the SEC on March&#160;1,&#160;2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in Accounting Standards Codification (ASC) Topic&#160;480, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC&#160;480), and ASC Topic&#160;815, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC&#160;815). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC&#160;480, meet the definition of a liability pursuant to ASC&#160;480, and whether the warrants meet all of the requirements for equity classification under ASC&#160;815, including whether the warrants are indexed to the&#160;company&#x2019;s own stock and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For warrants that meet all criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and on each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash change in fair value of warrant liabilities in o&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ther income (expense), net&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the condensed consolidated statements of operations. The fair value of the warrants was estimated using the Black-Scholes option pricing model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Option (FVO) Election&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company accounts for certain convertible notes issued during the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three months ended&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31,&#160;2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under the fair value option (FVO) election of ASC&#160;825, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC&#160;825), as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The convertible notes accounted for under the FVO election are each debt host financial instruments containing embedded features wherein the entire financial instrument is initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the estimated fair value of the convertible notes are recorded as &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other income (expense), net&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the condensed consolidated statements of operations, except that the change in estimated fair value attributable to a change in the instrument-specific credit risks is recognized as a component of other comprehensive income. Since the underlying financial instrument was issued on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we did not recognize any change in estimated fair values during the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three months ended&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31,&#160;2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basic and Diluted Net Loss per Share of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed by dividing net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares, including the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. The following table details those securities that have been excluded from the computation of potentially dilutive securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Related-party convertible notes (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46,726,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding third-party warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,163,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,159,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,819,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,188,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,149,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding related-party warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,638,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,638,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;86,875,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,606,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:94.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amount excludes the shares related to the related-party convertible note with a principal amount of $30.0&#160;million issued on March&#160;31,&#160;2023 as the conversion price has not yet been determined. See&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; &lt;/a&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Note &lt;/a&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;9&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Related-Party Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;, for further information.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Application of New or Revised Accounting Standards &#x2013; Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2022-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic&#160;820): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends the guidance in Topic&#160;820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. In addition, ASU&#160;2022-03 introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. ASU&#160;2022-03 is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years. We are currently evaluating the impact of this standard on our condensed consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, the FASB issued ASU&#160;2023-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842): Common Control Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires that leasehold improvements associated with common control leases be amortized over the useful life of the leasehold improvements to the common control group, regardless of the lease term. ASU&#160;2023-01 is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years. We are currently evaluating the impact of this standard on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC during the three months ended March&#160;31,&#160;2023 did not, or are not expected to, have a material effect on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMTM2NjI_4b65bc98-64dc-4bdf-96b3-086985004d0f">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.&#160;GAAP) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The unaudited condensed consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of our financial position and results of operations. The unaudited condensed consolidated financial statements do not include all information and notes required by U.S.&#160;GAAP for annual reports and therefore should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December&#160;31,&#160;2022 filed with the SEC on March&#160;1,&#160;2023. These interim financials are not necessarily indicative of results expected for the full fiscal year.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMTM2Njg_f3e1aad2-07be-40ea-bc3d-688210e1799a">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of the company, its wholly-owned subsidiaries, and a variable interest entity (VIE) for which the company is the primary beneficiary. Any material intercompany transactions and balances have been eliminated upon consolidation. For consolidated entities where we have less than 100% of ownership, we record net loss attributable to noncontrolling interest on the unaudited condensed consolidated statements of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess whether we are the primary beneficiary of a VIE at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMjExOQ_c8845dad-73f1-4a8d-aadb-203120bdb09d"
      unitRef="usd">-2500000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMjE3NA_4db1c66f-a078-4aba-9995-da9d0f2c0488"
      unitRef="usd">-84300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <ibrx:CommonStockValueAvailableForFutureStockIssuance
      contextRef="ib93ec4ea47c24cd1aacb10ddb65cfc49_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMzQ2NQ_64ac42b6-7c0b-423b-bc30-6935090e5165"
      unitRef="usd">225400000</ibrx:CommonStockValueAvailableForFutureStockIssuance>
    <ibrx:CommonStockValueAvailableForFutureStockIssuance
      contextRef="idecf558aeafa48f9b21a5ecd3fb24b40_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfNTQ5NzU1ODU3NjY3_6186171d-470f-4ae9-9a1b-82a6b72cba72"
      unitRef="usd">640000000</ibrx:CommonStockValueAvailableForFutureStockIssuance>
    <us-gaap:UseOfEstimates
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMTM2NjM_441cb3c2-9ea8-47bf-bbf4-2d73c8d0eb7b">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, contingent value right measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value calculation of warrants and convertible promissory notes, fair value measurements, and the assessment of our ability to fund our operations for at least the next 12&#160;months from the date of issuance of these condensed consolidated financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing coronavirus pandemic could have on our significant accounting estimates. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <ibrx:WarrantsPolicyTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMzg0ODI5MDczMjczNw_c271e04a-d76d-47a5-a6ac-1ec5392d12fb">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in Accounting Standards Codification (ASC) Topic&#160;480, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC&#160;480), and ASC Topic&#160;815, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC&#160;815). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC&#160;480, meet the definition of a liability pursuant to ASC&#160;480, and whether the warrants meet all of the requirements for equity classification under ASC&#160;815, including whether the warrants are indexed to the&#160;company&#x2019;s own stock and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For warrants that meet all criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and on each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash change in fair value of warrant liabilities in o&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ther income (expense), net&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the condensed consolidated statements of operations. The fair value of the warrants was estimated using the Black-Scholes option pricing model.&lt;/span&gt;&lt;/div&gt;</ibrx:WarrantsPolicyTextBlock>
    <ibrx:ConvertibleNotesFairValueOptionElectionPolicyTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMzg0ODI5MDczMjczOA_f7e7a384-77f6-411c-b07e-42bcad0c56b9">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Option (FVO) Election&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company accounts for certain convertible notes issued during the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three months ended&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31,&#160;2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under the fair value option (FVO) election of ASC&#160;825, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC&#160;825), as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The convertible notes accounted for under the FVO election are each debt host financial instruments containing embedded features wherein the entire financial instrument is initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date.&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the estimated fair value of the convertible notes are recorded as &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other income (expense), net&lt;/span&gt; on the condensed consolidated statements of operations, except that the change in estimated fair value attributable to a change in the instrument-specific credit risks is recognized as a component of other comprehensive income.</ibrx:ConvertibleNotesFairValueOptionElectionPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMTM2NjU_9dbee786-f968-4fb8-98ac-3476b884b1da">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basic and Diluted Net Loss per Share of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed by dividing net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares, including the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. The following table details those securities that have been excluded from the computation of potentially dilutive securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Related-party convertible notes (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46,726,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding third-party warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,163,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,159,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,819,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,188,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,149,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding related-party warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,638,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,638,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;86,875,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,606,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:94.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amount excludes the shares related to the related-party convertible note with a principal amount of $30.0&#160;million issued on March&#160;31,&#160;2023 as the conversion price has not yet been determined. See&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; &lt;/a&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Note &lt;/a&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;9&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Related-Party Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;, for further information.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMTM2NjY_6efbc88a-07b2-469b-961a-e07670402975">The following table details those securities that have been excluded from the computation of potentially dilutive securities:&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Related-party convertible notes (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46,726,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding third-party warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,163,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,159,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,819,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,188,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,149,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding related-party warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,638,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,638,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;86,875,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,606,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:94.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amount excludes the shares related to the related-party convertible note with a principal amount of $30.0&#160;million issued on March&#160;31,&#160;2023 as the conversion price has not yet been determined. See&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; &lt;/a&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Note &lt;/a&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;9&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Related-Party Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;, for further information.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i99fc5379a3c146e884bcdad311bb00a7_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfNC0xLTEtMS0zMjM2ODQ_a8261736-c312-47ff-807d-bdd222232292"
      unitRef="shares">46726407</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icca3815678964e2d94105dd050d212c3_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfNC0zLTEtMS0zMjM2ODQ_bda16b25-627c-4a81-8ebb-bb5cbeaade64"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iba6ebd8d72ea4824b03a047a8f09a82d_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfNS0xLTEtMS0yOTgzNTI_b1e9056b-15f4-451e-9cf8-4ab34fb0387b"
      unitRef="shares">23163524</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifb98e0036a3b43d497ef0476504101c1_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfNS0zLTEtMS0yOTgzNTI_8d689990-7af5-4e9f-93fe-570cdbceb738"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia50e8aab6bce4a40af1190886835cf90_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfNi0xLTEtMS0yOTgzNTI_84e947d5-d368-4be6-8239-97e8b555e215"
      unitRef="shares">9159665</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4bc712551fbe42fa830fbfe75a349bb9_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfNi0zLTEtMS0yOTgzNTI_1e167d62-87a3-47bf-a58a-d49f21b0f78f"
      unitRef="shares">8819466</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4561df868e434e67b57f7aa91baf077a_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfNy0xLTEtMS0yOTgzNTI_1cea852b-8958-4f1a-8e8a-28a7ba401e7a"
      unitRef="shares">6188292</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4868dd8bba544400bbb7baf280da9766_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfNy0zLTEtMS0yOTgzNTI_3414b4e9-cab4-45d3-84bd-e79f5c4cd2d5"
      unitRef="shares">6149411</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8a1967d8b16b4b2780d09eb32b721ead_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfOC0xLTEtMS0zMjMyMjE_63bef7c1-39c7-454b-adbf-1ca002faccc8"
      unitRef="shares">1638000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6785865c42404146b0f6e8d0fc2d2b8c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfOC0zLTEtMS0zMjMyMjE_9fd6a56f-c4ba-4444-923b-2e3e9315fe0a"
      unitRef="shares">1638000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfOC0xLTEtMS0yOTgzNTI_450863ad-8ecb-4e21-9b57-b5a3aa204bcf"
      unitRef="shares">86875888</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjUyY2I5NGQ3MWI5NjQ3NmE5YWU5ZmE5M2IxZWEyZTFhL3RhYmxlcmFuZ2U6NTJjYjk0ZDcxYjk2NDc2YTlhZTlmYTkzYjFlYTJlMWFfOC0zLTEtMS0yOTgzNTI_e15ee030-adfe-4c95-ac03-75fb50897abf"
      unitRef="shares">16606877</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <ibrx:RelatedPartyNotesPayable
      contextRef="i4d61f38abc9b467da5b3204da34fab5e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RhYmxlOjcxMWExNzEyMzAzMjRkZTJiYWVjNTM0OGUzYjMyMGY4L3RhYmxlcmFuZ2U6NzExYTE3MTIzMDMyNGRlMmJhZWM1MzQ4ZTNiMzIwZjhfMC0xLTEtMS0zMjM3MjcvdGV4dHJlZ2lvbjoxMDg4ZmQ4NWRmZmM0ZDQ2YjNjOTUwOTA2OTVhZTFiOV81NDk3NTU4MTY1NDA_5977bcfb-4220-4a7a-978a-233ae428b050"
      unitRef="usd">30000000</ibrx:RelatedPartyNotesPayable>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80MC9mcmFnOmRhYWJjM2Q5N2EyNTRkNmVhMTkwZjlmY2QwZjM2Mzk5L3RleHRyZWdpb246ZGFhYmMzZDk3YTI1NGQ2ZWExOTBmOWZjZDBmMzYzOTlfMTM2NjE_225c0db2-b239-4d21-b125-cec98814fcba">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Application of New or Revised Accounting Standards &#x2013; Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2022-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic&#160;820): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which amends the guidance in Topic&#160;820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. In addition, ASU&#160;2022-03 introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. ASU&#160;2022-03 is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years. We are currently evaluating the impact of this standard on our condensed consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, the FASB issued ASU&#160;2023-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842): Common Control Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires that leasehold improvements associated with common control leases be amortized over the useful life of the leasehold improvements to the common control group, regardless of the lease term. ASU&#160;2023-01 is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years. We are currently evaluating the impact of this standard on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC during the three months ended March&#160;31,&#160;2023 did not, or are not expected to, have a material effect on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfOTE3_ae2fc3da-3ff3-4fc5-87d1-c43a7a17ac01">Financial Statement Details&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prepaid supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid software license fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Insurance premium financing asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net, consist of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;68,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;68,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;67,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;81,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Furniture &amp;amp; fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Gross property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;227,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;212,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;69,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;154,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;143,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense related to property, plant and equipment totaled $4.2&#160;million and $3.8&#160;million for the three&#160;months&#160;ended March&#160;31,&#160;2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gross carrying amounts and accumulated amortization of intangible assets are as follows at the dates indicated (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31,&#160;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finite-lived: Favorable leasehold rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Indefinite-lived: In-process research &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&#160;&#160;and development (IPR&amp;amp;D)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finite-lived: Favorable leasehold rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finite-lived: Organized workforce&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Indefinite-lived: IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of the Dunkirk facility in 2022, we acquired finite-lived intangibles consisting of favorable leasehold rights and an organized workforce. We recorded amortization expense of our finite-lived intangibles totaling $0.5&#160;million and $0.3&#160;million in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the condensed consolidated statements of operations for the three months ended March&#160;31,&#160;2023 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense associated with our finite-lived intangible assets is as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Years ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Finite-lived&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Intangible&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023 (excluding the three months ended March&#160;31,&#160;2023)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other liabilities consist of the following (in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued bonus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional and service fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued preclinical and clinical trial costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing obligation &#x2013; current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest and Investment Income, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest and investment income, net consists of the following (in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Three Months Ended&lt;br/&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Unrealized gains from equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Investment amortization expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,049)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net realized losses on investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest and investment income, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income includes interest from marketable securities, convertible notes receivable, other assets, and on bank deposits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense consists of the following (in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.302%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Three Months Ended&lt;br/&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest expense on related-party notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization of related-party notes discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(29,816)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(8,491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfOTE0_387d5cde-88f6-4ce2-9780-eec0ee5af100">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prepaid supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid software license fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Insurance premium financing asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <ibrx:PrepaidResearchAndDevelopmentCosts
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfMy0xLTEtMS0zMjM3Mzc_75d9d173-97de-4773-a35b-685f47c37727"
      unitRef="usd">6741000</ibrx:PrepaidResearchAndDevelopmentCosts>
    <ibrx:PrepaidResearchAndDevelopmentCosts
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfMy0zLTEtMS0zMjM3Mzc_728ae1b4-138c-4ac1-b880-750e7fa4b2ed"
      unitRef="usd">11704000</ibrx:PrepaidResearchAndDevelopmentCosts>
    <ibrx:PrepaidServices
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfMy0xLTEtMS0yOTgzNTI_12019245-34fe-41ad-9eb3-32a0f37b8cce"
      unitRef="usd">3246000</ibrx:PrepaidServices>
    <ibrx:PrepaidServices
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfMy0zLTEtMS0yOTgzNTI_8419090c-2c07-4b3a-a2c8-63ebbe619f14"
      unitRef="usd">8013000</ibrx:PrepaidServices>
    <us-gaap:Supplies
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfNC0xLTEtMS0zMDMxMDg_50815611-53d6-4f87-8673-0afeb535bd61"
      unitRef="usd">2160000</us-gaap:Supplies>
    <us-gaap:Supplies
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfNC0zLTEtMS0zMDMxMTI_9168789f-47a2-4f29-a7c6-bafc84fa0cf8"
      unitRef="usd">2160000</us-gaap:Supplies>
    <us-gaap:PrepaidInsurance
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfNy0xLTEtMS0zMjM3NDk_eb5f5ef2-bfd7-420e-8e94-139857fce9ed"
      unitRef="usd">2150000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfNy0zLTEtMS0zMjM3NDk_f8e81ec1-f8a7-464a-9b16-2c888ea69166"
      unitRef="usd">2282000</us-gaap:PrepaidInsurance>
    <ibrx:PrepaidSoftwareLicenseFees
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfNS0xLTEtMS0yOTgzNTI_b0d93f08-e8da-48cd-92dc-e3f8b51faea1"
      unitRef="usd">1672000</ibrx:PrepaidSoftwareLicenseFees>
    <ibrx:PrepaidSoftwareLicenseFees
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfNS0zLTEtMS0yOTgzNTI_954ee688-1fd3-419e-bd36-2061a56dc3db"
      unitRef="usd">2195000</ibrx:PrepaidSoftwareLicenseFees>
    <ibrx:InsurancePremiumFinancingAsset
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfNi0xLTEtMS0yOTgzNTI_2501696c-b70b-4cf4-9ec0-3324bf31d826"
      unitRef="usd">357000</ibrx:InsurancePremiumFinancingAsset>
    <ibrx:InsurancePremiumFinancingAsset
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfNi0zLTEtMS0yOTgzNTI_67ecb0ff-10dc-4577-b2b7-1ee0a17a92bd"
      unitRef="usd">1417000</ibrx:InsurancePremiumFinancingAsset>
    <us-gaap:OtherAssetsCurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfMTctMS0xLTEtMjk4MzUy_b5a6b915-0be9-4d7f-9ec0-ec7b24f874ca"
      unitRef="usd">4428000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfMTctMy0xLTEtMjk4MzUy_83785217-847a-4c98-b1e4-b17492db571f"
      unitRef="usd">3732000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfMTgtMS0xLTEtMjk4MzUy_ae81dd50-e20a-4feb-a75d-c918e21e4cf1"
      unitRef="usd">20754000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmJlMTJiMWI2MzI4ZjRiYmVhNjdhZGJhZmJkMmE1Zjg5L3RhYmxlcmFuZ2U6YmUxMmIxYjYzMjhmNGJiZWE2N2FkYmFmYmQyYTVmODlfMTgtMy0xLTEtMjk4MzUy_524dd1eb-12fd-4223-b8a8-ef45edb7b22e"
      unitRef="usd">31503000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfOTE1_e356903e-a5ea-492c-8397-33e6da671a86">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net, consist of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;68,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;68,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;67,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;81,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Furniture &amp;amp; fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Gross property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;227,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;212,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;69,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;154,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;143,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i684e88f0565f4750ae31d08132ff423b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfMy0xLTEtMS0yOTgzNTI_f86c8c2c-f313-4ff2-a857-6fcc54f559a8"
      unitRef="usd">73078000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6e62b835f051443d9e55df382ca1fcce_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfMy0zLTEtMS0yOTgzNTI_70565aff-1a08-433b-b727-ef0d779de369"
      unitRef="usd">68710000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic374e7c516ef4b06beadcff3736ae51f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfNC0xLTEtMS0yOTgzNTI_6540e942-27d6-4269-8065-85ba3ead647d"
      unitRef="usd">68973000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iee11080abfef48cf9f5c6b933901142a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfNC0zLTEtMS0yOTgzNTI_248aab7d-5a37-46ee-b43c-9b8f1bb0b843"
      unitRef="usd">67945000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icdb4ac7d53c44d429b5802a108d42fb7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfNS0xLTEtMS0yOTgzNTI_3bca24cb-6994-464d-a2b7-d140067d71f1"
      unitRef="usd">81941000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id5437c21f4814f59a329a7b0373ddd7c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfNS0zLTEtMS0yOTgzNTI_83247069-8661-493f-8f6c-e0a50e91902d"
      unitRef="usd">72693000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id5ccb25eaaf340a293dbf719e9c93972_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfNi0xLTEtMS0yOTgzNTI_1425581e-9913-4019-9ed0-33fa10a56340"
      unitRef="usd">1931000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifcada495b71b4888ab1fd26a734a81a7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfNi0zLTEtMS0yOTgzNTI_dcfb4326-dc84-49f6-ac9e-d396fc97741b"
      unitRef="usd">1906000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if361174e18104c2d80d8a23d1e42afa0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfNy0xLTEtMS0yOTgzNTI_5bf6459e-5f0c-4d9e-977d-2dd64d679b57"
      unitRef="usd">1657000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9fdf6d04e3e64c0a85f416eb0b67673a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfNy0zLTEtMS0yOTgzNTI_e2ce7fff-377e-40ba-9c3a-50d942ad0dae"
      unitRef="usd">1657000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfOS0xLTEtMS0yOTgzNTI_11c24f7f-5525-4383-9c6c-cc726067dc09"
      unitRef="usd">227580000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfOS0zLTEtMS0yOTgzNTI_a4656f7d-e4a6-43fe-abdd-f8a19b6079dd"
      unitRef="usd">212911000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfMTAtMS0xLTEtMjk4MzUy_6ac149d6-e411-4b6c-a9c4-c471ab2fd382"
      unitRef="usd">73415000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfMTAtMy0xLTEtMjk4MzUy_4b0e3835-ff26-4a5d-8e58-e355cb8be2a1"
      unitRef="usd">69252000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfMTEtMS0xLTEtMjk4MzUy_8fac998e-31cf-450d-bea2-a74f6d9d4fb3"
      unitRef="usd">154165000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmFjN2NjYTc5YWZhOTRmMzBhN2RjMWMzYWZhODkyNTI2L3RhYmxlcmFuZ2U6YWM3Y2NhNzlhZmE5NGYzMGE3ZGMxYzNhZmE4OTI1MjZfMTEtMy0xLTEtMjk4MzUy_927b2b24-71a3-40f7-99a9-9f717a9cfab4"
      unitRef="usd">143659000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfMzQ5_5d7ea2d3-38d0-4452-aebf-cc5c03483ba6"
      unitRef="usd">4200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfMzU2_88714a94-fa0e-4190-8ee6-58fb7c026ad7"
      unitRef="usd">3800000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfMzg0ODI5MDcwMDc2Mw_cbf200c2-1cf5-4dec-9288-2aaec355f386">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gross carrying amounts and accumulated amortization of intangible assets are as follows at the dates indicated (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31,&#160;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finite-lived: Favorable leasehold rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Indefinite-lived: In-process research &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&#160;&#160;and development (IPR&amp;amp;D)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finite-lived: Favorable leasehold rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finite-lived: Organized workforce&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Indefinite-lived: IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i69a7813607634b75bf6094281fe5a9ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmU1ZmYwM2IyMTEzYzRkZjE4MjZiZGRlNTNjMzI4MmE2L3RhYmxlcmFuZ2U6ZTVmZjAzYjIxMTNjNGRmMTgyNmJkZGU1M2MzMjgyYTZfMy0xLTEtMS0zMjM3NzY_2c6cbc69-09df-46dd-99c4-780efc159d9b">P8Y10M24D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4ac85c2e74bb4d9e983ef489c9b27611_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmU1ZmYwM2IyMTEzYzRkZjE4MjZiZGRlNTNjMzI4MmE2L3RhYmxlcmFuZ2U6ZTVmZjAzYjIxMTNjNGRmMTgyNmJkZGU1M2MzMjgyYTZfMy0zLTEtMS0zMjM3NzY_c17b8964-4659-4252-b0f9-b814bbc19ec8"
      unitRef="usd">20398000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4ac85c2e74bb4d9e983ef489c9b27611_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmU1ZmYwM2IyMTEzYzRkZjE4MjZiZGRlNTNjMzI4MmE2L3RhYmxlcmFuZ2U6ZTVmZjAzYjIxMTNjNGRmMTgyNmJkZGU1M2MzMjgyYTZfMy01LTEtMS0zMjM3NzY_e24a1cab-7d9d-42f9-ba95-6ff653a2509c"
      unitRef="usd">2295000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4ac85c2e74bb4d9e983ef489c9b27611_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmU1ZmYwM2IyMTEzYzRkZjE4MjZiZGRlNTNjMzI4MmE2L3RhYmxlcmFuZ2U6ZTVmZjAzYjIxMTNjNGRmMTgyNmJkZGU1M2MzMjgyYTZfMy05LTEtMS0zMjM3NzY_07c56706-5868-4169-83bf-5431293d5724"
      unitRef="usd">18103000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmU1ZmYwM2IyMTEzYzRkZjE4MjZiZGRlNTNjMzI4MmE2L3RhYmxlcmFuZ2U6ZTVmZjAzYjIxMTNjNGRmMTgyNmJkZGU1M2MzMjgyYTZfNi0zLTEtMS0zMjM3NzY_98ac95a8-303e-45b7-9426-19f62aa315e6"
      unitRef="usd">1399000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmU1ZmYwM2IyMTEzYzRkZjE4MjZiZGRlNTNjMzI4MmE2L3RhYmxlcmFuZ2U6ZTVmZjAzYjIxMTNjNGRmMTgyNmJkZGU1M2MzMjgyYTZfNi05LTEtMS0zMjM3NzY_86d8a0e8-2856-4fdf-893d-a7ecff05e920"
      unitRef="usd">1399000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmU1ZmYwM2IyMTEzYzRkZjE4MjZiZGRlNTNjMzI4MmE2L3RhYmxlcmFuZ2U6ZTVmZjAzYjIxMTNjNGRmMTgyNmJkZGU1M2MzMjgyYTZfNy0zLTEtMS0zMjM3NzY_3cdac5ff-66c9-4dd4-b1c9-7c38216aee39"
      unitRef="usd">21797000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmU1ZmYwM2IyMTEzYzRkZjE4MjZiZGRlNTNjMzI4MmE2L3RhYmxlcmFuZ2U6ZTVmZjAzYjIxMTNjNGRmMTgyNmJkZGU1M2MzMjgyYTZfNy01LTEtMS0zMjM3NzY_31974813-8a27-4fcd-92d8-3042fd34a6a3"
      unitRef="usd">2295000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmU1ZmYwM2IyMTEzYzRkZjE4MjZiZGRlNTNjMzI4MmE2L3RhYmxlcmFuZ2U6ZTVmZjAzYjIxMTNjNGRmMTgyNmJkZGU1M2MzMjgyYTZfNy05LTEtMS0zMjM3NzY_744017aa-06fd-42f8-8579-2074092af1cc"
      unitRef="usd">19502000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="idb96fe0125b04e81861415c2d465f7f2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfMy0xLTEtMS0zMzIxMzc_81e3d560-085f-479d-a18c-804a65164f12">P9Y1M6D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4d984c547ea04fd4aca46b980c849ad7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfMy0zLTEtMS0zMjM4MTk_818a8e37-08b4-48d6-aa94-fcd7a1c516b6"
      unitRef="usd">20398000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4d984c547ea04fd4aca46b980c849ad7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfMy01LTEtMS0zMjM4Mjc_ad2085e3-dec1-4374-91b1-60d91da62c55"
      unitRef="usd">1785000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment
      contextRef="i4d984c547ea04fd4aca46b980c849ad7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfMy03LTEtMS0zMjM4MzU_2877440f-db31-452f-89a7-39f946dfb55b"
      unitRef="usd">0</ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4d984c547ea04fd4aca46b980c849ad7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfMy05LTEtMS0zMjM4NDM_1e8306f3-2f2d-40f2-b01c-3239abcfdbb1"
      unitRef="usd">18613000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2302952973d64c9dae6fea63aa9b623d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNC0zLTEtMS0zMjM4MTk_cb636844-c008-43b8-b91b-f01402278388"
      unitRef="usd">831000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2302952973d64c9dae6fea63aa9b623d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNC01LTEtMS0zMjM4Mjc_a188c7aa-fdbf-42c0-9e88-79608ef0b818"
      unitRef="usd">150000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment
      contextRef="i2302952973d64c9dae6fea63aa9b623d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNC03LTEtMS0zMjM4MzU_2cb492f2-37cf-4acb-9375-9f14a56e96b2"
      unitRef="usd">681000</ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2302952973d64c9dae6fea63aa9b623d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNC05LTEtMS0zMjM4NDM_ecb24917-fa95-4e3a-b12d-316519e35e3e"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNS0zLTEtMS0zMjM4MTk_c52230c0-c7ea-4a5d-b4f6-9b803b3be5fc"
      unitRef="usd">21229000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNS01LTEtMS0zMjM4Mjc_c17d7ac2-0de3-4ff9-9718-ff17f10417d4"
      unitRef="usd">1935000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNS03LTEtMS0zMjM4MzU_55338427-a52f-4c71-b1ff-db695826e9cb"
      unitRef="usd">681000</ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNS05LTEtMS0zMjM4NDM_4588536a-109e-41fb-8fa2-d895bee91f26"
      unitRef="usd">18613000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNi0zLTEtMS0zMjM4MTk_27c4105f-cd8d-48ad-8f69-e6ecfb8fc512"
      unitRef="usd">1390000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNi05LTEtMS0zMjM4NDM_aa35f196-82e8-484c-a939-a25f1def91d7"
      unitRef="usd">1390000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNy0zLTEtMS0zMjM4MTk_cfa3e311-b746-48fb-8ace-c6a4b87aeeb7"
      unitRef="usd">22619000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNy01LTEtMS0zMjM4Mjc_f8f1089e-967a-4b62-817a-29c683ef0f89"
      unitRef="usd">1935000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNy03LTEtMS0zMjM4MzU_11e3a892-13e8-4a4e-ad1b-bd65e05e0d36"
      unitRef="usd">681000</ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjEyNmE3MzUwMGM4YjRjNTZiNWY3ZjVmYTJkOTAyMmZkL3RhYmxlcmFuZ2U6MTI2YTczNTAwYzhiNGM1NmI1ZjdmNWZhMmQ5MDIyZmRfNy05LTEtMS0zMjM4NDM_a61bcdd0-5c06-4590-82ea-9f1a3d1bfde0"
      unitRef="usd">20003000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfNTQ5NzU1ODE2ODM0_7fe9273b-5200-4f9d-993b-9c70cb1caea9"
      unitRef="usd">500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfNTQ5NzU1ODE2ODQy_051f1b32-c03e-4a86-9bda-ad8d147709cf"
      unitRef="usd">300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfMzg0ODI5MDcwMDc2NA_8f34ff5a-6b33-49cd-a720-e6ef2186cb0c">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense associated with our finite-lived intangible assets is as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Years ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Finite-lived&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Intangible&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023 (excluding the three months ended March&#160;31,&#160;2023)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjA1Yjk3NzMzYjQ0NjQzMjk5YTUzNDY0MjJlN2UyZjA5L3RhYmxlcmFuZ2U6MDViOTc3MzNiNDQ2NDMyOTlhNTM0NjQyMmU3ZTJmMDlfMi0xLTEtMS0zMjM5MzQ_94476c07-67fc-4a25-b21c-d2cd1ca6768c"
      unitRef="usd">1530000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjA1Yjk3NzMzYjQ0NjQzMjk5YTUzNDY0MjJlN2UyZjA5L3RhYmxlcmFuZ2U6MDViOTc3MzNiNDQ2NDMyOTlhNTM0NjQyMmU3ZTJmMDlfMy0xLTEtMS0zMjM5MzQ_104507fa-3073-4c93-b01c-a67bdf9fecdf"
      unitRef="usd">2040000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjA1Yjk3NzMzYjQ0NjQzMjk5YTUzNDY0MjJlN2UyZjA5L3RhYmxlcmFuZ2U6MDViOTc3MzNiNDQ2NDMyOTlhNTM0NjQyMmU3ZTJmMDlfNC0xLTEtMS0zMjM5MzQ_084a2f79-0cae-4dfd-89f0-d981bf5729d3"
      unitRef="usd">2040000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjA1Yjk3NzMzYjQ0NjQzMjk5YTUzNDY0MjJlN2UyZjA5L3RhYmxlcmFuZ2U6MDViOTc3MzNiNDQ2NDMyOTlhNTM0NjQyMmU3ZTJmMDlfNS0xLTEtMS0zMjM5MzQ_d62f7140-7ec0-4bc1-a3be-6862c1d1105c"
      unitRef="usd">2040000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjA1Yjk3NzMzYjQ0NjQzMjk5YTUzNDY0MjJlN2UyZjA5L3RhYmxlcmFuZ2U6MDViOTc3MzNiNDQ2NDMyOTlhNTM0NjQyMmU3ZTJmMDlfNi0xLTEtMS0zMjM5MzQ_b259eb2f-f164-4d6a-a70c-17c1a4d2f125"
      unitRef="usd">2040000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <ibrx:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjA1Yjk3NzMzYjQ0NjQzMjk5YTUzNDY0MjJlN2UyZjA5L3RhYmxlcmFuZ2U6MDViOTc3MzNiNDQ2NDMyOTlhNTM0NjQyMmU3ZTJmMDlfNy0xLTEtMS0zMjM5MzQ_4d293256-d2ba-4243-b79e-16f3c8930c2d"
      unitRef="usd">8413000</ibrx:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjA1Yjk3NzMzYjQ0NjQzMjk5YTUzNDY0MjJlN2UyZjA5L3RhYmxlcmFuZ2U6MDViOTc3MzNiNDQ2NDMyOTlhNTM0NjQyMmU3ZTJmMDlfOC0xLTEtMS0zMjM5NDU_96c39035-a5e0-414f-8b2f-db29a9bf68e4"
      unitRef="usd">18103000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfOTE5_68ee42ac-9bef-41d1-af2c-d6a7aad613fa">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other liabilities consist of the following (in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued bonus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional and service fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued preclinical and clinical trial costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing obligation &#x2013; current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <ibrx:AccruedResearchAndDevelopmentCosts
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfMy0xLTEtMS0zMzc3NDc_072cc5d2-c0f8-4c20-9bad-421670a76704"
      unitRef="usd">15916000</ibrx:AccruedResearchAndDevelopmentCosts>
    <ibrx:AccruedResearchAndDevelopmentCosts
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfMy0zLTEtMS0zMzc3NDc_d86baf4d-edcc-4eb2-9734-aa35380fa49e"
      unitRef="usd">1930000</ibrx:AccruedResearchAndDevelopmentCosts>
    <us-gaap:AccruedBonusesCurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfMy0xLTEtMS0yOTgzNTI_b0854ad2-27d7-4313-b03c-561b127c2f84"
      unitRef="usd">14642000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfMy0zLTEtMS0yOTgzNTI_ca56ffe3-d631-428f-842d-6446fe2658d1"
      unitRef="usd">12068000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfNC0xLTEtMS0yOTgzNTI_412c0e93-2702-4098-be44-5d93c6959acb"
      unitRef="usd">9229000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfNC0zLTEtMS0yOTgzNTI_b282b435-54c7-41a5-80ac-2c7adcd4f3ea"
      unitRef="usd">6685000</us-gaap:AccruedProfessionalFeesCurrent>
    <ibrx:AccruedPreclinicalAndClinicalTrialCosts
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfNi0xLTEtMS0zMzc3NTg_76d31c52-aef4-4261-b695-e263bdb253bc"
      unitRef="usd">5523000</ibrx:AccruedPreclinicalAndClinicalTrialCosts>
    <ibrx:AccruedPreclinicalAndClinicalTrialCosts
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfNi0zLTEtMS0zMzc3NTg_6fad973b-dc9d-4da7-96f4-2d1f266bec92"
      unitRef="usd">4985000</ibrx:AccruedPreclinicalAndClinicalTrialCosts>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfNi0xLTEtMS0zMjQwMzU_3e2a8499-23bd-4349-a335-80bfbf69f14f"
      unitRef="usd">5327000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfNi0zLTEtMS0zMjQwMzU_bf392a61-0ad0-45b7-a5b0-97cfc3d7a5a0"
      unitRef="usd">6040000</us-gaap:AccruedSalariesCurrent>
    <ibrx:AccruedConstructionCostsCurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfOS0xLTEtMS0yOTgzNTI_d745ce2d-cc11-4e51-b18a-75c51dc9cf42"
      unitRef="usd">2136000</ibrx:AccruedConstructionCostsCurrent>
    <ibrx:AccruedConstructionCostsCurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfOS0zLTEtMS0yOTgzNTI_260f60b7-1295-436e-968c-c0bc89074b73"
      unitRef="usd">7072000</ibrx:AccruedConstructionCostsCurrent>
    <ibrx:FinancingObligationCurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfMTAtMS0xLTEtMjk4MzUy_df10a756-1a87-42f1-aad6-97f6fbbf804a"
      unitRef="usd">357000</ibrx:FinancingObligationCurrent>
    <ibrx:FinancingObligationCurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfMTAtMy0xLTEtMjk4MzUy_9c235f67-227e-4080-947a-090826ef85f6"
      unitRef="usd">1417000</ibrx:FinancingObligationCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfMTktMS0xLTEtMjk4MzUy_54c0d218-dc3b-4f59-aca6-cf3a6b11acff"
      unitRef="usd">988000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfMTktMy0xLTEtMjk4MzUy_dd69715d-362d-4cdc-945f-0add25d624e7"
      unitRef="usd">1628000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfMjAtMS0xLTEtMjk4MzUy_d2a0d2c9-8443-4308-a33c-67799a3d0dc8"
      unitRef="usd">54118000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOmQ1NmUyYjM1M2Q0YTQ4NTBhYmU2NDBkY2UxNjgyZmYxL3RhYmxlcmFuZ2U6ZDU2ZTJiMzUzZDRhNDg1MGFiZTY0MGRjZTE2ODJmZjFfMjAtMy0xLTEtMjk4MzUy_c4c4489c-a733-4478-9416-59da4d6c5dae"
      unitRef="usd">41825000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:InterestAndOtherIncomeTableTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfOTE4_5d49d76b-e72b-42f8-a3f1-6683e462585c">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest and investment income, net consists of the following (in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Three Months Ended&lt;br/&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Unrealized gains from equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Investment amortization expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,049)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Net realized losses on investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest and investment income, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestAndOtherIncomeTableTextBlock>
    <us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc3NjljYjQ4YWJmNjQzMjc5MGE3ODc3NDM2MDNlY2Q0L3RhYmxlcmFuZ2U6Nzc2OWNiNDhhYmY2NDMyNzkwYTc4Nzc0MzYwM2VjZDRfNC0xLTEtMS0yOTgzNTI_ef18c58a-4fad-4430-8645-14a4958ec88b"
      unitRef="usd">135000</us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss>
    <us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc3NjljYjQ4YWJmNjQzMjc5MGE3ODc3NDM2MDNlY2Q0L3RhYmxlcmFuZ2U6Nzc2OWNiNDhhYmY2NDMyNzkwYTc4Nzc0MzYwM2VjZDRfNC0zLTEtMS0yOTgzNTI_7aa14e13-cabe-4a3e-9a03-01fe6f85aeab"
      unitRef="usd">1419000</us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc3NjljYjQ4YWJmNjQzMjc5MGE3ODc3NDM2MDNlY2Q0L3RhYmxlcmFuZ2U6Nzc2OWNiNDhhYmY2NDMyNzkwYTc4Nzc0MzYwM2VjZDRfNS0xLTEtMS0yOTgzNTI_5a8d0469-a906-4c73-8dc4-5c846b213185"
      unitRef="usd">284000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc3NjljYjQ4YWJmNjQzMjc5MGE3ODc3NDM2MDNlY2Q0L3RhYmxlcmFuZ2U6Nzc2OWNiNDhhYmY2NDMyNzkwYTc4Nzc0MzYwM2VjZDRfNS0zLTEtMS0yOTgzNTI_a6712f90-6680-4161-a64c-003a51d51549"
      unitRef="usd">1296000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc3NjljYjQ4YWJmNjQzMjc5MGE3ODc3NDM2MDNlY2Q0L3RhYmxlcmFuZ2U6Nzc2OWNiNDhhYmY2NDMyNzkwYTc4Nzc0MzYwM2VjZDRfNi0xLTEtMS0yOTgzNTI_95e870b0-95e0-48c6-97f0-380029d16279"
      unitRef="usd">260000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc3NjljYjQ4YWJmNjQzMjc5MGE3ODc3NDM2MDNlY2Q0L3RhYmxlcmFuZ2U6Nzc2OWNiNDhhYmY2NDMyNzkwYTc4Nzc0MzYwM2VjZDRfNi0zLTEtMS0yOTgzNTI_94a76ff0-3e95-4ff2-b7b7-2fa919bbe829"
      unitRef="usd">-1049000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc3NjljYjQ4YWJmNjQzMjc5MGE3ODc3NDM2MDNlY2Q0L3RhYmxlcmFuZ2U6Nzc2OWNiNDhhYmY2NDMyNzkwYTc4Nzc0MzYwM2VjZDRfNy0xLTEtMS0yOTgzNTI_8d5aa5cb-7384-4cc5-ac75-14daf983050b"
      unitRef="usd">-6000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc3NjljYjQ4YWJmNjQzMjc5MGE3ODc3NDM2MDNlY2Q0L3RhYmxlcmFuZ2U6Nzc2OWNiNDhhYmY2NDMyNzkwYTc4Nzc0MzYwM2VjZDRfNy0zLTEtMS0yOTgzNTI_4e9ee94f-b49f-4c67-9fb8-2f8546112fa7"
      unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:GainLossOnInvestments
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc3NjljYjQ4YWJmNjQzMjc5MGE3ODc3NDM2MDNlY2Q0L3RhYmxlcmFuZ2U6Nzc2OWNiNDhhYmY2NDMyNzkwYTc4Nzc0MzYwM2VjZDRfOC0xLTEtMS0yOTgzNTI_bbfa2a1f-0e2e-4837-bea6-44e5d86fa76b"
      unitRef="usd">673000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc3NjljYjQ4YWJmNjQzMjc5MGE3ODc3NDM2MDNlY2Q0L3RhYmxlcmFuZ2U6Nzc2OWNiNDhhYmY2NDMyNzkwYTc4Nzc0MzYwM2VjZDRfOC0zLTEtMS0yOTgzNTI_bbda7f9f-8fae-4172-8ab5-02223bd90730"
      unitRef="usd">1666000</us-gaap:GainLossOnInvestments>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RleHRyZWdpb246MTNjNDlkMDNiOGEzNGZiZThmNjAzMGExNGVkM2M2YzJfOTE2_1afd2dba-1dde-4eae-8a95-1541b66dc21a">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense consists of the following (in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.302%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Three Months Ended&lt;br/&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest expense on related-party notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization of related-party notes discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(29,816)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(8,491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc4NGJhYTU2YWExMzQ2MjViY2RjNmZjZjJhMTNkYTMyL3RhYmxlcmFuZ2U6Nzg0YmFhNTZhYTEzNDYyNWJjZGM2ZmNmMmExM2RhMzJfNC0xLTEtMS0yOTgzNTI_203938cb-5007-4a52-8888-b9acde5a5b7d"
      unitRef="usd">18260000</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc4NGJhYTU2YWExMzQ2MjViY2RjNmZjZjJhMTNkYTMyL3RhYmxlcmFuZ2U6Nzg0YmFhNTZhYTEzNDYyNWJjZGM2ZmNmMmExM2RhMzJfNC0zLTEtMS0yOTgzNTI_15773bde-f3e5-436d-9b84-2622f0a5a92c"
      unitRef="usd">8101000</us-gaap:InterestExpenseRelatedParty>
    <ibrx:AmortizationOfDebtDiscountPremiumRelatedParty
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc4NGJhYTU2YWExMzQ2MjViY2RjNmZjZjJhMTNkYTMyL3RhYmxlcmFuZ2U6Nzg0YmFhNTZhYTEzNDYyNWJjZGM2ZmNmMmExM2RhMzJfNS0xLTEtMS0yOTgzNTI_32114311-badd-4ff0-892b-337e13444182"
      unitRef="usd">11536000</ibrx:AmortizationOfDebtDiscountPremiumRelatedParty>
    <ibrx:AmortizationOfDebtDiscountPremiumRelatedParty
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc4NGJhYTU2YWExMzQ2MjViY2RjNmZjZjJhMTNkYTMyL3RhYmxlcmFuZ2U6Nzg0YmFhNTZhYTEzNDYyNWJjZGM2ZmNmMmExM2RhMzJfNS0zLTEtMS0yOTgzNTI_9bef5756-69cb-4740-9fb1-e03bb2bad6f1"
      unitRef="usd">370000</ibrx:AmortizationOfDebtDiscountPremiumRelatedParty>
    <us-gaap:InterestExpenseOther
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc4NGJhYTU2YWExMzQ2MjViY2RjNmZjZjJhMTNkYTMyL3RhYmxlcmFuZ2U6Nzg0YmFhNTZhYTEzNDYyNWJjZGM2ZmNmMmExM2RhMzJfNi0xLTEtMS0yOTgzNTI_bc370ebe-4760-45f5-abfe-9dcc01a0268e"
      unitRef="usd">20000</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc4NGJhYTU2YWExMzQ2MjViY2RjNmZjZjJhMTNkYTMyL3RhYmxlcmFuZ2U6Nzg0YmFhNTZhYTEzNDYyNWJjZGM2ZmNmMmExM2RhMzJfNi0zLTEtMS0yOTgzNTI_307bafa2-f59c-443d-a567-a26a1ec5c340"
      unitRef="usd">20000</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpense
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc4NGJhYTU2YWExMzQ2MjViY2RjNmZjZjJhMTNkYTMyL3RhYmxlcmFuZ2U6Nzg0YmFhNTZhYTEzNDYyNWJjZGM2ZmNmMmExM2RhMzJfNy0xLTEtMS0yOTgzNTI_922ea20b-4779-43d4-9d44-604e3321dce8"
      unitRef="usd">29816000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80My9mcmFnOjEzYzQ5ZDAzYjhhMzRmYmU4ZjYwMzBhMTRlZDNjNmMyL3RhYmxlOjc4NGJhYTU2YWExMzQ2MjViY2RjNmZjZjJhMTNkYTMyL3RhYmxlcmFuZ2U6Nzg0YmFhNTZhYTEzNDYyNWJjZGM2ZmNmMmExM2RhMzJfNy0zLTEtMS0yOTgzNTI_afa8eb6d-7825-49c8-94b4-8172a774fc7b"
      unitRef="usd">8491000</us-gaap:InterestExpense>
    <us-gaap:InvestmentTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RleHRyZWdpb246ZThmMjMzMzg3MDVmNDM2NzkzMTYwYTk0NTYwM2RiYmNfOTQw_faaf1fb3-0ac7-4bf8-ab0f-851a54a8e66a">Financial Instruments&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31,&#160;2023, the weighted-average remaining contractual life, amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31,&#160;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;Unrealized &lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;Unrealized &lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2022, the weighted-average remaining contractual life, amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31,&#160;2023, 14 of the securities were in an unrealized loss position. Accumulated unrealized losses on marketable debt securities that have been in a continuous loss position for less than 12&#160;months and more than 12&#160;months were as follows (in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;March&#160;31,&#160;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;More than 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;More than 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We held investments in marketable equity securities with readily determinable fair values of $2.6&#160;million and $2.5&#160;million as of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively. Unrealized gains recorded on these securities totaled $0.1&#160;million and $1.4&#160;million for the three&#160;months&#160;ended March&#160;31,&#160;2023 and 2022, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;interest and investment income, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RleHRyZWdpb246ZThmMjMzMzg3MDVmNDM2NzkzMTYwYTk0NTYwM2RiYmNfOTQx_8e0eb086-619a-4084-9faf-e6a9cf27922a">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31,&#160;2023, the weighted-average remaining contractual life, amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31,&#160;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;Unrealized &lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;Unrealized &lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2022, the weighted-average remaining contractual life, amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod
      contextRef="i0b2b8940d45e44b5b593540d8f42fb87_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfNi0xLTEtMS0yOTgzNTI_ff720f91-fbbd-4ea3-90ef-bb47d29d936e">P2Y</ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i38d33d35c4f340d094daa523ef91b3a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfNi0zLTEtMS0yOTgzNTI_dde3eaed-d00a-4f7e-8424-95449d7fc8d0"
      unitRef="usd">107000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i38d33d35c4f340d094daa523ef91b3a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfNi01LTEtMS0yOTgzNTI_93c093b9-e0b8-461b-9b34-c8dcfa82af61"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i38d33d35c4f340d094daa523ef91b3a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfNi03LTEtMS0yOTgzNTI_471df32f-d27f-4687-9a58-bfda3ed024b0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i38d33d35c4f340d094daa523ef91b3a4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfNi05LTEtMS0yOTgzNTI_657b466d-24a5-45ae-bb72-1657c8a3da4f"
      unitRef="usd">107000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i93ed60d3f2964554accd7342f72a2587_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfNy0zLTEtMS0yOTgzNTI_c4d77eff-9d9a-4427-baa1-dccb4c4553f6"
      unitRef="usd">39000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i93ed60d3f2964554accd7342f72a2587_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfNy01LTEtMS0yOTgzNTI_b61afb71-1643-4b29-8bfa-369c1b76266b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i93ed60d3f2964554accd7342f72a2587_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfNy03LTEtMS0yOTgzNTI_44f5354b-0f5c-4998-a6aa-d4f97202321c"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i93ed60d3f2964554accd7342f72a2587_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfNy05LTEtMS0yOTgzNTI_c773e5dd-bfbd-4faf-8247-d4b6482457bc"
      unitRef="usd">37000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1d0dcfca4e8b4f1d959f8fc7308c7a47_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfOC0zLTEtMS0yOTgzNTI_ca996de9-6577-4795-a996-3f45053004ad"
      unitRef="usd">146000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1d0dcfca4e8b4f1d959f8fc7308c7a47_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfOC01LTEtMS0yOTgzNTI_0a3ab497-99b6-423f-96e1-5522fb034bc6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1d0dcfca4e8b4f1d959f8fc7308c7a47_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfOC03LTEtMS0yOTgzNTI_500e720a-3b80-4ea5-83e2-5e2b29c7484a"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1d0dcfca4e8b4f1d959f8fc7308c7a47_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfOC05LTEtMS0yOTgzNTI_d1b7ec60-5975-4d99-9617-7a255fe90efe"
      unitRef="usd">144000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod
      contextRef="ib572239e8f7a47589f3771ddf0d4f463_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfMTAtMS0xLTEtMjk4MzUy_79d78486-2830-4724-898d-86cb13332bfe">P0Y3M18D</ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9b9a73d45ec54296b71bec23a3b54530_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfMTAtMy0xLTEtMjk4MzUy_4e36826b-378f-4abe-a4db-001aa6c47a97"
      unitRef="usd">902000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9b9a73d45ec54296b71bec23a3b54530_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfMTAtNS0xLTEtMjk4MzUy_d90ed13a-61d3-4045-96ac-ea468aebd690"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9b9a73d45ec54296b71bec23a3b54530_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfMTAtNy0xLTEtMjk4MzUy_25c4fab2-4863-4809-9e1d-6979362e94fe"
      unitRef="usd">82000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9b9a73d45ec54296b71bec23a3b54530_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfMTAtOS0xLTEtMjk4MzUy_6c56ae35-19b8-4ee6-ad20-99c1b4b40b63"
      unitRef="usd">820000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfMTItMy0xLTEtMjk4MzUy_c26bb9a4-0658-48e1-80e8-edc96b876428"
      unitRef="usd">1048000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfMTItNS0xLTEtMjk4MzUy_4692a3ec-8ace-40f2-be12-53cb31dddfba"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfMTItNy0xLTEtMjk4MzUy_6b8155ef-64bc-43d6-9e77-93f670d22469"
      unitRef="usd">84000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmFhZWU1YWFkZjU0ZjQ4OGM4MWM2MWI2YWRkYTgyZTIwL3RhYmxlcmFuZ2U6YWFlZTVhYWRmNTRmNDg4YzgxYzYxYjZhZGRhODJlMjBfMTItOS0xLTEtMjk4MzUy_3191dd6c-9856-44b7-80da-ea6998ea1070"
      unitRef="usd">964000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iad866414f696494880846815781be54d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfNi0zLTEtMS0yOTgzNTI_d79b8f1a-207d-4396-a508-349547b15bb8"
      unitRef="usd">38000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iad866414f696494880846815781be54d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfNi01LTEtMS0yOTgzNTI_3c4eaa9c-ceed-4ee3-b50d-98e2b5c33434"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iad866414f696494880846815781be54d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfNi03LTEtMS0yOTgzNTI_536479be-3555-4da3-9caa-3d61ee86e03b"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iad866414f696494880846815781be54d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfNi05LTEtMS0yOTgzNTI_080c9002-b74a-4dd1-8902-d4713a28e43f"
      unitRef="usd">36000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod
      contextRef="i7db0daa0756249f385a861fd96f3d99c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfOS0xLTEtMS0yOTgzNTI_a6799d19-1a56-4884-abb0-5f2dc305a1a8">P4Y6M</ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i178b6f6abcac4b7da1c687641370dde6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfOS0zLTEtMS0yOTgzNTI_e77a2cdf-cae6-4cf9-8ade-ee26ea2f5dca"
      unitRef="usd">932000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i178b6f6abcac4b7da1c687641370dde6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfOS01LTEtMS0yOTgzNTI_0d19d6a6-7b9a-4770-83ea-5b1caec24f7a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i178b6f6abcac4b7da1c687641370dde6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfOS03LTEtMS0yOTgzNTI_d48e99a8-e0db-4eda-a4ee-9c98f4586775"
      unitRef="usd">92000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i178b6f6abcac4b7da1c687641370dde6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfOS05LTEtMS0yOTgzNTI_4cca908b-ccb4-49a9-aca2-4f7b169a3147"
      unitRef="usd">840000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfMTEtMy0xLTEtMjk4MzUy_09790500-a9de-4e60-a0ad-382612e998ef"
      unitRef="usd">970000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfMTEtNS0xLTEtMjk4MzUy_287b54a2-d369-46df-9ad8-5e2211034261"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfMTEtNy0xLTEtMjk4MzUy_ba5bde5a-3a52-4c45-a584-d10dfb61fc90"
      unitRef="usd">94000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOjcxZDJmMDEwOTJiMjQ4MTNiODhmYjRkMjAzNzFlZTIyL3RhYmxlcmFuZ2U6NzFkMmYwMTA5MmIyNDgxM2I4OGZiNGQyMDM3MWVlMjJfMTEtOS0xLTEtMjk4MzUy_7e623741-ee9d-493f-8267-a9dc4bd3df77"
      unitRef="usd">876000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RleHRyZWdpb246ZThmMjMzMzg3MDVmNDM2NzkzMTYwYTk0NTYwM2RiYmNfNTcw_956ceec9-62a4-46d1-bb61-0e0591244dc1"
      unitRef="security">14</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RleHRyZWdpb246ZThmMjMzMzg3MDVmNDM2NzkzMTYwYTk0NTYwM2RiYmNfOTQy_d810ff4b-a5c7-4df7-9342-bf089fe3fa53">Accumulated unrealized losses on marketable debt securities that have been in a continuous loss position for less than 12&#160;months and more than 12&#160;months were as follows (in&#160;thousands): &lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;March&#160;31,&#160;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;More than 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;More than 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="iea925c85eab4423786f1fbcb3163e30e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfNi0xLTEtMS0yOTgzNTI_4f1841de-fa55-4acd-8090-002f909e263f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="iea925c85eab4423786f1fbcb3163e30e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfNi0zLTEtMS0yOTgzNTI_2462cd57-addb-4e4e-af2e-6a9033d6c78e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="iea925c85eab4423786f1fbcb3163e30e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfNi01LTEtMS0yOTgzNTI_790d9671-7d22-4a27-b6e3-50f0195144b9"
      unitRef="usd">37000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="iea925c85eab4423786f1fbcb3163e30e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfNi03LTEtMS0yOTgzNTI_d461dd53-6103-4aac-b4c8-d679935eaf9b"
      unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="iecca882de63d47999c4cdc060161db0b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfNy0xLTEtMS0yOTgzNTI_d6cad31f-e649-4bac-ae81-6668af4fbfac"
      unitRef="usd">581000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="iecca882de63d47999c4cdc060161db0b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfNy0zLTEtMS0yOTgzNTI_d55874dc-f358-43cc-bd48-13ec747b97b7"
      unitRef="usd">58000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="iecca882de63d47999c4cdc060161db0b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfNy01LTEtMS0yOTgzNTI_d7d63929-5589-478a-a13b-ce4cc9dcbd15"
      unitRef="usd">346000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="iecca882de63d47999c4cdc060161db0b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfNy03LTEtMS0yOTgzNTI_8a1b7378-2eaa-40f0-a88a-bb7c79ef1243"
      unitRef="usd">24000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfOC0xLTEtMS0yOTgzNTI_ffce0c11-6a16-43f0-aa2a-30e934de82ea"
      unitRef="usd">581000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfOC0zLTEtMS0yOTgzNTI_a3334d00-9452-432c-abab-2be0c703efad"
      unitRef="usd">58000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfOC01LTEtMS0yOTgzNTI_bc480027-e473-4199-85b7-25d94df560b9"
      unitRef="usd">383000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmUxZGRlOTE3ZTA5OTRmYmY4ZjJmY2ExOTk2MTAyMDAzL3RhYmxlcmFuZ2U6ZTFkZGU5MTdlMDk5NGZiZjhmMmZjYTE5OTYxMDIwMDNfOC03LTEtMS0yOTgzNTI_b83852bb-81f0-4495-9def-e4c762c2f830"
      unitRef="usd">26000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ia7abc0bfb0d34a659f0c1f9d70a91b5e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNS0xLTEtMS0yOTgzNTI_3a37eac5-9856-46c1-8abc-81766ac40988"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ia7abc0bfb0d34a659f0c1f9d70a91b5e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNS0zLTEtMS0yOTgzNTI_36cee297-4112-46c0-b76c-1ad2f434465e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ia7abc0bfb0d34a659f0c1f9d70a91b5e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNS01LTEtMS0yOTgzNTI_7c0c12b3-3efe-4d1f-8609-6069a70cf8cc"
      unitRef="usd">36000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ia7abc0bfb0d34a659f0c1f9d70a91b5e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNS03LTEtMS0yOTgzNTI_37203de5-805e-4457-87ff-48967506c894"
      unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i94255247204f487f8a5e6a7b45fd5f53_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNi0xLTEtMS0yOTgzNTI_58199f17-3423-4c1c-8b95-9ef17700e344"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i94255247204f487f8a5e6a7b45fd5f53_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNi0zLTEtMS0yOTgzNTI_97eb5c4b-b9d6-4614-84a5-7ca73d419185"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i94255247204f487f8a5e6a7b45fd5f53_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNi01LTEtMS0yOTgzNTI_9e8e4ce3-9298-4a02-ac40-6ab9caec2e87"
      unitRef="usd">840000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i94255247204f487f8a5e6a7b45fd5f53_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNi03LTEtMS0yOTgzNTI_c9b741d5-27bc-4c4e-bfb8-98fecc242e4c"
      unitRef="usd">92000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNy0xLTEtMS0yOTgzNTI_5b761584-10e2-4e0d-9bed-66f2d1ae0fbd"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNy0zLTEtMS0yOTgzNTI_7c39eb8d-53d3-4444-99a7-65ecc08b9e47"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNy01LTEtMS0yOTgzNTI_6fa41586-8bfc-4bef-93cf-3a828c9605de"
      unitRef="usd">876000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RhYmxlOmQ2NTBjMzcyZGJkODQ3ODFhYTAwZGZjZGUxN2U1ZjFkL3RhYmxlcmFuZ2U6ZDY1MGMzNzJkYmQ4NDc4MWFhMDBkZmNkZTE3ZTVmMWRfNy03LTEtMS0yOTgzNTI_7a6ca6e8-3d4a-43f9-b960-419eedebb7ec"
      unitRef="usd">94000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:MarketableSecurities
      contextRef="ia818d8707e4c4c8d99bffda3de67924f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RleHRyZWdpb246ZThmMjMzMzg3MDVmNDM2NzkzMTYwYTk0NTYwM2RiYmNfMTA5OTUxMTYyOTA1MQ_3929104d-7ddf-4f02-b76b-b05775c8f21f"
      unitRef="usd">2600000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i37c25c0026ea4ccdbaa0613624232e13_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RleHRyZWdpb246ZThmMjMzMzg3MDVmNDM2NzkzMTYwYTk0NTYwM2RiYmNfMTA5OTUxMTYyOTA1OQ_45a2091f-598b-458e-ac35-cfbdf9730a30"
      unitRef="usd">2500000</us-gaap:MarketableSecurities>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RleHRyZWdpb246ZThmMjMzMzg3MDVmNDM2NzkzMTYwYTk0NTYwM2RiYmNfMTA5OTUxMTYzMDE4NA_f88c31c2-65f0-4997-bd06-b78416babcf7"
      unitRef="usd">100000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF80OS9mcmFnOmU4ZjIzMzM4NzA1ZjQzNjc5MzE2MGE5NDU2MDNkYmJjL3RleHRyZWdpb246ZThmMjMzMzg3MDVmNDM2NzkzMTYwYTk0NTYwM2RiYmNfMTA5OTUxMTYzMDIxNg_f409f054-1600-4b14-9388-c24de19ea788"
      unitRef="usd">1400000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RleHRyZWdpb246NDRhMzUzZTlhNjg1NDQyYmExY2ZhNzhiODI4MDM0OTNfMzE5NA_5a05b249-126d-4cb6-97d1-b7863ac2efc0">Fair Value Measurements&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The three tiers are defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 1&#x2014;Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these products does not entail a significant degree of judgment. Our Level&#160;1 assets consist of bank deposits, money market funds, and marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 2&#x2014;Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level&#160;2 assets consist of corporate debt securities including commercial paper, government-sponsored securities and corporate bonds, as well as foreign municipal securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 3&#x2014;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy. The fair values of financial instruments other than marketable securities and cash and cash equivalents are determined through a combination of management estimates and third-party valuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recurring Valuations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities measured at fair value on a recurring basis are summarized below (in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="24" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="24" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(Unaudited) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;88,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Related-party convertible note payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;104,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Liabilities at fair value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:94.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of March&#160;31,&#160;2023, the Level&#160;2 measurements include $15.0&#160;million in U.S. government agency securities with original maturities of less than 90&#160;days. As of December&#160;31,&#160;2022, the Level&#160;2 measurements include $32.0&#160;million in U.S. government agency securities and $8.8&#160;million in corporate debt securities with original maturities of less than 90&#160;days.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:94.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;As of March&#160;31,&#160;2023, the company has a related-party convertible note payable with a principal amount of $30.0&#160;million, which is accounted for under the ASC&#160;825-10-15-4 FVO election. Under the FVO election, the financial instrument is initially measured at its issue-date estimated fair value and subsequently re-measured at estimated fair value on a recurring basis at each reporting period date. The company&#x2019;s other related-party notes are not accounted for under the fair value election. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Note&#160;&lt;/a&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;9&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;, Related-Party Debt, for further information. The estimated fair value of the convertible note was computed using a discounted cash flow method with the following unobservable assumptions:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected market yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount factor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.98&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:94.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Third-Party Warrant Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;December 2022 Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In connection with the December&#160;12, 2022 registered direct offering of common stock, the company issued 9,090,909 warrants (December&#160;2022 Warrants). The warrants were classified as a liability at their fair value upon the issuance. As of March&#160;31,&#160;2023, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercise price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$6.60&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected average volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;129.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The change in the carrying amount of the December&#160;2022 Warrants was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Beginning fair value, at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOmUxNmRiNTMwMWViYTRhNmY4NmMxNTNhYjJhNjhiMWIwL3RhYmxlcmFuZ2U6ZTE2ZGI1MzAxZWJhNGE2Zjg2YzE1M2FiMmE2OGIxYjBfNS0wLTEtMS0zMTA3NzY_2350ba70-1f49-4ea5-8303-63ba7471fe59"&gt;Change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,818)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ending fair value, at March&#160;31,&#160;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;February 2023 Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In connection with the February&#160;15, 2023 registered direct offering of common stock, the company issued 14,072,615 warrants (February&#160;2023&#160;Warrants). The warrants were classified as a liability at its fair value upon the issuance. As of March&#160;31,&#160;2023, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following dates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31,&#160;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance Date&lt;br/&gt;February 15, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercise price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$4.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$4.26&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected average volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Changes in the carrying amount of the February 2023 Warrants were as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value at the issuance date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjQ1NjRiYjg3OWY4MDRmZTc5NzBhNDg1YWUzNmI0YWZiL3RhYmxlcmFuZ2U6NDU2NGJiODc5ZjgwNGZlNzk3MGE0ODVhZTM2YjRhZmJfNS0wLTEtMS0zMzA4Nzg_31727132-f847-41a1-942b-fae5179a937e"&gt;Change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ending fair value, at March&#160;31,&#160;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nonrecurring Valuations&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We measured the fair value of the fixed-rate promissory notes and variable-rate promissory notes before and after amendments that were entered on August&#160;31,&#160;2022, as they were accounted for under the debt extinguishment accounting model. We used discounted cash flow analyses for promissory notes without a holder conversion option and a binomial lattice convertible note model for the fixed-rate promissory notes with a holder conversion option. Since certain of the factors analyzed are considered to be unobservable inputs, both the discounted cash flow model and the lattice model are considered to be a Level&#160;3 valuation. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&lt;/a&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&#160;&lt;/a&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;9&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Related-Party Debt,&lt;/span&gt; for additional information.</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RleHRyZWdpb246NDRhMzUzZTlhNjg1NDQyYmExY2ZhNzhiODI4MDM0OTNfMzE5NQ_2210acc0-606b-4fe6-9e03-f83420762873">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The three tiers are defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 1&#x2014;Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these products does not entail a significant degree of judgment. Our Level&#160;1 assets consist of bank deposits, money market funds, and marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 2&#x2014;Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level&#160;2 assets consist of corporate debt securities including commercial paper, government-sponsored securities and corporate bonds, as well as foreign municipal securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 3&#x2014;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.&lt;/span&gt;&lt;/div&gt;We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy. The fair values of financial instruments other than marketable securities and cash and cash equivalents are determined through a combination of management estimates and third-party valuations.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RleHRyZWdpb246NDRhMzUzZTlhNjg1NDQyYmExY2ZhNzhiODI4MDM0OTNfMzE5Ng_cc4f71fc-5401-4275-a05b-69c623775d60">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities measured at fair value on a recurring basis are summarized below (in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="24" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="24" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(Unaudited) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;88,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Related-party convertible note payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;104,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Liabilities at fair value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:94.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of March&#160;31,&#160;2023, the Level&#160;2 measurements include $15.0&#160;million in U.S. government agency securities with original maturities of less than 90&#160;days. As of December&#160;31,&#160;2022, the Level&#160;2 measurements include $32.0&#160;million in U.S. government agency securities and $8.8&#160;million in corporate debt securities with original maturities of less than 90&#160;days.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:94.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;As of March&#160;31,&#160;2023, the company has a related-party convertible note payable with a principal amount of $30.0&#160;million, which is accounted for under the ASC&#160;825-10-15-4 FVO election. Under the FVO election, the financial instrument is initially measured at its issue-date estimated fair value and subsequently re-measured at estimated fair value on a recurring basis at each reporting period date. The company&#x2019;s other related-party notes are not accounted for under the fair value election. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Note&#160;&lt;/a&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;9&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;, Related-Party Debt, for further information. The estimated fair value of the convertible note was computed using a discounted cash flow method with the following unobservable assumptions:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected market yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount factor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.98&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:94.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Third-Party Warrant Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;December 2022 Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In connection with the December&#160;12, 2022 registered direct offering of common stock, the company issued 9,090,909 warrants (December&#160;2022 Warrants). The warrants were classified as a liability at their fair value upon the issuance. As of March&#160;31,&#160;2023, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercise price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$6.60&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected average volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;129.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The change in the carrying amount of the December&#160;2022 Warrants was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Beginning fair value, at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOmUxNmRiNTMwMWViYTRhNmY4NmMxNTNhYjJhNjhiMWIwL3RhYmxlcmFuZ2U6ZTE2ZGI1MzAxZWJhNGE2Zjg2YzE1M2FiMmE2OGIxYjBfNS0wLTEtMS0zMTA3NzY_2350ba70-1f49-4ea5-8303-63ba7471fe59"&gt;Change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,818)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ending fair value, at March&#160;31,&#160;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;February 2023 Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In connection with the February&#160;15, 2023 registered direct offering of common stock, the company issued 14,072,615 warrants (February&#160;2023&#160;Warrants). The warrants were classified as a liability at its fair value upon the issuance. As of March&#160;31,&#160;2023, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following dates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March&#160;31,&#160;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance Date&lt;br/&gt;February 15, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercise price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$4.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$4.26&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected average volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Changes in the carrying amount of the February 2023 Warrants were as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value at the issuance date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjQ1NjRiYjg3OWY4MDRmZTc5NzBhNDg1YWUzNmI0YWZiL3RhYmxlcmFuZ2U6NDU2NGJiODc5ZjgwNGZlNzk3MGE0ODVhZTM2YjRhZmJfNS0wLTEtMS0zMzA4Nzg_31727132-f847-41a1-942b-fae5179a937e"&gt;Change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ending fair value, at March&#160;31,&#160;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i03762b77d7b4408594a116ef19d68f4d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfNi0xLTEtMS0yOTgzNTI_21f4e585-3cc5-47bc-a50b-ba449f34abf1"
      unitRef="usd">88481000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaf88dacf0a484cb8938868ce11e3fd93_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfNi00LTEtMS0yOTgzNTI_0ccc80d5-521e-4bd8-8731-226135463a9a"
      unitRef="usd">73487000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6edc71b525cb40e5a5d6fb007bb51c16_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfNi02LTEtMS0yOTgzNTI_a34751c4-2602-4dca-b81e-ab2025000226"
      unitRef="usd">14994000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia015c55c47d246e6b83da57fa54d9457_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfNi04LTEtMS0yOTgzNTI_d9d80d01-745b-4fd7-b1db-180bea06b918"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i268f2b405ec94f05a3e088310fef2a41_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfNy0xLTEtMS0yOTgzNTI_86ffc6bd-4b4c-442d-bec3-4ef7b5ff74ae"
      unitRef="usd">2643000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5d9bd30014c24311a412cab8f1e6736b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfNy00LTEtMS0yOTgzNTI_26049632-f900-442a-a8d7-39da5be76dea"
      unitRef="usd">2643000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3e8a0351256343eeb4cc0af08ac1a51d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfNy02LTEtMS0yOTgzNTI_ac8e5dd7-ce07-481e-b436-daaa38739213"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i53ab60edafa6478689087569daf40626_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfNy04LTEtMS0yOTgzNTI_4114adee-6aaf-436f-9df9-028a5567e562"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2bd58f7537dc4e4f8fe02f6ad46a9783_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfOS0xLTEtMS0yOTgzNTI_74659b32-9d3d-4dec-97ac-0d19ebe550c8"
      unitRef="usd">107000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7f54811c3bb74c6fbfba10a31850e736_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfOS00LTEtMS0yOTgzNTI_994d9b72-fe76-4fd1-8370-4930a5cf2ec0"
      unitRef="usd">107000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9102c7f1073b4a35b9194887f3407199_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfOS02LTEtMS0yOTgzNTI_c512dab9-59f9-49d9-a771-168f5c3e487f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i14d57b1d76d54551b3b3e206ffde3432_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfOS04LTEtMS0yOTgzNTI_2f18f773-b826-43f8-8651-6362ba88357c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4dee1612809b472b83659b4a2b02d81b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTAtMS0xLTEtMjk4MzUy_b352e9d3-0895-4940-85a1-7f6a54eac901"
      unitRef="usd">37000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i104551fa9a6e4d0db14a884d59a96b54_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTAtNC0xLTEtMjk4MzUy_8bace789-32c6-4003-9e9b-f3d3f3af49f2"
      unitRef="usd">37000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ice4416a2800b4d009acab3013a489ab7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTAtNi0xLTEtMjk4MzUy_72bc4952-930c-4d42-abef-e23f17ca7e68"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i83982f7c2fc54aa7a359a7a7d975aff2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTAtOC0xLTEtMjk4MzUy_5c17e4c2-b74a-41a5-86e1-07951d0534e6"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iec99a9e278b242918d95bceb26bbdeec_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTItMS0xLTEtMjk4MzUy_1a40b5d7-fa4e-4a62-80f3-f968857c4b29"
      unitRef="usd">820000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icf5a9b13f35d422fa1732caa34e706df_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTItNC0xLTEtMjk4MzUy_8c337bbf-7b48-40a3-b38d-c34288f5b86d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i18b9e33de5fb420f85ada2e2f7aecc07_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTItNi0xLTEtMjk4MzUy_00d09398-3e28-4e4c-bf31-2fc3b0901d1d"
      unitRef="usd">820000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i16979a35fa1d40b997739a4cb809e6f7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTItOC0xLTEtMjk4MzUy_67141cb9-b086-4fa2-a30c-cf10b3165224"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i331682550ab14aec904426036c3b2a64_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTMtMS0xLTEtMjk4MzUy_a38f0912-9039-4976-b19b-61673ed6b0c4"
      unitRef="usd">92088000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ief94290369fc4061b4a36705889940e8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTMtNC0xLTEtMjk4MzUy_b18f7ef6-7089-4c0d-9e2a-bce314ea3ae1"
      unitRef="usd">76274000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i89f3b040139a4ffeb38a1cd82447d958_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTMtNi0xLTEtMjk4MzUy_b3028118-23a3-4e04-9210-cf69a0521aad"
      unitRef="usd">15814000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibe21c408c60145f1b9446e214b886786_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTMtOC0xLTEtMjk4MzUy_73471f57-ba8c-4b52-985d-aa5c0fa4959d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6b47701466154187b9f13a27115955bf_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTYtMS0xLTEtMzIxNzMz_8acf8667-bb35-4339-9a20-64915668a2ad"
      unitRef="usd">29850000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia28a5b94bbd2402daf1696b7e83ff97d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTYtNC0xLTEtMzIxNzMz_42a75a2d-11a4-474b-90b3-76630c8f2b11"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7436b01d201048599ef97748571d8dbe_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTYtNi0xLTEtMzIxNzMz_ecd36d7c-bfc0-4a1e-a8ef-bcbcca40bf95"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1038882c13304367a352a1ea0d5e9430_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTYtOC0xLTEtMzIxNzMz_98aa36ca-f2b8-43e2-99b0-5eaea10e4466"
      unitRef="usd">29850000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if9b73b9076d14e77bd7f75276c4a8d58_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTYtMS0xLTEtMjk4MzUy_2c14cb7d-52bf-4a5e-8a2a-59999944d35b"
      unitRef="usd">20000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i946cc463480045ae80cefa68e6b23ca8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTYtNC0xLTEtMjk4MzUy_70c11131-ab97-4e98-95ca-da84fbc8f104"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib6901e0e7cfd4bf4bd21eb35ec6aa8f0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTYtNi0xLTEtMjk4MzUy_8c3c15b7-9a16-49dc-9698-8c4500062009"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3f6382b087284b0ab540c7a4cd9db9da_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTYtOC0xLTEtMjk4MzUy_7e2615e1-6afe-43a7-9989-82d74f53a689"
      unitRef="usd">20000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2d1b12230e8f4233a449b44aa8b89dae_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTgtMS0xLTEtMjk4MzUy_0023f7f3-6b5d-4be3-a591-73cb01b0e739"
      unitRef="usd">17780000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i075d1102c0894f7aaf61aea36c69248e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTgtNC0xLTEtMjk4MzUy_cb303295-b503-4b3b-9310-20b578291f6f"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3a21a545f0c4436c9afb3e11ec80f767_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTgtNi0xLTEtMjk4MzUy_3da7f292-07e9-488c-bbac-76d8f8c8c052"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia5143b8cbe5a4e8990bf3e2deb701bef_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTgtOC0xLTEtMjk4MzUy_d1efbb40-b802-4afd-9553-cfd00b6add42"
      unitRef="usd">17780000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i331682550ab14aec904426036c3b2a64_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTktMS0xLTEtMjk4MzUy_49db4b1a-fba6-4529-8bbc-c6e5ca57b01d"
      unitRef="usd">47650000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ief94290369fc4061b4a36705889940e8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTktNC0xLTEtMjk4MzUy_89c12cb2-6855-4983-ac2d-b309a2ff9efd"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i89f3b040139a4ffeb38a1cd82447d958_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTktNi0xLTEtMjk4MzUy_84fd48b5-902a-4863-8564-566288e81f42"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ibe21c408c60145f1b9446e214b886786_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjFkYjQwMmEyNDUxYTRkNzhiMjE2MDUxMjc0NzJkNjhiL3RhYmxlcmFuZ2U6MWRiNDAyYTI0NTFhNGQ3OGIyMTYwNTEyNzQ3MmQ2OGJfMTktOC0xLTEtMjk4MzUy_c26cf239-2324-463d-b3cd-a6f665523226"
      unitRef="usd">47650000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaa82585cc76945718fa4c122a0abdf22_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfNS0xLTEtMS0yOTgzNTI_a30b5af5-3d62-4521-aa30-e89fbd883291"
      unitRef="usd">104641000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i34465ea1764e409786a6bf7a192ee52a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfNS00LTEtMS0yOTgzNTI_35a021bb-bf8f-46bf-b92e-051bf29ecee0"
      unitRef="usd">63860000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6711f0d932ba4e6a92c92baecc798ffe_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfNS02LTEtMS0yOTgzNTI_6e418c26-ae31-4de8-8ee7-c8c7fbd0de56"
      unitRef="usd">40781000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia9024e16e44b4b6a926b58cb4aec8d8f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfNS04LTEtMS0yOTgzNTI_8e8b3fe6-4451-4427-a536-0a73ece62136"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iadecc9749ad74d06bbf65eca3773b162_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfNi0xLTEtMS0yOTgzNTI_f6e582c7-301b-4167-94c6-3f7e91dede5c"
      unitRef="usd">2507000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie7d4c869961845049a837ecf93a7d2d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfNi00LTEtMS0yOTgzNTI_699e4181-60d2-4f8c-845a-da9561112e99"
      unitRef="usd">2507000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iba5d6bb2adc04bfeb0876c228f393f9b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfNi02LTEtMS0yOTgzNTI_72da1f46-a0f8-4a51-9a2e-d896409466ab"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia81b7b3cbfab49d8abed2fece23c4eb2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfNi04LTEtMS0yOTgzNTI_fde8fd68-dbd5-4e90-8055-e7d803c0e4f7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia6d9de146cd64ddd838411f8d960bb39_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfOS0xLTEtMS0yOTgzNTI_1cfda769-dedc-4aaf-9640-761cf7fdfd0a"
      unitRef="usd">36000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5ef6c543a47549d6ba626e9b621bef9d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfOS00LTEtMS0yOTgzNTI_6b44c6f0-c8ff-4030-b9fa-de8e99c910c2"
      unitRef="usd">36000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i609d1640d799407fa25e8d7bb019d122_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfOS02LTEtMS0yOTgzNTI_6dd02e4d-b8f5-4e5a-b9c6-8a0f5a9614a7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia99b37fb3a1e4839964854bb8c5cd0a6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfOS04LTEtMS0yOTgzNTI_d16e5d30-3669-4465-8aba-a26442b0f905"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6cfcae1f8c96411fa01b9df7155a5e1b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTEtMS0xLTEtMjk4MzUy_4e1124df-5311-40d8-8381-b15d80e095e4"
      unitRef="usd">840000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icc22baf6a9234b998bdacc85aa2baa32_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTEtNC0xLTEtMjk4MzUy_746ed330-7dc6-4647-886e-9f25bdef241a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ieed74cabe48d445d966192789eaffa46_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTEtNi0xLTEtMjk4MzUy_77b4a6e5-d25b-4e67-9da7-1e639c1b991d"
      unitRef="usd">840000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0e08fabb07e64dc89b54f50eb2cbab9d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTEtOC0xLTEtMjk4MzUy_d82c7ac6-40ce-455b-8a93-a854395a8199"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i89b6ead15154410fbde3c2433bcdd159_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTItMS0xLTEtMjk4MzUy_d9618255-d470-4258-b888-7555865ce5dd"
      unitRef="usd">108024000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7e78df5d936b4e6ea1a77cbeb8c49595_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTItNC0xLTEtMjk4MzUy_0724585c-6ac5-4ecc-b477-67c41ba1d388"
      unitRef="usd">66403000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia279b1b8a68047368e6c50d9ea885c6e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTItNi0xLTEtMjk4MzUy_3a1209bb-539f-48d7-8e4f-ad8480efdcb3"
      unitRef="usd">41621000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i274686603f6a451f837acc17b08d3411_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTItOC0xLTEtMjk4MzUy_3f5f82fc-f845-43d8-8103-28c0cb11af9c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic25536a0d63845739ff43e08195cd5c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTQtMS0xLTEtMjk4MzUy_73bac250-0f03-4a3c-8620-59953538cbf8"
      unitRef="usd">19000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="icef3562f20dc43dfa08930bb1bd2bc36_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTQtNC0xLTEtMjk4MzUy_6a5246bf-c472-4815-be90-94163be013c9"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i544de52cd9194dabb073582a30849b58_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTQtNi0xLTEtMjk4MzUy_5f96d716-4520-4905-97f2-c2a9e9c951b8"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i76b53cde4e3e4322a061ae53a8f05594_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTQtOC0xLTEtMjk4MzUy_a05405ac-7a01-4c48-8d0b-3054adce0a9a"
      unitRef="usd">19000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ifc84a0efc87f46c8aae6c011790df898_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTctMS0xLTEtMzAzMjE4_31e190c1-6ee8-42fd-814c-a10df24f6832"
      unitRef="usd">21636000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iccfd1df580444d909b6b2d6f8f806e7b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTctNC0xLTEtMzAzMjI2_91bfef8a-f313-4088-8442-45d1c1d8c184"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i63ac4d5eb374467ab54634d998aec6f5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTctNi0xLTEtMzAzMjM0_517b0985-fa14-4da8-975c-98ad50bb9e87"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="idcf19f6af9824b52a6d8e4395d10134a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTctOC0xLTEtMzAzMjQy_3a1f3c6d-2405-4560-a55e-4541e1b27448"
      unitRef="usd">21636000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i89b6ead15154410fbde3c2433bcdd159_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTgtMS0xLTEtMzAzMjUw_19a90834-0f38-4b7f-a3c0-e115662628f5"
      unitRef="usd">21655000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7e78df5d936b4e6ea1a77cbeb8c49595_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTgtNC0xLTEtMzAzMjU4_7e660ea3-36cb-44dc-a1d0-928afb8c642f"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia279b1b8a68047368e6c50d9ea885c6e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTgtNi0xLTEtMzAzMjY2_81d19a3c-2ac8-438a-aa08-167fa820b519"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i274686603f6a451f837acc17b08d3411_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjlmZTM4YjQ4MGYwNDQ1YjA4NjhmMjFkMTYzNmM2ZmE0L3RhYmxlcmFuZ2U6OWZlMzhiNDgwZjA0NDViMDg2OGYyMWQxNjM2YzZmYTRfMTgtOC0xLTEtMzAzMjc0_0cf7d338-50aa-4825-978d-cf5bdc902375"
      unitRef="usd">21655000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2c53736371164c6eb06bafd550e0f5fa_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjBjOWNlNWNjMTA0MTQzOTBhYjYwMmIyZWNiZjA3OWNiL3RhYmxlcmFuZ2U6MGM5Y2U1Y2MxMDQxNDM5MGFiNjAyYjJlY2JmMDc5Y2JfMC0xLTEtMS0yOTgzNTIvdGV4dHJlZ2lvbjpmODdiNjk2N2NiZTk0YzYxYmE5ZjVhM2U4ZGQ3YzA1YV8xMDk5NTExNjI4NDc4_955e2ba9-57fa-4d89-818f-edc8e04c9ebf"
      unitRef="usd">15000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i946b4f2294f644bcafcd5f32b36a4b6a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjBjOWNlNWNjMTA0MTQzOTBhYjYwMmIyZWNiZjA3OWNiL3RhYmxlcmFuZ2U6MGM5Y2U1Y2MxMDQxNDM5MGFiNjAyYjJlY2JmMDc5Y2JfMC0xLTEtMS0yOTgzNTIvdGV4dHJlZ2lvbjpmODdiNjk2N2NiZTk0YzYxYmE5ZjVhM2U4ZGQ3YzA1YV8xMDk5NTExNjI4NTky_903a345a-33b1-4ab7-8e6a-8d80251070c9"
      unitRef="usd">32000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2f8683e6989143198ff853a8fc97d338_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjBjOWNlNWNjMTA0MTQzOTBhYjYwMmIyZWNiZjA3OWNiL3RhYmxlcmFuZ2U6MGM5Y2U1Y2MxMDQxNDM5MGFiNjAyYjJlY2JmMDc5Y2JfMC0xLTEtMS0yOTgzNTIvdGV4dHJlZ2lvbjpmODdiNjk2N2NiZTk0YzYxYmE5ZjVhM2U4ZGQ3YzA1YV8xMDk5NTExNjI4NjI4_de747352-0259-46eb-b70e-d2cdc18529ba"
      unitRef="usd">8800000</us-gaap:AssetsFairValueDisclosure>
    <ibrx:RelatedPartyNotesPayable
      contextRef="i4d61f38abc9b467da5b3204da34fab5e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOmU1OTNlZDFjYTM0MTRmYmZhMmQ4NmM2YzZkODUwYjEzL3RhYmxlcmFuZ2U6ZTU5M2VkMWNhMzQxNGZiZmEyZDg2YzZjNmQ4NTBiMTNfMC0xLTEtMS0zMjE4MzgvdGV4dHJlZ2lvbjoyZWVkMTNjYTY4ZDg0OWQyYmUxN2U0ZmNlOGMwMjY0Nl81NDk3NTU4MjE3NDU_28189d53-790e-45e7-93a3-df4f7efc30ac"
      unitRef="usd">30000000</ibrx:RelatedPartyNotesPayable>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i25b2382ccad7475f812c01198c635ee0_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjRkY2EzYjZhZDc0YTQyZDk4ZWUxYzU0NzNlMjQxNjVkL3RhYmxlcmFuZ2U6NGRjYTNiNmFkNzRhNDJkOThlZTFjNTQ3M2UyNDE2NWRfMy0xLTEtMS0zMjQxMzI_cb7ea4d1-d37b-49f8-84ef-6efff2f80f03"
      unitRef="number">0.175</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i650984f3db47470a9f5389b2e032a01a_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjRkY2EzYjZhZDc0YTQyZDk4ZWUxYzU0NzNlMjQxNjVkL3RhYmxlcmFuZ2U6NGRjYTNiNmFkNzRhNDJkOThlZTFjNTQ3M2UyNDE2NWRfNC0xLTEtMS0zMjQxMzI_2b9ae93f-1cf0-4d33-881a-79855a99f8bb"
      unitRef="y">100</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i6f16749c92e842ce81ffb8d9ae2a9c3d_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjRkY2EzYjZhZDc0YTQyZDk4ZWUxYzU0NzNlMjQxNjVkL3RhYmxlcmFuZ2U6NGRjYTNiNmFkNzRhNDJkOThlZTFjNTQ3M2UyNDE2NWRfNS0xLTEtMS0zMjQxMzI_352d08dd-05d7-45b6-bd70-30909f4a53b9"
      unitRef="number">0.98</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i19f26457ccfe499cb0e3bbed35112923_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RleHRyZWdpb246NDRhMzUzZTlhNjg1NDQyYmExY2ZhNzhiODI4MDM0OTNfMTA5OTUxMTYzMzgzNg_2fa3b675-943f-4ae4-94d7-cae244a23c06"
      unitRef="shares">9090909</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ia1191e7cec0f4f78a48f0b7efe88df43_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjk4YTQzNTlkZGY2YzRjNjVhZGVlYjhiZDVkNjM0OWJhL3RhYmxlcmFuZ2U6OThhNDM1OWRkZjZjNGM2NWFkZWViOGJkNWQ2MzQ5YmFfNC0xLTEtMS0zMjQxNTY_3e3dc252-f88a-4d74-b591-aca395a8f0d9"
      unitRef="usdPerShare">6.60</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ib93fecbf92174118bdd72fa5e20ea20e_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjk4YTQzNTlkZGY2YzRjNjVhZGVlYjhiZDVkNjM0OWJhL3RhYmxlcmFuZ2U6OThhNDM1OWRkZjZjNGM2NWFkZWViOGJkNWQ2MzQ5YmFfMy0xLTEtMS0zMjIxMjQ_caa94ce0-ccce-4fe7-929b-fbabb7a8cd40"
      unitRef="y">1700</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i5be77fd9053a42c1821b000e6a63fc53_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjk4YTQzNTlkZGY2YzRjNjVhZGVlYjhiZDVkNjM0OWJhL3RhYmxlcmFuZ2U6OThhNDM1OWRkZjZjNGM2NWFkZWViOGJkNWQ2MzQ5YmFfNC0xLTEtMS0zMjIxMjQ_3a95fbb5-fa29-4f24-88e2-e46526a70a0b"
      unitRef="number">1.293</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i9270094ae41a49ccb211054939e04e29_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjk4YTQzNTlkZGY2YzRjNjVhZGVlYjhiZDVkNjM0OWJhL3RhYmxlcmFuZ2U6OThhNDM1OWRkZjZjNGM2NWFkZWViOGJkNWQ2MzQ5YmFfNS0xLTEtMS0zMjIxMjQ_024e5fa2-07e3-4daf-a76f-6bc21132638c"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="icf8421bdf082438eacb0d8a2bbb510e1_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjk4YTQzNTlkZGY2YzRjNjVhZGVlYjhiZDVkNjM0OWJhL3RhYmxlcmFuZ2U6OThhNDM1OWRkZjZjNGM2NWFkZWViOGJkNWQ2MzQ5YmFfNi0xLTEtMS0zMjIxMjQ_1e057db6-eb97-4370-bce6-2e5664a8d181"
      unitRef="number">0.042</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i6e247e3019ba40cfb87b176aa4e219b6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOmUxNmRiNTMwMWViYTRhNmY4NmMxNTNhYjJhNjhiMWIwL3RhYmxlcmFuZ2U6ZTE2ZGI1MzAxZWJhNGE2Zjg2YzE1M2FiMmE2OGIxYjBfNC0xLTEtMS0zMDg4Njc_ec6813d9-3a17-4950-ad6c-e300702829a8"
      unitRef="usd">21636000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i91d87f21eddb4e8ba52be9c983035646_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOmUxNmRiNTMwMWViYTRhNmY4NmMxNTNhYjJhNjhiMWIwL3RhYmxlcmFuZ2U6ZTE2ZGI1MzAxZWJhNGE2Zjg2YzE1M2FiMmE2OGIxYjBfNS0xLTEtMS0zMDg4Njc_9597c19f-d2e3-4aa7-891f-8004e71b794b"
      unitRef="usd">-15818000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i05ce9f5c06e84394bfde03b091dcbdf4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOmUxNmRiNTMwMWViYTRhNmY4NmMxNTNhYjJhNjhiMWIwL3RhYmxlcmFuZ2U6ZTE2ZGI1MzAxZWJhNGE2Zjg2YzE1M2FiMmE2OGIxYjBfNi0xLTEtMS0zMDg4Njc_01d5d1af-7772-4866-bf88-bacc55505c95"
      unitRef="usd">5818000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ie9e851daf28c4255b2112c4cd9cefdc6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RleHRyZWdpb246NDRhMzUzZTlhNjg1NDQyYmExY2ZhNzhiODI4MDM0OTNfMTA5OTUxMTYzNDUyNQ_790fab1a-1ef6-4319-ac6d-3af6f734447a"
      unitRef="shares">14072615</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i092d7c652fa9476b8e128260ffb7cf55_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjc3NGFiMTQ2YzE3MzRjMTBiMWIyNjRiZGI3MjBiMzZjL3RhYmxlcmFuZ2U6Nzc0YWIxNDZjMTczNGMxMGIxYjI2NGJkYjcyMGIzNmNfNC0xLTEtMS0zMjU3MjA_61a82b25-3b7c-4456-bda8-bb8b8fd95e30"
      unitRef="usdPerShare">4.26</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i4b1c02b83f5d4e588b5e7f5dfe24a69e_I20230215"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjc3NGFiMTQ2YzE3MzRjMTBiMWIyNjRiZGI3MjBiMzZjL3RhYmxlcmFuZ2U6Nzc0YWIxNDZjMTczNGMxMGIxYjI2NGJkYjcyMGIzNmNfMy0zLTEtMS0zMjU3NTk_38eb3e3d-aa9f-41bc-8a75-ec99007043ae"
      unitRef="usdPerShare">4.26</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i18ad3c2a3e4841d3b55094278b55ee00_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjc3NGFiMTQ2YzE3MzRjMTBiMWIyNjRiZGI3MjBiMzZjL3RhYmxlcmFuZ2U6Nzc0YWIxNDZjMTczNGMxMGIxYjI2NGJkYjcyMGIzNmNfNS0xLTEtMS0zMjU3MjA_aaee21e5-871c-48dc-8060-d69c83110591"
      unitRef="y">1900</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="iba41b7496e6d4908952cd0ecb8a9fcec_I20230215"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjc3NGFiMTQ2YzE3MzRjMTBiMWIyNjRiZGI3MjBiMzZjL3RhYmxlcmFuZ2U6Nzc0YWIxNDZjMTczNGMxMGIxYjI2NGJkYjcyMGIzNmNfNC0zLTEtMS0zMjU3NTk_7d1007b5-a7f9-4caa-b631-b9dc53fc4a9c"
      unitRef="y">2000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i8cc76b0fbcf84e109ae61be53b3d16fa_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjc3NGFiMTQ2YzE3MzRjMTBiMWIyNjRiZGI3MjBiMzZjL3RhYmxlcmFuZ2U6Nzc0YWIxNDZjMTczNGMxMGIxYjI2NGJkYjcyMGIzNmNfNi0xLTEtMS0zMjU3MjA_19d5bd6d-9649-4c4e-ad1e-339fcd1a6013"
      unitRef="number">1.278</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ib565990d93cd4919b9ad581d54993133_I20230215"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjc3NGFiMTQ2YzE3MzRjMTBiMWIyNjRiZGI3MjBiMzZjL3RhYmxlcmFuZ2U6Nzc0YWIxNDZjMTczNGMxMGIxYjI2NGJkYjcyMGIzNmNfNS0zLTEtMS0zMjU3NTk_43a1e88e-f38c-4ec9-9f0d-a06b8988014d"
      unitRef="number">0.970</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i5b96511d9e744c5099e21750e0d21d2d_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjc3NGFiMTQ2YzE3MzRjMTBiMWIyNjRiZGI3MjBiMzZjL3RhYmxlcmFuZ2U6Nzc0YWIxNDZjMTczNGMxMGIxYjI2NGJkYjcyMGIzNmNfNy0xLTEtMS0zMjU3MjA_19674086-df6e-4c46-851a-93e8f695511d"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ic3b821833563458f9405084b1ae950db_I20230215"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjc3NGFiMTQ2YzE3MzRjMTBiMWIyNjRiZGI3MjBiMzZjL3RhYmxlcmFuZ2U6Nzc0YWIxNDZjMTczNGMxMGIxYjI2NGJkYjcyMGIzNmNfNi0zLTEtMS0zMjU3NTk_cacc9ca9-3d75-479e-abef-2098cfbf5cd1"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="if5751565e9bc4821bce01dd4188d7302_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjc3NGFiMTQ2YzE3MzRjMTBiMWIyNjRiZGI3MjBiMzZjL3RhYmxlcmFuZ2U6Nzc0YWIxNDZjMTczNGMxMGIxYjI2NGJkYjcyMGIzNmNfOC0xLTEtMS0zMjU3MjA_aba2c5b8-41f5-47e8-838e-62d51228ed3f"
      unitRef="number">0.041</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i17c9c04b377c4dc0a52cd262037cb9ba_I20230215"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjc3NGFiMTQ2YzE3MzRjMTBiMWIyNjRiZGI3MjBiMzZjL3RhYmxlcmFuZ2U6Nzc0YWIxNDZjMTczNGMxMGIxYjI2NGJkYjcyMGIzNmNfNy0zLTEtMS0zMjU3NTk_57ff6b21-b2be-41ef-ac90-bdcf28d09a88"
      unitRef="number">0.046</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ib8bb04bc74374058a2c1efed036ac8cb_I20230215"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjQ1NjRiYjg3OWY4MDRmZTc5NzBhNDg1YWUzNmI0YWZiL3RhYmxlcmFuZ2U6NDU2NGJiODc5ZjgwNGZlNzk3MGE0ODVhZTM2YjRhZmJfNC0xLTEtMS0zMjU4MjI_f88bf806-c818-4f07-9740-2cd21fbca5d8"
      unitRef="usd">23698000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i9c148f91d4ce423f9b310ff8481860bb_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjQ1NjRiYjg3OWY4MDRmZTc5NzBhNDg1YWUzNmI0YWZiL3RhYmxlcmFuZ2U6NDU2NGJiODc5ZjgwNGZlNzk3MGE0ODVhZTM2YjRhZmJfNS0xLTEtMS0zMjU4MjI_5598e54e-c704-4224-b190-3c76a62be24b"
      unitRef="usd">-11736000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i2cd4532b1fc24c0ca2ef81c7e69794c6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81NS9mcmFnOjQ0YTM1M2U5YTY4NTQ0MmJhMWNmYTc4YjgyODAzNDkzL3RhYmxlOjQ1NjRiYjg3OWY4MDRmZTc5NzBhNDg1YWUzNmI0YWZiL3RhYmxlcmFuZ2U6NDU2NGJiODc5ZjgwNGZlNzk3MGE0ODVhZTM2YjRhZmJfNi0xLTEtMS0zMjU4MjI_75bee9bc-3833-4612-abea-3e7dc81732f2"
      unitRef="usd">11962000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfMTIwMTM_180bfdda-e22c-4cad-9084-0c61c2fece5d">Collaboration and License Agreements and Acquisition&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amyris Joint Venture&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December&#160;2021, ImmunityBio and Amyris, Inc. (Amyris) entered into a 50:50 joint venture arrangement and formed a new limited liability company to conduct the business of the joint venture. The purpose of the joint venture is to accelerate commercialization of a next-generation COVID-19 vaccine utilizing an RNA vaccine-platform. As part of the limited liability agreement, Amyris contributed $1.0&#160;million in cash and rights to its license agreement with the Access to Advanced Health Institute (AAHI) for an RNA platform for the field of COVID-19. ImmunityBio contributed $1.0&#160;million in cash and priority access to its manufacturing capacity for the joint venture product. Both parties agreed to enter into a separate manufacturing and supply agreement and a sublicense agreement following the execution of the joint venture agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The joint venture agreement stipulates the initial terms for equal representation in the management of the newly-formed joint venture. The joint venture is managed by a board of directors consisting of four&#160;directors: two appointed by the company and two&#160;appointed by Amyris. Both parties agreed to make additional capital contributions in cash, in proportion to their respective interests, as determined by the board of directors of the joint venture. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We considered the joint venture entity as a VIE and determined that we are not the primary beneficiary of the VIE. In February&#160;2022, we made a cash investment totaling $1.0&#160;million in the joint venture&#x2019;s common stock. We account for our investment in the joint venture using the equity method of accounting, and recorded our 50%&#160;share of the net loss from the joint venture totaling $2.3 million and $0.2 million, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other&#160;income (expense), net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the condensed consolidated statements of operations for the three months ended March&#160;31,&#160;2023 and 2022. Such losses incurred during the three months ended March&#160;31,&#160;2023 were attributed to expenses incurred by us on behalf of the joint venture. We are not obligated to fund the joint venture&#x2019;s potential future losses. As of March&#160;31,&#160;2023, the carrying amount of our equity investment in the joint venture was zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;3M Innovative Properties Company (3M&#160;IPC) and AAHI License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have licensed rights to 3M-052, a synthetic TLR7/8 agonist, 3M-052 formulations and related technology from 3M&#160;IPC and its affiliates and AAHI. In November 2021 we obtained nonexclusive rights in the field of SARS-CoV-2 and in June&#160;2022 we modified those rights and expanded the scope of the license to include (1)&#160;SARS-CoV-2 and other infectious diseases including malaria, HIV, tuberculosis, hookworm and varicella zoster on an exclusive basis in countries other than low- and middle-income countries (LMIC), and (2)&#160;oncology applications, when used in combination with our proprietary technology and/or IL-15 agonists. In consideration for the license, we agreed to make certain periodic license payments, including $2.25&#160;million each year through June 2025, with the June 2022 payment being partially offset by the $0.5&#160;million previously paid under the initial November 2021 license agreement. We have also agreed to make payments upon the achievement of certain regulatory milestone events and tiered royalties ranging from the low to high single-digits as a percentage of net sales. Beginning in April&#160;2026, the annual minimum licensing payment is $1.0&#160;million, which can be credited against any royalty payments due under this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, we made a payment of $1.75&#160;million for the annual license maintenance fee. We expensed $0.4&#160;million for the three&#160;months&#160;ended March&#160;31,&#160;2023, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the condensed consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AAHI License Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, we entered into two&#160;license agreements with AAHI pursuant to which we received a license to certain patents and know-how relating to AAHI&#x2019;s (i)&#160;adjuvant formulations for the treatment, prevention and/or diagnosis of SARS-CoV-2 (the AAHI&#160;Adjuvant Formulation License Agreement) and (ii)&#160;RNA vaccine platform as further described below (the AAHI RNA License Agreement). Under both agreements, we were obligated to pay one-time, non-creditable, non-refundable upfront cash payments totaling $2.0&#160;million. In addition, under the AAHI Adjuvant Formulation License Agreement we owe milestone payments to a total of up to $2.5&#160;million based on the achievement of certain development and regulatory milestones for the first&#160;licensed product and royalties on annual net sales of licensed products on a country-by-country and product-by-product basis of a low-single digit percentage, subject to certain royalty-reduction provisions. No&#160;milestone fees were incurred for the three months ended March&#160;31,&#160;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September&#160;2021, we amended and restated the AAHI RNA License Agreement, pursuant to which AAHI granted us an exclusive, worldwide, sublicensable license to AAHI&#x2019;s rights to an RNA&#160;vaccine platform for the development and commercialization of certain therapeutic, diagnostic or prophylactic products for the prevention, treatment or diagnosis of any indication, other than those subject to pre-existing third-party license grants, including, without limitation, SARS-CoV-2. Pursuant to the terms of the amended and restated AAHI RNA License Agreement, we made a one-time, non-creditable, non-refundable, upfront payment to AAHI of $1.5&#160;million and a license maintenance fee of $3.0&#160;million in June&#160;2022. The company is required to pay license maintenance fees to AAHI of $5.5&#160;million annually from 2023 through 2030. The company may terminate the restated agreement without cause by paying AAHI a $10.0&#160;million one-time early termination fee. In addition, the milestone payments to AAHI based on the achievement of certain development and regulatory milestones for the first&#160;licensed product were amended to a total of up to $4.0&#160;million. We are required to pay royalties on annual net sales of licensed products on a country-by-country and product-by-product basis of a low to mid-single digit percentage. We recorded $0.8&#160;million in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the condensed consolidated statement of operations during the three months ended March&#160;31,&#160;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the license agreements, in May&#160;2021 we also entered into a sponsored research agreement with the AAHI pursuant to which we will fund continued research of at least $2.0&#160;million per year, payable in four&#160;equal quarterly installments each year until May&#160;2024, or such year of earlier termination. No expenses were incurred for the three months ended March&#160;31,&#160;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dunkirk Facility Leasehold Interest&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;14,&#160;2022, we completed the acquisition of a leasehold interest in approximately 409,000 rentable square feet&#160;of current Good Manufacturing Practice (cGMP) ISO Class&#160;5 pharmaceutical manufacturing space in western New&#160;York (the&#160;Dunkirk Facility) from Athenex,&#160;Inc. (the Seller), which we believe will provide us with a state-of-the-art biotech production center that will substantially expand and diversify our manufacturing capacity in the U.S. and ability to scale production associated with certain of our product candidates. The company accounted for the transaction as an asset acquisition because the Dunkirk Facility&#x2019;s integrated set of assets and activities does not meet the definition of a business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total consideration for the acquisition was approximately $40.5&#160;million, including a cash payment of $40.0&#160;million, and transaction costs of approximately $0.5&#160;million. The following table summarizes the fair value of assets acquired as of the acquisition date (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other depreciable assets and prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_43" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note &lt;/a&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_43" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;3&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Statement Details&#x2014;Intangible Assets, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, for further information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the closing of the Dunkirk transaction, the company became the tenant of the Dunkirk Facility under the Fort Schuyler Management Corporation Lease, dated October&#160;1,&#160;2021 and as amended as of the February&#160;14,&#160;2022 closing date (as amended, the Dunkirk Lease), with Fort Schuyler Management Corporation, a not-for-profit corporation affiliated with the State of New York (FSMC) as landlord. The Dunkirk Facility, as well as certain equipment, is owned by FSMC and is leased to us under the Dunkirk Lease. Our annual lease payment will be $2.00 per year&#160;for an initial 10-year term, with an option to renew the lease under substantially the same terms and conditions for an additional 10-year term. As part of the transaction, we assumed certain of the Seller&#x2019;s obligations under various third-party agreements (the Facility Agreements), subject to the terms and conditions of the purchase agreement by and between the company and Seller dated as of January&#160;7,&#160;2022, and committed to spend an aggregate of $1.52&#160;billion on operational expenses during the initial term, and an additional $1.50&#160;billion on operational expenses if we elect to renew the lease for the additional 10-year term. We also committed to hiring 450 employees at the Dunkirk Facility within the first five years of operations, with 300&#160;such employees to be hired within the first 2.5 years of operation. We are eligible for certain sales-tax exemption savings during the development of the Dunkirk Facility, and certain property tax savings over the next 20 years, subject to certain terms and conditions, including performance of certain of the obligations described above. Failure to satisfy the obligations over the lease term may give rise to certain rights and remedies of governmental authorities including, for example, termination of the Dunkirk Lease and other Facility Agreements and potential recoupment of a percentage of the grant funding received by the Seller for construction of the facility and other benefits received, subject to the terms and conditions of the applicable agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although we believe that governmental funding will assist in funding a portion of the further build-out of the Dunkirk Facility, which we estimate to be approximately $8.0&#160;million&#160;to $10.0&#160;million of governmental funding remaining available as of March&#160;31,&#160;2023, there can be no assurance as to the final acceptance and timing of the requests for governmental funding that we submit, and we will need to plan and fund most of the additional build-out of, and purchase additional equipment for, the Dunkirk Facility in connection with our planned full operations. In addition, any future governmental funding will be subject to the eligibility of submitted expenses, as well as our compliance with the obligations that we are subject to pursuant to the agreements with parties regarding the Dunkirk Facility as described above.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i3c353c172ccf4147ac57fe34244f439e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODI2MTU2_93f12651-b79d-4f52-88b6-a648a844c1c1"
      unitRef="usd">1000000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i4a9fa31f8b884ef599ea8e3aa1c58f8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODM4MTU3_753b87a5-cef9-469a-b3b4-8b012a3fe7bf"
      unitRef="usd">1000000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:PaymentsToAcquireInterestInJointVenture
      contextRef="ic8d44b5214644e5e9b815f99ac56eaec_D20220201-20220228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODM5MDM2_a82e3a91-a78b-4786-acdd-675875d4240a"
      unitRef="usd">1000000</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ie5ee1d864d0f40ee97b16088a1116d91_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODM5MTg0_3852c574-cdad-466e-a094-583704a2f6b4"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ice37cb09a6664d4da416332415bda35c_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfMTY0OTI2NzQ3NzI5OA_0f32dc61-daae-4d0d-a28d-a962d23415b0"
      unitRef="usd">-2300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4156a8ceac6342d99ce39177a254d1cf_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfMTA5OTUxMTY2MzQ3MA_04b07dd3-6b4c-4e49-8523-d845a7e2069f"
      unitRef="usd">-200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="ie5ee1d864d0f40ee97b16088a1116d91_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODM5Nzc3_84e73026-2ba9-4408-8f0d-0b954afdeedc"
      unitRef="usd">0</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <ibrx:CollaborationAgreementsPeriodicLicensePayments
      contextRef="iee278c57618e46d09031d4531cc2f979_D20230101-20230331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQwNTg1_dbf0d2f6-3d56-4deb-af77-a0dde47f334c"
      unitRef="usd">2250000</ibrx:CollaborationAgreementsPeriodicLicensePayments>
    <ibrx:CollaborationAgreementsPeriodicLicensePayments
      contextRef="i490e76eedd0c4d68a5d119d4f2a8bf67_D20211101-20211130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQwNjYz_504cc988-4512-4e41-913d-957adce8bba2"
      unitRef="usd">500000</ibrx:CollaborationAgreementsPeriodicLicensePayments>
    <ibrx:CollaborationAgreementsAnnualMinimumLicensingPayment
      contextRef="iee278c57618e46d09031d4531cc2f979_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQwOTgw_425cec53-8285-452c-9899-3290d1d27e25"
      unitRef="usd">1000000</ibrx:CollaborationAgreementsAnnualMinimumLicensingPayment>
    <ibrx:CollaborationAgreementsLicenseMaintenanceFees
      contextRef="ia01f754739eb4399a5ec08bb300b5c9c_I20220630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQxMDk5_e1265cff-b43f-4a21-b36d-c11f5623ef89"
      unitRef="usd">1750000</ibrx:CollaborationAgreementsLicenseMaintenanceFees>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iee278c57618e46d09031d4531cc2f979_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfMTA5OTUxMTY2NDc0NA_9cf2c60f-fd10-4237-9887-c9f3d821915c"
      unitRef="usd">400000</us-gaap:ResearchAndDevelopmentExpense>
    <ibrx:CollaborationAgreementsNonrefundableUpfrontPayment
      contextRef="if7c90fc2a58d48e3bec3d91301b599c7_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQxODM0_73ec91f3-72b2-4477-b3ae-f6eb606160b6"
      unitRef="usd">2000000</ibrx:CollaborationAgreementsNonrefundableUpfrontPayment>
    <ibrx:CollaborationAgreementsMilestonePaymentAggregateMaximum
      contextRef="i717a4e9083794ab9bb82219c0132b1ee_I20220501"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQxOTUy_eed8814c-5358-4382-84a1-1a228890e410"
      unitRef="usd">2500000</ibrx:CollaborationAgreementsMilestonePaymentAggregateMaximum>
    <ibrx:CollaborationAgreementsMilestoneFees
      contextRef="i7c33c2ccc680481ab6ef920d4dfe6fb2_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQyMjUy_e2dd7a4c-1a32-40ae-8357-ea6fba61d497"
      unitRef="usd">0</ibrx:CollaborationAgreementsMilestoneFees>
    <ibrx:CollaborationAgreementsNonrefundableUpfrontPayment
      contextRef="i2177094498de4c7ca93c869ccafa1cd8_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQyOTQ3_332c739d-3a1e-42af-bbec-85607c41c87a"
      unitRef="usd">1500000</ibrx:CollaborationAgreementsNonrefundableUpfrontPayment>
    <ibrx:CollaborationAgreementsLicenseMaintenanceFees
      contextRef="if37fa4000f6b4e8d96490b940efbe768_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODUyOTA2_f1c49a93-e5e7-4843-8d6b-2b3f59d12b84"
      unitRef="usd">3000000</ibrx:CollaborationAgreementsLicenseMaintenanceFees>
    <ibrx:CollaborationAgreementsLicenseMaintenanceFees
      contextRef="i6d13c8c853924031bd029bd4c72b099a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQzMDQ4_8262718d-37de-4aff-85c8-b69b82d0b429"
      unitRef="usd">5500000</ibrx:CollaborationAgreementsLicenseMaintenanceFees>
    <ibrx:CollaborationAgreementsTerminationFee
      contextRef="id36600ac1af648c79b04e3c00fadca09_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQzMTYz_47bfe041-cb58-4bba-baf1-4a8538482d28"
      unitRef="usd">10000000</ibrx:CollaborationAgreementsTerminationFee>
    <ibrx:CollaborationAgreementsMilestonePaymentAggregateMaximum
      contextRef="i2f73c10bbad4443f9c60a048d6b10f17_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQzMzgx_34b2bbcc-c021-422c-8116-0af2dd068b93"
      unitRef="usd">4000000</ibrx:CollaborationAgreementsMilestonePaymentAggregateMaximum>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i37548de39d884f38a90265fc99953e00_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQzNjQ1_3e5f4805-3841-47df-9f63-4a4e8abf2b4c"
      unitRef="usd">800000</us-gaap:ResearchAndDevelopmentExpense>
    <ibrx:CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities
      contextRef="i2fbf30bc44d6480e870137c2cd85cdb9_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQzOTc0_1067083f-3375-4c78-9324-47e60bf9de6d"
      unitRef="usd">2000000</ibrx:CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibbb1145df96744e6a4b78a506fdab0e3_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfMTA5OTUxMTY2NjY2MQ_40ebd354-275e-4144-bd45-b340c0411c16"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <ibrx:NumberOfSquareFootOfFacilityLeased
      contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQ0MjE3_d644aeae-91ca-4a60-8b1d-d61d6e34bc62"
      unitRef="sqft">409000</ibrx:NumberOfSquareFootOfFacilityLeased>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="i425c575827bc4978bf0c2daa8ed81a96_D20220214-20220214"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQ0OTUw_d6431715-05a9-480b-8096-87a4fe55743d"
      unitRef="usd">40500000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i425c575827bc4978bf0c2daa8ed81a96_D20220214-20220214"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQ0OTgz_f8e3faa6-63b4-4241-9fb6-d3980907f643"
      unitRef="usd">40000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="i425c575827bc4978bf0c2daa8ed81a96_D20220214-20220214"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQ1MDI3_91bd7732-7e83-40e9-b5f3-52b831f787ab"
      unitRef="usd">500000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <us-gaap:AssetAcquisitionTableTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfMzg0ODI5MDczNDM2Ng_5eddb2da-ec42-4535-b1bd-9a887ba060f5">The following table summarizes the fair value of assets acquired as of the acquisition date (in&#160;thousands):&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other depreciable assets and prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_43" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note &lt;/a&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_43" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;3&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Statement Details&#x2014;Intangible Assets, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, for further information.&lt;/span&gt;&lt;/div&gt;</us-gaap:AssetAcquisitionTableTextBlock>
    <us-gaap:ConstructionInProgressGross
      contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RhYmxlOjdiMzlkYTcyN2JjNzQ3YzViZjJlNmJiNmZkYjk3MjUxL3RhYmxlcmFuZ2U6N2IzOWRhNzI3YmM3NDdjNWJmMmU2YmI2ZmRiOTcyNTFfMC0xLTEtMS0zMDIyMDE_305d4df9-ab56-45de-9415-ba367db8494f"
      unitRef="usd">10043000</us-gaap:ConstructionInProgressGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RhYmxlOjdiMzlkYTcyN2JjNzQ3YzViZjJlNmJiNmZkYjk3MjUxL3RhYmxlcmFuZ2U6N2IzOWRhNzI3YmM3NDdjNWJmMmU2YmI2ZmRiOTcyNTFfMS0xLTEtMS0zMDIyMDE_5a3355e6-e325-41ed-839b-2c9fc15d66f4"
      unitRef="usd">6253000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RhYmxlOjdiMzlkYTcyN2JjNzQ3YzViZjJlNmJiNmZkYjk3MjUxL3RhYmxlcmFuZ2U6N2IzOWRhNzI3YmM3NDdjNWJmMmU2YmI2ZmRiOTcyNTFfMi0xLTEtMS0zMDIyMDE_e33374b0-a731-4bc4-a4a5-ea22282ae211"
      unitRef="usd">21229000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RhYmxlOjdiMzlkYTcyN2JjNzQ3YzViZjJlNmJiNmZkYjk3MjUxL3RhYmxlcmFuZ2U6N2IzOWRhNzI3YmM3NDdjNWJmMmU2YmI2ZmRiOTcyNTFfMy0xLTEtMS0zMDIyMDE_e05e8364-2e8c-4762-a4d0-3039a6f0910b"
      unitRef="usd">2983000</us-gaap:PrepaidExpenseAndOtherAssets>
    <ibrx:AssetAcquisitionFairValueOfAssetsAcquired
      contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RhYmxlOjdiMzlkYTcyN2JjNzQ3YzViZjJlNmJiNmZkYjk3MjUxL3RhYmxlcmFuZ2U6N2IzOWRhNzI3YmM3NDdjNWJmMmU2YmI2ZmRiOTcyNTFfNC0xLTEtMS0zMDIyMDE_2b79886b-9500-4cee-97c9-b32f4b27ff72"
      unitRef="usd">40508000</ibrx:AssetAcquisitionFairValueOfAssetsAcquired>
    <ibrx:LeaseOperatingLeaseAnnualLeasePayment
      contextRef="i425c575827bc4978bf0c2daa8ed81a96_D20220214-20220214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQ2Mjg4_522cf9f7-b5c1-46df-8768-db0162c35307"
      unitRef="usd">2.00</ibrx:LeaseOperatingLeaseAnnualLeasePayment>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNDM5ODA0NjU0ODI1NQ_1e11353a-9322-46a3-bf2a-fda04b14b12e">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNDM5ODA0NjU0ODI1Ng_87c317c2-15a2-4bbb-ac9d-813563030519">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <ibrx:LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm
      contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQ2NzM0_8cc788d4-3b17-4033-a6d9-d08d06010567"
      unitRef="usd">1520000000</ibrx:LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm>
    <ibrx:LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm
      contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQ2ODA1_a65292e7-bc7b-4973-a523-1f57ef443865"
      unitRef="usd">1500000000</ibrx:LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNDM5ODA0NjU0ODI1Nw_a39afdb8-ad32-44f4-8e08-294bb7087537">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <ibrx:LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears
      contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQ2OTI2_b6b86851-a2d0-4bcd-a23b-6c2134382e4b"
      unitRef="employee">450</ibrx:LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears>
    <ibrx:LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears
      contextRef="i9bdaaaa534ee490db0798af2622eb12c_I20220214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfNTQ5NzU1ODQ2OTk1_0d5021a6-6968-4adb-b6ae-e67937e41767"
      unitRef="employee">300</ibrx:LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears>
    <ibrx:LeaseholdInterestGovernmentFundingReceivable
      contextRef="if6b39365bed8403baef862349455aa3a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfMTA5OTUxMTY2Mzc4Mw_55337d33-f628-4c38-affa-62c7280e8c43"
      unitRef="usd">8000000</ibrx:LeaseholdInterestGovernmentFundingReceivable>
    <ibrx:LeaseholdInterestGovernmentFundingReceivable
      contextRef="i3d26d616708f4d68a522f54d69fb3236_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF81OC9mcmFnOjM4Y2Q4OWQxYzNmNjQyM2E4ZTY4MWU3M2M3NzRmZDIxL3RleHRyZWdpb246MzhjZDg5ZDFjM2Y2NDIzYThlNjgxZTczYzc3NGZkMjFfMTA5OTUxMTY2MzgxNQ_ab2614fe-68b8-46ac-b19f-8218f4031b93"
      unitRef="usd">10000000</ibrx:LeaseholdInterestGovernmentFundingReceivable>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfMTA1MjA_bff3e036-f2ac-453a-8d13-ed02123558f1">Commitments and Contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Related to Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;VivaBioCell, S.p.A.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April&#160;2015, NantWorks,&#160;LLC (NantWorks), a related party, acquired a 100% interest in VivaBioCell, S.p.A. (VivaBioCell) through its wholly-owned subsidiary, VBC Holdings,&#160;LLC, (VBC Holdings) for $0.7&#160;million, less working capital adjustments. In June&#160;2015, NantWorks contributed its equity interest in VBC Holdings to the company, in exchange for cash consideration equal to its cost basis in the investment. VivaBioCell develops bioreactors and products based on cell culture and tissue engineering in Italy. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of VBC, we are obligated to pay the former owners contingent consideration upon the achievement of certain milestones related to the GMP-in-a-Box technology. A clinical milestone totaling $0.8&#160;million was earned by the former owners of VivaBioCell, of which $0.4&#160;million was paid during 2021, with the remaining clinical obligation settled in September&#160;2022. If a government agency unconditionally approves the GMP-in-a-Box technology for commercial sale (the regulatory milestone) in the future, we will be obligated to pay an additional approximately $2.2&#160;million to the former owners. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Altor BioScience Corporation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the&#160;2017 acquisition of Altor BioScience Corporation (Altor), we issued contingent value rights (CVRs) under which we agreed to pay the prior stockholders of Altor approximately $304.0&#160;million contingent consideration upon the successful regulatory approval of a BLA by the FDA, or foreign equivalent, for N-803 by December&#160;31,&#160;2022 and approximately $304.0&#160;million contingent consideration upon calendar-year worldwide net sales of N-803 exceeding $1.0&#160;billion prior to December&#160;31,&#160;2026, with amounts payable in cash or shares of our common stock or a combination thereof. As the transaction was recorded as an asset acquisition, future CVR payments will be recorded when the corresponding events are probable of achievement or the consideration becomes payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to the regulatory milestone CVR agreement, in May&#160;2022 we announced the submission of a BLA to the FDA for our product candidate, Anktiva (N-803) in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1 disease&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. I&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n July&#160;2022 we announced that the FDA had accepted our BLA for review and set a target PDUFA action date of May&#160;23,&#160;2023. On May&#160;9,&#160;2023, the FDA delivered a complete response letter to us regarding the BLA. The company plans to request a meeting with the FDA as soon as possible to address the subject matter of the letter and a response timeline, and plans to diligently address and resolve the issues identified and seek approval as expeditiously as possible. It is unclear when the FDA will approve our BLA, if at all. The FDA did not approve our BLA on or before December&#160;31,&#160;2022, and therefore the regulatory milestone was not met, and the regulatory milestone CVR agreement terminated in accordance with its terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to the net sales milestone CVR agreement, as of March&#160;31,&#160;2023, Dr.&#160;Soon-Shiong and his related party hold approximately $139.8&#160;million of net sales CVRs and they have both irrevocably agreed to receive shares of the company&#x2019;s common stock in satisfaction of their CVRs. We may be required to pay the other prior Altor stockholders up to $164.2&#160;million for their net sales CVRs should they choose to have their CVRs paid in cash instead of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. If we are served with any such complaints, we will assess at that time any contingencies for which we may need to reserve. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Altor BioScience, LLC Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, NantCell,&#160;Inc. (NantCell) announced it had entered into a definitive merger agreement to acquire Altor BioScience Corporation. An action captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gray v.&#160;Soon-Shiong, et&#160;al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was filed in Delaware Chancery Court by plaintiffs Clayland Boyden Gray (Gray) and Adam R. Waldman. The plaintiffs, two&#160;minority stockholders, asserted claims against the company and other defendants for (1)&#160;breach of fiduciary duty and (2)&#160;aiding and abetting breach of fiduciary duty and filed a motion to enjoin the merger. The court denied the motion and permitted the merger to close. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to the close of the merger, in 2017 the plaintiffs (joined by two&#160;additional minority stockholders, Barbara&#160;Sturm Waldman and Douglas E. Henderson (Henderson)) filed a second&#160;amended complaint, including appraisal claims, and which the defendants subsequently moved to dismiss. In a second&#160;action, Dyad Pharmaceutical Corporation (Dyad) filed a petition in Delaware Chancery Court for appraisal in connection with the merger. The defendants moved to dismiss the appraisal petition in 2018. The court issued an oral ruling in 2019 that dismissed certain claims and dismissed Altor BioScience from the action. The following claims remained: (a)&#160;the appraisal claims by all plaintiffs and Dyad (against Altor BioScience,&#160;LLC), and (b)&#160;Henderson&#x2019;s claims for breach of fiduciary duty and aiding and abetting breach of fiduciary duty. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the court issued a written order implementing its ruling on the defendants&#x2019; motions (the Implementing Order). In the Implementing Order, the court confirmed that all fiduciary duty claims brought by Gray, both individually and as trustee of the Gordon Gray Trust f/b/o&#160;C. Boyden Gray, were dismissed. The plaintiffs then moved for leave to file a third&#160;amended complaint to add two&#160;former Altor stockholders as plaintiffs and a fiduciary duty claim on behalf of a purported class of former Altor stockholders, which the defendants opposed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the court granted the plaintiffs&#x2019; motion, and the plaintiffs filed the third&#160;amended complaint. In 2020, the defendants answered the third&#160;amended complaint and asserted counterclaims against the plaintiffs. The defendants sought damages for attorneys&#x2019; fees and costs incurred as a result of the breaches of &#x201c;standstill&#x201d; agreements and of stockholder releases. The plaintiffs filed an answer denying the counterclaims and asserting defenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The shares of the former Altor stockholders seeking appraisal met the definition of dissenting shares under the merger agreement and were not entitled to receive any portion of the merger consideration at the closing date, given that those shares were the subject of the above-described appraisal claims. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In late March&#160;2022, the company agreed to the terms of a settlement with the appraisal petitioners, without any admission of liability or fault. The settlement provided that in exchange for complete releases, the appraisal petitioners, who as a group held 3,167,565&#160;dissenting Altor shares, collectively would receive an aggregate of 2,229,296&#160;shares of the company&#x2019;s common stock issued in a private placement, plus an aggregate of $21.13&#160;in cash in lieu of fractional shares. The company&#x2019;s Board of Directors approved the settlement and stock issuance in April&#160;2022, and the court approved the settlement and dismissed the appraisal petitioners&#x2019; claims on July&#160;9,&#160;2022. On July&#160;9,&#160;2022, the company issued 2,229,296&#160;shares of its common stock with an aggregate market value of $10.7&#160;million, based on the closing price of its common stock on the Nasdaq as of July&#160;8,&#160;2022, to the appraisal petitioners pursuant to the court-approved settlement agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In late April&#160;2022, the company also agreed to the terms of a settlement with the putative class plaintiffs without any admission of liability or fault. In exchange for class-wide releases, the company committed to make a settlement payment of $5.0&#160;million in cash by December&#160;31,&#160;2022. On December&#160;8,&#160;2022, the Delaware Court of Chancery entered a final judgment approving the settlement, and the company timely made the $5.0&#160;million settlement payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sorrento Therapeutics, Inc. Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sorrento Therapeutics,&#160;Inc. (Sorrento), derivatively on behalf of Immunotherapy NANTibody,&#160;LLC (NANTibody) filed an action in the Superior Court of California, Los Angeles County (the Superior Court) against the company&#x2019;s subsidiary NantCell, Dr.&#160;Soon-Shiong, and Charles&#160;Kim. The action alleged that the defendants improperly caused NANTibody to acquire IgDraSol,&#160;Inc. (IgDraSol) from NantPharma,&#160;LLC (NantPharma) and sought to have the transaction undone and the purchase amount returned to NANTibody. In 2019, we filed a demurrer to several causes of action alleged in the Superior Court action, and Sorrento filed an amended complaint, eliminating Mr.&#160;Kim as a defendant and dropping the causes of action we had challenged in our demurrer. The company believes the case is without merit and intends to vigorously defend against the claims asserted. Trial has been set to commence in Sorrento&#x2019;s Superior Court action on July&#160;17,&#160;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also in 2019, the company and Dr.&#160;Soon-Shiong filed cross-claims in the Superior Court action against Sorrento and its Chief Executive Officer Henry&#160;Ji, asserting claims for fraud, breach of contract, breach of the covenant of good faith and fair dealing, tortious interference with contract, unjust enrichment, and declaratory relief. Our claims alleged that Dr.&#160;Ji and Sorrento breached the terms of an exclusive license agreement between the company and Sorrento related to Sorrento&#x2019;s antibody library and that Sorrento did not perform its obligations under the exclusive license agreement. The Superior Court ruled that the company&#x2019;s claims should be pursued in arbitration and that Dr.&#160;Soon-Shiong&#x2019;s claims could be pursued in Superior Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the company, along with NANTibody, filed an arbitration against Sorrento and Dr.&#160;Ji asserting our claims relating to the exclusive license agreement. Sorrento filed counterclaims against the company and NANTibody in the arbitration. The hearings in the NANTibody arbitration commenced in April&#160;2021 and concluded in early August&#160;2021. After post-hearing briefing was concluded, the parties were notified on November&#160;30,&#160;2021 that the arbitrator in the NANTibody arbitration had passed away. A substitute arbitrator was appointed on February&#160;25,&#160;2022, and the parties worked with the substitute arbitrator to conclude the proceedings. Additional hearing sessions were held in May and July&#160;2022, and summations took place on August&#160;2,&#160;2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;2, 2022, the arbitrator issued a final award finding that Sorrento had breached the two&#160;exclusive license agreements with NantCell and NANTibody. The arbitrator awarded NantCell approximately $156.8&#160;million and NANTibody approximately $16.7&#160;million, plus post-award interest accruing at a daily rate. On December&#160;21,&#160;2022, NantCell and NANTibody filed petitions in the Superior Court to confirm the arbitration award; on January&#160;16,&#160;2023, Sorrento filed a response to the petitions and moved to vacate the award. On February&#160;7, 2023, after a hearing, the Superior Court entered orders confirming the arbitration award and denying Sorrento&#x2019;s motion to vacate. The Superior Court entered judgments against Sorrento in the aggregate amount of approximately $176.4&#160;million plus 10% post-judgment interest, of which approximately $159.4&#160;million is payable to NantCell, and the remainder of which is payable to NANTibody. On February&#160;13,&#160;2023, Sorrento informed counsel to the company that it had filed a Chapter&#160;11 proceeding in the U.S. District Court for the Southern District of Texas, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re: Sorrento Therapeutics,&#160;Inc., et&#160;al.,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Case No.&#160;23-bk-90085 (Bankr. S.D. Tex.) (DRJ). The company intends to continue to pursue vigorously, consistent with its rights in light of Sorrento&#x2019;s Chapter&#160;11 filing, the collection of the judgments from Sorrento, but we make no assurances that we will receive the full amount or with respect to the timing of our receipt of any funds. As of March&#160;31,&#160;2023, we have not determined the amount we are likely to recover, and thus have not recorded any receivables in relation to the judgments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Superior Court action remains pending, and it remains to be determined how, if at all, the award in the arbitration will affect the Superior Court action. An estimate of the possible loss or range of loss resulting from the Superior Court litigation cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shenzhen Beike Biotechnology Co. Ltd. Arbitration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we received a Request for Arbitration before the International Chamber of Commerce, International Court of Arbitration. The arbitration relates to a license, development, and commercialization agreement that Altor entered into with Beike in 2014, which agreement was amended and restated in 2017, pursuant to which Altor granted to Beike an exclusive license to use, research, develop and commercialize products based on N-803 in China for human therapeutic uses. In the arbitration, Beike is asserting a claim for breach of contract under the license agreement. Among other things, Beike alleges that we failed to use commercially reasonable efforts to deliver to Beike materials and data related to N-803. Beike is seeking specific performance and declaratory relief for the alleged breaches. On September&#160;25,&#160;2020, the parties entered into a standstill and tolling agreement (standstill agreement) under which, among other things, the parties affirmed they will perform certain of their obligations under the license agreement by specified dates and agreed that all deadlines in the arbitration are indefinitely extended. The standstill agreement could be terminated by any party on ten calendar days&#x2019; notice, and upon termination, the parties had the right to pursue claims arising from the license agreement in any appropriate tribunal. On March&#160;20,&#160;2023, we terminated the standstill agreement, and on April&#160;11,&#160;2023, Beike served an amended Request for Arbitration. We have until May&#160;19,&#160;2023 to file a response. Given that this action remains at the pleading stage and no discovery has occurred, it remains too early to evaluate the likely outcome of the case or to estimate any range of potential loss. We believe the claims lack merit and intend to defend the case vigorously and that we may have counterclaims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stipulation of Settlement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, following approval by our Board of Directors, we entered into a settlement agreement (the Stipulation of Settlement) with three stockholders of the company, each of whom had submitted a stockholder demand for the Board of Directors to take action to remedy purported harm to the company resulting from certain alleged wrongful conduct concerning, among other things, disclosures about Dr. Soon-Shiong&#x2019;s compensation and a related-party lease agreement. The Stipulation of Settlement called for us to adopt certain governance changes, and for the three stockholders to file a stockholder derivative action in the Superior Court of the State of California, County of San Diego, followed by an application for court approval of the Stipulation of Settlement. The court entered an order preliminarily approving the Stipulation of Settlement. Pursuant to the Stipulation of Settlement, we provided stockholders with notice of the settlement and the final settlement hearing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commitments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not enter into any significant contracts during the three months ended March&#160;31,&#160;2023, other than those disclosed in these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we are also a party to various contracts with contract research organizations and contract manufacturers that generally provide for termination on notice, with the exact amounts in the event of termination to be based on the timing of the termination and the terms of the agreement. There have been no material changes in unconditional purchase commitments from those disclosed in Note&#160;7, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commitments and Contingencies,&lt;/span&gt; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; that appears in Part&#160;II, Item&#160;8. &#x201c;Financial Statements and Supplementary Data&#x201d; of our Annual Report on Form&#160;10-K filed with the SEC on March&#160;1,&#160;2023.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ibrx:PercentageOfWhollyOwnedSubsidiary
      contextRef="ibc667aeaffb241769d40ebb768302772_I20150430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfMTg3_adba4861-c22c-4724-bfef-34de1fe0971b"
      unitRef="number">1</ibrx:PercentageOfWhollyOwnedSubsidiary>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i34694fa4373945b3a6a665c6a37f4262_D20150401-20150430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfMzEx_81373eaa-39f9-4c63-8801-cd8272686d57"
      unitRef="usd">700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <ibrx:BusinessCombinationContingentConsiderationArrangementsEarned
      contextRef="i0d13dc5189894b7d8628892cfb2e7a88_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfODQw_68f014fd-8538-437b-bbc6-8f3ff7819c27"
      unitRef="usd">800000</ibrx:BusinessCombinationContingentConsiderationArrangementsEarned>
    <ibrx:BusinessCombinationContingentConsiderationArrangementsSettlements
      contextRef="i0d13dc5189894b7d8628892cfb2e7a88_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfOTAw_86453043-6aee-4906-8a21-2768d4d8c272"
      unitRef="usd">400000</ibrx:BusinessCombinationContingentConsiderationArrangementsSettlements>
    <ibrx:BusinessCombinationContingentConsiderationArrangementsSettlements
      contextRef="ibdeaa2c7746d49a8bd99d6d3afb859aa_D20220901-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfOTAw_8e1e126a-3105-4b36-a5d7-e9c7e6a2e912"
      unitRef="usd">400000</ibrx:BusinessCombinationContingentConsiderationArrangementsSettlements>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh
      contextRef="i4947316a78a241dc928345e7c528266e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfMTE4NQ_cf0b81c5-8125-45e9-a87c-8f79abfc7c04"
      unitRef="usd">2200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh>
    <ibrx:ContingentValueRightsObligations
      contextRef="ida7588e0910c4bb28cb902bc775406de_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfMTQzNw_73badb9c-c598-4eaf-bf70-981e5a48989e"
      unitRef="usd">304000000</ibrx:ContingentValueRightsObligations>
    <ibrx:ContingentValueRightsObligations
      contextRef="i40bec98f02134e3b977953843f819e46_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfMTU4Mw_7746c9ca-5817-4014-a7fe-a2c15843d001"
      unitRef="usd">304000000</ibrx:ContingentValueRightsObligations>
    <ibrx:MinimumNetSalesMilestoneContingentValueRightsObligation
      contextRef="i74a7874a4fde4847942459ca136eee6e_D20170101-20171231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfMTY2OQ_523ff2d2-9cff-4fb3-963b-0000173d1745"
      unitRef="usd">1000000000</ibrx:MinimumNetSalesMilestoneContingentValueRightsObligation>
    <ibrx:ContingentValueRightsObligations
      contextRef="i5a799dcabd874b6e84ddb0e294bf7f8a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfMjcyMg_2a14dffc-2565-47a0-822f-a4135b71980a"
      unitRef="usd">139800000</ibrx:ContingentValueRightsObligations>
    <ibrx:ContingentValueRightsObligations
      contextRef="i1c8c3835e9294f019b36ddbb7bb615b8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfMjkyNw_487b8522-65ce-4be4-be19-9d054a1bc1cf"
      unitRef="usd">164200000</ibrx:ContingentValueRightsObligations>
    <ibrx:NumberOfDissentingShares
      contextRef="i83f402b4c65a4485bfb0dff6c6982341_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfNTQ5NzU1ODQyNDU0_ef62d96c-77f0-43e3-877d-6a0003ecaf41"
      unitRef="shares">3167565</ibrx:NumberOfDissentingShares>
    <ibrx:LitigationSettlementNumberOfSharesToBeIssued
      contextRef="i83f402b4c65a4485bfb0dff6c6982341_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfNTQ5NzU1ODQyNDUw_3c7f28c7-e0f8-471a-9671-268bb068cb2b"
      unitRef="shares">2229296</ibrx:LitigationSettlementNumberOfSharesToBeIssued>
    <ibrx:SharesIssuedCashDistributedInLieuOfFractionalShares
      contextRef="i83f402b4c65a4485bfb0dff6c6982341_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfNTQ5NzU1ODQyNDU4_1a9e5adb-a868-4fcc-bb6a-6b154724a692"
      unitRef="usdPerShare">21.13</ibrx:SharesIssuedCashDistributedInLieuOfFractionalShares>
    <us-gaap:SharesIssued
      contextRef="i3316090351fd4fe4b0dd3da042faabc4_I20220709"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfNTQ5NzU1ODQyNDYy_a27c227b-b668-4829-979f-4beec31e9eb0"
      unitRef="shares">2229296</us-gaap:SharesIssued>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i1bc9adb48922456fa879ef93b8dba645_D20220709-20220709"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfNTQ5NzU1ODQyNDY2_48e9774e-6963-431b-9835-0d016cd59ef6"
      unitRef="usd">10700000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:LitigationReserve
      contextRef="id9143fae2a394bf29dec9fb56f82a9a5_I20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfNTQ5NzU1ODQyNjAw_cfd5c57d-ab71-4cb4-b4c0-4d1213e87745"
      unitRef="usd">5000000</us-gaap:LitigationReserve>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="ic746e246685947fd8cfba45a1fed563e_D20221208-20221208"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfMjE5OTAyMzI4NDQ0MQ_67f20f3a-e126-4a3b-9c3d-9cf02d775ff9"
      unitRef="usd">5000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="i3f1bf0ab5b9b480192b280a3bffc0f0f_D20221202-20221202"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfNjM4Nw_78150b86-a53d-4193-a63c-0763e30bc8e7"
      unitRef="usd">156800000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="i947edf9e6bfb43b892a96c6c6549369d_D20221202-20221202"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfNjQxOA_e499a536-73cc-4dde-bff6-5f92af8cabb1"
      unitRef="usd">16700000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="i17ec39591f744eadbe2f276d7fed3a12_D20230207-20230207"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfNjkxMg_340e0087-42ac-42ac-946e-e65c6fc5b366"
      unitRef="usd">176400000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <ibrx:LitigationSettlementInterestPercent
      contextRef="i17ec39591f744eadbe2f276d7fed3a12_D20230207-20230207"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfNjkyMA_88832e43-c5b0-41ab-99d4-33e7b3544ea0"
      unitRef="number">0.10</ibrx:LitigationSettlementInterestPercent>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="i72f7554fa7494415af05bce0fcffd01e_D20230207-20230207"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF82Ny9mcmFnOjExMTYzN2UyNjBlZjRiNjc4ODdlOWQ5MTZiYzI0OGRlL3RleHRyZWdpb246MTExNjM3ZTI2MGVmNGI2Nzg4N2U5ZDkxNmJjMjQ4ZGVfNjk3MA_531572cd-ed1b-457c-94c8-6a1c0af6d20d"
      unitRef="usd">159400000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfMjkxMg_2a62108c-2719-4975-9999-baee47b527ec">Lease Arrangements&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease property in multiple facilities across the U.S. (including the Dunkirk Facility in upstate New York) and Italy, including facilities located in El&#160;Segundo,&#160;CA, which are leased from related parties. Substantially all of our operating lease right-of-use assets and operating lease liabilities relate to facilities leases. All of our finance leases are related to equipment rental at the Dunkirk Facility. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_76" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&#160;10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for additional information about our related-party leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our leases generally have initial terms ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfNTkx_1b5ac21f-8317-4cdf-9aa4-b1a83fbec98e"&gt;two&lt;/span&gt; to ten years and often include one or more options to renew. These renewal terms can extend the lease term from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfNjk5_f0f50d52-6d48-4a58-8a65-ea201cb85f30"&gt;one&lt;/span&gt; to ten years, and are included in the lease term when it is reasonably certain that we will exercise the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to our leases is as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;March&#160;31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNS0xLTEtMS0yOTgzNTI_716b2b64-20b1-40c3-9b02-a3d14868228b"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNS0xLTEtMS0yOTgzNTI_79bf86fc-1a0b-4632-b3b5-c9756666aba0"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTEtMS0xLTEtMjk4MzUy_1e304c6d-b6fc-4a07-96b6-252e1c6d5e68"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTEtMS0xLTEtMjk4MzUy_7f502521-7e3c-4089-bd21-ee4709a6ff0e"&gt;Accrued expenses and other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTQtMS0xLTEtMjk4MzUy_1cbef275-f42e-4514-b41d-8b9c75783db1"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTQtMS0xLTEtMjk4MzUy_cccafda1-bc6a-4e69-9eb2-a02fc2fcc607"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding our lease terms is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;March&#160;31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense consist of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.302%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease costs (including amortization and &lt;br/&gt;&#160;&#160;&#160;interest costs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities is as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.339%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash paid for operating leases (excluding variable lease costs)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Financing cash flow from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flow from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments as of March&#160;31,&#160;2023, including $14.8&#160;million related to options to extend lease terms that are reasonably certain of being exercised, are presented in the following table (in&#160;thousands). Common area maintenance costs and taxes are not included in these payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.331%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Years ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Operating&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Finance &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023 (excluding the three months ended March&#160;31,&#160;2023)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Tenant improvement allowance receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no other material changes related to our existing lease agreements from those disclosed in Note&#160;8, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, of the Notes to Consolidated Financial Statements of our Annual Report on Form&#160;10-K filed with the SEC on March&#160;1,&#160;2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfMjkxMg_ce7b4228-3d82-432c-b983-2c858a2d543d">Lease Arrangements&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease property in multiple facilities across the U.S. (including the Dunkirk Facility in upstate New York) and Italy, including facilities located in El&#160;Segundo,&#160;CA, which are leased from related parties. Substantially all of our operating lease right-of-use assets and operating lease liabilities relate to facilities leases. All of our finance leases are related to equipment rental at the Dunkirk Facility. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_76" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&#160;10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for additional information about our related-party leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our leases generally have initial terms ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfNTkx_1b5ac21f-8317-4cdf-9aa4-b1a83fbec98e"&gt;two&lt;/span&gt; to ten years and often include one or more options to renew. These renewal terms can extend the lease term from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfNjk5_f0f50d52-6d48-4a58-8a65-ea201cb85f30"&gt;one&lt;/span&gt; to ten years, and are included in the lease term when it is reasonably certain that we will exercise the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to our leases is as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;March&#160;31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNS0xLTEtMS0yOTgzNTI_716b2b64-20b1-40c3-9b02-a3d14868228b"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNS0xLTEtMS0yOTgzNTI_79bf86fc-1a0b-4632-b3b5-c9756666aba0"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTEtMS0xLTEtMjk4MzUy_1e304c6d-b6fc-4a07-96b6-252e1c6d5e68"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTEtMS0xLTEtMjk4MzUy_7f502521-7e3c-4089-bd21-ee4709a6ff0e"&gt;Accrued expenses and other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTQtMS0xLTEtMjk4MzUy_1cbef275-f42e-4514-b41d-8b9c75783db1"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTQtMS0xLTEtMjk4MzUy_cccafda1-bc6a-4e69-9eb2-a02fc2fcc607"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding our lease terms is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;March&#160;31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense consist of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.302%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease costs (including amortization and &lt;br/&gt;&#160;&#160;&#160;interest costs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities is as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.339%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash paid for operating leases (excluding variable lease costs)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Financing cash flow from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flow from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments as of March&#160;31,&#160;2023, including $14.8&#160;million related to options to extend lease terms that are reasonably certain of being exercised, are presented in the following table (in&#160;thousands). Common area maintenance costs and taxes are not included in these payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.331%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Years ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Operating&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Finance &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023 (excluding the three months ended March&#160;31,&#160;2023)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Tenant improvement allowance receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no other material changes related to our existing lease agreements from those disclosed in Note&#160;8, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, of the Notes to Consolidated Financial Statements of our Annual Report on Form&#160;10-K filed with the SEC on March&#160;1,&#160;2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i97684a88657d4f79b99ef808ef0e0de7_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfNTk3_02f68fc6-b874-4163-b56c-0f213be9f8b0">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i97684a88657d4f79b99ef808ef0e0de7_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfNzA1_595d689a-7e22-499e-a109-4105d3dfbf6c">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <ibrx:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfMjkwOQ_fd3f117e-9ce5-46ea-8b05-55877aaf4cbb">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to our leases is as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;March&#160;31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNS0xLTEtMS0yOTgzNTI_716b2b64-20b1-40c3-9b02-a3d14868228b"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNS0xLTEtMS0yOTgzNTI_79bf86fc-1a0b-4632-b3b5-c9756666aba0"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTEtMS0xLTEtMjk4MzUy_1e304c6d-b6fc-4a07-96b6-252e1c6d5e68"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTEtMS0xLTEtMjk4MzUy_7f502521-7e3c-4089-bd21-ee4709a6ff0e"&gt;Accrued expenses and other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTQtMS0xLTEtMjk4MzUy_1cbef275-f42e-4514-b41d-8b9c75783db1"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTQtMS0xLTEtMjk4MzUy_cccafda1-bc6a-4e69-9eb2-a02fc2fcc607"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ibrx:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNC0zLTEtMS0yOTgzNTI_b6661577-184c-4afe-8bd9-cadd20340c3a"
      unitRef="usd">44191000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNC01LTEtMS0yOTgzNTI_765b055e-cc77-44ea-9016-b84021612ba0"
      unitRef="usd">45788000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNS0zLTEtMS0yOTgzNTI_7fe32746-65db-4142-9921-5bd89f62d9ec"
      unitRef="usd">115000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNS01LTEtMS0yOTgzNTI_4638ec44-382f-4b0a-8713-6deb9bf93f72"
      unitRef="usd">135000</us-gaap:FinanceLeaseRightOfUseAsset>
    <ibrx:LeaseRightOfUseAsset
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNi0zLTEtMS0yOTgzNTI_a4c2ae70-ccf9-4c8b-a109-baa2e42a16f9"
      unitRef="usd">44306000</ibrx:LeaseRightOfUseAsset>
    <ibrx:LeaseRightOfUseAsset
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfNi01LTEtMS0yOTgzNTI_8b728968-d4d5-4dd6-970c-4306b5d85886"
      unitRef="usd">45923000</ibrx:LeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTAtMy0xLTEtMjk4MzUy_18eaf4b2-ca44-44a7-9f94-1357df518173"
      unitRef="usd">2844000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTAtNS0xLTEtMjk4MzUy_29f0cf30-ab75-432c-afe4-8557c662bf9e"
      unitRef="usd">2650000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTEtMy0xLTEtMjk4MzUy_90416e71-0a01-455a-a3f6-6792d4858f36"
      unitRef="usd">79000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTEtNS0xLTEtMjk4MzUy_36c1e299-7da2-4674-a0a8-6a219f902a8b"
      unitRef="usd">77000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTMtMy0xLTEtMjk4MzUy_2b90bf53-927f-4d61-a0ea-f1849b67a84c"
      unitRef="usd">46289000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTMtNS0xLTEtMjk4MzUy_52f19ea6-ca76-4c15-bca8-dcb6aace0443"
      unitRef="usd">47951000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTQtMy0xLTEtMjk4MzUy_2b67648c-fe98-4282-b382-b0fff7cfb979"
      unitRef="usd">43000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTQtNS0xLTEtMjk4MzUy_aa003073-c4dc-4537-811e-70cd3b5e1967"
      unitRef="usd">64000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <ibrx:LeaseLiability
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTUtMy0xLTEtMjk4MzUy_2c383324-aae3-480e-9759-72328c4eb322"
      unitRef="usd">49255000</ibrx:LeaseLiability>
    <ibrx:LeaseLiability
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOmU1MzkwYzRkN2M3NDQxZDM5ZGQ5OTEyYzE3MjZiNTZlL3RhYmxlcmFuZ2U6ZTUzOTBjNGQ3Yzc0NDFkMzlkZDk5MTJjMTcyNmI1NmVfMTUtNS0xLTEtMjk4MzUy_fcf5f91c-b9a3-41a8-a2f3-3cb167ebafd5"
      unitRef="usd">50742000</ibrx:LeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfMjkxMA_a919a662-c8ae-4376-bcae-ea76cf6d4ae3">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding our lease terms is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;March&#160;31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense consist of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.302%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease costs (including amortization and &lt;br/&gt;&#160;&#160;&#160;interest costs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities is as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.339%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash paid for operating leases (excluding variable lease costs)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Financing cash flow from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flow from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjlmMzhmN2I2MTJkNzQ1MmE4MTYzYTg0Y2ZmYjgxOGYwL3RhYmxlcmFuZ2U6OWYzOGY3YjYxMmQ3NDUyYTgxNjNhODRjZmZiODE4ZjBfNC0xLTEtMS0yOTgzNTI_55557dd3-7c2e-4c5d-810a-8b4649021b0b">P6Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjlmMzhmN2I2MTJkNzQ1MmE4MTYzYTg0Y2ZmYjgxOGYwL3RhYmxlcmFuZ2U6OWYzOGY3YjYxMmQ3NDUyYTgxNjNhODRjZmZiODE4ZjBfNC00LTEtMS0yOTgzNTI_d522ae2e-549f-49af-93d3-cf68ba87bc17">P6Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjlmMzhmN2I2MTJkNzQ1MmE4MTYzYTg0Y2ZmYjgxOGYwL3RhYmxlcmFuZ2U6OWYzOGY3YjYxMmQ3NDUyYTgxNjNhODRjZmZiODE4ZjBfNS0xLTEtMi0yOTgzNTI_368c0496-b16a-459a-a10a-f84395b6faac">P1Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjlmMzhmN2I2MTJkNzQ1MmE4MTYzYTg0Y2ZmYjgxOGYwL3RhYmxlcmFuZ2U6OWYzOGY3YjYxMmQ3NDUyYTgxNjNhODRjZmZiODE4ZjBfNS00LTEtMS0yOTgzNTI_739bdd9e-1ff1-4119-a7c4-44b7391ec130">P1Y9M18D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjlmMzhmN2I2MTJkNzQ1MmE4MTYzYTg0Y2ZmYjgxOGYwL3RhYmxlcmFuZ2U6OWYzOGY3YjYxMmQ3NDUyYTgxNjNhODRjZmZiODE4ZjBfNy0xLTEtMS0yOTgzNTI_f44eed6b-5855-4b52-9921-b712e71904b4"
      unitRef="number">0.106</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjlmMzhmN2I2MTJkNzQ1MmE4MTYzYTg0Y2ZmYjgxOGYwL3RhYmxlcmFuZ2U6OWYzOGY3YjYxMmQ3NDUyYTgxNjNhODRjZmZiODE4ZjBfNy00LTEtMS0yOTgzNTI_c9657675-cb22-4683-8810-6c1de5303f59"
      unitRef="number">0.105</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjlmMzhmN2I2MTJkNzQ1MmE4MTYzYTg0Y2ZmYjgxOGYwL3RhYmxlcmFuZ2U6OWYzOGY3YjYxMmQ3NDUyYTgxNjNhODRjZmZiODE4ZjBfOC0xLTEtMS0yOTgzNTI_18b703aa-b277-4c83-8ffb-19fbe4dc4b72"
      unitRef="number">0.117</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjlmMzhmN2I2MTJkNzQ1MmE4MTYzYTg0Y2ZmYjgxOGYwL3RhYmxlcmFuZ2U6OWYzOGY3YjYxMmQ3NDUyYTgxNjNhODRjZmZiODE4ZjBfOC00LTEtMS0yOTgzNTI_50843816-cb33-43c7-971e-d58e76c735f7"
      unitRef="number">0.117</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjgxOTdlNTY4NTI0MDQ5NjliZjJlOGUxMjZjN2E1OTlmL3RhYmxlcmFuZ2U6ODE5N2U1Njg1MjQwNDk2OWJmMmU4ZTEyNmM3YTU5OWZfNC0xLTEtMS0yOTgzNTI_1edbaac1-b9e7-4c5a-be17-cd58821aee5e"
      unitRef="usd">2921000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjgxOTdlNTY4NTI0MDQ5NjliZjJlOGUxMjZjN2E1OTlmL3RhYmxlcmFuZ2U6ODE5N2U1Njg1MjQwNDk2OWJmMmU4ZTEyNmM3YTU5OWZfNC0zLTEtMS0yOTgzNTI_5f373551-fb55-4e0c-bcfd-ea22c08ebae9"
      unitRef="usd">2308000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjgxOTdlNTY4NTI0MDQ5NjliZjJlOGUxMjZjN2E1OTlmL3RhYmxlcmFuZ2U6ODE5N2U1Njg1MjQwNDk2OWJmMmU4ZTEyNmM3YTU5OWZfNS0xLTEtMS0yOTgzNTI_b0652179-388a-4f43-81bf-5fd1c0e8e480"
      unitRef="usd">1050000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjgxOTdlNTY4NTI0MDQ5NjliZjJlOGUxMjZjN2E1OTlmL3RhYmxlcmFuZ2U6ODE5N2U1Njg1MjQwNDk2OWJmMmU4ZTEyNmM3YTU5OWZfNS0zLTEtMS0yOTgzNTI_ae7e2b9d-b22f-4dbb-bb5f-1eb13765434b"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <ibrx:FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjgxOTdlNTY4NTI0MDQ5NjliZjJlOGUxMjZjN2E1OTlmL3RhYmxlcmFuZ2U6ODE5N2U1Njg1MjQwNDk2OWJmMmU4ZTEyNmM3YTU5OWZfNi0xLTEtMS0yOTgzNTI_cd46575b-50ce-4af9-9e8d-ced575a7ef3c"
      unitRef="usd">23000</ibrx:FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense>
    <ibrx:FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjgxOTdlNTY4NTI0MDQ5NjliZjJlOGUxMjZjN2E1OTlmL3RhYmxlcmFuZ2U6ODE5N2U1Njg1MjQwNDk2OWJmMmU4ZTEyNmM3YTU5OWZfNi0zLTEtMS0yOTgzNTI_d2b904d2-ab6c-4038-9cdb-e6175e12d764"
      unitRef="usd">0</ibrx:FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense>
    <us-gaap:VariableLeaseCost
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjgxOTdlNTY4NTI0MDQ5NjliZjJlOGUxMjZjN2E1OTlmL3RhYmxlcmFuZ2U6ODE5N2U1Njg1MjQwNDk2OWJmMmU4ZTEyNmM3YTU5OWZfNy0xLTEtMS0yOTgzNTI_229463bf-6757-4ed8-83df-fb9f612d7372"
      unitRef="usd">970000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjgxOTdlNTY4NTI0MDQ5NjliZjJlOGUxMjZjN2E1OTlmL3RhYmxlcmFuZ2U6ODE5N2U1Njg1MjQwNDk2OWJmMmU4ZTEyNmM3YTU5OWZfNy0zLTEtMS0yOTgzNTI_cb561d4a-d5e0-497e-8c75-d1766ff9ccd8"
      unitRef="usd">1182000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjgxOTdlNTY4NTI0MDQ5NjliZjJlOGUxMjZjN2E1OTlmL3RhYmxlcmFuZ2U6ODE5N2U1Njg1MjQwNDk2OWJmMmU4ZTEyNmM3YTU5OWZfOC0xLTEtMS0yOTgzNTI_88e7da97-ea34-4d51-ac04-ea03ebfa4b2d"
      unitRef="usd">4964000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjgxOTdlNTY4NTI0MDQ5NjliZjJlOGUxMjZjN2E1OTlmL3RhYmxlcmFuZ2U6ODE5N2U1Njg1MjQwNDk2OWJmMmU4ZTEyNmM3YTU5OWZfOC0zLTEtMS0yOTgzNTI_57a542fe-65d7-40c0-be20-57482836f222"
      unitRef="usd">3490000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjQ1NWM3YzZhNTNmMjRjNWFhYjc0NDQwMWU2MWJkY2I0L3RhYmxlcmFuZ2U6NDU1YzdjNmE1M2YyNGM1YWFiNzQ0NDAxZTYxYmRjYjRfNC0xLTEtMS0yOTgzNTI_b4d6bec5-7c0c-4217-b764-d9e2c5ff6be8"
      unitRef="usd">3179000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjQ1NWM3YzZhNTNmMjRjNWFhYjc0NDQwMWU2MWJkY2I0L3RhYmxlcmFuZ2U6NDU1YzdjNmE1M2YyNGM1YWFiNzQ0NDAxZTYxYmRjYjRfNC0zLTEtMS0yOTgzNTI_ef035119-a96e-4b78-9031-5928f0ca5613"
      unitRef="usd">2151000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjQ1NWM3YzZhNTNmMjRjNWFhYjc0NDQwMWU2MWJkY2I0L3RhYmxlcmFuZ2U6NDU1YzdjNmE1M2YyNGM1YWFiNzQ0NDAxZTYxYmRjYjRfNS0xLTEtMS0yOTgzNTI_cfd14129-23fb-4bce-b040-3758045e216c"
      unitRef="usd">19000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjQ1NWM3YzZhNTNmMjRjNWFhYjc0NDQwMWU2MWJkY2I0L3RhYmxlcmFuZ2U6NDU1YzdjNmE1M2YyNGM1YWFiNzQ0NDAxZTYxYmRjYjRfNS0zLTEtMS0yOTgzNTI_fe2ccc85-4a17-47c7-8f2d-b1fcb1444ba4"
      unitRef="usd">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjQ1NWM3YzZhNTNmMjRjNWFhYjc0NDQwMWU2MWJkY2I0L3RhYmxlcmFuZ2U6NDU1YzdjNmE1M2YyNGM1YWFiNzQ0NDAxZTYxYmRjYjRfNi0xLTEtMS0yOTgzNTI_bd577679-a6f0-4e32-a1e5-294fbf8f22d5"
      unitRef="usd">4000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjQ1NWM3YzZhNTNmMjRjNWFhYjc0NDQwMWU2MWJkY2I0L3RhYmxlcmFuZ2U6NDU1YzdjNmE1M2YyNGM1YWFiNzQ0NDAxZTYxYmRjYjRfNi0zLTEtMS0yOTgzNTI_ce274daf-d491-4197-90c2-70ee6747de21"
      unitRef="usd">0</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfMjkwNw_6083cf4f-1168-4f27-806b-cb33f486f1f0">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments as of March&#160;31,&#160;2023, including $14.8&#160;million related to options to extend lease terms that are reasonably certain of being exercised, are presented in the following table (in&#160;thousands). Common area maintenance costs and taxes are not included in these payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.331%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Years ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Operating&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Finance &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023 (excluding the three months ended March&#160;31,&#160;2023)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Tenant improvement allowance receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <ibrx:OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RleHRyZWdpb246ZTQzNWUxNmFkOGU1NGU3MjhhNWNkZjY0NzNkYWUyYWNfMTE4NA_28d0ee6b-dbff-4eed-84da-7f13d38fbcd6"
      unitRef="usd">14800000</ibrx:OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMi0yLTEtMS0yOTgzNTI_a831e732-3c5b-4997-8a1b-2fbf50edda57"
      unitRef="usd">6748000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMi00LTEtMS0yOTgzNTI_93f7584c-f29d-420a-9528-e77136bb7c01"
      unitRef="usd">66000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <ibrx:LeaseLiabilityToBePaidRemainderOfFiscalYear
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMi02LTEtMS0yOTgzNTI_8a448724-b2ed-408a-a1d3-8044c5a85995"
      unitRef="usd">6814000</ibrx:LeaseLiabilityToBePaidRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMy0yLTEtMS0yOTgzNTI_b6280e47-f4e8-490d-b060-b5e13b776951"
      unitRef="usd">12119000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMy00LTEtMS0yOTgzNTI_e397216c-39ec-42c8-9037-65a68ca63e46"
      unitRef="usd">66000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <ibrx:LeaseLiabilityToBePaidYearOne
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMy02LTEtMS0yOTgzNTI_e78b537c-b21b-4c42-9e4e-4edfd0a48ae2"
      unitRef="usd">12185000</ibrx:LeaseLiabilityToBePaidYearOne>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNC0yLTEtMS0yOTgzNTI_476b4715-27f0-498c-88a2-8f6945ca7ae4"
      unitRef="usd">12145000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNC00LTEtMS0yOTgzNTI_74b87757-dc3b-45ae-841f-77e2a87e1d3d"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <ibrx:LeaseLiabilityToBePaidYearTwo
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNC02LTEtMS0yOTgzNTI_064ee884-43e4-4810-93ad-45a91b181b75"
      unitRef="usd">12145000</ibrx:LeaseLiabilityToBePaidYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNS0yLTEtMS0yOTgzNTI_38b1addf-00f2-4b58-a649-5d4bf4254f32"
      unitRef="usd">10290000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNS00LTEtMS0yOTgzNTI_de5e28c8-3f91-4b9e-9533-16b568ef3d9a"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <ibrx:LeaseLiabilityToBePaidYearThree
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNS02LTEtMS0yOTgzNTI_c37fc7c2-81e4-4183-8f1b-8b1f4fc00d2e"
      unitRef="usd">10290000</ibrx:LeaseLiabilityToBePaidYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNi0yLTEtMS0yOTgzNTI_443b94ee-451f-4792-9314-0b7c713861f9"
      unitRef="usd">8209000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNi00LTEtMS0yOTgzNTI_e03affde-8e7f-4098-bac5-01a60ee8d4bb"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <ibrx:LeaseLiabilityToBePaidYearFour
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNi02LTEtMS0yOTgzNTI_111f2caf-c64d-4a25-89e7-bbb094ab080a"
      unitRef="usd">8209000</ibrx:LeaseLiabilityToBePaidYearFour>
    <ibrx:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNy0yLTEtMS0yOTgzNTI_ab1cfed6-73c5-4639-833f-57eb0f531f8d"
      unitRef="usd">23247000</ibrx:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour>
    <ibrx:FinanceLeaseLiabilityToBePaidAfterYearFour
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNy00LTEtMS0yOTgzNTI_900cd633-c29c-499f-b461-261375f886c6"
      unitRef="usd">0</ibrx:FinanceLeaseLiabilityToBePaidAfterYearFour>
    <ibrx:LeaseLiabilityToBePaidAfterYearFour
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfNy02LTEtMS0yOTgzNTI_fdbe60c7-bcfa-476f-9b5e-954465a9f338"
      unitRef="usd">23247000</ibrx:LeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfOC0yLTEtMS0yOTgzNTI_a8db0940-612d-4fc0-a28e-2b48c80c30a1"
      unitRef="usd">72758000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfOC00LTEtMS0yOTgzNTI_7c93bf99-a76d-46c1-9a93-40399294c326"
      unitRef="usd">132000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <ibrx:LeaseLiabilityToBePaid
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfOC02LTEtMS0yOTgzNTI_5d8c0de7-3e1e-4b51-9f6c-d5e9efc70114"
      unitRef="usd">72890000</ibrx:LeaseLiabilityToBePaid>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfOS0yLTEtMS0yOTgzNTI_ee882fa6-c48b-4376-bff1-76791041b6b8"
      unitRef="usd">20684000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfOS00LTEtMS0yOTgzNTI_423b6336-694a-438c-9bc5-99408a90f03c"
      unitRef="usd">10000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <ibrx:LeaseLiabilityUndiscountedExcessInterest
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfOS02LTEtMS0yOTgzNTI_85eb0b9a-4279-42ab-a524-acdcd3b2c545"
      unitRef="usd">20694000</ibrx:LeaseLiabilityUndiscountedExcessInterest>
    <ibrx:LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMTAtMi0xLTEtMjk4MzUy_3b3d9b1e-8076-4d88-800b-8e522221679e"
      unitRef="usd">2941000</ibrx:LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable>
    <ibrx:FinanceLeaseLiabilityTenantImprovementAllowanceReceivable
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMTAtNC0xLTEtMjk4MzUy_3860de5b-efa7-4e7a-a77e-5c765abaf9e3"
      unitRef="usd">0</ibrx:FinanceLeaseLiabilityTenantImprovementAllowanceReceivable>
    <ibrx:LeaseLiabilityTenantImprovementAllowanceReceivable
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMTAtNi0xLTEtMjk4MzUy_166cff60-1c15-4d39-86fb-5dcebd389b5d"
      unitRef="usd">2941000</ibrx:LeaseLiabilityTenantImprovementAllowanceReceivable>
    <us-gaap:OperatingLeaseLiability
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMTEtMi0xLTEtMjk4MzUy_21fdb8bc-c14d-4c00-929f-90eea47de885"
      unitRef="usd">49133000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMTEtNC0xLTEtMjk4MzUy_6ccecabb-1cc9-4113-8561-c7805107e43e"
      unitRef="usd">122000</us-gaap:FinanceLeaseLiability>
    <ibrx:LeaseLiability
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83MC9mcmFnOmU0MzVlMTZhZDhlNTRlNzI4YTVjZGY2NDczZGFlMmFjL3RhYmxlOjRiY2QyZDlmYmI4MzQ1NjY5MmJiZjY5YjNiOGVmYmNiL3RhYmxlcmFuZ2U6NGJjZDJkOWZiYjgzNDU2NjkyYmJmNjliM2I4ZWZiY2JfMTEtNi0xLTEtMjk4MzUy_ebe5b0b9-f9a7-4abf-b059-0d86172d18e5"
      unitRef="usd">49255000</ibrx:LeaseLiability>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfODU4MA_0c2e159c-2ea2-4f6f-b7fb-70345b47fc5f">Related-Party Debt&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Convertible Note at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 31, 2023, the company executed a $30.0&#160;million promissory note with Nant&#160;Capital, LLC (Nant&#160;Capital), an affiliated entity under common control of our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder. This note bears interest at Term Secured Overnight Financing Rate (SOFR) plus 8.0%&#160;per annum. The outstanding principal amount and any accrued and unpaid interest are due on December&#160;31,&#160;2023 or upon the occurrence and continuation of an Event of Default (as defined in the note). The interest on this note will be paid on a quarterly basis beginning on June&#160;30,&#160;2023. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. The noteholder may convert the balance of the convertible promissory note and accrued interest in whole at its option following the Conversion Price Date, which is the trading day prior to the opening of the next open trading window, as determined by the company&#x2019;s board of directors in accordance with the company&#x2019;s Insider Trading Policy. The conversion price is equal to the greater of (i)&#160;the NASDAQ Official Closing Price and (ii)&#160;the consolidated closing bid price of the company&#x2019;s common stock on the Conversion Price Date. There is no floor on the conversion price for this convertible note, therefore, as of March&#160;31,&#160;2023 we cannot determine the total number of shares issuable upon conversion that may occur in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company received net proceeds of $29.9&#160;million from this financing, net of a $0.1&#160;million origination fee paid to the lender. The note is accounted for under ASC 825-10-15-4 FVO&#160;election. Under the FVO election, the note is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. With each such remeasurement, the note will be adjusted to fair value, with the change in fair value recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other income (expense), net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the condensed consolidated statement of operations, except that &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the change in the fair value resulting from a change in the instrument-specific credit risks are recognized as a component of other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As of March&#160;31,&#160;2023, we had a balance of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$29.9&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;related-party convertible note at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the condensed consolidated balance sheets related to the convertible promissory note measured at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;31,&#160;2022, the company amended and restated an aggregate of $315.1&#160;million (including outstanding principal and accrued and unpaid interest) of fixed-rate promissory notes held by entities affiliated with Dr. Soon-Shiong. Prior to the amendments and restatements, these notes bore and continue to bear interest at a per annum rate ranging from 3.0% to 6.0%, provide that the outstanding principal was and continues to be due and payable on September&#160;30,&#160;2025, and accrued and unpaid interest was or continues to be payable either upon maturity or, with respect to one of the notes, on a quarterly basis. Prior to the amendments and restatements, the company could and can continue to prepay the outstanding principal (together with accrued and unpaid interest), either in whole or in part, at any time without premium or penalty and without the prior consent of the lender, now subject to an advance notice period of at least five&#160;business days during which the lender can convert the amount requested to be prepaid by the company into shares of the company&#x2019;s common stock, as part of the amendment and restatement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of these fixed-rate promissory notes were amended and restated to include a conversion feature that gives each lender, at its sole option, at any time (other than when the lender is in receipt of a written notice of prepayment from the borrower), the right to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the company&#x2019;s common stock at a price of $5.67 per share. Upon receipt of a written notice of prepayment from the borrower, the lender has the right, at its option, to convert the outstanding principal amount to be prepaid and the accrued and unpaid interest thereon (as specified in the notice of prepayment) into shares of the company&#x2019;s common stock at a price of $5.67&#160;per share. No other material terms or conditions of these fixed-rate promissory notes were modified as part of the August&#160;31,&#160;2022 amendments and restatements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, the carrying value of the fixed-rated convertible promissory notes of $245.6&#160;million and $241.3&#160;million, respectively, was recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;related-party convertible notes and accrued interest, net of discount,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the condensed consolidated balance sheets. During the three months ended March&#160;31,&#160;2023 and 2022, the company made interest payments of $0.6&#160;million and $0.6&#160;million, respectively, related to our $40.0&#160;million promissory note.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Nonconvertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31,&#160;2023, the company had a promissory note outstanding with Nant Capital for $300.0&#160;million in principal and a carrying balance of $272.2&#160;million, net of unamortized discount of $27.8&#160;million. The note bears an interest rate of Term&#160;SOFR plus 8.0% per annum, payable on a quarterly basis. In the event of a default on the loan (as defined in both the original and amended and restated promissory notes), including if the company does not repay the loan at maturity, the company had and continues to have the right, at its sole option, to convert the outstanding principal amount and accrued and unpaid interest due under this note into fully paid and non-assessable shares of the company&#x2019;s common stock at a conversion price per share equal to $5.67. The company made interest payments of $9.4&#160;million and $4.4&#160;million during the three&#160;months&#160;ended March&#160;31,&#160;2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31,&#160;2023, the company had a promissory note outstanding with Nant Capital for $125.0&#160;million in principal and a carrying balance of $119.6&#160;million, net of unamortized discount of $5.4&#160;million. The note bears an interest rate of Term&#160;SOFR plus 8.0% per annum, payable on a quarterly basis. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. The company made an interest payment of $3.9&#160;million during three&#160;months&#160;ended March&#160;31,&#160;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31,&#160;2023, the company had a promissory note outstanding with Nant Capital for $50.0&#160;million in principal and a carrying balance of $49.8&#160;million, net of unamortized discount of $0.2&#160;million. The note bears an interest rate of Term&#160;SOFR plus 8.0% per annum, payable on a quarterly basis. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. In the event of a Specified Transaction (as defined in the loan agreement), the noteholder can request the outstanding principal and interest due on the loan be repaid in full upon consummation of such Specified Transaction. The company made a cash payment of $1.6&#160;million during three&#160;months&#160;ended March&#160;31,&#160;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our related-party debt is summarized below (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balances at March&#160;31,&#160;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;br/&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accrued&lt;br/&gt;Interest&lt;br/&gt;Added to&lt;br/&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less:&lt;br/&gt;Unamortized &lt;br/&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Related-Party Nonconvertible Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nant Capital (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term SOFR + 8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Related-Party Convertible Note &lt;br/&gt;&#160;&#160;&#160;at Fair Value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nant Capital (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term SOFR + 8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Related-Party Convertible Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nant Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nant Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nant Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NantMobile, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NantCancerStemCell, LLC (NCSC)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total related-party convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total related-party debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:94.132%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;The interest rate on our related-party variable-rate notes as of March&#160;31,&#160;2023 was 12.89%.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balances at December&#160;31,&#160;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;br/&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accrued&lt;br/&gt;Interest&lt;br/&gt;Added to&lt;br/&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less:&lt;br/&gt;Unamortized &lt;br/&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Related-Party Nonconvertible Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nant Capital (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term SOFR + 8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Related-Party Convertible Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nant Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nant Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nant Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NantMobile&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NCSC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total related-party convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total related-party debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:94.132%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;The interest rate on our related-party variable-rate notes as of December&#160;31,&#160;2022 was 12.59%.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated future contractual obligations for our related-party debt as of March&#160;31,&#160;2023 (unaudited; in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.404%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Payments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Convertible&lt;br/&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-convertible&lt;br/&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Convertible&lt;br/&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-convertible&lt;br/&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (excluding the three months ended &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;March&#160;31,&#160;2023)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal and estimated interest &lt;br/&gt;&#160;&#160;&#160;due on related-party debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;852,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest payments on our fixed-rate convertible notes are calculated based on contractual interest rates and scheduled maturity dates. Interest payments on our variable-rate notes are calculated based on Term&#160;SOFR plus the contractual spread per the loan agreements. The rate on our variable-rate notes as of March&#160;31,&#160;2023 was 12.89%.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Related-Party Agreements &lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We conduct business with several affiliates under written agreements and informal arrangements. Below is a summary of outstanding balances and a description of significant relationships (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;March&#160;31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due from related party&#x2013;NantBio, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due from related party&#x2013;Brink Biologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due from related parties&#x2013;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total due from related parties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due to related party&#x2013;Duley Road, LLC&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due to related party&#x2013;NantBio, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due to related party&#x2013;NantWorks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due to related party&#x2013;Immuno-Oncology Clinic, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total due to related parties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder founded and has a controlling interest in NantWorks, which is a collection of companies in the healthcare and technology space. As described below, we have entered into arrangements with NantWorks, and certain affiliates of NantWorks, to facilitate the development of new immunotherapies for our product pipeline. Affiliates of NantWorks are also affiliates of the company due to the common control by and/or common ownership interest of our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NantWorks, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shared Services Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the amended and restated shared services agreement with NantWorks dated as of June&#160;2016, but effective as of August&#160;2015, NantWorks, a related party, provides corporate, general and administrative, certain research and development, and other support services. We are charged for the services at cost plus reasonable allocations of employee benefits, facilities, and other direct or fairly allocated indirect costs that relate to the employees providing the services. For the three months ended March&#160;31,&#160;2023 and 2022, we recorded $1.0&#160;million and $1.3&#160;million, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;selling, general and administrative expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and $0.4&#160;million of expense reimbursements and an immaterial amount, respectively, under this arrangement in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the condensed consolidated statements of operations. These amounts exclude certain general and administrative expenses provided by third-party vendors directly for our benefit, which were reimbursed to NantWorks based on those vendors&#x2019; invoiced amounts without markup by NantWorks. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, we owed NantWorks net amounts of $0.6&#160;million and $1.0&#160;million, respectively, for all agreements between the two&#160;affiliates, which are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;due to related parties,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the condensed consolidated balance sheets. We also recorded $2.1&#160;million and $2.0&#160;million of prepaid expenses for services that have been passed through to the company from NantWorks as of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively, which are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;prepaid expenses and other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Facility License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, we entered into a facility license agreement with NantWorks for approximately 9,500 rentable square feet of office space in Culver&#160;City, California, which was converted to a research and development laboratory and a cGMP manufacturing facility. In&#160;2020, we amended this agreement to extend the term of this license agreement through December&#160;31,&#160;2021. Commencing on January&#160;1,&#160;2022, the license fee increased by 3% to approximately $56,120 per month.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;6,&#160;2022, we amended our facility license agreement with NantWorks to expand the licensed premises by 36,830&#160;rentable square feet to an aggregate total of 46,330 rentable square feet. Effective May&#160;1,&#160;2022, the license fee is approximately $273,700 per month, which is subject to a 3%&#160;increase commencing on January&#160;1 of each year. The space continues to be rented on a month-to-month basis, which can be terminated by either party with at least 30&#160;days&#x2019; prior written notice to the other party. We recorded license fee expense for this facility totaling $0.8&#160;million and $0.2&#160;million for the three months ended March&#160;31,&#160;2023 and 2022, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the condensed consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Immuno-Oncology Clinic, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into multiple agreements with Immuno-Oncology Clinic,&#160;Inc.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Clinic)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to conduct clinical trials related to certain of our product candidates. The Clinic is a related party as it is owned by an officer of the company and NantWorks manages the administrative operations of the Clinic. Pursuant to the terms of the Clinic agreement (as amended), we made payments totaling &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$5.6&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in consideration of future services to be performed by the Clinic. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, we completed a&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; review of alternative structures that could support our more complex clinical trial requirements and made a decision to explore a potential transition of clinical trials at the Clinic to a new structure (including contracting with a new, non-affiliated professional corporation) to be determined and agreed upon by all parties. Based on this decision to explore a potential transition, we determined that it was more likely than not that the previously recorded prepaid asset would not result in the collection of fees for services performed by the Clinic as contemplated in the original agreements. As a result, we wrote down the remaining value of our prepaid asset and recorded approximately $4.4&#160;million in &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the condensed consolidated statement of operations for the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31,&#160;2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We continue productive negotiations with potential partners around alternative structures, but there can be no assurance that we will be successful.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded $0.6&#160;million and $0.4&#160;million for the three months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31,&#160;2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2022, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the condensed consolidated statements of operations related to clinical trial and transition services provided by the Clinic. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31,&#160;2023 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31,&#160;2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;owed the&#160;Clinic an immaterial amount and $0.1&#160;million, respectively&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NantBio, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, we entered into a supply agreement with NCSC, a 60%&#160;owned subsidiary of NantBio (with the other&#160;40% owned by Sorrento). Under this agreement, we agreed to supply VivaBioCell&#x2019;s proprietary GMP-in-a-Box bioreactors and related consumables, made according to specifications mutually agreed to with both companies. The agreement has an initial term of five years and renews automatically for successive one-year terms unless terminated by either party in the event of material default upon prior written notice of such default and the failure of the defaulting party to remedy the default within 30&#160;days of the delivery of such notice, or upon 90 days&#x2019; prior written notice by NCSC. We recognized no&#160;revenue for the three months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31,&#160;2023 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and no revenue for the three months ended March&#160;31,&#160;2022. We recorded $0.1&#160;million and $0.1&#160;million of deferred revenue for bioreactors that were delivered but not installed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accrued expenses and other liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the condensed consolidated balance sheets as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31,&#160;2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and December&#160;31,&#160;2022, respectively. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31,&#160;2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and December&#160;31,&#160;2022, we recorded $0.9&#160;million in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;due to related parties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the condensed consolidated balance sheets related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, we entered into a shared service agreement pursuant to which we are charged for services at cost, without mark-up or profit by NantBio, but including reasonable allocations of employee benefits that relate to the employees providing the services. In April&#160;2019, we agreed with NantBio to transfer certain NantBio employees and associated research and development projects to the company. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31,&#160;2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and December&#160;31,&#160;2022, we recorded a net receivable from NantBio of $1.3&#160;million for amounts we paid on behalf of NantBio during the year ended December&#160;31,&#160;2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;605 Doug St, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September&#160;2016, we entered into a lease agreement with 605&#160;Doug&#160;St,&#160;LLC, an entity owned by our Executive Chairman and Global Chief Scientific and Medical Officer, for approximately 24,250 rentable square feet in El&#160;Segundo, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. The lease runs from July&#160;2016 through July&#160;2023. We have the option to extend the lease for one&#160;additional three-year term through July&#160;2026. The base rent is approximately $72,385 per month, with annual increases of 3% that began in July&#160;2017. We recorded lease expense for this facility of $0.2&#160;million and $0.2&#160;million for the three months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31,&#160;2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2022, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Duley Road, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February&#160;2017, we entered into a lease agreement with Duley&#160;Road, a related party that is indirectly controlled by our Executive Chairman and Global Chief Scientific and Medical Officer, for approximately 11,980 rentable square feet of office and cGMP manufacturing facility space in El&#160;Segundo, California. The lease term is from February&#160;2017 through October&#160;2024. We have the option to extend the initial term for two&#160;consecutive five-year periods through October&#160;2034. The base rent is approximately $40,700 per month, with annual increases of&#160;3%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective in January&#160;2019, we entered into two&#160;lease agreements with Duley Road for a second&#160;building located in El&#160;Segundo, California. The first&#160;lease is for the first&#160;floor of the building with approximately 5,650 rentable square feet. The lease has a seven-year term commencing in September&#160;2019. The second&#160;lease is for the second&#160;floor of the building with approximately 6,488 rentable square feet. The lease has a seven-year term commencing in July&#160;2019. Both floors of the building are used for research and development and office space. We have options to extend the initial terms of both leases for two&#160;consecutive five-year periods through 2036. The base rent for the two&#160;leases is approximately $35,800 per month, with annual increases of&#160;3%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31,&#160;2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and December&#160;31,&#160;2022, respectively, we recorded $0.9&#160;million and $0.9&#160;million of leasehold improvement payables, and $0.5&#160;million and $0.6&#160;million of lease-related payables, to Duley Road, which were included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;due to related parties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the condensed consolidated balance sheets. We recorded rent expense for these leases totaling $0.2&#160;million and $0.2&#160;million for the three months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31,&#160;2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2022, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the condensed consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;605 Nash, LLC &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;February&#160;2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, but effective on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;January&#160;1,&#160;2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we entered into a lease agreement with 605&#160;Nash, a related party, whereby we leased approximately 6,883 rentable square feet (the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Initial Premises) i&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n a two&#160;story mixed use building containing approximately 64,643 rentable square feet on 605-607 Nash Street in El&#160;Segundo, California. This facility is used primarily for pharmaceutical development and manufacturing purposes. The lease term commenced in January&#160;2021 and expires in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;2027&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and includes an option to extend the lease for one three-year term through &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;2030&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The base rent is approximately $20,300 per month with an annual increase of 3%&#160;on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;January&#160;1&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of each year during the initial term and, if applicable, during the option term. In addition, under the agreement, we are required to pay our share of estimated property taxes and operating expenses. We received a rent abatement for the first seven months. The lease also provides a tenant improvement incentive of $0.3&#160;million for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;costs and expenses associated with the construction of tenant improvements for the Initial Premises.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May&#160;2021, but effective on April&#160;1,&#160;2021, we entered into an amendment to our Initial Premises lease with 605&#160;Nash. The amendment expanded the leased square feet by approximately 57,760 rentable square feet (the Expansion Premises). The lease term of the Expansion Premises commenced in April&#160;2021 and expires in March&#160;2028, whereby the company has the option to extend the initial term for three years. Per the terms of the amendment, the term of the Initial Premises lease was extended for an additional three&#160;months and now expires on March&#160;31,&#160;2028. Base rent for the Expansion Premises is approximately $170,400&#160;per month with annual increases of 3% on April&#160;1 of each year. We are responsible for the build out of the facility space and associated costs. We received a rent abatement for the first seven months. The amended lease provides for a tenant improvement allowance of approximately $2.6&#160;million for costs and expenses related to improvements made by us to the Expansion Premises. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded rent expense for the Initial and Expansion Premises leases totaling $0.5&#160;million and $0.5&#160;million for the three months ended March&#160;31,&#160;2023 and 2022, respectively, i&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;420 Nash, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;27,&#160;2021, we entered into a lease agreement with 420&#160;Nash,&#160;LLC, a related party, whereby we leased an approximately 19,125 rentable square foot property located at 420&#160;Nash Street, El&#160;Segundo, California, to be used primarily for the warehousing and storage of drug manufacturing supplies, products and equipment and ancillary office space. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the lease agreement, the lease term began on October&#160;1,&#160;2021 and expires on September&#160;30,&#160;2026. The base rent is approximately $38,250 per month with an annual increase of 3% on October&#160;1 of each year beginning in 2022 during the initial term. The company is responsible for the payment of real property taxes, repairs and maintenance, improvements, insurance and operating expenses during the term of the lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company has options to extend the lease term for two&#160;additional consecutive periods of five years each. At the beginning of each option term, the initial monthly base rent will be adjusted to market rent (as defined in the lease agreement) with an annual increase of 3% during the option term. We have included the first&#160;option to extend the lease term for five&#160;years as part of the initial term of the lease as it is reasonably certain that we will exercise the option, which implies lease expiration in September&#160;2031. We recorded $0.1&#160;million and $0.1&#160;million of rent expense related to this lease for the three months ended March&#160;31,&#160;2023 and 2022, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;23&#160;Alaska, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;6,&#160;2022, we entered into a lease agreement with 23&#160;Alaska,&#160;LLC, a related party, for a 47,265 rentable square foot facility located at 2335&#160;Alaska Ave., El&#160;Segundo, California, to be used primarily for pharmaceutical development and manufacturing, research and development, and office space. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, the lease term begins on May&#160;1,&#160;2022 and expires on April&#160;30,&#160;2027. The base rent is approximately $139,400&#160;per month with an annual increase of 3% on May&#160;1 of each year beginning in 2023 during the initial term. We are also required to pay $7,600&#160;per month for parking during the initial term and extension term, if exercised. The company is responsible for the payment of real property taxes, repairs and maintenance, improvements, insurance, and operating expenses during the term of the lease. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company has&#160;an option to extend the lease term for one&#160;additional consecutive five-year period. At the beginning of the option term, the initial monthly base rent will be adjusted to market rent (as defined in the lease agreement) with an annual increase of 3%&#160;during the option term. We recorded $0.4&#160;million of rent expense for this lease for the three months ended March&#160;31,&#160;2023 in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the condensed consolidated statement of operations.&lt;/span&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <ibrx:RelatedPartyNotesPayable
      contextRef="i4d61f38abc9b467da5b3204da34fab5e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ1MzY4NQ_28189d53-790e-45e7-93a3-df4f7efc30ac"
      unitRef="usd">30000000</ibrx:RelatedPartyNotesPayable>
    <ibrx:RelatedPartyTransactionBasisSpreadOnVariableRate
      contextRef="i3a3e26a21876460b8624019e43e286e0_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMjc0ODc3OTA4MTQ3Mg_dabfbb08-a781-476f-9987-62083792c977"
      unitRef="number">0.080</ibrx:RelatedPartyTransactionBasisSpreadOnVariableRate>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="i44cc657d262146519329e8d5460c262d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY1NzEwMA_09b7fe3a-28d5-4a1b-8bec-3d15426d01e0"
      unitRef="usd">29900000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i4d61f38abc9b467da5b3204da34fab5e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY1NzExNQ_df0de141-7318-4e8e-8783-8f7e17af5202"
      unitRef="usd">100000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent
      contextRef="i4d61f38abc9b467da5b3204da34fab5e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY1NzEzMg_11c9fc27-5331-4312-84eb-080a90c74634"
      unitRef="usd">29900000</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <ibrx:NotesPayableRelatedPartiesPrincipalAndAccruedInterest
      contextRef="if421742d22da4377a2a2d5d3ad4dee90_I20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2MDc1MQ_681ddf6c-510a-4378-aa70-8573816e19b3"
      unitRef="usd">315100000</ibrx:NotesPayableRelatedPartiesPrincipalAndAccruedInterest>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="iad7a8cf8ad9546059a44a0c2f4102d99_D20220101-20220731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2MDc1OA_b898c81e-45dc-4c38-9221-3f00243a46da"
      unitRef="number">0.030</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="i9adb1d0654114ee5afbed60cfa9e4766_D20220101-20220731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2MDc2NQ_16f9d844-f6c1-49ef-9b7a-58e18416f908"
      unitRef="number">0.060</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="if421742d22da4377a2a2d5d3ad4dee90_I20220831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2MDc5NQ_3ebd101b-9ef7-4e80-ab39-edd321b65c08"
      unitRef="usdPerShare">5.67</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="if421742d22da4377a2a2d5d3ad4dee90_I20220831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfNTQ5NzU1ODU3MTQ0_3ebd101b-9ef7-4e80-ab39-edd321b65c08"
      unitRef="usdPerShare">5.67</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="ifeeaf31a1b7546b08e11b31f6de4b788_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2MTA5NA_b528d342-cde2-4fba-b378-9948a662a0eb"
      unitRef="usd">245600000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i3be51647022b41c5aac446b43954112a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2MTEwNQ_959fc23f-6ed7-479b-a64f-858e005e4a10"
      unitRef="usd">241300000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:InterestPaidNet
      contextRef="i700361120e53402ba852dcb639cda333_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2MTE4Mg_59b0d02b-6036-4628-9cbf-4e64da92e50a"
      unitRef="usd">600000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ia44124c82520433e872adbae39679ee3_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2MTE2Mw_e129a448-064e-4881-8fa1-2dd499a007dd"
      unitRef="usd">600000</us-gaap:InterestPaidNet>
    <ibrx:RelatedPartyNotesPayable
      contextRef="i3c27fb3d47934120827861b39628c2b1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMjE5OTAyMzI5ODE5MA_f95c9537-090e-4d1b-a144-a6529192c3cf"
      unitRef="usd">40000000</ibrx:RelatedPartyNotesPayable>
    <ibrx:RelatedPartyNotesPayable
      contextRef="iefda7cd80c064a8e958479a947e51afb_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2NjU5NA_b490ee2a-588c-4847-94e8-539ac0d23a6e"
      unitRef="usd">300000000</ibrx:RelatedPartyNotesPayable>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="iefda7cd80c064a8e958479a947e51afb_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2NjYxNQ_a0f9a645-c554-43b9-a32c-d98b833cdfa9"
      unitRef="usd">272200000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="iefda7cd80c064a8e958479a947e51afb_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2NjYzOQ_3f533217-6207-40c9-8ab1-faa78d9b82fc"
      unitRef="usd">27800000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <ibrx:RelatedPartyTransactionBasisSpreadOnVariableRate
      contextRef="if26e41fef20847b6b81445d4a3101377_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2NjcwNw_65fcf6d8-aa15-4ae6-86a4-893ec0c0bb35"
      unitRef="number">0.080</ibrx:RelatedPartyTransactionBasisSpreadOnVariableRate>
    <ibrx:OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare
      contextRef="id782271befaf426399ce9443216bb892_D20220831-20220831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTA5OTUxMTY2NjY1MQ_456ec889-ed59-4a8f-bf39-08c6b10e1c09"
      unitRef="usdPerShare">5.67</ibrx:OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare>
    <us-gaap:InterestPaidNet
      contextRef="id84e4096f5c442528938b4337cf7c8ed_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ4MDg4OQ_1b7c61b9-c2c5-45a8-a525-4b60938723df"
      unitRef="usd">9400000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i7f716744d3be43e38afdc26a656b33b7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ4MDkwMA_67b901b8-5a0a-4d1d-bae0-17aab5425098"
      unitRef="usd">4400000</us-gaap:InterestPaidNet>
    <ibrx:RelatedPartyNotesPayable
      contextRef="i604c474521cf4dd693f946bc8cff054d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ4MDk0Mg_5b666a2d-dc4b-41f6-88fc-2bef10c8c5e7"
      unitRef="usd">125000000</ibrx:RelatedPartyNotesPayable>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i604c474521cf4dd693f946bc8cff054d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ4MDk2Mw_9ee68348-a8b9-4503-88ee-5c74fd9193bb"
      unitRef="usd">119600000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i604c474521cf4dd693f946bc8cff054d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ4MDk4Mg_db4ff115-d4c1-4dd1-b657-32209e8e58d8"
      unitRef="usd">5400000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <ibrx:RelatedPartyTransactionBasisSpreadOnVariableRate
      contextRef="i168a4524f50644799beb0bf0791c2954_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMjE5OTAyMzI5ODI2OQ_bbeffc19-6129-4e60-b801-16f0e712d22d"
      unitRef="number">0.080</ibrx:RelatedPartyTransactionBasisSpreadOnVariableRate>
    <us-gaap:InterestPaidNet
      contextRef="ic72646472e3b48a295ebef3a0ebdf66f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ4MDkxMA_105f0a98-71d0-4daf-a3b9-8049a22ed797"
      unitRef="usd">3900000</us-gaap:InterestPaidNet>
    <ibrx:RelatedPartyNotesPayable
      contextRef="i8e671951edb7455ea24c2ac0392ea151_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ4MTAzMQ_4875bb4e-eaef-4f26-82e4-04ee595b0fb1"
      unitRef="usd">50000000</ibrx:RelatedPartyNotesPayable>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i8e671951edb7455ea24c2ac0392ea151_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ4MTA1MQ_6874fc88-b3ea-4666-aab2-0cb42ec60af0"
      unitRef="usd">49800000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i8e671951edb7455ea24c2ac0392ea151_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ4MTA3MA_5980b03e-b5d1-41a3-a9cb-b24c24967f64"
      unitRef="usd">200000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <ibrx:RelatedPartyTransactionBasisSpreadOnVariableRate
      contextRef="if3d09e78bc0148b7a0f1abb485cdc81a_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ4MTAxNQ_83b4a703-a8a2-436c-8293-87026fcbf3ab"
      unitRef="number">0.080</ibrx:RelatedPartyTransactionBasisSpreadOnVariableRate>
    <us-gaap:InterestPaidNet
      contextRef="if86dd819ffd041e19f08088aa305bbd6_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfMTY0OTI2NzQ4MDkyMA_70d13231-8aca-4350-819b-10e1756bb686"
      unitRef="usd">1600000</us-gaap:InterestPaidNet>
    <ibrx:ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfODU3OA_cd16c68c-b637-4e4f-94fd-e83c0865d62a">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our related-party debt is summarized below (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balances at March&#160;31,&#160;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;br/&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accrued&lt;br/&gt;Interest&lt;br/&gt;Added to&lt;br/&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less:&lt;br/&gt;Unamortized &lt;br/&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Related-Party Nonconvertible Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nant Capital (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term SOFR + 8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Related-Party Convertible Note &lt;br/&gt;&#160;&#160;&#160;at Fair Value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nant Capital (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term SOFR + 8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Related-Party Convertible Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nant Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nant Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nant Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NantMobile, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NantCancerStemCell, LLC (NCSC)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total related-party convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total related-party debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:94.132%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;The interest rate on our related-party variable-rate notes as of March&#160;31,&#160;2023 was 12.89%.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balances at December&#160;31,&#160;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;br/&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accrued&lt;br/&gt;Interest&lt;br/&gt;Added to&lt;br/&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less:&lt;br/&gt;Unamortized &lt;br/&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Related-Party Nonconvertible Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nant Capital (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term SOFR + 8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Related-Party Convertible Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nant Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nant Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nant Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NantMobile&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NCSC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total related-party convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total related-party debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:94.132%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;The interest rate on our related-party variable-rate notes as of December&#160;31,&#160;2022 was 12.59%.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ibrx:ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock>
    <ibrx:RelatedPartyTransactionBasisSpreadOnVariableRate
      contextRef="if26e41fef20847b6b81445d4a3101377_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfNy0zLTEtMS0yOTgzNTIvdGV4dHJlZ2lvbjo3MWZhMjYyOTJlMmI0NmJjOTJiOTA4MGVmOTU0NDUwOF8xMDk5NTExNjI3ODA1_b08d4e75-9568-481e-9d4a-dfd4740af3cc"
      unitRef="number">0.080</ibrx:RelatedPartyTransactionBasisSpreadOnVariableRate>
    <ibrx:RelatedPartyNotesPayable
      contextRef="i8c875c85efb244079066f90b6b550c50_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfNy01LTEtMS0yOTgzNTI_6035700d-9284-4d63-b99c-c5b302716135"
      unitRef="usd">475000000</ibrx:RelatedPartyNotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i8c875c85efb244079066f90b6b550c50_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfNy03LTEtMS0yOTgzNTI_e21bdfdb-e9fb-4cf3-a604-92e95719d6fd"
      unitRef="usd">0</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i8c875c85efb244079066f90b6b550c50_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfNy05LTEtMS0yOTgzNTI_833af451-8b05-4e90-9cf3-78d74a8a94e9"
      unitRef="usd">33372000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i8c875c85efb244079066f90b6b550c50_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfNy0xMS0xLTEtMjk4MzUy_425bf32c-914e-4585-95f6-ae958a2536b4"
      unitRef="usd">441628000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <ibrx:RelatedPartyTransactionBasisSpreadOnVariableRate
      contextRef="i3a3e26a21876460b8624019e43e286e0_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfOS0zLTEtMS0zMjI2OTgvdGV4dHJlZ2lvbjpiOWQwNzYzOGM3MDk0NWYxOTdkNmU2NGQwOWVhYTViOV8xNg_dabfbb08-a781-476f-9987-62083792c977"
      unitRef="number">0.080</ibrx:RelatedPartyTransactionBasisSpreadOnVariableRate>
    <ibrx:RelatedPartyNotesPayable
      contextRef="i4d61f38abc9b467da5b3204da34fab5e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfOS01LTEtMS0zMjI2OTg_91491102-1c86-49c9-ad78-e2068b2b5ce6"
      unitRef="usd">30000000</ibrx:RelatedPartyNotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i4d61f38abc9b467da5b3204da34fab5e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfOS03LTEtMS0zMjI2OTg_411ec9c1-478f-4cb6-b514-5d16b79c2c12"
      unitRef="usd">0</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i4d61f38abc9b467da5b3204da34fab5e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfOS05LTEtMS0zMjI2OTg_e42b3deb-2142-4eea-9385-aa627365d0a7"
      unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i4d61f38abc9b467da5b3204da34fab5e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfOS0xMS0xLTEtMzIyNjk4_e16f98c9-acf6-4fdd-a7de-04b6e0d67b9f"
      unitRef="usd">29850000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="i07cfde51688d493b82c4be4a684839e5_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfOS0zLTEtMS0yOTgzNTI_bb105d64-5ea3-4677-ba68-6330f300f3fa"
      unitRef="number">0.050</us-gaap:RelatedPartyTransactionRate>
    <ibrx:RelatedPartyNotesPayable
      contextRef="id87c72a123a646d7a99485bf28cfb653_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfOS01LTEtMS0yOTgzNTI_98eb3388-4247-4545-a9e4-425cf9d4a408"
      unitRef="usd">55226000</ibrx:RelatedPartyNotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="id87c72a123a646d7a99485bf28cfb653_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfOS03LTEtMS0yOTgzNTI_ec7d24a5-beb7-45a6-b53e-51a97fa956dc"
      unitRef="usd">10113000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="id87c72a123a646d7a99485bf28cfb653_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfOS05LTEtMS0yOTgzNTI_de110707-864d-461f-9336-0d7b2ed7e54c"
      unitRef="usd">4742000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="id87c72a123a646d7a99485bf28cfb653_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfOS0xMS0xLTEtMjk4MzUy_c3ee1559-0e01-403f-adf5-8588ee82461a"
      unitRef="usd">60597000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="ie84a9931057b4e4aae2bb4ed9870ba8f_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTAtMy0xLTEtMjk4MzUy_f7ebcf97-2b74-4b95-bc9e-be990ed15881"
      unitRef="number">0.060</us-gaap:RelatedPartyTransactionRate>
    <ibrx:RelatedPartyNotesPayable
      contextRef="i1743878cb0574c6cbbbcdd536eda339a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTAtNS0xLTEtMjk4MzUy_35433777-20e1-4c85-b8c0-377aa1e93b9d"
      unitRef="usd">50000000</ibrx:RelatedPartyNotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i1743878cb0574c6cbbbcdd536eda339a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTAtNy0xLTEtMjk4MzUy_d76b971a-33fb-4bcd-988c-ab6994e4aa60"
      unitRef="usd">7870000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i1743878cb0574c6cbbbcdd536eda339a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTAtOS0xLTEtMjk4MzUy_53e0aca8-f839-4376-a6a5-38cd8d438db4"
      unitRef="usd">3696000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i1743878cb0574c6cbbbcdd536eda339a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTAtMTEtMS0xLTI5ODM1Mg_2516e0ab-e8ce-4d60-87a3-5cb02327cdba"
      unitRef="usd">54174000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="i36630a5fb97140119768102b4c075987_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTEtMy0xLTEtMjk4MzUy_6479915e-d626-493a-9131-625a2fe5942e"
      unitRef="number">0.060</us-gaap:RelatedPartyTransactionRate>
    <ibrx:RelatedPartyNotesPayable
      contextRef="i3c27fb3d47934120827861b39628c2b1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTEtNS0xLTEtMjk4MzUy_14b7b5a9-5b87-431d-af8c-19fe2beca36a"
      unitRef="usd">40000000</ibrx:RelatedPartyNotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i3c27fb3d47934120827861b39628c2b1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTEtNy0xLTEtMjk4MzUy_1534254c-f755-4e09-a7b2-5a704d482601"
      unitRef="usd">0</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i3c27fb3d47934120827861b39628c2b1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTEtOS0xLTEtMjk4MzUy_5e060dd6-2027-4c2a-aa36-0d84e38c562a"
      unitRef="usd">2373000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i3c27fb3d47934120827861b39628c2b1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTEtMTEtMS0xLTI5ODM1Mg_2ddb4ff8-c6a7-4e85-a879-f60ca3d765f1"
      unitRef="usd">37627000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="i023872a5c0664193ae14daa63ba5eefc_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTItMy0xLTEtMjk4MzUy_63ce4d92-c5be-449d-99e8-9d9519982798"
      unitRef="number">0.030</us-gaap:RelatedPartyTransactionRate>
    <ibrx:RelatedPartyNotesPayable
      contextRef="i02d66470d5a1468c83c9015ed4ab3ab0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTItNS0xLTEtMjk4MzUy_db2c0a0a-650c-4857-8d8e-b24528c4cc03"
      unitRef="usd">55000000</ibrx:RelatedPartyNotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i02d66470d5a1468c83c9015ed4ab3ab0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTItNy0xLTEtMjk4MzUy_e89aae8e-cb24-4300-8306-f01caf3a93cf"
      unitRef="usd">5554000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i02d66470d5a1468c83c9015ed4ab3ab0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTItOS0xLTEtMjk4MzUy_55e20bf8-4869-412a-a5f9-4d8d1664e6db"
      unitRef="usd">5482000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i02d66470d5a1468c83c9015ed4ab3ab0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTItMTEtMS0xLTI5ODM1Mg_b8685d85-9d67-464f-918e-a552da197969"
      unitRef="usd">55072000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="i46483bc0e4034520a181080e17a40498_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTMtMy0xLTEtMjk4MzUy_690f036c-9735-40a8-86ae-038c681010f5"
      unitRef="number">0.050</us-gaap:RelatedPartyTransactionRate>
    <ibrx:RelatedPartyNotesPayable
      contextRef="i20b7ac56635b4a66a2d03236bce015d7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTMtNS0xLTEtMjk4MzUy_1c014a9c-acf2-49fd-889f-1426822dc4a8"
      unitRef="usd">33000000</ibrx:RelatedPartyNotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i20b7ac56635b4a66a2d03236bce015d7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTMtNy0xLTEtMjk4MzUy_d338e166-90bf-4ac0-86c1-f88bda135303"
      unitRef="usd">8176000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i20b7ac56635b4a66a2d03236bce015d7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTMtOS0xLTEtMjk4MzUy_d4576919-3a05-442f-94a5-1ff34e8984ae"
      unitRef="usd">3006000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i20b7ac56635b4a66a2d03236bce015d7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTMtMTEtMS0xLTI5ODM1Mg_81e4f438-35e3-491e-8176-a5ac4c7e2292"
      unitRef="usd">38170000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <ibrx:RelatedPartyNotesPayable
      contextRef="ia0c37984b4ee4c4e8d32a3fcda72fd96_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTQtNS0xLTEtMjk4MzUy_ad740198-e663-477d-8631-d48b2382750e"
      unitRef="usd">233226000</ibrx:RelatedPartyNotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="ia0c37984b4ee4c4e8d32a3fcda72fd96_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTQtNy0xLTEtMjk4MzUy_143ad46e-303e-41df-8c85-753f28b8db34"
      unitRef="usd">31713000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ia0c37984b4ee4c4e8d32a3fcda72fd96_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTQtOS0xLTEtMjk4MzUy_b73f3f3a-2d97-48a4-983e-a7104c11a713"
      unitRef="usd">19299000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="ia0c37984b4ee4c4e8d32a3fcda72fd96_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTQtMTEtMS0xLTI5ODM1Mg_0a7f01a5-159f-423d-a2bf-f74832ed06c2"
      unitRef="usd">245640000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <ibrx:RelatedPartyNotesPayable
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTUtNS0xLTEtMjk4MzUy_18fdb1f7-759f-454a-8f64-1a4d331c0474"
      unitRef="usd">738226000</ibrx:RelatedPartyNotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTUtNy0xLTEtMjk4MzUy_3d4e355e-2918-4512-b176-0ec2041b65fd"
      unitRef="usd">31713000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTUtOS0xLTEtMjk4MzUy_2bd56d9f-3b34-4cba-98db-874d77e18cc3"
      unitRef="usd">52671000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk5ODNmYmViOGUyMjRlMDNiZTRlOWJmZWQ2MjQxMWFkL3RhYmxlcmFuZ2U6OTk4M2ZiZWI4ZTIyNGUwM2JlNGU5YmZlZDYyNDExYWRfMTUtMTEtMS0xLTI5ODM1Mg_9134b6cc-4343-43b4-8a91-6442fe98b7e1"
      unitRef="usd">717118000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="i6c63ca50dfe64ec5a0637410c6d5397b_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOmI1MWRjOGJiNjc4NjQyMjU4NTk5ZDllNTQyNjg5ZmFmL3RhYmxlcmFuZ2U6YjUxZGM4YmI2Nzg2NDIyNTg1OTlkOWU1NDI2ODlmYWZfMC0xLTEtMS0yOTgzNTIvdGV4dHJlZ2lvbjpjOGQzNWE3NDIxOTA0ZjRjODE3M2Q2NjZmNGNmNTcyN183Ng_c745f04d-e007-4a39-a2a2-3282a31dcd61"
      unitRef="number">0.1289</us-gaap:RelatedPartyTransactionRate>
    <ibrx:RelatedPartyTransactionBasisSpreadOnVariableRate
      contextRef="if26e41fef20847b6b81445d4a3101377_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNC0zLTEtMS0yOTgzNTIvdGV4dHJlZ2lvbjo1ZTJhODQwMzk2OTI0MDY3OWIzZDI0MDAyNzNjNWJkMV8xNjQ5MjY3NDQxNjgz_b08d4e75-9568-481e-9d4a-dfd4740af3cc"
      unitRef="number">0.080</ibrx:RelatedPartyTransactionBasisSpreadOnVariableRate>
    <ibrx:RelatedPartyNotesPayable
      contextRef="i6bffc59bc82a4092b0b095eb4b104f99_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNC01LTEtMS0yOTgzNTI_15567468-30ca-434d-b111-31f4f24e947d"
      unitRef="usd">475000000</ibrx:RelatedPartyNotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i6bffc59bc82a4092b0b095eb4b104f99_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNC03LTEtMS0yOTgzNTI_0e13cf2d-4bb0-4178-a871-fb4f2f40f443"
      unitRef="usd">0</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i6bffc59bc82a4092b0b095eb4b104f99_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNC05LTEtMS0yOTgzNTI_d9b1b382-2dbd-4bb1-b218-aa34bc4eacde"
      unitRef="usd">43099000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i6bffc59bc82a4092b0b095eb4b104f99_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNC0xMS0xLTEtMjk4MzUy_ef1a0dc0-89a5-4342-bd8d-95a35ed84268"
      unitRef="usd">431901000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="ifa2f8dcc34a64a3f95777076fb02b849_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNi0zLTEtMS0yOTgzNTI_145d0129-acb6-4224-8a6b-c183f6f94df4"
      unitRef="number">0.050</us-gaap:RelatedPartyTransactionRate>
    <ibrx:RelatedPartyNotesPayable
      contextRef="i3f7988bcb71d43779a0096791bc726c6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNi01LTEtMS0yOTgzNTI_f788dad5-0d4b-4703-82d6-9a5d9f4e4309"
      unitRef="usd">55226000</ibrx:RelatedPartyNotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i3f7988bcb71d43779a0096791bc726c6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNi03LTEtMS0yOTgzNTI_ed3df53b-1341-432f-85eb-afe2e97c9871"
      unitRef="usd">9320000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i3f7988bcb71d43779a0096791bc726c6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNi05LTEtMS0yOTgzNTI_77dfb947-c0a5-430d-b278-a92027b4d5b8"
      unitRef="usd">5188000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i3f7988bcb71d43779a0096791bc726c6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNi0xMS0xLTEtMjk4MzUy_c7ea9599-5c7d-4d47-b47d-baaa2948fd9c"
      unitRef="usd">59358000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="i965c76f591504ffd870c02a47f91e4d1_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNy0zLTEtMS0yOTgzNTI_ff0e2ea4-0cd0-4a1b-903b-4147047b497b"
      unitRef="number">0.060</us-gaap:RelatedPartyTransactionRate>
    <ibrx:RelatedPartyNotesPayable
      contextRef="ib9880130e66047f2be4005667dcc04df_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNy01LTEtMS0yOTgzNTI_a7ea48cf-0fcd-4889-af0a-2f077fec8306"
      unitRef="usd">50000000</ibrx:RelatedPartyNotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="ib9880130e66047f2be4005667dcc04df_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNy03LTEtMS0yOTgzNTI_cbff73c3-e2c9-4f4d-83ac-c854ea35c93e"
      unitRef="usd">7039000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ib9880130e66047f2be4005667dcc04df_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNy05LTEtMS0yOTgzNTI_79d2b085-5470-44fc-82ba-c292725642f6"
      unitRef="usd">4068000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="ib9880130e66047f2be4005667dcc04df_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfNy0xMS0xLTEtMjk4MzUy_267c21ba-b292-4f6c-a8f3-1d2eef4e5463"
      unitRef="usd">52971000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="i3116163dc179457f83c1a522829e482e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfOC0zLTEtMS0yOTgzNTI_b91dcd6b-975a-4fc5-8288-17b864352fab"
      unitRef="number">0.060</us-gaap:RelatedPartyTransactionRate>
    <ibrx:RelatedPartyNotesPayable
      contextRef="ic800e90d3fa44e74bfd616fa559ef8f8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfOC01LTEtMS0yOTgzNTI_2f9bbdee-8671-4da6-813d-d83a1523ffb4"
      unitRef="usd">40000000</ibrx:RelatedPartyNotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="ic800e90d3fa44e74bfd616fa559ef8f8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfOC03LTEtMS0yOTgzNTI_df327ad2-d0d4-4a0f-850a-13569bd7dc97"
      unitRef="usd">0</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ic800e90d3fa44e74bfd616fa559ef8f8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfOC05LTEtMS0yOTgzNTI_b5813c01-c0b1-4368-b496-d7752cfbbbb6"
      unitRef="usd">2580000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="ic800e90d3fa44e74bfd616fa559ef8f8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfOC0xMS0xLTEtMjk4MzUy_5a79351a-978c-418d-9a96-506ed887db88"
      unitRef="usd">37420000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="i76bd041f34bc45308f8baecb04934003_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfOS0zLTEtMS0yOTgzNTI_94e9bd50-2d3e-441a-b35b-227298a9a023"
      unitRef="number">0.030</us-gaap:RelatedPartyTransactionRate>
    <ibrx:RelatedPartyNotesPayable
      contextRef="i273275e6ceed474fa66492ae83f982da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfOS01LTEtMS0yOTgzNTI_197e95ab-6ab9-4eb9-a88e-63e51b1ad028"
      unitRef="usd">55000000</ibrx:RelatedPartyNotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i273275e6ceed474fa66492ae83f982da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfOS03LTEtMS0yOTgzNTI_665709b3-727e-4621-8b3d-381d94b34de3"
      unitRef="usd">5110000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i273275e6ceed474fa66492ae83f982da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfOS05LTEtMS0yOTgzNTI_b72a8949-e1a2-49a5-abfa-7c59d6262961"
      unitRef="usd">5978000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i273275e6ceed474fa66492ae83f982da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfOS0xMS0xLTEtMjk4MzUy_a59626ce-90d8-45a6-88d7-1f247983eb46"
      unitRef="usd">54132000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="icde6ce22814d4976bf3ce94a8a10aa0a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTEtMy0xLTEtMjk4MzUy_c7899529-6ac4-4052-8e2a-78bc2cc371a7"
      unitRef="number">0.050</us-gaap:RelatedPartyTransactionRate>
    <ibrx:RelatedPartyNotesPayable
      contextRef="i34b60dc14eca495189c0a9fd77ab929d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTEtNS0xLTEtMjk4MzUy_8e210365-3b70-4ce2-b884-ff4388a8ed52"
      unitRef="usd">33000000</ibrx:RelatedPartyNotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i34b60dc14eca495189c0a9fd77ab929d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTEtNy0xLTEtMjk4MzUy_6fdf96d0-b8ee-4949-8c77-14dbf76bbafc"
      unitRef="usd">7684000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i34b60dc14eca495189c0a9fd77ab929d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTEtOS0xLTEtMjk4MzUy_c39222d1-0839-4ccd-8a0b-881ce5635939"
      unitRef="usd">3294000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i34b60dc14eca495189c0a9fd77ab929d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTEtMTEtMS0xLTI5ODM1Mg_08b8d9f5-a5ee-49cd-a05d-c3060727943a"
      unitRef="usd">37390000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <ibrx:RelatedPartyNotesPayable
      contextRef="i5b6fd5dc04474fc6ad30fdb536534995_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTItNS0xLTEtMjk4MzUy_963c34b9-a899-43e6-9336-ad3761469abf"
      unitRef="usd">233226000</ibrx:RelatedPartyNotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i5b6fd5dc04474fc6ad30fdb536534995_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTItNy0xLTEtMjk4MzUy_211f9faa-2ab8-4237-8bec-2f681cb06243"
      unitRef="usd">29153000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i5b6fd5dc04474fc6ad30fdb536534995_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTItOS0xLTEtMjk4MzUy_797a4fc9-770d-4b11-bc17-e33c99ef4b8e"
      unitRef="usd">21108000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i5b6fd5dc04474fc6ad30fdb536534995_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTItMTEtMS0xLTI5ODM1Mg_047b17cd-d31f-4b3d-b00f-5a700bea3950"
      unitRef="usd">241271000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <ibrx:RelatedPartyNotesPayable
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTMtNS0xLTEtMjk4MzUy_b8cd3378-4ee8-4390-9050-98928d4d0316"
      unitRef="usd">708226000</ibrx:RelatedPartyNotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTMtNy0xLTEtMjk4MzUy_2d8faa43-1a09-4355-9da2-743530f65357"
      unitRef="usd">29153000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTMtOS0xLTEtMjk4MzUy_def23971-2ca1-4720-bc8f-5767dccfc89e"
      unitRef="usd">64207000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjk2NDFjZjJhMmVjMzRhZDhiMTVmZGU2MTYyNzFlZWU1L3RhYmxlcmFuZ2U6OTY0MWNmMmEyZWMzNGFkOGIxNWZkZTYxNjI3MWVlZTVfMTMtMTEtMS0xLTI5ODM1Mg_6bffa494-4702-4afc-9763-ee7e0163b1a9"
      unitRef="usd">673172000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="ifa4a4292eb67427d8486a6d30953b1b1_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjFhZWY4ODZhMGQ0YzQyN2FiNjNjYzU4OWRjOWNiNDk1L3RhYmxlcmFuZ2U6MWFlZjg4NmEwZDRjNDI3YWI2M2NjNTg5ZGM5Y2I0OTVfMC0xLTEtMS0yOTgzNTIvdGV4dHJlZ2lvbjpjODMwMTlmMTAyMWM0YTc2Yjk4OGExYjliNjMyYmNmYl8xMDk5NTExNjI3ODcw_7fba8940-9be6-4bce-8451-10f9d23b0f27"
      unitRef="number">0.1259</us-gaap:RelatedPartyTransactionRate>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RleHRyZWdpb246NTA5MmI2ZTBlYmEzNDk5YmFmN2RlNTM2ZjMyZGU1ZDJfODU3OQ_1b2f3f12-14f9-42f0-b793-9be37d77b481">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated future contractual obligations for our related-party debt as of March&#160;31,&#160;2023 (unaudited; in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.404%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Payments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Convertible&lt;br/&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-convertible&lt;br/&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Convertible&lt;br/&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-convertible&lt;br/&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (excluding the three months ended &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;March&#160;31,&#160;2023)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal and estimated interest &lt;br/&gt;&#160;&#160;&#160;due on related-party debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;852,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest payments on our fixed-rate convertible notes are calculated based on contractual interest rates and scheduled maturity dates. Interest payments on our variable-rate notes are calculated based on Term&#160;SOFR plus the contractual spread per the loan agreements. The rate on our variable-rate notes as of March&#160;31,&#160;2023 was 12.89%.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i96fd516d0b2c4ab88b68926fb81bb129_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfMy0yLTEtMS0yOTgzNTI_b57c732d-0d2f-4843-8b9a-f80b1e684ac2"
      unitRef="usd">30000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i860cd6cdf17243bd9cb45083c2bd5bb7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfMy00LTEtMS0yOTgzNTI_5fa7beb4-2698-4f8e-82af-d6be5d8e5502"
      unitRef="usd">475000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i20deba0784bb4ee28b65cd1d2bd855dc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfMy02LTEtMS0yOTgzNTI_99a6ec11-53e2-402f-bc09-6847df7cc0b7"
      unitRef="usd">4724000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i55ffd3316fb8496aa86fcba67dffd60b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfMy04LTEtMS0yOTgzNTI_9d7b7711-1282-4800-b786-7d20a304b4b2"
      unitRef="usd">46131000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i46a185f9ec6445ec8b642258ea67180d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfMy0xMC0xLTEtMjk4MzUy_b9f25a79-f664-48dc-a371-7b8f8fbfe4eb"
      unitRef="usd">555855000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i96fd516d0b2c4ab88b68926fb81bb129_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNC0yLTEtMS0yOTgzNTI_f4e959af-211a-4588-aa0a-042098497a7f"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i860cd6cdf17243bd9cb45083c2bd5bb7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNC00LTEtMS0yOTgzNTI_9a722526-41cd-454e-a9f6-ea89f8a22319"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i20deba0784bb4ee28b65cd1d2bd855dc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNC02LTEtMS0yOTgzNTI_a3eda3c9-c02d-4fb0-b36b-19ad7460e5fc"
      unitRef="usd">2407000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i55ffd3316fb8496aa86fcba67dffd60b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNC04LTEtMS0yOTgzNTI_50a0d0df-fb2c-4185-a5d4-2b3ade05f452"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i46a185f9ec6445ec8b642258ea67180d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNC0xMC0xLTEtMjk4MzUy_728ac7fd-7d75-48f4-9b51-24868f6588ae"
      unitRef="usd">2407000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i96fd516d0b2c4ab88b68926fb81bb129_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNS0yLTEtMS0yOTgzNTI_e1dc3c81-e420-467a-8c1b-e77e8590c77f"
      unitRef="usd">233226000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i860cd6cdf17243bd9cb45083c2bd5bb7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNS00LTEtMS0yOTgzNTI_5e73f197-1f75-411a-9e00-57335903d145"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i20deba0784bb4ee28b65cd1d2bd855dc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNS02LTEtMS0yOTgzNTI_d995d368-c8fb-4efd-ad7d-5e5958c1d33f"
      unitRef="usd">61050000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i55ffd3316fb8496aa86fcba67dffd60b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNS04LTEtMS0yOTgzNTI_4008234f-b20d-4449-bb4e-017e8e2ff30c"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i46a185f9ec6445ec8b642258ea67180d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNS0xMC0xLTEtMjk4MzUy_63bdc6bf-98d3-49d0-8b17-55bdb26574ec"
      unitRef="usd">294276000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebt
      contextRef="i96fd516d0b2c4ab88b68926fb81bb129_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNi0yLTEtMS0yOTgzNTI_2af6c902-9587-45e2-ae3b-0c67799383c7"
      unitRef="usd">263226000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i860cd6cdf17243bd9cb45083c2bd5bb7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNi00LTEtMS0yOTgzNTI_44ed161f-8c1e-41e3-8483-759fcf1200ff"
      unitRef="usd">475000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i20deba0784bb4ee28b65cd1d2bd855dc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNi02LTEtMS0yOTgzNTI_edf3ebcd-eb95-4205-84a3-c210490330c8"
      unitRef="usd">68181000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i55ffd3316fb8496aa86fcba67dffd60b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNi04LTEtMS0yOTgzNTI_4b7e4473-f2b6-460b-b174-abaffa701124"
      unitRef="usd">46131000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i46a185f9ec6445ec8b642258ea67180d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOjVmOTI5NzVhMmMzMjQ1MWFiMGU1ZDE5ZjE2NjZkZjhiL3RhYmxlcmFuZ2U6NWY5Mjk3NWEyYzMyNDUxYWIwZTVkMTlmMTY2NmRmOGJfNi0xMC0xLTEtMjk4MzUy_98016a1c-5637-412d-b2a8-faaeec8bff32"
      unitRef="usd">852538000</us-gaap:LongTermDebt>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="i6c63ca50dfe64ec5a0637410c6d5397b_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83My9mcmFnOjUwOTJiNmUwZWJhMzQ5OWJhZjdkZTUzNmYzMmRlNWQyL3RhYmxlOmQ1MGZkMzlkYzRjOTQyZjdhZjc2N2E0NDc3YjFhZDU2L3RhYmxlcmFuZ2U6ZDUwZmQzOWRjNGM5NDJmN2FmNzY3YTQ0NzdiMWFkNTZfMC0xLTEtMS0yOTgzNTIvdGV4dHJlZ2lvbjpiNTZmNzcyYTFkYWI0ZDA1YjMwOGVhYTRkYjM0ZTJkNF8zMjA_c745f04d-e007-4a39-a2a2-3282a31dcd61"
      unitRef="number">0.1289</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM5NjE_baab2993-4a49-4fab-864c-0bf7de48475d">Below is a summary of outstanding balances and a description of significant relationships (in&#160;thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;March&#160;31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due from related party&#x2013;NantBio, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due from related party&#x2013;Brink Biologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due from related parties&#x2013;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total due from related parties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due to related party&#x2013;Duley Road, LLC&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due to related party&#x2013;NantBio, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due to related party&#x2013;NantWorks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due to related party&#x2013;Immuno-Oncology Clinic, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total due to related parties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="ie130450350ca4c9799e1e199a92ec29d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfNC0xLTEtMS0yOTgzNTI_301c1d80-c4ff-4357-8fb7-e6e1d10c4957"
      unitRef="usd">1294000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="i09080f29fd3f433ba1865fa559c0cc3f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfNC0zLTEtMS0yOTgzNTI_44978d34-60bb-4662-a9b9-7e90cd4b0783"
      unitRef="usd">1294000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="i343f173c97cd46298d5be473e16688aa_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfNS0xLTEtMS0yOTgzNTI_162f9b5e-8d25-43c1-8040-ccfc99afaa05"
      unitRef="usd">35000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="id4a76d55cff24142bdf23c290b7ebaac_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfNS0zLTEtMS0yOTgzNTI_ddc1757c-6518-4f3d-822a-786a00f3d798"
      unitRef="usd">271000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="ia7e60a6f6dd54abb86adb37dc98be31f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfNi0xLTEtMS0yOTgzNTI_bbfc1d40-3702-4459-af57-4befaf2a5889"
      unitRef="usd">135000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="i54c810b34f414a6199d96f563da4e9c9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfNi0zLTEtMS0yOTgzNTI_5a0c64f3-4b2e-4761-b07a-465820932443"
      unitRef="usd">325000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfNy0xLTEtMS0yOTgzNTI_f38edd8b-850a-4417-a6e8-44cc23f83b52"
      unitRef="usd">1464000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfNy0zLTEtMS0yOTgzNTI_f16a551c-61ed-4920-bc1c-1d83aa3c948a"
      unitRef="usd">1890000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i0fb0f449758c4a12bd185f822740269b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfOS0xLTEtMS0yOTgzNTI_df0ed7c8-1e18-4176-b0ca-ba5f1709c3a2"
      unitRef="usd">1356000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="ic0d461d8a57e4f1caf838c6337b4c516_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfOS0zLTEtMS0yOTgzNTI_e5bfa536-cf99-4427-95b9-77a95a886d0f"
      unitRef="usd">1431000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="ie130450350ca4c9799e1e199a92ec29d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfMTAtMS0xLTEtMzI4OTA0_bae0e11f-c9c9-439f-a44a-9958de6541de"
      unitRef="usd">943000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i09080f29fd3f433ba1865fa559c0cc3f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfMTAtMy0xLTEtMzI4OTA0_ab9b52db-e048-4328-b84a-63e61b8e7e6c"
      unitRef="usd">943000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="icd31b5f44a3b46e994f04fa346a23f09_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfMTAtMS0xLTEtMjk4MzUy_401c4dbc-b863-49ea-a73a-30fec5830cc5"
      unitRef="usd">592000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i0b77d70cfd06469091a1b47d242533d9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfMTAtMy0xLTEtMjk4MzUy_566eac90-73f4-4641-a95b-dd8fc4d9bc48"
      unitRef="usd">986000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i2f07f511c38b42188903e64e3779976d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfMTMtMS0xLTEtMjk4MzUy_ab522f8f-8d78-4078-940b-9ad20569b39b"
      unitRef="usd">41000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="ibfcb45a1b3c349189e4711ea15b357de_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfMTMtMy0xLTEtMjk4MzUy_2122a911-e261-4eef-8560-b517c71cef0a"
      unitRef="usd">109000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfMTUtMS0xLTEtMjk4MzUy_7b0e9dd8-aea3-4203-bfb2-4a5a0258c44f"
      unitRef="usd">2932000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RhYmxlOmE5MTg1NzNmM2M2ZjRlOGY5NzBkMTNjZTViM2E4ZWM2L3RhYmxlcmFuZ2U6YTkxODU3M2YzYzZmNGU4Zjk3MGQxM2NlNWIzYThlYzZfMTUtMy0xLTEtMjk4MzUy_cc6f89f7-d462-4a05-b249-3542aad52579"
      unitRef="usd">3469000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id7f7698c742a4d5185ef556099b8f431_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTI0MA_6a10790a-f597-44d7-827e-99f68be5bf6a"
      unitRef="usd">1000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="icdea96cd4382425faf718c8efb444b64_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTI0Nw_dbce4012-9b6d-4efe-889e-2cd5cf8e0a7b"
      unitRef="usd">1300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1d86297744454a6099ce0c427e3111e8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTMxNw_fbbf5e0e-1264-4bbb-9954-74788cba1e05"
      unitRef="usd">400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i4d993de6a09448f3af585a7df1769323_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTc2NA_c8695986-168e-45f2-81c2-45e0440ddb21"
      unitRef="usd">600000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i8890b549aaaa415492f2214c3dc3ac13_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTc3MQ_4c06127f-94ba-46d6-a843-ebfd09f8115a"
      unitRef="usd">1000000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="i38af9a7ebb684fc3a1ab4a463228f422_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTk0NQ_89240956-e87a-4b2c-9d11-f526780cfeee"
      unitRef="usd">2100000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="i8466a432fa1943f286f3af0a6ccac9e8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTk1Mg_121c0769-f123-40fe-b502-e69c05693960"
      unitRef="usd">2000000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <ibrx:NumberOfSquareFootOfFacilityLeased
      contextRef="i34815e4cfa9145e9981cf8ef165dd4fb_I20151231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMjMwNA_b9fe327b-584d-4ee4-b99e-bb05567f1d3e"
      unitRef="sqft">9500</ibrx:NumberOfSquareFootOfFacilityLeased>
    <ibrx:AnnualPercentageIncreasesToBaseRent
      contextRef="i030a8e572dcc4ea2a237d2800d4aa466_D20220101-20220101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMjU4Ng_14fc6b74-0198-4d20-ba65-c1d02d12d168"
      unitRef="number">0.03</ibrx:AnnualPercentageIncreasesToBaseRent>
    <ibrx:BaseMonthlyRent
      contextRef="i030a8e572dcc4ea2a237d2800d4aa466_D20220101-20220101"
      decimals="-1"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMjYwNg_5dca1c53-a833-49bf-9b0a-929a0e642018"
      unitRef="usd">56120</ibrx:BaseMonthlyRent>
    <ibrx:IncreaseToNumberOfSquareFootOfFacilityLeased
      contextRef="i630c47622bdc4c919e7634771cd094b6_I20220501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMjcwOQ_e83ded1a-cddd-4dba-a937-db1f77d36504"
      unitRef="sqft">36830</ibrx:IncreaseToNumberOfSquareFootOfFacilityLeased>
    <ibrx:NumberOfSquareFootOfFacilityLeased
      contextRef="i630c47622bdc4c919e7634771cd094b6_I20220501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMjc1OA_8cb50236-8129-400e-ad87-5419e4ef9356"
      unitRef="sqft">46330</ibrx:NumberOfSquareFootOfFacilityLeased>
    <ibrx:BaseMonthlyRent
      contextRef="i00d9386e0ac34e93abf5574655a19034_D20220501-20220501"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMjgzOQ_035905a1-b844-4c44-9ade-0e98b7b476c9"
      unitRef="usd">273700</ibrx:BaseMonthlyRent>
    <ibrx:AnnualPercentageIncreasesToBaseRent
      contextRef="i00d9386e0ac34e93abf5574655a19034_D20220501-20220501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMjg2NQ_e0c3ee85-3994-4835-91fa-3096b52237aa"
      unitRef="number">0.03</ibrx:AnnualPercentageIncreasesToBaseRent>
    <us-gaap:OperatingLeaseExpense
      contextRef="i4ab9c997cb0b4744a84d064e48fc1cdf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMzEzMQ_1c6e2413-6862-4087-83b3-d2f0a61aae5d"
      unitRef="usd">800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i8601e8ad3ce74646a29a91172dd7b478_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMzEzOA_7f34126d-e5a3-46f9-a790-a0593c9dc1d5"
      unitRef="usd">200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i8a83e300ee754efcafa7bc50023c4c0c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMzY4Mw_301c7a0a-dc4d-41a4-8e69-152276d83bd0"
      unitRef="usd">5600000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <ibrx:PrepaidExpenseWriteDown
      contextRef="i94b88764cea64ab3a669de4c146f1277_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNDQ3Mw_ce0d7d00-bda0-4ea2-a958-654d7276889d"
      unitRef="usd">4400000</ibrx:PrepaidExpenseWriteDown>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie8ed30fcfd154733b358cf49c7a83340_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNDYwMw_48ae9ff6-875e-4862-98f6-a0077ecd926d"
      unitRef="usd">600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7a419c5ac53b440da1bf811cf7835f7a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNDYxMA_70a05f9c-5ce4-4546-b84d-3336976bd763"
      unitRef="usd">400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i8c6db1e3cd124c76b9c449422588a8be_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNDg1OA_f3381ef5-3bdb-424e-a78a-a8b398af8251"
      unitRef="usd">100000</us-gaap:DueToRelatedPartiesCurrent>
    <ibrx:SupplyAgreementTermOfContract
      contextRef="ida6b89dae59349288b67324cfade250c_I20180831"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNTI1NQ_44ba4bb7-3399-4c3c-8908-747e6fc7b135">P5Y</ibrx:SupplyAgreementTermOfContract>
    <ibrx:SupplyAgreementPeriodOfExtendedTerm
      contextRef="i52d6bbd3e53f4ae6bd3377d2d890068b_D20180801-20180831"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM5NTM_8f8f375b-c3ec-4c4c-8ecc-3c7cbde577f2">P1Y</ibrx:SupplyAgreementPeriodOfExtendedTerm>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i46483bc0e4034520a181080e17a40498_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNTU5MQ_0bb3cacf-46fe-412e-94b2-f762640ee8bf"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i75ef1f10c34b47e9a73945153142eec4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNTYyMA_74bd46b4-fcb2-40b7-9637-b5502a9e6761"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i0b7101f16b5744f081cfce6bb570c9b0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNTY2MQ_dcf76948-ea5d-4951-b5db-8b2ba87d0589"
      unitRef="usd">100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i65810f20d431446aa5ab803112a83673_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNTY2OA_14ad46e4-824c-4fed-9c1b-10fbb8f12254"
      unitRef="usd">100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i0b7101f16b5744f081cfce6bb570c9b0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNTg5Mw_dddaa25f-1a27-470f-a4d0-2a3c6d668320"
      unitRef="usd">900000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i65810f20d431446aa5ab803112a83673_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNTg5Mw_ff5b84ea-aa92-469c-9136-02e6674230a0"
      unitRef="usd">900000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedParties
      contextRef="i88ef2e95606a433c97f1f5ade812375d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNjUwMg_3d03c8c8-0f3f-4416-af93-1135d15ddf17"
      unitRef="usd">1300000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="ida89ca2072e7405a83ed27b0d0e50e26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNjUwMg_6ab7001c-e3cf-4392-b650-2743c3fc21e8"
      unitRef="usd">1300000</us-gaap:DueFromRelatedParties>
    <ibrx:NumberOfSquareFootOfFacilityLeased
      contextRef="ic9e75b2cda544e9dabfb62fd1fae848d_I20160930"
      decimals="-1"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNjcyNQ_5ae75359-c129-474f-87bb-a6b6ad937992"
      unitRef="sqft">24250</ibrx:NumberOfSquareFootOfFacilityLeased>
    <ibrx:OptionsToExtendNumberOfTerms
      contextRef="i7e2a43e076864fbf9c872615bc186b9a_D20160901-20160930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNjkzNA_fcc7c2ab-efa3-42e7-aa52-925fe8afed05"
      unitRef="term">1</ibrx:OptionsToExtendNumberOfTerms>
    <ibrx:PeriodOfExtendedLeaseTerm
      contextRef="i7e2a43e076864fbf9c872615bc186b9a_D20160901-20160930"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM5NjA_b0b5476c-ba49-48cf-9705-04a6c6642f0b">P3Y</ibrx:PeriodOfExtendedLeaseTerm>
    <ibrx:BaseMonthlyRent
      contextRef="i7e2a43e076864fbf9c872615bc186b9a_D20160901-20160930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNzAwNA_27bdc60f-f8b4-4dee-ab74-a4db29870856"
      unitRef="usd">72385</ibrx:BaseMonthlyRent>
    <ibrx:AnnualPercentageIncreasesToBaseRent
      contextRef="i7e2a43e076864fbf9c872615bc186b9a_D20160901-20160930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNzAzMw_3e82d9c5-6894-42b2-9d1a-89e982445402"
      unitRef="number">0.03</ibrx:AnnualPercentageIncreasesToBaseRent>
    <us-gaap:OperatingLeaseExpense
      contextRef="i5f9e4846487241a5b60ad842bb55bb52_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNzEwOA_57b98374-a40c-4324-8d84-c6e86a80886a"
      unitRef="usd">200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="icc6ecb543ce2436c9134c23137273055_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNzExNQ_30946d9d-21dc-4f33-b101-fe5ae4af6bc9"
      unitRef="usd">200000</us-gaap:OperatingLeaseExpense>
    <ibrx:NumberOfSquareFootOfFacilityLeased
      contextRef="i76b07b7ed33b45539a4fff62c382480d_I20170228"
      decimals="-1"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNzM5NQ_ae42c7f2-0120-4958-a595-47dfc9b92f3c"
      unitRef="sqft">11980</ibrx:NumberOfSquareFootOfFacilityLeased>
    <ibrx:OptionsToExtendNumberOfTerms
      contextRef="i37723a8685db4f4b9403f2caefc75ecf_D20170201-20170228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNzU2MQ_3c3e836e-42e7-4129-9cd9-94bd7e728efb"
      unitRef="term">2</ibrx:OptionsToExtendNumberOfTerms>
    <ibrx:PeriodOfExtendedLeaseTerm
      contextRef="i37723a8685db4f4b9403f2caefc75ecf_D20170201-20170228"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM5NjI_72e9cccd-78e0-4078-90f5-2c84d3f38c15">P5Y</ibrx:PeriodOfExtendedLeaseTerm>
    <ibrx:BaseMonthlyRent
      contextRef="i37723a8685db4f4b9403f2caefc75ecf_D20170201-20170228"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNzYzNQ_253a9136-5451-4b8f-9030-f0193d2ff075"
      unitRef="usd">40700</ibrx:BaseMonthlyRent>
    <ibrx:AnnualPercentageIncreasesToBaseRent
      contextRef="i37723a8685db4f4b9403f2caefc75ecf_D20170201-20170228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNzY2NA_58d117d8-c02e-4598-93f8-cdbf9a7a10a4"
      unitRef="number">0.03</ibrx:AnnualPercentageIncreasesToBaseRent>
    <ibrx:NumberOfSquareFootOfFacilityLeased
      contextRef="i1669c0c201b646b2b7157ca12651f6fe_I20190101"
      decimals="-1"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNzg3MA_7eeda44b-efc0-41ad-9d79-ed53acd688af"
      unitRef="sqft">5650</ibrx:NumberOfSquareFootOfFacilityLeased>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i1669c0c201b646b2b7157ca12651f6fe_I20190101"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM5NTU_d3b4ac86-501f-434c-a274-c39f17446c02">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ibrx:NumberOfSquareFootOfFacilityLeased
      contextRef="i74cbb623279346b9ade405a13aa44d0e_I20190101"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfNzk5Nw_7a017b5b-b25f-4549-a842-d0de90159e91"
      unitRef="sqft">6488</ibrx:NumberOfSquareFootOfFacilityLeased>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i74cbb623279346b9ade405a13aa44d0e_I20190101"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM5NTI_3cac491c-fe62-4959-95af-0bb157ae94f3">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ibrx:OptionsToExtendNumberOfTerms
      contextRef="i79fafd177360495ea435675f878915de_D20190101-20190131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfODE5NQ_09eb6c09-c764-4a72-9c29-ff6e3ba93bba"
      unitRef="term">2</ibrx:OptionsToExtendNumberOfTerms>
    <ibrx:PeriodOfExtendedLeaseTerm
      contextRef="i79fafd177360495ea435675f878915de_D20190101-20190131"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM5NTE_36902744-0d5a-4a99-94ed-e1192f6653f6">P5Y</ibrx:PeriodOfExtendedLeaseTerm>
    <ibrx:NumberOfLeases
      contextRef="i79fafd177360495ea435675f878915de_D20190101-20190131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfODI2Mg_d4794fe2-79bc-433f-8d9f-6e68336ad35b"
      unitRef="lease">2</ibrx:NumberOfLeases>
    <ibrx:BaseMonthlyRent
      contextRef="i79fafd177360495ea435675f878915de_D20190101-20190131"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfODI4OQ_1feddf3b-339c-4f88-b441-faae52ddc4dc"
      unitRef="usd">35800</ibrx:BaseMonthlyRent>
    <ibrx:AnnualPercentageIncreasesToBaseRent
      contextRef="i79fafd177360495ea435675f878915de_D20190101-20190131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfODMxOA_ee8fe61f-f75b-4dad-a26e-e531b5360792"
      unitRef="number">0.03</ibrx:AnnualPercentageIncreasesToBaseRent>
    <ibrx:LeaseholdImprovementPayables
      contextRef="iac70357778c94cf1ac486623facee429_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfODM1MQ_e13d54d3-51bb-43db-b803-3770db346e07"
      unitRef="usd">900000</ibrx:LeaseholdImprovementPayables>
    <ibrx:LeaseholdImprovementPayables
      contextRef="i2a46905c230c4f93bdb4d9448b060e15_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTA5OTUxMTY0MjA1Mg_c38258d7-9e3b-49cc-b8e4-6773d37b577b"
      unitRef="usd">900000</ibrx:LeaseholdImprovementPayables>
    <ibrx:LeaseRelatedPayables
      contextRef="iac70357778c94cf1ac486623facee429_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfODQwNw_344708d8-ea72-40cf-bf50-ebef4aa01531"
      unitRef="usd">500000</ibrx:LeaseRelatedPayables>
    <ibrx:LeaseRelatedPayables
      contextRef="i2a46905c230c4f93bdb4d9448b060e15_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfODQxNA_93e9ba59-0c2a-4a2e-9432-58a40b7e9c3f"
      unitRef="usd">600000</ibrx:LeaseRelatedPayables>
    <us-gaap:OperatingLeaseExpense
      contextRef="iaef86b8724ee46feaafd52d401a7f967_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTA5OTUxMTY0MjcwNA_5dbcf5f0-6cc8-471e-b88f-433371b12e90"
      unitRef="usd">200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ie341383be88d425fa34bddb167224148_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTA5OTUxMTY0Mjc0OA_9a957f21-567d-4697-8f8e-cad59561b88b"
      unitRef="usd">200000</us-gaap:OperatingLeaseExpense>
    <ibrx:NumberOfSquareFootOfFacilityLeased
      contextRef="i9d95ef7c886d4db6963bcdfd488f1553_I20210101"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfODg4Mw_075fde94-ffb0-4989-9a37-f041fc0ce06a"
      unitRef="sqft">6883</ibrx:NumberOfSquareFootOfFacilityLeased>
    <ibrx:OptionsToExtendNumberOfTerms
      contextRef="i9f92b246bdb84f80a78af70f89f212ce_D20210101-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfOTIxOQ_500c8956-9e72-483b-b6cc-9aa0481cf2c5"
      unitRef="term">1</ibrx:OptionsToExtendNumberOfTerms>
    <ibrx:PeriodOfExtendedLeaseTerm
      contextRef="i9f92b246bdb84f80a78af70f89f212ce_D20210101-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM5NTg_cfb9a932-d475-4f8b-a903-197d6bfb2dfb">P3Y</ibrx:PeriodOfExtendedLeaseTerm>
    <ibrx:BaseMonthlyRent
      contextRef="i9f92b246bdb84f80a78af70f89f212ce_D20210101-20210101"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfOTI3OA_ff58af0b-d624-49de-b3da-0baafa153286"
      unitRef="usd">20300</ibrx:BaseMonthlyRent>
    <ibrx:AnnualPercentageIncreasesToBaseRent
      contextRef="i9f92b246bdb84f80a78af70f89f212ce_D20210101-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfOTMwOA_2595cb55-c40d-4508-a4d9-a17d156bc13d"
      unitRef="number">0.03</ibrx:AnnualPercentageIncreasesToBaseRent>
    <ibrx:RentAbatementPeriod
      contextRef="i9f92b246bdb84f80a78af70f89f212ce_D20210101-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfOTU2MA_839d97a0-edf9-493e-b8d5-3c23b5d885b8">P7M</ibrx:RentAbatementPeriod>
    <us-gaap:IncentiveFromLessor
      contextRef="i9d95ef7c886d4db6963bcdfd488f1553_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfOTYyMg_9edd883e-7e8b-429b-ab10-9d75f2e79355"
      unitRef="usd">300000</us-gaap:IncentiveFromLessor>
    <ibrx:NumberOfSquareFootOfFacilityLeased
      contextRef="idb46af1e101d4c7d85dc1fd805f5e351_I20210401"
      decimals="-1"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfOTg5NQ_4bb78b8a-585d-4726-9c5d-dabfe5154808"
      unitRef="sqft">57760</ibrx:NumberOfSquareFootOfFacilityLeased>
    <ibrx:PeriodOfExtendedLeaseTerm
      contextRef="i0ecc9935801543b1b67dcd2ff6f9f08f_D20210401-20210401"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTAwNzQ_4acb5631-a677-4482-a9eb-18b654670849">P3Y</ibrx:PeriodOfExtendedLeaseTerm>
    <ibrx:BaseMonthlyRent
      contextRef="i0ecc9935801543b1b67dcd2ff6f9f08f_D20210401-20210401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTAyNzA_5f08602d-c314-4f85-b5f1-62fed6834016"
      unitRef="usd">170400</ibrx:BaseMonthlyRent>
    <ibrx:AnnualPercentageIncreasesToBaseRent
      contextRef="i0ecc9935801543b1b67dcd2ff6f9f08f_D20210401-20210401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTAzMDg_e68bc4e7-ec0e-47dc-b6cf-b0e2a74d39ea"
      unitRef="number">0.03</ibrx:AnnualPercentageIncreasesToBaseRent>
    <ibrx:RentAbatementPeriod
      contextRef="i0ecc9935801543b1b67dcd2ff6f9f08f_D20210401-20210401"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTA0NTU_e06d7126-f87e-49c7-95d5-161d001b7550">P7M</ibrx:RentAbatementPeriod>
    <us-gaap:IncentiveFromLessor
      contextRef="idb46af1e101d4c7d85dc1fd805f5e351_I20210401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTA1Mzg_227b731c-931d-44f9-9d87-7fdc06691d77"
      unitRef="usd">2600000</us-gaap:IncentiveFromLessor>
    <us-gaap:OperatingLeaseExpense
      contextRef="i6fe81cf5951c403d960758745c545149_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTA3MDc_ca774185-f72a-4dcd-9cf7-42a277ab881d"
      unitRef="usd">500000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ifde6772fd7334f07bf86ccb8635eb843_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTA3MTQ_d4a07808-9b25-41b5-b887-10337d616295"
      unitRef="usd">500000</us-gaap:OperatingLeaseExpense>
    <ibrx:NumberOfSquareFootOfFacilityLeased
      contextRef="i7910abd612b44ff2a9ab87af3766fd8e_I20211001"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTA5NzI_5745b413-511e-4b7d-99f8-da038a34633e"
      unitRef="sqft">19125</ibrx:NumberOfSquareFootOfFacilityLeased>
    <ibrx:BaseMonthlyRent
      contextRef="ic4b84ae551264070b15b7f777a374c2e_D20211001-20211001"
      decimals="-1"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTEyOTA_d9c2e740-f799-43fb-bd5e-dfba842b8f26"
      unitRef="usd">38250</ibrx:BaseMonthlyRent>
    <ibrx:AnnualPercentageIncreasesToBaseRent
      contextRef="ic4b84ae551264070b15b7f777a374c2e_D20211001-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTEzMjA_bab14ca3-6f17-41eb-a4be-5651d8741d4c"
      unitRef="number">0.03</ibrx:AnnualPercentageIncreasesToBaseRent>
    <ibrx:OptionsToExtendNumberOfTerms
      contextRef="ic4b84ae551264070b15b7f777a374c2e_D20211001-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTE4MjI_f269c592-21ea-4ef2-b90f-66e8d5890edf"
      unitRef="term">2</ibrx:OptionsToExtendNumberOfTerms>
    <ibrx:PeriodOfExtendedLeaseTerm
      contextRef="ic4b84ae551264070b15b7f777a374c2e_D20211001-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTE4NTk_e8f4636d-5159-4ff3-b288-60a5a33689ad">P5Y</ibrx:PeriodOfExtendedLeaseTerm>
    <ibrx:AnnualPercentageIncreasesToBaseRent
      contextRef="ic4b84ae551264070b15b7f777a374c2e_D20211001-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTIwMzE_3feb3adc-3a5b-4dd9-8bf5-df148fe637fc"
      unitRef="number">0.03</ibrx:AnnualPercentageIncreasesToBaseRent>
    <us-gaap:OperatingLeaseExpense
      contextRef="if8add4a27fd94c3dbba9aebb333c9ce7_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTIyOTc_b3c24c9f-1d26-46da-b74e-d135d8b3be13"
      unitRef="usd">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ia4332025e778479f9e44ae4505eb4896_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTA5OTUxMTY0MjEyOQ_5126c50c-fe34-43b8-942c-a8cb2b621c48"
      unitRef="usd">100000</us-gaap:OperatingLeaseExpense>
    <ibrx:NumberOfSquareFootOfFacilityLeased
      contextRef="i83fb4e02761f48b8ad2de6942bf33580_I20220501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTI1NDQ_e09c6593-b2ac-4b55-9259-feec67808a83"
      unitRef="sqft">47265</ibrx:NumberOfSquareFootOfFacilityLeased>
    <ibrx:BaseMonthlyRent
      contextRef="ic48cb211ecb24790be4164033660ec75_D20220501-20220501"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTI4NTg_688b43e0-714c-44a2-8e49-0f8dbb662773"
      unitRef="usd">139400</ibrx:BaseMonthlyRent>
    <ibrx:AnnualPercentageIncreasesToBaseRent
      contextRef="ic48cb211ecb24790be4164033660ec75_D20220501-20220501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTI4OTg_104e1f4a-b3f6-4a73-aeac-46362280ac86"
      unitRef="number">0.03</ibrx:AnnualPercentageIncreasesToBaseRent>
    <ibrx:BaseMonthlyRentParking
      contextRef="ic48cb211ecb24790be4164033660ec75_D20220501-20220501"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTMwNzY_af095b1e-16a2-44c2-8d3a-cc958441d5f8"
      unitRef="usd">7600</ibrx:BaseMonthlyRentParking>
    <ibrx:OptionsToExtendNumberOfTerms
      contextRef="ic48cb211ecb24790be4164033660ec75_D20220501-20220501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM1NzA_8d3ed519-df23-4dd3-8951-b530eb235248"
      unitRef="term">1</ibrx:OptionsToExtendNumberOfTerms>
    <ibrx:PeriodOfExtendedLeaseTerm
      contextRef="ic48cb211ecb24790be4164033660ec75_D20220501-20220501"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM5NTk_b48e30c5-8afe-43aa-849d-a5b9fa28aa33">P5Y</ibrx:PeriodOfExtendedLeaseTerm>
    <ibrx:AnnualPercentageIncreasesToBaseRent
      contextRef="ic48cb211ecb24790be4164033660ec75_D20220501-20220501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM3NzQ_73825c28-afaf-4fab-a0b2-eae567d98b3f"
      unitRef="number">0.03</ibrx:AnnualPercentageIncreasesToBaseRent>
    <us-gaap:OperatingLeaseExpense
      contextRef="iea37f6978bb2478bbedbdc929ab45ee3_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF83Ni9mcmFnOjEzNGFjNjlhNTc0NjQzM2U5NzZmNmMzNTYzNmM4NGRmL3RleHRyZWdpb246MTM0YWM2OWE1NzQ2NDMzZTk3NmY2YzM1NjM2Yzg0ZGZfMTM4MTM_4c9f60b0-335a-44df-9a59-5c5f25b1c3a6"
      unitRef="usd">400000</us-gaap:OperatingLeaseExpense>
    <ibrx:WarrantLiabilityTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfNDM5ODA0NjUxMzE2OQ_7689c944-1b1a-48ba-908c-49dfe9ece97c">Warrant Liabilities&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;December 2022 Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;12, 2022, in connection with the sale of 9,090,909&#160;shares of our common stock to an institutional investor, we entered into a warrant agreement that allows such investor to purchase up to 9,090,909&#160;shares at an exercise price of $6.60&#160;per share. We classified the warrants as a liability at their fair value determined using the Black-Scholes option pricing model. The fair value of the warrants was estimated at &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$35.1&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; at the issuance date. Of the total placement agent fees and other offering costs of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.0&#160;million, $1.1&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; were allocated to the warrants and recorded to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other income (expense), net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the date of the transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31,&#160;2023, all 9,090,909&#160;underlying warrants were outstanding, As of March&#160;31,&#160;2023 and December&#160;31,&#160;2022, the estimated fair value of the warrants were &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$5.8&#160;million and $21.6&#160;million, respectively&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The decrease in fair value of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$15.8&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other income (expense), net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the condensed consolidated statement of operations for the three months ended March&#160;31,&#160;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;February 2023 Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;15, 2023, in connection with the sale of 14,072,615&#160;shares of our common stock to institutional investors, we entered into a warrant agreement that allows such investors to purchase up to 14,072,615&#160;shares at an exercise price of $4.26&#160;per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classified the warrants as a liability at their fair value determined using the Black-Scholes option pricing model. The fair value of warrants were estimated at &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$23.7&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; at the issuance date. Of the total placement agent fees and other offering costs of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.0&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.0&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; were allocated to the warrants &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and recorded to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other income (expense), net, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the date of the transaction&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As of March&#160;31,&#160;2023, all 14,072,615&#160;underlying warrants were outstanding, with an estimated fair value of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$12.0&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The decrease in fair value of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$11.7&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other income (expense), net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the condensed consolidated statement of operations for the three months ended March&#160;31,&#160;2023.&lt;/span&gt;&lt;/div&gt;</ibrx:WarrantLiabilityTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="icf169f3dab5647ae87fdc00595ada62f_D20221212-20221212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfNjU_8dcfd561-fcd4-4272-bb5e-f3803b5a404a"
      unitRef="shares">9090909</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i19f26457ccfe499cb0e3bbed35112923_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMTkx_2fa3b675-943f-4ae4-94d7-cae244a23c06"
      unitRef="shares">9090909</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ie7ac9b711c4447f78c760f85a936a47b_I20221212"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMjI1_2beaa802-5a5d-49ae-94b7-a59bf59901c0"
      unitRef="usdPerShare">6.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="i02a9bf96e8f246dab50bd1fc37514fa1_D20221212-20221212"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMTA5OTUxMTYzNzc2OA_29c3a612-1afb-4cbe-ae99-a6c965f72021"
      unitRef="usd">35100000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:DeferredOfferingCosts
      contextRef="i15ed851a2bba4c719f489412c5b04c93_I20221212"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMTA5OTUxMTYzODE1Mw_80fe11b3-b9bf-41fe-a491-2361ad7d7fcb"
      unitRef="usd">3000000</us-gaap:DeferredOfferingCosts>
    <ibrx:TransactionCostsWarrantLiability
      contextRef="id16bb7626e4a4ddf8aef9e47dd2b70f0_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMzI5ODUzNDg4NzkxOQ_cf2739a5-0a74-464f-9dc9-b82bb059c9ac"
      unitRef="usd">1100000</ibrx:TransactionCostsWarrantLiability>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i19f26457ccfe499cb0e3bbed35112923_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMzI5ODUzNDg4ODAxNA_2fa3b675-943f-4ae4-94d7-cae244a23c06"
      unitRef="shares">9090909</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i05ce9f5c06e84394bfde03b091dcbdf4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMjE5OTAyMzI2NjM3Nw_14c5e1c1-2e09-4b86-afb5-368d5597f3a4"
      unitRef="usd">5800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i6e247e3019ba40cfb87b176aa4e219b6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMjE5OTAyMzI2NjM5NQ_f6956e81-9ccd-4d21-af9d-8d500e31094f"
      unitRef="usd">21600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i91d87f21eddb4e8ba52be9c983035646_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMjE5OTAyMzI2NjQwMQ_0b59d72d-431f-4c4b-b685-46b91f93a4d6"
      unitRef="usd">-15800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i79b4caaa6e7c43ee92ac011ad4231f8f_D20230215-20230215"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMzI5ODUzNDg5MDMyMg_8370fb44-055b-492e-ba45-5b88f2fece37"
      unitRef="shares">14072615</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ie9e851daf28c4255b2112c4cd9cefdc6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMzI5ODUzNDg5MDMzNQ_790fab1a-1ef6-4319-ac6d-3af6f734447a"
      unitRef="shares">14072615</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ib8bb04bc74374058a2c1efed036ac8cb_I20230215"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMzI5ODUzNDg5MDM0NQ_5d57e1ce-e316-46a4-b6b3-b326de14d964"
      unitRef="usdPerShare">4.26</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ib8bb04bc74374058a2c1efed036ac8cb_I20230215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMzI5ODUzNDg5MjQ5NA_0e340fd3-1da2-440a-a756-75f7779a5f3b"
      unitRef="usd">23700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DeferredOfferingCosts
      contextRef="ib182c777505d49e8985cc1dfe3ec4883_I20230215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMTA5OTUxMTYzODI2MA_2f85a8af-510f-4120-ae8e-76b6ab83b714"
      unitRef="usd">3000000</us-gaap:DeferredOfferingCosts>
    <ibrx:TransactionCostsWarrantLiability
      contextRef="i9c148f91d4ce423f9b310ff8481860bb_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMzI5ODUzNDg5MjUxMw_cb4d96d2-f0a3-425d-850e-2a5f00f84c99"
      unitRef="usd">1000000</ibrx:TransactionCostsWarrantLiability>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ie9e851daf28c4255b2112c4cd9cefdc6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMzI5ODUzNDg5Mjc0Ng_790fab1a-1ef6-4319-ac6d-3af6f734447a"
      unitRef="shares">14072615</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i2cd4532b1fc24c0ca2ef81c7e69794c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMjE5OTAyMzI2NjQxMA_a6057380-d9ff-4124-ba7c-b33ddb32738f"
      unitRef="usd">12000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i9c148f91d4ce423f9b310ff8481860bb_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84Mi9mcmFnOjdjZTM3NDVmNzU1NTRhZTA5MGFhN2I1ODNhMjExODJkL3RleHRyZWdpb246N2NlMzc0NWY3NTU1NGFlMDkwYWE3YjU4M2EyMTE4MmRfMjE5OTAyMzI2NjQxOA_9c8fd9da-7255-4d63-9ddf-30257dcfbcac"
      unitRef="usd">-11700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMzYzMw_78452c3b-ad88-42c4-a80c-3a698202e40b">Stockholders&#x2019; Deficit &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No&#160;shares of our common stock were repurchased during the three months ended March&#160;31,&#160;2023 and 2022 under the company&#x2019;s 2015&#160;Share Repurchase Program. As of March&#160;31,&#160;2023, $18.3&#160;million remained authorized to use for share repurchases under the program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shelf Registration Statement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During February&#160;2023, we filed a $750.0&#160;million shelf registration statement with the SEC on Form&#160;S-3 for the offering and sale of equity and equity-linked securities, including common stock, preferred stock, debt securities, depositary shares, warrants to purchase common stock, preferred stock or debt securities, subscription rights, purchase contracts, and units. In February&#160;2023, we sold shares of our common stock and warrants valued at $110.0&#160;million under the shelf. As of March&#160;31,&#160;2023, we had $640.0&#160;million available for use under the shelf. See &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;Registered Direct Offerings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; below. This available shelf is in addition to the Open Market Sale Agreement described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Open Market Sale Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April&#160;2021, we entered into the Sale Agreement with respect to an&#160;ATM offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock through our sales agent. We pay our sales agent a commission of up to 3.0%&#160;of the gross sales proceeds of any shares of our common stock sold through them under the Sale Agreement, and also have provided them with customary indemnification and contribution rights. We issued no&#160;shares under the ATM during the three months ended March&#160;31,&#160;2023. As of March&#160;31,&#160;2023, we had $225.4&#160;million available for future stock issuances under the&#160;ATM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are not obligated to sell any shares and may at any time suspend solicitation and offers under the Sale Agreement. The Sale Agreement may be terminated by us at any time given written notice to the sales agent for any reason or by the sales agent at any time by giving written notice to us for any reason or immediately under certain circumstances, and shall automatically terminate upon the issuance and sale of all of the shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Registered Direct Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;12, 2022, we entered into a securities purchase agreement with an institutional investor for the sale of 9,090,909 shares of our common stock, as well as warrants that allow such investor to purchase an additional 9,090,909 shares of common stock at an exercise price of $6.60 per share, for a purchase price of $5.50 per share and accompanying warrant, generating net proceeds of approximately $47.0&#160;million, after deducting placement agent fees and other offering costs of $3.0&#160;million, of which $1.9&#160;million was allocated to the sale of our common stock and recognized as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;additional-paid-in capital&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of stockholders&#x2019; deficit, for the year ended December 31, 2022. The warrants became immediately exercisable and expire two years after the initial issuance date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;15, 2023, we entered into a securities purchase agreement with certain institutional investors for the sale of 14,072,615&#160;shares of our common stock, as well as warrants that allow such investors to purchase an additional 14,072,615&#160;shares of common stock at an exercise price of $4.26&#160;per share, for an aggregate purchase price of $3.55&#160;per share and accompanying warrant. This transaction generated net proceeds of approximately $47.0&#160;million, after deducting placement agent fees and other estimated offering costs of $3.0&#160;million, of which $2.0&#160;million was allocated to the sale of our common stock and recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;additional-paid-in capital,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the condensed consolidated statement of stockholders&#x2019; deficit for the three months ended March&#160;31,&#160;2023. The warrants became immediately exercisable and expire two years after the initial issuance date. The closing of the offering occurred on February&#160;17, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We currently intend to use the net proceeds from this offering, together with other available funds, to progress our pre-commercialization efforts and clinical development programs, fund other research and development activities, for capital expenditures, and for other general corporate purposes. We may also use a portion of the net proceeds to license intellectual property or to make acquisitions or investments. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_82" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&#160;11&lt;/a&gt;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrant Liabilities, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for further information.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="icf589f03986d4c4f8bd91e59ce16854e_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfNDYw_9e26e316-5cd4-4227-a86c-c0290a598bad"
      unitRef="shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i9923376a6fc640ad84dd1c26f06cb886_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfNDYw_ce1e68c8-bd21-468d-8fef-24a6fa38867e"
      unitRef="shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i7197e4073a6c44a993ccee88c9827d5b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfNTky_afd55d20-8ad8-4856-be06-36a492600c9b"
      unitRef="usd">18300000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <ibrx:SaleOfStockMaximumAggregateOfferingPrice
      contextRef="iee0c8df083bd402b92291e4cdef8b3e2_I20230228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfNTQ5NzU1ODIzNjAy_b106137c-c419-4296-9532-c9e4d0626a61"
      unitRef="usd">750000000</ibrx:SaleOfStockMaximumAggregateOfferingPrice>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i1b3c1aa995d649f0b87f547501a451bf_D20230215-20230215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfNTQ5NzU1ODI0MzQ5_0f4a420c-7e4b-4ea8-a1ba-d3887bbffa2d"
      unitRef="usd">110000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ibrx:CommonStockValueAvailableForFutureStockIssuance
      contextRef="idecf558aeafa48f9b21a5ecd3fb24b40_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfNTQ5NzU1ODIzOTM4_6186171d-470f-4ae9-9a1b-82a6b72cba72"
      unitRef="usd">640000000</ibrx:CommonStockValueAvailableForFutureStockIssuance>
    <ibrx:PercentageOfSalesAgentCommission
      contextRef="ifd22fd1d02ef4b8b97689228703adc95_D20210430-20210430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMTAyNw_d17c0f24-9f65-4277-ac22-e8fac817bdf4"
      unitRef="number">0.030</ibrx:PercentageOfSalesAgentCommission>
    <ibrx:IssuanceOfCommonStockUnderAtMarketOfferingShares
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMTY0OTI2NzQ0NjI0Nw_74882a33-96c6-4842-9cbd-537cdc221cff"
      unitRef="shares">0</ibrx:IssuanceOfCommonStockUnderAtMarketOfferingShares>
    <ibrx:CommonStockValueAvailableForFutureStockIssuance
      contextRef="ib93ec4ea47c24cd1aacb10ddb65cfc49_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfNTQ5NzU1ODE4NTE2_b2667a3d-fa57-4802-8dd8-6f3b9fa85871"
      unitRef="usd">225400000</ibrx:CommonStockValueAvailableForFutureStockIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="icf169f3dab5647ae87fdc00595ada62f_D20221212-20221212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMTA5OTUxMTYzNTgyNw_8dcfd561-fcd4-4272-bb5e-f3803b5a404a"
      unitRef="shares">9090909</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i19f26457ccfe499cb0e3bbed35112923_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMTA5OTUxMTYzNTgzOQ_2fa3b675-943f-4ae4-94d7-cae244a23c06"
      unitRef="shares">9090909</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ie7ac9b711c4447f78c760f85a936a47b_I20221212"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMTA5OTUxMTYzNTg0Nw_2beaa802-5a5d-49ae-94b7-a59bf59901c0"
      unitRef="usdPerShare">6.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i15ed851a2bba4c719f489412c5b04c93_I20221212"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMTA5OTUxMTYzNTg3MQ_61a00fd7-0a82-4053-8bc0-6b0298b54b68"
      unitRef="usdPerShare">5.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="icf169f3dab5647ae87fdc00595ada62f_D20221212-20221212"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMTA5OTUxMTYzNTg2Mw_7c98c1fd-5559-455e-839c-2d61e699f94b"
      unitRef="usd">47000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:DeferredOfferingCosts
      contextRef="i15ed851a2bba4c719f489412c5b04c93_I20221212"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMTA5OTUxMTYzNTg4Ng_80fe11b3-b9bf-41fe-a491-2361ad7d7fcb"
      unitRef="usd">3000000</us-gaap:DeferredOfferingCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i537431f5f3b94adb850787c5a596d104_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMTA5OTUxMTYzNTkwMQ_1832eb38-94b8-4d05-af2a-9456a99ebf87"
      unitRef="usd">1900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i62cf93746a5f40e7af8acd878f0d0942_I20221212"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMTA5OTUxMTYzNzM0Mg_8266f012-4a46-4bf9-80fc-a9107b1fe1b1">P2Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i79b4caaa6e7c43ee92ac011ad4231f8f_D20230215-20230215"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMjczNg_8370fb44-055b-492e-ba45-5b88f2fece37"
      unitRef="shares">14072615</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ie9e851daf28c4255b2112c4cd9cefdc6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMjgxMw_790fab1a-1ef6-4319-ac6d-3af6f734447a"
      unitRef="shares">14072615</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ib8bb04bc74374058a2c1efed036ac8cb_I20230215"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMjg2Mw_5d57e1ce-e316-46a4-b6b3-b326de14d964"
      unitRef="usdPerShare">4.26</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ib182c777505d49e8985cc1dfe3ec4883_I20230215"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMjkwMQ_07ad29bd-2096-4961-a2ac-dc42845c51ec"
      unitRef="usdPerShare">3.55</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i79b4caaa6e7c43ee92ac011ad4231f8f_D20230215-20230215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMjk4MQ_337ea193-8f0d-4ccc-ba23-3725e64434cb"
      unitRef="usd">47000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:DeferredOfferingCosts
      contextRef="ib182c777505d49e8985cc1dfe3ec4883_I20230215"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMTA5OTUxMTYzMjU4MA_2f85a8af-510f-4120-ae8e-76b6ab83b714"
      unitRef="usd">3000000</us-gaap:DeferredOfferingCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i2a8153bf4934499497bc454385181d0f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMjE5OTAyMzI2NjIwNg_975b0fb7-6a64-403a-b9fb-0f376c36c788"
      unitRef="usd">2000000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="iedf609af3963460b9da2409f804cfa4e_I20230217"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF84NS9mcmFnOjBkZTM2MDc4ODNkZjQzMDFiY2JjOWNkNzI4ZGIwNjU5L3RleHRyZWdpb246MGRlMzYwNzg4M2RmNDMwMWJjYmM5Y2Q3MjhkYjA2NTlfMzEzNA_d03ca589-d2ba-4ea6-96d5-4e29a4bbdab8">P2Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfNDkzOQ_51f1a242-c4a3-4f25-a1ad-37e5b9791e05">Stock-Based Compensation&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2015 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31,&#160;2023, approximately 18.6&#160;million&#160;shares were available for future grants under the 2015&#160;Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents stock-based compensation included on the condensed consolidated statements of operations (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.302%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Three Months Ended&lt;br/&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(Unaudited) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Stock-based compensation expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Stock-based compensation expense in operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity and related information for the three months ended March&#160;31,&#160;2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding at December&#160;31,&#160;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,262,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(81,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited/expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding at March&#160;31,&#160;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,159,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested and exercisable at March&#160;31,&#160;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,053,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31,&#160;2023, the unrecognized compensation cost related to outstanding stock options was $16.7&#160;million, which is expected to be recognized over a remaining weighted-average period of 1.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of stock options exercised during the three months ended March&#160;31,&#160;2023 was $0.2&#160;million. Cash proceeds received from stock option exercises during the three months ended March&#160;31,&#160;2023 and 2022 totaled $0.1&#160;million and $0.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2022, a total of 3,445,499&#160;vested and exercisable shares were outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity during the three months ended March&#160;31,&#160;2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Nonvested balance at December&#160;31,&#160;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,551,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;202,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(313,975)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited/canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252,106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Nonvested balance at March&#160;31,&#160;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,188,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31,&#160;2023, there was $61.9&#160;million of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted-average period of 2.6 years. The total intrinsic value of RSUs vested during the three months ended March&#160;31,&#160;2023 was $0.9&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs awarded to employees and consultants of affiliated companies are accounted for as stock-based compensation in accordance with ASU 2018-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Stock Compensation (Topic 718)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as the compensation was in exchange for continued support or services expected to be provided to the company over the vesting periods under the NantWorks shared services agreement discussed in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i5bbe340c9c8f435088d8011b72b6800d_76" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We have evaluated the associated benefit of these awards to the affiliated companies under common control and determined that the benefit is limited to the retention of their employees. We estimated such benefit at the grant date fair value of $4.0&#160;million on March&#160;4,&#160;2021 and recorded $0.1&#160;million and $0.1&#160;million of deemed dividends for the three months ended March&#160;31,&#160;2023 and 2022 in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;additional paid-in capital,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the condensed consolidated balance sheets, with a corresponding credit to stock-based compensation expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Related-Party Warrants&lt;/span&gt;&lt;/div&gt;In connection with the Merger, warrants issued to NantWorks, a related party, in connection with NantCell&#x2019;s acquisition of Altor were assumed by the company. After applying the Exchange Ratio at the Effective Time of the Merger, a total of 1,638,000&#160;warrants with an exercise price of $3.24&#160;per share were outstanding as of March&#160;31,&#160;2023. The fair value of $18.0&#160;million assigned to the warrants will be recognized in equity upon achievement of a performance-based vesting condition pertaining to building manufacturing capacity to support supply requirements for one of our product candidates.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i99b7bacac6fb4b6fa1a147bb0af0b1e3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfMTA5OTUxMTYzNTY2OA_3feace27-f2db-443f-a5bf-087c223cb43b"
      unitRef="shares">18600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfNDk0MA_3f6cb323-9633-4c35-85b7-a7f2b8695d6e">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents stock-based compensation included on the condensed consolidated statements of operations (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.302%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Three Months Ended&lt;br/&gt;March&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(Unaudited) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Stock-based compensation expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Stock-based compensation expense in operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic2e19134c3994d4892eb6d354d8783bc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfNS0xLTEtMS0yOTgzNTI_c0bcb102-f1ca-45c5-8d37-7b0cb7660cfd"
      unitRef="usd">3643000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia07604abb58a44c68163e1cc335f1f6f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfNS0zLTEtMS0yOTgzNTI_95be193e-9738-414d-bb2a-e6760f4951ed"
      unitRef="usd">2022000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib2e8096e87554843be3da2502f2fb4f8_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfNi0xLTEtMS0yOTgzNTI_16f2da67-acf4-4199-a606-e1bb3bfe0e3c"
      unitRef="usd">7235000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia9943c4a51f6441e85bc6598893e1fa6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfNi0zLTEtMS0yOTgzNTI_6f6fc8eb-0b79-44cb-93ad-74a9be01ad5c"
      unitRef="usd">8002000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfNy0xLTEtMS0yOTgzNTI_238485b8-1215-4bac-9e54-9a7d21ee55ba"
      unitRef="usd">10878000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfNy0zLTEtMS0yOTgzNTI_c06bcfbf-59a1-419c-9fe2-0d486fdcf3f8"
      unitRef="usd">10024000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie5cf1954f1b04fd3a05943c0f49aea0e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfOS0xLTEtMS0yOTgzNTI_fc8cd1cd-4d21-4c4b-bc77-89da7793d997"
      unitRef="usd">3634000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idabb2ea247194a5db776f4872b4ddd96_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfOS0zLTEtMS0yOTgzNTI_e55d425c-5b83-4e8e-8d46-cb85e7f19a2d"
      unitRef="usd">2985000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7d89f301dba24a82a81a3734a866f4df_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfMTAtMS0xLTEtMjk4MzUy_5bae0c76-5bde-4a54-a6d3-4ac5845f7140"
      unitRef="usd">7244000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5ff7cffbd9b44155b9d53cd05a219a87_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfMTAtMy0xLTEtMjk4MzUy_2fac9183-8d72-49cd-af7f-16e2e5a12192"
      unitRef="usd">7039000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfMTEtMS0xLTEtMjk4MzUy_b4d964e5-bf49-4dfb-b156-90e78c59e51d"
      unitRef="usd">10878000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1ed3ac76103c4ece80e72eb509eb5876_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOjYzODBiMTNjODRjZDQzNzQ4YjAzMTNiZDBjZTMyOTVjL3RhYmxlcmFuZ2U6NjM4MGIxM2M4NGNkNDM3NDhiMDMxM2JkMGNlMzI5NWNfMTEtMy0xLTEtMjk4MzUy_1064c350-0d50-4b0f-8431-12ab736e058d"
      unitRef="usd">10024000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfNDkzNA_1f6437df-65fe-433b-a0cc-d1a3756a6f90">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity and related information for the three months ended March&#160;31,&#160;2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding at December&#160;31,&#160;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,262,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(81,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited/expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding at March&#160;31,&#160;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,159,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested and exercisable at March&#160;31,&#160;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,053,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfMi0xLTEtMS0yOTgzNTI_f3aaa5d8-7e0f-4102-a32f-9ebad32b45df"
      unitRef="shares">9262926</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfMi0zLTEtMS0yOTgzNTI_672ccb89-e8f8-4bf5-bee9-c74df3eb65bb"
      unitRef="usdPerShare">9.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfMi01LTEtMS0yOTgzNTI_4849b24a-2422-4a7b-955f-d1f97adf30c3"
      unitRef="usd">4848000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i6da548dc0629406a8bc5d9e75d8d06d5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfMi03LTEtMS0yOTgzNTI_4a08cc3f-4484-4fd5-90b8-64081eaeb8c1">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfMy0xLTEtMS0yOTgzNTI_87612769-bc7a-449a-a04a-97b3bc494ae6"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfMy0zLTEtMS0yOTgzNTI_ca16cbf8-e0ae-4315-a8a7-cdd3a2996ed5"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNC0xLTEtMS0yOTgzNTI_ceeee07e-3956-4719-9802-04df8727f3a1"
      unitRef="shares">81037</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNC0zLTEtMS0yOTgzNTI_622ab5e7-5226-408d-aed4-5e3512d0f4b7"
      unitRef="usdPerShare">1.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNS0xLTEtMS0yOTgzNTI_17f10905-ca2e-455f-b02d-b9cf834c3225"
      unitRef="shares">22224</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNS0zLTEtMS0yOTgzNTI_d564c0f5-a1cd-4ad5-9506-a6abba8f2d31"
      unitRef="usdPerShare">5.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNi0xLTEtMS0yOTgzNTI_d61e5d5a-fa92-4038-90d8-c712795d7e1d"
      unitRef="shares">9159665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNi0zLTEtMS0yOTgzNTI_7205e4b3-1c1a-4b77-8dbd-a3f11cbb85e7"
      unitRef="usdPerShare">9.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNi01LTEtMS0yOTgzNTI_f2f4b1e7-cf46-429d-ae19-f1b7cdcd916c"
      unitRef="usd">234000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNi03LTEtMS0yOTgzNTI_9f504195-5369-489a-9d03-36382a667dbf">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNy0xLTEtMS0yOTgzNTI_ee35b653-1138-48d8-90c7-6acb16f6c539"
      unitRef="shares">5053597</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNy0zLTEtMS0yOTgzNTI_67f31eaa-e436-4929-9738-bb08a277b4ca"
      unitRef="usdPerShare">12.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i8b814f4f02ad4405944defaa7243cdee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNy01LTEtMS0yOTgzNTI_67571cfa-80a5-452d-932e-95c64bd87bc8"
      unitRef="usd">234000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmIyNTc1ZTE0MmU3MDRlYTM5YTViYTQzMTUxZTJiYmM5L3RhYmxlcmFuZ2U6YjI1NzVlMTQyZTcwNGVhMzlhNWJhNDMxNTFlMmJiYzlfNy03LTEtMS0yOTgzNTI_65758f70-fe08-4a74-a559-d6807d49a3c0">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ie8db8d0eea7146a6bf8d54b8044ef8d7_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfMjEzOA_1497ebe6-89c4-4a42-b812-efb62b300a48"
      unitRef="usd">16700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i266ebf8c5da54dd097877b98c122296e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfMjIyMQ_d3cec649-e18e-4585-bc9a-e47f69f446e0">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i266ebf8c5da54dd097877b98c122296e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfMjI5OQ_bdd9e14a-94f5-4ed5-ae9c-16e8a8e22f85"
      unitRef="usd">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i266ebf8c5da54dd097877b98c122296e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfMTA5OTUxMTYzNTYwMg_68ced9bf-3df0-4b61-b799-eaca3ed20d1d"
      unitRef="usd">100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i836c83fbf1c1488cb85f5c607bece830_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfMTA5OTUxMTYzNTU3NA_7bb18520-f4fa-4bc3-be23-0a634c2c09b1"
      unitRef="usd">100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i2021beb688ba4eae880d4d4d8f408525_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfMjQzMg_0fc10ef6-d90d-41c1-a4ad-70b9cb1d6f28"
      unitRef="shares">3445499</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfNDk0Mw_fab0ea4f-0f89-489e-baac-27f43f298291">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity during the three months ended March&#160;31,&#160;2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Nonvested balance at December&#160;31,&#160;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,551,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;202,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(313,975)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited/canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252,106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Nonvested balance at March&#160;31,&#160;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,188,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0d38e9904e994f3c8879c104feedb7da_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmMwOTg2MDI3MzA5OTRmNTc5NmJmZjRmNTdiMmE5NDI1L3RhYmxlcmFuZ2U6YzA5ODYwMjczMDk5NGY1Nzk2YmZmNGY1N2IyYTk0MjVfMi0xLTEtMS0yOTgzNTI_541aaa23-c871-4401-8f2c-09feff058926"
      unitRef="shares">6551388</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i0d38e9904e994f3c8879c104feedb7da_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmMwOTg2MDI3MzA5OTRmNTc5NmJmZjRmNTdiMmE5NDI1L3RhYmxlcmFuZ2U6YzA5ODYwMjczMDk5NGY1Nzk2YmZmNGY1N2IyYTk0MjVfMi0zLTEtMS0yOTgzNTI_afe328a9-94b2-4e0d-877c-eaeffa2f124d"
      unitRef="usdPerShare">18.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib2e8096e87554843be3da2502f2fb4f8_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmMwOTg2MDI3MzA5OTRmNTc5NmJmZjRmNTdiMmE5NDI1L3RhYmxlcmFuZ2U6YzA5ODYwMjczMDk5NGY1Nzk2YmZmNGY1N2IyYTk0MjVfMy0xLTEtMS0yOTgzNTI_cf9e9032-8599-4458-9073-606678bde5c5"
      unitRef="shares">202985</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib2e8096e87554843be3da2502f2fb4f8_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmMwOTg2MDI3MzA5OTRmNTc5NmJmZjRmNTdiMmE5NDI1L3RhYmxlcmFuZ2U6YzA5ODYwMjczMDk5NGY1Nzk2YmZmNGY1N2IyYTk0MjVfMy0zLTEtMS0yOTgzNTI_391e7fac-9e0d-49da-b2f4-4e7f07ba2b55"
      unitRef="usdPerShare">1.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ib2e8096e87554843be3da2502f2fb4f8_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmMwOTg2MDI3MzA5OTRmNTc5NmJmZjRmNTdiMmE5NDI1L3RhYmxlcmFuZ2U6YzA5ODYwMjczMDk5NGY1Nzk2YmZmNGY1N2IyYTk0MjVfNC0xLTEtMS0yOTgzNTI_f5b760a7-0e36-4acf-8160-8e0b7684a978"
      unitRef="shares">313975</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib2e8096e87554843be3da2502f2fb4f8_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmMwOTg2MDI3MzA5OTRmNTc5NmJmZjRmNTdiMmE5NDI1L3RhYmxlcmFuZ2U6YzA5ODYwMjczMDk5NGY1Nzk2YmZmNGY1N2IyYTk0MjVfNC0zLTEtMS0yOTgzNTI_c2380b2f-b1d0-4eca-acbf-f791279a3771"
      unitRef="usdPerShare">15.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ib2e8096e87554843be3da2502f2fb4f8_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmMwOTg2MDI3MzA5OTRmNTc5NmJmZjRmNTdiMmE5NDI1L3RhYmxlcmFuZ2U6YzA5ODYwMjczMDk5NGY1Nzk2YmZmNGY1N2IyYTk0MjVfNS0xLTEtMS0yOTgzNTI_e14da3d2-9f8d-4c8e-97c4-fa8a9d59988b"
      unitRef="shares">252106</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ib2e8096e87554843be3da2502f2fb4f8_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmMwOTg2MDI3MzA5OTRmNTc5NmJmZjRmNTdiMmE5NDI1L3RhYmxlcmFuZ2U6YzA5ODYwMjczMDk5NGY1Nzk2YmZmNGY1N2IyYTk0MjVfNS0zLTEtMS0yOTgzNTI_4e7d9d8e-bcfd-4ef6-aee3-a456ec68daca"
      unitRef="usdPerShare">4.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i48b4780d2b7c496aaab05e427e63b362_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmMwOTg2MDI3MzA5OTRmNTc5NmJmZjRmNTdiMmE5NDI1L3RhYmxlcmFuZ2U6YzA5ODYwMjczMDk5NGY1Nzk2YmZmNGY1N2IyYTk0MjVfNi0xLTEtMS0yOTgzNTI_a2c69360-a348-42ef-bd6c-863ef96751d6"
      unitRef="shares">6188292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i48b4780d2b7c496aaab05e427e63b362_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RhYmxlOmMwOTg2MDI3MzA5OTRmNTc5NmJmZjRmNTdiMmE5NDI1L3RhYmxlcmFuZ2U6YzA5ODYwMjczMDk5NGY1Nzk2YmZmNGY1N2IyYTk0MjVfNi0zLTEtMS0yOTgzNTI_8db01bc5-2ded-4880-a7c1-718ab2137dd4"
      unitRef="usdPerShare">18.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i48b4780d2b7c496aaab05e427e63b362_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfMzI3Mw_08fb7f47-e1d1-4221-b8f0-6a904aea9723"
      unitRef="usd">61900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib2e8096e87554843be3da2502f2fb4f8_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfMzQwOQ_ff0a3f72-4683-4cc4-b701-958b67af9051">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="ib2e8096e87554843be3da2502f2fb4f8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfMzQ3NQ_aa788fc6-89b1-4bf1-be35-9e7982a31445"
      unitRef="usd">900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <ibrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue
      contextRef="if52b579ea3554fc9bfe4ad51961a0c27_D20210304-20210304"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfNDE0MA_8d400f9d-ccdf-4a90-81db-8c0a93901919"
      unitRef="usd">4000000</ibrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue>
    <us-gaap:Dividends
      contextRef="i908b2f13981e477ca4efac4b387ad72c_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfNDE1Ng_9fe20ee1-0494-4447-ab39-4b12c07fee1c"
      unitRef="usd">100000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i3554fcc3e6c04d3d8d76fbad65e1995d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfNDE2Mw_2f527411-98e6-49d4-94ec-0d9db99b0cb1"
      unitRef="usd">100000</us-gaap:Dividends>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ia9664eda2c1e467c8dd040b2e7f90f76_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfNDYxMg_7c63ce09-2d66-4b8a-b187-9e5d696fd0cf"
      unitRef="shares">1638000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia9664eda2c1e467c8dd040b2e7f90f76_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfNDY1MA_67c4c662-1ee8-4745-ad56-5f8d06dbfc30"
      unitRef="usdPerShare">3.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="ia9664eda2c1e467c8dd040b2e7f90f76_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85MS9mcmFnOmNjMjQzYjE0YzEyMzRlN2RiODFmNDc1MTQ2NGJmYmUwL3RleHRyZWdpb246Y2MyNDNiMTRjMTIzNGU3ZGI4MWY0NzUxNDY0YmZiZTBfNDcwOA_2d19c255-0297-47ee-bc51-b9a92d3400db"
      unitRef="usd">18000000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85Ny9mcmFnOmI2MTM0MWQxMDAxNDRiMDQ5ZWYyOTI3MmUzNTU4MmYzL3RleHRyZWdpb246YjYxMzQxZDEwMDE0NGIwNDllZjI5MjcyZTM1NTgyZjNfMjQ3NQ_95da2ca1-80e7-4cdb-a6b7-7322acd13c4a">Income Taxes&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to U.S.&#160;federal income tax, as well as income tax in Italy, South Korea, California and other states. From inception through March&#160;31,&#160;2023, we have not been required to pay U.S.&#160;federal and state income taxes because of current and accumulated net operating losses (NOLs). The company computes its quarterly income tax provision by using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. No tax benefit was provided for losses incurred in the U.S., Italy, and South Korea because those losses are offset by a full valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our federal returns for tax years 2019 through 2021 remain open to examination, and our state returns remain subject to examination for tax years 2018 through 2021. The Italian and South Korea returns for tax years 2017 through 2021 remain open to examination. Carryforward attributes that were generated in years where the statute of limitations is closed may still be adjusted upon examination by the Internal Revenue Service or other respective tax authorities. No income tax returns are currently under examination by taxing authorities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inflation Reduction Act of 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Inflation Reduction Act 2022, which incorporates a Corporate Alternative Minimum Tax (CAMT), was signed on August&#160;16,&#160;2022. The changes are effective for the tax years beginning after December&#160;31,&#160;2022. The new tax will require companies to compute two&#160;separate calculations for federal income tax purposes and pay the greater of the new minimum tax or their regular tax liability. The company will be monitoring the impact of the act to determine if it will have an impact on the company for years beginning after December&#160;31,&#160;2022. We currently do not expect this act will have a material effect on our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Coronavirus Aid, Relief and Economic Security Act&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;27,&#160;2020, the U.S. enacted the Coronavirus Aid, Relief and Economic Security Act (the CARES Act). The Cares Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the U.S.&#160;economy and fund a nationwide effort to curtail the effect of COVID-19. The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic. Under the CARES Act, some of the more significant provisions are NOL carrybacks for five&#160;years to offset previous years&#x2019; income, or can be carried forward indefinitely to offset 100%&#160;of taxable income for the tax year beginning before 2021 and 80%&#160;of taxable income for tax years&#160;2021 and thereafter, increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. During the three&#160;months&#160;ended March&#160;31,&#160;2023 and 2022, we did not record any income tax (expense) benefit resulting from the CARES Act, mainly due to our history of net operating losses generated and the maintenance of a full valuation allowance against our net deferred tax assets. There was no material impact from the provisions of the Cares Act for the three&#160;months&#160;ended March&#160;31,&#160;2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;State of California Assembly Bill No.&#160;85&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;29,&#160;2020, the state of California enacted Assembly Bill No.&#160;85 (AB&#160;85) suspending California NOL utilization and imposing a cap on the amount of business incentive tax credits companies can utilize, effective for tax years 2020, 2021 and 2022. There was no material impact from the provisions of AB&#160;85 for the three&#160;months&#160;ended March&#160;31,&#160;2022. On February&#160;9,&#160;2022, Senate Bill No.&#160;113 was enacted that removed the limitations on the use of NOLs and the cap on the business incentive tax credits that were suspended in accordance with AB 85 effective for tax year 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7b965bbf47a941848ab9a9b930e7f952_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85Ny9mcmFnOmI2MTM0MWQxMDAxNDRiMDQ5ZWYyOTI3MmUzNTU4MmYzL3RleHRyZWdpb246YjYxMzQxZDEwMDE0NGIwNDllZjI5MjcyZTM1NTgyZjNfNDY2_4065c0f0-3b59-4bfa-a5b0-d9203fb29a86"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7e5c5c4ae84f441299889d36b9da25d8_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85Ny9mcmFnOmI2MTM0MWQxMDAxNDRiMDQ5ZWYyOTI3MmUzNTU4MmYzL3RleHRyZWdpb246YjYxMzQxZDEwMDE0NGIwNDllZjI5MjcyZTM1NTgyZjNfNDY2_c3535f2d-5d7d-42ba-ba21-1a3c0bbc61d0"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2c5705f6e6f94780a8e01cc108de9b88_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjViYmUzNDBjOWM4ZjQzNTA4OGQ4MDExYjcyYjY4MDBkL3NlYzo1YmJlMzQwYzljOGY0MzUwODhkODAxMWI3MmI2ODAwZF85Ny9mcmFnOmI2MTM0MWQxMDAxNDRiMDQ5ZWYyOTI3MmUzNTU4MmYzL3RleHRyZWdpb246YjYxMzQxZDEwMDE0NGIwNDllZjI5MjcyZTM1NTgyZjNfNDY2_d2af63c6-19d2-43e8-b86f-7f8886f49270"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MF^O)>WRU)+YV,!9_INP@3ZZ1IK+B_)N^N8VO)XY&Q#*V5CH$A:\]6[(LTY$
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M<#G"6*MJ3*TV1F[+26\E#<Z-Y3+#T1Z4-<#W:RG-\\9^H/EG8?$?4$L#!!0
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M@"I8)KB*B4F?BRA>Z"EF6DV)64S.P:A802IV4VHSBERAFH!)%D;!,(VPA_5
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MOW;7X ;RJ!"CRCX8-"XC5PRG$2?09J\:!XGX,;V2F\*XPD8L^_O?SF?'#Y]
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MT;8#>1Y\:>EH$;XK3=<6(:32$M.L:QTR(Z5:\)OP!/E-ED$]?O +":#T<XW
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MLL4.HO2*@N_ "3&!A=#1(5&$CAW-0#<OU\;7EZ5N0;40/)0&FULL%AM@I8K
M=TM&+)!,4!.ROYAY"E0(GZ.ET,B:QWO0<0O[SD93=W5PLL#N1ZNX[_@X,.O,
M!E#/Y;3!D@]YA\(^>^_XU-;+>R^N';BN'=\%4_]('E.,B3Z^^XU9E((4HU3*
M4#E9>4P'!D.+'9DGS+/2 P3IF;.)@$,?'##VQ+]K4/$VQK[Q_1\Y>O)S$<;)
MX12A\4>:$OGDN:<S>&[ BB^EJ:0NQI>9HP-F_:$P@S&$G.@>]"@NV./61#A
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M[;[,NYM2+>S7</BB5+F]G L.LX@ [Z<*ROL;6J#Y\XC+_P)02P,$%     @
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M1"-M&Q79MU'&S<CB;L#4UNI%1_<].IW.@#)E2>OK6N32^92P!&YLA\:?,H1
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M,(=<WU,I"J"5]1#D X,%^8:,WSW0#,&%P7\T$ZTH?CRU6O(,(P9E/&_TJGO
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MW+5*-Z6ZM4U7-0O3%)5IWUQTN((>O"@\N!L!-WT"W)5Z#P#+5GW7E*8<GK\
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M@Q2:2(^+'E(3L_;:0+X#[F?_'O*IHY HVC4R6Y$-05_I!LFJ5T6 KJL'4J/
M+$VN!W4'5V%PC^"CF<])PPD$SL]\M<HYL*\RN$0O?58 C) E+<6G(KONVI2D
M4O F?]1YMT^,I0/%H&@F(<?TCGC=1 WEF\:HGLDA<^WHU13\HX",@C()#^'0
M$]5$8BIHLQ #82&(Z[[EF%&:N2&GZB,,\OZ59%8MX5]2I AA.'&0G6KOD!&*
MAQ&-GDO%MY\_2YF>:1=R:,J7I:J5,N9=4XREDI?".P7*JN/P:+B^)9TC\1/>
M$"^UYN#H$!)=[LELJ/J/IN! M DA%!4X_0_X/S@P_G'@E$:*0B\\.+G6>>5+
MHSLH]8:TX'9);A*>]18\Z2BK%?E7\SF,M-;;FGAT8[<(.P+^E/X]8]9=EWJE
M/D'A=5V"P1(ETGF$[8VE!IYU5.3GCF+$6N7(20:;6FBR[=Q]9>)A2<.C=Z)H
MIY,S-:,J?4FRG5=(I*B;@8*QDU.G4V!8<?3G #R#=M O1P\)=V!,MO/UE6G^
ML-XB15 AAR!>@2.53_G\"0[I%(FZ+GPAXF77 ?<&R?2SEA*.)D8?_B)8A#S/
M;H"+LF[ 4'5*Z/CB>F/S.O$)+M]H-]-.JWLDVZL@)\;SSO:+&BKQW5C]:*@X
M:ZFNBS^>G45VM(;J8U0.]%V97 1A6=2],!GA35=P[5Z<8EKB#XB&3'YMY  \
MV,H^BI= VDE),[=+TI6%U IW6]C01T2XE2Y,WW')/RA'Z8&$\!II'']^1-'G
MOJP4I*O#=7$N\XR"7:2EWQ*!Y==#B*]RG?'%LJ9L"8^ZOO;-(CSX6ORK!TJ<
M]CV;+#RE+_><PYRC'G=^Q$%\YN9 7=N-]$H8B#1/3/FU.M5G.XC[1Z!<2/ER
MM6-](1F<!BL]Z"7/1.JGL[.D4BD%$>#$]Z-&^'>L=NR=\>N1=QLYB]7&D1T2
MIZGU4%&Q0!Z6&0XI>M[['D$2K\?8VW0K79UW^>E?". 97W[XNQP=Z-6\<JM0
M-!%G=Z@.;.=F+;M@\K CG_6A.'S$\]*9:KB@[ER/)"CZC!] H/7.^3-]I>87
MLPNK;L>YWZ9X#C.("K3KK E4XU6;A(0:X9$3*+(JJMV6E3O@!'PMQ.[(=Z(.
MI(54A@S521_D@N(B?:GKN93.ZYZ,W$<)R1N>O&1TV-W8-0H@(I=597J9RV;A
M\(CWU F_H0*D,B2C0#P-E^"'V;)S788/"KX-YP)'3GM!AP!)'1OC#L3)A-&>
MCVI%F1"@D?:(V:$ZM:XQVTC@W!@1!B=,Y,TI6Y6>#65)?=T%'1,+E *#CD\O
MOVD['&T[9(C\P>2;E,0(5#R:R8?R:&HLM'N*Y]UVXUE#<74;RO8=VB-;Z'N?
M_7F PP+H:56D@GD8L5!K!B%Q5B8)8TE6(C;M04L+,XOJ*6GC8&=\SD^GN 6=
ME6?<<8 FIWHK !EVJ'Q;A7(")I';0@M :$+/A9(%CQ#?F#<@/&0]@Q6?EZ8M
M7#4SY9Z'9^6D"M47M%*A#Q*O6%^REE+I+ :99=DQ2NY'/K%&WUEB>&76$:LK
M/:MJRE6HR4JC9"_!!)MZ"U49?.;>T"<U?D2E1D?Q6%K1Z 4<[%HM#2K.J]'D
MQ<O1\Q?/<S%[96'>CG!)S5/T1RJT-ERG)F&"00OJ+TGK:CJ:3E^/IJ]?_*TJ
M7,(4=2NHG'XD6#"*PE=YZ[IO]R[Z:CH93ZZR6AB\-#U[12=1GT81C,.@V14Q
MN+&HP.CY.]07?L0EC1S?NDPBX)HJ8LJ]E"I-,K.6CO>EQ^"DK.5).06?Y"W=
M^M:C- "GW!#,/QBJJ^?E(3G($##CNZ]W,\:NM'LP86I!7)X,AIUQ[)<;)MA0
MF(/P_8,?=%OJ/WW?B#%_%3&W3[.!(AYQ.U4'Q-SSR-R<L<'[)'/.I3,PY[JU
M?\^FUWVGN3Z5N)MYZ[]EUN]V+9>@G?-,8VB[ =."!_-^&K;2#V:(GY\4L)2>
M9V.58!&'AC*L._'35[G^I.* 51A08Y40*G;*4\BJ_NC+A;"=11'B4\(MMP>A
MA5N]*'%T*5YZ@/$^452U<[/(DNDZO>9*I_7=A:P!<>RQT_ E<G$$%7(KXL$&
MB=6[U:ION+#6ZZWZ</WA<S6SY39L)(3?S[+07(2*ABBY[U'E4@<P\4W7%03<
M5!I ;*NN(7%N\U'\WDH./3QU=JCBCXXJ;2AD;9:==JMP'!)S=--_52OQ>1Y5
M),QFD8\JLN0(M8"CAAWXPKVD,O$@[[^\6]PY?6]C@R?\?B:U%B$F16FVRB$?
M2'O$YV!92W,P)T,^09WFF%[VB,4T>9$1'0P$-7LCEA#1RRJ>C8D%;VE6E+EQ
MGZ$UCX9*2R9,+'S(D,,R#*4V81,5+(E_O_8W=<4==[*$]Q ,^"]A-O)97#\8
MO8[9W"Y.H(':8Z ;R#4>.VI8!HJ&,YL9+C5A,E\0KZKDD)!/57(G;9,@-25N
M/%8+ZV04(G@-M<ZGE3[3QF7<0X44<)5A(^76#<WY?0 ,O(F:>I"/,7Y1GU F
M6M?D@ZMAN9JZ7+N3!.%\X2S<I<?RF-PB55%TS >H^NVR,G/UW1=3].S/?YG/
M$;D<%>BPK9^J49909R4Z\HF^'&6%-R_NX++\,R$"N:D6E[RP%K6CE@#+/Y$@
M>4V$HI[CH93L^LSA7.-X)L'N&]HA@O-%>%TFKUH:H.9D N1(!^9PZKV+\LM-
MG3CY4S748U^]E#N1CX,3\BSB2PVN<"LYYO0STVU,'#\G446HV?[,GE: (^).
MZFKFR(N)E>M,0F&2!G%2M<+22GLL>;EQ!$NQCQV=<'V=.[Z]-%2XYH<O,R,Y
MA\]%W:SJ0BW29"S-E',74'$ SA"CO3Z-W^;2M0WCUBP():^3(W-(P8.LHP;;
MI!3YV.8OF;CC\9ZNN'-%2#'#FV:&K\AE:;3CV8Y_()W(20ONI1PDV!-?F7.+
M5;X#-+B4ZWY!-D*/P*O,:<:\1OU^[B^#LE=4R"ZXX1_/"^=I!%6%RA'*)W-D
MX/ !9BQ9T^5(;H_J$U"%,(^208Y\K3G+1U+%>V,4Q9':]MT "N&%+,I6W'NA
M>9V9N9Z,9/I\9UR<$+;(T<N4GQZ&S+Y:");3:;P&=%*S/+"*YEIL:\P/K@S]
M9@?='W<?!!U>X1;3[*Q]D&*-T \".91N3O-T,^=D:%)*=DE9*,T?&K^OD/L)
MXNO0@6WL,6WV"R A;1JJJD^1$B)\,R5 \?&=0?7S%]F@>JCVNX^^R,LF+F!9
M,86XN.*IB\+UW(&AG8M25S@+7,P.X^+FP&%"O*6&TNFI\"@:00W870L5RK_A
M2*T;5K_)BS#8W\V LOT-\2;I7L(J#@0>=4%U&%]%X)FFJ-XO WC-5JN#'HX.
M81X*$.Y>MX&*D$GM$>+CI'3.]L)1FF@)A@?#1K@QE#KMOM,-CB[6SCY7I6BZ
MHPPO7V0;G:P,D\M_BD+$6BKH1+8(NJ=^KS,P5=I;HZ0X%@9I482&&Z7LX B\
MG2/)#G+!3*[V!%\UW$*46-":>F<3V3>F9+H;E 2ER)H$.YEDGB?P[-?Q_9AV
M[3ND-ETVA&+1(W]%,=:D[X'_9_-%<UD'LKX^5O2%">\(51@T](,=J^G5^>SA
M_/7EY:OGZO1&-P\4P<=W8P(Z/E.G=Y]^.ANFUEG.+'/]GADF(3U+HT?2L&R[
MV"[@68KL>G)#BDH>H+^G@QEWP+"H]J'/EAJC2?^XS J D'DBR^?E@@<*7A3V
M>T?ENNQ.Q'V%T*;C/G!/CL,KJ6R[[6[_=!5;E=^TX,-KT6BP98XLK.4MQP/K
M/UR]/$K3MS2R@A1Z7'*E7[5(ZQJTV?A( R)165A%A)!6)INMIX'4EKDJR4S:
M^8TL.FC(OB80:X#^&PXK(U\3Q,\I,38YXDN[R7:^1LF-'4AP_&J(;)D\69?P
ME@(,G.TYR#>NT=661CK@.?>'J(5$'\C@@402)YH[L(?;(L2[F9$V"Z<L,'EJ
MO4#CEZ;Y-TVU;@P$0-/*;('[%F;R<P</?9T1%8<V&Q/4B S[DU\1)'O-'Y^E
M;;9WY,ID3Y.&TTO-48PZ([(D;D:[CX36R?5NUIAS66H,EI4.H7X4WE5(!5+:
M1*_^'?+EN%!"MB&][<$:BJR),F>D+'T6)FCI+*=JOO;W^XA=6+*3)9B\7RFG
MY:HX6K/^CH/5%F]J@B#:$2+CBJ3M464.O(<AF]! !45NHUDZRY[V&[KD(PE^
M&T>U&6M'@?8VJQ^T'T,.I]2A/LU*L@,UQ/6*BAE95X$2\NLTGG2N3Y.70F'L
MQT.TQY2HI$3(Z!;J0=9AYL"BD^U0V7I-S SK7GXI0'<ZKT:9+^-$7QAYD=M#
MQE^$DI.;^H?KZQB:0FT=!H <.+,7*R1COQR6%SOK3FE2*&X/'I^9'=7L-'\B
M?#IX9V!$'G6/O?F=<$5AS&ZVXIU"91WV*.*BX^$R^T +8!MX9IC+?EP:.NEA
MGE\:7=).;WO(3Y+_IYR$9XL4!<R7C@W*#[T.4)XJZFRME;8R:(C(2X04"4QZ
M7P"XI:DNE76%WR^65R \$%;ZG&64NW#:5/DVI8_V.UN.T0WO,X@Z!HTO!%"X
M<NY+KW<UM'#&.]PR7\PB9D92]P3]?B\O%,.3&'!%H_WB8M:6?,(_\R8FQU?$
M8@"BPF[B5\JSS8:0VX_5#_F@E1S#,)#J,'6'O-F>.KT0 VIX%XA#^Y;;A[:0
M6?IH&'"MK^%IM8SF3:%8\ F"WX>,O35*YZ2LC3&4DX,0+]>6TC!J65+D9')]
MBS1O;Z).?=CKCHI;X8YHO"IKEL;>CU_F9"X.VB((KUVU[GU>0@E?FFC$;D]:
M/XHKZK.M[(SO32)9.W8]QX%QEQ\F/'7Y66@2X/&]UXD&W:?@WC=+Z#?9 K^X
MP<,G/=A<*"&_IHPN\< 0E=(R'E85(4N#S VJU+3 0G.!W2)B)]4)?BKXW(V#
MRZ.WEF@9CE\5L32<:B29.^ /R_@J;TM+ /V1UATP@"VG1E\,(.?B87@XM]=G
M?%+B!>$L+.HE6RDMLNA D;QTQ_%&IH%^03"^R+(OK62?0U&$F=9?CJ1$2WS>
MF<^G_$R*"-!4<IF%#9H:_"RI*[R=4"HK!VG&+:^,'57"?.4O3A+#)MK:^=F)
MJ^+;AJ&N/P+QX\YD^,E'V9#B!L6 J6P:$B "#3NC>BZ:N">5?>'[%&.5OS?]
MNXDM;";1VRQMDE>+AO(,+6^Y<>[4AI<YD[A7\M:\N/#=VBHH-F=SM//B=3L.
ML#ASPM&FE9</6UOS6U3<1H.F\5N9)/[T1G)8EXTOVLI</"WFQ_<!(M*#^41,
M4R'(A6Y\JAU6J/PS<!4]+9/#")U/^1:FH9$<A.VE(GJ?PC+%NA"V8XL3Y3_
MA??UO)KSFV\LNNRT%'*#/854U(:11W@X"#F.0:2AD]NY\U&39V"-32\7>-LE
M9 8OS:;999$IB,\;]H3W 5&+>F%'7\(?'?JC 1?9WWS@]2EJ_[02E^3//\1/
MXQ_/N):_&9$>E[^\ 7U;4$RNS1Q'+\<OGY]('A1^Z>R:_X+$S':=7?&/, -8
M$3V [^<69/A?Z(+X)T7>_B]02P,$%     @ X#6K5I#\1L\A!P  (AX  !D
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MQ?.%/7#E$L=<J7L@N\09.FO58B,S<E$$_!1<\, @"?UK,"2W19%?W6Z H/4
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M :\^&M+JK?]E"^:6"M/)>PAFN*D$FS08C,!-AWRQ@M.5@'  P?T6;EG:HPY
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MH 4#8^D$\7%6V/VSO;"J= $*[!4VOK(D@'A80V;DRAIQJKXZEE$EKM%*A^,
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M:8G[$HNU*:@DMTA)//'>ZG]D9??IYW#>+*WCN?R6H3_42K:-I+/AZ-2,[3Y
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M.G[&;\*SOU3%COZ0SJ*HJF)+'S<2(J(2;X#OT9#:7W "]Y>57OX/4$L#!!0
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MU%;Z$'O7BG/.- WI[PU*:-YNR,2AB5EAY*3TX9WJG%)(?LM2_Q%&&[5"4'W
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M)^P&27-H(B9TL#MTYHVK .=#DCH?YGG&;M$LL35@*]% 3>4V\!)M2%*E.(K
MQ33%[R29/^<B^Z.+\1"$_C20_XH.Q"XAOET3&\FF%I6#23;^&"(!XA,A:ATB
MM4=$.$3VN7K"WK?U DP#LKTGGURW%N4QN[A#9"O!WMT+74@D[5K+0K"+U4J+
M%8RB&JR6.(0*]I%7K7C"B .:;@0=AA3A%9RBAM(B=;_)I=_[@-QCWQ^M!>F:
MDN2X96]%(9R3G=<QFP?Q%##$4V1S'N8S_*5!GN9L%L;L9ZH@1/K#=WD<Q3_B
M67_5QU&RHSP"*K,WA$:890RGV%(0.<>@@M0D$<=!'*<DD85Y\M2G_33"H2B;
M!]-IYAR:DU\QR#(+)^RC,.0-026\?8?MESJR8)(E03:G:*(XG">=DBQ,GNDS
M!'';:%&H50.6/&%ZH8P=V&$54SL1F+WZVG+46#0-9WV;"MAV+6%*&E<:1:=A
M(=B.,05,&<=*#^FVAYMW:*.^I"K)\P@MT($;.J);90&['-ASY]@#N7V_Q(!7
MV6I7%E_#:1_.!$SHH@G9%3=K-$15"%$:BD&@/$NVU*K>KZS>HODVBP2N(Z8+
M#,]A/AIZ/CW=70C@@:&LPHGJ(>S _8+E.$>Z1.%I$J1I%J3S.;L[S*?=@V4'
MZ9 Z&M+L(/0=YT,C[:O]!BWVL<U\2RYV.XJW]&47<!7*WE('^8E+W36/]ZKI
M8EMP''>%.%S[TR#+HB#)72?-PW@V%#P>N]9,-8W3HBN\HR1*@ODL<[6>A=%L
MI]@+,E.Y:L_B()I,22@-D_RP,T]0GP91G@?Q//:>I-GS90I0'"NG43@?> '1
MO>I]]J#NSZR=8G9'H%W#J:^IT1<J,_[*RG0&NY3\GVJ</U:C4\6W7)?>95%O
M*O4@P#HB-<T>>&W@W;S!ETM921<VY80WDN1H>BH*U3K<Z;3C+\XY3EB7#L>M
MM&MV 7ICL,J/)[-@;Y3JC@I?*7LSUM&?:H.$S*+\#0O(GA^9=B0H4DEH%6L:
MG)U?B 831DOHMIN-TI9AD69@'*1? (<.=2>[I/3:>?/@4:0%RC]EWL.W.R6^
M1[X^T=NJ;P3EHPV.P]H/\:4T>&LR;E8 P5%]T02AW'A6'5]SC5J_Z,4-"U&Z
M; W*,$$T\-2#+6Z,*CPD"PP_2VD)*#P!11VLI@_@('C>:=S7[I "U535C5M6
M: Q0S@R831IZ V!Y)6MI'Y.C(=W8KHZP@#XR$,EY3KFJ_03;@I"]IDZQF[,9
M3;AL23UH(/KW*0[MH42;CLZI8W/435Q$IM>Z/.DJ*94(3!*L&(F^?C![/%*(
MO24&9ZA$96ZX+(^Q5/"-1*4&K\SN??-R+\$F\.3GD-%T!"D_#!3@"Q*#O+[6
M@<(G9/G$M7M=.?0>-]YY\:Z%7KG/"X:YHO7OX,/J\ 7CPK^X/XK[SQ](S0KM
MB%5BB:V3<):-F/:?%/R-51OW&K]0UJK:7:X%!\U( ,^7"FSO;LC \%WG_#]0
M2P,$%     @ X#6K5D[LW,'@!P  %1,  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&ULE5C;<MLX$OT5E*9VRJG2ZN9<G(SM*MM):CR[N52<3!ZV]@$D
MFR(F)*  H&7MU^_I)DC1L9UD7B211-_[G&[Q>.O\EU 11773U#:<3*H8-R_F
M\Y!7U.@P<QNR>%(ZW^B(2[^>AXTG78A04\]7B\73>:.-G9P>R[WW_O38M;$V
MEMY[%=JFT7YW3K7;GDR6D_[&![.N(M^8GQYO])JN*'[:O/>XF@]:"M.0#<99
MY:D\F9PM7YP_YO-RX$]#VS#ZK3B2S+DO?'%9G$P6[!#5E$?6H/%U31=4UZP(
M;GQ-.B>#218<_^ZUOY;8$4NF UVX^K,I8G4R.9JH@DK=UO&#V_Y.*9XGK"]W
M=9!/M>W.'AY.5-Z&Z)HD# \:8[MO?9/R,!(X6CP@L$H"*_&[,R1>OM11GQY[
MMU6>3T,;_Y!011K.&<M%N8H>3PWDXNFES5U#ZJ.^H7 \C]#(]^=YDC[OI%</
M2!^J-\[&*JA7MJ#BMOP<G@SNK'IWSE??5?A&^YDZ7$[5:K$Z_(Z^PR&\0]%W
M^,/PU$L3\MJ%UI/ZSUD6HD=#_/>^D#N-C^_7R"!Y$38ZIY,)4!#(7]/D]-=?
MED\7OWW'W\>#OX^_I_V'Y?AY:?69E$:LH<W^ @)4=.K3[&JF2BK(ZUJ9[FS4
M-U.E@]H"%_R]OXV?ZC+J>C=55T!SI?[E@/JINM"U 1E8HY6VA7*Q(H \ZDAA
MIEY[U[ .V@CF8N5=NZX4RII70UVGL*8J?4W*NJ@R(H;WU]9X*MC-C=[==I7-
MB(&1=P@PHURW@90K 13OR48YJ?.\;=H:QPMEP6K@+Z^CL6N%Z@?(';Q]]^_P
M:*8^5J2@;J/M3KY;1*!,#.IKJWTD7^_&V=AX=VV$BK*=:@/KTPIY@!.!36EK
M6_A*94E"-"+DV6EQJO@+6 XLH-A>@6;TQ!%%:@(*941CT7K^0DI[)V;JK1-5
M&5DJ351;%$E\ >!$78H*KG(2"BX;RW,&IWT!V851$8?4Q<KA,VG@;G%E&9 S
MA(C@6K3$M:Y;W?%G#0+7*.U,O6O]4!Q$T7K;1<9^[DC[@#(OGP_51\V7.,<C
M@JMAN<ATH\%FHKESS[6IBP:-26+4P".AN_:.;MGKRLOA&VWOQ/^@T\]^UND9
M<.#]#@JVVJ.^,7J320?%2J-*A&2N43(O?0@=G8EMQ0^X/APKSG/WUJ8Q4;2B
MC$$Q2T&F 0Q"-*A!1JE_<+?=(/9Q'E J5G=IT2P6]?A UV1;4E=@)I-#OT\0
M!5EM1JVID0WG330,6_38J-7[['!#)&0!"RTHWM\QK6\$"6-EE[:LNP,?J&B[
MX7N& B)2)'75%>:!,WP ]% 9T 5[Y#>.,PA?U$5_H<YJB55">6.L:=I&&/[@
MXNS-QT=3@4@P:XMTL=IVC=2IY5,AGU7"?:7M.O7\'K+2#A6-6B*CM;%60BQA
M5+VDG)H,/Q*7)746VP<+;;E<B<L2MQAN"=<3C(I;IP)MM 22ZSIOZU1Y-GZ7
MG-6F1=@"3_0P4R,[N$83LSM(:4SFFY0(ENG",%SS-?1W/0X@9*8V<7>;^;:I
MPQIG370#_1@\[6K&5[K#7P'&\C"$QZ5B+F)9(7)@K)?HZ*=7SU']="H_C_NM
M<#(>Z&8CZ*^ #-8_L@F(0)$96)=M,XWD2*>K32'0*]&M-N=#PB[8)['$<C,Y
MJZ^-;X,Z,\44;5@;*B7)KR#O&I,#0O &"9/.?&?3%%L]$W<7TX%F%5EXQL,+
M-_Z^Y@,1._OPZHHOTV "NZ#F_)CC!N0;\N"3?*>H5P)RP)R#&>3]"Q;HCGG0
M.G5;0!9HMX6D&Y9E@J!IOD@S8ODANX99.XI!U.[D=-GRR%(=S+&/"D:<EQZ
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M9#F;!DB@#KSOK&/=DXTCU4C VW*R87N\QS$(4>>S[HXI>A%01C.#<8MU;&+
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MC]<'])^\[^3+FAF\4^(/7MIJ%N0!E+AAK; /:O<S[OT9.[Q"">/?L.MD)UD
M16NLJO?*Q*#FLONRU_T]'"GD\0<*Z5XA];P[0Y[E/;-L/M5J!]I)$YI;>%>]
M-I'CT@5E937]Y:1GYZLN&* VL.);R3>\8-+"HBA4*RV76U@JP0N.!KX\LK5
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M947S%+43H/\;16[M-\Y /Z'G_P)02P,$%     @ X#6K5F#\&)5-!P  .!4
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M=1A5+X/TB\T-AW^ZVQ1BJ^@A5+_6"/;2%JT-Q?\=LI:BLJV?_@9HP4N]=;W
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MLH?JFL=_=7_+42W<+543:PIARJM<M5M=A&?E_6\O7MZBB0 +&H1$JI14@_:
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MTZ90MWSU*VOC,0YFO)#F"2N[-XX&D#52\;(51@_*O++_]+'-0T\@<9\1(*T
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M)';!=Z(T@C!PO#AX3B#8=IQ@=GSP8TR-M?&13_.".?#AP\1*^:UC6BITPC#
M9Y 0\PH3JV4F&AGB3K%2EULK>WP]N9N<]&+#@] J$G0N CW&IYZX+2JV<=F'
M0:5S!@05Z.0@[&),CI<Z)$V!!*$3!?MU&&P?08QFM.!1)WH$(7&BV--K7HRI
M3N"O[9\Y^/LE@[Q#M$"]@%V%/V'0 ])&%]#79HOUE4K-WAV:K/"M1X9)^G*X
MQ:8KEK%RRD2WD_PPH7Z61.1[213@>6&R]<!S4M?[KP!/'9]H-'E) B%.PN2;
M^';]% GA1HD^O!0/[WOQ'2:NQG> !C?XW@=MS]//-$X,@WR$-B+X*8"1*DF
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MPQCY+^PES4X4K\W%:,H57K/,<(E!,Z$WX/J<8QCM1!M8WY3'_P)02P,$%
M  @ X#6K5IM"K?8= P  0P<  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&ULA55M;],P$/XKIX 0D\KRUI9VM)76#<2D =,VM@^(#VYR3:PY=K"==?OW
MG)TV%-2%#ZU]SCW//7?VV;.-T@^F1+3P5 EIYD%I;7T2AB8KL6+F6-4HZ<M:
MZ8I9,G41FEHCRSVH$F$21>.P8EP&BYE?N]*+F6JLX!*O-)BFJIA^7J)0FWD0
M![N%:UZ4UBV$BUG-"KQ!^[V^TF2%'4O.*Y2&*PD:U_/@-#Y9#IV_=[CCN#%[
M<W"9K)1Z<,9%/@\B)P@%9M8Q,!H>\0R%<$0DX]>6,^A".N#^?,?^R>=.N:R8
MP3,E[GENRWDP"2#'-6N$O5:;S[C-9^3X,B6,_X=-ZSN. L@:8U6U!9."BLMV
M9$_;.NP!)B\!DBT@\;K;0%[E.;-L,=-J ]IY$YN;^%0]FL1QZ3;EQFKZR@EG
M%]<HF,7\W173]AE."XU();<&WMZRE4!S- LMA7'.8;:E7+:4R0N4*7Q1TI8&
M/LH<\[_Q(<GK-"8[C<NDE_ +T\>0Q@-(HB3MX4N[G%//E_;G#&W.MYI)P_P9
M,?#C=&6L)NOGH;Q;VN%A6M<^)Z9F&<X#Z@^#^A&#Q9M7\3CZT"-ZV(D>]K$O
M;MJN ;6&;XTUELF<RP*63#"9H7'K+^WEH51Z@QU.Q7<P< -LU\(NJ-H3L]J)
M(9N\<C29YK7O/O(TO)!\S3,F+;4S2745+WE-9XU+L*5J#.',T0G0AF>EW_%S
MS+!:H?;&V^^2-3FG%(_@O$%8:U6U3+29M4OZS:M)$L<?OE*()5<#N)#9,;R&
M>)!,A]W8"UUJ+A^ P$(5/#.0CB!Y'Q_&<#1;U!W3G.1#3.YI,H);99F _ 60
M5S(<MXHFT\BS6W50SWDC\!FN%<L'<'EYYB'I:-Q2I'$?].\J3(>I__T'<.]>
M QA-$YA.QGW.%U752/7NF\Q<J9[AC,X0S[;!AC'$T72O#/^0M$5(!M,TH3&E
M8DSA4(^$>Q=;A;KPU[>!3#72MG=<M]J]$*?MQ?C'O7U>Z$P5G#I<X)J@T?'[
M40"ZO;);PZK:7Y,K9>G2]=.27CG4SH&^KY6R.\,%Z-[-Q6]02P,$%     @
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M4O[JYS^,W+CKUD(:O+RYX1IORZ"L <XOI33;#QM@=_\>_P-02P,$%     @
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MC+<(02V1OA]"&#3R-4YT[(W4,J>KS:EE&Y39!L9L)RQ])%S2^YB KZI]MK9
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M=MG?'/J.%JTMOH]"8RFWS1)O6R"- ?Y?"Z'W'5//Q_M;_B]02P,$%     @
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M;^_0[\OAY3 /B.,I3;Z2A5A/C)$!%GB)BD1\IMN_<3V0I_!BFO#R$VSK6LL
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MJY;B^8ZD_$2R;;9'YYY)R9+L<$-)2+E^0-U?,29?3[2#<E_8_%]02P,$%
M  @ X#6K5J>^]MM; P  H H  !D   !X;"]W;W)K<VAE971S+W-H965T,SDN
M>&ULK99;;],P%,>_BI5-$TBPQ,ZEZ6@CC8T))! 3Y?* >'#3T\8BB8/MMN/;
M8SM9Z!JWJA OK2_G?_([QY?CR9:+G[( 4.BA*FLY]0JEFBO?EWD!%967O(%:
MSRRYJ*C27;'R92. +JRH*GT2!(E?459[V<2.W8MLPM>J9#7<"R37547%[]=0
M\NW4P][CP">V*I09\+-)0U<P _6EN1>ZY_=>%JR"6C)>(P'+J7>-KVZP%5B+
MKPRV<J>-3"ASSG^:SKO%U L,$920*^."ZK\-W$!9&D^:XU?GU.N_:82[[4?O
M=S9X'<R<2KCAY3>V4,742SVT@"5=E^H3W[Z%+J#8^,MY*>TOVG:V@8?RM52\
MZL2:H&)U^T\?ND3L"'!T0$ Z 3E5$':"T ;:DMFP;JFBV43P+1+&6GLS#9L;
MJ];1L-HLXTP)/<NT3F5WK*9USFB)9HHJT NDT"THRDJ)7J+K/!=K6* W#WK;
M2)"(U@OT414@T'M&YZQDBNG19ZWBN59\F=VB9^?/T3EB-?I<\+74$CGQE68U
M7_3SCNMURT4.<'V@XA*%^ 4B 0D=\IOC\EO(>SEY*O=UAOHTD3Y-Q/H+_R%-
MWZ_G4@F]'W^XPFS]1FZ_YI!>R8;F,/7T*90@-N!E%V<X"5ZY@OY/SIZD(.Q3
M$![SGCWN!>.9BKRP>V$!&WT3-#8?.9?*N=*MW\3Z-=?*)L/Q&"<3?[,;F\-J
M' :]T1/FJ&>.3F*>\WKM1&OE\>Y'HR0B>V@.*Q(DJ9LM[MGBD]@:P9<@S;6H
M=Y?)J5DXE@-: CB9XP'-F)#Q'O+0*$G2V$V<],3)B<20ZSF6=\!]1PES0@[N
M@V3 %,?F<#\!'QI%XT/@HQY\=!)XSBMSCU%30%R HR%@2$9[@$.C)(@.[-.T
M!TQ/!*SU5;)N*]S!/*8# H+#_>,T-!H%(^+&'/>8XZ.8W2U8KQ"?EVQE\X@N
MSE*"\2M=K(0PUT##Q:'\C@=,8;R?WJ$-CO#(S8V#OU4N.$IN:Y:S"@7#TY2F
M>TP.(YR0 ^<?[Y1>?-*JPVYUY;:ZEG^KJY,:#R[+.,)XP#TTBW!*]D^3O_-\
M,&\W77M7K):HA*76!9<C';AHGT-M1_'&OBCF7.GWB6T6^@D)PACH^27GZK%C
M'BG]HS3[ U!+ P04    " #@-:M6;/S8K00#  "/"   &0   'AL+W=O<FMS
M:&5E=',O<VAE970T,"YX;6RMEM]/VS 0Q_\5*T,3DX#\:M/"VD@4AL8#$Z)C
M>YCVX";7UB*QB^VVP%^_LY.:TJ8=FO;2VL[=UY^[V'?I+85\4%, 39[*@JN^
M-]5Z=N;[*IM"2=6)F '')V,A2ZIQ*B>^FDF@N74J"S\*@L0O*>->VK-KMS+M
MB;DN&(=;2=2\+*E\'D AEGTO]%8+=VPRU6;!3WLS.H$AZ/O9K<29[U1R5@)7
M3' B8=SWSL.SBZZQMP8_&"S5VIB82$9"/)C)==[W @,$!63:*%#\6\ %%(41
M0HS'6M-S6QK']?%*_<K&CK&,J((+4?QDN9[VO:Y'<AC3>:'OQ/(KU/&TC5XF
M"F5_R;*V#3R2S9469>V,!"7CU3]]JO.PYH ZS0Y1[1!M.K1V.,2U0VP#K<AL
M6)=4T[0GQ9)(8XUJ9F!S8[TQ&L;-6QQJB4\9^NGTBG'*,T8+,M14 [X?32Y!
M4U8H<DRNN08)2A/*<YPL<&@MKGDF2C@BW_"8'5;FG]#\?GA)#@\^D0/"./D^
M%7.%?JKG:P0UV_E9#36HH*(=4#&Y$5Q/%?G"<\C?^OL8H(LR6D4YB/8*WE!Y
M0N+PB$1!%#?P7+S?/=J#$[NDQU8O_H>D_SH?*2WQ=/]NRENEVVK6-3?^3,UH
M!GT/K[0"N0 O_?@A3(+/34'_)[$W*6BY%+3VJ:?W'&M.P5X@)Q.L-8J,I2@)
M/,Z9?B8*LKEDFD'CV:F$$RMLBM0B#>-VSU^LA]9@TPI/G=$;Y+9#;N]%=I>!
MV=/?A%8)M->VC;JM#;1MFS Z39K1$H>6_ 7-74U:"JG9"[5%$IZPVBN\J!QT
M$V^RS9L$&[S;-L=AT-J1RXX#[NP%-H7#'8!"* 6*("]S<32^^<XV2K)!NVT2
M-)-V'6GW?6_=E,!7OOH0[,QL=^L )IUX@W7;)DR2S9/@K]7V$N3$MCQ%,C'G
MNBJ ;M5UU7/;3#;6!]AMJ^;X*E.U:BQO$W,%"QBC9'#2P?3)JOU5$RUFMH.,
MA,9^9(=3_&( :0SP^5@(O9J8#=PW2/H'4$L#!!0    ( . UJU;*GK>/R@(
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M8$%7!=Z)S4=H_.D;OE04RG[)IK'U')*N%(JR 6L%)>/UGSXV<=@":)YN0-
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MTW?0G"Y(&NN/8O,;S0/J&KQ(Q"K[1)O<UG-0E"HMDMP9&"2,;[_)EUR(/8<
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ML@;X?2:E>9A8!TW3&O\!4$L#!!0    ( . UJU87),:%#A0  )7Z   9
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MNEW5'XOG?_##&86MWJ)85;O_=YX/WYU=.(MM51?KP\%-"]99OO\W_7+PA'1
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M=[Z634NOG.HQ+9OSW/]C:.PMK?V>WUTZ;GC0E@2_E@8Q1HLQOGAIJ'=L*.$
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M P1Z>;,I908/2FU0-8924R,AJ,TC601UQW"PXKK*'<,\T=("W1AKUXV!69[
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M+#S(TZ+ZQ]]J(0X @J<;X-4 [[4 OP;XQX#A"X!A#1B^%C"J 6KJ=C5W)5R
M.9Y-*-DA*JT%FWQ0ZBNTT"LM9*(\<BK>I@+'9T+@#"\)Q578BAC=II'( T#S
M-040*<&9ZIY'7S<I2Y79!]2&'9A^0/,X5E8X0S=%E<G2YFT '*?9.V'QZ3%
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M#V.QDCUP+B*Q%7R_KR;_:<[]R;-U+J\<:)7/C47J*CLDS$/"*!+F(V$!$L9
M,$6^HT:^(WB7.T*J#PGSD#"*A/E(6("$,1!,4=^X4=_8V'A>\RQ*Y]&,Q'43
MN F?R@F,3G;C_;[%LO9ZE@MCCET%A831"C;<J8#C#/=KX",S#9 P!H(I6IDT
M6ID8M7*6)%LYF973[FB]7=>**1JN6C,ZR1B)75LJ),Q#PNAD3UBVI?EI^,A,
M R2,@6"*L(X:81T9A?4\_"H6%P5/BH$;67"N;8.,I*Z"0L(\)(PB83X2%ASM
M=0+V6-.&,E"FBJ!LJUW'L^!323.RJ[:@- ]*HS5MM[T:Z)HK:*X!E,90-%5@
M.PO%MKDS?,54\UVQZLNS^(E<>C>7^G5>8RZ=-8>D>5 :A=)\*"V TAB*IBK3
M:97IP">4-1(E0R3-@](HE.9#:0&4QE T58:MDV ;EXJG7]+D8\87VV0>WL6<
M;#>++)5*G(7YRCC)-&,[2Q%J*-2TW<&/HQOG4VBV/I060&D,15-5UCH&MMDR
MN(IBGHLT:18N/I!P*9N]92B*^<1C,5/5J@SJ&T!I'I1&H30?2@N@-&;O>Q_.
MBP4J566MPV";+89698>FI69 9SU!'0$HC=:TW;G#WK0!NM(/I3$43552N]AO
M&U=SWS)M..Q/:84(]0:@- ]*HU":#Z4%4!I#T53-MA:!/<9/*)"KWA=0F@>E
M42C-A]("*(VA:*H,6_?!-ML/;YY00#V(FJ:L?^I<, ^:+872?"@M@-(8BJ:J
MK+4B;+,7\>8)!=28L/=7V0>ZB:8'S99":3Z4%D!I#$53GY9M[0G';$\4P[<H
MJ1X(EE,*G:#,A*Z"@M(\*(TZ^VY$[9Z^G%A \PV@-(:BJ8IJ_0@'[D>\Z<$W
M<S$ZRQ)J6$!I%$KSH;0 2F,HFBK=UK!P\(:% S4LH#0/2J-0F@^E!5 :0]%4
M&;:&A6,V++H\A6)&=98?U*2 TBB4YD-I@;-OQ[BZ<0-#9:LJJS4I'+-)\9:'
M4<S(S@J#&A10&JUIN\._B7;P![4>H#2&HJD":_T)Q^Q/_(3!GTO$*DNWRY4\
M<"VM0J&6!Y3F06D42O.AM !*8RB:JN/6'7'P[T(X4,,#2O.@- JE^5!: *4Q
M%$V586MX..:7(CJ-!*%&!Y3F06G4V7][8JA;^?:AV090&D/15&6U'H;S@U<H
MWM11WV[2)$\SF;@923;MHU:34,<#2O.@- JE^5!: *4Q%$T5;FN+.$?XGAEJ
MB4!I'I1&H30?2@N@-(:BJ;M3M+Z)BW^MPXSL*D,HS8/2J+MOI+SLFZ$9!E :
M0]%4;;4.BOLS'!13WRPO7U4O2VIU"752H#0/2J-0F@^E!5 :0]%4";=.BHMW
M4ERHDP*E>5 :A=)\*"V TAB*ILIP9Q,ILY-2ORA>/T!#9)M)\NUFDV:"I N2
M-7UXL5%?)"+]Q-J<1V==8C>6PNXL]<JW2GQHM@&4QE"T2G+]G2W\9'^[++=S
MS,DLW2:BVLVL.=ML&7E6;I3XXORY?>S9FO/4/O:K#2%;?+4_Y568+:,D)S%?
MR*RL3V,YG,JJ+1^K Y%NR@T$[U(ATG7Y<<7#.<^*!/+Z(DW%\T&10;/QYO1_
M4$L#!!0    ( . UJU9$WTW0*0,  ((+   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0X+GAM;*V6;6_:,!#'OXJ555,KK>2!AT('D2@(K5*G57W87DQ[89*#
M6#AQ:AMHO_W.29J&-D1CX@VQG;M_[G>'[1MNA5RI"$"3YY@G:F1%6J>7MJV"
M"&*J6B*%!-\LA(RIQJE<VBJ50,/,*>:VYS@].Z8LL?QAMG8K_:%8:\X2N)5$
MK>.8RI<KX&([LESK=>&.+2-M%FQ_F-(EW(-^3&\ESNQ2)60Q)(J)A$A8C*RQ
M>SEQ'>.06?QDL%65,3$H<R%69G(=CBS'1 0< FTD*#XV, '.C1+&\52(6N4W
MC6-U_*H^R^ 19DX53 3_Q4(=C:R^14)8T#77=V+[#0J@KM$+!%?9+]D6MHY%
M@K72(BZ<,8*8)?F3/A>)J#BXG3T.7N'@_:M#NW!H9Z!Y9!G6E&KJ#Z78$FFL
M4<T,LMQDWDC#$E/&>RWQ+4,_[2,^IW,A:9[4)"0W+, J 1DO)0 63*ML>1P\
MK9EBF=GYN]E$8%E#*$0>)$W4 J2$D)Q.05/&U1E:/=Y/R>G)&3DA#(TBL5:H
MJX:V1@P3C!T4(5_E(7M[0IY"T")M]POQ',^K<9\TN\]@WB)NI\[=QN25&?3*
M#'J97GN/WE@IW&W5A/R^01-RK2%6?^KP<KU.O9[9MY<JI0&,+-R8"N0&+/_S
M)[?G?*V#/9+8#GJ[1&\WJ?LSEC -YQPW8HA%U319LCD'0DU*:BN;Z_4R/7/"
M;'S/];S!T-Y4F1J_^I],G9*IT\@T72<K)E=D1@/&F7ZIHVA4.+2 1Q+;@>V6
ML-TC_W>[QT0_DM@.>J]$[S76V9Q96J[SRP0/I%0*//!4[;^V4>E0Z-Z'+> Z
M3J==;H$=FHN2YJ*1Y@;P*HL$QVT8(\DF/[CK6!IU#F7)Q;H5EI[7W8/2+U'Z
M1SY4&O4.1>I_0-H]H7:8!B73H)'IAXY 8G>! 02,OM%D-RLNII2%!)Y3<_'6
M(C;*'XHX^(@XZ.^IFNN\-1).(^.#T)23H-H*U-[MC2J'HA1JU=W4<;I._QV,
M76F03'?ZG<HE2Q3AL$ _IW6!R9!YPY=/M$BSGFDN-'9@V3#")AFD,<#W"R'T
MZ\2T867;[?\%4$L#!!0    ( . UJU89DDNR% 4  .T<   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0Y+GAM;+69:V^C.!2&_XK%KE8S4J> <VG:22*UJ;I;
M:2[5="Y:K?:#$PZ)5<#4-DDKS8]?&PB$A+C-K/,EX79>_-@^]FLS7#'^(!8
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M,-V-;U'Z0^!'PN<T$:K8H0KU3L]4]O#BVUIQ(EF:?YZ:,BE9G!\N@*AUL'Y
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M970U-BYX;6RUF6%OFS@8Q[^*Q4VG5KHKV!!(>DFDK=6T29NN6KN[UV[B)-8
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M="!6FA(.=Q*I%6-8OHR!BLTPB(/=PCU9++5="--!@1?P /JQN)-F%E8H.6'
M%1$<29@/@U%\/8X3J^ D?A+8J(,QLJX\"?%L)]-\&$26$5#(M(7 YK>&&Z#4
M(AD>?TO0H+)I%0_'._1OSGGCS!-6<"/H+Y+KY3#H!RB'.5Y1?2\VWZ%TZ-+B
M98(J]T4;+]OM!2A;*2U8J6P8,,+]'V_+0!PH),D1A:14<($(O2''<H(U3@=2
M;)"TT@;-#IRK3MN0(]QFY4%+LTN,GDYOP;B$1E)BO@ 3;:W09S3*<V)CABF:
M<I]Y&\'S"6A,Z 4Z0X2C&:'4K*I!J T/BQ9FI<VQMYD<L=E&,\'U4J&O/(?\
M?_W0\*^<2'9.C)-&P!F6+=2./Z$D2MKH\6&"SL\N&G#;57#:#K=]-#A* 2 ?
MHPFH3)+"1>+WK9%$4PU,_:GSW\-VZF'M0;M6!<Y@&)B3I$"N(4@_?HB[T9<&
MTIV*=*<)/?U1@#3YX@M$'>\"O_B\2J!80XZT0,*YH>P0MAIX7LIJD*PVH=[D
ME3-I#_HZC3NM_B!<UQ"]K(A>-A*=$4[8BM69:U1\9?RZ%:WN^R2]^PZD>Q7I
M7F,LI]P<6'-<;0*1F)?IQ/MC74>X&3)!+X"E:B#7K\CU3U1D>9GX6H/#:JOC
MU8P6.UX-M*XJ6E?-]8>WQ^JO4?&5J8RC_94<O4\%EKAOS/O@*8G?O@A/8,;1
MR3*,DSW!Y$T+\01<$[?PX$EF(!>N\5 H$RNN_>M<K5;-S<@_Z7MQWQF9UVU!
MS&5-86Y4HU;/W([2-QM^HD7A'O@GH4V[X(9+TZ"!M )F?RZ$WDVL@:KE2_\!
M4$L#!!0    ( . UJU:I+=CQ\0P  *V9   9    >&PO=V]R:W-H965T<R]S
M:&5E=#4X+GAM;,6=[V^;2!Z'_Q7D6YU:J5N;X9?=2R*U84;74W]$R7;WQ>I>
M$'OBH-K@!9RTTOWQ!YAX/![\Q20?W^V+K>TPSX _, R/9^#L,<V^Y_=2%M:/
MY2+)SP?W1;%Z-QSFTWNYC/*WZ4HFY5_NTFP9%>7;;#[,5YF,9G6AY6+(1B-_
MN(SB9'!Q5G]VE5V<I>MB$2?R*K/R]7(993\_R$7Z>#ZP!T\?7,?S^Z+Z8'AQ
MMHKF\D86WU976?ENN*7,XJ5,\CA-K$S>G0_>V^_$V*T*U$O\'LO'?.>U56W*
M;9I^K]Y\G)T/1M4:R86<%A4B*O]YD)=RL:A(Y7K\U4 'VSJK@KNOG^BBWOAR
M8VZC7%ZFBS_B67%_/A@/K)F\B]:+XCI]_*=L-LBK>--TD=?_MQZ;94<#:[K.
MBW39%"[78!DGFW^C'\T7L5/ =@\48$T!ME_ .U# :0HXQ];@-@7<8VOPF@+>
M?@'_0 &_*>#7W_WFRZJ_Z3 JHHNS+'VTLFKIDE:]J..J2Y=?<)Q4>]9-D95_
MC<MRQ<6U7$2%G/UZ%67%3RN4MX7UJ_4ERK*H2MQZ%<HBBA?YZ_+3;S>A]>J7
MU]8OUM#*[Z-,YE:<6-^2N,C?E!^6KW^[3]=YE,SRLV%1KEM5PW#:K,?E9CW8
M@?5PK,]I4MSG%D]F<M92GM/E@Z[R@BYO,P(P++_4[3?+GK[9#XPDOE_/WUJ.
M_<9B(\;:OA"Z^.<HVQ9W6HJ'QQ=OJYW3Q?^U7I#%!5T\E--#Q;7OTMGNI4[-
M<^B]U-KLI;]E49)'FY;IST_EHM;'0B[S?[>LYX<-UVWG5LWVNWP53>7YH&R7
M<YD]R,'%W_]F^Z-_M"6&A(5(&$?"! BF)>UNDW8I^L5EFCS(K(AO%])*TD):
MJ^AG5+V)"NLNBC/K(5JL95O2)+=OTAN87\.JD_/#1>",&?//A@^[&2+KY$B8
M:-F D;8!6CK>-AV/3.<J2Z=2SG+K+DN75ISGZRB92BN]*SL9F_/(JCY"ISLI
MKLI%RR73[&<=:'FN2,H.4UED6WR:YD5>!AVWM=L?R#7JF^L&YNU\+6PR]D9[
ML7K&E[>W!$>NE #!M$3];:(^F>B7,HN5EFJ3I%4E&<NV4_D'$MDW$M^()+ #
MVQ[O98*LDR-APMP /W#L@+4?:L$VF( ,YF-2R++RHCXNJL[5-,KOV\(@,7W#
M"(QML3W/]O:R,)?R1LY>V\B1ZR5 ,"V)\3:),9E$W2F>Q?DT72=%6P)D\;X)
MC(VVQV-^8.\E@*R2(V'"7'_?9:.@_6"8;".8T*U4E!369;2*BVAA_<>ZD=-U
M5C917\N33%)=.EHB3LI329S,K>NR\;)>W7P5UZ_;LB+KZ9L5$A8B81P)$R"8
MEKP]4A>HHQ/U_1LP*&PH+832.)0F4#0]\!TC81]WYLNJ0WDCS%KC)3&]XVT\
M"=OM];T=[7=#H)5R*$V@:'IN3.7&CFZD6_,BB_?."TD+H30.I0D438]5J1?[
M5.[%ALH7*"V$TCB4)E T/7!E8&Q:P6S;WZHKU9HK5+4TM/V&=U^U0"OE4)KH
MW 0]"65;;%JW=+:H4#<"I850&H?2!(JFQZJ4B^V?JD6%FA<H+832.)0F4#0]
M<*5R["-=SL$6%2IQ&IKM:LV1S<:3_38562V'TL2AC? F!UI5I7-LVN=\7=7'
M6I$^:6HKFDZS=7E 1LG,6B>-<&LB*Q=K?NQ,[\H"RV59-"_2Z7?K59Q8LW2Q
MB++<6LELLUBK=&A6:+PK==[Z@9[&);W:O0]'J"*"T@2*IN\ 2B;9_RN;1%?4
M^[B%^B0HC4-I D73?YA72HF=2BDQJ%*"TD(HC4-I D73 U=*B6&4$HWI'2^2
M%D)I'$H3K$N>Z;DII<2.5THO:ZGIBGHG"Y5/4!J'T@2*IN\ 2CZQ4\DG!I5/
M4%H(I7$H3:!H>N!*/K$CY5-72PUU4*Q=X.S+?VBE'$H3*)J>FU)5['A5]<*6
M&BJUH+002N-0FD#1]!U 22UV*JG%H%(+2@NA- ZE"11-#UQ)+7:DU.IJJ:%N
MJZ%UMM10LP6E"11-STWI+T;KK]T1ME^J 9FMH4''-$%I(93&H32!HNG9*K/%
M)J=JA*$F"TH+H30.I0D439\6H4R60XJ3%PR7I\&]9T9L:+O#_ICCF /FH;5R
M*$UT;X,>DK)/#FV?KK6Q\<FA-I>F]$YD0^L:Z@ZME$-IHF431@>R4$;)Z3!*
MSQGO3C-[)\/,9%S/=XUHH%H(2A.MVV"SG7'*>CX[$[U(O] ]V)HNWSL+Q]@.
M>\(F^S^40BOE4)IHV01FVX?<JZ-,C$.;&*.?6%[6=PU(H9&]PT'20BB-0VD"
M1=.C5O+&\4[4;72@L@9*"Z$T#J4)%$T/7,D:AY[U]8)N(U36..;<*6=4_K??
M_$(M#)0F4#0]265A'-K"_#]F9-*KU'L?,&>3E2=@<Q^ &ATH3:!H^CZ@C(Y#
M&YU/,IG)S$JS>!XG4=UNW\GVHQ>J=1J:UGDR<X/:&BA-H&AZ;LK6./0XI&.O
M"Z%JIJ%U'FY0YP*E"11-OT&!<BXN[5R>=0E),_N&V-"Z+NZAE7(H3:!H>HC*
MR;BTD^F\SJ3+]PZ,4AE-6% 3 Z4)%$T/2TD;EY8V79>B;^IW?U1WXWIC??IT
MN7E_675ELIORVJ6Z<57SAVJ(;_7'S^EMO)#UAZWI0XT/E!9":1Q*$RB:OJ,H
M>^2>:KB0"]5*4%H(I7$H3:!H>N [=PNB)=7[^3R3\^H'Z%46)]-X%2WJ0_QI
M1/_3,/[6R%W#]SNV9_1@+^E5Z!TF5$-!:0)%T\-4&LJEQQ!MFOGZGH5EFN5E
MZ/$S+!IRQPP+NO[>24+]$I0F4#0]2>67W./]$OZ$7<(^QTF\7"];=P6HH8+2
M0BB-0VD"1=-W&26RW.!4IVZHCH+20BB-0VD"1=,#5];*I:U5YZ1(NGSO7*%C
MD* TWM#V![4Y^NE+H"K5 U.ZRJ5UU>D;]>C'P48=ZL"@M!!*XU":0-'TNT4J
M5>:=:J*=!_5E4%H(I7$H3:!H>N!*JWE'3K0[U*C3Y7OG"IUA!Z5QKWU.W-Z(
M.(&J5 ],J34/H=9>HM+H%>B=.%2E06D<2A,HFKYC*)7FG4JE>5"5!J6%4!J'
MT@2*I@>N5)I'J[1G_:Q%,WMG[9H_:[F>;_PX":V50VFB=1ML9W1@Y*JW<^OM
M8^Q8O_%X-+)W/%!]!J5Q*$V@:'K42I]YIYI+YT'E%Y060FD<2A,HFAZXDE\>
M/8KK^>/Q:'#OP,VQ6&[+>#QHI1Q*$YV;H$>D=)5'ZZKGG1ZA"LLSQULY@<^"
M_72@;@I*$ZV;X+)#Z2@WY=%NZNB[Y=.<WHF8@ZE:>BM'+,2AZR50-/V1$DK[
M^/0(J<[!-73YOBGX+:.AG&#/GH;0.CF4)MJVP!L?."I\96-\VL9<J8&^!V?Z
MTHC>44"%#)3&H32!HNG1*F_CLQ-U$7VHCX'20BB-0VD"1=,#5S[&IR?&/;^+
M2(-[!VY.-W,#S^PC0FOE4)KHW@8]).50?-JA'#FBFZ;T3L0T#JYK^\QX@A+4
MFD!IHFT;''LR.C"?U%?6Q.^X+]&SGF\%U2:^^="Q]GR@0@1*$VW;0.6S\_@Q
M>J10=U<1^["QE@EGCK/SK*XF"NS3QK"/&]O0?"V*T>3 ;9%]Y2#\SIED6F?Q
M"+U($WMG QUY Z5Q*$V@:'K22F7XXU/U':$^ TH+H30.I0D430]<V1'_^)$[
M/?N.4%WBFR:DGNYK]!VA(VJ@-(&BZ0^%5&HE.,'D,YK9-\6@158$C!DI0FOE
M4)I T?04E9@)CAPFT_EP3ZB="<Q9:!/7S,TV.QC&4ARZ9@)%T_-0-B6@1\%T
M]D+I\KUS:+E[3C V@X#:$"A-H&AZ8,J&!+0->49GE2;VCA Z+ 5*XU":0-'T
MI)52"=P3=58#J&6!TD(HC4-I D73 U?&)CA^G$N_SBH-[AVXJ3QLUB(ZH;5R
M*$V@:'J42NX$)WBX/,WLG:(I?&Q[8OY("ZV50VD"1=-3W'D0/>I)]-A'T9L#
M.1SS/B70.CF4)E T/3>E>8(7/K>>+M\[+W-HA]=R<0&U-%":0-'TO)2E"6A+
M\YP^+53/0&DAE,:A-(&B:4F/E<09GVI:U!AJ<J"T$$KC4)I T?3 E>\9T[[G
M^7U:&MP[<%, >2W^%5HIA]($BJ8GJ4S1^ 3WCZ:9O4,T[9$[,>T1M%(.I0D4
M30]1V:,Q;8^.[M'2G-[!M=QLVKP2@=;)H32!HNFY*1<TIH?7=/9HZ?*]\W(-
M$6[^R@&MDD-I D7;Q#7,[Z4LPJB(+LZ6,IO+:BYH;M5AG ^J%G3[:=DHWE7/
MX7WWG@V&QN>7]KO0KCX?*LS%V2J:R\]1-H^3W%K(NQ(Y>EOYBZQZ?-C3FR)=
MG0_*,\!M6A3ILGYY+Z.9S*H%RK_?I>79M7E35?!8W8V@6NV+_P)02P,$%
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MZQ;7QSTN-( +@R]Y5CV6X!_91FPL_I=N?X@< 98R28=,H1^9^HB<$;_$Q7N
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M$6IIB8R:Z1 5JQ,WJT^G3&*V.WC(#;P6JP /=!R)8GCB9OB)C$DLZQ\L,LJ
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MIV5!N< )CV7^%ZS*:_T.F"REXDD9K!4D+"U>R5O9B+4 G:<Y )4!:#L@W!&
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M.= J_X7K+S^P$"R=L(4^TJ@!:$4X[,,UHR4%.: 6%+/(G]"(CE5CZ;!6>C]
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MC]:,I1+$=*I#_;.>%BJ*31/%B>*+?-_!F"O%D_QP3DE$17:!_GS*M6&7)]D
MU=:5X?]02P,$%     @ X#6K5DS-[IP$!   :Q8  !D   !X;"]W;W)K<VAE
M971S+W-H965T-C$N>&ULM5A1;YLZ%/XK%G>:-JDMV! 2>A.D)='5*G5W5=MM
M#U?WP04GL0HXLTVS_OO90"$DA"62\Q(PG//E.\?GP,<9;QA_%BM")/B5)IF8
M6"LIU]>V+:(52;&X8FN2J3L+QE,LU9(O;;'F!,>%4YK8R'%\.\4TL\)Q<>V.
MAV.6RX1FY(X#D:<IYJ]3DK#-Q(+6VX5[NEQ)?<$.QVN\) ]$?EO?<;6R:Y28
MIB03E&6 D\7$^@2O9\C5#H7%=THV8NL<Z%">&'O6BYMX8CF:$4E()#4$5H<7
M,B-)HI$4CY\5J%7_IW;</G]#_Z<(7@7SA 69L>0'C>5J8HTL$),%SA-YSS:?
M21700.-%+!'%+]A4MHX%HEQ(EE;.BD%*L_*(?U6)V'* W@$'5#F@8QW<RJ'(
MG%TR*\*:8XG#,6<;P+6U0M,G16X*;Q4-S?0V/DBN[E+E)\-[DF!)XLL[S.4K
M^+3DA*A-D@)<@H=R9P%;@*^Y%!)G,<V68(H3G$5$Z.L'O3_,B<0T^:A@OCW,
MP8=W'\$[0#/PN&*Y4$!B;$O%7G.PHXKIM&2*#C#]@OD5<.$%0 YR.]QG_>YS
M$M7NJ.UNJYS5B4-UXE"!Y_8G#I2A/W*<"5Q6YG^WRA3<2)**_[O"+'&];ES=
MMM=BC2,RL51?"L)?B!6^_POZSM]=01L":Z7 K5/@]J&'CTSB!,0Y 0O.4M74
M94;6*B.4=.YPB><7>/H!\Q)"S_?&]LMV2!U&H\"IC5I4O9JJ=R15R8XA6J(-
MMCB@P$4[1/>-7,\/NHD.:J*#7J+_XDQ.*;L -UETU<6LU_W4ZC$$UHK4KR/U
MS]1 OLD4& )KI6!8IV!HN(&&>R4'4;#;0'\P:E$=U51'1AMHM,<A\-P=GOTV
M+9I!33/HI3GE-'L&JH$2MJ21.-Q&O3"GUI AL%;$T&G>X,Z9&JD"-I0%4VCM
M-&P)&6BXF2K U@-\L%.C'39H"+N+%#;: ?:^E\-YGI!7<,]P? %N;V>=Y(S*
M!%-H[7@;H0#=<Y5HKP0Y.0V&T-II:$0(-*M"X+["@.[ WRW1#BO//52CC1"!
M?U8B/_379"<SHS+$%%H[TD:(P',I$6A4BIA":Z>A$2/P6#5R9'7NZXQ!L*N1
M.XR"D7^@-ALQ OO5R$V:YAF[_)I%^D7_"F;*@$:'W_;]<"?ODR&T=O"-Q('!
MN<K5J.HQA=;^_&YD#^K5$R>7:P6W78D>W*G6#AOH'/BB0XTR0?W*Y#OFE.7=
MI'H]3QX&&$)KQ[DU$3G;2,3L3.0<8@<U8@>9'HN@CI''GA+M,'+18*<V[:U)
MH![#?L%\23,!$K)07L[54)4V+R>;Y4*R=3$<?&)2LK0X71$<$ZX-U/T%8_)M
MH>>-]7PY_ U02P,$%     @ X#6K5N1]9XS.(   CH(" !D   !X;"]W;W)K
M<VAE971S+W-H965T-C(N>&ULO=U;<]M&@H;AOX+2;FW-5#DV"1Z5=5P5"Z?&
MH;MA9W8NMO8"EB")%1XT(.7#5G[\@A0E$"38)))7>Q-3"O$T1,J?": _]/MO
MB^+WY7V>KZSOL^E\^<O%_6KU\/.[=\OK^WR6+=\N'O)Y^7]N%\4L6Y5?%G?O
ME@]%GMUL-II-W]F=SO#=+)O,+SZ\WWQ/%Q_>+QY7T\D\UX6U?)S-LN+'QWRZ
M^/;+1??B^1N?)G?WJ_4WWGUX_Y#=Y9_SU3\>=%%^]>Y%N9G,\OERLIA;17[[
MR\6OW9_3KMU?;[%YRG]-\F_+G<?6^F?YLEC\OOY"W/QRT5GO4C[-KU=K(RO_
M^)I?Y=/IFBIWY%];]>)ET/6&NX^?=6_STY<_S9=LF5\MIO^<W*SN?[D87U@W
M^6WV.%U]6GP+\NU/-%A[UXOI<O-?Z]OVN9T+Z_IQN5K,MAN7>S";S)_^S+YO
M7XF=#7K'-K"W&]A[&]CVD0UZVPUZ^R-TCVS0WV[0WQ]A>&2#P7:#P;DC#+<;
M#/<WZ!W98+3=8+2W0;=_9(/Q=H/QN;MTN=W@\MP-NIWG=ZYS[CO1?7FS]]_M
MXYL\O]W=L]_O[O,;WMU_QX]O\OR6=P_>\Z.;/+_IW?UWO3L^MLGSV][=?]^/
M;_+\QG<W[_R[I[]7F[^43K;*/KPO%M^L8OW\TEL_V/S-WFQ?_EV<S-<I]'E5
ME/]W4FZW^O IGV:K_.8GG16K']:O=T6>EQFS6EH_6;_>W$S609%-+3%_RKMU
M;/S-R5?99/KW]^]6Y?AKY=WU=BS_:2S[R%A=*UG,5_=+RYW?Y#<-VT?F[7NG
MMD].C&\;@'?E"_?RZMG/K]Y'VR@FV0^KTWUCV1W;MO[QV;'^]N]_MVY7__%O
MW='X/ZW?\F+6L)=79C/,YF\/T ;&,3/J>O7"=,_>-]>,_OI0&- &SSO_9SU_
M)_TST-X&[5Z^H-.\_*?JF!B<^+$?[U[$<</FPKRYEW]Y:]GCS>:CLW_*T(Q^
MSA_*?>ILT.'9:'3J][EX_D'MGN%W+SZ?,?T*)V;&R:]?F*Z!D6<SU>]# Z/.
MWQO3#Z7/_I4O]\;P5R<]_Z<:''%JF=9[^1>AMX%[YG\1K*=_$7XKLODR>_K
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M_<SG)>C>2513J*91+:6T>LI5%9WRX5\\"C]=?#2/T3H)2<U!-1?5/%3S42U
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MQ7*:Y5*,VPO7G3)2U[PR$C5?WCQ,^Z1EFTDHYSYSM=O'CD;#O2-UCQW69[F
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MD6:0H5.L4"<.2O.@-!]*"Z"T$$J+H#2*HNF2;ITX9P)-*J#>&Y3F06D^E!9
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
M+AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*
M(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC
M)8QQ8K3^-8+)#^Q^ %!+ P04    " #@-:M62NZ0;@L%  #W+0  #P   'AL
M+W=O<FMB;V]K+GAM;,6:2V_;.!" _PKARW8/6=MZM0WB $FSV360=H,XS1X+
M6J)C(A1ID%32]-<O*<?-J)8'>YGH9(MZ^!-I\AL.>?)D[,/2F ?VO5;:S49K
M[S?'X[$KUZ+F[@^S$3J<61E;<Q\.[?W8;:S@E5L+X6LU3B:38EQSJ4>G)[MG
M7=LQ/#!>E%X:'0ICP9T43^[U?#QDC]+)I532/\]&[7<E1JR66M;RAZAFH\F(
MN;5Y^MM8^<-HS]6BM$:IV6BZ/7$GK)?E7O$B0M[RI6M+/%_>\  R&Q63\,"5
MM,ZW5[3/YX'Q482+MT>--Y=2>6$ON!=_6=-LI+Z/CPEO,0:OT=;#[G-;B<?V
M_U2C6:UD*2Y,V=1"^VT]6J$BH'9KN7$CIGDM9J-/YE%8=LWO17RI\"OS:ON"
M/I"!ZK+',IRP\ZIEI.31E=!.5"Q\<T;)*G!4[)PKKDO! &2"0"8#0GY+ &2*
M0*:#0"XB3K@50&8(9#8@9*<F<P0R'Q(R!9 % ED,"9D!R/<(Y/LA(7, ^0&!
M_$ +>2%<:>4FEC.S8N>-DUHX!^ ^(G ?:>$635US^QS!%O)>RW ;UYZ=E:5I
MM)=P$)]@H_B$%O-2ZC 42JY^CC>>70C/I8+U.$5%0VR:5\2Y=MZVEW?@,,%,
MB0USR:5E=UPU@GT6W#56[.%A:IF2NT4IOC2V/<.XKMA5N#%T;'9V;T4GE,#D
M,B6W2UU+W]9<"QD&'1\"+1&:773J$I/+E-@N5Z%]0[U9RP/97BMC1ID2*^4F
M%HKJZ)I;_QRZ[])#,DPC4V*/=,G:_]Q>S6$&F1(KY%\>F].'7L';B<<O?S?,
M'U-J@7A3/JR-JH1UWT*CAMLD;-<$TT9"K(T6[NB<;R.$.CS)M1=!/LP9";$S
MYKHTM6"W_'NG01-T+D*L"C0BZ(30"::,A%@9."8,HA-,&0FQ,I# A;V[Y1 3
MDT9"+(W>X"4"!@SW.Z3$!)(0"^1 %+/CA)B831+R60D2S71[$":5A%@J^X%"
M;X-C<DF(Y;(?,?0AIIAB4F+%' H=7D A)F::E-@TATS8@XG))QU4/C#KD**I
ML$'E _,.*2:?=$#Y'+%KB(G))WTS^?1@=M.?F'U2:ON@M7D&,3'[I,3VP3'G
M$!.S3TIL'[S18?R68@9*B0V$8\(!*<,LE V7'PN8<$#*, ME0^3(PK_R93R%
MF)B%,NILV0',,+XW=:,@)F:AC-A"!S&K2H:+(2:Z)$-MH0-1^TNS0TS,0AGY
MJ@P6M<,!*<,LE)&ORV"8G0$)LU VZ!RH,R!A%LJ(+81C%A 3LU!&;*'7Q/-^
MWCGT([BLB5DH)[80BME=?<4LE!-;J&?B&\>BS4:U1Q 3LU!.;*$#F+N9!\3$
M+)036Z@7,TXQC?XEA9YC%LJ)+=1?F^'!5:,$@[+,T:T!;[YZ QJ]VX4P"^7$
M%NK%?(D[-(<14HY9*'_3=9TV?W3$OL3%E+A]JC-N8A;*B2UT,(>T;7J(B5DH
M?]-L7 ?S3]?9*U!@%BJ&RLC%VNQTH0*S4$%L(00S=B2(B5FH(+90S](C>_<R
MM81)V )S4$&=CP.+D+_M%B%[9T(%YJ""V$$'D[#[38XYJ"!V$((93T%,=(,:
ML8-0S&X_QQQ4$#L(P;Q9?(7Q48$YJ"!V$%R*[KB<S75X(,3$'%2T#AJW%[O3
MDRIT12VJ+^$G7"@ON2JO+8L?VRU161XW+ZP:I3Z%LG_TE>'5;M_R;L_UZ7]0
M2P,$%     @ X#6K5I=W<N0L @  ]B@  !H   !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<\W:2T[C0!2%X:U$7@"5NJ] BS#J"5/$!JQ0>8@DCEQN ;OO
M* R28_6@)\AG9)4M7_^C3U;9CR]EWPZ[[EBWNU.=?1[VQ[ILML-P^I5276W+
MH:UWW:D<SU?677]HA_.RWZ13NWIO-R7)?!ZIOYW1/#W>SIR]?IW*_TSLUNO=
MJOSN5G\.Y3C\8W#ZZ/KWNBUE:&:O;;\IP[))G_OKZ9HNAWQWGMS,GM^63?_\
MEILT=9! D$P?I!"DTP<9!-GT00Y!/GU00%!,'[2 H,7T0?<0=#]]T ,$/4P?
ME.<HXYP@:80U@=89N<X$7F<$.Q.(G9'L3&!V1K0S@=H9V<X$;F>$.Q/(G9'N
M3&!W1KPS@=Z">@N!WH)Z"X'>,GK9)M!;4&\AT%M0;R'06U!O(=!;4&\AT%M0
M;R'06U!O(=!;4&\AT%M1;R706U%O)=!;46\ET%M'FR4$>BOJK01Z*^JM!'HK
MZJT$>BOJK01Z*^JM!'HKZJT$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01ZVVBSFT!O
M0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T>]G4!O1[V=0&]'O9U ;T>]G4!O
M1[V=0&\??:PDT-M1;R?0VU%O)]#;46\GT-M1;R?0.U#O(- [4.\@T#M0[R#0
M.U#O(- [4.\@T#M0[R#0.T8_FQ#H':AW$.@=J'<0Z!VH=_RDWG7XVI=Z[?E>
MXT]!/TGU<+ZW7!]_67Z?1)P7%YS3;45]^@M02P,$%     @ X#6K5M9((R[W
M 0  *R@  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULS=K+3L,P$ 707ZFR18WK
M)P_1;H ML. '3#*E49/8LETH?X^3 A((*E"1N)M&K>VY$X]T5CV_>_84)]NN
M[>.\6*7DSQB+U8HZ&TOGJ<\K2Q<ZF_+7\,"\K=;V@9B8S0RK7)^H3],TU"@6
MYY>TM)LV3:ZV^>?8N'Y>!&IC,;G8;1RRYH7UOFTJF_(Z>^SK3RG3UX0RGQSW
MQ%7CXU'>4+ O$X:5[P->S]T\4@A-39-;&]*U[?(NMFU93,\MQ7)_B2]Z=,ME
M4U'MJDV7CY31![)U7!&EKBUW18_V)Z=\P[3[Y ?GCV7V!>:=M\'YF"<6Z/=Q
M;R,93D]]+D0A-?M?\3TQES[X_6B8=DWU#[/S]3ZYL![G$=GX./R./\[XO?XO
M^Q @?4B0/A1('QJD#P/2QS%('R<@?9R"],%G*(V@B,I12.4HIG(45#F*JAR%
M58[B*D>!E:/(*E!D%2BR"A19!8JL D56@2*K0)%5H,@J4&05*+)*%%DEBJP2
M15:)(JM$D56BR"I19)4HLDH4626*K I%5H4BJT*15:'(JE!D52BR*A19%8JL
M"D56A2*K1I%5H\BJ4635*+)J%%DUBJP:15:-(JM&D56CR&I09#4HLAH460V*
MK 9%5H,BJT&1U:#(:E!D-?\IZ[USZS^.'Y]E9YO^+9^-_Q%<O !02P$"% ,4
M    " #@-:M6!T%-8H$   "Q    $               @ $     9&]C4')O
M<',O87!P+GAM;%!+ 0(4 Q0    ( . UJU9<]L!T[P   "L"   1
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M965T,BYX;6Q02P$"% ,4    " #@-:M6Z@HH1] "   R"   &
M    @('L%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
MX#6K5HV;!&Z9!0  3!8  !@              ("!\A@  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( . UJU:Q.RQ/T0,  #@,   8
M          " @<$>  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    " #@-:M6SV+?MC,*  !S9@  &               @('((@  >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ X#6K5NC/_YYV @  _P4
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( . UJU;.4!T.R 0  %T-   9
M      " @01@  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ X#6K5J-:,,$/"P  *B$  !D              ("! V4  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #@-:M6R1_6;381  #Z+P
M&0              @(%)<   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( . UJU;=5\S@31@  %Y$   9              " @;:!  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ X#6K5I#\1L\A
M!P  (AX  !D              ("!.IH  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    " #@-:M6..2 '^\<  !9:0  &0
M@(&2H0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( . U
MJU8Y  %=\AP  &5I   9              " @;B^  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ X#6K5K8-0$I@!   L P  !D
M         ("!X=L  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    " #@-:M6,GI@R>,'  "Y%0  &0              @(%XX   >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( . UJU8K'6@V)P<  .,1
M   9              " @9+H  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ X#6K5D[LW,'@!P  %1,  !D              ("!\.\
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #@-:M6)O(H
M'+@1  !H-   &0              @($'^   >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( . UJU9[/F((C0,  *T'   9
M  " @?8) 0!X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
MX#6K5F#\&)5-!P  .!4  !D              ("!N@T! 'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    " #@-:M6#K,CJ4D$   J#   &0
M            @($^%0$ >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( . UJU9\)*!-@@<  (,6   9              " @;X9 0!X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ X#6K5HY ?L<9 P
M< 8  !D              ("!=R$! 'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    " #@-:M6[X!C[N %  !Z#P  &0              @(''
M) $ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( . UJU8R
MY:R5A04  #4/   9              " @=XJ 0!X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ X#6K5IM"K?8= P  0P<  !D
M     ("!FC ! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( . UJU:4YN))_P,  ",4   9              "
M@8)% 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ X#6K
M5IE$&-IY @  \04  !D              ("!N$D! 'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    " #@-:M6TYG4$14&   C)@  &0
M        @(%H3 $ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   ( . UJU:GOO;;6P,  * *   9              " @;12 0!X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ X#6K5FS\V*T$ P  CP@
M !D              ("!1E8! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    " #@-:M6RIZWC\H"  #9!P  &0              @(&!60$
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( . UJU8_VDD^
M+@4  '<=   9              " @8)< 0!X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L! A0#%     @ X#6K5I0 FETR!   =!,  !D
M ("!YV$! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #@
M-:M6SDE)1AT#  # "@  &0              @(%09@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( . UJU87),:%#A0  )7Z   9
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M970T.2YX;6Q02P$"% ,4    " #@-:M6(R&\A,L%   Z+   &0
M    @('RD@$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (
M . UJU8Q@?>R"08  *@R   9              " @?28 0!X;"]W;W)K<VAE
M971S+W-H965T-3$N>&UL4$L! A0#%     @ X#6K5DL'D]^F P  C T  !D
M             ("!-)\! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"
M% ,4    " #@-:M6,QB]PZ,"  #O!P  &0              @($1HP$ >&PO
M=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( . UJU:S$?%1[P(
M %@(   9              " @>NE 0!X;"]W;W)K<VAE971S+W-H965T-30N
M>&UL4$L! A0#%     @ X#6K5I?LT[KJ @  C <  !D              ("!
M$:D! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " #@-:M6
M06@*Z1P%   T'@  &0              @($RK $ >&PO=V]R:W-H965T<R]S
M:&5E=#4V+GAM;%!+ 0(4 Q0    ( . UJU8JK3Q]Z (  /X)   9
M      " @86Q 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%
M  @ X#6K5JDMV/'Q#   K9D  !D              ("!I+0! 'AL+W=O<FMS
M:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " #@-:M6Y8B>#O$(  #Y1@
M&0              @(',P0$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+
M 0(4 Q0    ( . UJU9>=?MF<04  ,8B   9              " @?3* 0!X
M;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ X#6K5DS-[IP$
M!   :Q8  !D              ("!G- ! 'AL+W=O<FMS:&5E=',O<VAE970V
M,2YX;6Q02P$"% ,4    " #@-:M6Y'UGC,X@  ".@@( &0
M@('7U $ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( . U
MJU9%PU.J.@8  "LS   9              " @=SU 0!X;"]W;W)K<VAE971S
M+W-H965T-C,N>&UL4$L! A0#%     @ X#6K5IUQ:HYU"   5EL  !D
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M=#8X+GAM;%!+ 0(4 Q0    ( . UJU:;;NN)]0(  (,-   9
M  " @2L8 @!X;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @
MX#6K5GP^3YI3 P  KA4   T              ( !5QL" 'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " #@-:M6EXJ[',     3 @  "P              @ '5
M'@( 7W)E;',O+G)E;'-02P$"% ,4    " #@-:M62NZ0;@L%  #W+0  #P
M            @ &^'P( >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ X#6K
M5I=W<N0L @  ]B@  !H              ( !]B0" 'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ X#6K5M9((R[W 0  *R@  !,
M         ( !6B<" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $T 30 2
)%0  @BD"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>382</ContextCount>
  <ElementCount>414</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>126</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficitParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Deficit (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Financial Statement Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialStatementDetails</Role>
      <ShortName>Financial Statement Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Collaboration and License Agreements and Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisition</Role>
      <ShortName>Collaboration and License Agreements and Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Lease Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/LeaseArrangements</Role>
      <ShortName>Lease Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Related-Party Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/RelatedPartyDebt</Role>
      <ShortName>Related-Party Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Related-Party Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/RelatedPartyAgreements</Role>
      <ShortName>Related-Party Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Warrant Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/WarrantLiabilities</Role>
      <ShortName>Warrant Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Stockholders??? Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/StockholdersDeficit</Role>
      <ShortName>Stockholders??? Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Financial Statement Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialStatementDetailsTables</Role>
      <ShortName>Financial Statement Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/FinancialStatementDetails</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/FinancialInstruments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/FairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Collaboration and License Agreements and Acquisition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionTables</Role>
      <ShortName>Collaboration and License Agreements and Acquisition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisition</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Lease Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/LeaseArrangementsTables</Role>
      <ShortName>Lease Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/LeaseArrangements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Related-Party Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/RelatedPartyDebtTables</Role>
      <ShortName>Related-Party Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/RelatedPartyDebt</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Related-Party Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/RelatedPartyAgreementsTables</Role>
      <ShortName>Related-Party Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/RelatedPartyAgreements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/StockBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail</Role>
      <ShortName>Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Financial Statement Details - Property, Plant and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail</Role>
      <ShortName>Financial Statement Details - Property, Plant and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Financial Statement Details - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail</Role>
      <ShortName>Financial Statement Details - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Financial Statement Details - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails</Role>
      <ShortName>Financial Statement Details - Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Financial Statement Details - Accrued Expenses and Other Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail</Role>
      <ShortName>Financial Statement Details - Accrued Expenses and Other Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Financial Statement Details - Interest and Investment Income, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeNetDetail</Role>
      <ShortName>Financial Statement Details - Interest and Investment Income, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Financial Statement Details - Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails</Role>
      <ShortName>Financial Statement Details - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Financial Instruments - Summary of Available-for-Sale Marketable Debt Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail</Role>
      <ShortName>Financial Instruments - Summary of Available-for-Sale Marketable Debt Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Financial Instruments - Accumulated Unrealized Losses on Marketable Debt Securities in Continuous Loss Position (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonMarketableDebtSecuritiesinContinuousLossPositionDetail</Role>
      <ShortName>Financial Instruments - Accumulated Unrealized Losses on Marketable Debt Securities in Continuous Loss Position (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Financial Instruments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail</Role>
      <ShortName>Financial Instruments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Collaboration and License Agreements and Acquisition - Collaboration Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail</Role>
      <ShortName>Collaboration and License Agreements and Acquisition - Collaboration Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Collaboration and License Agreements and Acquisition - License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>Collaboration and License Agreements and Acquisition - License Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Collaboration and License Agreements and Acquisition - Acquisition - Consideration Transferred (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails</Role>
      <ShortName>Collaboration and License Agreements and Acquisition - Acquisition - Consideration Transferred (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Collaboration and License Agreements and Acquisition - Acquisition - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails</Role>
      <ShortName>Collaboration and License Agreements and Acquisition - Acquisition - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Commitment and Contingencies - Contingent Consideration Related to Business Combinations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail</Role>
      <ShortName>Commitment and Contingencies - Contingent Consideration Related to Business Combinations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Commitment and Contingencies - Litigation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail</Role>
      <ShortName>Commitment and Contingencies - Litigation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Lease Arrangements - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Lease Arrangements - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Lease Arrangements - Summary of Information Regarding Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/LeaseArrangementsSummaryofInformationRegardingLeasesDetail</Role>
      <ShortName>Lease Arrangements - Summary of Information Regarding Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Lease Arrangements - Components of Lease Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail</Role>
      <ShortName>Lease Arrangements - Components of Lease Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Lease Arrangements - Schedule of Cash Paid for Amounts Included in Measurement of Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/LeaseArrangementsScheduleofCashPaidforAmountsIncludedinMeasurementofLeaseLiabilitiesDetail</Role>
      <ShortName>Lease Arrangements - Schedule of Cash Paid for Amounts Included in Measurement of Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Lease Arrangements - Summary of Future Minimum Lease Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail</Role>
      <ShortName>Lease Arrangements - Summary of Future Minimum Lease Payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Lease Arrangements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail</Role>
      <ShortName>Lease Arrangements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Related-Party Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails</Role>
      <ShortName>Related-Party Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Related-Party Agreements - Summary of Related-Party Promissory Notes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail</Role>
      <ShortName>Related-Party Agreements - Summary of Related-Party Promissory Notes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Related-Party Agreements - Estimated Material Contractual Obligations Related to Related-Party Promissory Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails</Role>
      <ShortName>Related-Party Agreements - Estimated Material Contractual Obligations Related to Related-Party Promissory Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Related-Party Agreements - Summary of Outstanding Balances of Related-Party Agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofOutstandingBalancesofRelatedPartyAgreementsDetail</Role>
      <ShortName>Related-Party Agreements - Summary of Outstanding Balances of Related-Party Agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Related-Party Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail</Role>
      <ShortName>Related-Party Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Warrant Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/WarrantLiabilitiesDetails</Role>
      <ShortName>Warrant Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/WarrantLiabilities</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Stockholders' Deficit - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Deficit - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expenses Related to Statement of Operations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail</Role>
      <ShortName>Stock-Based Compensation - Stock Based Compensation Expenses Related to Statement of Operations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Stock-Based Compensation - Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Stock-Based Compensation - RSUs Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/StockBasedCompensationRSUsActivityDetail</Role>
      <ShortName>Stock-Based Compensation - RSUs Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ibrx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrent in us-gaap/2022 used in 16 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. ibrx-20230331.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueFromRelatedPartiesCurrent in us-gaap/2022 used in 10 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. ibrx-20230331.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept NotesPayableRelatedPartiesClassifiedCurrent in us-gaap/2022 used in 5 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. ibrx-20230331.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept AccountsPayableRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. ibrx-20230331.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept NotesPayableRelatedPartiesNoncurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. ibrx-20230331.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept InterestExpenseRelatedParty in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. ibrx-20230331.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept NotesPayableRelatedPartiesCurrentAndNoncurrent in us-gaap/2022 used in 22 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. ibrx-20230331.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. ibrx-20230331.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueFromRelatedParties in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. ibrx-20230331.htm 4</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DueToRelatedPartiesCurrent, us-gaap:LesseeOperatingLeaseRenewalTerm, us-gaap:LesseeOperatingLeaseTermOfContract, us-gaap:ResearchAndDevelopmentExpense -  ibrx-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="ibrx-20230331.htm">ibrx-20230331.htm</File>
    <File>ibrx-20230331.xsd</File>
    <File>ibrx-20230331_cal.xml</File>
    <File>ibrx-20230331_def.xml</File>
    <File>ibrx-20230331_lab.xml</File>
    <File>ibrx-20230331_pre.xml</File>
    <File>ibrx-20230331x10qexhibit311.htm</File>
    <File>ibrx-20230331x10qexhibit312.htm</File>
    <File>ibrx-20230331x10qexhibit321.htm</File>
    <File>ibrx-20230331x10qexhibit322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ibrx-20230331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="927">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>88
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ibrx-20230331.htm": {
   "axisCustom": 1,
   "axisStandard": 37,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 1,
    "http://fasb.org/us-gaap/2022": 927,
    "http://xbrl.sec.gov/dei/2022": 29
   },
   "contextCount": 382,
   "dts": {
    "calculationLink": {
     "local": [
      "ibrx-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ibrx-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ibrx-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ibrx-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ibrx-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ibrx-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 693,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 12,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 17
   },
   "keyCustom": 87,
   "keyStandard": 327,
   "memberCustom": 73,
   "memberStandard": 43,
   "nsprefix": "ibrx",
   "nsuri": "http://www.immunitybio.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.immunitybio.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.immunitybio.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Financial Statement Details",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.immunitybio.com/role/FinancialStatementDetails",
     "shortName": "Financial Statement Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Financial Instruments",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.immunitybio.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.immunitybio.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Collaboration and License Agreements and Acquisition",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisition",
     "shortName": "Collaboration and License Agreements and Acquisition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.immunitybio.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Lease Arrangements",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.immunitybio.com/role/LeaseArrangements",
     "shortName": "Lease Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Related-Party Debt",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.immunitybio.com/role/RelatedPartyDebt",
     "shortName": "Related-Party Debt",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Related-Party Agreements",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.immunitybio.com/role/RelatedPartyAgreements",
     "shortName": "Related-Party Agreements",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibrx:WarrantLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Warrant Liabilities",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.immunitybio.com/role/WarrantLiabilities",
     "shortName": "Warrant Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibrx:WarrantLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Stockholders\u2019 Deficit",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.immunitybio.com/role/StockholdersDeficit",
     "shortName": "Stockholders\u2019 Deficit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.immunitybio.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.immunitybio.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "23",
     "role": "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Financial Statement Details (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.immunitybio.com/role/FinancialStatementDetailsTables",
     "shortName": "Financial Statement Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.immunitybio.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.immunitybio.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Collaboration and License Agreements and Acquisition (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionTables",
     "shortName": "Collaboration and License Agreements and Acquisition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibrx:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Lease Arrangements (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.immunitybio.com/role/LeaseArrangementsTables",
     "shortName": "Lease Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibrx:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibrx:ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Related-Party Debt (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.immunitybio.com/role/RelatedPartyDebtTables",
     "shortName": "Related-Party Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibrx:ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Related-Party Agreements (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.immunitybio.com/role/RelatedPartyAgreementsTables",
     "shortName": "Related-Party Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.immunitybio.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail",
     "shortName": "Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ibrx:PrepaidResearchAndDevelopmentCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail",
     "shortName": "Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ibrx:PrepaidResearchAndDevelopmentCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Financial Statement Details - Property, Plant and Equipment, Net (Detail)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail",
     "shortName": "Financial Statement Details - Property, Plant and Equipment, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Financial Statement Details - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail",
     "shortName": "Financial Statement Details - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i2021beb688ba4eae880d4d4d8f408525_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Financial Statement Details - Intangible Assets, Net (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails",
     "shortName": "Financial Statement Details - Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ibrx:AccruedResearchAndDevelopmentCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Financial Statement Details - Accrued Expenses and Other Liabilities (Detail)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail",
     "shortName": "Financial Statement Details - Accrued Expenses and Other Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ibrx:AccruedResearchAndDevelopmentCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestAndOtherIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Financial Statement Details - Interest and Investment Income, Net (Detail)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeNetDetail",
     "shortName": "Financial Statement Details - Interest and Investment Income, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestAndOtherIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Financial Statement Details - Interest Expense (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails",
     "shortName": "Financial Statement Details - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Financial Instruments - Summary of Available-for-Sale Marketable Debt Securities (Detail)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail",
     "shortName": "Financial Instruments - Summary of Available-for-Sale Marketable Debt Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Financial Instruments - Accumulated Unrealized Losses on Marketable Debt Securities in Continuous Loss Position (Detail)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonMarketableDebtSecuritiesinContinuousLossPositionDetail",
     "shortName": "Financial Instruments - Accumulated Unrealized Losses on Marketable Debt Securities in Continuous Loss Position (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Financial Instruments - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail",
     "shortName": "Financial Instruments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "ia818d8707e4c4c8d99bffda3de67924f_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ibrx:ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ibrx:RelatedPartyNotesPayable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i25b2382ccad7475f812c01198c635ee0_I20230331",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireInterestInJointVenture",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Collaboration and License Agreements and Acquisition - Collaboration Agreements - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail",
     "shortName": "Collaboration and License Agreements and Acquisition - Collaboration Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "ie5ee1d864d0f40ee97b16088a1116d91_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Collaboration and License Agreements and Acquisition - License Agreements - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail",
     "shortName": "Collaboration and License Agreements and Acquisition - License Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i490e76eedd0c4d68a5d119d4f2a8bf67_D20211101-20211130",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ibrx:CollaborationAgreementsPeriodicLicensePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i2021beb688ba4eae880d4d4d8f408525_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Collaboration and License Agreements and Acquisition - Acquisition - Consideration Transferred (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails",
     "shortName": "Collaboration and License Agreements and Acquisition - Acquisition - Consideration Transferred (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i9bdaaaa534ee490db0798af2622eb12c_I20220214",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ConstructionInProgressGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i97684a88657d4f79b99ef808ef0e0de7_I20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Collaboration and License Agreements and Acquisition - Acquisition - Additional Information (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
     "shortName": "Collaboration and License Agreements and Acquisition - Acquisition - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i9bdaaaa534ee490db0798af2622eb12c_I20220214",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ibrx:NumberOfSquareFootOfFacilityLeased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "ida7588e0910c4bb28cb902bc775406de_I20171231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ibrx:ContingentValueRightsObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Commitment and Contingencies - Contingent Consideration Related to Business Combinations - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail",
     "shortName": "Commitment and Contingencies - Contingent Consideration Related to Business Combinations - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "ida7588e0910c4bb28cb902bc775406de_I20171231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ibrx:ContingentValueRightsObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i3316090351fd4fe4b0dd3da042faabc4_I20220709",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Commitment and Contingencies - Litigation - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail",
     "shortName": "Commitment and Contingencies - Litigation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i3316090351fd4fe4b0dd3da042faabc4_I20220709",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ibrx:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Lease Arrangements - Supplemental Balance Sheet Information (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails",
     "shortName": "Lease Arrangements - Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ibrx:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Lease Arrangements - Summary of Information Regarding Leases (Detail)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.immunitybio.com/role/LeaseArrangementsSummaryofInformationRegardingLeasesDetail",
     "shortName": "Lease Arrangements - Summary of Information Regarding Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Lease Arrangements - Components of Lease Expense (Detail)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail",
     "shortName": "Lease Arrangements - Components of Lease Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Lease Arrangements - Schedule of Cash Paid for Amounts Included in Measurement of Lease Liabilities (Detail)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.immunitybio.com/role/LeaseArrangementsScheduleofCashPaidforAmountsIncludedinMeasurementofLeaseLiabilitiesDetail",
     "shortName": "Lease Arrangements - Schedule of Cash Paid for Amounts Included in Measurement of Lease Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Lease Arrangements - Summary of Future Minimum Lease Payments (Detail)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail",
     "shortName": "Lease Arrangements - Summary of Future Minimum Lease Payments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ibrx:OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Lease Arrangements - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail",
     "shortName": "Lease Arrangements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ibrx:OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ibrx:ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ibrx:RelatedPartyNotesPayable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Related-Party Debt - Narrative (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails",
     "shortName": "Related-Party Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "id782271befaf426399ce9443216bb892_D20220831-20220831",
      "decimals": "2",
      "lang": "en-US",
      "name": "ibrx:OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ibrx:ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ibrx:RelatedPartyNotesPayable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Related-Party Agreements - Summary of Related-Party Promissory Notes (Detail)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail",
     "shortName": "Related-Party Agreements - Summary of Related-Party Promissory Notes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ibrx:ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:InterestPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "ie6a407074713405e90702d702e4309b8_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders' Deficit",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit",
     "shortName": "Condensed Consolidated Statements of Stockholders' Deficit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "ie6a407074713405e90702d702e4309b8_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ibrx:ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i6c63ca50dfe64ec5a0637410c6d5397b_D20230101-20230331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Related-Party Agreements - Estimated Material Contractual Obligations Related to Related-Party Promissory Notes (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
     "shortName": "Related-Party Agreements - Estimated Material Contractual Obligations Related to Related-Party Promissory Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i46a185f9ec6445ec8b642258ea67180d_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i8b814f4f02ad4405944defaa7243cdee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DueFromRelatedPartiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Related-Party Agreements - Summary of Outstanding Balances of Related-Party Agreements (Detail)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofOutstandingBalancesofRelatedPartyAgreementsDetail",
     "shortName": "Related-Party Agreements - Summary of Outstanding Balances of Related-Party Agreements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "ie130450350ca4c9799e1e199a92ec29d_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DueFromRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Related-Party Agreements - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
     "shortName": "Related-Party Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i630c47622bdc4c919e7634771cd094b6_I20220501",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ibrx:NumberOfSquareFootOfFacilityLeased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ibrx:TransactionCostsWarrantLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Warrant Liabilities (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.immunitybio.com/role/WarrantLiabilitiesDetails",
     "shortName": "Warrant Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "ie7ac9b711c4447f78c760f85a936a47b_I20221212",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ibrx:IssuanceOfCommonStockUnderAtMarketOfferingShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Stockholders' Deficit - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
     "shortName": "Stockholders' Deficit - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ibrx:IssuanceOfCommonStockUnderAtMarketOfferingShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "ie8db8d0eea7146a6bf8d54b8044ef8d7_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expenses Related to Statement of Operations (Detail)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail",
     "shortName": "Stock-Based Compensation - Stock Based Compensation Expenses Related to Statement of Operations (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i2021beb688ba4eae880d4d4d8f408525_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Stock-Based Compensation - Stock Option Activity (Detail)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityDetail",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i0d38e9904e994f3c8879c104feedb7da_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Stock-Based Compensation - RSUs Activity (Detail)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.immunitybio.com/role/StockBasedCompensationRSUsActivityDetail",
     "shortName": "Stock-Based Compensation - RSUs Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i0d38e9904e994f3c8879c104feedb7da_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Income Taxes - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i7b965bbf47a941848ab9a9b930e7f952_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i2a8153bf4934499497bc454385181d0f_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficitParenthetical",
     "shortName": "Condensed Consolidated Statements of Stockholders' Deficit (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Condensed Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Description of Business",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.immunitybio.com/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-20230331.htm",
      "contextRef": "i1d94b8aa1a8740e6bdc3fb8a52206da9_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 126,
   "tag": {
    "country_IT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ITALY",
        "terseLabel": "Italy"
       }
      }
     },
     "localname": "IT",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_KR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KOREA, REPUBLIC OF",
        "terseLabel": "South Korea"
       }
      }
     },
     "localname": "KR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "verboseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "verboseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "verboseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ibrx_A23AlaskaLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "23 Alaska, LLC",
        "label": "23 Alaska, LLC [Member]",
        "terseLabel": "23 Alaska, LLC"
       }
      }
     },
     "localname": "A23AlaskaLLCMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3M IPC and Access to Advanced Health Institute License Agreement",
        "label": "3M IPC and Access to Advanced Health Institute License Agreement [Member]",
        "terseLabel": "3M IPC and Access to Advanced Health Institute License Agreement"
       }
      }
     },
     "localname": "A3MIPCAndAccessToAdvancedHealthInstituteLicenseAgreementMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_AccessToAdvancedHealthInstituteAAHIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Access to Advanced Health Institute",
        "label": "Access to Advanced Health Institute (AAHI) [Member]",
        "terseLabel": "Access to Advanced Health Institute (formerly IDRI)"
       }
      }
     },
     "localname": "AccessToAdvancedHealthInstituteAAHIMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_AccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policies.",
        "label": "Accounting Policies [Line Items]",
        "terseLabel": "Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "AccountingPoliciesLineItems",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_AccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policies.",
        "label": "Accounting Policies [Table]",
        "terseLabel": "Accounting Policies [Table]"
       }
      }
     },
     "localname": "AccountingPoliciesTable",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_AccruedConstructionCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Construction Costs, Current",
        "label": "Accrued Construction Costs, Current",
        "terseLabel": "Accrued construction costs"
       }
      }
     },
     "localname": "AccruedConstructionCostsCurrent",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_AccruedPreclinicalAndClinicalTrialCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued preclinical and clinical trial costs.",
        "label": "Accrued Preclinical And Clinical Trial Costs",
        "terseLabel": "Accrued preclinical and clinical trial costs"
       }
      }
     },
     "localname": "AccruedPreclinicalAndClinicalTrialCosts",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_AccruedResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development costs.",
        "label": "Accrued Research And Development Costs",
        "terseLabel": "Accrued research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCosts",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_AltorBioScienceCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Altor BioScience Corporation.",
        "label": "Altor BioScience Corporation [Member]",
        "terseLabel": "Altor BioScience Corporation"
       }
      }
     },
     "localname": "AltorBioScienceCorporationMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_AltorBioScienceLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Altor BioScience, LLC",
        "label": "Altor BioScience, LLC [Member]",
        "terseLabel": "Altor BioScience, LLC"
       }
      }
     },
     "localname": "AltorBioScienceLLCMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_AltorStockholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Altor Stockholders",
        "label": "Altor Stockholders [Member]",
        "terseLabel": "Altor Stockholders"
       }
      }
     },
     "localname": "AltorStockholdersMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_AmortizationOfDebtDiscountPremiumRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization Of Debt Discount (Premium), Related Party",
        "label": "Amortization Of Debt Discount (Premium), Related Party",
        "negatedTerseLabel": "Amortization of related-party notes discounts"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremiumRelatedParty",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_AmyrisIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amyris, Inc.",
        "label": "Amyris, Inc. [Member]",
        "terseLabel": "Amyris, Inc."
       }
      }
     },
     "localname": "AmyrisIncMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_AmyrisJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amyris Joint Venture",
        "label": "Amyris Joint Venture [Member]",
        "terseLabel": "Amyris Joint Venture"
       }
      }
     },
     "localname": "AmyrisJointVentureMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_AnnualPercentageIncreasesToBaseRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual percentage increases to base rent.",
        "label": "Annual Percentage Increases To Base Rent",
        "terseLabel": "Percentage of annual increases of base rent"
       }
      }
     },
     "localname": "AnnualPercentageIncreasesToBaseRent",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ibrx_AssetAcquisitionFairValueOfAssetsAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Fair Value of Assets Acquired",
        "label": "Asset Acquisition, Fair Value of Assets Acquired",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "AssetAcquisitionFairValueOfAssetsAcquired",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Balance Sheet Information Related to Leases"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibrx_AtTheMarketOfferingProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-The-Market offering program.",
        "label": "At The Market Offering Program [Member]",
        "terseLabel": "ATM Offering Program"
       }
      }
     },
     "localname": "AtTheMarketOfferingProgramMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale securities debt securities period.",
        "label": "Available For Sale Securities Debt Securities Period",
        "terseLabel": "Weighted- Average Remaining Contractual\u00a0Life (in years)"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesPeriod",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ibrx_BaseMonthlyRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base monthly rent.",
        "label": "Base Monthly Rent",
        "terseLabel": "Base rent - monthly"
       }
      }
     },
     "localname": "BaseMonthlyRent",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_BaseMonthlyRentParking": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base Monthly Rent, Parking",
        "label": "Base Monthly Rent, Parking",
        "terseLabel": "Base monthly rent, parking"
       }
      }
     },
     "localname": "BaseMonthlyRentParking",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_BrinkBiologicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Brink Biologics, Inc.",
        "label": "Brink Biologics, Inc. [Member]",
        "terseLabel": "Brink Biologics, Inc."
       }
      }
     },
     "localname": "BrinkBiologicsIncMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofOutstandingBalancesofRelatedPartyAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_BusinessCombinationContingentConsiderationArrangementsEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration Arrangements, Earned",
        "label": "Business Combination, Contingent Consideration Arrangements, Earned",
        "terseLabel": "Contingent consideration arrangements, earned"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsEarned",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration Arrangements, Settlements",
        "label": "Business Combination, Contingent Consideration Arrangements, Settlements",
        "terseLabel": "Contingent consideration arrangements, paid"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsSettlements",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreements, Annual Minimum Licensing Payment",
        "label": "Collaboration Agreements, Annual Minimum Licensing Payment",
        "terseLabel": "Annual minimum licensing payment"
       }
      }
     },
     "localname": "CollaborationAgreementsAnnualMinimumLicensingPayment",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual payment for support of research activities.",
        "label": "Collaboration Agreements, Annual Payment For Support Of Research Activities",
        "terseLabel": "Annual payment for support of research activities"
       }
      }
     },
     "localname": "CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_CollaborationAgreementsLicenseMaintenanceFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreements, License Maintenance Fees",
        "label": "Collaboration Agreements, License Maintenance Fees",
        "terseLabel": "License maintenance fees"
       }
      }
     },
     "localname": "CollaborationAgreementsLicenseMaintenanceFees",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_CollaborationAgreementsMilestoneFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreements, Milestone Fees",
        "label": "Collaboration Agreements, Milestone Fees",
        "terseLabel": "Milestone fees"
       }
      }
     },
     "localname": "CollaborationAgreementsMilestoneFees",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreements, Milestone Payment, Aggregate Maximum",
        "label": "Collaboration Agreements, Milestone Payment, Aggregate Maximum",
        "terseLabel": "Milestone payment, aggregate maximum"
       }
      }
     },
     "localname": "CollaborationAgreementsMilestonePaymentAggregateMaximum",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_CollaborationAgreementsNonrefundableUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonrefundable upfront payment.",
        "label": "Collaboration Agreements, Nonrefundable Upfront Payment",
        "terseLabel": "Non-refundable upfront cash payments"
       }
      }
     },
     "localname": "CollaborationAgreementsNonrefundableUpfrontPayment",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_CollaborationAgreementsPeriodicLicensePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreements, Periodic License Payments",
        "label": "Collaboration Agreements, Periodic License Payments",
        "terseLabel": "Periodic license payments"
       }
      }
     },
     "localname": "CollaborationAgreementsPeriodicLicensePayments",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_CollaborationAgreementsTerminationFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreements, Termination Fee",
        "label": "Collaboration Agreements, Termination Fee",
        "terseLabel": "Termination fee"
       }
      }
     },
     "localname": "CollaborationAgreementsTerminationFee",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement and Arrangement Other than Collaborative, Fee One",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative, Fee One [Member]",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Axis]"
       }
      }
     },
     "localname": "CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Domain]"
       }
      }
     },
     "localname": "CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement and Arrangement Other than Collaborative, Fee, Tranche Two",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative, Fee, Tranche Two [Member]",
        "terseLabel": "2023 through 2030"
       }
      }
     },
     "localname": "CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_CommonStockValueAvailableForFutureStockIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock value available for future stock issuance.",
        "label": "Common Stock Value Available For Future Stock Issuance",
        "terseLabel": "Available for future stock issuance"
       }
      }
     },
     "localname": "CommonStockValueAvailableForFutureStockIssuance",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_ConsiderationForFutureServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consideration for Future Services",
        "label": "Consideration for Future Services [Member]",
        "terseLabel": "Consideration for Future Services"
       }
      }
     },
     "localname": "ConsiderationForFutureServicesMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_ContingentValueRightsObligationRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights obligation at December 31, 2022.",
        "label": "Contingent Value Rights Obligation, Regulatory Milestone [Member]",
        "terseLabel": "Contingent Value Rights Payable, Regulatory Milestone"
       }
      }
     },
     "localname": "ContingentValueRightsObligationRegulatoryMilestoneMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_ContingentValueRightsObligationSalesMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights obligation before December 31, 2026.",
        "label": "Contingent Value Rights Obligation, Sales Milestone [Member]",
        "terseLabel": "Contingent Value Rights Payable, Sales Milestone"
       }
      }
     },
     "localname": "ContingentValueRightsObligationSalesMilestoneMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_ContingentValueRightsObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights obligations.",
        "label": "Contingent Value Rights Obligations",
        "terseLabel": "Potential contingent value rights to be earned"
       }
      }
     },
     "localname": "ContingentValueRightsObligations",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_ConvertibleNoteReceivableNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible note receivable, non-current.",
        "label": "Convertible Note Receivable Non Current",
        "terseLabel": "Convertible note receivable"
       }
      }
     },
     "localname": "ConvertibleNoteReceivableNonCurrent",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Notes, Fair Value Option Election",
        "label": "Convertible Notes, Fair Value Option Election [Policy Text Block]",
        "terseLabel": "Fair Value Option (FVO) Election"
       }
      }
     },
     "localname": "ConvertibleNotesFairValueOptionElectionPolicyTextBlock",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibrx_CurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current assets.",
        "label": "Current Assets [Member]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "CurrentAssetsMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_CurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Liabilities",
        "label": "Current Liabilities [Member]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "CurrentLiabilitiesMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_December2022WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2022 Warrants",
        "label": "December 2022 Warrants [Member]",
        "terseLabel": "December 2022 Warrants"
       }
      }
     },
     "localname": "December2022WarrantsMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_DrSoonShiongAndRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr. Soon-Shiong and related party.",
        "label": "Dr Soon Shiong And Related Party [Member]",
        "terseLabel": "Dr. Soon-Shiong and Related Party"
       }
      }
     },
     "localname": "DrSoonShiongAndRelatedPartyMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_DueToRelatedPartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due to related parties.",
        "label": "Due To Related Parties [Member]",
        "terseLabel": "Due to Related Parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_DuleyRoadLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duley Road, LLC.",
        "label": "Duley Road, LLC [Member]",
        "terseLabel": "Duley Road, LLC"
       }
      }
     },
     "localname": "DuleyRoadLLCMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_DuleyRoadMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duley Road.",
        "label": "Duley Road [Member]",
        "terseLabel": "Duley Road, LLC"
       }
      }
     },
     "localname": "DuleyRoadMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofOutstandingBalancesofRelatedPartyAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_DunkirkFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dunkirk Facility",
        "label": "Dunkirk Facility [Member]",
        "terseLabel": "Dunkirk Facility"
       }
      }
     },
     "localname": "DunkirkFacilityMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_ExpansionPremisesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment for expansion of premises, lease term.",
        "label": "Expansion Premises [Member]",
        "terseLabel": "Expansion Premises"
       }
      }
     },
     "localname": "ExpansionPremisesMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_February2023ShelfRegistrationStatementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "February 2023 Shelf Registration Statement",
        "label": "February 2023 Shelf Registration Statement [Member]",
        "terseLabel": "February 2023 Shelf Registration Statement"
       }
      }
     },
     "localname": "February2023ShelfRegistrationStatementMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_February2023WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "February 2023 Warrants",
        "label": "February 2023 Warrants [Member]",
        "terseLabel": "February 2023 Warrants"
       }
      }
     },
     "localname": "February2023WarrantsMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease Costs, Right-Of-Use Asset Amortization And Interest Expense",
        "label": "Finance Lease Costs, Right-Of-Use Asset Amortization And Interest Expense",
        "terseLabel": "Finance lease costs (including amortization and interest costs)"
       }
      }
     },
     "localname": "FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 1.0,
       "parentTag": "ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable",
       "weight": 1.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Liability, Tenant Improvement Allowance Receivable",
        "label": "Finance Lease, Liability, Tenant Improvement Allowance Receivable",
        "terseLabel": "Less: Tenant improvement allowance receivable"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityTenantImprovementAllowanceReceivable",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_FinanceLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Liability, To Be Paid, After Year Four",
        "label": "Finance Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_FinancialStatementDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial statement details.",
        "label": "Financial Statement Details [Abstract]",
        "terseLabel": "Financial Statement Details [Abstract]"
       }
      }
     },
     "localname": "FinancialStatementDetailsAbstract",
     "nsuri": "http://www.immunitybio.com/20230331",
     "xbrltype": "stringItemType"
    },
    "ibrx_FinancialStatementDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Statement Details [Line Items]",
        "label": "Financial Statement Details [Line Items]",
        "terseLabel": "Financial Statement Details [Line Items]"
       }
      }
     },
     "localname": "FinancialStatementDetailsLineItems",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_FinancialStatementDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Statement Details [Table]",
        "label": "Financial Statement Details [Table]",
        "terseLabel": "Financial Statement Details [Table]"
       }
      }
     },
     "localname": "FinancialStatementDetailsTable",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_FinancingObligationCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Obligation, Current",
        "label": "Financing Obligation, Current",
        "terseLabel": "Financing obligation \u2013 current portion"
       }
      }
     },
     "localname": "FinancingObligationCurrent",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      },
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Accumulated Impairment",
        "label": "Finite-Lived Intangible Assets, Accumulated Impairment",
        "negatedTerseLabel": "Impairment"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedImpairment",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_FourTwoZeroNashLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Two Zero Nash, LLC",
        "label": "Four Two Zero Nash, LLC [Member]",
        "terseLabel": "420 Nash, LLC"
       }
      }
     },
     "localname": "FourTwoZeroNashLLCMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_ImmunoOncologyClinicIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immuno Oncology Clinic Inc.",
        "label": "Immuno-Oncology Clinic, Inc [Member]",
        "terseLabel": "Immuno-Oncology Clinic, Inc."
       }
      }
     },
     "localname": "ImmunoOncologyClinicIncMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_ImmunoOncologyClinicMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immuno-Oncology Clinic.",
        "label": "Immuno-Oncology Clinic [Member]",
        "terseLabel": "Immuno-Oncology Clinic, Inc."
       }
      }
     },
     "localname": "ImmunoOncologyClinicMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofOutstandingBalancesofRelatedPartyAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_IncomeTaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax.",
        "label": "Income Tax [Line Items]",
        "terseLabel": "Income Tax [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxLineItems",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_IncomeTaxTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax.",
        "label": "Income Tax [Table]",
        "terseLabel": "Income Tax [Table]"
       }
      }
     },
     "localname": "IncomeTaxTable",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in due to related parties current and non current.",
        "label": "Increase Decrease In Due To Related Parties Current And Non Current",
        "terseLabel": "Related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase to Number of Square Foot of Facility Leased",
        "label": "Increase to Number of Square Foot of Facility Leased",
        "terseLabel": "Expansion of licensed premises (in square feet)"
       }
      }
     },
     "localname": "IncreaseToNumberOfSquareFootOfFacilityLeased",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "ibrx_InitialAndExpansionPremisesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial And Expansion Premises",
        "label": "Initial And Expansion Premises [Member]",
        "terseLabel": "Initial and Expansion Premises"
       }
      }
     },
     "localname": "InitialAndExpansionPremisesMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_InitialPremisesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Premises.",
        "label": "Initial Premises [Member]",
        "terseLabel": "Initial Premises"
       }
      }
     },
     "localname": "InitialPremisesMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_InsurancePremiumFinancingAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance premium financing asset.",
        "label": "Insurance Premium Financing Asset",
        "terseLabel": "Insurance premium financing asset"
       }
      }
     },
     "localname": "InsurancePremiumFinancingAsset",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_IssuanceOfCommonStockUnderAtMarketOfferingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock under at-the market offering, shares.",
        "label": "Issuance Of Common Stock Under At Market Offering Shares",
        "terseLabel": "Shares issued under ATM (in shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockUnderAtMarketOfferingShares",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ibrx_IssuanceOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Of Warrants",
        "label": "Issuance Of Warrants",
        "terseLabel": "Initial measurement of warrants issued in connection with the registered direct offering accounted for as liabilities"
       }
      }
     },
     "localname": "IssuanceOfWarrants",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_JulyTwentyNineteenLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "July twenty nineteen lease.",
        "label": "July Twenty Nineteen Lease [Member]",
        "terseLabel": "July 2019 Lease"
       }
      }
     },
     "localname": "JulyTwentyNineteenLeaseMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_LeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "order": 3.0,
       "parentTag": "ibrx_LeaseLiabilityToBePaid",
       "weight": 1.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail",
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "order": 2.0,
       "parentTag": "ibrx_LeaseLiabilityToBePaid",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability, Tenant Improvement Allowance Receivable",
        "label": "Lease, Liability, Tenant Improvement Allowance Receivable",
        "totalLabel": "Less: Tenant improvement allowance receivable"
       }
      }
     },
     "localname": "LeaseLiabilityTenantImprovementAllowanceReceivable",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_LeaseLiabilityToBePaid": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability, To Be Paid",
        "label": "Lease, Liability, To Be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LeaseLiabilityToBePaid",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_LeaseLiabilityToBePaidAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability, To Be Paid",
        "label": "Lease, Liability, To Be Paid [Abstract]",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LeaseLiabilityToBePaidAbstract",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_LeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 4.0,
       "parentTag": "ibrx_LeaseLiabilityToBePaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability, To Be Paid, After Year Four",
        "label": "Lease, Liability, To Be Paid, After Year Four",
        "totalLabel": "Thereafter"
       }
      }
     },
     "localname": "LeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 1.0,
       "parentTag": "ibrx_LeaseLiabilityToBePaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability, To Be Paid, Remainder of Fiscal Year",
        "label": "Lease, Liability, To Be Paid, Remainder of Fiscal Year",
        "totalLabel": "2023 (excluding the three months ended March\u00a031,\u00a02023)"
       }
      }
     },
     "localname": "LeaseLiabilityToBePaidRemainderOfFiscalYear",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_LeaseLiabilityToBePaidYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 3.0,
       "parentTag": "ibrx_LeaseLiabilityToBePaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability, To Be Paid, Year Four",
        "label": "Lease, Liability, To Be Paid, Year Four",
        "totalLabel": "2027"
       }
      }
     },
     "localname": "LeaseLiabilityToBePaidYearFour",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_LeaseLiabilityToBePaidYearOne": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 6.0,
       "parentTag": "ibrx_LeaseLiabilityToBePaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability, To Be Paid, Year One",
        "label": "Lease, Liability, To Be Paid, Year One",
        "totalLabel": "2024"
       }
      }
     },
     "localname": "LeaseLiabilityToBePaidYearOne",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_LeaseLiabilityToBePaidYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 5.0,
       "parentTag": "ibrx_LeaseLiabilityToBePaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability, To Be Paid, Year Three",
        "label": "Lease, Liability, To Be Paid, Year Three",
        "totalLabel": "2026"
       }
      }
     },
     "localname": "LeaseLiabilityToBePaidYearThree",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_LeaseLiabilityToBePaidYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 2.0,
       "parentTag": "ibrx_LeaseLiabilityToBePaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability, To Be Paid, Year Two",
        "label": "Lease, Liability, To Be Paid, Year Two",
        "totalLabel": "2025"
       }
      }
     },
     "localname": "LeaseLiabilityToBePaidYearTwo",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_LeaseLiabilityUndiscountedExcessInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "order": 1.0,
       "parentTag": "ibrx_LeaseLiabilityToBePaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability, Undiscounted Excess Interest",
        "label": "Lease, Liability, Undiscounted Excess Interest",
        "totalLabel": "Less: Interest"
       }
      }
     },
     "localname": "LeaseLiabilityUndiscountedExcessInterest",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_LeaseOperatingLeaseAnnualLeasePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Operating Lease, Annual Lease Payment",
        "label": "Lease, Operating Lease, Annual Lease Payment",
        "terseLabel": "Annual lease payment"
       }
      }
     },
     "localname": "LeaseOperatingLeaseAnnualLeasePayment",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_LeaseRelatedPayables": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease-related payables.",
        "label": "Lease Related Payables",
        "terseLabel": "Lease-related payables"
       }
      }
     },
     "localname": "LeaseRelatedPayables",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_LeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Right-Of-Use Asset",
        "label": "Lease, Right-Of-Use Asset",
        "totalLabel": "Total lease assets"
       }
      }
     },
     "localname": "LeaseRightOfUseAsset",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_LeaseholdImprovementPayables": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leasehold improvement payables.",
        "label": "Leasehold Improvement Payables",
        "terseLabel": "Leasehold improvement payables"
       }
      }
     },
     "localname": "LeaseholdImprovementPayables",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leasehold Interest, Commitment to Hire, Number of Employees, First Five Years",
        "label": "Leasehold Interest, Commitment to Hire, Number of Employees, First Five Years",
        "terseLabel": "Commitment to hire, number of employees, first five years"
       }
      }
     },
     "localname": "LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leasehold Interest, Commitment to Hire, Number of Employees, First Two and a Half Years",
        "label": "Leasehold Interest, Commitment to Hire, Number of Employees, First Two and a Half Years",
        "terseLabel": "Commitment to hire, number of employees, first two and a half years"
       }
      }
     },
     "localname": "LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ibrx_LeaseholdInterestGovernmentFundingReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leasehold Interest, Government Funding Receivable",
        "label": "Leasehold Interest, Government Funding Receivable",
        "terseLabel": "Government funding for leasehold build-out"
       }
      }
     },
     "localname": "LeaseholdInterestGovernmentFundingReceivable",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leasehold Interest, Operational Expenses, Commitment to Spend, Initial Lease Term",
        "label": "Leasehold Interest, Operational Expenses, Commitment to Spend, Initial Lease Term",
        "terseLabel": "Commitment to spend, operational expenses, initial lease term"
       }
      }
     },
     "localname": "LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leasehold Interest, Operational Expenses, Commitment to Spend, Renewal Lease Term",
        "label": "Leasehold Interest, Operational Expenses, Commitment to Spend, Renewal Lease Term",
        "terseLabel": "Commitment to spend, operational expenses, renewal lease term"
       }
      }
     },
     "localname": "LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 2.0,
       "parentTag": "ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable",
       "weight": 1.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Tenant Improvement Allowance Receivable",
        "label": "Lessee, Operating Lease, Liability, Tenant Improvement Allowance Receivable",
        "terseLabel": "Less: Tenant improvement allowance receivable"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due after year four.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_LicensingAgreementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing agreement.",
        "label": "Licensing Agreement [Line Items]",
        "terseLabel": "Licensing Agreement [Line Items]"
       }
      }
     },
     "localname": "LicensingAgreementLineItems",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_LicensingAgreementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing agreement.",
        "label": "Licensing Agreement [Table]",
        "terseLabel": "Licensing Agreement [Table]"
       }
      }
     },
     "localname": "LicensingAgreementTable",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_LitigationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation.",
        "label": "Litigation [Line Items]",
        "terseLabel": "Litigation [Line Items]"
       }
      }
     },
     "localname": "LitigationLineItems",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_LitigationSettlementInterestPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement Interest, Percent",
        "label": "Litigation Settlement Interest, Percent",
        "terseLabel": "Interest related to litigation settlement, as a percent"
       }
      }
     },
     "localname": "LitigationSettlementInterestPercent",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ibrx_LitigationSettlementNumberOfSharesToBeIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Number of Shares to be Issued",
        "label": "Litigation Settlement, Number of Shares to be Issued",
        "terseLabel": "Shares issued for litigation settlement (in shares)"
       }
      }
     },
     "localname": "LitigationSettlementNumberOfSharesToBeIssued",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ibrx_LitigationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation.",
        "label": "Litigation [Table]",
        "terseLabel": "Litigation [Table]"
       }
      }
     },
     "localname": "LitigationTable",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_MeasurementInputDiscountPeriodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Discount Period",
        "label": "Measurement Input, Discount Period [Member]",
        "terseLabel": "Discount period"
       }
      }
     },
     "localname": "MeasurementInputDiscountPeriodMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_MeasurementInputExpectedMarketYieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Expected Market Yield",
        "label": "Measurement Input, Expected Market Yield [Member]",
        "terseLabel": "Expected market yield"
       }
      }
     },
     "localname": "MeasurementInputExpectedMarketYieldMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum net sales milestone contingent value rights obligation.",
        "label": "Minimum Net Sales Milestone Contingent Value Rights Obligation",
        "terseLabel": "Minimum net sales milestone for contingent value rights payable"
       }
      }
     },
     "localname": "MinimumNetSalesMilestoneContingentValueRightsObligation",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_NANTibodyLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NANTibody, LLC",
        "label": "NANTibody, LLC [Member]",
        "terseLabel": "NANTibody, LLC"
       }
      }
     },
     "localname": "NANTibodyLLCMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NCSCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NCSC.",
        "label": "NCSC [Member]",
        "terseLabel": "NCSC",
        "verboseLabel": "NCSC"
       }
      }
     },
     "localname": "NCSCMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantBioIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nant Bio.",
        "label": "NantBio Inc [Member]",
        "verboseLabel": "NantBio, Inc."
       }
      }
     },
     "localname": "NantBioIncMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofOutstandingBalancesofRelatedPartyAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantCapital3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nant Capital 3",
        "label": "Nant Capital 3 [Member]",
        "terseLabel": "Nant Capital"
       }
      }
     },
     "localname": "NantCapital3Member",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantCapital4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nant Capital 4",
        "label": "Nant Capital 4 [Member]",
        "terseLabel": "Nant Capital"
       }
      }
     },
     "localname": "NantCapital4Member",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantCapital6Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nant Capital 6",
        "label": "Nant Capital 6 [Member]",
        "terseLabel": "Nant Capital"
       }
      }
     },
     "localname": "NantCapital6Member",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantCapitalIssued33123Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nant Capital, Issued 3/31/23",
        "label": "Nant Capital, Issued 3/31/23 [Member]",
        "terseLabel": "Nant Capital"
       }
      }
     },
     "localname": "NantCapitalIssued33123Member",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NantCapital.",
        "label": "Nant Capital [Member]",
        "terseLabel": "Nant Capital"
       }
      }
     },
     "localname": "NantCapitalMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nant Capital, NantCancerStemCell, LLC, and NantMobile, LLC",
        "label": "Nant Capital, NantCancerStemCell, LLC, and NantMobile, LLC [Member]",
        "terseLabel": "Nant Capital, NantCancerStemCell, LLC, and NantMobile, LLC"
       }
      }
     },
     "localname": "NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC",
        "label": "Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC [Member]",
        "terseLabel": "Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC"
       }
      }
     },
     "localname": "NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantCapitalOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nant capital one.",
        "label": "Nant Capital One [Member]",
        "terseLabel": "Nant Capital"
       }
      }
     },
     "localname": "NantCapitalOneMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantCapitalTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nant capital two.",
        "label": "Nant Capital Two [Member]",
        "terseLabel": "Nant Capital"
       }
      }
     },
     "localname": "NantCapitalTwoMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantCellIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NantCell, Inc.",
        "label": "Nant Cell Inc [Member]",
        "terseLabel": "Nant Cell Inc"
       }
      }
     },
     "localname": "NantCellIncMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantMobileMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NantMobile.",
        "label": "NantMobile [Member]",
        "terseLabel": "NantMobile"
       }
      }
     },
     "localname": "NantMobileMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantWorksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NantWorks.",
        "label": "NantWorks [Member]",
        "terseLabel": "NantWorks"
       }
      }
     },
     "localname": "NantWorksMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofOutstandingBalancesofRelatedPartyAgreementsDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NonCashInterestIncomeExpenseFromOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash interest (income) expense from operating activities.",
        "label": "Non Cash Interest Income Expense From Operating Activities",
        "negatedLabel": "Non-cash interest items, net (including amounts with related parties)"
       }
      }
     },
     "localname": "NonCashInterestIncomeExpenseFromOperatingActivities",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_NoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent assets.",
        "label": "Noncurrent Assets [Member]",
        "terseLabel": "Noncurrent Assets"
       }
      }
     },
     "localname": "NoncurrentAssetsMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent Liabilities",
        "label": "Noncurrent Liabilities [Member]",
        "terseLabel": "Noncurrent Liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilitiesMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NotesPayableRelatedPartiesPrincipalAndAccruedInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable, Related Parties, Principal And Accrued Interest",
        "label": "Notes Payable, Related Parties, Principal And Accrued Interest",
        "terseLabel": "Aggregate principal and accrued interest"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesPrincipalAndAccruedInterest",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_NumberOfDissentingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Dissenting Shares",
        "label": "Number of Dissenting Shares",
        "terseLabel": "Dissenting shares to be released (in shares)"
       }
      }
     },
     "localname": "NumberOfDissentingShares",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ibrx_NumberOfLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Leases",
        "label": "Number of Leases",
        "terseLabel": "Number of leases"
       }
      }
     },
     "localname": "NumberOfLeases",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "ibrx_NumberOfSquareFootOfFacilityLeased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of square foot of facility leased.",
        "label": "Number Of Square Foot Of Facility Leased",
        "terseLabel": "Number of square foot of facility leased"
       }
      }
     },
     "localname": "NumberOfSquareFootOfFacilityLeased",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease payments related to options to extend lease terms.",
        "label": "Operating Lease Payments Related To Options To Extend Lease Terms",
        "terseLabel": "Operating lease payments related to options to extend lease terms"
       }
      }
     },
     "localname": "OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option to Convert Accrued and Unpaid Interest to Shares of Common Stock, Price Per Share",
        "label": "Option to Convert Accrued and Unpaid Interest to Shares of Common Stock, Price Per Share",
        "terseLabel": "Option to convert accrued and unpaid interest to shares of common stock (in dollars per share)"
       }
      }
     },
     "localname": "OptionToConvertAccruedAndUnpaidInterestToSharesOfCommonStockPricePerShare",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ibrx_OptionsToExtendNumberOfTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to extend number of terms.",
        "label": "Options To Extend Number Of Terms",
        "terseLabel": "Options to extend number of terms"
       }
      }
     },
     "localname": "OptionsToExtendNumberOfTerms",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "ibrx_OrganizedWorkforceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organized Workforce",
        "label": "Organized Workforce [Member]",
        "terseLabel": "Organized Workforce"
       }
      }
     },
     "localname": "OrganizedWorkforceMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_PercentageOfSalesAgentCommission": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Sales Agent Commission",
        "label": "Percentage Of Sales Agent Commission",
        "terseLabel": "Percentage of sales agent commission"
       }
      }
     },
     "localname": "PercentageOfSalesAgentCommission",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ibrx_PercentageOfWhollyOwnedSubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of wholly-owned subsidiary.",
        "label": "Percentage Of Wholly Owned Subsidiary",
        "terseLabel": "Ownership percentage acquired"
       }
      }
     },
     "localname": "PercentageOfWhollyOwnedSubsidiary",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ibrx_PeriodOfExtendedLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of extended lease term.",
        "label": "Period Of Extended Lease Term",
        "terseLabel": "Optional extended lease term"
       }
      }
     },
     "localname": "PeriodOfExtendedLeaseTerm",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ibrx_PrepaidExpenseWriteDown": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expense, Write Down",
        "label": "Prepaid Expense, Write Down",
        "terseLabel": "Write down of prepaid expense"
       }
      }
     },
     "localname": "PrepaidExpenseWriteDown",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_PrepaidResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Research And Development Costs",
        "label": "Prepaid Research And Development Costs",
        "terseLabel": "Prepaid research and development costs"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentCosts",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_PrepaidServices": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid services.",
        "label": "Prepaid Services",
        "terseLabel": "Prepaid services"
       }
      }
     },
     "localname": "PrepaidServices",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_PrepaidSoftwareLicenseFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid software license fees.",
        "label": "Prepaid Software License Fees",
        "terseLabel": "Prepaid software license fees"
       }
      }
     },
     "localname": "PrepaidSoftwareLicenseFees",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_PromissoryNotesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory Notes Payable",
        "label": "Promissory Notes Payable [Member]",
        "terseLabel": "Promissory Notes",
        "verboseLabel": "Non-convertible Notes"
       }
      }
     },
     "localname": "PromissoryNotesPayableMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_ReimbursementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursements.",
        "label": "Reimbursements [Member]",
        "terseLabel": "Reimbursements"
       }
      }
     },
     "localname": "ReimbursementsMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_RelatedPartyConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party, Convertible Notes",
        "label": "Related Party, Convertible Notes [Member]",
        "terseLabel": "Related-party convertible notes"
       }
      }
     },
     "localname": "RelatedPartyConvertibleNotesMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_RelatedPartyNotesInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Notes - Interest",
        "label": "Related Party Notes - Interest [Member]",
        "terseLabel": "Interest Payments"
       }
      }
     },
     "localname": "RelatedPartyNotesInterestMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_RelatedPartyNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Notes",
        "label": "Related Party Notes [Member]",
        "terseLabel": "Related Party Notes"
       }
      }
     },
     "localname": "RelatedPartyNotesMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_RelatedPartyNotesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related-party notes payable.",
        "label": "Related Party Notes Payable",
        "terseLabel": "Principal Amount",
        "verboseLabel": "Convertible note payable at fair value"
       }
      }
     },
     "localname": "RelatedPartyNotesPayable",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_RelatedPartyNotesPrincipalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Notes - Principal",
        "label": "Related Party Notes - Principal [Member]",
        "terseLabel": "Principal Payments"
       }
      }
     },
     "localname": "RelatedPartyNotesPrincipalMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_RelatedPartyTransactionBasisSpreadOnVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Basis Spread on Variable Rate",
        "label": "Related Party Transaction, Basis Spread on Variable Rate",
        "terseLabel": "Interest Rate",
        "verboseLabel": "Interest rate spread"
       }
      }
     },
     "localname": "RelatedPartyTransactionBasisSpreadOnVariableRate",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ibrx_RelatedPartyWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Warrants",
        "label": "Related Party Warrants [Member]",
        "terseLabel": "Outstanding related-party warrants"
       }
      }
     },
     "localname": "RelatedPartyWarrantsMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_RentAbatementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent abatement period.",
        "label": "Rent Abatement Period",
        "terseLabel": "Rent abatement period"
       }
      }
     },
     "localname": "RentAbatementPeriod",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development arrangements with the federal government.",
        "label": "Research And Development Arrangements With Federal Government [Line Items]",
        "terseLabel": "Research and Development Arrangements with Federal Government [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangements With Federal Government [Table]",
        "label": "Research And Development Arrangements With Federal Government [Table]",
        "terseLabel": "Research And Development Arrangements With Federal Government [Table]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementsWithFederalGovernmentTable",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_SaleOfStockMaximumAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Aggregate Offering Price",
        "label": "Sale Of Stock, Maximum Aggregate Offering Price",
        "terseLabel": "Maximum offering"
       }
      }
     },
     "localname": "SaleOfStockMaximumAggregateOfferingPrice",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of related party notes payable.",
        "label": "Schedule of Related-Party Promissory Notes Table [Table Text Block]",
        "terseLabel": "Summary of Related-Party Promissory Notes"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibrx_SecuredOvernightFinancingRateSOFRMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secured Overnight Financing Rate (SOFR)",
        "label": "Secured Overnight Financing Rate (SOFR) [Member]",
        "terseLabel": "Secured Overnight Financing Rate (SOFR)"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSOFRMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_SeptemberTwentyNineteenLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "September twenty nineteen lease.",
        "label": "September Twenty Nineteen Lease [Member]",
        "terseLabel": "September 2019 Lease"
       }
      }
     },
     "localname": "SeptemberTwentyNineteenLeaseMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award estimated benefit at grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Estimated Benefit At Grant Date Fair Value",
        "terseLabel": "Estimated benefit at grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share-based payment award, options, aggregate intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_SharedServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shared services agreement.",
        "label": "Shared Services Agreement [Member]",
        "terseLabel": "Shared Services Agreement"
       }
      }
     },
     "localname": "SharedServicesAgreementMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issued, Cash Distributed In Lieu of Fractional Shares",
        "label": "Shares Issued, Cash Distributed In Lieu of Fractional Shares",
        "terseLabel": "Cash to be distributed in lieu of fractional shares (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedCashDistributedInLieuOfFractionalShares",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "ibrx_SixZeroFiveDougStLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Zero Five Doug St, LLC",
        "label": "Six Zero Five Doug St, LLC [Member]",
        "terseLabel": "605 Doug St, LLC"
       }
      }
     },
     "localname": "SixZeroFiveDougStLLCMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_SixZeroFiveNashLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Zero Five Nash, LLC",
        "label": "Six Zero Five Nash, LLC [Member]",
        "terseLabel": "605 Nash, LLC"
       }
      }
     },
     "localname": "SixZeroFiveNashLLCMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_SorrentoTherapeuticsIncLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sorrento Therapeutics, Inc. Litigation",
        "label": "Sorrento Therapeutics, Inc. Litigation [Member]",
        "terseLabel": "Sorrento Therapeutics, Inc. Litigation"
       }
      }
     },
     "localname": "SorrentoTherapeuticsIncLitigationMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_SponsoredResearchAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsored research agreement.",
        "label": "Sponsored Research Agreement [Member]",
        "terseLabel": "Sponsored Research Agreement"
       }
      }
     },
     "localname": "SponsoredResearchAgreementMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_StateOfNewYorkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State Of New York",
        "label": "State Of New York [Member]",
        "terseLabel": "State Of New York"
       }
      }
     },
     "localname": "StateOfNewYorkMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_SupplyAgreementPeriodOfExtendedTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Agreement, Period Of Extended Term",
        "label": "Supply Agreement, Period Of Extended Term",
        "terseLabel": "Optional extended term of supply agreement"
       }
      }
     },
     "localname": "SupplyAgreementPeriodOfExtendedTerm",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ibrx_SupplyAgreementTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Agreement, Term Of Contract",
        "label": "Supply Agreement, Term Of Contract",
        "terseLabel": "Initial term of supply agreement"
       }
      }
     },
     "localname": "SupplyAgreementTermOfContract",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ibrx_TransactionCostsWarrantLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction Costs, Warrant Liability",
        "label": "Transaction Costs, Warrant Liability",
        "terseLabel": "Transaction costs allocated to warrant liabilities"
       }
      }
     },
     "localname": "TransactionCostsWarrantLiability",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_TwoThousandFifteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fifteen equity incentive plan.",
        "label": "Two Thousand Fifteen Equity Incentive Plan [Member]",
        "terseLabel": "2015 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandFifteenEquityIncentivePlanMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_TwoThousandFifteenShareRepurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2015 share repurchase plan.",
        "label": "Two Thousand Fifteen Share Repurchase Plan [Member]",
        "terseLabel": "2015 Share Repurchase Plan"
       }
      }
     },
     "localname": "TwoThousandFifteenShareRepurchasePlanMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unpaid offering costs included in accounts payable and accrued expenses.",
        "label": "Unpaid Offering Costs Included In Accounts Payable And Accrued Expenses",
        "terseLabel": "Unpaid offering costs included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "UnpaidOfferingCostsIncludedInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_VariousMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Various.",
        "label": "Various [Member]",
        "terseLabel": "Various"
       }
      }
     },
     "localname": "VariousMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofOutstandingBalancesofRelatedPartyAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_VivaBioCellMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VivaBioCell.",
        "label": "VivaBioCell [Member]",
        "terseLabel": "VivaBioCell"
       }
      }
     },
     "localname": "VivaBioCellMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_WarrantLiabilityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Liability",
        "label": "Warrant Liability [Text Block]",
        "terseLabel": "Warrant Liabilities"
       }
      }
     },
     "localname": "WarrantLiabilityTextBlock",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/WarrantLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibrx_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants.",
        "label": "Warrants [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_WarrantsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants",
        "label": "Warrants [Policy Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsPolicyTextBlock",
     "nsuri": "http://www.immunitybio.com/20230331",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r595",
      "r599",
      "r697",
      "r742",
      "r743",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An affiliate is a party that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with the entity.",
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r250",
      "r447",
      "r448",
      "r451",
      "r452",
      "r502",
      "r595",
      "r599",
      "r688",
      "r691",
      "r692",
      "r763",
      "r764",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by consolidated entity or group of entities.",
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r250",
      "r447",
      "r448",
      "r451",
      "r452",
      "r502",
      "r595",
      "r599",
      "r688",
      "r691",
      "r692",
      "r763",
      "r764",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity or group of entities consolidated into reporting entity.",
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "auth_ref": [
      "r762"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.",
        "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Estimated Future Contractual Obligations for Related-Party Promissory Notes"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r248",
      "r249",
      "r347",
      "r364",
      "r609",
      "r615",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.",
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.",
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r332",
      "r392",
      "r533",
      "r561",
      "r596",
      "r597",
      "r630",
      "r637",
      "r645",
      "r693",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r332",
      "r392",
      "r533",
      "r561",
      "r596",
      "r597",
      "r630",
      "r637",
      "r645",
      "r693",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r332",
      "r384",
      "r392",
      "r419",
      "r420",
      "r421",
      "r509",
      "r533",
      "r561",
      "r596",
      "r597",
      "r630",
      "r637",
      "r645",
      "r685",
      "r693",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r332",
      "r384",
      "r392",
      "r419",
      "r420",
      "r421",
      "r509",
      "r533",
      "r561",
      "r596",
      "r597",
      "r630",
      "r637",
      "r645",
      "r685",
      "r693",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r248",
      "r249",
      "r347",
      "r364",
      "r616",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r297",
      "r298",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r598",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r631",
      "r644",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r297",
      "r298",
      "r583",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r598",
      "r600",
      "r631",
      "r644",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r11",
      "r643"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r11",
      "r154",
      "r155",
      "r667"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Related Parties, Current",
        "terseLabel": "Due to related parties"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Accrued bonus"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional and service fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r13",
      "r614"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r88",
      "r205"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r214",
      "r555",
      "r566",
      "r567"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r22",
      "r25",
      "r137",
      "r495",
      "r562",
      "r563",
      "r659",
      "r660",
      "r661",
      "r669",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Financial Statement Details"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r428",
      "r429",
      "r430",
      "r669",
      "r670",
      "r671",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedLabel": "Net share settlement for RSUs vesting"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r119",
      "r120",
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AgencySecuritiesMember": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities issued by government sponsored entities.",
        "label": "Agency Securities [Member]",
        "terseLabel": "Government-sponsored securities"
       }
      }
     },
     "localname": "AgencySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r423"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r359",
      "r476",
      "r628",
      "r629",
      "r663"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of related-party notes discounts"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r45",
      "r78",
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r22",
      "r25",
      "r137",
      "r659",
      "r660",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "verboseLabel": "Total ImmunityBio Stockholders\u2019 Deficit"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r639",
      "r726",
      "r727",
      "r728"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Total consideration"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": {
     "auth_ref": [
      "r639",
      "r726",
      "r727",
      "r728"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Transaction Cost",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredTransactionCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Asset Acquisition [Line Items]",
        "terseLabel": "Asset Acquisition [Line Items]"
       }
      }
     },
     "localname": "AssetAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]",
        "terseLabel": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTableTextBlock": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of asset acquisition.",
        "label": "Asset Acquisition [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Assets Acquired"
       }
      }
     },
     "localname": "AssetAcquisitionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r157",
      "r176",
      "r209",
      "r245",
      "r287",
      "r290",
      "r294",
      "r308",
      "r333",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r447",
      "r451",
      "r467",
      "r643",
      "r689",
      "r690",
      "r745"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r201",
      "r217",
      "r245",
      "r308",
      "r333",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r447",
      "r451",
      "r467",
      "r643",
      "r689",
      "r690",
      "r745"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r301",
      "r315"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r63",
      "r300",
      "r315",
      "r549"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationRSUsActivityDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r141",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r445",
      "r635",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r124",
      "r125",
      "r445",
      "r635",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r126",
      "r127",
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Business combination, consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High",
        "terseLabel": "Maximum milestone payment due if certain conditions are met"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r49",
      "r50",
      "r51"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment purchases included in accounts payable, accrued expenses and due to related parties"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r47",
      "r203",
      "r610"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents, and restricted cash, end of period:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r41",
      "r47",
      "r52"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash, end of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r41",
      "r148"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]",
        "terseLabel": "Cash Flow Operating Activities Lessee [Abstract]"
       }
      }
     },
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsScheduleofCashPaidforAmountsIncludedinMeasurementofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r107",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Number of warrants outstanding (in units)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r107",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r18",
      "r165",
      "r182"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r327",
      "r328",
      "r585",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r669",
      "r670",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r4",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r4",
      "r643"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001\u00a0par value; 900,000,000\u00a0shares authorized as of March\u00a031,\u00a02023 and December\u00a031,\u00a02022, respectively; 435,923,104 and 421,569,115 shares issued and outstanding as of March\u00a031,\u00a02023 and December\u00a031,\u00a02022, respectively; excluding treasury stock, 163,800\u00a0shares outstanding as of March\u00a031,\u00a02023 and December\u00a031,\u00a02022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r132",
      "r140",
      "r223",
      "r225",
      "r232",
      "r551",
      "r557"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r134",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails": {
       "order": 4.0,
       "parentTag": "ibrx_AssetAcquisitionFairValueOfAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r380",
      "r381",
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r0",
      "r158",
      "r174",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Notes",
        "verboseLabel": "Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r632",
      "r634",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_GainLossOnInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in debt and equity securities.",
        "label": "Debt and Equity Securities, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized gains from equity securities"
       }
      }
     },
     "localname": "DebtAndEquitySecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r158",
      "r159",
      "r174",
      "r250",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r477",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r93",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.",
        "label": "Debt Instrument, Measurement Input",
        "terseLabel": "Significant unobservable inputs, Level 3 valuations"
       }
      }
     },
     "localname": "DebtInstrumentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r15",
      "r250",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r477",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r149",
      "r151",
      "r694"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "terseLabel": "Less: Unamortized Discounts",
        "verboseLabel": "Debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r306",
      "r318",
      "r622"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "More than 12 months, Estimated Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonMarketableDebtSecuritiesinContinuousLossPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r306",
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "More than 12 months, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonMarketableDebtSecuritiesinContinuousLossPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r306",
      "r318",
      "r622"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less than 12 months, Estimated Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonMarketableDebtSecuritiesinContinuousLossPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r306",
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Less than 12 months, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonMarketableDebtSecuritiesinContinuousLossPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r304",
      "r622",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r305",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of securities in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonMarketableDebtSecuritiesinContinuousLossPositionDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r150",
      "r694"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Lender origination fee"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r683"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Placement agent fees and other offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r45",
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense related to property, plant and equipment"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r45",
      "r284"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r396",
      "r424",
      "r425",
      "r427",
      "r431",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r105",
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "terseLabel": "Dividends"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r162",
      "r186",
      "r213",
      "r335",
      "r336",
      "r337",
      "r341",
      "r342",
      "r343",
      "r499",
      "r667"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "terseLabel": "Due from related parties"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r213",
      "r335",
      "r336",
      "r337",
      "r341",
      "r342",
      "r343",
      "r499",
      "r611",
      "r667"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due from Related Parties, Current",
        "terseLabel": "Due from related parties",
        "verboseLabel": "Total due from related parties"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofOutstandingBalancesofRelatedPartyAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r11",
      "r335",
      "r336",
      "r337",
      "r341",
      "r342",
      "r343",
      "r499",
      "r667"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Due to related parties",
        "verboseLabel": "Total due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofOutstandingBalancesofRelatedPartyAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r233",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r264",
      "r266",
      "r268",
      "r269",
      "r270",
      "r272",
      "r456",
      "r457",
      "r552",
      "r558",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per ImmunityBio common share \u2013 basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r233",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r266",
      "r268",
      "r269",
      "r270",
      "r272",
      "r456",
      "r457",
      "r552",
      "r558",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per ImmunityBio common share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r54",
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Basic and Diluted Net Loss per Share of Common Stock"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r734"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r724"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to non-vested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r724"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to unvested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Outstanding stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r98",
      "r198",
      "r226",
      "r227",
      "r228",
      "r251",
      "r252",
      "r253",
      "r255",
      "r261",
      "r263",
      "r273",
      "r309",
      "r379",
      "r428",
      "r429",
      "r430",
      "r436",
      "r437",
      "r455",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r474",
      "r495",
      "r562",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Percentage of ownership interest"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r559",
      "r676"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedLabel": "Unrealized (gains) on equity securities",
        "terseLabel": "Unrealized gains (losses) from equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r73",
      "r175",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r45",
      "r94"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedTerseLabel": "Change in fair value of warrant liabilities",
        "terseLabel": "Change in fair value of warrant liabilities"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r458",
      "r459",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r143",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r352",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r459",
      "r506",
      "r507",
      "r508",
      "r626",
      "r627",
      "r632",
      "r633",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r145",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r458",
      "r459",
      "r461",
      "r462",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r352",
      "r385",
      "r390",
      "r459",
      "r506",
      "r632",
      "r633",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r352",
      "r385",
      "r390",
      "r459",
      "r507",
      "r626",
      "r627",
      "r632",
      "r633",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r352",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r459",
      "r508",
      "r626",
      "r627",
      "r632",
      "r633",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Decrease in fair value",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r144"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "negatedPeriodEndLabel": "Fair value, end of year",
        "negatedPeriodStartLabel": "Fair value, beginning of year",
        "terseLabel": "Estimated fair value of warrants"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r352",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r506",
      "r507",
      "r508",
      "r626",
      "r627",
      "r632",
      "r633",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r464",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).",
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r482",
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash flow from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsScheduleofCashPaidforAmountsIncludedinMeasurementofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r479",
      "r493"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 2.0,
       "parentTag": "ibrx_LeaseLiability",
       "weight": 1.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r479"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails": {
       "order": 3.0,
       "parentTag": "ibrx_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "verboseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r479"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "ibrx_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "verboseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_2": {
       "order": 1.0,
       "parentTag": "ibrx_LeaseLiabilityToBePaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 1.0,
       "parentTag": "ibrx_LeaseLiabilityToBePaidYearThree",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r741"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2023 (excluding the three months ended March\u00a031,\u00a02023)"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 1.0,
       "parentTag": "ibrx_LeaseLiabilityUndiscountedExcessInterest",
       "weight": 1.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r481",
      "r488"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Principal payments of finance leases",
        "terseLabel": "Financing cash flow from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/LeaseArrangementsScheduleofCashPaidforAmountsIncludedinMeasurementofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r478"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "ibrx_LeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "verboseLabel": "Finance lease assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r491",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate, Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofInformationRegardingLeasesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r490",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term, Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofInformationRegardingLeasesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r302",
      "r303",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r317",
      "r319",
      "r320",
      "r360",
      "r375",
      "r453",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r622",
      "r673",
      "r674",
      "r675",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonMarketableDebtSecuritiesinContinuousLossPositionDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Weighted- Average Life (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r207",
      "r323"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      },
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2023 (excluding the three months ended March\u00a031,\u00a02023)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r82",
      "r536"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails": {
       "order": 3.0,
       "parentTag": "ibrx_AssetAcquisitionFairValueOfAssetsAcquired",
       "weight": 1.0
      },
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      },
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount",
        "verboseLabel": "Finite-lived intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails",
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r79",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r82",
      "r535"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "terseLabel": "Total definite-lived intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignGovernmentDebtMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities (such as bonds) issued by a national, local, or municipal government not within the country of domicile of the entity.",
        "label": "Foreign Government Debt [Member]",
        "terseLabel": "Foreign bonds"
       }
      }
     },
     "localname": "ForeignGovernmentDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonMarketableDebtSecuritiesinContinuousLossPositionDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture &amp; fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r32",
      "r61",
      "r655"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "terseLabel": "Interest and investment income, net",
        "totalLabel": "Interest and investment income, net"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncentiveFromLessor": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r735"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of incentive received by lessee from lessor.",
        "label": "Incentive from Lessor",
        "terseLabel": "Tenant improvements incentive"
       }
      }
     },
     "localname": "IncentiveFromLessor",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r28",
      "r156",
      "r168",
      "r189",
      "r287",
      "r289",
      "r293",
      "r295",
      "r553",
      "r621"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes and noncontrolling interests"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r29",
      "r45",
      "r74",
      "r167",
      "r187",
      "r285"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Loss on equity method investment",
        "terseLabel": "Loss on equity method investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r246",
      "r433",
      "r434",
      "r435",
      "r438",
      "r440",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r247",
      "r262",
      "r263",
      "r286",
      "r432",
      "r439",
      "r441",
      "r560"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r662",
      "r739"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r662"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Statements of Stockholders\u2019 Deficit [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      },
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "terseLabel": "Indefinite-lived intangible assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r206"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r77",
      "r80"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndOtherIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_GainLossOnInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest and Other Income",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestAndOtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndOtherIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and income classified as other.",
        "label": "Interest and Other Income [Table Text Block]",
        "terseLabel": "Interest and Investment Income, Net"
       }
      }
     },
     "localname": "InterestAndOtherIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r150",
      "r170",
      "r229",
      "r283",
      "r475"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      },
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense (including amounts with related parties)",
        "negatedTotalLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense classified as other.",
        "label": "Interest Expense, Other",
        "negatedTerseLabel": "Other interest expense"
       }
      }
     },
     "localname": "InterestExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.",
        "label": "Interest Expense, Related Party",
        "negatedTerseLabel": "Interest expense on related-party notes"
       }
      }
     },
     "localname": "InterestExpenseRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r238",
      "r241",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest",
        "verboseLabel": "Interest paid in cash"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r164",
      "r184"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Interest Payable",
        "terseLabel": "Accrued Interest Added to Note"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeNetDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_GainLossOnInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "terseLabel": "Investment amortization expense, net"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTextBlock": {
     "auth_ref": [
      "r672",
      "r677",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investment.",
        "label": "Investment [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "InvestmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r657"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Advances to support operations"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r492",
      "r642"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Information Regarding Leases (Detail)"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails": {
       "order": 2.0,
       "parentTag": "ibrx_AssetAcquisitionFairValueOfAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements, Gross",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Lease Arrangements"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_2": {
       "order": 2.0,
       "parentTag": "ibrx_LeaseLiabilityToBePaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 2.0,
       "parentTag": "ibrx_LeaseLiabilityToBePaidYearOne",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r741"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 2.0,
       "parentTag": "ibrx_LeaseLiabilityToBePaidRemainderOfFiscalYear",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2023 (excluding the three months ended March\u00a031,\u00a02023)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 2.0,
       "parentTag": "ibrx_LeaseLiabilityUndiscountedExcessInterest",
       "weight": 1.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Optional extended lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Initial term of lease arrangement"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Lease Arrangements"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r12",
      "r245",
      "r308",
      "r333",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r448",
      "r451",
      "r452",
      "r467",
      "r620",
      "r689",
      "r745",
      "r746"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r9",
      "r161",
      "r180",
      "r643",
      "r666",
      "r678",
      "r733"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r14",
      "r202",
      "r245",
      "r308",
      "r333",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r448",
      "r451",
      "r452",
      "r467",
      "r643",
      "r689",
      "r745",
      "r746"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "negatedTerseLabel": "Liabilities measured at fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "License Agreement Terms"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r18",
      "r686"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Accrued litigation expense"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded from other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded from Other Party",
        "terseLabel": "Amount awarded from other party in litigation settlement"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r2",
      "r159",
      "r177",
      "r351",
      "r361",
      "r626",
      "r627"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Total principal and estimated interest due on related-party debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r91",
      "r250",
      "r355"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r91",
      "r250",
      "r355"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r668"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2023 (excluding the three months ended March\u00a031,\u00a02023)"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r15",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Investments in marketable equity securities with readily determinable fair values"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable securities, noncurrent"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount factor"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "auth_ref": [
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset.",
        "label": "Measurement Input, Exercise Price [Member]",
        "terseLabel": "Exercise price per share"
       }
      }
     },
     "localname": "MeasurementInputExercisePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk free rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r20",
      "r160",
      "r179",
      "r245",
      "r308",
      "r333",
      "r336",
      "r337",
      "r338",
      "r342",
      "r343",
      "r467"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MutualFundMember": {
     "auth_ref": [
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective.",
        "label": "Mutual Fund [Member]",
        "terseLabel": "Mutual funds"
       }
      }
     },
     "localname": "MutualFundMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonMarketableDebtSecuritiesinContinuousLossPositionDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r275",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r240"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r240"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r41",
      "r43",
      "r46"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r30",
      "r46",
      "r169",
      "r188",
      "r200",
      "r221",
      "r224",
      "r228",
      "r245",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r262",
      "r263",
      "r267",
      "r287",
      "r289",
      "r293",
      "r295",
      "r308",
      "r333",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r457",
      "r467",
      "r621",
      "r689"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to ImmunityBio common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r135",
      "r139",
      "r221",
      "r224",
      "r262",
      "r263",
      "r661"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r130",
      "r379",
      "r669",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense), net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Summary of RSU Activity under Equity Plans"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": {
     "auth_ref": [
      "r10",
      "r154",
      "r667"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Notes Payable, Related Parties, Current",
        "terseLabel": "Related-party notes"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r153",
      "r185",
      "r667"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), due to related parties.",
        "label": "Notes Payable, Related Parties",
        "totalLabel": "Total",
        "verboseLabel": "Net proceeds from related parties"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r16",
      "r153",
      "r667"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).",
        "label": "Notes Payable, Related Parties, Noncurrent",
        "terseLabel": "Related-party convertible notes and accrued interest, net of discount"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OffMarketFavorableLeaseMember": {
     "auth_ref": [
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifiable intangible asset established upon acquisition based on a favorable difference between the terms of an acquired lease and the current market terms for that lease.",
        "label": "Off-Market Favorable Lease [Member]",
        "terseLabel": "Favorable Leasehold Rights"
       }
      }
     },
     "localname": "OffMarketFavorableLeaseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r287",
      "r289",
      "r293",
      "r295",
      "r621"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r485",
      "r642"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r736"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r479"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "order": 1.0,
       "parentTag": "ibrx_LeaseLiability",
       "weight": 1.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r479"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails": {
       "order": 4.0,
       "parentTag": "ibrx_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities (including amounts with related parties)",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r479"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "ibrx_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion (including amounts with related parties)",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r483",
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating leases (excluding variable lease costs)"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsScheduleofCashPaidforAmountsIncludedinMeasurementofLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r478"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "ibrx_LeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets, net (including amounts with related parties)",
        "verboseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r663"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Non-cash lease expense related to operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r491",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate, Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofInformationRegardingLeasesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r490",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term, Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofInformationRegardingLeasesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r216",
      "r643"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets (including amounts with related parties)"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized gains (losses) on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r27",
      "r98",
      "r222",
      "r225",
      "r231",
      "r468",
      "r473",
      "r474",
      "r550",
      "r556",
      "r659",
      "r660"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive (loss) income, net of tax",
        "totalLabel": "Total other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of income taxes:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r132",
      "r133",
      "r136",
      "r222",
      "r225"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Comprehensive loss attributable to noncontrolling interests"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r132",
      "r133",
      "r136",
      "r222",
      "r225"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to ImmunityBio common stockholders"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r23",
      "r26",
      "r72",
      "r220"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedLabel": "Reclassification of net realized gains on available-for-sale securities included in net loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net (including amounts with related parties)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Settlement payment"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Commissions and offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficitParenthetical",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Net share settlement for RSUs vesting"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Purchase of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInJointVenture": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.",
        "label": "Payments to Acquire Interest in Joint Venture",
        "negatedTerseLabel": "Investment in joint venture \u2013 an equity method investment",
        "terseLabel": "Payment to acquire interest in joint venture"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInJointVenture",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable debt securities, available-for-sale"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r236",
      "r726",
      "r727",
      "r728"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Cash payment to acquire assets"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails": {
       "order": 1.0,
       "parentTag": "ibrx_AssetAcquisitionFairValueOfAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Other depreciable assets and prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionConsiderationTransferredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r658"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets (including amounts with related parties)",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "auth_ref": [
      "r163",
      "r183",
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.",
        "label": "Prepaid Expense",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r612",
      "r623",
      "r682"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Registered Direct Offering",
        "verboseLabel": "Registered Direct Offering"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficitParenthetical",
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from equity offering, net of issuance costs paid"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from issuance of warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r60",
      "r234",
      "r235"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Maturities of marketable debt securities, available for sale"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Proceeds from Related Party Debt",
        "terseLabel": "Proceeds from issuance of related-party convertible promissory notes, net of issuance costs paid"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sales of marketable debt and equity securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r117"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercises of stock options",
        "verboseLabel": "Proceeds from stock options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r200",
      "r221",
      "r224",
      "r239",
      "r245",
      "r254",
      "r262",
      "r263",
      "r287",
      "r289",
      "r293",
      "r295",
      "r308",
      "r333",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r446",
      "r449",
      "r450",
      "r457",
      "r467",
      "r553",
      "r621",
      "r640",
      "r641",
      "r661",
      "r689"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r87",
      "r204"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Gross property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r89",
      "r181",
      "r554",
      "r643"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r190"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeNetDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_GainLossOnInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Net realized losses on investments"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r391",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r194",
      "r498",
      "r499",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofOutstandingBalancesofRelatedPartyAgreementsDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofOutstandingBalancesofRelatedPartyAgreementsDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Consideration for future services performed by related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofOutstandingBalancesofRelatedPartyAgreementsDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.",
        "label": "Related Party Transaction, Rate",
        "terseLabel": "Interest Rate"
       }
      }
     },
     "localname": "RelatedPartyTransactionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r391",
      "r498",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r496",
      "r497",
      "r499",
      "r500",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related-Party Agreements",
        "verboseLabel": "Related-Party Debt"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreements",
      "http://www.immunitybio.com/role/RelatedPartyDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r121",
      "r192",
      "r753"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development (including amounts with related parties)",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements and Acquisition"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r47",
      "r52",
      "r584"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Outstanding RSUs",
        "verboseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationRSUsActivityDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r6",
      "r105",
      "r178",
      "r565",
      "r567",
      "r643"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r198",
      "r251",
      "r252",
      "r253",
      "r255",
      "r261",
      "r263",
      "r309",
      "r428",
      "r429",
      "r430",
      "r436",
      "r437",
      "r455",
      "r562",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r230",
      "r245",
      "r281",
      "r282",
      "r288",
      "r291",
      "r292",
      "r296",
      "r297",
      "r299",
      "r308",
      "r333",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r467",
      "r553",
      "r689"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r489",
      "r642"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Sale of stock issued in transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficitParenthetical",
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accrued Expenses and Other Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Securities Excluded from the Computation of Potentially Dilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonMarketableDebtSecuritiesinContinuousLossPositionDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Available-for-Sale Marketable Debt Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r69",
      "r70",
      "r71",
      "r171",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-Sale Securities [Table]",
        "terseLabel": "Schedule Of Available For Sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonMarketableDebtSecuritiesinContinuousLossPositionDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r124",
      "r125",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r115",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expenses Included on Operations Statement"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r154",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofOutstandingBalancesofRelatedPartyAgreementsDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Summary of Outstanding Balances of Related-Party Agreements"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r393",
      "r395",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationRSUsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r111",
      "r112",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity and Related Information under Equity Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r210",
      "r211",
      "r212",
      "r274",
      "r362",
      "r363",
      "r364",
      "r366",
      "r370",
      "r375",
      "r377",
      "r630",
      "r656",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Future Amortization Expense Associated with Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative (including amounts with related parties)",
        "verboseLabel": "Selling, general and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited/canceled (in units)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationRSUsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited/canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationRSUsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in units)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationRSUsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationRSUsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested, ending balance (in units)",
        "periodStartLabel": "Nonvested, beginning balance (in units)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationRSUsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationRSUsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested, ending balance (in dollars per share)",
        "periodStartLabel": "Nonvested, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationRSUsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationRSUsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in units)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationRSUsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationRSUsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationRSUsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common stock reserved for future grants (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted- Average Remaining Contractual Life (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r415"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock option exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Forfeited/expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited/expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Outstanding, ending balance",
        "periodStartLabel": "Outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "verboseLabel": "Vested and exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationRSUsActivityDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Aggregate intrinsic value, vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Shares to be issued in private placement (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedLabel": "Net share settlement for RSUs vesting (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r486",
      "r642"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease costs"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r53",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r19",
      "r98",
      "r198",
      "r226",
      "r227",
      "r228",
      "r251",
      "r252",
      "r253",
      "r255",
      "r261",
      "r263",
      "r273",
      "r309",
      "r379",
      "r428",
      "r429",
      "r430",
      "r436",
      "r437",
      "r455",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r474",
      "r495",
      "r562",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "verboseLabel": "Total ImmunityBio Stockholders\u2019 (Deficit) Equity"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r273",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r3",
      "r4",
      "r98",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock in a registered direct offering, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r98",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted stock units (RSUs) (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r3",
      "r4",
      "r98",
      "r105",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r3",
      "r4",
      "r98",
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of shares in a registered direct offering, net of discount and offering costs of $2,046 and value ascribed to associated warrants (Note 11)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Value of shares to be issued in private placement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r98",
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Remaining authorized repurchase amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r3",
      "r4",
      "r98",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "terseLabel": "Repurchase of common stock, shares (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r4",
      "r7",
      "r8",
      "r59",
      "r643",
      "r666",
      "r678",
      "r733"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total ImmunityBio stockholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 deficit:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r130",
      "r131",
      "r138",
      "r198",
      "r199",
      "r227",
      "r251",
      "r252",
      "r253",
      "r255",
      "r261",
      "r309",
      "r379",
      "r428",
      "r429",
      "r430",
      "r436",
      "r437",
      "r455",
      "r468",
      "r469",
      "r474",
      "r495",
      "r563",
      "r564",
      "r666",
      "r678",
      "r733"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r108",
      "r244",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r379",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders\u2019 Deficit"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentandContingenciesLitigationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofStockholdersDeficitParenthetical",
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Supplies": {
     "auth_ref": [
      "r613",
      "r624",
      "r682"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Supplies",
        "terseLabel": "Prepaid supplies"
       }
      }
     },
     "localname": "Supplies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction [Domain]",
        "terseLabel": "Transaction"
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]",
        "terseLabel": "Transaction Type"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r302",
      "r303",
      "r360",
      "r375",
      "r453",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r673",
      "r674",
      "r675",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonMarketableDebtSecuritiesinContinuousLossPositionDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsSummaryofAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury stock, common shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized gains (losses) on marketable debt securities, net"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r56",
      "r57",
      "r58",
      "r276",
      "r277",
      "r278",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r487",
      "r642"
     ],
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Outstanding third-party warrants",
        "verboseLabel": "Warrant liability"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrant liabilities"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Measurement input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Term of warrants outstanding"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity.",
        "label": "Warrants Not Settleable in Cash, Fair Value Disclosure",
        "terseLabel": "Fair value of warrants"
       }
      }
     },
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r265",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average number of common shares used in computing net loss per share \u2013 diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r264",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of common shares used in computing net loss per share \u2013 basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.immunitybio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "https://asc.fasb.org/topic&trid=2155941",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.23)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.10)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "https://asc.fasb.org/subtopic&trid=2197926",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39896-112707",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e40010-112707",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123386226&loc=d3e41620-112719",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(m)",
   "Publisher": "SEC",
   "Section": "4",
   "Subparagraph": "(1)(iii)",
   "Subsection": "08",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(7)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6283291-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r649": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r651": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r652": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r653": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r654": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "321",
   "URI": "https://asc.fasb.org/topic&trid=75115024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "325",
   "URI": "https://asc.fasb.org/topic&trid=2197064",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123388062&loc=SL77916639-209961",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "303",
   "Subparagraph": "(5)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>89
<FILENAME>0001326110-23-000064-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001326110-23-000064-xbrl.zip
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M9_0X>B;'_3;:V7]Y^'+[<+2[_T3@>@@O]G][]?+!"[.[G3^\?'!_M'-T_Y5
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MB >10?+IH-4@:@D4E*P.JA#EF#^+Z$^7ZV"F7%EN;N;99\IW6OW/G=FB-DE
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MT'LJ5DDXLUJR,K,VT*Q" BX/)B5ZPHMK"VTN0D=&%8-*SEARUGE;U@:F6Y6
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M5;YB#JC75%E6:5W(J6VX:T/(4++"EN\8;Y0-F1+A.GJ5[XTJ2_(J%(F$*3F
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MVW#I6W70DKADLPF5;(&0++0"%Q.B%R64O(G94(<WN]Q0Z.94#M>"(9>HLO*
MD9-K:WFP54<X+>E?7UFQ0.3Q='(TG,TFTY.5,^(&AE%OA _5> 9=N8J#@$">
MH@9P!=#JUO4P7(DX79:_2\7GVF>]H:FC6PTYRUJO54(T)FCBBJT)AVW;MB8
M:[2G5G%U1J9HS^1+A\?;5VWL5\&\.(C]%_HA+@G," PJ^>HD#Q9!&I.-D@W;
MD&O(D?L_#_<=A(S59S2A!MT:C!9+K3# 1JPE&X_>>;*6KL:7#8NZSJ*5Y#)>
M088 SNA<H12?;$W@*<=<JW)0-JIU.>2!GJA6[2,*&Z ZR6(D?TG$I*BJD'0V
MR4&/8M-2\>F[:EU)B,K!>/ 0#%N"B,(?%@5K43&5ZGWM$9F^6R^S>A9%]D$G
MI[F0!"K':" ;S,HFPZA=;X?;ND8>WY,056U1B4.DK#1$"JBJ1A('XW+)46./
MO,I2\=F$J*\A4_2E1)W:BA30+ ]45#$B6N6(BN\1F;Y;+[-Z%JF0:VE%#C$6
M:&T'3 ;)RM%'B#:QZQ&+O@C,=<2RQ""Z%;6Q*.*U!$QIT8;%M)7NWMGNRXUE
M0OB-WN?;IA2[HC@X@K# :N4"@9@ULA&]P27%H ACG_*8+^+&FFY#I@/8&&(F
MP1.RST242W'6<RLKZL,NODM&<6/DK:K#>ZO054I!@]*ZK7_4BTY<*CBQ]'4U
M\C4M^)+O:C5>+BOO02>+K*$@>DOHF&M>.SA/JSO7$\KB6_EP<:C!QQQM3DH[
M+H!DD=2Z^.MK(;CQU6TEJY>\BK)B4!:<4:C%54?%.B H2'&]C/ONTYM>(K6:
MW6 5!<Q.PJXC294]FJ+:!E*M18AVI<,-!I:*W<:@VS1T]C:C4Z6R!\X.E;<!
MM,I>='D*M%X&O>:5*15-C25G*U8-:&MR(005?"61TQ&NKN==F\K'+M6'+*OP
MT-:08J1,09>VOC^A4FW)A*8VN9M]]]=N;4;#EKPL*WF7Q9A=:IN_U5IB4%D9
MA%"39BAZ7<W[YD?#5F+A)/8M]U:Q]THP-"2B6HDJ"^+!%92Z9A:^UJ-ARS-R
MJ[77WI:L0P(7JN3<NNWT&DUBB(;7U<@[MF1M64:>HU*<5+$5 3@ U;:%;T7G
M6E.W&KMOY)LE:S>PP-I3JWJH%BB#LTJ(0,B9%"0K0>#JHM@NTZ-#8Z0K,7 3
MK F.?68N$*"B]Y ,<I3T*YK2@QX+FS'2Y1IW+HT-$K$U%$ABZM6V-6,842M$
MA>MEW#<_1KJ:]!O(*Q%AP!DAM8V=L\)42PA(R:2R%F:]UF.DRS-HD6X()ADF
M'\"$$B%Z],6JY"QI6MN\NU/KKI9EV,G7XK0OBDP&I!C)QV1\I:B)M$G=G_Q8
MJ2!O)WTHIC0];E=]@3<7F75ZXNEPG(=OEC>T]R4[T;6&<%NU#D=#/&_?_E>;
M379E1B9ZE8O/I>I@P%))F<"I:+.AXHAZ,#NWLGKH#3EOFIQ&%294(4*KPV0C
MWM/EHHMP,SI7.KPMP)=SY*'\[BG/YEV62!M^7ME>V=7:>GZW> [)(T9?,Z$/
M15[W:M,+J(N&\9UP$SSJZ&KB[ $<9_&=8(R++/344?5@Q?_U*;*AQI>M<]!6
MB<BS3F6$G$)*W);$)92D,Y^/-G2:&M=++'\93FYDOZ0; 44E%54U20)*!6M)
MK->[Q<Q-5CG;M9F?O050EC@]"E82(RLVD@MXDZ+D1 S!LO:^K1Y=!TOY19*3
MUX+*:')PNK%93PRF  9?G,NU&M @.4$UDK8F14&2!LSK8#"WB\WR[ 8#>X6^
M^E(<(%'T6,B&DE,DMKJN@]VTY?63X[_2'EVQ%@<Y:D46JM@*>HGVI76F\[8@
M<,II':SE-A!9GHVH2JH"I.!B!M3BOYI>;_T?01F?>I \_C4BV\<C/GDRP=(3
M*\E*PKPN$5U@J#ICC39F;VT@R$ZO11GL[6"RS ENJ\F)I: E\)P25 45K22X
MQE;5@RF4ZPGCQ8XV/;$3T5BA!)5K41Y\4JGM%@.A&##.VK(6T>1V,%F>G9BJ
M0G5:Y]9EUN@8D[)ME4VKYD^BE-?!3AX>'1V/)WOCW!3QR=W1<#SL2[I"M<VL
MB9G8;"'IV/8'T[IU-B/K0N%U,)E;AV=YUE-"#3[%', @%"=2C*MS7J5$L8+5
M:[<R[3JN[=JG;%,'>W5K.FV;I%T9K7UZB%,N3WGZ=IAYMG4PY<41-USML9I&
MF(4Q^5S QA8)*]:@8XY<"0#(0X]Z-6](M*I6S9)^>)-"$,HXR=15VP- 93"!
MK9: T:=%[Q>(<V5R\0D/C^AX.EN@>-/S-]\7:5>SYWA)R1;VJ!) K!:KBPY#
M*RORR9H>=%/;</5VN'HS56R2[)"#A/(/:'E@JFAIR+9DBUG;[HOK#?UNG7Y+
MG":,6!,&)O(1JE!.(P&"M\9(\F!,][W?A@[+]$;@/8(U%74"6TWT+2 J]#EC
M3MR#59@;.BRUB"!JQ]#VA-?@.*6H<Y6D4'M7"ISN&*C=]T&';\)$N^5-OEF%
MD5TP)6=@-&AL*"8J54 4A/=7,W5YL %GN>GRQ4._96<C*\EQ\,90R9"33AR\
MA1!T+I*+T-F4G7*] _"S58>W.C.AW 6(OL785$DV>E:8+7"R2-6Y -XY"9#*
MG@^+N7-CVV#U5;;GKF][;CFV!T@IIQ0R*8( @!':A"!#K%GL;_T:9B]5\3P<
MY\D1/YW+>=O%/IID_'3*3]<U8YSFPRU!B=_R:/*F'7OO_1OYMK7L AN]TARQ
MV,SB(MHD?Q+=I"52ER DBYLQ]%YS:B5#ZA&C9:L4<W# -6/%0-DIX:UH!K5H
M$BV1Z)13.O5;BM^5<"1GFBZ OS^9WC^>'T_Y/'E:Q5*)/YT;OI&"UHMTT^G:
M=)-#E[;H&RC&X"%S:XQ)%KU/11) #;YJ<[8EN#YW8;K?=/LZ7-?'H>GK.S2]
M-(9QY&)5S;5H!\%:LB[F"BD'\706U%H)KY5XCA5M]HR@4W:8G24 55!3C5KG
M&J)U-5QMYK/!M2\")/M"FFTNVD .7M(F@+18CRG:A-:V^*L_*U8*>HJI(+MD
M(9G6J"58TP9M"QNG%JN)=%2QSPC=3/>L"^.S<:#BDI:KF.*)BF5G*R![>6A#
M**;$I)2/BT;Q#8Y3Q;[!Y:]T\ *9Z^G@*R!^2S1S7'75*EN0S)T3!IO :6<U
M&.:\9N5P'6M-M[1=>2@(0%5[<@&@JC9YE<4@Y:G*:4UVY;EAQ[C,'31<U*H:
M54"L"#RB0XK*2A(IRE]"UCHHB1N'8WFR(4:NAI/SJLWXMX7BXO&<:(8H$ 37
MWT47_WY&HU>=%0K&E-&H8#B <FTLL)A JBAVBDU_%_6M'*,E+O)+'!R97- !
ML.APJN1-+;HB1X@+.])>):MZAM'%*I;A^Y<\G=P?ON7MR?'!T_FC1S<KQ_U
MI8%52X GL!'WQBKXZ*%233D&N8..LHZ2S"[&)1H\IW)\@].7RO,%4M>3YU=
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MJ'IT%10'K!%SB2%6U39V-+<W@+>J83(NU:N$U29OP2M*!0VH5*-JVQ( ?\S
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M6*91"N3-^B>/BR&8 1PJU9A--488/83H2B]FT(N]<;VP0C,AD05&JVCU(*B
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M(4681A:JT/XU0X\T_7)!UD9U7FHA(0'P^L 4?NR!J>H8Q=.WY9X37]<=_:7
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M( $*"8S$PDK@5)1<QJP4RFUL(5$3LG* K+$JSXM95*J\-%6^'%-E!8E##EN
ML#.15$@)-#4P:3970C&K4]@ 1C5.YE4&IMH@7%-/S5PROSX'BVRNY91O!5S<
M-L4J8+P',$Y)BJ\0EHXS#RA.IU'B:@:,XCJR'>9]_+^S:>^5\NIPV?KJZ5R+
M)E=Z.A<]'?>**,\5E5P"BY@%-&@+=- 8>.4\-<8YJ4S44R9*I*?/LC3RG)PC
MSS9 <P&1V95M-3=HNIJ6"9X(@XE2P$+& $4, VFI 8PC&(BV7D"[L24%JZ''
ME[&XIWJLD _EV6K\ D*R*XV?J\:/DQ'C(Q.A2@,7"4<ZA"&!"@Y%M4=61*,!
M28BCQB-<0V)5-/X)4L<_3:7/;KN=#]K^.O%[4L78?M^QQ=GV*F1Y3B'+7(Q"
MED7)0Y;O5]KW3MV[7OH6P_0N^OG+3M[ZWXU![]R/ _\MD=[NN->W!;I"^!D0
M?DK&=,@)=X0RH)!)IVVD P9Y 10V6"/-!?6%SW<,VLM0?'J.$GH?9E))Z&(E
M=)R#!!(E5 0#K#($4"4$, YY$!3B@F%!$<9W2N@S"-8X''3MUY-N*ZI%OTA?
M*%ZE(B^YS0=59>_Y&7;K/V*EJ:DDKQ^21SK6&;P$-"']\L>)C5AT-[TT*EDM
M^^]?K2G_^-[AB>[YN?BY]AIOIJTMW4ZA[O_HWG[O<)#"OS^FI/D_7CVR>&&U
MVLRPVM0']=<_KS;Q>2W_[X/+XT_NS&#*Z[C1/FHWVL>G>^@(O[]HO*W3^FGK
MZW[S"VTT=R]C.RZ/3X_;#?PQ-&([&U<?T/[.;NSO>_89(F@HUCH%'[BX<ED3
M5R[, 6>6&RH95TC^FJ;<(5(/<Z14(K4&(L5-P ):0%R (,X] H:[*%=1! QF
M LN -K;@9L3$R9C9.QPT9WI4>N-5=J<L]I,H])> ;(7,];?/!R?=7D1I-YN#
MKY+-Y<MF_6KO,^:2!!6%,"!4(%P B@@#I#62)8B+B^@O$&ZJ5"T"W"JI6B6I
M4IXHY1@$%M&4IDPS()F,2$<#PMI&,=-1JA2$-3C\=U:D&\I;IF_D(/O99;82
MC'38E=M_ZG[*1E'7/7LR_(*@VO!#PM_"^;OCK6\;WYO\'=>R."9G/H[3-]^Z
MO.\:L#AMW>OWSRM-+:^F[C<_?.8:*FZ\ )KPM#\44FUPZ@!7T@BI/#44WA?_
M%\<J*HDJOT3I8"7WEH,4JPVH51H8[2'0S!$590 *:5.=/U93F-00G,PY._%%
M L"UP/FR(/.]3S-4RO3DIN/%9Z08@5X*P*-"1=/1>A"Y% &66>:0XU:%7WDC
MEHS5E8RMHHP%8A".\ ("L0I0$R"0GBD0Z0#T5&(J$(_HC5&-<56+.#<#>H](
M>UXLW@69[?Z0C>SWW'<MH/\>_-U?7&<+&?2\[I_W+J^]UT^DV\U1,PKM'BGZ
MZ(658J^$8J//1 B"%7/ 89R.U2$'E)8:!&$=MEX3580)/ U!J01L]05,.9'^
M#X'B*E6_HA0HY.-" HFP6DN$0K0D$2<U>5]_SUHL /=;\V;W]SPBS>5S.#$U
MKT,*M_AML;M6A2;?%WS& ]=,! 7"J07$! 0H]2%2S9!R0UDA+ \6<Y0<!24Z
M)E4=9RSG>8)*.1^KG.,Q>\0+[X+'@'$CHQWHHAU(,(S*J9CBQ&.I8;(#2Z2<
MSZSNW79L=1IQW<K.=.XBZ<FL/LL'NK4NF9Y*RP5^#/T_<>3W.J^'XWX+A:I3
M3?-#IRFE9;04'MNT384\2SEB C!IHX$Q(3!3A%$>HJU14YS5))$E2A/SS#,^
ME99!5"J]9)6>J+4K%0G<DF@#( XH(A@8#Q' 6 0NM>0.TD*E"8S_KE#FIWMQ
MGE7@'=:>M\^'B:M'IQ2>5UJE%TMA'/W8S?AI'*<._$#'%KE=W>O$8>O?FHV=
MX614.#4_G/HP23V((P@&KH&W0:2 204,<@8(HEP(WJ52X:D")U4T4H_)$-Z)
M).^5WV(%]?KAM*/2ZW+H]3C_@-))#-.Y6:\"H"SJM836 N$HY 0)$B<\Z341
MLD;EI$GQ)'K]W%P>MZA'M\CM:+OMLYX_\9U^_LUG+UK=?O^/+._$K_WS\H(\
M*2FY-2]%8KG7MV=EKYB-=W%F&GZP'YKZH@*K>X'5E()?3E@H4D ]%PZG^'H%
M-(46*$N8)UX1B=3&%IG<.ID=I2J?Q_K[/"JU7:S:CG,,Y )D(9**2"<(H"&=
MB!'1E( VA>8$&*!B&UM(/GK+LZ3>C97)#+G7;B?]N_PK[PY#[Z9G9WB,WV.]
M<L@]*?VXG3]C]S_G<=XJ6VE^.#:EC)?@A!D(%<!,<D %\T!SR(&0DD K(!4I
MEI!A65-3L.S>EE)9,DC.T3OR?+5_[IZ32OL7K/T3GA+GE+=$@H!,B-IO--"&
M&< MLH@+I1EU&UN4BAK!DSFN2Z?]S\R'DC*]QXMZW58K1:+F435[OC]8F_)@
M*\!7ZGFGVXLXM3<:^PJOYH=77Z;LV)"XSNAH=4%L(:"&**"TX, 9 QU3T%!A
MDV=75/Z2-=7@N7..2H,7JL$3=48AU<8%#(@(D7%X8X!R:0M6!D^9)59).]QS
M+8D&/TNG2>4H*3OQF#25]JX+T_\S+%6_/1CT<G,^T*;EF]V?N6(%=O,'NREE
MON)$,XJ#!R9$RXH:*X'VC@ 9K!=<>>^=W-AB!-7$E!H=I3.O*N?**A.="C%*
MB!CC]$@81R4-#B@N;2I^+("65@,FL48J+A[!I,* 5-4DGCQY6SK$>.ZUR(KC
MO_<@4S.68QGV\26)(^.ZYU%;L^NN/0HORS:<__UTPU/J9>1IZ[IM=USEIU_<
MLM#8F5+LS03AC1(,($<<H)$ZIA(A'!#$C--6"H[%QA:AI$:G)&1X5.FGQRO3
M$_O.*DRM,+64,5L5IBX54\>IMN968\\=$)Q&XUP$"TQ!M9$*0B"$G4N!EQS7
M")MS.;VGP]2"D/]96'A3<O"T=>]+WBG>CL:HMO7) )RW;B+X.^7$,/'J$Y]I
MFP+$=><R;75VNH-$KGOQZTZQ[_FE5YR=[PU2,I[!B>_[I+/.=_J^*+97#&,1
M;![RCN[8O'!RQB^*ZE";=V8E&C6#QJEX==;M%^=*7_9\2Z>$/:^^YVYP$CN1
MVGC[KM'\PA^W:!-;<#ZX^Y:R##4:RT%TZ\_4V@)J?EN%+T4LCVXZZ?U(\/3%
M ]/S^BO0(7;PI6Y]UY?]C3]_%L$H?Z,&<9$T8&+$YEPE<:9Q65*9Q,>V9?8Z
MB9$M-A,()'5)A=&2%MRNF#@^[T\FI6*JE-X*ZJQE>QV[61C:A^>FG[M<]_)?
MY!DK2Q=>W\#3Z]OP='@#2FEJ]L_\<)++WY\7>2<";_<\/L/U:RGQI4_+U\D0
MI%T6>W+]MW9<&0?]/\K?I0\=?>[R."UWMW66);-8;G^L#<4*'_O0TF=]__+Z
MPRN7]\]:^O)EWBE:4MST:O3XT8*2X'!L>2_>-_QYA)1*;3(N$UB.'&^C%X]P
M=+/ T3'",OQ-H,UH1][Y,]Q$=_[VJ\<BO(D$>]!C?_T;PP^[\[>-G7D,IMBG
MU],8R:(OQY6_<<+^=IM&35PZQ<X="OMR+#KY.^V%0]+8\SZKQ^M.^MEN!%OW
M+]/[<^OG3(TS5"E\VL&_Y?B8W30H]\0DC^,LU2'O45SVF0P;7KBX+E %QDPJ
M4DS<4K1BAL<L_XVEG:=%EQR- [=\/E?X^ [\-]\YGSA-_NCT%\OS\?[>0+RG
MDW=:%Y_(3SMCW^[AJ$5.42.U1EH*"CTWSI(0OV 80^ZT^KQ3;'ZAE)IJIEVP
MD0#U2^-\W3^\=KX>Y'7\IEW?B<\__1+?\1X??=JCQSM'%_'?R_JG1OMXQ^7U
M9AW=.%_;?Y_6<;RF^>7RJ+U'&E<')_7VWWGCZBLZ/OWX=?_MF[SQJ7%:;[^'
MX\[7HW;]ZNCTI+6_\W<>^T :;W>+9^PW/[8;G][3^&YTA.N7QSL'H9Z/'*^'
M\'*_F=JV]QD93Q6D'&@G4IB#<$ )R(",<^218P%)G7ROC][+*E_BG0IMUA5M
MO"/:"HX@L:F@CX1>8&\85/$/*7B!-O@:;7"%-HM"FZMQM"'$8$&, ,(("2AF
M'*@HB8!!(H,AUDJ6RAE,5B\K&]BL 6><'N!5!LXX'0!&'MC.E\Q?G"5_;?_E
M++;K@P_XE.\9:R!T#S-4;C1RNKL7;HIB5_"GNB6H.#3Z1+)ZX/L^>;<*?[N+
MJT>K>Y:V$K(7^76D[[7S_>Y:NZ7NX60IEN_YX"0K-F2]*S: <S^^L[#J*0]7
MPC :2MYVQ^W\D+O=(6*N1AS+*I";QNM)4\IH'Y0Q!D"/(KG13 $I=)RXP!QE
M*9.I41M;0M4P+S_!>39I3%?"_*AT>CDZ/6&P:":@I($ C3P$U'H'M)<6:!&8
M-=B9X/7&%F,I@VGI=7H-^./#C):5XX^'OCCJ5<N^^(Y/ 76)1VK7SCMY?] K
M0MXJ*KG2^1A6@$J.A/#M4 3CXK/]DP!6Z\^\UY_#24X)F4$N( N8\!S0E ].
M>:\ )"QP1BR&DF]L$5SCHDS5.YYYLI45X)25<B]=N2?(I416:"6BP2B8B0:C
M(4!!3D&0%#%H/88N,B4*:QR6O]K6RI'+\C5X5:Y\@D0\3[?M,#Q)WIW8?'@.
MV7=6@*3>[ J-5JP9B]M72]8,2];E)!]5-E@L.0<RLA! $1= 2NM G$A.A,#*
M.;VQA1"J*3JOD)&RG&Y^ALET5H#(5@"P2 "8X*P88T90B&9H\!Y0@PS0PG@
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MTJU+R9@5\!V_U7DG\9;]SM[-5%1G?.YUQJ<Y)44F8Q(S)350$*9#/D@"PTT
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M7TAQME*\RG9\R&T^*'T'?ZJ=4<O\A?5I-2NJ\NIV7!H'546-!574B&"Y"8>
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MG_.\GP_\H>]]RZT?\I,#;[M?.L53"JI2,90%./MN#JEBH0VTP<4%#DI M3%
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M1=AC"AY6REQ!;C5+U2RMXBS=9V%<Y*']:F%<[,(X&2+HA3<6<@2(@R*=VF1
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M@>?+*>Q\YX&,5,70O_?EM\+ZM]#W@7OG[>"PGY[RC^Z-?,L[EL8[WL\'#[#
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M*+7S+?9<"WM>SY.'P$C.->%(^(S$%$43"]^"^9(KS@&6N&%X8RO+5B;$MO5
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M"O&<L%B@+""EF6:8NLQ; Z @29?*6]?$N*< K;7W'EV+$GGX\$(R=,5]V+I
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M\5EUE01 +I8M[55-(/S4Y$S8,%6N^K)Y>LED?W:#(VPN[=^E=D%3_VQL:Y0
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M6-LTZT28=2EOJ]98/#&K 0#<>46H$"2YR&FRFN6(R*B$9=PX9VJ@P!0 >!
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M7H+?8DKA6/P4M^(/DX0H'HDFF'L:- [:4A9(Y-0FBXLJ43/\N2%"1+@DN0#
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M)0R1OYK=DEW0-RBLC3#)>7E!T?+/I^M5A7]G<HZB.YGF'4V2C@JZ/@JZWD#
MP"@("B,$.5C .0$)(VVH0XRI2!CGG&@*JA]9%ZS$U*^J<"]*5_H5X2[R>Q_Y
MG4\@=#$))222!NPW#N"<(^D)BI@Y1T&H92)KFTP]Q&XK ?2KYM"[K'%[&48S
M&R^R\GG9M7-X51-2$/$^B'@#AX+S@'8Q$^PIB1$722#K4D0F>(^)Q53JF$_K
MZFPL%O:$&F@S14H7)Z5S>@O#RMED*4K"^,S;&Y 54B%+I271"\\XKKN4KH#:
M\@/5;JGR_FY17G[6[_M%DJOK1]:KGK;R*&-4VWWF.0@D?KC/%+_7PO:?&V@D
M#*714IQ-9F40;#\<%$3.D<0\,D9) ,4!]A^SKLD"_%X+E:%G=IP53"V86F/F
MLX*I3X6I\Q2PR>KH9$!*4X&X\;GPKN-($T6M4CQYY?))+3</.:FM/Z36U"[X
M<2)@_CW+8J=_6KGNKV7?3 2:Y\28*C$.OO"J.DOM?(V3?)A)G>TK5TU#OB\O
ML0[FX/3D]DMN2NMYCCPFPJ]G(EW]F9M;X8-P+H*9ZF&A)\X$UCIH3(A3U$F-
M<=C/C,>3BPXN GR/[9>(W##:(V03]/"5[7ZS9Z.U?U_/=^KTIRT2')H\.V"W
M#DM*CS8L8^$ M!P,JR7R"J0R#O.WH$VV-FUI' SS9O)?/Y\?M;99)2+FR( _
M\CY4!0'8S9OF_O;4SRF2H*R75,EWU[+QT).DX]V<#,HWQHDV\S\?/1-TFGU?
MER3/G;\GFVJU@;X[;YXW>>M\BU3/R:GRYZ]I\^UKT=K^E%/EC^#>A[-)GCFA
MLWD(5YY_8<WM?WHYK;YU?G3>;.]^VVT?X58[I\I_A'ZTTD[[P[?]9&TBR3&$
M0:M!W.5BV0XGI 6Q@L-N*:4=JT  NS%L9<5$*N:QDU@G17C0U!*E$U9<&RTU
M=7HV*?1-IV_[OF.[C7?]$;PU(7Z<A?>9+."K4#^>F)\_]WH[F6$F,!%!3X.N
M> 86E;&P/JC@"1OL?Y2N6J-LZ0N6B$:GWVA>9I'G@^O&W_.U )\@C?IO?Q##
M:3?NI*VOMM/-S7DS&/X-NNEE>SX"\L&L=SO5#-8JG?H9).W[OHXX.JPEDL18
MQ+$&>S[9A**TQB>J8'4N83KU5I4W?3UC<OPBKYWU*J-Z?(,8D 55%72+QC#V
M;*>?4ZSSPLP*]BF 0[>3XOJ46#]FS7%TLMX U7HT HOL>CW,&]Z?T,MFCH1D
M.\/&5]L]K?;-*\0+(8O,5?:%;P<=?P -'$[RP&&'AEM9N,UT72.PQ]#(9C(&
M=]8X.3NN[CFYQ]GX4OC^.&M\=&/.^!*EC(/ZMH''*MQ]<\89WP#(6'P:-MG@
MCY(SSA0OC2V-?;3&LCO=]HZIK<O@8[R9*NGRW%_=->%ZJ1)Q;]OZKHW#,LSR
M;'<7-,FKFVI=>!OFANKS5-.K>#2VQNI>]?KC5.6K?OOC4NT;+Z@_0?>K/@']
MJ7$6[7!TE[3V)TSZ7HKAW[K0G2>C/+J]'%49Q=M&\6UE650C>%E_>/Q[Q;Q>
MAG210SKFL2]C>N\Q?9.-W&H(_\F6[DU;T\SA2+T8.\H3E^V)3Y1R  UZ)@OF
MC]/A,/O3[H)&OQS_7.Y1[G%/R:K?<?U+_N9"0YAQG?'PS6 (O_8;;M /=U+1
M:LX*>3]Z^!L/S["C3AN. Q>1<R><,$S KSIQFIQ6/S@\&^>>WGI>EH_S+G_[
M"QX]"->BP: [_E4X'6;S>#D/T,;Q7[TW!WN?/Y'=SV^.]@X_8;@&VM7DS<]-
M"L^ANY\_'NVVOYSMM=]]FXW_@FNZ>^U_#N [O58;_FY_X;OG7[[OGN]"G_8.
M]MY^/-C9AGX<_GYCYE5*BN)D"$K.A4QIS)#!,2'GN K4!,-DSKS:P+>>3C]A
MF.H+B#)=HB#1>\2(,AT8"TQXGAA  S8\6"LHB[#R'+-\_]W=PNUGL>(Z0EPX
M>[*;YW<[ZM2G[LZ2P,-<>&@(D44; PH86\23BDASRI$1G)N@DM<A%XK JO8%
MWPH8%3!Z4C#R_K1W6K%F5+Z^2R]?=IG^'D&-B6W[O?;E*I<$N<A<LA#SV#!G
M4,1.(RZ)0\8QC@"Q?+*:VB3)\I2K+.A5T*L>Z)5/)PIZ+1B]V%RQ745"8C2A
M0%4"]-(*&2LT<BE8%@.FW.&"7@6]:M&W&J#7;4ZC D3W R(Q"T12*,>E#(AR
M*Q 7-B+G%$4$/O#:LF!YJIL!N-!*VK5V1S=/JSCQ=/JKWNBG/ I:.9JC^X*?
M@9U;XL 2-9*+G(#C@V*<)D4M%5H5+U@=0/"&)&G/@U*P/I$).5&%4X6<M00%
M[QWW,)4LR;5-9A94*[5PE+U<X2U>HZ>4]#FOD9/$)J<(Z#><(>ZH0=HEBY@T
MGC@EJ<QUYA=D=Q5Q?V)QOP^MR7/+^XR?I<CU?>1ZWI_"DV"".X23\(@;HY&5
MUJ+ DU%Y(BGQ:YNTSLR%19AKMW<7K\-BQ'7.Z^"58E&$@%S*42DY*5Q3KD!<
MG>3P2BCG,T-ZC7;@A<; F3H['28QP8WC;&<.^H\1"+30>]RA6,1=4R#J#XWC
MC.#[,&+BX).W/&K'$PE&F*235PQKKRPO/HDZ0.3.#26VO#5&AFB0%$HAKHQ
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M+MU&$:4KE'TD>:WN^*IS HWV/\YGIU4*JAT>Q3$WU>O_/>V<G#4N9>MB1G[
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MA[6BFCMLG>#8*\M],,&98"OM^]<Z $:B-U))1"1(VA019Q9XUVB#- V*)\%
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MO\;6X)?#J.9Y!JQ:L^U;_1!K_V<59=0+!J8\4X1(#C:\P]+9%$1&KR12F8G
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M0]#^@HP$ZRSUPFG$2<H0%#72#&PO28,@E.H86,HAU/GAI<_3UJJ<-&O'#:)
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M:NZ5F:' Y=F=F+M)EK[)^+\^_+T;+X#'X L#S;<L&X"=V8%N,'AFH!6TKM%
M25@@Y>?$>KE$J+GK[,WLV&Z!3^7HE.Q6++Q\O<O!_)34Z0_4G-$5+VN75T 3
M%Q=YY7*AR;DJA?_PJE-^:>JJ4G;?2G#G]DN<-+F!?K->.0;)8L+$@ VV\@]
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MCNQG:K=5L'0Z9?3LD-;?'W,<76""(ZI$1)QPCES@ KDL7W >"T#DPG#IN+'
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M^[9LT[=;?ES\4O>V'C+8$!V[T"U!$CL@2\]0^&".WGKPZUX"*\8&=H78Z88
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M_[E:LF]F:;IH=F&:N<K75:@C739!/YJXKX68B**CBE#.R+)NPQ5D'$M$SH&
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M7P<#!TY#$5J(/R$MQDZBZ.4-8S%LT;XV@'$V+0:=W7O2Q]ZX8+R!8WDXL\K
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M7.2F(R?H*E[:KF:WSK+KL]EEW1]5@F7:D0U%9E$&.-?'K>@!'\^Q0#?PJO7
M[+LQA%\"8,HFVN.J'W312JX.[BZ^73QJ6N,_*)^Q,DL?VXO#"V$?0Y2YTU=;
M>BN_8BYM,:T#EO+RL-O7\70.)]CP9CQ3Y7C_T;3E16UKV]6[CVJY)EWV;YCO
M3E*!&VJI_!7Y)C"Q4;O@LY'%<<YT]>H1W#!37D%WRVIO[+4X>TN,(GD] O)
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MJ\0Z7[15SZK$/5R^-%1P#C12*=FS0Y M*(?B;)Q8>J3GVM<XX(Z^FRJF%07
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M\G&=@#&2F8PPP3R%WPN?J6;/U[OG,H@$]I<2Z5/8\T3EQ#CX)W;137*=A9"
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M$1YL$"&GEIA<@]BD6A'-0DI2:V@FO='!B2<O1-*6G/T28C.:\/^)(_I>E!,
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MLXGR1OL<Q5*:J(T72[^ 7?JX$*G1[_YP.!B."=;!7F:83M_^MV_-O'9++AX
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MC:7Z;8J9F\+CIO#X80J/FX+>:Q?T-L6W#SY?"Q;T0&'/>3MJL-#TN/74?Z_
M=-]69("7H')-D=DC<;HWK/;U'WV.1OKH=_# W]'.)_"4?WPY[.R#SWST_JCS
MZ?4AK"GI[+P[V_WTD>U^^NOX,WN;+'K@G9V/]/,/=]0Y>45WV>?SSIM=^OG3
MZV[GQSOX[O;W+_N?OW\^>7_T^>C]ROI7PUUFO!5$VL02SJ@D1F:<N-PS*T*
M#Q5ZX%3F&P\#:NI?&]%T+_6OC6BZ ]&T%!ST(4E%G#R29YYP(Q7)DY02D3,5
M$JM%1E.L@:5BDTKS[PGY]W#F88'H1?//HJ$8>H.S5A@.3EKA>LV=&X31NNVF
M.L;ZGV$7#N=4]V8RJA%#UQ=#*^I*;7"44Y83!J<$8LAZ8A*>D%0*E7#A&<UP
MI-A/FT<-*'"#67;=]L05+/M+5SW<&RLO610!?!IKE2!<@Y_#I95$!>:(H<$:
MRCDW>GU5#VODYU\^Y#1KHK9^F^+W*-JZ2YNB*LHJY=->_^\R77K>2*2;2*05
M!9?&"2DS"3Y.%A+"?<J(IEX0EO-@ @@GYL23%^L"CFU0Z*5AW7NQ+2YCW<;(
M6 =++Q<@>":YTX$XGN/HU%R2/+&,R,3[3'+IP&/8Q-+*%9B?A=FN\=](N]W^
M)!;LKOI-#0Y3<@1'I,KI8-3%"YX/?0^N_.9+@$K)+K5O58GIV5>T&0UZD_'%
M7UF%LWD(!!++YJ%!]3\/I]G44_T57,BAU\=$!UCL<]T[T^>C)_^9QQ)U^]7-
M!8>G+[[[A6\8PIV]84%1('L&PWC:SX$2_1"O@C7IC5E+ZW"(DO5_=84Q/N6)
MS:T*/!6)4DXEE!K)3*:2Q!W()R_V8P)S$%HO42CWL<A#OUAUC N47@A'O+?W
M.I7.&"Z4SX5FFE)I-5/*6OKD@N]1$/1P31KR/ <_Q&GIX19IXI,\!"_YDTNG
M:M_*VEL$N(Y&WL^'M:>Z85>/)T/X.^[-/CSVS][ 'C].?=#S__/^_,LG=VH8
MS[[LPYH^??S>.7E]O/?F(^V\^9CN'AT>=CYUCK\<?4XZ/SK'GS]]//_\J1-V
MCX[/.F<'6:)2&W@@E&:*\,# 9TPR$V?T!*ZR0$/RI.5!:9ZB)!I._)/',(7F
M]02.V+= RG1/)E6+P-,R ($ 2."(>117\0/24[LUZZ?S7_?HI(BYSA*K4S+O
M4;UXMS_8.\7EC/8'K[X#6[OIJ/AK)FVRWXW:]U_QSO8!4P[-%$.<"8'@(&"B
MP)@A,M#4I2H8Z[(G+RC?NJCM*)!J#\E@6)Q#:SQH#8J3P!]]/(N2VK W)?SV
M4(];&D@1%.)HT >)<]ZR8*?H;A]IT'BD,O_=#VUWY%T[7GH*)BWJ^2FH=S8D
MJ8#7KD#M;H& /SG!ID_PH-:)Q@9/16RAZ!&%O:#&^CMP&#ZA/Q@O(H=K_+'U
MB!# 8#%L)875<%,(L,BWLB+SNFZL[BWO>BE6EVZE['9XY5]HL:F\W3>O6FRZ
M5A3T@R(IKH>,_.SU<-0"885"90>L-1RSV$KI\VL =6^ /KSMCJP6.<F6%!<(
MG7O>0E$/ZEY'6F[6TO^>#S<77L!='_AFP8-%K9=BQ/3_?7D(_M??C=@.X"=A
MTFL"+=\_3/K7>N)]-T*]+%YSIXDU]*/JB&TTEL>Q9N>DJ-GQ6+-SH:?W[-HB
ML,%>-MC+GQE<OZH$^Y((U<S=1T\.F'\OO.ZBZXYVV^\ RWS?_<S>G7_9Z9U\
M/GG+X9FT<_19[)[\U07/7GP^ZG3WWOP+GW6Z2_F--W\=?=GYZWCOTY?NYZ.O
M\'X?6>?H^!S6?H)UW[OL+?^"G[&_PFXW.5]JTJU2ZF7*2&J%(3S/)5&:&L*"
M"2+QSFDAG[S(VI)O_FB21FHU4FN]4JN>?+VNM&H$TDT$4K(HD/(T2*&X)8'E
MCG"6:)(+IHB7DJ:9,=(F% 12UDBC1AK])M(H)DCF9=#^X$__C^ZZQF*Z:P'%
MECJ$:<X5'!TQS(. 2I0FFKJ4J(3CP$DE\ER@Q01GOD$RZG=H80U<Q*_3>:%!
MSC^T774M;W!GXCOPY/TSW_OFBZ8DC61;FV0[7_8%3<94XKDD@7L%OF#BB$FR
MA!CA:6JDS'(!IA=E;=K4QS1<_I/>TTKN;ACX)@R\Y#OY-)=8P$;2W&/YOXTU
MMI)D0F?*ZBSU/%N'[]0P[Z_+O)<X&^A;[/5]HX37R,-+[H67RHA46G OJ"'<
M<D9RSST.L @NT5QISPHEK,0&\?$O/HRP\B_$K?R+W[9Z9M/]"Y1H^V>#1J*M
M2Z)U7BZ[%5QFADLJ")-8%9<K2Y32C*B0Y5Q8+;7GA43C/RW1-B^JVS#W?;L5
M*YGZERN)NS=^7O(R)#=*XDPM9U.P4(3V1'$:B)2>:24]=:G;Q)*XAJ$WC*&O
M<#4:Q;Q>1EYR-9*,>Z\4)SSU\(>B"<E3[9"E<VJHHD:*#53,OTDJ(VM2&9LL
MO&[E:B!6LY%I:Y-I'Y:=C509"G0;2)($1K@1BNB,YT0X;@)G@H<4PR=)F_W\
M$)(F#/KKL_>UG(UEMF[<C=MR])*[X;SP3%E%TH =.$SN22[2E-#,B$SYD+I<
M;V*;KX:E-XREKW(W&N6\9E9><CAL*H.5EA%%T>&@*B4J4$- 9\.YVB1QS&^@
M<OY-<ANRR6ULLOBZC</Q>C!IT*#K$VDKZF<X3TW.O2=<T$"XS!G)4\I)8J25
M-%49#?F3%ZK-DE]PXD+#W _A;BPS=>-MW):?ER%42:I#<)XH+X&?DUP1(&E!
M$JJSQ'OEN#%-<J/AZ)_U-AK-O&9.7G(V**6!61V(S;@C7#-!5.XE,<8D.=<F
M48G>/,W\.R0W]@_]T,=FF4V*XRY[$:])A%WB;E02#2R3;3S/1K*M7;*MJ-/0
MAMK@749D"I8)S]*<J#0-1$AODB!2&I0#CSYM,RXW*(S2\/<F\O=*CZ/BZTN8
MNO$Y;LO/RR7O26)=EJ;$LMQB#XY #,\H81E-I0A*939K,AP-0_^,S]&HY[MB
MYR7'(SCCL\2"IV&#)EQF@>1&8-:2\TSH/*2IVD#UO*8L1\&4R::[(-C]KQ4N
M:YO]T-F0ZXZEWWPQN.F9DD8<KDL<[JTH_]#*8< E(1EECF":EVBF/&&&*ZL2
MFR::/GDA65N*=;48NR[K/*)@:R,-[CJUTC#ZS1A]N2[$YJD)>4ZTS(#1,TM)
MKO.4\"3-<Y9SFS*<-I"RALL;+K]'UZ=1[VOD^B5O1SAE$^<E23W%N>X"N#YD
MECCA<Q^L3( 4HGI7/X_INB?&_QUR,&@;/V]5 P6;/,PFR[9K^3,?^ZX[LK"W
M8^]>?;=PZ?8)_JN1?FN3?BO*3;!^C@6=$<N5(3R5&3$A4()38&G"J<D,QGJ2
M=J9^NAM@$[G]]5E\I9-R,6LWW'L3[EWR6#A+39:F&<ERKH%[E26YL8+D.;;U
MS).0I!;QZ WG-IQ[ \=CF5\K.ZM1QFMDY^7.O,*;Q.3 R4SF\(<V1 O&B;;.
MNM0P*[@HE'&^2<KX=R@O*=R-?9S1.&YU3TZ'@V\> V\MC:,>XUBJH;>^^PT'
M(SYTYJ41>#^)"HO'_'9VRMO5(;^?GG$C"=?61'!_>[S;3;Y':7AT#,_Y>'Z0
MFM3EAGJB$G!)N%,*?DH,45XP^(^">^)!%+9S3C<(_-KP^B;R^FJ$V(UYO &,
MW9J].R\7V5MEB?/"$#A,2;B7FF@I/1%69D(;'7*?-E4J#8/?*FW2:._[9N]%
M[4VSS(:0)81:*D![(\ ["X8(9[UQJ<J-<)NGO=>4-BEX--]PA^:?8FA]ZYON
M33R.MB_ 8[V2B[K7FJU[X[#-5=\K,V/E1/D4-M,-)CB?/N;&?BJ[O'$G</WA
M4NO=G$9W+,2L+_ "&QVQ/AWQ:MG#8S0XHXPEEF)YHTT2DK,\D#SQ7G/IO%+B
MR0N>MVF:KBG8M1X&>N#(=R-"&Q&Z<2)TI8O=R,@;RL@E-SD#Z]9J8\".MCGA
ME*9$B8P2*U4B:"(]3['?%/MI1&(C(!L!V0C(^XE/-';E6F7FHEWIC1>8124A
MQ]"B-H$8.#>2.)51R1Q5OK KF5C7_*&'%9LQ;/&?,8:UX&_7_?:B>JW.Y 08
MQ+[X;_AE]1(G>OBUVX^KF88H< !O?_P\S:(<O6>.9$G54:-UJ+_YEO&^W^H/
M6H,Q_*X%? )WU+V6/=3]K_# H>_!KUQK#%=,ABW_O3M"UZT,7^BO0Q]C?J-6
M& Y.6N/# ?P6T0P]^,&UNOU69S#VQ3&K=JLZZ3MZYWC'Y]TQ')N]QBY$.=':
M'@[Q5>=J^![B3-H8%8)#B#LVP@U_.>A'VHT'4)A\>#0?QO"+8M/A&W@JV_W^
M!#YX[T\'PW$+).QKD'C%IM.$_-]6Z/;@#F?=\6%\P(=7+_&B73VTA^55[>)O
M%*Y;4W:<TC:*Z"X\(O+LBM\@O4?I*8SQ*4]L;E7@J4B4<BJAU$AF,I4D[D"F
M3ZH;KV82JF"S2C8EJ-\CF\SQ#;D7QI$K#RG?*C9J^<__GI,!\UJ-NIP;I375
M2O+$9\;9-, O!&-)YG1^L!.U&DTHF:FW>8O_?<&'_^CA^'P?"'942-#13L%K
MDZ'?A\?]V1O8XX?69.>E)CN":_;_ZG9./IY]^?37(7Q?[,'?7X[<\9=]>/[)
MYQ^[)Z#=/KT[!ZW4\__S_OS+)W=J&,]@/0+O^67_S][GDU>PUF/Q^>3U28?!
M]?N[[,O1[OF7-Q\I:*ZPM_.1[VX?))9Y*G)+F->,\)"!'I+!$)FD7!@N@Q6A
M,#: ;KW;1GN ^20H8:2WF>()S<'TERQ7&G].J95/6A[,@U,XAO%P I9_>0@D
MGD)KQYOQDNB?XYT%1BG.Y>J'SB\R315W"6>*991KX"R9P9<UE3:5/G7RR46L
M=*=<<D-1.[]S(-BBBD6=C=*NI<>MU[H[;/V+T?'Y/;SPW39%E^Z5DK25TG8+
MV;<=A:P=G,!BSD%C>CM! :Y;_W4#0YB[C(94:6-SPS/IM# I2[C3*0_:B(L,
M83%G"->%1M0J_^CSZZ?CLM],D.SN?T[V]M^R#IC/NS\^\\Z[ Z:HRIU(B<P3
M;-GJ)4Z\28D#%T7Z@+7(]LF+--FZ"/(+]-;#DSX%ZZ@[&@V&YV!K <%'7=S1
M_7%QV4M]BJS4;OW]]\O6TZ7?/VNW@*YU #W>C<8 D#QX-D _8.DBI9W (Y!\
MAH->91.\BG37!0OOY2&P%I!YN_6F-S!@)[P\[/K0^F"[>)L RDKW76O7.S1Y
M6WOP%.N'[?C+TV$7;(Y3^/5H#)KE<-"#!VZU]@^[H^(]C-?#$9AY!5P5^7C?
M#T]:'^#90UCG'K!Y'WFE,E_ <GP/;]!Z^F'O]?MGK=/>9-2ZD"N ,(T?+C &
M;+]GF684Y"#/$J,RAI(30S-,93Y9J4MG'/*V\_I"%JGIU3_UJ#OZ<#KTVNWU
M_]5@$@/;X,JGW$'8[\8>1S;9V['I'KS#[OZ[=/?K@0-OSYA$$2T5+3N7Y$J2
MC"4JE3FSN03UI%9PQ_\NZ/L4R%>#\7J"-.6!;L>C,= =DLF,]'0L7HCTB )5
M6PO*V,5_3_JGNNMJ] =>C</\:A^TL_5(/L6#TKJ%VQH,6Y-3N ;E], "J0X]
M(DKQCG/Z&E@)^.[5-TS<PL\[/NA);]QZJD= 40$T0?1P\"[(#,^*EY@N)CZ@
M8I0S$ 3 +:VX7OA$M_[?!&C.#WOG+8/$!A^"<NOCJ\/'?TWZI=>4)G7;/#ZA
M4BTG^ARVR9_"7^.EW9N3-VWD3/S*&#1?&Q=]!KSL<2/@YU-82#N*)+A%Z]3W
M=6]\7CP*OUQP?7R:+11W?!Q(DHC#+;T66]/IB](N'EUY;-/MF2X"EM9%7^8T
M[GD8('P$WP'O6E@*(_S@'["O?&M'X]N<'79!X<*FX37CH8[O[.)V=.&=P'>*
M&P*O$O>S6&$?9$C\W?0;\!@W.(/-P?.$99W$(S7G=04>05'R#SB?@1XZO)?K
M#KT=#Z+<P]<:#%W<B*E_M?C-M_U1%W=POWSL/^#4V?/J+*<O>!I?$%[*_S_T
MYLJ7  \;?7)\\-/NLX(4HI>X_6%G^UTAKM$K? E>0+QYO ON^--N_7I;=R9M
M>;'INO*QTU.<7WJI6Z+T;Y4<L_),XML,X_+[@U;H#> 8RNN77C'@$2%GU&FF
M(%,,0GCXW,=#@475G-1Y'CZ#&X/H&(QG1U=00^S44Z@.O,'H$(0"'-5H-$$9
M7C!^;4GC0Z _I.TH""I^+CK];%W'%*5L<VS1NG0H\/%PV'T_1HZTWKNXI3<R
M0[FUF9".98SR3("'PG*OG #-:^%W[@IM.[-'*S_VGW(AKT%$U'4O.E.-6;K:
M+-T6>_L?OX-Y2CL_7IVAKYN#:^M331@<!>$ZCD3QEJ2."LXREU"?/'G!\JV+
M.A579FD9M -6#)5]UH[T@IKO7OV5BCY QWI0QZ[,<+X<C,:CCF](XSJD\1T\
M%A<2YRFG1*94$>Z5)TK&N3G24ZF#@&-X\B+9N@@(6%'&8-@% 5>80<&7=DNI
MDGJ^7[H!A=A&H8]Z,!:P1>E>.";;'UZV%!.$)@1AB:W7_^X5#_$]'Y^YU?H8
M+\2;PH>MZO?MJ4V%M^X"U8&& T/IQ.M1]"M*DP&%NB>HTEI@471/HFX+&$@H
M8':H!4<3,P*%"H*YAS*Q?HN5WXFVV1#]EV'4D-$VPXLU6!S#&&&-!A8(Z(%K
MN:CZ/J'FCQ>,)O&J\BD8I*V]2V4#:G<T&95!]=F3VS4#(@;?41?5%@9K&GSM
M@S*(1N=F1=*+Y $8[(,3\.W\=S"R1OY9%"4/'%*?FB .E^3FS:!1%4F/3G,!
M2X//VRW_W?K3<6$;K'J!"U-3]_5F\U02+98ZI8S 34$JC?)=+US9[8_&PPF^
M-AF=@@3%"( %ENB.6\/NZ'@4O:@:M8$AIJ-5,>A76Q6/&W\U](>PKQAE* [_
M(4][J[5]J<G81IOQ4&,DKN:[;.3Q/H3FK0<(:Y99UX]>]O1H!&3BW<OH*C?:
M^#K:^,?NUP-*;1XLDT3 ]A.>4D84]X;@+(D\L9)G*;^.H?:0;!6]W W3-V56
MFIS&=,*B&XGJ>B8.-UD!57)H=.C]>"[9?E5(I6['S-[URMQMS84M%\H%)EP'
MHRY>\#RN ,3Y'V==-SZL.E+7OE6"+I+95[2!]YF,+_Y*#5YA/49_'L@YK@TL
M+':G]N?AL%K-J?[JB1EZ?4SBR)'GNG>FST=/_C/O_X/S7]Y<<'CZXKM?^(8A
MW-D;%D$(D,*#PHYY'JUPO K6I#=F+:W#(>JM_W4-L,"3%_LQ9@-J^B6JO(C0
MT"]6'>/*5.N5J=.%5*MT*LM%ZDR>*:ZU4($&Q:S/#<N=2"Y.M2)JX9'D6D>/
M+[VZ/?D*_M*R1<?F,ZU@S<!JB\0 1IBC*,6\V=>O0_\5G<0;!K\"9U1RYAAS
MFJ=2:J:9$R[5CCOO\R1:5ICJN"P'>[%9]4^5X=CNN^TB.GZSOB^_L8'%=G<L
MW7UWD"GJ'+:/%#3!CDQ2$:UE0I20J:*9I[E)G[Q(J;@RX/$4#J,WB?'Y"])0
MM23&BMS3,Z2NHF9]B+2VH+!'K4/?B[F%F+N%XZ_G<Z/GOS/<:GT8#/KDPR$L
MZ.L61M=GR8Q(W07JJT;@\1>1#4:^?(X9#.=261@2CWG:N32M;DUS;ZVX7@3!
M35W&FZ5DM9-:V:"TRS$P+'+-N4XL"YPFS.4%O(E506*6R M3LE>@G7[S!.P"
M^>]M'QB5*ZNPCZIPEG";*I(S1DD:DH3Q5//,:2#_50E8I(J;'7.NG:$NR02G
ME'LO=##>98D-.O=<9EESS'=QS*SS[H!F(7>*<Q*P23;//4X(D9H(Y:GB^&FB
MGKS(5AUS&P71MZ[S13!K.4]<B;<S/9J3&J-";,1T>H2"%"H,'9H/_G1<SZW7
M,M2B?96<C \:#)>>4]W?=V-P*:;I0 -.A@AT&0S+Z"C<X=3;<80C]Z=9RRCX
MVBO3ZC>4HE-CP@XFO6+]5O?G1.F%&?=J)Y^.!U]]?(FXY,MT1KMZW949^5K.
M?I:='_J3+LALN*Y,U,<;5Q_CJHH<./J99;AN%K-OPU:=84C\J-Q$-(_<M^B#
MPB9B<K8,;&,":!Q1WN!?@D-8G+"9C,! &XTPUPY_3&*(O$C&SQY2[=@4*5 "
M.(88AJ_BWGCBN)'=Q7P[;LZ@RMI>(RL=$\6X7]7%TR->/.%'F<W%U':U#Z#B
M+S,PSC#_OM((A@TMK!L?([G3W'?P.@ZTB:+A*YSRJ,AB5,12IEE&D3!/B\Q,
MG2B?%H%@^#J2K^_7B2 F;HHD]&F93SP#7A[':H-Q"3DH>"D>5IF*]&B_# ?P
M+L\*AHP5&?@&=8I"&VIX';S0)7((!5N1IXKO7 6.(H8 7PZ65]NJ&U)E:6)5
MT(I+O8Y__/ #WG@MW@=;3JB:\=MIQ+_F#<Y@'!'%0:<:-_F]%:X A9MZX\".
M,014+?9+4@G1)LV)=RYEU&3"HL(56]GR0*YH5T="V6I]1"7V$RS0KC/4H1[-
M&*(]CYIJ+S+(I9PQ+WZ1-Z+<O(17(BP'G2180YDSFL.^+;W+LX9A?EV&Z>R_
M$YT?'^G>SL=T=_]=\C/L,L.!ECS362I%*U5@-&E<C#G?1"&>#%Q!K0MFPH5!
MI<MLQ$=G0ER>$8WO=S%0MHJOZ>'P' 7)M'=1S#=/-]Y=EJBX,>(L>*]#2C4U
M4O#,).#B4)/2D#G/C51J#>G,(HFYW7>=0=\V&<UK:D;XN;-]8 13+N6,6.>Q
MS,IH8C#JEN=<Z2QC.O'FR0O&@=FO"+@A[=V$,%+C!<VX!+HTG%JAM>5 (#S-
M,2#!="'>*6L(X[X)X]49F$RYP$QW&DCF'>@ F1NB,QZ($LHGB?!<4\0D<KIU
M47NADC#:E9,/_DCOO!WC!8A&&;I-1#Y=GHD>K82^3R&65=OW]H/F]V^2HMYJ
M[11.?W23#H<>%6Q_? B.8W0[+]4TRRF;$^UJ!1/5)-6;J@R9)&D&(B#Q(N4)
M,UH)YJS)TMPZG:;IC4'*51H&IX$UX-/KR0"^^_5 Y"9Q<  D@P,A/&.@%ZP)
M8!%FW.F<>9%H!)^N6S5HSBGC5C'!$IZF7DFFG=$^S;%OM4\7(],- =P! ;#=
MLP-/&29_%$DR[@E7BA(5-.RZ<SS/=9)(YZY! (LJ8*$)Q8VL!LMD,*D#A90"
MD22*296!09D#<5IF:%-'>P>%@J^ +K;/=W^\%7L[K\3N]D'(A<U%*DD2ZV@=
MN(J:<@X6@F YS9E-;7CR@M^XCO9Z_MCF@C/0SGSD^(RK,+=U=5^ ;Q>A;/58
MU;0NNE66/L=R@ILPO ].2^M48D$&:>5SH8#W=<XEN \ZF(;A[U01=(X^1C>1
M8U]1ABE*94$1<$ER[A41::YMXEBJ,X^%\U=S?+>_B,&8!21J,.[[))'&D[PK
MVOF,)4PZ"3FXCH)8(3CAJ<F)3IDE+E=&I:EU0>>(YF1;%_5AG)H1I9\U@7/#
MNAVL9JA\KH<BFOGP\L?9RG;*A35T<@TZ^;'W[B -(DT9C>T&)$$@*5':4(+M
M I7+C6+!(IULJ<O)I%;(5K2ST/V93SHL<8/8UJ+X%G:NN$WCBL RSVGP 8Q0
M+G'0)UA PG&=@E^22KG@I"P&LIK&%>LA'7O6.3O(1+ A<P@6Q,I$[3.B,LV)
MRE-O@<.-2<4%C2MFN+EV'1.S GCRMHBK^*I]A,:F$;&!1!EQZ0UT?[&9A!F4
M-8!E 6:I\U9E]1<C[<_:K1F&L3N7<FNY@8^-*%HS\$I\>JQ]+T V*TRU13A0
M;!BXG(.<PP?<)!%Y_13]K)%&S"N&"9:#3M.7<$!$CT9^-(K'<=.LXU*#@FDZ
M:M:*X38)22<58Y(:./7 69;FN?4YYR"S,F-4SDJ.5VD9EK@H,QGY?2_N[_Z@
M3$B6@&&P,#[&3:LB%ON#N)+17G@9W_,#OF;,5\X6^9NF+1=4",*'N<B\50HS
ME2('.: ",2'-2:)L9FCBJ4WR"Q*7BZU8UA'(=(I[GN19$)9S)AB((V5XFDH;
MI%7^YMT6FCC6S?I^P9J_<C MJ)$VHV!X6F9!/PBM<#(H_&2R!,Y$LM0%; 9Y
MT5C0VP8R99 TDYR[U&!#JU3IX"S+="8RDZ9FT49H". .". 8.VQDTN0)->"P
M:JPK<-01HWU"J-3:".#-)%=/7O K"< M9$O*3V/*I.R%<-V\23TD^HOA$.X_
M2I0EW'+)!:,V<.>R/ TYSXQ5-H1$<-=$B>Z:RQ+,%YDLRS1SQ%EN"#A'8(:K
M8 D#DXDF<!C"2YRW(!XB2O2S)-)$B>Z,=C#5E'N?J92#8E:@I[E(4J ='T=:
M\N!RFJ?& .W0_.IDTQJC1.LBFB9*M XZP9RT,SP$"EZ^XU@[XQPE)A.2I& ^
MY5YYH5S$)EZAR>\I2$0SI8%Z>!!)QKG,<X,CZD,B<VI9+GC3W?1>DI:PCG<'
M!K10L#0G&64Y8A@28A1L/,U"XB6-0..?#A+=<S_/.7^U3L(5!OV&\LY*EO&,
M2^93PY4&$O6P:RFB %W(LM!XK/<@YKZ#PT(3$1*=*R*I2T#,Z4 T9DY4PG/-
MF'<REU@)>E5'P*G#<@MGI?%*?M(K43Z3-!?4.P,VA/":<<NT3=*<>4U% U:Y
M8U;:W_Z!04$EA3'<$Z]](#PP\$J8YR3!HN=<F"08"A;#@Z2N?Y9"&J?DSDBG
M:$<!SH=5BIC4:\+!NR5:&T82:SCS-DMT2' 8UE4IR;7Z).NBF<8G60>9I*"L
M1:X2DZ2>& 'N"*<Z)3JWAA@\&9YG,F0<89)7X!ON*W&=.O"4I#(VH5P9J9-
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M!:E%.@5'D@);.,L^P2W227)$+ ]P8!YS!::Q8GJ-HUO7PSR/&0$MP%F <P.
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M\D/B@!S-<5T#QZ<<#\)I$,E-HM?5ZZ?P\4_)QR6Z\&A,/1]=\"I:(XQ!PJN
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M*J>F200K2%"0X+Z0H/AK'A0'YOPURB@+YV>04CB/!"<$.4\4BHQY8V+B3D?
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MI[7W/.-.K17]>,MW]Y[C?6<CCH0DY(T'\&$F(<NY1<8(':(4G(2XM6,XVZ!
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MH2EA7,NF2@HW!L,3N.3IY!FW&Q]C/=T0GOT UI E=-Z@BTTXA77D,8EYMB%
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MV92,<<#DO-$=/>.5 :A*#3L!^_E[)_M(P$2^$NT'_TVG<W/E-!&1^V0- 3/
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M_KS];E]8. ,F#/)5@U'%$]+*.62EDS88IHRA6SN4-ZE8MK\]*(ZO1AKG^W@
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M%8U!Y2A(UK2#BH)%NKX;N?0ST-F4A:F6.161Y)SE3'$>19'(A6IY^!Y6_L&
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M7MW75MRP$W]CQ?"/45D>.GZ,P^$;-L$<NM8M<(WM^>Z\^^[$YW$NTQ!V9A0
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M 3,0*I.(Y%)J$OEAG$JAN3")\\%6>YJ*-EEBIY(EUI-_7I.[);XQ=TNTG+]
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MFD$\0!A'+O BV+@"7VR I74X!HYA&54:1QN68SB_A,VD+!LX%;6KO3CHGR6
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M/4;]+GS=H>URZ13PC!GHE'M3W;OV6*8RMC8N74N&J^Y=9<Y@"7T3N5MG7-G
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M_%%_AB0HUNKIN,7"\;'!J")#P 9Q>F*YK.UO +4A 8)%S].+<94K<H[HSV)
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M_/W*S'L.*%?@]GFO>_CKZQ=V1@&A EJ#4: <E\5TYCU_??C!?3B:IQT<,T-
MZDZ5VK0'V-IE%P[P^V%H,_( B6"JIW0<<4W66V8Z=+EX+6Z?C37MM?9?N\-@
MTJ\C,/"UQ?DQSVX_@^>\WF-NI=29N?]]UK]L\MFTGN8S.-8M(XNR@6E<!CTO
MT#'&%K*V.-/"^Q,F34P*DX-JDX\^PDB]MTIY^[!,S_\\^/AV_X7K[%8GI3[E
M1I@+8M2I)R7:\XX:,IHW/NG4DR,!GWPU0216)TC.P6\?%?C$57TMDNK!)!J:
M#FGFBEL$]^C)]C^3?S=((EL*'(37R8S?EDJ!'Z:. :?_0]T&S'OS==G!_B0
M G/\SD$C3M&X NW7-QES9[;PP&QQF^%O":@J_6<I%J98F-B&O.8AKW!SR.L&
M^2A!_*P-E&VQ(KUEH&Q['& FM;J94?U;]\^E]!-DQA8F)#5U5.@6\\ZFZ*HE
M2I[:&/[2S[!J83(M2N7XTIB\(-,1L5>8,W0O$'29E$.#,"V2P@H2&-/[_V6#
M\<N#93Z'CKMR[4.IFS8ZKW/3ZS)5;'#-7+VG2_$R+41)D'M_.DZ+ZQ*.;(E
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MZ70PX!FX,A:GH0Z=MY_;V%-X?IZZ5!)S]F$)?_-<J A/\?4"XW E4O,%-'>
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M:W.7NP#,<U"#5SH+7N&OW<D]T<F):V-N;9!8,4"OF'7M)LO6I2NX "_B0R,
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MQ%KTYRWMO\3&*JDS'?*LHF,5W9:QF35UAAMBP8KB;G*X*ERR@$YPKG:%10]
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ML?/+T!=!N)WU3A>$&WZ=E94QC&L8F<-34!$:LP !.5.ES.*%(8WHFRSY1*K
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M.$;U(SL@T\8J^0^;1KU1[\0.M J<M<Y)%8U8)N'_Q3_S12)WH_'?EB(,V(?
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MFED_X.%I<90D:K;J 9I8U-#% D<-^V.6?]/FA.Y6MRNJ#]%1X=F!X@\GL2F
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M/J>]L&7==%<N-(T.$\&3VG]U8>GVPJ/;SQ::^[4NI8 !!^@1)V+^D87(=S&
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MT.Z1)S8\R;!VM5EWI^[O"/':5RV(][4O%C780[CV *]4 .1S2 <^4'.L)&7
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MQBY!G"]WU[EKD9L]23)ZS=8$@YN?OEU9#H*=F!YB%DMFCS\^_G1UYEOO9,[
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MBL)I[H4QAC>A:0!B3]"$X<3BJK<O\# $G$_047D$@>]ECT!/U@Q:VE5;%XJ
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M.O6"<#'6X8GC+><J%HGTK[9+'BTJ*OIKD?DN7/U1/"C5DIBXRB1:L8'.YX@
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M;LA4+&Y"DV4$<STC]8NJ$_TZQ4(XB(*3MQ,. );6P$. _R"%AP< 7P3P/7\
M\-V!L?Q> 7Q:NU=>+2E;]ZP.QS!XP76,Z-1O4N=CY'C:=E5^'"MJ-=R: ?4S
M$* :OJW= E^D,Q<9>SEG7 DO+ECR')M@JG7?_;%C+;Y=.>0] =4VD>,NJFZ"
MPY;-\Z1:,2;F31 5JY'6#<TGM+F0D^;ZQI&RAF#R=NUQOI7;7M=W9/>_AHA9
M4SH-,WJO9T^>?AUVS=_W%=\F]+YG]4!]IT2>25)%Q>KE__ZLS'O"]UIRSKC0
M+@YIP6X%*T10)>H UH?QCOF@/'M_>/[DB],GL@?";2G?RR0-Y\(8$"D"&',5
MOH+_PI6=YK:Q@?R$^QBRAHY#CU"?X(L.)XZ6FT]_^/"KL"6()YJ_Y?G3C/_C
MV9-GS[*(L_WG7H+8X4BR[>0 7?2VJXMKZM!I2L7BAD?PB,H/FS#!M&7_\%2_
M9RW?PU,=YGYYS%])3@EMVT1$<9"6[3"&_@)4A61\C#_)]\RC*VG2%E&VV_O7
M8O?+2-V,F5ILUX1O+,,K-R7M\5@' ?/]F_P0=X G".+&E#&'$VTY^0*RE(L!
M>K8Z:]X'%R]?/<)"/YZ]7KY[^>=8M34>;L]@KA\[V3?"IDF9W!_>O/[N)?_N
MY>NW<LX[NP'>Y?2O=T\CV4FP"_^UKX^\J6.B)#X2SBF5# *D=]ZV2NC'@ +*
M.^FE]=.KOWY_MN+\XPHTL>$-XKP^C]OU^>GJ1S?E+]QOHBJA!+?DCT? O9&<
MAG\-+,>Y'XM5A'%F\.=-]2[,N2H2%>$6JNB^6_V4=P-_[^ML]7HH=S((Y9GZ
MQ('-(A9Q?FN_L2XL*>?VJU=5O]GSGJ2U. /C3-7?,.Y_U@W]J''_YD[ROVIT
MMW>;GW[UG&/AI\^^?;M?,T!^ $]^ZC_?C7UT*K1IGR]L_[?_$+788'-J7(S$
MOZ"GGC7/5:B1K8YKD8_.:;"OJ:BC6"BFTA-,^HVW/*XZ?'3QKKC.E:EV\/Q?
M-]TJ*^8\$04+LJ1M5\3R#[&NHBA^NUOV#OF6<Y=L]&@6[]@<SL?1!7G5G?(_
MW[9M<_+VHFH%MT8M*4I^QC4)\CG'+MK3YR].OYFX:'%H<&QE 94XMJ6EZ$@-
ME$IQ!^?H:K4T.D[25QJF_& V.'&D*.R#CK+<@?PW58=OME:;$3>'.M0J]T6^
M'KO1B7.]OZ0/_^'I5U^</DO?,7*:C5Y5&*3PMI%'R/4UX5.7>568HU@U_5#F
M+#'L:968::<B>FFF/ %GA M'^5WZLGSOHTH3)MRJML^$!LT%<//A+#4NJ3 T
MQKBMV^M[U\@3UI[:(CA1KUW:8@HB-!KSL\F+DJJK7(?M+OF3M.V;$1U1A'A!
MKDEHXCU# T<73K)^G)G>HH?L.LF!'-.;'_^]T#7,??6R?EV,^LL/U&<CQ"%N
MXR"WZGL&F<2 H0[#2,1/2 5\[_O]ZS7AUIZR@:A%V6GCCC#K0:&+YIOI(03/
M^T=T8'"9"KU9&BTL<4<D/TQZ] P2+$6I8/LN!S:?FCI):&NE!]]:?#!<9KEQ
MI%Z_3A?O#O6[D+,A-3<)033P'S5\S=SP;&,)3-6&X?;2N4()PUUK\HY4&CP'
M^>&X-X97>I60"L](6UU?&-.A)+^X?XP) NF$1"HRNX)\@YC?76T7&\;F&#MY
M;PQ,I;&PRSBSZ!7*I 'NWMGL[UR&-LX\DU=6OGO.MP.B'TP$N2;WH_;.,1G,
M=G;Z) ('P>8LSPN"].0)KD]S'[.J0D\1OG#\"LGF24@C+9$Q,RHVLS,C.EV]
M"0XT76(QJ[T /XF2A22$0G<:5>:8$T0H<'=()Z,F%SSN"^IJ1;*>#E:G5N^J
MZLB"<5HCIDPRETE/&86XC[O=F,( *];1HHN"[BQ+#)"O>''J<+PH=ZT2*<56
M?/+O"3O3QELQZA$:!C?6#1/]!5&P(?A7/A@5G)Q];\^='F2Z!O?N6+VRFTTX
MRMC:2-/HC-5!RDF-3DK.JDPJA3 IB& +7S=L#8D#\IQ!\> HMD;\I1Y8W\"L
M(F>I\>=V&"]T,;KHQK9<:+B8R3G5AUYB40!D@'DCD(I7,(C_<W0I@S'_H>X<
MZ\Y?/-2=[\!8?M.Z\UURY']<9FL5EL0F5B 36CMP@%_%3 #@^':=*+-K/<AM
M-N?("WF("J4R'1I]>*9VEDG-59X6X6-.B;YSMM97M)ORG"7+/27(?7/N?W:\
M$5&-4JWN54E\)""8@XW?-ZX+JJ?ZN[9!I9*T?DDSO1F4*Y,BZP@DVESD!-<.
M3P*8\#1L_QAN>Y_BP%M J![[F_2CQ;_)^[[=,-\M A)X6-M.$M33D7F6M>27
MIZN_'MFSR<0,[8<0JV#78K<72O ]VSI.,VW4H6VZ2YWB&5@NPS1U^TN_PW$6
M9GAN0A16SGNQ(@]5YQNFQTQ8/Q3Y/B)KXFD+/PC/ -B/T04B?A9'$W9SQ07I
MN3IU+$]'ILB%MT7\U!R4+-*Z..<A&NS^YP9H*(\HQQE?T0QI'6L43#,&\]H:
MDEI<6GK&PFFTJ=&/BGHE'E G5FCD%F&_3W4G*882U,Z^YX"UWZ^]7G#X#3MP
M--W'3*UHB*9'D.DFF<^^5-P _HT3'WETW7L+@WHJ3!E.SR5C0TF;($[,Z$C.
MAEK-+,]5))L2VQN\3>+7F7J;&F6.'[Q'RQZD*X/U#6''((S@]6%W>=%N#H-*
M!1Y8>:X[+^?@."XD\FB?&/10LNX 8B J[*#P6BP"8Y._<,)S;3/^="(^K8EH
M3=./U19UC'H +5/E(!O:/*-E_7VSS:_:;LQVKXD.$Q85=%&<!FSAV 3)G/0X
MK2Q=RH<Z[DLC41)+S:DU3I\9V)SR![D8&TR>OX EEKS.NX832#$KO&X_T'3;
M;YBETUF/S&BV6$RB3[^'D .$TY(>T=NUA$_:DC*VYZ;?V!OS+.'7P9YN^41/
ML@F1^JJN*5[*O*V,3TI2X*N?2:#F3ZP$HJ7P-Q6R,?3/M]"G/3^L'OW\IS=O
M'Z-!N6TH62)I%LPCD28Y_6N_1IF*#D- 7KVJO5#5^/?65Q!6&T;>>5X;_L(Z
M)FXFC.)S"L5CB8B>W ^FEK)K6LR:+ZK$9A)TXF[:L'G^H>+SA"4PO7B<4*B:
M2"]06/WM%A4[9]/Y2D3C^!&.'M7R;NCP0*-%,]J1FY7GIYZQ+)B^,"H=")E1
M@K%QV?<@'&!7+FL9EFL=9N,J27\CXZ,O%5_!%Q[HT"'A%)P(DF&F3Q9[%MK0
M+U7^P'#.+ZKM$/\9C@@M LU29(;&=N<2)8!TN*0K]7*(Y8;W7E>ZNR3,($0%
M"C_3+5.K1S&D\"87H\1$=%#8<W*@&7 'DFWJ3>NXLV(T2Q\G0DY+=Y#_NK^5
M[24A;/ZQQ#??'&)B!+5!T9L9Z4'-"%/,"$_H%:B",O>NF/,NT5._@3Q,Q+]3
M?KA8!_+Y^:K19\ 81-&7^B!@VUB65WK0)#I4]@;<"2U3G).(+751["]UG"->
M!VH_$J8(I:"3++&OR2M-HVM$]DV$;CJZWKT?KE#_DA.2,-ICY+N9M#3Q9M;'
MNIUQT\S$!?'3*>DZXTLDF9O-%K5(N>"R+'Q)DCI'&JU=NVZQA +AJL(GP(T1
M[O4])N"^!<H?L9V;J[:^*FU3ZRXL(:5&W6^8%:TRK"MPKV_";Z_**,.^*>O:
M/-'E G+>E?'P4)R.BP[629IX',VY48ZCM)PH;WEL1WB6W!7\$Z$T<2]_\Y@K
M/M=RS462>B:F[_((CZ K,MCANMR0=#G5%[07]S(<CZ*/>*/T2.K9IE(3_?\D
M=63RDY4(5=JA8C>9YU$TV$>K.3?AO?I<?>)XHG0XH+H+23J@.J0"IF!:=<YF
MTMTF2)&^$'CXJ[^K%J"^GY@IJC EYF-QR-RQ\"NL)^6WV X2TD9%K>/'E5(X
M_"3,\\[D.M)O@ V.?Z02!J25594UK>?$ ,?9ZB/D):4*CN$O/<D(>*BKC:L*
M[#YGS BK0N&Q3AD=&FGM3W@(.*\!3PTL(<5J6Q*,G2*H 0CFNE5JWE%^@5,1
M$N4C-O4TPA]Q!8[W*QT4XB#:5$194F3.^40I+*7FEIV=ELJC@MF12V*>8'ER
M'5AFE&\>B4.#/X6(Z*I2W SYQ>SXSI_7<JIMQ_79PF\:W2JQR5=SB8;?D1LP
MA(J4$N-E>*G\JXN"860OW9(4DA"(@Y.S*D&"<FY#JB\;<4HYZ3Y_RZ=*[IX=
MCH*"/:GX_:.,2E=F#69NZTE$^2#F[HI<7SX4N>[ 6'ZOS95F:_AT.RL_;WFB
MT\QXFF@PE,#.XUE&4<78 9O_CM/5G/@?=V=+_CE19O-7]91JG -6LV"6F2&C
MB7+\YL]O?E(PRI_;MEB]0]"_^@G\.YMRE;#Y1'_5+MGU82%+SR^R5$&<L@R8
M[[.0-T8Y 7FZ=")3"L!9#,_(+>9J5Q,^5 ^'^5C1%.* J\<; \Z3*R3*H9#2
MB)"[\R^9#MK-L9M'UY??"73;46.D SERZ>][4^+A_-"J:,/^0VA+?X8M*06.
M#?!%HTG#,X#MNL:'YNC67??M/+/BQT6OX;<W>R6FNVMO@3 5\J-9;$?(1/:"
MD"4E,_V/*0'#8W8:ZFNB74\17+R\#H]KN 2\S"HY1.G,?1I%J H\/XRB$ZK)
M2?R KP4L38+KZ:>D&X3CG4'6(54&FZ^-B(N3:;?P4FNT<9LO G3<:G!,Y58$
MC1T(=YH#X-6.6#>F%Q"ZQ8H#O%[ZMG#6)!_NZ7@U$J3=UO2E-$3(#N8T;K#H
M6SY;,6EO"F<''UF5#KJ;2./=-S 9V4J5NE0EUH,F>^@,2*?&S(=TI_>)L4[$
M8AB7'O8=B1$N ,5X[W$9>-09)(V2,N>Q'IJV/13E+GPORA3>5FA9E[=NU.VV
MRI%SY//!RY#'$TA%5\AY@'3 E[H&K^ZI AHL6V/U/%^XBWDS*60X77'_E=FX
M6!:FPUC#^T_=]LD'43X3*W"3ME83I);?58/JOFHWF3P0&,,!U>!>B+AV,2FC
MC]OE!?1OH<=1R#[BAH8.]^Z%-->'(>=5KP8C!'98ZTVEI[ET/<768A2^^Z0.
M+D6#E@PN*[M%'#4DI=&8Z/.-[D9/VGJZ>JLM2[QE$0&Y+^#ZBKQ4F"+>;IR?
MF!U899FC0MOP=#85F&)V\VU9/O3A/O3A?O(^W-.[UXA[%_IP[]MM'RY0I!GS
M+NVAY$NFC)0^LY@:)/-Q0QONSSYORMR33!25=&*'W@GNH9:^EQ!3:[#8J$K7
M.Q8:#9_.E/5/&/]HF&$BMEV^HUCK^^B,(/:8I 4E3+3>+(U^M.!_N5_75"X^
MW#OT_\^E))^!DUFN#Q)+0\_]@3)3S+<6_L-8:=CU,FEPKO6H=*%SC^:3Z2W1
M:U*QRB7A__V!EN\3T?(E&7O5"QX'CTE]8Q*3ALW"KH$FAB1-\$ Y_SD65"L7
M17X(DWA2Y%;46I&U/%*U/")?DZ=564$L+IJ)K6!D<T:*3-- L:_U82-\ZHTP
M67VG(V 0>XJ4^G+3E530>M^TUR<7[;6K;#%HK1PH=>$AF-PB6/41UE8QT4>P
M*W0G0MB@"(YXS?<%0>KH3]8E2KJB#,YXS=4UE2M9.=;WG\>^A]KP@P_;YE-M
M&T.D\3HV;8-\)$/H1Z?XYJN D?K4T8?<70Y:*B09*;Z7N%/0IU2US7?YN>3.
MM/5 ?:^8PYW@%V:JDLN)W >:WT^Y?5SM6Y,F4?SU9@!:*T7TBOX1.U4,@DC.
MA=:A1.O:Q$[I^K*O&N-=UGGSG@86@<3^B_WWWLIUOT.\/[% !,5A!<)$SH"(
M"T3QP95%@+RA=F^MG_CJ!;$DCC-41+$W]=C3WM]<DJY5)(_RM) +3C\W",\+
M$_LJHQNAK]H(8-%+9+& =^P'(2NS!-:UCJ%,D>0*E><1*4QJGJ1C)"Y[@_UQ
M[4RS_<FZGZUP1) ,+;_XA52]8<G,2@PMT??"/"T."O&T4&J$Z+DRC3'GN0,V
MY0IL=?4>'T\ E^6B'F*O2%KY:[KAX]T>%>\E'4_ (J&02K[!42< !QC>Z;Q5
M.H(EG9UV5=.*:>489&:6@:=],B CRS(\Z"A ?XFBYU!5 O8:E&CMO.IBGNQ/
M0O4_]']':,Q7#]"8.S"6WRLT9MRMLQ #PVS%0IWV?)H%\] Y)=2B8^\0S;CP
MIJ!,#R=Q16T'Q!;KZ$U\@I.!:<V9AE$EJF[U94M-6@3D ,41%;B;\Q9=:F3[
MI7#.. _7*J;@V@E:=@I^C0!I:A%N5/Z(JG%=P?-<M)L]V-4,R&NO<[015V7S
MM$;L!JCZF[*$!U?_2L#*(T3$;D]M $0E+"T:Y8DMD'N"[Q:.]T@"7X+1HE64
MIS$4QQ%TU;';+R[$=W\YXRGYX=49<\;)UXP!UD!?4*;=[3=NG-S3<VZ<OF1"
M5E&28\HAYF KU[R:8\>=D2P\<X"]YMBK"G!X^>9ENL(<Z%]>MMT0N9J)^OO5
MV=3[8+35#%Y@$=4R:?WP<(*IR$\FNY\A1X;: D^YX*L7SE5ZFHRLE.JK3;LZ
MW^?A  QE::9B<IX=QB 1#KS,R0"E:;-\:3/.=JX?[S-_J/(_5/D?JOQWJX[^
M4.7_K%7^U><L\_\RTZ\("R 6L!J0Q]D/S(8G:8I%JURY.Y0SKHZ?.TU\H%<[
M-SRU83(;P7E'_AV73YMI"&9C; F+^U;S_JE%RDO*(Z80R-H>AL<,X](N<2:0
M&.+'N'.N1'H%C?_G2MHC-";AX3FET^$KL%J(KXQ(Z[JNK>.60F^K:SR;2VIH
M"ETJ[72O;@85&*'ELDXY[44#>'A7;;IV75$G&?@:L^!1A_]HA>IX?O1P/:F0
MTUXI9\!R4X&\SC%=>]Z.1SNBBE*8/([Z?+Z+@%)*A:9TPAXCBC[TV55MH3*-
MO 1*#%H*=^JN+ YRO.2=F5O9'1K.:LXA6&(:;])'/VK,AA-(;^=//'I$-<9T
M)"3D'XZ$*3VKSVV)BS)9D1D>7&DR7/9N79.8 +,=M3&>$#F'KTO'I^HEL+&&
M^E8)6<P-8.^CVME9XG:[KDLZ%66%";G!^_9YY?@NL>OO7[<"KANR8M*VV>8#
M#?)=)C=RM R)(!F+*(X2ZFIB\)#X62$QX:SLZ>K5J#4R/5[)]]+B*\.E@J]Q
M6.BQNS+O01,Z4\N3%APZ<"?$1;??Q18-%C8:%0L/0E=>EY931T% ,@X TI<[
M(EUGQIMPJ,.XZ:-,J!$E@$94N*.J!LL[=<<>:+5J>IIF$IA+ UMY.@$@_*0>
M)%*74N*/22T4I^[Z(LSX=1FC S8NQ[@X[MV]>M;/&77ED+(DC2<P0TUDR@HW
MS4O,5ULR'"N3?<"&)*9KW,DQFAX7CC&D?!<)H]*CH#S'>51.%Z\':1@FS\F)
M* 9/ON:B%UT]VRUE.:A >4E$M\$(HGM8MK7_CG4^;(A"ZA_AL@MGA#\<^]-5
M>P$J9OT@]J+6IB]QU4(H!Q)H\28V>==)TP.1,&D ?G"BJ/)83J$A0T<W98ND
M4G5%N8*$.L:>[*@!ETLMX2C1=,5&A%IXF2/]K_,Q%PA_759CCEZY'_<,PH#+
MFEBC8,+U(Q?X,;[XS*R<^ )XN_"Y=5<5YZQ<.!DEOP^HOK7PYYA\)M^@W,AC
M0R75-1ZEKY@>*2,Z_I\)V9R_@F_1+)5YCJPREN/NF_%YUTH[%@[+-62$<?UG
MVK[F"HNJV>95)Y?9$>8F;*[C]>RFKJ;1#>MI!\Q_F(4:G^>D!#-J\!3<Q#Y)
M*6_IZF!C65U58C8[(MT&?U?X7T^]-:Z'DVY(U7-$D"4W;!<I-P70X;D[JN9O
MP2V1@'&&@G/,!FBX"\W?MQ,GK,]2.M ^H<U:.,7"LL<TJ.%<UF4A83*.^$Q>
MG,[+OC$_3Q\ YPJ@[G"XP,#'Q'224#3+H^PS]/3MOL]KL8-"Y L/H0-2B:!M
MW3!RW!RM1%]6_]A3P;]0;G6A[-L@C)>('(Y:7 =:(\J4,O*6'BQD(;+ZWX=9
M":> 55?/PK<\^O[EV>/,Z=C0'7#>I0#?C&F$0746;):$$O3.19=?SZ_HO;,7
MXWL.M'/EK[HS[MPED2F@9@I/81?%?Q-+5CA !1NX<:XHY3;4G-%1WKAL/J7$
M%T[77G,?H[#*/2 F##'Q]0-BX@Z,Y;=&3-P9ML2T+=J1RE8-4Y4:MG)?U<4)
MM,WGR"=<P@Y10.1:-G$0EN<[<"DZS48PUG,A0W7?&/O"E++\C#&O$HV"@A5J
MLL,.QR:!T:A^F-I/G2"G%#;6"._*63\W636X##J.,#."X!BO%9=.QW_9E^,U
MUE'14DFHO>_"Y=I'E!QH"$$&R/2#(,%5 A E+"2<0S_DG,924CLP+82;!5Z2
M,$WP;0U*"Q"W=LH:3X3&P$^"QF%C!#E*]A]"9\=_(8A9R5[Q;7A%!/?D$HY\
M9&$/=*/QT,YU:31@5^6XE"*)S9F2C DXI"69.3+6=J%2<[KZ'FYF3E,<7 5A
M\J,%KKH>^8-N8#H*4YK>2,4XYST(%4]0^P<?4[/Y7SQYD873(?+O]!3:2\$X
MO-HW[ZON?7 R9?\D&L_KDG0A5[]<5#61EM"_)?60#XG$8HCSF1:7T9D]Y3M0
MR) ?Y\++2.ZSJY!K>G*RG<?#8N"J!U1!^1')G3WE9<3W02(A$O#[YTK()UO9
M?RIN]"T1U<U]/^LVAA.]<;*-[I@3""19Q@2RQODMU17"[!%T:\.G<>"OK%ES
M:50A$4Q%:]PFG->H^(<T!&=3<$PH96(G99GPS_X,R)1RZP 59--#L%GG(ZY'
M)YG"PXKL@@RVMA=L-<]J-1H#F#?FA/XSIT2;EO6.2[ X7M/234#4MS3B\!FK
M9*IL;B'6N9#G,]:CMY1C-#DDO,Q]ST+LK?B:A"IXKECRD0AT4(A?ESAEH[("
M :4)W1R9J6;WU?TCI#$TFU@S22IR'0H4/55L:/,D\*@<Z3FY;I9]&US;4PKO
MV;2;I6D6PK:SYGVX!?)9J=?O7O[9[G!3V$OE ^5C!')X\N);ZICAZS^<MQ_>
MO/[N)7_BY>NW8H4Z$QAXE]._WCUE*R]"?IF323!H(YP.16D9JHP%HQ?D%9V]
M=+E_,JIY?1@0Y<YS;&FA,.DE$7333(58L]5T0UE)B:[ZUT9A%2[TQ)^-9#]Z
M6:8\/Y"S17]0KU_,&6VZ2?/9[Y\M7O.O "J8=LRPRH2T3TUD/)/"!=U<[:11
M)DWZDI<QSJ9Q7M\!'<!-NX6@#;!XR!>P5;B1SYOM^"UT3P2Q,E6Q6:[_CDW:
M,K_@Z\7QJ09)U!Z)W4OQO><A,;\BS>$K,C.9CIO$""4&6FB>F>'9GE0.%[]%
MDOG+ [QW6;O$-_)>U'P'('TBN46]M(E<!4L=ZMD8X-_LPZZDRF("F\E6%\%G
M&%B43++$=7ZM\9 C9GZ'B&GN=^(/STL1*SJ%]#=9OB9\97@ 2]Z$B M9/ #K
MJV#N>\X++N#P<R4 .[##>I'_(S@;]%*19!/8+LEK@SI9?I$JK[(R"05KR!A?
M['<49P7G@M+'>3B]37M>AF/OV=-W>Z+#3GYH'-C\+X,4R+F$#(<[C,J;SAO
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MA89QH^=' J2X:<GR@ D#7$K^%DT&6$/[20!F23L)!Z&W&H\G\4Y6Z[W9J47
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MKI[6'D41N4EX]#('$;>&W4RZ/AAA<EEVDE)FFO"/Z4F^4\# 'Y>Q,I 3\ER
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MD5=1[*4<^-C3;-LAS0PO-@CXIMF$+1(<0BFY8\ROQ-YB[G$7GD>BA2R@%WP
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M;2AJ]A F''I@3@M7CJ(GQ+AQ$F7#>7*T<Z5E:Y4%N"J[DC&(C"[DZ),09YJ
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M7O9S+C.E#(M*<2MI)!VVO;6V4Y0=JA4$KM%9I-7X[A.B .)8N<A+8A_ %/[
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M">.%&X1TN 7*3Z^=.2[9W'VQ6VRWFZ)HKG*.LU\M&HTT],MBA:Z%NM@Q"$*
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M&. C1S!K7A76E#P:A6\JF\6!T=M=R<O!_J?3)D%[6>.[./)?YO5'RL;&")J
M_-HS<I$SF8]1;RD,R53@M5X6_[K:E)7\O=,YX8A$#H@.+(SWRJUR8BL2/;W)
M)#>-(7>%,2M@,6PTF*!N1Z$/-#)<\W1=$#4 96Y!ZU]*8Q[7&]<TIG)^#F%U
MS'Q2T!>^MMF"XIOILYR2,I4GZR[L3W/F%2_*'U2F$_!F:^&;0X9VKY5%^SA&
M-MB[E(D(+U,UV"]YK/,CV2M/I,?7FBR([P-@#)ZI#RVC6JO)/S.W!F]A(NP#
MG$EV**??.N&#O&9)ZS8JW?GA,Z"MWHMLW4 QY5KL>1KY)K=2RGZ&V3S;[L,
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MELY$V%VJ@G\[?7\ZD9MV)>,!2,MIVOH.^5'3@UFT$J"U\ (U@Z9;Q&\P2,H
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M7 )NQ0T!G98JZ"E%.:!A@!MZ9(EJR4<RJHQ(HT=5?[6!?9MV4PV()0V9^-"
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M+Q8%<+0M>ER,Z).K*YS$@I@J%&)'"56XGF[F?-Z2-XE9?YI-%O0HW&3J9(D
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MH/7)CDYBD^#:ATO7VD24RYW-4O(FN&3J$]97HCP4<Q$>-D>GBV\Y'<,,-I"
MGR155-M[('%V+5J>ZR+$X?#HT,MQ>  =I8=V!(?@U??UL>!5K+EL/,R>.372
M8 '"@8/53'%25A"+_/?&J#@2NO^ 'HYX6_93YBA\.!RD[=36.&B^9ZSWL4 7
M"W1/C@6Z>S"6/VR+J)!#6K$M#?6M(T6#)2U<2&H4]RWG2QV,)D:LQ789WKMA
M:..N/*&0AU4=0@Q]+=K9](M@-XL]&DO73)QGOTZZ]UZ.\3$=2&<!KV5LC&8$
M*5U7CGJ4R+85;)[7P4L@ZRM>PX2.K=+F<L+4(M:<U6TYJ@W#D:<[%B>)/4=]
M%EPW& :'8Y3& _-N#W5Z#ELC_&;Q^V=JP7U:2;']G/CXCI]SYG(H84^]\W\:
M/_P2B>K./QG?1,D86J9@$.IF*QLA/(O *KJ'TS^2KX-;(F60^#4?*'%(N897
M!:5-R,$S:N@W="/"9GPO)^BLZT@I^:4=&Z3Y7KX]RP:/M6VZ;,LE"0N2VT 9
M#]'N9*S0D[_PI^GO7LI?TO]^_>+IXR?#1WYH<Z*T.2-<#7[S_HQ_\?;LP[O7
M;S[0;Q1 3YE Y=ZD;V9;82<%IU='=L-Q]I+3\(^4,=(DG,A]00F44OU3]J)E
MX?(VA*F J!)CM'0,APW(1'S<^:%Y)LX)%\%N-'O&6)]S,<_7#_%,R,*T:-7^
M%>Q E*X@1Y(^4U-AD5/]'JC _B>7;O]N"'C!Q3?4Q!I3LL&G$Y0^I7V8:)(\
M-/XO0.5;2E80LY3AKI<A%MN4.^DH7967I2IOPROL@^NUXN>75[0X74' "A@N
M<MQ>OGO3";$V1YKC*"%!:'!S;'U.[%?S$\3<.=1 -4.Y1.X\.6!\:OCKFYK1
M<W"WN$%GT(-X"?G8 ]TE8G@CQB[BZ[B 1QVPX9S5G8+I58)YW-6"*9*O.O"F
M!E_@=?)KQA^UQEC4I=$W;_KQNND&5.K6N=+(D3IIKFO.P.<;0BQS14Z( ^P2
M(IWR @4RQ1 (22O.2!2X"E87%V(\33$%=VC3@\ RGI,!-:EJ:@EN)SD3>J0<
MG% );3Y15%BBJU]."6:=<WW<)4RPA1 >G<,\6I51[<"\&K9<_I/WQG61N"T2
MV,0%F4+YQ')(-2%3@%0V&QK-8_.1+;NFEL:@"_"B,D'D)ZTBR_U&![0,"\,-
M]$L2G,??Y)]0<")%.D$9D)_/5+N&40(@ILW[M>O6Q@KU.S7$<"+BED^JP \M
M<?R+I)1 W@^B_)'["-[^?82%UFPAI@#4=*FZF9EV1&-J7Y)$5@K>7;0$1R'D
M.3WMNFFK]>GBK\UUH=TGK9W/6N@?<HO=TVW'%]*LL9&>%+_%2Y&5V#.6@@['
MQ/A/%S\W]<F(,&/PR1NN9REB)Q6K,+W=KBJ6S*N +R!-!'AF+HF6>OW!L=E5
MBIE)< IBH 9_:I9KJNA!):$4>D R$\Q PPKGT;)RS4IE_FKW!]S=M'80'C%0
M!#LBVR)U5W%XB@D#X$]>6H28+#;,@=BBZ1DTRQ?KP6W,@$=V?AN,CJ> MPFD
M.SQ'1^X?Z)-)X;P'0ZT%]KS.F>O2?--\I^B8E,."FRW=<P@'TBG@P;9:9&XS
M@G9CVD1;&UY++3&RLEFZT@[Y!O>#;A'/?A$.)_RQ,>^;CD$0E],5MS"C$"[7
M80X*K\N^#8][@,4ABKIF$&SP*C+OI<-Q2H-<@!O":NVXJCYYDPZH!IP3,\DZ
M,-@QKN)K? 2JB#.!JAD!01]:'!S%!>H^^+846]JDFC+.5>$GF>4L2\)@H$HB
MZ=Y-L49S$F8441=82#O%93&J,;C\*V%L"B:V%3*?<-040(1""/^]?MJN.^IT
M#"/5$ H@3/KJOQ9AS2ZHP4CNL;?$Y>5R'$2A1"5L^1'%BH_^^OKMV=E7O+2Q
M)R[)W23L'R_#'@_[IRYSU$4 F%+Q(Z<A!!OU] 4-R_W%2Y .!%/S5MZ)AA!L
M6XAT_[)X]#)<]U_)'VJ$J>6N6$;^C[SN0]S 8>^33!J^'C]]S!GQEPC$Q[KV
M&;-0@JG_6D_0Q#)XYANC%"[6@]B4@T)YF#ZGI0T%N^=>>26O/$J)X-/P62@$
MZ!F<K:U_94=-K8#T<010MAY '%^5<5HVG(UEM]P)=D02%FWRMU-11V\F,3X]
M-O8ZWX*]"<_30=&<L8M;=.(^4273"7T(9Q,, 40ZAFV6N7\*47DP8I@=\/Q:
M6XXZQA("W4C$W,.4DA^6QU53B%]@*X:7)4<-DSKL[N^X\V]31NZ)\-W ,VRC
M/E<A(8#:.($B2X<ZDXT3[M=]_0C-3V% ,'!#,&>>;!M\]^"@Z/EXQUL*)_7E
MVW=G7Q%.J(M8W##_[J^N&L()T3O]''Y+H.-X.@3,-3A/U$1/C0$&W1#X6G?H
MI#V3[1?&,T!.,L$*ZVW(2?2R%]PBSJX!/KJ7F:5-J(Z+:;'E0H*G %$C!--*
MU\B-B70PEML]7;S42-(EPCBIQ7WSRDJAR^$,@-QXX>S\Z3&_/?Y<B"LD,Q:I
MW:+AV-F13%MO*4Q60Z,G29LR>DJNT.E8HOPMW$RL8C:YV\B_PBIB&VO)F+QX
MO",R&AKGX^6'IEP7*;Q.A^S7Y4Z6#@9=)8*4J!"]#''Z*.<1/K(V'F;C>8D?
MBL@WVI/A[_]/TW[,PK]=Y>L\6_Q72;Y F?,\OZ2[/@2.V%V:'U!VJO8C!K8,
M-TQ=RQG,J1Y/<5ESG;=KOA0)T%:?"ULX'R\G;&?; .4164SZ;I&2D2GPD'W*
M[#6=-D[2'(QN^!/F&9_X0NAF84)9F(\3'VX2G6WF@8W=!W_]>QM(0S$?94I4
MC_^ '89A:(P]X3#+GW.DM-6BNXQ-5N/=B>0PK+&L(>55+# XI[MX4(%QA'_I
M0(Y59U=U?GJL.M^#L?Q1VT)CG 2_4^MPDP&H&5MB[NG6I97E*@X56?YAY($/
M+JGO>BJMA#?]6TUFY=%W?_MJL85OX^VW&$^IT"5?Z&WF^V"Z_AZ6,"=FSR11
M>:N06LA2U&^(X;*S6-X-",_IK?T2ME!S-4*X<\$1&[Y</-'O_D;X( [78ZTR
M_%2P?8M7].&W<:2Q=+IX],.KM^^^XB^D?U7OJZ0$Y;HX(;44:57H5F%6V;UA
MTC.ZH@C^U+:4CRG94>57[<P%&+-NR4**L]N)RZ 0)G%).!\IK!YV6^"MF;I+
MBJC^_A#_24!LX*AQ+@XH?M23XK16O2'D%5U5(B,S^K+,!Q^)8Y9)?TM4G(6'
M';:GOX%Y49B9(^ZIJ$.+"&$M.'R3^*,I#I_<B3=)7R2K[_/)$ETTK11;21@N
M!F:[*/\YC#_HE>**BWZ=+ALZM!9MCXXLWE]A8'6W$=\F60J)07F[)=%JX_CY
M+-0DYKR)7.#>H $T N;2CK$H?*BF]E*\:50<_0WZ*)=NJ'7UDD;Q__X_?WGV
MY^<A!&%G?$N\R4)@A=\__Q_\"WD+[H5 VI^V_T)8N\ZK9HF]?%74?6Q5<\/:
M<0E/BQ2T^7$HD4!HW6RGK:/PM*!Z6+/+Y1<8\VY--TNB"J:EHD_)BK"RJSL"
MRV)W30H;2@5*<-9^V956]XM3IX6*-$F0)*5+"^@6(89[0ETS5=5<PQ[LZ/B'
M\->H=V@#8,W_-P\/.7C\!.^-$)+^RB .%+QCJ])/J5_29:[MSQZQ+JFN-6]8
M.1/AFX:6S26'OEH\"A^ >;-4,2D[(NK4S0:C$&*2E+VX\\.>BW:3G,YPY]&F
M>O;BR=>G?YK==XL[WG(/K0XX24JJJ=64<931]0A@!FTX8T%4$PIB6SJ30V>F
M-Y<T;3BPCC>&!;#4S:H_#*<)-PC &WQ',/^^[M=MV<5K 6>*:\9:N.IKJY2O
MG;G.%M+S%+-Z'%;7%'U<:3N475\*^LXL=QB_8BK4<FWJ>Z3I'< <*)+&!WZ:
MD)/WMQ1INY9V?;)62J9Q4*K\,WMXO+DB\T>&4K-\N^;?T]HB!WXOXDF=*.(S
MM5R81>3B,Z7S"E=47Y>6K1_E-%^X>N"+Z+2T(.RPID))3$TDB"U;]2(U_\JU
MZA,_Z.T/4>V:4HM<Z4*"1%2"#8_(GZ#&2)7XL8_8TA-=_Q49"OO5KI'\9)H
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M0^)<@_O\IG5*LU<T[9PCY/*;:0S$Q*"E.X(ON:[BX65*8VW!M<$[CG_7FXU
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M'J,8N%4$1:UDXT'+ &:\/,@>/VM'FK<LXPRYS22B%AGW.."ID>M45]0>@LD
M\0* ;8/EIX&T<"R7 ^JB9BV(^0GF$JD("C$MS$S,TP0[1PU24#!RT"\"T%#T
M27CY$ J<Y"' \1 #Q- &O D--#.661,"%RPAW1/1YW!TD7L1.NKV3%\F/18S
MM[7NX5XI? D<U[Y8A DR@+[/V8(ZEYH&9ZFQ X :4S\Q13;%>+1(4)5!.0E]
MQ:Z$3#E_GA'S&>9[8.^YN[@M 5<F)V7A7AB)-'%:&%<)!";HE2E5-?6% >)C
MQ"H';PKBZ:C62HFQ::@=04TM7B_,/"/M(>7(PV&290B/X]RO\H(.T1A%S4^
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MWDT>R:PR9>9&>*37' T67K*D5:*H_Z'8;HKMSX9B^QUXEH=:;/^=XB:F&19
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MQ0'-=GEQY7-8_-S#:KE_JP4Z3CN;115RV9"9(N18:KE)AWG_!H='9T9(SP!
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M0\&@8U'S8B0\JN  I:[@#?GDJW&-^4=BFM?>?1Y5.VWSYNMT*2M[^"CB<SA
M7\-5[49O7 NV>]2[X:=1E5:D>$4<L.TECV<!])64*3+V1*,LFI%,F)RM;';
M$#"3;U94&)6ZAP..H!F/*] "I.N:%SND$)Q=O4@XA2#7Q0661J(W#]Q00?/6
MDX((HW@29#)+7A7Z6-I+-);H&%F:/$W/F.08A-((/Q^[DSCL^*&=9U*+#"^M
MNI^L_507B'M5H@L_EEU2N3QP:$5ED=E(@,M!)D1#-$ 6,>>V-J[L3H,9S18@
MJ:X?Q)7N'2<D44$5ANF&!>B0H$*Y&-23]3)T! 7.59')_8$=5N$$]?W3H-C&
M#$HKMP1D:D2%S6-U;Y8RX7ZZC@3)_4/EMA(!TJ<.F_^R6!/-!9V_O'C8MZ:
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M=TRKRW)X,.'UT]#&PV]A AT^1K[SAG,J\O;$ND^;$D9BF3 3(SX<#Z@$Y/
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MIC4D]X(MXXZ,U;!\6D-R=%?Z0>[(> Q+I#4D\)=A0,R /!Y&PXS&D 5\0%G
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M271]EY3]T4%_RO[)M(@W[C^+]3+[]_\?4$L#!!0    ( . UJU;)W(1A.AH
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MG4@D@R6%\\\],9WT8ROYNPMF[WA-XB(% 7G5%S\?<1+HWJ8MB6F%]GWN,0Z
M"\.^,;GA*PJ;-IR3,#Y+2:#_Y=MO [=I^SF)';C_'LUWX+QI\SD)XBN-YJT7
MU%/^NX6<S[TKPE?!#V#!:R>^__9X4[N<D9)3FIAQS#JMTY=C^=^)U4_7SGU+
M4EJ"].>C38(-5@&#SAA_D7]O:GI$'!6I(=Q0$6VZ?-^6DD5?QIU9V\78@9@3
M\S\8<9$C-A"7P!5KALD20I\UZGLE,R4H X[$A/<F3%")>%I9IE;$U0K9'@#+
M]/$#H+QY2^@C7N%.T<MS5D)YV@9*Z\><E/_9=VB3#F1D/N966]9QZT%9P54)
MZ9D>I"E[B\RM5, !S+3;KXC'6[CD9= SO"6L4TR+S)70OF\#;4Z.)00=($Y1
MF/C$?EH2UX&477/)-O*[!+F,O1+F\S8P9R7]MQ7).B!="T6GTW C64H=^-"9
M#AQFZQH;#-ARY)*7;@U[PE2)\L=6!IWSMZ2 /8+R&C*;HI7@1N:7 4,8-IJ.
MR^F5 'T2^T_$;)>P@$+Q(>4CL(@Y[1$2D\#S %US(X<6&'$3 [ _M*4'$^'%
M U=:&\$FT&@R5&%U<KR)5<186L:4M97RMF+F>P3?"&&^E4/ 38S*-?0!<IL@
M5LU#"=+))D@)KXPAC+CM(RHWF/E4NKM: 9(E5V(QJ,8BPV>?4 "(_@;< -Y!
M(+JD,0RE]$H<3@LX<#Z69&1E.>T1$E?$=<&,A#X)@)U;9(MUT7!!8=@7_+NA
M_4> F)38:/G6C+,2O;--]'(2+,[.BF18J1#Y=4;,7D'K><B/NYJO<\5,#''#
M14,=%R5D[XN0)=PD,CE^>X3-+;<V<$@IX&UO:OR*M$H<SC=QD#RL+),]ZOQ'
MZ(K='M^M^^MK.&OBARJ0*KO^PV;71RSZDH<EF.QIUZ=&NB4 &09*&#[6PY"R
MVB,PO@,Q_OU;!&;(17ZS>:&$6 E"89,?,;$R7/:H_[=SB;?Q> ^*6_<,E__Z
MSX^#DP__NX<^;=D+ET#Z&KT57T*"AHO="@9*/ J[=,FH+SE9659[!,8-YMT*
MI^"UD3W*4BF[O; A#ZDM2;Y'7:WG$=R9JU';Y3@H[-SU78[6C_%?^W0BHP?
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M/#?B4--^U_"G:=$:BM[&L]I\__+$U:YZJJXH;NIZ):-P^KF[C,K8M1%3ITX
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MY2F-[M:O+3M#=H:9(\4S[</'LS?!\^<CW@#&]XD>^/+#_P-02P,$%     @
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MW.K3;:M3-M@>Y-:<JBG*]'9>/JU^^'.H*_O>RLPN;LK/F>F?K,QW5!?+2S^
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MJ*E4RRX-5&KO>UH+ME \@HC.6&(//.C>'L)VE(TI+!\,3P,*ZRA^P">X?];
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M I3M3C,S^J+%#%*5K(LV(M1#U-?5.F.(Y8\L[IW9.Z2\GU:.&*^I*B2K-9A
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M 2F9 X9=04#C) 13A S.&^4&&*NZ$XUCT."CP-9!PCL:Q*ZR>4($G4,,P%%
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ML?CFX-1H"$Q$/@_6J3;D/B:O7,;NJ?2ANHX>V(I8. [ # K(WC$B<FD3&7V
M0J5$X5,TZ9 66?U[1P^KS+LBIU.WZ%U$-.P1>O"4&U-MEMX""E'9OC"=2*E=
M<F2G!&6!\B@7_V-NV#(HQ(87V\ )_YI-S!D5Z$W[ QT]A&(,*$*T-:#(W1]
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M;[#N*K7\0XEH(&860;K(:W@2'6^=$.B*[<DG!'M10@\Y@1LX5T,<I:2HO#2
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M3H*@:P>VU+X^1?DZ72J LT*(%'3@J7E?M(?#/6WN'4J/?93B=KJZPIV)V9H
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M7@8ZTT&74DL,M(7(; 3%7+9:V83L<?%Z=07?B=R+KGL(XK9=S>IKJ81/0MD
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MG:+=U5=#LO@,/G,'LCCFF?.$N\<V,W<!?=M6>3M=]=FK:_^6C:O+6UZWZ;#
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MO-) _O;RS?-G-8>9<%:O,^;/-:J;_X%A-/_X<CR;#^?G<US-:RZ3[[F8HGD
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M %9XR]L9'0#V9(!L!7<< Z2Q4KM19D^-]&"*; ?*=(E)QT"^F^"@,J.OF!/
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M:5(*\\;8@&!%3J"*0B!_1-)!IJ3/A9&@K,LR/SV:E&:G>4L5#T@$O+YPOXN
MORA0>D/9F]IB&QP.0H%"&V/AR.E@E#5UQZ0 @0Y%< 59%"6&T*W[WO$;RI84
M*,/:21_U#TR!\A"3*LF"Y)6<U?(""A4#5_GTH_>:2>4P=:1)6S?",5*>]$)B
M ^7)=FH<P$UXZ,M2RT_?ET5FS\*D)2M%RV1!**]!);)FSZJKY W+GOG,HVV\
MYM<*<_*N0ALU#Y H]4B<VD#V?7E4:G9K\UTD',A;>%FZP[@+C>!<-I)AL!C
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M;4:=%:O](@6"T^232\R:8T2I3>ON\X_'/V-SZ*7: :XV-Y5:!Y-XD!&!:2E
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M-]1''SX;\'916.N&-6_KM?+D_3C5_>#':_H[H[L-06MD,FL.UFEQTSXBI,#
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M%TI>72[&LY%#_[;O*7XLR[BWJJL?_7E[MV RDKSC3:@"-UPA"8B1GB96%RY
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M6OW4KGO>\@#WEC8%N(*KNS9Z2W66(!M#>0R*1FI]OEWJ;[BX@Y6>DY>?L8I
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MP2,W[_U#!MN()R:&%7+M84N.(V&>+$&_BMJA# :GT1S!G3O*BK^%5'O$)KQ
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M1C<$ G&$@'8!/M-</ SL%- G*H8\V,[.R(S)OT;("'DX\/7N"=F_]?4U" $
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M8];"%^NU!G5[BR.&"WZM$ X+..10F#CP?.J:VCQNN_9M;5C.8(A:,0^Q.$=
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M0S1$->_9M'+WX-CXFY#8\E9I*J6UHL7,VGJ:F&-: G?9D063(0O9I'[W["^
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MK7(/N*:#MT_5$M!+Y/:_^QW3.<9K,,K<9_W5L7G]3Q([K;@.U.415#7\UH5
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M*D*'!,,KJ."&3P(C1*WO<&RT72-C0I6S*GJS;F^R (>/N4YXG*^/F($JS,#
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MAU/;S5S?F:5X@W?O@DAL']$G@/R)9_7+9S3\B'3=[$H3HPS=\((D4)I$&0(
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MYI]<E^/S?W\Z&;=[WL >1^L3DXNX0;CRZ_-OHX+[!NR$6O'HBK<MOLZ1F,$
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M^5F()#/>JFW3TEJJAI5:-R[P)C6Z8[Q4;\#$];CO*M'P,R$C?C?>_!U;1$:
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MW,IJM=GCWE"R9EH(Y&:[X?B5-PVE</%4*G8@_FQ'I%G&](I:?-=\=64R& "
M'8SMX0>2L#E8GSV \[DXI)#QT](E0V]<"XV;J-LEN>%AW67!<S9117]\-MS3
M5A[4BR*MG:ZJ+9@-OONB!;''/,4OWHV[1N7VCZ8+T*BP"JBM;;PK+(.1(6@R
M $];>D8Z/81-%+WG6K0F\8_OZ*RSR.DBE?FF]H%/'Z\,WN0;^E5>L>#>W\%\
M>96RXMMXN9<F&?[E=G(L=[T8<Q Q9)GK5='JOL%RV9A'%7OG#'"[-$<8JQ ?
M !))W"=5^+SVR<*+"I;/E)NYQMGRI+Q88SN O?&->E]$N,N[]UX_QO>\_'QF
M,GOZ/5OT(FW1<;P2']"HZ<N'VX =M/V?^=+"+ >&L"7Q*&?(+%"[Z27R4$6A
M8><O!'6Y7O--#?5?ET1O7I?X7OPB'[_?5SEW'/7UA'8LTU7\9,WV,]UFYAPU
ML_"1Q3'O&%1]?-4%75;["-\H?'Z.*F0MT:2??^_$7(QBB();+6#WPVMSRYY/
M6B&!BT#OFK[,%"<ZCJS-!*I)5*GB9()]:U_:&#.GPO(9&U4C^FT HYL^>:OZ
M&P4'8V@F7Z":E.2MMSQ3&U1X?1(_^!)J/_E#M1JCK)!BE<,TS;$B%Q\]NJ/O
M#,Y:86?T+T? 5>4=L,&G%_*7;Z$,W1G%<V7.+VM1WTA=Q!MA!]###1V'/#J^
MV;2I*MBS4CUN^?C $3#H"IUJ9*88#MNN^*#YC9:W[JR$$;$^^E&S'15/TZ#T
MLWK(KR=<1\$$Q8=];Q-YK"*8:,-%)_1-?9\34N2%=X##'>P)]C?C:BGX -^J
M^,C[RL^?1>P!;1Z9%S!H F>P_"PK\]3#L>W]=3'Y6I9FQ7;_C??V@HBE)3XJ
M=[F%KNZZKHJ!,,T:Z6Z7+3TW/E4I+Y$9&\7"]L+@<F0<SVT@8&[X!2-T%5W?
M\?0"05TIZ%U#<]U@:FYI5,<%F.80O?4M9B;:6 5VGN"&@$G6HW4EJ]=&>GJU
M=CAI<75@DFB4[]IGQB&5O2[IAT,E9 KN@ZCKM^MKQ4D8%$_.7N9IO\XQR_KG
MB:FG(2\]A?17S"3SE$Z#?'GSZH9[5W<XG%/31T_&; 7B2'B(6^/QPV'/(>_T
M5K@]43(Y@:L.VKBR[^74/^Y?3-14(IOM!RDMF7!3K>?,<$[0*%7,%GRIIG%L
M>G5U#07540Z]LG9E99D%E?IN5E%6-'ZL*EK[KB*5S5[53>^.,S%VPI@EMWHI
M-$TQ.5@UQ;+IR9]0M[8B(PXR#8999K.AN86A_^P)"S$[D*DNP]QH4$Z4L9[S
M$!QOQI'3\6&??/BDNV,A:QC6F/[03X.OV@"(I I9'W?[WK)SYH@IL>BG!=-^
M#Z*DU?CKB3HE'"*[L^B24_!31>?>HJJC;F9SV ".:R5 /QYCAJ_9PN+;HP@Y
MI+LU-760\3XH?0E0VG4S%U?G;!T->-A;;P1]A:>L0.5L]Z.Z?HGL/F]6H==A
M-)YU287<8:('/2=HSHBX5N\&;3\U9EM-S+_$6<US>9:D/*Y!-638PA@;^+%:
M<2:?AV4S,HHR5B.S$OSCU^<*VI,<&F.F!F5&J)I!*M7UCS4^_M5KYY0*A>@O
M$P\*4MM37;(_:6[P,R2;.Y*CU_KZ=0F8I'"61J-"7SQH/=6&]6"*JD!@5.D8
M;.S,F,&=/8S E\JOD%V&*I%K$J;+VU^K),6UE?!(@UW&0XXQ+0BH0QBR[M>*
MU$'N\J!B_OP$OB5RT[A5?7S+(;96\&R"K,::-.#DNY5QR&]<;?/^7 XKOUF>
M24Z86K"#0&-T#Q\,)X$$#7&=8H;4!,@!6[C&T'.[[.':J<4K8-MNQ,5S$5 _
M@Y89A<Z ?>%GE"-QX*SN/861JXY[O7;0']8,5'.UQ[4=*RIB5JAB4!Q,K[!B
M+]B7Y,+GQ9YBNWRV0/0M;U&/&*3U_$[>;G \XF7CS0O)PI>N'S*[F^.T;ZT]
M.@22J*GK^ASM19V-CX%@D1@_;:+NNJ&@ESUJ$+?VSP%J2,2S&HYF%1%5L&>9
MI,P?A^ON:R!I$VBZIK&]WWUF#/LM,:)S.$;>6\IA!*V123NPL_=%ANKA:7S$
M>78PK-\7@:TD>V9E:O7D$%AW1J<I0&KB> M!ZY'U+ARKNWG;<NS%6.D^=M-^
M8%!N8-;9]%AG@SM9-M;UW* R<'L7X6T'[C!I;6/GF >UE+3!DK+<N>9IXG^2
M?9?(R^F)S*MV^@R[%6C*ZPJ[=4'-+JRNLB;LTSB,1\M@^_04OZ]3ROCDIZE=
MO]!H.FRO\YSV6X+\V1YI.GM="]/R.=^5,U^84- JUV93,S[H*AA=(=L?/2NX
MA"T,G:BAQVAH-KF\^&/-5(*Q2G@(":=:5!. LF^FWT.8JEF+ANCXSHUGC[2$
MIW]]D^Q6J+UP]7%Y@Y;K=U<CZ>V51LZ>#6_'>&\W>P.8Y[$IL!>P-4)0^*K
M-O55URW]@[GK]U<*RE\-(-[(WJI."?">G0(R_E;/'*@7]-Y&#S @'S_I/8QI
M=O^#:!E,@5E:DZ+_54\]<EV77O-YT#-"''9P,<9I(#L:%6UCAFRZ,KT&H,%&
M-FI[+JH25>"-K(*D'_NGUA O^QDJP8WO%B!,0'M28(K00RS_324JSSC'=DFO
M6#/G<KE-#4'B*XC))_G1% !Z(Q@.N3C];53'<G1$F2%_^VJ,)W. SB[7T$8-
M)"@_C8_/,YF>PA5J#9+^Q3JC;/NB(O"D7N@\@70EF:+.86_8H@F0M9A5BD[5
M*@R]%HL:LG":MQ@"/G+1(D=:Q@+@CJ^,Q?6(5U'ON4;J-L@!5MECKZYMJ5P<
MVMUKYHH<W_BUP#X_140\#(2,>'=!PE*9@S'/;)(8EX(6A'TN<MQ>6O)P& X(
M7$[MRG09N;;2%5^A5';!4 AIC+"@@V+S3F5>%-V+48B[X82U"G,3*]=D"FHC
M7"WM;.V.JF+BSL-T=GD^T]GJ /2C,^#)AEB;"WC%K?!NTOG$VV_U3CY7;46I
M#[D-_JOYKI_'H[<PAV'9U0H72E!Y,FY5>65$?@COO1"3$NQ8#AACU,5Q%ON?
M30RZV!CDP*2O9.#?3=_\>D+UC@1K8,HSU_\024 %Y;XO$[T7Y94%8=;75"I[
M:R+&%/@C;F.:^3E]3)"Q;_JX.:L*>CJU97ES4=^+.ACK-.CNHD8)#4E,BF=
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MG#Y0),!L<_8WVTWQF\?KM:9C6#TU8K9:!-#XR%$Y(=RI,N8FZ=I\!KWZKK<
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M$OQU'WJ,[A2&:D@U>G0R?OUQ;S-X:>S%F< KUY.:"IU6%Z.>:1YD_TGTD!$
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MGQZ%$\>:4+$NBX^T!2<^(#M8S=6F]>J5CE\#O'LI0Q^.(>XF^JM+*2JUU<-
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MOFE\:^S>CC-[)P8 %,=4.'M\*K^-ITX-064V2/XE)$P<-@S63#<-C[8RWF6
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MQ" PSRFJ]H[UB)5OBR?KJJ>RUZ/;SA?A'FDP1]G,-!,82%_4GO(RV#$L9<*
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ME,,F_=8(V%X(]/_<%?G_&^N"PY;$J41U<%VT= #%UX&CN(#X+H?B>,K!#O%
M,"OCTE^"$;_]QW_O_D=3U'&S1D#]JN=ATZ<CDLNC(\GT9! ?XLS)E- &9\.
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MVM?[BYCI;M,QG('.$I@)SU63.=HTYQ;!G*":W<?0^@8T@!WCW V?;K^<<0J
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MD2WLSKBPJR97GD<!!):;SX+M;B;CI-L3.$WP=0Y,\,Q3W5D*&74'V0C3.EJ
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M)_+7+9GI8,[0FL,<>LEFG=+LAR&\K!:DZV#N3JXS*IQIHM?,.0D*TM:K<G[
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MI/MU_[/;OS4$>'W,.RU6 @RB43G,2%6MA]5Y8Q'%.X6[*P$9;[2'2TLFTLH
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M9[*?4>H6KT*;[6U"K_J<B !YL">]ISRL923B$]SG+7LUQ#Q8A0X2K)TL86S
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MB7&Z_G*9:EJW7#Z C>_2%I-$*URMEEKT51.L\9_*R,GG545UYQ3EGX@D8(P
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M,RO'5*<2W\J\>#U:&T]RN)9KK9-*&J^";FMMO1HKXF3FWZ:6Z Q N@24H.Y
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MJ-YEKJ1'CQFV(<#DHF:(PW#WA<R.$&%'ZSQ-K>ANX;<+F^O&2^9O;>@ZM,;
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M(^/3$?HU2+_>*]?N.F\^ZKL]K=\GF*6(L&&;"-J)I5#J7*AUI$Y5Z4.'$<M
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M?-7<H?4#O_?\@J)OX&0JH'BFHWZM++/,%FX/A?C:8M0T*?5YYPH7W'#U3VC
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M?U>.#RL[9NSIR+[UPEYX7!>6O=HJ.^F*O9MXZ.^]+>[BRS=,F94BI')$F5Z
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MQ.3?FQLF<SI&.KW^:F[X[BJ2AQRA _.*.>9!1O_ZC\;(?].)<=XL&+WR<>S
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MCY/[]NJ!:U6=O4=U7;"'1W4M,=@?K1] K:RD=5[3$SKJR[HF9%Y_#^^.+
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M";,7B]+.ES.W4,9<K5_9P^_P0T\O1JO[F^[G3-8H1];DPCCB(,<3/R;<XX?
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M;3/H/>ED9VP%.0F#@+J@RFA$<,7K"Z/.W,I><;24R)8R5VF3Y5U46Z%9 [&
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MU%X98!%WU[#XVJ\!^G'(JUPK9I7J_DN<H]S6I7Y1BXVK^LU(8P7ZF('9Q.J
M6!>97G0:&I#' "POU&EFR/=M>LR$:XF<FF>C= *9 8Y*6C.;-"5N2PDO.X]T
M3"==^*HYX?++GHK#+$8[/95>;LF#B5ITZ(17CSTAS1,=.1;95Q:5K:,%^]Y;
M7L1^J+3X*<4J]^+"Z3C%I"?95AE5%/V*#^3\2V^>=US@)K3NVD*@_RQ#0OI7
M/4[)8Q>9TG(.@@^O9]?V+2:<FEU#'^B'S'BS^XC"$R$72Z_N/IW-.6:L6KS)
M[+;U4%653>3I(UBL# EYH6V$L%O^K!\.'@@%V;D)$"$NLD*%GL5A\8DHM "!
M)6A/7.)^B$Y+P R]!AGL'=;WQ$4I*SPI;=*S<Y2MNF*S2"##<4:TNHHT+/SC
M/4[G2(37X>W^;5VQL@P,Q26;UQDK!U2!ZQPI/#/M[$+E#!D^*/**;H^R^9N&
MF(1!)(]6Y4DQBY5CZS7OWPZV=I3Q25E$N36OR$&\^16JPIG(*-O+(X/;SI=V
M[3Z(K'"#;(5EEX_++JKLCJUE>DA:<+,]FNI_%;8B:I(:QUB_Z@KTT'>NTJ#5
M()]CRJ,A7PM;^G9T[JRF/(^S9@[Q#%S5*)<+MBW2'L_IN[33T&"9^QO- /1)
M/N)0-4'.QG5Q&/EWKR;DOQJ\U%[0F[4KS/\ '@+<V>"$C.[]&#CRO/;Y\GCW
M82L2GEP8);1=<8'D++D]QY2B.4RTM$R=XN3R'[7BW@U1J[2+:O'ZK\'LD\9Q
M7G2S>[[O3=UR3$W!3_,J=3IJAPX]!_>FLX4<>5N;>#^?"0$FL3M@N^!52Z=H
MK+BH3L7W<O?JW#=I-7;+SB90ITDQ]>,.QT5EO0%KF'=Z.@!Q&BSEE\$5I$\
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M;06'S?Q.Z-CG)GJ47LRKQ.113/-&CUCX$F-6=HGQ'')8=NCVK/3K8ZJ>^9'
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M=+U5[4CZ;&)Y)P#7,';E^7$W^"VM E1:H=T04%!\T%)0]WQRF6D'&\R"9",
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M[E<YNUHZ!2,_Z^5J[5C%[B L<O7G;MD"1",<@]FQ*V^,[$+*7V6'KCCLBEC
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MS;JMSC6TB!TF-!B:_8M.QS<ZZ=_HK!J?>GG,K !D.S"HL'-!7OP@YC4!AE7
M1YD/0H1J7>VY"__IBL+_&?+#)RS+IYC=JUQ5N<1=O0)KQ"9$)E+:%O/VNID6
MJZ\P&E()@S%.C 70GJ1R\JZA=SH@%+:);_BB<2/O>#C CRJFT7CP\TI.(Q8=
MGHWG(A?W"Y7@EV8V:5>F@ZCSO\[V5&66-MI?0QH,HCW+-I8#4X'FS-:)L!P,
M;28<Y,LBC>[4SQ%4S>M@5P^][J0#X5^]7\6W#WRXM88;27AQ)$"?G$GCF5J5
M'KJC;[652:JO?<V3D]6[L.8YLHS"E@*'=E+TXLHP9-?.%99!N@?*EGW:6DZW
M998X\XTXVU,MVN,T\/(P3]9Z<6S@*MS6Z]79F1:N2J!>UGN+AGP7^IE[56O;
MT;=B[L^+P70]8QRDY52#M*3!PYN'6<#B"FA3?M]MK"U^#8*S:_0/A4A]#<N&
MM'W-R+CZL*7^5MM"[OX2TZ&QZY9ARTI8YH>=_%_^TZ84$/C+5K-?S>#BW(:(
MT-+LRG1D8V9"6/:;MIU7Q05>P?I/ D_CD,S,@XAHZ.]?!W94#=5ZX8//JD(G
MIEL1'U1MI6JZYY@/N\LIT6+77S9V0I?V"X5Y%V4W:==6;E7+_;ITKXKF5(LD
MB6ANF6)BWL&Z001[M/:*?IO9[!=]NQ#_%;[>]*K))?PXU=0 FZ1F13(Y=FM3
M3+S&4[I45_7D$XK8#Y.+5!WW@+4ADYB;#)VZSZ"N:?>DI*==0Z^\RN<*0K=/
MO>BUGG<6$MJ1&BU;^S;ZV*<X[GQD$DHR://1:/=M9=U.;5[PQK7<Q;(C@3-V
M;L2']7IJ4HR:3D?TS\2S/[SZ@#=*^-G[2,"N+&TW5*M5>VE@MW]3S"?P]\VW
M##5>M&ZV2,,UZQX-[%77V0T>+*>U8Q*\S4U5MI$\O^GV_+@0[KC]*6CG$% \
MOU/-HGLU(B[N&9[Q\3]MT/_3) ;MXY3 !DJREFT)\(2?LX&I/:"R'(<;>';7
M!*AM=8YBD1)1,P[>GK@^#FBX,MOS8AHIOCE\@U.60?<*/9 S30=D%&X63?LZ
M?@LN(+]T"=4ASN6_ELT5Y@7,::]8<\5@-HV2>J^_:)LC?E_S')5TL[35R7YQ
M:D'6 P4Z$G  NG*S9"%T2<'=4!>Y:R8>7,M*=15VSVIEZV+H:ZKUG':L'8LW
MA=-=%4I!GP@'+?<@D.L^RQ?P;R?N+AP)9,YGP:#XV*S5.BOCL&O?(I>V>D0I
M1&/WQ89@13OK2& ();3C:<?RL_J:/U#[15MA[]QUO_+N C9NN(.I+\J[<@C+
M8]TR+G0+"[\V'90A^RO7\@7WM0_[$3$D?]-WU> =[U9;4/=AE5ZOR^Q3\TYL
M1P3N6]05J=H-C^P,%]L?>INN:J-+0.])<@B:+75L8#?$9[0T*-RAI"!+)C \
MYF__W::,OLED#7K/;51:EZ718;G[+:!NMD5 QC#N6R2Q"_1-C]8E'OO0WF"B
MK(<*6(,4Q\IWCZ(V3:)7E-AZ%S;?<KH[8THK[@\>"4R8"L<,U)]&Y)=?)DU%
M)E$Z/D6\YULYJN0&/ASP.1*PUU')WST^(\P+@:$CDP/3:*H.4CD-NH=?@M\F
M#JSLL8\$@'\$DX#G6=]"@1/@G*U4QIJR\;TC =.4@9@=<]4C@0<,G481O0:Y
MFO8OK/;-MR-=$C&KE\P68\JW;;X]G/SM8<1S6<S*+?7/W?5V(?@+B58U!(+Z
MD4!I+LCUX$?O!*3N0.NW.-+!>44Z.S'U/MH#K1GCGFIO@(_(Q!L\BW'\??N?
M4>1Q:SGAC^]<3\@S45:'K\X2(1:(++HN+V]OS+Y Z\K2/1-3RR.!T*+8<\N^
M/C&9<6Y87&C7F*'Q_,?PZ/]NX_U?*'_9-Q5^6(VSXRC&Y$;(INV<C([/'+-P
M6YMC+ .E*D=N7'>UW&!JQZ3_/^R\=U33Z=[NS6RWXXR-C8"@M!D0D"XE=&1F
MI$@WAA Z(U5"$T(HH8W.B-0@()T$!4U( HF4  D$1NF$(H300D!Z!RD!Z6^<
MO=>SSKO.><YZW[.><_;YP^O? /G]?M_<U_VYKIL5Q@TWB@@>?=1@1?5Y(FXY
M(O/C;5K8=>^54QX(4V('R068VB\6$[*[P%VAY)%0ZLZ]'JMC9+'Q":I7K>U-
MK';P^IV6.:6^,YT%/IOMRV^'QG]T^UEP4Z>IP[X_+MLSU6XU*.%8C\2?48)T
MM66I6C;M11U5G/)X8DU/>=1,N!:"OA[I*BLE^@52" 7P[:@>Q<:<2)&9$Q\'
M+M]$^.8D=C#?J<@'O.XJ/JF5OF2SJU-8Q*C V#.5;$3UK<WKIKE41?2Y3%@U
M10P>#<+>;\S!N3OQ#>A56>Y./!U2^\58GGG=\QM.&]:S.:ASD=U)F%'T7NU;
M,8V9]G?F^IJZ(_'%P7YK#?Z2/FU6)6@;>+$B+)&M.AF1+Y^ZJ?(8" RU[0=U
M/:M]_K]U7(;V+]'P@>\\\V)D "Y'S;-,/MJNI-=R<^HLX'KX584_2IOR S3P
M19U+'UIUDH,;2S>:!QV)$=(K/_\V+W@]/$R.13KV*$D^"-=HUUE1/?C 78.9
MW#4XUOW>17?I!^Q)IY[0@7%P$EQ!M5E]/"H%U2M;?KEW]G*_3YW3M/'.]257
M'-=YQHKH?UF';"9J70VPV<Q\YC7G.I;R.&6'):96O^\G%9?KCG+5EIO;-&@S
M11)-"9=[QD2PA2XKTCN'->T2V\!Y'2;A(T9\1LKF(A=3?(/O5J\XCJ$,5V2,
M3M)35:UQB(B2NKUK>C$YA,OC#YXOO<FKU#$$W& 8NG5!EK[0D] "%X37U6IF
MN/24,/TISJE]46@ \F<[:<LU"2/7XU(T]"_S6&X.K&5PS59@YR!2KRZWQ_!Y
M@D=!EO5^3AU&*O0VH_DKB/QOT9E/^?GYKS30:!W&0'K"QGQQD3LN=6!?]<H6
MIBVX*S5JY5*CL9M"=KXRB<N,7BFM(UQTF9L. .KS37#QY$2,ZRPWG4C'3K-I
M!Z;5]&LK_0=]_-FU^KSR 806Z>'B_.("MP/*.#5NB7--"D03535H3^QDY61J
M]HZ(';O/N5TYL+%'%W6E<A<_\5%+")<[D-]S7Z57P!VCG_;L%$BKJ6P-&)T\
MR ;$ZD9&V_"G3Q/2N4P3GKTROP>5BU'>O)&VGQK)=17M?[K*K2W,6'2E$D+$
M%(0]=A[C[JZ8H3PIVRK]X/&(0E1O<V=!8-5- ,3!=6=G)EOHE$>.!%9KBVTY
MJ7WZ+U])G/WD-^&Q=XF_:Y[1L7-B ;Q'OT8 '?1/1A0 VO_>D%>JL$3>3I+[
MR*!/F,QS-]=_T(7D4 Q>?LNVS]'/L'_^UPWF9%0T0\72/Q1Y B_%-W7QJWXK
M3-/V%QHK.J1E4^,(8OK$$P]+4.QX$%[OT][5952_BIVHB'*1=?(E$)R[LQNE
M'<!]D; :#\ZK=;6]+]F%O/^BR2THJ6BY$WCEE.?N@C#V?H6H?L;>-8LOMC)Z
ME'6@2,[^S-]OO66JM_^]^!?C($"UC$Y0PW6=D'9>1[%<0A@Z.#9)Q:;^<=^)
MW\@_?2,J)>43G?G,.Z"'T:L"5SN(&;=,V\=OBRXS'X%X@].1UQ ?UL25Q%&S
M3,Z%14Y7B\WQW3%WU/U5KM^8([F_&'"K(W1HH.J+:6RK;*4O<K.']2LN<F2(
MSR@$:HM7:WO+?8L2/N:OYMY3XHV3HM)6G7INK-F[JM3^=P-[_]W\ /V)8;-O
MT=;KW[&.VEXA X?UYJ,V@HU5J3\N2G(EDX VNB/"./ZO&\Q7_<\5776OWW9E
M0>"1#2FG(94XO'\36THL9:OM:[1L/,O4E$L9])L845HFS,%\9Z"G/-*E25XI
M/2-_):(>_G=<XZAO]F&Z>'H(Q@C/Y15U^?5?K"AJDBC_&%%83OG()8/;TLJT
MBP3,\ DQ( [KEY*.FT#*K>M;6X]O-N!J KLV#FE#-2H6#7=G3SSLO5(=%R[=
MVM2Y'B'C:LE27F=B.X Q,IU6V*T!\']G*CG<]6Q/N6=QRF/EY<ZU!J1:6WE0
MO&SZ= C@D:5^7@U!.=DU"0%%&2XO0.-L!CQ3K;L_=8>+R\J&B-NR8G+?D5R0
M$&[ZMOO\^B2=:Y6<Q..@"RUS1%,N1@EW+'$<RK2^E8QTF1]0B,M(_4"_5@"B
MEFXT6.%GGKC:#I(UCK,$MOYL?)$"B\M/\$HJ#K=H:6G;^Q@3_;\X!<-!XY!B
M@&!7HY$U\TQ_?$\XCM&S!LY<F5W_F#[9#<V=Y_!QB8-F+&B]R-VZA;+ZL,9/
MR%1NQ#/ADIS-@$?A7.[QPZAD(=DGKM5Z/GGTXG+<V^(3J-F4S9P4,^Z%.\JD
M);;V!JWM_NPG _NPY)N9UEN(\Z$[P"T:A/L(M(2Q8+(H/S>$SDB[/5BY4Z5U
MSG=!B!I!N[TNVWG$?) $AT;(Y=1U]%WDYA'WU*:]Y)T!KG5<2MLG12+AB+J_
M?.5++_)0M73' ;K.3RI.OA$0M'7%("[;'66WNOZ%/X,S2BHY#U@7-55(M6;W
M<(N=0&X4>CZ?BP4VZ>L_Y_I:M(V=J,25W[F6J/#%/J"=Q[IUK3KT+_9Q+2KX
M':^CB&!&D8U6U8=WV,QZ;&I3-U1XGO.E%)F89G/]8ZDB)96F6E$&C;P^:&0S
M^R/21ZAVYW]U'E_U7Z'/WF26/'P[&:YXL!_58<_%%?3T')#J-?\P<9)7QM_P
M:I'KML0KJVC"7TWM'47O]?85&VXH .K_8PO#\E<+@(S$+M'W2^?SFKI6&/LF
M]H,J[2LAW+ 3\"7L^*HZP!=CX%J[.OE-C(JVNTP54X$]<5GIH,HMS"@!1.8&
M&5O7G(@VLZ/>WQ6AS$_<;3\=^\1KMJ=*\'MN[.V0RAPPDV,6T<U$O5)=M7WG
M-O6_U"A<9QGE!]C[E6]+(L[OVS=U_*NHG?R/HC93<VA>U:_?^)+IKLZ,S1(3
M<W>PK.^R6'MBES/R7);FN9QWG%WY9UQK@?3+[B"#L]5K?#BOID/VI![/]B G
MES@;JUF?BA$JF"S^?7F&HK=2[W))$R\_M&[RRM9L_$,(YF$1?Q,J"DPXJKIA
M:;V0F"*1M_/_Y6%_L]OL3['UG=\]R.-LA0<;3'8;ZUMU>40W#P+5J=R=.1YT
M&S5AZ)K0:!S-FVK(Z;\(*B!+E(OMU54X?[+@[NS;.M6V564!)PBS5T%;60>G
M/#?;=9\F' >:1:64=W[D<H$R1&68FE1T>*/7;4EX1F Y^Z_^(X,R@GB[RAP=
MBVR=SN#"AF=&'$#8'>6(/._%C3"/N@T>AKG_G=&K=JZ)<7<IO8GN(,HED8B_
M$HR)-C=>58UL:S@0UOGE$9>B+6W6H$UTU5X"[(E4#C<!:01S/<7OT>?JE1(T
MUN:@<]8J;D<0(S=(LKEH&KRNECWS>+GYL?L_?/O=L6%%G*1]0RPL!82B&9:K
M!.?4BO(ZBL(DL(RZB@]&N'T,PRCY"(VR!.52]);11[16O%3HG<&D[QY8YS[P
MM#J!IYI@MU)@ZGH3Q;>^UJC_M^G<YWGR8CD,V..F  ;\I#]:5H- 14\S3&\W
MNFY]QSX:PF6H0$3PZ,,6%B:\11_WMLPZ!K$J$,!E#HVT ^M,11\5TQ6+EI%:
MKJUXLQ0U71 !@8\A_<C(IMP%?-S-SNNIGZ=FG^5U.:&YR_?#S!5HQ2"$07J9
MFI54=-"//^51I%\O'_F8]E>'JJ<B'Y#W,JPQ*+HT>6#C1\^B;MC%"@*XV9)K
M'MK27&\!E _W;+RU6 I_3C6<UYFW9RY-8;.F0]3?J<@$O.HL8;KC:WO13VYD
M .*>+_8;?JEG!C<2_ZIG2&^YIB?:I80(*$/Q]R,CN%<'L*PH'4&+FT44ONF5
MS=3DR^92RY/RL3AF5<-)NK-7RES>\<.(0EK'QYPL ))C0RIT6/F5&W5 '9/S
MY(L5B/%UO-X&?V#IY)5MY_8*, E:T3GGEVE\XI A*Y0BT?'?/>=O=IJ-'4#8
M@@&KVXW6ZUIZ^PG8/&+NY*U#@>[U9^67%3)M?=GVRI>-MW1\9Z%QTCU&JM;>
M@]Q$LQ'L3?G(Y1+V/&B)X9F>N-1Y WC*8[FCVAO+Q8ZGZVK#?R6::_Y4>+N9
MS7%&J-L27YO<X&J[Z)[XC&Q(!+I,3R>*FU;@?S6HG8;Y0\)8N]IWEK0V$^(U
M[AO3L>Z#GKH' <B"4QY\91SG(HBP":)/1Z6DB3FGV8D55FA9GRRXJ& _5*CO
MEP4CX7Z%?**DX'1LO!?W7;53'.'-8&Z^]%PN&I"R!.$FT#?7#=JLQ[D@M'>9
MBQNBUHR32C//$]2R>R%G_SCHS+A7>?N9H6=";4L[ZV6:N_A(L?E-0E-&.9A[
MNZL;>&Y>\4[X^(QP25KZ-CK(2N!ZI%X-H*G;2+4'I#>W+BD%6]1O_.W__"+Y
MJO]?XIV^6Y*EZY5:J;4_+"D?IWC(?^O7+]4L^/I^:_:3@!@A1LO<B9-E>NQL
M(#YJ:U-S";7)*^\OQ/?E%%:=&]D)IJ;'DM7T:ZS^@X%-G:B_CG>.=%T0-Z6Q
M7-^)A!R$:W=>S_IB+(E=3M.1(/\3S6.[ZZP_+BS*.@<&;5WEHK'7_ZN:M62I
MFJ]%3W#M)C;#S'KXE$=U5:V-I*^QU?#%6;A8 I%9F=_#^\8H;VFU'_56*4('
M/S%4^-/1WW-3ECCH*FV\&B">8T2R69KQS0!8@-K^.O&1#R!W3PU;F%O^5<UR
M,<KX!)@-N,!_,)ZQJ>.4SKWJYI!2P(;JP1SCA"AK=BP+S%8/^\(K?S6S(,?
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M0!VT]W[JX,,I&>PNB$&Q65Z0BB42<WU\X-GPW=Q!'PF90D/KL=97EE&*87,
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MNU3)A0TG4K^7PS_@8M%.IT"YWQA57CGIF?K*V3'EA76F40L#X)];Z!X67(Z
M\YNX)N!O%8I\>!;XFQUO@N8WJ/F<GLJ"R^])HYZV D*:$ OO&B:D1LA,2;?B
MAF/$1"I$"F(5316[@+O&NH90;F6]Z$]A/#-W+PS?["*31BAA>%V![BGD8MXT
MI-!)NO$#/%S$%'V'R6&SGRRR0[?\7I^=AD?_L4$+6F/TDMILU$5*2305UD>_
MN$;Y\#.<I)7C/_<W7 R''0]MMQL/97PZ2#0E7&7$U;TID5=)\T(&F#[IXC9/
M',7*1CIC?C#/%R>3_KR8*F"-$TUHPQ;C$U"O TF%'?,AY#$,IP'Z_G:6OKI(
M^*>@@%G_>257#+64]%U;N(T F=WL33F3XYE5:X%FS*?5SP[+R1-6EOTAW[D[
M)G5F;9G=2'M\O8UC  9#C&SDFDP(V!&R  ,Q:9+[7E(>$V84-L;TW-92R,N7
M;_-)BG#YVT?AF&^_^6.Z#EQK7-(6\&)WUSP1BUBT3[R!1Q>F,5<XMM.1XTP'
M H=-B &I3Z^KU"@9$T+[18IO><T3Y MT".W=8RY312I_WHJ: /KVE!83*4H9
M;)#SF-\?AH76HU?R=73UVL@9DO4KA0N^L[I86W(]7^8.9!UDV:]M:NZNB@EK
MV__($IN[X]#A7'"L%]K="GS'KQ>5*/=GUGAT^)6NFCV#]R'Z[L@^>SI:U0%1
M _[0\GD%$&"E'UB*U'!-%,YXF$\BA#P7"]WUJRUM\IX#6+8)AD(3V=0PFZN]
MTZ:_[%0#P?4ONA]HMZFJ-NW,/6C\4?LJ+'\HX,[;<;7#[!KVI27ERU5.>+^!
MLUF#+F/FU9M-)8178WYS_:%;(C&FO2-T1M3 ."8%H1V*D6M?"FRSAQ\**?>(
MG?=^U!YJN7F;Q*LOI/6^H+[)VQZ^?677S%^\/4H]$/=R&[DP*KY'W4Z865E<
M"8)84Z'Y^_>VAU/F4MI?[8 9KF+Z"'7!!VFFL;PTMXJ0X==+#%6DR+1'JN?<
M60]P4X+XI \%#:X%"\?RQ='E%@, Z4-]7S[+E4+4, 4G*=P, @#FMS765;D/
M&XVF$2K"YC2ZF<*A^*0(/;6RE?VH'&C)*\O>3C:_XG;SQOGNMPU!(3]T!RL,
MR1K >Y^8WPS2$!3@S4N)MX65!!CY0R3EB^5?O1GV9Q>VLD!0*C0AL;U$%7(Q
M6'U1TX]L'.RB+N(1_>O;]\@BGC^UM *"8\:: ^NL7<RKQM:M3(V!5U/1V:]0
M%;8@&A#AZ;XO9"4(@!:3P4+A-GU<]$X>POJ'8[3=HRY>*Z1=2Y))VC-_L>?T
ME-57"^#85-G[C(OZBNX!7<N NI&'KUU;T(DTD.I!&,E<IS%S<$4WR$G-@>J!
MA920XN5'Q;IJ(V3?8N:K_79]YMO-T=KS#]M&]@+11:LQ-=&-YTU5^P^_>\%9
M2[7G<*S6=8$:X"W,'^V8SNZ= [O-F;:B"Q;]DPF+4W:B3DY!_A&/::Q,%\NT
M5N@CND 2$M>A)EQDU&9*@K9:[YC-@:W -,4E-^,>ZP&M>RLFIG*61Y^)1/FP
MK?4TAH>?TFMO%9O^Q7;1U=D)*KM@] CB^8EJJ2>4NBUI  T22NS' =WL=HRB
M!W9V9=VE' =7_8#\M61(QC+U#=MDATT92_B(T7X5TCEWD^ZT"&*C-2YLGF&M
M'JK3P[:PO.]5]ET,!(N)\J.K0UWXW5_VK)E^GG#](!,\%BJ9<_OU0N5^%,1]
MK<LW#W]K"2SP*<SK'&ENW86(?*JN)QMJ67/NV81@WH/<MAG&O';6 C^:NG1'
M6D H_WS2N>ZV.Y(Z_36O4KCS7L3'I[E4A<&$ JSP2WC)O"_SYGU0]'.5"UXA
M:2F7)3)S]G<+ 5#K#?ZVT5=Y^,Y7"*G\78H&S)FY:FN[:GL_DU]5^WT<(H7R
M8\OXY+EQZ"G/[_Z2^UE30B>$IYDC3C%6S=VZ[/TY@8D@T:3>-?K^6/U*+FZ,
M:.H[HB%>.=(]5S*F#++J"K,Q=T?GK)GH1QN@IS-+ER!*+D6FECWJ-;=2'JWZ
M6YR<G]AS$ZMUWL4&AYWR*%0XW'20IO,VLLL%JU]\D$(G W]9PB:F6F/U:*F
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M%F;@MGHTDH94RXV8SG-&/P%ZL#$UOYSRP%Y5CM1F?DMS#81IHEF^+SO*R0
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MCAF*EN!)&*UM9,HL8O@U7HWP"&V_?=/>[L* 2D8ODEFW1O*?J=C$L"P-:(]
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MQ)X85?R2.^W:JWKJ>][N+-E?\DAC[.7;O@.!.Y.C]@,=1P;N"R@OVT[Q5Q\
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MK<4M,ZZ%Z_G'$7$,9!KQZ)E AWFL!TV \%U2?K9R\FO,K^ADV5!D25>7&=7
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MS"^S*UQ['?*NZ]([TWPLSK6>Q1 4+A*;V<HI_<FX4[SX_17]@]#EG%E4P '
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M-_0%$!U7?K#2[H"X6S;O^5H@E-&PXIUN!#7!TI/_!GF<!P:32AA94["PE;T
M?M# +XI34M53 .IFX+O G1!A_Z?MGP5&%S9>G!=%[O4.["ZTI7JE 3. S8B
M63#0I76YZ?T,";P"OM>8(HC3%6F/%_YO'VO1 <T?^ZB..)^3R42?//;6O'TH
MS\.';GORKNYZ0!?*$XLIH7 016&H>F&1MWK*%&+_$]. OW=YB^_[HE]N8/HT
MLD<B[5Q#?C_B%7W01>D>HC"NYN0O3&*SQ;;X9NSJT]VQUCR07"?TE5_U]![/
M^(CRL*)F)9&(CJ9&66Z[X*R>LY5.MOW3UI+?^X/] MY6L.(LMMJTC^^SJ3_/
M&CA=Z'^NWDM"GL_S):/;UB_)ELGZ1"TJK'@FCK(>PL:1A8&H.)1#B]P[]K>
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M6Y)>$*"*=,N'Z%E&*_TYO]__TVB@18$QSBL87"_:-&N9EQ,.D?;$$#N&S>N
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M[:%X*!Z*A^*A>"@>BO^>8DLX'5U9&3AY*K2BKW0*Y;X "H-/,C3=DJ73-"9
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M2GE^:SROE^>O$PFJMF,A-J[GLL;*VPRE^!I&%CF<#(*MN'@<C$!85IM5(2M
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M$NVT\$>"])Q];)2"I1J%KLVJ#]A6?:#[@%,V%BJMS'G4(KF</1B6-.KCYD_
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ML+)R*(SH*=64IKS-WC4+41PC5NOYU%97S@+K-V;"YE<#;SFK>8*2I]>22M5
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M625F+)V+R(?-VQ\E&:#1/J:SUJU:?>>DL[MM#:;RW4.9P[9GKNM8OGY"KJH
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MC+/E3AZK,%%\H8 -'RHS+T7]\? 17+N42J]%WGH2K#78L&)0*>&648?4A(+
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M0LQ(MN:OG;)37C1GKLS'!4[_,Y1D=CJRC\[CB77^=#]F 2WH;=M\9,:4C91
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MZ=PYK%LA8\#FZ'PZBRGPFQM2R7RNRWG;(V:E M]7!@XPQ<QO68X%X&@V;V#
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MWK0*)YP)E903C"5L$?!U<?\FEZ@TMSOQ>4W7FL'>3ZW!8-,=K_E4IF+2PP)
MG#XR\\#,&D>5NM;2&3%=H9Q6*=,2_1;J^OF1PTHJ?!5E\T )UGVM#UFC#X'7
M5]Q?Q5_VY_3R1%EX2B2+U2N%G-]A 1^^9+,9^M7M[T;ZSXW"2JK+8L/HIR;0
MQY?XJWN72_F.@%]F2 WYQK1;DC79)TR;UQ::$GB&DJ9\ #)6Q@V5*C>V!=^*
MZ2\,'-0:,3!@Z48I>@J>MX&.1,== ]%)!8]:R'\V<F-$:"_&,.0&$OUNU5JV
MOLNBF-:[(> $.B=!?O<0Z[K,C@1C'R.;=D+630<L%,ZY$VR 2*)\SIF086U;
M0_RE*49G/6"^1(U3&K2Z?XNK33O7%\5V]4GO)7A'RGN<,Q]7S">:1E6.8#+(
ML>6N=9-6"SR:+Q_0]L-;].E47&ZJ3].+=^O3V"K''<^XDX6.OA:=NT<)K; R
MD]"U2>UX6W#=I,?/1Y#>"O_A7A<CE]BB'I2;D@ OJ1?4.DFL4>?\K1#I35;+
M9+@1Y255_J,N:+EK SM)G0F*'K/W1_<GU ^\=@VDJ GR=+#!;+//[(S2@_]<
M#7XNYQVVBP9<!EPR"Q<42GAW_DT-(D3::IN+7.RO<PV8RMY#5P1XYIT/,KBO
M_#"TCV@7$1&0;QK6*?O0]<#;U U48\<$XESPPI#6ML(13[GY ;8!+ONDM2,Q
M-S/X)M:-:<^<E ZG:A2U/VAC"@M:'%?<*OSM&A5O0 Z5I@_.A,#\'3&/'$'W
M@4CJV*EL@<9_*1>N;Z1*1DEY*F"J>Y]@:7-1UU#?-"DU4H<P\6DH2U%F'.23
MM]->I2M2/7-X,0+WE+5[W/BW7&GN/^5*=M]GK9=&*>TT=FRV._[Z21W4?'"S
M[4I[P+8[J4E1^:&U>-J81IN':IT>@$Q.YRSJ 7[,&X2J^:C9<BD13W-&H-*4
M &?B;JB9<%;?VQIW2>I%VU:E.EOVG_53TQV/;P7NX=2%-?K0=J=62#,WDR71
M.%YBD]B3H(&!4*;;=1OE3>S:[A= </T/I9));#.(2K> $OK\\(+P&H=I=AX_
MI,G\$QXG9Z\Z,FSDBI.,5?>:&482:)#/>&#O$D9=_C#5P7)=3_^,!VCC*8LG
M564L(E\@L!C$Z#8;9'_38/ TA'?2WKVW-1Z&;7":OQY!=H4A]SLE'1R83NN8
M>K9Z;3) :\<1R=8^%W8MEL06T;"3DJ_7D%5YJ%18UCG1)/)LJ%>BRA<TNTT;
ML_QX:'UQ?;+ /KX6 BGQ1,!@<?%JV</Z&/Q388Z&UHAY!144X0^*.S?M0CRP
MSG4<MQD1[3(4T8;+Z1Y<*8HX/SI@IBF2M4^_.PGX]-1=G)/'I#<$T'=@#3;U
MCY:#&,9-@^)DTHB'!>VX\D'LF9"%M4_)TL>=QOW7!RX:[+[7I]Y>G(_':9HM
M4BJH (3I0)+VG]G9-?[\>G><=!T ;-II&OX^%\)FXW&CW7)Z-,SGZL)IMFIY
M3%LJP4"3'F_W:6U[_8'O5M27/BQB=-.*'_U'W=7 PK_6 ;R-%T4EVWJ"V\)W
M$7J2?7#]@K1<PBN6*PV_MU3>O\IW\V,OC09WFY>D52B@6@S %Q5O.D&FYG1W
M7J/-"Q>^$P^[V-4Z7_HFN"]P[RA1.T,?DJEM>K=F..ZJZ.YE<P:2HC]"UK;K
MO$DCC1G$6$?P816^,%+\D]3!MY*0UB+0,F8')&%F0'<FG/??RS>8EOY-8T!\
MX*C QM9277OX=J2%A4@!X 8.!:Q*HZE_CL&GE0#')0@"Z_53\+ [X?OWB&MK
M%H))I[I)ZQ(D3<O<^/LU;!6VW>Y 6THV@8>7BGSCG'E3^V*%50_D3,CLRF,8
MSA6W&]=P_'M)%&G'S./NP  <UIY_KD6)HT]U[!ZD"ANE=?-3LJ>-A=<+V1S_
MNRZ!9NIQ6=P)09 VO&<^HPZI<!)1#VC#Q0H;@+SB#H$@>+:M9;9*[:3K6FA0
M-5(%-;&.[@!U<]/\%K5<)F-C =LXA-K)O,O;4%C-G$;G:XYD<?7*74+M37PA
M,;$J0Y$], '9KP2 S0D4MQ_)OML:A?5NDUF>7P9Q9=QEXNAN6A87.J)&DN0W
MUZ>XMFK2A?%X5JZ3$_B^Y4*NF>'%%#U07-_G^D;YGBXR8Q&N3,JM)CJ:53NO
M##I1T05B0&$10Y$IQ "&&)FXJU%7C2*YJ&]^9'A.@!:5X"N0!<)K%[PZ6%^Y
M-&)T-!M1J&.M4!"(!.]I$SBO7^:HC"-O>V!F7I8I%Z<5%Y=PZ^'"LW$,]F$M
M%TD+K=/@U;=] %^+!_^LFM1."C0J8MX-?$?"+E=V/$W()#^:7X4<+I#B]VYC
MQ?15P$?*HNH,V'4$\UHL-# \ZP02%;6X7N/FWA]!M)T\<<OEEE]-AN%07IEH
M(C=F\4PH^ZF73;H?76M;K'K;O39RW'W[W4@O)SS'B[IZRDH=$$2$KL[F_.:W
MLQ-K;Y$SV'Y]@>_V*2NPB'P@KD3;.TQ$!J3(_KJE)(E*?VS%SBNTN%TA^-<R
M=-XTU719X>5(DSL$Q[4?Q%(,CD;V"]"O^:_QI>3VNKAX:?0W4-0_7*P"_P\<
M(.<62&/Q1!3X02B^34'7(/Q-O]$SC+4E'8EX$8!%))J6$S99S74E,@];1-EB
M2/770U[Q&OY+BM$< ?A,Z!<2</PPE.L9<CAQ)M1U)?Q+<W707O+"QJ5NZ)%L
M/+;>=^Q3Z<4WI+RA^(I8YD/G+O6<]5=.% "3K5^\1^G%*V,R,IHNWG;N7W9:
MH/_7G_S^PA8XC/+$-9AG>(5ZZ5^KR5R?UP8OHN+X-Q?B!V.M.VPJ$>9U*$25
MYPV80 NLCF?0%+>.]#P@VK':4A]9&,];Z=C@2^QVRUY089/NH)&J8FX5];?.
MLC]"252%39>MTH36F6Q/1&$%$W"!H(7N[#1ZR"+YUMHUK-H"R99!A%W$M -/
M#U)=@B3,2#S9?IU22*IBQ^(88N;"=NMC:N%=M?7S1,OZ3[R9X*:W^><Z8(JD
M0(),7G+!Y62OFH)\O:&(2QY@92-.Y&W/4X=@_\.4$J@>2&=KVRU.@R"M*W_I
MND)K:2%SW%.!-YAM$))E8(1)?QW:KC&=+> -/%AK;FQ@DO4GE6^#K9IOC"WP
M2SS1%;<^^ .JNPGZE)$5;D6,92EG%V5RTW?M'I8U+F%J>B)3W&%G@NG*9NBW
M,(]>V(8.IW,GGY3]/G<=V#U!QO=W+N?(-7F3JE.4ER5>9;^VM<N*BI*S7&*0
MV+286#>!5*RB<R LWQ5@,Z(U6Q?MZ1Q^&!ACH^"KH)A>O=<?O"&%1<U%BZ6O
MILSE@J+4\ 722^_3LR+J;7:"88VZ$XO*BJ\LEZ]Q[CJI,-R7O=K>"/,*,9!.
M\+H9+:K/?OU,Z%PP5^_?TYK<O=E)@I):T.^W E\#1^_!2O W VPRM*-\6W&N
M;0"QA*\85;N-TR^+,4QQ?'H9?$Y*3EX4'6Q.4 L* KD&>-)EVD]ZI_M=8[3$
M1(L+955S$(4'80&(/)R7FW1#PZKI8TG$*EB/&51=G8'/2!G\WQ759.^&3&JU
M(.A+/".34A(@/R-R8GZ*=$+C%9U=)W8/<ZQ_)YWBW'-.?Y,X$Y*'CI^*%K6'
MIV[K&?J%ML;[3QDE5[\LO>FCQI6A];WF;,7YHY>A VG$=1]_SGBGHI5*KC12
M66Z'RE,?9E>N'"38*:C-?9%6)@7ISNV\,(^SI;]HKVI43!&?[)!Y3@]H_"X,
ML1'_JF6H9,@R.OU%:,\8D#Q:8YKMII#!9X.;3$\]H)HKYB3SRD1]K0$S8:VU
M60Y%H*=<-[9XK;OJV996TQW=^N=!VOLWIL\G H.;N!]K ,.CC_$_%?CF3S1C
MJV.U5]FX,50Z'JZDQDXD<_M<L"H@$4U0W-P%8_B/P^P=&@FD4U']5HG'Z72<
M,#]?&&1L9I;Q!/YXHZF//Z;O+*S_6%)9OJK0PF]B+@@WNJ\L%PM]- A5Y:LQ
M^REF6MV"9Z%#3\!D3SK;3-3\[FO#\'8OY9J*E !2>&VCY&(3WDHJDN:2[TR8
MA_7?V(G%Q^KKV%N"^QR"=P_9VD^"1MG2X1KV"F**M;MAU)SR+\3INN\WU"DA
MGK3Z."BV(V@G+MOB06<>9L;ZZZ5UMXNVKDLXUP,7];1RR"1HY: 01\?NCJL4
M$V_1;;@ELR5=Z-75=D:JSQ^:?TY39)0_DV.C^2L^AL3J0&6*5\GP#:ON"@J$
M[XZ21CNRXJNZ8%D:]]^_=DUMKP]3W=-?0=%O-\SK*/MQ&AKU'REZ4ZY0>T:S
MZRPK73@,(CPMG4/[R9(\7D/I^X"LQA>CKQ5/E%/91PTCFF*F0R(*V,WQ/AFO
M;21CF#+B;33CP"D)0EII)=DQ5)SK-0[])PA3B0 2V*,V8C-34^OCG,1)F<E\
MKXPKJ3)K7&*O,>KXT7:]Z\,IU/PV'56'G_%I]UM>K/1]XKC8>JY[A.J\^S*Y
MUE(AV"$AME**;T=\Y92/)#W>XB2*LD6T!SX77O%>?+NEM4#T!Q/%5[R!M2PY
MM+'QL'VBZN'0/0OUK8>+L?#VU?-T1H+Z]N3%I%VK_:.O-$[-ATC'2B8IBY<7
MPJ)9(@FZ;YKIEQ<H^_.85L_]'^(R#-&3T_K?]F-P8@^OC]&N4H5!U30*Y[9U
M 0"@>FCB',9!:[&RM;N7!T^G0M\J&F'<^@()@9KMWW^PE__W%V._XT;4YI/\
M,Z$M#^RO*@F!9T)7H_833Y1LKVY'1"6NT@YU\9^$OLXXU3@3.MPX$^+,G/;I
MFYP)?7Y_RIDZ$T*2QNS/A&0WXM.=(R)=_[N4!IHHF?1I?2WIWQ"31K;T-NE,
MJ+^>2WAS_C;8N&!P-)[PF ZI'>>Z=?5'52)F872@M478RQ+]2N0/$S5Y.HJO
M%O 59=.\OEJVV(BNC9V&43'$'Z.2CH%W4,?G+PVYPJW#-G23'UAJ(\VV5QT6
M=LZ$6KB8L'TKPD3&)[:XSIF0*=MQU=$ DXX'5O-Q=%GK2$"G8_#&!J*]'+J5
M7T#7"@F!%]%?>_P5-'A2-='VZ$$HPW][_$QHE;!A]?'Y,:.-</T[D[CP8[7W
M28%C;2,?9>I-#@S*'4AT97&7@]$3OTW2QO,SH;_,-TZJ>6="5CVA;I>W]XP9
MQF+;OQPSA@C&__QQ-DF$LJ<2HW-W<G)9>=/0$X?V8%J$XKS:\L^#C^1.?Z5&
MDFKH6]285;!CPN<\7!27_5VEP(7DED.053U&[93Q%177I*YYN6@7;+I%J>]^
M58L>79.5N6#'QKDXC1[WJ3,NN(_CD_01#@SV- F,<Q6,U[$U&Z//A'R-'[^W
MA,6B]" AV,!P.GFR0,3C=E%\X49HV\RZ)H^D$S,##&L>I7JH#C,BP\L(QZ^V
MY."*3R96)RN8PF;"R1H2I@]RW2+!CFS'N;M; Z2+@BYF(X:7L/CVHU16 C]W
M]W:SQR2W<JG:>3E=#HZJSE>YH@;L'7WH?W#0,T]TPPJ>/(,O^AHQ3[KV4(59
MG8=^*.XB119SOG_FXG#CJN_8=/CM.QD5UMXA[^8*G02B0-  3L80HF-7J"'L
M/A^\($F#+X6>R-L1')A ?YDC&+HC&#W3K](8I7W-1=-=JM$4[IB>P ?_Z_8^
M-3AL/7)A7!X3\9H;&$Y#9-P L>4##6,UF#"XHH?#(8S B>0:N8RL =[M. [Y
M>EW;V/ZU:ASOZT^H&BE>"TC.^7B$_)2\'0S#3K?@9Q#\YK4'0$=05/ R[>>]
M70N@C)I6D'N#HU//!!=3C5A=%EA=;V*KC&T+7[-2P"MG)=9\]-*<[IYWKI-D
MBGUF^3Q',T#_Y%NQM7[IE8 FQ4B\IE%=(1YB77OA8H]"=17$R=;M.T>W'=O8
M2K:LB)?9LC\8)Q87J7X"Z5VHBWE$*6Z7*&G_H=M[TSY*+ G4!MM=1Q$EN%QO
MEY_:;?NF71RO&5*T)IQ^ G/O1S=W'2@28.J?"PP5?=#J:?:&%WA;>9UW!W8"
MZW^ZRVQ.)S;/"-,,PKLGN)/>O7[[X1K#AUH?AR[#I YW9W%)V)=Y-E&12^I-
MXDW.2^OB)7Y/PADWD<KX)L4SH8N/7-R2FK3CCS2%)PC7+3/BU0X/J8[_ET'S
M<.IB2_]>FT)-1[V_8:,_4U)^6$?96.EE(D/DODID0"[=C,7T4%96__L@O'XL
MO+%B#4G&Q!B(=-ZZT.5.%]M1R;H992A]0/FU?/9J3L"RG<789^B),G \F7"+
ML.\#\C;[ZL)OHS\C2P),-O G_4O 8^FD$1,XB# S;W+2LUD;5R2KHS9Z8INZ
M,__=O>7N Q4CZJ;5""'1J76\_U*LW?L_C0S4EE<0O,_((A/1V-^)@8-<@GZ\
M;?.<*;FKL>IQ'V 3%0B IU<T=Y5D*>C.KF<L9%3@H3^D+!X PB[/^7[9[=5M
MO_RH/#7B3 AH'T/=,!PJ4A%P7% )*[#&P>U(?!Y- .]493<I"\"/%:K1*==N
MYJXL$<KX(-U!;%!I#+T!*&$*=C0--;5YW\)71M:P-%N?YGR573=H$\P3!^6Q
MAM>K]LY]#@IOK7=W(\SK=!?C(*.[QJ:F[U8.@DB"74B%+U.7J?%FPB%H^7$Q
MT5,%M?7<4(H9UG*4&T78\TG ]Y!,?MU],=TS9D"T6];GJ*? TE#IH[0?42%]
MD#[!* M6C"FW%'D&QS_R*R+0D4A"&;326,)JVCL '=IZFS,0=0'SVY64QD6C
MY8_.NQEY&5>[[<9:P7)Z?41'1W]G=MC>GE\&SF692/*RW1E7'_R$_3Y[V\ !
MV66UX/_25CH\:]-\/KJHW7RUD)]W<?I5WAH+#^CUS7UQ$IL0G%B 2$0>&HWS
M17+'#_5= C[72%5-#-8!8)M->WWJ.SV>,_^ST3!GH!U:QZG1T:KP41N4X *L
M@5\?]<%H3\5Z^C)BQ"2)7@5X5'7&YU=:=;5;Q)KY8.*7,<-=ZP/VHG^&/X9L
ML7=4LFLJ?9K/A)KC!)'5%>U+GE@*MVRT99ZR'N&HQ7"K[HR#+!J;V8UZ"8-9
M;E(<_V7.M(=MQ7\TQ \^PGV*%)_3D66WLG-;H6$!V)3D]@'62HN6($3 ?LKX
M(RF<C<UG;*_7:N_$FMRJ/DZRM_YR^L6=7CK&D;YDX<"UZ'?M<;HKS5P1%YN!
M.H3DBDR7&8+]@ELF\,/$*H(C^.&0I5>"-4$<T.UJE6L:'K*3':6&&S'.",'K
MC!C,U4\B!J)"'D(CCJB/#XZP$5V+<Z_CKL7,#! %&9.D"/BU6B><>OV84YVE
MY,+=Z%^7_+UL(T$E5YO>/?S?'>8_/>\%E1+],)YWLAR>G,K07Y38?I-;XH.Q
M5FT((E#G3SH$8@9YIE[_\K:NK,H5$!K,3$WM'>?9M/$YDEZPF?:.LL#K&3 K
M<'7NS0^RJ>L['] OGG2]U?NN/1/1Z=D0$Z[S5:;22T+SPP"?KY>\_ZS)JWA)
M"I?Z9V!A51W<G._F.MVQ.MX3Y)< PSK0[S&D1S1$=.>&L^1SO']MKWXJ4E")
M'4G/"N$].ZZA![48-:FHU@^[AQTC_A *C ] (D?4# O8JUXCA%/6>8^OY> 9
M:&P+6#&WAVU[T77?;6M,Y8M![\YL][FX_*;KV^H>/]/#ROR+L>36Q[O<=JO=
MBUHD\CI/["U9JD9K=R_FUEPX0]%:S,V*8HS72/K7,&7\4"$QH21M%933>UV\
M\S_E&&M=LJJ$H[#&H3L<5V+])69M:[>; #)9$2>==Q]H+X>W -@KPXT0K(C/
M *;BFC;O:-WX\)=Z-.5JP*#64*)B1MPMZ4%("R/AW-P/UE->_XXA GZ?.^A4
M"/=#J&9T6L>_HL10;/+EE06E#CV1,#\2:VEZR)2PH+_BR3RL8=): X%VNEU2
MBA<<QAJDBM0Z0QT#T]#7)3J7UV92X0GYCW%!!UTNEO^VA73U7\QM"*(ZF8XK
M5!>H60KFLF?>54[AEI9H+W.,QLL8R(52+=L!W="E[G#O@?V7*[?91P4CV9$1
M<1)>1KR![^*B+9M++;T(_6I@JX!]\48-'SJ;]=<AK.]1*4=0517.'[MW^G0@
MEZ>$IPI7XX,$,D']4*(9OL*/&.6EV[$G!P]<Z[@#C7"AQL:&&BE[)4E'213)
M-C.BYB]B?Z(^UK0&9<2'$95A7#=7H+6.Z4?"A]+M!I;DKC\'15MFWXML)0.J
MQFVUN4@:(,OF2<K@Y9'LS)\PH%*,+[+BCJ?!T>L2\;_F"S._V5JTC4O9#]X^
M/$^1DI56=^K[]"K5TB"V9)CM4;U0"E&G!#M20!&F(ZPR!<7VP] [BW^/ZX"5
MA6:%QAQ=K6M:VQ_@MZ]J[^P5.7 7J&"><O%^^P4-O5Q,]2 ;;&Q.,<E?NKZ;
M#9DN@0Z/B^@.F)HFHE++$%8U[,%DS90!%\6D:%S4A'00*ZG5=X\^-4Y/+?Z%
MX_<>J5>6G;[5>Z\.'E%?5=T&ZO'S8WA7.M)!HB[(6(VL@8$H>IL\U*2*_:)"
M&5]=!KT@_'-=Q;__&^V5LL\H-QY425Q/BA.#ZIX)+<F>"5T^.A/:A.@WG0G-
MG\P4#*</BO_]G?\7&U%_F)F=.39P2QQ5E\4L94#=DWZR'\_YQG*0=.KYQ6JG
MV/*H[0_I\VLODRSMP+3D T(YD/^LW+FMP'[L0'0^TNQ^M+NL@\W)[W$^(*>'
M^:XE]O@#"?((]7.N&PQ'W!^/3AN]%R.\1:1]QV^+332]L-@2JOE\/\J<UNJB
M5KN-?;63#"D_K'VP.$HMCP+NXC?_W)UAVL/$OWMCVW#T[23$)J6NG,8(TK:H
MU[X4YK?S$J;JJ K:@=0LE[1-GK-WC;S\=) I;')O*B*NK;:_OAG];FLZ\_8P
M:C=P/21\_Y?4%RZ,W-X^*\,B&0P>G0\E**GMP<EY46%,L]L)K@B6F%8>V/AJ
M;"!,?)TH@,]9E48I:#!$-#G%;]$[3XP:U+&E!*Z^XRE&6(9YW!_6!E&5HC<6
M[.$*?+J;OFT_Z%@/)@1H;\K/EDBV6M3C2/:6@$L^OFL#*;[*.55!1 @T(#[3
MIT]I /+%;*8>L&7]3;]H3W!QYX*L#MUK=U=\)<OX#U],+LO$S$,9-MVY\\M&
M3-S.3)-MGW'VWW:STL(%'M!F(_U-G/2_#NK7SH3V_+L;*5#IE:0#@S;Z_I-H
M5I*2152[:G[.X]1ZM@LWBWD;9"=,+1'3TO#'-^;1ZJR:40=AK=['E=]2"W8
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M3?)+-FNN93;P VP!4DK9N>\=N_XQN/:A8DK%;<2P[7[4FQ7_QS*G;\1:D0I
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MCN-CS^$'0>3,TV8W$9K'3Z>&0"_M6C/SJ;%B+(WP[U34-?J&VG1\Z91$^ZE
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MZ-!+3E#NGBWV[POT%&^5T!-7?./:.!6_,).:>P[\?G[C"H0!8#J&,-2_
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M/ TM]*U+DBP9WNZ6^=O;=IZ(:.0@I&+E)S*=&&"+&V_4^KGB?J9.7$LT-66
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MK=!QZVDO'*K/0O#^>52-,_YV#9FE[3G;5_(EO'??#!D^CR2U\,7/_TC.+0C
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M<TQ<GG_8I2VB87OO90.WT["_O>_ L^5G BD!6U'7?#Q/)YQ\OV3@Y2<\YIG
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M/I.[OJ7T!7_<L %0@TG:7/_JG4+/)DS[W#,><_;7E1(TCG#MW%  (+O JM@
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MT<,+&R<"=\ZI"PMIK'T*B4Q*8E&VBTO$%&?;CT66KONGG\B9P_'4V( 9QIG
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M$YCY0W71C,Y4 5^+?FA]?X(QL_D6P=TH#1L>!$VF?R634_%KV'YDW/=BWQ,
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M <6XJ#,!8,AILG)')1S#$N_NF4-C\[J](M"[_(%V:Q^VI6GO>\1NF<X/-@6
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M1/F?[GV*3( &[RK(- X['!5UD-"QG,8/C%^[UCYY9 + /0R^BIV4:]_4H$>
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M7[Z=G79_#U_^Y"&&U9N,A#X JEIG6MAH^&<D28T3JTQ@1*B!G8+=EHH-YF"
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M]*J\%OC,"M7G04&\%X9C/&=0)(3PJ,4-CZA2'7:"AL(0$+96%6$-Y6EL4/A
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MT*PP]R%'.DW*Q=__\?X2(_R6YYB$=6M[% >IGEXEYC2](2%HV'K. 7K O^#
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MDJ9$;=:].7.;] %!=0D0) F\MZW7RX)2Y_8R'U")A L$K;#&(O"+N@WD0DO
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M"N5Q[WC+V_Y&\%&'-=+#?]F0EBLL$H2%Z^&^/$2M\3Y/;^KI0_\8<\].G?"
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MY* -="V##@[%$I8QL!_KHC6L]ZLZG0L"$A%G7GRX/Q0W"AQS'P!)J([D!-N
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MZ* "2ATIHE01 M($AR9-:FBA*+TE2!<"8AF1(C"@@ 0(&&H"! F00"!!I8.
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M'CA6IFJ[<I+!+?.H\TF3"LJE2Q)7]U@Y%<@W1PVH[]9/U,%\=S)?VP.J#"B
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M/(?;Y]]V6GWQ:B^*F;L:?<+LV\N)@CY&@DHUN+-F*Z56%=$6#I6-&_0-[!D
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M.?IN[>W]@!00J"2K8MU["OKJ7G,.%^,?O9VUQ:V^1U8'#/7'F[^[4#PLJ>K
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M5*??^U)SU=^"!T)BOYV1\\=1?J#N">WC5>(?)(HV^'ODQFZXI>H]T .?*4$
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M^]^U05J^RG$&7OL7C)\&C&>9Q !5A/,/;IA#;0$ ,C5/B$3?\3S_,GEVN)(
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MSO,K(._B:)8(#.Z%S =$TX09(4@8K"GAV*+R:D8:2IU\;Q:FJ2&,JPB& H!
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M%"<$\E<<U@2B=XTD#6'Q.%ZO"[.E8OLZI.AWSL_G2,,536WRI#J1Y(A=Q9D
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MZ>K2'6"1._=3[3S>XXE;SG$=,+B/W:YMV[UVRS>?<7" S3Z-2LV@AOE4%HB
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M-<6;WC\%VEB(H9RQ[UPS]/>Z$H9_$[IW+7A%2;&(0$0:XSB_@-X<*54^[]9
MZZ?PT/.^(;6DLA*,EC-73F!$6O )1.2N'F++U=W;;P3]HV?@T+-T#2[\*4H2
M-0"U&H*RE@__=G;EAE;V0Z!+^-!3\W8!Y!ALFU='X$J:4.J%.\!3K5VA)>%.
M %42A&SW"-$Q]\N#6%OH/+CY[O^<&0)3CN:"Y#XIH2E-'WU;YVW]%%LY?^]8
MN-1P.V5^&EU:E+V$A"VCB[.$AG1+"EW52D/*O<*2YOJ[,[[XK/EOO$']PE]4
MED?T3ZZ8B3C=!::U8&Y^;Z3OC["4@ZC$X?[VSLAE^!4^252.V8%0+=2%PW&V
MPPL.-^=N-I..KFJY-HP:UABD/[P,B%U>6W0<EOT @MC*98M$:^:OY6>58O%)
MIP)7CR2ZTOE22URI]BX'X[L&'A7#5Q0$S[N+Q5I:@26]416J_!:,@1K_.90Z
M'8^+SB6Z9 $@ M7/1U$>C7E?&\<Y]/L+$8JL]5;Z![R)9MOX4$EDV</2D+BP
M$9EEF*PSR.IDT%Y&D55X,#:JB*F:INZ5NL99H$6F; P=DB/GU@61G' :U+K#
MG0+M [GR_PDQ/0'3'K++LMN.6D2Z2KP:/'&L[O&MU^S49EPX+40C,.J3NIQB
M(?(0\>"%"N6F7S73*'-@L,D$-O8(HF0Z6/;"2HOF'$<?>U*K+;\OU$CQ!S7&
M!$[*<<)L,SGBY5DTYD"\5N73;CF/@H9^ZR$-9ZF[(,UJ]V#V@GBH.J'TK; P
M/' O'=6X-Z?VL"U.SU\LK'=U8LR::34[ZDFU]RG*EPL%8:R'&>;W%A=RWF5#
MZQAE<I=WQ34.9'4^7U2*_M;<E7_6K7]]HGLS]08[+?P2+B5F18BJ5I:A(C/K
M80I1H,(ZEV$-HGM+TI: #?'",0*6_D0M6*RK4^/5U%34N!B./E$EUI78+375
MYXYFVAR\KK1;S0N7B[$<;.^03"G.N#>"(7) K<0=XX*K;<^&CISVVM+(!T[X
M?6A\SV[/DE6ZQRNMO]?+*@A/NA:L!:R,)7+W=@R4@AEST*!/<Q;B33^YULQF
M-T]\*O2+6"#3GJ*F&RZ,D='A4J_GAFK&>6QSZD?A];F:*+O^L69V?WV9$!9J
M_7V@X&J/.44K52CMD5!]AA>%W^[DT%#YB)8BVJ^6;LM;7L9DG%5Z3)@4-\;7
MKF02.D\W;%A,T#EC36#?9VK]"_:G4O"%_(G8Y\+UP]8J"35S@ %BOG2O_JC(
M*0,F)"E93C05*Y'A.'*F,O%QY6M'N=,!3;3T#AJZOTXD\)5S#>O4N^MT4Z=#
M_,CR]T[U+J4%*W)^J"]!V@I:B:#_1D?JOSCZW;X'_F:#H-ZXD/UL78TVZ._9
MDX)9B6NP9N/=2SPQW1(//9B6][;==$$4X=028M 2'B=<V!(>%"YTBMTC9?%0
M8PWTW&*2:/MH\N9JN DM!(KK9!E<1LN79*FBA4=%DX=2L1H3F"?BVA84D0;1
M\!$1J-FHC6['R[4+=ZYJ9UO[ ;-8QO.UC%ZI6Z^L/=;7,*T:D"B'RN"0*("%
M^%61J6%ZY-"(?7@X[T(B)(I=CNH2F& &%S0X>9)-(:H^LI;%8UH8AAQDI:\V
M!)8Z5AWG<98RQ<H*2MPA99_6Z/1U%"?-W49TWJR.*94J-8GJJJC! OI1^,7]
MXA*4M$1Q%&R>CB&@!3H%S_V'[?Z_?;G[@EFC0XW.1TK03R[9*D\TM/O3!@M:
M^&5L5)9>YU?/Z+NC  3>$C*B>)2OLR23,(3L/D*1GR$W\*M7^]Z%O;;RSDFT
M]=#PPY%YR+QCI)5#913HTD";E*?"K3<_N:I3@#"L^#:I-^I&7H'3K\%LX@$Q
MZE5K5I/N[$97F3B6_RQ_OQ5T0O!46?VX>W$ 6"_?L TD&=3*,%*+8./3#.&O
MC[)"_N;.]&ETO=TL3#O?[2]2G^J069.?,'/:ZMS'7DE(G\N,7Y1XJ1=8.ZJT
MH,"TYV+$"W;XC&:FFWK7Q:?')FZS+%E@L&3PP("3UUOW-U 00,"R"6:"FT'T
MVA#8P]OO:@!&I _<C19[FA]RMH3@858A*OC< '>U36YG?[C42<M>[2!GVQZY
MTGM3ONDQA'L90"%<.,@J-WDY#Q>0>G04H3FYN^97@_K@3K83,ZI[:<L=)Q!<
M2K.D%?.2_F0//('1MJV!]F(2N3^Y)/.\\2F7AY\*+@Y5],:09>4.*T<\$^PV
M8R[YN,>8WYO%A8HYE2/-H2+2YNJ9-.L=Q657N=PSW5]Z_>LG%&/ZZ\9Q,FM9
MA&(;9>-@,O13Q]*RST(<4+2JFS]I7B?='4V$9T @(1;*-\,J?85:+2O];?V5
M0UE#+ CG@V O<%5%:U4,K6,<L!8SZ;(?W1VE^XX9&^XMV$]Q*IT.YX.O:MGF
MSI&[\=E^YZDS(['$#X&QDC9+R]+)-4 Q;(*W.+PDT=5JA(HEYE%Q\33S'A?Y
M=23\3GVT(Q7<&2R2*R# KQ92ZX*C3A<C'F6/[_B=_+W45/B7IQ.(Y;$^1]G
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MN6/:NKIB)QJ8 &%<P0T %-4O6]"W%T;"898&L(&CGR.,__RRJSLYMSQ]$&0
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MO;O^/"GC#QIBAKV2'/A0;,B\(;^;H\(N_Q),'UQ.\1N3S2B'#O9U=)"#^KT
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M_T/1311_VX@Y:?PW2I\/GN52LVDO.F^?4\_Z6I3TE@)V?-TN 5TQDK,NO%B
M&ZBR4G4( ;:6\4G57FR6M_F.$JOXE,)]"R@AR)IJ>R93+YS^@UKLC*0OQ/!6
M_H*S\W#-W8=[@!YT=]9$;0,\!7T&(_71>P>J#H6=-/"H'LIU*Y\V .CC3'28
M!GFIB62YQSKZ1EH49!3UT9\6%S"\EVYO/FN)^&081'MO_UY/?P A=GLLK%]I
MT)9ZE!1,.C#[X@N012^, OG=SHP]"+C'+JU1J^3D!PX.U7J\:;6^-S[HLNR!
M<H[']2V?1<Z1J/N\M5,WX_J]2S6Y<4EV#<?NO/?FPL7H[Z]7,/L^.IG U,MP
MV:6Y&1FY"5']4L!L_+E$M8"W(SO8 J&\Z8Q0,(N[B>Z\B[DOM]+7I^"J87\W
M1"QRTR,PB):.C\I#.UMP/G,F@%"=DD4?\DFER7QZ"GS2FGYA]F4<R*_,ED+<
ML"L>>23F_FS$+BBPOW@M"V][W]ET-'1$:+:O;;Q*&=SPVJCQA.].PALGLNU[
M[LH+ 8[ =&OQH9GE^.G[]CX;?GPXS&&RU1R\GA8X@C=#TPS<271S)__<P, _
MN]3U'V9?6\IT)IF ):@VRTMU=''/2\+LATQL+6]21>"?_.59G_Q%PW&41^W"
M\P'IE8/EG^8@-5U%Q7C%C$4$N0@C5'G*=:J$/=UPM8XY4;_(-CNVB2XLI]DM
MK*2J6!X3357<XCLA6?+,.(/(!JC.A)@E,\K4+2&9<*>IL4F9SU*E.RUKRU]E
M+\G**IU9$\)$ F@RML$N?L03NCI*B<NG;>>,9V+!_<;SH-HJAP=,F%:WS1W6
MZ%=-FOGWD#VG)>='FW(\[Q[]LXMCOOFONSB8!J"3BNZ+P[LU&#^'XT=';DZ_
MF5 :K,VG#O6JK<GLYHVT-@K7NJ\X/<!'8,2>M5LF:0@7S;@US-\W"X)\<0%#
M.=':J:D4RQ(;4O@5>Y&K=;=N3#Y9>62>]N" ^LHCS(#3!3[)&V=;\N<0$P)C
M_#5G33'7.1-86=:RLY0ZH$[4EGM<XLG@Y_LZ62DR)I#PS69RYMP]5@Z;M1(4
M>JC3M1A(BW.0.Z%K$9>=*$6PVP^R&))P)&3W\LO]AQ.D/_;4?O+\)MIZ:-W:
M:#YQZT?F#YWPGL'*PZ\M)U*W$EP?7:YNKAE6D)(ASJ3@=QHGT:CP'*[] .6N
M8.NB=A8E4J\A!<L+@@N%=&@5OE]O?#5R0H<1ZM/1]/!NDI=HB9M!B39S3#:\
M#W1Q,#,_GQ0/:UMK7SV3J;E(<?^\!K(?1,&?SA@/D3QC8E$%?8(\^4[\ E-K
MLVE+.(^#_LQCOJ'7(X9WA=:R'G+Q7TYF;V3\Y'&H#MC/3W[TYL.1FCH7#=C5
M,?/8SU42P,S(_LBWM5"HT^+5^/Z[G0:C-TB%A<[J .B'SN.*R15E1$NH8=DM
M%EQA"M5RNM9CQ<[]JX];XXDN!7R!W=LIS=^6=#:J?A-'0A3.><=SR#@C$ET]
MKC 08B2!*+*2$XD#CO"*1]AELY=.7:=P7^7Z?OG09SDBIS"TXA-^2M-T$";A
M&J&V@AG%%B0$) (B,@.K3_CME4:T[<KM6(MQIU).LYI@<W<^-!;N.OD4_=WO
M>.V=7D(DC6X^\G'51)J#-A=-O=;A_NAQ:%ES,57-;&#IO;Q8Q>U91/@T$B7N
M>1D6M?NG^XPTT[SJPBP;516"7)S&EI?G'D)%XL3)1F:.LX[,]K.+IY='Z;O^
M6N&Y1^71ES?Z.*U[ZLQ1TUL*3<GO(IK#-"MJ#!FN"QU>BLK?QI4>V02UHVH'
MJ)TF=A?# E'O*(D%A4Q@1I=UP1GCHN3 =3:3Q?^<?8*04>2R]=Z%$ARVX]^'
MN>J?FT&Z(8G0+IS%G U-%3)8 RP.;Q\=JW.L.KM5_?9YF<.=CQG4M**=CJ2=
ML,SX#DK2=& Z&F][B;(I!_Y'Z.;V1FW_T?#A.M70!ZBR$4J:V)NL!@>%0;5M
MZJ^B?) M74PX3VB7E?0.HB"U8>(UX()8,O>(XP_INC]&%0J'EPTYWAK'A$7
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M3#?AGW4FA+[PB7R.8];F67Y0HV'JU*L(S>&MZG3U*,^9Q' 7U-@H^\*QL<&
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M<V"@!>GO%5S@JT*LC'RLX0\. 8O'\=XT2+P2STE5-PAPJ+]O7"J8 >1X**X
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MWW/O^/M[OCGFG-\WYGC',\?[ O4NW7.+-010%\.$X[T2_<%PW9Z,N-;;FDM
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M/_L>U613 JU)'C1[SJEIJX5]'9+;6D0U^=(M'W@0).8!R&^ H!X-V^8\H\U
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M[[WCFEKVM7%LVP+*5D"DJA21OI$F73>]AI(0.ELZ"45Z"<4*4A($!"1(1$J
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M"&\9=]K8I+=,SGRDV8ASM5KY:8*0$*;F/H5IDT']Z\6 +S87!_W/QPW6]*V
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M*J!E'(5-UF53:/70EKLE.-RS84#<D#L%:#3DY(XO0]>P8"(@@KG>))W<+)*
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MOJ,2,;'6?"ZZ<Y:%);3.NV5O=/0(;XX.(VA-4U9MQ5 />&KF=GW6Z?TWZ"/
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MQ9-C6&ZF/:+X1]MV>NBGD%9A>6D+,S;Y7%EAE>SG-3_^(;-;/_ #_QM.;0)
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MWKTS6>9+,G6D\.]O"YP>=U;2#D\7IH77+EAY6MYW(YBNZ>TE7'A50BX/?(I
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MIDOC5FN'GZK5T:,,P60#1?-@CB<8JY(+"+U7<);&T"FQ*F=0?VHI'Y4/GDY
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MT!GB0@EY85/!H!WY#*YJ9R"I_)0OK9K38E0 /2)'%9_]5!],]ZLZ0IZOLK
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M8])2B4]G*Z+MD'ZXON*)YL3P0#F'F\*$NL&IU14<(069E]YAF81SMQ]T%(0
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M.J1SAA1(L*HL,SP@#J/%F38-@IXP:R"6I3:]7*XMYU;VBXF$VDYI)]4IB\C
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M9^71#A@XOC$9&*SI'#085KK/ZZO=@UE0L "#W>4PB\!]LP]LTA!"=BPYPR@
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M>&M[-R%$H'R)0V]VU7?B8 (X!8&36Y&W\0D" E-19&NS@DJ$(-KOV^2.W$H
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MLLM0HQ8P!?KU7Z]2?=4/'*OVUDD(S3=!:ZU.AST%$%&6,"\&Z/K8NV=:X3)
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MV]"*&PD:&F*B;P?M[#_T\_-#>ET)MU\.# %>\<OPE/0$"8\2^/GY!8QN$QB
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MZG9)RX,NTF>6+9ZTGO54#C[2%YZ]!M%PGGG/&#4WN$B.;S\]R4YBQ2'7I#(
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M<(I"^('D:7ZB+PFB;N(MGSVTXHV2*RNQ?S+8?;&L2[_T RSO;-_E'%47I>R
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M-2:1S2E(_S$@:%3';\17U[):)5VF-)_OFF>FR5P0O:+?\6$M8+7D>]SK0[P
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MM.)O#$WR+"JWY>>02M77CYVJE?!]D4(A6&IGB'Q:K/O=3B-.0,!8VMX'#Z/
M@+V"&YU^5?2[VN6S[B(DW=>Z6/!+C]QU8O.095Q_F/E(=O=%:5U4@#>Z*D9R
MKM#?*Y>_>G^!# :#JG8;I"!WXC0B!5*^@QM#!=1)P0:"TEX:2ROQTJ)Y^T5P
M2ZOFGFZK/5^33[NR]QYD!XS4 #V@J3^O?0MAE4QY;@3E]59?5PQF$"<.YJ?F
M" [[N21GN0(U6\R+7$1F8X!<=O!V.I=C4GMTNSJMZMY <)"R!JDR,;2/IC@V
MN5_7"0K/II/"K]A?9MVJV8FPJ/W\:3SHZ)!?(1DMA8!(Z)AH][QY\/J0/_*G
M,36ENK7<0L6/3GQ'WV'OZRB3$U0$7F/'>1"T+[%?NMFO?OS2ZK.<I^?N>=GQ
M(,X_:HT7 W?21F]FV1K4U';5[K[7B.AT-%4E]8H.R7_-TDNEV^C8K_^Y5\*(
M__#PA*=(2]#W2^]F75?"KE!F8- CN P/G[6>:T)T@=!$^\LMRE-8PJ43'C6*
M.$ED8?/1J6&>6<TV23%D^UY)UWEOJM2STG*)(/H0R<AJ9\7$.J0@UK TNZ+G
MS,RZ[M]WECM?P-.B8+_D.]5\(+A7K82'8;9&1@_T(2;^%3$$$"A-ZILQVVK$
M![OXTV!)*KVIJ7>Z1]=ILJ(OTCH<!W/$Y5]W&;L9\)#CE6T"P*_ZHQ]YX,U%
MRB5AYB)S?@+U65.7BW)J8\TC62Z)H8H'15>EC4FBS!O/&(I$9%ZJ^B@2E;5:
MA39+NLMRE[4UJFH+RQ*RY-F-D]PSSWYTT'R_,SUU#>##6G6R/TK_/-*U8 *E
M @6X3MQX^**W\\/%J;9EQZN:$<H0&Q/QR\VIW_G85E!FD'CA5^>\%I^HEOOA
M&>C0K./XT^';BJO8Z\KF=DN>#C&\?[IG)IW=/E0),;R(Q&,WBXN@7@F"<2:Z
MD&KU"YXUPW[-%,4K66KH.)SGD?2IO";GR/H9PQSZ-7TB?D"E.9>D*?ZT.M(^
MF#*R17>5LC;M#^VTFMN:.35XJ!K!'>Q8%6;K;A?=Y?(6SV<W:K<,?BXYC%K)
M*_5^D\$?SN5FY-BKD0@R=V]=BB!!(LAI5/_XQKW^ Z6!U<_CW]+-?A7]?LL#
M4T9!$D$J/1F>PG@C\#(WE&*"MRM^\S AZ$MKXU@'?71>P[6OWOO@J3^)0ITA
MCD1POB*\4PTVG*#G<U"A@\H>1/5X=;]=OQ++D5]F9MI[7/X/=MT[J,GN_Q;%
M@N\K"(H(*%5!!*FB!J0)2A.0GA @%*430N_=2D\0$) @**$G)*&%D-!4>I<2
M>D Z! +2@O3CN67FSIFY]Z\S\[MSSG?-/#//K)EG9C][[\]GK;UFIR9E[28X
M@,!N&>Y!3U?U[7ND[M=WZ5_:Q7NH2O<DTK7UC80KL>TY:)E"_"(HU^G_.R,K
MJ[-1?)OZJ[?*I]+#RVP4=X.YG!C1W6C\?!F=\J9@0,L ZI@(]'=3DALP0*%(
M"7R1Y1M:+/A9M?,*?AGN(;6S!/,U?>8VM$KG:I:M<MM3VE3TLZJ/94_C]PO<
M!4=J5RV&@+10262\T)+,(Y':SYH!R-4T$*1BDD>XV$K2W,-E@X_5G2,I^:[$
MUTR.WYV+<GU>(X#VA(%=<](5:9T?RI](CWT/,WB),MNJC$8A GFEFH<V)B"M
M]],4(U)"Z)),L]YYCX-]<!]/U+V!U[\>RS4S6[\].=DXU!TT'FJLXGGGMU](
M")XM4#L39M$P/0.+$7Q[K_XVI3.I$(YW(D\_&R%8CXJD\<^O.O -(25(G1?(
M"].7]L1B;VBE4S*&^QUK6O\V;?N0 @(>P5)DYA_2?+7I#C[:]; 530#]M5*2
MUAM ."OZ]YOY=1VRQ05010AEV+UGVVTF']TL0S"RE+A3-D3J#ZE*\L5D+_H2
ML%!\BN+UYK477)RS/ML+TUZ_$RYO1(Y?:)L%QR!H?@I<V,FU))_L-R^'%[5>
M-.,S].[B 0K7"$_'S9\8L*+=R'?=+/ENZNS%QV+-Y1)^TL]>W2CLFS\*G;HT
MZ'8_M-BE\1=ELVDMFY=4#M1X*$?IIVCAT5YAY_O;8^NQ(UIT=;'+U_\HUH<?
M']Z="C\,6"H;&RB7MG-1&+W38(TC5)6U)O#?(Z.R+%[ +5J2!U#"!^D JLS*
MOR;MTJD=?^;J%*/[G;C*P-1-ED]A"3U753^ !D%/!$#2SUUW=!1P=ZUPGIB!
M]4):O=+KP3L]OKUS\#_0N:.,7E'(B4'\[.['RU9%$N2Y0.+D8CDD)9?>WTEX
MH,/2.;]K6]*[];KG_[^-R+%!0:CI<<]Q 3#,X=X58NRD(77*U;K@QQH)/#HU
MX8&6-A@^]-N NF(K;6S1Y?TF<FNZ4 GE]W[)_,TK]@'U#^W%(SX/_L*Y-25$
M2YIX=Y;XK<G>WYBI7  .(8CMG9T> J(  Y'"XO7)4C_;%EU^A"%>N(I5XK<^
M%7+\8Z1.6<$7$V'S5M"*_\OU:!W)NOY=? JR01Z*&>C@;[>%&W (#&](#K%0
MEKPX'PC>6V=FZY+L@(V=AQ"]&Z9*^\?#Y]!(<?1<:$5>8_Q#&A#M-4S+CO_G
ML!G!O"XDN[G6*/QC6RKH>F$3[B&#-BH;&32E+ZJI_\!&*.N)A&LL4@;]*F E
MP<JY;.[Z @*E;6#B3.C_V?<P=$=UYW>%F"(9)1./I0#457\IMFPVG'!6R])M
MEPX"7CUE%_$C>@='N/1(C9H+)#E=<=[]&$#8FCK:P/'TM]V&P6P]'NJB\A-P
MY->RITP"N*-PTU]V%3EU9\?KU/9M/OFNNF]?6GW0NO:GIXF_T[%LT&0L?(Z4
MPFUB2KF=M!WG% 0&TK(3"F-?&?/$?^E+"HKZ+M?H*L[4%#SXO5=]FWTPLNL>
M>57K@G(\F4_"D>01 33N,S$P$@IZHCMI-ORLOIGUJBO6_3H%*GS !)GZ]A*,
MOV3+XR6_O Y'O%> 'H;:W2^_CY.(1>?#.[S*S:2&UGT? \)3023>XOFX=2WM
M>G3LM0<&W+N^2Z$KKNGH1E\%%U])*O]54'<L;L4]WS?@&1;!$AJ,7'+-ED+(
M,X2%S[PX?/^+VJZB<*:T2^I&).#+O#P:#)HL"X- <TO22@U+;F@ -*YWQJ"@
MQ2.WH?2'GC@@]-V3F1&IRDBQ]6S\K>H1$.B% K3&C2C&LNH[.&*,(0L]$ :M
M>!@H@^Q8![4H2ERA_(O%-CJ)"YW1VRT11;7C-$L(C+PN6E%!M11R%WT3)C#\
M;!YZ8.B>;,S".U?8NQXDO+T:V4JGP*I^+Z1=F=RR9?S]H*"(4&U>T$I*IB'T
MG(?:1W<-0O.7O6#9N7="L#,S:=[;UYO]7#R9[\S9ATAWC>IU_J'W$HRT? *4
M:2_C?I(+L;<=RYLD\OI7BG3<S8!G'ZUIWZ@[BFFT/[+_5L';9N$K.42DM*%I
MBTXI\2A>3V06]KD!#2H%7!LLX<79M@*X>C6-4_G[?B]T/7K_;G;B76V,3LTH
M97VQ2W36PJ,"(O85C[PH]EZ94(S6?1GV(EFYQ8^+'VZ8!!J]&O5=S?\^K\=/
MJL#G] 9+'^76>VO5*501 H(UK:$"$;<1A]G%/ 3DX(UD WO"8__1^1]R/OG>
M@>"OOF9.C#G.\36E5/;4&TVNP_$_#]_C0FCFHLE;)V$B[B(ZLF8C!-Y7,+LV
MH2[\*9/<MRA+:$0D\^<_T&U(\+Y#%#7!>>5)DH;!^PDZP#R@PKCKV4($C""5
M4?]7 &@&PIY(M^77?_Y@+??5OKP831^'>4[/A\BS!5BN*W_Q;NM/[0"6D>*T
M/ -4C+8S6N.3,I<3S4EAC1($8Y:FV9'WC]<WJ-%[J>O2B[4O/ (/1B:P@:L,
M51!@JMH5.:(O]@EHY&61"R7Q)H'1I/9Y[8-L]03^;[,YNLT&/PLF:ADZNAG]
M4](<=G)K*8A_3 NT;E<:&&*1F1MI]LDIZG2KI%"W@>*%D3(E_M]U4ZP(LQ^=
M?+T!(2EH@:*:*2D0#YHD()5(F+@53[Z6W(5&FPT.W?8P>I((/=.;)+9_XXMO
M8[#G6,%6:&="A);#<N#J)?N&9_3TI?;$PH(WW)ADIV0.C"02V2'FE5IP1>HJ
MY5=Y?5JM?R97Y()#>O8/9$+OUPGB8(\46QIDZ&.EC:68_NU!;70U3[G V#!V
M5UU]7=8%,M=V?$"8#_-*G ^RCKE.#N/*>2D?K[AZ&Y^+R+UA!RMY<^%9/&X9
M"$6'QG'@/1%0<>[].1=@)QT_1_'W,;@4D-&5OQ:-4M!X<%5/(DC$$;Z,<$BU
MX4(C40SQ:Q,M4ZJ>7G<?[,%.IJT'*)[HN(SNUAE+J9YJDX&?DKD(7.'UW0U'
M>XJ4-]$05\+%844)^W![Y+X*X('AG5_5],[\25[5[J9I.[:*8S,!TC 2$[XK
M;3NS>@Z-GKAM% ;*?K8#]"4.+9._>O8Q'X\U6NP1'XRM2,QG<?:6KVR80";W
M)&_66ME=E0\>)1,PHBH5\EJ:6D'/0_'%ZDHOF/X1%Y0Y95+!;(P38@XU7DV%
MLVT*C:[+K-V&V'V9W6^9OI5TLX9JCA'*K1XR*07$\00.18 ZTXYU?Y*+M'-2
MB@5/F22/;*5J\P@DPU%8^IG0,ID KY**>4M;XZK^'N;J"C$-D("H-/\NVX:H
M R5[KF#W7W0QQ1=5)2D6 S&(F$+H>0C><$2EH+D='RJ$I^26@N^G#\)RE)!C
M\W8B)B+V!#(:N@=H -_D49R+.N);TYF0GMCYK.ZN=B[JR"O%[M<C/&.B^ 8^
M05ZT2W6L4ZY.P;.:*-,AK\--;/%&IPJ^]KQ$MET$8Q;3T^$#AB4&/,]]\N;6
M?-L7&8K7_FUI,_I7M7-*FI371^14B^P$V=I(EGX*B%15#>BY"5^'B^+BH;6A
M@U+Q%+\;>10+K.\*[A4XZ%:USITY\RVG,-WDR95U<*(VU/(NOOJD6L.,&:0"
M\A]L1>P^!SEB:=!C]V2SO]Z%]6>?O+Y?W9-@T99)5-9] J0"9CAM9Y=FL]%;
MDJ*?0.]&#N^'_HH'^0^0DVUW Y$D<!5[H%R7U/X=#?LV-R<$2]9Q:SK50(6\
M!TM!F_\842O@\M<*Q*#.A 9/OYW:LJJ>\RE#]PPV<1/EL&64B=5;3BV;VND9
M%+)Y%\6P3<P*6*2'DDVM8@%3ZTDU=.XEES"[('PAF7I/DF*3TK"@G?1,+#U%
M"SZ@F2)B,X!&%I84\T"^&[%AVUL>V"IO(3#>/NC/MN@QKVX(O$7 'EP 6!RJ
M:#E+ZK]M ]-+SZLWST[X>F6U.>.3XN.3#6Y]8C7?T$ZM8O6((I;;75JJ5P^"
MC;B$B$>M&L.!,/0*1\];&Y-RE*2_WQ1:<$_P2#RH*YRQ.$+*D$*V5:?#D&F$
MT?<-=/Y= &&H@B#$#$Q61SZYUEY<"E:TQ>[:"$A0C*,/OU<>MC0+_$KBZ5C,
MXNKU*6H*;JG($C6;$-!D%4E!SGBA70)/,I04A*%P/VN$.Q*AI:Z4_/O/ L#N
M+D,PY90I5>GV).P.?BU*=1V97($.GH-]W+O02N4=*HEKQVGV7]5NAVM" 4P+
M&Y^^*)WH1FQ51,%H3%.U0C,3'3AC#WK@K@-!7BD,-%Z(9<0G%BZ8<?TX?GA5
M,8W3#.-&XS!Q=I];S7FV&RKKB:RY".IF5[-^-#:#*8-$)1OK>/5*$I\J,Z+.
M^VK=EU_UKJ*FV5N^])L+_7[NUFOK-D4,E48!&DNJ(;*429,)?=A#/B*H8K I
M':CAUQ$VYN11D9XS/&:5P;NH@U:\FV4FXD !T%)SZRL"WV4N$F.B04W=#AP]
MV377LN!Q\T39EY*2<T0EBBI7R]!&2;384QJR*CFE[1(Z2:<P6P!K8/SO7/EU
MY^TMP>.$S82S[>X"+]OQIM-@00PF,UU/(M:-#/4DR"F4%)>;51KF0TEAUX?
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ME@[>VK]JOQR/@R__+'9/RQ,?5VW.Z4\9':!F>"SLBI!'94P"6L>[_)>7M!X
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MT9F]E))"!,BH^)^,\CKS45OYGI0A&.XBXX:\;>>S+;'#N_XU^TVNYDY%!C*
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M @.'IZ/JS9H_F,[O;""G_1'RQP[<U8AG3F%\^^G/</:!!SF4L_?'Z^X\LO3
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M")G;[$$0AON@5R[BND<;VR9G<^<)*/R_L>_>84VFZ_YOUHS.C(HZB/0V@H"
MH)30P35*42 @A! Z2JBA20L=UCC2 @1!6@(!!0F00) 2,,' 4GH)2 DM!$1Z
M(""]PV'6FCEK[;U_^W==OW/6M?<^US%_Y)]/WN=YKC?W>W^_]_T\[_*^Q5$3
M3*3F>N/P"6 \-+^5OOMB/RHX_I^L1W3%">#MQIVDK^ K^ J^@J_@*_@*_D>"
M!*EWVF2C#NWA6?DI;Y6UE8H//$K)WD>@E5C11V7;^0=A4&NT$--R_[[+%J?E
M_9Z,5!L*JQ0OF5[N:+K-04=HV,NC!)\T"3G),)/6UHJKK/,]JGEO-PDA?)E*
M%ZK%;?_,_?[S+XWAE6W>3YN5[',[CYO6/7&?;)<SAN\HO'P;]-$43AGLN!ST
MI+@T 9B)^6W?>J)8UY[;[&[YLE;CO,M*F^N[PY)#QFB80-BDRL&Y5E'F7C/H
M12&A.X<^0,=1)!M2HSJV1,=NF@4/3 W@9)I>H81OM%U^371<^KZ #!%)$9*$
M15_=SJO[AU>+[=T_ 1RD*.V.-%P_SL=^UOF'HQ%=.@&L:/5.ZWP%7\%7\!5\
M!5_!5_ _$M@8Q*YLK+3N>&W/.*JF*!YH=%2">MXY;:KVPDKD,!\?,MAIK3V?
M)\]P1MOG&;!*B%LVLAF<RB_G%8][H^JMIC_B/=H0VOQ-W*B622,?S)<FOH35
M#Q] K@_/_[)F.RMRX%?QB?<36/W@PH'R@?2!Q E@P84X/:_3%LXYU[B;(0$U
M,, :;6$UML+* T'?\$3@]T8W2P]B6[7= Z.W3@ [(FYK^!/ E6C3GC51F09$
MI$S45&6*S>7?4?Y7\!5\!5_!5_ 5? 7_WP(WNSZ< *)V8*F:9[/FZMLRCK*=
MAZA_?6M]PR<*]K/OPLNG='@I2H0U:0JZLBAGC&)9$JB62(J86$#,*]@G /'R
MU8L'3)2F%\\US/(<=%OTA;WJ-Y/.1/)>\MDFXM-PR!#N?C@A1MOX05E-7WVI
M &I+0VP!C^3V?3Q[ M"\A= $SL\:S$UT?1P8VJL;,;E]O-HCYH45=G">(.:5
M _N FXG;IB7'?4Z)#?F7L J6PAQ/%O75(B7\3P!6VMR=)9LA4TJ"N\4U6PW_
M\%4JT;_OX[2L26T>KG*N$^;=^HM7!/FV7OYQ@H3_*_E*OI*OY"OY2KZ2_Q^0
M*X$AC_WO1=;-[75HJFRM?#^Z^KX(<4<OV>* VY,4[! D-Z=1O,GP\-BOGU1*
M" RK+S8U+\4O_=SC<I1WA*AL>V4Q@%H.4XJ5%4YLR&0"IV(5N"9C:C#=+SF_
MS:LOPB[7<=79^F_W'VP#<V .[\//A6_8V/3,]]ZJW9<^ :B5(T/LZ1RKOGBG
M16)I82KW-\_?H#P"JA5;V&BISH"12>?ZU0/>$0<%58, K>='T=G5]F' _?ZE
MUT%W&.LUCIM,D4Q-#;6I9S3-?;.6YE]ZEJ)H8=Z;"DT7WTXUB(6@'?^Q%_0L
MZ_>]H+'&_WYC^15\!5_!5_ 5? 5?P?\)N+X35R<=*D4Y+!J7PTUHTW?OMOJ5
M-Y92/S8M<^<-G !\#9>4Q'/PDP\X&@ID.OC[JV2A]A"@;G\&8?'X/8;89E34
MU^3#!TO2LZW,TU'>-E)BJSC-\<%0M /<8X2SISL </%/7:*8-HF&+>NLFJ"_
M!#C^<@(HV75C<==OUKA%]#6*PXXI.LOJ/>$;O#HD!WX7YQ<6_Y(WBL9TKHAJ
M'ZT=&'0T1M0&_+)T)Z_Q!. 2'68O*+X7'FV9?T8#+&[[YQ^_;1&=DVJ()N=/
M:K\^?V94]%,3WPE@/MJD!T$LC4XD'4Q&%5VV.61&]M9?++/F?/2O6-EWAU\^
M[!WXWIK %VYNJ_B9U)X TNL/&OTS-O0.BX0GJ?+(\Y\??O,R G[LR7=YTI+.
M%OYRGOC7$\!@A-+6>>:^C5*#^V1JY0G 7A0A-*^]EYAO4\%15?4 _Z]8&\ F
M[EG<%_&&.]$W<\88ZG_=RN\]M;95C53YY-1#:B/!]"E/B7[M7VY\WZ9YS!N-
MF)P#B'7LJW?]]5\R-P_H4^F&56_#?IVC^[+;/.]#VR\ F>];*^8J_W*TY>W0
M-PG +U\^,FBZ\[!\LJA0<RYY3U!TJV_G<4_ 9#9Y"_^E2_8ZYN6_8B%G^KYX
MG0 <U G[]<E1Z/:>[\N.PTX 1QE'BX%>*;/L(YN('ZF*P)H_ ;3,CIW"YP_0
M1QMC?WX)2CWF4$@Y#MY<GH>SLG;K':D[K(=;%;3A\8,W8RVI//^*E0%\>SEN
MY=>N'['P=TQA;E>7?/>,&NMWI!V5'3O-F ?]"R^)$J>_^BA4N5?F;[L*08<;
M6'T/W!7=3XF->F7;:*0?3!-<5[FS5+C2E#O?J!"P!)G*M'P _/._8FD7"Z>N
M;4Q.BM9$Y.QTN:F)5.\MG0"VH3M%?55WLNJV/+[<*_H??-/^6P+M;$G(_>AO
M-*=WUCNHY=6YEZT/3Y/S@>SIDD9%NQC[-;O7X,\\W;_Y2T1 XU3PCO?QHV]N
MYA?FOOM73 WXD_/$^7Q@TL$J(6@;U1KE%W2V$?#?E75 HM_U;DUC&@EOAQ=S
MDSZ%]<Y7G !&'2>R]-N/'2;IQ>\O#/Q/3M;_[T7N&QLVE&/'*/A+CFMXLH,?
M4A8X9IB]^(A,I[>8)QHI?0HC/^_K'M0+X#6%S,AJ9-FLDR]LN,X":6:Q"TDJ
MK5K N[:RA1/=MHGI-#53$2U:XBYYIVF[X]D)(,5.NT=91[-]CU=S\%BRK6D4
MI1&^T=WJ+_*M_S=M!D 788G$&U8"%3::H/?A\V*A8;90;D7UJ )YPH(@C\9B
M\3CA'*:4W=JKXH*<BT$7*"1)D;1VK\U.]"+:5H)J;6=K<;W!M9UOQN4R4C7X
MIU(;+!M4"]0)>S=LO.T+V KV7%S&*]F,*_%$9 D:5_+A\3R_B*VF^W:6S$1N
M*X?4CS;WB>;FO;;:WN_7#8S.7%W FF:L&<CV<?=X<NG?PON'<M6@!K<T;8+R
M0<%""O$?5+M[>92$J>Q<G/D[6N1YU6WS;S4^$=<?J<7>0X_[A+0,,9/-&AJF
M]+P(99FECQ+U,M:J;&YD4SGH*_1%EEFDR <NJ6&A3/B62BGR,SQ7S%6<(T05
MHKES_=9",-L,V#V@((@PWKB6X'5/"4MB+,VQ7+>%OA?$H/*VGC>XFIDZBG_&
M^?J=R;AL+2IXW5]*UV0=& [2OJ>M;]@")<+ZBCF>3-8Z:0IY[7E1H2MZE.!>
M@4?'\I%?CJH>WYD>OAR K&L+%16;#\MOSMH-5V@SC0I]WJO]H<(V('M&3>?>
M>/F\("%(PG,Q=_[#EJZ!ROW<[<K.-E+[')[$J[=^S;/#=8$VBML2U2]I59AD
MWINLAF#FD'5-=T;E?J75K2Q&D!Z35"B\TYN5=#M9^0T0QP\O[A2HC2W\A.W<
M<9_5M2QPI[.529'P5K0>T#XA+WU*6$@RU)5_W?H"FIQ=>#$W^O5KXP;A\$D.
M<\/E%^<MF^GAJ;)$@85!>N )8,'OK'!8>_=4'WFB>.VZ%&$O?JJX4:N=6EVO
MG>X;92LI&$^W=5]YPI@C&YD%95IY]/.)"@JS7B'=@F2+?.*3;]H02SU-JA=]
MFKMAG-512HSLS_K.ZQESA 6S6#4823J:5V<W:O1V_MI2'+DE8/I=2FH U?2S
M881V]O3I-+T??"_1-A/P<PY?QC),Q<4KRO4<CS2^*U[O-1LN>W9<WKYB\#DB
MKV).;7&U5U'9!]?JXT.#@-_GP=)L2V4=*AD5#[5)5X&7X$&RUEKP$M1 W:LC
M^8&ZXKO1)D.*E&?&HP3^Y#4*C+R^HC]7I>I_ZG>K;B]_ ?+?& 1DV=I_8-.9
M[P2ZWO+-SO.]JIK,++KQB RAMX&+Y(QK*J!5 NH83(.4!^M=#,QLR14L'D7@
ME2;"3^,@OLE+]PM=R,.+F!RNX",/5I[2"M *\1/'1<;8(^85VV\GSFR25+U\
M2CUDYPO"9XH#^DK8L,"DY$[,K8)!*7]KBA+"@ZJO #)+@C7.&OSQ7_^HDOWG
MTZPM7FN4>!#3:)E#7[I,MO+>1,C4FD'"%<S,+DS*3J_>T;POC0?JZH$@D!^$
M'<NL(Q4I[O7<QG2^PY&$+]W7_6U<QIE*$"[..-%CB;^L;/?/Y,AFWSG729"C
M#[LO?"H/W":[9.;7E[ 634I?_3)6;.I;JAI(-1DJ=!NP34#Z93-B-37!-_G?
M%87"][D?ISPF=/"4_&^S9]^7YWNKJREC.J"#V?^EOO6C!<8 ?Q&Y<0)0T-XX
MZC[>8__T4++]!/ =7]L)0',?$4 *,CJTKY@XV+H1-CRWM!(YXNW4GO@?)_*K
M'3F[%%CM>>DLJM< %-KNG*DAO32QNXAYTW1]Q5I4R)_,A0/^]L1J'2.2,I 5
M=JT>Q5&".U,CTVY=5OBC]CJ3O6GC6RV]#:*UQE*'85,K?I:[J^(S=JO@W;03
MP&77WP),:3VKB1 Q[43.6E8,%D/H=^[/0 Y1]>'@/;>1I2']:,OYL#M<,UM_
M?[I3IP-WV?7AF@*6KF]KGH\Z;+?QZ.ENTS_*,D>&*.X9X23_O2NZ\(J7SU:P
MQ%FE@YO#&^_0H]#P.#+R#K!XHLN;B,T-GWK] )$6;+8;NAH4=%8N GH(3"(4
MN^@^T:&0K^NFEFQZUM01@MA]@8A\"]SP<%(R$*0MF".%O'/%7Z,Q.[M-X#33
M/X,FZG6^1Y"M5I7];5>&PDK=5RR4)%-B0T3*4E&F(*+>72:<K>J.7,CUR&Z5
MJKQALX"1P;@Y-SE[#=%<;&<S!J=V8^QKD;,/O#%+VGI#UH]_^2G6JL _Z!['
M"E06YY,PL.<:2\"/#7CK,2J5N-2\/KCQMX:XJN6H:V%#\?M7'Z/XV,X'4ZV'
M2X^<6HNZB0C-7_VS(%7CF:$L24NY*W>K@JE'0!W,#GL %"EZK>*UYQ#P 5%.
MSZRO221=U[<-Z9;P0K/8KO/Q0':N'W-DY>Z=%]YGDD;E;ZVH'-FL9I7=Q=.\
M:D?PA05Y^ UMW8N8X.IW ==63I\ J[%RJ"<."QIP8/X4%/5FMJ9SL6 9HF0!
MVW"2<G/C3SX4?HTR,J[/2< GB8FGG "N'*E6)X:GOMD.!YX Y/%5XVPHONVA
M'L0UKR P-C#9!2:YNEBZN2HP+!LXO 2UUP3NO0Y*E"L=AO 4E&0G107JPH23
M)(,C<,'&]>DXF8IS":/5)X ?DV?VU;[58FA3ZU=PWLY_+0-N+WE_/EY$_PP.
MRKSO$385LT&PVRW,:"=ZP9-UX2S*M:(2MY(.*_R6GQ)(#18[RE#S:]*QO04Y
M2/5!QZ.G[V-;IKY;9>-XHWI\>;5<%^%MC[WU/J"&(=9RT, J%57M) R21T9!
M>)#M@ %RAT<\XS$HW].:W?<:X&ZF5RG$-Z65WG=5MMV6HP4H=QOP:+4'VJ1>
M3""%P])6O_/T>J^@5X1D!Z!";2%V>^)%L1HA6-E)I6D4%*AM:NA.WS),6, (
M9+[RO.;D:]]6R.<SJ=8CJ*JB2(9O\(HA5;O"5E(X@E7=W^34AF8XAZ1G)MY[
MZ9P^",FH@H D=+MCDF+2'C8/:T)9%+(F)_3CM<T5TFS SF*U#V8?C-I-4M'7
MC JLJ[;1'J>2R18#SQ!N:,Y$C>M_N"-?>[4+[X8B?*;3+1TK+RN0&*X4"+BJ
MECRP\_!N-379]+8^8=^F)(]P&D2Z);9+.,/9D;JKPTD]@H47J^/2,82[C2 N
M"YJ:+JPA]/FSNE=__D_2U9\:M6XW1#&Z=O E1]K)N>#RQEGYX]7QHHB^:&F#
MX%6C@J=OTP$EH@*-F-9O=^BD<(.(;PAO[FR)<AS=K8O*3%K%J,YX10\;,./4
M>Z.<YH<(33?+TN!_^?>S?!OF%2>JY'U(:'?_,K:D_>U:B<?<6Z.0O!"K4HM%
M00&#\9\?XANQ]?9F/\;2M^H%[,"J3J6+L#A]L6#$G!IC]&9,]WBWF4+U;U'[
M?#(Q/^*.5[;I[E;3^.?+?ZCG_3_4L\?Q4OE&,GYN\DU'QIW;O^6K$T!_'>E.
M9B2*ZNRVY1-<N*9C"JT6"MR91[]2-4TZ:*H>=.B:W>V%_%I>62]6VSG6J38^
MJT^2"(PBRA=9Z%H+#$+LN2"2-2MOG#>V KVAOR4M[1Z=:0,@;K)+'SA0C5)I
MLO.>.!<Z/M[__BFLO_]]2/M\X%4P5'MMH-):<#;@=3B_>"IGF:,X).I58UZ/
MV8M*"&MM8:#QXJ%];*U#RZESNKJ:GM6K=NO=[G?7(KL)!+\NYG?:QJ2L\Q?T
M(,[TR"9NS5%^H<$G)',5UD[8J1T8<+SFV!'4)H&A@DJ0BYCB'S %M]M^#0(W
M^AL>)T31N.RZC0UXU'9__$AZU0]S"2E]RV"C[-:3[BZF,-BU]2_8X-I5,)B#
MB'W>HIF1_#3SE899M2H)HAGY32,AZ(4<SBXQV*D4G13EI;_LJN:JEF:M+;\"
M3\ GQ,?GJDS3Y,"4<,^HL9N?5__B3+( 9N7(>N1#S+S3'GCD9EBL#5:_6F^Y
M,*S?'D^IU PZ3#,R&92;7P9'C1N#U58GJYY\0G^&SU71759 E#>M:O7L,%]@
M?X7[VU!*#BWN7BXL:/<(WP6!:LMQ^7(#']+NY. 5UEM'I*7@U16E& *)Y5FO
MK3%1/)2+RP__.([$E<2C%YI-^+YX9S.:F(8NRHFC&(W ;EV$WUSF.>IX5$_M
MI2FGE]USM9;5XL68 L:3FB[E0=8;;<&;)H%?_CP3KC&&QVJXS[#7%\FO/1%
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MW\DX6'*^G!-A1XRI.9]<7Q<7GY-5%8)T1=M/"Q))<H$JFT_I8"C0(%Q#F^:
M+OGD:Q@HWT!8CT^^5;;GK;]30 +YJ1FSXYO<X"[U.?T^L^Z+PPJQ:EYM:!XC
M@9O_F:?C>35U[?"'U93)+LGMVIXGVFX;PR> Y8I5HT+GZ%N^K(%/,7C.\I?G
M_[36<P*(F636[?WEAZHHE/^7WZ[M6..X)=-;D3XR(?B8T%X1%%9F<=6+Y:_
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MMB20!DQPBQ4^SS4:K?S'7 +[3C42K[!7R55=G=1Z?*G?0 )G3VNFZW-RMIT
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M9[&)WP<T]5ER=CE/#(V#AK0NE1O97Z3^1+*@T\PF>E("H#BXFF _]D(%_K!
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M0.'IPCNM[1/ <CC\%C_-0IA[](@VX2%6#&>PD;MBZ_L!E.@.T"73X:35(MJ
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M;RG2A1!""VP3:F@20H#0SG8KT@*;#J%I(@$2" *&D" @O8,00@L!D1I*0*J
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MS6L4"15]CCRWA4A=X/XR<N/Z5Z%_5A8?V]2>9B1_8"W_2XE06V'^]"U#5'^
ME%X]#=-^OLK;W,T*'CWJ.)5MIMK$9=W_%DOZS"WSUK>_-/_S3G2M2RQ]]$K,
MJ]@_3WH.18^^"BTVXPR@UPNCS8.BG\PF#;Y;""M(Z4,0FVUP=<=2ROI^"_AD
M[VAI7H C1QR.-+I)KY3$V_$T_^I'+,!B7P=YJ',\ 83R^ +D=[/<E%@O9MV'
M#Y]#W;[W();T5HVM&5MYJ(]6I)FZ0*0O18KT$:FV1^22^X:C5(FHQKYJ=#G!
ME\ P_0Z1W[<VKL(C)Y U^TU_$JX0#0\A#-"Y2EW@%R_C%IV2WRO#]2_>+Y@H
M0>M7\M&U=%$.[GLYBY[.$) QH?0LY7&'?GZSIC+4U43[UQI#"97(3\&_?16Z
M1ODJM%9XX8-2<R6U\?QL>YA>_*)WC,Q!!%JX-K:*W3H5415ZE7+X D&AIY07
MS2L2.&X\$3@1Y1NZ-.I<FTTT= "D[$*$3]RK2N%3]5O%%V26ZZ2REB/[&'7"
MX!NT'E51Q&"DC\]-3)7?Y;IHMSWK3A!H(R1+1%],?4]5RT\YO0$^123@(I?I
MPK@-@F"62)#UPNG)O+%_&_S3MPSBG^.\445+3[^JE*X61XEC85!86N9NUN5^
MZI[(L_1QIUUN%@;Q%U$C@W=$SE)V"S@BR<-Z&3V74]1,;ZF9"0^S%!#H&L>B
MQ''0 /P;):"+72GZKW+K._]OE5M/7'/K$Y _.B\W/M(&L6^]8=NS4OR>W?*I
MOK7NY[9R5%!.(;EQX/KJ%EI43[4LC*IK(JI-6CZA:-!Z;X5O:]FOIA2$;UC,
MY@5=];LZ/4U1K#YZ]NKM@>!)NB3N*=+#$6X+N64;2G)-K#0%[)>2?^OW.Y2Z
M H&'(<^3KLVJ [N>&O7=;@0#T5X*Q&#\E^M7Q0HV4F+K&(F1ET*28,AQ\\Z]
M]RU@Y_U1+;?"W[)O1Z%7J,1='8Q;6Y!\F>=.IM4W1DG4V@<'@Y&L_^24DOS<
M[(&N\,+N*&)*41.'?G"7C\H?OR!0&^&Z5KK+'H2R_[%KO NR'C'X*N2$60-9
M@=R2D4F23>L67C-9!.:U#E%>JYZJ(G#>Y.B#PU12ITW=N*X%7,[UJ/<(]LOC
MQ*M:]*&L4;O!9!1.!9NP9YGG]MI#'6JL*6CO%R1T%D3"[S[/GPI$_"MSQ+X;
MCB?LRZ.JTL[%)6'<ZM<:/R\6S?WIKCFVXU?K7#X+1=?;B#IW/T*@EILYJ/B$
MQ779BC6F%+WC"IR,^I;B\4RWXEQB'H5R1_9ZIWP'_JO00.4]=^ )O=["CX*P
M,(/"0;<;FO 0AR9-F-69HG'9U7%9GZ8GN;7ZR/_FM@G&<O(:9 #_:7)7AA0R
M!NO&EOI,PI)@\Z 1.MQRJGXWQ8N.@=U7AP[WQC<F5J!?-F<,30Q"1FI=H3(I
MEZ:#4M;<3MT6$UI97K?3$?DB;R4&TO/EVNM.-V*J'0Q,[*;Y)%2'W$M<ERP(
MVE-E02AKA@I+%'K+9],">$PKD.EW-<[=LPTVYHEW'OWN,='Y2]RL8G4%F6V+
M;'81PU?1.5IDQ^P'7$7=#,9:[C[3@)B?%]7QMJ.>&5A&R>,!9WYCHJBA5B 3
MT9^\SW&3U]" -9][KH@&>2KCUZG$%9_<%$=2",MY^1L91S7&(P:6USUE 8VN
M$-$&\0:=R!PR(M'K<;13)R?PSE3=U)>=R[0.;KB3W1B]TB]R[P]2X\IP7Y5-
M."_V]D\Z^A;*!5WOQ\4>-5\2=@]:#)QH*[7L5(X) OWW(D.IG;8+RQMOFW&4
M5/;$9(<N]]1N4W#2"QL0W\X,B]EEW55,^(>0D,:/2C%^TMG''"^WX;'_&(CY
MWW$S_J?KPL:'V8&J'[\*G6\X]K0+CJF/S6!.E0I:]X@Q#D6;<5#CON:"&/YI
M&?LTO537QL&P<W+#)@X:X+(#W3]]X.M_AP_QZ/^D." U!FBP6GI20S Y=+DE
M)IQ&G=QSMO#:Z.@##8/)>2E?--8Y&M-DY)-'(YI++A\; CIC_0KQZ5(I.J'D
M;*T(L9H1\P[C4[,6S-%2\@"+](3EG2TCJFYCS@GN$OT08OM;]33:;R-?NO8=
M7<ME+U2_B6M=G%]$-NF0BE4>O-_LWFB5'^I*]8"(JD_A:2&!";0RLE;_!_X/
MLQ8IZ]B1^]:T!Y]X]"XQSF6B'%SQ[M]AO2>&Q7D#L&B8]@<.)\1N8/YH7/&8
M_2'U#!%R9=%_7R'U;^<?R^,"=;RL6/79%DXST]O.ASLN:)V^TFB(K.EC)&@7
MA &,E::)]+KB^*_8"$Y^W;PG\.HR_8;IXL(O*TX]3#@&VN1=,K2MYR[26/-5
M",((G+4Y'5RH0L2RB^)@OE^%>(XT]Q71$?50T8='$<ZE^^5;T&V;Z/D*G2 2
M%@S9CBK+;_NIH/,;//5B'D,=G7#CIVK??OZJK;/ATHK@\VV,5$/NR3.'@(M1
MZ0>8L.AW+ZK'96GX$)5,\?..1SDC_E7(YKN+DEZP*85F&V%G ND 18ZZ1M-I
MF$D,&)()EOF<:U+U\[3Z)*_HC>?K^^/0/V8^1FWSJZQD.O2F[+\P&Y[$EATV
M&Q=01@6T(F?L9]T'@M=.?,?$+WD+A472ER^<?4F>&-2=G(2+/CH6:BL.?OMK
M8_QJ?7FADP-/7VMP>:7(;414RW75&>\8>ZCR2*8"!^SY(Z8#F-7;:4BU5N>V
M22QZ'@<Y08*GI,_/.0&&G.#/IU8!I6%9VQ9!"9OH$R@4"@K9-9;HR^Q<H97M
ME.2HJFLJY&TCWY7_]-.-N9G%_9+')R 3S,S;TU\-WH8#H+K-_VK(?):,+GZT
M&7D</U^_F'AX'U%6,Z.?3B VUC!3O?/[?K*PNP4=AQ'W,ZUI?AJ^810F7-W>
M2MM_H[U"EVQ2P1.Q4A=Y.D\7W8J]=$Y!=>QH_=B0S'1<6?2G8_VLE)+3RZ6X
M/*4='7 =Y01-$H."C/ANHS7+NH<C#*#7= >D3;VA]FG0)K$B-.P\,1":'/QK
MZP'DL1(7QF!J^F&+ *A(&>&4%Z5HD@.QTKFRA(S7%S>3MX#8R&=%BMB3^$S
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M1_@>U/Y-J)P^OR;$*XQ;K%E9W3=BY'<8\^PS30LJ77WTZV X[Y\,?ZSIF2X
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M4I9NQ_-(#^L*=)*L-,($>@1E#7S[DE)3'+O#,3A*X'+31$0#WB 5SI_<:6A
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MEP1\[/9LXPU%J:V/IS^J_\30+?9;N9C2%(--/9K?M._BS"Y ]YH>>.LE+9H
MN_S>7-O+_SE)KK_&1/-3V!,=%^/O@AO,L3801;FT$?/]EI%1MELVD9JF:XO9
M5:'!.3Z$M2J2L:&FMG?JV62LR<R7VE7)$@E=%M :9#WY89.ATA9D3(I^?5;=
M#\ZRT/CD8!70Z%22=L?9N5ZRBXG/DQS\1)6NP(%+#!J,K1XFCF$(N_WMDY3@
MR63K=42DM!3")4]Z48<:K9VL?0<,^&/ASOO64R?7_7G1A,R?O0[R_3-%Y&+!
MY.BY-+.'@NR5!*E;4:G#>OAUFYOL77T[I%G2 797@7I]Z+XTN/:::8#=T*+A
MB3^7Y&V.S K*^'(].,.;LEI>YL!]_F%4.=WQA9\#N>;E:C>!YFZ76D2&@2C+
M 'F[HXO6@X^N#U=XR]X)IC$%1D$"XWMU0\3NB4ZY\[XI7X52;&L]=#C>//@[
MTKO-"9?J<ZK;NM*H19FP(I/#8<I2R\,D80 'IV7"9!$;3%:*[&)AJZ$12F]G
MB,LVI%V2L&9PYZ3) KTW1#Q:QGXWF,>X2O]T?C)?#YODL.-8)D=JT*Q3=$"\
MIE_+LNT?CZ#;Q\<3&E.\L;1MIO2H6V?^B2G'C["LX#IO?8T]T1:%K8_,Z!P?
MW\;L(O: #&GYA:R',@K0?Q]:<^'AUI^GWX5U;2YF1+IX:U^O/5S[*K0/.R@9
MKC',8>SY;OW*.3OV_GNAS\NQK9L"[I=WWSD9FNJ$_R4$7AIQ^:TQD#;IM.HX
MZ4N;A&>G$.6C_?+T,4"F^"I >WA48/6V9&H^RM;^@.@B88Z#E27,4?14_CCH
MW8 B)PM'&QXV#CL,(W*\1RQYMOTY [=,],7TKU*(!::F#''U.M]"-MS@FGLM
M9T!3,7=VN/@,8:=)IT]0QU/!HLCCSBH@!\H2<-W34WKHB;T_WD&_[#.'-CP
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MU]3T!TG/1JUN^G8#UW8;W%_0>\^L<(29Y?IFJ2HX\$)V$WH@CXQ97C8WM[O
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M(8S==3'1E-K9:)-9FC&*@<H'2,;8>)8=#3S]&Q3K?WFMU+3M4%]X-MBM4;X
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M'L"7PW!&(=YW7DFWY.4C(/299< SF%'LQK^FNKE,'%K3U@X84JRO?R)FWS.
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MHO+,?>M*=RGEQWWJX=+:^G:M3@(+W]MIM,PUZ9]$4Q8LN0ERZRD6"XBC_G3
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MO$#:W9:<B\J_B8X!:T^RPGKJA1U]KWA]TNH#ZH]]HOZ0IMF%YTU+#.OUC8/
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M3Q8LCJNZ*13>7A;F09\XJURR$;98>L"2<]3'&[ YX(.,P@SP ?;U']:#]C9
MBZ4C-]X$WSBCL*_9APINT9__-._T[.*-E9K#<A[]S+B2C<<]-V0E"9^MDQ#9
M$50#'9_;D2*BT='D!H[4,A*.J=5VF*JP'5:&&I@[!+S7N+1YNII "V[1"R_/
M_:WZ=;\P5_(%K:=;N:(&I5 *EA*WUG.Z@=ZFLHWP?,=>Z_>4O@XTS+AJP]K)
M2>_*E$E]W<CD<A$D:_%R4>* N[GW0*&'E(<\CQ+DG3:_@Y[W?G$52[Q9K%Y&
MR#IW7:6\D"IA1$PMS56*XQ8DID<<BT+1WBOU.N^&W/[I[ /^2'%O^FIR'8WK
M\SDP7P35M10]Q!/XYG8^UR(';AQ%[I7WVL:!Q+<.,4*JSU]DWM$;[E'-GRDC
MK4;(XYZ6'5I=:W[Y"NMWD.D5LS9FK]!ZY@">L9P8=_AG8NR&,U&4O"TA"F@[
M>W8>?^!?=#YEUNVR2DC#)"E,KQ1*]&5T&-?J:NGEA>*O&^^L645K&Q,)E:\<
M#^K+)T;6(:$"CKCD[';X;.I,FBO04Q1GK4Q45H6%\T[$"B!"AU3ROH-\X?D_
MSI5%XM-N.4L-1"8ZKVM,3<]+P^/3LS$BSQ)!DN0IT3-M8\F]2IR,GA4*J16[
M&KBR/9D7]$;2'N)1(PY\N>/<L];ANOS9DD:R[T!1XRM]W[U=GK#T<,#[]LM
M6Y!]>P'OFV2Q _R^ 3VU*ZSOG"^%/#Q[.&/6G_6-1"EO"_LC_A=S19*1V?X.
M;1WG=V1P'W$N_XO6B1B,<HJ$/!'K.CZ,?1383"O<B.B-OM+A'%63;4G$X7+
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MO22EVE^=_M<7SN'H':66&M*$T2<IK]]/Q*J^!*Q(,78: A*&6E6@QW13@<$
M:EO:E.HMZ^_WPOE_^<[EY)F*$[&,T/4OBD5?_1\-&IZ([=R*63D10_=S6BNB
MJ$H:L*C*.)I>X+H'O+^E9[%SEN$T6=%D(:FS?3?@_75#2TJ(N9/R3OG8QYW[
MQY6!;IXBZ403<1<)>WG8'=:5FRD#M&)&/C'+RD5F=DOWV:4XHXUY&)FU1=$M
MFPR.T>UU4S1$1G@^YCBF023C*3;8><N>$8&%2Q-=A>ZA.!I*036^(T\!X!3=
MV,JYS1#N,-4,C@^D++-N16R73^O'LLXX>>XQ?D2_%OW,A U6DU06PA"B$[%6
M4'EN3SLT?WM4C;#LW6"YPW ;J(I.B<C ">X</>!_K=^R/[Z@FD+#"XIVDG82
MFI>BVY6*4T9/Q)YQDK()FB;?8(<\BGI%QCS0#%M.V[+N;?[E1.S?^DE<X?0$
MT?J'_[B)?'D$_0;F-+\.;=66?!_6RLU34V7/1>/B;DO89[%@N5-D\@ :$QQ(
MR1TA5@T*X/VFU)[@Z$'+7=04.]34/VJ;(95\^7CJ5OQEU+#C$G':?FTL_2]<
M7@*\_U%U%ZE&)Z2\5/U=Q>C>T#@7?C@E!\ZO[$(O?0IP*0';)1 K=-=\&0UL
M*7MMVT>*U;#P];[*&S0["8 "(&-W+P&ML?C#@(_9<5O +O&YP.OAB9ALV%[+
M3M7!?SM3!31K\!S^8&:^Y;B ]O3ZA+W97E+=*\/J>=0;LQP4PCJF=D(K>R!B
M,)Y;A?*.KTK;;T@87TN\[8GZ6/^8&W8O/PTG"EF8"\&]'\=4\FTJ%%?-VJ%=
M:RX'SF5E57G$.LG,4ZBY9<M?C(,/%HG$9>)!8JJE7W3QE'5:64>B3&%GC.6Q
MP"9(.[N^H"2W)Z) T*OZ5\SB.=[9:^\6SOJ'/.D%>N927OEM#TP=N]1FQ6N:
MYQ@ [_/&TRO+\41\"](,9>#SA@FQKK[#^A&#ZTKQD$7%W%P:DOF5:6S9V#L0
M\BY%Z+$LRILX$:L]S!;:3WT&(T:<C!R4[]IOHDE+S"IOP[2J1^ X>&7R0"6-
M3K95:U(_$7.-'._0@_[A=X@N-G0G_A?45-$C76 :]T)(#3[2*<P]XZDIWH0R
M/IY$4Z 2[!S<>N2)&/37M+'JK#>]0P6I//,9,Q=RX$:UB7<?(A0<FNRNG3D9
MVWQ685*S@!I05-A@E.9<JYO84%-=4O:#&I'@]U;DM$37"I:R]4NCX#\_R^:0
M>OW#QK.^46^KJ-"I(_T/'07=[!@AX\5!O>GMG08],Z2TP";@:GN@VMH:(]U[
MXKKO[2R;1+G&,D*W2(H_$B2Z\F;,J<ZTU& 9INN1D1P?8]5KTIG)+-B),11O
M(<QA3L24\8U604%Z+R(W^[[/HXQ_"<UYH#D\A['2-%$T4KRU!23-(VWBW4L'
MU8/&$34^CI4.O>!XJ(*>E<) U^:NE&>>2Y2>[V0PZZ]W*T+R9XK,YHU(SQ>7
MJ:Q3EU@VI]>V;6GIN5X>6.+H!ZZ;:HZ!#)$@(3-B#A9ICLR_A!N2ZU%#/'+$
M]%/ 1[Q*/2,@3-:#V#.WI8,@XHVB&F')]FKU=0KE[VGUMQF/"G2!T8T>FU]M
MR&>C*)EG8B<S2F[(2SZ\=XVNPN!$JA-CU$8+J$GD:78U.T:$Z..XR%@"W@-:
MPC^CNN$QV^!^2?-V<RCUTO_!W'L&M95M:X"\VW:[V[$Q)J=N,&# @#&(),)M
MFV"RA9!$ILD@<LYPVVZ;+%I@DDAM, ))2)@@"20$;9.S"4)DC,E!(@J,2$/?
M^V[5FWGOQ\S45,W[<_[M7:?J[+W6]ZVSUO>=FHE><,$G<SD@]QNG>?:MG(Z\
M"ZY25NM)Z9Y!>'9\RW9WK4Y1":K2^Y 48V!0D<==1[F=0^=N<;N=<NST) /;
MWAER8'%>["1H\SB4QS5=.W]'\T/? WF\K86I'T5Y=P;/L.OU?7G?(N_=KL7A
M,X3!GI*58F54'\P\H@I;/,JM//5A2'%4E:$,_.)!\M;H:F'XN0[E3ZEM+$1T
M;8]5XXGT86-+[;J_GX\#!Q9S/"W>,<UMIW[SB'?I!D7@(([)V(*/P9UJASMM
M.42+PGQL,N%!0<J9>J"=3-*,1?FDWPLZV((C7U&IT@1V7/.$UWEC!2T-$>[I
M$0AX64R.@:6<R#9A=&1PU-I"66T]OZ3S<?T:]ZN4E'E>"YVUO[=$?8*!]I1^
MQ.#<IBW#B798?T2(-^+7!GQE2&W\O6V7F 2+BE%,SBBTV,SP*ZHL-FKQ<_[/
MOF_Z/=%>KR7_'+%/K 764*#VZ)__\87'/8(*, '-R+PN0\FH>;@:?^I>R57O
MKJ(;./WF"'AB#ZQ>?@SIX,>M]7<JUT5&2GJ%5[A)QIRI0"C!R4QU=8%'6[BK
MRYZ3-O4B"53A9C638UIFXY,U=YM2_VK#[K&0&#26"!(I+OX-9A,*K=<RGV)"
M>,'U?OYG<'N4!XKI]0#=F%],/;%Z+_Y#X.?O2_W&YYGA5V4PXDMZ(0GZAZW'
M@7.9.1E?@Q._*4B:+K8D'GS;Y:P'-#H+/L*Z;6SOR7'F[_^D!UR):\[H$5B&
M^.O4T46\6UXH2(J7)=B_(;'5'HUZ,^D+3WVS+[@V*HEB5X9W/H<01E:J3_M"
MUAU2V- 7F<XKO+HM1A=<.#);;UD6\6]5 7N6J#E )AG-H^#,KJ0P;NC5#03$
M@1(WF]#GA@4X7)Z$GF]6M1>R)C\_PZ(H5NSJJX!#T,N%QJO;$C.QIH%1_M]@
MXO/^B.=1O!D9"Q():AK;DR!V3SITT./2IJQ4FVFGG:Z%$7)K#(T%C8,H&5':
MN_, )C5B!8?,T 8J/]W4>] 8;!GV1\D'<O4+]I6!K$E Z]T*?[ T?(/Q9 V5
M:21Q6$9N:'#<8-6KFL$B5W860X)87Y++P=WM7889M%277T,"<PMUFJB:!9_Y
M^)T*LQU* ^V^D\</5KJ)FSI;@F3LB]C0FDCA[![VK;D:MI=F]J#])2A]*[#X
MVV)+0>:-;RNP$ZVNN+#%](4/DZ^L1*6@_U\J+CV.DS[-)W@E+]]VI37.;KQ8
M6U'OQ1B!1#@R2P="DU3=DH&(4ZPG</>E0F$)8AD0;&89/6+HY?YN1J>Y5WG#
MI/%=^4 PIU=(Z[#&&M[W2GX1X8F-!M/+D<\_-YF.YO2#'#JGY%+R.?5-PX$@
M?CS$+*'!+')A0&JO)Z*SAA]X]?"%O<?*$%A*JG<>&..>ZEV$#W4HS2JQWG*6
M$^4,;"B!>(<U1I7338M@!M805;J V7TC/K5;A?LE$+MM^:"RMH?6C\>6U'UC
MZC1M'V9 K9Z*U'7)<V]GT[WQCG9="<;7QG5\9PNBL.G2R^#?]/<&^S4T/>\*
M.3V=8KEH'+BJ]8>H#)KM\F6[^-UK"J?J(HY\FAQL ][6P<"1O&>!;DMLI90A
MA+ZO&R0TIWJTOAYB'D9I'8\>8YEC\0?PY$Y/&:'HQ9Q2JQ$W64L+N4[IH+97
M/VIKD&4(-QEP^0T=:[F93-&,ON.\,/!X+>" .S9/0@;-/NBV:'%_5!B-<CN$
M[XSN[:ESJ 4<:"597*D[2QW_JW];GL#X;H600NK-$#@UO5B+R*"H^M_2<WZ'
MLP0Z#>&N_ZY&)""03C#QXM'D3(R>5K3;]YP>H3V!5=>C;\7"_':BA(S:O8+/
M,MIW1=^_+47CI+'V WMJ-7 02,D *%8ZV /,Z6&[2G%2?E^?JU%6KLM?ZPJ(
M/"K?5J6TY:\-FU<M3.M4[7[E#OR'LX:6WMB-TH/:7$7*!5=F*=Y$Y>?3_HB*
MAZ?/1B^X%DCS-6\/32ZX1D)R"&\3/%?'CEWDQY660=/'@I9)\0:J5/Z(UZ)W
M8_PH-&+*))8VUA#@FZ.WAI59%IJ-1KOIF0W=XE[ Y.'VQ8;^&E=X4;1+GGUP
MS/L['=9Y.#R+SZ6D2<[0#2G%;])_/;NQ5F9^#W5FM3PVM8:S0,O.\UA;!HK$
M\7RG$U*0/M:_T^XRM^KA)*:V66%X-!N@BNS.W8Q0MIDF/@'$<,N4%$MD#.Y)
M-#$W] ]B8", RKZC,C+5*XXA$"D1? 9\2'-&>RFK")<5="%EM)]A,8(D 5'A
MF7G=T@?;F,(:K(U+694?-F5=\IUGZQL8Y979":3G\UI<;=(+*T?7_ /5KCNF
M2V^Z)_4^^_KHCFSI,OX."0\<G/MG2Z%L>MZ>PIG-SM/M]DC@U2%64WS:O5;P
MW.9[5*?]GH8+VPQA*X M5N0PR%!:*IZNA5HZN".(USV'ILHWF8WR=JJ>%]$P
M23C-PD@L%B4C6.E>=<&5>W*?63 KU&FW#A615]I6S"]'H8RN:\X?IMZ_X+H6
MB^36VY@9,@+7A'O!CEY#M<"7+Y*1$Y<3&:>!L2.83M;X<51(FM22FSR,MI=?
M?^H_GY$^;$E&A^_OYYZ_B]_(ICF>&_SEX2J[&CFH+GUFWG">G4X*5S_U%Z4T
M/W ,W8=$E/])N?6AX. $5CAFB)W\L4/12KEGH@K_%@D"'U][T-VIB0L^"?OJ
M$MQOP?<7VPU52_@U--),L#SGQ#Q79Y:0(.6TJD2WNU9:NH=\'9!9(QX]HI0H
M78/3O2*Q,X5!)\RS%(3UMG]W?V2N=RCK(S1QP94GW!?I[%/J3=06%=SYNG"#
MWI-IX!"18+@Y[[BXB)Y?N0?UGVG#;$=+&6"%*%J<M*LZ/7$]>Y?YL;Z?[GC7
M4&_LF!NV@=32S:E:J1Z(MEM!!7]TJU1E?M20K'T9J5/4.UESHV%1(UA_RT5@
M_E'4APR0@USM3;O%7\C/#F/E05Z=DZ8W2L:<MEO"]4PA(-ZP#0YZ^1RWD8=-
MICI M$7E=DM6'O*QXRJX50Q4N"<JKT:'G$3LX%=G^G1M7[3@#Z?\ E"3=AN]
MB>I(N L.EP,1QA$M6)[2%8M8CL>9G@($-^$&Z._D0?1+:"O+G>,+R054WF'J
M34T/7E,)A:!S$8$*0F&@BA_]IXPC*O',;QO#6:W+2D5]/RV4"*1+F>: AX<I
MQS\LT^+Z&9II$8E0V?5(3T]M[@5["A4N08?L]"_,)",B2"M#$NHJ/+-I%CRO
MG>5V33U_NGIKRMA'I#K\8UW@$*J^)NN9P*S@+!#:%$-!SA8#SZP^[3'V<IRH
M9A# HG B5-WO2\G@V02 C7_"I X;\/P&_NUPM?!]T4S"_,W(WP6^">A/_4YI
MS,__MG\ZU>@=#PV;6M6U07@19@"5VYS$P>B #CW[$46?: 1B+IV))FBL(L0N
MN*X'_E1<J1XH)B9PIB%5,"^_PTR;ZL-W(N9Y"^_^R0PU-X GX2K'L-5!R@X$
M)XQ'#( 7MED\!;<M.ZQ I7H&$YJF]91"!''8='Q!?KHL6EV31'& 7R:5C+FF
M=2G_$2R\MX=;U<@4.&Z$E7F+*ZJ,)0<HC-[K7$L'#H9#P-;]@\=Q,N2<WJC
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M?D'X"."6#4(DPRT-L"6_]FL=.0(\UY+G[_EO#XI7>OAOL%7XX 6S@+B,R!:
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MU!B)1"VV-.6H<M%<$.46.8!KL^P3G?!FQZK\1H?'!N^AS?M<O'%-FJYS[!>
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ML1R!<]YD7>1,$%]B16!.WM.\2W,JJ0NY0]U?-^NBPSF+V4O42+]F9\*@T4P
MY,;C%ICD7568Q+,,NM"8_K!>KM$$(W1<H8,:Z2F;,7P9RD,M^V:P<&QR0=[V
MSX$3L\D-#.OG76G^'4W,S1K,9F5%;D"FA";+Z1!BV4^&.,:E8$M\:W0P#&X=
M8/:'EJ#C']%%+5;2;N5F<EWY#CCR]M] G^WC[V_^.@T7M@VEF@O_$3](T+%2
M3)XOG[[IC:W*U(<!B7;%"HSR<'M<N+LR+?$X6T _<*WK3D2L<#FI&LYYYYG(
MGN8HMW5I]WVS@)A6#SA4$LHMNX?8+ZR<E+H,WJCU:K>X8=1QF+^*&\3RY]XO
MV>/-%US$U<UDCFK<!"MPOY;U2^GPWER2DDBX_S9K"2JNHFY2KS[OD(6:#"G(
M=9#%=_DS7\, B"SDH!T9"P#QQBWLJ3L;X'T^43"5X-QN$,!HL&;5,C*R\$5]
MM2>:Y>HJXP$$3A^#P).^-<<6EP0O0^:"RZ$N1DZCO#EM?4CH6,.E"3$3CWAO
M8&]%Y)^1ZLMTG#F"'ZGEX.V,^9WH&Y6AW XM,$"7T*93Z5;!QOO,0N=!!.O<
M(39?24O7:]1C4?1@JS0;*1IPXCUSIYV'B_;\(]*6S*T8.>4.]QX?UV+8BX;J
M27E8L!/K>$C$.SX;[%Z9=?NUT9EU\/#2Y(P1/?? +D=%&-L9VVBA?3;>O7OW
M_&_5\P&JXN\V,VZ7)R34<%;;3-VJQ?,R\6+?>Q3Q]NOV1IVYD_N48FU?S<C[
MA5_';5"$#K OZT>>887:+[C*X.PN^;7PZ]@,>CMDS_*ABG<D3=I.LJ<@,V_9
M0.^N=M=@73SUSX6\,5LF79WR=8J6)A6&N:+C#,E QU2.1;MO\,%NP (M;W8H
MSTSK"FQ+4#IBA=;('0)'%UP[=:+8\ZL1\TSI(::?U!VK4^;\B=S)2*U'HI(1
M/?-OZ#CMQ*38O*F<M@.ZX AG__B[2T".@6Q<HBJ9C:'7=]/:D[XJ?="=2CRY
M_@>!?6,?IEO9][UN;:+T7[I41;>K+B_-?R06R1S7,DN7G.*;"/_-_#WGKT*R
M;N[9?G5II>SM7[,NN*Y><&W1/^<$7' =B\]GWE00SVM5.QL]LT2?Z5B$MN N
MN++JITNO5'/(R[[,N/?EM\K.^=3:F*0^3@+/^XW$-U2VW$G=.P^]8J-+.'*H
MZ5U5%#;K"+,\?V7$\>1!A/O^2S)K%WL.;6'T_CIS=\DQ\XY'PLAJ9+(_7V$.
MK&2!'$.^'[8SUC<),GY(8#\TYN7>@GD7.QH3"'!^Q29OF(J I]]H!D@ PMUZ
M^_ODA;:PPT=??O:.>:6V2PP)2IG5DXAGY0E%Q$8'O(F6=G&-(R?_Y&<:11YK
MR35)%I[J[*^M,4L>XS#DPB4B)-8GK Z8B9J5PVI,R'X46OECK(CQUGBAFXJ.
MW&*@R&-\+<W?[R;%'\VP?$(Z:TC-0BT\]7/:0^6P$<4#*9X&(<9*UI9A."P5
M$V_%ED--O:H>6\CO=\OH]Y2.'!3P;WNAUBE2*!A"GTSWGVJ['D75V-O%2I;V
MIG7+$>:E]?P8QW=%@1CGQ<5-R)Y<S%_"!\3BU[,SX!BUE9X0\HPL?)O;_FU%
MW^Y1$TX' '9[MNKWGH";I75CN^2\5VHJL3+JXV%]E 1/+#PE-;@ '26MH;:[
MNZL@*#(K6 A2!@9-W_H9U#FHY!?/,I]KE7G?<.@S3IDTCB#8/I"%V[$:Q[,*
M*YMS#6O8)+E6@]$*2MG=-YL<=(51W3#)\U&1Y*I9A%>8D<C6%E'&HM<#?D#W
M:PN8G)S)/'W']\4!LPU4*II=YUXW#O]("'^#D0AKI9;,WD_?T(<,AT4&^GR/
M)*OMD]:+=T/RMR&W3CM 4"<,0LCKS_+SA]O9:DHA;LVSM@^_YOYLN>4)N2([
M]G4!5OX%ZZ:GNN:$6E^&XI! R&WJN([XG&W *SV+@LZ2@.VDJTJF@R<*,UYK
M@SVK+$6<5#LI,LO&D2= MVM5HS_3I! R]:+"RBXZ;!@JNQ"B*[,^<:A8DCT]
M^;:G[KAH!9D0HS'LM)Z2<=8SJ9.RK0A3L!F<3@_":BSL?VF$]N^6<U-,_>U$
MQ,5* C6;G0+"X776)LD886?5;9B.':I<,I"^'FA%:*G7;&;5QFC9,*!KR1FS
MW<MY?5 _]ZJB1V@-3P^KV/)>[&D2\O#67(<;"GC[VD-KC=DKV.IP2%,F4B[7
M<'V##U_7G3:)L\,;,'U&55GX45]SG'SH.HR$^8)[N;4@.@,Q&\< 5LK80,RD
M*$&,,^G/8!8M2\] [,NP%;W*TV/<^/'N]5@LY_O"\JFLSJ[(WTUY#H9[)EH+
M8(#8:'R?Y@"_"J^9.0!,2816;0696:X3X>CE]+-J]?9MA,!*E#VH2^&/Q6;R
M%J%+QSH<8CV8VGJ_V_>G2!2(#=A.R;H?9"0"7R$Z$,QA^O1.1U.G07BM.67G
MHXR':CNS1%>P(*IW??QQ%,,RP2LL1/YI(7 W+8 $@W?NN%<2NFKYS8A-JB!E
M'20^VU"N3;'8XK4T.L,Q+ 27 X K]WW2*B]W[)XJS*M-Q<U:9HOF+Y98<,AX
MKZI^V+UABD;4:H%[G,IQ S/I\$8>*>?5#7SBTG;$^LG[6N\+KC?EU(6<!X$?
M-UN$VZLH92N,,_X++I)*L>^_/6#0JZW*H9N6K_2B #W:6FUI9&\57(6B.N@I
M3,=0)JXZ]L=W)7*51YD5N5[>&3EUM$%76E@(L$(56J:5P[CU-_9T"]U3NBH_
M&2OIURFB+&(3^&6N>!@@]*#\$T,CV/*:C]21Y>M8'>JQ]B0MWGSE0R15\C[%
MV@;K,WG5EP*ZZU47$_.ZG%Y5@D%)'$-X8Y_= N*C^U_5/#4#0Y2I%3SI$6IF
M(>_J[732.^(U.Z6C&J.EBA6&O*+*2=9\)M11ORAVKER* I1#R=1H<I".G55-
MN0FO6G>^CW#&PY4IAP?DGHJU?=0<W#<U!F(AT&]X;U28M*MO%$E^>"8O> -D
M-L@M>OP\=\63;H\L79ZDN^OZ*EJ&EI"T+ B$+_S49RX;PUK4QF$\PV(6 #0L
M?9..=DI3)I=SB[9HLGK3"FCJ!(C#3M\U=8'_RS2"6N9O24.)<0G#>X'S"D6?
M8X96+[/\I/-<GN&__QN^Z1[_=(5KU^@X9;N4Y74TY/.W7]6,OC[JU#N>'ZTO
MQF&=OS 3CN8Q3\=;U9U#66V^?/HV_VWFX3[C-B]/5J$S]I(=P?]'D8;=%0%/
MI5(;K'+1QZ%;G [HUZ4JTIC\<&:<DE$G[M-*#29$XM@"D#,PVSN3EHM=HXO(
M#VRJ.E66.[C=@AAW$K0GO"H;NXA?M^Z"L+J"\"_;^:GT#8-0N-BA)BA>U<H$
MGPBB\EBB<8%\0]] 56?PPC$_=*AGYMJ;-JBE]IK(S_)!<MLL5J:43;4SBO$Y
MPN]\(*IV71;MC@ #IY92O&NA%@Q:'\WYXEF 3H^@0P</+"9++#1=!^&DD(,%
M'A[8%:.^]C+M^@<TSTF%?85N;//>T>_CIH[!5:,5N/L$AJ'ZO@(\)I>HG9R<
MY-[G4=5GAZ8W?D2Y?0=BS6*9H8[VR\,(K]/K'HD^@+GQY@5-R\'A"R[W^-4G
MM..8ENJO(@S H"]R .*+HA![)JHP2];@%LW>TZB7+?@Y?]+KW'UHUJJ-O2MY
MJ9M]NH?6S3&!,W7$CO'6,1=<XX Y?6B1,UY(G;JO,2S.V9RV=$.4K%YSN[IM
M/!1K7BVS#JY+,#[3L!-N%Q=M]#@JT?E"RBUG14M]V?3[PR@^,-[ZQ,\,IO1'
M,H$.&Y&.0284WO,,@%!0/@6LL(KRFNG"'#NT>G]_%$]+;JG(U"UBZA5G0,?A
MIC@[)$*R>7S:$C?74CB3#G$V[P5CL2N)*@@."])G72DAVS=UAG+[<U7\X6#(
MP]8'W2&XC-Z*G$G>3O0B6%@Z\:DH6/+=FBL<!: Y*EC^_ -KTJ^8RH<AFQG>
M:S=DR6A3$W Y V"@9W""QHH/\LOQU4PIDB/</O@];'3F0<X>S:YN]-FD$,*"
M,(XE&U@:W('MY6[;8V<OL00/SVP<.087;@ "N@:')7DU+E)KR&'J]U*(C9V?
M;5#'&*<JFC7Y>OS]5^?92+'JD)@;F ^$Z29DOSD01X8IJ-"&'V"+.JI*Z5AM
MQ>!(_IN$Z>;MAQ\5%;?E@@N+#>Y<AC.WC+Y9LY2U^TB<4VE69!PBH&@V50E,
MJ4I912QMA?9W%-2'8&5>!+F\GKZQ16:,V^'6 G*/9TV=_:M2L:\QQ0B$MU-F
M!I.##Y%X^X4B0?%$E0OD?XRML::K]IL%)IF>>*&&66KS7P0[[IBZ].##V%D?
M.^@2Q0,C4>$'7W)$.CA50;>>RFJ:=41XL3W=FC[H3$RM'?L.Q] !73?EAMJ=
M@^-S!W8=&\I*L=EWR^R+5]1J7!D.W$"TCH[&9U=-W7?8,*>RI1@^^7XS?T(0
M@@X\V?\,U6K+7W= SP09JDR7\K]RXDM[<^A+).R:)1/5L(WRLL-QQ4'/)H5K
MEAN:9\G\#U!>8>U=\<YEA R0\I]KB_?ZU39_IP:"%>H(-^: ;Z8=GR)M8\=,
M4)9:*?8 !5,;5M4[N!RZ]7@ 8GYO0;"(X&72WP[A,;<>5!VZL@"4UEB\X+J[
M%E%C-V@W29)6Z^)W!6T++I)%-,BA7Y]WU\7D;WB7'$[@0DP:G:9@W:D=^R8Q
M46YA(P=-8*<\K Q<(MJXOY.*\;4^T:%(?C]_KYW)[.]?$%V*I^G)(TM-(8[5
M7G].:U=WPNO%M%GAV-EW.<IVB]2G99MCTX[ZL&OE\8"P($V>O6>#^!5)I:HI
M+'YBX;#,9Z<OT)JL_IC8'NPV-[WWH]*U:(7,7\+8A>!&?HVM0]-7;KA:A]>8
M[EXX/ 5Y]_+!7Z>F8Y?IRS LIU#RZ#^%;R;\&JJB7% K0.=^!1)>T9#66%$W
MB_C=3KK"O.H )O-=\>C>0YZ0J-5Z87K0'SU[_?%D^4*?:1'UOG"'-T.8RM']
M!N3!MF%OQFDO 9LRD5;I\JS;MVE6JX ,KY84'158T)GMV1HL=5-1A@2G[[:W
MSFR'D/+2J8F63^^_@<:82OVM*^5S0Q9Y2(Y..7C\8(: ! TYP^39^A"8)B2N
MNN2I>K6G=$0_74^K:5:TY?98Y(^M!?5(XNONCVI&-\^+X)D3)>:PS\#UQ)ET
M,@U;QU(P?QKJ_2.=]8H(/AH>NJ&-6QG<,KS@HK,!P#"M@'HZ)]3V>L@A"1(@
M63Z3_J@4OP!YK/5FLM^\]PC2>K 5Q7\KZXL]L.>A8@I9W&V_R-.HPAS+_-D*
MHZ!-\<;=VVD2YSG8BN6W-&9N?5INBAL,?=:J(^)=$];>>;ZT5=)^E+N96^WE
MWZD!$0DZWG60]XP:3IZ5(N%OW\FT5"^:4U+7(MK*2>E;9]2@(G$E>',0DKQQ
M0,; G&V+YB)M:*(/?7%A^H:LI9"^99S:8VL+ ;"(RN.* %"@>^QR$]OV5IWF
M+QU;#0,-7W8&<$X<[Y(CRMNMK?6PH1BJI9QZ!8Y=:;O!0FH%0!_@UOL788%I
M38/HC>AY.&TDLUQ8\F"KQDCW_'L52^*-O/7O;^MDG<ZVUHC'\,?]W]&7>/45
MF7A=0'R*?,'E.28<_^04/U2S]_2.36NQ)?W8(S?J$C)].:&=7_,XG[2!LR^X
MUFS^JO#R.>'/Y"]7(Z*0FO:-)U'X2--IQ+,E:T=>/6:6-[KK>:M"Y&9<>KSK
MN;]H38Y*XT#/3:/H]X7F+RZX(BN2@KT?%/R,G/"=Z30.MIE 4K#?TL(*ZF5\
MI^;&FR"\6C$0NNY[;_6&$S;,0&4-'8QV8\?R="1=$W(S'_/NGTZ%EY:^GB@1
MZSOJBK*OS2<E&C>J42$=<DRBCS.\"XTS5@@C/HQT".FZVS57$\$4&0LCP.5D
MO%SV+KCL51AU^ZZ8=.E'!6V7C.3(GZD[/5QWR.(\2YDDWXQ(*!Y/7[TF\2CJ
MT=09M@.G<*QF'P=MB\97LN!E#2/$M;I:#XMW_OK%.J*R&RAZ:%Y%#"!_XW52
M0J"AYY*Y*IBBUF42I1:MW%H_.34R3KP1'. /_NTRMHD!](H-0/^;U2>.=Q4N
MN+K4LD^_W3XCO0G_9LV).;I7[,:!GH#WY!F!H7WGDRM0D7G!JOU8VNN*^G8Z
M@XH"L!]_D)-&U4'E:GO6E;Q\HH;<F:L/Z9Y+<5/EM [ER8R-<Z<SJ*)!V':2
M06QX\9>3/C*IFO1I8O-A 4"XO-%NU;#[?7=5[=CP& !L %7$A\AY+S$MK:J"
MF@\M6*7Y6+J]'#K"\D55V$,:1T6MK'%6[]W'FN"S[$)W31J9I&6H,U'!HM2M
M)EDW0?I6LD!TB5%:'Z'F5TYM.--Z/7(%D90(RS!Z2G4XTW*5(,PIDZFMK2+7
M!YKSZC;N@<4-/3V!-I:_RFK_5\F)[?^4G)#Y5TL)..$_BIPCYI6[]N,"$KYL
M9T)(Z"L0IQ1;=EV;A R\#BJ?OW208U%9W#,],(D=Z#XF&HJ,3J=,5=FT0@J1
MCL"%X97IU4.%3Q^#MS9%\@B3B15^/=>Q#]_LRV!0)>9ZZO>25X![ (N!V]RE
M/0X]SMB!@8.AQ-386N*G/<9Z:X!\91C6-RZ"?8(9G"KB-]@WI4.0 4/P-?Q;
M= /8&H)5^H/6'[C.H8C*&PW%\KWD;W25:]LT!W/WR1$BE=;98DEB H?OTZ/Y
MD,VV ](C3#6W_/8)#$.$J)EKXJ[_[)2E;Q+S -EB47*\9<ZMG00<J0LM&1CV
M[<4%^L:#YSJ\!IW3:2C<EXSBEFL:(7/;*GWW1QUQ4KE>\LO(T6Y":!$%BV5'
M8#&S7P:X!0R4YT*;")@%/SQJ5IXPR4H01/4$85&I \$9 0>;DG-9SP>J 7[K
M$&N(C1.K9(@P;'X+9E&NF=/D]5VGFU> 6I>\EPRJD!]3(XH$QCHH_H.L<H/(
MZISR$/ ;Z5#@LX7'17#&V,%U'G!3X^=T\W!#D_%GJ!@CGM']</=05<>, P@)
M*(P&UJ8K-14JYQ,A(CSB7T-A07_@B#"&W>:"7<RFOWX#L8$U:K/R:J.+&'90
ME)H47]9(R,<6CPJT%='-1E5X6L1_8BZCF)U>]N3H%:G"3^%:Y8(4,$.+CY#V
MT"PF\A.68]5)<#TS4-T_-@F-CMFB4ZKR5TJ6F%Y]<X7JL@0-J=%;=8L&4:1I
MUN'D-"2  C:P_=EJ")\E.)%E>,!!^"(M_B-D%KJ!@J=+RWS/;"L?M89P*U.L
MO08S.D[4YX5S<K,2#H?)8_VUHW]I$^/Y:?B$DI=9L"/3LXS;'\:V,NO=79LR
MBT-B' ?&]OQ9&*TYMY$5Z?Q9B\'M.^K!A*_$)E(Q>J[(6;9;;"UX?1KD1Z,#
MM'*_DY>T&?&PE"-I:HDQ@3&@,'KL+5;M.GNU#C)=ONZ7O]4?%.F64X/V].F;
M1V/) 24;3+*1+^D(F<_+6\8,"H]'1)=3W(ZELM R6IIV#.6Z#XI9[8=--:$0
M7EY>_E%]ZR541'G^2"@/1/F5/1I5%CLJ+!4VX.'OI=!NMC7/<Y/?FW3DJK$>
M4S%=%'#!)5+XLHBM:1N,\3"8JM-Z]JYJ/?0G-\&;9JXZ _1J(Z6R56%42:P>
M#J3. E]P81$//N9WNFI$#K*T@3<%S5J<96#EZ(1XA]C5.W_3C,IV98?GHZ<\
M'Y4IB+Y8=883]/?*"<$&#RU&1RP?AR28O 6.B;2#(YB8>6O]+E9_^]E2I W3
M;-@@#JP\?\'5=KR@)*/\JIU)U2MQ^K%VKEHQ3"-CG&+886EO+$GOK[!UJAKO
MXRG"N\I5@F- E"9^9UK !GO>7!.G.F!-/RA3;]]=Z-#6MO*FY(A^5Q\2E#\[
MB;A?,? 54UN8EJ,'Z%&^4L*&KA@'YV81RG*%N@ @T'[7E0S?HB5SD:5AAQ((
MA"E?8%'G59=+NT4Y]POHE ABNKZA52QOPT:QQ2W\!:U%OWU0NW8#2[+'/9#J
M?_O6GT_RMV&*;B,_=>V%\5M/6C\W@#O>2L9*QC2.5J#J>/L<DR"'E1E>S(!8
MWA'C:5-9S$L_?QLH&_A=6\7K[C,-WMJV *-/3&GGV#HO2!WYAR$I!'RZC?-N
M7SB-MWNJ@!L04F<=0S(PAZCZ-B=7G.#M;MENJC(\=>.%RQ$EBC-!D9 !<5 Z
M+=0\T9 @)KNX:M?YV>]\<.\VP[UI*9=CAL[-H2VGW2?2<4[O6XDVO5C8VM?9
MY<O;SB"J.HT6+A'-5O(@UM,%:*]X%?'[K)Q*Y3>U1<FH<C'9E&.7\\@3E0YF
M,R(%[AU4;3>7;6EI?+]/RC'\2:5UFK![: 6F@",1X3M9%@'@,12<]5)&\#B&
MSB7O@,71^\*"PC9^Z/SM(6WLHA=9C1RE^2%ME1ZDBP .?*21^D)GQQO&@NS@
M+I5IUEMT@7:8SP0!IE06]G^P]]X!36;;WG!F''6L#"*"U!%4I(OT$I@9*2($
MA"3T,M()3;H0BCJ*U#"@M !!@P3RA("4@(2F@O0B)002 BH]$'H-[4//.??.
MG'/O>\^]U_N][Q]WY^\\ZWG67NNW?FOOO=:VA1KG7WA.=5#ZR!F_U$'ADF??
MD3ROT3&I>-S;^&0W\AC$^ ^=+@S^VNFBZY_J=,&AMN=WWI49GK\:KU.-'QW[
MW-OBJ4S5%E!M\@%B?VH?]"%'>=OKR>JC"]#9J4G6KO'635="?2MA-NSWZ!U*
M[;!OERG%Z1PB+[=Z$%\8N$[#;3D4Y#]*;EIH\S<Q4(85]B%OQDK&NP.(&)8A
M-A ]&3]U4[GI3-DN<42P>!QW6/K0Q'. 4$UGZ&=\4$S4+GCDY%#A$HPHV&BL
M!5K/3[O3J%BL?Z>>0:?[>53J8'26>Y%RD'J-[[+4D,U$%JM&R2NA? _#$U.1
M=6.(F-..ZY[[P09'-M6[1K<-*G3J7Q]H:58R?QTC@(AC )6 'MB$&VE(>VQ9
M5K6M^:#F:I;<=!.7N8^/\#F.\UZ7FZSJ]8U4UEW]SJT4_W[7Y3;D>@6O(N3T
M+VR)"OC$>8B\ ^9RX8U:BJ#BS<# T+S9) NR2*XUP"XW<(66&PR%9+V;1OO&
MB^."@ICIBX[T3]<],K:#1:1-'BYUMW)]-+O_GOOE/[(I$L<QC@]Z81%[ELJD
M"O_[LUJ8^GV0<V2H+;_HYSJDG.^D;R5X@6YQH()W9/98]1T@G2>K_FGW/N_]
M%2P=2C]W O)@B*1>'.#U/#5(*?.'=J;Y37M%[QA!0>M]T+IM;Y">:*V>;H(?
MR2IVWG< 11@N&I_TZT&I(W#*8Q-Z0AIR]8*,.-TD0A]$#C'W,6IFZY+Z"B1E
MR.M3H/2V5*.TI4WWHX2\^K[VBZ;M)\S-Q+)-VODQ_:N<-@50/W1%\(6$<P0
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M@X64A%?C(8<O1K.MT#BYCBC,T<I27=U$_ZQQ.*(ZWYC87[VF]7-52K-\Z%7
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MU:Y9U?@[Z%G,JMZ#]%WE],$66H.S0G-$R(31V>WECLP4)6EFBV,XN2/C$M=
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M4GSWO_ ;4ND^*+QT;?M4:''Y!J&PSADJ)6B RZZE9^)C)S+_'$T;X);FMO*
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M[3*WN=RJZ,I-[H)ND>CKJ%&FG?Y5IU.E';6WU4_E3'750\ZG)Q2LWVC!7:$
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ML?T 63]^F!.Y9C$:;BE">08RA9V4#+$L//V<*NSA_*/+H[+?XV.I-1WZ9^^
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M^2U &F8DCZIGV$WH(-1.H$;C:HW+WJ(TXZY-]3G6,[6?*-%RJFQM(496'(^
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M67"<?_B8H?]K2:,88;U4F[GNRL3G1KGTKRFX"T?0T_%("26E$"$'EQ>LQ#*
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M@,8NIJBL7AT.N_TE1</B[IY7Z:(1GS'$(#M(H&&:J+.Y+FMD3X6QE.^JA@(
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M_>2YNMGY"B,JF+; A6NIGOSF%94WWI,\2'5V[J3I=9G=74@5HUH[Z=_)9ES
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ML;-O.C*:8T$2AB2#+4%5:X:E*K21[@MEW$\!XFC::\;SJTTAD86XUL>SGPF
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M)S $;GP</0?05@[II+(FAVZ$_^0S**!U(JID93U)):K@ZB5/7YC+3GZ4>NM
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M^/1EUVT&(<TDXW(0/4_UC$,V3?YTRE1\+(P.?NH3 N]YOPV)..'S.%D\I>%
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MD2#J&>DYJP+[>\4M=%=-&FWX4U<BP6WX4)"-3<Q;R??"VU>A:#!G2?5 K&
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M)&E' 1=\9HY#L46TD$(DRN#OC<G]._R/Y<#N6/U*+QS3VYCB/B1#("G1K[S
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M<)]^WP(8%;VMGM;T74]#SZ[?6D:8+R5;YWKDC*;([EU?52S63S==MKBHX",
MDO%2FS#B:A&,OBSQG'Y:;0#IMZIG9<_XX]<WC33)^;!!EN..:U384%IK57A&
MVJQ _!Y1,!OGNUR,"S#D4ZQ%]#-\6 0/JYXL"PBNUO XAZ>RX2+])>>\07!/
M[D^CNNXK9(4491)4TF]S5/[<]>M?<![52.;F0/.2O7UI/HI 3Y@];A7<>ZGA
M2]3CD;/2"F]W%.2:?M=%=:9"=(;+-E%+HOZ7MOF0[_7OO>F3%M!^/0^(PF#_
M ,_27M F3J&)AVFVDWJB2I [;;XUMSSPN,&MINNK?@5N&2[A;W8P'$E__6?@
M(=1;=<;V.B3S\&3G2GK&F&VK$BTCH'M)?KGR-?W^>PV'_! 8-+@86YJ# G=>
MJM&D)VUM((AP$RGXTM<#\JT 77,M>K+.+V-=$.'I3)8)/T%@B.I$Z@1'8LO<
M&)DYA<++V)+0R!F_(ED'Z:#M5@3EA8&,W+.PEC52QWH97",+2=H.YMT&32T^
M:DH?,8=&PAY2V ^?%F&?$$I2*T(-J!7)@9BM@3;LJ=S)ARV<Q>EX?II&TGRC
M?F.@%F!CPM&C;,>8$[PV^23GW@P21,665_3U&/8M)2X>>Y#;5^L0<QB0"25&
M=$OFN^\'\)<79V,2 8JKP&@]J#8-Z/_>;*BM><,O1_FOEV9;>?RF:+NRUL:(
MVK?#L[&T4 _R!!Z>S5'J9RD"RA4$Y1VGBY+QVR_\%Y[/F'Q"<^!A?P2]X6,H
M!3&^K9E(A'1C/L9T5'V[C,ZV:!S1@5[(P8X]>'/ 04!UTV+"FEU[1M?,.TY^
M/&8Z]NV+_M*L* V]895@7V+1F3EYTOBA=V'E.Z*Y>$NBZ?4@>#^KU^H"A,J7
M3L:!M82/LA!F;YVX':Y('6FVF.5\?=V= .Z\=NIO7:IU2PO+;\WJ0.X((]U!
M@( JTFXA#4#WFT/ =4"!6%'K?^_3_MTYWS\B$_FGX.]03?&$%WUKVNW=O7$X
M7_O'U[K]A!5O;NYN;]CQ_YN)^4'N4Y(H@KIC/YV;]:?C#9I,2/%72!#<>LCD
M4AMZ,%-YF^ P_AR;?Q\(%>HXQ?[S@;#^J,.5YK!=OMJ'-V=O3"AJF"N)J0/;
M9=ZX2K7R.J%W?9?RZ+@%S.5'?P6&M>>/U]&/W+>M?OV^>TVHB6'T4\&M7Y(^
M5 =8=FQ>"*G6W'+\W4>1A7MJ8T-(K7V%-+TH")N-(ABZ\_>%%!Z;V@M:3^&;
MG;O=$!4WXZ78M?1D_W&T$C:G$(4-EZD?:B,KY"W4#MQ9ZW%45'1#R/M*IULV
M'6<^%IP_K?^;TF."YF/78\#Z*S36H]XF_M";S:G,]I]EW[#,4T8],6%):>%4
MW#J6#)M%&*EWGD_8IZ0"5GYBT6=__VK7K'"C%RE8@#I7,;[ %5#N<.2?<;^F
M=OFWBIQW%0D$\#Z^XTVA?2%"FA\O0JT2XW<O$)L<UI$405X0_HB\*SJF.X!0
M/:B'259/@[4CTPN?K%[L9X*8^JD;)3IN3TQPMA8":WUX*X)]?.77N=Q@W_J;
M-0?THJB L5'14COPTU:9L^7^+)'P*YF_Z)1'W\WTUJ19$KJ=T6\CO_&NBU0%
M&JNF38D5C>$D1&GAVT.%9K"D'SQ=ZW]Y$%@JU9!%N;XXHJ>>%"DI6HLBE[0S
MEP[N*(=GKHVK=-Z?\+I):X4E*<^-BZ9&,#]]]TGO4:JD@(SF:C_?!HEHI54+
M%V<ZSKE5^ <6E*-<^X56G[A]?2AL+!K7WY8VX":H@T@K %KP=9$'3.XS#5VO
ME@M?MA8;'N147^ EP&<=STV($2C^/W,958/IUHU%KMX$C!E)+=6Y7!0;8(<U
M7F"V$5+(@\45(2=;^T+7G@D,#ZAA]D^B/P;"]0[Z@(.F)]LQ"5AB0)KQ: ^A
M%W^/N/5'V?UE1$W*14O8*N>I1VG;>E()6__Y?,<"5EZ)"-]Y-M@J.[XJ/14I
M;B5KIOKRHR38=JN5D R6OOM@;\CTW-7@9HKG8^1)@-[WC7NS8)\6X"@3!$*
M^G[EU?CFYJRX]X/G_0^>K\H2Q&-[376.ZS]X'O[@^>*LYW="8_WQQ(&._<<O
MN>"$L30L+EK^"W6PW8I0[3[$72HO*#,,B6B^_VJ)$T,1WODK!PCU]XZW$JXX
MO$56URFO57=4GI%%IT5-K=E!0Y)-QI8N3PPV#YQT#BYZ&#ET=6%P6\DBTF!
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M2&^0$[;]-VQ23PH=KFQDH@41%:MD@@QP$V<DK@60]CAK-&+66/49W5SW3;'
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MD_BEGF*$(O-W_6OS07>(HRWSTNE&1BLKUM=HRE]9LQK7T1[[]\>^M,'<6O
MLJ,/6V\].:/VD3XB28P,, 1+J[,,-#6?>L&RO6A&-*)6)@35Z><3<A".P:H
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M+3!M1!4<J$6@@SA<N$/(4E'8[]=W>(.7/5+^VM@95XA4"H@(UA'02?M9H>]
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M'_WM45T5-ZK]')87%G/'A\PO!>*PZ'?2[B#NDW?))D3<$C6UXI'3A3-:UWJ
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MU.+3=:B+*(P(>!W#V.-^"2^0N]'OIKLXV3/IR4\2NSI6MT76D@/Y\S5ZMW/
M+KOR.U)(P-DE5]-?>0_=1Z1%90)-6K9,5%>A-C:1-C9V'>A3MPX?!I=TZ_K5
ML+GB:L#AE8*.CS$YJ:BI);*[JI/\8:N<5\(C0Z.CE/=GET/K0,WZ(8$2DUP5
M8>3XV=#@5<0C,%<60$KS.[R?);_;M;>LCNIG7/>3/(O>OY*ZLA0$OJ,'<N8;
MT&BKO_T-H/PZ>EEM;!CI[1O($B#WLW&!"*'$ *NPY@R?K)%?1B"WI9I8>HG'
MMZ2(D2[/\8_,W@C?1S]3F1)LG\UD-+BKO9CJ#B,C$XIH:/;)_G!J^F>7K-*W
M5G[Y8V1_$U[5[^.4OLCK%D]7X]!442=33@3''+_UOG]@-T?GG6R!L2JT<)%
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M;X_F,>=)QXR  L4#:9*!9)'!?4GJ##)J7,F.WDRN[0+;+CLKD92FEIV?7[C
M-+6<]'X+MB*JDH<R&#>G'0@7$GXGJ,M+7[4RI9,%VHOGE52(@^^MVF3/9.06
M?);5/K'7^$0/A3":8S+UX>9Y*>G>CXVV[W)SV+Y[VL.4ZF$[^D09 NV6W^0M
MB!PSHN_NAOH+YQ05?0&;B?<NW_TX4[^TLZOHSL7,N]^K.K0<N+CDP^M9_"8]
MT4\;=03_BR=F0L!.T<FK'[<0=D*?I,@D)3EZD][7"4[&&4!1V$]3?J1GYS:E
M:N[HCNU^J@D,F8MS?303OV5\1>7:,%P7D-SFB+*G:?06T6+I0O[#C0]>9!08
MH3:HJ/O2/]>YE!<U8PEB5QY/Y"Q!)K62#\).Q3H)VLV14![CN.+C).Z60<92
M[/J&A=G.D+$@'.)')'_$'QJHM/GI8M,Q/ZW/?7L39C^[<GLB_I%I=&7^T$>%
MC.&VO+J,O)81=)\NB6PFY+5:XQO=-;OT<VAR8=Y\= ;:OY9S2;BPMMT:48ZH
M:TW8<] [N^0J];"@U!M-O)[@8?W!;PNZ8D3PX'>R+?2.S+2/,R*L>V:<U3O[
MY(7^QIX;[6?<NY.<(5782%ENY7 !RS%XK9AO3Y_"G!BXW=@;%Q=7U%\N:YLT
M8;@0;]V[(4#31ZR#%!4^:"N\]ONN[>WIC)ZJ8R[#JS&T4] 7-]10F4X:KOK=
MYD-#GA& T<"B=8H4[*TGS8*R+'SZW?S9?TAP_T8&_D<L_P\AJ6KLG;J"'Z.<
M[W#&:)MBH!+ *:B1S,RK+IH=!:0HK5018'BH.DSWVHMR.X-:AF)-N7:KZY9-
M$G*6S(US@@+BU4%" . X]A[M \03#_7SZ,:;Z9]5B AZ,2&6&#%9=MH-A5^+
M<J'O4!@57E7&EU)8BI2@^$+/V6D=H.TD2![WAM?@QUB-%2:XNJE_*;[C:IV&
M"H-A:4_I,[*"P.66;+'U!0$Q>3GA1P(6GYA(-T;G^4DO=%,/.ZV!G^Y%5X16
MO_4#XY-?&#[W.7I#0DSIRI*?&?C(*H=MF5"<2KI $HJCZTN'^1D4-=8:0'U(
MH A6Q8I2+2@N84A9YH-X1'U12FY<<%93T;X)0<2.JO)L=I-NU'/?\O:D'TU(
M=]I?E"LU7&[[YNCTC_WO"8N/]F1&L>*9,G7%*E4=<L1DX7 JB8XH -/;( ,2
M\/.]YSMI+KGY^VM$T.PF4;ND] RYYA=/1$5:G=[[)VIBK\/KEC4YN38>>0V#
M>#:LU_B4NWQYDR)4#BDD#8 JV?1T%JX"D4  WW+MU:CR7SS*FS["G+;R2J=-
M!#OF:E8C:;[8!$?RA%M^\2ZSU'D;+B'GU&<8CA 2L(XD MDHXF47!*-V2']I
M'*;3H,?<D"#NQ$S011&/K6XV0+X88XLM#0][7A2//)7]JKF_R,(";SU<;<O5
M/'Z*'N:V@AC<MT]S^R&QPMGEKZ9I6?ONL5$<VWG1$,FIV5R,62HV1X$$10E1
M47K1L'1)WC.OKF]_%ZLHX0SB?.1>7&\ON"BGA6 RE*NPNS?TR[X\PE-:B6M8
MW3DYK]C,@:T.&;L9;)91)M-64*;VSJMRD*IO.(O,V4\=P[M5.-DXJ*0"*Z8C
M<%3"](?11PU@L'BWH9($2##33]UJ(3:@/_^P,,V7_+&\\ RCQDE[S+_H4[^?
M/PD7^"!$Q1 #*>TMM;@>O1Q!#^86-4:R[VT!$.)XZ!,2Y'!/P[9'^6;A:=Q/
M:8B#;]"2&50N3&!T@D1!B.J2I<,'<264<Y#9=^6BU9M/"A>Y/J1#AC^JG?VJ
M='TK?.BA6F6VWDE:E_<JJ( ^';?45W./*F#PNA%C*U[-J"P,/PACE$I& LR$
M;@/]COU^Q,S]D0%[$R?&L'T4[] 0D/_Z+8\R-JPA,*FO@A8>UF+*IVEU<S(
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MBT?[V^%2<+BG_FFUIO8W7@47S6RGMK2((]R.[+CPHN7.OYFWGI7)LDDS$V5
MK-/+BK5 G(%H'W=)V-+D1U5V<,E8R?7[0VD(QBC&#.E$H62'8\3/K]J,/^^Q
M+6T<%';WR'$SC8T.NA?MSX2V0@ZG*VL'!+IAO4IJ7KI=RYD<),^E2(331Y#&
MOJCTT( PJ";%?[@7@A1ONI :EWX6&'-=:N>,A(Y/LH^Y8.(@)53_?8U_9A8'
M"X.&]$(P!R,&D'FJ0>1%,%142=^*=5LZY&:Q<H-2\;>/">!DYWACPYAQ+5)+
MVQ(E8'\I+D*DX^I[J!GT0ET7SS30.?"8]'0?;WN[T:16 ]15Q'LUG!&8,D]?
MX;_C$P^!D/('*-D1J=%IG6:Y#X2CORM4_>(Y&89R'4.2PR:N#(K2!Z:<1M@R
MB^R[.Q3+PJRW*)=<3RS_*_V_5*[])W?0_V;,(N_-;?9^WU]2513R$/";X"^>
MR#$ 7O-@_O.8^^S?8]_^P26$6MH=SG@%?01L]SEYMZ8Q]J+>WE?)8'A<T?N)
MJQJ*:]*#;)S-^LS"XVR<_66=*F/\=*@;BG\W;=_X8N?V6CB,F*V1[U^Y!5B2
MKIJ,,IW6[.RV)(_PJZAHAUXEI(#A^DM8,EMLH->,)_7![V!'U*?7*R&5:(S6
MZ&J)6G:M[V)5CLDG(U9'$NV'G?N%MVO-O!%7V++/:'?Q\TX?*5C:+,4O72@>
M\X,TV=<"@SI76DR64I!ATTI6\V1?4M-0)-G1QGTR+SL?:B:XUAL=-3O[U*?C
MS)*OMRL&/696/9DY06J]=N!.KK+S,[IU7NC]?8Z4)ORRDHUY]&^1YR!FVU\D
M2!'"TF#D88$*%$,D[:?TSFG?6"Y]J6=ER[V(_/Q^#2_=XXK#J1S#!%WWF<RH
M#L5<9\4&DZT6\?#\SNC^K.,+X\=JPU[@M^6/Q7N#Y?PD5H?O?=V3$P)4;8RM
MW[K#JQG7VR%&5B*[QMHH9;C!*&#X$&&6MV^I.;,2X.<F/8\?N!8OLNHE\.RL
MGKP6V#7H3%0_>?0;6E[DTR@B%9G'"6I4%EY(L?R=PX:G;[^'?I'9%2WTR\1T
M"<%[#I]8.?GM0+[5JM.O Y=0Q^%0Q]@@)&%"^$*WKN== E<L,#W' &8P$(_U
M_!,5FAV-W17M:^H55O]"10SIH$OO3_HW\!;Z%FG7>0U_P@IUQ;++"74(<S;4
MSXJ=:3<M?8"*79E?PF>?_#[9L/+%MV=?[.)/CCUOE']#Y.9/V"(M'#=VY/=N
M3/P]<K.9JV!Z@_NF=CE/-C:@6[2>=H$+-V+)Q&)FN^X0N.Q)*CC%]\61B<!)
MRW[0IT5[-UD8B=FG4Q+*+R%AJ/:1+7-@)9^>!,P">>P,%3%18O&W=W526+]X
M#J5*]KDP^D*H5N7!KZ).UC.16=&(%%IJN%+ AO%(EP9:/,UVP\W'\P^>:[E?
M'OM9<85U4KQ^\5SB)NL\&-'5#8L<&(+:><P[G&^%9!&R+V7&XHIO=6_.3G51
MP:#[@-?:USQ:1JJ_7F'LA6H37P=Q(GH[A\Y5Q9&J;/>0 +NE)5=0K]7-Z&C%
MU+Y-("0LNJ>K4VWK3>CW8W]NK] K4N<&599FO-"G'PIJ&N+7?!RTJ(:.X9[&
M2L(PA;48S]U+QC<OW_C7)H3"*AV2"IP=1#%[4RGL[)WRCWYF01RETA3E7SQT
M&<&J]#C#GKLHT5XG&E)T'6_8GVEX&L6 QY5?Q]3S"49S8DV1DOY%(9]B;4D+
MUM-MBYH!F/-53I"8C7N$Y\Y+L1*Y,Y[U<P7>T-/E]"?;LD-C-#&%N>,W!]+_
M'=;X#PI_]\_@@_95?W*K6WD<_L&IU,.KJ<'Y&80<HE$-+U!"MKL\ &5=RVZ'
MKL>>/>Y:):VG;-[Q>N^8V\_QZK[TQ^NC?XK_18K_,^K=M0G[9>G6H3+$CD]"
M"@4\^4SA<^7:B>%0H>L6C!UT&J#!\]/TK=!B6 W2I- UQ6OY0>A0C'=5/HF9
M2WSJ\O1_1@<[[OWB*4FB3KF(W<#-E(I0FK^.YR=?KOWF-7(@=GD:EXJ);8^6
ML5^R&:@S\-LLG'Q6=G.-NH5"1_0$5(TJR3"&E$O?]X^@II RSPD$;5/-0DA_
MT5M/TK/"S31L8$78HM"@>8^K9@C]AE?9=;:#/]&YU1D36W=^Z96E^T1@OGAK
MD*/'T-&N_X=^I[KM%QFG7O5UW0HB4I@#"<*CW \; DW_THP-_QHO &C>KJ@G
MEK/NIA@//<4^?<")*;=6[1K7%E_VTS#Q @N45AU?$F&68NO$YEV\SM(LY5GS
MU%BNI_M3HR?U,E\[8O;._%X&OV]CJ+ W]M'\ 51(XLR?OA=<DV8;1QP@>V'8
MPO<V*)E7T6 2M?.$D[&-\:/LG,)T4@0]@BX/!MF8;S:=+[K[9OJZ-@U*1<5:
M6%@$0 [)('=V:EJ$^F:<*GQ8./R"*YD0,75WEFQ7!+%J+#*I\[_RB3WG#P48
M0@[OE?HO1&PQ&_/<RT_@[N@M&:EO]+3<.DV>G"=0+SMYAD/]+IUK?_[]%B8C
MJWQHP6,)QGFIG)=>9MDXF)YZ44"\23H61PFUP^%P4<1TT6,!.VX-9N^;G&H8
M8 S:.M!,Y3Q<V&9^T'(GK"](/[:15:L!$&B/'I*FLIZB\O;O!".5ANI7#TN"
M= (,PS %X!;__%C!G4MW#U@CR-*19-/E9)=4ZY(*B"I*D;08WPF3/1/(4DXI
MTFF/;"'N)A+5>@_?^-_>V_]@AD>>E&@UH?[P%IL6"@H[]&0%.%U4G\:"B7$E
M+HC]5QTGVK[PBZ=.9$EA_^=_:C;QO\+Q_J911:Z#\E],\1M^<PL>V<50W8J+
M35R-XE/1S!#1MXGE847-#1HPHFPL"X\J]=S4*?"_8^-[YVF%>FUR](Q<K2)U
MQQ4=EFU[8K5E_9VN+59!IS <( M9,6A,EOG8KP_/7R JP,$/!%_^2S1JVGG*
M)^;2+YYSQ6X3ZW[#/A4N_EEM>7F7S)P))R_,Y% -P*"*+%("4I"&U30?X5D)
M4]M1BOS]>XG/(PS"!OCT%)>?KO=X);I-"6&E4AQUE[)1ND+%;8>-540V$]99
M)'R7$.Y;:G)2^4?SCN_:!S7#2AO7@5%.'SKR"ZDIC7@LC42).(IB*W<K!C2(
M8?Q3!M[PNFX_6BV,K<QKUR8<I+2@ ]LGXECJ>7$<"7T7 +H^O\>BTQ!ZJ'[0
MQO1N@VP*.HS E(/O%D($R-Z_>/ M6K]X<C$'\W^=^L5#</?(2" 28;>.\-G(
MIX)DK.L! /]/4UT" D HY+1/F '#G--VVG0Q44Q+:^&H@R&^K\V;U,B-,2%<
M]&9$_KG6)), @)GR\JIHZ*_2L%8V5DBQ/ G)^UU6G+P\[KIO%N3#61#8]%R(
MF+B9D7KUAS=/8=513UJKE?8</S_^Y'[NU/.QJTO \&Q$==9]3;5+:Z-2RYN_
M>#C7H%7 \)"RI<.Z;O4:.]^>/\>?(*EPRXIUQ4JA;TF&*9$CZ[+(<R:CKZ5)
MFOR(,CW5[[G'-WL>!6VH"#&\<B^4PO8EF^+M]E>*QCP?Q $#() V9_4JEZ0V
MF,YB;%<F#-)E3;UYL"\:N#H1Y9LKUZ8:T-T3)N?"!L"<0[&6" S]>-[@50P7
M8AO1J]V]<0F1=UZ_]9B6FC!5AFEH!-AL-1.="90F%P8%$A4F"Q\(5B>'2>5,
M.Z(S/1E:N=Z##*5@6'%J'R<.1N&TAMKAR=FS2Y4=)0NT!0?YE SA3:NOHH,E
MR31&1:[PSWYGC0?P9M,>93^G@ART93=+:D2YR2_>&M]CAA4!W^5W>4]4B_XI
MC"/D%N4QU7(^&CJF"S>T2!$:Y*HV;!)+XY]"10YM^3$>[FL$D0,I']3MO >\
M+4+S2BS:^Z^+P'JMAO(]8*Y%ME/1)??Z]06L>HF;N1_XK>KQ4DN);X0%X57#
MSR:K+ !Q>X'D#/IXZ;F0%G9IS-*T7['-N;A(%C;S3WR*%1@Z2,4),)+U0@94
M59?EF]$YG<[:7B]D<PA*^*F.D,+GQ3G'P' 3^G866E-SY?94='%35R=^SE^<
MA6,?F@G[5P5O=#O/'7[P*:V3J41Y,/BZZNS,<Z/,CYNZ.1GB_0",H:%AE\7-
M'/V?7U?'^$8MV6Z<D%OZL*_+^KSUD?1K;,NT5C(B&Y/1S(I4X8OQ6J<Z*.F*
M4H-FTDW 1Z2^=80_'N0^R<HZ;!CL@6X7(?B'OAL\#7V04S6\N5J\$E@S2?8)
MD1 *8S#NS-R+#C=IK%=<UVEDG629=37BGBGH08-?(1,&/78L2GM++'XSM^'Y
MG1H5E@44-C0+E>)O5@!E5HZ/=./A"B1KJY:=%H';YL%A_J*OXT,MF^UPI O:
M47_@1)5WAU/4*5Z>*7\ATZ,US7'X%%FCG+?QX@09I&3&@TO_B (O'WM:79_<
M!MZ*V=MB_/'D[_]0B_Q7X)\NM)P.KWRP/58Y2)_Z5E'STE'[[0)_3IUT_5)I
MGXD'>5X%$Q!/BT<N]G8"EKVLBO,U8T7S\(Z9;&9)GM:Q%PT2C"=>TR/ZK<-Z
MC@LOK#7F3XH9 1TKO\@)(0,^]!AKQGMG)5'B8^MQ;Z/;#186@LSS",]"+O'\
MT3$6N7G5JTVGJY9/=^L0U*:X<64!,)0T:GP%M>IQ9=KQ%T^W$YNG"C?L78>,
MAGY?L\U'O.U#R):T.#LKHQ7O-YWLH0 ?&LS>W:/-&<WEI!#<>:6V)<!*1:IW
M>I3B'T8LXUO$](\$O(/36G;<:P])^SN]V_PMEFN//M_P:T Q3J&#5S#$DA)!
M.I -9[98S8B<A\[&Y@TJ#<_:<T5(6@#]2UH^:F&W5U(M%[T-:8*^#:I%(Y[S
M>=3@=D.+^TU)MY @#6"5-<<$-QFFFB!GX$#![O D7S]3L?PCLF$OM0>Y %R,
M<2'OCSZ+"2PV=F3JFN"T/5GDD7OOZXB!@$A1[.4CJ DT\SVFTD'G\+MI"XWO
M2,8YYXW@%L4*B_<VI+R5707UJ &RD#)I&FOR9IUK<%\%E&*M\N+1M9CJA)8#
M6:CZP(\%JJE'@IE IYTRI-ONBDOT3U@%]70\9)76_CL;WGR=*KR==7'FC^)*
M2=($W#VGM?"B"SZ'>[/ A&2]I%EDI>LN;,2*E/50L,(2\DGR>>EHLQ<_&!/R
M+55<1*RU#2L1NQO!?%X(R,HAYQ!S40%W'3.,0BJ&IZ!P_46_0D?M; ',R1\K
M>A.N0G4M/SM7M6,"++B8T;"H-B45X8"E_$M,BX:94D#O(\^"U\4B]+L#H]S1
M;*P%].!6Y]'AJ=-MFUM'VJ3.)%>K-:"#<K]T4V81KV2ABJ/Q7#-@F^;]JY=T
M;@SRDR9=%U>7W\/LM;RSK_>XP#A]IHAP%L0.16G+9^Q=+]IA&M\R@VRI83>!
M((!@"1)SR,>N3&#<*<&RQ:5E)\54)8(6Q=^<D':YR=GX8:QFJ.RKTO-M\:2T
M)/_2^PHW3EP3C'BTB=\+L7NVLS0U%;#2-:K1= 5AS*\B*!Y'D>"3\&.]#7N#
MCVW'%N#J5=_.=?+%^/I*7O"/*%ZF;RVD:I<G/?Y#G*RWJ;L4-1(K;#]NCR.Y
MR0SUQFN&><-![%R$4,"A*L:9+R:#9O?WVNN64SJDRKJ!532$!@'62HD'(K+;
M1Z:7HPQ7%:WT;ZX&.S5=_RV0KUSZ[J:@!K )$-&!C3RLL//LF[#R(8=+]W6V
MF/D^+N[MAM9'.VH80J/M1H!521<RI,,>!%5_6\/W<:DT]I;.Z0V[;ESVV\ X
MK294  ;:;FC>NQ#O,0[9[Y%</R2R JI%"$_(UX^+@8SK%[^N(5W7")41OWCX
M[_QILO?*>9G@L2MQ;\K  %;?"V5?J$\757OQZ64I%PST]-;4$AVI'N+N5/0-
M))XO!](YO.,4UU+I0@,T))=\]SMH-D6]_* *>8?TGR6P_[*3YM(W-+:3HE>7
M41=?VBVUO'7>/%G+_'X1X;C,,89W%C6)_\C\6'Q'#]6]#I(F9MH3R+H0I:JZ
MAD*13U(7LX<*G)[\M?-H(5P)34_>C_\+;&%JU+?EA==MKKA*Y9]U?<,VSU47
M$,";G3T16D,][&3G\V5M_E[??D5T66C-S;W'4P[A"(^P=M?F.(NN@K0T)?N2
M<N<$0]#=I<2 $@/WLS6GOB7JE64DNKQ; 8:H>W(K6Q0_;EDXZZLD9N F(TR8
MN@3%CPAELR"3%K!\L70@3=#H4AB"\MVWF7^79A]T)B3DE&,K8RFHV](I84;.
M4/6J(1H/T@T.G47/R<!!Y(^-[@.]CTE;^O94=QL7UR9OZ-I+FGA(E5W1\LO!
MS;I';J-7YA537#%V$,F'O'=R,$J> GB4Z SI%DFQPJCPP85^GFL]*;Y63DL(
MC[(@%/_TGDU\_Y@CN<&-E)=E@B5Y7K.N"T>JR.QV]2Y!S:,U>VBA 2?R'S$Z
M1_*4*'"3:]["+2EZI8FB)R.T[KH]=U62Q1GI"(GWTZ!"0IJ00RETJ9JQQV7E
MS9R(&:]1]&NS(NVHEQ_@=KHKC\KK A/%"T*=PX%$_(C>F3SB$U(NMCW%LWZC
M/%*FZ[#/;U%]:@OT2&>")IY1XE#DZ768-Z)#8K0+ ;5MJ8WR"3?-7OH3'W%7
M@G1O-#6?,[N0+NS%J^J?^W5&>O+T J@"*!5:YPO,,36O/M[W">?9;(+%S6(1
M0AC%+@L82K9U,4F\+]?*8K>\(_@B7&7[8M5P0OE*BVANZ^<]U5ZNI Z:YG*^
MI&\8X4<H7XH08YF)JW/2^"*G>[OH::S8*#:;W8D_-,1-:#ZE0A]SHUDVW$&5
M]AB"T!F1FGC1X NQ=6*"G4:TO#='SU3LH5U'):@=@54_WR143C?9N!,P/I9_
M[TQ (C(B]_?/K3>.S1*>WDH[3;V\/'9.>2\R8NDQ^/7D-5<PW#2X?JZ(R7EU
MKS=(ONA!@?^@C4^FIT9PTAF4'2E*-#!PGC?A#QM@]=>#KN'3P5S09:_^1=MD
MGB\/2QJ"2F%L6/&*-&?,<B[TC5-&W#'/]]JYI,!=W5G>Y#],/\W]*&\L/\SL
M6FIO&%VQ,Y^+ZRG\"LB5)A3'I1*9D@EU2)-2")30=!4H#P+D]_8^IOJ/\E8^
M"%2L=#A:HY[\\EV; WZ TM<\F,]N?]5C:07BPT?;]^G84AU)BC01\"V>YK__
MG57Z?SI.\G_@V*L/OWC(%Z7FD6Z;B<_:MEYN7=A4>T='+Y-&]:MSVG+K4%X"
MUK*I5&9R6Q)<(C37P$3WC< (ZM3U"@>%!\)UV!]_?Q>:'K.XW?813?#X./W%
MGV&_K ZY.2--O-O.[*^?\F82[S9H]W@^@P^?C5BKKQ;@?IFXKO2^=Y(3&IBP
MXUI>$$666C033U04S1^4?&M">,SU2)TT,'.0EI;/>R/!ZWUT_,$>%(>\&EW7
M?%F=S[*]G;G'KH?@M4@'7E[F_<8R;$UG+Y!^RT ?:?,/WBMZ\#(P- QQ>TFE
M+R$6*B9I>/U& /H4&PZ^G=+#6$6>NR1\ C\9R,=L0#45H=C"AOC1.0[4G<7)
M=3%3N:>V.RA- /C;1<T1GXDQ%@B5CR8P83#]CH[QK&;7R/<E9VD];7[E6E<$
M8=?=/88FGXFG4&P^M6?MCMQLH /3/ME/"M\!OWZ0M)=_5;07RG#<FC>FQ$,]
MWU#]KZ1H!%W5%R"1&B?ALX3U6=P1:K/&)]2)STB-@J\'M]XZP:QA1&XX$P(R
M-0:+*BI WIM04!BH@1F<!A4 0DX>D%<>?#>36QYX.2Q&0RK931N_N_6@7#>2
MQ.ZQ'T  8\-YO4R>FH<SARN/!:D# WWIY<AJ]3KO/#(HF&'<UY[50[IBG1>#
M,T)E3L120N%%;8:';R/+6^HX1^\PK]7M!5PJ06ZBI3;#A5QXP^[EQ.E&6!;\
MI=^["S4I9HD.S.T.+[$]%:7S1&N\*\VW7Y3;O*HX09O!](G1IK,_!-J2#XJ)
MSW$D(DC&*5K1#N]LLH$4+5$2@)<@H0)W^D8ZSDG*+[8_1#QW3N(:SLB5FI?V
MS]_#/@_] !$$8!W.;P@0[_35L27K]=L=B;1&_.(AT\71+?3C7SP/.V>2S1*L
M7#Y.S&#D[JW\9L)LDI/M5@_;JK7/E"\:-;242 -X9KZ'D11?7?"27$2/-F]_
M7 /?&!&GQIRIY28L,G66,.'>\!9Y0X_9B...J*E4^"Q+O;9!)P!JT'7^E")G
M6=!;PEO+PO0-AZ&*XNV;@@P!]09YZ=01$%QF[V(/7!;%=W=JT?R@:YZ5"KTI
M?WVB+AK"'0TYZ@*5DY2PP",OQL.^]!8;>H7+YL-EP_E#F<DGRZVR2<P=@9L1
M>I*D<1COYXJH)Q/V<&PE&O#\%X]?Q30C>1)0Y6N&-$9E)A02=>:N3/E?-!8W
M-W#V9F,,H/:U9VQGQL$U9-<3AF5J(Q#2[X?MJ;*9#!%N_L7CXNF:;:3<CC[R
M3L/58'1%0"Y63)1* 9%C[_,E.NYPZR7O.)_]OGTT;/:J8MZ8BO"5L,S40;CE
M6ZZ?E:[KUE5]07@ 2":M&[>4(@ ]9&M?" OSZWE4[:QM"Q3"]QR>IS*B7J[T
M6/;<$O7<<27  6]15C1H\QM>[)2D4IA*_<(DH\>;MT<Q3(-Y<=Z+;K)S96B:
M1"296DD G;WS!V;9C540Z$W9Z9K5&*<0)>\R./>H+SBVP_5NWXYSPL4\JJ:Q
M:EZ#F:EEX^0LU- @-F]:<5.&=KBI9>=9@]=A_Z6*&P1O@-;53]845=;H%>_S
MM$==/19:B1VZDX4!5\Q(=41:OH+5I[Q:0VSF3?SZ8Z5A17(ULY'[A=G5O94R
M;"-G&#$^=(Q4D2TD])D92 MC5LD:@%6?FHRP)U6[N.8]C&"_RN[C@9O30\$%
M@V94'>J[WBH6>9KZS/VB+JNP!^*G &8?BMZ7*]>G[?D\&A:7"?!7'- ^%7I5
MC%=5NFE.:>G<\,+\B(JB,MO"4,EZIN-^+?S>^NJ&XASI65>G4,,X:TUFN)!]
M+XB#NZ\I<O3:U3K]_O'4SJ73W[C\PL8?G0/@%WW@Y=XB=QV WYDPJWJRN%!L
M/0$DAIBW307?XW_5>.-4JDP_U]4W\&O1%:W<RY]ME*@)E23<@F\JX<KE_,F4
M?+@9TLKB5 ;49P;71SNX#DH7K?B"\->H3/,(LO(NC(\7VI2@57)R:[-3VK%6
M-5A\]EI7[91]XZ"*8G,T6";;;_?2G<=\*SVN.Q+-J?<G]MI>'WP<4I\GT[YV
M&2^^^CHRW%NUO?WI9P7&[.H(63P_,]YJWI,WR1O\<N:TS\=7NXGG:E'T]H-I
MOR94\YQ/HDF]Y;UZ<I)LY_ \B1AV-W^^Q\ ^)< ?;G@3;W^B(B9Q],?('$>)
MYK6E;'JHH&2XR#"V/?1R5F7(*K2GENI@)8[/]J(X!LHD@$+LTSU^!CW\V#>^
M3?2"G?C("?]8YS>D?)O];FAO+G]_/"YG BY>M%6ZC(=A %" 4U?3[&5A$/2[
MTQ?<&X?SB*N 4\.XZ+P7<HWQ7"A8499Q16QPPS8=LB4?*'7UQY?1\,JQ\&=-
M2]!D_]B^)J,]:+,]0^ON.H'8XNM_H0\,MCJIE(%E4$@-:OWU@^(2DM]LXC-]
M_PH#WOBLTU$TW6=[BIOAD&MK97=ET.+<#4,(2,;^3?[LY8L/_M?T^5\\I//_
M5?"@X C_JT%:'/V_RYKJAS0#E[TU-4N@#LE\4,#Y@K+>ZPFX.)SN2VN$9D=T
M>UBQ=);7'*0+V?=W5]<C4&WSQ.TDB2< %&7'KG7YX*DW,BY;T\</$Z0:=[Q;
M>)8IG2D-P]JF7P3SER<VVH%BK7[,)'(W04JI-I>+PI@9L5K%NGTW:??OZ/5R
MO: !&X]R/K?E.EC2Q&=DJH&GRO_'__O#7%(-.%81JOY@H)R>^\CGVOE!_J\_
M6X;IV%>Y&%,/QPQKA#31,Z\N?E>!?6CBWQ,N_Q_^KVT<I%H&FB[,3GI>UR;2
M%OT\<5$#>7E5D/N*@J%ATIO+:FUNPTC<<%3"5V>HD'=A. F7V,Y]9SYIGXN(
M.S$[0V0WDS.=0\4*32_4S[X1;4[\*O+H:G(=E?QD!_UNIL_4;C>;>LUS03'M
M3"R"UZ6;F5':[B<=F'7NCT=BH-+@T_7?8&9TCBE?\$\E1Z>XU"12L:EFMQJ$
M)G05"#=5QG/]AZLM-#VE+\%4?_%L6PYK%X;[LY9IJ[J9/ 5MBN,D?)?IVZH<
M6TU\G"A<7>EB2#9\0]:6M(5>G=NXV7<C$KO@ZZ#='!(47LV1R VYLPF4 71A
M5CM"\WTR]K\)'ZOS/ND5(VC)7'AE!7=.:AM**DV\M[J_G4.Y"Y@/._\6=VTB
M)W*IRR[:/-=]E%&=K7DB]8CK5(/$=0A'+7!(JD3JLX.+JM;>Z\$S13^; T+>
M-JF!DD/:Y%E8C\)@ M;DZ-<!UN=MH<&#BJ&75>%Q!T\'KQ3\[ AA).V,)>>D
M+"=OE6R%.[1OX7MZ[DO/J)>=>NG'9'XA=+D DATJ@@ONY9:Z!<Z>RRBY=9ZU
MKL[^.^[FEJX(.>&B3#S>L1RS8/[A)@YB?[XBJBQ$B,#X($YO9@0)?S9E&T?+
M+&0E&&D;&-&I$S:6'V;7S:1&OE(A]@W$W715)9%Z]7TEB6)'ZVPBH2;:Z<-]
MSF*@IU' '3.SPQ:Q];7KL8+-+/*4?:=^IU):LJ04+!7A/.#];4A;.-<KZ-09
M(CH_,<%")4Q(4QUB##4?C8!8-IW_;*89XQR-/? C,AKSSKF]3;X1OVC>:4WO
MOSK,9 U6#I)0N8%.2+[.#EE,_)D\+]7E>=)D4$"QDD6+PGN#+LW#3YX=IH;)
M;8(^"=N[[,MO7:_I":G^TO"9A9SYQ7-SN@03JC SUW,0Q.II2VSJF=WX0SG(
MC7?[_E!;"^>&B_Z+;8,ZGVL=)>$-GW;2BM>O6NPT^(X:CFXAE^$@!+:T)U\O
MW?"G[J/W%P>]M5T_H5J+/XS<<P 6,J'V"P=X!##A5 I 'TAT-H9;4\+"O^H7
MRQ(R2R$&L/D,OI6.4V:K0Z$IXYS/P_U-6C-_5$-UL15VFO$64'5=B^BPZ,S"
MYR>F419BHYF.4(-5A7=G^A5_N-7X;(_03= [C57"LA5-F)8MV-;-!?*2AXSF
M4B9Q\W;20TCL.?.5M1;I0DNE>"'=VW^7 QM.O9;;_L5C59SH=5 VU?=MSV!+
M;R0A#>A%$QYT(MB(^9@TZEH&J0?X/&:)[B#3Q8[%))O^$"P1"R]U<)9R<7B0
M,.94U1C6TQJVL#8HMZS'J<I;^EEM!FQX?%<2)%>V\\;/W[U8/[]E9-IB>&BH
M(%3:V5AS,SGK>!4:<4JH=1ZF%%_H9H6=\!_L3;%]EG/M5HU:+/5JBE/U":GC
MOWA<&;J(Q-30,XLWDD-*55]7S*[-CZZ1R4AL<F[6L6=UYJ?"DK1?!P4Y?3==
MY'RWH)EM'AX .X75M'N?<OC%$[RV2]W+M8]9\.IOV>!)ZP:)=S6=+Z);9WL6
M6Z>^F2ZGF@D)B119W#])_JJGX5 RG(#\.7"P^GC$NF]^-WMH:R+UB0F]F88B
M4TZ3T'W)I%3#^27::^MJ(&0^S'WJ%/P?,=G_;ZQ._P4G)5;._%0WYWN</RY5
M-75H.[$QW1_TO:0R8(^WKMW;NQ;OECK>Z;3P &=@Z,6P+:.>3Y@=3HU"0C7#
M'3KGJYZ>J_B2Z.Y)V0LM#WO>^%O$K?E3%UR+AA4Q <4(;J&-DJ*8]"8) KL[
M70W=G>5A?M,IKI<+.JQG22[:0J&&1@;+0K+4<_-RT>^5D^0R_:T:WZ:7T:3A
MBJ@NP0/]FX/[GVL8\)=A'3N>W"49JX]<(Z\9X]3[W9EQBB&H2UXBNKI-UH/"
M1]NW.5"^=A]0Z+R(?8JXU&N%L'M7=%1*;!(Z5ABHM2NJ.X#G]%S?Y2T<]FZ2
M1T->.@;:Y816,;.RB\F-7 R+4W;O4US/3)U>CYC[,<UI"G*KB;K!\0PM2% <
M[I[[,,1-+!O>U,53W2^9>$8[0;!9?NOE%B(T :NN0^HKJ*20H-><DM/ U1KT
M:K^%%9+DO5TW/2:.$4*'C:BWO]M97.^"6K3.[C5.X^P;E#9 &.S3M2V'1PRI
MNL20S2T?>@DOZ_O>L6=P%:,["783,=04&O($%&DCBY(#*MRU+NJQTH"3/U']
M*K+;EVHR48"<B!IWFC7EW0Z+W@+BY:WBQ\P^)VC5B6%VHSTO2;X3_QGL$G:@
M\^H7SQWY@W6#_V[Q9/I$J^/)_HT0EP^KR:Y%%_W1.1V>J 6U6- 1]OG/MX*2
M%*G"%8F/HN2N(BQK$U+1ND 90[CB=0!_Q_8RO7_@VLSVB:9$61A*A3QH>T,=
M-#>)]@D:543-[C ?W[S@(*#5$A82U&JT%A3T>>ZS^!E)?\_/>UXK+:>4Y'*S
M;)4P@,.>HG&F?,?)FB6ST6&LMV#(]&=U_IK8X:$5>-$#KF$YFEK?ERW4K/9;
MQZ]X")-F1FE 35)Y11OV?7.=FT^6Q/EGQO97.4HJ8SZ!6^\"+S@(37BK7GG8
M1+[$+M8:](N5,@2FIE!,L/7KVH:[\T^50U]SQJ3^+)NCAZ8HM\7M^=*U7OSE
MZ(YK:2N')91CK18LC65LK-/:]=.-'_WG5M4_L(OZY^W)_FG\7\Y<U%/./;!N
M_,5CN7"CM/*TY35>AW:LDO>LPNF"A!8:7[Q6?$>*;W@\J<DB_K'CVTW;8#B-
MM<D:K>["\J!9.]/:D>V=P^Y_(:<KZTIZ7.Y9YVL<+^A+NA1P&E8<XK&D>;9?
M'78>J]27TAY/(!)EF#>+ED__Y!O:1*[Y2:D-FWHO+:F.#_6AY(W=";8M+OI"
M;0@+"RM^%Q,MV_SY1//R3_6*"E8!]KF*+_]<N3.\<-2G%4D9-.ML)OFRWG(:
M53#E!1\$3/56FC .UZ@I,J^*]5<ITH;G[3-&),S]%$B!&55J>SO?%IYPRNG-
MIKSXP0<8T6X+.Y5M:'LJUV3I@U%OC;\)+VFYRT+(.0#OOQ^'(9(NHQQ.H-?3
MSGQ>#?66P@::/D?3J.3K7_?ZJHXQ3]KO*O87%6/SDN[W655G6/7JV%7!KYW1
M_KKPT-?\WE1R1Q/E9ZFE=_A.N0B!H[+5* :_S3"I5W'!V/5V;Q@J%KTW:+3>
M)#N9004ACJ7R#4IA %_]R:8??&M.**^P)^U%V'7"6E@I(O0-R>8DW=8DPLI"
MF<^$$&*-&]0W(</9.EB;=,,.H>$T0(?VG:C*N\1&I$G2<-_0,-$V.$5(!5._
M[(LF/ ^JZ9N"W9*%GO$*1VW,D4B9T$/MZE6G5\!BG#RMMN0_<<C%2,/I^"U$
M"CTU9QFVX4G;L!P>[M UCK<C]1<;D?5BUZ6E+T%!)ZXLA4%71$=^*B#4KD*Y
MFU823I2$^6PXD$1XQFB!#"T<8'4O.@@.1V;NDU*BY_A!#. ?KU<5ZL#AOEZ[
ML=[!$5?BG,N1\PV]%!?L_?X[1S1[% .WS G9N'4PU5,)PST<LEWEV^(:N."R
MV?!H<\';=_'0EO''.U&]5*!/+AT$-;1!4\D&>?CX6#K(:%=XG=5(-?!_;]\I
M#S^W#6P0555'MX;@>YR2ZLW*+V17'20[;PT=1U$UH/8>-G#9@ T_6G</_?2&
M3$R9_W6:U($OM/GL\E?AU'O:H3OA=-AN4G:#%Z"TR_*.$GN4U.]79@&23S7/
M->**YZ4P%;*.1G%4@8YA[U9,)T\#4[OWY%X]M!$VBQ];])Q13SR?759C##;9
M*K*==,HE.XV^J<I_Z_\$D"<L,GZQ1@5?M9*LU_J#16OX2[S?$WW.81'^UF_0
MS&OY\JQF'!6?_<$KLKA^/K ZDR)2\1CO'=F+/Y/V!I@;,N+ -TPB2U,0\3,G
M:C3V;^>4SY-EOM,X.6NRL5 X7"/.VIH\A038LP\!@]V?B#Q1KH;XWQB-YQ%=
M^RJ"XX"9%Y;&?51GOM.'-XD-X3&B=<I;S>X+Z-X.7((BD_G:LA6/LQ&/5P>0
M940R#6&;%9 SKVLKW/Z2O+9Z)FHOLWA[2GAX>#6J@ VE<_C4N^X75T@5TEMX
M(9I=,DZ1'2;MB9D"HDL?D "XXBNF_XL'WI7O!D^R6-DC."2Q^)9_+LLEB#D/
MULDB$].=8] JIGW4^,^U[Y7]=>:IW&A6ZINSR?S#'2?M=='9B6AJ8@IK.+F.
M-":D"G[\XL)C4ZO00B.%%,CUH@]07[+S^_Q6SX[.^MF^0.D_^+<%XKEUX$C,
M;NZ#?.J%I8YI6,MZ($+(2?@8/:;5QG9;XDR(:FQQ\>D\ A5J)*,7-?!LT2_7
MG2*V/,YV&2IXYKHGU?RXH?\2/J6YR3D]O4BKBB3/(N'JXA2#KN8#$=3\H:<V
MQ]2#G>KI*^! MWIZJ'"-#\+GM=VJ.%RZ".$QZ_U7AVM6N!-"Q>Z>5PD=\LI&
M^M[,!D:IJAIT">5S:@&3&%"F/(SP+="J7)"LUZB8DDAM>4)\/F'*YTM7'-A]
MF._\EAW';IRF$G)83T%G>-M8?_M5/@DN5LX\UK!Z[X50XZ+0!=;FG%=V00&]
MM9$D[_4!(UB_<\G?V<D^2BS6HC%JRN!P^B6EF+K0:5"Y ^GC,N-\.BQ&9-E>
ML1?Q!Z-M8O.*2_GBOB8MZE7'_7T71=G7'?.PS'S:1BR8! DB8&@B8 77IQZ?
M&._"ODUZ?R\\MY46I,)1@<;"BKL>%SGDV>![P)K-[?/X'.)SG/'H4 0+2->9
MXQNB"<'S":]OZNF-)ZC4AI.]C[F4 V4:?0"H@+;B0>F[$@YV!5[HN\1Y; .?
MLJ>6EE+BFCET'ONL0TU\A6H].1P_Z:)]KGA(&70EAXF<;"8M.&=%%W/ZUJ35
MHVV9G@GS<;.L-U$;-S^(-7T>5=N1//&.H]&Z&38FGI^-'5TI\.2B<TCD7!0F
M[CR.</** @B@:4V86M@=352<S?A3[U)0J <RPD6,U^.KYR.5L?HQN67-!"8F
MU>Y%1>@5UWSSLO&PT]FAR>=ZE *BA<3QH2G2Z9Z2=D_$$B]6SWV_/@1]UGE!
MR&Q"?(AW7$Z179Y_?WBUF5Z*!-CLCY:+1Q9FCBA'#1Q)_P816M_7F6@-DNW.
M&'BE'+OS9&F5M9R[^HMGR>YON<;_-7O^5WNVK,B^C="1BV]L'/>L A7&BO:R
MH4\NGW9?B[EXL)KHN["PN7>FSIW>C&<MEDQL>9I$+BQ<MCX0DT-",.I;?HVU
M\]U:ZT5P<(<N]I/$T<6$N2$&P^,1_T!Q5XLW8R80&YJL4J(C):=<:)XT]YLI
M9!*NV$YCI.69*.(?I4]_AS]Y=^721.#^_67O47^I&&%L >G@1<]]T)//G+G]
M369"3H]>7 ],(S*OD/3<>G(IVTG KM>;&5#>_'=#X')]<8>9;"!Z8V"!KA^4
MZ7<GL&R<S9=R#K(82.?$]1B?CMJ)S\,^TPY\K?:MX2]MT1?8O[ H+2O6M3#-
MN/J]9$5WM<W9V53J<P>-^$6OZ,ANC]'ZP0N$3.A/@\/P[4^K,]H#XN#C'/W4
ME/6*PHH>L)#*4*IF*FG$^U775[*I*/$7SY!B3E)1[5+\G%%CWIN?KR^Y*[E%
M;*D46%MZ0S,_[CB+1ZQ!RCMB*.&AW!ZVP@S9FS EATI1)9.4)I\Y^;-,DSI9
M#X)3A8$<%I#5=/IF1T52]"[7-D$!VCL>OQ&/\J'#*>W7IEU4JCPDA-1NS[='
M '2M>G,B!XZB:[C-PW8QM6,) ]ZWTIR#6J]_\6Z!U>'L5.,Q6LUR.4TJ]V^6
M]OHUSSI:CX=^'(W(B88:+$(/(8,_NH08B=2@.QL?+>+G(L?F%%<V+1V4V?[W
M^PP&"R$6C;&]5JPX@&2#$C*SP@(J4G3S2V!,B#;H[(_>&H:35(FS6$V%<NTH
MW41RFK[G2RWK'<[.QA&SB[9H@B#SF&47]A-*?7YOZOT_-SM^5"=\*OW2$Z1S
MJOGMEH^2WQ A:;$B.!8&\,C P0T&<Q@[(_SZHOJ+<(T+Z6"+[BD_I=*;]9M@
M^4GPR1W.2]\7>B,5U$4T=9RBJ:D^[*DH_VJ]']8F(836 _A!=/'6I Q88^,D
MK#R/"QVBM?'5-$@=V$TDSB>8'>0,'2E?D9D6-JOW$CQ?%UA^@3LVXID_YSO$
MZ,F&%ZUKCO#ED? *,A]W1F2[&D[9]P.@=E.&LUVWU:PK-<L1'\8_)$W[M-VK
MJF-A/J2&@CW1+MW%A#&]Z 6T.$/++C->2,2(]:.N1W2A<]!" *+5__J)HK;_
MGQT,A4B[.')X3V!@2@DE32Z9W=MOA<A%JS@#,">(YMM]=[-P+N;Y3OZ?-J#F
MN4?N3LLO^3T>'%=X-'3P>MATBLE-0!1\W%3!7_]^?\%0EA%E=R^5<CEUIL=H
MMAO47%Q@#G,O5B!Y7I;$[S[2C@_EI]M(7?)M=W0)2?")N,_<(72"H &,UM+.
MQZ%P.4#HDA4SXT\?*W9Q?3N=6.@X6W?JS+B"ZLSP:6&(W[$@DM"6/BV[LJ9,
MV\3:NHX2'LO:!?,)9%K'@0^/&Z(L!)RA<T8TB[-*A6XKDG;!GY :!]W-6WW+
MQ6)RWF5-[I^=+BS,QQ$\9 SB/=*)$3GQ[X.48UE<Z)WA*;_U(M(;RMOKK>_E
M)I=?32^CY]V 7P+''@.6^"TM^JXOT:ZVF?(#,]?H7\!6%I;SNA]E$BNCI9,K
M4@39\OE9#SO-5*#Z&!4 6I:2FE L#S8#/J:M-/;ZVZ596& ._SL."SS_]T-4
M_SG\V[:7_\@L^K\"_V"3]Y^O7Y^96G1^&^ 'D!+KLMW4 1@:+D(@#HJ7)<.+
MV]R*ZY2%4682.1<G;5PC<,>_H2:#XI>\T)Z*A3GIV)LA#%-]XLZ]4C@9*C$:
MW4+.5WJ )\HYF-G(V*4U'][*2,^@6]89HHG/QPP/>?#*::)Q\M)44K23@&A*
M5=P?&T__);IZVN<"[8[NA4TYETT+D7Q5^X?@&=$%*FLYB#VUF^[\]S]Q%_Y!
M >G_\-/'/P'^/_YG*R_FZ<TSO&!"??@6F[D'<CHT]O2/F]=UQGY4[-%_\?SU
MWYM#_W><.77E%P],XT8OLX.K=BAZ__0-]D_0SSS'W[F#^@!Q1F%[)=(OR&T5
M6=@L@T_-*0:0:E>%'*\CH*/"%6V>$^L!AO9)HK@4W_)%-J#W).I'YZ210P-W
MO'$;5/7>U.,YHL[LJ( 0:L.E\)+3</'].IE2L'89<>L=2<VDF0*3WII/#_LI
ML\V2;UY[XEXNE_Q-4V>SPZ6(D[^:K!\N+K0>[X^X,*^[:S,W;[V-E+9@ZCPT
M%@3IL-*L2<]TO75F7DE4^\@/ES;0#U6U29SKN^.2U>#;/R8?!$)X)+G;NO;)
M+BV:<U=H5LU+"?/I*&\>UP2JN1.'ZT_W1:$W%4Y1Z1!'S8L1?[H\Y\ #T&W%
M0;T:37Q\QLG@<T8[I7[:E-:NJG=&8#[61EU9+F'91V2'/X3(4>K1D"711]4$
MLP$T58@O1<[Y'+NEY[Q9PC5BW G)Z6*CA4P:3.:Y^9I3K;G=]3D&T*E6G%17
MSBF,&YUP&1MX\[WQ<C)8!G8R--3YV8+8O*);/#G+!ZY^(6\I-:M7TP?G^F>Y
M6'C"RIWX'LZ<3R*2L2G-2>[KI/WHT=A"%;B,)O;N,D"\!C\?]:F2>X@ .%S[
M?@D?*K72I'%SGK\I<-MQ$^C7%3+R&!A0=@<<EATK2@V_RC59!H91?J>B6*,E
M%B#:GFUXGWSZ#&0TQ&K\:H5=(6.0A-X^"I (Y6Z=C%#%S1.$K;F00F2 <=KM
MAGN;#(B;20Z+TJLQ*O9$3$WM%X^5QB^>,=YT_H8)^)K-OS3357NH/;5>EJCR
MX8ALL>KU23F'TBM5'@=6<@X@Y,W=4OX3=/&HVN"1\=A&KQ<W2)B*4VVKXN_/
MLT:9T$4&!=I^DH0MMQT=Y19WTV(@AG-.PUR1FPI/WKA=TU+DU"]R#G%830T,
M,:V14,0BC/-8V_?YC(0<OYLI2I$LEQ7V]M6Y8SH%3L/XT$\$@&T,+,*T+CJC
MVJLC@@YV:LX+?]ND$2:EVDRE]TMGO9/K&[.04_YO[+V'5U/KNC>*(A8070B1
M#DJ5ONC2!)<$!*1)0H004(I 0I$NA&)9($5 0& 1))10$Q*D!$AH*AT$I(22
M4*37T'OS<Y\[[KWC?GN?W<\WQA[C_OZ ^3YSSO?IS4<H1\K1T+)YD&)L3;>N
M*SSW9/W;J>RI56CA7%B=)(/*WJO4KGBO.X><5UW=/L&UN==V.M]H8P-5%V,8
M>!E;RD6[W#6DB(,LTCN@ZJ?F20/E2BD9:XX^G08F(_CM\NU=M;@ I*1R9P'(
MV!]%!#".#Y_4K9?0ZE*:MI8Z(T:<Y"+:C6$A]7. BBI$+:6NTT[#L8+2+H7)
M$,2*:H(6"NLB*;:4BW*-[I2F/6BSFN*Q7N,5X:C9E8;^*:ZMFQ')-S&8C^U,
MBLA(;8W8M8A4_->GA='82-SL6:#C1&M8^&F^^)K01Q;;V88N:&)#T&@#%9YU
M8^WUJ$GZFX!"JYV?!N.@XB9,_[?(<SKKWN-UQ;3GJLX,/>5&_L(I<R2F5]*&
MO;Y!GXY^[S&,-IEB\O8MCI)^Z_D;H;Y(0S/+UY#):[\DN&U/:L>"?W?J_65:
M(V3NWL>&HCT[#]RG/MM;'^[$AU22C4<^TPW$5MV-^9)O=3P-#7M>VEQ,5#+J
M7\J4YB^_.PL+FH8CA%P$(>%[OSZ=$1LRKN*>'4-4!< 7IZ/+RO).P)PQ0EA]
M(]M9VZ'V:XN7EZGD/6^UH+RS-;=9ZFN,2OD(LS)K_EMP:2$*$KU\#X['.ZZY
M45CKZX&Q1>>\90L'P'0=F2JA#=E)2RW78G*P4I^=8WXLC#6GU[-Z@#*@I9G0
M-*&"8(.TX\8'"W)FSI9I*K@=R.YL08,#@1ZMHBV5FSEN<5A3H=^HQW%$(L?N
M0)#+B&,<I[H5N"A'4AG,._[KU>4/)%NM5_OY;@(.*3"A,H?;7;*"7O5C<_KJ
MZG!K9"QT-KFMA=01"T<,1V=9 ^TBURXM9"7FN!^7U]^F$GP>9Y--A190AW],
M89#)H3DW.$XZ37Z;.#:L\G1_OM9R'#1O\?LC@L*HI%S 1<MS184!)VAH'<B:
MY+JP\!U)!AS>GTWHLO0CO67,.6EH=$?ZO'H"#7&$D+M>/\(/LECD'NY9T%PQ
M>5$]IU%0'LD3,X7O_U]9_S>"HO]HG_/5#7,  *#\4UW;Z3)+=&NREW8.3@^-
M/^N:36*G(?.0RW>:Q<L/9OWJ+PD.+AE:EZC')LJS@4O)>O"6[9V Z&@"2S8M
MI*%EM^!LD__$+_F)J=Q?\+Z[Z9H/&VJ3GQ38RPM*;9L4U/GY#.E2.K#GW?YT
MI&5P_0UE_SO>74W%-*:JJ>H58FPE5?%@]5I ,@#@/P>!)ML'F[<,#M31PPOC
M G ^%G:WV).>53JX[-FG#:2G5E8/^O"4U\1!N\I0A.=)/QA\--]:V8.V 7%
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M"TCFQJJ72X\MSX(K^WW3&M!&QJR_4<8DK=> 1'#/8L"VV1D_'3,(MVN?-I>
M;EZR4K:;FFZ5Y^FBS+6NF1\,VP4W.)?^HCKYM^T9^ ?PUQNZF<]L=/]@")\8
MJSIXP?(WXOM_)_Y&%\'_@9S*O]YR<@:KFN2HTO".Z_6O6J,M=SJ][B]/DA4H
M\\0*'G!_I1Y0/.2NEF9]GJBWZU#.,A6MHVASC^/CX^?YRK_;OQ=H=N *)R1V
MQM$T1IRW@GBXH*:FG$B-F>03ME+VHE6?U XL]GP1;55A)6+0PS*@9EB ?>7Z
ME(<-L?SIR-4RB&2)5DA+J2S :(X"MK!H'C++",O0&[M#)*M^O%J#K%XKKXTM
M'=GHFFT\_>HVR#Q+LG8Y>5<-/<+F17TKSO!?0CG7#&A9Z*M9+,'/CU5""U=V
M:2$Y8U?3:73?7O-O%CMJ)Z._R@O'UIE"U'P1YLI@\/:G(QW*47D9S:K^C\:/
M=.H7]X-*[?'<]8>#F!$9S?:1\7[0IX7YETL9T0MH"H@"\ 7K"%7R3B8T7A87
M?BV>376LL^PU2;Z^Q$OOKI^_RYC4%J-OKI&=5K1H,L* ELO-2TG>5K  BG(D
M2%\S)\4^RKA6E>=@*>F+ ]>A7/-?Z'QH;;P:3LI80N[H]>-?599E4Y0'=GGQ
M7R8,I-!8[$!N=.C4]:4&* M7U,(9<15$_)%&*XU53ZV"B[_F<M4@*9[48SIN
M:O5H_Y#,#X&:'<#%%Y8"# V$,'ZV&6PZ&P$!;WFY&[C/\[]?K;RZ"P[Y9#,_
M!1YO'UT([NU)4:,@R3QD?P/<E/WI\Z% I4WX^6-&HS5G 7_/!'\I2]7:Z@?<
M&?FMUE4LNI[8XFP4.MO!U\373XF]_VNL#PR3-M1'YR$ +:MT.KQD")^?P<A5
M=!4IAUTY3[IEN]OV]:MJV,R:G#2!1. \>Z?H;TN)&A3IZ-7Q9D:6X5,5MQ)>
M^MZ19>=DV),*;BU=Y8 VK022#?*@:'AA*@#<@BWZNHA(5K+/D<LYOW56XHG-
MS:G3T54?U1@FVKGF@"OJ'1T+:RK+74M<O#)!]ZDI>6<A@2C=[>3V,1$MJOA/
MX2[V4DKGK[+(7QC"\+=Z/O\]G/F_#>O\^Y)Y )FO]0IKH<M;VM'0TA=/[O30
M3ZE##DE/JWXP..(KZAT[+L?T+$&ZEK#9A:DYF913/U[BIAAAY2P5Q,PW!>$\
MB&HE*'K/"\3#,^_6\*;INU32\64:.U'=275.,'YW*-RAFGP19@!XV#&^08>H
ML?'$G;7==]RPD)T6Z)[I)%5R;="_C;(L8]<&!P?Z!M518Y[VGSU?]O=V:LK"
M8$KC^<!>45T87_0+JU\YHM*\KB8@(5,2GC.A7^A+CC18HJW$&G=Z5HVU"[)P
M3<9/!6BR%+34$>CHC<O%VE<J>UJ,Y.!0Y/.!7:%L:_S]02O!-5/&W3S\DQ6!
MM6E7E ZR\A/+@NY?3U'OL)),ED O2B3<0'.#BY'L,+#-S#-7UK[F8(O ^%<P
M%=HS_WX^*A]/7'0^>8OI\OOMI!F_W84,BWLZ<P,PR8E<BGQ++,S^)<&6)%#8
MI"/FS'2[-?7[J&:[/_N[1Z^&)7UX(^X9A7Y4(<>5KE7"OL=EXI,YV >:AM3J
M8)+Q2_ <V:CA<S<_JP@VF;X(%'-^.CVGZ#01F]4.SX 9&UCNS\2*ZJY.%2:^
M[G&1_(Y;10UVCI(VM-C(N&3\XM4P[I\NK>Q!6CT7@;[E'S'VVKT;(.)9Z9XA
M-0DJ>IFH OG6;_Y9Z^%G5MVWIK=3\IW2NGKQ%'7+7^MVY1-*$UI:6OG<]5IY
MS=GP<+'(R*@97<9#Q@]&^CR:ABI&"<C)&B0+L>*9ZK.2$48)64J5FW5VLDKT
M40UNTONNE;>^7LE"['A1X<RFI#C\##FT[=CS!X.+BN"I"MMJY+5[T:GQ[-9C
M8]FOW_^11^BMZ'0G6"]U&,BGWD\N;-K2U24.&IOGU,!\/=!_\-0D:_)-\(6%
M3<Y.7%ZMV/ 0A3D@%(K/YCR_1;-XN-"GGI:=@KU?-!N-+\K3O49"%X%7O'$5
MCUTS>ALUS4@D(SA5JXL6C'2H[$I>[TFU*?K0 ;=.M6@;4C"@'L5^P>8)>?NU
M\MT:'MT&(FMXYL+[5N)ZIS78B+?U^NRU/$LG+>=Z&R&20D9@C?%%+#9/;U=X
M23QAD\1>"J"*/^:^/C7F+75]8IZS^+<>E7LIUFZ</%_M&TUBK1 >O_;?/[3V
M%Z;@!PW,\728ALZK>JZ:,VENEI]A,Z.=_.#7WJKL$B7UCKZ )4IQ-!?95<(A
MS7I>:"? -$,#'*9UMI5A<^U]OZ65)\?[KVN2DH7PFZ^TS-71^Z.#^=C"*&Q)
M3I:/4RM:?1_OY9\IE4=E+<PJ;TQKUY<Y(%:Y_49R]#O[8%C].C*=K&0P04#;
M=9S5/TG8GSC]YJ9]["8\]HN8':O'AY.2#D4Q'Q:^*BOY/^C/-*ZF1.U>(.TL
M:\_C S[N@*_V"IV&L&G)?E,2C H 5,TGT9(^*J4'OB'_8*BJQD@)=Y8(=$!=
MTG];SG.2@CNN2BYEH8#N6@H:6_D:[3G^NV<\-X!\;/KGY"MO/8$KW$*AE/%P
ME\A(M*XNXS8#$^M&1]IMXE1V+=+(3Y\F#]O-K88\81$O>@49,DPE7WDCEUSJ
M"^Y3M9..ZI_=#(]^_M)=Y;MG &#KI(IZ=&'DCBL25];I5AY($>4,ZC#*DWFP
M/#'8=4YF,4Y5@Z*EW*]+03+L52M6!M9W;T!<_2>\5C(=2/F*QKYQ!T^W4/#N
M20HGG%J8U(!)>6Y'X2@.* Q:),10HU_<?[M$@P9^4>0%5@JJ58^Y!3"K,X?F
ME]>B@ER%8S-,+8G*/@G*8-WM3WA!YE,53PCO^M@HT?,.YRZO7=(XGNA_6RNA
M<A2Y[[HX&Z?O!\5B4=VI:NSZ6,E#!OMJY^M5X_U3L>^]92=?'=1WC=H]L]9L
M'=& 'O8%AU3(_V 83K,D1A4O]M*N4NPLJ$R?&1@NW*G=7#^9L?5L>]NO-8V^
M456L^+QXP*CZ<L0&@MC2L;]T,^0!^ST8Q%2DM%V&5<L:9SUCI;QM_0(VWD$/
MSW2J3/>LQ#;W+8>R.N81#SJA_?/L+5UPN WZ=4%:3_($N..\USL[_"-BQ%[2
M!([;LW3Z/4#5J"LXTXI)E,\$%0C;X6J1+.1(GE1]"PN0\SO0ZL3M<'P+^3".
MD^%:V0KD.\KS'I?UJJHROMF7$%7@#"=JOK!]_!=5SY^%<OZ%2I>_4]G]=4/X
MUH56C5/.,/^).0:Y?T^KZW_TBMU_"O\Q)01_'6=LQF_P@;I4\T>JCAI*\>[:
M-W=-%DV??=E&H9,]E/!%<7YYOCMRT6+UEZR3=,NTN$^\8DY\0)?&7HUN(@>Y
M8V#E-J[/5KY,(O(R;S4'3S%79%6KJ^"--20E<E$2/.W*>J02&#3G /G_;L1Z
M_>&@\8")#-4P+:]A>ELV?6?>!D-<%8!JM41'L&B%$QRPZC0+31^C>>;"(1&V
MMM7%LJJ"HJ\#(F)?W+KE6\=ROU0F71N$V@K_]J[+*Z&P'8$3]>Z"6$F*D=4#
MT?.+)45 O0+[&[S!?_%E__\JN_\#LN>G@1]\.6PJ9H_]-.S?<$'_-OZ,)?ZF
M./IWX,^2 O^XJW_**^()P0@,%2/ZMH' 13N#D!O:'_\A(OXCIY;_$_CK3/0_
M'\EBR!)D%-S/.6GZP9#YZ>_(Q?RK^$\:D($Q_47SU8GG!M,D*^'5GMT]-SQI
M*C30HZ HY9;HFD+]F[T$^;8A/V4V'-:_X#&GJ??74A;E#E170,?*+J[N*=H5
M7DPH>)4/\^W/X188JH&%G&,4.?NKCQ02VCJNZA$Z8T$15;EKA/ K9Z7O& 62
MY%"]:D4'A-G-@&[3>:[O:L??NQ<\ GC5A$LY9?KK1C->>D,$W'Y!WK32TI7)
MJ8'T #VP <'8%BUBA1>ILZ3HE3'8 J>CGL.X45A8D/L*CB5-Y^47V+>;6T@E
M))3&&H.[?9+9V-@[L.?L9J\X/*W9T$_8<U.5R"&UN]-6$GA]RH;TU?N[.WT/
M0Y$F>[Y: "TE,V'MW]T'YY]/*0%2D;'@OI*5ENT>]>*TK?:^@8+>.F^I5-VA
M]D) U8LG-F_FG45)=^],>"N*TA[<N]*.D)0AQ,W[AO"Z+!$ 2KM4%]=%^*1C
MT&?#>7A&1LP(]1R^Y5A)#?*TK5@U:-73C@"RQ,7*.#F1**K-[KIF#T8$KV$(
MDF,"@SBDN44%"Y'A@KI:/K!-^YJ'I8=M^Q-DJCGQB+<2 !B@O.N_ RH( 3#9
M_2$#,U;6+%4GYQ!@,#YOK>+8C$@\R+M6\3CI<Z9(HS1%3;9M4W+Y^K3U33]@
M/C-6M**2X"^$U></X;=N?S OYV"##T+,]FJ8B5P-[Y$)$ QR3W]9KD&!:DUX
M5::34Y)N%NL:+I&9TK;+[]D4%=@,)"GCK0#JZ'B3.EN*SZN1=(CA@6.!TP-3
M-,>@BSD=4JJEJ@JSZ%QX.6U=MO+PQ KB43JSF][UY258:L$%\;@0Q03/D33@
M,_5)S\$&FEU]\\Q-]7+!V:Z-&.//E>GY^H])UO0JB-J*NS+02?I=LP)9&Q3%
MBXZCU-5EO-#A#Q^^?/263VO&1"+-PUCVN]WRPN:'5[0$ZR5XWM:CL?CF<UXB
M1)[[0V6&SEKJ2/8B@(;.8/WEU)BZM=B:-Q:!Y$'8DL,H>0%3B$<;OB%&.5>0
M>.(2ND'&8(@IEJG2R.[NY79393<VD(;)'X+"UCM+FRX4&%+G,-F\D."-L1Z@
M@)%L; RM]$!_B>!B7)65 M)X:E*G3GE 2?DCR)BY(%O$JZ[;<S:+^R(# _"D
M:K9RR"/E:!4B((\RV@X<I-RUNF,,@1I<MARJC" PJR6BG@[<T2\)-!M3QW@4
M1M>G9-]B.&.,5H+0QN(=*U%&,E/D'E&]9[L]H@#=]ZO(A[2'A7&/1L?,.?L9
M-]<SYT3U9J>2-OJ]"7VFU>EA#Q8_XI*#HXF<1B)&F,4/\R46!5E@O84Z''-5
M^59!]25Z%XK:&7"-= GJB4-%E&5>(JNC"6A]H!3_F"1\J-3<W-?NKDZL[;54
M:#(M4N5PN;DC?Q:\:Q6,P$F)!??Y*O>Z1!\ (+K'[Z2_H+$H?(RHC"Y8GC@F
M)6**H,;I OLML;N[+T]-(49&8WG&#T#+DHN<0;OE11;?3/*,@[-"&!PXW6B7
M/T+NN=7/#D)E.@I,5:N&AOK[3<4A<%]]Z5COY9U?+B>J":>H&+'31!XJ\_/%
M@BQ)6%1.3H%]3A:'^_>A=W8E)$'9DP]UHW)W$-[-M;0>K%/AZE%[V97ZN)WN
MQ:5%8]_-A1>VFOV-QI>3 >P*Z(O6):A OK<./&BP3ZJNKBGV0KQCA_R'Y/(&
MOC9\&J.$;>E /0W":JVW#0.4/+)=309N<USUO7IV+WEJO^.WE201HL/BPQEW
M]5'<C5P#/ER.,'*^' Q>66$<*2@LP$5(HJRFBPK2"O?A0MY:\? #  &.E0S5
M$?S(A9?U^WT(9F>?\]7-+[5MK.](B9/959)*]^U][!:]#0O-XC83 $^=.+06
M\=N%U7X;7H#N4*J8(XMRC#7)]1#EAD[&S3+'/U:-'RR->IQXM-T:7GU#H<&S
M<5%\183H?9MM8/_2R\4>L+%AK)^Q+H@>M%WJA'P479_H)PG/>EX57,/1NE1T
MJV1$*[_=RF[DGH$=E$FI/,S!L01>L_GN\DL @,W<#T@'ZFC6-.^VQS^4^?*#
M(3"[])NRKY_[EQQ)%W/?(6#B?U%Q6#%>/+2D8B,-@4M1SF4.+A>*Q^5SANHF
MJ'79S;P$D(BE5IE"*E8J1TS=BRJKZ[03IC[$B=L.QSI>2_%_L?>>46UEV=8H
MY5Q.%":9Z#)@8[()(@<'@HDR""$R93+"@(D"D1P*3!0&3$;")@DD)$Q&@*!L
M<C8(D04FYYSSDZO[AC?ZOJ]O]ZW^NN\;S#^,(;&6]CAGK[GG6CO==1R#=.\3
M3>=8<\('!O9H7*[%UPG[^A>SF;TVSZ>S9HX09R@:$$[HY]RI-])]J,8H7W+5
M#X5KCVZ#<%66E15?Q9M6,KS>XI22!#J\Y4HI9;NR\(N3XP&=O[9L395Y/9#[
M098?\\\UVA,*Y;WJ^9[K Q]+VH<';X$$<HVR11Y-S@69?4V6 ?O2MYR??/FG
M >TO*L5_\Y&#?SO^RD*REW[N-6.P':?C7_ZD;_\ _)7)N7^\BOR?[(+_>_ 7
M\N:OR<H_ G\Y[?K73M8^$^6G[T,@LK&@G@U)%?65?.%P;>1J+M0JO7D[N=2+
M3";K/537F0^9?*YEERRSX@O*;9E.E\GIXWXCO8J;-E]<YX#1.L->CP_CUX*Z
M]"B+/LFD>J#N'<'UBA\=H-THZ7%X >4*V[YN"]+,S)CKE>L#FA\ZRL+?&YD>
MEDY8W^30*O:IZQ5PO-_2=(O2RCC0-]<=_&1TJ'NZ\VM.]>M7A/R JXEFM@.C
MPC"AH58QCD-L6;MKRL\H8Q]!,B0NTL;/[>'WPZX01G&ZUIYJ/D-]Z+@PEA.:
M-\%KMG)!A4G+UQ+,,?F+@ZUD]IOM-L_QR=Y"9?RP"ED)7[)I0>T=^7!6_GQ-
M:C@"<,K7 .-%"2-E:-_=HUIY3FP5OL)T3IC QH*=0(S!HNUQ"V)<V2A'K:*.
MHT!1?I$/%^K7C"; F(1P$YOX;_$[>B*L!J_;-=YM:W+*@-B9CLFV83./Y24Z
M5 Y;!!&+2V=^\[:I=EWG1K Y$>A[2C.XXD?B4P=R<GM:R67'G88S ,6R:G<]
M+_1&C,3E^,FC"=<]2H?=Z@%K&_^: G((1B18Y3*:,<28C%GWR>XGTK6M9%FO
M2R(N$,%Y7E%=LB,7YUJ5KJ8P<WI9W*>,2#M?M]%V;1",DQ@*C3+#\DT[#7%B
M[5*&X=99Z,RYN=#E&,,1A%4_>4Z5D-MS@[Z6Z\BMWD^A*!75_A#D6645MQ?9
M379,#]IB!  DWNNV7[U?RRJSKK!B"<!!^3'XD)<0BTO;X75BZ?7E3#I*F;X"
M=D0S![,4.QFG6P4;/3W=]5R/U=GC/#P]^:-Y.GPK0P#0&K)2R4\_"CE.\TIX
M:U8E5H^Z:Z2GO) D"7@X9;=^"$M6JU<=8&/?VIX?E(7[\#,AK562+R?VJFC+
MPF639\X?D?1)O210KYY62YAQ^0  H Q%6$<WA4P3,"A]?3/=!T>_S>SX2<>V
M=@BXL8E/!EZW3!-HV(!7#!Y42SF'\0\.VIK::6 J/<%X%S!$IPB>8W9&5C7]
M+O$Z5.'S_OBQF%S"&S/NACVV1N;!Y7<8R2G QRTOC?YH.<:1>DJ2&"$@O4>4
MID18V 7")G7<Z-VYS15,<JY4%TZJ+RFM<+19CT_/;95,8'I$L1@A,#9S6_"X
MN,FI$=J]7CVB7]P.;'*A"WBRB+^3T/<L<<0N=C2MHB_L#GG4JG1_=R9&JB@7
MRZ7^])UJ+__F%B%LTZ#D0:Q\\2JY87>HA+1^,2*IP>)9FU=L1<4(5UZY&L^&
M;B,WBY"-D+:\/C[8D*Z5FU0292E#A]/O^JP@Z1CHS/YN=;]EAW^W(-L\\3K8
MMHUR13?"OWO@(>AJ; E.M:3Z19WUD9 V6U\W,N0<_VK[L8@PY#AWVH+(3\.M
M=&VO)G2-+=@W5%UUT"_<NQ!72U"Z6(N:,AR+?+Z=<Q1;S@UF'[0?(:N6,'*(
M=QG6*ZO?NJD3\-.J%7^E38U M;FZ(J3*1T53Q!O/YZ4<[>0"Y_Z QX?K!/>(
MYO2@T<JJ( #;O)ZRX[-K,FWR)S1N,J_:X.9TSWSJ*GU*I!N5?<-=5^C>];:?
MEW-<P$!9^QJ*"B\0WCT^.QQI%(L;A")^@0]UC4&*O9D&*>(=BLO'FG849.7'
MF .[G'+*+&IPSVFMXF-;Z.8+/4W-I\M1'9E6^\9+=.U+"_;:@=><M2;]XB;6
M(79@X7+G"R.46PCK/C0WZT(L&ST_GX!I+Q>7PIHZI::(K( (G"Y^\.D=/^G=
M,3^;76/D6)N7VUZIC.)CK]I;RBU#Q*N;NJ26^4%6^/2.4[P.D77P5^@\2O\I
MO]PSG[F@)9'[4@LQ4L^9MCP^.4\I#%XQD%%7$#/0\SGJB*D )*T+6)G'@_CE
MLORP Y@?X*:*,\[,;9IX=VC]?=\1;N%KZH\A)D*#4 <3.<<T":?G_K6I.3A#
MB)G_?=ZG#/D33H<7ERX.M:%Z]5^QRR ;A[%62T/G.]K?J@W@O2J%187'"Z-1
MZ?'3[R760*:3D17<'_-4-J#9^) 9 7A%Y4P.$PM!_G6]C]18394)-AS+EUG^
M#::AA:KMZ[N#7P%>T<,C5-9G^_AEI?AY39VM-G4^2#"?901]&?4F,ZMHFH_S
M\P=D/[D _L_IOT/G34^+H #6N\10]RI^ZEBM8'/&;C=QW>+.!.R6D>XKB%#^
M"RG6Q3;8K2I1.ILRT(X8T,2$68\?%A$92L_<TO<D"H@[P_%<Y-> :^6^$+MA
MQ8<S!&2M!XQSB'$=5SH_Z"4Y-+,F:6\B'_<4W Q^VN,FB'?OJL"4L,W#A]E@
MM0>.,F:-URC#1Y&=N+*(-$3\=D_E#QT+=\+;;V->&_8F;>IJRF4A^"M@E<0P
M24)>7&XV"M=Q3>@;[KA@X\J6)OTQY=TK7!'K<&==;:+1",E,BJG(97>H* [,
M)U3X8[I=JN20[K2 +KN+?I@Q9F"?PC:EQD/GF '6-?G9UR]M]:BNO/(5L*F:
MSX5)[9=VR:**<M.EK01C]1E4+"Y:4XAGLP DDV^I8":HQST@()N2[N_XQ<R4
ML -[6YL>&UN\Z9%'8?OU:OWMS#B<ADNA=:[G5;)3*)W)UXC(+5RXMD0W8)'\
M($S><'4@8^K"J.XZ;QQ;;-*H&Y(4V2? R,CAH8VQ.9LZ_1!L!(%<,\GTP"G[
MZ1;<;)J84YGORWH5.C17QO:%E'#SPMG'*6;NPH 51E.!13/?Q,AE?K0&7Z:?
M>J86[H/O>/1Z72]/UV:)+M%,\!IEW*@J!5<N-U'B=VN@<G-W8J/WJ6:JJ<-=
M#]K<F(6GN]^R<N*0(AIP>RY/Y7;H')<"G2Y<XNF^N\4%[4\E3MI?M F=ZX/(
MV4(3BID-T:!=H]7?OP6EN/;))_,I8'.M97N.+08F"]"'R&I+/'T_+%_MMM]9
M=X@?K6+S]2AWT;FBZ?K&D2]_RR,2V\3EQ*KN&%;JPQ^;M9C3R]PLEXAE!;3@
M8:"707*T8Q^1+D<ZSRKE-YO%I=U;#C+?QZ<Z"R!9VZ<+ /G&25##P::ARX1E
MZ_L/O_9R _;[ #ET@7"OWL]C*ZW7WM>XDF#\;FS:Q]7GFPI"\1YD0/&:BM$Y
ML-=!^M.=)_OPG.S#)9Y0+$9&%]RF]H.PO#,&<Z\ (4TF/2G0UQMU(?UV1 >W
M1K RBPX*YU2(9+^TE@L<NQ/J+#F,=VF*K&O#IQR4%U>W3THU0<<,ESRW"C)Q
MKPW181#]:F:Y;!N/$$27R2VO$,39NM5!BG;GH.)#9_1YF.4)C:2*6G!IA>F9
MTG0US>GN(1[+:E8PG+"4G9<9QV_$ALST9^7B(OZFW,+O5#A5)K730&KGF,X?
M:C7GAE<:E:ZP)E=? 7.;/'2-00@X"D G_!6D/!F<(%)9^2@5B"<5Y[(JO&'+
MP9]=5'M6+IYS:VD+IX_WZIF6;*W?C[G)H0F4$/84G[=\KIV7A0_MM"RK],TP
MV/+DQ\H^>KC;P(_^:6X3K.U>R<\/#TPUR&$-?W>8V+R[-E90/\]^9N9.K )%
MGIFI8##_DUQZ^NC#:PB48Q!8O-@\R<-PS#%6Q<6GEZP&P%Q0*E:DE68R*_9*
MS? NH[W_UGO#Q .6W(+UV*QVA&)PD;P(EO2<UP[\F9&=W3#!]@4S7>0M\X_L
MTN(ASA=&=Y&FG\R^$GLF"=FWG*H'\"S73/.3-0:A;"8_?\A1:YI1,+K#?=M=
M-B&7I3M\\*+6+W]6P*?[@/[5]P']/?C?LX@K>/C3M^U.MV6V\^:>=T@<K:+>
MF=F%TY)\7(A</AN822Z415ZO4>+>%J2$D:[=K?)C^SQ<6F%$8'7#P3L*,9)W
MX-4:V;L6V\I 4+2 Q\@X+MQ(RR]_NY$XCI!.7^'H;A#O KL1?!_$O:3YX3&*
MZQ)BC?Y;JVER^G !@[Z%BF*K_I4)"ZY7#U&7F1V=WIR=.K^]!N&H[K+)^02A
M.$Z9<;].3HZ?$>PF^I^S8L5\4.4(ZF='UV'?#;\9P0;[N@U=T;[6(3ODN1^3
MT(%)G&^LOF)3#=@(\Y<?>9V2M>P8!U+U@G^X6P][XV_6$0.]DB LMA#$^(@;
M>F_>22>9-YV?G[O_(+W$5Y>YA*;GF$'F:,6Z[(0&7NZ#:I\NB?/<(C-IP#"9
M 9U6RYX*[K^HK.^1V6[HPZ*-SO#[/-B7/O!*'PAD)NY\LJ.7[%.<TX[6M0(
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MJA]VO.&!DE?_K3 [)*I/\1LYH6% )?CH3 >*KH@UY+-+K%?IJ'I3Y4+1'C?
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M#"V1QJC+-LMBXK4BQAR)F<XHUX!D"V#EJ[QCQQ$KI#G^LH_Y!#?[=\5Q%:K
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MAS2'4GEX!?W]DMRDM5;VFXYPAY4>I1@CG>VY,:?BM;ZSCUV1249]&L>=F@+
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MD1=PCF:\KFK=24[A>L+G.Z68(E,4=HRJOM,'?KTG9M-*V &:G8ODV\0Q,C@
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MX:[<-YGBE=M:CCN5V3+L;R!<CTP&:],*Y+PEA)7#\X',R7(D/<=B#>M7GZ1
MJ)Z'JOSR_,XD@;:8MH9#V1I0J<$W57EP6RL-34VV?.04U-82H?E"^6+,(:K
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MFX#GZ9JK2= /'XLAE*\-G*7T'6#*C[W.15Z>4H\#JHZ?_F.LSJW[2\[0&8T
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MK;VN*?PF,<RZNT IV3M(ZDB]C,C#"$CE;;X(,:G/XJF?Q#GG(F)YG1Q!3N7
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MLZI-[P;H,5 9=>(W3$%FR=1%X6(%%[HFYY[0H4AU1WA?!RC&*L54M =?@VH
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M/MK>"(?H_CP]JE:>G])#OB3WZ:G1-\/L(^%]0YLYU:ST8X65HYBA/(.1)OT
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M^X<UDI?R]>>>[9T_]("JFDF#!_=2&+Z:Y<1T0G3H1U+&.]#2=#0CSYZ7%XC
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MWJ#>^VI&4NE_$2IAWKZ]SMP]W9T98!]DAD=E,I9LDCF_8+)L:FSVA_W8WMA
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MB=IQHX7FEROA=H[UKPRD%V(ZO:9P$U$S_ILK4@%=#US7A%E=([6B=V\;O:Y
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MM+GNRUZ/_OKGO,[QP\>@%I]NZLN]G+:N--=/KD>_-CA@U CQO0$KUO>6B0A
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MLO(JSS/R3G67#1Z*-R?Y R9D*E#,^*%R EH?AM_-'%XET,2O9R<&:PBTU1E
MH1-9N%3V>G<B!3RU%Y-;-UYXDX=J]ZNI\=;E!?'KV&%/\1PR>I[QC]&7$Q4M
M5A:(FP(@N2B;QSE44EYY:F&DBXC%84II'_69-DOX_@[#/B7H4E&7=&N;&ZS+
M6EJLU#.JPD\&99HX.VWVN&T?H#_1@\?DL\LEW50$:-#!-@\4R<>0^MR#XDV!
M0@\I0454VDGQ(HK[.3,$V*_=84F':@GHA2LN_&WKJ#Y5DT7'DX+C.KZ#GU[X
M^.)61_!TOOV]0/0H#U@O11MI"RK",63;!!\,55--@>QZ9C:D#XD7_2R=$/^:
M3!EVIU!-[1BEWSDGN34L$HKQ>X*UDBB&EB-2,T@/"W5"PLH:#?N:W[K:L!L=
MV=Z8MZ:Q13)-GG7=B47*!<Y&QDJ39H(E:?H3ABD(93;+Q!$0%I[__#Z0B@8!
M@A3=>C2TQ\!:CGJ].PR-I-;6@4M>_,R%C#)6+T4<0:Z7EB#&YP9G=_ W!F]I
MVH@L9B85!&R(8/NL\-16-7>O &(Z- 32)>B=+!^R2MW@C,2OZ)88QL6.04+'
MM,1OU+O.+Z^^OU71KB'=Q^R]5D":(&WZE!*69))FI2L$?VE4^>=*:[6FV$(&
M>$B/4!E9J+2,LX95@6S3]4PU#[2>D'4F3]&W@QZ%?,T,D6NP<PZ\WAU/(=S*
M=U\UE^HVN'Z8_KF!W0XBPE<S;=7M\5V=VI1;36]61=462ST)X;VH7(V#6C.A
M^X(IE\*#0]>3;2@>^FZ][1I6#U&'M7L 7$/]6 ((Z3\Y>6+_9- :YU:%N('2
M_)T6.C+,:K&9IF?M$*.H2(8 E,2RF6X#CU6'5DC;=K&[85AU0;"#2?]!5A;N
M&Y^%'TKRC3GBV+4'DDGB9BVSK+R:?!7YC[8"4#)+F4G#B(62)M:MNOK+#4TL
M6V<%TOZ0G(;E&?C8&CX/Y7<L4N\^9$\T>-8[:G8^/6D09JJX]S ^"0MOA/!O
M5"PI]_H\I 83_"Y@Q4PZ-%7F1Q/RG8.F?X,_;G#H>.J%2W.)?.169MUT(TT)
M\2"3)K;"<C2C"WI0A^O++&)=^MQ\6,HDKOTRL0.3+OA,NT/4,FH@Z$WE!,U@
M-(9(]1L<_MCQ2_+&00#J]RVO"^TW$>LS@<35 .@X61(:4D>Q8FF,V!<1TNZ.
M]>\WZ;;M'A;5.H"M@1]>KJD[A!Q$U2YJ5FGW2?IJ9+?K^07,"TI.,L9@%1-5
MN@$FP]J\K'8_L8V-K&E.CM9;-%WQ"C+4HG^/ES:K+3R2Z<2BIEDP&+^ QD5-
M#\L,'G"NV)7AN^>PQJ.KS<5]ATWH\+GR C8IJQWTJ%UZRH[M7J9;+1@>SC*Q
MLO7UQ^5]>2?RZ* Z=3-O[>:4$3N_:5X*)K,(QQ;(:^/1:1KR>)]02*5W<-6Z
M*2UA1BT/ATJ$K(X^DVCKR<Y=Z.VPO/"=I6;TMDQ,Q4SN3^-H/$GS?1QZIG<>
MA$&U1Q0]_=F\*UEGUNEGJ<;G]4GE'=^5SEYS%NE"+,.MYSNV=MV/&HBJ2$W3
M;\X9_EX1-APJ#0U73>LYLH%+&&B)M6N!EBYX^HEW2.DY[_+.];L,E%7AM*S:
M-9+Z#UI\0<%M\N%E8=1]JL&[!HSCK947$X&B5PR03DNWJ*7LZH[+._6T_FR
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M]6F(RQD.J2)+0#TQ\+QN*YU-YY_2G#?#0;G)^+V)TI2BPD?PH12$?B5R?$)
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MD*)DYQ,7 "$Q8_#N^ZT2/A'Z825:>D ->M*"8^)>P>3.D_4*89(+:IH7'%+
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MQ=2<ZA3YTO(,&KZ09[$LDS'<TAI.EUG4(V.5Q8P]3:Y3 \0B7) U_JLK$"&
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M30PT)<C\+E2"-JD<UBG)O_'$__1-94CAQ#X-9S/8:9J..P _<MDP@9#;]!W
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M-1W[2N@5>M28_A8U09F"B5)2YFTP;S=!TA2W!?CPU4AB"I((U_\I\"JV<!8
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M=B?<-79ET@;MY+-V! (^"GAF.WC&?Z)$KDM/7JJ[O7D,:HIG<)=N40?,*V9
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M2%9?@$:E'Q>K6QFJL*H7E28P_@,HT8MZR@[NE;:^S/B\YGJ[:_).8O\=?$'
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M%A#*F,Y/#GV9'/)XXS>C=>4,%WCK!X?NEX%$:%=^_WTZI0]E#9>J.!]F]0X
M(GCHEK.+Y"(055DFEX;SW>1R0V9DI31Z*CF$W)0B)>8X0+B?PAR>J^.G)-*5
MLJ'K=.C@D/DOPL6CW[,0@C4K8W/,6EVXJ["55K.Q_%=:!;^B>X9E2B94%6")
M@Q'QJ;YV7CV#@[]M7_DIT-=KM.ZBGQ5(:2/]%#"R%"05KFRZ$I,L3^7<9%Z<
M<5OSBB"P?19P!X /'KO)_Q300'W?MWB]R8X_Z;D-;:H?EM@YD!PXY^)+FZS$
M.A\O.6]&^?B<",Z#6Y[7%\4;I&F:TQ8J*AH?P*%VR:06;0D94!UM>>,/EF-A
MSDC]RWG_D10,4@%B5S'0]/R0>I#Y](J:H:[>$E?]B8*3PWW@^2S!]Q=+++''
MG*]$>0:0U0(L9I'B.]Z9'6RR7M90->/A4*G@4_T$5]TDF3B25/*];A2K=];=
MM67@Z(H6.DQ,J5,\Q122O*&T$8BOLL5M/NQ(:9E*6V%_1QD=QZ0[TUWW@+4<
MM:],D$H-& 8S[6JOQ&TH8W4,PX;A)BOFB2GI$R#+(.I Z[6K5T^@OT%NJ%>W
MGE '2D@'5Y?'L\GE\?$)A><D(^[_"B+E>\;;K,"(OR?!\%3M6<OPLA@1+@HJ
M")5K*%FS&9CU!9_=GBA$5(:FB8K5G7#WOO*TW=: #1CVIW0]DFJRM-K577?R
M(535,R6@I'0@@8CSEQRN$((2(4$>X>$'NF'Q<6%W^B)3F:)D<A+TL&YTN#HR
MR=W^D"%6NU_ENMU5_1'N_'W3>;7"(]9&LCGVM\?<SB_S!?,?]2A_=1$\X_UB
MB"&DB*^?]"^L""V!F/)3+H".VX.KG_W"7$H/&37\O1%&$\,Z>3ZG/_:VKHA0
MN]:FU ]0 (5=HPLFZ-#S"86Z0E6V; +5S.[<GV?X=6["V8<_>>WEI,WK7[O?
M%<)Y,8RI80<*2O8#X-;T^;0Z]0D)NYUIEMM*^3!+J:KPT'/^<KU(O?GE'#C4
MJY+3A?@#'WRTNO-U.?F\J$:$>DV*LZ_1^>0\F:,?Z8JX* $?D_]28?-_V&O9
M@[+;A?LM/P5>O6WZ]%_MS7_2RF4EFW!M![=89 PH^K?[:_ISU6VO& Y2?!EQ
MJ7]*T7.I;8/;46-!=2*; W7'-5J_J]9;AK0%<Y)]!B#=,/> 8CPA4T/_:U0Q
M]HSA4A&R7Q@*738]Z!ITZM&DU'J [7)/,6H:%>IW:29#%A_353B+PI40H2E*
M'15Y!GF<85,82-YUDK3AK.PJ=/#]\>>Z^T_#-<ZJS0XKX98=:B;ND-I0HNE;
M%;X-SMPDZ"&-*MAU,(BKNPQ"%XVD(.1HO$^MM<;3I45[T6_VKEH<&@_ICMD$
MI7)\OC='\=$TH.#U'[[)MU.+2TF5="A-""ZJ)>ILGNP9 TD-*7*>5"4YD-_=
MT+JG%%TP?GCO8)OM)0[C85W110!V3 HZJ1 C8V!C_D[8"6%UT6,A6:H(P\26
M>2@^,&4B9W._][XQ "O,NFE_!Z%FF[0-K%IXRMYDB? PE17>5[_QO13&>TO"
M!\;1F=W9WU"K\/>4U'=)B$N+4>SCE7?WSW>7H&VGJ/X(*=9B&>:XL9K)^5>/
M10FC05,3-92X*QRGZ&ZUS(AL<791GD$(Z'HOV98%B1/_-OSQ-TBH;2>J:>U"
M6IV.8P$.*\AL<O4(X(. 2JBZ$(<!FE#8ADW^8678QQ"Y,C]1]RDQ=Q?$M)A2
M();;Y(4BAT)O1""+]A8":HR,,K^)X85-@*!8 &'4B!\$Y?E-AW$Y"1\'7&9"
MG:L"1#,GPF14W8;,P@R<%S> !XM-=/&?X%A.\G;1ZF%]GT1QP)GCI5,<X@TP
M64+X$C[PYK7CGDBT*4*]/#YAX4!5]*W)R,:OI_O]+'S*T5=L_C?VWC.JR;5K
M%\4"%@07"B($4.F=)1*0JBX(57I"I"M-2"@2>A-Q+9%B@H" !D&D)R%!2A(2
M3%@J'0$I"24$1'KHO>/V?;_SC?.]>Y]SQCY[GW/V'F.?Z_<SQC/O^YGWG-><
MX[GGA7I^I<1J=+6&X=!6['<HV$N[)7U&5U@FUOU^RLUK$\4"AKRVZ49?'8S@
M3OT]HDE9>4E))T,GLX23@Q2#1V)$V ;:4.J?E^OH,[#\GOMATHMH4U?>X3EQ
M6]6*$%=L:3X8M,'U.H;MV565QC,L]A 1/#QBK=ZBX)^-R[\5_!!DJ1?JZ&]C
M%T:&]!'>I-,,BE[RU7]G/"@CKAJLAR&C.0C_O46HS905LUCPE<8+'WI&A.+R
MP=3QH2?'.OBC;"5:(^OHZW')S'VO^LH[H>68<*2'[>2<( K#<6OR='8AA.=G
M9K:CC_6O<$DZ3*VG(@'ZU*"AQ=81[N8;E^?\%$O\7PD1!=-W.6&?!(F"'[X.
MCD[['E[IS5.%S0_S"'=VV03OHVXVE08,?5'9?Y\U:9E^79^6D8'"%D86#1 *
M(YCJQGU]P#V@>^\45/6%YT:$J4.<6LJIF]OQ4'^MRPJ*>'M:CZ&KH2?="Y5L
M&QT#FYLL*[7*6H"$1C^^_=N5W.U GTFM 'H#8F]X7@74COZQ2*FA B!JP7<'
M^G8G[/)'"6^2F54_N4:A^'AUJF1"S]82@2Y!V=L-&]19&AMA/?F5]D_@0,J1
M8Y)JK6BF@TM5^RG%,F:3)=]G<$]\H>. >^MM%?O7P=5N\@BS:J!8/^MNWFSJ
MP;I*&#_LR*Y07LC^>P,$:E*K]QK[WK.THJC.>:;P&1UZMR/.^77R)L3V-S[>
M[QAX0=W:^3#UL]N:I>L!G_+;A2TYD[VD*5/B16 7([I!%PX9=17#S):+JR6<
MIOB17TNP@STSM?E' T:U4[RT7"0/%_##+7Y%[W%YJK_1B-6=0+V[,8R%]*5H
M"@3:3BL(Z?[T8OMU?3#_)#L20U+I?D"G#YB]8=)[Y]^AJ4C%=Q8 EZ'W]_9Z
MHX3:6(RBN*MRV^WP9M[956&:7UPT#W7E8##?_KY+'RG09V*AY"<77\N-FVL.
M4]MO?#\RQTS)9V$ITT \)\)0'"(87$6CPI)XSGPDB<;F-)N/P7"N"GF4>Q"7
MSCYPM*VS2EC<V?S,?4+6P4N="*Z3OM/>EB"YB]I75)2$UAH"J^5=DG]R08$G
M>\P;7K4H)MRCGZKMQW_2.L+G&<3H[[7P_2$93> H.I6!L'M.K8>WE'E/KY[>
M?8W@70RX9=F7<%;OPD^N)Y:#^_'NL-DG2#>EM[9UBX]# J?H?5^ A0.QU#Z+
M? ,60S#[!;(:N)'CFR>1QX+E]W,0?GTV28N0/MF$J;6!K*U1:&3H=Q%N_V]W
M*/=0TX.+NKD^J<:AS!+T.AL*$O4K!B)AK:.=HI,9&I"ES>.]'U4-/'(!^Z6'
MZ^PG&''RD79]VIB2TA;A.X_)#^<'U."RW'W[MH].63WVWD&D282FEA) ?T L
M6Q2.5-\[/8318U\YV(X\C .> ?[8;6 .K$[ P[=_HVA2579P):UYT@88Q>O[
MH8^8MZERF71,_IL%=Y/Z\'<V8M@AIK_:7YTX?Z\R\QA:MIY'F3PL',M>$O95
M"A2EQ+@@R]\LP"JGG?H7C+[Q=7[?7]<KWD?0X[=N"B%)\2U7$/L+4PTEA*OF
M\6+NF]:HGUS87>&M%"[-LDL'VC<3*"YA0V_WU5EG4PF0'(_L^9*C'ZQ-3IXL
MMCQ97*I77LD1 '2_@S?:>^*O//\9D!2EDD%Z?K'6?6MZ4SIP2V<WL)XQ4*Q^
M],"KC&)F-R12.0 4PF((:;#9<J',OUV_CBPIAAC7I+Z16;)(%'_IQ=AY;.*Q
M#.E7H7X:U4R<-VJ!LZG0YF9"GGYP&Z?'I3DTL7F5UJ2((<MYKJ<!(]ZX!>.0
MR7 !8%!,0(5Y_F+'K)IE.*8RAVPMF1#U,?AK>03O_?"'-\@=HY]>/B#!DH%@
MB-><"4!1$E&*88CA0\0W;6^SKYJPCR:/.E<S_KQ$#>(WT;P%>@WMN/,P3E\<
M%,+X9IQAJ?2^U"LC(K@(C0IQHA%@?L,\7:S.+U^TW/FJEOA'QSS:'BUD:,M4
MCXZC[KW1O9:U8EK>-B2&=&@#H,NG"SE/[,G(*?T;))R7XEC?S,NIG-/W0=80
MMH4A0S9U#@X 'A0HV_])A !C_YBH(/H[F'\59? ZT=TXI^WD<]8&F[''%&__
M2\N-!Y02*6>6^6-GU&(M.^#\$!\6-3/M_J!#+F3FD7K@<N40*2QT<Z[2'#YW
M%7!*8D6G"8.3RE2:M&2NWT[=750I$WLZI%Y6/%16!R7>VH%Q5Z\N(V,LFI5U
M[MZ *:N1[:'FP[F;2]76VA07SN449@?4MG>T!*98Y,0D(AG13FC"^V.4YS^N
M5;D\&DE>_7H+AM?%T7:6<*&MMJ]>O71\6.[Y1OJ"B_,YAEKY4CY&.KA04HKJ
M*JF+21)(R<TSD-O_4AP#;1Y<N,39^LFUH;-KD>)Z!>"TL:GJ_&SXO6]63!C(
MH3#N]K7FKUI1CC_<2>_DY;19S0O3@P?C+K5G:?NS1:&F].;X(7O32QJ]JHUK
M:H$%=[O%&@X,7_SD^KX;O[%U7_4GE_="^$?XPZW**]5-8IJYFC+>1>3J2T6.
M;) AKU,Y<F'3%%U9RNVV,^ <4!/<$$!8U]2@?@O45U$YB>UWU$7C+#LWS\$_
MEJ=\,,;-1K_:>^+W]NG$(\J.&$M1%;99GG)6T30;!''7*NYVMK8LI3\U! @8
M%%Q(^S0VG;!/IOWD@A<?I^W\7W>]LC]E/J@+$@^^BWN$FPV(A/QYLI8Y&38@
M2]SHZ0/=.5N/1YF$80E)S$)%2CL2II3UVUF/^IW:D0N'(5\B$YK:3]DY])LY
M6A$U[.C8<9TBSSB7;/A%#S $?ID!R5L"&S'LJWX#$M:735(25Q<OC3-\ *ZJ
MPP&"#J)SVSPR'_KN95@8/D#TDRTVJJ':0NC9EVI.>Z()T@>_07]RC1/VY?8M
M80L_N28GC\NN''VQCE[U[<3"H."6D+QV*NA":?FNP+:.#_PG%^@AQQK[)'3I
ME!K%W_WJF*"B!4MX$$]I"UJ@EL%,CGN*A+SC\PC=DHLPU)V:!6W<#_*]<+$Y
M/AQ7&=&9-^'P>S44"FY]XWTT9)6RW0T!;[,J5H" J8C#*0CN8 ,^!Q.6:1$O
M+!R,0[)42HO\7:?%/9_F+^LI%,E1.O&@YM"]#(:%5!]''O#A'XS\1^7;6[JC
MH$.::P-97MC]1U1C]S/+U":M;5Y2Q-!6OV<MOMWONT=$CEA E::C"SWUW>T9
M'9^?7$MLM2S;)&ZA@(&K"#UA[^UNC\EEU<L.:[;.TN:JA';>)L*,B:.XER^N
M4/J#/5U$X"+T<2CU**+PK]45UUWFU$^N& "9Q'RD=3Y92UU;K4;L7?WW^@=4
MX@Y*#I0VK.BWL-'_ZL)U6<RS7O/-V(U>?4B7.^CO.V=O"=#A;5 +P/;2TK39
M#=&M722.*-2:\F[[ZJVQWURW.K0F7@&>F[DBRG,NL>8WPZ6>3'2H'69G\X;.
MFVBLUH!A!M6^#@]I<7:%1"Q-&7;51:7H4]&#HS,*"\(?TZ[NN**'!Y@/^QEF
MTX_80GE6_@Z;#\,Y/@W]&Y28EAL_N7P'5,L%RYK%1[LC<]I8RK5D+3M#_S96
M2F!8MHA+;01OC%)L+U6NL%"JGB8N;>W &2ARG2O\B[3ZGM1IT?["F-:CK;"4
M&P2/M??CN.P$1IB.]KM;EB,A!Z^.#\7*P3VPXYJCGP#IW23VFJ)?SRWU;5>8
MG)'[P9#M[<)W@NB=>4K;Q[F+Z5_?^^A:]*<.$GQN!4++IK3;W[TZ97H@2++T
M&]\6GWN(](BM<Z43\1%9CDX,K&?#>JZBXC&REC47"[_U&8'/[RP+^!7.099;
M)MX%E6% )Q-+B!#8B9XWIQS@^""0;FGO4.E1+GC]A_WX:LW^&2(I;F)(QVD$
MAAJ+**GQ?HUW#0/%Z54YD(P2"?GF9(L;7OYX8WWL)HPX3!3%NWT8SC\G]J1C
M[<I?$K>\R%&5FGIV??QF"22LB9D,/4]1Q,+9[ (%:@I9_[QU7<-8V[UL8(M[
MX]A9RJ=&Q]UD\D[V>>MW)N2N9O63=)T9F:K 9'49Z0UV=V@6F'9K@$JEYK25
MYB<)1K5W\\)&?U\@@#[:!_F+%(>?K8]3G%AHR0MRC#TBZ+A5WG3.,K$VB6*4
M_3%?FI=OHR%WNL[6]FM'_CC+;UM"_Z,+3S;+;JZX%C_017L99RA0G@PU8V]$
MB,[CB /?OO'6CZ<E(A]>V'Y<%#HS:AK2;)W&'#S\"_5Y'E;(Z+!6BQO#?\;-
MQR!UHG7#UK:.P;G^4!/XR?5&\^AQL4T,W.B4^L&UP;N&&2.)S>$YVA0WE9M3
MG+$P'!9?96G-#7<W-)$Q\FUAV#.,DP@>4D1DC!XZZG;]W(%@7?/LR"M6*F6E
M'<.YHO*Y0\KV,<[YH4?EVNU25. JS_(7_<X/CN4(C+J_NU)QQO)?7G'#O<S&
MVAHIF:?O+],4-/@=U%S@1>F=X4A7IX20$;51__GLV+-CYZ[<P.=*CYR+N-+V
MN\-H6;RK:Q=ZW#MS<!<F7JA48G7X#9<#O55O0H$L(1*ZWXG4B/(U3!JW3)-A
MB7:.JQ^GFYRC<.G1CD(7E=ZOOQ&*.^EO/G6BKA$,!H$8PJT%OJ-&:Z>X)U0'
M1R*@CXKJ((/E2K[X56<5@2\J<1"0?QO LPQ5"(L<J0@"$YA&F^<0I;A"^0?U
M?%^7=!#F98-Y^.X?=5ZK?0:$,OXZ>^L@2I-@G/Y$AF@BL)J89]8_Z[)52K?1
M]I[IN@9]%G+QY:5VK$GOOEP6PWTNO:W03&@5$.*/=)<L^CCS;2/,6E%>W.B1
M]:.%_9Q&?,K'X4"^.@NO)I5!QCHQII6@>5,D"(-RJ(1INYYW@F]VAKCDH4#'
MJW=[QIM:\PW7K-79KO3'RB-.^R#?I\]4<[05L-&S^!5["\9%OV(CJ[H!:\CP
M$SNK77_"PQ9:!WW1^+O*\:E["Z&(D4M#.OV]&P-V35!A(X(7K"&OG1UG[9'
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MOM7!HDK&KU#Y[H>&1+-/)%$TK']DX5M%IJ&MQ=GP-MN[,Q0A)"@VG2) K0B
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M^KFEX3Q:[PU4YCE]N4GEW&H?Z47\Z\0T=&D*?R_+4F1KDV45GVX2CSV-(K/
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M3G)!3IJ84% ?EG]-M42]1+?W?)6?#_[RD>A8ZLSV_6+'91P<-^ $XNB9Q/7
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MY:#(K*>R5X8L1)IWK"MC:WJ^[\H1=$"<\!*3N3F7UV!7J<A5V2FDF%V0TA%
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MGWWC2M;_5X/*_W_I9?^_"?AT]'3;V.P6V^8PP_"!^Q^QJ:3HQ;R#@ZJ79C,
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M?A:%\U6'+#GTU+TM+N9<MB'D_^N_&=WQ@%LZSJ=YLB+XRT#%>M 1X,4MB=)
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MSI]B.FSH,9X4A!Z4_\>)=Z2\SCEYHI?\.L8973R,\MD7H]H9FMO'/;?77:1
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M?V+0:6..P9,RE_4HI@Z\,L//P/![FP.VA/DK)=6STJ#]_MM#Q27WQ\(5H25
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MNLN, @P*73'=H0YBKQV['JQ^UO&;R@>H=CY8[M1C#AY*#"/)KDDC*=/49%8
M;<WDM6VL]VXN"[V8F&2XPF\]W@!#T9$GX[E.7<Y:E>:C!].?HBO3@.<!L;83
M/ &[;7]DC/+5$*WJ^.%00;CC;C:4CZNNHOC->P76MC#9(6\491@$Q36=9%06
M^6HOW6]-P3[RSX!X9Z!$RW\^T[K&=5O;+?:W'(*G*,\-NI-B,0QEVY]'GI??
MD9 ())/$IC9!#0G:+->!HD_3O,.Z")YR<RE!]WDC 3][ZH;!-FJ&P30(\]]J
MRR>% MU"/;;\/5C7$$KB1UR$ZA=@991W]9KC8R]G)M&>C/.*K4G+H/0=<>G$
M.#82Y57FGHV,AJ_+S,PU3J"7@CJHH+(_F@!V07]N<*H4,O>@_K#<RJYQMJ5>
M0;$ASM]SGS0:'7W:2O0V<R]P#UTAPPP6]QUPT0X7@4,5H^,)9T3FP7H:*V"8
M5XE)D^$6&,9!+I )LF*9*UKR^T#_&<VAH57[YZ,Z!^ F'\6^@)W8UTFS4HI]
MO0X?<?<D(WL+O>/;X<A2NYZ"H;QG@?\;[?[T5;'D681T87KL!$4J]0WHE7N9
M31"_#&-H1>"R5"L!CT_"+UGR_*[/8TE_[>I3*M)/Y^/[_?QG.;@#Q&Q>OJHS
M)G9>)05N^^SIMW^-I_"XX;;Z&(]HO&9U1<],R!659-C<#M,D#J\"M32U+\?D
M4)/N'0R#O:(;PKP0'DSE&!)?W)\ROD$3NBV,&O'ICLVP"OR(5VE-G9"#TY-"
MUXO&0.?[Y8OVNP!X<_^V_[X_Y,ZG&UQ<&VM!H;I/VX)J[>$KC"%9LL)2AFAH
MYIM>PT57*T:W(YX:S7UY:EQ>N_%PH]@]L E5.OA=*:]F]FVY,"$N_0E[?'6+
M%@!XK[7=['FIQC$ZI8M]N]B#_%7EV7_HA/H?UO_R>O^.3JNDS__2&,6L)'L?
M<>4RCO5=XI)_7-^;]KZE00'?9;&B7^C3]-[22:;FUMH_Z#B$Q:V7)3D1F8WQ
M$)FGK S6,YO.8R%%S=_O*URO4A":?EHRX@U<$@V]5 9_T*28H;32K9/.O";X
M:NIQ^]CL5,:(A]*!Q9*8CWMY*CEN9+5/P7H[@.>MUTO SQT-I,3]%2SH3CHV
MIFI(6:'!OBZXJ.#>SYJ&"L$0M'#$16:*]PU;<=O.2L(<N8QEUI^=7%9F(3M_
M=MU[9L<A1IK[-7JL%C112-S;\QD>"2?;R'FN9&(N&#RQ\\SUIP,55$)G_48'
MIYV!<$EV\]<-OTR78,HZ!Q7H]*DBC;2.>JDOD9=7Z[R34U:#H'>AU3DK4'U%
MC)_MK*'.Q^+NOZG-0>FZ,[/O\:*J7J.MYU"*PDQD2^$07K,%.]=MOTAH8@%"
MB=K=;6*O4V(+R  F HXD":YT./$O9V,8THQ'-]L2'KA=9E/I%:_C%$AY2;/=
M 5A"ETL1[$;UYOYTZ"[&K[ME'"5B2,ZXXW$N2^ZG3>#Y6-ZOXUY"IJNC-.L9
M9K=#H17^0>\70#=+W=3%"PZ+K;4=Z&0"4H!&R.B/S)MQ4_K5/_&SL\7>2'0%
M]GR?*VPWM"T\1DZ'"FO/9AA#_SH6C342[0 @^]>8!T_=:@S.-9YH:%%Y.]@)
MBFA1L"W.;BIB(^0KZ%!!YYR7O7I\B%+0I0^^LY-CD:"4GR.UJU%S/16[D(2:
M^<HA;L458T^D,EWP-5H0-"+-I&F3L?U:+3FR$T7+)\A/5 N[?F_:_&DJ^:=:
M=5B0/4:QHF^X.'"?3Y#6"S<L;8XA*\=ETY'[?Y7GE3O7+O!\ BF%W6TO#NFX
M\GV\S#3CQP"06-/^]G<[=))E3?!\3,^?-/:]?6?KWMQ%0!AUN;OU&<H[8.\M
M;'U)S2%QZ)-5LL98S5SB;EQ*1(@>+]5VQJBW1Q.7T8[/R[LW/I =.MR?/73H
M [?^&L.N3IYV@WK9=XJY+WK3"DT1R^)Z+P0"3(SRG8Q*>_65VBAFG;C,6GVS
M#UK%)\),-COFQJQW+D0L"[59N?BYN5HWFNJ;*S&-!KZJ]IAC*J$F\W0:!9!H
M.[<;JLT:;J3ZRHK*U(^DB38TB,2GY0^_L@%X!XC_,EU.#14L"JQ@,W+.",^7
M9EO^ZOM%;1@HZSDN.;J_UH4S'_-NJUNA4$H?[G"C06OKMAZKP*36U^PV.,)W
M36F]>6O;\R0:H2IL5G6KD@?C\1,:HE=VP+A;\:FV1*VBC]ZW9>.U*ZH;J+!-
MU$EY#$8:F8K];LIO_6O;MN1'12#-8+E/1X[*'%&J8+;-_CEI;N3.Z&EQL L@
M&-(RY:W?T5K49^"+AL!H*D)^,=]#X%A5IISNJ_&.SO=>-Z&,PVV)-@7%W8*B
MS%8G9=4O@S^ZM-*L\+@LAE/7NUF#1;_Q!KCS*:6(.48,0V!I?:1+ZD9HV(N+
MGV"[$%,6;<"<VX0"7X*(=UTQK#MY^!O5Q=4(9 "W'HVW4'Z!"7$IMUD3YT\V
M#K8[-6$Q(D-MZ:'?7A%J)0 7R!\3XR&N*;1?02*JM_40JC;%=@%GO:KW$C:=
MDH>V1P0F^T>5HCHPG*24KR.>W@-6E@':I7WVG%7QP!_>FP;=&;+1:P^2C&=/
MS*=F.5ZW?]!:"/M4/+*P8>^]+I_]WK?BJUTN*1;X<UMIP!1@9T K@\%1:3+N
M!&( X%F-7OE8H7FP)N7JV*?C94,\&-ERYBS*)O'BO<QZ/[<\DHO8S-_.  R
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M':)7#U98XSXBWUGQ-8K-8I$&/&>.3]S,KZK,Y/A,>/JVVZY#?'+=%9!$EI%
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MXZ=<,<GQZV+$X]U-CZ!YL>R6G3(0W4TC0%7-Y'V8((_I2_[Q<>I<17QK\EU
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M12(@/W&.51"->"[.XP=JU("[+-J(OD*<_> (^^V'=2)%)(?J%?&+960A=36
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MI@Y9T+Q8\IYQ!3T5FUA#(6K@4Y)7+B3UP]$7; ,UO??;(^"A)C\G[UVW'0P
M8%=D_+>):BMPBXDTD#(?D>D5!KJ8J!FF/-+\<Q7POC&\L(ZURN*6-GP165UW
MV9]'"PI/S:+[I,H>=,ERF&Q'$/'#6-Q%IN.NKDF^KN<_Y^ES[:-&E=?3-SJW
M]B97N[\%N$& KTO#=SE(S_J'!H%B7J&*!DHZJ!7+?:4-O\P2 45WI'8QFN,7
M"W\6\XRP\7#E^"^)I6B2_$$,2@%>+_!L3<PML^IVXHGXU'MWZ"^6OF:2V+\S
MC6HO<K6LN8JY3W$M/VWJW.!.;;&8O?$S1H)LB"_*+S)P%<5ATSL65M#*L"59
M7.YM[J#:,\F0]U/XGB1X+;AF!?QT'.!8 UV5Z2%/R;[^1@[:!AD,FNJ>E_!,
M4EJ-*B[SY0G^X\^0^/2S>R$VI=7V1YR1S<BF#7^9]P(AE1-SN0F08;RZ[(/M
MQVW.ODK+!H(+Z^!EA-$']O+97HER+0OF^[NS+SU2QR'&]_N<:C-!$\<X\-<X
MH!IO'5DL@8J-1^GH (E(LS*@?$X7_NH=W(.&GBQMS^$JP4A)"KV*XXSA0C3O
M6G:K7Z0M0#A\>A9%J%:WJ(8CRX3!HA+RWNVG1F6B&B\EY=M5LHJN$6H\Z&ZG
MR:D]70Y=Y<VZ XFE\7DA/M",Z_+^D#I&W)[A1K=VA<F%P[^L@[QTO1OO4Z3Y
MLK8<1O8G9:L5/>T=/:O=1!U"G2Z\0B[$.2+'$G7V$*8@<)D/(.]\9;U96"R[
M<\.S\E\L7E+:RW)!"/=K8]2*+A4;U9)0+97(9WBH[>L\B^!HV\5F4Z,+=HM$
MIRR72F41K 0H":PSK)T+TT(&1FQ31!I:FX4JWPDVKV_G73<$L$G]G=P='!P!
M@?Y#"BF%P6%1 0%>TRZL2-V3ZQVJ#;/^S3'=N9Y/'%]#97@-^JNWYI75X>9*
M^@P+?<D-RVW0M\3=7 +J0 HI6&IQ]'B_!O@AT',/KJ7>X'?5Z*ZJ3[6Y;=EN
M5?L4>52FH=ZCY7>[$2)T4HLW5[U #1,U;RSX%XASM F(^9D]"<_@GGG#:-6-
MM>+IU+5-G;"F)SZOZWFE! %0,AA>A7X,MM(X:TP "6N2J=TJ]W-V2V;6?[7Q
MX=W7J*>1M^J-^[GD;M ]%)7TNRWTW3QK-XTU?'?W<S7%S$W-*[#GW&^.WCYX
MZ!<8YS!]Z]:<3$<5O+5+O'*.])M#EJ%S@?4@XW8*.HMOQ-"E60Q&#89A2'9?
M5)OF FPZ2L.2;Z8^JAR+O7GKS)R@G6[\-A?SNY5 (0X(Y27[];5,15,TC4XT
M.;673=47C9=B/YE_02@D!NY 0K9109(W:Q1-4&CKSCSQ!+LA"YDG+][R!0M)
M1X_$K<)$I*9&BBU253M[>>R,!B85."._Y5:]?#W<-0'+D$D<J48E -9,.KK>
M.QM&5B@"#XS*()^G\1<4QTUY-)?IFCV>@[X0-H^:!]BYS_5.U^A0&&5"+,7/
MP]B)RR\B-]/,>L%/VF$7MH^@%6!Y']$RWKW^LL\>H *\FH4B+T5_/_B4Q%>2
MHC&+MBIF;@^#--M:5>KC.D;*'"F@_O.1/\)N>!HOCME_W1<G[09-W]G&_?PP
MYZ_<^60^KZ"J)E7<9/'M[]EB>YJKA@N^NZ@'_8(;U</\MV3MNZ>Y>A3L2U4R
M?U96/GUSH(;GP?QB>4%\XHEUOR8DK@$><9U!BND1BM'IMEE@6&'QI:.>GR:D
MI3#9&IF&[QL#HQ:O%,9+/%7?[U>&R_HK\OCJC/8:7Q!;R4?Q!_$X6*.25U*F
M+5N*#.L5W^<UQ7P*@4^N6<AT3#IYC;1;J&Y:". QJ'Z?4)H53PS8 UO3;&HJ
M\;BB;=B"BK:H0Q732G+>J,?3**$UZC*(:1RSV^6+Q\@#N6I_\[9,IA\8'^?Z
MLO 5JLD*D*T(CQ,LSC0Q*= 9?G9O(SYKZDX]H:UL:PL(_]PJC]0H;DI$O47-
MB"O89>6DC-I,&[-U[>[IM[0T#^X H@C/FBK17H>9W@X[KAD?QB9YC70'_#PT
M@CC1=![.YRK@1#9DJD;RCWSJ/5PNM6.J58J']HQ&T]CT5&_+S/R&0-X,'U)4
M=1+(MG(-B99.YAG:5F,C ZG\/04HU\DAA*&_"C!71)6%<?N?@'.9)V3F:&I;
MCKG*/*W3WJH=I*6'<2.F;TT:J@%J)5K=Q8@N@?G=?EQ@NEB":.TS8\%,0#M7
M7DG4[M[U"K3YGMJY@;(HV9?HC<N1 2M+?"D=ZBT**>,5&07H)=Z1;F-0*+%=
MH-INA!"3AZ'BH6;(9VSH']"CD85?+$@!4LW(:[5HELLB4Y("'BDO)K],&NUM
MH'*D;1(6$>MZV_MU+[%%A@\DE^(2 7Y[H&Z!/%\S?_=@WK;%<,^/#=$J5_&?
M0-5F0U.B3ON#[Y[$F\/+*HCL&BFOZ0,)'NL#%PNL$5B_?*IKSWMF_T0YF\>/
M0?JG,JV%LZ&1N6K_*S7?_3?:[W?6ZY=P"G&*/7=-I%XSTYC5A<N8=DN=BH&U
MTVXIUV6"W^QZW)@^*+-YHQ#1&0JW/HY_4#_:;;(W.+A<4[6=_/O:]ZUW$UM3
M$@W2;U/B*!LWP'ZE=1"_HL!#CPT/5@W IIR..P<:%LQV$/S"S#[*[JH;?<II
MLT;=,=^)D^#>K;3*9CE8J*QUY%5 [HJ%!8@^MRY:CA[+TMD^-VA"=ZSQM/B1
MY"'/:,+7:3'J**$O8OXDD,R/\'#B'T],CM,J/=-6IDS/[XGDYA+!N(4+QNMI
MYP[7OH4,BLUSWZ0N(L'OA/!%H18OQ3GZK'+2MVBY-6HHF+6_^\!=-9E@_V7D
M(*F8+7[+:N%6CX^<$IW=I&^$)%%(QTCAY-*;_+8?<=JFJ4I:J.G?< :*Q1;M
MN*B7V/3A1';E1@'O<PX?>;RQ)]6_J+7;[I!D>GMZFFD9Q-!=@/)K[M9JAI:P
M$141J9"9/M7NLV!%Q\&*-E;<N5E['UO?&_GHAKL-=.^)FP7Z(G@R^(D!5X&/
M5*(RS44>NZ"'72&01<(MIR1MDDB0,_ZED9@KH6B[#2+"_3*&?D^V.D7I^@'B
M@5B8CIGA$J4@#B(;/1:%O<CSPZJSXJFI^#Q'NHFI6TNZ#;S51N<$#^=VN]^J
M%$P5M9KJ(63ECYK>_>QWQW&2@_TNWL93)6/L/CM*;R7U+=VG )<N"LM5/9V\
MK\FXA\40LJ)NOOXCK"EFT: AK,1BTV-9^W/O[V%9!,[CR \GT'M"]O;VCNAV
M1-+=4([ >3]?M>,33%.R@5XL.!-FX=5S0HL+/CXUP:R-7>:D+/^\=M)/N3)Q
M.!?I"9&M#_T;>#[W2VJ#1EHW,OYTH#6W)8;>7TC];$=Z"/5#O)_F%PH!*F\O
MU^QYXH-==XMM/?.HJ[K;ZCCHFV+^"U]%#^%3PM51H95_78GST7 7ZI(F<7A)
ME].WX<',ZU_]*AB2N;C\XKB0TM3?,8N:6KF?!7U\!QVD?P;,+R+#'7ZHI7&6
M&MJ<">LO25%0 I\, (.Y%+#%U_M&7#Q@L/40&.I_H=#KJD=G[4;9'\J.8O5#
M[5;!).O%5D**@IQMHE8[6(8F>6N/Z9O-<8W:0<5BR?OABBRC LT_KWEF3[S?
MV?W[NW=9XV8F0N#-T<>&FN3O 5,L_[ KH,&3*#OB82),Y!5,5<_ZOL!C@2,\
MC)%Y/@+][,$^;PC4!996R4.(CCKF]KK<;+J,#<Z-J6_>^\TT :*@94JC1&=Q
M!4Z9T18M\^T!P-5]3<C*1LS+0KMA7YE8$5RTO  Y@$VEL-_\H?R+I25(XHP5
M%0:GG.N+8GE 6_020T@EJ%?XI+U>J"E%!D']6[<P[DX2&??5E"$=)5, Z@9R
MM* 82]C5R((^"7QMDV'#J*Y3'O#^Q<*-:6%2NU2N#YLB(FJFIRT0"/*QM74U
M.J=2W@:G9$&(R?W%<OM*M?:Y-A**U!OI_XOE2T6#:[%V[\P6<&H=Y*9<YKS/
MWPF, C&G1#VKIWPF.NYMC*J1,?S.RKFNMU/$"M]>PD&+;'U4K3-AI:,Y%QCC
M#_EN 1U4-:MF4MT#UE^"AN331L1KT*,!;S-[=$*JG]/G"L/MFIAZ1OQYNRNK
MSE17(6E;$A<GT6/!;G7$_K;S!=T7 6;*>L.0QS6%@T%+GZITAMN60T%F7.!=
M=>W%@V -1\0OEGOMGG^N$\G]-;5PA4ZA1&LR'R$-%16<(HHI&=9D*@@NYLHA
M! WCP.9K217:PZF]/%?\7Y+TN>YU+LN5Q1>ZC/M(.TSKCSL&D$43WV:]]4S9
MY2DS;;_PV8[+9V2TDU&4H>015UMC%3=YHQLS5]%1]4CHN5Z[8W%!0EN\I8OC
M'DQ3#3./5$*8VKQ+N_+ZYV80[_Y>P-GDY\!)M^FG#2CUS7A/<2$>6ZXY8J)U
M5?US9_+O6&:B?L+DO;MHDY17T?U#3<'!T9:M@.!,EA5($^^?K8@+C12_G5C#
M!:&YFQWK8]T#K;XQ:\Z%);2)^;@).7>(;G_W/T&GF%K,"@S\O_]!=K,AKN$'
MO6K:=?O$Z=GEK\T]K^="C+ZG3(V_"I4Y"?;I6CS\:">[!VS5O=YO,T8R>F=-
MKN%C8.4S8Q0&"\A*E9KAMB?VI).<+IF?)(>$Z<2M6IMTGV(\S4FEKO\:?XM:
M824!#.5IYW[JF_A@$'J-KV6E,'RT5> !@V1K1[<)8#!/>9\7&9N8)IFT%/C/
M?L?K)&(+VG]&R/,6*A\G[X(?:__UWZI._Q,X_U<(1]ALS '76=CY7RS_QU__
MWXOSGT-@9^Y\5Z<MAIE"/W[_Q=*TB6GE?[-GZ57M]\+KO_*MX9P^3269Q\=#
MJQW*=R#.>LO&W@@DO&@!P["&&#: !2YBWNAS.3;Z;#T*GM%KZO;R"U54[E@+
MM87;C9B;3:[.I AFO:VS&::OK,T_4[CBQE!E=QVC9'KQ.1#2_.D!I/OAJ:MJ
M@)6?W0-EF6Z<(3[?2OH7P)XER^>>$C-2YD!>>;@R?&&GY/)R3F(N(6=L1&J@
M+0]&W8#>"XGZ)_0E_RA;:+A]Q%5+*8C?O/M=78%H*=]A$Y>5N=_IQ/;UV6I3
M= ^P[SE(E6$<@$*#3?5_HW[-G@,Q&H89K:</GUWJW^K\Q4+;2CNY]/)4*?GW
MASV"/0U__&@J_^H):35+=^334A=_^L;R>TE$8G#<F_P$$%G\./["W \O.OLE
MI19ZS>(3O58G]90$"]W7=13=A'LR5W9@,&<"AHA/HR6 ^B'[1P*?K6@K'BTJ
M% HBW:,0JC>QCE0DFMO(7JOC*LG<X1'%*)G;I=\)>QKK$T#LUC6]+;AU*#,_
MFL$KHF+O69C0;^/UT7SX *#H@PTZ35PPNGAEW2[[><?XH#WVDG +9V7Y1A@J
M:V;@536\=N(U\UM/)?%SDB[:.L-IH,#UN-\L.%$M733)%%BDNSYT)?>OA;V:
M3H1@B#W^\.R.8"J2,V#6YMYG$@B0;US4O>PV>>SG[F>RDFB[Z^[77SQTYL=1
MU,Q[^*7&?8_]ZOYV-?O*O'(/T_/0(XY^9<K*J>B+ZX+3QJ:54/M^\<K U&A;
M4N_ST8H207WL 2(K1Q$H-_*9I^+O'4KC080EY,M9O^UVYI=J*P)/BC^/!>"&
M!1E;2= -2=2B$?>77?2*GGJ$P$KZ6G*EJH<?_^&+;!ID7[@R,%D3R3U^DH)%
M5<X\\8W\DP;YDL*=V->%UD6ALB0S2F-]\R!!WUS1=LU#OT_/?'W?6W<F:-5#
M![[>5[9=.:I1,O*&^A7Z#Z2X9<A&3Q2W&@^5+(>;GW"U>3X*=-VXZ_MN >DH
MN#O.W7?7.&I:0$;B$WFJLI*MTZE%F8IM%2/H).!358B@*G-=[4K5>OU#S4Y!
M$\[R^:D+H8WPX93JE$&0K9 9!(:NS.QDJ*9)*7X8J2JP+298BGH98E6#P<_8
M8>.QPK" $\_2&S)))+H'W4/#LW8NKAJL58ER78/0K&:*0ZJDHP$4' [O/_I,
M]>>/W3,%X_FS[FPDO$^CC =VS.Q;ND1G*E89&<!)UMZ3P0G7S*Y)-$"TK%:M
MAE 8G$M<3)G+DNME SZTY(NOWG D>[-'O[5\O07#&%9!?VE\DU-&V@-U5Z*P
M>*002\52<1.LRH$CS-"(!K> P4"'S^[WZWTEG.5!WLYQ?JFX3'$P1(<6,P!
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M![52TM3:2BR<FZJ? G'73?)A=4J#':P!A[B00X3]3W:!?=3?[-L_QB?@((_
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M$G1)9U:_:S(;O^L=@5 +Q6R_>1"Y]FK4SP=[^7<,GS[GB+FH@/FTE$A8+MK
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M5>.8JRG([^",Y!%P_@)C"DB5? S1?>$?7UQ9P*XGJ7I4WWK;6%'-R&MW;BT
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M6*PH8BFZ#A&V@%V54!S79V4?V#7'_F_MO7=44^NW]QMEJWN+#:E2E2)(W92
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M8M%WY_3DE-B+DHYIM:^51X#G*__PK:3*!T6Y'CQA2_3L$]-M@DGSE2!2V&;
MYF;M$*7_>,>L9ZAP\E*) XBX!RE^ F[_34<GTOA2KW/F#Z4?$A%IH]GN;(WE
MJ-'$Z>)BV<1]$MNTMF)OTM+2-#20TL\1X-?W7,BL&Z- U.GK79OH$XU=G;ZT
M55+0=PT5AAG)#9DQ=#<XO<58"(J+K] ?Q06]!S%7[6F"TL-C\'?9J!<\Y;8U
M./5QV'U[NUG+I=0[N  +2A'0\$W_37F-EZ(B#6:M#(K[FB.CEC^@I"A0HLHL
M32>@?\!8W$L.7FT>T.1+ER[SI\DG@1G#_I!YH/[.O-(O>O9;V;"_#KB'KX:>
M'5=<&;WAH;,Q9GQ/&QKQ^CUKOQEX&(_!] ]52U^]E!3Q<FJG^-I\;D?$*_L%
MN%X4;1MZ!,BTKCRWW<"(,G8V(NF:E;P!'9?8D'BF[?M5SA"%I UB.">$(;^5
MK;UC1 LP>#_<(<',H'>V/-^U))&9WK?;E;MF80/"FX]LS]9^I(0NEN7$WDA'
MY%-WM:;3R<;ZC^UR>+K)<N")VE\7#R!L=. "9I8CP$/O#%79CZKC>_YC%37]
M6K:#8F)%1[#6TJWE'L/>4RT+-*-4*Q!U*EJ]<W"'C,:9\PI7V 9>=O]!HV;7
M].] )]G$K71<H,-3AS5M"94T%%O7NZQTG3,\@#@4O*7+*?SKG\$LKL$I%]<3
M<!.'D GQFY[ 3 ,S_)6_KF,0&EJ45-I#Z3H3CJ52.:^RAA=#!2B?_J;?7&UQ
M*4:SAI9R?[J>7TJH2B>ZD2IQCL\B-5 E6C5#31K#TT&F]EYBD&39@"^Z7<5>
M4C[>(YOU$@D5 Q%W7MD8'E]1G@CZ\G+49Z=)V:L([UIW(*S&9P;D\>+5!:J=
M,3+DN>/K L0:&!R_N/.6_&VS48E^TE,F,:8R-^8,Y&J]D.I*O#TG\Z"7A!F2
M")LQ. *,J5OJW[V2%]W;H1#O&WPJDC4<P3LVZ^T:\FH0J)5"@05#W? -NV,,
MLH3-8=@[SN9_L5/W<#L[>C]4$>SOK-HNL67?Y<-]VS#VJ66S/IVAWCS*Q&Y[
MU=W@'#T+').X=_M$#T1&-Y[@H)"S$K4<**GVYT[=TM+97U 54P+ZTRH,W;UB
MK!ZB$;MQM3U6I41Z1Z_GT7BF;GR/>*U43U_ML,;&WJ6RQKDW6!S2CJW=N'4Z
M<4#7@7#6\-/*V;R4<TO0;>VIO*GS8XXN%<)L[N7@T=R57O0"H^'PSR<SI86%
M#Y7\2[-8F=K 'P. 8Z<U/3\J9,\2@, ^&3A8NBX]R]AJ3.-T_ZN-],]HTFMP
MRQ' "L0IC"ZER#G1H ,26CFEH'_DGLI$02_QZ#RK;.IJ=GX4$5V49K++TVDW
MIW0$N 2H.B>V$P%7NNBL:'8+"LICI<'E4P/KM]HDBWW4UC'@V_!-^12P->'@
MM^%Y/1-^@G;O\\7C#HATROW]GF@W(=^Z$1D_84NI9_5U=\TPCA2@U8#YF82!
M@6[N =%V0B LF>>T:D_C!809LBP#$3R>5C<SB"E=\-.V'JG)E7(NCS"4)$VP
M#'X,&O(U]^9S<[\4Y<_V;VLLCO=;_X$R'YY WM,<9>HO#,90O).9B_;YQ?;2
MX54HV0)WY( 0#IN &^C@2YPC,/U%A_T=XQ*]BTM+FVQLCF=I<GR;KA&*3Z&X
M-VB^,ZOFAKIGH1=C+6\M%[WW3.O:@DB:QH5Z": Q#&!R[&@R(<'@H> +Q(\+
MWTH:[X)9Q;M2;9V66GI32:[@C%M F]O-=M3G(/T4A0BQ?>TF5$DJ9P/5O.IC
M#?(W/)P^X3J\TW0ET6 !&Y05B$PF(>PE4TPD_0M33$1G_>G;<N]F02 .[;_/
M:?^]_#PE_)_@3Z.?YZD*/9CFFV*"Z1]-K-)GWMCG^<00WU^[;_.^P6K$G"R7
M;$4TY*Q>9CJU*(N=-__'A*+&&C/[<7WUL%J]JI]93H]++5D=)Z:!]KDFN)U@
M8![Q!^.)Q7WEKVV3@0TNFN:X+U"IREV_:MM[8[B['7@32UN@]M@OY<G:D#E=
MJXZFZ.)\?YA]B^]%O5NSZ6=@KR\!NX2UNN^^G,!(=WGY!@0D*R:DAVF=-NV<
M30DVGF&X14 3PA/6\P-<"?O^KYA\] ?[GC&#V*O YPZ7">/38:@.=NNDK1K.
MP" @A0253!PB]((V;_;]G4OV'\S/N/R_"S\+_/];\+/ _[\%QY^$GXGZ'K_-
M?1AU_ CPY#_[=OY]',\/]SZ$"9R?!).9(JN_'0%:5[+:!2.W['RK ^[[_I\>
M7?W[^!EG_G?@OW#GYI7#H9VN<'ZFQSB\I+-]K.]9X[V>5T@@VWF.'KIL>$;-
MZ?$$\C>E0/HV%"J"6*18E(3>'!5+TCZTC60V]P-NB ;_P!U0H_(!D3HKN]#]
MFB/ 3<"/T,GUAFWXX9-C.QO-L\$LZ@& 8VT^JFN%5KL'.#7=>P1(FVSPW02<
M;\\Y L@U!TTN 'XJ_E3\J?A3\:?B3\6?BC\5?RK^5/RI^,\HAOP7RA?_Y"<_
M^<E/?O*3G_SD)S_YK\'1V/\%4$L#!!0    ( . UJU:/50@8TE ! ([4#0 5
M    :6)R>"TR,#(S,#,S,5]L86(N>&ULW+UK<^2XE2WZ?7X%KGUC3CM"</,!
MDH ],R=4C_:I$]6EBBJU?7PZ;F3@*7$ZE=20E*KD7W\!DOF2,ID $Z3HB8EI
MJR226'N!7-@ -O;^M__Y_6X)'F59Y<7JWW\7_C'X'9 K7HA\=?/OO_OE^B>(
M?_<__^-?_N7?_A\(_\^;+Q_!NX(_W,E5#=Z6DM92@&]Y?0O^)F3U&U!E<0?^
M5I2_Y8\4PO]H;GI;W#^5^<UM#:(@BI__M?Q30DC,TC"#)!(((D89I$&6PCB6
M"0I1)K,07=S\*<5Q&A"2PHP@!E&H4HAY@&$:*RY1E-(TYLU#E_GJMS^9_S!:
M2:"-6U7-/__]=[=U??^G'W_\]NW;'[^S<OG'HKSY,0J"^,?UU;_K+O_^XOIO
M<7-U2 CYL?GKYM(J/W2A?FSXX__Y^>-7?BOO*,Q754U7W#10Y7^JFE]^+#BM
M&\Y/X@)'KS#_@NO+H/D5#",8AW_\7HG?_<>_ -#2419+^44J8/[WER\?CC9)
M?C17_+B2-Z9G/\LR+\37FI;U1\KD4J-OGE8_W<M__UV5W]TOY?IWMZ54AQ^[
M+,N]IQJ4Q* ,4X/R]\<:^_$,^)[PUB^Q>@#7F/O)%\8^3C]Y@WNM]4&.#WBG
MF;,AMR_4^Y68ZMW=-'4V]/$1^WHMBIHN)W@MMLWL0%Z:7WS4/W7-F ?UB&G3
M3B?=.U#E]UJNA&S5<N_1(!?__CO]TR)GY??%1ZD5]K98B@^K6I:RJJ_N9=D(
M.%V^_WXO5Y6LWA9W=WEM!L?KXJO^E;XVKW,-W=RKW^V[11A0,Z*ED"5Q!A%B
M9A1C(>24Q6$88XEXLJ@W7\%"KN O7]> &U2^(?W.@;WZB KHMHN'DF_'S[OE
MH4%1CX=F!,4_KNB=K.YI=X.VR[@:K:G_L04,Z@)4!O(%*+:& =E9=@'RUA2P
M-+8 #>[NWW[<$C5)?RYGV$O+<3MH8P]8&W0!=DP"[S?]L]^57]NN["P#S6/
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M]#'#]/&C5EPINX7$U4VS3/@QIRQ?ZF8^TZ?F(W_W(!<B8XC$VFTBB%&(4AI
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MUEQ>[=TVQWO#.[#=%@$U(!T7I_K(M?.L/!$VLA:LF>H6_QN@L%!00P4-U@M
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MQ[:=-^./PY$5\/.&N,\;XC9@+T #U^MI? M:_)W0[VMLZE/[%H8?.,EO<]<
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MA;O[D._7[NZ]<H2H^B_2[.3HAUVIG_**TZ4)F%TDE&2!Q!P*J9TD1.,(LB1
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MPN3G*F%SBYM$5&7=K:W\+.O;0GQ8/>HO0LI/^J7HUNW"-**")PHJ1I!6B#"
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M0254E 4TP#P-;=(]N37K]$U/E>8)Z*ZL<M'$YQ0KE]S%UFQ;K-B.PN'8<F"
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MU(/G2H;/S/5947#]Z.DK^STSZF"%O>?7G!5PN',\=ATDIV20*JH_Y!#3$**
M(#V+)0',5(Q9HGB4I8'37MNQEN8VI5V'U<GO)NI0?^2F+'J[.+?<@A\4B'B
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M+NLODA<WJ_P?&GV3SO.GHNQ^9:X+%RS. H4(@7&28A-%'&O55PIB<YXM8$%
M,J>%U&GASVT\6"=+A;1+ WS?H :J*$&YQ>TV6$S\1M@-(_/MYY$'F(,IHK>"
MT83WM$:O,T<;*_5O:_ D:[ U]*)+'MV\'%\L7@[GX>IU^LC30#8Q^$F'N-?I
MF.>#WRNA&!"KL#YP<*5TTW?%JCFL^<M*WWU9_TS+W\RBC]*-KF[:PLF++&**
M,)Q"'(8Q1-C$G4>Q@"P-)5=Q2((TLPYF<&U];H-25\F\JV'^8("#R^N?W0N7
M#^L+BPB),1D>>\MP?1;F2H$6/&C0@U]:GFO0&@#6%K0U!EQ"+9P9=XC%&)/Y
MB8(U-CU0*,#;'JB:'FC?=%K#^E:"N[87BLZ:B^[-]Q79,93'WM /YX=.%QLR
MU-Z]X)'!#QDPA'Q]N+]?/EW>E+)QT]HAZDJ]_UY+W:"XEN7= DG.DI"DD&<H
M@"@1*20A-0FAXB1B6<@3;E_MS*+!N0T4;0D(N@2R PETJW?FNZH:8P!=6^.@
M7C;$6PP1GND<>Y+0\K6!N_'U]2BQA@P,9L]$.BB_9T(G$OOSB773=0>6>J7<
MYCG3J;>#57N"[7*?FT8+F2_>K^J\?OHB;W*3>&55FR6U!:$HC)0*H?XO@8A3
M!2D),41$I"*()#9)EJP.8!UKPN4MG^;$58L2;&$"@]-.*HX2V:^Q/L@965,=
M6;'^SD^9?F ]HY+\CS?%XX_ZUG8I0_^P7<$X^L!)/O!3YJP_Z)/7G9$O[4,S
MU7SW8%RW5B1:!^Z3_-;\J5I(Q#%.>0P%YL0<#!<0JR;C489BAE%$,_?<:2>;
MG9O#=73JHF?F%)1-O\A2CV@B+R7?G;VL]%S&>?[NV$>6^XG>F1_;-VL8;A&#
M%O*FC%^+VH2J?6NO\)C/PHTHGPG93C<Z?7(V:R(.)FJSOWO 5'$_0/BZ>",_
MTUQL\A)2FI X$0&4@4P@RJ( ,B4CB*0F0U 5JLA^EMC?UMSTJEG]=9BRG&#2
M8MKGCY^15>7E,>_K KR1P,!UKB5C0Y[#5,\?B1/-\OK(]#2QL^.D=TYWXA'3
M3>?L;-F;R5G>,B0+T%*S_B8OOO)<:NAOB_*^V*O;'I(D5I%*82JQF<>1 )+
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MBY-]#0ZR>*L_OF%K]8X5J_J, K$<)=28/%$L&<19FD%B>UO9& S!!>:,>/D
M)Z/9U+ASMXE-WXX#DP-YZ-)C+_E2#+P6!*A/5J.S8X^6N_D:'9UUCLHW5)<
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MPF!3X\--_Z6VD;*'B^<2K@Y.L8!H#4Q<C:2@$A54L@*X;5_5PT-V"3X/-UE
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MFV%LRT^_E#/)8R3R&$/*S4(-YQI!DE$!.4D)IE+B)'9*TKLD:&I\4>O:;GJ
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M96V$2PU?S"]]CJMXSYD;XPTY$P,3W[8S1J7[3=T5QV)L] >5 3=@UX2V@\8
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M"]8Y;?^MBQ5*$A$K*"AE$"N604XP@BIC&8D(2=),7]D]K?^W9XPN/WV^/2[
M.GQC L,U=,Y"9_^O_M\,%S"O;JPV]6] &'!#=%CSYW27<7YVI[7+'.US7[\
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MDNKWJJKTOWL>MG.>#S>Z&@3E@1FKT1ELE*[:B6S4!I7>X/=6\Y G]7S1"G6
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MRS)(2"IAP&G(&!6!"JUVQBUD38W>MJJ"<J.K&\MU(6O'99[P&IBQ=J#:JCE
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M"H65LR!(,0L4@3&C$42I$) &"D/".(J$9AH466W87Z7%U'AGNZ%<GU8_-9:
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M6BLLP<=\D3^N'P^J[WK,_#XS.'9L-C#D@\<^7,X ;XUHHO"!L0-4AGATA:^
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MDCENCHP+#$?Y+TXW]Z2G-2MSD=/EBVGUW BJ(F]BLR>H$EZ5(=64)#4Y*97
MA*99I'_/4N34W_.LI,G1$&U2V(R"CCQS%DU+;O&!T=!\L@N/]_BEBPCXXHJS
M<L;EATOF'G'"Q1MZU"/^8K+E6$,VG^4R+\0,(X[#) P@C16"*$FU,Q*;5IF(
M"DIE&D7"*MCAG("I??5?JDR#5D?P5"GI4)CW%(;='[T/9 ;^UBM0-NJ!SSY
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M60"G0@ ?@_,\,F]D17NQM?I^Z&@XNUE-M"U!Y/ULL723_W?\I7.=DK0R2,)
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MNK]-;PYLHFA2+D8P6?'"#P?O)0>%]/(8LPM^RQUZXH)TC\5:<'U.0DHO4FW
M_+Q#0^K*>_TWR2W2AS)FYUW^<[':!^CN>Q&=$4!E*K$D96"M#*6E%Q['0C"M
M:V>#=A(T3 OH'@Q./;&W@*&[.''#D8N!RZPCGL,Y8*BHF $37 :5'9%,:1YW
MMFT]"CN/$3),,^@^,'.RF!O RHK^49+)*!H\9"%*]^J(8:-2I:S$&!-DD&+G
MG*3C0_%A^CWW=MEUD" ;B+K?C)T?3[J8#_WV[IGFY]D$A;XH/OSR^ZUH&,U6
MI6+]RD@RP;P"'XD';CPM:?)D:.T+KGUI:Z3JHL[5>B\*:<#.;/"UG?+*.7AA
MN8+$$P:(5"@P2BI0PMIH=':>U4X#/DW-P 6$O6C_:8B=HHH&0'410IG <%/,
M=NOR9XS\2,A *2M]$%4&ZYR ;&RB@4;!0VU/YW%*F@'327K>/NA.%WI[T+F]
M70EA?HW$/!#=*"I97J8I<)(Q$$DP\#EKC".#E(HY;4-U#^E &@<N6CT+W.HJ
MJ@$@;E;C;ET@3]QB,<[C%&]8XX0)[="=8.A)H!PI,ED>&L0@B<PJ:LUKYZ\/
M(&_8='9/\.M+/0T@;VMG/5Z]@)XL=9QJD$*I<HL8P 6T\B('QA*UUNR<+%;!
M[!U?0=);IOL\INYTA30 LON)M1O!W70G'8D2*VOI@#*,E 7!P-DJ5L;@D$B(
M<9G8VK[_;HJ&38SW!*R*2F@ 4H^<^0QIUM18C+/+'!3I"1BI.2@TQR89Y5GU
M*LDCW:_>DN$]0>=$83>0XGKZ!-_(VC(:E>':8A3-4$3<!C",2DA)N6PXYZ3Z
MD_E]Z&K&H^\O&U%=/0U8J"?L[09#)3',%!$@E0@@C-5@"'*E'+&1:.&8J%V0
M^RQ1S?CO_8&MKF(:0-K?W;R,KBTBZRXM[[579%K%6'B)AIK2XP(-M58$#746
M22<?;*AMU';1TXS/WA^^JJFC 6AU:98-J6UL$JVU-Z7SEDJJ1!XFH0=@&92.
M*ED8QJFO7H;P)#7->.P]FJTZJF@ 5!M,C(0446K" #<!+7VC42*&!8A!$"\8
M]\Y5[SESMWPSWOI9+GH.$G8#3GMI&SQ>7J65+7TQFY9#.TU#8843%BW#@,.)
M4M$E) 47M .KD_8D^TQ%[2SH#G*&+6<Y"XYJ*:,!^[-#0I(0(Z(78$J'4:'Q
MH,9(EH"3,A#+4F2^]JWAB34-O97%G 55E531 *@V>IROWA]G;ZF1*4$2I9MQ
MC!9<LA0HC]0%$[3DM;.:VS0,W6^BCFX?,41'"[H!H%S$V'4A=)/W;AQ?3U^X
M+V,\,3?8&D7&3+;!K]]_A9)F"^7U39(FN1PEB=6;4#Q+U= 55KV J;(R&H#7
MA[1TXVF*O[GY%$_HQ44(UU?774KM9<KC,%Z.<+]X789Y*9ICR=UF%%A)X&;N
M>,Q,4K)KL,4Q\'J>JF$33SW!J[(R&H#7!@==0%I&O\S3YS1=C+^FU],PNTIO
M9HOR5N==_N2^C1SQG-(HP?LR1XZ( );$#$$2RQT+S-0W98>1.&Q&JB^[UJ.:
M&D#A0ZF-@E.9!^>!TL1 V%)OFUB&:#2CQ(6D9>UD^D,JADU#]82E$X7=0"+A
MC_%T-K^9=9D6* Z5LNDFHUOC,&"E&HQB%-"+1#GE9-W.T3U'/23?HF$OJ%1O
MPG_6X.XDL3=I9=!RKMZ?OB_S=%%5R^5\[*^[A_.?9B4C.YLND0K\Q,M;KKG*
M>+9K X09BEQ[!E;) $I02Q2E^-_^<PK'4+Y?^%A]H.G "8C>==R 07Q.M*,8
MC-)&*[3H*8"@V8#/Z!2DS(4G3IO(:]\:/D?3?FC\IWF5<;I>JN%LB/DF[SNE
M?$[+<7"3^QS5&G9R?XGS33[9P=HYQZ!0R055R9;A>^4/=-^,*X^:#3/<9Y)$
MJIT%.,<8E(W4#0KZW;Q;,W:9PO=IWHV?Q%V4:<C<@R=,@.!"@$V4@@^"ZZ@9
M<E[;NNU!UM#9VLJ8V9&WK:*8!AS$!W--+ZZ7G]'E_:\41RQDGU @D+0M4R"R
M+,.M&%!MG4B!<49V39H^$6/;Y R=O#T?MDY21(N8>KU87",;PE,B'+J4F8DR
M)A7=3$LQ K?4*AZMQ&_T<>']""E#9VK/C:4C%- BCC:KT$@PVE/J(496TGU9
MHX^J-$8OTD6ODM#5*YU/'G/=8PKVW(@Z5A4-P.K3/+G%]?Q[Q\V:L8ZG449!
M)(_"X8JCA(ACX*70D **)Q,:2/5^L$\2,W0>MF= U5%"-32=*3Z\%>MBEM<U
MW/C3:K'A$Q_?:URX#TN58L+5I<_M@G<W T%QG1F#+$W)*.")9J13H-#?CC09
M8DSMH4M/D'+ZS??7-+TN98[H\@DC+$819:*\=FA2M<#C6FF3K,Q"6%?]?GNU
M]K Q7 T=/[S"/D*J#1Q4MZ\\UJVS[QH\D6Q<+$_7B-0,!/(.UIH(Y?VCHD(X
MQ6N7'#])S+!Q61]XJ2/W!@#T 76!!)1)(R]Q#TQF73/;-5<C5;J#69/ L3(Z
M5K@(1A,+Y0".3DA#5.UP;"=!PQJ>2DI_8'IJ:: !.'U,W8W1[VF*HIH@2Q?Q
M:CP=%S$MQU_3#5>4NZ!3&5P>E2_59@F,S>5E!R=6>2L4JYTVVH^R82U5/P#K
M02<-(.V!K$;>$\J5M)!L5ZXA/#AK-!BC?."$*.YJMRUZ0,2P6:-^\'.:I!NX
M![YEX*XD;$1$XD:)#(05%B(Q8%+.D#(-@9=NR;)V'/\(&</"I5?'Z$A9-P"7
MM[/I[#X7-W-I;K,:GGL,M D0ZA4(YS-8*1G8($J0H)1+M3N$/DO4L-G%/J!4
M5P\-'%F_N_&T;(AWT]?3KVFQ>F8VRBXS9\M;:8ND"VH<&,X2Q(PV6RF>J:R=
MI7Z4D&%]Z\K*GM66? /PN2G#NG'8(FXASKNA$*6742B=0LJ+(&>$DSPR$DSM
MX&R+A&&]Y7XA<XJT#P>+78%EFBY+PK027&X.X#*P;U59]4=:?I[%S3T@?*#$
M*0E$<P("HTIPBN&68*6)=R1*TGX2H\\0-JQGU#>T:FNF >OTRHWG79G+1?S?
MURL>WN6;)B$CQRE)429P,EIDIDR&M#E"R$E%(B2WJ78;C9T$#>LM]0NO>IHX
MU8Y]JMNAY4FQC3S&L=1% E26YV5<Y=*QC0)1)G.%D:^VU7M,[:1HV*O9?O%5
M41<-V*VG&='<EP=%>-B[4K-0VGR[; PD1GA6PEE-:Z<(3L-3;RU<^L53'0TT
MD#BX?ZZOFH=<(U-W=]Z_ICR;KU\F?G+?TN*W;R@_5-]XZN;?NY$:3SR]T%%(
M2Y,L@YAT>8MFP!.*\K8Q61,#>I^U;WM[9&=8\]A'LJ(5W3>S#9#%]3;^-4U3
M'B]'5NH4>'E]:T("H0,%8T4 [72I F-65)^K\P0IPUK3_N!WFLR;B%K?SV=(
M=Y<V#I+KQ', &A0II:BIO#8S8%TBAJ"O2F3M1_5WJP_;ZZH/B!PIV08,RMNT
MO#.O>SU4%#(8SM$3P8"FO+!(Y3$N56!+D!,%I?6?)1Q,Y+!]KWI)V/>JIQ9B
MA4T&1S9GJH74D"@K0WE]&;RJ"3"OG6,J!U^]Y^P] H9]6]\[@ Z2;P-6ZJ;[
MS<TSKU_=8AQ&G&7&)0I!$%MF6%@&WF8%23$;E7:"\MI%"8\2,O K]S[0<KK
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MK.[4^R&A=!?C9?J8YE_'(:VD\2&%V>6T^Y1.,*/HG%,L^S)<@.)FI.CX<$6
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M3W*<185[P,A2\DM8 !_0"93.9D\RY:&'Z^KSM^SQ*GB5N :9<-.+(,LD]12
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MA[LF\R-N9*#H*8)2P8%@/H)Q*4&0W.7LJ$:Q]X#49PD;]I9\ , \ MFZVFL
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M^$ S,<+4#ICO4S!LT\.> '."D(=NI7G3?W8;YD8+FH-QH&V)'@W^X3E*1ZI
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MFW([DGATF-5HN'*QQ6#$PUC(6+26RM.1D+49?@JT69X#,*1(EHA,Q;6N,CF
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M'U%UX"?<\*]>?6Y>>I3!B)EY8%$+\F^RA,B#!)NS%6@D3[9] \%=*OJ_P#A
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M3.%6FH+CM0+8JRQYM+DI?=C[(V73';H>K*#D/DOC:A-.1;Q1P2%$7HA+RJ=
M#K1BN75Z]@LL6]Y+[ON7+>\CA Y@]4CE;#!:\V(]Z71&!ZZ(!,'+#!3&"6,B
MTS*V'@/U0LN6]Y+WL++E?9C? 83NM:06I(YE- J,H5A=H;+@I"H0+!&HA"6>
MM X=^IK_/3)LCF)X!X!YJJ5T$5:72)Z>=J[&1,Y X!A 2U>GGOMLG6L==A[9
M WRT2]B18=1*#!T@ZN$P8F/N<V 978K M:D[811NLYQ!FR3H1\%JV3HM^7%J
M!N')_+U=\4:RZ@!U'^ET+F=IC?GA/3T9W"+7=+Z"!2&4HKUF"2$Z3GSTV5/0
M+!FV;D=Y#+W3^F&M,+.82( =@/75EUKB<L_7C%+S[$V"$K@%%9V#X.@/JZPG
M;S-'9UM?D3U,R;0 .QT2=H>]'B^6#L#U>K'\OEB2@W*W6>N5DZ+)%<F(D,RF
MWJE$<#QIVDR0HJ"17K;VZ9XD:-K@8#*HM1-2!XB[]:IRY<3\O'E9D3D+[Q19
M 5^=E.(S^,P=R.*89\[3/D<L_+Y/T"#$V;^WW]=.8CW![VE.#GM1N<N.JRI4
M3#FS*$!:-,1O32==,@W%DPTP0=; ;RP(C[6I3A[ C@?@8]#N @U3ITA]Q$U[
M]0]A27M8S'_@<CVCS?ZQ6-]D?&'4Q0L%G!FD[1#;??(1K(ND1SBS>7=6T2.9
M4L^OU0GF^D#&8CPQ38VZRT$ Y$VOZ:O5C,1Z^YY,69N,*AJBHNVH: /$K#/P
M$)@4*BDEXB# /;E,)\5O_6&MG7 ZL/W_'9;+,+^Z*46,HNB"X&P=L!A0@$O"
M &IRE8ATKYN/CKY#0"?%2UUA[GA)'0PS4J-QT2JJKFQX7[:[>+_\./OR]7*P
M<516*Y8\B,!$S1R3$$NVX*,P(C+K8VG]PO8H,8, Z/[>L4T;276@VQ[<R%6&
M-]=&HY>0@PB@Y*;+J&1@B\N:>1U*:7UC_00Y$U](MQ'X$!@=P/T.@'17]5(T
MY9![#T98!G4H.X2L&!TP^II^[J43DQO)TX+E$+$^:=[VX?'4SOJOF#9$5ZEM
M=W%=*&B2=<8GT#87VH8B*VVRK#??6J)V2"[ ($_]\36F==-;HZ$E0Z?&Q1N,
MRXNP_%FEN;,-$UBRM=^YC.3"J6P5!0G.@BS<6>F=<"(,PL7C:TSK2H^"BT8,
M[<"@W&JZL0D>KO,YI?1$JLD@E2=\HV'@,2.PP*/Q3KI26E^4/D;+( #YO[<K
MW$1.G>+MJN#!IBA-X$2_II#4T$$,(430VND2)#<LM7Y=>IR::5V;-M(> *$#
M6#^U,=O=QF]_?<?Z['LYT^-_9GA^E;_IO$'C1 +![29FB!#HU$$IA5O41:(:
M=CLY>,G^4'.(@!>C<[LW#-7V\8N+^?H#+F>+JPWE+(7G2H,HU3M 3AZ>2YI\
MO62RCCY9D0^"ST.K3>L\GP(Y1_.X0^MUM:>/88U7"1\8R,W3" &C(G[56W=M
M-?@<C$W:9&.:3W)ZEJII7?#&Z!I)&!W"Z[>_<)EF*_RPG*6K+6EM8W045217
MRT)]Y1CW#E 5%WB1]6)_9'P]0-:TS0].!+!CQ=$EPB[-^6=<?MON*&6G(D7&
M('0BE>RM!*\2 IEP^@5S-NXF$8P L%VJIBVV/1F^CA)&A_#:G)1_+<Y)4O4!
M\DHKBV2S9 XLJW557I"G2+$+6"VTYR4SX5LGK@XB;-HRDA.!['B1=(BSJY/S
MZ^S'+.,\WW(!A,=2R),$J34#)>D/3Q1!L4YQS)JIYO,3AE,W;0+KB=7:D<+I
M$'8?9ZM_OUDBOIW3&KBZ[7DJ$SS9?@44$M.!4G2TO([D>1;4OFBCLV[=X7DX
M==/F%IP(=HV$TP'L/EW$U2S/PO)GG4_ZOGQ:+]*_+ZNTN,M:"P8B24%!,T=R
M#Z(!3OSR)5JI7&OE]B@QP^Z^V%BHZN.:OHVH>L#<#?E_A&_TY>=EF*]"NM6:
M,#K.=50(+F8*?0HI;Z<I".)H<@Q)D"?1.G'E>:HFGF#=1OR[H&HKBP[014[H
M#U+''\Y#VBCL*W= N%A",:!]R*"83A"8"V BV03G<Y*Z==+GPY1,C*+&\EXT
M9WX7>9SO%O,O!,EOM>[N^H',&>:58 %81 \4(@=B#*]YK5QE&T--Y6D,H8?H
M& :@O_DTTJ,%U(&FVMW#]OQ9DP(KE@,O6,>%^ Q..0J:C2E,YRB9&1MF/=B[
MXR7\#&0.8'<'H-FM^_D0?M;#=!5]2!Y,,0&($85T-^TH9&8!72:V%<NB:9[P
M^Q1!?4'H$(G?J\ANQ?X.L'2[GNR6'[ Y:499Q:WQY 74H46N1/ L!\@A"Q,4
M-S*WOF1X@IQA./J;3P1M):Y^D7<UB"MG[6,V(%"1EN?!@Z^O7T(FDWE)O)36
MK0R?)&CJ1B>-Q#X,3@?(8.J4FS_"?/TZ?)^MP_G;U>H"LY1<7$U?X\8J*7*&
M4B="JZ)2?:>7H)VP%,]H8W<;^CXVXN&)5;I$R"&27(S!U@X43@L-_FXVQ[=K
M_$;'SBFFN/9@K"4[+R(%RX8Q,#(F.I B9"T;*ZBF&Q@&U[_Y_+SI(-'!>;C<
M\S4+:G[3^:+N^,Q$;732"%A+>%6LH^[1(/!$UJ3.JF3-&Z _2DPGG2!.#Y#=
MEF--I-4![&XQ\*'=H&*8'?DOQBA9$S4CU,&\8%&ZXI*-*;3.WGB:HD[:0TP.
MP(9RVQ^%_A*%<_P2+C.86K>\N1W)GW&EO I$O#(J5#;5O=3D3BL+9T(+#,.J
MUAY;H9/V#Y-AJAW[.U!H]6KI[7RU7EY</G?<S1,X<R$)DTL=G%@+%Z+T$(V@
MW7C#8_$FF-1:H3U-T<N?)-9&H3646P<H?+ 0]?W%>K4.\TR,.S/$*9]T 1NS
MI:/%%<00) 2D&,X4ZZ5JWL_S&9I>_HR;-DAL*KL.L'A5LTP<VVQE=6LO]\^9
M3-*C8W2P?!U!23YLM,41FFSU*-0(TY;VH>_E-W]O@]'19-H!7AOVPWH=SM/%
M^>;+CXOS\S>+Y9]AF<^44,5IIR"PFF@? S'$D9\<G N^9%:$Z+@OZ,.;>OGM
M<=N<C+[0T]-QNJ47_GNV_GIO\ZN[NU]]W)'.MK'<YK/.0E$I%/2022B@I*PO
M'J[.S''2<I>84:W?M4?92"<76GV ];&C-!ERCKV:N"P__K2FH';2L_0(0_XK
MS.;O%JO5VWDZO\B8W\Y_"\LY_352@9+QY%5MX.DT*'2>1*8%9.=K<QE2@66T
M!XVQ-]?)'=[?ZLR-B["_K1G+J;C(ZVV63[6/A:VS(+(';65ASFDO\FA##DYN
MQEY"!]N.CE0[Y+0Q8[_-<]N3M)=@[JD4LJKK#2_?%](NBV_XVU]KG*]J(MZ[
MV8JBSB0C8RG55L'$(*?IJQ 0BA7:IFR8;-Z[X#0[>_G->AM'6OW@J)F=^O_^
M\YYPB6G_WOQJ\YOZKSYB^7_J?__Y\>V=SY]]^W8QIQW&V>(_:$.7*[PF;1;B
MXK)I>ZA22[1+?/5EB9O=K^AGK]+_7LQ6LXT>O/W7;_[2JYPWOP[G;^=EL?RV
M^?6ON ZS\[L\6,V^?3_'YY[%QB?J/V]8MLO,+6WW3D</[,.*0?*7_M^CIQLB
MH;'.HOH5?^#YXGLEXU5<K9<AK<\$<\FZ1 $0.5PU65"!UX6!#9X'Z4I@I75A
MP=,4'?F ^^!'UXO*+Y?LKU;W#=;)!><W$U,O\X:"2SS228=D@@*58X$8> ++
MI&4Q"J_ML*3 8ZB8.FFP&5AV7G9/))<)HX35<GWV*7W%?%&KZ2YG@O^.ZZ^+
M?#, ^/Y/$6O)W29O5UN#T88,AOOZRBT0@H\.<I:!EQR\LX/NLXB06\>0OKLY
M@L?2. TZ3PRAQ03RG!BWC^UCFRVL(O,,/0>C$4%Q7H.@0.SC%/G0T;>XV\S[
M(&0^3<4TV#LM"A:CB&3J5/Q7WWXN9ZO_?S&;K_]%[*+HX*HTBA6I3>$@@JZO
M@EC(GG@)41OOL^&R6#?(XCZVPG28:2F^16M>3@B(C+.S=_@EG/\V7Q.#-D<D
M4/S$4]Y< ](1T:DF,PAB1I&"<XO<[,+@CGI98?J/+XL?_TD??:E=Z(L;Q?+
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MW9F'@*B Z>2XDD6'LO<5S_/+=O4>,!ZH&O"\@[?OAU_@?OOK>]W;64K(Z@D
M@]77+(6#0PII4N)>RJ1\/%'#SBU!7=T/'@>M]@(X&$T_<!D7(VJG33_F<C'/
MU>_\YW=B['Q]I7R9<"6IDD S,O)T/AB$FM\7;)#HDE 'W.\-7+LKGWP\/=6*
M^YV:OF=+'#V7G+&$A)DH:[QL(&8;B+.YJ)2EC_M?2#2O1VT^PNWD,&LJA]ZQ
MMK'TTEE+!Z2 \+4)HDT%O,$,BC2S2"(XB[X)L 8[5<W'G4V'HKTYW"ED:H;:
M;+[Y(6WI3&$L+ <#.=2':FO(GA>3(9!7J%S6V>M\#&;N+C?-Y(:3@^8('G>*
MFLN =:M)WRR6GRZ^?U\LU^_+M;>8UK,?FQ$89R%9&6118)RL>8\FT$Z= 53:
MBFR%,[G!!<(@6@;AS;]XO(TEG;]/@X4[DRE(++7A1?UF4T-TN;'+5@&KNWL?
MI;W"'L1,U%SA4':=IK5"%"%PXPT4&1*HJ*L5KNU)M);,,,GH=)VFEN/(U@K7
M96YUDM MGF];5)9@N'"!O%))9L/Y E$5#<RG(G062O/6\YL>)*3+'/]#L'"O
MUOEHMG=P7[:[B4T>C?-11,45N& MJ)SK:VQ,$#4740J#);=NN_D0'1.7*A\O
MWF< LS>O.\3+54O^P'BJ\8S6IK[DQP).>P^&.Y.24Q9#ZZX=#U/2%V;VE_ S
MD#F W5.'!+]>S/\]6_[[34B;L7%7R1:,L1@L!\R.=L #AY ]0N2"J>1L]FI8
MDL*#']\7"@X1VJ(I!SM4'#?A3+:8HJ'05E9%J@)QR'G2JT9X;XLNA>]V)6BN
M.][ME=<R7K^"T4W.85SO #XUCE@O+S;M&M[./RP7%'JL5O^U7*Q69\BYL9@I
M -;*@[)1UI9:A0X&S]9GH7W&Q@!Z@IR^=,^! E^,P_T.@/0.PPJ_+L[SVV_?
MEXL?E^'KY4Y8B$%*P<'6.EM5)PQY[R38[+2V6J2B6D=,CU/3ER9J Z-&O.\
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MDU$0<QR#NT+(C>OVZMOB@O[\,Y D\AMBX ;[FUXJ9UY1 %#S>5)TM<= 4!0
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M1^Q/WAL<)(,.D'0['OFPG,W3['LXO]Y,4(Y+$S00HT0M+1<0?69@L$C%0\+
M6C^V/TG0M#<*I\%5.XET!J_K_A27>WD_OY5OC(DE%A",+K7A9''@ T_@2Z[O
M"]JSYB73PRB;]M+A](!K)*.7]/QRG=WTYF)-/O!V$O0=I3Y&.M>SJXV?SK7?
MAL=Q^:,5,I2L@0OIZEMRJ077%DP4)D5M4HFM[X/&?)^Y%39=\_+BYI@FCK'.
MA "1ZAFBK9,S*R)8D>JTDFRT/DUI[L/T=>7X[X.,865Q#832@4F]U/R/%/Y=
M[>\R9RC7UKQO9JL4SO\'P_(L:F\8Z@A<>0N*FPA.67)0:SH1&1#!;.OXX'!J
MIP7C> BZ=V=W$G&^%. 26_\@2_/Y3SS_@;\OYNNOJS-.WHM(Y->P8B/YO#%!
M0"$ A9,A>5D<:YT,=BBMTP8H?8'V6%&^(,C6X_CYS\69%,HASP)2J-G !0M$
MX1*88$1DGGXGVG>VVHO$:0.:[@!ZB.!>&BX):'@6N'6.3 0435&BJLW3:8.1
M@CDG;60Z)]>ZB&!O(J=]E^T3FWL+[X6A\\WBHD[0\QX+RX IR5I$H2'FE,$8
MK4+./D??>O#<OC1.^T;<)3;W%MW4>5!/;J[.+JG/HY63A1:\WF&D3Y$A<+!U
M3*0BCQM<4AZ8-IS1=TKOCK5[M&_$ <M/VZEF=-R=2"XO2"F>62<Q&IX@VGJ5
M*U6MF*T#3YS+*#ECQ,N)E.&TC6ZZ4X)[B:J#-BE/[NN?\[RMN<#\VU^ISM#=
M9(F<%>)5<,2Z:.N+4^W\XS,C=@JMF4]HN&L]M>8@0J=MQ-,'.)L(L6\SC?,P
M7[_]]GVY^'$Y*>'\?/%G?;_ZB EG/S8S$;F6)DN*YGS(BDR#M1 5G5 3(P5S
MVOM[!1('F>P!I$S;FZ<'\]U:7AV8\D>V>A:9*=Q(6?M_JIJJ9" 4[\!;YG2P
M,J:1"_7W>[8>KZG.R91A"TETV_3P$7YQ[DUV20/#.N\WF%H&&4FS9UMBKM>K
MNG6P/)RZKDI^CGE!'$D@'6BO!QO\///0Q*T5QCJ*K4@UJV@"!&XC&.E#L46F
MV/Q:>W\JIWTO' LO0[HSM1->[_!\Z$DI2&.CL8)\V>H\!",A,OJ6<<5CUK1A
M<Y(^U=V^"O8 S6,%]P* >?64I)B-RO@"$3EMRSL&T6D%QBGODS>*XYBYC-V^
M_74"PT/$]%+0MWDL\A3A1\D*R%)]7^/)]TV>UUGN-DANDHUL"OQ-_\+7$P+W
M%M4+P>#F:KYDH;@B[AG+-(5T:"$PBL&L84;(*)"EU@D[0VF;]AVO(P3N+:BI
MKP4?W-35Z]#=IR'MM$LE&!!:U-'PM+?HG **_:-/DG-3=DSP@(X%3Z\Y[3O=
MR+@:D_\O0*^=%9-B\CF!3,&!*L'3,1$9I.62AUR*$J<.,:9]BNM$C^TEF X>
MX![<SZ-O-M9+Z[DUD*RGS1'_(":=R&%U/CI9-.K6U=![$3CM@]N4$&PBLC[M
MZ9#GFL2Y#)RXJ'/U&JS+%,(C Q&$P62"3;L1[E[FM?MGM>FL;6OI]&I\SZ3(
M0@:5( 2?2;$S18J=TR9B\#PR%"&=Q.)._) VI9+;2P93*[-'O-*;\EC-O)02
M3/&!F),<.,P<D%B4=3'9R#T&HSZZ3E<MR@YY_6K-RSYA\? [B8K*L)+(>735
M=HM"9P?K'RR&X%B18;<2=2^,=/1FU5S*SZ/G>)9/Z+X_L:^ZC?=S/(N&\Y2=
M!J$2@G*>4\3K"U $0O]G#-ENH_R]P+-=9IIWI G@<@A;^P5(?6X@E5O?%!@0
M/V@G1D0(25J0/ M>F$'.C[% D[[P3 20?=G:,4 N7P-TLBAC !MXO8P-@3RO
M@N"<MEGH: D)QT)DND>8J4"R-VO[A<GF;M6$7$2=,$,*, %9T/IJ+NBKVAF(
MUTGC]MFN) /6F>:=9"*0[,W8/C%R]Q*><]I"[?XI*%0#5:NLO;4>T%HN"[?,
M#JY;ZO3U8P*T',[B/B%S%E3PI=)<&*<@/P<)(09.7XDB0A0"-3L")=,\4TP
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M=SHU5R?H\^+35V+^JG:6_/9M,?^T7J1_;[R!#[C<_.K,FA CMQQ<-IOPQD'
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MRVU=%1U5"(P.<\=M97L4#J)'L@N1.<Z-B"X,:X2R[YN[*/INA:%1Q=Z7#36
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MBK;8,LC#.*",=SS^O5X =*S$N]BX-H'&]V%U_N,VS^4O/VY_LK%0M"^<>XZ
M&,FA)]\,G#"UFX^627M?-+;NF#E\=-TP0D[HIXRDR\Y0NEVO2AGCA$Z0R!Z@
M&53&5.9J22 MXA@*2M7ZKO_G44QKSHVE[T=@=8#PIP[(_4&;\]^6JS^O-NC
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M2XQ@Q5,[#LKL):6NTK+B,;7(*TKP$CWE@K*Q40"]@B]:QH+9FQJ=!UHP097
M (03"K90I#A2KK%XVXVJ;:6W-"HU!X<,T#9VRD"7BC"/*;(_A&6=6(H Z.$D
MQ:H2@M\"CH9 T-"?L^T)^=5!.]@=:!=\O([LK4GM"<"WI\.M<0Y[8R(8PI=J
MF5+D?:H!^JA0$=-P]ISC"Q O:"!B./*@*M@T+>XV"T6+,K=1UDQ7%*XM+P]%
M0%FN,D"YMBHF#*5BU@&K=4<\!7$2 ]BAA6>XB] $=+P#-.PVD0'# UF?O$U$
MA[N#Z#E9^Q,:YY;1,-\\BD!JB@ED2F^0C L%L@5#N\?-*M(B&#H"NVJG50.9
MF^<]V*:&T(4U1R$>_?EYB@1SB6\W)7<K ?XX3L49WB0*V>Z@<,ZK+K]/<8+G
M_$( VI:-8/P*-D45(,,P5XB&E9*[8=1$:@/O\=(3QM(A#/2[NTERPXRI7@@*
MI#2+6\XLU]L "AZ>D5C<\[BX8'AD7_[+,7T=5E_?H>Q@Y\#Z;8<R>S')YC@O
M+[D'J7 5:TL:0A+["HWQ1+\N7*.@88U4>E'6[0L8,DF$,9S_ =$'$B^MH9T)
M\,\.L@\ !U[5R-OP+RKI^3;BO^<"W+=;)D]#>P_Q_O]GK^]8SKLQ:#-8*P'8
MPP,P'J5#P0$L14E>G(&FG-YCC75:S599JS+MG>G\%NFK(%@<5]SUPP;VHPPZ
M:KX@OV?A6FA3Z *8 PE9=H5>0Y77>0*(@56RP1158N-]VQLOXKMW..I"K8X4
M4$L9@, M&P*4[*5W@;FRJYPBG<AXPK%\IG14W-VK@D!YDL5RQJ%U.I:.->D:
MH@&!_Q,Q4/V6/[@M_@1J[ FKZ!  1KFJP.+'--.\/?^E WR?Q736%JE=0MNI
M4PP?2&-DTH:EZTRP:(# *":Q\[GFY<<6U;K[X,(H^)_-9RZ:J[:I9MC3MM9Q
M]:3^?'.]ZCW;]D?#-JN'K>=[?NNHK5;5.SC9:MB:70BW&+#>.J/IAU*S-.]0
M(+3=R!Z(MYY#!.WC)7>K_?VWLLW,!6P/6R3)SW1&/*]LO_-9P+-8B5<>Y/EL
M70>\C:CL)R':_GST%_ZU0+<$:QWC+6VU.%N8%JR$-%9'AB;V\I+@HG1>TQKO
MVKJ^IK7KC06/B/_ PQSO5,CURIGD1H'>8_:KP=>ZI+9ROX3ZVO^;Q9<=L2T,
MQ!MNX<Z-NSL%>?,DU2^G$DMG[Q]]?[G 5\TJH0W2J^C>0E642?>5;=O]A6;"
MG_WRM)!2]647&@#9Y>9I%[<09Z<!>K'FW.I/]]VL_8+W[+]02P,$%     @
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M!#NKL..GH#WU]ANT='] >UKW3C /%UQ#IF#];"W\8W!5L4R'M-"[=\%Z&7
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M?=LK+^+[=SCJ0:V.%%!+%8# +1L"E.RE=XFYJJN<(IO*9,JQ?&9T4M[=JY)
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M0"1P*60,CFV\AU#(0OBY5 *&L%)X1V2P*IGC.O7RICA%'_*AM'Y/AW =H<\
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M?I<JOI"=_P-02P$"% ,4    " #@-:M67EW>E*)O! !(;R@ $0
M    @ $     :6)R>"TR,#(S,#,S,2YH=&U02P$"% ,4    " #@-:M6R=R$
M83H:  !F. $ $0              @ '1;P0 :6)R>"TR,#(S,#,S,2YX<V10
M2P$"% ,4    " #@-:M60$\1O6<R  #K"@( %0              @ $ZB@0
M:6)R>"TR,#(S,#,S,5]C86PN>&UL4$L! A0#%     @ X#6K5NM-TZ'2C0
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M>"TR,#(S,#,S,5]P<F4N>&UL4$L! A0#%     @ X#6K5C,16D=U"   '"P
M !\              ( !O<42 &EB<G@M,C R,S S,S%X,3!Q97AH:6)I=#,Q
M,2YH=&U02P$"% ,4    " #@-:M6!K6#;E@(  ! *P  'P
M@ %OSA( :6)R>"TR,#(S,#,S,7@Q,'%E>&AI8FET,S$R+FAT;5!+ 0(4 Q0
M   ( . UJU:7BAT0]00  ) 4   ?              "  037$@!I8G)X+3(P
M,C,P,S,Q>#$P<65X:&EB:70S,C$N:'1M4$L! A0#%     @ X#6K5J0ZG,W=
M!   ?!,  !\              ( !-MP2 &EB<G@M,C R,S S,S%X,3!Q97AH
A:6)I=#,R,BYH=&U02P4&      L "P   P  4.$2

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
